result
intens
induct
protocol
neuroblastoma
morocco
khattab
elkababri
cherkaoui
benmiloud
j
elhoudzi
l
hessissen
c
lam
n
parikh
howard
k
matthay
pediatr
univers
moham
rabat
morocco
hematolog
hospit
casablanca
morocco
pediatr
univers
hospit
hassan
ii
fez
morocco
oncolog
univers
hospit
moham
vi
marrakech
morocco
oncolog
intern
outreach
program
st
jude
children
research
hospit
memphi
tennesse
usa
hematologyoncolog
connecticut
children
medic
center
hartford
connecticut
usa
pediatr
ucsf
benioff
children
hospit
san
francisco
usa
object
surviv
neuroblastoma
morocco
despit
recent
improv
countri
activ
first
treatment
protocol
neuroblastoma
morocco
report
earli
result
first
aim
test
feasibl
toxic
respons
intens
induct
therapi
method
elig
patient
newli
diagnos
neuroblastoma
rabat
n
casablanca
n
fez
n
marrakech
n
treat
five
cycl
rotat
pair
combin
chemotherapi
without
pediatr
blood
diseas
evalu
perform
diagnosi
end
induct
result
fifti
seven
patient
enter
studi
includ
stage
diseas
stage
median
age
year
initi
evalu
show
metastas
bone
bone
marrow
liver
adren
primari
mibg
scan
perform
patient
mycn
copi
number
determin
patient
februari
patient
complet
cycl
induct
progress
induct
studi
still
induct
therapi
regimen
toler
without
toxic
death
hospit
complic
consist
feverneutropenia
sepsi
complet
induct
therapi
evalu
patient
complet
respons
partial
respons
stabl
diseas
progress
diseas
surgeri
primari
tumor
perform
patient
complet
resect
conclus
intens
induct
therapi
neuroblastoma
set
feasibl
morocco
without
unusu
toxic
respons
would
allow
proceed
myeloabl
therapi
asct
improv
chanc
surviv
futur
effort
underway
improv
access
mycn
test
mibg
scan
pbsc
harvest
asct
late
recurr
mortal
second
cancer
survivor
high
risk
neuroblastoma
r
modi
c
van
ryn
wb
london
jr
park
md
hogarti
l
diller
pediatr
univers
michigan
ann
arbor
usa
biostatist
univers
florida
gainesvil
usa
pediatr
cancer
institut
boston
usa
hematologyoncolog
seattl
children
hospit
seattl
usa
oncolog
children
hospit
philadelphia
philadelphia
usa
object
investig
late
outcom
survivor
neuroblastoma
treat
method
identifi
cohort
patient
enrol
cog
neuroblastoma
biolog
studi
surviv
least
five
year
diagnosi
timepoint
chosen
compar
survivor
cohort
clinic
demograph
biolog
featur
group
examin
includ
caus
death
cod
subsequ
die
year
surviv
ef
overal
surviv
os
standard
error
calcul
use
method
cumul
incid
secondari
malign
neoplasm
smn
calcul
second
tumor
describ
result
median
time
diagnosi
survivor
cohort
year
rang
year
eleven
smn
report
year
diagnosi
osteosarcoma
sarcoma
meningioma
thyroid
cancer
aml
unknown
cumul
incid
smn
year
diagnosi
patient
reach
timepoint
without
event
survivor
ef
patient
die
cod
includ
progress
diseas
n
treatment
relat
toxic
n
smn
n
n
os
year
diagnosi
n
conclus
within
patient
surviv
least
origin
diagnosi
progress
nb
remain
major
caus
mortal
howev
patient
without
relaps
year
appear
favor
outcom
investig
newli
establish
cohort
probe
incid
impact
ill
identifi
genet
factor
associ
late
toxic
includ
second
cancer
relaps
hdc
asct
high
risk
neuroblastoma
patient
clinic
present
treatment
prognosi
factor
c
dupraz
c
pascalini
c
dufour
b
geoerger
v
minard
colin
valteau
couanet
chu
poitier
poitier
franc
gustav
roussi
villejuif
franc
institut
gustav
roussi
villejuif
franc
object
studi
aim
analys
neuroblastoma
recurr
high
dose
chemotherapi
hdc
autolog
stem
cell
transplant
asct
purpos
focus
clinic
present
treatment
perform
prognosi
factor
method
gustav
roussi
cancerolog
institut
children
affect
neuroblastoma
receiv
hdc
asct
present
tumour
recurr
result
patient
progress
relaps
male
femal
median
age
diagnosi
mo
year
year
year
patient
stage
neuroblastoma
stage
mycn
amplif
patient
present
mycn
amplif
hdc
consist
busulfan
melphalan
patient
median
time
transplant
first
relaps
month
median
surviv
recurr
month
month
patient
die
aliv
month
month
month
patient
n
treat
temozolomid
alon
combin
topotecan
longest
time
progress
median
day
oral
etoposid
patient
even
administ
late
increas
surviv
good
qualiti
life
median
day
prognosi
factor
influenc
life
expect
recurr
age
diagnosi
month
mycn
amplif
time
year
diagnosi
transplant
recurr
conclus
outcom
recurr
post
hdc
asct
poor
howev
factor
involv
life
expect
durat
identifi
factor
taken
account
trial
evalu
new
treatment
strategi
well
stratif
criteria
random
studi
avoid
bia
wrong
conclus
virotherapi
deliv
autolog
mesenchym
stem
cell
children
metastat
refractori
neuroblastoma
result
trial
compassion
use
j
r
alemani
gj
melen
l
franco
miron
ruano
l
madero
hematolog
oncolog
hospit
madrid
spain
cellular
biotechnolog
unit
instituto
de
salud
carlo
iii
madrid
spain
cancer
virotherapi
instituto
idibel
barcelona
spain
object
develop
new
strategi
system
deliveri
oncolyt
virus
celyvir
celyvir
consist
autolog
mesenchym
stem
cell
msc
carri
oncolyt
adenoviru
previous
report
pilot
studi
use
celyvir
children
metastat
neuroblastoma
nb
cancer
gene
therapi
present
extend
clinic
experi
program
compassion
use
celyvir
new
patient
method
spanish
medicin
agenc
hospit
intern
review
board
approv
trial
patient
fail
least
line
therapi
present
metastat
diseas
children
receiv
multidosi
celyvir
weekli
basi
minimum
maximum
total
concomit
treatment
total
cell
min
max
viral
particl
min
max
vari
among
patient
hematolog
biochem
test
done
blood
sampl
time
infus
clinic
outcom
evalu
dose
result
toler
excel
mild
autolimit
toxic
peripher
blood
lymphocyt
rais
profil
tumor
infiltr
lymphocyt
whenev
biopsi
avail
chang
celyvir
therapi
clinic
outcom
progress
stabl
diseas
partial
remiss
complet
remiss
patient
complet
respons
relaps
month
receiv
second
round
celyvir
achiev
partial
remiss
msc
cultur
present
differ
express
level
adhes
molecul
molecul
suggest
interpati
differ
home
immun
modul
capac
therapi
administ
conclus
celyvir
excel
safeti
profil
children
metastat
nb
use
strategi
need
order
find
factor
relat
efficaci
statewid
assess
childhood
central
nervou
system
tumor
air
pollut
h
danysh
l
mitchel
k
zhang
scheurer
p
lupo
depart
pediatr
section
baylor
colleg
medicin
houston
usa
divis
epidemiolog
human
genet
environment
scienc
univers
texa
school
public
health
houston
usa
object
risk
factor
identifi
childhood
central
nervou
system
cn
tumor
due
increas
concern
regard
air
pollut
childhood
cancer
risk
conduct
assess
evalu
associ
select
air
pollut
benzen
diesel
particul
matter
dpm
incid
childhood
cn
tumor
method
cn
tumor
diagnos
year
age
texa
period
n
identifi
texa
cancer
registri
inform
correspond
popul
obtain
unit
state
us
censu
annual
censu
pollut
concentr
estim
us
environment
protect
agenc
air
toxic
assess
categor
low
medium
high
use
cutpoint
base
quartil
statewid
distribut
pollut
poisson
regress
use
estim
rel
risk
rr
confid
interv
ci
adjust
age
diagnosi
sex
raceethn
poverti
tumor
phenotyp
independ
evalu
includ
astrocytoma
n
medulloblastoma
n
ependymoma
n
primit
neuroectoderm
tumor
pnet
n
affili
institut
institut
review
board
approv
studi
waiv
inform
consent
result
medium
dpm
level
associ
increas
incid
cn
tumor
rr
ci
astrocytoma
rr
ci
compar
low
dpm
level
medium
level
associ
increas
incid
astrocytoma
rr
ci
rr
ci
respect
suggest
increas
incid
pnet
rr
ci
rr
ci
respect
compar
low
level
statist
signific
associ
found
medulloblastoma
ependymoma
incid
conclus
larg
assess
indic
posit
associ
air
pollut
childhood
cn
tumor
particularli
among
astrocytoma
addit
result
suggest
strong
posit
associ
pnet
although
statist
signific
tempor
cluster
neuroblastoma
children
young
peopl
northern
england
cr
muirhead
da
tweddl
r
mcnalli
institut
health
societi
newcastl
univers
newcastl
upon
tyne
unit
kingdom
northern
institut
cancer
research
newcastl
univers
newcastl
upon
tyne
unit
kingdom
object
aetiolog
neuroblastoma
nb
unclear
hereditari
nb
germlin
mutat
account
nb
singl
nucleotid
polymorph
predispos
nb
case
environment
factor
also
implic
possibl
infecti
agent
may
involv
tempor
cluster
occur
case
display
irregular
tempor
distribut
may
provid
evid
aetiolog
involv
agent
exhibit
epidem
test
presenc
natur
tempor
cluster
date
diagnosi
method
extract
case
nb
diagnos
children
young
peopl
age
year
northern
region
young
person
malign
diseas
registri
registri
includ
case
cancer
children
young
peopl
resid
northern
england
time
diagnosi
test
tempor
cluster
appli
use
modifi
version
method
estim
variat
beta
togeth
standard
error
se
obtain
result
case
nb
diagnos
studi
period
analys
fortnight
month
found
signific
variat
estim
beta
se
p
analysi
month
within
quarter
se
p
analysi
fortnight
within
month
restrict
analys
case
diagnos
age
year
show
signific
evid
variat
although
borderlin
evid
analysi
fortnight
within
month
estim
beta
se
p
conclus
studi
suggest
transient
environment
agent
may
involv
nb
aetiolog
children
young
peopl
particular
find
indic
initi
factor
might
agent
infect
occur
constitut
mismatch
repair
defici
syndrom
clinic
descript
french
cohort
c
cola
g
sebil
cabaret
c
charpi
frebourg
n
entz
werl
q
wang
lejeun
leroux
g
couillault
g
leverg
f
bourdeaut
muleri
caron
l
brugier
genet
univers
hospit
pari
franc
dermatolog
gustav
roussi
villejuif
franc
biolog
medic
patholog
gustav
roussi
villejuif
franc
patholog
gustav
roussi
villejuif
franc
genet
chu
rouen
rouen
franc
strasbourg
univers
hospit
strasbourg
franc
genet
centr
lyon
franc
clinic
genet
jeann
de
flandr
univers
hospit
lill
franc
genet
grenobl
univers
hospit
grenobl
franc
pediatri
dijon
univers
hospit
dijon
franc
pediatri
armand
trousseau
univers
hospit
pari
franc
pediatri
institut
curi
pari
franc
cancer
inserm
umr
pari
franc
medic
oncolog
gustav
roussi
villejuif
franc
institut
gustav
roussi
villejuif
franc
object
constitut
mismatch
repair
defici
syndrom
recent
describ
childhood
cancer
predisposit
syndrom
involv
biallel
mutat
mmr
gene
case
previous
report
case
report
present
first
seri
unselect
patient
method
perform
retrospect
review
case
diagnos
french
genet
laboratori
order
describ
clinic
characterist
treatment
outcom
malign
biolog
diagnosi
data
unselect
seri
patient
result
overal
tumor
diagnos
patient
hematolog
malign
brain
tumor
lynch
malign
tumor
median
age
onset
first
tumor
year
patient
calm
hypopig
macul
brain
malform
featur
overal
patient
die
due
primari
tumor
median
surviv
diagnosi
primari
tumor
month
among
patient
surviv
first
malign
develop
second
malign
obviou
excess
toxic
treatment
report
famili
histori
cancer
found
famili
consanguin
case
mutat
patient
frequent
mutat
pt
pt
pt
conclus
sever
condit
associ
multipl
malign
childhood
rariti
warrant
intern
collabor
defin
diagnosi
criteria
guidelin
surveil
prevent
order
decreas
mortal
molecular
chang
saudi
patient
famili
hemophagocyt
lymphohistiocytosi
sheereen
elamin
jabr
awwami
alsmadi
l
eibaik
aya
b
al
saud
viqaruddin
k
siddiqui
hawwari
pho
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
genet
research
center
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
patholog
laboratori
medicin
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
pediatr
allergyimmunolog
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
object
famili
hemophagocyt
lymphohistiocytosi
fhl
differ
ethnic
describ
literatur
first
report
saudi
arabia
describ
mutat
present
fhl
gene
saudi
patient
diagons
fhl
method
dna
patient
diagnos
fhl
use
mutat
detect
variou
gene
sequenc
method
result
total
patient
gene
novel
mutat
c
identifi
patient
tribe
anoth
one
identifi
one
patient
among
patient
gene
mutat
one
patient
found
nonsens
novel
mutat
patient
gene
stop
c
identifi
one
five
one
two
patient
respect
previous
report
mutat
c
identifi
patient
although
found
common
defect
gene
fhl
saudi
one
novel
mutat
found
one
patient
remain
patient
found
previous
report
mutat
four
patient
found
novel
mutat
splice
site
c
splice
site
c
lyst
gene
anoth
two
novel
mutat
identifi
one
two
patient
xiap
respect
patient
mutat
one
tribe
major
patient
mutat
anoth
tribe
molecular
defect
identifi
remain
patient
conclus
almost
half
mutat
fhl
cohort
novel
data
show
high
consanguin
rate
saudi
popul
still
genet
aberr
discov
subset
patient
molecular
defect
identifi
quarter
patient
analysi
palonosetron
vs
ondansetron
prevent
nausea
vomit
cinv
pediatr
patient
receiv
moder
highli
emetogen
chemotherapi
mechec
g
kovac
ae
wachtel
ev
basharova
spinelli
p
nicola
e
kabickova
second
depart
pediatr
semmelwei
univers
budapest
hungari
depart
pediatr
institutoi
nacion
de
enfermedad
neoplasica
lima
peru
oncohematolog
center
chelyabinsk
pediatr
region
clinic
hospit
chelyabinsk
russia
research
develop
helsinn
healthcar
sa
luganopazzallo
switzerland
depart
pediatr
hematolog
oncolog
charl
univers
medic
school
pragu
czech
republ
object
evalu
efficacysafeti
two
palonosetron
palo
compar
ondansetron
standard
compar
prevent
cinv
pediatr
patient
receiv
mec
hec
multicent
multin
random
studi
method
patient
malign
diseas
schedul
treatment
mec
hec
random
receiv
palo
mcgkg
palo
mcgkg
ondansetron
three
mcgkg
dose
stratifi
emetogen
hecmec
day
age
result
total
patient
random
includ
full
analysi
set
palo
mcgkg
palo
mcgkg
ondansetron
patient
rang
age
day
year
major
male
white
cr
rate
across
age
group
rang
ondansetron
palo
mcgkg
mcgkg
patient
treat
hec
cr
rate
higher
palo
mcgkg
mcgkg
respect
compar
ondansetron
mec
palo
mcgkg
cr
rate
higher
mcgkg
compar
ondansetron
percentag
advers
event
includ
prolong
electrocardiogram
qt
seriou
advers
event
accord
age
strata
emetogen
similar
studi
withdrawalsdeath
unrel
studi
drug
conclus
palo
mcgkg
given
singl
dose
effect
prevent
cinv
pediatr
patient
receiv
mechec
compar
ondansetron
result
indic
palo
requir
dose
adjust
accord
patient
age
safeti
profil
rais
concern
six
present
clinic
variabl
robustli
predict
risk
microbiolog
defin
infect
febril
neutropen
episod
b
phillip
behalf
picnicc
collabor
centr
review
dissemin
univers
york
york
unit
kingdom
york
unit
kingdom
object
risk
stratifi
manag
febril
neutropenia
fn
also
known
fever
neutropenia
allow
intens
manag
case
earli
discharg
case
singl
intern
valid
predict
rule
exist
children
young
peopl
individu
particip
data
ipd
pool
analysi
undertaken
devis
one
method
predict
infecti
complic
children
cancer
picnicc
collabor
form
engag
intern
clinic
methodolog
expert
author
studi
identifi
systemat
review
parent
repres
healthcar
research
picnicc
collabor
consist
differ
studi
group
countri
result
ipd
inform
episod
fn
patient
provid
episod
patient
studi
countri
suitabl
multivari
analysi
univari
analys
show
anticip
associ
microbiolog
defin
infect
mdi
higher
temperatur
lower
white
cell
count
diagnosi
acut
myeloid
leukaemia
clear
relationship
demonstr
age
risk
mdi
episod
osteosarcomaew
sarcoma
patient
patient
sever
mucos
associ
decreas
risk
mdi
multivari
risk
predict
model
deriv
ipd
six
compon
tumour
type
temperatur
clinic
sever
unwel
haemoglobin
white
cell
count
absolut
monocyt
count
model
show
moder
discrimin
auc
roc
good
calibr
calibr
slope
figur
robust
bootstrap
sensit
analys
conclus
new
risk
predict
model
microbiolog
defin
infect
robust
intern
valid
techniqu
requir
prospect
valid
studi
implement
basic
implement
model
made
live
http
valid
could
adapt
work
web
page
smartphon
app
assist
clinician
individualis
decis
make
regard
locat
intens
therapi
reduct
cathet
associ
bloodstream
infect
paediatr
oncolog
patient
use
ethanol
lock
random
control
trial
r
schoot
ch
van
ommen
stijnen
wj
tiss
h
heij
j
lieverst
l
spanjaard
hn
caron
md
van
de
weter
skion
aristocath
paediatr
oncolog
emma
children
hospitalacadem
medic
center
amsterdam
netherland
paediatr
hematolog
emma
children
hospitalacadem
medic
center
amsterdam
netherland
biostatist
univers
hospit
leiden
leiden
netherland
paediatr
oncologyhematolog
univers
hospit
groningen
groningen
netherland
paediatr
surgeri
academ
medic
centr
vu
amsterdam
amsterdam
netherland
datamanag
dutch
cancer
oncolog
group
hagu
netherland
microbiolog
academ
medic
centr
amsterdam
netherland
paediatr
hematologyoncolog
emma
children
hospitalacadem
medic
centr
amsterdam
netherland
paediatr
oncolog
dutch
cancer
oncolog
group
hagu
netherland
object
prevent
central
venou
associ
bloodstream
infect
cabsi
pediatr
oncolog
patient
essenti
ethanol
lock
elimin
biofilm
embed
pathogen
known
microbi
resist
date
random
control
trial
pediatr
oncolog
perform
efficaci
ethanol
lock
reduc
cabsi
studi
object
determin
whether
ethanol
lock
caus
reduct
cabsi
pediatr
oncolog
patient
method
conduct
random
doubl
blind
multicent
trial
pediatr
oncolog
patient
year
newli
insert
cvc
patient
randomli
assign
receiv
two
hour
ethanol
lock
ml
heparin
lock
ml
iuml
maximum
frequenc
weekli
primari
outcom
cabsi
cvc
remov
death
due
cabsi
result
includ
patient
alloc
ethanol
heparin
lock
ethanol
group
patient
diagnos
cabsi
versu
heparin
group
incid
cathet
day
respect
p
result
patient
particularli
cabsi
ethanol
n
heparin
n
p
reduc
less
cvc
remov
cabsi
ethanol
group
ethanol
n
heparin
n
p
patient
die
cabsi
ethanol
lock
patient
experienc
significantli
transient
symptom
compar
heparin
lock
maximum
grade
nausea
p
tast
alter
p
dizzi
p
blush
p
suspect
unexpect
seriou
advers
reaction
susar
occur
conclus
rct
show
ethanol
lock
prevent
cabsi
pediatr
oncolog
patient
particular
cabsi
caus
bacteria
implement
ethanol
lock
daili
practic
consid
random
open
label
parallel
group
phase
iii
studi
antibiot
alon
vs
antibiot
plu
pediatr
cancer
patient
febril
neutropenia
set
b
arora
banavali
vora
g
chinnaswami
prasad
paradkar
pa
kurkur
r
havaldar
g
narula
talol
pediatr
oncolog
tata
memori
hospit
mumbai
india
clinic
research
secretariat
tata
memori
hospit
mumbai
india
biostatist
clinic
record
tata
memori
hospit
mumbai
india
object
granulocyt
factor
use
children
febril
neutropenia
fn
countri
shown
decreas
durat
fn
hospit
admiss
antibiot
usag
reduct
infect
relat
complic
mortal
fn
countri
lic
associ
higher
degre
morbid
mortal
due
limit
support
care
limit
manpow
host
comorbid
malnutrit
henc
reduct
durat
fn
lic
set
may
much
impact
morbid
mortal
would
potenti
method
prospect
random
studi
pediatr
patient
fn
random
receiv
antibiot
filgrastim
microgramkgd
subcutan
antibiot
alon
children
stratifi
diagnosi
focu
infect
gcsf
start
within
hr
antibiot
studi
protocol
requir
resolut
fever
neutrophil
count
l
hospit
discharg
result
patient
random
shorter
durat
neutropenia
median
v
day
p
shorter
durat
grade
iv
neutropenia
median
v
day
p
shorter
febril
neutropenia
median
v
day
p
fewer
day
total
antibiot
use
median
v
day
p
less
sever
neutrophil
nadir
mean
vs
p
differ
icu
admiss
shock
infect
relat
mortal
reduct
durat
fn
significantli
reduc
cost
per
patient
admiss
conclus
gcsf
use
antibiot
onset
fn
children
cancer
lic
acceler
neutrophil
recoveri
shorten
durat
febril
neutropenia
well
antibiot
usag
reduc
hospit
admiss
cost
therapi
mortal
earli
precursor
etp
acut
lymphoblast
leukemia
character
aberr
activ
jakstat
pathway
profound
respons
ruxolitinib
xenograft
model
sl
maud
dolai
c
sp
hunger
ml
loh
cg
mullighan
ml
hermiston
sa
grupp
r
lock
dt
teachey
oncolog
children
hospit
philadelphia
philadelphia
usa
leukaemia
biolog
children
cancer
institut
australia
medic
research
randwick
australia
pediatr
ucsf
benioff
children
hospit
san
francisco
usa
pediatr
hematologyoncologybmt
children
hospit
colorado
aurora
usa
patholog
st
jude
children
research
hospit
memphi
usa
object
novel
therapi
urgent
need
earli
precursor
etp
acut
lymphoblast
leukemia
recent
describ
subtyp
poor
prognosi
defin
uniqu
immunophenotyp
express
myeloidearli
progenitor
marker
addit
marker
harbor
unifi
genet
lesion
fraction
mutat
gene
involv
jakstat
signal
studi
sought
determin
depend
jakstat
signal
activ
therapi
method
jakstat
signal
primari
sampl
pediatr
patient
evalu
phosphoflow
cytometri
immunoblot
xenograft
sampl
establish
null
nsg
mice
approv
institut
anim
care
use
committe
diseas
burden
monitor
flow
cytometri
peripher
blood
human
cytoplasm
xenograft
random
inhibitor
ruxolitinib
vehicl
develop
peripher
blast
result
identifi
aberr
hyperactiv
jakstat
pathway
sampl
heterogen
mutat
case
markedli
increas
level
compar
immunoblot
phosphoflow
cytometri
moreov
show
hyperactiv
respons
effect
abrog
ruxolitinib
vivo
ruxolitinib
display
activ
xenograft
model
profound
efficaci
ruxolitinib
treatment
decreas
peripher
blast
count
rel
level
yield
significantli
lower
peripher
blast
count
compar
control
p
sampl
reduct
mean
splenic
blast
count
p
jakstat
pathway
activ
ruxolitinib
efficaci
independ
presenc
known
jakstat
pathway
mutat
conclus
result
strongli
suggest
blast
depend
jakstat
signal
establish
ruxolitinib
potenti
novel
therapeut
option
translat
clinic
trial
rapidli
loss
function
mediat
resist
toward
apoptosi
p
hoogerbrugg
r
mark
j
havinga
j
cloo
l
yuniati
demk
l
escot
ingen
e
sonneveld
r
kuiper
g
kasper
f
leeuwen
b
scheijen
pediatr
oncolog
radboudumc
nijmegen
netherland
pediatr
oncolog
vumc
amsterdam
netherland
lab
dutch
childhood
oncolog
group
hagu
netherland
genet
radboudumc
nijmegen
netherland
object
glucocorticoid
gc
critic
compon
treatment
initi
respons
prednisolon
major
prognost
factor
relaps
resist
gc
common
repres
import
determin
treatment
failur
recent
studi
perform
us
other
identifi
gene
delet
mutat
independ
prognost
factor
children
b
cell
precursor
howev
establish
whether
loss
function
directli
impact
respons
glucocorticoid
method
examin
whether
haplodefici
gene
express
mous
lymphocyt
affect
apoptosi
assess
effect
overexpress
glucocorticoid
receptor
gr
transcript
luciferas
report
assay
use
express
cell
line
establish
investig
loss
function
human
leukemia
cell
line
furthermor
mtt
assay
perform
primari
leukemia
sampl
treatment
individu
chemotherapeut
agent
compar
patient
sampl
control
result
haplodefici
show
significantli
enhanc
surviv
treatment
gc
compar
wild
type
cell
measur
mt
assay
annexinv
stain
case
prednisolon
inhibitori
concentr
higher
splenocyt
compar
cell
gene
express
analysi
reveal
splenocyt
display
lower
express
level
well
diminish
transcript
activ
sever
target
gene
ie
furthermor
luciferas
report
assay
reveal
overexpress
enhanc
transcript
activ
respons
prednisolon
express
cell
line
inhibit
prednisolon
apoptosi
final
mtt
assay
patient
sampl
reveal
signific
gc
p
conclus
data
provid
evid
loss
function
mediat
resist
apoptosi
may
contribut
poor
outcom
delet
pediatr
acut
myeloid
leukemia
j
de
rooij
e
beul
obulkasim
j
trka
reinhardt
baruchel
e
sonneveld
be
gibson
r
pieter
fornerod
mm
van
den
cm
zwaan
pediatr
oncologyhematolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
dept
pediatr
oncologyhematolog
medic
school
charl
univers
pragu
czech
republ
studi
group
pediatr
hematologyoncolog
medic
school
hannov
hannov
germani
dept
hematolog
hopit
loui
pari
franc
dutch
childhood
oncolog
group
hagu
netherland
dept
haematologyoncolog
royal
hospit
sick
children
glasgow
unit
kingdom
object
ikaro
famili
zinc
finger
zinc
finger
transcript
factor
import
lymphoid
differenti
act
tumor
suppressor
acut
lymphoid
leukemia
recent
studi
suggest
also
involv
myeloid
differenti
method
investig
whether
delet
play
role
pediatr
acut
myeloid
leukemia
aml
screen
panel
newli
diagnos
pediatr
aml
sampl
obtain
dcog
hagu
netherland
studi
group
germani
czech
republ
hospit
pari
franc
royal
hospit
sick
children
glasgow
unit
kingdom
delet
locu
chromosom
use
multiplex
probe
amplif
mlpa
result
median
age
patient
year
rang
year
median
white
blood
cell
count
rang
major
cytogenet
subgroup
includ
patient
treat
intens
base
pediatr
aml
protocol
patient
delet
case
show
monosomi
case
show
focal
delet
delet
includ
complet
gene
n
exon
n
lead
loss
function
focal
delet
case
year
old
male
diagnos
fusion
relaps
die
year
old
femal
diagnos
acut
monocyt
leukemia
relaps
year
old
male
diagnos
acut
myelomonocyt
leukemia
surviv
gene
differenti
express
monosomi
case
significantli
correl
gene
express
chang
focal
delet
case
compar
signific
differ
sampl
n
suggest
loss
may
import
determin
pediatr
aml
monosomi
gene
increas
express
delet
sampl
includ
gene
involv
myeloid
cell
cycl
conclus
find
suggest
evid
drive
role
haploinsuffici
pediatr
myeloid
leukemia
defici
children
adolesc
myelodysplast
syndrom
wlodarski
hirabayashi
j
stari
r
masetti
h
hasl
schmugg
van
den
heuvel
dworzak
b
de
moerloos
c
niemey
depart
pediatr
hematolog
oncolog
univers
children
hospit
freiburg
freiburg
germani
depart
pediatr
hematolog
oncolog
univers
children
hospit
freiburg
freiburg
germani
dept
pediatr
hematolog
oncolog
univers
hospit
motol
pragu
pragu
czech
republ
paediatr
oncolog
haematolog
universtiy
bologna
bologna
itali
depart
pediatr
aarhu
univers
hospit
skejbi
aarhu
denmark
dept
pediatr
kinderspit
zuerich
zuerich
switzerland
sophia
children
hospit
univers
rotterdam
rotterdam
netherland
pediatr
st
anna
kinderspit
vienna
austria
dept
pediatr
ghent
univers
hospit
ghent
belgium
object
etiolog
childhood
myelodysplast
syndrom
md
remain
larg
unknown
recent
germlin
mutat
identifi
hematopoiet
stem
cell
disord
variabl
phenotyp
unifi
predisposit
myeloid
malign
studi
aim
defin
frequenc
clinic
characterist
defici
within
primari
md
children
adolesc
method
investig
cohort
consecut
patient
md
primari
secondari
diagnos
germani
enrol
studi
european
work
group
md
childhood
result
mutat
identifi
patient
primari
md
none
secondari
md
case
interestingli
children
mutat
karyotyp
either
indic
monosomi
trisomi
next
identifi
addit
case
defici
refer
diagnost
bring
total
number
patient
diagnos
institut
intriguingli
total
cohort
children
monosomi
patient
underli
defici
age
diagnosi
md
significantli
higher
mutat
patient
median
age
diagnosi
vs
year
p
overal
surviv
surviv
hsct
compar
patient
monosomi
without
underli
investig
unaffect
parent
sibl
reveal
silent
exon
mutat
carrier
conclus
summari
defici
account
primari
childhood
md
third
primari
md
case
monosomi
famili
investig
impli
full
penetr
md
exon
mutat
might
help
guid
clinic
decis
make
term
earli
transplant
investig
critic
better
defin
clinic
penetr
prognosi
novel
md
predisposit
syndrom
juvenil
myelomonocyt
leukemia
affect
function
mesenchym
stromal
cell
fgj
calkoen
c
vervat
pac
hoen
mm
van
den
lm
ball
mjd
van
tol
rm
egel
pediatr
immunolog
hematologyoncolog
hematopoiet
stem
cell
transplant
leiden
univers
medic
center
leiden
netherland
depart
human
genet
leiden
univers
medic
center
leiden
netherland
depart
pediatr
oncologyhematolog
erasmu
children
hospit
rotterdam
netherland
ofhematologyoncolog
hematopoiet
stem
cell
transplant
hospitalfor
sick
children
toronto
canada
object
aberr
mesenchym
stromal
cell
msc
function
link
diseas
contribut
pathophysiolog
malign
disord
murin
model
juvenil
leukemia
jmml
aggress
diseas
affect
young
infant
character
presenc
high
percentag
blast
studi
present
impact
jmml
msc
method
sampl
children
jmml
collect
diagnosi
n
hsct
n
patient
expans
msc
healthi
pediatr
control
collect
time
stem
cell
donat
msc
character
phenotyp
differenti
deepsag
analysi
function
studi
assess
immunomodul
hematopoiet
support
result
gene
express
profil
differ
significantli
control
figur
differenti
express
observ
ao
gene
encod
protein
superfamili
leptin
pathway
adhes
molecul
chimer
analysi
confirm
patient
origin
msc
expand
sampl
gene
express
eg
msc
expand
jmml
patient
hsct
compar
control
msc
significantli
alter
compar
msc
patient
collect
diagnosi
wherea
hematopoiet
support
suppress
pbmc
activ
affect
suppress
differenti
monocyt
toward
dendrit
cell
significantli
stronger
jmml
deriv
msc
compar
healthi
control
depict
figur
decreas
express
conclus
first
studi
show
impact
leukem
cell
microenviron
man
use
msc
children
jmml
diagnosi
hsct
treatment
shown
alter
partial
revers
data
shed
new
light
chang
occur
microenviron
children
leukemia
natur
killer
cell
receptor
genet
profil
outcom
allogen
hematopoiet
cell
transplant
r
faridi
tj
kemp
p
v
lewi
n
berka
j
storek
f
khan
depart
patholog
laboratori
medicin
univers
calgari
calgari
canada
depart
oncolog
alberta
children
hospit
calgari
canada
depart
patholog
laboratori
medicin
calgari
laboratori
servic
univers
calgari
calgari
canada
depart
medicin
univers
calgari
calgari
canada
object
allogen
hematopoiet
cell
transplant
hct
cur
therapi
hematolog
malign
well
numer
disord
hematolymphopoiesi
common
indic
hct
acut
myeloblast
leukemia
hct
follow
lymphoblast
leukemia
chronic
myeloblast
leukemia
refractori
inhibitor
lymphoid
malign
spite
high
resolut
hla
match
optim
care
complic
hct
includ
graft
versu
host
diseas
gvhd
relaps
underli
diseas
reactiv
otherwis
latent
viral
infect
substanti
recent
natur
killer
nk
cell
genet
system
regul
activ
inhibitori
killer
receptor
kir
garner
substanti
research
interest
modifi
hct
outcom
set
determin
influenc
kir
gene
repertoir
hct
pair
hct
complic
includ
gvhd
relaps
posttranspl
lymphoprolif
disord
ptld
cytomegaloviru
cmv
reactiv
method
kir
type
obtain
paediatr
adult
match
pair
addit
healthi
individu
rsso
method
effect
kir
genotyp
hct
outcom
analys
use
binomi
regress
test
peripher
blood
mononuclear
cell
pbmnc
healthi
volunt
stimul
differ
target
enumer
kir
depend
target
specif
nk
cell
respons
result
pair
match
bx
genotyp
significantli
protect
gvhd
hr
p
without
effect
diseas
relaps
hr
p
incid
ptld
strongli
correl
donor
kir
linkag
group
p
wherea
higher
activ
protect
cmv
reactiv
p
uniqu
function
respons
higher
number
induc
function
nk
cell
individu
lack
kir
observ
conclus
nk
cell
respons
function
kir
gene
repertoir
modifi
risk
gvhd
ptld
cmv
reactiv
indic
relev
kir
gene
profil
predict
hct
outcom
metastat
medulloblastoma
uk
result
induct
high
dose
chemotherapi
hyperfraction
acceler
radiotherapi
milan
strategi
vivekanandan
r
breen
r
ramanujachar
h
trauneck
b
pizer
gaze
f
saran
n
thorp
english
k
wheeler
michalski
da
walker
saunder
f
cowi
cameron
v
lee
parashar
g
horan
william
clinic
oncolog
cambridg
univers
hospit
nh
foundat
trust
addenbrook
hospit
cambridg
unit
kingdom
paediatr
oncolog
cambridg
univers
hospit
nh
foundat
trust
addenbrook
hospit
cambridg
unit
kingdom
paediatr
oncolog
univers
hospit
southampton
nh
foundat
trust
southampton
unit
kingdom
paediatr
oncolog
children
hospit
wale
cardiff
unit
kingdom
paediatr
oncolog
alder
hey
children
hospit
nh
foundat
trust
liverpool
unit
kingdom
clinic
oncolog
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
clinic
oncolog
royal
marsden
nh
foundat
trust
surrey
unit
kingdom
clinic
oncolog
clatterbridg
cancer
centr
nh
foundat
trust
wirral
unit
kingdom
paediatr
oncolog
birmingham
children
hospit
nh
foundat
trust
birmingham
unit
kingdom
paediatr
oncolog
oxford
univers
hospit
nh
foundat
trust
oxford
unit
kingdom
paediatr
oncolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
paediatr
oncolog
nottingham
children
hospit
univers
nottingham
nottingham
unit
kingdom
clinic
oncolog
nottingham
univers
hospit
nh
trust
nottingham
unit
kingdom
clinic
oncolog
beatson
west
scotland
cancer
centr
glasgow
unit
kingdom
clinic
oncolog
univers
hospit
bristol
nh
foundat
trust
bristol
unit
kingdom
clinic
oncolog
sheffield
children
nh
foundat
trust
sheffield
unit
kingdom
statist
cancer
research
uk
cambridg
institut
univers
cambridg
cambridg
unit
kingdom
clincial
oncolog
cambridg
univers
hospit
nh
foundat
trust
addenbrook
hospit
cambridg
unit
kingdom
object
histor
overal
surviv
os
metastat
medulloblastoma
mb
less
milan
strategi
induct
chemotherapi
follow
hyperfraction
acceler
radiotherapi
hart
respons
direct
myeloabl
high
dose
chemotherapi
hdc
mainten
chemotherapi
report
studi
patient
metastat
mb
improv
os
ci
os
report
uk
outcom
strategi
method
questionnair
sent
uk
paediatr
oncolog
centr
collect
retrospect
data
treatment
deliv
toxic
surviv
milan
strategi
result
februari
octob
patient
fulfil
entri
criteria
origin
studi
treat
de
novo
metastat
mb
centr
median
age
present
year
rang
median
interv
surgeri
hart
versu
day
milan
seri
induct
hdc
toxic
incid
grade
toxic
febril
neutropaenia
blood
platelet
transfus
respons
highli
correl
surviv
patient
achiev
cr
end
therapi
remain
aliv
remiss
lesser
respons
still
aliv
p
follow
induct
chemotherapi
milan
studi
month
estim
overal
surviv
cl
result
outsid
ci
milan
result
encompass
histor
result
observ
major
late
neurotox
cohort
although
children
residu
cerebellar
sign
chang
follow
mri
conclus
replic
improv
result
report
milan
group
reason
could
includ
differ
patient
protocol
complianc
small
cohort
tandem
chemotherapi
stem
cell
rescu
follow
radiat
children
cerebr
primit
neuroectoderm
tumor
result
pnet
c
dufour
mb
delisl
geoffray
laplanch
frappaz
c
icher
ai
bertozzi
p
leblond
f
doz
n
andr
e
decarli
p
schneider
c
berger
lejar
p
chastagn
pagnier
c
soler
n
entz
werl
valteau
couanet
pediatri
gustav
roussi
villejuif
franc
epidemiolog
gustav
roussi
villejuif
franc
radiolog
chu
lenval
nice
franc
pediatri
institut
dhematologi
et
doncologi
lyon
franc
pediatri
chu
bordeaux
franc
pediatri
hopit
de
enfant
toulous
franc
pediatri
centr
oscar
lambret
lill
franc
pediatri
institut
curi
pari
franc
pediatri
chu
la
timon
marseil
franc
pediatri
chu
anger
franc
pediatri
chu
rouen
franc
pediatri
chu
saint
etienn
franc
pediatri
chu
tour
franc
pediatri
chu
nanci
franc
pediatri
chu
grenobl
franc
pediatri
hopit
larchet
nice
franc
pediatri
chu
haut
pierr
strasbourg
franc
object
assess
surviv
pf
rate
patient
newli
diagnos
medulloblastoma
mb
supratentori
primit
neuroectoderm
tumor
spnet
year
treat
accord
prospect
multicent
trial
pnet
method
children
receiv
postop
induct
chemotherapi
two
cycl
etoposid
carboplatin
follow
two
cours
thiotepa
per
cours
autolog
stem
cell
rescu
convent
radiotherapi
rt
deliv
around
day
second
transplant
craniospin
rt
dose
gy
patient
metastat
diseas
unfavour
histolog
anaplast
mb
larg
cell
mb
mb
myc
amplif
follow
tumor
bed
boost
gy
patient
local
spnet
receiv
focal
rt
dose
gy
mainten
treatment
cycl
temozolomid
plan
start
month
end
rt
result
januari
februari
patient
mb
spnet
year
median
age
year
enrol
five
patient
nt
receiv
rt
due
progress
diseas
mainten
treatment
administ
patient
median
month
rang
month
pf
overal
surviv
os
ci
ci
respect
pf
ci
children
mb
ci
spnet
major
unexpect
toxic
death
report
conclus
treatment
base
chemotherapi
convent
rt
result
high
overal
surviv
rate
children
adolesc
newli
diagnos
cerebr
pnet
clinic
outcom
children
standard
risk
medulloblastoma
treat
proton
photon
radiotherapi
b
eaton
n
esiashvili
kim
e
weyman
l
thornton
h
kasper
c
mazewski
macdonald
ebb
macdonald
n
tarbel
yock
radiat
oncolog
emori
univers
atlanta
usa
biostatist
bioinformat
emori
univers
atlanta
usa
radiat
oncolog
massachusett
gener
hospit
boston
usa
pediatr
aflac
cancer
blood
disord
center
children
healthcar
atlanta
atlanta
usa
pediatr
massachusett
gener
hospit
boston
usa
object
compar
surviv
rf
overal
surviv
os
children
treat
proton
photon
radiotherapi
rt
standard
risk
medulloblastoma
method
cohort
studi
includ
children
treat
chemotherapi
proton
n
photon
n
rt
os
rf
estim
method
compar
test
effect
rt
type
covari
outcom
assess
multivari
analysi
use
logist
regress
backward
select
method
alpha
level
remov
result
median
rang
age
diagnosi
yr
proton
patient
vs
yr
photon
patient
p
cohort
similar
respect
gender
histolog
extent
surgic
resect
craniospin
total
rt
dose
whether
rt
boost
deliv
posterior
fossa
tumor
bed
median
csi
dose
gy
median
total
dose
gy
median
time
year
proton
patient
vs
year
photon
patient
p
signific
differ
os
rf
patient
treat
proton
vs
photon
rt
yr
os
ci
vs
ci
yr
rf
ci
vs
ci
multivari
analysi
femal
gender
p
higher
csi
dose
p
associ
better
rf
margin
signific
relationship
better
os
older
age
diagnosi
p
classic
histolog
p
femal
gender
p
second
primari
malign
occur
four
photon
patient
median
time
year
vs
proton
patient
p
conclus
diseas
control
proton
photon
radiotherapi
appear
equival
standard
risk
medulloblastoma
therapeut
implic
medulloblastoma
subgroup
singl
centr
popul
base
experi
v
ramaswami
remk
j
adamski
u
bartel
u
tabori
huang
md
taylor
e
bouffet
neurosurgeri
hospit
sick
children
toronto
canada
hematologyoncolog
hospit
sick
children
toronto
canada
object
advent
integr
genom
fundament
chang
understand
medulloblastoma
although
surviv
differ
shown
exist
four
principl
subgroup
treatment
relat
differ
yet
elucid
sought
delin
differ
larg
referr
centr
method
patient
older
three
year
age
treat
surgeri
craniospin
irradi
adjuv
chemotherapi
identifi
hospit
sick
children
toronto
result
patient
met
inclus
criteria
two
period
identifi
patient
treat
prior
per
open
protocol
children
oncolog
group
patient
treat
treat
per
protocol
progress
free
surviv
entir
cohort
stratifi
treatment
surviv
pre
post
ident
subgroup
specif
manner
find
signific
differ
surviv
pre
post
strikingli
found
group
patient
excel
surviv
compar
previous
report
year
surviv
averag
risk
group
patient
averag
risk
group
patient
regardless
treatment
protocol
surviv
shh
patient
rel
poor
across
treatment
protocol
year
progress
free
surviv
like
owe
higher
proport
mutat
patient
center
conclus
cohort
homogen
treat
patient
progress
free
surviv
appear
improv
compar
initi
report
base
retrospect
cohort
impact
subgroup
affili
children
age
need
assess
larg
prospect
treat
cooper
protocol
determin
prognost
predict
implic
subgroup
affili
experi
metronom
antiangiogen
therapi
children
recurr
medulloblastoma
atrt
variou
malign
cn
tumor
slavc
peyrl
chochol
aa
azizi
czech
k
dieckmann
c
haberl
u
leiss
pediatr
medic
univers
vienna
vienna
austria
neurosurgeri
medic
univers
vienna
vienna
austria
radiotherapi
medic
univers
vienna
vienna
austria
institut
neurolog
medic
univers
vienna
vienna
austria
object
patient
recurr
malign
cn
tumor
poor
prognosi
irrespect
salvag
therapi
use
report
updat
extend
seri
patient
recurr
medulloblastoma
atrt
variou
malign
cn
tumor
partli
includ
previou
public
treat
altern
approach
consist
antiangiogen
combin
therapi
method
patient
variou
recurr
brain
tumor
start
treatment
antiangiogen
consist
bevacizumab
thalidomid
celecoxib
fenofibr
etoposid
altern
cyclophosphamid
without
intraventricular
therapi
etoposid
liposom
cytarabin
diagnos
medulloblastoma
n
atrt
n
ependymoma
n
cn
pnet
n
etantr
n
pineoblastoma
n
hgg
n
dipg
n
nggct
n
mpnst
n
choroid
plexu
carcinoma
astroblastoma
paraganglioma
meningioma
oncocytoma
epitheloid
sarcoma
endolymphat
sac
tumor
neuroblastoma
one
result
patient
medulloblastoma
aliv
month
patient
atrt
aliv
month
last
recurr
therapi
patient
cn
pnet
etantr
hgg
dipg
oncocytoma
neuroblastoma
appear
respond
strategi
two
patient
pineoblastoma
surviv
month
respect
despit
extens
leptomening
diseas
two
patient
nggct
show
dramat
drop
level
conclus
propos
antiangiogen
regimen
current
evalu
medulloblastoma
intern
phase
ii
protocol
memmat
http
clinicaltrialsgov
identifi
seem
also
efficaci
recurr
atrt
number
tumor
entiti
time
progress
could
prolong
maintain
good
qualiti
life
peyrl
et
al
pediatr
blood
cancer
long
term
neuropsycholog
follow
young
children
medulloblastoma
treat
accord
ccg
regimen
k
walsh
mabbott
smith
j
madden
chi
e
well
e
owen
r
packer
n
foreman
e
bouffet
l
pediatr
hematolog
oncolog
bone
marrow
transplant
alberta
children
hospit
calgari
canada
pediatr
oncolog
children
nation
medic
center
washington
dc
usa
pediatr
oncolog
hospit
sick
children
toronto
canada
pediatr
oncolog
arnold
palmer
hospit
children
orlando
usa
pediatr
oncolog
children
hospit
colorado
denver
usa
pediatr
oncolog
dana
farber
cancer
institut
boston
usa
object
high
dose
chemotherapi
hdc
strategi
develop
infant
brain
tumor
protocol
prevent
neuropsycholog
np
impair
associ
radiat
howev
comprehens
np
evalu
young
children
treat
strategi
remain
scant
aim
examin
long
term
np
outcom
young
children
medulloblastoma
treat
sequenti
hdc
accord
protocol
ccg
method
retrospect
studi
includ
young
children
diagnos
medulloblastoma
north
american
institut
neurocognit
data
extract
institut
np
report
children
old
enough
test
result
initi
cohort
includ
patient
twenti
survivor
least
one
np
assess
sampl
male
n
mean
age
diagnosi
month
sd
posterior
fossa
syndrom
pf
report
five
patient
eight
receiv
radiotherapi
focal
csi
receiv
chemotherapi
receiv
hd
mtx
induct
averag
children
assess
year
sd
year
age
sd
fsiq
rang
mean
sd
major
children
low
averag
averag
np
function
four
children
receiv
rt
account
major
impair
score
percentil
sampl
size
limit
power
patient
treat
radiotherapi
lower
work
memori
score
wmi
mean
vs
p
patient
pf
lower
perceptu
reason
score
pri
mean
vs
p
patient
hear
support
lower
verbal
comprehens
score
vci
mean
vs
p
np
outcom
statist
differ
age
diagnosi
gender
extent
resect
metastasi
histolog
conclus
np
data
obtain
sampl
survivor
infant
medulloblastoma
treat
accord
regimen
encourag
indic
averag
neurocognit
function
unilater
wilm
tumor
treat
partial
nephrectomi
enrol
children
oncolog
group
cog
renal
tumor
biolog
classif
studi
p
ehrlich
em
mullen
j
geller
naranjo
e
gratia
barnhart
r
dasgupta
f
ferrar
k
gow
r
glick
hamilton
j
kandel
ying
e
pearlman
j
kalapurak
j
dome
pediatr
surgeri
univers
michigan
ann
arbor
usa
pediatr
oncolog
boston
children
boston
usa
pediatr
oncolog
cinncinnati
children
hospit
cinncinnati
usa
biostatist
univers
florida
gainesvil
usa
pediatr
oncolog
univers
tennesse
chattanooga
usa
pediatr
surgeri
children
onoclog
group
philadelphia
cog
usa
pediatr
surgeri
children
onocolog
group
philadelphia
cog
usa
biostatist
univers
florida
gainesvil
usa
pediatr
patholog
children
oncolog
group
philadelphia
cog
usa
radiat
oncolog
children
oncolog
group
philadelphia
cog
usa
pediatr
oncolog
children
nation
medic
center
washington
dc
usa
object
long
term
renal
failur
rate
children
unilater
wilm
tumor
wt
less
standard
recommend
surgic
treatment
unilater
wt
nephroureterectomi
lymph
node
sampl
despit
recommend
patient
unilater
renal
tumor
undergo
partial
nephrectomi
littl
known
technic
consider
outcom
patient
purpos
studi
increas
understand
report
oper
outcom
event
free
surviv
ef
overal
surviv
os
patient
enrol
unilater
wt
undergon
partial
nephrectomi
method
elig
patient
enrol
unilater
surgic
review
form
indic
partial
nephrectomi
surgic
procedur
consid
analysi
elig
criteria
includ
enrol
bilater
studi
confirm
histolog
diagnosi
wt
central
patholog
review
surgic
outcom
ef
os
assess
result
total
patient
unilater
wt
anaplasticwt
underw
partial
nephrectomi
median
tumor
weight
rang
local
stage
distribut
stage
ii
iii
patient
lymph
node
sampl
among
patient
stage
iii
diseas
intraop
tumor
spill
microscop
residu
tumor
upstag
ef
os
estim
conclus
patient
unilater
wt
undergo
partial
nephrectomyhad
greater
expect
occurr
microscop
residu
diseas
intraop
tumor
spill
result
local
upstag
consequ
increas
therapi
potenti
renal
benefit
surgeri
must
weigh
potenti
risk
addit
chemotherapi
abdomin
radiat
patient
incomplet
surgic
resect
treatment
stage
diffus
anaplast
wilm
tumor
result
children
oncolog
group
studi
n
daw
j
anderson
j
kalapurak
f
hoffer
j
geller
e
perlman
p
ehrlich
e
mullen
warwick
p
grundi
j
dome
divis
pediatr
univers
texa
md
anderson
cancer
center
houston
usa
cog
data
center
omaha
children
oncolog
group
madison
usa
radiat
oncolog
children
oncolog
group
chicago
usa
qualiti
assur
review
ctr
children
oncolog
group
lincoln
usa
hematologyoncolog
children
oncolog
group
cincinnati
usa
patholog
children
oncolog
group
chicago
usa
dept
ped
surgeri
children
oncolog
group
ann
arbor
usa
pediatr
hematologyoncolog
children
oncolog
group
boston
usa
pediatr
hematologyoncolog
children
oncolog
group
bethesda
usa
alberta
health
servic
children
oncolog
group
edmonton
canada
divis
oncolog
children
nation
medic
center
washington
usa
object
nation
wilm
tumor
surviv
patient
stage
diffus
anaplast
wilm
tumor
dawt
treat
vincristin
doxorubicin
cyclophosphamid
etoposid
plu
radiotherapi
xrt
regimen
evalu
whether
intens
regimen
contain
carboplatin
addit
agent
use
regimen
regimen
improv
ef
patient
method
patient
stage
dawt
without
measur
diseas
receiv
regimen
patient
stage
iv
measur
diseas
option
receiv
vincristin
combin
irinotecan
vi
upfront
window
partial
respons
pr
vi
incorpor
regimen
regimen
dosag
doxorubicin
cyclophosphamid
etoposid
reduc
revis
due
excess
toxic
studi
design
detect
improv
ef
compar
histor
control
treat
regimen
studi
approv
central
institut
review
board
result
elig
patient
treat
vi
window
follow
revis
nineteen
patient
stage
iv
measur
diseas
particip
vi
window
pr
ef
patient
ci
nineteen
event
observ
versu
expect
base
data
p
ef
ci
stage
ii
ci
stage
iii
ci
stage
iv
patient
stage
iv
dawt
ef
ci
patient
treat
vi
window
ci
patient
treat
upfront
three
patient
die
toxic
cardiomyopathi
n
pulmonari
hypertens
n
pulmonari
edema
n
conclus
regimen
appear
produc
better
ef
patient
stage
dawt
regimen
albeit
increas
toxic
malign
rhabdoid
tumor
kidney
mrtk
data
patient
treat
accord
protocol
gpoh
german
societi
paediatr
oncolog
hematolog
r
n
leuschner
c
vokuhl
f
niggli
l
kager
mc
n
graf
pediatr
hematolog
oncolog
univers
children
hospit
homburg
germani
paidopatholog
schleswig
holstein
univers
hospit
campu
kiel
kiel
germani
pediatr
hematolog
oncolog
univers
children
hospit
zurich
switzerland
pediatr
hematolog
oncolog
st
anna
children
hospit
vienna
austria
children
hospit
swabian
hospit
augsburg
augsburg
germani
object
analyz
data
consecut
patient
mrtk
regist
framework
siop
austria
switzerland
germani
method
children
histolog
proven
mrtk
enter
onto
studi
eleg
analysi
median
follow
year
result
patient
present
metastat
diseas
frequent
lung
n
simultan
mrtk
atrt
occur
patient
die
treatment
patient
underw
upfront
surgeri
receiv
preoper
treatment
dactinomycin
vincristin
av
av
plu
doxorubicin
avd
unknown
mean
respons
avd
significantli
better
av
volum
reduct
vs
increas
volum
p
local
stage
distribut
surgeri
stage
respect
undetermin
patient
achiev
complet
remiss
treatment
cours
continu
cr
end
treatment
patient
die
due
progress
diseas
due
postop
bleed
year
event
free
ef
overal
surviv
os
respect
age
younger
month
rr
ci
local
stage
iii
rr
ci
signific
analysi
os
patient
stage
iv
n
compar
n
local
mrtk
patient
achiev
macroscop
complet
remiss
local
stage
iii
significantli
improv
os
undergo
flank
irradi
vs
p
n
patient
achiev
macroscop
cr
show
os
local
metastat
mrtk
respect
conclus
younger
patient
especi
metastat
diseas
still
apal
prognosi
earli
histolog
diagnosi
intens
postop
treatment
includ
irradi
import
treatment
mrtk
treatment
outcom
patient
relaps
clear
cell
sarcoma
kidney
ccsk
combin
siop
aieop
studi
goosken
r
furtwangl
f
spreafico
h
van
tinteren
j
de
kraker
gm
vujan
leuschner
j
godzinski
g
schleiermach
stoneham
c
bergeron
k
n
graf
mm
van
den
depart
pediatr
hematolog
oncolog
erasmu
mc
sophia
children
hospit
rotterdam
netherland
depart
pediatr
hematolog
oncolog
saarland
univers
saarbrucken
germani
depart
hematolog
pediatr
fondazion
ircc
instituto
nazional
dei
tumori
milano
itali
depart
statist
netherland
cancer
institut
amsterdam
netherland
depart
pediatr
hematolog
oncolog
academ
medic
center
emma
children
hospit
amsterdam
netherland
depart
patholog
cardiff
univers
school
medicin
cardiff
unit
kingdom
institut
patholog
univers
kiel
kiel
germani
depart
patholog
hopitaux
universitair
est
parisien
pari
franc
depart
emerg
medicin
pediatr
surgeri
medic
univers
wroclaw
marciniak
hospit
wroclaw
poland
depart
pediatr
oncolog
inserm
institut
curi
pari
franc
depart
pediatr
adolesc
oncolog
univers
colleg
hospit
london
unit
kingdom
depart
pediatr
centr
lyon
berard
lyon
franc
molecular
hematolog
cancer
biolog
institut
child
health
univers
colleg
london
unit
kingdom
object
clear
cell
sarcoma
kidney
ccsk
uncommon
pediatr
renal
tumor
relaps
occur
patient
detail
clinic
inform
relaps
ccsk
scarc
current
studi
aim
describ
outcom
patient
relaps
ccsk
treat
accord
recent
european
protocol
order
find
ration
creat
futur
intern
ccsk
relaps
treatment
protocol
method
analys
prospect
collect
data
ccsk
patient
develop
relaps
complet
respons
initi
therapi
enter
onto
intern
societi
pediatr
oncolog
siop
associazion
italiana
ematologia
oncologia
pediatrica
aieop
trial
result
ccsk
patient
treat
accord
siop
aieop
protocol
develop
relaps
median
time
initi
diagnosi
relaps
month
rang
month
year
relaps
metastat
common
site
relaps
brain
n
lung
n
bone
n
relaps
treatment
consist
chemotherapi
n
surgeri
n
andor
radiotherapi
n
follow
high
dose
chemotherapi
autolog
bone
marrow
transplant
abmt
patient
patient
achiev
second
complet
remiss
cr
develop
second
relaps
surviv
ef
relaps
ci
overal
surviv
os
ci
conclus
largest
seri
relaps
ccsk
patient
ever
describ
overal
outcom
poor
relaps
tend
occur
late
extens
desir
relaps
metastat
brain
relaps
common
previous
recogn
intens
treatment
aim
local
control
follow
high
dose
chemotherapi
abmt
seem
benefit
enhanc
surviv
novel
develop
target
therapi
urgent
requir
gain
biomark
wilm
tumour
siop
wt
trial
siop
renal
tumour
biolog
consortium
studi
chagtai
c
zill
l
daines
r
william
j
wegert
maschietto
g
vujan
n
sebir
leuschner
p
ambro
l
kager
osullivan
blais
c
bergeron
gisselsson
kool
van
den
n
graf
h
van
tinteren
coulomb
gessler
k
molecular
haematolog
cancer
biolog
ucl
institut
child
health
london
unit
kingdom
wuerzburg
univers
fuer
biowissenschaften
wuerzburg
germani
anatomi
et
cytologi
pathologiqu
hopitaux
trousseau
pari
franc
school
medicin
cardiff
univers
cardiff
unit
kingdom
dept
histopatholog
great
ormond
street
hospit
london
unit
kingdom
dept
paediatr
patholog
kiel
univers
kiel
germani
children
cancer
research
institut
st
anna
children
hospit
vienna
austria
depart
pediatr
st
anna
children
hospit
vienna
austria
patholog
depart
ladi
children
hospit
dublin
ireland
ihop
institut
et
doncologi
lyon
franc
depart
clinic
genet
lund
univers
lund
sweden
divis
pediatr
neurooncolog
german
cancer
research
center
heidelberg
germani
paediatr
oncolog
erasmu
mc
rotterdam
netherland
paediatr
oncolog
univers
saarland
homborg
germani
depart
biometr
netherland
cancer
institut
amsterdam
netherland
fuer
biowissenschaften
wuerzburg
univers
wuerzburg
germani
object
improv
outcom
wilm
tumor
wt
clinic
need
molecular
biomark
suffici
sensit
specif
use
risk
stratif
trial
enrol
patient
centr
countri
aim
evalu
util
loss
heterozygos
loh
relat
histolog
risk
group
assess
chemotherapi
incorpor
analysi
new
potenti
biomark
gain
method
biolog
consortium
contribut
frozen
tumour
sampl
trial
patient
countri
molecular
analysi
loh
microsatellit
analysi
copi
number
assess
sever
loci
interest
wt
mlpa
analysi
analys
conduct
laboratori
exchang
blind
qualiti
assur
sampl
set
result
date
analysi
tumour
show
loh
combin
loh
signific
associ
loh
anaplast
histolog
siop
high
risk
wt
gain
found
increas
frequenc
blastem
anapaest
wt
similar
lower
frequenc
across
histolog
subtyp
preliminari
surviv
analysi
case
show
signific
hazard
ratio
relaps
death
gainnorm
respect
final
assess
gain
multivari
analysi
incorpor
histolog
risk
group
tumour
stage
patient
age
patient
plan
april
full
molecular
dataset
integr
intern
clinic
trial
databas
conclus
gain
potenti
advers
biomark
wt
associ
high
risk
histolog
featur
chemotherapi
independ
impact
surviv
requir
assess
larger
number
patient
consider
clinic
use
risk
factor
chronic
kidney
diseas
children
surgeri
unilater
renal
tumor
cozzi
ceccanti
frediani
falconi
morgant
r
iaconelli
f
cozzi
pediatr
surgeri
unit
sapienza
univers
rome
rome
itali
object
chronic
kidney
diseas
ckd
associ
increas
risk
cardiovascular
diseas
overal
mortal
analyz
characterist
cohort
patient
ckd
long
surgeri
unilater
renal
tumor
childhood
identifi
modifi
risk
factor
ckd
method
observ
studi
children
underw
nephrectomi
children
underw
surgeri
nss
unilater
renal
tumor
glomerular
filtrat
rate
estim
egfr
modif
diet
renal
studi
schwartz
formula
appropri
age
ckd
defin
egfr
result
mean
sd
age
year
surgeri
ckd
present
patient
older
age
p
nephrectomi
p
renal
dysfunct
p
higher
tumor
stage
p
blood
hypertens
p
albuminuria
p
acquir
renal
cyst
p
frequent
associ
ckd
adjuv
therapi
second
tumor
preval
influenc
ckd
develop
conclus
surgeri
unilater
renal
tumor
childhood
main
risk
factor
ckd
subject
includ
ablat
renal
parenchyma
declin
renal
function
adapt
renal
hyperfiltr
children
unilater
renal
tumor
nephrectomi
might
longer
regard
gold
standard
surgic
treatment
nss
feasibl
brain
tumour
biolog
molecular
classif
ependym
brain
tumor
h
witt
sill
k
wani
sm
mack
md
taylor
ellison
korshunov
kool
dtw
jone
k
aldap
erc
sm
pfister
pediatr
neurooncolog
german
cancer
research
center
heidelberg
germani
biostatist
german
cancer
research
center
heidelberg
germani
neuropatholog
md
anderson
houston
usa
brain
tumour
research
centr
sick
kid
hospit
toronto
canada
neuropatholog
st
jude
children
hospit
memphi
usa
neuropatholog
univers
hospit
heidelberg
heidelberg
germani
ependymoma
research
network
germani
object
histopatholog
grade
ependymoma
accord
classif
cn
tumor
extrem
challeng
comprehens
molecular
stratif
scheme
absolut
essenti
contemporari
sinc
modern
technolog
reach
routin
practis
past
decad
biolog
understand
ependymoma
improv
significantli
especi
molecular
subgroup
base
transcriptom
alter
defin
two
distinct
biolog
entiti
ependymoma
identifi
sever
studi
design
show
strike
differ
genet
characterist
clinic
outcom
similar
consensu
supratentori
spinal
ependymoma
lack
method
studi
dna
methyl
illumina
primari
ependym
tumor
includ
ependymoma
subependymoma
se
myxopapillari
ependymoma
mpe
distinct
local
identifi
meaning
molecular
subgroup
conduct
unsupervis
hierarch
cluster
gene
express
profil
use
valid
molecular
subgroup
identifi
differenti
express
epigenet
silenc
gene
result
dna
methyl
data
show
ependym
brain
tumor
classifi
sever
molecular
subgroup
tumor
tumor
mpe
se
form
robust
distinct
cluster
supratentori
ependymoma
classifi
two
principl
molecular
subgroup
one
associ
highli
recurr
rela
fusion
display
poor
prognosi
occur
young
children
infant
notabl
signific
number
ependymoma
previous
classifi
histolog
grade
iiiii
look
like
se
dna
methyl
also
extrem
good
surviv
conclus
summari
use
dna
methyl
analysi
could
delin
meaning
molecular
subgroup
ependym
brain
tumor
includ
supratentori
ependymoma
diagnos
tumor
challeng
histopatholog
featur
support
easili
dna
methyl
technolog
henc
approach
offer
opportun
replac
current
ambigu
histopatholog
grade
system
unbias
molecular
classif
readili
distinguish
biolog
genet
clinic
meaning
subgroup
ependym
brain
tumor
posterior
fossa
ependymoma
subgroup
distinct
therapeut
prognost
implic
v
ramaswami
sc
mack
e
bouffet
k
aldap
cho
wa
weiss
x
fan
korshunov
sc
pfister
taylor
neurosurgeri
hospit
sick
children
toronto
canada
hematologyoncolog
hospit
sick
children
toronto
canada
patholog
md
anderson
houston
usa
neurolog
stanford
univers
school
medicin
palo
alto
usa
neurolog
univers
california
san
francisco
usa
neurosurgeri
univers
michigan
ann
arbour
usa
pediatr
german
cancer
research
center
heidelberg
germani
neurosurgeri
hospit
sick
children
toronto
canada
object
recent
integr
genom
studi
shown
posterior
fossa
ependymoma
compris
two
distinct
molecular
subgroup
cimpv
group
group
cimpv
patient
typic
younger
wors
prognosi
current
standard
care
posterior
fossa
ependymoma
includ
surgeri
conform
extern
beam
radiat
tumour
bed
irrespect
extent
resect
subgroup
sought
delin
prognost
implic
extern
beam
irradi
subgroup
specif
manner
method
assembl
cohort
posterior
fossa
ependymoma
subgroup
use
dna
methyl
clinic
detail
ascertain
retrospect
chart
review
result
order
character
treatment
implic
ependymoma
subgroup
overal
surviv
stratifi
treatment
extern
beam
irradi
restrict
analysi
cimp
ependymoma
gross
total
resect
extern
beam
irradi
confer
surviv
advantag
p
subtot
resect
cimp
ependymoma
dismal
prognosi
without
signific
differ
surviv
administr
extern
beam
irradi
p
cimp
patient
administr
upfront
extern
beam
irradi
result
improv
progress
free
surviv
p
howev
overal
surviv
across
patient
p
conclus
surviv
benefit
adjuv
extern
beam
irradi
posterior
fossa
ependymoma
highli
depend
subgroup
cimp
case
extern
beam
irradi
benefit
patient
subtot
resect
tumour
patient
consid
enrol
clinic
trial
signific
proport
cimp
patient
cure
surgic
resect
alon
remaind
like
salvag
irradi
recurr
epigenom
alter
defin
lethal
ependymoma
infanc
sc
mack
h
witt
sm
pfister
korshunov
md
taylor
gene
global
ependymoma
network
excel
development
stem
cell
biolog
hospit
sick
children
toronto
canada
divis
pediatr
neurooncolog
dkfz
heidelberg
germani
object
ependymoma
tumour
children
commonli
aris
region
brain
known
posterior
fossa
pf
pf
ependymoma
compris
two
clinic
molecularli
distinct
diseas
term
pfa
pfb
pfb
ependymoma
occur
often
older
children
exhibit
larg
degre
chromosom
instabl
favor
prognosi
pfa
ependymoma
aris
often
infant
chromosom
alter
associ
poor
surviv
purpos
studi
character
mutat
epigenet
landscap
pf
ependymoma
identifi
driver
tumourigenesi
target
therapi
method
perform
sequenc
pf
ependymoma
sequenc
pf
ependymoma
undertook
dna
methyl
profil
ependymoma
pf
ependymoma
illumina
microarray
pf
ependymoma
bisulfit
sequenc
find
support
pf
ependymoma
result
find
reveal
pf
ependymoma
harbour
stabl
mutat
landscap
exhibit
zero
recurr
mutat
code
space
contrast
widespread
epigenom
alter
level
dna
methyl
distinguish
pfa
pfb
demonstr
pfa
ependymoma
character
dna
hypermethyl
cpg
island
describ
cpg
island
methyl
phenotyp
cimp
dna
methyl
converg
upon
gene
known
silenc
complex
embryon
stem
cell
show
ependymoma
cultur
highli
sensit
inhibitor
dna
methyl
inhibitor
shown
vitro
vivo
conclus
studi
repres
first
subgroup
specif
therapi
shown
effect
pfa
ependymoma
suggest
agent
target
dna
methyl
andor
patient
harbour
ependymoma
may
efficaci
use
clinic
trial
combin
model
molecular
clinic
prognost
marker
enhanc
risk
stratif
medulloblastoma
djh
shih
pa
northcott
remk
korshunov
dtw
jone
kool
sm
pfister
md
taylor
development
stem
cell
biolog
hospit
sick
children
toronto
canada
divis
pediatr
neurooncolog
german
cancer
research
center
dkfz
heidelberg
germani
ccu
neuropatholog
german
cancer
research
center
dkfz
heidelberg
germani
object
medulloblastoma
compris
four
distinct
molecular
subgroup
wnt
shh
current
medulloblastoma
protocol
stratifi
patient
base
clinic
featur
patient
age
metastat
stage
extent
resect
histolog
variant
stark
prognost
genet
differ
four
subgroup
suggest
molecular
biomark
could
improv
patient
prognost
method
molecular
biomark
identifi
discoveri
set
medulloblastoma
citi
around
globe
combin
risk
stratif
model
design
base
clinic
cytogenet
biomark
identifi
multivari
cox
analys
identifi
biomark
test
use
fish
medulloblastoma
tissu
microarray
n
subsequ
valid
risk
stratif
model
result
subgroup
inform
improv
predict
accuraci
multivari
surviv
model
compar
clinic
biomark
alon
previous
publish
cytogenet
biomark
prognost
within
singl
medulloblastoma
subgroup
profil
fish
biomark
myc
ffpe
tissu
reliabl
reproduc
identifi
patient
within
shh
medulloblastoma
conclus
combin
subgroup
cytogenet
biomark
establish
clinic
biomark
substanti
improv
patient
prognost
even
context
heterogen
clinic
therapi
prognost
signific
molecular
biomark
restrict
specif
subgroup
identifi
small
panel
cytogenet
biomark
reliabl
identifi
group
patient
make
excel
tool
select
patient
therapi
intensif
therapi
futur
clinic
trial
mainten
molecular
subgroup
affili
metastat
medulloblastoma
x
wang
dubuc
korshunov
v
ramaswami
gendoo
mack
remk
e
bouffet
sm
pfister
md
taylor
development
stem
cell
biolog
hospit
sick
children
toronto
canada
ccu
neuropatholog
univers
heidelberg
heidelberg
germani
medic
biophys
princess
margaret
cancer
centr
toronto
canada
haematologyoncolog
hospit
sick
children
toronto
canada
haematologyoncolog
univers
heidelberg
heidelberg
germani
neurosurgeri
hospit
sick
children
toronto
canada
object
previou
genom
molecular
analys
reveal
medulloblastoma
compris
four
distinct
molecular
variant
distinct
genet
transcriptom
outcom
subgroup
affili
previous
shown
remain
stabl
time
recurr
like
reflect
distinct
cell
origin
howev
import
question
remain
unansw
subgroup
stabil
metastat
compart
method
assembl
cohort
tumor
collect
magic
consortium
establish
molecular
subgroup
affili
perform
integr
gene
express
methyl
analysi
frozen
tissu
collect
profil
use
affymetrix
gene
express
array
illumina
methyl
array
class
predict
hierarch
cluster
perform
use
exist
publish
dataset
result
molecular
analysi
establish
unequivoc
mainten
molecular
subgroup
affili
metastat
medulloblastoma
valid
find
interrog
cohort
tumor
burdenko
neurosurg
institut
use
orthogon
techniqu
immunohistochem
stain
confirm
perfect
concord
identifi
use
integr
molecular
analysi
molecular
subgroup
affili
primari
site
metastat
lesion
basi
immunohistochem
stain
conclus
investig
repres
largest
report
pair
cohort
profil
provid
uniqu
opportun
evalu
molecular
aberr
within
metastat
compart
although
previou
studi
shown
exist
clonal
evolut
metastat
compart
match
primari
tumor
mainten
subgroup
affili
present
treatment
opportun
target
event
find
support
notion
medulloblastoma
subgroup
aris
distinct
cell
origin
carri
forward
ontogeni
oncolog
recurr
medulloblastoma
highli
distinct
match
primari
tumor
l
garzia
morrissi
p
skowron
jelveh
p
lindsay
l
collier
dupuy
lagaerspada
r
hill
md
taylor
btrc
hospit
sick
children
toronto
canada
radiat
oncolog
princess
margaret
cancer
centr
toronto
canada
pharmacolog
univers
madison
usa
anatomi
cell
biolog
univers
iowa
iowa
citi
usa
depart
genet
univers
minnesota
minneapoli
usa
object
medulloblastoma
mb
common
paediatr
malign
brain
tumor
way
optim
surgeri
radiat
chemotherapi
medulloblastoma
treat
despit
best
therapi
diseas
recur
case
develop
protocol
studi
genet
differ
primari
recurr
tumor
vivo
use
transposon
mutagenesi
driven
mous
model
method
novel
murin
model
metastat
mb
highli
penetr
short
latenc
involv
random
secondari
genet
event
model
base
mobil
sleep
beauti
transposon
cerebella
ptch
mice
perform
surgic
remov
murin
tumor
treat
mice
craniospin
irradi
way
next
gener
sequenc
identifi
mutat
driver
gene
primari
tumor
compar
recurr
result
mice
treat
surgeri
csi
recur
local
smaller
fraction
recur
distal
recurr
diseas
spinal
cord
recurr
genet
diverg
match
primari
tumor
sequenc
primari
recurr
tumor
identifi
sever
potenti
synthet
lethal
gene
primari
relaps
driver
found
mutat
recurr
select
action
target
perform
vitro
radiosensit
assay
small
molecul
inhibitor
predict
driver
gene
show
revers
radiat
resist
conclus
primari
mb
highli
genet
differ
recurr
urg
scientif
commun
develop
differ
therapeut
approach
effici
target
primari
recurr
human
tumor
mous
model
show
rate
pattern
recurr
observ
human
patient
extrem
valuabl
translat
platform
design
new
strategi
recurr
mb
highli
target
event
gene
known
play
role
apoptosi
prolifer
potenti
driver
local
distal
mb
recurr
zoledron
reduc
risk
treatment
failur
osteosarcoma
result
french
multicentr
randomis
trial
l
brugier
mc
le
deley
f
p
h
pacquement
c
lervat
jc
gentet
n
entz
werl
b
bui
n
corradini
e
bompa
n
penel
md
tabon
g
de
pinieux
p
petit
k
buffard
jy
blay
gustav
roussi
villejuif
franc
epidemiolog
gustav
roussi
villejuif
franc
laboratoir
de
physiopathologi
de
la
osseus
et
therapi
de
tumeur
osseus
primit
umr
nant
franc
pediatri
chu
lyon
lyon
franc
pediatri
institut
curi
pari
franc
pediatri
centr
oscar
lambret
lill
franc
pediatri
chu
la
timon
marseil
franc
pediatri
chu
strasbourg
strasbourg
franc
pediatri
chu
bordeaux
bordeaux
franc
pediatri
chu
nant
nant
franc
pediatri
chu
nant
unicanc
nant
franc
pediatri
aphp
trousseau
pari
franc
danatomi
et
cytologi
pathologiqu
chu
tour
tour
franc
imageri
denfant
la
timon
marseil
franc
clinic
research
unicanc
pari
franc
pediatri
unicanc
chu
lyon
lyon
franc
medic
oncolog
institut
curi
pari
franc
object
base
effect
zoledron
vitro
experiment
model
rat
osteosarcoma
assess
whether
zoledron
z
combin
chemotherapi
surgeri
improv
surviv
ef
children
adult
osteosarcoma
method
experiment
treatment
consist
pre
postop
mginject
adult
mgkginject
younger
patient
chemotherapi
includ
childrenadolesc
adult
balanc
randomis
zarm
stratifi
centr
age
chemotherapi
type
risk
group
localis
resect
diseas
versu
unresect
primari
andor
metastas
studi
plan
superior
trial
three
interim
analys
earli
stop
efficaci
harm
disclos
independ
data
safeti
monitor
board
dsmb
patient
event
requir
achiev
detect
ef
versu
hr
event
zoledron
alpha
result
second
interim
analysi
perform
inclus
patient
localis
resect
tumour
recruit
z
signific
increas
toxic
found
z
except
expect
hypocalcemia
grade
p
median
year
event
death
report
includ
one
death
risk
failur
reduc
z
compar
hr
event
p
hr
death
p
result
similar
exclus
eight
zpatient
receiv
homogen
across
randomis
strata
futil
analysi
perform
dsmb
request
show
probabl
demonstr
benefit
follow
dsmb
recommend
trial
steer
committe
decid
stop
accrual
trial
conclus
current
addit
zoledron
chemotherapi
reduc
risk
failur
osteosarcoma
patient
model
therapi
identif
novel
repurpos
drug
class
activ
osteosarcoma
ahp
loh
aa
shelat
cl
bradley
fr
krafcik
gm
miller
dr
goshorn
e
stewart
vm
daryani
cf
stewart
aj
funk
p
vogel
dyer
depart
surgeri
st
jude
children
research
hospit
memphi
usa
depart
chemic
biolog
therapeut
st
jude
children
research
hospit
memphi
usa
depart
development
neurobiolog
st
jude
children
research
hospit
memphi
usa
depart
oncolog
st
jude
children
research
hospit
memphi
usa
depart
pharmaceut
scienc
st
jude
children
research
hospit
memphi
usa
anim
resourc
center
st
jude
children
research
hospit
memphi
usa
veterinari
patholog
core
st
jude
children
research
hospit
memphi
usa
depart
paediatr
surgeri
kk
women
children
hospit
singapor
object
treatment
outcom
osteosarcoma
stagnat
current
therapi
yet
mani
novel
drug
class
explor
integr
exist
regimen
sought
screen
novel
agent
repurpos
drug
cytotox
osteosarcoma
develop
preclin
model
human
therapi
order
integr
candid
compound
exist
treatment
regimen
method
iacuc
approv
orthotop
xenograft
human
osteosarcoma
creat
athym
nude
mice
femor
tumor
pulmonari
metastas
develop
recapitul
human
diseas
earli
phase
cultur
xenograft
tumor
osteosarcoma
cell
line
expos
compound
focus
drug
librari
grade
concentr
insol
combin
agent
hour
exposur
atp
cell
viabil
assay
use
determin
valu
rel
activ
compar
refer
curv
result
compound
formul
screen
assay
drug
sensit
profil
primari
metastat
tumor
show
minim
differ
use
rel
activ
threshold
sensit
activ
highest
hdac
proteasom
inhibitor
inhibitor
mek
mtor
lowest
parp
raf
erk
mek
inhibitor
panobinostat
hdac
inhibitor
greatest
potenc
class
hdac
inhibitor
show
addit
effect
combin
doxorubicin
separ
use
auc
dose
mice
subject
multimod
regimen
incorpor
methotrex
leucovorin
rescu
doxorubicin
cisplatin
ifosfamid
etoposid
hind
limb
amput
local
control
conclus
identifi
class
novel
repurpos
drug
activ
human
osteosarcoma
cell
hdac
inhibitor
particular
efficaci
effect
potenti
combin
doxorubicin
identifi
compound
test
use
preclin
regimen
priorit
agent
introduct
exist
clinic
protocol
whole
genom
exom
sequenc
reveal
heterogen
landscap
cancer
gene
osteosarcoma
behjati
ps
tarpey
mr
stratton
flanagan
pc
campbel
cancer
genom
project
wellcom
trust
sanger
institut
cambridg
unit
kingdom
cancer
institut
univers
colleg
london
london
unit
kingdom
object
aim
studi
describ
unbias
next
gener
sequenc
somat
alter
drive
osteosarcoma
method
seri
osteosarcoma
tumour
along
normal
tissu
dna
patient
select
base
avail
dna
subject
whole
genom
n
whole
exom
n
massiv
parallel
sequenc
seri
compris
paediatr
adolesc
n
adult
n
osteosarcoma
ten
case
aros
secondari
radiat
underli
cancer
predisposit
syndrom
class
mutat
ie
substitut
small
insert
delet
indel
structur
rearrang
copi
number
chang
call
use
analysi
pipelin
cancer
genom
project
result
overal
configur
genom
vari
greatli
term
mutat
burden
mutat
signatur
process
includ
chromothripsi
kataegi
strike
differ
found
paediatricadolesc
adult
osteosarcoma
focus
analysi
cancer
gene
landscap
cancer
gene
mutat
high
frequenc
includ
establish
osteosarcoma
driver
novel
cancer
gene
previous
implic
pathogenesi
osteosarcoma
also
identifi
howev
gener
mutat
low
frequenc
number
potenti
therapeut
target
identifi
includ
mutat
differ
tyrosin
kinas
receptor
conclus
landscap
cancer
gene
drive
osteosarcoma
markedli
heterogen
although
studi
identifi
cancer
gene
previous
implic
pathogenesi
osteosarcoma
novel
driver
mutat
high
frequenc
identifi
lack
osteosarcoma
specif
driver
distinguish
osteosarcoma
bone
tumour
other
studi
unbias
sequenc
nevertheless
find
may
guid
effort
utilis
target
therapeut
osteosarcoma
furthermor
find
enabl
studi
clinic
cohort
target
sequenc
cancer
gene
describ
investig
whether
tumour
genotyp
accur
predict
clinic
outcom
cess
cess
ewe
sarcoma
trial
h
juergen
c
hoffmann
u
dirksen
paulussen
ranft
pediatr
hematolog
oncolog
univers
hospit
muenster
germani
vestisch
und
jugendklinik
wittenherdeck
univers
datteln
germani
object
sinc
patient
ewe
sarcoma
treat
accord
consecut
protocol
cess
german
societi
pediatr
oncolog
hematolog
gpoh
post
treatment
surveil
also
includ
long
term
method
patient
pt
enter
cess
n
cess
n
ewe
sarcoma
trial
analyz
pt
male
femal
pt
local
metastat
diseas
median
age
diagnosi
year
rang
median
age
survivor
last
time
observ
year
rang
median
time
survivor
year
rang
result
pt
aliv
last
event
observ
pt
local
relaps
distant
relaps
combin
relaps
secondari
malign
surviv
ef
se
local
se
metastat
diseas
overal
surviv
os
se
local
se
metastat
diseas
late
morbid
avail
survivor
cardiovascular
renal
abnorm
secondari
amput
former
patient
rate
health
statu
less
good
poor
unemploy
year
last
year
handicap
pass
conclus
observ
crucial
pediatr
cancer
survivor
nearlyhalf
patient
earliest
phase
iii
ewe
sarcoma
trial
survivor
patient
recurr
approx
die
diseas
outcom
score
current
investig
observ
studi
inclus
guidelin
better
predict
qualiti
survivor
support
deutsch
krebshilf
support
bmbfdlr
prognosi
children
adolesc
soft
tissu
ewe
tumor
stet
treat
consecut
prospect
studi
cooper
weichsteilsarkom
studiengrupp
cw
e
koscielniak
dantonello
b
blank
g
seitz
leuschner
b
kazanowska
r
ladenstein
g
ljungman
f
niggli
bielack
e
hallmen
klingebiel
pediatr
oncologyhematolog
immunolog
olgahospit
klinikum
stuttgart
stuttgart
germani
depart
pediatr
surgeri
pediatr
urolog
univers
children
hospit
tuebingen
germani
depart
paidopatholog
univers
hospit
kiel
germani
depart
paediatr
bone
marrow
transplant
oncolog
hematolog
medic
univers
wroclaw
poland
children
cancer
research
institut
st
anna
children
hospit
vienna
austria
depart
pediatr
haematolog
oncolog
children
univers
hospit
uppsala
sweden
depart
pediatr
haematolog
oncolog
children
univers
hospit
switzerland
depart
pediatr
oncologyhematolog
immunolog
olgahospit
klinikum
stuttgart
stuttgart
germani
depart
pediatr
oncologyhematolog
hemostasi
univers
children
hospit
frankfurt
germani
object
intens
chemotherapi
cht
aggress
local
therapi
regard
golden
standard
treatment
ewe
sarcoma
howev
optim
extent
local
modal
still
known
differ
ewe
sarcoma
studi
differ
concern
cht
intens
recommend
local
therapi
present
therapi
result
patient
stet
treat
three
consecut
method
pt
age
yr
regist
n
n
cw
n
pt
ir
group
ii
iii
cw
combin
evaia
ifo
vcr
dox
actd
use
patient
random
drug
combin
vaia
ifo
dox
actd
vcr
vs
drug
cevai
instead
dox
plu
carboplatin
cw
vaia
plu
mainten
cht
cyclophosphamid
vinblastin
recommend
irradi
recommend
depend
result
primari
secondari
resect
result
yr
ef
os
overal
surviv
ef
os
studi
cw
respect
yr
ef
vaia
cevai
p
os
vs
p
ef
os
irradi
n
vs
irradi
patient
vs
vs
respect
conclus
prognosi
improv
cw
cevai
inferior
os
comparison
standard
regimen
vaia
stratif
criteria
allow
correct
alloc
irradi
addit
mainten
cht
cw
may
associ
improv
prognosi
examin
randomis
way
intens
surveil
affect
surviv
surgeri
sarcoma
result
random
noninferior
trial
puri
gulia
r
hawaldar
p
ranganathan
r
badw
orthopaed
oncolog
tata
memori
hospit
mumbai
india
object
hypothes
less
intens
follow
protocol
would
inferior
convent
follow
protocol
term
overal
surviv
os
ask
whether
chest
radiograph
follow
group
inferior
ct
scan
follow
group
term
detect
pulmonari
metastasi
whether
less
frequent
monthli
follow
interv
inferior
frequent
monthli
follow
group
term
detect
pulmonari
metastasi
local
recurr
method
prospect
random
non
inferior
trial
conduct
januari
june
non
metastat
patient
random
demonstr
non
inferior
margin
delta
hazard
ratio
hr
primari
end
point
os
year
result
minimum
follow
month
median
month
rang
month
year
os
df
patient
respect
os
chest
radiographi
ct
group
respect
hr
upper
confid
interv
ci
df
rate
chest
radiographi
ct
group
respect
hr
upper
ci
os
group
respect
hr
upper
ci
df
group
respect
hr
upper
ci
conclus
inexpens
imag
detect
vast
major
recurr
diseas
patient
sarcoma
without
deleteri
effect
eventu
outcom
although
less
frequent
visit
adequ
detect
metastasi
local
recurr
trial
could
conclus
demonstr
non
inferior
os
interv
follow
visit
monthli
might
function
small
sampl
size
longer
follow
larger
popul
may
confirm
find
stand
pin
needl
pattern
sever
peripher
neuropathi
children
acut
lymphoblast
leukemia
first
year
treatment
e
smith
l
lang
r
ho
em
well
rj
hutchinson
j
skile
chakraborti
cw
chiang
k
thoma
j
renbarg
school
nurs
univers
michigan
ann
arbor
usa
depart
medic
molecular
genet
center
comput
biolog
bioinformat
school
medicin
indiana
univers
indianapoli
usa
depart
pediatr
vanderbilt
univers
school
medicin
nashvil
usa
depart
neurolog
brain
tumor
institut
children
nation
washington
dc
usa
depart
pediatr
univers
michigan
school
medicin
ann
arbor
usa
depart
pediatr
indiana
univers
school
medicin
indianapoli
usa
depart
medic
molecular
genet
center
comput
biolog
bioinformat
indiana
univers
school
medicin
indianapoli
usa
indiana
univers
school
medicineriley
hospit
children
indiana
univers
school
medicin
indianapoli
usa
object
studi
purpos
describ
peripher
neuropathi
vipn
pattern
sever
children
preb
acut
lymphoblast
leukemia
first
year
treatment
method
newli
diagnos
children
year
age
receiv
vincristin
maximum
per
children
oncolog
group
cog
treatment
trial
recruit
four
site
indiana
univers
univers
michigan
vanderbilt
univers
children
nation
evalu
quantifi
vipn
base
symptom
physic
examin
use
total
neuropathi
vincristin
addit
assess
conduct
use
vipn
assess
first
year
therapi
data
analyz
use
descript
statist
correl
pair
cluster
analysi
vincristin
dose
densiti
curv
calcul
use
kernel
densiti
function
result
vipn
assess
n
perform
equal
number
male
femal
caucasian
mean
age
sd
year
rang
score
pattern
similar
score
reveal
granular
detail
regard
specif
sign
symptom
reflex
affect
meansd
rang
vipn
score
peak
month
approxim
two
month
reach
maximum
vincristin
dose
densiti
illustr
coast
effect
vipn
improv
month
despit
decreas
dose
densiti
vipn
score
posit
associ
age
p
gender
cluster
analys
result
reveal
children
n
experienc
sever
vipn
unrel
dose
densiti
conclus
vipn
sever
six
month
onset
treatment
improv
first
year
treatment
despit
decreas
dose
densiti
cluster
analysi
identifi
cohort
children
risk
develop
sever
vipn
research
ongo
elucid
baselin
predict
signatur
identifi
patient
genet
variant
associ
cardiotox
children
h
visscher
cj
ross
sr
rassekh
gs
sandor
hn
caron
ec
van
dalen
hj
van
der
pal
lc
kremer
bc
carleton
mr
hayden
depart
pediatr
amalia
children
hospitalradboud
univers
medic
centr
nijmegen
netherland
centr
molecular
medicin
therapeut
child
famili
research
institut
univers
british
columbia
vancouv
canada
divis
pediatr
hematologyoncologybmt
depart
pediatr
univers
british
columbia
vancouv
canada
divis
pediatr
cardiolog
depart
pediatr
univers
british
columbia
vancouv
canada
depart
pediatr
oncolog
emma
children
hospitalacadem
medic
center
amsterdam
netherland
divis
translat
therapeut
depart
pediatr
univers
british
columbia
vancouv
canada
object
risk
cardiotox
act
seriou
advers
drug
reaction
cancer
therapi
part
mediat
genet
variat
recent
sever
genet
variant
predict
act
children
identifi
replic
studi
aim
identifi
addit
genet
variant
associ
act
assess
whether
variant
could
improv
act
risk
predict
model
method
carri
associ
studi
discoveri
cohort
seriou
act
case
control
replic
independ
cohort
case
control
sampl
genotyp
singl
nucleotid
polymorph
snp
key
gene
relev
drug
transport
metabol
toxic
predict
model
includ
genet
clinic
risk
factor
train
discoveri
cohort
assess
replic
cohort
result
identifi
signific
genet
associ
act
discoveri
cohort
two
snp
p
p
respect
subsequ
replic
p
p
combin
odd
ratio
ci
ci
addit
evid
associ
found
variant
sever
gene
relat
oxid
stress
ad
two
variant
risk
predict
model
improv
discrimin
abil
area
curv
auc
combin
cohort
p
conclus
identifi
replic
two
novel
genet
variant
predict
act
addit
variant
risk
predict
model
improv
model
could
use
risk
stratif
patient
may
benefit
altern
treatment
strategi
intens
cardiotox
monitor
prevent
treatment
measur
metabol
syndrom
cardiac
dysfunct
adult
survivor
childhood
cancer
result
st
jude
lifetim
cohort
studi
gt
armstrong
v
joshi
k
ness
n
zhang
srivastava
da
mulrooney
th
marwick
mm
hudson
robison
jc
plana
epidemiolog
cancer
control
st
jude
children
research
hospit
memphi
usa
pediatr
cardiolog
univers
tennesse
health
scienc
memphi
usa
biostatist
st
jude
children
research
hospit
memphi
usa
oncolog
st
jude
children
research
hospit
memphi
usa
cardiolog
menzi
research
institut
hobart
australia
cardiolog
cleveland
clinic
cleveland
usa
object
cardiac
dysfunct
anthracyclin
chemotherapi
radiotherapi
rt
well
establish
addit
contribut
tradit
cardiovascular
risk
factor
metabol
syndrom
age
survivor
less
well
defin
method
analysi
includ
yr
survivor
median
age
yr
rang
echo
includ
systol
ef
abnorm
diastol
function
grade
abnorm
global
longitudin
circumferenti
myocardi
strain
metabol
syndrom
defin
use
iii
criteria
logist
regress
poisson
regress
adjust
current
age
age
diagnosi
raceethn
sex
chest
rt
anthracyclin
exposur
calcul
odd
ratio
or
rel
risk
rr
confid
interv
ci
result
systol
dysfunct
detect
diastol
dysfunct
abnorm
strain
longitudin
circumferenti
survivor
metabol
syndrom
obes
triglycerid
hdl
cholesterol
abnorm
hypertens
diabet
metabol
syndrom
associ
increas
risk
diastol
dysfunct
ci
strain
abnorm
longitudin
rr
ci
circumferenti
rr
ci
reduc
ef
ci
conclus
although
ef
preserv
metabol
syndrom
increas
risk
diastol
dysfunct
systol
dysfunct
detect
longitudin
myocardi
strain
independ
chest
rt
anthracyclin
exposur
intervent
prevent
metabol
syndrom
may
reduc
cardiac
risk
consid
advers
social
outcom
survivor
childhood
cancer
medic
record
linkag
studi
eam
feijen
e
van
broeder
hj
van
der
pal
ml
rb
gesku
h
grootenhui
hn
caron
lc
kremer
depart
pediatr
oncolog
emma
children
hospitalacadem
medic
center
amsterdam
netherland
depart
pediatr
oncologyhematolog
vu
univers
medic
center
amsterdam
netherland
depart
medic
oncolog
emma
children
hospitalacadem
medic
center
amsterdam
netherland
depart
social
medicin
academ
medic
center
amsterdam
netherland
depart
clinic
epidemiolog
biostatist
bioinformat
academ
medic
center
amsterdam
netherland
pediatr
psychosoci
depart
academ
medic
center
amsterdam
netherland
object
determin
likelihood
advers
social
outcom
marriedregist
partner
live
independ
use
social
benefit
adult
childhood
cancer
survivor
cc
compar
gener
dutch
popul
method
link
complet
cohort
cc
treat
emma
children
hospitalacadem
medic
center
n
two
administr
regist
municip
person
record
databas
dutch
acronym
gba
social
econom
categori
regist
dutch
acronym
secmbu
includ
cc
diagnos
age
year
studi
period
aliv
januari
retriev
anonym
social
outcom
data
last
year
person
regist
gba
compar
randomli
select
sampl
gener
dutch
popul
obtain
gba
match
gender
year
birth
calendar
year
per
cc
retriev
sampl
rate
maximum
conduct
multivari
logist
regress
analysi
estim
likelihood
marriedregist
partner
live
independ
use
social
benefit
compar
gener
dutch
popul
furthermor
use
multivari
logist
regress
within
cc
group
analyz
associ
risk
factor
advers
social
outcom
result
complet
linkag
obtain
group
uniqu
cc
refer
person
respect
individu
retriev
gba
inform
social
outcom
cc
higher
likelihood
odd
ratio
confid
interv
marriedregist
partner
live
independ
use
social
benefit
compar
gener
popul
radiotherapi
without
surgeri
increas
likelihood
use
social
benefit
well
central
nervou
system
tumor
diagnosi
conclus
target
prevent
advers
social
outcom
need
consider
increas
possibl
survivor
develop
social
line
peer
hospit
among
adult
survivor
childhood
cancer
treat
stem
cell
transplant
schechter
pc
nathan
gassa
ali
agha
ml
greenberg
j
pole
divis
hematologyoncolog
hospit
sick
children
toronto
canada
research
unit
pediatr
oncolog
group
ontario
toronto
canada
object
knowledg
regard
burden
morbid
hsct
pediatr
cancer
survivor
reach
adulthood
spars
frequenc
hospit
serv
proxi
measur
morbid
popul
aim
studi
assess
number
hospit
episod
adult
survivor
childhood
malign
treat
hsct
method
use
record
linkag
sickkid
clinic
transplant
databas
canadian
provinc
ontario
pediatr
cancer
registri
pogoni
health
care
util
data
hous
institut
clinic
evalu
scienc
ice
studi
popul
includ
adult
year
post
transplant
survivor
childhood
cancer
treat
allogeneicautolog
hsct
sickkid
result
adult
survivor
follow
mean
year
allogen
autolog
hsct
mean
age
hsct
sd
sd
allogen
autolog
group
respect
hospit
document
adult
post
allogen
hsct
repres
rate
hospit
per
year
univari
analysi
reveal
age
year
cancer
diagnosi
rr
ci
age
year
hsct
rr
ci
femal
gender
rr
ci
associ
increas
rate
hospit
underli
diagnosi
vs
aml
associ
increas
rate
hospit
despit
use
tbi
among
patient
hospit
document
adult
post
autolog
hsct
repres
rate
hospit
per
year
age
time
hsct
rr
ci
femal
gender
rr
ci
associ
increas
rate
hospit
conclus
age
year
time
hsct
femal
gender
associ
increas
risk
hospit
futur
studi
focu
length
stay
indic
hospit
posttranspl
lymphoprolif
disord
pediatr
transplant
recipi
c
sergi
yu
girgi
b
chiu
depart
lab
med
patholog
univers
alberta
hospit
edmonton
canada
object
recipi
solid
organ
transplant
sot
carri
substanti
increas
risk
develop
posttranspl
lymphoprolif
disord
ptld
excess
risk
cancer
larg
due
immunosuppress
oncogen
viru
infect
object
perform
clinicopatholog
review
ptld
pediatr
transplant
institut
materi
method
recipi
pediatr
age
transplant
year
sot
review
ptld
classifi
use
criteria
ptld
earli
ptld
monomorph
organsit
involv
nodal
extranod
result
sot
perform
ptld
develop
patient
patient
age
mean
rang
case
classifi
earli
ptld
case
monomorph
ptld
latenc
period
ptld
onset
rang
month
year
involv
nodal
site
extranod
site
gi
tract
lung
upper
aerodigest
tract
liver
commonli
involv
diffus
larg
lymphoma
case
common
cancer
type
associ
ebv
infect
cumul
incid
rate
ptld
pediatr
heart
transplant
lung
transplant
recipi
respect
conclus
ptld
rel
common
pediatr
recipi
sot
commonli
involv
nodal
extranod
site
particular
organ
lymphoid
tissu
malt
oncogen
virus
especi
ebv
play
etiolog
role
develop
ptld
pediatr
transplant
popul
neuroblastoma
neuroblastoma
risk
classif
model
develop
countri
studi
intern
neuroblastoma
nb
risk
group
inrg
databas
w
london
v
moroz
b
hero
jr
park
nakagawara
f
berthold
kk
matthay
g
schleiermach
machin
pediatr
hematologyoncolog
children
cancer
blood
disord
center
boston
usa
cancer
research
uk
clinic
trial
unit
univers
birmingham
birmingham
unit
kingdom
pediatr
oncolog
univers
children
hospit
koln
germani
pediatr
hematologyoncolog
seattl
children
hospit
seattl
wa
usa
pediatr
adolesc
oncolog
gustav
roussi
institut
universit
villejuif
franc
pediatr
oncolog
chiba
cancer
research
institut
chiba
japan
pediatr
oncolog
univers
cologn
cologn
germani
pediatr
hematologyoncolog
univers
california
san
francisco
san
francisco
usa
pediatr
oncolog
inserm
institut
curi
pari
franc
biostatist
univers
leicest
leicest
unit
kingdom
object
current
method
stratifi
nb
patient
diagnosi
inrg
group
base
prognost
clinic
genom
histolog
factor
cohn
et
al
jco
develop
countri
test
tumor
genom
biomark
histolog
featur
possibl
howev
clinic
test
serum
ferritin
serum
lactat
dehydrogenas
ldh
like
avail
method
retrospect
analysi
includ
inrg
patient
suffici
data
clinic
risk
factor
surviv
ef
surviv
tree
regress
perform
consid
age
month
month
inss
stage
ferritin
ldh
patient
categor
clinic
risk
group
ef
low
low
intermedi
high
risk
ef
time
diagnosi
first
event
relapseprogress
second
malign
death
last
contact
event
occur
result
inrg
patient
abl
risk
classifi
accord
inrg
definit
includ
genom
histolog
factor
known
agestageldhferritin
clinic
risk
group
assign
low
n
low
n
intermedi
n
high
n
ef
respect
clinic
risk
classif
similar
inrg
patient
base
ef
inrg
overestim
risk
clinic
factor
correctli
assign
risk
patient
clinic
factor
overestim
underestim
risk
inrg
correctli
assign
risk
patient
conclus
patient
clinic
factor
age
stage
ferritin
ldh
well
better
clinic
genom
patholog
factor
current
use
inrg
group
assign
risk
stratif
show
promis
develop
countri
assign
treatment
intens
wherebi
patient
spare
unnecessari
expens
chemotherapi
risk
factor
within
european
high
risk
neuroblastoma
trial
r
ladenstein
u
poetschger
r
luksch
elliot
v
castel
yaniv
v
papadaki
j
mali
p
kogner
studi
statist
integr
research
children
cancer
research
institut
vienna
austria
paediatr
oncolog
haematolog
istituto
nazional
tumori
di
milano
milano
itali
paediatr
oncolog
haematolog
leed
gener
hospit
leed
unit
kingdom
paediatr
oncolog
unit
hospit
la
fe
valencia
valencia
spain
paediatr
oncolog
haematolog
schneider
children
medial
center
israel
petach
tikvah
israel
paediatr
oncolog
haematolog
agia
sofia
children
hospit
athen
greec
paediatr
oncolog
haematolog
univers
hospit
motol
pragu
czech
republ
paediatr
oncolog
haematolog
karolinska
hospit
stockholm
sweden
paediatr
adolesc
oncolog
depart
institut
gustav
roussi
villejuif
franc
object
evalu
unselect
patient
cohort
trial
includ
patient
method
sinc
trial
accru
countri
centr
patient
pt
inss
stage
elig
pt
mycn
amplif
mna
stage
mna
age
median
age
four
randomis
question
address
rapid
cojec
modifi
induct
pt
insuffici
respons
receiv
addit
line
treatment
ie
tvd
cours
proceed
myeloabl
therapi
bumel
cem
mibg
contain
regim
local
control
aim
complet
surgic
resect
achiev
radiotherapi
gy
primari
tumour
site
till
mainten
treatment
ra
alon
mab
base
immunotherapi
introduc
modif
toward
randomis
question
date
receiv
base
hour
infus
scheme
result
stage
pt
mna
frequenc
yr
ef
os
pt
rate
stage
mna
stage
lower
rate
infant
stage
pt
prognosi
declin
age
infant
pt
yr
show
compar
outcom
n
follow
pt
n
pt
n
partial
respons
better
frequent
observ
younger
children
follow
rate
age
group
yr
age
conclus
stage
age
remain
major
prognost
factor
whilst
mna
pt
clearli
benefit
intensif
imag
defin
risk
factor
idrf
neuroblastoma
incid
evolut
treatment
correl
surgic
outcom
l
pio
c
granata
g
erminio
k
holm
h
rubi
p
buffa
v
castel
sarnacki
r
haupt
pediatr
surgeri
unit
istituto
giannina
gaslini
dinogmi
univers
genoa
genoa
itali
pediatr
radiolog
unit
istituto
giannina
gaslini
genoa
itali
epidemiolog
biostatist
committe
unit
istituto
giannina
gaslini
genoa
itali
depart
pediatr
surgeri
st
georg
hospit
london
unit
kingdom
unit
children
hospit
toulous
toulous
franc
pediatr
surgeri
unit
istituto
giannina
gaslini
genoa
itali
pediatr
oncolog
unit
hospit
la
fe
valencia
spain
oncologi
ghu
clcc
institut
de
gustav
roussi
pari
franc
pediatr
surgeri
depart
necker
enfant
malad
hospit
pari
descart
univers
pari
franc
object
describ
idrf
preval
among
patient
enrol
european
unresect
neuroblastoma
eunb
studi
evalu
modif
chemotherapi
influenc
surgic
outcom
method
idrf
report
treat
physician
imag
report
review
code
specif
idrf
assign
idrf
relat
size
tumour
big
patient
exlud
studi
surgic
outcom
relat
idrf
respons
chemoterapi
result
patient
enrol
eunb
studi
exclud
imag
pre
second
surgeri
big
tumor
stage
first
surgeri
evalu
patient
total
idrf
frequent
encas
carotid
sheath
cervic
tumour
n
infiltr
left
junction
thorax
n
infiltr
renal
pedicl
abdomen
n
follow
chemotherapi
idrf
disappear
new
appear
complet
idrf
disappear
observ
patient
decreas
number
persist
patient
chang
disappear
appear
new
idrf
idrf
number
increas
second
surgeri
perform
patient
cr
mrd
chemotherapi
still
inoper
patient
underw
second
surgeri
biopsi
incomplet
tumor
excis
minim
residu
complet
resect
complet
resect
minim
residu
frequent
among
children
numer
reduct
idrf
p
conclus
chemotherapi
effect
idrf
patient
new
idrf
appear
despit
chemotherapi
second
surgeri
success
patientstumor
chemotherapi
relat
respons
document
revis
risk
estim
treatment
stratif
neuroblastoma
patient
integr
clinic
molecular
prognost
marker
fischer
oberthu
juraeva
r
schmidt
faldum
f
berthold
f
westermann
b
bror
simon
b
hero
pediatr
oncolog
univers
cologn
cologn
germani
theoret
bioinformat
german
cancer
research
center
heidelberg
germani
biostatist
clinic
research
univers
muenster
muenster
germani
tumor
genet
german
cancer
research
center
heidelberg
germani
object
precis
risk
estim
essenti
avoid
overtreat
neuroblastoma
patient
optim
neuroblastoma
treatment
stratif
aim
develop
novel
risk
estim
system
integr
gene
classif
establish
prognost
marker
method
gene
express
profil
gener
primari
neuroblastoma
classif
model
built
use
train
set
tumor
contrast
cours
diseas
subsequ
valid
independ
test
set
n
estim
multivari
cox
regress
analys
use
assess
prognost
variabl
investig
result
classifi
consist
probe
correspond
gene
predict
patient
outcom
accuraci
sensit
specif
valid
cohort
highest
potenti
clinic
valu
classifi
observ
current
intermedi
risk
lr
ir
respect
patient
classifi
significantli
distinguish
patient
diverg
outcom
lr
os
vs
ir
os
vs
p
multivari
cox
regress
model
risk
patient
classifi
outperform
risk
assess
current
german
trial
ef
hr
os
hr
p
base
find
develop
revis
risk
stratif
system
lrir
neuroblastoma
patient
integr
establish
prognost
marker
classifi
accord
system
newli
identifi
patient
subgroup
poor
outcom
ef
propos
intensifi
treatment
patient
subgroup
benefici
outcom
ef
may
benefit
treatment
conclus
integr
gene
classif
establish
prognost
marker
improv
risk
estim
lrir
neuroblastoma
patient
propos
implement
revis
risk
assess
treatment
stratif
system
upcom
prospect
clinic
trial
lrir
matur
immatur
teratoma
result
second
pediatr
aieop
associazion
italiana
di
ematologia
oncologia
pediatrica
italian
studi
terenziani
g
cecchetto
inserra
f
siracusa
r
boldrini
p
dall
igna
g
riccipetitoni
g
bisogno
cont
p
indolfi
md
de
pasqual
f
spreafico
p
tamaro
p
dangelo
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
pediatr
surgeri
unit
azienda
padova
itali
pediatr
surgeri
divis
ospedal
pediatrico
bambino
ircc
roma
itali
pediatr
depart
di
palermo
palermo
itali
patholog
unit
ospedal
pediatrico
bambino
ircc
roma
itali
pediatr
surgeri
unit
ospedal
dei
bambini
buzzi
milano
itali
divis
azienda
padova
itali
divis
istituto
giannina
gaslini
genova
itali
pediatr
oncolog
unit
seconda
degli
studi
di
napoli
napoli
itali
divis
ospedal
pediatrico
bambino
ircc
roma
itali
divis
ospedal
pediatrico
burlo
garofalo
triest
itali
divis
ospedal
pediatrico
g
di
cristina
palermo
itali
object
teratoma
demonstr
benign
clinic
behavior
howev
may
recur
malign
compon
small
group
patient
prognosi
fatal
protocol
malign
germ
cell
tumor
mgct
context
aieop
collect
patient
evalu
prognost
factor
type
relaps
outcom
method
patient
enrol
initi
evalu
includ
clinic
examin
tumour
marker
imag
procedur
surgic
resect
recommend
uniqu
treatment
immatur
classifi
grade
result
matur
mt
diagnos
patient
respect
median
age
month
f
ratio
patient
gonad
tumor
ovarian
testicular
extragonad
sacrococcyx
sc
mediastinum
retroperitoneum
site
patient
show
associ
congenit
tumor
complet
resect
perform
patient
partial
resect
biopsi
one
event
occur
patient
contralater
metachron
ovarian
develop
adren
neuroblastoma
patient
relaps
local
mt
within
median
time
month
diagnosi
mgct
compon
malign
transform
two
patient
die
one
progress
grade
surgic
complic
median
month
ef
rf
os
follow
respect
analyz
mt
separ
os
ef
respect
conclus
show
good
prognosi
especi
one
surgeri
remain
standard
approach
howev
rare
case
especi
partial
resect
may
progress
repres
real
challeng
term
treatment
outcom
childhood
malign
germ
cell
tumor
mgct
treat
carboplatin
base
chemotherapi
centr
experi
pakistan
r
khan
ashraf
children
cancer
hospit
children
cancer
hospit
karachi
pakistan
object
studi
clinicopatholog
featur
outcom
children
mgct
treat
carboplatin
etoposid
bleomycin
jeb
cch
pakistan
method
retrospect
studi
cch
children
less
year
diagnos
extracrani
germ
cell
tumor
januari
till
treat
carboplatin
base
chemotherapi
includ
etoposid
bleomycin
jeb
without
risk
stratif
demographi
clinic
present
primari
site
histopatholog
stage
treatment
receiv
review
outcom
analyz
result
total
patient
includ
male
femal
ratio
median
age
present
year
rang
month
year
median
durat
symptom
month
day
year
abdomin
distent
pain
common
symptom
patient
gonad
germ
cell
tumor
ggct
ovarian
testicular
tumor
extragonad
tumor
sacrococcyg
teratoma
common
yolk
sac
tumor
common
histopatholog
diagnosi
follow
mix
gct
teratoma
dysgerminoma
gonad
tumor
receiv
chemotherapi
patient
receiv
cycl
jeb
chemotherapi
patient
complet
treatment
left
die
chemotherapi
progress
diseas
patient
stage
diseas
stage
stage
iii
stage
iv
diseas
overal
surviv
os
respect
patient
receiv
chemotherapi
os
ggct
extragonad
os
whole
cohort
conclus
carboplatin
base
chemotherapi
shown
good
surviv
children
ggct
suboptim
surviv
extragonad
case
could
due
advanc
diseas
poor
local
control
ovarian
sertoli
leydig
cell
tumor
children
adolesc
analysi
european
cooper
studi
group
pediatr
rare
tumor
expert
dt
schneider
orbach
g
cecchetto
ib
brecht
b
brummel
g
bisogno
ferrari
reguerr
j
godzinski
g
calaminu
c
patt
clinic
pediatr
klinikum
dortmund
dortmund
germani
pediatr
oncolog
institut
curi
pari
franc
pediatr
surgeri
univers
padova
padova
itali
pediatr
hematolog
oncolog
endocrinolog
medic
univers
gdansk
gdansk
poland
pediatr
hematolog
oncolog
univers
erlangen
erlangen
germani
pediatr
oncolog
univers
padova
padova
itali
pediatr
oncolog
istituto
nazional
tumori
milan
itali
pediatr
oncolog
centro
anger
franc
pediatr
surgeri
wroclaw
medic
univers
wroclaw
poland
pediatr
hematolog
oncolog
univers
germani
pediatr
hematolog
oncolog
institut
gustav
roussi
pari
franc
object
analyz
ovarian
cell
tumor
slct
potenti
prognost
marker
use
treatment
stratif
method
patient
includ
patient
prospect
report
german
makei
studi
n
french
tgm
protocol
n
italian
trep
registri
n
polish
pediatr
rare
tumor
studi
group
n
tumor
classifi
accord
stage
accord
figo
result
median
age
year
patient
underw
resect
tumor
enucl
n
ovariectomi
n
adnectomi
isol
n
hysterectomi
n
ia
pt
ic
pt
iiiii
pt
one
patient
bilater
tumor
four
patient
stage
ia
stage
ic
develop
metachron
contralater
tumor
otherwis
stage
ia
patient
remain
complet
remiss
among
patient
incomplet
resect
tumor
spread
stage
relaps
patient
die
eleven
patient
initi
treat
cycl
chemotherapi
seven
patient
continu
remiss
poor
histolog
differenti
associ
higher
relaps
rate
compar
intermedi
high
differenti
tumor
retiform
pattern
heterolog
element
show
high
relaps
rate
median
month
surviv
surviv
overal
surviv
conclus
prognosi
slct
determin
stage
histopatholog
differenti
complet
resect
care
avoid
spillag
prerequisit
cure
impact
chemotherapi
incomplet
resect
advanc
stage
tumor
remain
evalu
sex
cord
stromal
tumor
children
teenag
result
studi
b
fresneau
orbach
c
c
verit
mp
castex
n
kalfa
h
martelli
c
patt
pediatr
oncolog
gustav
roussi
villejuif
franc
pediatr
oncolog
institut
curi
pari
franc
pediatr
oncolog
institut
et
doncologi
lyon
franc
pediatr
oncolog
centr
hospitali
universitair
bordeaux
franc
pediatr
oncolog
centr
hospitali
universitair
toulous
franc
pediatr
surgeri
centr
hospitali
universitair
montpelli
franc
pediatr
surgeri
centr
hospitali
universitair
le
franc
object
sex
cord
stromal
tumor
sct
rare
children
teenag
account
malign
gonad
tumor
present
result
nation
sfce
trial
ovarian
testicular
sct
method
franc
children
ovarian
testicular
sct
prospect
regist
primari
gonad
resect
recommend
whenev
feasibl
complet
surgeri
patient
dissemin
diseas
incomplet
resect
receiv
neoadjuv
adjuv
cycl
vip
etoposid
ifosfamid
cisplatinum
everi
week
result
ovarian
sct
regist
median
age
endocrin
symptom
present
case
histolog
diagnos
juvenil
adult
granulosa
cell
tumor
cell
tumor
mix
germ
primari
oophorectomi
salpingectomi
led
complet
resect
patient
receiv
adjuv
treatment
two
relaps
year
periton
contralater
achiev
complet
remiss
surgeri
vip
fifteen
patient
primari
incomplet
resect
due
tumor
ruptur
andor
malign
ascit
receiv
vip
recurr
median
receiv
chemotherapi
relaps
month
fatal
outcom
case
cell
tumor
os
ef
eleven
patient
local
testicular
tumor
median
age
juvenil
granulosa
cell
tumor
sertoli
andor
leydig
cell
tumor
otherwis
specifi
sct
treatment
surgeri
alon
inguin
orchiectomi
none
relaps
median
conclus
childhood
ovarian
sct
surgeri
complet
complet
resect
neoadjuv
chemotherapi
necessari
tumor
ruptur
formal
indic
adjuv
chemotherapi
effici
prevent
recurr
childhood
testicular
sct
prognosi
excel
inguin
orchiectomi
rais
debat
testi
spare
surgeri
epidemiolog
earli
diagnosi
influenc
train
primari
health
care
profession
suspicion
pediatr
cancer
brazil
v
junqueira
project
instituto
ronald
mcdonald
rio
de
janeiro
brazil
object
brazil
cancer
lead
caus
death
diseas
among
children
adolesc
year
region
brazil
time
symptom
diagnosi
pediatr
cancer
long
mani
patient
refer
treatment
advanc
stage
ngo
instituto
ronald
mcdonald
irm
develop
earli
diagnosi
program
build
capac
primari
health
care
worker
context
primari
health
care
program
call
famili
health
strategi
esf
cover
approxim
popul
thu
consid
crucial
chang
scenario
dissemin
knowledg
main
sign
symptom
diseas
among
profession
evalu
perform
health
primari
care
profession
suspicion
pediatr
cancer
brazil
method
train
health
worker
order
promot
earli
diagnosi
childhood
cancer
live
learn
cours
hour
workload
per
train
within
week
class
includ
discuss
health
manag
local
content
cover
everyth
organ
nation
polici
cancer
care
role
esf
profession
earli
diagnosi
cancer
book
freeli
distribut
irm
develop
partnership
brazilian
societi
pediatr
oncolog
nation
cancer
institut
besid
multicent
survey
measur
impact
program
locat
project
execut
perform
result
program
exist
sinc
alreadi
train
profession
team
state
impact
year
children
adolesc
invest
r
us
conclus
region
program
implement
increas
number
children
refer
suspect
cancer
averag
delay
time
referr
diagnosi
fell
receiv
train
week
fetal
macrosomi
risk
factor
childhood
lymphoma
nationwid
swedish
cohort
studi
skalkid
e
petrid
sergentani
c
antonopoulo
n
dessypri
svensson
stephansson
h
kieler
k
smedbi
dept
women
children
health
uppsala
univers
uppsala
sweden
dept
hygien
epidemiolog
medic
statist
univers
athen
medic
school
athen
greec
unit
clinic
epidemiolog
centr
pharmacoepidemiolog
depart
medicin
solna
karolinska
institutet
stockholm
sweden
object
birth
weight
explor
risk
factor
sever
type
childhood
year
cancer
nationwid
swedish
cohort
studi
aim
evalu
associ
crude
adjust
characterist
fetal
growth
birth
weight
length
head
circumfer
ponder
index
larg
gestat
lymphoma
nhl
risk
method
singleton
live
birth
includ
among
incid
nhl
case
age
year
diagnos
identifi
linkag
swedish
cancer
regist
proport
hazard
model
use
estim
hazard
ratio
hr
confid
interv
ci
nhl
core
multivari
model
includ
infant
sex
matern
educ
matern
age
deliveri
birth
order
index
child
child
gestat
age
latter
omit
analys
sga
aga
lga
variabl
appropri
result
male
sex
associ
doubl
nhl
risk
hr
ci
lga
birth
weight
birth
weight
per
se
associ
increas
nhl
risk
hr
ci
subgroup
analys
sex
latter
associ
confin
particularli
femal
hr
ci
growth
variabl
consist
associ
nhl
risk
prossibl
due
smaller
variat
measur
error
conclus
fetal
macrosomi
seem
repres
consider
risk
factor
childhood
nhl
wherea
effect
may
differ
gender
approach
assess
associ
sole
use
crude
birth
weight
proxi
seem
inadequ
given
elabor
lga
indic
may
portray
acceler
intrauterin
growth
meaning
compon
futur
studi
aim
disentangl
physiolog
mechan
underli
relev
associ
late
mortal
among
survivor
earli
onset
cancer
regist
studi
kero
ls
arola
n
malila
lm
j
pm
pediatr
turku
univers
hospit
turku
finland
pediatr
tamper
univers
hospit
tamper
finland
finnish
cancer
registri
helsinki
finland
object
investig
mortal
among
survivor
earli
onset
cancer
age
year
diagnosi
death
extend
method
survivor
cohort
identifi
via
finnish
cancer
registri
mortal
data
extract
nation
death
certif
file
statist
finlanda
total
cancer
survivor
surviv
least
year
age
less
year
cancer
diagnosi
identifi
healthi
sibl
cohort
gener
popul
data
serv
refer
cumul
mortal
among
cancer
survivor
standard
mortal
rate
smr
compar
gener
popul
data
hazard
ratio
hr
caus
death
compar
healthi
sibl
cohort
analyz
result
overal
standard
mortal
ratio
smr
cancer
patient
ci
highest
smr
found
malign
ci
infecti
ci
cardiovascular
diseas
ci
malign
cardiovascular
diseas
account
largest
death
number
childhood
ya
cancer
survivor
primari
cancer
diagnosi
display
elev
overal
smr
rang
except
markedli
higher
valu
childhood
hodgkin
lymphoma
highest
cumul
mortal
due
cardiovascular
diseas
steadi
rise
throughout
strongli
depend
primari
cancer
diagnosi
age
diagnosi
differ
survivor
ya
malign
reduct
cumul
cardiovascular
mortal
observ
childhood
cancer
survivor
toward
recent
treatment
period
howev
overal
mortal
show
declin
tendenc
toward
recent
period
childhood
ya
cancer
conclus
find
mortal
stress
need
set
individu
focu
cardiovascular
late
effect
earli
onset
cancer
survivor
especi
ya
cancer
survivor
still
lack
creation
composit
indic
assess
impact
econom
cultur
factor
outcom
pediatr
hematolog
malign
b
truong
p
friedrich
k
bona
c
k
ribeiro
medic
scienc
harvard
medic
school
boston
usa
pediatr
oncolog
children
cancer
blood
disord
center
boston
usa
depart
social
medicin
faculdad
de
da
santa
casa
sao
paulo
brazil
object
contribut
socioeconom
factor
racial
ethnic
dispar
pediatr
cancer
remain
understudi
partli
due
complex
synthes
effect
multipl
individu
factor
studi
aim
construct
util
composit
index
analyz
impact
socioeconom
factor
surviv
common
pediatr
hematolog
malign
method
standard
valu
seven
differ
dispar
variabl
us
censu
util
calcul
two
indic
econom
index
util
level
poverti
incom
educ
crowd
unemploy
cultur
index
util
level
languag
isol
immigr
high
valu
indic
greater
social
disadvantag
select
factor
includ
test
face
valid
consensu
evalu
correl
factor
confirm
domain
use
principl
compon
analysi
pca
obtain
surviv
outcom
seer
registri
patient
age
diagnos
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
hl
lymphoma
nhl
surviv
distribut
function
disadvantag
advantag
counti
compar
use
test
valu
comparison
defin
median
index
within
cohort
result
construct
two
indic
support
pca
reveal
two
main
latent
variabl
set
seven
chosen
variabl
econom
disadvantag
high
index
score
associ
lower
surviv
rate
p
aml
p
hl
p
nhl
p
differ
signific
counti
stratifi
cultur
domain
conclus
studi
result
creation
index
synthes
varieti
measur
se
econom
factor
show
strongest
impact
valid
cultur
factor
appear
less
signific
mediat
outcom
may
combin
econom
factor
creat
composit
index
futur
neuroblastoma
integr
analys
epigenet
regulatori
gene
neuroblastoma
n
hoshino
masafumi
k
yoshida
kato
r
nishimura
miyano
hahashi
oka
iwanaka
ogawa
j
takita
dept
pediatr
surgeri
univers
tokyo
tokyo
japan
dept
pediatr
univers
tokyo
tokyo
japan
depart
patholog
tumor
biolog
graduat
school
medicin
kyoto
univers
kyoto
japan
dept
cell
therapi
transplant
medicin
univers
tokyo
tokyo
japan
laboratori
dna
inform
analysi
human
genom
center
institut
medic
scienc
univers
tokyo
tokyo
japan
depart
hematologyoncolog
gunma
children
medic
center
shibukawa
japan
depart
patholog
tumor
biolog
graduat
school
medicin
kyoto
univers
tokyo
japan
object
neuroblastoma
nb
one
aggress
pediatr
solid
tumor
childhood
nb
display
remark
clinic
heterogen
heterogen
genet
target
implic
pathogenesi
recent
screen
appli
discov
mutat
alk
atrx
nb
howev
sinc
overal
frequenc
recurr
mutat
rate
gene
rel
low
molecular
basi
nb
complet
elucid
meanwhil
previou
methyl
studi
suggest
epigenet
aberr
may
also
import
littl
known
role
pathogenesi
nb
elucid
role
epigenet
regul
pathogenesi
nb
target
captur
deep
sequenc
enabl
minor
clone
detect
array
base
methyl
analysi
carri
method
target
captur
follow
deep
sequenc
epigenet
regulatori
gene
use
sequenc
iliumina
hiseq
perform
nb
specimen
extend
cohort
nb
specimen
analyz
deep
sequenc
select
gene
addit
methyl
analysi
iliumina
infinium
beadchip
kit
perform
nb
specimen
result
among
epigenet
regul
gene
includ
polycomb
trithorax
group
relat
gene
mutat
case
although
mutat
mostli
found
singl
case
mutat
detect
two
case
subsequ
deep
sequenc
reveal
novel
mutat
observ
total
case
nb
hand
base
methyl
profil
nb
case
divid
subgroup
independ
clinicopatholog
find
age
stage
mycn
statu
conclus
result
indic
genet
alter
also
epigenet
regul
may
play
import
role
pathogenesi
nb
compar
express
pattern
genet
alter
methyl
plofil
would
necessari
disclos
role
epigenet
regul
nb
surviv
follow
infus
antibodi
combin
pilot
cohort
neuroblastoma
patient
correl
receptor
polymorph
hn
lode
c
jensen
endr
l
pill
n
siebert
p
brock
h
loibner
r
ladenstein
pediatr
hematologyoncolog
univers
medicin
greifswald
greifswald
germani
pediatr
hematologyoncolog
great
ormond
street
hospit
london
unit
kingdom
pediatr
hematologyoncolog
institut
gustav
roussi
villejuif
franc
apeiron
biolog
vienna
austria
pediatr
hematologyoncolog
children
cancer
research
institut
vienna
austria
object
treatment
use
infus
lti
antibodi
subcutan
may
improv
outcom
high
risk
neuroblastoma
nb
method
nb
patient
receiv
cycl
sc
lti
oral
singl
center
program
effector
cell
subset
level
specif
kill
neuroblastoma
cell
adcc
cdc
analyz
kirkirl
mismatch
polymorph
determin
valid
method
kir
hla
clinic
respons
assess
follow
inrg
criteria
mibg
mrict
bm
catecholamin
result
lti
translat
expans
effector
combin
cytokin
respons
effect
level
gml
end
antibodi
infus
associ
specif
activ
nb
cell
function
assay
cdc
adcc
wbt
interestingli
level
function
paramet
subsequ
treatment
cycl
indic
persist
activ
measur
entir
treatment
period
month
respons
rate
mibg
mrict
bone
catecholamin
overal
respons
ef
observ
year
mean
year
os
observ
year
mean
year
observ
patient
high
affin
fcgr
allel
associ
longer
surviv
p
support
mediat
adcc
mechan
action
conclus
surviv
follow
lti
correl
high
affin
fcgr
support
mediat
adcc
primari
mechan
action
myeloabl
therapi
mat
immunotherapi
high
risk
neuroblastoma
updat
news
randomis
result
trial
r
ladenstein
u
poetschger
r
luksch
elliot
v
castel
yaniv
g
laurey
w
balwierz
hn
lode
studi
statist
integr
research
children
cancer
research
institut
vienna
austria
paediatr
oncolog
haematolog
istituto
nazional
tumori
di
milano
milano
itali
paediatr
oncolog
haematolog
leed
gener
hospit
leed
unit
kingdom
paediatr
oncolog
unit
hospit
la
fe
valencia
valencia
spain
paediatr
oncolog
haematolog
schneider
children
medic
center
israel
petach
tikvah
israel
paediatr
oncolog
haematolog
univers
hospit
gent
gent
belgium
paediatr
oncolog
haematolog
jagiellonian
univers
medic
colleg
krakow
poland
paediatr
oncolog
haematolog
univers
greifswald
greifswald
germani
paediatr
adoloscent
oncolog
depart
institut
gustav
roussi
villejuif
franc
object
trial
randomis
essenti
treatment
concept
randomis
investig
bumel
superior
whilst
randomis
test
benefit
ad
subcutan
interleukin
immunotherapi
method
rapid
cojec
induct
patient
pt
randomis
bumel
cem
till
median
follow
year
elig
includ
complet
bone
marrow
remiss
improv
mibg
posit
spot
local
control
includ
surgeri
radiotherapi
gy
initi
aim
receiv
infus
day
ci
ra
total
cycl
schedul
requir
high
dose
morphin
control
neuropath
pain
address
question
use
dose
day
twice
weekli
interv
given
week
parallel
result
superior
bumel
ef
os
cem
ef
os
vs
p
maintain
significantli
lower
relaps
progress
rate
bumel
vs
major
factor
sever
toxic
rate
icu
toxic
death
higher
cem
p
henc
mat
toxic
profil
favour
bumel
spite
vod
rate
grade
vs
cem
august
reach
target
randomis
current
suspend
last
patient
popul
undisclos
treatment
arm
show
current
year
efso
arm
carri
significantli
higher
toxic
burden
relat
associ
side
effect
like
fever
capillari
leak
number
pt
arm
stop
treatment
earli
conclus
bumel
maintain
siopen
standard
treatment
whilst
disclos
detail
result
expect
signific
prognost
result
siopen
mibg
score
method
cooper
independ
high
risk
neuroblastoma
trial
r
ladenstein
boubak
b
lambert
mr
castellani
z
oudoux
kaminska
sg
kreissman
kk
matthay
u
poetschger
studi
statist
integr
research
children
cancer
research
institut
vienna
austria
nuclear
medicin
centr
hospitali
universitair
vaudoi
lausann
switzerland
nuclear
medicin
ghent
univers
hospit
ghent
belgium
nuclear
medicin
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
nuclear
medicin
schneider
children
medic
center
petach
tivka
israel
nuclear
medicin
centr
lill
franc
nuclear
medicin
children
memori
health
institut
warsaw
poland
pediatr
hematolog
oncolog
duke
univers
medic
center
durham
usa
pediatr
san
franscisco
school
medicin
san
francisco
usa
studi
statist
integr
research
project
children
cancer
reserach
institut
vienna
austria
object
harmonis
evalu
standard
mibg
scintigraphi
stage
neuroblastoma
nb
intern
aim
trial
popul
siopen
score
sisco
associ
significantli
poorer
event
free
surviv
ef
pre
post
induct
mibg
analysi
valid
sisco
prognost
valu
independ
dataset
ds
children
oncolog
group
cog
protocol
method
siopen
score
evalu
mibg
uptak
skelet
region
score
maximum
mibg
scan
stage
nb
pt
collabor
trial
review
siopen
nuclear
medicin
review
committe
dsa
n
siopen
trial
dsb
n
predefin
categori
dsb
use
sisco
median
time
respect
result
ds
show
significantli
superior
ef
sisco
diagnosi
ef
dsa
vs
p
dsb
vs
p
post
induct
sisco
also
reveal
signific
superior
outcom
ef
dsa
vs
p
dsb
vs
p
pt
sisco
post
induct
best
outcom
ds
mycn
amplifi
pt
pre
sisco
show
signific
impact
group
whilst
mycn
pt
effect
seen
post
induct
sisco
independ
statist
signific
cox
model
includ
age
mycn
conclus
siopen
score
mibg
scan
carri
relev
prognost
signific
manag
patient
nb
diagnosi
end
induct
chemotherapi
trial
confirm
independ
cog
data
set
histor
gold
standard
ttp
surviv
pf
relapsedrefractori
neuroblastoma
modern
era
patient
wb
london
r
bagatel
b
weigel
e
fox
c
van
ryn
naranjo
md
krailo
ch
ahern
jr
park
pediatr
hematologyoncolog
children
cancer
blood
disord
center
boston
usa
pediatr
hematologyoncolog
children
hospit
philadelphia
philadelphia
pa
usa
pediatr
hematologyoncolog
univers
minnesota
minneapoli
mn
usa
children
oncolog
group
statist
data
center
univers
florida
gainesvil
fl
usa
children
oncolog
group
statist
data
center
univers
southern
california
monrovia
ca
usa
biostatist
baylor
colleg
medicin
houston
tx
usa
pediatr
hematologyoncolog
seattl
children
hospit
seattl
wa
usa
object
earli
phase
trial
investig
agent
pediatr
patient
pt
relaps
neuroblastoma
nb
histor
use
respons
recist
endpoint
challeng
nb
bone
bone
marrow
nt
measur
ttp
pf
better
suit
measur
therapeut
benefit
nb
especi
target
agent
immunotherapi
histor
data
pfsttp
exist
small
potenti
bias
cohort
studi
largest
cohort
date
relapsedrefractori
nb
pt
treat
modern
era
frontlin
relaps
therapi
determin
pf
os
ttp
use
histor
compar
futur
phase
studi
method
enrol
consecut
distinct
pt
phase
children
oncolog
group
trial
analyz
pf
relaps
progress
diseas
death
overal
surviv
os
death
ttp
start
phase
trial
enrol
pt
multipl
trial
enrol
analyz
independ
pf
death
censor
use
recist
phase
trial
met
prospect
respons
rate
bar
success
pt
plan
frontlin
therapi
includ
hsct
receiv
antibodi
result
relaps
studi
enrol
pfso
respect
median
ttp
day
ci
median
pt
without
progress
mo
risk
factor
diagnosi
within
subgroup
stage
mo
old
amplifi
histolog
mycnamplif
prognost
wors
pf
relaps
studi
enrol
p
median
time
diagnosi
first
relapseprogress
mo
ci
n
conclus
pfsttpo
repres
comprehens
histor
cog
trial
nb
cohort
use
phase
trial
gold
standard
compar
identifi
promis
new
agent
nb
human
antibodi
given
chemotherapi
parent
natur
killer
nk
cell
children
recurr
refractori
neuroblastoma
federico
w
leung
pappo
f
navid
vm
santana
j
wu
b
shulkin
dr
shook
pm
sondel
wl
furman
oncolog
st
jude
children
research
hospit
memphi
usa
object
preclin
studi
demonstr
antibodi
act
via
cytotox
adcc
enhanc
effect
chemotherapi
howev
unknown
chemotherapi
combin
feasibl
effect
children
neuroblastoma
studi
evalu
safeti
feasibl
administ
uniqu
human
antibodi
chemotherapi
parent
nk
cell
enhanc
adcc
method
pediatr
patient
recurr
refractori
neuroblastoma
elig
receiv
six
cours
day
combin
altern
cours
cyclophosphamidetopotecan
cours
irinotecantemozolomid
cours
ifosfamidecarboplatinetoposid
cours
parent
nk
cell
administ
cours
result
ten
heavili
pretreat
patient
median
age
year
rang
includ
prior
treatment
complet
cours
one
patient
develop
unaccept
toxic
character
prolong
thrombocytopenia
day
four
patient
came
studi
advers
event
allergi
prolong
viral
infect
surgic
death
myelodysplast
syndrom
common
toxic
includ
grade
myelosupress
patient
grade
pain
patient
eight
patient
receiv
nk
cell
infus
median
number
nk
cell
infus
per
dose
rang
respons
therapi
includ
complet
respons
cr
good
partial
respons
vgpr
partial
respons
pr
stabl
diseas
sd
five
patient
patient
receiv
nk
cell
infus
measur
donor
nk
cell
day
chimer
rang
chimer
rang
respect
none
patient
progress
therapi
one
patient
remain
cr
month
complet
therapi
conclus
administr
concurr
chemotherapi
parent
nk
cell
safe
feasibl
result
clinic
meaning
respons
patient
neuroblastoma
accrual
trial
ongo
brain
tumour
biolog
microrna
express
atyp
teratoidrhabdoid
tumor
atrt
new
potenti
therapeut
target
k
patel
mdf
bonaldo
cc
huang
tomita
st
sredni
neurosurgeri
ann
robert
h
luri
children
hospit
chicago
chicago
usa
cancer
biolog
epigenom
program
ann
robert
h
luri
children
hospit
chicago
chicago
usa
biostatist
joseph
j
zilber
school
public
health
milwauke
usa
neurosurgeri
feinberg
school
medicin
chicago
usa
neurosurgeri
ann
robert
h
luri
children
hospit
chicago
chicago
usa
object
atyp
teratoidrhabdoid
tumor
atrt
aggress
pediatr
tumor
central
nervou
system
effect
treatment
new
therapeut
option
need
microrna
mirna
small
noncod
rna
modul
entir
set
gene
modul
mirna
may
provid
new
avenu
cancer
treatment
method
compar
mirna
express
profil
atrt
meduloblastoma
mb
gene
express
ge
profil
atrt
mb
illumina
microrna
chip
illumina
whole
genom
express
array
illumina
inc
ca
usa
use
analysi
total
rna
isol
use
trizol
reagent
invitrogen
ca
usa
fold
chang
fc
calcul
appli
assess
signific
differenti
express
gene
mirna
fc
mrna
fc
select
ingenu
pathway
analysi
ipa
http
wwwingenuitycom
use
determin
pair
highli
predict
invers
express
correl
determin
enrich
biolog
function
differenti
express
gene
select
mirnamrna
valid
pcr
result
among
differenti
express
mirna
differenti
express
mrna
pair
establish
mirna
mrna
among
atrt
fc
accordingli
follow
predict
target
found
significantli
fc
regul
express
fc
essenti
neural
develop
conclus
gene
involv
neural
develop
regul
atrt
may
indic
mirna
might
concur
poor
differenti
natur
tumor
specul
manipul
specif
mirna
could
induc
differenti
atrt
cell
lower
aggress
behavior
cknowledg
research
fund
ralli
foundat
childhood
cancer
research
memori
haley
trainer
dr
ralph
marian
c
falk
medic
research
trust
use
drosophila
melanogast
identif
gene
involv
biolog
atyp
teratoidrhabdoid
tumor
k
eikmeier
ling
jeibmann
kool
w
paulu
hasselblatt
institut
neuropatholog
univers
hospit
germani
divis
pediatr
neurooncolog
german
cancer
research
center
dkfz
heidelberg
germani
swabian
children
cancer
center
children
hospit
augsburg
registri
work
group
augsburg
germani
object
major
atyp
teratoidrhabdoid
tumor
atrt
character
inactiv
one
singl
gene
howev
littl
known
target
downstream
pathway
therefor
aim
perform
broad
function
screen
gene
potenti
involv
detriment
effect
defici
method
use
drosophila
melanogast
andth
system
amodifi
screen
perform
order
identifi
pathway
involv
phenotyp
associ
ubiquit
knockdownof
fli
homolog
function
role
identifi
gene
pathway
investig
human
rhabdoid
tumor
cell
line
well
atrt
tumor
sampl
european
rhabdoid
tumor
registri
eurhab
result
silenc
express
drosophila
melanogast
result
lethal
phenotyp
well
increas
volum
prolifer
larval
fli
brain
cross
knockdownfli
strain
express
specif
rnai
shift
lethal
phenotyp
screen
candid
gene
includ
merlinkibra
expand
whose
product
repres
key
upstream
regul
hippo
pathway
human
rhabdoid
tumor
cell
line
silenc
homologu
merlin
kibra
expand
result
reduc
prolif
activ
mtt
brdu
assay
cytotox
unalt
furthermor
main
effector
hippo
pathway
atrt
associ
shorter
surviv
overal
surviv
conclus
highlight
role
hippo
signal
biolog
atrt
result
demonstr
fli
model
employ
identif
clinic
relev
pathway
human
cancer
support
izkf
delin
transform
mechan
therapeut
target
oncomir
cluster
p
lu
c
kleinman
picard
spenc
kc
ho
j
chan
c
hawkin
j
majewski
n
jabado
p
dirk
huang
arthur
sonia
labatt
brain
tumor
research
centr
hospit
sick
children
toronto
canada
depart
human
genet
mcgill
univers
montreal
canada
depart
patholog
laboratori
medicin
univers
calgari
calgari
canada
object
central
nervou
tumor
repres
distinctli
aggress
clinic
heterogen
class
embryon
brain
tumor
poorli
understood
biolog
recent
shown
amplif
andor
high
express
compris
singl
molecular
entiti
span
variou
histolog
categori
anatom
compart
tumor
classifi
group
distinguish
highli
primit
neural
gene
signatur
taken
togeth
prior
observ
mirna
alter
human
neural
stem
cell
hnsc
phenotyp
find
suggest
oncomir
may
critic
modul
cell
differenti
growth
pathway
promot
tumorigenesi
method
elucid
molecular
mechan
tumorigenesi
combin
mirna
target
predict
algorithm
compar
gene
express
analys
primari
amplifi
tumor
hnsc
stabl
express
mirna
result
analys
reveal
multipl
cell
cycl
regulatori
tumor
suppressor
candid
gene
target
includ
display
highli
conserv
bind
site
observ
directli
synergist
target
mirna
cell
line
stabl
oncomir
express
significantli
mirna
hybrid
analys
confirm
bonafid
gene
target
primari
human
tumor
cell
observ
stabl
mirna
express
confer
prolif
phenotyp
hnsc
thu
suggest
oncomir
may
synerg
activ
pathway
recent
identifi
gene
fusion
demonstr
distinct
methyl
landscap
group
correl
target
consequ
consist
observ
growth
primari
group
cell
robustli
inhibit
vorinostat
treatment
conclus
studi
collect
suggest
oncomir
promot
tumorigenesi
target
cell
cycl
regul
modul
epigenom
provid
one
first
ration
therapeut
devast
tumor
signific
tumor
associ
macrophag
medulloblastoma
margol
n
robison
j
gnanachandran
g
dhall
r
drissi
fouladi
f
gill
judkin
r
sposto
asgharzadeh
pediatr
children
hospit
lo
angel
lo
angel
usa
pediatr
cincinnati
children
hospit
medic
center
cincinnati
usa
patholog
children
hospit
lo
angel
lo
angel
usa
object
children
medulloblastoma
subgroup
least
four
molecular
categori
offer
potenti
target
therapeut
approach
reduc
treatment
relat
morbid
littl
known
role
tumor
microenviron
medulloblastoma
contribut
molecular
subgroup
tumor
microenviron
shown
import
sourc
therapeut
target
adult
pediatr
neoplasm
studi
investig
hypothesi
express
gene
relat
macrophag
tam
correl
medulloblastoma
molecular
subgroup
contribut
diagnost
signatur
method
gene
express
profil
use
human
exon
array
n
analyz
identifi
medulloblastoma
molecular
subgroup
express
gene
express
gene
analyz
use
taqman
low
densiti
array
tlda
card
medulloblastoma
sampl
build
gene
signatur
predict
molecular
subgroup
tam
medulloblastoma
n
compris
four
molecular
subgroup
assess
immunohistochemistri
ihc
result
medulloblastoma
subgroup
classif
score
inclus
gene
develop
misclassif
rate
tumor
sonic
hedgehog
shh
subgroup
increas
express
gene
significantli
higher
infiltr
tam
tumor
group
group
subgroup
p
p
respect
ihc
data
reveal
strong
associ
locat
tam
prolifer
tumor
cell
conclus
studi
report
first
evid
presenc
tam
medulloblastoma
provid
novel
tlda
signatur
accur
determin
medulloblastoma
molecular
subgroup
data
suggest
shh
tumor
uniqu
tumor
microenviron
interact
tam
shh
tumor
cell
may
contribut
pathogenesi
reveal
tam
potenti
therapeut
target
neg
regul
enhanc
signal
medulloblastoma
zollo
medicina
molecolar
e
biotecnologi
medich
univers
napl
federico
ii
napl
itali
object
brain
tumor
common
caus
childhood
oncolog
death
medulloblastoma
mb
frequent
highli
invas
embryon
tumor
aris
cerebellum
dissemin
cerebrospin
fluid
coat
brain
spinal
cord
recent
studi
reveal
mb
compris
least
four
distinct
molecular
differ
term
clinicopatholog
featur
diseas
outcom
within
molecular
group
metastat
diseas
diagnosi
characterist
subtyp
even
though
mechan
metastat
cell
dissemin
still
poorli
studi
method
studi
identifi
one
differenti
express
function
relev
gene
mb
group
highli
amplifi
network
analysi
studi
illustr
signal
activ
uniqu
moreov
mb
oncogen
promin
target
signal
develop
nervou
system
result
identifi
protein
found
neg
regul
signal
prevent
activ
smadss
protein
found
neg
regul
enhanc
signal
silenc
rna
interfer
sever
well
establish
mb
cell
line
result
strong
inhibit
cell
migrat
prolifer
adhes
suggest
requir
growth
mb
cell
demonstr
silenc
neg
regul
otx
protein
quota
mb
immort
cell
line
final
knockdown
model
impair
tumor
engraft
orthotop
xenograft
given
relev
mb
accordingli
effect
silenc
vitro
vivo
also
present
new
drug
abl
impair
protein
stabil
conclus
find
primari
tumor
togeth
function
studi
mb
cell
line
provid
strong
evid
import
role
progress
metastat
dissemin
suggest
futur
way
ration
therapi
molecular
mb
chromosom
engin
stem
cell
differenti
technolog
model
somat
copi
number
aberr
medulloblastoma
j
peacock
wataya
k
zane
md
taylor
development
stem
cell
biolog
hospit
sick
children
toronto
canada
divis
neurosurgeri
hospit
sick
children
toronto
canada
object
medulloblastoma
common
malign
brain
tumour
childhood
major
caus
oncolog
death
children
recent
progress
genet
analysi
reveal
number
chromosom
abnorm
medulloblastoma
chromosom
aberr
includ
loss
gain
isochromosom
seen
across
medulloblastoma
subgroup
chromosom
delet
mous
model
develop
howev
model
embryon
lethal
earli
stage
develop
like
due
haploinsuffici
critic
development
gene
unclear
neuron
precursor
form
mous
equival
region
delet
mous
embryon
stem
cell
cultur
embryoid
aggreg
sfebq
condit
differenti
mani
cell
type
brain
includ
cerebellar
progenitor
cell
hypothes
differenti
delet
es
cell
cerebellar
progenitor
cell
embryon
lethal
method
sfebq
method
optim
use
chromosom
engin
mous
embryon
stem
cell
harbor
million
bp
delet
equival
human
delet
eb
differenti
cerebellar
progenitor
cell
intracrani
inject
nod
scid
gamma
nsg
immunodefici
mice
result
mous
es
cell
equival
delet
success
differenti
cerebellar
precursor
vitro
delet
cell
prolif
stain
compar
parent
flox
cell
without
delet
immunofloresc
stain
demonstr
delet
es
cell
give
rise
granul
cell
precursor
purkinj
cell
gabaerg
neuron
conclus
sfebq
allow
us
gener
cell
type
cerebellum
chromosom
engin
mous
equival
delet
cell
prolif
insuffici
caus
medulloblastoma
addit
oncogen
overexpress
gene
knockout
allow
us
model
event
transform
cerebellar
progenitor
medulloblastoma
pediatr
malign
mesothelioma
european
expert
group
experi
ben
arush
orbach
g
bisogno
v
bajciova
p
leblond
r
dvir
brecht
n
pediatr
hematolog
oncolog
children
hospit
rambam
medic
center
haifa
israel
pediatr
hematolog
oncolog
institut
curi
pari
franc
dipartimento
di
pediatria
clinica
di
oncoematologia
padova
itali
pediatr
oncolog
depart
children
oncolog
hospit
brno
czech
republ
pediatr
oncolog
depart
medic
univers
gdansk
poland
pediatr
oncolog
depart
centr
oscar
lambret
lill
franc
pediatr
oncolog
depart
souraski
medic
center
tel
aviv
israel
pediatr
oncolog
depart
children
hospit
erlangen
germani
pediatr
oncolog
depart
children
hospit
la
timon
marseil
franc
object
mesothelioma
except
tumor
aris
surfac
pleural
periton
caviti
pericardium
tunica
vaginali
adult
patient
need
medic
oncolog
therapi
surviv
uncommon
littl
known
characterist
tumor
pediatr
set
method
european
expert
group
pediatr
rare
tumor
review
retrospect
children
adolesc
year
diagnos
europ
mesothelioma
result
patient
pt
identifi
male
femal
mean
age
year
rang
primari
tumour
locat
peritoneum
pt
pleura
vagina
case
pericardium
multipl
site
pt
metastasi
diagnosi
present
patient
histolog
epithelioid
case
chemotherapi
deliv
patient
regimen
ad
pemetrex
patient
addit
cytoreduct
surgeri
hypertherm
intraperiton
chemotherapi
cchip
perform
patient
first
line
therapi
patient
relaps
progress
diseas
ten
patient
went
complet
remiss
cchip
chemotherapi
median
month
patient
remain
first
complet
remiss
residu
stabl
imag
one
progress
diseas
patient
die
two
patient
lost
conclus
mesothelioma
rare
tumour
pediatr
popul
pediatr
mesothelioma
seem
differ
adult
counterpart
less
primari
pleural
local
much
better
outcom
despit
frequent
relaps
seri
provid
interest
insight
safeti
effect
treatment
pediatr
mesothelioma
patient
highlight
role
chemotherapi
cisplatin
base
pemetrex
cchip
establish
european
recommend
recommend
pediatr
melanoma
analysi
case
french
pediatr
rare
tumor
group
fractur
vittaz
l
martin
c
robert
orbach
c
bodem
c
mateu
fraitag
plantaz
p
lutz
e
plouvier
j
rakotonjanahari
pediatr
clinic
chu
anger
franc
dermatolog
depart
chu
anger
franc
dermatolog
unit
gustav
roussi
cancer
center
villejuif
pari
sud
franc
pediatr
adolesc
young
adult
depart
curi
institut
pari
franc
dermatolog
depart
necker
hospit
aphp
pari
franc
depart
patholog
necker
hospit
aphp
pari
franc
pediatr
oncolog
depart
chu
grenobl
grenobl
franc
pediatr
oncolog
depart
chu
strasbourg
franc
pediatr
oncolog
depart
chu
franc
pediatr
oncolog
depart
chu
anger
franc
pediatr
oncolog
depart
chu
saint
deni
franc
object
describ
clinic
present
treatment
evolut
malign
skin
melanoma
mm
occur
children
method
descript
retrospect
multicent
nation
studi
children
adolesc
result
patient
french
center
includ
median
age
year
rang
less
year
old
tumor
amelanot
rais
breslow
thick
tumor
histolog
show
superfici
spread
n
spitzoid
n
nodular
present
n
diagnosi
diseas
local
patient
metastasi
clinic
lymph
node
involv
present
primari
excis
perform
patient
sentinel
lymph
node
biopsi
perform
patient
posit
sixteen
patient
relaps
die
progress
diseas
despit
variou
treatment
surgeri
chemotherapi
immunotherapi
ef
rf
overal
os
surviv
respect
ci
ci
ci
cox
univari
analysi
older
age
diagnosi
neg
impact
os
hr
ci
p
clark
level
iiiii
vs
ivv
breslow
thick
ajcc
stage
signific
prognost
factor
ef
os
differ
children
adolesc
discuss
conclus
pediatr
melanoma
rare
patholog
amelanot
concern
mainli
adolesc
primari
surgic
resect
primari
involv
node
optim
manag
earli
stage
therapi
advanc
stage
relaps
unclear
prognosi
remain
dismal
efficaci
target
therapi
unknown
pediatr
mm
intern
cooper
clinic
biolog
studi
warrant
nasophareng
carcinoma
children
adolesc
demograph
clinic
therapeut
characterist
long
term
outcom
r
kebudi
r
meral
gorgun
b
cakir
celikarslan
ayan
f
yaman
agaoglu
e
darendelil
b
zulfikar
altun
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
oncolog
institut
istanbul
turkey
radiat
oncolog
istanbul
univers
oncolog
institut
istanbul
turkey
pediatr
hematolog
oncolog
bezmialem
vakif
univers
medic
faculti
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
oncolog
institut
istanbul
turkey
object
aim
studi
evalu
demograph
clinic
therapeut
characterist
outcom
childhood
adolesc
nasopharyng
carcinoma
npc
retrospect
singl
center
method
novemb
januari
file
patient
year
npc
treat
istanbul
univers
oncolog
institut
patient
receiv
three
cours
neoadjuv
chemotherapi
regimen
bleomycin
etoposid
bep
sinc
ep
follow
radiotherapi
given
primari
tumor
metastat
cervic
lymph
node
result
male
femal
median
age
yr
present
mostli
lump
neck
headach
ear
nose
problem
median
time
month
year
biopsi
n
npc
type
iii
tumor
patient
advanc
stage
tumor
iii
iva
ivb
distant
metastat
site
ivc
accord
ajcc
stage
system
chemotherapi
follow
radiotherapi
primari
tumor
involv
lymph
node
cervic
nodal
region
overal
os
surviv
ef
rate
respect
patient
exclud
analysi
signific
differ
ef
patient
receiv
bep
ep
vs
vs
respect
eight
patient
die
due
relaps
diseas
secondari
malign
develop
two
patient
two
other
die
caus
unrel
malign
late
effect
includ
hypothyroid
neck
fibrosi
xerostomia
boni
hypoplasia
skin
problem
hear
loss
conclus
children
adolesc
advanc
npc
rel
good
rate
surviv
neoadjuv
therapi
radiotherapi
lead
high
locoregion
control
thu
surviv
advanc
stage
npc
ep
seem
effect
bep
survivor
follow
morbid
salivari
gland
carcinoma
children
adolesc
italian
trep
project
experi
chiarav
guzzo
g
bisogno
md
de
pasqual
r
migliorati
f
de
leonardi
p
collini
casanova
g
cecchetto
ferrari
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
otorhinolaryngolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
divis
clinica
di
oncoematologia
pediatrica
di
padova
padova
itali
divis
ospedal
pediatrico
bambino
roma
itali
pediatr
oncolog
divis
ospedal
pediatrico
pausillipon
napoli
itali
pediatr
divis
di
bari
bari
itali
soft
tissu
bone
patholog
histopatholog
pediatr
patholog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
pediatr
surgeri
ospedal
universitario
di
padova
padova
itali
object
salivari
gland
carcinoma
sgc
extrem
rare
pediatr
age
annual
incid
per
million
person
year
report
clinic
featur
seri
childrenadolesc
sgc
prospect
regist
italian
trep
rare
tumor
pediatr
age
project
method
diagnostictherapeut
guidelin
develop
dissemin
italian
pediatr
oncologysurg
center
period
case
rare
pediatr
tumor
differ
center
regist
patient
sgc
number
sgc
expect
year
itali
year
popul
observedexpect
ratio
result
sgc
mainli
aros
parotid
case
case
tumor
case
clinic
present
often
favor
diseas
tumor
tumor
ie
size
cm
without
extraparenchym
extens
region
nodal
involv
patient
underw
surgic
resect
achiev
margin
concern
patient
parotid
gland
tumor
receiv
parotidectomi
total
superfici
tumorectomi
facial
nerv
injuri
report
case
adjuv
radiotherapi
given
case
due
incomplet
resect
associ
tumor
andor
tumor
overal
prognosi
good
one
patient
huge
tumor
tumor
progress
die
diseas
case
aliv
first
continu
remiss
year
diagnosi
noteworthi
case
sgc
second
tumor
year
primari
cancer
ie
acut
lymphoblast
leukemia
osteosarcoma
ewe
sarcoma
hodgkin
diseas
conclus
seri
repres
prospect
cooper
seri
pediatr
sgc
complianc
trep
recommend
high
tumor
rare
manag
pediatr
oncologistssurgeon
larger
intern
cooper
network
surgeon
expert
adult
sgc
advis
tracheobronchi
mucoepidermoid
carcinoma
pediatr
key
clinic
patholog
issu
r
fan
patholog
indiana
univers
school
medicin
indianapoli
usa
object
mucoepidermoid
carcinoma
first
identifi
malign
tumor
major
salivari
gland
later
also
describ
tracheobronchi
tree
submucosa
mucou
gland
though
extrem
rare
pediatr
popul
tracheobronchi
second
common
primari
neoplasm
locat
common
carcinoid
tumor
larg
seri
studi
entiti
childhood
scarc
medic
literatur
molecular
mechan
method
retriev
pediatr
case
tracheobronchi
mucoepidermoid
carcinoma
literatur
institut
analyz
relev
clinicopatholog
featur
age
cutoff
year
old
result
gender
distribut
appear
equal
popul
present
age
rang
month
year
mean
year
pneumonia
especi
recurr
pneumonia
manifest
cough
fever
salient
present
featur
less
one
third
case
hemoptysi
typic
endoscop
find
polypoid
endobronchialintralumin
mass
intermedi
grade
case
frequent
encount
pediatr
popul
high
grade
case
observ
one
case
region
lymph
node
metastasi
identifi
studi
group
patient
surviv
surgic
resect
alon
molecular
patholog
level
transloc
detect
associ
cyclin
immuno
posit
case
test
posit
egfr
gene
mutat
one
case
test
posit
conclus
slow
growth
insidi
cours
featur
recurr
pneumonia
characterist
pediatr
mucoepidermoid
carcinoma
import
differenti
diagnosi
consid
includ
carcinoid
adenoid
cystic
carcinoma
differenti
inflammatori
myofibroblast
tumor
histoplasmosi
nodul
chondroid
hamartoma
infantil
fibrosarcoma
neurofibroma
hemangioma
bronchogen
cyst
mucoepidermoid
carcinoma
resist
radiotherapi
chemotherapi
surgic
option
well
term
prognosi
compar
adult
case
pediatr
case
fare
better
surviv
rate
rare
recurr
clinic
analysi
pleuropulmonari
blastoma
larger
chines
pediatr
hematolog
oncolog
center
x
xs
wang
xf
sun
wang
jy
tang
jin
dw
zhang
w
zhao
hematolog
oncolog
center
beij
children
hospit
capit
medic
univers
beij
china
hematolog
oncolog
center
sun
univers
guangdong
china
oncolog
surgeri
children
hospit
chongq
medic
univers
sichan
china
hematolog
oncolog
center
shanghai
children
medic
center
shanghai
jiaotong
univers
school
medicin
shanghai
china
hematolog
oncolog
center
beij
children
hospit
capit
medic
univers
beij
china
object
retrospect
analyz
pleuropulmonari
blastoma
ppb
larger
chines
pediatr
oncolog
center
recent
year
provid
basi
collabor
treatment
ppb
china
method
clinic
featur
patholog
find
outcom
ppb
case
observ
clinic
data
surgic
note
summari
treatment
taken
chart
correl
outcom
standard
statist
method
result
seri
includ
patient
male
femal
median
age
month
median
day
onset
diagnosi
ten
patient
develop
lung
involv
site
extrapulmonari
involv
mediastin
pleura
pericardi
abdomin
lymph
node
liver
tumor
size
cm
seven
patient
cm
max
nine
patient
unknown
fourteen
patient
two
patient
type
eight
patient
type
thirteen
patient
type
histolog
subtyp
unknown
seven
patient
diagnosi
twelv
patient
total
resect
recurr
die
lost
complet
remiss
cr
three
patient
partial
resect
remain
patient
biopsi
initi
surgeri
fourteen
patient
treat
chemotherapi
nine
patient
receiv
cavi
regimen
cours
three
receiv
ivad
regimen
cisplatin
cours
two
receiv
ivadand
iva
regimen
cours
got
cr
partial
remiss
recurr
die
lost
patient
total
surgeri
partial
resect
andor
chemotherapi
conclus
ppb
aggress
neoplasm
achiev
total
resect
tumor
time
treatment
andor
chemotherapi
result
significantli
better
prognosi
wherea
extrapulmonari
involv
diagnosi
result
significantli
wors
prognosi
compar
role
hydroxyurea
hyperhydr
versu
hyperhydr
alon
decreas
total
leukocyt
count
children
acut
leukemia
hyperleukocytosi
random
control
trial
sharma
singh
r
seth
r
kumar
kabra
rm
pandey
pediatr
india
institut
medic
scienc
delhi
india
laboncolog
india
institut
medic
scienc
delhi
india
biostatist
india
institut
medic
scienc
delhi
india
object
acut
leukemia
hyperleukocytosi
tlc
oncolog
emerg
hydroxyurea
use
treat
hyperleukocytosi
evid
limit
demonstr
addit
hydroxyurea
convent
manag
caus
signific
declin
total
leukocyt
count
compar
convent
therapi
alon
newli
diagnos
children
acut
leukemia
hyperleukocytosisto
demonstr
differ
complic
tumor
lysi
pulmonari
complic
cn
complic
hemorrhag
complic
mortal
time
taken
initi
chemotherapi
group
method
children
random
two
group
one
group
receiv
convent
treatment
intraven
fluid
dextros
salin
meqlit
sodium
bicarbon
oral
allopurinol
group
addit
receiv
hydroxyurea
result
treatment
respons
hydroxyurea
group
seen
patient
convent
group
differ
signific
p
valu
signific
differ
complic
p
valu
bleed
complic
petechia
ecchymosi
melena
epistaxi
retin
hemorrhag
respiratori
complic
tachypnea
cough
respiratori
acidosi
infiltr
chest
radiograph
cn
complic
papilledema
photophobia
headach
median
durat
start
chemotherapi
less
hydroxyurea
group
p
valu
signific
advers
drug
effect
hydroxyurea
observ
conclus
addit
hydroxyurea
convent
treatment
lead
rapid
earli
declin
tlc
without
signific
advers
drug
effect
hydroxyurea
treatment
given
standard
conserv
treatment
includ
intraven
fluid
alkalin
allopurinol
monitor
mrd
childhood
aml
use
set
seven
gene
simpl
method
strong
prognost
impact
steinbach
p
bader
willasch
bartholoma
km
debatin
zimmermann
u
creutzig
reinhardt
b
gruhn
pediatr
oncolog
univers
medic
center
ulm
germani
pediatr
oncolog
univers
medic
center
frankfurt
germani
pediatr
oncolog
medic
school
hannov
germani
pediatr
oncolog
univers
medic
center
jena
germani
object
studi
evalu
prognost
impact
simpl
highli
standard
assay
monitor
minim
residu
diseas
mrd
acut
myeloid
leukemia
aml
method
express
seven
leukemia
associ
gene
prame
msln
measur
taqman
low
densiti
array
bone
marrow
children
aml
healthi
control
patient
treat
accord
multicent
studi
sampl
collect
analyz
prospect
standard
time
point
diagnosi
lab
measur
mrd
blind
clinic
cours
patient
result
relaps
free
surviv
rf
n
se
express
gene
normal
n
se
express
elev
normal
n
se
patient
still
show
elev
express
least
one
gene
p
prognost
impact
still
highli
signific
p
patient
stratifi
establish
risk
factor
relev
time
point
measur
treatment
respons
conclus
method
strongli
predict
outcom
childhood
aml
easili
adopt
group
taqman
low
densiti
array
commerci
avail
fulli
standard
method
toxic
associ
age
dja
j
abrahamsson
sy
ha
og
koskenvuo
b
lausen
j
pall
b
zeller
h
hasl
depart
paediatr
aarhu
univers
hospit
skejbi
aarhu
denmark
depart
pediatr
institut
clinic
scienc
queen
silvia
children
hospit
gothenburg
sweden
depart
pediatr
queen
mari
hospit
hong
kong
pediatr
hematolog
oncolog
studi
group
hkphosg
hong
kong
china
depart
pediatr
landspitalinn
reykjavik
iceland
depart
pediatr
turku
univers
hospit
turku
finland
depart
pediatr
adolesc
medicin
rigshospitalet
univers
copenhagen
denmark
copenhagen
denmark
depart
woman
children
health
uppsala
univers
uppsala
sweden
depart
pediatr
medicin
oslo
univers
hospit
oslo
norway
depart
pediatr
aarhu
univers
hospit
skejbi
aarhu
denmark
object
due
high
intens
treatment
childhood
acut
myeloid
leukemia
aml
almost
patient
experi
sever
toxic
life
threaten
children
year
aml
wors
outcom
compar
younger
children
part
due
treatment
relat
mortal
investig
rang
toxic
protocol
method
review
toxic
regist
databas
protocol
includ
protocol
patient
nordic
countri
hong
kong
n
censor
patient
time
hsct
result
mortal
day
diagnosi
occur
therapi
sepsissept
shock
significantli
common
year
old
compar
year
old
vs
p
admiss
intens
care
unit
common
year
old
compar
year
old
vs
p
differ
also
seen
infant
compar
year
old
significantli
vs
p
noteworthi
differ
seen
reach
signific
assist
ventil
common
infant
year
old
compar
year
old
vs
creatinin
elev
x
normal
often
infant
year
old
compar
year
old
vs
bilirubin
elev
x
normal
often
infant
compar
year
old
vs
toxic
seen
often
year
old
central
neurotox
vs
year
old
p
conclus
infant
year
old
experienc
toxic
aml
treatment
especi
true
admiss
icu
sepsi
assist
ventil
molecular
cytogenet
analys
pediatr
acut
myeloid
leukemia
patient
obtain
complet
remiss
induct
therapi
report
jplsg
studi
hara
k
ohki
n
shiba
shimada
tomizawa
taga
adachi
h
arakawa
tawa
hayashi
pediatr
gunma
univers
hospit
japan
hematologyoncolog
gunma
children
medic
center
japan
pediatr
hematologyoncolog
japanes
pediatr
leukemialymphoma
studi
group
nagoya
japan
purpos
recent
improv
chemotherapi
increas
surviv
rate
patient
pediatr
acut
myeloid
leukemia
aml
howev
subgroup
still
poor
prognosi
despit
intens
chemotherapi
hematopoiet
stem
cell
transplant
hsct
indic
necess
specif
identif
subgroup
prognosi
patient
remiss
induct
therapi
consid
extrem
poor
littl
known
molecular
characterist
studi
report
molecular
identif
pediatr
aml
case
patient
method
analyz
pediatr
aml
case
enrol
studi
japan
induct
therapi
case
achiev
cr
kit
detect
mlpa
method
result
wbc
count
significantli
higher
case
vs
p
conclus
convent
chemotherapi
hsct
thought
insuffici
pediatr
aml
patient
distinct
biolog
therefor
novel
target
therapi
genet
mutat
expect
refractori
cytopenia
children
acquir
aplast
anemia
clinic
patholog
studi
case
x
qin
baumann
j
chen
p
shen
jf
chen
mz
yin
depart
hematolog
oncolog
shanghai
children
medic
center
affili
shanghai
jiao
tong
univers
school
medicin
shanghai
china
depart
patholog
boeblingen
hospit
boeblingen
germani
depart
patholog
shanghai
children
medic
center
affili
shanghai
jiao
tong
univers
school
medicin
shanghai
china
object
explor
clinic
characterist
histopatholog
morpholog
featur
bone
marrow
biopsi
refractori
cytopenia
children
rcc
acquir
aplast
anemia
aaa
facilit
diagnosi
differenti
diagnosi
treatment
rcc
aaa
method
retrospect
analyz
clinic
data
histopatholog
morpholog
bone
marrow
biopsi
rcc
aaa
patient
januari
decemb
hospit
result
total
patient
studi
final
diagnos
rcc
case
aaa
case
ratio
rcc
aaa
studi
median
wbc
count
absolut
neutrophil
count
blood
platelet
count
hemoglobin
level
reticulocyt
count
higher
rcc
children
aaa
pmicromegakaryocyt
found
aaa
group
cellular
bone
marrow
biopsi
specimen
megakaryocyt
found
respons
rate
immunosuppress
therapi
ist
use
csa
rabbit
globulin
patient
rcc
aaa
month
p
month
p
conclus
rcc
aaa
uncommon
childhood
bone
marrow
failur
disord
rcc
patient
show
milder
cytopenia
bone
marrow
hyperplasia
aaa
patchi
distribut
hematopoiet
cell
erythroid
island
mark
left
shift
micromegakaryocyt
decis
histomorpholog
pattern
use
separ
rcc
saa
ist
effect
therapi
patient
rcc
aaa
outcom
ist
patient
rcc
superior
patient
aaa
condit
children
acut
lymphoblast
leukemia
prepar
regimen
allogen
hematopoet
stem
cell
transplant
ebmt
paediatr
diseas
work
parti
studi
c
peter
n
zubarovskaya
p
bader
jh
dall
hamidieh
c
lankest
f
locatelli
j
wachowiak
yassilibek
stem
cell
transplant
unit
st
anna
children
hospit
vienna
austria
stem
cell
transplant
unit
univers
hospit
frankfurt
frankfurt
germani
stem
cell
transplant
unit
univers
hospit
pari
debr
pari
franc
stem
cell
transplant
unit
univers
hospit
teheran
teheran
iran
stem
cell
transplant
unit
univers
hospit
barcelona
barcelona
spain
stem
cell
transplant
unit
univers
hospit
leiden
leiden
netherland
stem
cell
transplant
unit
hospit
bambini
gesu
rome
itali
stem
cell
transplant
unit
univers
hospit
poznan
poznan
poland
stem
cell
transplant
unit
univers
hospit
ankara
ankara
turkey
object
total
bodi
irradi
tbi
backbon
condit
regimen
children
high
risk
acut
lymphoblast
leukemia
situat
preclud
applic
tbi
eg
young
patient
age
morbid
centr
facil
get
detail
outcom
inform
children
receiv
condit
ebmt
paediatr
diseas
work
parti
initi
longitudin
retrospect
studi
method
identifi
children
adolesc
receiv
first
hsct
regist
ebmt
data
base
major
transplant
unrel
donor
bone
marrow
result
stem
cell
sourc
bone
marrow
peripher
blood
stem
cell
receiv
cord
blood
patient
centr
intend
myeloabl
condit
reduc
toxic
reduc
intens
condit
regimen
chosen
prefer
condit
regimen
combin
busulfan
cyclophosphamid
follow
regimen
consist
busulfan
cyclophosphamid
etoposid
remain
patient
receiv
differ
combin
like
fludarabinethiotepamelphalan
treosulphan
time
analysi
patient
aliv
caus
death
relaps
transplant
relat
complic
patient
transplant
overal
surviv
compar
relaps
incid
lower
incid
mortal
compar
whole
cohort
children
transplant
age
year
lower
relaps
incid
overal
surviv
conclus
children
receiv
condit
regimen
allogen
hsct
differ
donor
differ
remiss
statu
aliv
observ
justifi
request
prospect
evalu
whether
tbi
still
superior
compar
condit
regimen
chemotherapi
compar
cohort
patient
transarteri
embol
primari
hepat
malign
tumor
pediatr
patient
singl
institut
experi
j
wang
q
shu
li
q
xiong
lou
pediatr
oncolog
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
object
purpos
studi
evalu
feasibl
efficaci
transarteri
chemoembol
tace
treat
pediatr
primari
hepat
malign
tumor
phmt
method
patient
age
month
year
initi
unresect
phmt
enrol
studi
case
hepatombalstoma
hb
case
hepat
carcinoma
hc
case
undifferenti
embryon
liver
sarcoma
uel
percutan
punctur
biopsi
patient
receiv
tace
time
chemotherapi
surgeri
materi
obtain
patient
tumor
respons
surviv
rate
complic
analyz
result
follow
tace
visibl
reduct
tumor
size
well
dramat
decreas
afp
level
patient
hepatoblastoma
tumor
volum
evalu
use
ct
mri
decreas
mean
valu
multipl
metasatsi
mass
found
one
patient
hb
tace
patient
pretext
stage
iv
tumor
hb
hc
remain
unresect
time
tace
complet
surgic
resect
achiev
patient
patient
underw
surgeri
case
receiv
least
year
one
patient
found
lung
metastasi
lesion
month
surgeri
event
free
surviv
ef
rate
complic
includ
fever
transient
impair
hepat
function
abdomin
pain
conclus
tace
safe
promis
method
low
rate
sever
complic
treat
pediatr
phmt
result
surgic
treatment
children
hepatoblastoma
netherland
nation
wide
analysi
wijnen
l
busweil
j
wild
j
ziro
c
terwisscha
van
scheltinga
r
bakx
h
heij
surgeri
radboud
univers
nijmegen
medic
centr
nijmegen
netherland
pediatricsurgeri
pediatr
surgic
center
amsterdam
emma
children
hospit
amc
vu
medic
center
amsterdam
netherland
pediatr
pediatr
surgic
center
amsterdam
emma
children
hospit
amc
vu
medic
center
amsterdam
netherland
pediatr
surgeri
erasmu
medic
center
rotterdam
netherland
pediatr
surgeri
pediatr
surgic
center
amsterdam
emma
children
hospit
amc
vu
medic
center
amsterdam
netherland
object
surgic
resect
remain
cornerston
success
treatment
hepatoblastoma
better
insight
result
surgeri
may
improv
outcom
hepatoblastoma
patient
even
therefor
aim
studi
review
result
surgeri
treatment
hepatoblastoma
netherland
retrospect
focus
surgeri
relat
complic
complet
resect
intrahepat
tumour
morbid
surgic
mortal
long
term
surviv
method
retrospect
chart
review
perform
patient
treat
hepatoblastoma
one
paediatr
surgic
center
academ
hospit
amsterdam
nijmegen
groningen
rotterdam
result
total
patient
includ
among
patient
underw
partial
liver
resect
patholog
report
show
complet
tumour
resect
patient
microscop
tumour
residu
patient
patient
one
complic
report
patient
report
haemorrhag
need
transfus
nine
patient
develop
biliari
complic
need
one
addit
surgic
intervent
overal
year
surviv
group
patient
partial
hepatectomi
year
surviv
group
patient
initi
transplant
year
surviv
conclus
partial
liver
resect
children
hepatoblastoma
associ
high
complic
rate
gemcitabin
oxaliplatin
treatment
pediatr
patient
hepatocellular
carcinoma
af
oneil
mh
malogolowkin
l
brugier
casanova
ji
geller
schmid
r
venkatramani
p
thompson
j
feusner
aa
rangaswami
pediatr
oncolog
cancer
institut
boston
usa
pediatr
medic
colleg
wisconsin
milwauke
usa
pediatr
institut
gustav
roussi
villejuif
franc
pediatr
ircc
fondazion
istituto
nazional
tumori
milano
itali
pediatr
univers
cincinnati
cincinnati
usa
pediatr
dr
von
hauner
children
hospit
munich
germani
pediatr
children
hospit
lo
angel
lo
angel
usa
pediatr
texa
children
cancer
hematolog
center
houston
usa
pediatr
children
hospit
research
center
oakland
oakland
usa
pediatr
stanford
univers
palo
alto
usa
object
pediatr
patient
hepatocellular
carcinoma
hcc
often
treat
therapi
despit
distinct
histolog
natur
histori
patient
unresect
metastat
diseas
fare
poorli
less
overal
surviv
indic
need
new
therapeut
approach
adult
studi
demonstr
hcc
respons
gemcitabin
oxaliplatin
gemox
either
retriev
therapi
compil
data
pediatr
oncologist
regard
experi
treat
pediatr
hcc
patient
gemox
method
intern
work
group
compris
children
oncolog
group
cog
international
doncologi
siop
gesellschaft
onkologi
und
gpoh
japanes
studi
group
pediatr
liver
tumor
jplt
member
met
tubingen
germani
march
discuss
prospect
treatment
strategi
pediatr
hcc
patient
design
secur
electron
survey
collect
patient
inform
regard
histolog
age
dose
respons
toxic
result
physician
poll
respond
eight
physician
treat
patient
convent
fibrolamellar
fl
gemox
patient
age
rang
year
patient
receiv
gemcitabin
oxaliplatin
major
receiv
week
dose
gemox
given
time
use
recist
criteria
seven
patient
achiev
upfront
partial
respons
pr
seven
patient
achiev
stabl
diseas
durat
month
patient
fl
respect
pr
sustain
cycl
patient
becam
resect
ten
patient
progress
eleven
patient
experienc
toxic
includ
grade
cytopenia
grade
nauseavomit
feverneutropenia
hepatopathi
neuropathi
allerg
reaction
conclus
comprehens
report
date
gemox
use
pediatr
patient
hcc
retriev
set
respons
rate
promis
report
adult
result
support
potenti
trial
gemox
therapi
pediatr
hcc
undifferenti
embryon
sarcoma
liver
multicent
experi
cw
ppggl
group
p
czauderna
murawski
dantonello
leuschner
j
fuch
g
seitz
klingebiel
e
koscielniak
surgeri
urolog
children
adolesc
medic
univers
gdansk
gdansk
poland
cw
cooper
weichteilsarkom
studiengrupp
group
stuttgart
germani
institu
patholog
cooper
weichteilsarkom
studiengrupp
group
kiel
germani
depart
pediatr
surgeri
univers
tubingen
cooper
weichteilsarkom
studiengrupp
group
tubingen
germani
univers
hospit
frankfurt
klinik
und
jugendmedizin
cooper
weichteilsarkom
studiengrupp
group
frankfurt
germani
depart
pediatr
oncolog
olga
hospit
cooper
weichteilsarkom
studiengrupp
group
stuttgart
germani
object
liver
sarcoma
rare
repres
primari
hepat
tumor
among
undifferenti
embryon
sarcoma
liver
uesl
prevail
aim
studi
assess
outcom
uesl
multin
studi
method
patient
uesl
treat
trial
germani
poland
median
age
diagnosi
year
month
year
patient
male
femal
lesion
involv
singl
hepat
lobe
case
right
left
lobe
case
case
inform
miss
tumor
multifoc
case
tumor
size
cm
case
greater
cm
four
children
distant
metastasi
present
disappear
follow
chemotherapi
fifteen
patient
receiv
preoper
chemotherapi
result
good
respons
chemotherapi
observ
case
partial
progress
diseas
miss
data
postop
chemotherapi
administ
children
local
radiotherapi
use
children
tumor
resect
perform
patient
primari
delay
complet
resect
achiev
patient
aliv
resect
margin
posit
patient
aliv
one
child
macroscop
incomplet
resect
aliv
five
tumor
never
becam
oper
die
median
fu
month
seventeen
patient
aliv
evid
diseas
eight
patient
die
progress
relaps
death
three
patient
relaps
oper
andor
relaps
die
conclus
patient
ud
liver
good
prognosi
ane
treat
multimod
therapi
complet
resect
tradit
consid
cornerston
treatment
uesl
howev
experi
even
microscop
incomplet
resect
associ
rel
good
surviv
potenti
novel
therapeut
target
hepatoblastoma
shi
r
patel
c
kettlun
j
nuchtern
j
yang
k
bissig
vasudevan
michael
e
debakey
depart
surgeri
baylor
colleg
medicin
houston
usa
center
cell
gene
therapi
baylor
colleg
medicin
houston
usa
depart
pediatr
baylor
colleg
medicin
houston
usa
depart
molecular
cellular
biolog
baylor
colleg
medicin
houston
usa
depart
patholog
baylor
colleg
medicin
houston
usa
object
hepatoblastoma
hb
common
malign
liver
tumor
childhood
continu
poor
outcom
unresect
andor
metastat
diseas
major
hb
patient
diagnosi
wild
type
tumor
suppressor
gene
endogen
mechan
major
neg
regul
copi
number
gain
amplif
observ
subset
hb
patient
hypothes
primari
regul
function
hepatoblastoma
block
caus
tumor
cell
death
due
uninhibit
tumor
suppressor
activ
method
mtt
assay
measur
cytotox
perform
hb
cell
cell
line
treat
vari
concentr
inhibitor
inhibitor
luciferas
assay
use
assess
activ
cell
treat
western
blot
use
measur
express
level
bax
puma
cell
treat
result
test
show
signific
cell
death
inhibit
caus
signific
cell
death
increas
activ
observ
hour
exposur
p
indic
induct
apoptosi
western
blot
express
downstream
transcript
target
bax
puma
increas
cell
hour
exposur
conclus
data
support
hypothesi
activ
suppress
hepatoblastoma
inhibit
may
viabl
therapeut
strategi
develop
novel
consult
servic
paediatr
rare
tumor
siopel
clinician
onlin
consult
servic
rangaswami
e
rinaldi
oneil
b
haeberl
r
maibach
roebuck
eiso
hiiyama
r
meyer
p
czauderna
pediatr
stanford
univers
palo
alto
usa
pmp
cineca
bologna
itali
pediatr
oncolog
dana
farber
cancer
institu
boston
usa
pediatr
surgeri
univers
munich
germani
trial
activ
ibcsg
bern
switzerland
intervent
radiolog
great
ormond
street
hospit
children
london
unit
kingdom
depart
patholog
immunolog
baylor
colleg
medicin
houston
usa
natur
scienc
center
basic
research
develop
hiroshima
univers
hiroshima
japan
depart
surgeri
univers
utah
salt
lake
citi
usa
depart
surgeri
medic
univers
gdansk
gdansk
poland
object
liver
tumor
children
quit
rare
individu
clinician
experi
usual
limit
yet
treatment
decis
must
made
complex
diagnost
dilemma
common
especi
true
relapsedrefractori
patient
optim
care
requir
coordin
disciplin
effort
improv
care
clinician
repres
four
major
intern
trial
group
cooper
develop
novel
consult
servic
method
support
grant
encca
repres
siopel
gpoh
cog
jplt
develop
servic
access
siopel
clinician
may
submit
consult
request
assist
diagnosi
radiograph
patholog
evalu
manag
patient
request
direct
specif
disciplin
group
disciplin
surgeri
oncolog
radiolog
patholog
disciplin
request
review
one
two
moder
sent
panel
recogn
expert
four
disciplin
repres
cooper
group
panel
provid
inform
regard
diagnosi
treatment
option
websit
facilit
opportun
onlin
discuss
amongst
expert
option
summar
circul
back
panelist
treat
institut
treat
institut
must
attest
ultim
respons
make
manag
decis
order
gain
access
site
total
consult
time
seven
day
result
consult
servic
final
develop
anticip
launch
juli
conclus
servic
repres
opportun
enhanc
care
children
rare
tumor
facilit
educ
clinician
care
challeng
patient
may
serv
model
cooper
manag
paediatr
rare
malign
research
lead
result
receiv
fund
european
union
seventh
framework
programm
project
encca
grant
agreement
comprehens
molecular
character
clear
cell
sarcoma
kidney
ccsk
children
oncolog
group
target
project
goosken
gadd
meerzaman
j
khan
r
de
krijger
van
den
j
guidri
auvil
gerhard
gerhard
smith
e
perlman
depart
pediatr
hematolog
oncolog
erasmu
mc
sophia
children
hospit
rotterdam
netherland
depart
patholog
northwestern
univers
feinberg
school
medicin
robert
h
luri
cancer
center
chicago
usa
center
biomed
informat
inform
technolog
nation
cancer
institut
nation
institut
health
bethesda
usa
pediatr
oncolog
branch
nation
cancer
institut
bethesda
usa
depart
patholog
josephin
nefken
institut
erasmu
mc
rotterdam
netherland
offic
cancer
genom
nation
cancer
institut
bethesda
usa
cancer
therapi
evalu
program
nation
cancer
institut
bethesda
usa
object
clear
cell
sarcoma
kidney
ccsk
rare
childhood
renal
tumor
compris
approxim
primari
renal
tumor
children
molecular
background
ccsk
poorli
understood
current
studi
aim
identifi
recurr
pathogenet
chang
result
develop
progress
ccsk
method
therapeut
applic
research
gener
effect
treatment
target
initi
analysi
ccsk
sampl
perform
includ
omic
platform
gene
express
profil
affymetrix
snp
array
analysi
affymetrix
snp
array
whole
genom
sequenc
complet
genom
illumina
truseq
result
gene
express
analysi
show
enrich
multipl
gene
set
involv
sonic
hedgehog
pathway
signific
recurr
copi
number
chang
identifi
whole
genom
sequenc
reveal
extrem
low
somat
mutat
rate
variant
identifi
case
verifi
apart
transloc
identifi
one
case
signific
fusion
mutat
detect
case
conclus
although
gene
express
analysi
continu
show
sonic
hedgehog
pathway
activ
report
recurr
copi
number
chang
recurr
fusion
recurr
somat
mutat
explain
henc
result
suggest
genom
ccsk
rather
stabl
hypomethyl
potenti
marker
blastema
wilmstumor
nj
farinha
p
afonso
h
barroca
l
antun
r
henriqu
c
cancer
biolog
epigenet
group
research
center
portugues
oncolog
institut
porto
portug
depart
patholog
portugues
oncolog
institut
porto
portug
depart
patholog
centro
hospitalar
de
porto
portug
depart
epidemiolog
portugues
oncolog
institut
porto
portug
object
wilm
tumor
wt
tumor
variabl
compos
admixtur
blastema
epithelium
mesenchyma
pretreat
children
residu
blastema
carri
poor
prognosi
howev
blastema
easili
discrimin
compon
glioma
pathogenesi
relat
gene
previous
shown
hypomethyl
wt
express
blastema
correl
clinic
aggress
neoplasm
object
studi
determin
whether
hypomethyl
differenti
blastema
compon
wt
method
patient
wt
institut
admit
homogen
sampl
dna
extract
avail
enrol
four
normal
adult
kidney
fetal
kidney
dysplasia
renal
serv
control
studi
approv
ethic
committe
upon
patholog
review
area
less
blastema
select
macrodissect
dna
extract
bisulf
treat
quantif
promot
methyl
use
real
time
pcr
control
dna
input
case
consid
hypomethyl
methyl
level
lower
normal
adult
kidney
test
use
statist
analysi
result
wt
patient
compris
children
median
age
month
rang
one
adult
overal
area
select
wt
less
blastema
hypomethyl
observ
wt
sampl
fetal
kidney
dysplasia
although
methyl
level
significantli
differ
wt
normal
adult
kidney
p
statist
signific
differ
depict
malign
benign
renal
tumor
p
area
blastema
display
significantli
lower
level
methyl
compar
p
conclus
wt
hypomethyl
level
may
discrimin
blastema
eventu
provid
clinic
use
biomark
confirm
studi
renal
tumor
extens
vascular
diseas
manag
challeng
pediatr
seri
hospit
sick
children
g
zanett
e
wehbi
william
rm
grant
lr
brandao
hematologyoncolog
hospit
sick
children
toronto
canada
urolog
hospit
sick
children
toronto
canada
object
pediatr
renal
tumor
long
recogn
ideal
manag
instanc
vascular
invas
remain
controversi
describ
clinic
behavior
patient
diagnos
renal
tumor
extra
renal
vascular
involv
hospit
sick
children
toronto
canada
method
retrospect
analysi
conduct
patient
diagnos
data
collect
includ
age
gender
symptom
present
stage
patholog
report
radiolog
evid
intravascular
thrombu
ie
renal
vein
rv
inferior
vena
cava
ivc
right
atrium
ra
intraop
find
therapeut
protocol
implement
anticoagul
outcom
tumor
andor
thrombu
recurr
thromboembol
phenomena
surviv
result
patient
renal
tumor
identifi
includ
wilm
renal
cell
carcinoma
rcc
clear
cell
sarcoma
kidney
ccsk
other
median
age
group
year
day
year
extra
renal
vascular
diseas
identifi
patient
median
age
year
year
year
includ
wilm
tumor
rcc
ccsk
pecoma
kidney
vascular
involv
compris
exclus
evid
rv
microscop
diseas
radiolog
find
without
intraoperativepatholog
confirm
macroscop
rv
involv
macroscop
rvivc
vascular
diseas
treatment
escal
vascular
diseas
includ
neoadjuv
chemotherapi
wilm
rcc
intraop
thrombectomi
wilm
cavotomi
wilm
rcc
ccsk
patient
place
cardiopulmonari
bypass
anticoagul
administ
patient
tumor
relat
thrombu
without
complic
one
patient
evid
pulmonari
embol
chest
ct
conclus
renal
tumor
vascular
invas
rare
challeng
entiti
treatment
includ
mostli
therapi
role
vascular
surgic
approach
andor
system
anticoagul
remain
clarifi
long
term
outcom
adolesc
adult
treat
nephroblastoma
retrospect
analysi
siop
gpoh
trial
n
sw
warmann
r
leuschner
jp
schenk
c
n
graf
pediatr
hematolog
oncolog
univers
children
hospit
pediatr
oncolog
homburg
germani
pediatr
surgeri
urolog
univers
hospit
tuebingen
tuebingen
germani
pediatr
hematolog
oncolog
univers
children
hospit
homburg
germani
pediatr
patholog
univers
hospit
kiel
kiel
germani
pediatr
radiolog
univers
hospit
heidelberg
heidelberg
germani
radiotherapi
univers
hospit
homburg
homburg
germani
pediatr
hematolog
oncolog
univers
hospit
homburg
homburg
germani
object
wilm
tumor
wt
adult
rare
sinc
renal
tumour
studi
centr
germani
regist
case
wt
older
year
age
uniform
treat
accord
siop
pediatr
wt
protocol
adapt
adult
wt
guidelin
intent
identifi
risk
factor
relaps
adolesc
adult
wt
method
retrospect
analyz
patient
older
year
treat
wt
german
hospit
data
collect
form
use
children
result
patient
treat
neoadjuv
chemotherapi
underw
primari
surgeri
initi
tumor
volum
document
case
mean
tumor
volum
patient
metastasi
time
diagnosi
central
patholog
review
done
patient
local
stage
distribut
primari
surgeri
compar
preoper
chemotherapi
versu
stage
versu
stage
ii
versu
stage
iii
overal
surviv
os
patient
primari
surgeri
vs
metastat
versu
patient
time
diagnosi
multivari
analysi
includ
age
diagnosi
sex
metastasi
time
diagnosi
time
treatment
initi
treatment
histolog
subtyp
local
stage
confound
reveal
local
stage
iii
independ
risk
factor
relaps
p
conclus
data
show
local
stage
iii
main
risk
factor
relaps
adolesc
adult
wt
patient
similar
wt
patient
age
data
emphas
regist
group
patient
prospect
multicentr
trial
molecular
genet
analysi
need
done
understand
aetiolog
adult
nephroblastoma
find
new
treatment
approach
signific
renal
dysfunct
surgeri
children
unilater
renal
tumor
cozzi
ceccanti
frediani
morgant
falconi
r
iaconelli
f
cozzi
pediatr
surgeri
unit
sapienza
univers
rome
rome
itali
object
adult
kidney
tumor
baselin
renal
dysfunct
rd
consid
signific
risk
factor
progress
renal
function
declin
nephrectomi
children
unilater
renal
tumor
urt
data
avail
renal
function
outcom
children
baselin
rd
evalu
renal
function
cohort
children
urt
baselin
rd
method
retrospect
identifi
children
urt
underw
surgeri
institut
serum
creatinin
poorli
reflect
renal
function
estim
glomerular
filtrat
rate
egfr
index
serum
creatinin
measur
age
sex
race
updat
bedsid
schwartz
equat
mdrd
equat
appropri
age
use
calcul
egfr
rd
defin
egfr
result
children
suffici
data
evalu
baselin
egfr
present
baselin
rd
second
decad
life
surgeri
patient
baselin
rd
despit
excis
per
cent
renal
parenchyma
present
signific
increas
mean
sd
egfr
vs
p
five
children
baselin
rd
underw
surgeri
nss
present
second
decad
life
surgeri
mean
sd
egfr
similar
subject
two
healthi
kidney
vs
p
overal
none
patient
underw
nss
underw
nephrectomi
present
persist
newli
acquir
rd
four
patient
rd
present
baselin
egfr
conclus
children
urt
baselin
rd
appear
paraneoplast
clinic
manifest
subject
reduc
renal
reserv
capac
renal
tumor
associ
baselin
renal
dysfunct
may
clinic
surrog
marker
low
nephron
number
endow
embryon
sarcoma
liver
popul
base
analysi
use
seer
databas
j
smith
b
crompton
k
ribeiro
l
frazier
school
medicin
boston
univers
boston
usa
pediatr
oncolog
children
cancer
care
boston
usa
faculdad
de
ciencia
medica
santa
casa
medic
school
sao
paolo
brazil
pediatr
oncolog
children
cancer
center
boston
usa
object
embryon
sarcoma
liver
esl
rare
entiti
adult
case
occur
children
previou
case
seri
rare
tumor
report
overal
surviv
local
diseas
high
howev
recent
may
et
al
describ
patient
current
aliv
diseas
free
first
remiss
month
time
diagnosi
incid
surviv
patient
esl
studi
use
retrospect
analysi
object
evalu
incid
organ
patient
demograph
well
surviv
malign
use
unit
state
nation
cancer
institut
surveil
epidemiolog
end
result
seer
registri
method
seer
databas
search
patient
diagnos
esl
data
analyz
includ
patient
demograph
incid
surviv
result
case
age
year
identifi
repres
liver
tumor
children
median
age
diagnosi
year
year
tumor
common
male
femal
vs
tumor
undifferenti
grade
iv
tumor
although
tumor
local
diagnosi
region
distant
diseas
patient
surgic
resect
patient
receiv
radiotherapi
seer
collect
info
chemotherapi
surviv
stage
respect
report
overal
surviv
esl
conclus
analysi
esl
allow
accur
assess
surviv
outcom
previous
possibl
case
seri
analysi
demonstr
prognosi
esl
improv
time
prognosi
excel
local
diseas
increment
valu
pet
role
earli
interim
pet
respons
predict
outcom
pediatr
nhl
n
thacker
b
arora
v
rangarajan
banavali
g
narula
shah
g
chinnaswami
medhi
gujral
sheth
laskar
pediatr
oncolog
tata
memori
hospit
mumbai
india
nuclear
medicin
tata
memori
hospit
mumbai
india
nuclear
medicin
tata
memori
hospit
mumbai
india
pediatr
oncolog
tata
memori
hospit
mumbai
india
radiolog
tata
memori
hospit
mumbai
india
patholog
tata
memori
hospit
mumbai
india
radiotherapi
tata
memori
hospit
mumbai
india
object
studi
object
studi
role
earli
interim
pet
pediatr
nhl
term
respons
predict
final
outcom
studi
increment
valu
baselin
pet
bone
marrow
stage
method
newli
diagnos
case
pediatr
yr
nhl
non
lymphoblast
interim
petct
scan
includ
studi
januari
decemb
done
cycl
chemotherapi
patient
treat
mcp
protocol
cycl
relat
cr
pr
interim
petct
scan
pf
os
analyz
use
surviv
analysi
post
complet
therapi
patient
follow
per
institut
protocol
result
patient
includ
studi
advanc
diseas
stage
iiiiv
median
age
present
yr
median
follow
month
bm
posit
patient
uptak
pet
howev
patient
marrow
uptak
pet
upstag
diseas
patient
bm
involv
pet
significantli
lower
pfso
compar
pet
neg
marrow
margin
better
pfso
compar
convent
stage
iv
interim
pet
show
cr
patient
pr
patient
progress
diseas
patient
cr
interim
pet
continu
end
treatment
respons
interim
pet
could
predict
progress
free
surviv
pf
p
overal
surviv
p
conclus
petct
scan
pediatr
nhl
pick
addit
site
marrow
involv
lead
clinic
relev
upstag
diseas
poor
prognost
signific
interim
petct
significantli
predict
pf
os
nhl
make
import
respons
assess
prognost
risk
adapt
strategi
futur
prognost
impact
cytogenet
abnorm
children
adolesc
matur
lymphoma
report
japanes
pediatr
leukemialymphoma
studi
group
jplsg
sekimizu
mori
kikuchi
mitsui
sunami
r
kobayashi
n
fujita
h
inada
kikuchi
takimoto
saito
watanab
j
fujimoto
nakazawa
k
ohshima
k
horib
tsurusawa
lymphoma
committe
japanes
pediatr
leukemialymphoma
studi
group
nagoya
japan
object
limit
inform
cytogenet
abnorm
prognost
import
childhood
matur
lymphoma
method
perform
review
abnorm
karyotyp
childhood
matur
treat
jplsg
result
total
case
classifi
burkitt
lymphoma
bl
lymphoma
bll
classifi
diffus
larg
lymphoma
dlbcl
other
total
stage
stage
ii
stage
iii
stage
iv
acut
leukemia
murphi
stage
compar
patient
without
abnorm
karyotyp
signific
advanc
stage
especi
patient
leukemia
high
ldh
level
almost
cytogenet
aberr
whole
popul
occur
incid
previous
report
childhood
studi
except
rearrang
incid
cytogenet
aberr
blbll
distinct
report
except
pattern
chromosom
alter
dlbcl
similar
report
prognost
valu
cytogenet
abnorm
event
free
surviv
ef
studi
cox
model
control
clinic
risk
factor
der
del
independ
associ
signific
inferior
ef
hazard
ratio
p
p
respect
advers
prognosi
del
observ
blbll
tendenc
ef
decreas
patient
del
previous
report
prognost
factor
childhood
matur
conclus
cytogenet
risk
factor
studi
differ
report
childhood
matur
result
emphas
signific
biolog
differ
ethnic
develop
cytogenet
therapi
childhood
matur
clinicopatholog
find
treatment
outcom
juvenil
mycosi
fungoid
cutan
lymphoma
frequent
follicular
involv
good
respons
skin
target
therapi
e
hodak
feinmess
b
davidovici
david
zvulumov
f
pavlotski
yaniv
g
avrahami
dermatolog
beilinson
hospit
rabin
medic
center
sackler
faculti
medicin
tel
aviv
univers
israel
dermatolog
beilinson
hospit
rabin
medic
center
israel
patholog
beilinson
hospit
rabin
medic
center
sackler
faculti
medicin
tel
aviv
univers
israel
dermatolog
beilinson
hospit
rabin
medic
center
sackler
facult
medicin
tel
aviv
univers
israel
pediatr
dermatolog
schneider
children
medic
center
israel
faculti
health
scienc
medic
school
intern
health
univers
negev
israel
dermatolog
sheba
medic
center
sackler
faculti
medicin
tel
aviv
univers
tel
hashom
israel
pediatr
hematolog
oncolog
schneider
children
medic
center
israel
sackler
faculti
medicin
tel
aviv
univers
israel
pediatr
hematolog
oncolog
schneider
children
medic
center
israel
sackler
faculti
medicin
tel
aviv
univers
israel
pediatr
dermatolog
schneider
children
medic
center
israel
sackler
faculti
medicin
tel
aviv
univers
israel
object
mycosi
fungoid
mf
common
type
cutan
lymphoma
case
diagnos
age
year
studi
north
america
europ
report
rate
occurr
age
year
sever
report
suggest
juvenil
mf
much
common
asian
countri
preval
aim
evalu
characterist
juvenil
mf
larg
cohort
method
data
collect
patient
mf
age
year
clinicopatholog
diagnosi
attend
dermatolog
depart
rabin
medic
center
follow
prospect
result
sampl
includ
patient
male
mean
age
year
diagnosi
fitzpatrick
skin
type
diagnos
diseas
except
iib
eight
classic
mf
lesion
variant
alon
combin
mainli
hypopig
mf
n
delic
clear
clinicohistolog
featur
folliculotrop
mf
fmf
n
among
variou
therapi
appli
psoralenuva
puva
systemicbath
prove
effici
fmf
vast
major
young
patient
present
diseas
unusu
variant
especi
hypopig
mf
novel
find
studi
high
percentag
fmf
affect
patient
character
superfici
clinic
featur
histopatholog
fewer
infiltr
adult
fmf
show
good
respons
puva
year
mean
patient
progress
stage
ia
ib
iia
conclus
report
largest
seri
juvenil
mf
first
focu
fmf
fmf
uncommon
childrenadolesc
character
superfici
clinic
featur
fewer
heavi
infiltr
adult
fmf
good
respons
puva
prognost
signific
childhood
fmf
remain
unclear
macrophag
polar
pediatr
classic
hodgkin
lymphoma
correl
viru
statu
outcom
barro
p
segg
g
r
hassan
g
niedobitek
institut
patholog
unfallkrankenhau
berlin
berlin
germani
bone
marrow
transplant
center
brazilian
nation
cancer
institut
rio
de
janeiro
brazil
object
shown
recent
viru
ebv
pediatr
classic
hodgkin
lymphoma
chl
tumor
microenviron
tum
character
profil
higher
number
cell
compar
adult
chl
object
studi
evalu
macrophag
polar
mp
tum
pediatr
chl
median
impact
surviv
method
mp
analys
combin
cmaf
marker
express
level
lyz
gene
investig
result
analyz
context
age
histolog
characterist
clinic
previou
studi
popul
case
chl
case
studi
includ
nodular
sclerosi
ns
mix
cellular
mc
case
result
case
patient
year
display
higher
number
cell
p
compar
oldest
higher
number
macrophag
observ
case
tumor
microenviron
profil
disclos
ratio
cell
cell
p
p
respect
ebv
case
exhibit
high
number
p
macrophag
level
lyz
express
associ
number
macrophag
ebv
presenc
better
observ
case
high
number
macrophag
p
wors
surviv
pf
observ
case
high
number
macrophag
p
gene
express
associ
surviv
conclus
result
suggest
pediatr
chl
macrophag
polar
may
depend
ebv
statu
hr
cell
predomin
polar
associ
wors
pf
post
kidney
transplant
lymphoprolif
diseas
sorrentino
garaventa
f
ginevri
cioni
zecca
p
comoli
oncolog
istituto
giannina
gaslini
genoa
itali
nephrolog
istituto
giannina
gaslini
genoa
itali
oncoematologia
pediatrica
fondazion
ircc
policlinico
san
matteo
pavia
itali
object
lymphoprolif
diseas
ptld
heterogen
group
lymphoid
disord
may
complic
transplant
due
clinicopatholog
heterogen
patient
peculiar
unifi
treatment
approach
method
retrospect
monocentr
studi
enrol
patient
mf
ptld
kidney
transplant
result
median
age
diagnosi
year
year
median
time
ptld
month
month
case
earli
ptld
month
transplant
major
part
ptld
month
ptld
earli
lesion
case
polymorph
monomorph
lineag
patient
lineag
unknown
one
treatment
surgic
case
antibodi
one
chemotherapi
deriv
lineag
receiv
associ
antibodi
chemotherapi
administr
accord
aieop
protocol
without
methotrex
reduc
dose
nine
patient
receiv
autolog
cytotox
end
treatment
consolid
remiss
complet
remiss
achiev
patient
three
patient
develop
second
ptld
two
case
histolog
type
respect
month
first
plasmacyt
hyperplasia
month
first
polymorph
hyperplasia
third
monomorph
ptld
month
extramedullari
plasmocytoma
patient
plasmacyt
hyperplasia
develop
month
second
form
ptld
treat
chemo
radiotherapi
obtain
remiss
one
patient
die
infect
one
diseas
thirteen
patient
aliv
diseas
free
median
month
month
therapi
well
toler
patient
maintain
good
function
conclus
multidisciplinari
approach
allow
good
clinic
cours
complic
hematopoiet
stem
cell
transplant
relaps
alk
anaplast
larg
cell
lymphoma
children
adolesc
studi
behalf
sfce
strullu
j
kanold
bertrand
jh
dall
c
paillard
baruchel
chevanc
mc
le
deley
g
michel
l
pediatr
oncolog
hematolog
chu
de
nant
nant
franc
pediatr
oncolog
hematolog
hopit
esta
clermont
ferrand
franc
pediatr
hematolog
insitut
ete
doncologi
pediatriqu
lyon
franc
pediatr
hematolog
hopit
robert
pari
franc
pediatr
oncolog
hematolog
hopit
hautepierr
strasbourg
franc
pediatr
hematolog
hopit
robert
pari
franc
biostatist
epidemiolog
unit
gustav
roussi
villejuif
franc
pediatr
hematolog
hopit
la
timon
marseil
franc
pediatr
oncolog
gustav
roussi
villejuif
franc
object
allogen
hematopoiet
stem
cell
transplant
option
treatment
relapsedanaplast
larg
cell
lymphoma
alcl
children
date
paediatr
report
assess
effici
toler
method
analyz
data
patient
year
median
age
prospect
regist
de
greff
de
moell
et
de
cellulair
databas
receiv
treatment
alcl
alk
transplant
patient
complet
remiss
cr
wherea
detect
diseas
condit
regimen
mostli
n
donor
unrel
n
includ
donor
donor
cord
blood
unit
result
median
year
rang
overal
surviv
respect
se
se
whole
seri
se
se
patient
receiv
first
relaps
six
patient
relaps
median
time
day
durabl
cr
obtain
patient
donor
lymphocyt
inject
n
treatment
n
overal
cumul
incid
relaps
mortal
trm
se
se
respect
eventu
patient
die
due
transplant
toxic
progress
diseas
five
ten
patient
transplant
die
trm
contrast
three
patient
transplant
later
hazard
ratio
trm
ci
conclus
children
relaps
alk
alcl
valid
therapeut
option
howev
high
level
trm
rais
question
place
area
agent
allograft
requir
condit
could
help
reduc
toxic
heavili
patient
epigenet
copi
number
analys
rhabdomyosarcoma
seki
shimamura
k
yoshida
sato
n
riki
kato
g
naga
oka
miyano
h
aburatani
hayashi
ogawa
j
takita
depart
pediatr
univers
tokyo
tokyo
japan
laboratori
dna
inform
analysi
human
genom
center
institut
medic
scienc
univers
tokyo
tokyo
japan
depart
patholog
tumor
biolog
graduat
school
medicin
kyoto
univers
kyoto
japan
genom
scienc
divis
research
center
advanc
scienc
technolog
univers
tokyo
tokyo
japan
depart
hematologyoncolog
gunma
children
medic
center
shibukawa
japan
object
rhabdomyosarcoma
rm
common
pediatr
soft
tissu
sarcoma
histolog
classifi
two
major
subtyp
alveolar
arm
embryon
erm
case
arm
characterist
fusion
gene
erm
subtyp
commonli
harbor
loss
heterozygos
loh
howev
epigenet
alter
underli
pathogenesi
rm
larg
unknown
explor
epigenet
basi
rm
perform
micro
array
base
methyl
copi
number
analys
case
erm
case
arm
method
dna
methyl
microarray
analysi
rm
case
perform
use
infinium
beadchip
illumina
addit
copi
number
analysi
perform
use
array
affymetrix
determin
dna
methyl
profil
select
probe
varianc
rank
top
unsupervis
cluster
analysi
result
unsupervis
hierarch
cluster
identifi
distinct
subtyp
interestingli
subtyp
correl
clinic
featur
genom
alter
includ
fusion
statu
copi
number
gain
chromosom
loh
case
fusion
neg
erm
classifi
cluster
wherea
fusion
posit
case
classifi
either
cluster
importantli
among
cluster
cluster
significantli
associ
favor
outcom
fisher
exact
test
p
valu
conclus
analys
could
separ
rm
case
distinct
methyl
subtyp
associ
clinicopatholog
find
integr
epigenet
analys
enhanc
understand
genet
epigenet
mechan
underli
pathogenesi
rm
role
manag
childhood
rhabdomyosarcoma
systemat
review
g
norman
fayter
k
j
chisholm
h
mandevil
gatz
levin
jenney
k
mchugh
b
phillip
centr
review
dissemin
univers
york
york
unit
kingdom
paediatr
adolesc
oncolog
royal
marsden
foundat
nh
trust
london
unit
kingdom
paediatr
adolesc
oncolog
children
hospit
wale
cardiff
unit
kingdom
radiolog
great
ormond
street
hospit
london
unit
kingdom
object
rhabdomyosarcoma
rm
incid
per
million
children
adolesc
manag
depend
risk
stratif
current
stage
includ
comput
tomographi
ct
magnet
reson
imag
mri
bone
scintigraphi
bone
marrow
biopsi
advanc
function
imag
potenti
improv
stage
accuraci
manag
strategi
method
conduct
systemat
review
prospero
diagnost
accuraci
clinic
effect
function
imag
paediatr
rm
ten
databas
search
novemb
elig
studi
compar
positron
emiss
tomographi
without
ct
diffus
weight
dwi
mri
convent
imag
point
rm
patient
limit
heterogen
data
requir
narr
synthesi
sensit
specif
plot
receiv
oper
curv
space
result
eight
studi
six
two
pet
rm
patient
includ
studi
met
inclus
criteria
pool
estim
calcul
due
spars
data
limit
evid
indic
initi
result
predict
surviv
report
chang
manag
patient
three
studi
nodal
involv
sensit
rang
specif
convent
imag
sensit
specif
distant
metastat
involv
sensit
rang
specif
compar
sensit
specif
convent
imag
spars
data
particular
metastat
site
respons
predict
outcom
report
conclus
may
increas
initi
stage
accuraci
paediatr
rm
specif
detect
nodal
involv
distant
metastat
spread
assess
popul
ideal
repres
unbias
transpar
select
patient
cohort
ie
enter
randomis
control
trial
treatment
fund
children
cancer
leukaemia
group
uk
role
doxorubicin
treatment
rhabdomyosarcoma
preliminari
result
epssg
random
trial
g
bisogno
gl
de
salvo
c
bergeron
carli
ferrari
jenney
h
merck
kelsey
gallego
j
chisholm
orbach
h
martelli
oberlin
steven
depart
pediatr
univers
hospit
padova
padova
itali
biostatist
unit
e
padova
itali
depart
pediatr
centr
leon
berard
lyon
franc
pediatr
unit
istituto
nazional
tumori
milano
itali
pediatr
unit
children
hospit
wale
cardiff
unit
kingdom
depart
pediatr
oncolog
emma
children
hospit
academ
medic
centr
amsterdam
netherland
depart
diagnost
paediatr
histopatholog
royal
manchest
children
hospit
manchest
unit
kingdom
pediatr
oncolog
hospit
universitario
vall
dhebron
barcelona
spain
pediatr
oncolog
royal
marsden
hospit
sutton
unit
kingdom
pediatr
oncolog
institut
curi
pari
franc
servic
di
chirurgi
pediatriqu
hopit
de
bicetr
le
franc
pediatr
oncolog
institut
goustav
roussi
villejuif
franc
pediatr
oncolog
institut
child
life
health
bristol
unit
kingdom
object
doxorubicin
effect
drug
rhabdomyosarcoma
rm
valu
incorpor
establish
multidrug
regimen
remain
controversi
previous
evid
lack
benefit
may
relat
use
low
dose
intens
epssg
studi
incorpor
random
explor
benefit
earli
dose
intensif
doxorubicin
high
risk
patient
method
june
octob
patient
age
month
year
random
cycl
standard
iva
n
ifosfamid
day
vincristin
day
day
ivado
n
experiment
arm
consist
cycl
iva
doxorubicin
day
follow
cycl
iva
tumor
respons
evalu
cycl
local
treatment
surgeri
andor
radiotherapi
deliv
cycl
statist
plan
random
patient
order
detect
power
rel
reduct
event
experiment
arm
hr
result
interim
analysi
perform
includ
patient
iva
ivado
adequ
follow
data
patient
least
event
iva
ivado
median
month
event
free
surviv
ci
iva
ci
ivado
overal
surviv
ci
ci
respect
toxic
greater
ivado
futil
analysi
led
recommend
dmc
stop
random
earlier
plan
conclus
addit
dose
intens
doxorubicin
standard
chemotherapi
fail
show
improv
outcom
patient
non
metastat
rm
epssg
trial
continu
evalu
role
mainten
therapi
cyclophosphamidevinorelbin
alveolar
rhabdomyosarcoma
nodal
involv
group
unfavour
outcom
experi
european
paediatr
soft
tissu
sarcoma
group
epssg
gallego
g
bisogno
c
bergeron
carli
ferrari
jenney
h
martelli
gaze
oberlin
j
chisholm
jhm
merk
orbach
kelsey
gl
de
salvo
steven
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
barcelona
spain
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
padova
itali
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
lyon
franc
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
milan
itali
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
cardiff
unit
kingdom
paediatr
surgeri
european
paediatr
soft
tissu
sarcoma
group
bicetr
franc
paediatr
radiotherapi
european
paediatr
soft
tissu
sarcoma
group
london
unit
kingdom
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
pari
franc
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
london
unit
kingdom
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
amsterdam
netherland
paediatr
patholog
european
paediatr
soft
tissu
sarcoma
group
manchest
unit
kingdom
biostatist
european
paediatr
soft
tissu
sarcoma
group
padova
itali
paediatr
oncolog
european
paediatr
soft
tissu
sarcoma
group
bristol
unit
kingdom
object
alveolar
rhabdomyosarcoma
arm
nodal
involv
account
rm
result
previou
european
studi
suggest
poor
surviv
year
ef
compar
stage
iv
diseas
although
outcom
better
one
recent
studi
siop
ef
epssg
protocol
receiv
intensifi
initi
chemotherapi
ivado
ifosfamid
vincristin
dactinomycin
doxorubicin
addit
mainten
chemotherapi
systemat
local
treatment
primari
nodal
site
method
patient
n
patient
enrol
epssg
octob
octob
primari
surgerybiopsi
receiv
cycl
ivado
cycl
iva
mainten
therapi
cyclophosphamid
vinorelbin
local
treatment
schedul
ivado
includ
radiotherapi
primari
site
andor
node
without
secondari
surgic
resect
primari
andor
involv
node
result
incid
advers
prognost
factor
high
patient
year
age
gross
residu
diseas
ir
group
iii
initi
surgerybiopsi
primari
tumour
local
invas
primari
size
cm
occur
unfavour
site
median
month
ef
ci
outcom
data
avail
patient
eight
demonstr
refractori
diseas
earli
progress
die
relaps
complet
therapi
median
time
relaps
month
die
conclus
patient
may
benefit
intensif
therapi
although
fail
respond
initi
chemotherapi
prospect
salvag
relaps
poor
addit
strategi
need
improv
outcom
high
risk
group
enrol
phase
iii
studi
justifi
achiev
earli
local
control
relaps
proton
therapi
rhabdomyosarcoma
earli
clinic
outcom
indelicato
r
rotondo
j
bradley
c
morri
bradfield
e
sandler
n
mendenhal
radiat
oncolog
univers
florida
jacksonvil
usa
pediatr
oncolog
univers
florida
jacksonvil
usa
object
studi
report
earli
toxic
diseas
control
children
rhabdomyosarcoma
rm
treat
proton
therapi
pt
method
februari
novemb
patient
median
age
year
rang
year
treat
pt
rm
common
primari
site
paramening
orbit
bladderprost
median
tumor
size
cm
rang
cm
patient
intergroup
rhabdomyosarcoma
studi
ir
stage
patient
ir
group
iii
patient
receiv
chemotherapi
per
epssg
rm
n
contemporari
cog
n
protocol
median
interv
start
chemotherapi
radiotherapi
week
rang
median
year
variou
patient
treatment
factor
examin
identifi
predictor
diseas
control
outcom
result
actuari
year
overal
surviv
progress
free
surviv
local
control
freedom
distant
metastas
respect
multivari
analysi
tumor
size
cm
paramening
site
durat
induct
chemotherapi
week
associ
significantli
lower
rate
local
control
progress
free
surviv
p
note
children
cm
paramening
tumor
inferior
rate
local
control
compar
tumor
vs
p
perman
toxic
limit
patient
cataract
patient
requir
unilater
hear
aid
patient
requir
hormon
replac
therapi
conclus
date
largest
cohort
children
rm
treat
pt
earli
data
suggest
highli
conform
radiat
compromis
earli
tumor
control
increas
earli
toxic
group
young
patient
unfavor
risk
characterist
consist
previou
report
recommend
delay
radiat
beyond
week
patient
diseas
evalu
orbit
rhabdomyosarcoma
children
institut
curi
experi
h
boutroux
c
levi
v
mosseri
l
desjardin
c
plancher
helfr
p
freneaux
c
cellier
j
michon
orbach
pediatr
adolesc
young
adult
oncolog
depart
institut
curi
pari
franc
ophtalmolog
depart
institut
curi
pari
franc
depart
biostatist
institut
curi
pari
franc
ophtalmolog
depart
institut
curi
pari
franc
radiotherapi
depart
institut
curi
pari
franc
depart
patholog
institut
curi
pari
franc
depart
radiolog
institut
curi
pari
franc
object
orbit
rhabdomyosarcoma
orm
associ
excel
surviv
rate
greater
consid
favor
site
tumor
treatment
base
combin
chemotherapi
togeth
best
local
therapi
sometim
surgeri
often
radiat
therapi
local
therapi
associ
frequent
potenti
sever
late
sequela
pediatr
oncolog
group
therefor
tri
mani
year
reduc
sequela
without
jeopard
outcom
orm
respons
adapt
treatment
strategi
retrospect
analysi
set
order
clearli
defin
statu
orm
survivor
method
among
patient
local
orm
treat
institut
curi
survivor
analyz
studi
result
median
age
diagnosi
year
rang
month
year
median
year
rang
month
year
globe
conserv
rate
ophthalm
dysfunct
present
patient
impair
visual
acuiti
va
defin
va
affect
eye
present
patient
sever
visual
disabl
va
late
effect
orbitofaci
structur
present
patient
ocular
palpebr
sequela
present
survivor
mainli
cataract
ocular
surfac
lesion
keratoconjunct
eyelid
abnorm
gener
late
effect
rare
conclus
data
suggest
ocular
orbit
late
effect
frequent
treatment
orm
indic
need
systemat
ophthalmolog
patient
radiat
therapi
import
part
total
burden
therapi
homeobox
gene
regul
tumour
suppressor
mous
retina
develop
implic
mous
human
retinoblastoma
j
zagozewski
h
aghazadeh
j
bush
eisenstat
medic
genet
univers
alberta
edmonton
canada
biolog
scienc
univers
alberta
edmonton
canada
patholog
univers
manitoba
winnipeg
canada
pediatr
medic
genet
univers
alberta
edmonton
canada
object
retinoblastoma
common
malign
eye
tumour
childhood
human
sporad
germlin
mutat
retinoblastoma
gene
implic
almost
case
howev
mutat
either
pocket
protein
famili
member
necessari
induc
tumour
mous
model
diseas
development
regul
rel
unknown
dlx
homeobox
gene
encod
transcript
factor
express
ganglion
cell
amacrin
horizont
cell
embryon
adult
retina
method
chromatin
immunoprecipit
chip
perform
embryon
mous
retina
tissu
use
polyclon
antibodi
electrophoret
mobil
shift
assay
emsa
use
confirm
specif
protein
dna
interact
report
gene
assay
perform
use
luciferas
report
construct
contain
promot
gene
express
assess
doubl
knockout
mous
dko
express
assess
mous
model
retinoblastoma
human
retinoblastoma
sampl
result
chip
demonstr
occupi
sever
region
gene
promot
vivo
emsa
confirm
specif
transcript
factor
promot
dna
complex
vitro
activ
promot
gene
express
vitro
express
reduc
dko
mous
retina
express
nuclei
condit
dko
retinoblastoma
well
almost
human
retinoblastoma
tissu
studi
conclus
homeodomain
transcript
factor
directli
activ
express
tumour
suppressor
member
rb
pocket
protein
famili
essenti
cell
cycl
regul
express
mous
human
retinoblastoma
support
development
tumour
partial
differenti
contribut
knowledg
regard
cell
origin
futur
studi
determin
whether
modul
express
regul
cell
prolifer
differenti
retinoblastoma
impact
mutat
prenat
diagnosi
children
risk
retinoblastoma
b
galli
h
dimara
hsl
chan
e
j
sutherland
day
day
ophthalmolog
vision
scienc
hospit
sick
children
toronto
canada
divis
hematolog
oncolog
dept
paediatr
hospit
sick
children
toronto
canada
object
canadian
guidelin
retinoblastoma
recommend
test
infant
affect
parent
mutat
prenat
birth
infant
carri
mutat
may
deliv
late
week
gestat
optim
opportun
minim
impact
treatment
small
tumor
evalu
effect
gestat
age
first
eye
examin
outcom
children
carri
mutat
method
retrospect
studi
infant
carri
famili
mutat
born
june
may
treat
sickkid
inform
collect
includ
affect
parent
sex
gestat
age
birth
test
first
eye
exam
pregnanc
perinat
complic
type
sampl
test
mutat
locat
first
subsequ
tumor
intern
intraocular
retinoblastoma
classif
tumour
node
metastasi
stage
treatment
deliv
last
followup
date
overal
visual
outcom
result
twenti
infant
carri
parent
mutat
detect
prenat
birth
nine
test
prenat
elect
deliv
week
gestat
spontan
prematur
infant
test
prenat
born
term
newborn
infant
weekli
eye
examin
tumor
present
birth
infant
deliv
earli
born
prematur
infant
posterior
tumor
appear
age
month
infant
patient
eventu
develop
bilater
retinoblastoma
good
vision
maintain
children
born
earli
treatment
includ
focal
therapi
later
chemotherapi
stereotact
radiat
enucl
one
eye
due
chemotherapi
intoler
infant
receiv
focal
therapi
chemotherapi
enucl
one
eye
bilater
macular
tumor
blind
one
child
conclus
prenat
molecular
detect
earli
deliveri
facilit
optim
outcom
nation
retinoblastoma
strategi
canadian
guidelin
care
canadian
journal
ophthalmolog
prospect
singl
institut
trial
use
topotecan
base
chemotherapi
treatment
bilater
intraocular
retinoblastoma
r
brennan
mw
wilson
mao
j
wu
qaddoumi
c
oncolog
st
jude
children
research
hospit
memphi
usa
ophthalmolog
univers
tennesse
health
scienc
center
memphi
usa
biostatist
st
jude
children
research
hospit
memphi
usa
oncolog
dana
farber
cancer
institut
boston
usa
object
evalu
efficaci
system
use
topotecan
advanc
intraocular
retinoblastoma
method
newli
diagnos
bilater
retinoblastoma
patient
male
median
age
month
wors
eye
ellsworth
group
receiv
cycl
chemotherapi
topotecan
vincristin
tv
x
follow
three
altern
cours
carboplatin
vincristin
x
tv
x
intens
focal
therapi
appli
first
cycl
event
free
surviv
ef
defin
avoid
extern
beam
radiat
ebrt
enucl
result
eye
intern
classif
ic
patient
complet
prescrib
chemotherapi
one
remov
due
persist
viral
infect
two
progress
diseas
requir
ebrt
eye
receiv
focal
therapi
seven
patient
receiv
subconjunctiv
carboplatin
therapi
six
receiv
plaqu
brachytherapi
eleven
eye
enucl
one
diagnosi
nine
progress
diseas
includ
three
eye
treat
ebrt
one
develop
neovascular
glaucoma
year
cumul
incid
ebrt
se
ef
patient
se
ocular
surviv
group
eye
se
se
ic
group
eye
patient
experienc
thrombocytopenia
episod
cours
episod
febril
neutropenia
fifteen
patient
document
sourc
infect
viral
etiolog
grade
diarrhea
present
patient
one
patient
react
carboplatin
patient
aliv
median
follow
year
conclus
topotecan
combin
vincristin
carboplatin
aggress
focal
therapi
effect
regimen
treatment
advanc
retinoblastoma
avoid
radiat
result
globe
salvag
measur
vision
toxic
anticip
manag
appropri
support
care
treatment
recurr
progress
intraocular
retinoblastoma
preliminari
result
nation
phase
ii
studi
swiss
pediatr
oncolog
group
beck
popov
binaghi
mc
gaillard
diezi
e
garcia
houghton
mt
galley
cornu
pampallona
f
munier
pediatr
hematolog
oncolog
unit
hospit
lausann
switzerland
intervent
radiolog
hospit
lausann
switzerland
jule
gonin
eye
hospit
univers
hospit
lausann
switzerland
pediatr
unit
hospit
lausann
switzerland
statist
medicin
form
evolen
switzerland
object
determin
effect
safeti
inject
melphalan
via
ophthalm
arteri
soac
vitreou
caviti
ivc
periocular
topotecan
pot
salvag
therapi
recurrentprogress
retinoblastoma
rb
accord
site
recurrenceprogress
evalu
eye
preserv
rate
cours
soac
cours
ivc
cours
pot
enucl
andor
radiotherapi
method
nation
singl
arm
phase
ii
prospect
studi
includ
patient
pt
recurrentprogress
rb
month
year
age
failur
prior
treatment
chemoreductionfoc
therapi
plaqu
therapi
extern
beam
radiat
retcam
imag
ultrasound
biomicroscopi
identif
meridian
mandatori
ivc
patient
enrol
evalu
one
treatment
arm
respons
evalu
treatment
cours
retin
tumor
andor
vitreou
seed
treatment
stop
time
case
progress
toxic
parent
refus
result
pt
regist
unilater
bilater
diseas
elig
failur
prior
chemotherapi
chemotherapyradiotherapi
salvag
treatment
consist
soac
ivc
pot
pt
respons
favor
soac
ivc
pot
administr
enucl
radiotherapi
median
month
six
pt
need
treatment
eye
soac
ivc
combin
soacivc
contralater
eye
combin
ocular
hemorrhag
eye
soac
worst
advers
event
observ
treat
success
conclus
heavili
pretreat
rb
patient
soac
ivc
pot
effici
treat
recurrentprogress
diseas
prevent
enucl
andor
radiotherapi
howev
almost
half
treat
eye
need
treatment
diseas
control
treatment
combin
consid
futur
efficaci
second
cours
ophthalm
arteri
chemosurgeri
retinoblastoma
recur
follow
prior
ophthalm
arteri
chemosurgeri
ij
dunkel
yp
gobin
bp
marr
tendler
se
brodi
dh
abramson
jh
franci
pediatr
memori
sloan
ketter
cancer
center
new
york
presbyterian
hospit
weill
cornel
medic
colleg
new
york
usa
neurosurgeri
memori
sloan
ketter
cancer
center
new
york
presbyterian
hospit
weill
cornel
medic
colleg
new
york
usa
ophthalmolog
memori
sloan
ketter
cancer
center
new
york
presbyterian
hospit
weill
cornel
medic
colleg
new
york
usa
pediatr
memori
sloan
ketter
cancer
center
new
york
usa
ophthalmolog
memori
sloan
ketter
cancer
center
mount
sinai
new
york
usa
ophthalmolog
memori
sloan
ketter
cancer
center
new
york
usa
object
ophthalm
arteri
chemosurgeri
oac
highli
effect
retinoblastoma
patient
achiev
remiss
develop
recurr
follow
complet
therapi
aim
evalu
efficaci
second
cours
oac
patient
method
retrospect
studi
eye
underw
oac
center
may
juli
achiev
remiss
suffer
retinoblastoma
recurr
least
month
outcom
measur
includ
estim
ocular
surviv
pf
ocular
surviv
test
use
compar
curv
result
eye
previous
receiv
mean
first
cours
oac
infus
develop
diseas
recurr
median
month
follow
complet
initi
oac
median
month
follow
initi
second
cours
oac
estim
ocular
pf
ocular
surviv
follow
second
cours
oac
confid
interv
confid
interv
respect
presenc
vitreou
seed
seen
eye
requir
oac
significantli
associ
inferior
ocular
pf
confid
interv
versu
confid
interv
p
ocular
surviv
p
factor
associ
ocular
pf
includ
treatment
histori
age
initi
oac
earli
month
versu
later
recurr
addit
new
drug
second
cours
oac
number
infus
second
cours
oac
conclus
eye
recurr
retinoblastoma
follow
first
cours
oac
treatment
may
cure
second
cours
oac
howev
signific
portion
eye
may
requir
addit
therapi
third
fourth
cours
oac
treatment
modal
chemotherapi
particularli
vitreou
seed
present
time
initi
oac
failur
age
risk
second
malign
neoplasm
retinoblastoma
survivor
studi
r
nave
r
amorim
b
truong
green
p
friedrich
k
ribeiro
c
depart
social
medicin
faculdad
de
da
santa
casa
de
paulo
paulo
brazil
pediatr
oncolog
harvard
medic
school
boston
usa
pediatr
oncolog
children
cancer
blood
disord
center
boston
usa
object
retinoblastoma
rb
survivor
increas
risk
develop
second
malign
neoplasm
smn
aim
studi
assess
risk
smn
among
retinoblastoma
survivor
use
data
method
retriev
data
surveil
epidemiolog
end
result
seer
databas
children
age
diagnos
rb
iccc
group
v
includ
studi
standard
incid
ratio
sir
correspond
confid
interv
ci
calcul
use
seerstat
result
cohort
compris
children
rb
mean
age
diagnosi
year
children
unilater
bilater
rb
patient
develop
smn
sir
ci
children
bilater
rb
higher
risk
develop
head
neck
second
malign
n
sir
ci
site
n
sir
ci
observ
increas
risk
present
even
children
bilater
rb
receiv
rt
sir
ci
modest
risk
develop
smn
site
observ
sir
ci
children
bilater
rb
diagnos
year
higher
risk
rt
sir
ci
without
rt
sir
ci
diagnos
year
correct
use
rt
rt
sir
ci
without
rt
sir
ci
conclus
risk
smn
among
rb
survivor
higher
patient
diagnos
one
year
age
children
bilater
rb
increas
risk
smn
hn
regardless
use
rt
need
use
diagnost
studi
hn
emphas
integr
genom
elucid
rel
spatial
homogen
pediatr
brain
tumor
remk
f
jorgensen
morrissi
v
ramaswami
r
packer
u
schueller
e
bouffet
sm
pfister
n
jabado
taylor
development
stem
cell
biolog
hospit
sick
children
toronto
canada
center
neurosci
behavior
medicin
children
nation
medic
center
washington
usa
depart
neuropatholog
munich
germani
divis
pediatr
hematologyoncolog
hospit
sick
children
toronto
canada
depart
pediatr
neurooncolog
german
cancer
research
center
heidelberg
germani
depart
pediatr
human
genet
mcgill
univers
mcgill
univers
health
center
research
institut
montreal
canada
depart
neurosurgeri
hospit
sick
children
toronto
canada
object
comprehens
profil
sequenc
base
studi
dramat
improv
understand
pediatr
brain
tumor
biolog
past
decad
howev
vast
major
these
studi
base
assumpt
singl
biopsi
repres
entir
primari
tumor
intratumor
heterogen
compris
common
phenomenon
previous
describ
renal
cell
carcinoma
breast
cancer
glioblastoma
multiform
highli
dispar
genet
profil
spatial
separ
tumor
area
within
tumor
may
preclud
develop
person
molecularli
target
therapi
base
singl
tumor
biopsi
method
address
issu
conduct
multiregion
whole
exom
sequenc
dna
copi
number
analysi
cytoscan
hd
dna
methyl
profil
infinium
beadchip
distinct
pediatr
adult
brain
tumor
median
six
spatial
distant
biopsi
per
tumor
rang
histolog
entiti
includ
atrt
n
dipg
n
ependymoma
n
glioblastoma
n
medulloblastoma
n
medulloepithelioma
n
assess
degre
intratumor
heterogen
subgroup
affili
use
integr
genom
unsupervis
hierarch
cluster
algorithm
result
epigenet
signatur
highli
similar
individu
multiregion
biopsi
within
singl
tumor
howev
identifi
cpg
dinucleotid
differenti
methyl
compar
intertumor
heterogen
dna
methyl
pattern
even
within
diseas
subgroup
pediatr
brain
tumor
display
highli
similar
focal
broad
dna
copi
number
alter
unlik
adult
counterpart
multiregion
sequenc
reinforc
rel
higher
degre
intratumor
homogen
pediatr
brain
tumor
lastli
show
subgroup
affili
stabl
multiregion
biopsi
medulloblastoma
conclus
result
demonstr
singl
biopsi
repres
tumor
genom
landscap
subgroup
affili
pediatr
brain
tumor
stabl
adult
counterpart
spinal
myxopapillari
ependymoma
exhibit
warburg
phenotyp
sc
mack
md
taylor
gene
global
ependymoma
network
excel
development
stem
cell
biolog
hospit
sick
children
toronto
canada
object
myxopapillari
spinal
ependymoma
distinct
histolog
variant
aris
predominantli
conu
medullari
cauda
equina
filum
terminal
despit
gener
favor
prognosi
metastas
subarachnoid
dissemin
late
recurr
report
current
maxim
safe
resect
effect
treatment
myxopapillari
ependymoma
character
genom
transcript
landscap
spinal
ependymoma
effort
delin
genet
basi
diseas
identifi
new
target
therapi
method
gene
express
profil
perform
spinal
ependymoma
use
affymetrix
gene
microarray
spinal
ependymoma
use
rna
seq
copi
number
profil
also
perform
overlap
cohort
spinal
ependymoma
use
affymetrix
microarray
western
blot
analysi
use
confirm
gene
express
valu
function
valid
experi
perform
tumour
lysat
consist
assay
measur
pyruv
kinas
activ
pkm
hexokinas
activ
hk
lactat
product
result
transcript
level
demonstr
grade
ii
myxopapillari
spinal
ependymoma
molecularli
distinct
find
support
copi
number
alter
occur
histolog
variant
pathway
analysi
reveal
myxopapillari
ependymoma
character
metabol
network
name
transcript
target
find
valid
western
blot
analysi
demonstr
increas
protein
express
phosphoryl
function
assay
perform
myxopapillari
tumour
lysat
demonstr
decreas
pkm
activ
increas
hk
activ
elev
lactat
product
conclus
find
suggest
myxopapillari
ependymoma
may
driven
warburg
metabol
phenotyp
mediat
transcript
network
key
enzym
promot
warburg
phenotyp
pdk
target
small
molecul
inhibitorsactiv
inhibit
glycolysi
test
studi
therapi
myxopapillari
ependymoma
new
intraop
monitor
corticobulbar
motor
evok
potenti
children
bozinov
j
sarnthein
neurosurgeri
univers
hospit
zurich
zurich
switzerland
object
motor
function
cranial
nerv
cn
continu
monitor
transcrani
corticobulbar
motor
evok
potenti
comep
neurosurg
intervent
sever
public
new
comep
adult
feasibl
safeti
comep
children
yet
document
method
includ
consecut
procedur
involv
patient
median
age
rang
male
oper
first
author
comep
monitor
author
use
reduct
comep
respons
amplitud
warn
criterion
approach
keep
respons
amplitud
constant
increas
stimul
intens
establish
warn
criterion
base
method
facial
nerv
threshold
increas
greater
elicit
comep
reliabl
facial
nerv
target
muscl
consid
predict
reduc
postop
facial
nerv
function
subsequ
warn
issu
surgeon
result
monitor
comep
feasibl
surgeri
least
one
facial
nerv
target
muscl
mentali
muscl
yield
best
result
trial
follow
orbiculari
ori
orbiculari
oculi
muscl
median
stimul
threshold
initi
rang
comep
mep
thenar
muscl
initi
comep
threshold
exceed
mep
threshold
patient
median
differ
comep
deterior
show
specif
hb
deterior
ci
conclus
intraop
comep
monitor
feasibl
safe
also
young
children
found
evid
procedur
threshold
differ
comep
adult
comep
monitor
valid
indic
cn
function
neurosurgeri
use
adjunct
direct
electr
cn
stimul
continu
emg
monitor
cn
target
muscl
report
studi
current
registri
ur
kord
hartung
hasselblatt
v
ruland
pietsch
rd
kortmann
garami
h
trauneck
jea
wolff
pediatr
hematolog
oncolog
univers
medic
center
hamburg
germani
univers
medic
center
institut
neuropatholog
germani
univers
medic
center
institut
neuropatholog
brain
tumor
refer
center
bonn
germani
univers
medic
center
radiooncolog
refer
center
leipzig
germani
univers
medic
center
neuroradiolog
refer
center
germani
semmelwei
univers
depart
pediatr
budapest
hungari
children
hospit
wale
heath
park
paediatr
oncolog
cardiff
unit
kingdom
cleveland
clinic
children
hospit
depart
pediatr
hematolog
oncolog
ohio
usa
object
analysi
variabl
patient
choroid
plexu
tumor
cpt
age
group
grade
recruit
intern
registri
treatment
outcom
accord
treatment
stratif
method
studi
registri
recruit
patient
refer
review
cpt
treatment
algorithm
stratifi
observ
group
classic
plexu
papilloma
cpp
atyp
plexu
papilloma
app
treatment
group
metastat
cpt
incomplet
resect
app
choroid
plexu
carcinoma
cpc
patient
older
year
diagnos
cpc
receiv
primari
focal
irradi
result
median
age
diagnosi
year
cppappcpc
equal
gender
distribut
primari
locat
cpt
later
ventricl
without
rightleft
prefer
increas
age
cpp
local
frequent
ivth
ventricl
cpc
occur
exclus
within
iiird
ventricl
primari
metastasi
recogn
cppappcpc
germlin
mutat
analysi
identifi
patient
syndrom
median
time
studi
patient
year
overal
surviv
surviv
cpp
n
app
n
cpc
n
extend
follow
show
differ
carboplatin
base
regimen
compar
cyclophosphamid
base
regimen
cumul
incid
secondari
neoplasm
compar
infant
brain
tumor
popul
differ
histolog
nuclear
accumul
show
prognost
impact
conclus
adjuv
treatment
improv
outcom
high
grade
choroid
plexu
tumor
carboplatin
well
cyclophosphamid
base
regimen
equal
effect
grade
signific
prognost
marker
cknowledg
fund
german
childhood
cancer
foundat
dkk
upon
new
event
patient
glioma
use
van
gool
de
vleeschouw
microbiolog
immunolog
ku
leuven
leuven
belgium
neurosci
ku
leuven
leuven
belgium
object
multimod
strategi
develop
treat
patient
high
grade
glioma
hgg
activ
specif
immunotherapi
rapidli
emerg
new
treatment
modal
provid
immunotherapi
adult
primari
diagnosi
gbm
childrenadult
relaps
hgg
retrospect
analysi
question
whether
second
immunotherapi
upon
new
event
use
patient
alreadi
got
immunotherapi
diseas
method
patient
treat
two
vaccin
treatment
adult
primari
diagnosi
gbm
patient
relaps
hgg
time
first
immunotherapi
time
leukapheresi
perform
dc
load
lysat
newli
resect
tumor
tissu
result
enrol
patient
treat
two
immunotherapi
median
os
versu
patient
n
treat
one
immunotherapi
program
age
distribut
former
younger
latter
group
similarli
patient
treat
two
immunotherapi
median
os
versu
patient
n
one
immunotherapi
program
age
former
patient
group
younger
risk
profil
better
time
interv
first
second
leukapheresi
longer
patient
second
immunotherapi
approach
similar
less
inject
second
immunotherapi
compar
first
immunotherapi
number
inject
similar
number
given
patient
got
first
vaccin
time
relaps
os
calcul
second
leukapheresi
patient
similar
os
observ
patient
treat
first
time
relaps
second
immunotherapi
feasibl
extra
toxic
observ
conclus
retrospect
result
show
second
immunotherapi
worth
consid
along
diseas
cours
patient
hgg
adult
survivor
childhood
cn
tumour
promin
late
effect
difficulti
sequela
surveil
need
l
b
lanner
g
gustafsson
kk
boman
depart
women
children
health
childhood
cancer
research
unit
karolinska
institutet
stockholm
sweden
depart
clinic
scienc
pediatr
oncolog
univers
gothenburg
gothenburg
sweden
object
part
longitudin
swedish
childhood
cn
tumour
life
studi
studi
aim
identifi
promin
sple
among
survivor
vltss
extent
sequela
experienc
disabl
sple
analys
relat
need
current
involv
clinic
method
studi
target
entir
cohort
swedish
year
old
mean
vltss
diagnos
sple
data
collect
use
questionnair
second
wave
data
collect
singl
predictor
factor
data
eman
prior
wave
year
earlier
sple
studi
address
question
format
rate
difficulti
use
respons
format
data
analys
quantit
qualit
result
three
hundr
thirti
survivor
report
preval
one
sever
sple
sixteen
identifi
categori
problem
experienc
survivor
cover
rang
sple
medic
neurolog
neurosensori
neuropsycholog
origin
preval
sequela
involv
one
sever
vision
balanc
endocrinopathi
fatigu
hear
pain
memori
seizuresepilepsi
sple
experienc
harmless
somewhat
clearli
difficult
respect
complet
disabl
occurr
sever
vari
diagnosi
age
gender
whether
past
cancer
treatment
includ
radiat
therapi
survivor
consider
entir
disabl
sple
experienc
need
lack
access
expect
health
statu
year
earlier
predict
sple
later
life
conclus
major
cn
tumour
vltss
experi
late
effect
intrud
upon
function
qualiti
surviv
enquiri
reveal
subject
experienc
promin
difficulti
inform
perceiv
manag
today
mani
studi
cn
tumour
vltss
may
lack
requir
specialis
surveil
bortezomib
reinduct
chemotherapi
first
relaps
pediatr
children
oncolog
group
studi
horton
x
lu
obrien
borowitz
devida
e
raetz
p
brown
hui
zeng
hunger
j
whitlock
texa
children
cancer
hematolog
center
baylor
colleg
medicin
houston
usa
cog
oper
center
children
oncolog
group
arcadia
usa
pediatr
oncolog
cincinnati
children
hospit
cincinnati
usa
patholog
john
hopkin
univers
baltimor
usa
cog
data
center
children
oncolog
group
gainesvil
usa
pediatr
oncolog
primari
children
hospit
salt
lake
citi
usa
pediatr
oncolog
john
hopkin
univers
baltimor
usa
cog
data
center
children
oncolog
group
gainesvil
usa
pediatr
oncolog
children
hospit
colorado
aurora
usa
pediatr
oncolog
hospit
sick
children
toronto
canada
object
bortezomib
bortez
revers
inhibitor
proteasom
promis
result
report
ad
bortez
reinduct
chemotherapi
patient
pt
later
relaps
messing
blood
primari
object
studi
compar
rate
end
block
histor
control
rate
biolog
object
includ
assess
b
proteasom
activ
method
phase
studi
bortez
reinduct
chemotherapi
relaps
pediatr
enrol
pt
either
cell
lymphoblast
lymphoma
report
summar
result
evalu
pt
yr
old
either
stratum
stratum
diagnosi
evalu
patient
initi
therapi
consist
bortez
day
reinduct
chemotherapi
vincristin
prednison
doxorubicin
rate
determin
end
first
therapi
block
compar
histor
control
studi
result
evalu
pt
assess
toxic
grade
hypotens
grade
typhliti
grade
pancreat
grade
sensorymotor
peripher
neuropathi
grade
enterocol
death
due
infect
although
grade
infect
infrequ
infect
patient
block
infect
block
report
respiratori
distress
syndrom
grade
peripher
neuropathi
patient
stratum
stratum
attain
end
block
patient
also
achiev
studi
met
primari
respons
object
conclus
addit
bortezomib
reinduct
therapi
appear
quit
effect
worthi
studi
pediatr
clinic
trial
inform
therapeut
effect
romidepsin
histon
deacetylas
inhibitor
hdaci
alon
combin
natur
killer
cell
pediatr
burkitt
lymphoma
chu
yahr
j
ayello
c
vandeven
cairo
pediatr
new
york
medic
colleg
valhalla
usa
object
outcom
children
burkitt
lymphoma
bl
improv
significantli
patient
relaps
progress
prognosi
dismal
due
resist
cairo
j
clin
oncol
group
success
engin
expand
peripher
blood
natur
killer
cell
expbnk
cell
chimer
antigen
receptor
car
expbnk
target
relapsedresist
bl
chu
cairo
ash
romidepsin
histon
deacetylas
inhibitor
enhanc
ligand
express
tumor
cell
chu
cairo
embt
investig
effect
mechan
romidepsin
bl
combin
effect
romidepsin
car
expbnk
cell
bl
cell
nsg
mice
method
bl
cell
treat
romidepsin
provid
celgen
cell
viabil
micab
express
cell
cycl
signal
pathway
chang
analyz
flow
cytometri
cell
inject
nsg
mice
car
expbnk
romidepsin
combin
given
mous
week
week
cumul
luciferas
signal
tumor
size
measur
system
calib
result
romidepsin
induc
strong
cell
death
rituximab
rsensit
raji
p
found
micab
express
significantli
enhanc
romidepsin
treat
bl
cell
line
p
expbnk
cell
combin
romidpesin
significantli
increas
surviv
xenograft
nsg
mice
compar
control
p
conclus
romidepsin
effectsin
bl
induc
cell
death
cell
cycl
arrest
enhanc
car
expbnk
cytotox
bl
clofarabin
combin
cytarabin
liposom
daunorubicin
pediatr
aml
result
phase
combin
studi
itcc
consortium
cm
zwaan
dworzak
klingebiel
c
g
leverg
j
stari
es
de
bont
cm
niemey
gj
kasper
bertrand
ramnarain
ea
ghazali
reinhardt
pediatr
hematologyoncolog
erasmu
mc
children
hospit
rotterdam
netherland
pediatr
st
anna
children
hospit
medic
univers
vienna
vienna
austria
children
adolesc
univers
hospit
frankfurt
goeth
univers
frankfurt
germani
pediatr
hematolog
oncolog
univers
children
hospit
muenster
muenster
germani
pediatr
haematolog
oncolog
unit
hospit
armand
trousseau
pari
franc
pediatr
haematolog
oncolog
charl
univers
pragu
univers
hospit
motol
pragu
czech
republ
pediatr
oncologyhematolog
univers
medic
center
groningen
groningen
netherland
pediatr
hematolog
oncolog
univers
medic
center
freiburg
freiburg
germani
pediatr
hematolog
oncolog
vu
univers
medic
center
amsterdam
netherland
hematolog
oncolog
le
hospic
civil
de
lyon
lyon
franc
center
bart
cancer
institut
queen
mari
univers
london
london
unit
kingdom
pediatr
hematologyoncolog
medic
school
hannov
hannov
germani
object
relapsedrefractori
pediatr
aml
poor
prognosi
despit
salvag
therapi
includ
transplant
chemotherapi
use
flag
plu
liposom
daunorubicin
current
consid
standard
europ
flag
base
potenti
cytarabin
fludarabin
flu
increas
level
clofarabin
clo
novel
purin
nucleosid
analog
design
improv
efficaci
method
initi
ongo
phase
studi
use
design
defin
optim
dose
clo
replac
flu
dosag
consist
day
escal
dnx
day
clo
day
without
gcsf
prime
day
intrathec
administ
serum
csf
collect
pharmacokinet
pk
clo
plasma
csf
concentr
analyz
use
result
report
safeti
pk
data
dose
level
accrual
aml
patient
patient
treat
dl
updat
result
dlt
present
meet
pk
sampl
avail
patient
day
median
auc
ngmlmghr
rang
mean
hr
day
day
result
similar
csf
level
measur
patient
ngmlmg
patient
detect
level
conclus
clo
claradnx
cours
relapsedrefractori
pediatr
aml
exclud
patient
evid
prior
subclin
aspergillu
evid
pk
interact
clo
drug
current
test
safeti
augment
dose
dnx
aml
patient
n
repons
central
review
disclos
meet
blinatumomab
pediatr
patient
relapsedrefractori
rr
precursor
acut
lymphoblast
leukemia
phase
studi
j
whitlock
von
stackelberg
r
handgreting
f
locatelli
c
rizzari
trippett
borkhardt
obrien
rheingold
l
gore
hematologyoncolog
hospit
sick
children
toronto
canada
pediatr
oncologyhematolog
campu
virchow
berlin
germani
pediatr
oncolog
univers
germani
oncohematolog
ospedal
pediatrico
bambino
gesu
univers
pavia
rome
itali
pediatr
san
gerardo
hospit
univers
monza
itali
pediatr
hematologyoncolog
memori
cancer
center
new
york
usa
pediatr
oncolog
univers
germani
pediatr
cincinnati
children
hospit
medic
center
cincinnati
usa
pediatr
children
hospit
philadelphia
philadelphia
usa
pediatr
children
hospit
colorado
aurora
usa
purposeobject
blinatumomab
bispecif
engag
antibodi
demonstr
activ
adult
rr
phase
part
phase
studi
optim
blinatumomab
dose
evalu
children
rr
materi
method
elig
patient
result
patient
receiv
median
rang
cycl
patient
refractori
diseas
relaps
hematopoiet
stem
cell
transplant
hsct
relaps
without
prior
hsct
advers
event
ae
grade
cytokin
releas
syndrom
cr
gastrointestin
hemorrhag
instanc
cr
grade
grade
respiratori
failur
mtd
mitig
cr
stepwis
dose
day
subsequ
evalu
patient
dose
patient
develop
cr
grade
across
dose
common
ae
regardless
causal
includ
pyrexia
headach
hypertens
one
patient
perman
discontinu
treatment
due
grade
seizur
within
first
cycl
overal
remiss
rate
achiev
minim
residu
diseas
mrd
neg
patient
achiev
respons
day
respect
respond
receiv
hsct
cr
conclus
phase
studi
establish
mtd
cr
could
amelior
stepwis
dose
respond
underw
hsct
follow
blinatumomab
treatment
phase
studi
inhibitor
patient
malign
rhabdoid
tumor
neuroblastoma
b
geoerger
f
bourdeaut
sg
duboi
ji
geller
marabel
ad
pearson
r
kan
matano
sg
bhansali
parasuraman
sn
chi
de
institut
gustav
roussi
villejuif
franc
de
inserm
institut
curi
pari
franc
pediatr
hematologyoncolog
univers
francisco
san
francisco
usa
divis
hematologyoncolog
cincinnati
children
hospit
medic
center
cincinnati
usa
institut
pediatr
leon
berard
comprehens
cancer
center
lyon
franc
children
young
peopl
unit
royal
marsden
hospit
institut
cancer
research
london
unit
kingdom
oncolog
translat
medicin
novarti
institut
biomed
research
cambridg
usa
oncolog
translat
medicin
novarti
pharma
ag
basel
switzerland
clinic
pharmacolog
novarti
pharmaceut
east
hanov
usa
pediatr
program
cancer
institut
boston
usa
object
major
malign
rhabdoid
tumor
mrt
mutat
depend
cyclin
genesi
surviv
genet
aberr
frequent
neuroblastoma
cell
line
oral
bioavail
select
inhibitor
demonstr
tumor
growth
inhibit
mrt
neuroblastoma
model
multicent
phase
studi
evalu
patient
mrt
neuroblastoma
cancer
document
cyclin
pathway
aberr
method
patient
age
year
receiv
day
cycl
fashion
use
bayesian
logist
regress
model
overdos
control
primari
object
maximum
toler
dose
mtd
andor
recommend
dose
expans
rde
determin
secondari
object
safeti
pharmacokinet
efficaci
studi
approv
local
institut
review
boardseth
committe
patientsguardian
sign
written
inform
consent
result
februari
patient
mrt
eight
primari
central
nervou
system
cn
two
nine
neuroblastoma
one
alveolar
rhabdomyosarcoma
receiv
five
nine
six
median
age
rang
year
two
toxic
report
one
grade
g
fatigu
one
thrombocytopenia
studi
ae
n
grade
includ
neutropenia
leukopenia
thrombocytopenia
anemia
lymphopenia
vomit
fatigu
decreas
appetit
preliminari
pharmacokinet
data
suggest
exposur
similar
adult
slightli
higher
demonstr
rapid
absorpt
hour
median
tmax
hour
current
best
respons
stabl
diseas
conclus
demonstr
accept
safeti
profil
pharmacokinet
enrol
continu
identifi
mtdrde
expans
arm
patient
mrt
neuroblastoma
rde
phase
studi
racotumomab
neuroblastoma
refractori
malign
w
cacciavillano
c
sampor
guthmann
gabri
e
lagomarsino
mtg
de
davila
eandi
l
fainboim
alonso
g
chantada
hospit
de
prof
dr
juan
p
garrahan
bueno
air
argentina
laboratorio
elea
bueno
air
argentina
laboratorio
de
molecular
universidad
nacion
de
quilm
bueno
air
argentina
farmacia
hospit
de
prof
dr
juan
p
garrahan
bueno
air
argentina
servicio
de
hospit
de
prof
dr
juan
p
garrahan
bueno
air
argentina
laboratorio
de
hospit
de
universidad
de
bueno
air
bueno
air
argentina
object
object
evalu
toxic
maximum
toler
dose
secondarili
immunolog
respons
vaccin
target
gangliosid
includ
racotumomab
formerli
known
candid
immunotherapi
method
phase
studi
enrol
children
relaps
resist
neuroblastoma
neuroectoderm
tumor
carri
due
express
tumor
dose
escal
level
mg
racotumomab
administ
intraderm
drug
level
includ
patient
receiv
total
dose
everi
day
clinic
radiolog
laboratori
evalu
day
last
dose
administ
confirm
cohort
ad
higher
dose
level
antibodi
respons
assess
upon
studi
entri
interv
least
immunolog
determin
patient
result
fourteen
patient
enrol
neuroblastoma
retinoblastoma
wilm
tumor
brainstem
glioma
patient
includ
confirm
cohort
one
patient
die
tumor
progress
complet
applic
remain
patient
complet
applic
schedul
racotumomab
well
toler
common
local
side
effect
includ
grade
erythema
indur
local
mild
pain
inject
site
racotumomab
elicit
antibodi
igm
andor
igg
respons
direct
patient
igm
racotumomab
evalu
patient
maximum
toler
dose
reach
toxic
seen
antitumor
activ
evid
patient
conclus
racotumomab
vaccin
show
favor
toxic
profil
dose
mg
patient
elicit
immun
respons
activ
immunotherapi
neuroblastoma
test
clinic
trial
mutat
delet
pediatr
acut
myeloid
leukemia
e
beul
jde
de
rooij
obulkasim
baruchel
j
trka
reinhardt
e
sonneveld
r
pieter
fornerod
mm
van
den
cm
zwaan
pediatr
oncolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
hematolog
hopit
pari
franc
pediatr
hematologyoncolog
medic
school
charl
univers
pragu
czech
republ
studi
group
pediatr
hematologyoncolog
medic
school
hannov
hannov
germani
dcog
dutch
childhood
oncolog
group
hagu
netherland
object
gene
encod
transcript
factor
act
transcript
repressor
requir
hematopoiesi
lineag
pediatr
adult
acut
lymphoblast
leukemia
adult
acut
myeloid
leukemia
aml
mutat
delet
lead
silenc
gene
describ
howev
preval
alter
pediatr
aml
fulli
address
method
mutat
delet
recurr
mutat
exon
determin
direct
sequenc
delet
multiplex
probe
amplif
outcom
paramet
analyz
result
cohort
pediatr
patient
aml
avail
data
median
age
year
median
white
blood
cell
count
wbc
po
found
patient
mutat
affect
predict
amino
acid
sequenc
three
case
show
heterozyg
insert
result
frame
shift
shorter
predict
amino
acid
length
point
mutat
lead
amino
acid
chang
addit
delet
found
patient
median
age
patient
gene
alter
year
median
wbc
po
patient
encount
relaps
die
complet
remiss
demonstr
poor
clinic
outcom
cytogenet
aberr
n
pmlrara
n
n
one
previous
function
demonstr
gene
high
express
associ
poor
prognosi
acut
leukemia
patient
mutat
n
delet
n
gene
respect
significantli
includ
conclus
conclud
mutat
delet
rare
recurr
pediatr
aml
may
associ
poor
prognosi
product
affect
cytokin
gene
variant
biomark
post
allogen
hematopoiet
cell
transplant
complic
g
tripathi
p
khan
rm
faridi
v
lewi
j
storek
n
berka
fm
khan
patholog
laboratori
medicin
univers
calgari
calgari
canada
patholog
laboratori
medicin
univers
calgari
calgari
canada
pediatr
univers
calgari
calgari
canada
blood
bone
marrow
transplant
program
tom
baker
cancer
centr
calgari
canada
patholog
laboratori
medicin
calgari
laboratori
servic
calgari
canada
object
complic
hematopoiet
cell
transplant
hct
mainli
diseas
gvhd
infect
substanti
lead
caus
morbid
mortal
cytokin
act
chief
mediatorsregul
immun
respons
genet
control
cytokin
product
evidenc
polymorph
cytokin
gene
regulatori
region
result
low
moder
high
cytokin
product
investig
impact
cytokin
gene
variant
allogen
hct
outcom
method
total
adult
pediatr
donor
healthi
individu
analyz
singl
nucleotid
variant
locat
regulatori
andor
exon
region
cytokin
cytokin
receptor
gene
genotyp
perform
primer
base
assay
pbmnc
healthi
individu
stimul
cmv
lysat
cmv
peptid
seb
enumer
cmv
specif
immun
respons
result
donor
carri
low
produc
genotyp
high
incid
acut
gvhd
grade
p
hr
chronic
gvhd
p
hr
vs
hct
recipi
develop
signific
gvhd
receiv
graft
donor
carri
high
vs
low
produc
genotyp
respect
p
allogen
hct
perform
donor
carri
low
produc
genotyp
show
high
rate
cmv
reactiv
p
hr
recurr
cmv
infect
p
hr
low
count
cell
conclus
genet
predisposit
low
product
low
product
strong
predictor
gvhd
post
hct
cmv
complic
respect
result
implic
import
assess
cytokin
gene
variant
develop
new
algorithm
improv
allogen
hct
donor
select
outcom
childhood
acut
promyelocyt
leukemia
apml
treat
sequenti
arsen
trioxid
ato
tran
retino
acid
atra
base
therapi
retrospect
studi
tertiari
care
centr
sp
panda
nd
pradhan
n
shah
prasad
vora
g
narula
g
chinnaswami
pg
subramanyam
chougul
p
amr
b
arora
p
kurkur
sd
banavali
paediatr
oncolog
tata
memori
hospit
mumbai
india
hematopatholog
tata
memori
hospit
mumbai
india
medic
oncolog
tata
memori
hospit
mumbai
india
cancer
cytogenet
laboratori
tata
memori
hospit
mumbai
india
object
studi
clinic
profil
outcom
children
treat
novel
protocol
use
sequenti
ato
atra
base
chemotherapeut
regimen
apml
method
children
year
age
apml
diagnos
retrospect
analyz
patient
receiv
induct
ato
week
along
oral
prednisolon
etoposid
thioguanin
pet
consolid
atra
anthracyclin
follow
monthli
cycl
mainten
atopetfour
cycl
atra
total
treatment
durat
result
forti
four
patient
regist
period
median
rang
present
symptom
fever
mucos
bleed
cutan
bleed
cn
bleed
patient
wbc
count
per
sanz
risk
stratif
low
intermedi
high
risk
evalu
die
start
induct
still
induct
evalu
patient
receiv
induct
expir
cn
pulmonari
bleed
infect
rest
achiev
cr
induct
develop
differenti
syndrom
pulmonari
bleed
fungal
pneumonia
asymptomat
qt
prolong
except
initi
phase
induct
patient
requir
admiss
bloodplatelet
support
post
consolid
except
one
achiev
complet
cytogenet
molecular
remiss
median
follow
month
high
risk
patient
patient
cr
die
home
uncertain
caus
ef
df
conclus
sequenti
use
ato
atra
show
favor
outcom
minim
toxic
pediatr
apml
minim
support
care
need
novel
protocol
abl
achiev
high
rate
ef
high
risk
patient
bleed
rather
relaps
continu
import
caus
treatment
failur
apml
haplotyp
influenc
clearanc
intraven
busulfan
occurr
sinusoid
obstruct
syndrom
children
undergo
hsct
behalf
pdwp
ebmtgroup
ansari
rezgui
cr
uppugunduri
chalandon
dupui
ih
bartelink
jj
boelen
jh
dall
azarnoush
p
sedlacek
v
lewi
mezziani
mf
vachon
duval
champagn
c
peter
h
bittencourt
krajinov
depart
pediatr
unit
cansearch
research
laboratori
univers
hospit
geneva
geneva
switzerland
depart
pediatr
chu
cancer
center
montreal
canada
clinic
pharmacolog
unit
depart
pediatr
cancer
center
montreal
canada
depart
pharmaci
divis
haematologyoncolog
hospit
sick
children
toronto
canada
depart
paediatr
divis
haematologyoncolog
hospit
sick
children
toronto
canada
clinic
pharmaci
depart
bioengin
therapeut
scienc
univers
medic
center
utrecht
utrecht
netherland
pediatr
blood
marrow
transplant
program
univers
medic
center
utrecht
utrecht
netherland
pediatr
hematolog
depart
robert
hospit
assist
de
pari
inserm
pari
diderot
univers
pari
franc
depart
pediatr
hematolog
oncolog
teach
hospit
motol
medic
school
charl
univers
pragu
czech
republ
depart
oncolog
paediatr
alberta
children
hospit
calgari
canada
depart
hematolog
hospit
verdun
montreal
canada
depart
pediatr
stem
cell
transplant
unit
st
anna
children
hospit
vienna
austria
object
intraven
busulfan
bu
base
condit
regimen
wide
use
children
undergo
hematopoiet
stem
cell
transplant
hsct
assess
predict
differ
bu
pharmacokinet
pk
import
sinc
bu
narrow
therapeut
window
bu
mainli
metabol
glutathion
recent
report
relationship
haplotyp
bu
pk
relationship
hsct
outcom
children
receiv
myeloabl
condit
regimen
uhcsj
valid
observ
extend
analysi
includ
children
diagnos
malign
condit
recruit
differ
centr
method
patient
receiv
iv
bu
dose
first
dose
decid
base
age
bu
plasma
level
measur
hplc
method
major
patient
steadi
state
concentr
ngml
genotyp
promot
variant
loci
infer
haplotyp
analyz
associ
bu
pk
occurr
sinusoid
obstruct
syndrom
so
result
accord
suggest
function
role
haplotyp
associ
lower
bu
level
higher
bu
clearanc
p
appar
influenc
femal
patient
higher
incid
so
observ
b
haplotyp
carrier
p
associ
also
potenti
femal
patient
p
conclus
result
confirm
prior
observ
support
possibl
tailor
first
bu
dose
accord
haplotyp
statu
also
demonstr
possibl
segreg
patient
higher
risk
so
develop
base
haplotyp
statu
applic
bone
marrow
bm
peripher
blood
pb
minim
residu
diseas
mrd
monitor
infant
enrol
protocol
g
tsaur
popov
riger
nasedkina
solodovnikov
kustanovich
aleinikova
streneva
e
shorikov
l
saveliev
l
fechina
pediatr
oncolog
hematolog
center
region
children
hospitalresearch
institut
medic
cell
technolog
yekaterinburg
russia
biochip
laboratori
engelgardt
institut
molecular
biolog
russian
academi
scienc
moscow
russia
pediatr
oncolog
hematolog
center
research
institut
medic
cell
technolog
yekaterinburg
russia
genet
biotechnolog
laboratori
belarusian
research
center
pediatr
oncolog
hematolog
immunolog
minsk
belaru
director
belarusian
research
center
pediatr
oncolog
hematolog
immunolog
minsk
belaru
chair
laboratori
medicin
ural
state
medic
univers
yekaterinburg
russia
object
estim
prognost
signific
mrd
bm
pb
qualit
detect
differ
mll
fusion
gene
transcript
fgt
infant
alltreat
protocol
method
fifti
three
infant
male
femal
defin
mll
rearrang
includ
current
studi
median
age
month
rang
mrd
detect
perform
bm
pb
sampl
pcr
nest
sensit
defin
absenc
fgt
assay
median
period
observ
group
year
tp
mrd
assess
follow
day
remiss
induct
time
point
tp
end
remiss
induct
cours
atra
administr
result
estim
pair
bmpb
sampl
among
sampl
doubl
posit
doubl
neg
thu
concord
mrd
result
bm
pb
sampl
achiev
discrep
result
sampl
bm
led
unfavor
outcom
ef
significantli
lower
group
comparison
one
vs
p
tp
bm
signific
factor
diagnost
model
initi
risk
factor
age
diagnosi
initi
wbc
count
immunophenotyp
cn
diseas
presenc
combin
respons
criteria
number
blast
cell
day
tabl
could
find
tp
mrd
data
obtain
pb
sampl
prognost
valu
conclus
despit
high
qualit
concord
rate
bm
pb
sampl
could
show
prognost
signific
mrd
monitor
fgt
detect
pb
univari
multivari
analysi
reveal
bm
signific
independ
prognost
factor
unfavor
outcom
genet
metabol
determin
methotrex
induc
mucos
pediatr
acut
lymphoblast
leukemia
den
ho
e
ml
te
winkel
w
tiss
jde
de
rooij
e
den
boer
r
pieter
smf
pluijm
r
de
jong
mm
van
den
pediatr
oncolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
depart
genet
physic
anthropolog
anim
physiolog
univers
basqu
countri
leioa
spain
pediatr
oncolog
beatrix
children
hospit
univers
medic
centr
groningen
groningen
netherland
depart
clinic
chemistri
erasmu
univers
medic
center
rotterdam
netherland
pediatr
oncolog
princess
maxima
center
utrecht
utrecht
netherland
object
methotrex
mtx
import
effect
chemotherapeut
drug
treatment
pediatr
acut
lymphoblast
leukemia
howev
mtx
induc
toxic
lead
amend
treatment
subsequ
impair
surviv
aim
studi
identifi
metabol
genet
determin
mtx
toxic
method
prospect
studi
dutch
pediatr
patient
treat
four
high
dosag
mtx
everi
week
accord
protocol
toxic
previou
cours
prospect
score
cours
nation
cancer
institut
nci
grade
consid
clinic
relev
toxic
plasma
mtx
level
measur
hour
infus
erythrocyt
folat
plasma
folat
plasma
homocystein
level
determin
start
protocol
seventeen
singl
nucleotid
polymorph
snp
candid
gene
mtx
pathway
analyz
result
mucos
occur
patient
skin
toxic
diarrhea
neurotox
hospit
admiss
necessari
patient
mtx
cours
mucos
associ
plasma
mtx
plasma
folat
plasma
homocystein
level
patient
mucos
higher
baselin
level
erythrocyt
folat
median
moll
vs
moll
p
wildtyp
gene
snp
associ
higher
frequenc
mucos
aa
vs
aggg
p
conclus
higher
baselin
erythrocyt
folat
variant
snp
determin
mucos
pediatr
treatment
contrast
plasma
mtx
plasma
folat
unrel
toxic
prognosi
impact
remain
lung
nodul
metastasectomi
osteosarcoma
patient
respons
recurr
c
cellier
le
deley
l
h
pacquement
tabon
jimenez
larroquet
e
fadel
sarnacki
irtan
radiolog
curi
institut
pari
franc
biostatist
gustav
roussi
institut
villejuif
franc
paediatr
oncolog
gustav
roussi
institut
villejuif
franc
paediatr
oncolog
curi
institut
pari
franc
paediatr
oncolog
trousseau
hospit
pari
franc
paediatr
oncolog
unicanc
pari
franc
paediatr
surgeri
trousseau
hospit
pari
franc
thorac
surgeri
mari
lannelongu
hospit
le
franc
paediatr
surgeri
hopit
necker
enfant
malad
pari
franc
object
aim
studi
surviv
patient
pulmonari
metastat
osteosarcoma
improv
complet
remov
metastas
due
dramat
increas
qualiti
year
allow
detect
millimetr
nodul
unabl
found
surgeri
aim
determin
remain
nodul
impact
recurr
method
retrospect
compar
lung
ct
scan
perform
diagnosi
first
relaps
surgic
patholog
report
patient
treat
osteosarcoma
methotrex
base
chemotherapi
protocol
oper
lung
nodul
main
result
three
patient
exclud
countless
nodul
one
tuber
sclerosi
patholog
among
patient
final
includ
classifi
metastat
diagnosi
doubt
nodul
median
month
diagnosi
rang
patient
relaps
experienc
progress
among
nodul
median
per
patient
describ
diagnosi
remain
neoadjuv
chemotherapi
new
nodul
detect
among
nodul
found
surgeri
prove
lung
metastas
either
viabl
n
necrot
n
patholog
analysi
addit
nodul
remov
viabl
necrot
metastas
among
nodul
found
surgeri
still
present
end
treatment
eot
involv
relaps
nodul
describ
progress
nodul
describ
conclus
lung
nodul
found
surgeri
still
remain
ct
scan
eot
seem
respons
recurr
pulmonari
metastat
osteosarcoma
patient
clamshel
thoracotomi
plausibl
altern
bilater
pulmonari
metastasectomi
pediatr
patient
osteosarcoma
j
palacio
j
shalkow
hernandez
leon
j
echavez
j
vazquez
surgic
oncolog
nation
institut
pediatr
mexico
citi
mexico
pediatr
surgic
oncolog
abc
medic
center
mexico
citi
mexico
object
osteosarcoma
common
malign
bone
tumor
children
adolesc
patient
eventu
develop
metastat
diseas
lung
frequent
site
techniqu
describ
bilater
metastasectomi
includ
stage
posterolater
thoracotomi
median
sternotomi
present
experi
bilater
pulmonari
metastasectomi
pediatr
patient
osteosarcoma
use
clamshel
thoracotomi
describ
indic
advantag
disadvantag
method
review
case
osteosarcoma
case
bilater
lung
metastasectomi
identifi
underw
stage
posterolater
thoracotomi
median
sternotomi
case
underw
clamshel
thoracotomi
result
seven
male
nine
femal
median
age
year
common
primari
site
distal
femur
common
tumor
type
osteoblast
patient
frequent
time
present
pulmonari
metastas
follow
preserv
sternum
synchron
bilater
anterior
thoracotomi
five
case
five
patient
requir
reoper
local
recurr
surgic
time
rang
hour
averag
blood
loss
ml
chest
tube
remov
postop
day
two
hospit
length
stay
day
thoracotomi
identifi
lesion
ct
case
periop
mortal
surgic
complic
minim
three
case
postop
pneumothorax
requir
extra
hour
pleural
drainag
lesion
remov
histolog
confirm
chemotherapi
initi
day
postop
conclus
clamshel
thoracotomi
safe
feasibl
altern
bilater
metastasectomi
pediatr
patient
osteosarcoma
procedur
well
toler
minim
postop
pain
allow
adequ
simultan
explor
lung
includ
segment
decreas
time
recoveri
need
chemotherapi
thoracotomi
via
approach
easili
perform
anterior
lesion
technic
difficult
surgeri
play
key
role
treatment
pulmonari
relaps
wilm
tumor
data
siop
siop
j
fuch
n
nourkami
jp
schenk
n
graf
warmann
pediatr
surgeri
pediatr
urolog
univers
children
hospit
germani
pediatr
oncolog
hematolog
univers
hospit
saarland
homburg
germani
radiolog
univers
hospit
heidelberg
germani
object
evalu
outcom
children
suffer
pulmonari
wilm
tumor
relaps
regist
within
multicent
trial
siop
siop
societi
pediatr
oncolog
hematolog
gpoh
method
data
children
pulmonari
wilm
tumor
relaps
retrospect
analys
regard
patient
characterist
well
oncolog
surgic
outcom
result
studi
trial
children
nephroblastoma
relaps
lung
histolog
reveal
intermedi
risk
high
risk
patient
relaps
singular
multipl
patient
data
locat
unilater
bilater
case
data
primari
lung
metastas
initi
present
patient
wherea
patient
primari
lung
metastas
patient
receiv
neoadjuv
chemotherapi
first
line
treatment
tumor
nephrectomi
perform
first
line
local
treatment
primari
tumor
patient
partial
nephrectomi
patient
median
time
pulmonari
relaps
month
local
treatment
pulmonari
relaps
surgeri
irradi
perform
patient
surgeri
part
local
treatment
overal
surviv
patient
conclus
vast
major
children
pulmonari
relaps
undergo
surgeri
local
treatment
surviv
relevantli
inferior
compar
children
without
relaps
aggress
approach
seem
justifi
order
treat
affect
patient
surviv
lung
metastas
pediatr
solid
tumor
systemat
review
g
mullasseri
w
jawaid
p
losti
depart
paediatr
surgeri
institut
child
health
liverpool
unit
kingdom
object
metastat
lung
lesion
pediatr
solid
tumor
treat
use
multimod
therapi
surviv
report
improv
perform
systemat
review
literatur
robustli
analys
surviv
outcom
children
dissemin
diseas
link
primari
tumor
role
surgic
metastectomi
method
studi
identifi
use
medlin
embas
cochran
databas
use
key
relev
search
term
literatur
review
case
report
patient
adult
studi
age
year
exclud
data
extract
independ
follow
paper
select
least
studi
author
overal
surviv
os
surviv
ef
assess
differ
primari
tumor
result
origin
search
retriev
articl
follow
applic
exclus
criteria
remov
duplic
data
studi
patient
includ
final
review
publish
studi
cover
era
common
primari
tumor
dissemin
lung
osteosarcoma
n
follow
wilm
tumour
n
overal
patient
surviv
ci
ci
ci
osteosarcoma
wilm
tumor
ewe
sarcoma
respect
surgic
metastasectomi
perform
patient
link
cancer
therapi
programm
achiev
cure
insuffici
high
qualiti
data
avail
address
answer
real
therapeut
benefit
surgic
metastasectomi
vs
chemotherapi
radiotherapi
patient
pulmonari
metastas
conclus
surgic
lung
metastectomi
oncolog
practic
review
found
individu
case
seri
subgroup
pediatr
case
exclus
manag
without
consid
potenti
role
oper
metastectomi
true
valu
surgeri
manag
patient
advanc
pulmonari
metastas
fulli
establish
current
examin
publish
world
literatur
allow
us
though
summaris
benchmark
outcom
subgroup
patient
tumour
type
pulmonari
metastas
local
control
diffus
intrabdomin
pelvic
rhabdomyosarcoma
result
phase
studi
cytoreduct
surgeri
hypertherm
intraperiton
chemotherapi
hipec
hay
jordan
hl
green
p
anderson
w
huh
surgic
oncolog
univers
texa
md
anderson
cancer
center
houston
usa
pediatr
univers
texa
md
anderson
cancer
center
houston
usa
pediatr
hematologyoncolog
levin
children
hospitallevin
cancer
institut
charlott
usa
object
diffus
recurr
intrabdomin
pelvic
rhabdomyosarcoma
rare
form
rm
instead
local
mass
rm
multipl
present
sarcomatosi
abdominalpelv
caviti
present
secondari
tumor
ruptur
de
novo
incid
sarcomatosi
rhabdomyosarcoma
unknown
approxim
rm
case
per
year
usa
abdominalpelv
non
case
method
perform
cytoreduct
surgeri
hypertherm
intraperiton
chemotherapi
hipec
cur
intent
part
neoadjuv
adjuv
chemotherapi
phase
phase
trial
rm
patient
subset
larger
cohort
patient
sarcoma
histolog
patient
includ
rm
multifoc
abdomin
caviti
andor
recurr
post
radiat
patient
imag
characterist
consist
surgic
resect
diseas
cisplatin
use
continu
minut
surgic
resect
result
patient
age
year
underw
cytoreduct
surgeri
hipec
procedur
three
eight
patient
success
local
control
abdomin
diseas
greater
one
year
two
eight
patient
aliv
without
diseas
month
five
eight
complet
resect
prior
hipec
patient
incomplet
resect
recur
less
month
surgeri
dose
limit
toxic
grade
higher
elev
creatinin
one
patient
requir
chronic
dialysi
major
postop
complic
includ
high
grade
bowel
obstruct
wound
infect
skin
separ
conclus
dose
cisplatin
hipec
safe
children
rm
sarcomatosi
complet
partial
respons
seen
patient
rm
sarcomatosi
altern
intraperiton
chemotherapi
need
cisplatin
insensit
patient
evalu
necess
surgeri
local
therapi
rhabdomyosarcoma
bladder
prostat
year
experi
tertiari
care
centr
mitra
agarwala
bakhshi
jana
pathi
thulkar
sriniva
bajpai
dk
gupta
v
bhatnagar
pediatr
surgeri
india
institut
medic
scienc
delhi
india
medic
oncolog
brairch
india
institut
medic
scienc
delhi
india
radiolog
brairch
india
institut
medic
scienc
delhi
india
radiotherapi
brairch
india
institut
medic
scienc
delhi
india
object
assess
whether
surgic
resect
essenti
good
outcom
children
rhabdomyosarcoma
rm
bladder
andor
prostat
bp
method
record
children
treat
analys
outcom
term
overal
surviv
os
event
free
surviv
ef
analys
accord
age
presenc
metastas
local
therapi
given
resect
vs
resect
event
includ
death
recurr
progress
multimod
chemotherapi
vincristineactinomycincyclophosphamid
extern
beam
radiotherapi
rt
use
children
result
children
includ
analysi
older
month
present
event
includ
death
give
os
ef
ef
significantli
better
p
month
age
tenof
metastasi
five
event
includ
two
death
give
os
ef
os
p
ef
p
significantli
differ
without
metastasi
receiv
neoadjuv
chemotherapi
receiv
adjuv
chemotherapi
rt
surgic
resect
upfront
part
local
therapi
death
event
achiev
complet
remiss
cr
give
ef
among
oper
upon
event
includ
deathsand
achiev
cr
give
os
ef
conclus
though
achiev
cr
without
resect
chanc
achiev
three
time
greater
undergo
surgeri
upfront
neodajuv
chemotherapi
os
p
ef
p
differ
two
group
result
lead
us
question
need
aggress
surgic
excis
patient
high
dose
rate
brachytherapi
success
treatment
childhood
lower
urinari
tract
malign
j
stenman
pj
svensson
n
pal
c
merck
depart
paediatr
surgeri
karolinska
univers
hospit
stockholm
sweden
depart
paediatr
oncolog
karolinska
univers
hospit
stockholm
sweden
depart
oncolog
radiumhemmet
karolinska
univers
hospit
stockholm
sweden
object
low
dose
rate
brachytherapi
bt
shown
reduc
long
term
morbid
treatment
rhabdomyosarcoma
aim
minim
long
term
morbid
radic
surgeri
develop
introduc
high
dose
rate
brachytherapi
use
treatment
childhood
lower
urinari
tract
malign
method
children
male
age
year
diagnos
n
malign
triton
tumour
bladder
mtt
n
treat
karolinska
univers
hospit
patient
accord
cw
protocol
surgeri
limit
placement
patient
tumour
diamet
less
cm
induct
chemotherapi
blind
end
brachytherapi
cathet
place
interv
mm
cover
clinic
target
volum
margin
mm
direct
perform
anaesthesia
given
twice
daili
first
five
postop
day
hdr
nucletron
netherland
dose
per
fraction
gy
total
dose
gy
treatment
perform
mild
sedat
result
children
treat
primari
tumour
mtt
aliv
evid
diseas
month
child
receiv
part
salvag
treatment
recurr
die
patient
aliv
retain
bladder
function
detail
urolog
includ
void
pattern
upper
urinari
tract
ultrasonographi
kidney
function
erectil
function
ongo
conclus
report
use
wide
avail
instrument
platform
reduc
need
radic
surgeri
potenti
morbid
clinic
result
promis
warrant
investig
martelli
h
et
al
j
ped
surg
jenney
et
al
pediatr
blood
cancer
reduc
longitudin
boni
resect
margin
surgeri
extrem
osteosarcoma
impact
oncolog
outcom
ahp
loh
h
wu
bahrami
f
navid
mw
bishop
mb
mccarvil
j
wu
nc
daw
md
neel
bn
rao
depart
surgeri
st
jude
children
research
hospit
memphi
usa
depart
biostatist
st
jude
children
research
hospit
memphi
usa
depart
patholog
st
jude
children
research
hospit
memphi
usa
depart
oncolog
st
jude
children
research
hospit
memphi
usa
depart
radiolog
scienc
st
jude
children
research
hospit
memphi
usa
divis
pediatr
univers
texa
md
anderson
cancer
center
houston
usa
depart
paediatr
surgeri
kk
women
children
hospit
singapor
depart
pediatr
univers
tennesse
health
scienc
center
memphi
usa
object
boni
resect
margin
surgeri
osteosarcoma
suffici
wide
maxim
preserv
nativ
bone
howev
optim
distanc
margin
well
establish
studi
investig
effect
decreas
boni
resect
margin
associ
surgicopatholog
factor
oncolog
outcom
patient
method
retrospect
review
children
adolesc
newli
diagnos
osteosarcoma
enrol
consecut
institut
trial
longitudin
boni
resect
margin
surgeri
serial
decreas
cm
associ
boni
resect
margin
surgicopatholog
factor
local
surviv
lrf
surviv
ef
overal
surviv
os
determin
result
one
hundr
surgeri
perform
patient
plan
actual
resect
margin
correl
lrf
ef
os
serial
reduct
plan
boni
resect
margin
cm
advers
affect
surviv
outcom
median
year
local
recurr
distant
recurr
concurr
local
distant
recurr
patient
die
diseas
multivari
cox
regress
analysi
metastat
diseas
diagnosi
independ
associ
decreas
lrf
ef
os
p
respect
tumor
necrosi
independ
associ
decreas
os
ef
p
respect
earlier
year
treatment
patholog
fractur
independ
associ
decreas
os
p
respect
previou
cancer
histori
male
gender
associ
decreas
ef
p
respect
conclus
surgeri
osteosarcoma
children
adolesc
reduc
longitudin
boni
resect
margin
cm
increas
risk
local
recurr
advers
surviv
outcom
establish
prognost
factor
continu
relev
group
patient
lymph
node
sampl
pediatr
extrem
soft
tissu
sarcoma
surviv
outcom
ea
perez
j
tashiro
je
sola
divis
pediatr
surgeri
depart
surgeri
miller
school
medicin
univers
miami
miami
usa
object
extrem
rhabdomyosarcoma
rm
subtyp
soft
tissu
sarcoma
nrst
commonli
involv
region
lymph
node
sought
determin
effect
lymph
node
sampl
ln
surviv
pediatr
extrem
soft
tissu
sarcoma
st
method
seer
registri
analyz
patient
year
age
extrem
st
multivari
match
analys
perform
obtain
assess
surviv
result
overal
patient
identifi
overal
incid
per
person
signific
annual
increas
p
studi
period
patient
commonli
male
age
year
white
diagnos
local
diseas
lower
extrem
origin
muscl
rm
fibrou
tissu
undifferentiatedanaplast
grade
iv
rm
alveolar
type
major
patient
surgeri
radiotherapi
ln
perform
rm
nrst
patient
overal
diseas
specif
surviv
rm
higher
age
year
local
diseas
arm
nrst
adipos
fibrou
vascular
type
p
surviv
advantag
ln
stage
grade
histolog
type
site
rm
nrst
multivari
analysi
reveal
poorli
differenti
undifferentiatedanaplast
grade
nerv
tissu
type
signific
independ
prognost
indic
mortal
local
region
diseas
signific
independ
prognost
indic
decreas
mortal
p
propens
score
match
analys
reveal
ln
associ
improv
overal
surviv
rm
vs
p
synovi
sarcoma
conclus
analysi
seer
propens
score
match
demonstr
surviv
advantag
ln
pediatr
extrem
rm
retroperitoneoscop
adrenalectomi
adren
tumor
children
tran
q
tran
surgeri
nation
hospit
pediatr
hanoi
vietnam
object
report
author
result
retroperitoneoscop
adrenalectomi
ra
adren
tumor
children
method
medic
record
patient
undergo
ra
adren
tumor
center
decemb
decemb
review
rel
small
adren
tumor
well
defin
border
without
encas
great
vessel
without
lymph
node
involv
ct
scan
select
ra
later
retroperiton
approach
use
case
result
patient
identifi
femal
male
median
age
year
rang
year
tumor
left
side
case
right
median
size
cm
rang
cm
three
port
use
case
case
requir
addit
fourth
port
ra
success
case
minim
blood
loss
median
oper
time
minut
rang
minut
convers
open
surgeri
need
case
cm
pheochromocytoma
due
bleed
periop
death
major
complic
patient
resum
oral
feed
day
oper
patholog
studi
show
ganglioneuroma
case
pheochromocytoma
case
ganglineuroblastoma
case
neurobastoma
favor
histolog
case
median
follow
month
patient
aliv
diseas
free
conclus
ra
pediatr
adren
tumor
feasibl
safe
care
select
case
techniqu
give
good
result
benign
tumor
also
malign
tumor
includ
neuroblastoma
favor
histolog
thoracoscop
assist
resect
pediatr
chest
wall
tumor
g
ahm
elshafiey
surgeri
children
cancer
hospit
egypt
cairo
egypt
surgeri
nci
cairo
children
cancer
hospit
egypt
cairo
egypt
object
evalu
role
thoracoscopi
facilit
resect
pediatr
chest
wall
tumor
without
rib
spread
could
decreas
number
resect
rib
without
compromis
margin
method
retrospect
studi
includ
case
rib
ewe
sarcoma
case
rabdomyosarcoma
chest
wall
one
case
rib
chondorosarcoma
one
case
treat
surgic
resect
result
averag
age
year
neoadjuv
chemotherapi
given
case
ewe
sarcoma
procedur
start
thoracoscop
assess
case
could
identifi
margin
case
made
incis
directli
around
lesion
resect
done
without
rib
spread
thoracoscop
assess
fail
identifi
one
margin
case
tumor
aris
rib
one
case
case
tumor
attach
diaphragm
thoracoscopi
attempt
case
due
larg
tumor
diamet
massiv
adhes
resect
includ
rib
case
respect
primari
closur
feasibl
case
rib
transposit
done
one
case
reconstruct
prolen
mesh
cover
muscl
flap
done
case
margin
neg
except
one
case
conclus
pediatr
chest
wall
tumor
rare
thoracoscop
assist
resect
help
accur
choos
site
incis
case
avoid
rib
spread
decreas
number
rib
resect
lararoscop
retroperiton
lymph
node
dissect
paratesticular
rhabdomyosarcoma
children
mudegoudra
r
nerli
patil
urolog
depart
urolog
kle
kidney
foundat
kle
univers
jn
medic
colleg
belgaum
india
object
paratesticular
rhabdomyosarcoma
usual
present
enlarg
painless
scrotal
mass
major
patient
clinic
stage
diseas
common
site
metastas
retroperitoneum
lung
patient
retroperiton
metastas
undergo
modifi
unilater
rplnd
retroperiton
lymph
node
dissect
increas
use
minim
invas
surgeri
spread
rplnd
report
experi
adolesc
method
children
paratesticular
rhabdomyosarcoma
present
us
form
studi
group
children
underw
detail
evalu
imag
surgic
procedur
laparoscop
rplnd
involv
placement
three
port
one
mm
periumbil
camera
port
two
mm
port
one
midlin
xiphoid
one
midlin
pubi
colon
medialis
incis
along
white
line
toldt
spleen
sigmoid
colon
expos
common
iliac
vessel
bifurc
testicular
vessel
uret
first
spermat
cord
dissect
taken
point
previou
orchiectomi
uret
dissect
nearbi
vessel
avoid
ureter
injuri
tissu
split
begin
dissect
lymph
node
dissect
carri
renal
vessel
bifurc
aorta
common
iliac
pericav
interaortocav
lymph
node
dissect
result
studi
period
jan
dec
three
children
mean
age
year
underw
laparoscop
rplnd
mean
oper
time
min
mean
blood
loss
cc
major
intrapostop
complic
mean
hospit
stay
hr
conclus
increas
use
minim
invas
surgeri
spread
rplnd
laparoscop
rplnd
pediatr
patient
ptrm
safe
diagnost
therapeut
procedur
benefit
rapid
convalesc
enabl
earli
commenc
adjuv
chemotherapi
endosurgeri
diagnosi
oncolog
children
rybakova
p
kerimov
kazantcev
rubanski
children
oncolog
feder
state
budgetari
institut
nn
blokhin
russian
cancer
research
center
russian
academi
medic
scienc
moscow
russia
object
summar
analyz
experi
use
diagnosi
endosurgeri
neoplast
diseas
children
method
perform
diagnost
oper
patient
diagnost
thoracoscopi
diagnost
laparoscopi
thoracoscop
lung
resect
differenti
diagnosi
cancer
infecti
process
oper
laparoscopi
thoracoscopi
oper
age
patient
rang
month
year
median
year
averag
time
laparoscop
oper
thoracoscop
min
mean
blood
loss
laparoscopi
thoracoscopi
intraop
complic
appear
case
oper
case
bleed
tumor
superior
vena
cava
injuri
wound
duodenum
case
case
requir
convers
one
case
bleed
tumor
site
elimin
without
resort
convers
case
identifi
postop
complic
surgic
complic
registrar
patient
case
eventr
omentum
incis
periomphal
region
two
case
pneumothorax
nonsurg
complic
also
occur
patient
two
children
pneumonia
one
case
acut
bronchiti
chickenpox
result
two
surgeri
materi
histolog
examin
obtain
requir
one
case
endosurgeri
oper
suddenli
open
surgeri
case
materi
obtain
morpholog
examin
use
narcot
analges
fentanyl
promedol
need
surgeri
postop
period
first
day
patient
receiv
prophylact
antibiot
therapi
averag
number
hospit
day
day
conclus
thoracoscopi
laparoscopi
allow
perform
biopsi
tumor
chest
abdomin
caviti
retroperiton
pelvic
caviti
given
minim
invas
short
postop
period
rapid
recoveri
oper
may
start
special
treatment
soon
possibl
surgeri
safeti
diagnost
accuraci
tissu
biopsi
children
cancer
r
interiano
ah
loh
n
hinkl
fn
wahid
malkan
mao
j
wu
pappo
r
gold
davidoff
depart
surgeri
st
jude
children
research
hospit
memphi
usa
depart
surgeri
univers
tennesse
health
scienc
center
memphi
usa
depart
paediatr
surgeri
kk
women
children
hospit
singapor
depart
biostatist
st
jude
children
research
hospit
memphi
usa
depart
oncolog
st
jude
children
research
hospit
memphi
usa
depart
radiolog
scienc
st
jude
children
research
hospit
memphi
usa
object
tissu
biopsi
frequent
use
pediatr
cancer
may
increasingli
employ
research
purpos
yet
inform
associ
risk
diagnost
yield
lack
studi
sought
evalu
safeti
diagnost
accuraci
tissu
biopsi
children
cancer
method
irb
approv
surgic
percutan
biopsi
perform
children
suspect
establish
diagnosi
cancer
januari
decemb
retrospect
review
patient
diseas
procedur
factor
correl
diagnost
accuraci
incid
complic
use
logist
regress
analysi
result
one
thousand
biopsi
perform
patient
median
age
procedur
rang
year
median
bodi
mass
index
bmi
rang
biopsi
least
postop
complic
use
common
terminolog
criteria
advers
event
minor
grade
major
grade
advers
event
death
occur
common
major
advers
event
blood
transfus
case
infect
requir
intraven
antibiot
debrid
case
nine
hundr
biopsi
provid
definit
histolog
diagnos
yield
unconfirmatori
result
biopsi
site
use
multivari
analysi
thorac
site
p
decreas
age
procedur
p
increas
bmi
p
decreas
hematocrit
p
associ
increas
risk
complic
musculoskelet
site
p
incision
biopsi
p
increas
white
blood
cell
count
p
histolog
result
p
malign
primari
diagnosi
p
method
perform
biopsi
p
associ
histolog
result
conclus
tumor
biopsi
children
cancer
associ
low
incid
complic
high
rate
diagnost
accuraci
predict
factor
identifi
advers
outcom
may
aid
preoper
counsel
risk
assess
bilater
anterior
sternothoracotomi
clamshel
incis
suitabl
altern
bilater
lung
sarcoma
metastasi
resect
children
joseph
r
guatta
diezi
k
pinnagoda
abbo
pediatr
surgeri
chuv
univers
lausann
lausann
switzerland
pediatr
oncolog
chuv
univers
lausann
lausann
switzerland
object
aim
studi
assess
postop
cours
bilater
anterior
sternothoracotomi
bat
children
sarcoma
lung
metastas
cur
care
perspect
method
review
record
patient
year
old
underw
surgic
procedur
sarcoma
metastasi
lung
compar
postop
cours
bat
group
patient
underw
unilater
posterolater
thoracotomi
plt
etiolog
result
surgic
procedur
bat
unilater
plt
mean
age
time
procedur
year
old
bat
year
old
plt
mean
oper
time
bat
group
minut
plt
group
p
patient
receiv
epidur
analgesia
case
mean
time
day
bat
group
day
plt
group
p
chest
tube
remov
day
bat
group
day
plt
group
p
total
hospit
stay
day
bat
group
day
plt
group
p
conclus
experi
bat
seem
suitabl
show
similar
outcom
plt
sarcoma
metastasi
resect
bat
procedur
allow
manual
explor
lung
singl
surgic
intervent
reduc
delay
therapi
improv
treatment
patient
suffer
embryon
comparison
cw
trial
g
seitz
j
fuch
tm
dantonello
leuschner
j
godzinski
klingebiel
e
koscielniak
depart
pediatr
surgeri
pediatr
urolog
univers
children
hospit
germani
depart
pediatr
hematolog
oncolog
olgahospit
klinikum
stuttgart
stuttgart
germani
depart
paidopatholog
univers
hospit
kiel
germani
depart
pediatr
surgeri
marciniak
hospit
wroclaw
poland
depart
pediatr
hematolog
oncolog
univers
children
hospit
frankfurtmain
germani
object
modern
treatment
bladderprost
rhabdomyosarcoma
bprm
aim
improv
surviv
reduc
therapi
intens
well
increas
bladder
preserv
rate
aim
studi
compar
treatment
result
patient
suffer
bprm
treat
within
trial
precursor
trial
method
total
number
children
embryon
bprm
treat
within
n
n
trial
analyz
fourteen
patient
exclud
n
n
patient
receiv
cycl
neoadjuv
chemotherapi
vaiacevai
week
reassess
carri
depend
tumor
size
age
respons
local
therapi
consist
radiotherapi
andor
surgeri
initi
local
control
adjuv
system
therapi
continu
result
patient
age
rang
year
trial
median
follow
month
whole
group
higher
one
third
patient
receiv
radiotherapi
trial
success
local
control
feasibl
use
radiotherapi
andor
surgeri
outcom
differ
local
control
approach
compar
bladder
preserv
rate
matchabl
conclus
despit
reduct
chemotherapi
burden
outcom
patient
suffer
bprm
treat
within
trial
regard
os
es
obvious
better
precursor
trial
although
differ
individu
local
control
rate
improv
outcom
caus
fact
number
prognost
unfavour
incomplet
resect
salvag
radiotherapi
significantli
lower
novel
concept
requir
futur
improv
bladder
preserv
rate
wilm
tumour
respond
preoper
chemotherapi
j
godzinski
h
heij
j
fuch
von
schweinitz
g
cecchetto
g
audri
b
sandstedt
b
sznajder
n
graf
dept
paediatr
surgeri
chair
emerg
medicin
medic
univers
marciniak
hospit
wroclaw
poland
dept
paediatr
surgeri
amc
vumc
amsterdam
netherland
dept
paediatr
surgeri
univers
tuebingen
tuebingen
germani
dept
paediatr
surgeri
univers
munich
munich
germani
dept
paediatr
surgeri
univers
padova
padova
itali
dept
paediatr
surgeri
hospit
trousseau
pari
franc
childhood
cancer
research
unit
dept
patholog
karolinska
institutet
danderyd
hospit
stockholm
sweden
statist
nki
amsterdam
netherland
dept
paediatr
oncolog
hematolog
univers
homburg
homburg
germani
object
major
patient
nephroblastoma
wt
preoper
chemotherapi
decreas
tumour
volum
risk
intraop
tumour
ruptur
stage
diseas
becom
lower
howev
tumour
volum
decreas
even
increas
aim
review
describ
surgic
clinic
patholog
characterist
wt
respond
preoper
chemotherapi
method
patient
unilater
metastat
wt
evidenc
stabl
increas
volum
tumour
preoper
chemotherapi
age
rang
month
median
localis
tumour
metastat
abdomin
stage
miss
patholog
low
risk
intermedi
risk
high
risk
stage
iii
rate
intraop
tumour
ruptur
rate
patholog
group
remain
patient
compar
result
stage
iii
rate
remain
patient
differ
p
intraop
tumour
ruptur
frequent
vs
p
patholog
low
intermedi
risk
less
frequent
respect
vs
p
vs
p
stromal
predomin
subtyp
howev
frequent
vs
p
wherea
rate
blastem
predomin
subtyp
differ
vs
p
high
risk
patholog
frequent
vs
p
outcom
local
tumour
metastat
case
cr
metastat
patient
aliv
month
conclus
patient
wt
preoper
chemotherapi
higher
rate
high
risk
patholog
variant
stromal
predomin
subtyp
intermedi
risk
elev
risk
tumour
ruptur
outcom
remain
accept
wilm
tumour
intravascular
extens
time
reflect
resect
report
siop
l
adamson
r
squir
b
sznajder
h
van
tinteren
j
godzinski
n
graf
powi
depart
paediatr
surgeri
leed
gener
infirmari
leed
unit
kingdom
statist
center
netherland
cancer
institut
amsterdam
netherland
pediatr
surgeri
marciniak
hospit
wroclaw
poland
paediatr
haematolog
oncolog
saarland
univers
hospit
homburg
germani
object
preoper
chemotherapi
recommend
children
wilm
tumour
intravascular
extens
extend
chemotherapi
may
improv
resect
increas
tumour
adher
vascular
endothelium
preclud
complet
resect
evalu
optim
length
preoper
treatment
report
review
patient
tumour
thrombu
treat
siop
studi
method
patient
wilm
tumour
wt
thrombu
identifi
siop
studi
preoper
chemotherapi
vincristineactinomycin
recommend
patient
overal
os
event
free
ef
surviv
tumour
regress
complet
resect
use
cardiopulmonari
bypass
cpb
cavectomi
analys
patient
receiv
standard
preoper
chemotherapi
cours
week
versu
extend
treatment
cours
result
regist
patient
thrombu
tumour
extent
cardiac
caval
renal
vein
receiv
chemotherapi
detail
avail
receiv
standard
treatment
stc
extend
treatment
ec
tumour
regress
observ
stc
ec
complet
resect
achiev
respect
cavectomi
requir
ns
surviv
significantli
higher
receiv
stc
ec
os
vs
p
ef
vs
p
though
tumour
ec
group
vs
stc
patient
intracardiac
extens
receiv
stc
ec
slightli
tumour
regress
vena
cava
observ
ec
group
vs
reduc
cpb
stc
ec
without
improv
surviv
conclus
extend
preoper
chemotherapi
confer
ad
benefit
intracav
thrombu
intracardiac
extens
current
data
inadequ
guid
valu
extend
treatment
improv
tumour
regress
cava
may
permit
resect
without
bypass
adrenocort
carcinoma
children
review
nation
cancer
databas
roja
shi
w
zhang
e
beierl
j
doski
goldfarb
k
gow
golden
langer
vasudevan
j
nuchtern
michael
e
debakey
depart
surgeri
baylor
colleg
medicin
houston
usa
outcom
impact
servic
texa
children
hospit
houston
usa
depart
surgeri
univers
alabama
birmingham
usa
depart
surgeri
univers
texa
health
scienc
san
antonio
san
antonio
usa
depart
surgeri
univers
southern
california
lo
angel
usa
depart
surgeri
univers
washington
seattl
usa
depart
surgeri
tuft
univers
portland
usa
object
adrenocort
carcinoma
acc
rare
occur
children
prior
studi
suggest
acc
children
may
repres
differ
patholog
entiti
compar
adult
purpos
studi
compar
surviv
trend
children
adult
acc
method
util
data
nation
cancer
data
base
ncdb
analyz
patient
adult
year
age
children
year
age
acc
logist
regress
model
use
analyz
trend
factor
associ
improv
surviv
result
total
patient
primari
acc
identifi
adult
children
factor
significantli
p
affect
surviv
includ
ethnic
tumor
grade
region
lymph
node
statu
extent
surgeri
primari
site
surgic
margin
age
patient
acc
year
age
significantli
superior
os
ci
compar
year
age
ci
p
improv
os
younger
age
group
remain
signific
stratifi
tumor
size
cm
posit
lymph
node
statu
p
p
respect
patient
complet
resect
achiev
younger
patient
better
os
older
patient
ci
vs
ci
conclus
acc
patient
year
age
better
os
compar
older
adult
find
persist
subgroup
complet
resect
data
support
acc
children
behav
differ
patholog
entiti
observ
adult
predictor
outcom
pediatr
hepatocellular
carcinoma
review
nation
cancer
data
base
shi
roja
w
zhang
e
beierl
j
doski
goldin
goldfarb
k
gow
langer
j
nuchtern
vasudevan
michael
e
debakey
depart
surgeri
baylor
colleg
medicin
houston
usa
outcom
impact
servic
texa
children
hospit
houston
usa
depart
surgeri
univers
alabama
birmingham
usa
depart
surgeri
univers
texa
health
scienc
center
san
antonio
san
antonio
usa
depart
surgeri
univers
washington
seattl
usa
depart
surgeri
univers
southern
california
lo
angel
usa
depart
surgeri
tuft
portland
usa
object
examin
demograph
characterist
factor
associ
surviv
children
hepatocellular
carcinoma
hcc
method
nation
cancer
data
base
queri
pediatr
patient
year
hcc
subtyp
diagnos
examin
demograph
diagnost
treatment
variabl
identifi
factor
associ
surviv
use
comparison
surviv
curv
also
compar
variabl
pediatr
adult
patient
hcc
result
total
patient
hcc
less
year
old
pediatr
patient
averag
age
year
better
overal
surviv
os
adult
patient
vs
p
pediatr
cohort
children
fibrolamellar
hcc
compris
case
older
year
better
os
patient
hcc
vs
p
white
children
better
os
black
children
racial
group
vs
vs
p
addit
improv
os
observ
children
neg
lymph
node
vs
p
underw
type
lymph
node
sampl
resect
vs
p
neg
margin
resect
vs
p
resect
wedgesegmentectomi
anatom
hepatectomi
extend
hepatectomi
transplant
os
type
procedur
respect
children
neither
size
primari
tumor
treatment
chemotherapi
associ
improv
os
conclus
histolog
subtyp
race
lymph
node
resect
statu
complet
resect
primari
tumor
signific
predictor
surviv
pediatr
hcc
prognost
implic
mulifoc
hepatoblastoma
qureshi
kembhavi
bhagat
vora
g
chinnaswami
laskar
n
khanna
ramadwar
p
kurkur
pediatr
surgic
oncolog
tata
memori
hospit
mumbai
india
radiolog
tata
memori
hospit
mumbai
india
medic
oncolog
tata
memori
hospit
mumbai
india
radiat
oncolog
tata
memori
hospit
mumbai
india
patholog
tata
memori
hospit
mumbai
india
object
evalu
impact
multifocalilti
hepatoblastoma
outcom
method
analysi
includ
patient
treat
march
februari
tumor
characterist
like
lobe
affect
unifoc
multifoc
diseas
extrahepat
extens
involv
portal
vein
hepat
vein
presenc
metastas
record
serum
level
measur
patient
tumor
assign
pretext
group
risk
categori
per
siopel
system
retrospect
patient
except
one
receiv
induct
chemotherapi
cisplatin
doxorubicin
cisplatin
vincristin
right
left
hepatectomi
perform
patient
extend
resect
resect
patient
left
later
sectorectomi
median
hepatectomi
enucl
perform
one
parenchym
cut
margin
neg
patient
result
median
age
month
rang
month
male
femal
postop
mortal
complic
occur
patient
biliari
fistula
wound
infect
intestin
obstruct
project
overal
surviv
respect
diseas
relaps
patient
within
month
local
site
lung
multifoc
signific
prognost
factor
overal
event
free
surviv
p
conclus
multifoc
hepatoblastoma
associ
increas
risk
diseas
relaps
death
singl
centr
review
hepatoblastoma
year
new
zealand
j
mccall
p
johnston
j
skeen
r
cockcroft
r
corbett
j
arudchelvam
bartlett
p
morreau
nz
liver
transplant
unit
auckland
citi
hospit
auckland
new
zealand
paediatr
oncolog
starship
children
hospit
auckland
new
zealand
paediatr
oncolog
christchurch
hospit
christchurch
new
zealand
nz
liver
transplant
unit
auckland
citi
hospit
auckland
new
zealand
paediatr
surgeri
starship
children
hospit
auckland
new
zealand
object
hepatoblastoma
hb
rare
childhood
malign
surgic
resect
remain
chanc
cure
aim
studi
review
outcom
children
underw
surgic
resect
liver
transplant
lt
hb
singl
centr
new
zealand
method
patient
identifi
retrospect
data
includ
patient
demograph
associ
condit
pretext
stage
ct
scan
histolog
treatment
outcom
result
children
age
month
median
male
femal
ratio
identifi
european
asian
indigen
maori
two
patient
famili
adenomat
polyposi
one
patient
neurofibromatosi
wiederman
syndrom
major
pretext
ii
n
iii
iv
stage
avail
patient
six
lung
metastasi
diagnosi
one
tumour
involv
diaphragm
ivc
except
one
patient
small
tumour
treat
neoadjuv
chemotherapi
accord
siopel
protocol
patient
underw
hepat
resect
patient
lt
common
histolog
type
epitheli
follow
mix
type
one
patient
develop
intrahepat
recurr
post
resect
treat
lt
conclus
mean
follow
month
five
patient
develop
recurr
two
pulmonari
one
cerebr
metastas
resect
evid
recurr
month
respect
die
patient
remain
aliv
well
year
overal
event
free
surviv
respect
one
largest
singl
centr
report
hb
surviv
rate
exceed
multicentr
review
malign
hemoperitoneum
children
singl
institut
experi
j
palacio
j
shalkow
guzman
leon
j
vazquez
surgic
oncolog
nation
institut
pediatr
mexico
citi
mexico
pediatr
surgic
oncolog
abc
medic
center
mexico
citi
mexico
object
present
experi
malign
hemoperitoneum
children
tumor
may
produc
hemoperitoneum
spontan
ruptur
present
acut
abdomen
diagnosi
made
surgeri
tumor
risk
includ
neuroblastoma
wilm
hepatoblastoma
ovarian
tumor
method
retrospect
review
case
malign
hemoperitoneum
result
five
male
five
femal
two
year
underw
surgeri
malign
hemoperitoneum
diagnos
includ
ovarian
germ
cell
tumor
ogct
follow
wilm
tumor
wt
hepatoblastoma
hb
neuroblastoma
nb
ovarian
leukem
infiltr
rhabdomyosarcoma
urachu
urm
seven
histori
malign
three
present
acut
abdomen
diagnosi
made
laparotomi
underw
primari
tumor
resect
two
nb
hb
underw
surgeri
alon
free
periton
blood
found
surgeri
ml
requir
intens
care
surgeri
five
patient
aliv
without
evid
diseas
one
wt
four
ogct
five
children
surviv
three
wt
nb
hb
die
multipl
organ
failur
hour
event
patient
rm
die
diseas
progress
one
hb
die
later
multipl
organ
failur
relat
hemoperitoneum
conclus
delay
cancer
diagnosi
commonin
develop
countri
patient
present
acut
abdomen
tumor
incident
found
laparotomi
patient
present
hemodynam
instabl
sign
includ
abdomin
massdistens
compart
syndrom
hematocrit
drop
ideal
diagnosi
howev
unstabl
patient
bedsid
ultrasound
identifi
massfre
fluid
guid
diagnost
paracenthesi
malign
hemoperitoneum
seriou
complic
pediatr
cancer
patient
entail
dismal
prognosi
elev
mortal
rate
high
index
suspicion
time
diagnosi
manag
individu
accord
tumor
characterist
patient
statu
manag
ovarian
mass
children
ovarian
spare
surgeri
appropri
r
clark
r
robert
burdal
roger
depart
paediatr
surgeri
bristol
royal
hospit
children
bristol
unit
kingdom
object
ovarian
spare
surgeri
children
present
ovarian
mass
controversi
aim
report
preoper
find
may
predict
safeti
approach
method
retrospect
review
children
year
present
ovarian
mass
januari
decemb
oper
approach
discret
oper
surgeon
ovarian
spare
surgeri
perform
gynaecolog
expertis
present
result
fifti
six
children
treat
studi
period
benign
borderlin
malign
forti
two
oophorectomi
perform
fourteen
ovarian
spare
procedur
benign
oophorectomi
thirti
seven
benign
histolog
nineteen
histolog
viabl
ovarian
tissu
malign
tumour
larg
mass
size
mean
cm
sd
posit
tumour
marker
bhcg
afp
mainli
solid
element
preoper
ultrasound
scan
benign
mass
smaller
mean
cm
cm
sd
preoper
tumour
marker
taken
posit
appear
uss
cystic
mix
solid
benign
mass
predominantli
solid
element
underw
oophorectomi
two
tort
ovarian
cyst
viabl
ovarian
tissu
either
two
consid
ovarian
spare
surgeri
due
suspici
intraop
appear
oophorectomi
perform
conclus
experi
ovarian
spare
surgeri
perform
surgeon
appropri
expertis
children
present
ovarian
mass
safe
effect
combin
preoper
find
may
help
select
surgeri
mass
cm
diamet
primarili
cystic
neg
tumour
marker
benign
viabl
ovarian
tissu
frequent
seen
benign
mass
therefor
consider
ovarian
spare
surgeri
patient
three
preoper
find
desir
singl
trocar
laparoscop
assist
surgeri
benign
ovarian
cyst
children
tran
q
tran
surgic
depart
nation
hospit
pediatr
hanoi
vietnam
object
report
techniqu
result
singl
trocar
laparoscop
assist
surgeri
stla
benign
ovarian
cyst
boc
children
method
medic
record
patient
diagnosi
boc
undergo
stla
center
februari
februari
review
stla
mm
umbil
trocar
place
mm
camera
engraft
mm
work
channel
use
ovarian
cystic
wall
grasp
brought
umbil
site
cystic
fluid
aspir
outsid
periton
caviti
cyst
brought
abdomen
via
umbil
incis
excis
cyst
perform
extracorpor
spare
ovarian
tissu
possibl
deliveri
cyst
umbil
site
imposs
due
short
adnex
pedicl
cyst
deliv
abdomen
via
minim
transvers
suprapub
incis
fluid
aspir
cystic
remov
perform
describ
result
thirti
patient
identifi
median
age
year
rang
day
year
median
size
cyst
cm
rang
cm
case
cyst
matur
teratoma
case
simpl
cyst
case
dermoid
cyst
patient
cyst
excis
via
umbil
incis
via
suprapub
incis
spare
ovarian
tissu
perform
case
mean
oper
time
minut
periop
complic
mean
postop
hospit
stay
day
median
follow
month
patient
good
health
without
recurr
postop
cosmesi
excel
conclus
stla
feasibl
safe
excel
cosmesi
could
viabl
approach
minim
invas
manag
boc
children
posterior
sagitt
approach
sacrococcyg
teratoma
excel
altern
bhatnagar
pediatr
surgeri
bj
wadia
hospit
children
mumbai
india
object
chevron
shape
buttock
incis
standard
surgic
approach
sacrococcyg
teratoma
major
disadvantag
due
ugli
scar
deform
buttock
persist
throughout
life
modif
surgic
approach
posterior
sagitt
incis
midlin
natal
cleft
provid
excel
cosmet
result
almost
scar
buttock
deform
method
prospect
descript
studi
perform
march
till
decemb
patient
sacrococcyg
teratoma
present
neonat
age
group
later
oper
posterior
sagitt
approach
singl
surgeon
includ
studi
featur
tumor
difficulti
face
surgeri
approach
outcom
analys
result
nineteen
patient
sacrococcyg
teratoma
male
femal
oper
midlin
posterior
sagitt
approach
major
present
neonat
period
wherea
present
year
age
size
tumor
vari
cm
horizont
dimens
type
type
type
per
altman
classif
excis
tumor
posterior
sagitt
incis
done
eas
except
type
tumor
wherein
slight
later
superior
extens
incis
need
adequ
exposur
complet
excis
includ
coccygectomi
done
wound
heal
well
except
patient
superfici
wound
gape
heal
spontan
conclus
compar
chevron
incis
posterior
sagitt
approach
requir
meticul
midlin
dissect
rais
flap
side
without
damag
extern
anal
sphincter
surround
structur
slight
extens
incis
even
presacr
compon
could
complet
excis
cosmet
result
excel
without
deform
buttock
gastrointestin
stromal
tumor
children
report
italian
pediatr
rare
tumor
project
trep
ilari
ferrari
g
bisogno
g
cecchetto
v
kiren
p
tamaro
ladogana
p
pierani
martino
pediatr
surgeri
g
salesi
children
hospit
ancona
itali
pediatr
oncolog
nation
cancer
institut
milano
itali
pediatr
oncolog
univers
padova
padova
itali
pediatr
surgeri
univers
padova
padova
itali
pediatr
oncolog
ircc
burlo
garofolo
triest
itali
pediatr
oncolog
casa
sollievo
della
sofferenza
san
giovanni
rotondo
itali
pediatr
oncolog
g
salesi
children
hospit
ancona
itali
object
gastrointestin
stromal
tumour
gist
import
group
mesenchym
smooth
muscl
neoplasm
aris
anywher
within
gastrointestin
tract
howev
incid
childhood
case
per
million
per
year
tumor
mesenchym
origin
express
membran
protein
kit
mutat
factor
pdgfra
consid
gist
purpos
studi
defin
characterist
gist
patient
recruit
studi
italian
trep
method
patient
enrol
studi
less
year
old
diagnosi
stage
workup
includ
follow
investig
digest
endoscopi
magnet
reson
imag
mri
case
comput
tomographi
ct
sampl
tumour
tissu
also
stain
antibodi
kit
pdgfraa
histomorpholog
gist
subtyp
accord
fletcher
et
al
three
categori
spindl
cell
type
epithelioid
type
mix
type
result
nine
patient
male
femal
gist
enrol
studi
tumour
locat
stomach
patient
cm
proxim
ileocec
valv
common
symptom
gastric
gist
anemia
associ
bleed
patient
jejun
gist
complain
abdomin
pain
patient
underw
spare
surgeri
one
patient
gastric
gist
requir
afterward
radic
gastrectomi
local
recurr
patient
aliv
recent
although
patient
current
undergo
chemotherapi
sunitinib
hepathicperiton
metastas
second
look
surgeri
conclus
current
intern
treatment
gist
childhood
howev
import
rememb
children
gist
probabl
surviv
therefor
spare
surgeri
consid
even
case
multifoc
diseas
local
nodal
metastas
incid
outcom
pediatr
extrem
melanoma
propens
score
match
seer
studi
ea
perez
j
tashiro
rosa
je
sola
divis
pediatr
surgeri
depart
surgeri
miller
school
medicin
univers
miami
miami
usa
object
pauciti
literatur
treatment
melanoma
children
surgic
manag
often
extrapol
adult
experi
sought
determin
incid
surgic
treatment
outcom
extrem
melanoma
pediatr
patient
method
seer
registri
analyz
patient
year
age
extrem
melanoma
multivari
match
analys
perform
identifi
independ
predictor
surviv
result
overal
patient
identifi
overal
incid
per
personsyear
annual
percent
chang
p
patient
commonli
femal
age
year
white
diagnos
local
diseas
lower
extrem
superfici
spread
nodular
histolog
surgic
procedur
includ
wide
local
excis
excision
biopsi
major
amput
sentinel
lymph
node
biopsi
slnb
lymphadenectomi
la
slnbla
perform
patient
local
diseas
region
diseas
overal
diseas
specif
mortal
lower
surviv
male
region
distant
diseas
nodular
histolog
upper
extrem
p
region
distant
diseas
surviv
advantag
slnb
la
vs
sampl
multivari
analysi
reveal
local
diseas
lower
extrem
site
signific
independ
prognost
indic
surviv
distant
diseas
nodular
histolog
indic
poor
surviv
p
match
analysi
found
differ
surviv
rate
slnb
la
vs
sampl
local
region
diseas
conclus
multivari
propens
score
match
analysi
pediatr
extrem
melanoma
seer
demonstr
surviv
advantag
children
undergo
sampl
procedur
sampl
localizedregion
diseas
assess
qualiti
surgic
treatment
children
aggress
fibromatosiss
studi
patient
k
bronowicki
rapala
b
kazanowska
w
sulka
balcerska
e
bien
j
bohosiewicz
chrupek
k
dylewska
kurylak
w
madziara
k
perek
prokurat
raciborska
rybak
g
sobol
w
wozniak
wysocki
e
zielinska
j
godzinski
polish
paediatr
solid
tumour
studi
group
wroclaw
poland
object
aggress
fibromatosi
af
local
destruct
prolif
process
mark
tendenc
recur
aim
studywa
assess
risk
factor
failur
surgic
treatment
children
af
method
children
median
age
yr
af
treat
centr
cooper
within
polish
paediatr
solid
tumour
studi
group
clinic
data
regard
localis
tumour
treatment
modal
resect
retrospect
evalu
correl
result
treatment
complet
stabl
progress
occurr
relaps
result
fifti
patient
pt
resect
cht
use
xrt
case
median
follow
month
pt
cr
sd
pd
relaps
develop
pt
achiev
cr
resect
p
resect
enter
cr
sd
vs
pt
enter
sd
p
pt
cr
sd
resect
vs
sd
pd
p
pt
without
symptom
mutil
achiev
cr
vs
p
rate
relaps
qualiti
resect
follow
p
resect
like
extrem
trunk
vs
p
howev
localis
tumour
influenc
outcom
p
occurr
relaps
p
conclus
import
radic
surgic
margin
seem
clear
patient
resect
also
achiev
good
outcom
mutil
surgeri
improv
outcom
achiev
sd
classifi
neg
treatment
result
extrem
trunk
seem
favour
site
regard
possibl
resect
resect
stage
ia
lymphocyt
predomin
hodgkin
lymphoma
j
aldrink
b
appel
joel
kaplan
c
schwartz
kara
kelli
k
mccarten
p
ehrlich
pediatr
surgeri
nationwid
children
hospit
columbu
usa
pediatr
oncolog
hackensack
univers
medic
center
hackensack
usa
pediatr
oncolog
levin
cancer
institu
charlott
usa
pediatr
oncolog
md
anderson
houston
usa
pediatr
oncolog
morgan
stanli
children
hospit
new
york
citi
usa
radiolog
rhode
island
hopsit
rhode
island
usa
pediatr
surgeri
univers
michigan
ann
arbor
usa
object
outcom
children
withhodgkin
lymphoma
hl
excel
short
long
term
toxic
may
signific
lymphocyt
predomin
hodgkin
lymphoma
lphl
subtyp
hl
typic
present
local
peripher
diseas
recent
children
oncolog
group
cog
studi
demonstr
excel
outcom
lphl
stage
ia
singl
node
diseas
treat
surgeri
alon
purpos
analysi
assess
feasibl
extend
surgeri
treatment
children
stage
ia
lphl
method
initi
imag
patient
enrol
cog
stage
diseas
lymph
node
review
independ
two
pediatr
surgic
oncologist
diseas
locat
extent
nodal
involv
resect
concord
surgeon
compar
reason
unresectabl
note
result
patient
identifi
male
femal
median
age
year
rang
year
eleven
case
evalu
due
insuffici
imag
avail
review
case
evalu
involv
nodal
locat
includ
submandibular
inguinaliliac
cervic
mean
number
node
requir
resect
rang
case
felt
resect
least
one
surgeon
surgeon
agreement
resect
resect
opinion
differ
surgeon
cervic
iliac
case
reason
unresect
disagr
includ
morbid
due
extent
anticip
oper
proxim
vital
structur
surgeon
agreement
type
oper
requir
occur
case
conclus
technic
feasibl
surgeri
children
stage
lphl
high
howev
approach
treatment
stage
lphl
consid
standard
care
must
studi
within
context
clinic
trial
physiolog
oncolog
outcom
inferior
vena
cava
ivc
thrombosi
malign
abdomin
solid
tumor
children
ahp
loh
mw
bishop
mj
krasin
davidoff
mr
langham
depart
surgeri
st
jude
children
research
hospit
memphi
usa
depart
oncolog
st
jude
children
research
hospit
memphi
usa
depart
radiolog
scienc
st
jude
children
research
hospit
memphi
usa
divis
pediatr
surgeri
le
bonheur
children
hospit
memphi
usa
depart
paediatr
surgeri
kk
women
children
hospit
singapor
depart
surgeri
univers
tennesse
health
scienc
center
memphi
usa
depart
surgeri
st
jude
children
research
hospit
memphi
usa
object
evalu
physiolog
oncolog
outcom
ivc
thrombosi
children
abdomin
malign
order
better
understand
risk
benefit
multimod
intervent
employ
manag
method
retrospect
review
children
malign
ivc
tumor
thrombosi
treat
januari
decemb
extent
tumor
thrombu
classifi
accord
hinman
level
complet
thrombu
resect
caval
patenc
imag
evalu
patient
wilm
tumor
diseas
characterist
treatment
oncolog
physiolog
outcom
correl
overal
surviv
os
result
twelv
patient
wilm
tumor
hepatoblastoma
adrenocort
carcinoma
thirteen
patient
receiv
neoadjuv
chemotherapi
reduc
hinman
level
patient
six
patient
complet
thrombu
resect
partial
resect
resect
patient
extent
resect
unknown
imag
patient
ivc
patent
residu
thrombu
surgic
interrupt
imag
patient
complet
thrombu
resect
patient
partial
thrombu
resect
patent
ivc
patient
receiv
addit
boost
adjuv
ivc
radiat
patient
periop
complic
patient
experienc
transient
effect
relat
ivc
occlus
among
wilm
tumor
patient
os
associ
histolog
subtyp
p
ivc
patenc
imag
p
test
conclus
children
malign
ivc
thrombosi
complet
resect
thrombu
associ
mainten
caval
patenc
adjuv
radiat
may
effect
clear
residu
ivc
thrombu
complet
clearanc
malign
ivc
tumor
thrombu
wilm
tumor
may
confer
surviv
benefit
independ
surgic
manag
thrombu
periop
physiolog
complic
encount
oncolog
function
outcom
multimod
manag
malign
pediatr
musculoskelet
tumor
pelvi
tertiari
cancer
center
india
gulia
puri
laskar
orthoped
oncolog
surgic
oncolog
tata
memori
hospit
mumbai
india
orthoped
oncolog
surgic
oncolog
tata
memori
hospit
mumbai
india
radiat
oncolog
tata
memori
hospit
mumbai
india
object
evalu
morbid
function
outcom
oncolog
result
pediatr
patient
malign
tumor
pelvi
treat
surgic
resect
part
multimod
treatment
method
nov
dec
patient
pelvic
tumor
undergon
surgic
excis
medic
record
imag
oncolog
function
statu
review
male
femal
mean
age
year
rang
year
diagnosi
includ
ewe
sarcoma
osteogen
sarcoma
chondrosarcoma
synovi
sarcoma
bone
case
result
eighteen
resect
includ
acetabulum
two
patient
involv
margin
patient
histolog
respons
chemotherapi
assess
patient
show
good
respons
chemotherapi
seven
poor
respond
five
patient
ewe
sarcoma
postop
four
poor
respond
one
good
respond
larg
soft
tissu
compon
two
patient
die
chemotherapi
complic
month
respect
one
patient
urethr
injuri
two
wound
dehisc
requir
secondari
sutur
three
infect
one
patient
progress
painless
ankylosi
hip
patient
avail
rang
month
mean
month
nineteen
patient
current
aliv
two
local
recurr
overal
surviv
year
musculoskelet
tumor
societi
score
rang
conclus
surgeri
malign
pelvic
tumor
extrem
challeng
requir
utmost
surgic
plan
care
execut
provid
good
local
control
oncolog
outcom
accept
function
patient
support
care
nurs
evalu
pediatr
oncolog
nutrit
screen
tool
murphi
white
psw
davi
children
nutrit
research
centr
queensland
children
medic
research
institut
univers
queensland
brisban
australia
depart
dietet
food
servic
royal
children
hospit
brisban
australia
object
pediatr
oncolog
nutrit
screen
pon
tool
propos
method
assess
nutrit
risk
children
cancer
aim
studi
assess
valid
pon
tool
determin
current
nutrit
statu
children
cancer
method
valid
pon
tool
test
children
treat
cancer
queensland
children
cancer
centr
pon
tool
perform
subject
involv
question
relat
cancer
type
therapi
side
effect
oral
intak
weight
loss
measur
bodi
size
repres
current
nutrit
statu
bodi
mass
index
bmi
mid
upper
arm
circumfer
muac
tricep
skinfold
percent
fat
fat
measur
child
result
total
inpati
outpati
n
liquid
cancer
assess
year
use
pon
tool
popul
class
low
nutrit
risk
moder
risk
high
nutrit
risk
pon
tool
strongli
correl
p
weight
z
score
r
bmi
z
score
r
tricep
skinfold
r
muac
r
fat
r
mean
weight
z
score
bmi
z
score
muac
cm
high
risk
group
significantli
p
lower
moder
low
risk
group
fat
high
risk
group
significantli
lower
p
low
risk
group
conclus
pon
tool
identifi
current
nutrit
statu
children
undergo
treatment
cancer
signific
nutrit
differ
evid
group
classifi
pon
low
moder
high
risk
next
step
evalu
involv
assess
concurr
predict
valid
tool
assess
feasibl
reliabl
applic
intern
site
impact
nutrit
statu
qualiti
life
children
treat
cancer
brinksma
r
sanderman
pf
roodbol
e
sulker
jgm
burgerhof
esjm
de
bont
wje
tiss
depart
pediatr
oncolog
hematolog
school
nurs
health
univers
medic
center
groningen
groningen
netherland
depart
health
scienc
health
psycholog
section
univers
medic
center
groningen
groningen
netherland
school
nurs
health
univers
medic
center
groningen
groningen
netherland
depart
epidemiolog
univers
medic
center
groningen
groningen
netherland
depart
pediatr
onoclog
hematolog
univers
medic
center
groningen
groningen
netherland
object
malnutrit
childhood
cancer
patient
associ
lower
level
health
relat
qualiti
life
hrql
howev
associ
never
actual
test
therefor
aim
assess
impact
nutrit
statu
hrql
children
treat
cancer
method
children
age
year
diagnos
hematolog
solid
brain
malign
nutrit
statu
hrql
assess
diagnosi
month
use
version
pedsql
gener
core
scale
pedsql
cancer
modul
score
scale
rang
result
undernourish
children
bmi
ffm
report
significantli
lower
pedsql
score
compar
children
domain
physic
function
social
function
cancer
summari
scale
nausea
overnourish
children
bmi
fm
report
lower
score
emot
cognit
function
cancer
summari
scale
wherea
score
lower
social
function
weight
loss
sd
associ
lower
score
physic
function
emot
social
function
pain
nausea
parent
report
wors
social
function
pain
children
weight
gain
sd
conclus
undernutrit
weight
loss
associ
wors
physic
social
function
wherea
overnutrit
weight
gain
affect
emot
social
domain
hrql
find
stress
import
adequ
nutrit
care
treatment
measur
improv
nutrit
statu
contribut
enhanc
health
outcom
children
treat
cancer
pediatr
oncolog
nurs
investig
social
challeng
relat
nutrit
south
african
studi
mngomezulu
pediatr
chri
hani
baragwanath
academ
hospit
soweto
south
africa
object
effect
cancer
treatment
modal
affect
compromis
nutrit
intak
social
even
greater
impact
individu
societi
gener
taken
balanc
meal
nutrit
benefici
prevent
reduc
cancer
treatment
side
effect
provid
well
prevent
malnutrit
obes
benefit
nutrit
achiev
nurs
insight
import
environment
social
patient
effect
proper
nutrit
highlight
social
impact
patient
famili
interpret
nutrit
term
lifestyl
cultur
norm
belief
religion
age
gender
educ
emphas
simpl
chang
diet
interpret
avail
prepar
provis
increas
benefit
nutrit
intak
improv
patient
qualiti
life
regardless
statu
method
prospect
observ
survey
parent
children
age
perform
basi
twice
week
clinic
day
three
month
subject
sign
written
inform
consent
survey
includ
question
environ
attitud
present
serv
meal
therapi
cancer
verif
background
done
relat
food
prefer
attitud
eat
time
hospit
home
environ
serv
portion
especi
teenag
even
home
result
complianc
nutrit
recommend
found
main
problem
due
divers
social
issu
ignor
patient
nutrit
intak
remain
compromis
introduc
new
eat
habit
treatment
cancer
went
food
social
norm
conclus
despit
social
challeng
nurs
must
provid
children
adolesc
parentsguardian
nutrit
inform
appropri
level
statu
adequ
nutrit
remain
cornerston
improv
chanc
recoveri
throughout
treatment
decis
make
children
cancer
make
big
treatment
decis
k
kelli
c
mowbray
k
p
hind
nurs
research
qualiti
outcom
children
nation
health
system
washington
dc
usa
center
cancer
blood
disord
children
nation
health
system
washington
dc
usa
center
cancer
blood
disord
stanford
children
health
palo
alto
ca
usa
object
inform
control
prefer
construct
develop
child
adolesc
decis
involv
scale
cadi
use
children
adolesc
cancer
cognit
interview
undertaken
ascertain
content
valid
new
instrument
initi
larg
scale
psychometr
evalu
interview
techniqu
provok
discuss
involv
treatment
decis
meant
child
adolesc
particip
focus
access
inform
along
decis
involv
conduct
addit
analys
better
understand
children
perceiv
interchang
inform
decis
involv
method
twenti
children
adolesc
year
cancer
particip
cognit
interview
ask
particip
recount
previou
treatment
decis
make
tdm
experi
interpret
cadi
statement
employ
constant
compar
analysi
verbatim
interview
transcript
gener
code
descript
statement
use
atlasti
result
major
particip
align
five
cadi
statement
accord
degner
origin
control
prefer
scale
metric
particip
interpret
statement
use
person
theoret
tdm
experi
children
recogn
limit
authority
make
big
treatment
decis
describ
part
tdm
help
gain
diseas
treatment
knowledg
understand
decis
made
know
expect
children
discuss
inform
need
independ
necessari
tdm
children
also
uniqu
inform
want
contribut
tdm
children
describ
larger
role
involv
small
support
care
decis
particip
age
relat
desir
limit
inform
decis
involv
conclus
child
descript
tdm
role
follow
tradit
share
decis
make
paradigm
addit
research
need
understand
tdm
child
perspect
intervent
research
intiati
thing
enjoy
whole
hospit
experi
experi
massag
therapi
receiv
cancer
therapi
f
gibson
j
hallman
l
pratt
j
bayliss
centr
outcom
experi
research
children
health
ill
disabl
great
ormond
street
hospit
nh
foundat
trust
london
south
bank
univers
london
unit
kingdom
palli
care
loui
dunda
centr
children
palli
care
univers
colleg
london
institut
child
health
london
unit
kingdom
great
ormond
street
hospit
nh
foundat
trust
london
unit
kingdom
centr
outcom
experi
research
children
health
ill
disabl
great
ormond
street
hospit
nh
foundat
trust
london
unit
kingdom
loui
dunda
centr
children
palli
care
great
ormond
street
hospit
nh
foundat
trust
london
unit
kingdom
object
use
complementari
altern
cam
therapi
children
cancer
report
high
systemat
account
famili
experi
let
alon
proper
investig
impact
pain
symptom
relief
qualiti
life
studi
occas
follow
identif
therapi
room
introduct
complementari
therapi
nurs
specialist
children
cancer
unit
aim
captur
child
experi
receiv
massag
alongsid
convent
cancer
therapi
examin
impact
child
famili
method
children
young
peopl
year
parent
well
parent
infant
year
admit
larg
tertiari
centr
uk
access
servic
period
recruit
approach
participatori
research
method
symptom
sort
card
use
alongsid
scale
measur
sleep
pain
children
qualit
content
analysi
use
detail
stori
children
experi
account
parent
reflect
child
experi
result
children
parent
descript
experi
posit
massag
help
rang
symptom
includ
pain
anxieti
also
provid
safe
space
children
relax
think
someth
els
enjoy
calm
thought
children
spoke
special
room
clearli
mani
nurs
specialist
taken
import
role
care
head
massag
particularli
popular
children
help
headach
sleep
major
case
scale
complet
indic
perceiv
improv
conclus
present
focu
account
suggest
massag
place
care
children
cancer
research
need
assess
specif
impact
outcom
differ
popul
eg
children
receiv
palli
care
complementari
altern
medicin
use
manag
fatigu
psycholog
stress
pediatr
oncolog
popul
l
e
bomfim
nune
l
nascimento
g
bisson
r
lima
depart
nurn
public
health
univers
paulo
preto
colleg
nurs
preto
paulo
brazil
background
fatigu
crf
describ
stress
preval
symptom
pediatr
oncolog
patient
occur
case
psycholog
stress
gener
hospit
neg
influenc
immun
system
neuroendocrin
behavior
pathway
patient
modal
treatment
complementari
altern
medicin
cam
necessari
scientif
evid
support
use
cam
manag
symptom
adult
cancer
howev
pediatr
oncolog
popul
studi
still
scarc
purpos
identifi
analyz
scientif
evid
use
cam
manag
fatigu
psycholog
stress
inpediatr
oncolog
popul
materi
method
conduct
integr
literatur
review
eight
databas
access
search
pubm
web
scienc
cinahl
lilac
embas
scopu
psycinfo
cochran
librari
articl
includ
studi
english
spanish
portugues
publish
last
year
control
uncontrol
descriptor
well
synonym
cross
locat
articl
exampl
fatigu
fatigu
cancerneoplasm
stress
psycholog
child
adolesc
complementari
altern
medicin
intervent
two
research
independ
analyz
studi
initi
articl
found
exclus
duplic
articl
match
inclus
criteria
full
read
obtain
final
sampl
nine
articl
result
nine
studi
group
five
theme
physic
exercis
therapeut
touch
music
therapi
massag
therapi
nurs
intervent
health
educ
among
nine
studi
six
show
signific
p
valu
crf
andor
psycholog
stress
evidenc
use
cam
decreas
symptom
conclus
use
cam
improv
symptom
crf
psycholog
stress
pediatr
oncolog
popul
baselin
standard
provid
paediatr
oncolog
nurs
care
low
middl
incom
countri
posit
statement
siop
podc
nurs
group
day
r
holli
j
challinor
e
bosomprah
divis
nurs
educ
st
jude
children
research
hospit
memphi
usa
paediatr
oncolog
haematolog
leed
teach
hospit
trust
leed
unit
kingdom
school
nurs
univers
california
san
francisco
usa
paediatr
oncolog
teach
hospit
accra
ghana
object
paediatr
oncolog
nurs
low
countri
lmic
lack
educ
resourc
support
adequ
staf
need
provid
qualiti
care
major
impedi
childhood
cancer
program
contribut
low
surviv
rate
lmic
childhood
cancer
occur
congress
intern
societi
pediatr
oncolog
siop
nurs
work
group
establish
one
new
work
group
within
pediatr
oncolog
develop
countri
podc
structur
group
partner
advoc
nurs
healthcar
team
worldwid
improv
paediatr
oncolog
lmic
one
first
goal
group
develop
posit
statement
regard
baselin
standard
provid
paediatr
oncolog
nurs
care
lmic
method
siop
nurs
work
group
repres
countri
collabor
develop
posit
statement
baselin
nurs
standard
need
safe
implement
qualiti
pediatr
oncolog
nurs
care
result
six
baselin
standard
develop
includ
recommend
staf
plan
base
patient
acuiti
paediatr
oncolog
orient
programm
continu
educ
train
acknowledg
nurs
core
member
multidisciplinari
team
avail
resourc
safe
care
nurs
polici
procedur
guid
deliveri
care
conclus
baselin
standard
repres
need
provid
minimum
level
qualiti
care
howev
rare
met
lmic
even
program
support
twin
partnership
countri
intern
issu
need
address
order
improv
surviv
rate
children
cancer
lmic
standard
serv
critic
tool
alloc
much
need
nurs
resourc
deliv
cultur
compet
nurs
care
global
perspect
l
abramovitz
c
baggott
nurs
univers
california
san
francisco
san
francisco
usa
pediatr
stanford
univers
palo
alto
usa
object
pediatr
oncolog
nurs
must
develop
cultur
compet
care
children
vari
background
cultur
compet
includ
knowledg
differ
cultur
languag
valu
belief
purpos
studi
explor
nurs
deliveri
cultur
compet
care
high
incom
countri
hic
lowmiddl
incom
countri
lmic
method
brief
survey
cultur
compet
develop
focus
nurs
attitud
practic
challeng
march
nurs
lmic
hic
care
children
cancer
receiv
email
invit
complet
survey
multipl
choic
question
result
data
survey
analyz
nurs
lmic
compris
respond
remaind
includ
nurs
hic
commonli
identifi
challeng
includ
languag
barrier
obtain
inform
specif
cultur
develop
trust
relationship
nurs
share
success
strategi
deliv
cultur
compet
care
eg
recogn
cue
listen
respect
consult
knowledg
staff
member
use
humor
well
desir
resourc
eg
increas
access
interpret
written
inform
patientspar
access
onlinewritten
resourc
prior
educ
cultur
compet
differ
group
nurs
lmic
receiv
prior
cultur
train
compar
nurs
hic
p
overal
nurs
state
educ
need
develop
cultur
compet
among
lmic
nurs
lectur
written
modul
video
top
format
identifi
conclus
nurs
lmic
hic
view
cultur
compet
vital
practic
felt
exposur
cultur
provid
opportun
individu
profession
growth
addit
gain
new
perspect
life
show
increas
sensit
nursepati
relationship
survey
result
guid
develop
resourc
educ
program
support
nurs
written
teach
modul
propos
implement
lmic
hic
intern
pediatr
oncolog
nurs
partnership
complex
overal
histori
norwegianu
ethiopian
exampl
h
haug
morken
j
challinor
children
divis
oslo
univers
hospit
oslo
norway
pediatr
akershu
univers
hospit
norway
school
nurs
univers
california
san
francisco
san
francisco
usa
object
describ
complex
intern
pediatr
oncolog
nurs
partnership
countri
countri
review
histori
twin
use
specif
exampl
collabor
ethiopia
method
review
histori
pediatr
oncolog
twin
start
late
nurs
itali
collabor
nurs
nicaragua
earli
st
jude
children
research
hospit
intern
outreach
program
world
child
cancer
twin
includ
provid
exampl
local
partner
nurs
train
equip
purchas
travel
nurs
local
partner
site
attend
intern
confer
within
context
larger
twin
agenda
review
earli
model
didact
clinic
teach
nurs
train
week
distanc
learn
specif
curriculum
materialsstrategi
util
past
result
nurs
collabor
train
operation
countri
set
complex
role
nurs
mani
countri
may
understood
entir
distinct
nurs
role
countri
nurs
practic
defin
constrict
local
hospit
administr
regul
dramat
impact
visit
nurs
abil
provid
special
train
local
nurs
commun
percept
hazard
work
children
cancer
chemotherapi
complic
educ
effort
conclus
understand
histori
intern
pediatr
oncolog
nurs
twin
program
reveal
challeng
nurs
train
collabor
countri
low
resourc
cultur
languag
educ
differ
identifi
complic
collabor
notwithstand
local
nurs
experi
knowledg
strength
current
twin
ethiopia
includ
nurs
us
norway
highlight
provid
specif
exampl
complex
partner
provid
train
program
pediatr
oncolog
nurs
special
countri
nurs
care
prioriti
time
new
pediatr
oncolog
unit
african
countri
seifu
tikur
anbessa
special
gener
hospit
black
lion
hospit
addi
ababa
ethiopia
purpos
describ
nurs
care
prioriti
time
set
limit
resourc
ethiopia
newli
open
april
dedic
ward
childhood
cancer
materi
method
unit
nurs
children
treatment
approxim
patient
receiv
free
care
offici
recogn
live
extrem
poverti
nolittl
educ
gener
children
arriv
hospit
advanc
cancer
surviv
result
ward
newli
dedic
pediatr
oncolog
nurs
learn
manag
complex
diseas
social
issu
advanc
made
scope
nurs
care
sinc
two
newli
graduat
pharmacist
ward
mix
chemotherapi
newli
graduat
volunt
psychologist
provid
play
therapi
thu
assum
task
new
outpati
hous
mother
teresa
hous
reduc
nurs
attent
famili
support
issu
teach
pediatr
nurs
cancer
care
govern
hospit
begun
conclus
remain
challeng
nurs
concern
side
effect
prepar
chemotherapi
high
death
rate
low
staf
lack
parent
teach
child
diseas
infect
control
side
effect
chemotherapi
famili
extrem
poverti
reflect
low
level
person
hygien
exposur
health
care
educ
famili
arriv
remot
area
often
speak
dialect
local
hospit
personnel
understand
thu
compound
challeng
famili
teach
nurs
must
use
critic
think
skill
includ
knowledg
multipl
ethiopian
cultur
practic
strive
safe
support
care
children
famili
present
highlight
nurs
continu
priorit
care
time
public
hospit
sever
limit
resourc
set
signific
profession
hierarchi
nurs
alway
strong
voic
establish
pediatr
oncolog
nurs
educ
depart
children
cancer
hospit
pakistan
r
punjwani
khatoon
nurs
children
cancer
hospit
karachi
pakistan
object
develop
countri
far
behind
care
pediatr
oncolog
children
cancer
live
pakistan
develop
countri
total
popul
million
nurs
pakistan
like
profess
also
transit
phase
emerg
new
dire
need
educ
train
program
area
method
keep
sight
identifi
need
educationaltrain
program
nurs
children
cancer
hospit
initi
pediatr
oncolog
nurs
educ
depart
pone
depart
develop
three
major
program
nurs
period
four
year
two
cours
alreadi
success
run
one
start
septemb
pediatr
oncolog
technician
cours
diploma
certif
one
year
cours
young
adult
interest
health
care
career
secondli
short
cours
regist
nurs
alreadi
work
pediatr
oncolog
setup
offer
twice
year
two
week
certif
cours
design
enhanc
knowledg
practic
thirdli
one
year
post
rn
diploma
first
ever
pakistan
start
septemb
focu
creat
case
manag
nurs
result
first
ever
fulli
oper
pediatr
oncolog
nurs
educ
depart
cours
regist
licensur
bodi
technician
cours
sindh
medic
faculti
rn
diploma
pakistan
nurs
counsel
complet
cycl
technician
cours
success
nurs
technician
cours
rn
train
nurs
pakistan
conclus
children
cancer
hospit
taken
lead
profession
train
pediatr
oncolog
nurs
vision
creat
centr
excel
pediatr
oncolog
model
health
care
institut
look
childhood
cancer
swedish
perspect
care
scienc
research
paediatr
oncolog
literatur
review
k
l
darci
depart
nurs
school
health
scienc
sweden
child
research
group
school
health
scienc
sweden
object
bodi
knowledg
paediatr
care
scienc
increas
thank
dramat
improv
outcom
relat
research
advanc
treatment
aim
review
investig
content
publish
studi
paediatr
oncolog
relat
care
scienc
method
systemat
literatur
review
publish
articl
paediatr
oncolog
relat
care
scienc
sweden
perform
result
result
show
studi
descript
compar
studi
quantit
design
parent
focu
focu
child
studi
investig
wellb
use
questionnair
interview
result
state
articl
demonstr
child
diseas
affect
wellb
peopl
come
contact
child
posit
neg
way
also
child
diseas
caus
distress
relat
physic
psycholog
existenti
social
aspect
sever
mediat
factor
experi
distress
wellb
found
diseas
treatment
sever
gender
time
sinc
diagnos
use
intern
extern
support
frequent
report
health
promot
aspect
famili
togeth
cope
strategi
engag
activ
normal
life
well
qualiti
care
emot
support
inform
famili
particip
care
suggest
clinic
implic
state
articl
often
describ
diffus
manner
make
translat
clinic
practic
difficult
howev
area
clinic
implic
could
identifi
describ
conclus
reflect
child
perspect
paediatr
oncolog
requir
futur
research
take
challeng
includ
children
biggest
challeng
futur
would
make
shift
explor
studi
intervent
studi
urgent
need
transform
research
result
clinic
practic
explor
nurs
view
regard
profession
boundari
care
child
young
person
famili
life
threaten
condit
j
cargil
teenag
young
adult
cancer
servic
univers
hospit
bristol
nh
foundat
trust
bristol
unit
kingdom
object
profession
boundari
pb
central
establish
therapeut
relationship
tension
exist
balanc
involv
benefici
therapeut
relationship
one
close
potenti
destruct
challeng
one
common
occurr
nurs
prolong
involv
care
intimaci
form
basi
nurs
care
deliv
present
report
find
small
exploratori
studi
conduct
uncov
experienc
nurs
view
pb
care
child
young
person
life
threaten
condit
method
conduct
larg
teach
hospit
within
south
england
interview
undertaken
six
experienc
nurs
care
child
young
person
famili
life
threaten
condit
content
analysi
util
extrapol
mean
transcrib
interview
result
knowledg
understand
pb
awar
mean
good
yet
pb
routin
concern
manag
pb
current
insuffici
nurs
work
area
practic
strategi
requir
improv
awar
support
nurs
support
senior
staff
could
help
reduc
incid
consequ
boundari
cross
violat
conclus
studi
suggest
determin
pb
within
profession
yet
therapeut
relationship
one
signific
challeng
nurs
care
child
young
person
level
intens
emot
natur
work
child
young
person
life
threaten
condit
studi
suggest
cross
violat
pb
consid
occup
hazard
must
given
due
attent
motiv
drive
boundari
cross
violat
govern
place
determin
behavior
import
research
requir
understand
behavior
develop
improv
cope
techniqu
balanc
compass
profession
interpret
experi
childhood
cancer
care
j
granhagen
jungner
p
pergert
k
k
blomgren
e
tiseliu
women
children
health
karolinska
institutet
stockholm
sweden
depart
swedish
languag
multilingu
stockholm
univers
stockholm
sweden
object
linguist
cultur
divers
integr
part
societi
even
childhood
cancer
care
children
cancer
famili
share
common
languag
health
care
staff
fragil
vulner
situat
purpos
paper
describ
interpret
experi
interpret
childhood
cancer
care
paediatr
cancer
care
unit
astrid
lindgren
children
hospit
sweden
method
ten
n
interpret
interpret
experi
childhood
cancer
care
interview
individu
interview
data
interview
analys
use
qualit
content
analysi
result
analysi
data
result
report
paper
balanc
compass
profession
interpret
strive
constantli
keep
balanc
empathi
compass
perform
task
profession
balanc
sometim
complex
keep
difficult
circumst
client
face
interpret
handl
balanc
spare
tear
feel
compass
basic
desir
help
human
perspect
also
sinc
countrymen
cultur
background
particularli
vulner
situat
interpret
sometim
step
outsid
profession
role
eg
term
neutral
becom
view
fellow
human
instead
conclus
interpret
struggl
neutral
parti
profession
code
conduct
requir
relat
famili
interpret
explicit
two
phenomena
struggl
first
emot
involv
children
suffer
cancer
secondli
strive
meet
point
understand
requir
commit
beyond
interpret
oblig
neutral
establish
meet
point
understand
requir
explan
context
cultur
aspect
translat
word
creat
meet
point
understand
open
understand
requir
creation
relationship
parti
creat
taxonomi
teenag
young
adult
cancer
care
england
map
studi
c
vindrola
finlayson
l
hooker
pearc
r
taylor
j
whelan
f
gibson
children
nurs
london
south
bank
univers
london
unit
kingdom
teenag
young
adult
cancer
servic
southampton
univers
hospit
nh
trust
southampton
unit
kingdom
patient
safeti
infect
control
cnwl
nh
foundat
trust
london
unit
kingdom
depart
oncolog
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
object
cancer
servic
teenag
young
adult
england
current
organis
around
princip
treatment
centr
know
place
care
term
diseas
age
appropri
specialist
set
increasingli
acknowledg
impact
outcom
object
studi
undertak
map
exercis
princip
treatment
centr
develop
nation
taxonomi
care
method
studi
combin
observ
review
annual
report
interview
young
peopl
famili
member
healthcar
profession
activ
young
peopl
model
mosaic
approach
centr
main
purpos
interview
document
differ
view
care
interview
transcript
analys
content
organ
framework
facilit
data
manag
framework
summar
list
compon
care
list
group
three
broader
categori
creat
themat
analysi
list
includ
staff
environ
care
activ
inform
includ
categori
use
develop
taxonomi
care
england
result
analysi
interview
transcript
reveal
share
percept
care
england
despit
wide
divers
model
specialis
servic
current
oper
differ
context
care
even
though
found
differ
percept
care
three
group
agre
overal
goal
teenag
young
adult
care
individu
specialis
servic
made
possibl
care
support
staff
environ
feel
like
home
activ
conclus
taxonomi
allow
us
highlight
import
compon
care
england
taxonomi
could
use
countri
current
develop
shape
teenag
young
adult
servic
understand
bodi
imag
sexual
date
friendship
fertil
adolesc
cancer
adolesc
parent
perspect
j
stinson
la
jibb
luca
white
barrera
gupta
greenberg
child
health
evalu
scienc
hospit
sick
children
toronto
canada
hematologyoncolog
hospit
sick
children
toronto
canada
object
assess
impact
cancer
treatment
adolesc
bodi
imag
date
relationship
sexual
well
fertil
perspect
adolesc
parent
inform
need
adolesc
parent
regard
issu
whether
intervent
appropri
tool
address
need
method
twenti
adolesc
year
either
cancer
treatment
remiss
parent
recruit
one
pediatr
tertiari
care
center
particip
complet
demograph
medic
histori
adolesc
questionnair
interview
particip
observ
primari
data
collect
method
interview
transcrib
transcrib
data
enter
nvivo
independ
code
accord
studi
object
two
train
analyst
code
organ
categori
reflect
emerg
theme
discrep
code
resolv
discuss
result
analysi
reveal
main
theme
adolesc
parent
around
impact
cancer
bodi
imag
ie
hair
loss
scar
weight
lossgain
amput
b
date
relationship
ie
relationship
put
test
sexual
relationship
readi
c
friendship
ie
social
isol
need
support
network
fertil
ie
lack
knowledg
parent
specif
chang
famili
work
dynam
note
parent
adolesc
gener
thought
resourc
would
benefici
especi
endors
notion
interact
engag
site
anonym
privaci
websit
cite
main
advantag
medium
conclus
find
studi
highlight
specif
bodi
face
adolesc
cancer
inform
glean
studi
inform
creation
evalu
development
appropri
onlin
program
adolesc
parent
healthcar
provid
onlin
program
provid
inform
relat
bodi
imag
relationship
fertil
ultim
improv
psychosoci
health
adolesc
cancer
creativ
box
patient
center
commun
tool
use
adolesc
young
adult
cancer
v
van
de
veld
n
belpaem
e
decoen
quaghebeur
l
dillen
k
smet
vandierendonck
rae
v
cocquyt
verhaegh
pediatri
hemato
oncologi
en
stamceltransplantati
univers
hospit
ghent
ghent
belgium
univers
centr
nurs
midwiferi
univers
ghent
ghent
belgium
oncologisch
centrum
uz
gent
univers
hospit
ghent
ghent
belgium
hematologi
univers
hospit
ghent
ghent
belgium
object
grow
recognit
take
care
adolesc
young
adult
aya
distinct
children
adult
studi
conduct
explor
person
view
aya
cancer
order
get
insight
perspect
treatment
survivorship
integr
studi
result
patient
center
tool
order
enhanc
commun
aya
multidisciplinari
team
secondari
object
method
qualit
studi
base
principl
ground
theori
conduct
twenti
four
adolesc
age
year
interview
interview
transcrib
code
use
nvivo
constant
comparison
use
analys
data
datacollect
took
place
cyclic
process
result
aya
perspect
cancer
someth
temporarili
pass
diagnosi
shock
cope
strategi
focus
preserv
ident
guard
normal
life
three
phase
identifi
cancer
freez
life
maintain
normal
life
hard
cancer
chang
life
forev
aya
director
treatment
custom
inform
social
network
contact
friend
key
aspect
aya
carea
creativ
ayabox
develop
meet
specif
need
enhanc
commun
aya
box
belong
aya
contain
booklet
reveal
stori
aya
experi
postcard
uniqu
aya
tag
sticker
mention
feel
concern
card
inform
instruct
smart
aid
commun
rel
profession
caregiv
conclus
result
translat
practic
meaning
tool
base
experi
aya
inspir
caregiv
pediatr
ward
provid
patient
center
care
accord
specif
prefer
wish
aya
develop
onlin
psycholog
support
intervent
teenag
young
adult
tya
j
cheshir
dolbi
p
spencer
anstiss
p
beynon
v
britton
j
cargil
steven
target
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
psycholog
health
servic
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
strateg
health
ltd
strateg
health
ltd
buckinghamshir
unit
kingdom
tya
cancer
servic
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
object
find
bristol
target
programm
identifi
tya
receiv
psycholog
support
diagnosi
cancer
show
signific
gap
patient
need
avail
informationadvic
specif
issu
highlight
need
access
inform
common
psycholog
problem
cope
tool
use
approach
patient
ask
engag
develop
content
design
function
onlin
psychologicalemot
support
websit
method
patient
profession
work
collabor
varieti
techniqu
includ
design
studio
event
session
focu
group
meet
email
correspond
engag
patient
profession
allow
prioritis
develop
content
focu
approach
common
psycholog
distress
area
anxieti
bodi
imag
low
mood
anger
seri
event
held
brought
togeth
patient
healthcar
profession
websit
develop
establish
refin
requir
function
agre
aspect
design
site
result
creation
prototyp
websit
produc
tangibl
product
evalu
team
form
basi
specif
develop
final
product
process
ensur
intervent
built
way
repres
tya
ask
psycholog
support
deliv
engag
content
format
base
tya
appropri
approach
content
includ
interact
wellb
tracker
abil
user
customis
conclus
abil
engag
fulli
integr
patient
servic
develop
demonstr
abil
tya
work
healthcar
profession
design
deliv
complex
intervent
evalu
confirm
accept
product
creat
use
approach
increas
avail
psycholog
support
tya
time
immedi
need
usabl
test
onlin
program
adolesc
cancer
jn
stinson
la
jibb
gupta
f
dupui
b
dick
c
laverdier
lemay
l
sung
e
dettmer
gomer
j
lober
cy
chan
child
health
evalu
scienc
hospit
sick
children
toronto
canada
hematologyoncolog
hospit
sick
children
toronto
canada
health
outcom
univers
hospit
research
center
montreal
canada
faculti
medicin
dentistri
univers
alberta
edmonton
canada
viral
immun
disord
cancer
univers
hospit
research
center
montreal
canada
psycholog
hospit
sick
children
toronto
canada
transplant
hospit
sick
children
toronto
canada
research
institut
mcgill
univers
health
centr
montreal
canada
research
institut
st
michael
hospit
toronto
canada
object
studi
util
design
approach
develop
bilingu
english
french
teen
take
charg
manag
cancer
onlin
cancer
program
accept
understand
easi
navig
adolesc
parent
method
iter
cycl
qualit
usabl
test
involv
user
observ
use
refin
intervent
cycl
n
cycl
n
cycl
n
cycl
n
year
old
cancer
one
parent
recruit
two
pediatr
tertiari
care
center
brief
intervent
demonstr
provid
particip
use
websit
think
aloud
issu
encount
interfac
content
train
observ
record
difficulti
navig
error
particip
answer
question
address
experi
recommend
websit
improv
data
transcrib
verbatim
french
interview
transcrib
english
bilingu
transcriptionist
content
analysi
transcript
observ
captur
emerg
theme
relat
intervent
usabl
result
french
english
adolesc
well
parent
provid
similar
feedback
need
intervent
chang
overal
particip
like
websit
aesthet
content
group
rate
intervent
content
appropri
credibl
relev
cancer
experi
usabl
issu
identifi
cycl
english
french
test
relat
aesthet
ie
recommend
elimin
page
navig
tool
english
french
translat
chang
made
new
issu
identifi
follow
second
phase
either
french
english
test
conclus
multifacet
usabl
approach
util
provid
insight
program
made
amen
adolesc
cancer
next
step
includ
feasibl
test
ultim
test
intervent
effect
multicent
random
control
trial
expect
accept
trust
cultur
compet
intervent
improv
health
outcom
adolesc
cancer
improv
qualiti
life
sibl
children
cancer
particip
psychosoci
group
intervent
random
control
trial
rokeach
k
hancock
f
schult
e
atenafu
p
nathan
barrera
psycholog
hospit
sick
children
toronto
canada
oncolog
paediatr
alberta
children
hospit
calgari
canada
biostatist
univers
health
network
toronto
canada
pediatr
hosptial
sick
children
toronto
canada
psycholog
hosptial
sick
children
toronto
canada
background
social
emot
need
overal
qualiti
life
qol
sibl
children
cancer
often
ignor
systemat
research
assess
psychosoci
intervent
design
exclus
sibl
children
cancer
rare
object
determin
particip
sibl
cope
togeth
sct
manual
group
intervent
experiment
group
eg
improv
sibl
qol
rel
attent
control
group
cg
method
studi
employ
control
trial
rct
design
repeat
measur
inclus
criteria
sibl
age
year
patient
least
three
month
diagnosi
group
complet
weekli
group
session
three
assess
immedi
three
month
later
eg
session
design
around
theme
follow
sct
plan
educ
social
therapeut
activ
game
craft
cg
session
focus
social
compon
game
craft
outcom
measur
includ
parent
proxi
qol
analys
anova
partial
indic
effect
size
institut
approv
obtain
particip
sign
consent
form
result
preliminari
analys
base
complet
data
sibl
assess
parent
report
signific
group
time
interact
suggest
improv
total
pedsql
school
function
eg
compar
cg
time
group
improv
emot
pedsqlov
time
greater
score
eg
n
trend
suggest
gener
improv
sibl
total
pedsqlscor
greater
improv
eg
pedsql
score
compar
cg
school
function
feel
conclus
preliminari
find
suggest
manual
group
intervent
effect
program
result
major
improv
emot
school
relat
qualiti
life
sibl
children
cancer
psychosoci
qualiti
life
cohort
childhood
cancer
survivor
implic
survivorship
care
k
ruccion
j
wood
r
sposto
j
malvar
zavala
c
chen
freyer
divis
hematolog
oncolog
bone
marrow
transplant
children
hospit
lo
angel
lo
angel
usa
divis
pediatr
cardiolog
radiolog
children
hospit
lo
angel
lo
angel
usa
keck
school
medicin
univers
southern
california
lo
angel
usa
children
hospit
lo
angel
divis
hematolog
oncolog
bone
marrow
transplant
lo
angel
usa
object
part
larger
studi
character
iron
deposit
among
childhood
cancer
survivor
cc
qualiti
life
hrqol
construct
includ
psychosoci
health
physic
health
fatigu
assess
method
design
singl
institut
cohort
studi
particip
parentsguardian
complet
valid
outcom
pro
measur
english
spanish
primari
outcom
variabl
psychosoci
hrqol
result
particip
complet
pedsqltm
gener
core
scale
parent
multidimension
fatigu
scale
parent
cc
rate
overal
hrqol
good
although
subset
rang
score
indic
statu
diminish
hrqol
cc
endors
fatigu
symptom
everi
scale
healthi
children
cognit
fatigu
often
report
sex
age
studi
evalu
durat
follow
tumor
resect
cumul
red
blood
cell
transfus
volum
physic
health
fatigu
consid
multivari
analysi
psychosoci
hrqol
final
reduc
multivari
model
higher
psychosoci
hrqol
associ
older
age
evalu
p
better
physic
health
p
fewer
fatigu
symptom
p
statist
signific
posit
correl
patient
parent
proxi
report
aspect
hrqol
fatigu
although
varianc
note
rate
individu
item
studi
measur
conclus
find
underscor
clinic
valu
systemat
assess
hrqol
fatigueoth
symptom
use
valid
pro
measur
survivorship
care
patient
parent
inform
whenev
possibleapplic
hrqol
assess
may
identifi
symptom
risk
factor
may
otherwis
elicit
use
guid
person
intervent
mitig
advers
psychosoci
effect
cancer
experi
improv
hrqol
cknowledg
st
baldrick
concern
thinkcur
oncolog
nurs
daisi
foundat
grant
number
chla
nation
center
advanc
translat
scienc
nation
institut
health
practic
program
within
children
oncolog
group
nurs
disciplin
c
rodger
j
withycomb
w
landier
hockenberri
school
nurs
duke
univers
durham
usa
pediatr
palmetto
health
columbia
usa
cancer
center
citi
hope
duart
usa
object
practic
ebp
increasingli
import
compon
nurs
care
especi
within
pediatr
oncolog
nurs
administ
intens
therapi
despit
signific
ebp
much
nurs
care
lack
evid
base
recommend
effort
promot
ebp
nurs
leader
within
children
oncolog
group
cog
nurs
disciplin
develop
mentorship
program
train
pediatr
oncolog
nurs
ebp
process
program
launch
date
complet
four
ebp
project
present
provid
overview
ebp
mentorship
program
highlight
project
method
focu
ebp
project
solicit
nurs
discuss
regard
nurs
practic
care
variat
pediatr
oncolog
patient
interest
group
nurs
appli
mentorship
program
formal
call
sent
cog
membership
one
team
select
three
team
select
team
receiv
didact
inform
individu
mentorship
ebp
process
includ
develop
focus
question
perform
comprehens
literatur
search
summar
evalu
evid
creat
recommend
statement
dissemin
inform
result
team
complet
ebp
process
provid
posit
feedback
program
team
identifi
physic
activ
recommend
childhood
cancer
survivor
singl
kidney
team
identifi
fertil
preserv
recommend
childhood
cancer
patient
prevent
treatment
recommend
punctur
headach
pediatr
patient
hydrat
recommend
prevent
bladder
toxic
patient
receiv
cyclophosphamid
conclus
pediatr
oncolog
nurs
interest
develop
ebp
recommend
pediatr
oncolog
popul
structur
mentorship
program
didact
inform
along
guidanc
ebp
skill
applic
success
process
futur
cog
nurs
ebp
project
plan
cknowledg
project
support
nation
cancer
institut
children
oncolog
group
chair
grant
servic
design
pediatr
radiotherapi
experi
mullaney
nyholm
j
lindh
v
lindh
k
nilsson
g
institut
design
univers
sweden
depart
radiat
scienc
radiat
physic
univers
sweden
depart
radiat
scienc
oncolog
univers
sweden
school
nurs
univers
sweden
oncolog
uppsala
univers
akademiska
hospit
uppsala
sweden
oncolog
karolinska
univers
hospit
stockholm
sweden
oncolog
univers
hospit
sweden
object
radiotherapi
consid
treatment
cancer
stress
challeng
children
endur
often
requir
use
sedat
gener
anesthesia
costli
neg
side
effect
procedur
aim
reduc
distress
parent
children
import
child
cope
health
radiotherapi
research
project
investig
benefit
use
servic
design
creat
support
pediatr
radiotherapi
experi
children
age
focus
decreas
fear
anxieti
prepar
method
servic
design
method
employ
research
pediatr
patient
experi
three
radiotherapi
clinic
sweden
control
studi
observ
fieldwork
well
interview
care
staff
pediatr
patient
parent
current
radiotherapi
experi
conduct
materi
analyz
use
servic
design
map
techniqu
use
identifi
opportun
area
design
new
pediatr
patient
journey
focus
prepar
result
final
result
prepar
kit
compris
digit
physic
element
use
visual
storytel
play
therapi
way
introduc
radiotherapi
younger
pediatr
patient
start
treatment
preparatori
materi
directli
connect
treatment
experi
clinic
differ
tangibl
touch
point
servic
involv
design
materi
well
minor
chang
clinic
routin
ensur
consist
cohes
inform
provid
child
parent
implement
within
three
particip
clinic
current
undergo
evalu
conclus
servic
design
use
approach
studi
pediatr
patient
experi
creat
new
servic
aim
properli
prepar
support
young
pediatr
patient
parent
throughout
radiotherapi
treatment
experi
effort
chemotherapi
error
reduct
computer
pediatr
chemotherapi
order
entri
system
h
shin
lee
e
choi
k
koh
h
im
j
seo
pediatr
hematologyoncolog
asan
medic
cencer
seoul
korea
object
chemotherapi
medic
error
occur
pediatr
cancer
unit
chemotherapi
administr
high
risk
process
high
toxic
low
therapeut
index
analyz
caus
number
near
miss
case
relat
chemotherapi
order
error
discov
report
organ
multidisciplinari
team
work
feasibl
solut
method
computer
pediatr
chemotherapi
order
entri
system
cpcoe
design
one
pediatr
clinic
nurs
specialist
pharmacist
one
computer
system
develop
march
august
cpcoe
gradual
appli
prescrib
patient
chemotherapi
order
septemb
collect
data
prescrib
administr
error
januari
octob
pediatr
cancer
unit
survey
doctor
nurs
satisfact
system
applic
result
total
diagnosi
protocol
sheet
set
three
month
cpcoe
put
practic
monthli
averag
chemotherapi
order
error
dramat
decreas
case
level
doctor
nurs
satisfact
increas
term
perceiv
eas
reduc
time
consumpt
enter
verifi
order
also
increas
level
total
process
satisfact
doctor
nurs
administ
chemotherapeut
treatment
conclus
prospect
cpcoe
help
minim
chemotherapi
order
error
promot
patient
safeti
absolut
prevent
chemotherapi
error
imposs
take
effort
reduc
chemotherapi
error
possibl
team
approach
effect
prevent
manag
tumor
lysi
syndrom
import
contribut
oncolog
nurs
h
li
school
nurs
univers
hong
kong
hong
kong
hong
kong
china
object
present
publish
guidelin
describ
correspond
nurs
intervent
prevent
manag
tumor
lysi
syndrom
studi
aim
identifi
appropri
nurs
manag
procedur
prevent
treatment
tumor
lysi
syndrom
line
current
avail
medic
guidelin
literatur
method
systemat
approach
use
identifi
relev
studi
refer
materi
collect
includ
review
report
guidelin
journal
articl
random
control
trial
studi
confer
review
search
result
limit
public
past
year
jan
full
text
avail
result
base
comprehens
literatur
review
treatment
algorithm
prevent
tumor
lysi
syndrom
medic
nurs
perspect
establish
particular
studi
highlight
import
oncolog
nurs
contribut
prevent
manag
tumor
lysi
syndrom
commonli
overlook
exist
literatur
moreov
studi
provid
oncolog
nurs
inform
preval
pathophysiolog
prevent
treatment
intervent
tumor
lysi
syndrom
inform
crucial
deliv
appropri
high
qualiti
care
improv
patient
outcom
importantli
studi
describ
multidisciplinari
approach
involv
collabor
medic
healthcar
profession
oncolog
nurs
prevent
treatment
tumor
lysi
syndrom
conclus
studi
address
gap
literatur
describ
nurs
manag
accord
current
avail
medic
guidelin
risk
identif
prevent
treatment
tumor
lysi
syndrom
physic
activ
fatigu
children
cancer
mc
hook
l
gilchrist
j
withycomb
l
tanner
n
hart
school
nurs
univers
minnesota
minneapoli
usa
cancer
blood
disord
program
children
hospit
clinic
minnesota
minneapoli
usa
chldren
center
cancer
blood
disord
program
palmetto
health
columbia
usa
object
children
cancer
identifi
fatigu
pervas
distress
symptom
fatigu
increas
corticosteroid
puls
given
acut
lymphocyt
leukemia
mainten
explor
feasibl
inexpens
devic
measur
step
motion
activ
program
data
upload
internet
allow
real
time
access
aim
evalu
children
stepday
goal
receiv
daili
coach
week
mainten
steroid
puls
increas
step
determin
relationship
stepsday
fatigu
puls
method
particip
includ
children
mainten
age
receiv
steroid
puls
home
internet
access
child
fatigu
scale
administ
baselin
weeksbefor
steroid
puls
day
steroid
particip
wore
day
establish
baselin
stepsday
tailor
weekli
step
goal
set
phone
child
parent
daili
shot
sent
encourag
feedback
steroid
puls
particip
determin
level
activ
still
wear
result
signific
increas
stepsday
week
p
decreas
fatigu
signific
correl
r
p
identifi
stepsday
week
fatigu
steroid
puls
step
associ
lower
fatigu
conclus
intervent
feasibl
effect
small
sampl
mean
stepsday
time
period
week
steroid
import
find
demonstr
children
abl
reach
recommend
stepsday
fund
st
baldrick
pediatr
palli
care
childhood
cancer
patient
use
fudan
model
implement
china
wang
g
shen
hematologyoncolog
divis
children
hospit
fudan
univers
shanghai
china
nurs
depart
children
hospit
fudan
univers
shanghai
china
object
mani
children
childhood
cancer
china
could
benefit
pediatr
palli
care
one
nation
barrier
nt
medicar
hospic
reimburs
regul
respons
critic
need
provid
palli
care
earlier
kind
children
hematologyoncolog
divis
children
hospit
fudan
univers
develop
implement
model
pediatr
palli
care
shanghai
china
object
describ
chines
experi
design
implement
model
method
survey
conduct
parent
staff
firstli
accord
result
survey
construct
fudan
model
pediatr
palli
care
develop
area
china
includ
multidisciplinari
work
team
comprehens
intervent
protocol
team
nurs
pediatr
oncologist
psychologist
therapist
hospit
social
worker
volunt
protocol
contain
three
session
hospit
home
commun
three
session
met
children
famili
member
need
support
emot
financi
difficulti
result
juli
februari
enrol
program
approxim
parent
report
satisfi
program
parent
would
recommend
program
conclus
fudan
model
first
nation
provid
model
pediatr
palli
care
point
diagnosi
onward
lesson
learn
fudan
experi
help
guid
citi
china
depress
symptom
children
hematopoiet
stem
cell
transplant
recoveri
c
rodger
p
hockenberri
school
nurs
duke
univers
durham
usa
pediatr
baylor
colleg
medicin
houston
usa
object
depress
symptom
anxieti
sad
report
among
pediatr
patient
prior
hematopoiet
stem
cell
transplant
hsct
hospit
symptom
occur
less
frequent
one
year
post
hsct
howev
littl
known
preval
immedi
month
follow
hsct
hospit
studi
describ
depress
symptom
score
report
pediatr
patient
first
month
post
hsct
evalu
associ
score
qualiti
life
qol
method
repeat
measur
design
use
evalu
depress
symptom
qol
among
children
adolesc
hsct
recoveri
demograph
transplant
inform
obtain
medic
record
patient
complet
questionnair
monthli
total
six
month
post
hsct
depress
symptom
measur
children
depress
inventori
questionnair
qol
measur
ped
qualiti
life
cancer
modul
result
although
signific
differ
total
depress
symptom
mean
score
fluctuat
time
highest
score
month
lowest
month
post
hsct
emot
problem
subscal
mean
score
steadili
declin
first
month
post
hsct
increas
month
function
problem
subscal
mean
score
minor
fluctuat
time
highest
score
note
month
lowest
month
post
hsct
depress
symptom
score
statist
associ
qol
rate
month
follow
hsct
conclus
pediatr
patient
experi
depress
symptom
throughout
hsct
recoveri
may
affect
qol
nurs
perform
routin
assess
depress
symptom
appropri
intervent
promptli
initi
studi
relationship
chines
children
qualiti
life
hematopoiet
stem
cell
transplant
parent
cope
wang
xy
wu
fj
chen
wu
liu
hematologyoncolog
center
beij
children
hospit
capit
medic
univers
beij
china
nurs
depart
beij
children
hospit
capit
medic
univers
beij
china
object
aim
studi
assess
relationship
qualiti
life
children
hematopoiet
stem
cell
transplant
hsct
parent
cope
method
descript
studi
design
use
pediatr
qualiti
life
gener
core
scale
cope
health
invent
parent
chip
children
outpati
clinic
beij
children
hospit
decemb
march
recruit
lost
admit
inpati
ward
final
sampl
includ
patient
parent
parent
ask
complet
chip
children
age
year
complet
age
appropri
year
children
parent
use
independ
sampl
spearman
correl
perform
result
median
age
children
year
rang
year
median
period
month
rang
month
father
age
year
mother
age
year
physic
function
score
emot
function
score
social
function
score
school
function
score
overal
total
score
cope
score
mother
rel
higher
father
list
help
least
help
chip
famili
cope
style
medic
cope
style
support
cope
style
spearman
correl
coeffici
reveal
statist
signific
posit
correl
children
physic
emot
function
parent
support
cope
style
r
p
r
p
children
social
function
parent
famili
cope
style
r
p
signific
differ
found
parent
medic
cope
style
children
qualiti
life
p
conclus
qualiti
life
chines
children
hsct
low
chines
mother
cope
well
father
parent
maintain
famili
integr
social
support
could
increas
children
qualiti
life
parent
experi
healthi
children
particip
support
child
famili
cancer
jenholt
nolbri
b
hedman
centrum
children
right
queen
silvia
children
hospit
sahlgrenska
univers
gothenburg
sweden
depart
nurs
health
cultur
univers
west
sweden
object
aim
studi
investig
parent
experi
healthi
children
particip
support
child
famili
cancer
method
qualit
descript
method
employ
interview
studi
parent
famili
child
cancer
healthi
sibl
individu
interview
experi
healthi
child
particip
support
intervent
combin
educ
learn
reflect
sick
child
newli
diagnos
cancer
receiv
treatment
maximum
month
data
collect
spring
seven
parent
particip
studi
mother
father
famili
healthi
children
interview
conduct
form
convers
interview
parent
qualit
content
analysi
use
draw
systemat
conclus
text
extract
messag
result
result
compris
preliminari
theme
parent
perceiv
healthi
child
via
hisher
contact
could
think
form
opinion
ask
question
receiv
answer
healthi
child
acknowledg
involv
intervent
child
becam
calmer
hope
parent
felt
unburden
profession
healthcar
provid
healthi
children
profession
inform
sick
child
cancer
also
support
understand
manag
reaction
conclus
result
allow
better
understand
parent
experi
situat
healthi
children
studi
also
indic
person
centr
nurs
intervent
use
order
help
famili
may
eas
famili
burden
surviv
incomprehens
parent
live
experi
lose
child
cancer
sundler
johansson
k
hammarlund
depart
nurs
school
health
scienc
sweden
depart
nurs
school
health
care
social
welfar
sweden
depart
nurs
school
life
scienc
sweden
depart
nurs
health
scienc
centr
lund
sweden
object
aim
studi
illumin
parent
live
experi
lose
child
cancer
method
studi
part
longitudin
research
project
famili
member
experi
live
childhood
cancer
within
famili
seventeen
famili
child
diagnos
cancer
follow
child
cancer
trajectori
seven
famili
lost
child
cancer
three
famili
particip
studi
interview
perform
three
mother
three
father
either
one
two
seven
year
child
death
interview
analyz
util
hermeneut
phenomenolog
approach
result
preliminari
result
essenti
theme
identifi
surviv
incomprehens
relat
essenti
theme
four
relat
theme
emerg
want
keep
child
see
suffer
want
protect
dead
child
keep
spirit
aliv
feel
vulner
empti
tri
see
light
conclus
staff
import
offer
one
meet
parent
child
death
abl
identifi
need
extens
support
enabl
contact
respons
lie
staff
parent
preliminari
result
suggest
parent
need
one
contact
close
child
death
one
two
contact
year
impact
social
support
bereav
sibl
anxieti
nationwid
eilertsen
g
steineck
nyberg
u
kreicberg
faculti
nurs
univers
colleg
trondheim
norway
divis
women
child
health
childhood
cancer
research
unit
karolinska
institutet
stockholm
sweden
divis
depart
clinic
cancer
epidemiolog
karolinska
institutet
stockholm
sweden
object
assess
adolesc
young
adult
sibl
percept
social
support
prior
follow
loss
brother
sister
cancer
two
nine
year
earlier
anxieti
method
nationwid
studi
sweden
implement
use
anonym
questionnair
adolesc
young
adult
sibl
age
year
age
lost
brother
sister
cancer
januari
januari
live
sweden
invit
bereav
sibl
particip
hospit
anxieti
depress
scale
had
use
measur
anxieti
rel
risk
rr
confid
interv
ci
calcul
show
proport
report
anxieti
within
dichotom
group
bereav
sibl
written
inform
consent
obtain
result
sibl
higher
risk
anxieti
perceiv
need
social
support
unsatisfi
brother
sister
last
month
death
rr
time
death
rr
rr
furthermor
higher
risk
anxieti
shown
sibl
perceiv
parent
neighbour
care
brother
sister
death
rr
rr
respect
conclus
bereav
sibl
greater
probabl
report
anxieti
perceiv
need
social
support
satisfi
prior
follow
death
inform
nurs
profession
famili
impact
social
support
may
contribut
lessen
sibl
risk
anxieti
free
paper
session
noth
without
parent
patient
view
clinic
trial
result
encca
project
lesson
futur
karner
jck
dupont
vienna
austria
doncologi
institut
curi
pari
franc
object
ethic
european
network
cancer
research
children
adolesc
encca
parent
patient
survivor
possibl
identifi
main
expect
concern
ethic
issu
paediatr
oncolog
research
especi
clinic
trial
method
two
literatur
review
clinic
trial
ensur
address
relev
ethic
issu
literatur
review
follow
collect
view
stakehold
profession
parent
patient
repres
due
process
possibl
characteris
area
agreement
discrep
stakehold
result
one
hand
view
stakehold
collect
two
workshop
topic
avail
research
know
care
parent
survivor
repres
european
branch
intern
confeder
childhood
cancer
parent
organ
icccpo
young
peopl
young
person
advisori
group
ypag
birmingham
children
hospit
express
expect
concern
sampl
data
paediatr
cancer
hand
view
clinic
trial
consent
procedur
process
given
questionnair
topic
noth
without
expertis
paediatr
cancer
research
gain
parent
patient
repres
base
person
experi
activ
nation
intern
level
central
ethic
consult
process
conclus
ethic
deliber
preclud
disagr
profession
parent
patient
within
group
discrep
well
agreement
clue
way
improv
research
practic
therefor
feedback
parent
patient
survivor
highli
appreci
definit
encca
guidelin
confidenti
encca
guidelin
clinic
trial
potenti
develop
interact
openli
discuss
qualiti
care
research
impact
qcri
anoth
dimens
childhood
cancer
support
advocaci
group
r
arora
ahuja
lederman
r
bhalla
prabha
p
arora
r
misra
p
bagai
medic
oncolog
max
hospit
new
delhi
india
qualiti
care
research
impact
new
delhi
india
reproduct
medicin
nova
ivi
fertil
clinic
new
delhi
india
medic
oncolog
medanta
medic
gurgaon
india
object
presenc
centr
provid
awar
advocaci
patient
support
children
cancer
everi
year
india
nation
footprint
natur
lend
us
particip
research
withwithout
partner
nation
intern
individu
andor
institut
time
initi
assess
improv
qualiti
care
potenti
creat
larger
impact
qcri
team
form
april
idea
bring
togeth
one
umbrella
projectsstudi
done
cankid
evalu
servic
assess
impact
conduct
research
role
team
initi
new
project
appropri
provid
input
ongo
project
act
focal
point
activ
plan
put
mechan
place
deliv
desir
output
set
team
hold
regular
meet
monitor
progress
eventu
assess
perform
current
qualiti
care
improv
initi
includ
immunis
children
cancer
survey
practic
india
develop
dissemin
guidelin
patient
support
implementationfertil
preserv
support
children
cancer
pilot
fertil
clinic
survivor
develop
dissemin
fertil
preserv
guidelinesnutrit
support
children
cancer
develop
algorithm
nutrit
assess
intervent
appropri
local
set
patient
support
implement
current
research
project
includ
pilot
studi
cost
ill
children
cancerpati
navig
track
reduc
abandon
treatment
children
cancer
pantracc
india
pilot
startincid
cancer
children
young
adult
studi
delay
diagnosi
treatment
children
cancer
india
protocol
develop
tragedi
inspir
hope
parent
call
action
creat
implement
psychosoci
standard
care
childhood
cancer
v
p
brown
psychosoci
program
matti
miracl
cancer
foundat
washington
dc
usa
object
matti
miracl
cancer
foundat
share
experi
childhood
cancer
mission
creat
nation
standard
psychosoci
care
import
assembl
multidisciplinari
team
profession
challeng
oper
larg
initi
complex
implement
discuss
method
oral
present
power
point
slide
discuss
histori
project
natur
multidisciplinari
team
leader
team
assembl
methodolog
use
establish
standard
care
andan
updat
project
current
close
gap
build
framework
optim
organ
pediatr
palli
care
input
expert
parent
lcm
kremer
mrn
uitdehaag
lmaj
venman
aae
verhagen
paediatr
oncolog
emma
children
hospitalacadem
medic
center
amsterdam
netherland
na
saxion
univers
appli
scienc
devent
netherland
na
pediatr
associ
netherland
utrecht
netherland
pediatr
univers
medic
center
groningen
groningen
netherland
object
creat
nation
framework
optim
organ
pediatr
palli
care
use
idea
factori
method
input
profession
parent
recommend
organ
pediatr
palli
care
import
high
qualiti
palli
care
method
extract
recommend
optim
organ
pediatr
palli
care
select
inter
nation
guidelin
categor
priorit
topic
sent
inform
particip
work
confer
idea
factori
method
creat
intens
knowledg
exchang
import
theme
gener
good
idea
take
theme
forward
creat
energi
support
implement
best
idea
gener
confer
particip
discuss
small
team
idea
juri
pediatr
palli
care
score
idea
use
five
predefin
criteria
work
confer
expert
panel
redupl
discuss
priorit
idea
defin
final
set
recommend
result
identifi
eight
guidelin
focus
organ
pediatr
palli
care
extract
recommend
gener
practition
pediatrician
pharmacist
nurs
differ
care
set
student
psychologist
remedi
educationalist
chaplain
social
worker
polici
staffmanag
healthcar
insur
parent
particip
work
confer
interact
session
written
verbal
commentari
round
result
list
care
recommend
organ
pediatr
palli
care
base
input
profession
parent
conclus
studi
defin
uniqu
set
recommend
nation
framework
organ
optim
pediatr
palli
care
base
literatur
creativ
idea
expert
includ
parent
final
set
recommend
provid
basi
improv
program
regard
organ
pediatr
palli
care
free
paper
session
opacc
parent
intervent
group
parent
liaison
program
hospit
sick
children
kuczynski
parent
liaison
program
hospit
sick
children
toronto
ontario
parent
advoc
children
cancer
barri
canada
object
parent
play
crucial
role
care
child
cancer
diagnosi
social
isol
fear
anxieti
realiti
famili
children
admit
pediatr
oncolog
ward
need
social
network
support
commun
famili
children
cancer
diagnosi
signific
richard
et
al
peer
navig
help
normal
experi
embark
similar
journey
et
al
method
ontario
parent
advoc
children
cancer
opacc
mission
educ
advoc
support
enabl
famili
children
cancer
collabor
hospit
sick
children
hsc
opacc
identifi
gap
pilot
parent
support
group
dual
track
support
initi
survey
result
suggest
parent
want
parent
support
group
ie
two
facilit
one
member
psychosoci
team
parent
child
treat
hsc
mani
parent
want
peer
support
group
respons
opacc
engag
collabor
initi
hsc
offer
parent
intervent
group
sinc
parent
intervent
group
parent
group
creat
safe
support
environ
parent
connect
provid
support
parent
liaison
program
began
volunt
capac
activ
member
haematologyoncolog
program
hsc
sinc
incept
parent
liaison
program
evolv
two
parent
liaison
posit
hospit
result
consist
offer
program
particip
valid
need
met
initi
posit
impact
overal
care
conclus
opacc
parent
intervent
group
parent
liaison
program
bridg
gap
facilit
social
network
famili
face
pediatr
cancer
diagnosi
engag
youth
nation
awar
campaign
youth
gener
public
lebanon
r
farah
nasr
n
najjar
b
tohm
c
asmar
n
ghantou
pediatr
st
georg
hospit
univers
medic
center
beirut
lebanon
chanc
children
cancer
associ
beirut
lebanon
chanc
children
cancer
associ
beirut
lebanon
object
although
childhood
cancer
highli
curabl
cancer
remain
lead
caus
death
among
children
sever
countri
awar
campaign
extrem
need
countri
method
order
rais
awar
cancer
interact
way
nationwid
poster
competit
theme
healthi
environ
balanc
lifestyl
cancer
free
world
launch
chanc
associ
collabor
ministri
environ
among
profession
media
compani
univers
school
eighteen
univers
visit
period
month
team
deliv
awar
lectur
site
result
entri
obtain
student
major
univers
profession
addit
numer
entri
middl
high
school
student
public
privat
school
juri
compos
sever
public
figur
countri
poster
judg
accord
power
convey
messag
top
poster
select
prize
award
person
lebanes
minist
environ
chanc
team
poster
expos
capit
beirut
waterfront
gener
public
view
beauti
poster
power
messag
view
live
hundr
peopl
seen
tv
thousand
sever
nation
region
televis
station
conclus
nationwid
campaign
highli
effect
achiev
goal
rais
awar
cancer
among
youth
school
univers
gener
public
initi
rare
middl
east
wide
encourag
due
immedi
impact
free
paper
session
poor
outcom
brain
tumor
develop
countri
experi
tertiari
care
children
cancer
hospit
pakistan
hamid
ashraf
belgaumi
pediatr
oncolgi
children
cancer
hospit
karachi
pakistan
life
scienc
univers
michigan
michigan
usa
object
studi
featur
surviv
brain
tumor
pediatr
cancer
referr
centr
karachi
method
retrospect
chart
review
children
brain
tumor
children
cancer
hospit
cch
data
collect
demograph
age
sex
locat
resid
primari
site
morpholog
investig
time
intervent
treatment
modal
outcom
result
regist
patient
diagnos
brain
tumor
male
femal
ratio
mean
age
year
patient
karachi
remain
distent
area
pakistan
mean
durat
first
symtom
present
month
mri
first
diagnost
modal
case
averag
interv
first
scan
surgic
intervent
day
posterior
fossa
commonest
site
patient
glioma
medulloblastoma
ependymoma
three
common
tumor
either
visit
abandon
reciev
palli
treatment
mostli
radiotherapi
treat
cur
cohort
tumor
resect
str
gtr
remain
either
inoper
shunt
surgeri
hydrocephalu
immedi
scan
perform
chemotherapi
radiotherapi
given
per
protocol
activ
treat
patient
aliv
mean
follow
year
whole
cohort
patient
surviv
conclus
outcom
brain
tumor
group
dismal
delay
suspect
diagnos
intervent
lead
poor
outcom
poor
statu
distenc
treat
centr
low
literaci
rate
among
parent
might
caus
high
rate
abandon
children
brain
tumor
surviv
metastat
neuroblastoma
standard
treatment
option
podc
set
bhatnagar
pediatr
surgeri
bj
wadia
hospit
children
mumbai
india
object
standard
treatment
option
metastaticadvanc
neuroblastoma
chemotherapi
surgeri
stem
cell
transplant
radiat
therapi
isotretinoin
antibodi
csf
rcn
resourc
challeng
nation
standard
treatment
option
feasibl
surviv
rate
situat
judici
use
chemotherapi
surgeri
radiat
therapi
isotretinoin
present
herewith
method
retrospect
case
cohort
studi
conduct
wherein
data
children
metastat
neuroblastoma
collect
januari
decemb
treatment
detail
surviv
rate
analys
result
children
male
femal
present
metastat
neuroblastoma
depart
pediatr
oncolog
pediatr
surgeri
period
year
abandon
therapi
upfront
chemotherapi
given
patient
confirm
diagnosi
biopsi
receiv
ceca
etoposid
cyclophosphamid
adriamycin
wherea
other
receiv
opcojec
regim
oncovarin
etoposid
cyclophosphamideoncovarin
carboplatin
etoposid
cyclophophamid
except
patient
underw
surgic
intervent
incomplet
excis
residu
tumor
present
isotretinoin
given
pateint
patient
die
due
uncontrol
diseas
spread
surviv
children
form
treatment
show
residu
lesion
primari
site
conclus
dilig
manag
avail
resourc
treatment
metastat
neuroblastoma
surviv
rate
inspit
residu
diseas
major
children
remain
well
regular
immedi
intervent
plan
children
case
diseas
spread
control
along
long
term
system
therapi
help
control
tumor
spread
great
extent
kaposi
sarcoma
children
novel
clinic
stage
classif
determin
risk
stratif
n
w
kamiyango
j
villiera
c
kovarik
g
schutz
ahm
p
kazemb
p
mehta
pediatr
new
york
medic
colleg
valhalla
usa
pediatr
baylor
colleg
medicin
children
foundat
malawi
lilongw
malawi
dermatolog
univers
pennsylvania
philadelphia
usa
pediatr
baylor
colleg
medicin
houston
usa
object
kaposi
sarcoma
ks
common
malign
africa
pediatr
ks
distinct
adult
diseas
aim
evalu
clinic
characterist
pediatr
ks
method
retrospect
analyz
hiv
children
ks
lilongw
malawi
diagnosi
local
chemotherapi
includ
bleomycin
vincristin
haart
base
local
protocol
statist
analysi
perform
use
surviv
curv
result
median
age
year
femal
male
common
site
present
lymph
node
skin
subcutan
nodul
oral
woodi
facial
edema
pulmonari
gastrointestin
sever
suppress
occur
present
platelet
count
hgb
diseas
statu
reveal
complet
remiss
cr
stabl
diseas
die
pediatr
ks
clinic
stage
classif
devis
follow
stage
limit
skin
flat
oral
mucosa
lesion
total
lesion
stage
lymph
node
involv
subcutan
nodul
facial
edema
skin
palat
lesion
without
viscer
involv
skin
lesion
stage
woodi
edema
stage
clinic
pulmonari
gastrointestin
involv
skin
lesion
zero
stage
patient
stage
stage
stage
stage
classif
reveal
dramat
differ
outcom
stage
patient
cr
month
stage
patient
cr
overal
surviv
os
outcom
stage
patient
month
os
conclus
novel
pediatr
clinic
ks
stage
system
differenti
pattern
dramat
contrast
prognos
identifi
patient
critic
guid
treatment
strategi
improv
overal
outcom
observership
program
exampl
academ
center
set
help
boost
profession
develop
p
friedrich
nicola
albanti
g
escamilla
l
vega
l
lehmann
l
diller
c
pediatr
oncolog
children
cancer
blood
disord
center
boston
usa
pediatr
oncolog
hospit
infantil
de
hito
queretaro
mexico
queretaro
mexico
object
observership
program
profession
train
project
develop
dfbc
hito
children
trust
goal
ensur
hito
faculti
nurs
expertli
prepar
begin
treat
patient
hospit
open
novemb
hito
pediatr
oncolog
hospit
aim
becom
center
excel
pediatr
oncolog
care
medic
curriculum
aim
familiar
accultur
hito
clinician
practic
oncolog
center
excel
b
provid
assist
creation
multidisciplinari
clinic
program
clinic
protocol
polici
procedur
c
expos
provid
rich
clinic
research
environ
motiv
incorpor
research
clinic
practic
method
program
ground
adult
learn
principl
assum
learner
independ
intrins
motiv
b
combin
formal
inform
practic
experi
c
encourag
particip
ongo
coach
result
program
ran
month
total
physician
nurs
pharmacist
administr
visit
dfbc
month
nurs
pharmaci
experi
report
separ
physician
includ
oncologist
intensivist
pathologist
infecti
diseas
specialist
radiologist
radiat
oncologist
pain
palli
care
specialist
surgeon
observ
develop
goal
base
interest
role
respons
observ
direct
patient
care
attend
clinic
educ
confer
nation
confer
formal
cours
work
qualiti
research
method
improv
english
skill
meet
attend
review
protocol
met
regularli
organ
monitor
progress
present
summari
experi
conclus
stay
conclus
academ
institut
center
excel
meaning
contribut
boost
profession
develop
provid
countri
support
leadership
foundat
essenti
success
paper
polici
patient
outcom
priorit
children
nation
cancer
control
plan
africa
weaver
cg
lam
jj
attebi
yao
pediatr
oncolog
st
jude
children
research
hospit
memphi
usa
pediatr
oncolog
univers
teach
hospit
treichvillemed
scienc
train
research
unit
abidjan
abidjan
divoir
object
increas
burden
noncommunic
diseas
prevent
earli
detect
treatment
complet
palli
care
essenti
prioriti
cancer
control
framework
necessari
organ
servic
includ
pediatr
popul
method
identifi
african
countri
report
world
health
organ
nation
cancer
plan
conduct
compar
content
analysi
health
system
perspect
structur
analysi
base
exist
develop
evalu
framework
element
cancer
control
outlin
item
includ
timeli
scope
world
bank
countri
incom
group
organ
framework
stakehold
comprehens
specif
plan
element
pediatr
result
african
countri
report
cancer
control
plan
two
publish
sinc
nine
current
nation
plan
one
continent
plan
english
french
access
intern
cancer
control
plan
portal
repres
incom
set
benin
cote
divoir
ghana
kenya
mauritiu
morocco
south
africa
togo
zimbabw
plan
span
year
rang
four
discuss
cancer
control
context
noncommunic
diseas
nation
plan
report
incid
data
nation
n
subnat
n
hospit
n
registri
two
plan
explicitli
note
famili
participatori
stakehold
along
govern
civil
societi
organ
propos
pediatr
prevent
public
health
measur
earli
detect
diagnosi
treatment
children
specifi
five
plan
one
budget
item
pediatr
cancer
palli
care
strategi
frequent
emphas
analges
access
specifi
pediatr
need
two
plan
resourc
palli
care
strateg
eight
plan
item
five
budget
conclus
explicit
strategi
fund
pediatr
palli
servic
nation
cancer
plan
may
help
guid
priorit
develop
implement
advocaci
fund
account
remain
essenti
shift
plan
paper
improv
popul
outcom
free
paper
session
parent
experi
childhood
cancer
treatment
kenya
f
njuguna
mostert
seijffert
j
musimbi
langat
rhm
van
der
burgt
j
skile
mn
sitaresmi
pm
van
de
ven
gsl
kasper
depart
child
health
pediatr
moi
teach
referr
hospit
eldoret
kenya
depart
pediatr
doctor
doctor
program
vu
univers
medic
center
amsterdam
netherland
depart
pediatr
divis
indiana
univers
school
medicin
us
depart
pediatr
dr
sardjito
hospit
yogyakarta
indonesia
epidemiolog
biostatist
vu
univers
medic
center
amsterdam
netherland
purpos
studi
explor
psycholog
experi
parent
cancer
treatment
children
academ
hospit
kenya
method
studi
use
questionnair
parent
whose
children
came
cancer
treatment
consecut
novemb
april
interview
result
famili
interview
cancer
treatment
result
financi
difficulti
inform
cancer
treatment
requir
contact
doctor
need
diagnosi
cancer
perceiv
curabl
howev
parent
told
provid
children
cancer
die
parent
difficulti
understand
doctor
vocabulari
common
reason
miss
hospit
appoint
travel
cost
hospit
cost
parent
use
complementari
altern
treatment
cam
children
provid
told
parent
use
cam
parent
discuss
cam
use
doctor
commun
member
isol
famili
child
cancer
believ
child
bewitch
advis
use
cam
stop
convent
treatment
parent
share
experi
parent
ward
would
otherwis
understand
diseas
treatment
conclus
parent
suffer
financi
hardship
dissatisfi
doctor
commun
regard
children
condit
cam
commonli
use
doctor
need
improv
commun
skill
discuss
cam
openli
parent
support
group
would
use
financi
support
facil
parent
children
stay
cours
therapi
pilot
studi
determin
expenditur
famili
children
treat
cancer
public
hospit
india
ahuja
lederman
p
bagai
tsimicali
martiniuk
r
arora
qualiti
care
research
impact
new
delhi
india
ingram
school
nurs
mcgill
univers
montreal
canada
faculti
medicin
univers
sydney
sydney
australia
medic
oncolog
max
hospit
new
delhi
india
object
absenc
insur
andor
social
support
cost
lead
abandon
treatment
object
pilot
studi
determin
feasibl
assess
cost
india
two
week
prior
b
week
follow
diagnosi
method
prospect
cost
ill
design
repeat
assess
pilot
famili
household
perspect
parentscaregiv
whose
child
treat
cancer
india
institut
medic
scienc
safdarjung
hospit
cost
resourc
util
impact
cost
record
result
eleven
famili
particip
children
year
diagnos
n
neuroblastoma
n
nhl
n
bone
sarcoma
n
wilm
tumor
n
half
famili
incom
unskil
worker
wage
least
one
parent
per
famili
illiter
school
eight
famili
live
outsid
new
delhi
median
cost
prior
diagnosi
rs
us
rang
rs
nearli
cost
prior
diagnosi
investig
support
care
follow
indirect
medic
cost
travel
lodg
food
median
weekli
cost
week
follow
diagnosi
rs
us
week
rang
rsweek
half
weekli
cost
follow
diagnosi
direct
medic
cost
support
care
investig
chemotherapi
half
indirect
medic
cost
food
travel
lodg
date
five
famili
interview
regard
impact
deplet
save
borrow
money
debt
four
famili
opt
sell
asset
three
famili
indic
employ
affect
school
children
suffer
conclus
despit
free
treatment
govern
hospit
india
signific
pocket
expens
impact
employ
school
hous
rediscov
joy
learn
ycmou
initi
childhood
cancer
survivor
chawr
jha
e
chaudhari
deshmukh
goswami
n
dalvi
prasad
v
dhanmankar
p
kurkur
survivorship
cancer
societi
mumbai
india
educ
yashwantrao
chawan
maharashtra
open
univers
mumbai
india
pediatr
oncolog
complet
treatment
act
clinic
tata
memori
hospit
mumbai
india
object
young
survivor
childhood
cancer
depriv
educ
due
interrupt
result
long
treatment
socioeconom
constraint
encourag
induct
pursu
vocat
train
achiev
goal
yashwantrao
chavan
maharashtra
open
univers
ycmou
collabor
tata
memori
hospit
tmh
offer
educ
assist
survivor
subsid
rate
free
cost
method
ugam
support
group
childhood
cancer
survivor
complet
treatment
act
clinic
tmh
function
survivorship
program
indian
cancer
societi
ic
collabor
ycmou
empower
cancer
survivor
educ
assist
ycmou
provid
graduat
post
graduat
cours
like
manag
train
media
graphic
anim
etc
also
offer
preparatori
cours
english
hindi
patient
abl
attain
reput
degre
nomin
rate
free
cost
survivor
poverti
line
result
fifteen
young
survivor
enrol
differ
cours
bsc
media
graphic
anim
bcom
mba
civil
supervis
etc
benefit
initi
survivor
capabl
achiev
respect
trade
profess
owe
strong
educ
background
due
subsid
fee
also
opt
multipl
degre
per
choic
survivor
provid
offici
certif
univers
conclus
ycmou
allow
survivor
overcom
limit
financi
obstacl
abl
chase
dream
compet
ever
challeng
world
survivor
encourag
part
project
establish
studi
center
within
premis
near
hospit
implement
ycmou
facilit
overal
develop
patient
survivor
absenc
social
support
network
increas
risk
treatment
abandon
children
cancer
ospina
ca
portilla
quintero
le
bravo
aristizab
ramirez
behalf
vigicanc
work
group
school
medicin
universidad
del
vall
cali
colombia
pediatr
oncolog
hematolog
pohema
centro
imbanaco
universidad
del
vall
hospit
universitario
del
vall
cali
colombia
pediatr
oncolog
hematolog
pohema
centro
medico
imbanaco
de
cali
cali
colombia
registro
poblacion
de
de
cali
patholog
depart
universidad
del
vall
cali
colombia
pediatr
oncolog
hematolog
univers
california
san
diego
ca
usa
universidad
del
vall
pohema
cali
colombia
object
treatment
abandon
ta
main
reason
therapi
failur
children
cancer
lowmiddl
incom
countri
explor
predict
factor
ta
cohort
children
cancer
cali
third
largest
citi
colombia
method
includ
children
diagnos
cancer
cali
public
univers
hospit
extract
inform
predictor
interview
appli
pediatr
oncolog
unit
social
worker
unit
psychologist
caregiv
outcom
death
relaps
ta
event
monitor
cali
pediatr
cancer
clinic
outcom
surveil
system
vigicanc
estim
rate
ratio
rr
among
differ
predictor
adjust
hazard
ratio
hr
potenti
confound
use
multivari
cox
regress
analys
small
sampl
avail
final
appli
bootstrap
approach
accur
estim
result
period
patient
diagnos
psychosoci
interview
appli
male
ethnic
came
rural
area
incom
colombian
minim
wage
classifi
without
social
support
network
ssn
ta
ssn
rr
ci
rr
famili
children
live
home
ci
ethnic
ci
found
signific
associ
gender
child
caregiv
age
diagnosi
caregiv
relationship
caregiv
educ
household
condit
famili
monthli
incom
parent
job
place
origin
multivari
analys
ssn
household
children
preserv
independ
relationship
ta
bootstrap
adjust
hr
ssn
ci
conclus
found
strong
associ
classifi
without
ssn
ta
independ
covari
includ
surrog
measur
wealth
highlight
imper
understand
social
tie
around
famili
children
cancer
plan
strategi
prevent
ta
dexamethason
induc
neuropsycholog
side
effect
prednison
pediatr
acut
lymphoblast
leukemia
systemat
review
l
warri
mm
van
den
heuvel
eibrink
mah
den
ho
fk
aarsen
r
pieter
elt
van
den
akker
pediatr
oncolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
pediatr
endocrinolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
object
neuropsycholog
side
effect
major
impact
qualiti
life
larg
proport
children
treat
acut
lymphoblast
leukemia
dexamethason
prefer
prednison
higher
activ
cost
higher
potenc
induc
metabol
side
effect
evalu
whether
dexamethason
also
lead
neuropsycholog
side
effect
prednison
perform
systemat
review
literatur
method
articl
select
pubm
embas
cochran
basi
titl
abstract
two
independ
review
use
follow
inclus
criteria
children
leukemia
receiv
dexamethason
andor
prednison
short
andor
long
term
neuropsycholog
side
effect
mood
cognit
behavior
sleep
compar
steroid
origin
research
written
english
exclud
case
seri
subject
grade
level
evid
use
grade
system
result
potentiallyrelev
articl
identifi
includ
studi
review
half
includ
studi
report
neuropsycholog
side
effect
dexamethason
compar
prednison
howev
none
randomis
control
trial
neuropsycholog
outcom
primarili
view
show
signific
differ
dexamethason
prednison
mood
behavior
random
trial
cognit
function
show
subtl
signific
differ
dexamethason
prednison
limit
minor
decreas
word
read
minor
decreas
iq
measur
fluid
reason
dexamethason
group
absenc
clinic
signific
differ
conclus
base
review
literatur
conclud
clinic
outcom
valuabl
drug
dexamethason
seem
induc
neuropsycholog
side
effect
prednison
children
effect
qualiti
life
particip
combin
physic
exercis
psychosoci
intervent
program
childhood
cancer
patient
em
van
ki
braam
gjl
kasper
veen
grootenhui
streng
takken
e
van
broeder
j
huisman
medic
psycholog
vu
univers
medic
center
amsterdam
netherland
pediatr
oncologyhematolog
vu
univers
medic
center
amsterdam
netherland
psychosoci
emma
children
hospitalacadem
medic
center
amsterdam
netherland
pediatr
oncologyhematolog
erasmu
mcsophia
children
hospit
rotterdam
netherland
pediatr
physiotherapi
exercis
physic
wilhelmina
children
hospitalumc
utrecht
utrecht
netherland
medic
psycholog
wilhelmina
children
hospitalumc
utrecht
utrecht
netherland
object
qlim
qualiti
life
motion
studi
design
evalu
effect
intens
intervent
program
combin
physic
exercis
psychosoci
support
random
control
trial
exercis
therapi
program
psychosoci
intervent
aim
enhanc
patient
wellb
offer
simultan
improv
wellb
qualiti
life
hrqol
hypothes
increas
willing
motiv
engag
sport
activ
result
enhanc
efficaci
exercis
program
vice
versa
method
childhood
cancer
patient
age
year
within
first
year
treatment
ask
particip
particip
underw
physic
perform
test
complet
questionnair
prior
random
intervent
abstract
present
result
patient
parent
fill
pedsqol
gener
core
scale
cancer
modul
multidimension
fatigu
modul
result
patient
mean
age
sd
particip
parent
intervent
group
n
report
signific
improv
hrqol
children
compar
parent
children
control
group
n
subscal
physic
function
mean
respect
p
pain
hurt
mean
p
procedur
anxieti
mean
p
signific
differ
improv
two
group
found
patient
conclus
children
cancer
posit
effect
hrqol
perceiv
parent
found
physic
function
pain
hurt
procedur
anxieti
particip
combin
physic
exercis
psychosoci
intervent
program
studi
continu
determin
chang
grant
support
alp
dhuzeskwf
grant
number
treatment
insomnia
adolesc
young
adult
survivor
childhood
cancer
e
zhou
lm
vrooman
pe
manley
cj
reckliti
perini
famili
survivor
center
cancer
institut
boston
usa
pediatr
cancer
institut
boston
usa
object
pediatr
cancer
survivor
high
risk
develop
insomnia
due
treatment
side
effect
inpati
hospit
medic
late
effect
insomnia
link
behavior
emot
disturb
substanc
use
compromis
schoolwork
perform
adolesc
young
adult
howev
insomnia
undertr
medic
issu
pediatr
survivor
treatment
insomnia
empir
valid
cancer
popul
adapt
use
pediatr
cancer
survivor
offer
part
routin
clinic
practic
even
major
cancer
center
deliv
special
survivorship
care
method
pilot
abbrevi
program
region
cancer
center
survivorship
clinic
evalu
whether
modifi
treatment
session
telephon
follow
up
would
feasibl
accept
effect
cancer
survivorship
set
particip
monitor
sleep
use
sleep
log
complet
sleep
questionnair
program
evalu
result
adolescentyoung
adult
survivor
childhood
cancer
age
year
complet
ongo
protocol
report
improv
sleep
effici
pre
improv
pittsburgh
sleep
qualiti
index
insomnia
sever
index
score
particip
indic
abbrevi
intervent
prefer
standard
treatment
open
webmobil
intervent
futur
indic
intervent
help
would
recommend
program
conclus
clinic
need
incorpor
effect
treatment
insomnia
routin
care
popul
ongo
pilot
data
suggest
brief
feasibl
accept
effect
improv
insomnia
pediatr
oncolog
survivorship
set
find
support
potenti
adapt
treatment
model
webmobil
platform
discuss
plan
improv
dissemin
insomnia
treatment
childhood
cancer
survivor
intervent
deliveri
caregiv
distress
patient
qualiti
life
psychosoci
screen
pediatr
cancer
treatment
l
pierc
j
fleischer
mc
hock
alderf
ae
kazak
l
barakat
oncologypediatr
children
hospit
philadelphiath
univers
pennsylvania
school
ofnurs
philadelphia
usa
oncologypediatr
children
hospit
philadelphia
philadelphia
usa
center
healthcar
deliveri
scienc
nemour
alfr
iduponthospit
childrenth
children
hospit
philadelphia
wilmington
usa
oncologypediatr
children
hospit
philadelphiath
univers
pennsylvania
school
medicin
philadelphia
usa
object
prior
research
focus
identifi
famili
psychosoci
risk
factor
cancer
diagnosi
order
improv
pediatr
cancer
care
studi
aim
evalu
presenc
famili
riskresourc
caregiv
distress
first
year
diagnosi
determin
associ
famili
riskresourc
caregiv
distress
patient
qualiti
life
hrqol
method
parent
children
cancer
complet
recent
experi
strength
care
protocol
via
ipad
clinic
visit
within
one
year
diagnosi
care
includ
psychosoci
assess
tool
famili
riskresourc
strength
difficulti
questionnair
patient
adjust
pedsql
patient
hrqol
distress
thermomet
caregiv
distress
ptsd
caregiv
traumat
stress
result
patient
rang
age
month
year
sd
year
femal
sampl
equal
distribut
across
leukemialymphoma
solid
tumor
brain
tumor
diagnos
mean
time
sinc
diagnosi
day
sd
day
distress
thermomet
score
indic
moder
distress
sd
gender
age
type
cancer
time
sinc
diagnosi
significantli
correl
famili
riskresourc
caregiv
distress
caregiv
traumat
stress
reduc
patient
hrqol
significantli
correl
famili
risk
r
p
caregiv
distress
r
p
caregiv
traumat
stress
r
p
conclus
moder
level
distress
regardless
time
sinc
diagnosi
associ
caregiv
distress
reduc
patient
hrqol
highlight
import
psychosoci
screen
care
throughout
cours
pediatr
cancer
treatment
target
time
focu
psychosoci
intervent
futur
research
aim
screen
psychosoci
risk
base
patient
parent
report
use
adapt
version
care
cancer
treatment
health
care
provid
rate
util
psychosoci
screen
tool
childhood
cancer
di
battista
k
hancock
cataudella
johnston
punnett
w
shama
u
bartel
pc
nathan
barrera
psycholog
hospit
sick
children
toronto
canada
psycholog
london
health
scienc
centr
toronto
canada
pediatr
children
hospit
eastern
ontario
ottawa
canada
pediatr
hospit
sick
children
toronto
canada
social
work
hospit
sick
children
toronto
canada
object
clinic
use
standard
psychosoci
screen
tool
pediatr
oncolog
rare
use
tool
perceiv
health
care
provid
hcp
unknown
studi
examin
hcp
perceiv
util
two
psychosoci
screen
tool
design
use
pediatr
oncolog
psychosoci
assess
patrev
psychosoci
care
checklist
pccl
method
pediatr
oncologist
onc
nurs
nur
social
worker
swk
treat
patient
four
pediatr
cancer
centr
particip
institut
approv
obtain
studi
site
particip
sign
consent
form
particip
ask
rank
use
found
psychosoci
summari
inform
deriv
patrev
pccl
instrument
complet
hcp
regard
psychosoci
need
particip
famili
receiv
psychosoci
summari
inform
use
assess
use
visual
analogu
scale
va
va
minimum
score
maximum
score
higher
score
indic
greater
endors
util
measur
use
analys
effect
size
report
result
hcp
particip
onc
nur
swk
nurs
report
greatest
util
endors
patrev
summari
compar
pediatr
oncologist
social
worker
similar
result
found
pccl
util
nurs
compar
pediatr
oncologist
nurs
compar
social
worker
overal
nurs
report
psychosoci
screen
use
hcp
conclus
result
suggest
variabl
belief
util
endors
psychosoci
screen
tool
among
practition
futur
research
examin
specif
barrier
uptak
implement
tool
sibl
children
cancer
perceiv
chang
place
role
within
famili
cancer
diagnosi
nevil
mr
simard
k
hancock
rokeach
l
brister
p
yogalingam
saleh
barrera
psycholog
hospit
sick
children
toronto
canada
child
life
hospit
sick
children
toronto
canada
object
sibl
children
cancer
often
report
express
number
social
emot
difficulti
qualit
studi
aim
examin
sibl
percept
place
role
within
famili
brother
sister
diagnos
cancer
method
institut
approv
obtain
particip
sign
written
inform
consent
particip
includ
sibl
age
year
particip
four
round
sibl
cope
togeth
sct
program
manual
group
intervent
program
sibl
children
cancer
data
consist
materi
complet
sibl
session
feel
tree
mind
map
session
homework
sheet
piec
artworkpost
log
record
event
within
group
session
complet
observ
group
facilit
ground
theori
framework
use
themat
data
analysi
result
three
theme
emerg
regard
chang
sibl
percept
place
role
within
famili
sinc
brother
sister
diagnos
treat
differ
percept
burden
famili
way
includ
left
cancer
experi
percept
less
import
child
cancer
see
less
love
affect
child
less
privileg
percept
chang
role
famili
whole
assist
care
give
ill
child
sens
increas
respons
within
famili
eg
chore
becom
independ
share
thought
gradual
increas
session
form
basi
group
intervent
conclus
preliminari
find
provid
rich
insight
sibl
view
chang
place
role
within
famili
view
emerg
throughout
particip
sct
intervent
allow
improv
cope
strategi
sibl
cancer
emot
experi
growth
throughout
cope
cancer
intervent
simard
nevil
rokeach
k
hancock
l
brister
saleh
p
yogalingam
barrera
psycholog
hospit
sick
children
toronto
canada
child
life
hospit
sick
children
toronto
canada
object
qualit
studi
examin
emot
experi
growth
sibl
children
cancer
particip
manual
group
intervent
program
sibl
cope
togeth
method
particip
youth
partak
four
differ
round
group
intervent
sibl
patient
least
three
month
diagnosi
sibl
elig
particip
year
old
data
deriv
materi
eg
feel
tree
graffiti
wall
complet
sibl
session
session
homework
sheet
piec
artworkpost
complet
sibl
log
record
event
within
group
ground
theori
framework
use
themat
analysi
data
studi
approv
institut
particip
provid
sign
consent
result
sever
overarch
theme
emerg
regard
sibl
emot
experi
group
feelingsrel
person
experi
regard
exposur
cancer
sens
loss
sens
dismiss
brush
asid
famili
guilt
neg
thought
ill
child
emot
confus
feelingsrel
percept
brotherssist
experi
cancer
feel
badli
worri
death
hope
cure
feelingsrel
famili
context
stress
emot
labil
depend
treat
child
health
sibl
report
sever
differ
way
attempt
regul
feel
adapt
eg
find
someon
talk
maladapt
eg
avoid
difficult
feel
share
emot
experi
cope
improv
session
intervent
conclus
find
provid
rich
evid
captur
sibl
view
ill
child
famili
experi
progress
emerg
throughout
group
intervent
inform
critic
treatment
plan
ultim
help
sibl
navig
experi
brother
sister
cancer
reduct
anxieti
level
parent
sibl
children
cancer
sibl
particip
psychosoci
group
intervent
random
control
trial
barrera
rokeach
k
hancock
f
schult
e
atenafu
p
nathan
psycholog
hospit
sick
children
toronto
canada
oncolog
pediatr
alberta
children
hospit
calgari
canada
biostatist
univers
health
network
toronto
canada
pediatr
hospit
sick
children
toronto
canada
object
childhood
cancer
diagnosi
treatment
result
major
psycholog
distress
famili
program
target
specif
psychosoci
need
sibl
rare
examin
effect
intervent
sibl
parent
distress
previous
investig
determin
manual
group
intervent
program
sibl
sibl
cope
togeth
sct
experiment
group
eg
improv
anxieti
sibl
directli
parent
indirectli
compar
control
group
cg
method
institut
approv
obtain
particip
sign
consent
form
andom
control
trial
rct
repeat
measur
inclus
criteria
sibl
age
year
one
parent
patient
least
three
month
diagnosi
group
complet
weekli
group
session
three
assess
immedi
three
month
later
eg
session
follow
sct
educ
social
therapeut
plan
game
craft
cg
session
focus
social
game
craft
parent
sibl
complet
standard
measur
anxieti
multidimension
anxieti
questionnair
multidimension
anxieti
scale
children
anova
conduct
partial
indic
effect
size
result
preliminari
analys
base
particip
assess
point
parent
two
signific
group
x
time
interact
found
physiolog
panic
reaction
social
phobia
suggest
improv
parent
eg
compar
cg
across
time
signific
effect
time
suggest
group
improv
measur
total
anxieti
neg
affect
respect
signific
group
x
time
interact
panicsepar
suggest
improv
eg
rel
cg
maintain
time
conclus
preliminari
find
suggest
major
improv
sibl
parent
anxieti
sustain
time
follow
particip
manual
group
intervent
program
new
system
intervent
sibl
children
cancer
parent
feasibl
pilot
studi
c
besani
higgin
c
mccusker
mccarthi
clinic
psycholog
depart
royal
belfast
hospit
sick
children
belfast
unit
kingdom
frcpch
medsc
haematolog
oncolog
depart
royal
belfast
hospit
sick
children
belfast
unit
kingdom
object
aim
studi
determin
feasibl
accept
new
system
intervent
sibl
children
cancer
parent
examin
outcom
pilot
studi
preliminari
evid
gather
assess
whether
current
intervent
promot
psycholog
adjust
sibl
term
mood
cope
resili
reduc
psychosoci
risk
famili
improv
famili
function
commun
materi
method
studi
recruit
sibl
children
treat
cancer
type
region
pediatr
oncolog
hematolog
centr
uk
period
month
twelv
famili
children
parent
particip
system
therapeut
intervent
intervent
develop
combin
three
therapeut
compon
system
narr
problem
solv
strategi
studi
use
longitudin
repeat
measur
design
includ
assess
week
qualit
assess
particip
experi
week
result
enrol
retent
attrit
satisfact
data
support
feasibl
accept
intervent
also
highlight
challeng
outcom
data
show
chang
desir
direct
week
sibl
intervent
group
show
improv
score
psycholog
compet
resili
cope
scale
parent
show
improv
scale
famili
function
commun
reduct
psychosoci
risk
scale
effect
size
small
larg
conclus
current
studi
fill
gap
current
literatur
prove
feasibl
accept
deliv
system
intervent
studi
sibl
children
cancer
parent
region
centr
uk
author
develop
manual
current
intervent
allow
replic
current
studi
differ
oncolog
centr
cerebrospin
fluid
biomark
oxid
stress
motor
dexter
behavior
chemotherapi
childhood
acut
lymphoblast
leukemia
k
krull
hockenberri
k
insel
pasvogel
p
gundi
montgomeri
olga
taylor
moor
epidemiolog
cancer
control
psycholog
st
jude
children
research
hospit
memphi
usa
school
nurs
duke
univers
durham
usa
colleg
nurs
univers
arizona
tucson
usa
object
examin
associ
cerebrospin
fluid
csf
biomark
oxid
stress
perform
fine
motor
dexter
task
behavior
children
undergo
chemotherapi
treatment
acut
lymphoblast
leukemia
method
children
diagnos
n
mean
rang
diagnosi
age
year
follow
diagnosi
end
chemotherapi
one
two
pediatr
cancer
center
southwestern
unit
state
children
receiv
cranial
radiat
therapi
csf
collect
diagnosi
prior
intrathec
inject
analyz
biomark
oxid
stress
includ
concentr
oxid
phosphatidylinositol
pi
isoprostan
high
perform
chromatographi
elisa
use
pi
assay
respect
children
compet
measur
fine
motor
dexter
visual
process
speed
integr
follow
induct
continu
end
chemotherapi
parent
complet
rate
child
behavior
result
compar
popul
norm
sd
children
demonstr
significantli
lower
motor
dexter
mean
ci
visual
process
speed
integr
follow
induct
end
therapi
visual
process
speed
normal
motor
dexter
integr
remain
averag
concentr
significantli
correl
motor
dexter
integr
multipl
point
therapi
oxid
pi
significantli
correl
motor
dexter
begin
continu
phase
visual
process
speed
relat
csf
biomark
oxid
stress
motor
function
continu
associ
increas
hyperact
anxieti
decreas
function
commun
end
therapi
conclus
central
nervou
system
oxid
stress
occur
follow
chemotherapi
childhood
relat
impair
fine
motor
function
earli
intervent
consid
children
prevent
progress
deficit
behavior
problem
look
wild
thing
polymorph
predictor
late
onset
longterm
cognit
behavior
disabl
j
blom
l
pomicino
l
montanari
c
migliozzi
g
rigillo
cellini
g
zanazzo
pediatr
ooncolog
univers
modena
reggio
emilia
modena
itali
institut
matern
child
health
ircc
burlo
garofolo
triest
triest
itali
pediatr
oncolog
univers
hospit
univers
od
modena
reggio
emilia
modena
itali
object
good
news
stori
medicin
two
particular
thing
common
led
earli
detect
earli
intervent
insel
abl
cure
complex
diseas
childhood
acut
leukemia
children
diagnos
good
reduc
morbid
disabl
develop
patient
natur
disabl
often
cognit
behavior
recogn
constitut
major
burden
diseas
question
drive
late
onset
cognit
behavior
disabl
hypothesi
test
variou
polymorph
partial
explain
individu
variat
develop
anxieti
mood
disord
well
behavior
disord
method
patient
yr
old
diagnos
belong
two
pediatr
oncolog
center
enrol
protocol
genotyp
bdnf
comt
polymorph
patient
famili
subject
psychosoci
assess
short
neurocognit
behavior
age
appropri
screen
batteri
treatment
schedul
visit
result
patient
sl
allel
significantli
compromis
score
area
execut
function
patient
allel
cognit
area
affect
involv
modul
emot
respons
flexibl
solv
task
problem
due
sampl
size
asymmetr
divis
polymorph
clear
correl
polymorph
comt
bdnf
found
conclus
gene
regul
neurotransmitt
vulner
stress
may
repres
factor
indic
suscept
toward
develop
cognit
late
effect
children
treat
thu
offer
partial
mechan
individu
variabl
among
similar
treatment
histori
provid
possibl
earli
predictor
cognit
behavior
disabl
effect
train
program
promot
regular
physic
activ
among
childhood
cancer
survivor
ok
chung
school
nurs
univers
hong
kong
hong
kong
hong
kong
china
object
research
indic
regular
physic
activ
enhanc
physic
psycholog
childhood
cancer
survivor
nevertheless
grow
concern
declin
level
physic
activ
childhood
cancer
survivor
studi
aim
examin
effect
train
program
promot
chang
exercis
behavior
enhanc
physic
activ
level
qualiti
life
hong
kong
chines
childhood
cancer
survivor
method
random
control
trial
pretest
repeat
design
conduct
childhood
cancer
survivor
old
particip
experiment
group
join
train
program
control
group
particip
receiv
amount
time
attent
experiment
group
way
specif
effect
outcom
measur
particip
exercis
behavior
chang
level
physic
activ
qualiti
life
assess
time
recruit
month
start
intervent
result
childhood
cancer
survivor
experiment
group
report
significantli
higher
level
physic
activ
control
group
besid
statist
signific
chang
physic
activ
level
childhood
cancer
survivor
experiment
group
conclus
train
program
found
effect
promot
chang
exercis
behavior
enhanc
physic
activ
level
qualiti
life
hong
kong
chines
childhood
cancer
survivor
impact
posttraumat
growth
among
survivor
childhood
brain
tumor
k
kamibeppu
sato
higuchi
yanagisawa
murayama
kumab
k
sugiyama
mukasa
n
saito
sawamura
terasaki
sibui
j
takahashi
r
nishikawa
ishida
depart
famili
nurs
graduat
school
medicin
univers
tokyo
tokyo
japan
depart
comprehens
cancer
center
intern
medic
center
saitama
medic
univers
saitama
japan
depart
neurosurgeri
tohoku
univers
graduat
school
medicin
sendai
japan
depart
clinic
oncolog
program
cancer
treatment
center
hiroshima
univers
hospit
hiroshima
japan
depart
neurosurgeri
faculti
medicin
univers
tokyo
tokyo
japan
sawamura
neurosurgeri
clinic
sapporo
japan
depart
neurosurgeri
kurum
univers
school
medicin
fukuoka
japan
depart
neurosurgeri
nation
cancer
center
hospit
tokyo
japan
depart
neurosurgeri
uji
hospit
social
welfar
corpor
kyoto
japan
pediatr
medic
center
ehim
prefectur
central
hospit
ehim
japan
object
import
resourc
childhood
brain
tumor
survivor
adolesc
adulthood
purpos
studi
identifi
associ
posttraumat
growth
ptg
among
childhood
brain
tumor
survivor
hypothes
ptg
relat
independ
sever
diseas
combin
treatment
relaps
posttraumat
stress
symptom
ptss
method
one
hundr
thirti
eight
survivor
recruit
eight
hospit
clinic
japan
ask
answer
set
questionnair
includ
rosenberg
scale
impact
event
sarason
social
support
questionnair
satisfact
sss
posttraumat
growth
inventori
ptgi
posttraumat
growth
inventori
children
ptgic
besid
sever
diseas
combin
treatment
relaps
use
intens
treatment
rate
scale
inform
presenc
absenc
late
effect
collect
primari
physician
result
total
survivor
answer
questionnair
howev
valid
analysi
result
multipl
regress
analys
ptg
p
sss
p
physician
report
p
perceiv
treatment
intens
p
ptss
p
independ
relat
adjust
sex
late
effect
higher
brain
dysfunct
differ
questionnair
ptgi
ptgic
conclus
conclus
hypothesi
prove
ptg
relat
independ
object
subject
treatment
intens
ptss
childhood
brain
tumor
survivor
addit
sss
also
relat
manner
therefor
even
sever
diseas
undergo
harsh
treatment
ptss
childhood
brain
tumor
survivor
maintain
perceiv
ptg
sss
knowledg
find
may
empow
survivor
famili
medic
profession
session
avarthec
studi
cerebrovascular
diseas
follow
childhood
adolesc
cancer
radiat
therapi
v
e
desand
c
carri
c
alapetit
radiat
oncolog
institut
de
de
lorrain
franc
statistiqu
institut
de
de
lorrain
franc
radiat
oncolog
centr
leon
berard
lyon
franc
radiat
oncolog
institut
curi
pari
franc
object
describ
clinic
imag
characterist
cerebrovascular
diseas
cvd
survivor
irradi
brain
tumor
bt
childhood
identifi
patient
develop
cvd
adapt
fu
studi
could
help
elabor
recommend
new
radiat
techniqu
consid
potenti
risk
factor
cerebrovascular
morbid
method
studi
perform
french
center
patient
aliv
time
studi
irradi
age
year
bt
patient
sign
consent
clinic
exam
angiomri
fullfil
questionnair
qualiti
life
qol
mri
imag
review
independantli
final
retrospect
analysi
dosimetri
collect
radiat
criteria
dose
receiv
abnorm
result
includ
patient
avail
analysi
final
refus
mri
inclus
median
age
diagnosi
moment
studi
respect
year
median
fu
cvd
observ
patient
cavernoma
case
patient
seriou
abnorm
carotid
stenosi
sever
second
tumor
detect
averag
dose
receiv
site
cavernoma
gy
one
hundr
six
qol
questionnair
avail
conclus
survivor
irradi
bt
childhood
develop
cvd
characterist
correl
dose
discuss
well
impact
qol
singl
center
result
follow
proton
beam
therapi
atyp
teratoid
rhabdoid
tumor
central
nervou
system
j
buchsbaum
c
haskin
b
jyoti
hine
v
simoneaux
radiat
oncolog
iu
health
proton
therapi
center
bloomington
usa
object
atyp
teratoid
rhabdoid
tumor
atrt
rare
embryon
tumor
seen
predominantli
infanc
childhood
outcom
gener
dismal
median
surviv
estim
around
six
month
year
purpos
studi
evalu
proton
beam
therapi
pbt
outcom
popul
method
sixteen
patient
diagnosi
atrt
treat
novemb
januari
center
patient
treat
pbt
fraction
size
gyfract
use
deliv
fraction
seven
patient
receiv
craniospin
pbt
male
femal
patient
median
age
diagnosi
month
rang
month
year
eight
metastat
diseas
diagnosi
fourteen
patient
underw
surgeri
fifteen
patient
receiv
chemotherapi
result
mean
surviv
year
standard
deviat
year
median
radiat
dose
tumor
bed
patient
gy
eight
patient
receiv
craniospin
irradi
csi
addit
cranial
irradi
median
dose
gy
median
time
year
rang
year
patient
stabl
patient
deceas
patient
develop
progress
diseas
four
patient
suffer
nausea
vomit
ctc
grade
result
treatment
four
patient
also
suffer
moder
skin
erythema
ctc
grade
two
patient
suffer
weight
loss
gener
fatigu
treatment
patient
local
diseas
aliv
metastat
diseas
shown
steadi
declin
survivor
number
p
conclus
pbt
well
toler
heavili
treat
popul
background
poor
surviv
earli
outcom
data
promis
especi
without
metastat
diseas
necessari
role
cranial
radiosurgeri
pediatr
patient
e
murphi
chao
l
angelov
g
neyman
c
reddi
g
barnett
p
rasmussen
tekautz
j
suh
radiat
oncolog
cleveland
clinic
cleveland
usa
neurosurgeri
cleveland
clinic
cleveland
usa
pediatr
oncolog
cleveland
clinic
cleveland
usa
object
indic
radiosurgeri
pediatr
patient
often
extrapol
adult
patient
reduc
normal
tissu
exposur
ideal
toxic
treatment
well
character
outcom
toxic
analyz
institut
experi
gamma
knife
radiosurgeri
gkr
pediatr
patient
method
queri
gkr
databas
perform
identifi
patient
age
time
gkr
diagnosi
factor
gkr
data
neuroimag
studi
toxic
inform
evalu
surviv
time
calcul
use
method
result
pediatr
patient
identifi
femal
male
median
follow
month
rang
diagnos
includ
avm
schwannoma
astrocytoma
pituitari
adenoma
ependymoma
medulloblastoma
metastasi
median
age
yr
median
lp
gkr
six
patient
prior
fraction
radiotherapi
chemotherapi
ten
patient
prior
resect
gtr
ntr
str
gkr
initi
treatment
patient
use
recurr
progress
patient
median
prescript
dose
gy
rang
gy
dose
conform
dose
heterogen
median
treatment
volum
cc
max
tumor
diamet
cm
follow
gkr
patient
progress
distant
local
combin
local
progress
free
surviv
progress
free
surviv
overal
surviv
respect
ctcae
v
cn
toxic
grade
occur
pt
grade
pt
median
time
toxic
month
rang
conclus
pediatr
patient
toler
gkr
well
reason
toxic
local
control
good
across
spectrum
diagnos
treat
prospect
evalu
perform
develop
guidelin
use
radiosurgeri
popul
signific
primari
tumor
volum
recurr
surviv
pediatr
patient
nasopharyng
carcinoma
e
eldebawi
ahm
h
ammar
elnashar
zaghloul
radiat
oncolog
children
cancer
hospit
egypt
cche
nation
cancer
institut
cairo
univers
egypt
radiat
oncolog
children
cancer
hospit
egypt
cche
cairo
egypt
biophys
children
cancer
hospit
egypt
cche
cairo
egypt
statist
children
cancer
hospit
egypt
cche
cairo
egypt
object
primari
tumor
volum
ptv
recogn
promis
prognost
indic
treatment
adult
nasopharyng
carcinoma
npc
studi
design
analyz
valu
primari
tumor
volum
gross
tumor
volum
primari
site
predict
treatment
outcom
pediatr
patient
npc
treat
intens
modul
radiotherapi
imrt
method
retrospect
review
consecut
pediatr
patient
age
year
stage
npc
perform
patient
receiv
three
cycl
induct
chemotherapi
cisplatin
three
addit
cycl
cisplatin
alon
radiat
therapi
radiat
therapi
administ
use
intens
modul
radiotherapi
imrt
techniqu
invers
plan
system
gross
tumor
volum
primari
tumor
plu
retropharyng
node
gtvprn
calcul
index
treatment
outcom
result
median
ptv
larg
gtvprn
ml
associ
significantli
poorer
local
control
lower
distant
rate
poorer
surviv
overal
surviv
larg
tumor
volum
group
ml
small
tumor
volum
respect
p
diseas
free
surviv
larg
tumor
group
small
tumor
volum
group
p
year
local
recurr
free
surviv
larg
tumor
group
small
tumor
volum
group
p
overal
surviv
surviv
local
control
distant
rate
patient
respect
conclus
ptv
close
relationship
surviv
rate
recurr
rate
pediatr
patient
npc
larg
tumor
volum
group
ptv
ml
associ
recurr
poor
surviv
rate
colorect
cancer
screen
cancer
survivor
treat
radiat
therapi
samie
ahm
k
hui
r
gryfe
pollett
cino
g
ng
hodgson
radiat
medicin
princess
margaret
hospit
toronto
canada
clinic
research
princess
margaret
hospit
toronto
canada
dept
surgeri
mt
sinai
hospit
toronto
canada
dept
patholog
mt
sinai
hospit
toronto
canada
dept
gastroenterolog
toronto
western
hospit
toronto
canada
radiat
medicin
farber
cancer
institut
harvard
medic
school
boston
usa
object
due
increas
risk
colorect
cancer
crc
among
childhood
cancer
survivor
receiv
abdomin
pelvic
radiat
therapi
rt
guidelin
recommend
survivor
start
crc
screen
earlier
gener
popul
howev
evid
suggest
earlier
crc
screen
survivor
would
effect
undertook
prospect
studi
determin
polyp
detect
rate
among
young
survivor
compar
preval
rate
expect
among
averag
risk
individu
year
old
crc
screen
accept
method
asymptomat
cancer
survivor
age
year
treat
abdomin
radiat
tbi
least
year
prior
elig
patient
past
medic
histori
polyp
crohn
diseas
ulcer
coliti
colorect
screen
within
last
year
exclud
patient
underw
full
colonoscop
examin
adequ
bowel
prepar
retriev
polyp
review
gastrointestin
pathologist
result
fifti
five
patient
male
femal
median
age
year
enrol
total
polyp
found
patient
patient
ci
adenomat
polyp
found
patient
ci
polyp
deem
within
radiat
field
ci
polyp
found
beyond
ascend
colon
beyond
reach
sigmoidoscop
either
transvers
colon
descend
colon
cecum
ci
conclus
preval
adenomat
colorect
polyp
survivor
compar
greater
describ
among
gener
popul
age
year
crc
screen
gener
recommend
provid
indirect
support
guidelin
recommend
earli
initi
screen
recogn
polyp
occur
outsid
rt
field
complic
interpret
limit
margin
radiotherapi
pediatr
patient
ewe
sarcoma
achiev
high
rate
local
tumor
control
talleur
f
navid
spunt
e
mccarvil
neel
davidoff
mao
j
wu
krasin
oncolog
st
jude
children
research
hospit
memphi
usa
hematologyoncolog
lucil
salter
packard
children
hospit
palo
alto
usa
radiolog
scienc
st
jude
children
research
hospit
memphi
usa
surgeri
st
jude
children
research
hospit
memphi
usa
biostatist
st
jude
children
research
hospit
memphi
usa
object
determin
rate
local
failur
lf
use
limit
margin
radiotherapi
rt
dose
escal
tumor
cm
pediatr
patient
ewe
sarcoma
ew
method
elig
patient
ew
treat
phase
ii
institut
trial
limit
margin
rt
treatment
volum
base
ctmr
treatment
plan
dataset
clinic
target
volum
ctv
includ
gross
tumor
gtv
plu
cm
anatom
constrain
margin
plan
target
volum
ptv
rang
cm
unresect
tumor
cm
receiv
standard
rt
dose
ctv
boost
gtv
tumor
cm
rt
dose
escal
includ
boost
gtv
patient
margin
resect
receiv
adjuv
rt
ctv
initi
occur
everi
month
includ
imag
primari
tumor
site
result
patient
ew
local
metastat
diseas
enrol
trial
thirteen
primari
pelvic
tumor
median
rang
age
tumor
size
year
cm
month
month
patient
remain
respect
patient
receiv
system
chemotherapi
median
rang
rt
dose
patient
fifteen
patient
receiv
adjuv
standard
dose
escal
rt
ten
patient
distant
failur
one
patient
local
distant
failur
cumul
incid
lf
within
local
metastat
patient
group
differ
surviv
statist
signific
base
initi
tumor
size
age
site
diseas
conclus
treatment
limit
margin
rt
includ
dose
escal
unresect
tumor
cm
provid
favor
local
tumor
control
trial
rt
approach
warrant
investig
larger
trial
incorpor
standard
chemotherapi
preliminari
result
pediatr
proton
consortium
registri
ppcr
collabor
us
proton
center
acceler
proton
therapi
research
yock
dj
indelicato
w
hartsel
h
symecko
h
kasper
perkin
c
mahajan
al
chang
child
f
lauri
j
buchsbaum
l
raek
c
nevil
ladra
yeap
dept
radiat
oncolog
massachusett
gener
hospit
boston
usa
dept
radiat
oncolog
univers
florida
proton
therapi
institut
jacksonvil
usa
dept
radiat
oncolog
cdh
proton
center
chicago
chicago
usa
dept
radiat
oncolog
mgh
boston
usa
dept
radiat
oncolog
washington
univers
st
loui
usa
dept
radiat
oncolog
univers
pennsylvania
philadelphia
usa
dept
radiat
oncolog
md
anderson
cancer
center
houston
usa
dept
radiat
oncolog
hampton
univers
hampton
usa
dept
radiat
oncolog
mayo
medic
school
rochest
usa
dept
radiat
oncolog
qarc
univers
massachusett
provid
usa
dept
radiat
oncolog
indiana
univers
provid
usa
object
pediatr
proton
investig
unit
form
pediatr
proton
consortium
registri
ppcr
acceler
research
role
proton
radiotherapi
prt
children
comprehens
redcap
databas
pediatr
cancer
patient
creat
earli
demograph
prt
describ
method
proton
patient
year
treat
ppcr
center
elig
registri
captur
baselin
demograph
insur
statu
diseasehealth
inform
treatment
detail
consent
childrenfamili
basic
inform
demographicsdiagnosi
collect
unenrol
patient
result
six
site
irb
approv
enrol
pt
enrol
refusedor
miss
nine
site
open
ppcr
data
reveal
median
age
femal
white
black
asian
insur
medicaid
intern
referr
pediatr
oncologist
neurosurgeon
radiat
oncologist
time
il
ny
fl
state
lead
enrol
europ
asia
australia
canada
compris
intern
patient
cn
tumor
tumor
primari
recurr
metastat
cn
histolog
glioma
medulloblastoma
ependymoma
craniopharyngioma
histolog
chordoma
rm
bone
sarcoma
st
genet
syndrom
kpslanski
radiotherapi
intent
cur
type
prt
passiv
scatter
pencil
beam
scan
pb
mean
total
rt
dose
gyrb
receiv
csi
receiv
chemotherapi
enrol
cog
trial
return
proton
center
fu
care
conclus
ppcr
success
multicent
us
base
registri
children
receiv
prt
earli
demograph
demonstr
ppcr
use
understand
popul
refer
prt
track
outcom
us
proton
center
treat
children
invit
join
ppcr
high
dose
rate
brachitherapi
childhood
soft
tissu
sarcoma
g
scarzello
ms
buzzaccarini
ee
pane
g
cecchetto
p
dalligna
di
carlo
canonico
g
bisogno
radiat
oncolog
istituto
oncologico
ircc
padova
itali
pediatr
univers
hospit
padova
itali
physic
istituto
oncologico
ircc
padova
itali
object
evalu
efficaci
children
undergo
treatment
st
method
children
year
median
age
st
receiv
iov
treat
primari
lesion
relaps
extrem
commonli
involv
follow
head
neck
vagina
orbit
wall
histolog
embryon
rhabdomyosarcoma
alveolar
rhabdomyosarcoma
fibrosarcoma
no
rhabdomyosarcoma
leyomyosarcoma
myoepitheli
carcinoma
ten
children
lesion
greater
cm
limb
wall
vagina
surgic
margin
posit
vagina
limb
orbit
non
paramening
wall
orbit
macro
residu
patient
underw
local
excis
follow
temporari
interstiti
use
patient
treat
alon
receiv
plu
ebrt
dose
gy
fraction
twice
per
day
children
receiv
ebrt
underw
irradi
total
dose
gy
fraction
gy
twice
per
day
gy
boost
result
year
median
follow
patient
aliv
without
diseas
aliv
without
diseas
amput
two
children
fail
local
develop
lung
metastasi
nodal
lung
metastasi
without
lr
die
tumor
progress
local
control
df
os
respect
late
mild
subcutan
fibrosi
evid
near
patient
one
femal
wrist
sarcoma
underw
surgeri
finger
movement
impair
satisfactori
outcom
two
children
present
esthet
unaccept
scar
well
correct
plastic
surgeri
one
femal
present
hematocolpo
menarch
conclus
select
group
children
result
excel
local
control
function
outcom
reduc
morbid
second
malign
neoplasm
caus
death
patient
treat
hodgkin
diseas
childhood
slovenia
l
zadravec
zaletel
b
jereb
radiotherapi
institut
oncolog
ljubljana
slovenia
object
studi
frequenc
second
malign
neoplasm
smn
caus
death
patient
pt
treat
hodgkin
diseas
hd
childhood
slovenia
method
one
hundr
pt
age
treat
hd
slovenia
diagnosi
med
year
old
nineteen
pt
die
hd
med
year
diagnosi
decemb
time
remain
pt
med
year
result
smn
found
pt
med
year
diagnosi
breast
cancer
treat
cht
alon
thyroid
cancer
basalioma
one
malign
melanoma
pleural
mesothelioma
treat
rt
alon
thyroid
cancer
breast
cancer
acut
myeloid
leukemia
basalioma
parotid
cancer
colon
cancer
lung
cancer
uterin
cancer
rm
maxillar
sinu
intracrani
meningeoma
one
pt
treat
rt
cht
smn
aris
insid
rt
field
cumul
incid
smn
year
year
year
seven
pt
die
smn
aml
one
lung
cancer
mesothelioma
colon
breast
cancer
rm
med
year
diagnosi
caus
heart
damag
pt
med
year
diagnosi
infect
conclus
studi
incid
smn
treatment
hd
childhood
high
thyroid
cancer
frequent
smn
import
caus
death
year
diagnosi
hd
longlif
includ
screen
smn
heart
diseas
patient
vital
import
carotid
arteri
diseas
neck
irradi
survivor
hodgkin
diseas
childhood
l
zadravec
zaletel
zaletel
radiotherapi
institut
oncolog
ljubljana
slovenia
vascular
neurolog
univers
medic
centr
ljubljana
slovenia
object
studi
shown
carotid
arteri
diseas
pediatr
cancer
survivor
treat
neck
irradi
rt
although
contradictori
result
compar
paramet
carotid
arteri
diseas
patient
pt
treat
hodgkin
diseas
hd
childhood
neck
rt
cardiovascular
risk
factor
match
control
method
pt
treat
hd
age
slovenia
aliv
pt
receiv
neck
rt
elig
studi
refus
cooper
femal
male
includ
med
year
old
diagnosi
evalu
med
year
later
age
med
year
receiv
neck
rt
med
gy
pt
receiv
chemotherapi
aloka
alfa
use
determin
plaqu
intima
media
thick
common
carotid
arteri
carotid
arteri
stiff
measur
new
echo
track
use
duplex
sonographi
follow
carotid
stiff
index
calcul
local
puls
wave
veloc
pwvb
ms
strain
pressur
elast
index
ep
kpa
beta
index
augment
index
aix
variabl
two
group
statist
analyz
spss
result
valu
local
carotid
stiff
index
signific
higher
beta
stiff
p
pwvb
p
ep
p
aix
p
signific
arteri
wall
calcin
p
group
survivor
thick
p
number
plaqu
p
differ
two
group
neither
either
group
signific
carotid
stenosi
conclus
result
reveal
mild
arteriosclerot
chang
carotid
arteri
preval
survivor
hodgkin
diseas
childhood
neck
rt
need
prevent
stroke
associ
advanc
carotid
diseas
helic
tomotherapi
askin
tumor
chest
wall
clinic
outcom
laskar
n
kalyani
n
khanna
vora
qureshi
g
chinnaswami
kembhavi
ramadwar
r
upreti
p
kurkur
radiat
oncolog
tata
memori
hospit
mumbai
india
pediatr
oncolog
tata
memori
hospit
mumbai
india
surgic
oncolog
tata
memori
hospit
mumbai
india
radiodiagnosi
tata
memori
hospit
mumbai
india
patholog
tata
memori
hospit
mumbai
india
medic
physic
tata
memori
hospit
mumbai
india
object
evalu
clinic
outcom
patient
askin
tumor
chest
wall
treat
use
helic
tomotherapi
method
treatment
compris
multiag
chemotherapi
cth
local
therapi
form
surgeri
sx
radiat
therapi
rt
definit
rt
alon
result
pt
yr
median
treat
radic
intent
januari
decemb
includ
male
median
tumor
volum
underw
sxrt
surgic
margin
closeposit
median
percentag
necrosi
median
local
control
lc
diseas
free
surviv
df
overal
surviv
os
respect
tumor
volum
inferior
lc
vs
p
df
p
conclus
primari
tumor
volum
surgic
resect
margin
percentag
necrosi
presenc
pleural
effus
influenc
diseas
outcom
combin
cth
sx
rt
result
superior
outcom
askin
tumor
radiosurg
treatment
tumor
vascular
brain
lesion
children
devriendt
n
massag
f
de
smedt
gamma
knife
center
erasm
ulb
brussel
belgium
object
object
present
studi
assess
safeti
effici
gamma
knife
radiosurg
treatment
brain
arterioven
malform
tumor
children
method
review
outcom
seri
children
age
year
underw
radiosurg
irradi
tumor
vascular
brain
lesion
center
includ
arterioven
malform
cavernoma
pilocyt
astrocytoma
grade
ii
glioma
glioblastoma
ependymoma
hypothalam
hamartoma
schwannoma
meningioma
choroid
plexu
carcinoma
craniopharyngioma
hemangiopericytoma
patient
radiosurgeri
use
gamma
knife
c
perfexion
gener
anesthesia
patient
patholog
mean
size
cc
rang
cc
irradi
mean
margin
dose
gy
rang
gy
result
period
patient
rang
year
mean
year
obliter
rate
arterioven
malform
bleed
occur
radiosurgeri
morbid
limit
children
patient
avm
seizur
irradi
patient
vestibular
schwannoma
lost
hear
unilater
observ
excel
tumor
control
patient
pilocyt
astrocytoma
grade
ii
glioma
schwannoma
meningioma
hemangiopericytoma
none
children
glioblastoma
ependymoma
hypothalam
hamartoma
craniopharyngioma
tumor
control
long
term
radiosurgeri
conclus
gamma
knife
radiosurgeri
repres
safe
quit
effect
therapi
brain
arterioven
malform
brain
tumor
children
serum
folat
level
methylen
tetra
hydroxi
folat
reductas
mthfr
genotyp
complic
induct
chemotherapi
children
acut
lymphoblast
leukemia
n
roy
moulik
kumar
agraw
mahdi
pediatr
king
georg
medic
univers
lucknow
india
medic
genet
sanjay
gandhi
post
graduat
institut
medic
scienc
lucknow
india
biochemistri
king
georg
medic
univers
lucknow
india
object
major
death
children
lowmiddl
incom
countri
undergo
treatment
occur
initi
phase
chemotherapi
mostli
due
malnutrit
infect
though
folat
defici
wide
preval
develop
countri
effect
outcom
treatment
children
studi
present
studi
examin
effect
folat
statu
mthfr
genotyp
cours
complic
induct
chemotherapi
method
children
regist
septemb
august
assess
serum
folat
baselin
end
induct
mthfr
genotyp
clinic
laboratori
paramet
monitor
induct
chemotherapi
studi
approv
institut
ethic
committe
result
folat
defici
seen
children
baselin
end
induct
chemotherapi
folat
level
declin
ngml
p
induct
mark
mutant
genotyp
low
count
seen
often
children
baselin
folat
defici
p
p
higher
proport
folat
defici
children
experienc
episod
febril
neutropenia
compar
children
normal
folat
p
children
succumb
neutropenia
relat
sepsi
folat
defici
compar
induct
survivor
p
transfus
requir
red
cell
platelet
higher
folat
defici
children
respect
higher
incid
mucos
seen
children
mutat
p
concomit
folat
defici
accentu
advers
effect
mutat
genotyp
multivari
analysi
reveal
associ
baselin
folat
defici
low
count
day
p
mthfr
mutat
mucos
p
conclus
folat
defici
mthfr
mutat
led
higher
incid
hematolog
complic
mucos
poorer
surviv
children
undergo
induct
chemotherapi
secular
trend
surviv
acut
lymphoblast
leukemia
among
children
live
area
low
socioeconom
statu
ss
viana
lmmr
lima
oa
caf
cardoso
jb
nascimento
mru
rangel
r
cipolotti
medicin
univers
sergip
aracaju
brazil
object
evalu
secular
trend
surviv
acut
lymphoblast
leukemia
children
live
area
low
socioeconom
statu
method
evalu
patient
year
acut
lymphoblast
leukemia
treat
pediatr
oncologist
use
standard
protocol
servic
link
public
gener
hospit
divid
patient
two
cohort
treat
cohort
cohort
b
find
compar
patient
treat
singl
privat
hospit
local
team
protocol
cohort
c
result
obtain
patient
cohort
cohort
b
cohort
c
overal
mortal
rate
mean
overal
surviv
month
cohort
month
cohort
b
month
cohort
c
month
respect
overal
mortal
rate
higher
cohort
p
note
cohort
mortal
rate
higher
infant
adolesc
compar
toddlersschool
children
p
respect
median
surviv
p
respect
cohort
b
patient
rural
area
higher
mortal
rate
p
male
longer
mean
surviv
p
cohort
b
c
obtain
higher
mortal
rate
among
patient
live
rural
area
p
way
median
surviv
time
p
also
higher
among
male
p
whose
mother
year
school
p
conclus
mortal
rate
consid
decreas
increas
median
surviv
time
associ
male
gender
live
urban
area
mother
higher
level
educ
outcom
morbid
primari
resect
hepatoblastoma
protocol
e
hiyama
hishiki
k
watanab
k
ida
yano
oue
iehara
k
hoshino
k
koh
tanaka
kurihara
pediatr
surgeri
hiroshima
univers
hospit
hiroshima
japan
pediatr
surgeri
chiba
chidren
hospit
chiba
japan
pediatr
kyoto
univers
school
medicin
kyoto
japan
pediatr
teikyo
univers
school
medicin
mizoguchi
tokyo
japan
pediatr
akita
univers
school
medicin
akita
japan
pediatr
osaka
univers
school
medicin
osaka
japan
pediatr
kyoto
prefectur
medic
univers
kyoto
japan
pediatr
keio
univers
school
medicin
tokyo
japan
saitama
children
medic
center
saitama
japan
patholog
kanagawa
children
medic
hospit
saitama
japan
object
japanes
studi
group
pediatr
liver
tumor
jplt
launch
conduct
two
protocol
name
evalu
cure
rate
hepatoblastoma
hb
protocol
primari
resect
permit
pretext
ii
case
follow
postop
chemotherapi
studi
examin
outcom
surgic
complic
primarili
resect
hb
case
method
among
case
primarili
resect
hb
case
enrol
pretext
pretext
ii
ruptur
hb
clinic
featur
surgic
procedur
surviv
rate
compar
among
three
group
result
pretext
case
underw
complet
resect
left
lobectomi
left
later
segmentectomi
n
right
lobectomi
n
partial
resect
n
among
two
case
show
recurr
one
older
case
mo
one
partial
resect
case
pretext
ii
case
except
one
underw
complet
resect
right
lobectomi
n
left
lobectomi
n
resect
n
three
case
portal
hepat
vein
involv
among
oper
death
occur
one
newborn
recurr
case
includ
case
involv
vein
one
older
case
mo
ruptur
case
show
recurr
overal
surviv
rate
year
pretext
ii
ruptur
case
surviv
rate
year
group
respect
case
case
show
biliari
duct
complic
cure
conclus
outcom
pretext
ii
case
primari
resect
unsatisfactori
recurr
primari
resect
case
perform
anatom
resect
accord
strict
surgic
guidelin
intensifi
chemotherapi
requir
primarili
resect
case
tumor
ruptur
comprehens
updat
pediatr
renal
tumor
epidemiolog
analysi
first
patient
children
oncolog
group
cog
renal
tumor
classif
biolog
protocol
ea
mullen
ji
geller
e
gratia
ej
perlman
pf
ehrlich
g
khanna
naranjo
cv
fernandez
k
gow
f
ferrer
hamilton
r
glick
j
kandel
barnhart
r
dasgupta
f
hoffer
serva
j
da
hill
v
huff
pe
grundi
js
dome
pediatr
hematologyoncolog
children
cancer
blood
disord
center
boston
usa
hematologyoncolog
cincinnati
children
hospit
medic
center
cincinnati
usa
pediatr
hematologyoncolog
children
oncolog
group
monrovia
usa
patholog
ann
robert
h
luri
children
hospit
chicago
chicago
usa
pediatr
surgeri
cs
mott
children
hospit
ann
arbor
usa
pediatr
radiolog
washington
univers
school
medicin
st
loui
usa
biostatist
cog
data
center
gainsvil
usa
pediatr
bioethic
iwk
health
centr
halifax
canada
renal
tumor
children
oncolog
group
monrovia
usa
oncolog
children
nation
medic
center
washington
dc
usa
cancer
care
alberta
health
servic
calgari
canada
object
studi
conduit
enrol
cog
therapeut
renal
tumor
rt
studi
via
central
review
support
comprehens
biolog
tissu
epidemiolog
repositori
defin
present
day
spectrum
pediatr
rt
analyz
first
patient
enrol
method
patient
radiolog
identifi
rt
wilm
wt
malign
rhabdoid
tumor
mrt
enrol
requir
submiss
includ
abdomin
ctmri
chest
ct
institut
patholog
report
tissu
diagnost
h
e
slide
oper
report
tissu
loh
test
avail
blood
urin
tumor
normal
kidney
tissu
bank
result
overal
elig
median
age
diagnosi
year
rang
day
year
male
congenit
anomali
includ
predisposit
syndrom
histolog
distribut
unilater
patient
favor
histolog
wt
fhwt
anaplast
wt
renal
cell
carcinoma
mrt
clear
cell
sarcoma
kidney
congenit
mesoblast
nephroma
cystic
nephroma
metanephr
adenoma
patient
subsequ
enrol
therapeut
studi
among
patient
fhwt
stage
distribut
ii
iii
iv
v
stage
iv
patient
pulmonari
metastas
loh
tissu
bank
support
biolog
epidemiolog
studi
date
conclus
largest
clinic
epidemiolog
biolog
databank
pediatr
rt
present
new
insight
pediatr
rt
epidemiolog
modern
era
contrast
histor
cohort
studi
enrol
unilater
patient
wt
incid
rare
rt
increas
studi
enabl
time
risk
stratif
onto
clinic
trial
serv
valuabl
repositori
rt
discoveri
research
integr
genom
analys
identifi
recurr
structur
alter
atyp
teratoid
rhabdoid
tumour
atrt
j
torchia
picard
kc
ho
da
l
louterneau
bourgey
chan
b
golbourn
l
md
taylor
p
dirk
e
bouffet
c
hawkin
j
majewski
sk
kim
n
jabado
huang
depart
laboratori
medicin
pathobiolog
univers
toronto
toronto
canada
arthur
sonia
labatt
brain
tumour
research
centr
hospit
sick
children
toronto
canada
human
genet
experiment
medicin
mcgill
univers
montreal
canada
genom
quebec
innov
centr
mcgill
univers
montreal
canada
pediatr
oncolog
alberta
children
hospit
calgari
canada
divis
neurosurgeri
hospit
sick
children
toronto
canada
paediatr
hematolog
oncolog
hospit
sick
children
toronto
canada
patholog
hospit
sick
children
toronto
canada
pediatr
neurosurgeri
seoul
nation
univers
children
hospit
seoul
korea
object
atrt
atyp
teratoid
rhabdoid
tumour
repres
one
aggress
pediatr
brain
tumour
paradox
atrt
report
exhibit
balanc
genom
alter
locu
sole
recurr
somat
genet
event
better
defin
molecular
mechan
underli
atrt
biolog
comprehens
interrog
atrt
use
integr
genom
approach
method
integr
combin
resolut
snp
genotyp
rna
sequenc
copi
number
structur
alter
map
use
orthogon
bioinformat
techniqu
structur
alter
mutat
valid
target
use
sanger
method
andor
miseq
ion
torrent
analys
result
atrt
exhibit
recurr
deleteri
snv
except
loss
function
mutat
snv
tumour
report
previous
observ
low
mutat
rate
primari
atrt
significantli
observ
structur
alter
predomin
genet
mechan
primari
atrt
notabl
structur
event
lead
loss
function
observ
major
primari
atrt
tumour
includ
novel
intrachromosom
transloc
detect
use
convent
diagnost
techniqu
observ
novel
recurr
structur
alter
associ
correspond
copi
number
driven
gene
express
chang
novel
loci
previous
implic
atrt
nearli
primari
atrt
includ
focal
delet
bcr
conclus
integr
high
resolut
genom
approach
uncov
novel
loci
predict
function
cell
adhes
dna
damag
respons
epigenet
regul
inform
better
understand
atrt
tumour
biolog
identif
novel
structur
event
gene
indic
scope
genet
alter
atrt
date
underestim
underscor
wg
import
tool
gene
discoveri
well
clinic
diagnost
atrt
anaplast
wilm
tumor
retain
intact
pathway
ahag
oom
gadd
ds
gerhard
smith
jm
js
dome
mm
van
den
rr
de
krijger
ej
perlman
patholog
ann
robert
h
luri
children
hospit
chicago
chicago
usa
offic
cancer
genom
nation
cancer
institut
bethesda
usa
cancer
therapi
evalu
program
nation
cancer
institut
bethesda
usa
children
nation
medic
center
washington
usa
oncolog
erasmu
mc
sophia
children
hospit
rotterdam
netherland
patholog
erasmu
mc
rotterdam
netherland
object
therapeut
applic
research
gener
effect
treatment
target
project
includ
diffus
anaplast
wilm
tumor
dawt
show
anaplasia
slide
goal
evalu
character
pathway
dawt
identifi
novel
mutationstarget
method
singl
sampl
frozen
tissu
tumor
underw
whole
genom
exom
sequenc
gene
express
affymetrix
copi
number
analys
snp
array
immunohistochemistri
perform
avail
block
taken
differ
sampl
respect
tumor
result
somat
variant
identifi
dawt
germlin
mutat
identifi
variant
associ
copi
number
loss
dawt
remain
variant
involv
allel
dawt
lack
variant
copi
number
loss
identifi
normal
copi
number
present
signific
upregul
gene
involv
biocarta
hypoxia
pathway
identifi
dawt
support
activ
pathway
sampl
analyz
variant
identifi
within
pathway
tumor
lack
abnorm
relaps
versu
remain
dawt
examin
dawt
without
abnorm
abnorm
protein
accumul
identifi
anaplast
area
immunohistochemistri
consist
mutat
sampl
sequenc
slide
request
remain
case
conclus
result
support
key
role
loss
develop
anaplasia
major
dawt
whether
anaplasia
aris
absenc
mutat
remain
unproven
tissu
heterogen
difficulti
perform
interpret
immunohistochemistri
rariti
dawt
remain
import
obstacl
stratifi
patient
anaplasia
base
abnorm
characterist
igtcr
gene
arrang
pattern
applic
mrd
detect
chines
childhood
acut
lymphoblast
leukemia
w
li
lei
cui
z
li
wu
chao
gao
hematolog
beij
children
hospit
beij
china
object
accord
analyz
characterist
igtcr
gene
rearrang
pattern
correl
clinic
biolog
featur
childhood
establish
quantit
detect
system
target
igtcr
gene
rearrang
method
use
standard
igtcr
amplif
system
propos
europ
collabor
group
clonal
gene
rearrang
igh
igk
includ
kde
igl
trd
trb
trg
screen
children
includ
b
cell
precursor
cell
sequenc
analyz
junction
domain
prepar
resultsf
clonal
igtcr
gene
rearrang
childhood
respect
posit
rate
clonal
rearrang
igh
igk
trd
trg
trb
igl
trb
trg
trd
igh
incid
trg
rearrang
significantli
higher
mll
rearrang
respect
p
childhood
trg
rearrang
pattern
associ
age
initi
wbc
count
p
p
igh
rearrang
occur
mostli
patient
good
prednison
p
establish
quantit
detect
system
children
conclus
incid
clonal
igtcr
gene
rearrang
high
childhood
divers
junction
rearrang
pattern
differ
significantli
childhood
differ
fusion
gene
associ
age
initi
wbc
count
igtcr
target
display
wide
coverag
molecular
marker
higher
sensit
specif
quantit
approach
appli
mrd
detect
childhood
loss
tumor
suppressor
promot
cell
surviv
control
function
l
van
der
meer
l
yuniati
e
tychon
l
emst
alkema
c
rodenbach
p
hoogerbrugg
f
leeuwen
pediatr
oncolog
radboud
univers
medic
centr
nijmegen
netherland
object
b
cell
transloc
gene
locu
affect
genom
delet
pediatr
acut
lymphoblast
leukemia
patient
howev
remain
unclear
loss
promot
clonal
outgrowth
method
detect
increas
express
cell
expos
variou
challeng
condit
test
function
role
cellular
respons
stress
challeng
knockout
cell
nutrient
depriv
found
knockout
cell
show
improv
surviv
rate
compar
wildtyp
cell
result
activ
transcript
factor
master
regul
cellular
stress
signal
hypothes
improv
surviv
loss
regul
via
inde
target
gene
differenti
regul
knockout
cell
addit
show
complex
immunoprecipit
experi
function
transcript
act
recruit
protein
arginin
methyl
transferas
transcript
factor
complex
methyl
assay
show
direct
target
mediat
methyl
furthermor
found
interact
domain
essenti
mediat
modul
function
search
addit
evid
function
interact
perform
global
express
analysi
cell
express
marker
reveal
signific
deregul
target
gene
knockout
cell
compar
wildtyp
cell
conclus
togeth
data
indic
suppress
activ
respons
cellular
stress
loss
function
occur
leukemia
develop
enhanc
activ
therebi
promot
cell
surviv
cellular
stress
condit
nutrient
depriv
er
stress
leukem
cell
carri
delet
may
thu
benefit
increas
resist
cellular
stress
leukemia
develop
also
treatment
frequenc
hla
b
allel
accord
risk
group
children
precursor
acut
lymphoblast
leukemia
patiroglu
hh
akar
depart
pediatr
hematolog
oncolog
erciy
univers
faculti
medicin
kayseri
turkey
depart
pediatr
immmunolgi
erciy
univers
faculti
medicin
kayseri
turkey
object
previou
studi
demonstr
signific
differ
hla
allel
frequenc
leukem
patient
normal
subject
purpos
studi
evalu
frequenc
hla
class
b
class
ii
allel
patient
acut
lymphoblast
leukemia
compar
unrel
healthi
subject
central
anatolia
turkey
method
studi
perform
children
whose
age
rang
year
twenti
nine
patient
standard
risk
group
srg
moder
risk
group
mrg
high
risk
group
hrg
respect
accord
berlin
frankfurt
bfm
standard
type
b
allel
patient
unrel
normal
subject
central
anatolia
turkey
low
resolut
method
luminex
technolog
use
hla
type
result
allel
frequenc
higher
patient
compar
control
group
p
p
p
respect
contrari
allel
frequenc
patient
lower
control
p
p
respect
allel
higher
hrg
mrg
srg
p
allel
higher
srg
hrg
mrg
p
observ
haplotyp
b
p
patient
could
find
haplotyp
neg
associ
observ
homozyg
allel
p
present
cohort
conclus
result
suggest
allel
may
play
presumpt
predispos
factor
wherea
allel
found
neg
associ
addit
allel
found
associ
hrg
mrg
also
allel
may
play
presumpt
predispos
factor
srg
preclin
vivo
efficaci
pathway
inhibit
acut
lymphoblast
leukemia
sk
tasian
li
ryan
sl
maud
dt
teachey
ml
loh
sp
hunger
cg
mullighan
carrol
sa
grupp
pediatr
children
hospit
philadelphia
philadelphia
usa
pediatr
ucsf
benioff
children
hospit
san
francisco
usa
pediatr
colorado
children
hospit
denver
usa
patholog
st
jude
children
research
hospit
memphi
usa
medicin
univers
pennsylvania
philadelphia
usa
object
acut
lymphoblast
leukemia
associ
variou
genom
alter
known
predict
activ
oncogen
signal
transduct
previous
demonstr
constitut
phosphoryl
pathway
protein
therapeut
disrupt
signal
leukemia
minim
investig
hypothes
dual
pathway
protein
inhibit
would
robustli
inhibit
prolifer
vivo
abrog
aberr
signal
method
immunocompromis
mice
pediatr
treat
inhibitor
inhibitor
idelalisib
inhibitor
inhibitor
vehicl
treat
mice
assess
pharmacodynam
inhibit
phosphoprotein
hour
phosphoflow
cytometri
b
residu
murin
spleen
week
treatment
quantit
flow
cytometri
result
xenograft
model
de
novo
relaps
tabl
demonstr
potent
vivo
inhibit
relev
phosphoprotein
phosphoryl
mtor
andor
erk
pathway
inhibit
treatment
result
model
mean
rang
leukemia
reduct
versu
vehicl
treatment
p
via
anova
dunnett
multipl
comparison
idelalisib
treatment
inhibit
prolifer
model
mean
rang
rang
rang
leukemia
reduct
respect
p
model
highest
basal
pathway
phosphoprotein
level
respond
robustli
pathway
inhibitor
genom
lesion
igh
igh
igh
igh
igh
conclus
pathway
inhibit
effect
biochem
relev
therapeut
approach
dual
inhibit
potent
treatment
strategi
evalu
model
result
continu
inform
develop
clinic
trial
test
signal
transduct
inhibitor
chemotherapi
children
improv
therapeut
strategi
use
predict
biomark
pediatr
activ
within
eu
network
encca
introduc
newli
discov
molecular
inform
clinic
practic
stanulla
g
te
kronni
g
cazzaniga
von
stackelberg
dworzak
attarbaschi
ml
den
boer
jp
bourquin
g
basso
schrapp
depart
pediatr
hematolog
oncolog
hannov
medic
school
hannov
germani
depart
women
children
health
univers
padua
padua
itali
children
hospit
univers
monza
itali
depart
pediatr
hematolog
oncolog
univers
hospit
berlin
germani
depart
pediatr
st
anna
children
hospit
children
cancer
research
institut
vienna
austria
depart
pediatr
hematolog
oncolog
erasmu
medic
center
rotterdam
netherland
univers
children
hospit
univers
children
hospit
switzerland
depart
women
children
health
univers
padua
padua
switzerland
depart
gener
pediatr
uksh
campu
kiel
kiel
germani
object
late
major
progress
achiev
pediatr
improv
risk
stratif
treatment
base
measur
leukem
cell
reduct
minim
residu
diseas
mrd
analysi
outcom
data
clearli
indic
howev
larg
proport
recurr
predict
sole
mrd
respons
pattern
part
network
project
encca
stepwis
integr
approach
european
clinic
studi
group
taken
molecularli
character
new
risk
group
systemat
adapt
exist
trial
infrastructur
associ
common
futur
treatment
approach
method
first
survey
diagnost
conduct
second
develop
harmon
pipelin
molecular
diagnost
european
virtual
laboratori
set
use
vhrl
character
molecular
persist
intensifi
treatment
model
system
start
third
molecular
diagnost
pipelin
integr
preclin
model
system
molecularli
target
treatment
algorithm
identif
prioritis
target
develop
fourth
harmon
integr
clinic
platform
promot
practic
pave
way
introduct
molecularli
target
treatment
result
far
main
achiev
project
implement
coher
diagnost
strategi
develop
recommend
diagnost
approach
pediatr
b
implement
laboratori
softwar
system
tailor
agreement
share
dataset
biospecimen
promot
joint
research
activ
includ
interfac
addit
differ
laboratori
system
c
coordin
joint
evalu
molecularli
defin
prognost
entiti
eg
implement
xenotranspl
repositori
e
develop
access
function
clinic
trial
infrastructur
intreal
conclus
overal
project
exemplifi
complex
need
solut
adapt
current
fragment
infrastructur
associ
differ
clinic
trial
group
prepar
common
futur
molecularli
base
treatment
approach
new
pediatr
entiti
europ
fund
ga
refin
risk
classif
pediatr
acut
lymphoblast
leukemia
base
genet
featur
present
minim
residu
diseas
sidhom
mokhl
n
ali
k
shaaban
yassin
salem
soliman
n
hamdi
youssef
w
rash
mehanna
haddad
pediatr
oncolog
nci
cairo
univers
children
cancer
hospit
egypt
cairo
egypt
pediatr
oncolog
beni
suef
univers
children
cancer
hospit
egypt
cairo
egypt
clinic
patholog
nci
cairo
univers
children
cancer
hospit
egypt
cairo
egypt
clinic
pharmaci
children
cancer
hospit
egypt
cairo
egypt
research
depart
children
cancer
hospit
egypt
cairo
egypt
object
appli
genet
characterist
earli
respons
therapi
toward
refin
risk
classif
method
studi
includ
precursor
patient
present
low
risk
lr
featur
age
year
wbc
dna
index
cn
testicular
diseas
unfavor
genet
abnorm
treat
children
cancer
hospit
egypt
juli
decemb
accord
st
jude
total
studi
xv
pui
et
al
nejm
result
patient
provision
lr
featur
good
earli
respons
end
induct
minim
residu
diseas
present
treat
lr
arm
base
favor
genet
featur
mrd
respons
rf
lr
patient
mrd
conclus
therapi
success
base
favor
genet
featur
mrd
irrespect
age
wbc
present
mrd
implement
autom
electron
risk
assign
pediatr
acut
lymphoblast
leukemia
report
children
oncolog
group
cog
k
rabin
pa
c
wood
dai
j
aj
carrol
na
heerema
b
wood
mj
borowitz
p
brown
j
hilden
angiolillo
w
salzer
mj
burk
ea
raetz
ml
loh
sp
hunger
devida
pediatr
baylor
colleg
medicin
houston
usa
pediatr
md
anderson
cancer
center
houston
usa
biostatist
univers
florida
gainesvil
usa
laboratori
medicin
nationwid
children
hospit
columbu
usa
genet
univers
alabama
birmingham
usa
cytogenet
nationwid
children
hospit
columbu
usa
patholog
univers
washington
seattl
usa
patholog
john
hopkin
medic
institut
baltimor
usa
pediatr
john
hopkin
medic
institut
baltimor
usa
pediatr
univers
colorado
denver
usa
pediatr
children
nation
medic
center
washington
dc
usa
pediatr
walter
reed
nation
militari
medic
center
fort
detrick
usa
pediatr
medic
colleg
wisconsin
milwauke
usa
pediatr
univers
utah
salt
lake
citi
usa
pediatr
univers
california
san
francisco
san
francisco
usa
object
treatment
significantli
improv
surviv
childhood
cog
classif
studi
link
clinic
trial
requir
time
risk
assign
children
annual
accord
complex
risk
stratif
scheme
integr
clinic
inform
laboratori
data
local
site
three
central
refer
laboratori
assess
minim
residu
diseas
dna
ploidi
central
review
cytogenet
fluoresc
situ
hybrid
data
purpos
studi
develop
implement
valid
autom
risk
assign
methodolog
method
algorithm
implement
cog
remot
data
entri
system
erd
automat
gener
risk
assign
patient
requir
data
sourc
enter
individu
site
review
valid
assign
elimin
need
manual
central
assign
algorithm
success
modifi
studi
accommod
new
data
prognost
impact
intrachromosom
amplif
chromosom
refin
risk
classif
result
within
year
enrol
nearli
subject
patient
treat
three
frontlin
studi
standard
high
risk
classifi
post
induct
therapi
comparison
programmat
gener
risk
assign
automat
assign
erd
demonstr
discord
evalu
case
one
case
demonstr
discord
risk
assign
two
method
due
alter
data
entri
site
valid
risk
assign
remaind
risk
assign
simpli
miss
one
method
due
incomplet
data
discontinu
protocol
therapi
patient
inevalu
reason
conclus
autom
risk
assign
integr
multipl
sourc
data
rapid
accur
flexibl
mechan
use
cooper
group
clinic
trial
signific
concord
earli
minim
residu
diseas
mrd
level
assas
flow
cytometri
pediatr
acut
lymphoblast
leukemia
dawidowska
kosmalska
l
sedek
twardoch
sonsala
b
k
derwich
szczepankiewicz
witt
szczepanski
dept
molecular
clinic
genet
institut
human
genet
polish
academi
scienc
poznan
poland
dept
pediatr
hematolog
oncolog
medic
univers
silesia
zabrz
poland
dept
pediatr
hematolog
oncolog
transplantolog
univers
medic
scienc
poznan
poland
dept
pediatr
pulmonolog
allergi
clinic
immunolog
univers
medic
scienc
poznan
poland
object
minim
residu
diseas
mrd
assess
fc
rearrang
immunoglobulin
receptor
igtcr
gene
signific
prognost
factor
compat
method
studi
pediatr
object
compar
analysi
mrd
level
pediatr
fc
igtcr
aim
assess
mrd
kinet
concord
result
method
mrd
assess
children
treat
accord
patient
marrow
mononuclear
cell
sampl
fc
patient
marrow
sampl
consolid
week
mrd
evalu
accord
protocol
euroflow
protocol
inform
consent
patient
approv
local
review
board
mrd
result
method
avail
comparison
sampl
spearman
rank
correl
test
use
estim
relat
patient
comparison
assign
base
standard
criteria
feasibl
result
highmrd
level
observ
earli
result
equal
method
consolid
lower
mrd
level
result
signific
correl
observ
r
p
r
p
consolid
r
p
risk
group
assign
base
concord
patient
conclus
signific
concord
demonstr
result
specif
mrd
kinet
consider
proport
high
mrd
level
earli
consolid
longer
need
prognost
signific
mrd
measur
method
assess
research
support
particip
polish
pediatr
leukemia
lymphoma
studi
group
ppllsg
financi
nation
scienc
centr
poland
grant
acut
lymphocyt
leukemia
normal
hematimetr
valu
time
diagnosi
mf
mininni
guitter
j
rossi
p
zubizarreta
felic
hematolog
oncolog
hospit
de
prof
dr
juan
p
garrahan
bueno
air
argentina
object
frequent
hematolog
malignaci
childhood
clinic
suspicion
allow
diagnosi
opportun
treatment
abnorm
blood
count
valu
observ
case
howev
normal
hematimetr
valu
detect
rare
case
aim
analyz
caus
consult
sign
symptom
time
diagnosi
time
elaps
first
symptom
diagnosi
outcom
patient
present
normal
blood
count
valu
method
clinic
record
laboratori
data
patient
diagnosi
disclos
normal
hematrimetr
valu
diagnosi
blood
count
consid
normal
wbc
count
without
neutropenia
blast
appropri
haemoglobin
level
age
platelet
count
reason
consult
sign
symptom
time
elaps
sinc
first
symptom
diagnosi
biolog
characterist
outcom
case
analyz
result
case
diagnos
present
initi
normal
blood
count
averag
age
rang
year
averag
time
elaps
symptom
diagnosi
month
rang
month
sign
symptom
observ
fever
bone
pain
asthenia
weight
loss
joint
compromis
respiratori
involv
abdomin
mass
pericardi
compromis
compromis
renal
compromis
skin
cn
immunophenotyp
precursor
case
complet
remiss
achiev
case
relaps
conclus
normal
blood
count
valu
observ
patient
fever
bone
compromis
frequent
clinic
find
show
extramedullar
compromis
sever
local
case
thu
normal
hematimetr
valu
diagnosi
thorough
clinic
examin
essenti
reach
accur
diagnosi
allogen
hematopoiet
stem
cell
transplant
infant
acut
lymphoblast
leukemia
retrospect
studi
pediatr
work
group
jshct
kato
hasegawa
k
koh
j
inagaki
k
kato
h
goto
j
takita
h
yabe
sawada
atsuta
k
kato
depart
pediatr
univers
tokyo
tokyo
japan
depart
hematolog
oncolog
hyogo
children
hospit
hyogo
japan
depart
hematologyoncolog
saitama
children
medic
center
saitama
japan
depart
pediatr
nation
kyushu
cancer
center
fukuoka
japan
depart
hematologyoncolog
ibaraki
children
hospit
ibaraki
japan
divis
medicin
kanagawa
children
medic
center
kanagawa
japan
depart
cell
transplant
regen
medicin
tokai
univers
isehara
japan
depart
hematologyoncolog
osaka
medic
center
research
institut
matern
child
health
osaka
japan
depart
hsct
data
manag
biostatist
nagoya
univers
nagoya
japan
depart
hematolog
oncolog
children
medic
center
japanes
red
cross
nagoya
first
hospit
nagoya
japan
object
infant
acut
lymphoblast
leukemia
wors
outcom
older
children
recent
clinic
studi
report
improv
result
infant
use
intensifi
chemotherapi
follow
hematopoiet
stem
cell
transplant
hsct
howev
optim
role
hsct
first
line
therapi
infant
defin
studi
obtain
fundament
inform
establish
standard
approach
infant
retrospect
analyz
hsct
infant
base
report
japan
societi
hematopoiet
cell
transplant
jshct
registri
method
total
infant
analyz
patient
select
accord
follow
criteria
diagnos
younger
year
old
allogen
hsct
perform
first
complet
remiss
n
hsct
perform
compar
infant
undertook
allogen
hsct
primari
induct
failur
pif
period
also
analyz
result
overal
surviv
os
year
group
receiv
hsct
pif
figur
p
signific
correl
outcom
factor
includ
donor
type
figur
condit
hsct
figur
age
hsct
initi
leukocyt
count
cytogenet
conclus
result
confirm
hsct
valuabl
option
infant
first
cr
although
compar
outcom
chemotherapi
late
complic
assess
patient
induct
mortal
childhood
acut
lymphoblast
leukaemia
combat
infect
experi
tertiari
care
centr
anwar
faizan
nyla
asghar
n
zia
ali
mari
collabor
taj
pa
hematologyoncolog
children
hospit
lahor
pakistan
pa
hematologyoncolog
lahor
gener
hospit
lahor
pakistan
pa
oncolog
royal
marsedan
cclg
podc
group
uk
london
unit
kingdom
object
main
object
studi
determin
common
caus
mortal
treatment
acut
lymphoblast
leukaemia
children
especi
induct
remiss
method
present
retrospect
descript
studi
conduct
patient
unit
haematologyoncolog
depart
children
hospit
lahor
novemb
octob
newli
regist
patient
year
age
expir
one
year
period
includ
mortal
data
collect
analyz
regard
age
gender
wbc
count
risk
categor
time
death
respect
treatment
phase
caus
death
lahor
group
protocol
acut
lymphoblast
leukemia
modifi
bfm
ukallxi
use
treatment
result
new
patient
regist
studi
period
die
treatment
major
year
age
thirti
patient
belong
high
risk
group
induct
die
remiss
die
initi
therapi
infect
alon
combin
factor
respons
death
patient
septicemia
pneumonia
document
patient
respect
ten
die
due
hemorrhag
due
progress
resist
diseas
conclus
infect
lead
caus
mortal
patient
studi
popul
key
solut
better
support
care
improv
decreas
patient
load
increas
nurs
staff
educ
famili
regard
infect
prevent
control
measur
acut
infect
central
nervou
system
cn
children
acut
leukemia
c
ruiz
gomez
j
rossi
guitter
c
la
rosa
e
alfaro
p
zubizarreta
felic
oncolog
hospit
de
prof
dr
juan
p
garrahan
bueno
air
argentina
infectolog
hospit
de
prof
dr
juan
p
garrahan
bueno
air
argentina
object
infect
frequent
caus
morbid
childhood
acut
leukemia
al
howev
cn
rare
local
high
mortal
aim
analyz
case
acut
infect
cn
patient
al
evalu
caus
immunocompromis
statu
moment
complic
method
al
case
diagnos
infect
cn
local
detect
case
review
clinic
record
featur
imag
patient
result
observ
case
infant
aml
etiolog
infect
bacteri
n
fungal
n
parasit
n
viral
n
without
germ
isol
highli
suspect
bacteri
n
patient
disclos
neutropenia
moment
event
n
n
caus
infect
occur
induct
patient
block
follow
hsct
receiv
mainten
therapi
nine
patient
present
seizur
also
neurolog
impair
present
show
mening
syndrom
csf
cultur
confirm
diagnosi
case
requir
biopsi
lesion
confirm
pathognomon
imag
laboratori
test
eight
patient
die
due
cn
infect
present
sequela
sever
remain
aliv
without
sequela
conclus
infect
occur
low
incid
al
symptom
mainli
seizur
neurolog
impair
fungal
infect
frequent
caus
increas
risk
found
induct
consolid
phase
confirm
mainli
csf
cultur
biopsi
patient
either
die
surviv
sequela
howev
one
third
aliv
good
perform
statu
preval
invas
fungal
infect
ifi
children
febril
neutropenia
year
treat
acut
prospect
studi
j
yadav
amitabh
r
seth
sk
kabra
ima
xess
jana
pediatr
india
institut
medic
scienc
delhi
india
pediatr
india
institut
medic
scienc
delhi
india
microbiolog
india
institut
medic
scienc
delhi
india
radiolog
india
institut
medic
scienc
delhi
india
object
object
studi
ascertain
preval
determin
etiolog
speci
invas
fungal
infect
ifi
outcom
dischargedeath
febril
neutropen
episod
children
acut
leukemia
year
age
group
chemotherapi
method
episod
febril
neutropenia
durat
hr
enrol
investig
fungal
infect
blood
investig
includ
galactomannan
antigen
aspergillu
serolog
bactac
fungal
cultur
radiolog
investig
done
serial
monitor
galactomannan
ag
done
assess
treatment
respons
revis
definit
ifi
european
organ
research
treatment
cancer
eortc
use
analysi
result
total
febril
neutropen
episod
screen
patient
fulfil
enrol
criteria
thirteen
ifi
per
eortc
thirteen
three
classifi
proven
seven
probabl
three
possibl
two
patient
die
admiss
common
fungal
isol
n
blood
candida
one
patient
trichosporon
radiolog
find
suggest
ifi
present
ten
patient
nodular
opac
lung
consist
find
galactomannan
antigen
posit
thirti
patient
conclus
studi
ongo
preliminari
analysi
show
candida
common
fungal
agent
caus
proven
ifi
aspergillu
commonli
associ
radiolog
abnorm
galactomannan
ag
found
use
earli
diagnosi
monitor
respons
antifung
therapi
prolong
neutropenia
day
consist
associ
risk
factor
ifi
eortc
guidelin
ifi
limit
children
nasalor
swab
urin
cultur
show
fungal
growth
ct
show
fungal
ball
solid
organ
kidney
posit
galactomannan
ag
test
also
benefit
antifung
therapi
suggest
like
system
fungal
infect
although
includ
criteria
ifi
platelet
count
avoid
traumat
lumbar
punctur
totadri
trehan
r
srinivasan
bansal
rk
marwaha
pediatr
hematolog
oncolog
postgradu
institut
medic
educ
research
chandigarh
india
cytolog
postgradu
institut
medic
educ
research
chandigarh
india
object
first
diagnost
lumbar
punctur
immens
prognost
signific
acut
lymphoblast
leukemia
studi
assess
whether
thrombocytopenia
associ
increas
risk
traumat
lumbar
punctur
tlp
newli
diagnos
patient
method
children
diagnos
januari
decemb
evalu
platelet
count
day
diagnost
lumbar
punctur
lp
cerebrospin
csf
statu
note
routin
practic
transfus
platelet
otherwis
well
children
prior
lp
procedur
done
short
sedat
midazolam
ketamin
result
children
median
age
year
rang
year
diagnos
evalu
csf
statu
first
diagnost
lumbar
punctur
lp
tlp
mean
platelet
count
patient
tlp
significantli
lower
lp
ntlp
p
platelet
count
pc
l
observ
patient
tlp
significantli
higher
ntlp
pc
p
platelet
count
l
seen
patient
tlp
ntlp
p
receiv
oper
curv
construct
predict
risk
tlp
base
platelet
count
area
curv
ci
platelet
count
l
time
lp
sensit
specif
predict
tlp
conclus
low
platelet
count
significantli
associ
risk
tlp
develop
countri
high
patient
load
occasion
inadequ
infrastructur
platelet
transfus
alway
given
prior
perform
lp
ensur
adequ
platelet
count
prior
first
lp
newli
diagnos
patient
necessari
avoid
tlp
subsequ
associ
morbid
possibl
increas
risk
relaps
feasibl
safeti
full
dose
anticoagul
therapi
act
children
treat
accord
cancer
institut
dfci
acut
lymphoblast
leukemia
consortium
therapi
protocol
md
bhatt
j
fowler
ak
chan
u
athal
pediatr
hematologyoncolog
mcmaster
children
hospit
hamilton
canada
object
guidelin
act
low
molecular
weight
heparin
lmwh
relat
platelet
count
examin
impact
thrombocytopenia
lmwh
dose
incid
bleed
children
lymphoblast
lymphoma
develop
thromboembol
te
therapi
accord
dfci
protocol
method
patient
record
review
demograph
detail
allll
te
diagnos
therapi
platelet
count
act
lmwh
dose
bleed
episod
institut
act
polici
full
dose
lmwh
platelet
hold
lmwh
platelet
also
hold
lmwh
hour
prior
invas
procedur
result
te
dvt
pe
csvt
cardiac
diagnos
patient
mean
age
year
f
diagnosi
year
one
patient
diagnos
te
induct
phase
consolid
ii
mean
time
te
month
allll
diagnosi
patient
receiv
lmwh
mean
durat
act
month
rang
month
platelet
measur
weekli
mean
count
occas
platelet
nadir
none
henc
patient
requir
lmwh
dose
adjust
thrombocytopenia
procedur
lp
cvl
insertionrevis
requir
withhold
lmwh
bleed
episod
although
asparaginas
held
te
diagnosi
patient
complet
schedul
dose
per
protocol
conclus
cohort
thrombocytopenia
interfer
lmwh
dose
time
te
diagnosi
could
like
explan
abil
administ
full
dose
lmwh
lack
bleed
complet
asparaginas
dose
act
suggest
act
feasibl
safe
children
allll
develop
te
dfci
consortium
therapi
protocol
significantli
higher
incid
allerg
reaction
intraven
compar
intramuscular
children
high
risk
acut
lymphoblast
leukemia
macdonald
k
kulkarni
bernstein
c
fernandez
yhap
pharmaci
pediatr
hematologyoncolog
iwk
health
centr
dalhousi
univers
halifax
canada
pediatr
hematologyoncolog
iwk
health
centr
dalhousi
univers
halifax
canada
object
quintessenti
part
treatment
acut
lymphoblast
leukemia
histor
administ
intramuscularli
im
children
oncolog
group
introduc
intraven
iv
administr
effort
improv
qualiti
life
patient
perhap
efficaci
patient
experi
allergi
requir
administr
im
erwinas
howev
pauciti
publish
data
allerg
reaction
iv
object
studi
determin
incid
allerg
reaction
iv
compar
im
patient
method
number
patient
receiv
im
januari
may
receiv
iv
june
decemb
determin
hospit
databas
ethic
approv
number
high
risk
hr
standard
risk
sr
patient
comput
hospit
drug
databas
util
determin
number
patient
receiv
erwinas
given
children
react
peg
comparison
incid
allerg
reaction
variou
patient
group
perform
fisher
exact
test
result
patient
manag
author
institut
studi
period
allerg
reaction
seen
patient
receiv
im
peg
receiv
iv
p
allerg
reaction
occur
significantli
frequent
patient
versu
p
allerg
reaction
iv
versu
im
peg
occur
significantli
frequent
patient
respect
p
conclus
present
studi
demonstr
significantli
increas
incid
allerg
reaction
patient
receiv
iv
peg
compar
im
peg
studi
need
confirm
observ
consid
chang
drug
administr
polici
non
steroid
drug
tolfenam
acid
enhanc
efficaci
chemotherapeut
agent
leukemia
cell
line
r
sutphin
eslin
connelli
u
sankpal
p
bowman
r
basha
pediatr
hematolog
oncolog
uf
health
cancer
center
orlando
usa
pediatr
univers
north
texa
health
scienc
center
fort
worth
usa
object
leukemia
common
malign
affect
children
current
chemotherapi
effect
associ
mani
deleteri
effect
object
studi
test
novel
strategi
enhanc
respons
chemotherapi
without
addit
morbid
recent
demonstr
first
time
tolfenam
acid
ta
nsaid
inhibit
leukemia
cell
prolifer
target
specif
protein
sp
transcript
factor
evalu
efficaci
ta
enhanc
chemotherapeut
respons
doxorubcin
dox
vincristin
vin
leukemia
cell
method
jurkat
reh
molt
cell
grown
presenc
ta
dox
vin
ta
doxvin
cell
viabil
measur
h
use
celltit
glo
express
survivin
determin
western
blot
analysi
apoptosi
monitor
determin
express
western
blot
activ
kit
apoptot
cell
popul
stain
use
flow
cytometri
result
combin
ta
dox
vin
caus
significantli
higher
cell
growth
inhibit
compar
individu
agent
ta
inhibit
express
survivin
chemotherapeut
agent
effect
survivin
confirmatori
result
show
apoptot
marker
express
activ
annexin
v
posit
cell
increas
h
effect
propos
combin
cell
cycl
phase
distribut
marker
dna
damag
repair
evalu
conclus
result
confirm
ta
combin
doxorubicin
vincristin
effect
inhibit
leukemia
cell
growth
studi
evalu
mechan
action
propos
combin
vivo
assay
current
investig
studi
suggest
target
sp
protein
ta
may
enhanc
effect
standard
chemotherapeut
agent
vitro
dexamethason
sensit
acut
lymphoblast
leukemia
cell
influenc
interven
hydrocortison
l
warri
mm
van
den
heuvel
eibrink
im
ari
r
pieter
elt
van
den
akker
ml
den
boer
pediatr
oncolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
pediatr
endocrinolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
object
base
recent
studi
hypothes
dexamethason
induc
neuropsycholog
side
effect
mood
behavior
cognit
children
acut
lymphoblast
leukemia
caus
dexamethason
induc
cortisol
deplet
mineralocorticoid
receptor
mr
brain
therefor
feasibl
side
effect
could
amelior
intervent
hydrocortison
exclud
interfer
efficaci
glucocorticoid
cell
perform
current
studi
method
investig
respons
leukem
cell
line
fresh
patient
leukem
cell
dexamethason
prednisolon
presenc
physiolog
dose
hydrocortison
perform
addit
express
mr
glucocorticoid
receptor
gr
leukem
cell
differ
subtyp
studi
gene
express
profil
valid
quantit
pcr
result
vitro
glucocorticoid
sensit
glucocorticoid
resist
sensit
leukem
cell
line
patient
cell
independ
ad
dose
hydrocortison
mr
express
level
leukem
patient
cell
low
compar
gr
express
level
mr
express
wide
variat
patient
rel
higher
subtyp
differ
sensit
prednisolon
dexamethason
found
addit
hydrocortison
subtyp
patient
cell
subtyp
conclus
present
studi
show
like
mr
activ
hydrocortison
interfer
efficaci
glucocorticoid
cell
find
enabl
current
ongo
clinic
random
studi
hypothes
hydrocortison
decreas
neuropsycholog
side
effect
dexamethason
children
function
genom
wide
enrich
associ
analysi
vincristin
neuropathi
jl
renbarg
ch
li
j
skile
l
li
pediatr
indiana
univers
school
medicin
indianapoli
usa
medic
molecular
genet
indiana
univers
school
medicin
indianapoli
usa
object
vincristin
among
commonli
use
anticanc
agent
littl
known
regard
disposit
optim
dose
vincristin
associ
highli
variabl
cumul
peripher
neuropathi
vipn
often
treat
pain
medic
andor
dose
reduct
may
compromis
efficaci
studi
carri
function
enrich
analysi
use
data
across
human
genom
evalu
associ
genom
variat
vipn
children
acut
lymphoblast
leukemia
method
germlin
dna
subject
enrol
pog
genotyp
use
affymetrix
genechip
human
map
set
vipn
captur
use
nci
ctcae
grade
use
cutoff
vipn
gwa
analysi
complet
report
separ
three
function
analys
conduct
gwa
result
first
focus
gene
target
drug
treat
pain
manifest
neuropathi
second
analysi
focus
snp
gene
region
differenti
express
fibrosarcoma
cell
line
vincristin
treatment
third
analysi
focus
snp
report
express
quantifi
trait
loci
eqtl
cerebellar
tissu
genotyp
tissu
express
databas
result
drug
target
analysi
snp
enrich
gene
fibrosarcoma
cell
line
express
experi
snp
associ
neuropathi
p
includ
snp
identifi
origin
gwa
eqtl
analysi
cerebellar
tissu
identifi
two
addit
snp
associ
vipn
conclus
function
enrich
analysi
identifi
number
gene
across
human
genom
may
associ
vipn
inform
signific
potenti
clinic
relev
given
widespread
use
import
drug
treat
childhood
cancer
genet
determin
vincristin
neuropathi
children
acut
lymphoblast
leukemia
jl
skile
ch
li
l
li
jl
renbarg
pediatr
indiana
univers
school
medicin
indianapoli
usa
medic
molecular
genet
indiana
univers
school
medicin
indianapoli
usa
object
vincristin
among
commonli
use
anticanc
agent
howev
littl
known
regard
disposit
optim
dose
gap
knowledg
lead
neg
clinic
outcom
toxic
due
drug
overdos
lack
efficaci
due
dose
vincristin
associ
highli
variabl
cumul
peripher
neuropathi
vipn
carri
associ
analysi
explor
associ
germlin
variant
vipn
pediatr
acut
lymphoblast
leukemia
patient
method
germlin
dna
n
subject
enrol
pog
genotyp
use
affymetrix
genechip
human
map
set
qualiti
control
qc
perform
remov
unreli
sampl
marker
popul
stratif
approach
appli
adjust
potenti
ethnic
effect
vipn
captur
use
ctcae
sensori
motor
neuropathi
primari
outcom
defin
develop
neuropathi
grade
secondari
outcom
time
develop
neuropathi
neuropath
pain
snp
associ
evalu
three
genet
model
addit
domin
recess
snp
effect
vipn
adjust
clinic
demograph
popul
stratif
variabl
cox
regress
analys
result
qc
total
snp
individu
remain
analysi
use
cox
model
associ
analysi
total
snp
gene
identifi
across
primari
secondari
outcom
gene
potenti
biolog
relev
includ
valid
independ
cohort
ongo
conclus
number
gene
across
human
genom
may
associ
vipn
inform
signific
potenti
clinic
relev
given
widespread
use
import
drug
treat
childhood
cancer
genet
variant
vincristin
transport
neurotox
marker
childhood
acut
lymphoblast
leukemia
echebarria
n
j
uriz
p
navaja
genet
physic
anthropolog
anim
physiolog
univers
basqu
countri
leioa
spain
univers
hospit
cruce
unit
pediatr
hematologyoncolog
bilbao
spain
univers
basqu
countri
depart
genet
physic
anthropolog
anim
physiolog
leioa
spain
servic
hematolog
hemotherapi
univers
hospit
cruce
bilbao
spain
depart
pediatr
univers
hospit
donostia
san
sebastian
spain
depart
oncohematolog
univers
hospit
la
paz
madrid
spain
object
acut
lymphoblast
leukemia
common
pediatr
malign
therapeut
advanc
increas
surviv
due
part
standard
treatment
protocol
vincristin
use
differ
phase
treatment
induct
intensif
reinduct
howev
individu
experi
neurotox
marker
predict
vincristin
narrow
therapeut
rang
pharmacogenet
studi
may
use
predict
toxic
studi
perform
date
conflict
result
gene
mapt
recent
group
found
new
methotrex
toxic
marker
analyz
depth
gene
involv
methotrex
transport
gene
involv
vincristin
transport
could
also
role
vincristin
toxic
aim
present
studi
analyz
depth
role
genet
variat
gene
involv
vincristin
transport
marker
neurotox
larg
cohort
children
homogen
treat
method
dna
extract
remiss
blood
sampl
pediatr
patient
homogen
treat
lalshop
protocol
studi
snp
cover
gene
involv
vincristin
transport
illumina
goldeng
platform
associ
snp
neurotox
analyz
use
fisher
exact
test
result
result
suggest
pharmacogenet
studi
may
use
neurotox
predict
adjust
vincristin
treatment
pediatr
patient
conclus
conclus
polymorph
vincristin
pathway
gene
may
use
neurotox
predict
adjust
vincristin
treatment
pediatr
patient
project
support
retic
basqu
govern
associ
polymorph
gene
methotrex
therapi
childhood
acut
lymphoblast
leukemia
j
yang
h
jiang
h
li
hematologyoncolog
shanghai
children
hospit
shanghai
china
object
investig
associ
gene
polymorph
mtx
relat
toxic
method
case
enrol
depart
februari
januari
gene
polymorph
detect
treatment
plasma
mtx
concentr
liver
kidney
function
peripher
blood
cell
count
detect
time
hour
data
analyz
spss
result
gene
polymorph
associ
mtx
toxic
risk
hepatotox
myelosuppress
time
higher
p
p
signific
differ
gene
polymorph
elimin
delay
mtx
prognosi
p
conclus
genet
polymorph
associ
hepatotox
myelosuppress
hdmtx
chemotherapi
would
use
risk
indic
toxic
signific
associ
found
among
plasma
mtx
concentr
elimin
delay
prognosi
childhood
gene
polymorph
effect
cranial
radiat
therapi
crt
bodi
mass
index
bmi
treatment
acut
lymphoblast
leukemia
children
exploratori
analysi
athal
nayiag
j
badhiwala
u
athal
depart
clinic
epidemiolog
biostatist
mcmaster
univers
hamilton
canada
mcmaster
children
hospit
hamilton
health
scienc
hamilton
canada
depart
pediatr
michael
degroot
school
medicin
hamilton
canada
depart
pediatr
mcmaster
univers
hamilton
canada
object
crt
shown
associ
obes
survivor
childhood
howev
impact
bmi
therapi
well
studi
object
studi
determin
effect
crt
bmi
children
age
receiv
therapi
accord
cancer
institut
protocol
mcmaster
children
hospit
method
retrospect
chart
review
conduct
collect
baselin
demograph
age
gender
risk
categori
therapi
steroid
type
crt
anthropometr
data
five
time
point
therapi
month
studi
impact
factor
bmi
z
score
calcul
accord
center
diseas
control
prevent
guidelin
pair
independ
sampl
use
compar
bmi
within
group
respect
result
total
children
mean
age
month
includ
male
receiv
dexamethason
receiv
crt
signific
increas
bmi
month
end
therapi
month
whole
cohort
vs
p
patient
receiv
crt
significantli
lower
bmi
month
first
time
point
follow
crt
compar
without
crt
p
moreov
rate
chang
bmi
month
two
group
vs
p
differ
covari
significantli
impact
bmi
six
month
differ
bmi
z
score
month
patient
without
crt
conclus
patient
receiv
crt
tend
signific
reduct
bmi
soon
administr
effect
transient
observ
suggest
need
differ
nutrit
strategi
patient
receiv
crt
research
need
confirm
find
outcom
young
children
cn
posit
acut
lymphoblast
leukemia
treat
without
cranial
radiotherapi
experi
wilejto
gupta
g
di
giusepp
b
spiegler
j
hitzler
abla
hospit
sick
children
toronto
canada
psycholog
hospit
sick
children
toronto
canada
object
acut
lymphoblast
leukemia
common
cancer
children
treat
combin
system
chemotherapi
cranial
radiotherapi
crt
increas
recognit
sequela
crt
modern
trial
larg
omit
prophylact
crt
patient
cn
diseas
diagnosi
howev
decis
omit
crt
less
clear
children
year
age
particularli
challeng
subgroup
endocrin
consequ
crt
except
devast
primari
aim
studi
describ
outcom
young
children
age
cn
posit
treat
without
crt
method
retrospect
cohort
studi
children
age
diagnos
januari
may
hospit
sick
children
data
abstract
chart
review
studi
approv
institut
review
board
result
children
met
inclus
criteria
present
cn
involv
diagnosi
one
child
treat
upfront
crt
part
bone
marrow
transplant
bmt
condit
form
therapi
intensif
cohort
includ
tripl
chemotherapi
dexamethason
high
dose
methotrex
patient
aliv
last
three
children
die
treatment
relat
toxic
one
child
isol
cn
relaps
salvag
bmt
conclus
cn
leukemia
young
children
effect
treat
intensifi
system
chemotherapi
without
crt
maintain
favor
outcom
studi
add
grow
bodi
literatur
support
omiss
crt
modern
protocol
attempt
minim
acut
long
term
toxic
underweight
weight
loss
neg
influenc
outcom
children
acut
lymphoblast
leukemia
den
ho
smf
pluijm
ha
de
ml
te
winkel
elt
van
den
akker
p
hoogerbrugg
h
van
den
berg
ja
leeuw
mca
bruin
brester
ajp
veerman
r
pieter
mm
van
den
pediatr
oncolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
pediatr
oncolog
dutch
childhood
oncolog
group
hagu
netherland
endocrinolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
pediatr
oncolog
radboud
univers
medic
center
nijmegen
nijmegen
netherland
pediatr
oncolog
academ
medic
center
amsterdam
netherland
pediatr
oncolog
beatrix
children
hospit
univers
medic
centr
groningen
groningen
netherland
pediatr
oncolog
univers
medic
center
utrecht
utrecht
netherland
pediatr
oncolog
children
hospit
leiden
univers
medic
center
leiden
netherland
pediatr
oncolog
vu
univers
medic
center
amsterdam
netherland
pediatr
oncolog
princess
maxima
center
utrecht
netherland
purpos
studi
influenc
chang
bodi
mass
index
bmi
outcom
pediatr
patient
treat
accord
protocol
dutch
childhood
oncolog
group
dcog
patient
method
data
bodi
composit
prospect
select
nation
cohort
newli
diagnos
dutch
pediatr
patient
n
age
year
treat
bmi
express
standard
deviat
score
sd
categor
overweight
sd
normal
weight
sd
underweight
sd
dual
absorptiometri
dxa
scan
perform
nest
singl
center
cohort
assess
contribut
fat
lean
bodi
mass
bmi
bodi
composit
reassess
week
treatment
outcom
measur
defin
event
free
surviv
ef
cumul
incid
relaps
cir
overal
surviv
os
multivari
analysi
perform
examin
associ
bmi
surviv
result
underweight
patient
diagnosi
increas
risk
relaps
hazard
ratio
hr
ci
increas
mortal
rate
hr
bmi
decreas
first
week
treatment
associ
higher
mortal
rate
hr
higher
relaps
rate
hr
dxa
reveal
bmi
decreas
consist
loss
lean
bodi
mass
patient
show
increas
fat
conclus
underweight
diagnosi
influenc
likelihood
relaps
bmi
decreas
seem
consist
mainli
muscl
loss
associ
decreas
overal
surviv
children
oestradiol
dhea
testosteron
modul
osteocyt
vegf
secret
vitro
implic
pathogenesi
osteonecrosi
adam
jenney
hiscox
j
gregori
b
evan
institut
molecular
experiment
medicin
cardiff
univers
cardiff
unit
kingdom
paediatr
oncolog
children
hospit
wale
cardiff
unit
kingdom
object
interrupt
vegf
signal
major
patholog
mechan
osteonecrosi
disabl
side
effect
therapi
acut
lymphoblast
leukaemia
adolesc
femal
greatest
risk
relationship
sex
steroid
puberti
vegf
signal
osteocyt
previous
document
previous
demonstr
dexamethason
reduc
osteocyt
vegfsecret
hypothesis
sex
steroid
may
influenc
osteocyt
prolifer
andor
vegf
secret
either
via
nuclear
steroid
receptor
via
pathway
method
osteocyt
incub
hour
oestradiol
dhea
testosteron
presenc
absenc
dexamethason
cell
number
mt
vegfsecret
elisa
measur
mechan
investig
blockad
oestrogen
receptor
er
select
oestrogen
receptor
modul
serm
tamoxifen
fulvestr
inhibit
convers
dhea
oestradiol
aromatas
inhibitor
anastrozol
effect
dexamethason
er
well
protein
receptor
express
also
measur
qrtpcr
result
oestradiol
dhea
significantli
reduc
osteocyt
cell
number
reduct
respect
p
serm
oestradiol
anastrozol
dhea
effect
abolish
oestradiol
significantli
increas
vegf
secret
p
p
respect
serm
anastrozol
amelior
increas
suggest
firstli
oestradiol
act
via
genom
pathway
secondli
dhea
exert
independ
activ
rather
convers
oestradiol
dexamethason
prevent
increas
vegfsecret
caus
fold
reduct
p
er
alpha
gene
express
effect
testosteron
cell
number
vegf
secret
demonstr
conclus
studi
reveal
novel
interact
sex
steroid
dexamethason
osteocyt
angiogenesi
may
contribut
understand
high
incid
osteonecrosi
adolesc
patient
parent
occup
area
remot
lead
social
dispar
surviv
childhood
leukemia
databas
kourti
sergentani
c
perlep
e
papathoma
g
tsilimido
e
kontogeorgi
baka
moschovi
polychronopoul
v
sidi
e
hatzipant
e
stiakaki
e
petrid
pediatr
hematolog
oncolog
unit
depart
pediatr
hippokr
gener
hospit
thessaloniki
greec
dept
hygien
epidemiolog
medic
statist
univers
athen
medic
school
athen
greec
depart
pediatr
pan
agl
kyriak
children
hospit
athen
greec
unit
first
depart
pediatr
athen
univers
medic
school
aghia
sophia
gener
children
hospit
athen
greec
depart
pediatr
athen
univers
medic
school
aghia
sophia
gener
children
hospit
athen
greec
pediatr
hematolog
oncolog
unit
depart
pediatr
aristotl
univers
school
medicin
ahepa
gener
hospit
thessaloniki
greec
depart
pediatr
univers
hospit
heraklion
thessaloniki
greec
object
advanc
treatment
greatli
improv
surviv
children
suffer
leukemia
last
decad
concern
rais
howev
regard
social
dispar
surviv
due
potenti
interfer
statu
se
health
care
access
compon
treatment
avail
primari
data
two
databas
along
follow
systemat
review
literatur
aim
shed
light
effect
parent
occup
area
remot
term
ruralurban
statu
upon
surviv
childhood
leukemia
method
nation
cancer
institut
surveil
epidemiolog
end
result
program
seer
data
critic
along
greek
nationwid
registri
childhood
hematolog
malign
narechem
data
wherea
systemat
review
literatur
contribut
subsequ
addit
studi
arm
publish
evid
overal
surviv
main
outcom
model
appropri
use
calcul
pool
effect
estim
result
largest
ever
analys
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
case
less
privileg
parent
occup
predict
consider
poorer
surviv
pool
rr
ci
wherea
respect
find
childhood
aml
reach
signific
statist
signific
associ
observ
regard
rural
vs
urban
place
resid
surviv
either
pool
rr
ci
aml
pool
rr
ci
conclus
lower
occup
relat
se
may
unfavor
impact
surviv
least
less
aggress
varieti
function
poor
complianc
refus
abandon
treatment
modifi
attitud
health
care
provid
inadequ
health
insur
access
qualiti
health
care
contemporari
satisfactori
transport
infrastructur
may
underli
minim
non
signific
associ
resid
remot
comparison
efficaci
safeti
econom
cost
vindesin
vincristin
newli
diagnos
pediatr
acut
lymphoblast
leukemia
retrospect
analysi
j
zhang
zhang
x
li
rm
jin
pediatr
union
hospit
tongji
medic
colleg
huazhong
univers
scienc
techn
wuhan
china
object
botan
vincaal
kaloidsm
vindesin
vd
vincristin
vcr
worldwid
use
compon
chemotherapi
although
associ
seriou
advers
effect
compar
efficaci
toxic
econom
cost
vd
vcr
induct
intensif
children
newli
diagnos
acut
lymphoblast
leukemia
chines
children
leukemia
group
cclg
protocol
hospit
method
archiv
medic
record
review
children
diagnos
hospit
trial
receiv
vd
administ
vcr
per
week
induct
intensif
result
may
octob
children
year
age
vd
vs
vcr
newli
diagnos
exclud
matur
includ
cr
rate
similar
vd
vcr
respect
p
result
treatment
group
similar
overal
surviv
vd
vs
vcr
p
surviv
vs
p
mortal
trm
continu
complet
remiss
children
lower
presenc
vd
vcr
vs
p
total
case
includ
casestim
vd
group
casestim
vcr
group
record
advers
event
statist
vd
lower
rate
grade
decreas
hemoglobin
p
thrombocytopenia
p
vcr
total
neurotox
p
three
case
vcr
group
occur
unbear
paresthesia
signific
movement
disord
disappear
vd
expens
hospit
lower
vd
vcr
rmb
vs
rmb
p
conclus
given
dose
vd
similar
antileukem
activ
compar
vcr
caus
less
mortal
continu
complet
remiss
children
decreas
rate
neurotox
hematotox
reduc
expens
hospit
worthi
clinic
studi
use
childhood
acut
lymphoblast
leukemia
middl
east
neighbor
countri
prospect
intern
collabor
studi
middl
east
childhood
cancer
allianc
mecca
alnass
n
almulla
p
chandra
khattab
f
madanat
farranoush
e
torfa
z
g
zain
muwakkit
mahmoud
tuncer
h
barsaoui
r
arceci
howard
kulozik
ravindranath
g
reaman
mecca
middl
east
childhood
cancer
allianc
doha
qatar
object
middl
east
childhood
cancer
allianc
mecca
establish
compris
member
institut
countri
middl
east
surround
area
littl
known
childhood
middl
east
studi
fund
qatar
nation
research
fund
undertaken
mecca
initi
effort
collabor
data
collect
provid
clinic
laboratori
molecular
genet
character
induct
toxic
outcom
data
children
middl
east
method
clinic
laboratori
molecular
genet
character
induct
toxic
outcom
patient
januari
prospect
collect
institut
middl
east
countri
enter
induct
phase
laboratori
studi
includ
cytogenet
done
local
institut
result
voluntarili
enrol
patient
mean
age
year
male
repres
diagnosi
cn
diseas
distribut
common
genet
abnorm
reflect
similar
percentag
hyperdiploidi
lower
percentag
transloc
compar
larg
seri
report
western
popul
clinic
criteria
lowstandard
risk
intermedi
risk
major
patient
receiv
care
local
region
hospit
patient
excel
induct
respons
chemotherapi
overal
complet
remiss
rate
induct
toxic
accept
conclus
conclus
believ
studi
provid
proof
principl
collabor
clinic
research
central
data
repositori
feasibl
middl
east
despit
limit
incomplet
studi
provid
first
comprehens
baselin
data
clinic
characterist
laboratori
evalu
molecular
genet
character
induct
outcom
toxic
work
plan
uncov
possibl
biolog
differ
region
improv
diagnosi
manag
surviv
children
leukemia
south
africa
lesotho
stefan
van
zyl
dk
stone
paediatr
child
health
stellenbosch
univers
cape
town
south
africa
paediatr
child
health
free
state
univers
bloemfontein
south
africa
object
leukemia
remain
common
childhood
cancer
south
africa
lesotho
cure
rate
acut
lymphoblast
leukemia
develop
countri
reach
africa
pauciti
data
regard
surviv
children
leukemia
aim
studi
calcul
surviv
rate
children
diagnos
treat
south
africa
lesotho
method
retrospect
studi
includ
children
year
diagnos
treat
januari
decemb
centr
south
africa
tygerberg
hospit
cape
town
universita
hospit
bloemfontein
patient
lesotho
diagnos
confirm
certifi
nation
health
laboratori
servic
south
africa
result
patient
treat
lesotho
sa
male
femal
averag
age
diagnosi
month
rang
month
black
children
follow
color
popul
patient
final
white
patient
overal
surviv
group
south
african
centr
lesotho
follow
time
month
surviv
black
children
lowest
follow
white
children
color
children
best
surviv
rate
patient
treat
protocol
conclus
surviv
rate
children
diagnos
south
africa
lesotho
low
show
signific
differ
corel
ethnic
group
clinic
genet
research
requir
standard
risk
childhood
acut
lymphoblast
leukemia
morocco
experi
case
treat
singl
center
khattab
elkababri
kili
l
hessissen
elkhorassani
u
athal
pediatr
univers
moham
rabat
morocco
pediatr
mcmaster
univers
hamilton
ontario
canada
object
event
free
surviv
childhood
acut
lymphoblast
leukemia
morocco
main
caus
failur
abandon
drug
almost
patient
nation
therapi
protocol
maral
develop
base
french
protocol
frall
herein
report
result
standard
risk
sr
group
method
treatment
includ
induct
consolid
intensif
interphas
cours
month
follow
mainten
year
chemotherapi
consist
vincristin
doxorubicin
corticosteroid
high
methotrex
cyclophosphamid
cytarabin
dose
tripl
intrathec
therapi
children
yr
diagnos
de
novo
wbc
absenc
central
nervou
system
diseas
categor
sr
dedic
team
physician
nurs
social
worker
data
manag
supervis
ambulatori
therapi
patient
free
access
medic
ngo
hospit
health
insur
weekli
team
meet
review
patient
manag
data
problem
arrang
aid
patient
result
total
patient
diagnos
sr
median
age
year
f
ratio
fab
classif
case
remiss
rate
refractori
therapi
abandon
rate
overal
mortal
patient
relaps
median
time
month
diagnosi
median
month
event
free
overal
surviv
respect
conclus
compar
histor
data
maral
protocol
result
increas
surviv
children
sr
low
abandon
rate
achiev
close
dedic
team
commit
drug
procur
social
support
patient
develop
evalu
qualiti
life
acut
lymphoblast
leukaemia
equal
questionnair
measur
effect
corticosteroid
qualiti
life
adam
sherratt
johnson
j
tomlin
j
grainger
jenney
paediatr
oncolog
children
hospit
wale
cardiff
unit
kingdom
tya
haematolog
christi
hospit
manchest
unit
kingdom
paediatr
haematolog
manchest
children
hospit
manchest
unit
kingdom
object
use
corticosteroid
particularli
dexamethason
within
acut
lymphoblast
leukaemia
protocol
contribut
greatli
excel
surviv
rate
howev
without
cost
addit
physic
side
effect
corticosteroid
influenc
behaviour
mood
cognit
function
lead
impair
qualiti
life
qol
patient
ukal
randomis
mainten
therapi
without
dexamethason
puls
surviv
qol
primari
outcom
measur
aim
studi
develop
qol
measur
sensit
effect
corticosteroid
may
detect
potenti
differ
qol
patient
receiv
dexamethason
method
patient
age
year
parent
children
age
year
receiv
mainten
therapi
uk
centr
invit
particip
studi
compris
stage
focu
group
interview
ask
particip
describ
experi
dexamethason
theme
identifi
formul
version
equal
b
version
email
electron
healthcar
profession
patient
evalu
import
relev
question
amend
made
creat
version
c
cognit
interview
confirm
face
valid
explor
question
interpret
modif
made
defin
version
result
six
parent
eight
patient
attend
focu
groupsinterview
interpret
phenomenolog
analysi
transcript
identifi
patient
feel
dexamethason
advers
effect
behaviour
appetit
bodi
imag
mood
famili
relationship
healthcar
profession
patientspar
complet
electron
survey
lead
amend
question
face
valid
confirm
cognit
interview
patient
equal
compris
question
within
domain
version
conclus
equal
first
qol
measur
corticosteroid
complet
minut
children
age
year
valid
reliabl
test
undertaken
within
ukal
outcom
pediatr
acut
lymphoblast
leukemia
patient
undergo
chemotherapi
use
regimen
protocol
univers
philippin
philippin
gener
hospit
arca
e
melendr
alcasaba
p
fajardo
medina
pediatr
univers
philippin
manila
philippin
purpos
determin
impact
surviv
rate
toxic
abandon
treatment
among
childhood
acut
lymphoblast
leukemia
patient
use
low
incom
countri
lic
regimen
chemotherapi
protocol
univers
philippin
philippin
gener
hospit
method
medic
record
newli
diagnos
patient
june
septemb
age
year
review
demograph
data
collect
treatment
outcom
evalu
studi
endpoint
decemb
includ
death
treatment
refus
abandon
relaps
phase
treatment
result
patient
diagnos
june
septemb
diagnosi
immunophenotyp
morpholog
patient
refus
treatment
patient
underw
lic
regimen
without
radiat
male
femal
ratio
age
rang
year
mean
year
nci
standard
risk
high
risk
one
cn
involv
diagnosi
none
testicular
involv
start
therapi
remiss
induct
n
ten
patient
die
induct
studi
endpoint
complet
therapi
mainten
relaps
occur
patient
cn
n
bone
marrow
n
fifteen
abandon
treatment
seventeen
patient
die
treatment
due
sepsi
intracrani
bleed
end
studi
period
patient
aliv
n
n
remiss
conclus
lic
choic
therapi
consid
avail
support
care
asid
good
infect
control
access
blood
product
databas
financi
social
work
support
imper
surviv
rate
among
patient
still
low
howev
use
lic
regimen
associ
improv
surviv
rate
reduct
toxic
death
abandon
bioimped
analysi
bia
anthropometri
prognosi
complic
graft
function
hematopoiet
stem
cell
transplant
hsct
cancer
children
g
tseitlin
vashura
konovalova
balashov
maschan
rehabilit
dmitri
rogachev
feder
research
centr
pediatr
hematolog
oncolog
immunolog
moscow
russia
transplant
dmitri
rogachev
feder
research
centr
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
hsct
becom
establish
treatment
malign
hematolog
diseas
solid
malign
autoimmun
diseas
goal
assess
valu
bia
anthropometr
indic
prognost
factor
sever
complic
steroid
diabet
eros
ulcer
duodenitisenterocol
bleed
gastroenterocol
day
destruct
pancreat
pancreanecrosi
diseas
hemorrhag
cystiti
day
renal
insuffici
toxicodermia
day
toxic
infecti
encephalopathi
heavi
toxic
polyneuropathi
mukos
higher
degre
septic
shock
hsct
method
patient
examin
period
start
condit
till
day
hsct
bia
anthropometri
use
children
age
anthropometri
without
bia
use
children
age
month
year
old
result
patient
follow
index
condit
phase
angl
pa
ratio
activ
cell
masslean
bodi
mass
acmlbm
shoulder
muscl
circumfer
smc
percentil
risk
sever
complic
significantli
higher
earli
period
hsct
p
similarli
patient
pa
acmlbm
risk
graft
hypofunct
consider
higher
compar
patient
pa
p
conclus
low
pa
acmlbm
smc
condit
prognost
factor
sever
complic
graft
hypofunct
hsct
low
pa
acmlbm
smc
symptom
malnutrit
malnutrit
condit
signific
factor
high
risk
sever
complic
graft
hypofunct
hsct
thu
nutrit
statu
correct
includ
mandatori
compon
children
prepar
hsct
bia
good
method
assess
nutrit
statu
prognos
risk
sever
complic
graft
hypofunct
hsct
quantif
circul
tumor
dna
plasma
sarcoma
patient
krumbholz
b
steif
semper
g
koehler
u
dirksen
metzler
depart
pediatr
univers
hospit
erlangen
erlangen
germani
depart
patholog
univers
hospit
muenster
muenster
germani
depart
pediatr
hematolog
oncolog
univers
hospit
muenster
muenster
germani
depart
pediatr
univers
hospit
erlangen
erlangen
germani
object
quantif
tumor
specif
molecular
marker
diagnost
tool
therapi
monitor
acut
chronic
leukemia
respons
assess
solid
tumor
mainli
base
imag
studi
particularli
sarcoma
lack
secret
tumor
associ
protein
marker
releas
metabolit
blood
stream
howev
major
sarcoma
character
specif
chromosom
transloc
repres
potenti
marker
diagnost
purpos
also
assess
therapi
respons
quantif
circul
tumor
dna
ctdna
patient
blood
sampl
method
correl
ewe
sarcoma
es
volum
evalu
nod
scid
gamma
mous
xenotransplant
model
es
cell
inject
intraven
blood
sampl
taken
week
tumor
growth
ctdna
quantifi
plasma
fusion
sequenc
span
probe
set
use
high
sensit
droplet
digit
pcr
optim
assay
plasma
sampl
es
patient
treatment
collect
analyz
comparison
tumor
regress
assess
mrt
result
abl
document
tumor
growth
quantif
fusion
sequenc
plasma
xenotranspl
mice
tumor
growth
correl
increas
ctdna
level
percentag
fusion
dna
fragment
circul
dna
molecul
reach
serum
sampl
patient
es
treatment
initi
tumor
size
regress
induct
therapi
could
monitor
ctdna
copi
number
conclus
chromosom
transloc
repres
genom
marker
enabl
highli
sensit
dna
quantif
uniqu
sequenc
composit
fusion
site
enabl
superior
specif
compar
singl
nucleotid
mutat
predominantli
identifi
common
epitheli
cancer
convent
blood
sampl
volum
suffici
allow
detect
quantif
circul
tumor
dna
experiment
xenotranspl
mous
model
es
patient
treatment
monitor
angiogen
factor
relev
patient
osteosarcoma
tabon
l
selva
p
h
pacquement
c
oukhatar
chevanc
n
mc
le
deley
paediatr
armand
trousseau
hospit
pari
franc
paediatr
oncolog
gustav
roussi
institut
villejuif
franc
medic
oncolog
curi
institut
pari
franc
biochemistri
armand
trousseau
hospit
pari
franc
institut
paediatr
haematolog
oncolog
leon
cancer
centr
lyon
franc
paediatr
oncolog
curi
institut
pari
franc
clinic
studi
unicanc
pari
franc
biostatist
gustav
roussi
institut
villejuif
franc
paediatr
oncolog
hautepierr
hospit
strasbourg
franc
object
osteosarcoma
common
malign
bone
tumour
adolesc
young
adult
angiogenesi
essenti
progress
metastasi
solid
tumor
relev
monitor
angiogen
factor
patient
osteosarcoma
still
need
address
aim
studi
determin
level
vascular
endotheli
growth
factor
vegf
basic
fibroblast
growth
factor
bfgf
patient
osteosarcoma
investig
whether
biomark
diagnosi
well
kinet
treatment
associ
diseas
characterist
provid
prognost
inform
method
patient
local
metastat
osteosarcoma
regist
os
clinic
trial
prospect
includ
level
vegf
bfgf
serum
plasma
bfgf
urin
measur
elisa
diagnosi
surgeri
end
treatment
result
sampl
diagnosi
avail
patient
male
year
local
diseas
lung
doubt
lesion
metastas
median
year
surviv
se
high
valu
serum
pgml
plasma
pgml
vegf
observ
patient
respect
serum
plasma
vegf
level
correl
r
p
high
vegf
level
frequent
larg
tumor
cm
p
observ
signific
vegf
decreas
chemotherapi
p
variat
associ
histolog
respons
outcom
signific
associ
found
blood
urin
level
bfgf
clinic
characterist
histolog
respons
outcom
conclus
high
level
angiogen
factor
detect
bodi
fluid
osteosarcoma
patient
clinic
util
measur
demonstr
receptor
tyrosin
kinas
ron
therapeut
target
metastat
ewe
sarcoma
c
schleithoff
tillmann
b
lechtap
c
schaefer
h
g
hempel
u
dirksen
j
potratz
paediatr
haematologyoncolog
univers
children
hospit
germani
institut
pharmaceut
medic
chemistri
germani
gener
paediatr
univers
children
hospit
germani
object
novel
treatment
option
ewe
sarcoma
patient
metastat
diseas
urgent
need
yet
therapeut
target
receptor
tyrosin
kinas
rtk
cell
prolifer
improv
prognosi
mani
cancer
role
rtk
cell
migrat
metastasi
undisput
remain
less
well
understood
also
emerg
rtk
network
target
inhibit
remain
elucid
previou
work
suggest
rtk
ron
possibl
resist
factor
therapi
paediatr
sarcoma
object
therefor
elucid
target
ron
function
paediatr
sarcoma
metastas
method
see
result
ron
express
ewe
sarcoma
mrna
express
level
primari
tumour
patient
metastas
significantli
higher
patient
local
diseas
support
role
metastasi
ron
protein
phosphoryl
ie
activ
presenc
serum
specif
msp
ligand
downstream
signal
element
akt
erk
also
ron
knockdown
impair
cellular
migrat
assay
format
investig
evalu
ron
therapeut
target
sarcoma
cell
line
treat
antibodi
monolay
cultur
surprisingli
activ
observ
either
alon
addit
antibodi
independ
baselin
antibodi
sensit
prompt
us
investig
ron
variant
includ
sfron
lack
extracellular
antibodi
bind
domain
first
experi
found
sfron
ewe
sarcoma
cell
line
keep
activ
inhibitor
target
ron
tyrosin
kinas
domain
conclus
ron
express
activ
ewe
sarcoma
evid
cellular
function
experiment
therapeut
target
challeng
possibl
due
ron
splice
variant
given
clinic
impact
metastasi
ongo
develop
kinas
inhibitor
studi
warrant
cknowledg
project
support
deutsch
krebshilf
role
megatherapi
mgt
stem
cell
transplant
sct
high
risk
ewe
tumor
et
year
ebmt
activ
r
ladenstein
e
glogova
h
juergen
burdach
j
michon
h
van
den
berg
lewi
yaniv
c
peter
studi
statist
integr
research
children
cancer
research
institut
vienna
austria
paediatr
oncolog
haematolog
institut
gustav
roussi
villejuif
franc
studi
statist
integr
research
project
children
cancer
research
institut
vienna
austria
paediatr
oncolog
haematolog
univers
children
hospit
germani
paediatr
oncolog
haematolog
children
hospit
schwabe
germani
paediatr
oncolog
haematolog
institut
curi
pari
franc
paediatr
oncolog
haematolog
emma
children
hospit
amc
univers
amsterdam
amsterdam
netherland
paediatr
oncolog
haematolog
st
jame
univers
hospit
leed
unit
kingdom
paediatr
oncolog
haematolog
schneider
children
medic
center
israel
petach
tikvah
israel
paediatr
oncolog
haematolog
sct
st
anna
children
hospit
vienna
austria
object
registri
data
european
group
blood
marrow
transplant
ebmt
et
help
explor
indic
outcom
method
sinc
patient
pt
et
male
regist
countri
mgt
indic
primari
multifoc
local
diseas
relaps
median
age
year
yr
rang
median
surviv
time
yr
allogen
pt
autolog
sct
peripher
blood
stem
cell
use
pt
result
overal
surviv
rate
asct
primari
treatment
local
diseas
multifoc
relaps
allosct
p
age
signific
impact
p
presct
remiss
statu
import
asct
first
complet
remiss
partial
remiss
stabl
diseas
primari
refractori
p
second
complet
remiss
result
other
significantli
wors
p
primari
treatment
total
bodi
irradi
tbi
regimen
inferior
mgt
vs
p
signific
influenc
mgt
type
year
observ
busulphan
base
pt
melphalan
base
pt
treosulfan
base
other
p
cox
proport
hazard
regress
model
identifi
age
respons
statu
stem
cell
sourc
mgt
regimen
independ
risk
factor
conclus
ebmt
ewe
data
show
improv
result
pt
favour
busulphan
base
mgt
suggest
explor
depth
result
role
busulphan
versu
treosulfan
front
line
trial
risk
stratif
number
metastat
site
ewe
sarcoma
ranft
u
dirksen
h
juergen
pediatr
hematolog
oncolog
univers
children
hospit
muenster
germani
object
outcom
variat
subgroup
ewe
sarcoma
patient
metastas
initi
diagnosi
high
major
current
criterion
stratifi
ewe
sarcoma
patient
accord
site
metastas
eg
patient
pulmonari
metastas
distinguish
patient
bone
metastas
metastat
site
project
outcom
ewe
sarcoma
analyz
accord
number
metastat
site
method
patient
ewe
sarcoma
metastas
diagnosi
retrospect
analyz
patient
includ
gpoh
german
societi
pediatr
oncolog
hematolog
ewe
sarcoma
registri
receiv
similar
treatment
strategi
standard
andor
chemotherapi
accord
appropri
gpoh
protocol
median
year
rang
outcom
ef
analyz
univari
multivari
analys
result
patient
isol
pulmonari
metastat
diseas
se
n
compar
se
n
patient
dissemin
site
lung
alon
primarili
bone
metastas
p
patient
one
metastat
site
se
n
compar
se
n
two
se
n
three
metastat
site
p
overal
outcom
patient
one
metastat
site
also
includ
patient
isol
pulmonari
metastat
diseas
se
n
multivari
analysi
number
metastat
site
persist
major
signific
risk
factor
hazard
ratio
hr
vs
vs
p
wherea
risk
group
affili
hr
p
even
model
control
treatment
intensif
chemotherapi
hr
p
vs
p
n
conclus
stratif
virtu
quantiti
metastat
site
appear
discrimin
prognosi
ewe
sarcoma
patient
support
deutsch
krebshilf
mainten
therapi
oral
cyclophosphamid
celecoxib
patient
metastat
ewe
sarcoma
preliminari
result
italian
sarcoma
groupaieop
studi
r
luksch
abat
tamburini
f
fagioli
c
manzitti
n
puma
podda
asaftei
g
bisogno
ferrari
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
depart
chemotherapi
istituto
ortopedico
rizzoli
bologna
itali
depart
pediatr
ospedal
pediatrico
meyer
firenz
itali
depart
pediatr
ospedal
infantil
regina
torino
itali
depart
pediatr
ospedal
giannina
gaslini
genova
itali
divis
clinica
di
oncoematologia
pediatrica
di
padova
padova
itali
object
amelior
prognosi
patient
metastat
ewe
sarcoma
onset
isg
aieop
design
phase
ii
treatment
protocol
includ
mainten
phase
oral
cyclophosphamid
celecoxib
isgaieop
eudract
method
isgaieop
open
april
inclus
criteria
histolog
proven
previous
untreat
ewe
sarcoma
synchron
metastas
lung
solitari
skelet
metastasi
age
year
isgaieop
consist
cours
chemotherapi
radiotherapi
andor
surgeri
primari
tumor
busulphanmelphalanautolog
stem
cell
rescu
radiotherapi
lung
respons
patient
receiv
continu
mainten
phase
cyclophosphamid
mgd
celecoxib
pt
year
age
exclus
criteria
mainten
phase
progress
diseas
cardiovascular
gastrointestin
aim
studi
evalu
feasibl
mainten
phase
surviv
probabl
result
april
consecut
patient
male
femal
median
age
year
rang
enrol
conclud
mainten
phase
inelig
previou
progress
diseas
n
concomit
n
treatment
one
pt
interrupt
mainten
day
progress
diseas
temporari
suspens
mainten
occur
day
mainten
schedul
occur
patient
rang
day
suspens
median
day
due
follow
reason
hzv
grade
hematolog
fluid
febril
ef
probabl
patient
enter
mainten
phase
conclus
schedul
mainten
phase
feasibl
encourag
result
enrol
ongo
longer
need
evalu
efficaci
monitor
side
effect
late
sequela
local
control
ewe
sarcoma
chest
valu
combin
modal
local
treatment
b
bedetti
ranft
h
jurgen
k
wieb
u
dirksen
thorac
surgeri
lung
transplant
univers
hospit
muenster
germani
pediatr
hematolog
oncolog
univers
hospit
muenster
germani
pediatr
hematolog
oncolog
univers
hospit
muenster
germani
thorac
surgeri
lung
transplant
univers
hospit
muenster
germani
object
primari
ewe
sarcoma
es
may
present
tumor
multidisciplinari
manag
includ
system
treatment
local
treatment
consist
surgeri
radiotherapi
improv
surviv
patient
local
es
best
approach
achiev
local
control
howev
remain
controversi
method
retrospect
analyz
data
patient
regist
databas
german
societi
pediatr
hematolog
oncolog
histolog
confirm
es
chest
wall
treat
juli
april
median
age
year
patient
male
surgic
resect
perform
patient
patient
underw
surgeri
group
patient
treat
surgeri
combin
radiotherapi
group
seven
patient
receiv
radiotherapi
group
result
overal
surviv
os
patient
year
surviv
ef
year
group
group
group
multivari
analysi
includ
tumor
size
local
therapi
modal
op
vs
op
rt
surgic
margin
vs
pleural
effus
vs
ye
show
poor
histolog
respons
hr
ci
initi
pleural
effus
hr
ci
remain
signific
risk
factor
seventeen
patient
show
late
complic
secondari
malign
thorac
bone
hypoplasia
myelopathi
valvular
diseas
lung
function
reduct
conclus
addit
benefit
radiotherapi
term
surviv
could
demonstr
also
true
patient
addit
risk
factor
larg
tumor
inadequ
surgic
margin
poor
histolog
respons
main
limit
current
analysi
consist
natur
retrospect
analysi
prospect
evalu
role
radiotherapi
chest
wall
ewe
sarcoma
warrant
base
combin
chemotherapi
ct
valid
choic
high
tumor
burden
nutrit
challeng
osteosarcoma
j
bajpai
mv
chandrakanth
v
agarwala
dsouza
ajay
puri
b
rekhi
g
chinnaswami
laskar
banavali
gupta
medic
oncolog
tata
memori
hospit
mumbai
india
surgic
oncolog
tata
memori
hospit
mumbai
india
patholog
tata
memori
hospit
mumbai
india
radiat
oncolog
tata
memori
hospit
mumbai
india
object
standard
treatment
osteosarcoma
includ
howev
consid
signific
toxic
need
complex
pharmacokinet
monitor
non
base
ct
regimen
worth
explor
method
prospect
studi
evalu
efficaci
toxic
ct
regimen
compris
doxorubicin
ifosfamid
cisplatin
ct
respons
evalu
hn
grade
good
respond
gr
defin
hn
baselin
tumor
burden
nutrit
paramet
correl
outcom
toxic
surviv
analysi
perform
use
method
compar
test
result
elig
patient
enrol
median
age
decemb
decemb
present
malnourish
anem
iron
defici
defici
mean
lesion
size
cm
metastasi
high
ldh
high
sap
post
ct
underw
surgeri
till
analysi
gr
mean
month
median
overal
surviv
os
reach
nonmetastat
nm
patient
metastat
patient
month
p
estim
nm
metastat
patient
grade
iiiiv
chemotox
like
fn
thrombocytopenia
manag
success
complianc
chemotherapi
multivari
analysi
hn
low
albumin
fn
identifi
independ
variabl
os
ts
identifi
independ
variabl
fn
conclus
base
ct
regimen
produc
outcom
compar
regimen
accept
toxic
complianc
even
nurtit
challang
high
tumor
burden
osteosarcoma
case
albumin
fn
identifi
nonconvent
potenti
prognost
marker
noval
marker
toxic
predict
baselin
merit
explor
function
outcom
qualiti
life
assess
survivor
pediatr
ewe
sarcoma
b
stish
sk
ahm
ps
rose
nn
laack
radiat
oncolog
mayo
clinic
rochest
usa
orthoped
surgeri
mayo
clinic
rochest
usa
object
collect
function
outcom
qualiti
life
assess
pediatr
patient
treat
ewe
sarcoma
mayo
clinic
assess
impact
diseas
characterist
primari
tumor
treatment
modal
method
surviv
patient
treat
mayo
clinic
ewe
sarcoma
elig
complet
qualiti
life
questionnair
assess
tool
includ
toronto
extrem
salvag
score
tess
age
appropri
gener
core
instrument
inventori
score
calcul
accord
publish
tess
pedsql
guidelin
higher
score
indic
better
outcom
instrument
rang
univari
analysi
tess
pedsql
score
patient
clinic
characterist
assess
use
chi
squar
discret
variabl
anova
method
continu
variabl
result
patient
male
complet
median
age
diagnosi
year
rang
median
age
survey
complet
year
rang
median
tess
score
pedsql
total
score
patient
iqr
iqr
respect
within
pedsql
instrument
score
highest
social
domain
median
lowest
physic
domain
median
pedsql
total
score
correl
strongli
tess
score
pearson
correl
coeffici
median
tess
score
differ
significantli
base
primari
tumor
locat
axial
extrem
pelvi
p
local
therapi
affect
tess
score
significantli
mean
score
rt
rt
p
conclus
studi
largest
singl
institut
assess
qualiti
life
survivor
pediatr
ewe
sarcoma
function
outcom
seri
excel
rel
publish
valu
healthi
subject
appear
influenc
tumor
locat
mode
local
therapi
data
provid
benchmark
comparison
futur
studi
methylen
tetrahydrofol
reductas
polymorph
toxic
effect
methotrex
children
osteosarcoma
v
ilic
z
bekic
j
bokun
pudrlja
slovic
tufegdz
radulov
l
paripov
paediatr
depart
institut
oncolog
radiolog
serbia
belgrad
serbia
depart
experiment
oncolog
institut
oncolog
radiolog
serbia
belgrad
serbia
object
methotrex
dihydrofol
reductas
inhibitor
methotrexat
one
import
agent
therapi
osteosarcoma
children
major
side
effect
includ
mucos
nephrotox
hepatotox
delay
mtx
clearanc
follow
toxic
effect
acut
delay
still
repres
clinic
problem
methylen
tetrahydrofol
reductas
mthfr
key
role
folat
cycl
usual
polymorph
mthfr
gene
repres
replac
citozin
c
timin
posit
result
allel
enzym
activ
allel
enzym
activ
consequ
lower
mthfr
enzym
activ
reduc
folat
pool
witch
may
caus
addit
toxic
delay
mtx
clearanc
method
evalu
patient
pt
osteosarcoma
delay
mtx
clearanc
toxic
effect
administr
dose
median
age
year
year
use
method
analyz
peripher
blood
detect
polymorph
mthfr
allel
prior
hd
mtx
infus
pt
normal
laboratori
find
result
evalu
pt
delay
mtx
clereanc
hour
hepatotox
grade
three
pt
nausea
vomit
eight
fifteen
pt
polymorph
enzym
activ
one
patient
enzym
activ
one
patient
allel
develop
mucositisstomat
grade
conclus
mtx
toxic
delay
mtx
clearanc
explain
mthfr
polymorph
posit
prolong
mtx
exposur
polymorph
mthfr
gene
relat
lower
level
folat
pool
caus
loss
catalit
function
mthfr
carrier
mthfr
polymorph
recev
chemotherapi
protocol
could
grater
risk
toxic
effect
respons
chemotherapi
estim
fdg
pet
import
prognost
factor
patient
ewe
sarcoma
raciborska
k
bilska
k
drabko
r
chaber
pogorzala
k
polczynska
g
sobol
wieczorek
k
dziuk
surgic
oncolog
children
youth
mother
child
institut
warsaw
poland
pediatr
hematolog
oncolog
transplantolog
medic
univers
lublin
poland
pediatr
oncolog
hematolog
bone
marrow
transplant
medic
univers
wroclaw
poland
pediatr
hematolog
oncolog
collegium
medicum
nicolau
copernicu
univers
bydgoszcz
poland
pediatr
hematolog
oncolog
medic
univers
gdansk
poland
pediatr
oncolog
hematolog
chemotherapi
medic
univers
silesia
poland
pediatr
oncolog
pediatr
oncologicol
children
centr
chorzow
poland
pediatr
oncolog
hematolog
medic
univers
bialystok
poland
nuclear
medicin
depart
militari
institut
medicin
mazovian
medic
centr
warsaw
poland
object
respons
neoadiuv
chemotherapi
prognost
factor
patient
ewe
sarcoma
es
role
fdg
pet
predict
respons
neoadjuv
chemotherapi
patient
thoroughli
investig
evalu
diagnost
accuraci
potenti
positron
emiss
tomographi
fdg
pet
compar
chemotherapi
cht
respons
degre
necrosi
defin
histolog
method
analyz
data
patient
es
median
age
year
patient
treat
neoadiuv
cht
underw
surgeri
excis
patient
petct
diagnosi
induct
cht
prior
local
control
compar
respons
assess
histopatholog
fdg
pet
use
standard
uptak
valu
suv
also
analyz
fdg
pet
uptak
diagnost
imag
studi
result
patient
aliv
median
month
diagnosi
median
suv
diagnosi
rang
median
suv
initi
chemotherapi
histolog
patient
classifi
good
respons
necrosi
poor
respons
necrosi
suv
cht
significantli
lower
patient
good
histolog
respons
patient
poor
histolog
respons
median
vs
addit
fdg
pet
sensit
bone
scintigraphi
detect
bone
metastas
howev
sensit
detect
lung
diseas
low
conclus
pet
demonstr
high
diagnost
accuraci
respons
initi
chemotherapi
sensit
bone
scintigraphi
detect
bone
metastas
fdg
pet
may
use
tool
estim
histolog
respons
patient
es
outcom
pediatr
medulloblastoma
canada
report
canadian
pediatr
brain
tumor
consortium
l
grimard
johnston
keen
strother
carret
v
perci
c
fryer
afzal
v
larouch
eric
bouffet
radiat
oncolog
ottawa
hospit
ottawa
canada
pediatr
oncolog
children
hospit
eastern
ontario
ottawa
canada
pediatr
neurolog
children
hospit
eastern
ontario
ottawa
canada
pediatr
oncolog
univers
calgari
calgari
canada
pediatr
oncolog
hopit
saint
justin
montreal
canada
pediatr
oncolog
cancer
care
manitoba
winnipeg
canada
pediatr
oncolog
british
columbia
children
hospit
vancouv
canada
pediatr
oncolog
iwk
children
hospit
halifax
canada
pediatr
oncolog
centr
hospitali
universitair
de
quebec
quebec
canada
pediatr
oncolog
hospit
sick
children
toronto
canada
object
canadian
pediatr
brain
tumor
consortium
cpbtc
examin
incid
medulloblastoma
outcom
treatment
type
especi
use
radiotherapi
present
method
treatment
children
brain
tumor
centralis
institut
canada
form
cpbtc
order
assess
chang
incid
data
collect
outcom
accord
treatment
group
statu
gender
age
use
radiotherapi
first
line
treatment
present
result
patient
treat
year
male
femal
patient
diseas
metastat
diseas
patient
age
greater
proport
diseas
vs
older
first
line
therapi
chemotherapi
patient
radiotherapi
decreas
first
decad
latter
decad
combin
chemotherapi
radiotherapi
patient
period
high
dose
chemotherapi
use
alon
radiotherapi
surviv
year
patient
receiv
radiotherapi
receiv
radiotherapi
p
stage
vs
age
year
also
significantli
relat
surviv
p
cox
hazard
model
differ
surviv
gender
period
conclus
improv
surviv
studi
time
period
use
radiotherapi
first
line
import
prognost
factor
younger
children
year
present
wors
stage
independ
effect
young
age
stage
prognosi
much
lower
extent
use
radiotherapi
first
line
therapi
long
term
follow
infant
medulloblastoma
treat
sequenti
high
dose
chemotherapi
l
chi
j
madden
smith
e
well
e
owen
strother
n
foreman
r
packer
e
bouffet
pediatr
oncolog
alberta
children
hospit
calgari
canada
pediatr
oncolog
dana
farber
institut
boston
usa
pediatr
oncolog
children
hospit
colorado
denver
usa
pediatr
oncolog
arnold
palmer
hospit
children
orlando
usa
pediatr
oncolog
children
nation
medic
center
washington
dc
usa
pediatr
oncolog
hospit
sick
children
toronto
canada
object
high
dose
chemotherapi
strategi
develop
avoid
craniospin
irradi
prevent
unaccept
neurotox
young
children
howev
outcom
includ
neurocognit
outcom
approach
wide
describ
method
retrospect
studi
collect
data
institut
young
children
medulloblastoma
receiv
carboplatin
thiotepa
accord
protocol
data
patholog
molecular
subgroup
chemotherapeut
radiat
ototox
neurognit
evalu
surviv
collect
result
male
patient
diagnos
median
age
month
nineteen
metastat
diseas
underw
gross
total
resect
gtr
fifteen
nodular
desmoplast
nd
subtyp
three
patient
receiv
intrathec
chemotherapi
receiv
hd
mtx
induct
underw
mainten
chemotherapi
post
hdc
fifteen
patient
receiv
radiat
includ
adjuv
set
complet
continu
remiss
ccr
rate
induct
consolid
respect
two
patient
die
treatment
relat
toxic
thirti
seven
patient
aliv
median
year
diagnosi
project
pf
os
respect
gtr
stage
nd
histolog
ccr
significantli
associ
better
pf
ccr
post
consolid
stage
remain
signific
better
os
non
irradi
children
better
pf
compar
receiv
radiat
pf
versu
p
outcom
molecular
subgroup
pend
sever
ototox
brock
grade
present
evalu
patient
nine
requir
hear
support
neurocognit
assess
avail
patient
mean
fsiq
cohort
rang
conclus
young
children
mb
treat
strategi
encourag
os
less
patient
receiv
adjuv
radiat
although
ototox
regimen
signific
neurocognit
profil
survivor
appear
within
normal
rang
acut
toxic
treatment
outcom
pediatr
medulloblastoma
patient
treat
craniospin
irradi
holland
ra
lustig
z
tochner
paltin
h
zhai
mj
fisher
je
minturn
p
phillip
ce
radiat
oncolog
univers
pennsylvania
philadelphia
usa
oncolog
children
hospit
philadelphia
philadelphia
usa
object
csi
deliv
use
cranial
photon
field
spinal
proton
field
allow
field
size
limit
institut
report
acut
toxic
outcom
techniqu
method
septemb
patient
treat
patient
receiv
rbe
csi
tumor
bed
proton
boost
rbe
hr
rbe
rbe
respect
spine
boost
rbe
gy
rbe
patient
receiv
vincristin
hr
patient
receiv
addit
daili
carboplatin
toxic
document
accord
result
median
age
year
rang
femal
requir
daili
anesthesia
radiat
baselin
mean
neuropsycholog
abil
across
broad
rang
perform
base
measur
parent
report
function
averag
rang
wechsler
iq
mean
sd
rang
toxic
grade
toxic
nauseavomit
n
anorexia
n
max
weight
loss
decreas
hemoglobin
n
leukopenia
n
n
thrombocytopenia
n
patient
leukopenia
also
thrombocytopenia
medulloblastoma
treat
spine
boost
vincristin
carboplatin
bone
marrow
toxic
occur
hr
patient
patient
receiv
carboplatin
hepat
renal
toxic
mild
patient
avail
audiogram
median
month
end
rt
rang
hear
loss
none
patient
detail
imag
avail
none
radiat
necrosi
data
avail
patient
median
follow
month
rang
aliv
without
diseas
aliv
cerebellar
thecal
sac
recurr
aliv
ventricular
recurr
conclus
csi
techniqu
safe
proton
csi
may
decreas
gi
bone
marrow
hepat
renal
toxic
depend
chemotherapi
regimen
clinic
outcom
irradi
plu
adjuv
chemotherapi
prognosi
recurr
molecular
subgroup
medulloblastoma
n
kagawa
r
hirayama
kijima
chiba
kinoshita
k
takano
eino
fukuya
f
yamamoto
k
nakanishi
hashii
n
hashimoto
j
hara
md
tylor
yoshimin
depart
neurosurgeri
osaka
univers
graduat
school
medicin
osaka
japan
divis
neurosurgeri
hospit
sick
children
univers
toronto
toronto
canada
depart
neurosurgeri
osaka
medic
center
cancer
cardiovascular
diseas
osaka
japan
depart
neurosurgeri
suita
manucip
hospit
osaka
japan
depart
development
midicin
osaka
univers
graduat
school
medicin
osaka
japan
depart
pediatr
hematologyoncolog
osaka
citi
gener
hospit
osaka
japan
object
therapeut
challeng
recurr
medulloblastoma
difficult
problem
although
prognosi
medulloblastoma
improv
craniospin
irradi
adjuv
chemotherapi
retrospect
analys
recurr
pattern
differ
clinic
outcom
base
molecular
subgroup
medulloblastoma
treat
irradi
chemotherapi
method
patient
medulloblastoma
treat
institut
classifi
four
subgroup
nanostr
assay
use
frozen
specimen
age
distribut
one
year
old
subgroup
distribut
four
shh
five
group
eleven
group
without
wnt
case
case
older
year
old
craniospin
cranial
irradi
gy
plu
adjuv
chemotherapi
done
tumor
remov
chemotherapi
perform
group
result
recurr
seen
shh
five
group
case
four
recurr
medulloblastoma
period
initi
treatment
recurr
within
month
year
surviv
recurr
cell
rapidli
extens
dissemin
progress
despit
mani
therapeut
chanlleng
period
recurr
death
month
year
overal
surviv
eleven
group
asymptomat
recurr
shown
four
case
period
initi
treatment
recurr
month
although
chemotherapi
intrathec
inject
chemotherapeut
agent
littl
effect
condit
partial
respons
stabl
diseas
maintain
stereotact
radiotherapi
metronom
chemotherapi
use
oral
etoposid
temozolomid
conclus
therapeut
regimen
includ
irradi
surviv
time
recurr
group
signific
longer
group
molecular
subgroup
may
predict
recurr
pattern
respons
treatment
prognosi
group
function
genom
approach
identifi
mechan
drug
resist
shh
medulloblastoma
murin
model
kc
bertrand
cc
faria
sc
mack
aj
luck
x
wang
agnihotri
x
wu
l
garzia
ca
smith
pb
dirk
md
taylor
jt
rutka
cell
biolog
hospit
sick
children
toronto
canada
neurosurgeri
hospit
de
santa
maria
centro
hospitalar
lisboa
nort
lisboa
portug
development
biolog
hospit
sick
children
toronto
canada
depart
surgeri
univers
toronto
toronto
canada
object
despit
improv
surviv
medulloblastoma
mb
patient
face
multitud
neurocognit
sequela
due
aggress
therapi
mani
novel
mb
target
therapi
emerg
howev
like
reveal
drug
resist
pathway
present
acquir
respons
therapi
previou
work
group
demonstr
foretinib
inhibitor
cmet
activ
effect
treatment
sonic
hedgehog
shh
subgroup
mb
current
seek
identifi
pathway
may
lead
foretinib
resist
shh
mb
inform
combinatori
therapi
could
uncov
evalu
method
mb
sleep
beauti
transposon
mutagenesi
murin
model
use
frequent
spontan
develop
primari
metastat
mb
mice
treat
vehicl
foretinib
via
alzet
osmot
pump
cerebrospin
fluid
day
rate
transposon
common
insert
site
identifi
splink
pcr
tumour
dna
follow
illumina
sequenc
hiseq
data
identifi
differ
insert
control
mice
versu
foretinib
treat
mice
relat
differ
pathway
select
respons
treatment
result
demonstr
sleep
beauti
mb
mice
statist
greater
surviv
upon
treatment
continu
csf
infus
cmet
inhibitor
foretinib
despit
improv
surviv
foretinib
treat
mice
eventu
succumb
tumour
format
metastasi
use
unbias
function
genom
screen
identifi
novel
mechan
pathway
resist
cmet
inhibit
target
identifi
converg
upon
regul
cell
cycl
apoptosi
tumour
invas
reveal
pathway
may
leverag
combinatori
treatment
foretinib
conclus
studi
identifi
potenti
pathway
shh
mb
cell
may
overcom
foretinib
inhibit
provid
system
drug
resist
pathway
mb
target
therapi
may
identifi
longitudin
child
parent
report
health
relat
qualiti
life
children
enrol
proton
radiotherapi
phase
ii
medulloblastoma
studi
j
luca
k
kuhlthau
j
delahay
pulsif
e
weyman
mcbride
macdonald
n
tarbel
yock
radiat
oncolog
wake
forest
baptist
medic
center
salem
usa
pediatr
massachusett
gener
hospit
boston
usa
psychiatri
massachusett
gener
hospit
boston
usa
radiat
oncolog
massachusett
gener
hospit
boston
usa
radiat
oncolog
memori
sloan
ketter
new
york
usa
object
describ
longitudin
hrqol
patient
treat
prospect
phase
ii
trial
pediatr
medulloblastoma
proton
radiotherapi
prt
method
patient
medulloblastoma
enrol
assess
pedsql
prt
annual
thereaft
evalu
pedsql
survey
fu
patient
receiv
prt
median
dose
gye
csi
tumor
bed
tb
posterior
fossa
pf
boost
gye
compar
hrqol
risk
group
srhr
age
se
median
incom
vs
boost
volum
tbvpf
use
anova
pair
result
median
hrqol
follow
fu
among
baselin
evalu
year
n
parent
proxi
report
ppr
less
child
csr
baselin
total
core
score
tc
vs
physic
score
ps
psychosoci
score
ss
score
vs
mean
tc
ps
ss
last
fu
similar
across
ppr
csr
n
vs
n
vs
n
vs
p
ns
ppr
csr
hrqol
measur
improv
follow
treatment
although
differ
signific
tc
ps
among
ppr
across
hrqol
domain
ss
minim
improv
time
fu
hrqol
score
improv
differenti
across
age
vs
tc
cl
vs
ci
p
ps
vs
p
among
ppr
csr
differ
chang
time
tc
ps
ss
across
gender
risk
categori
se
boost
volum
conclus
pprcsr
hrqol
domain
improv
time
across
domain
ss
largest
improv
ppr
tc
ps
se
correl
hrqol
score
baselin
fu
chang
time
siop
podc
adapt
regimen
manag
children
standard
risk
medulloblastoma
set
j
park
davidson
bailey
hendrick
p
ssenyonga
e
molyneux
j
mugamba
ayn
meeteren
qaddoumi
e
bouffet
howard
radiat
oncolog
univers
cape
town
cape
town
south
africa
paediatr
oncolog
red
cross
children
hospit
cape
town
south
africa
paediatr
oncolog
great
north
children
hospit
unit
kingdom
paediatr
oncolog
univers
cape
town
red
cross
children
hospit
cape
town
south
africa
neurosurgeri
cure
children
hospit
mbale
uganda
paediatr
colleg
medicin
blantyr
malawi
paediatr
emma
children
hospit
amsterdam
netherland
paediatr
oncolog
st
jude
children
research
hospit
memphi
usa
paediatr
oncolog
hospit
sick
children
toronto
canada
paediatr
oncolog
stanford
univers
palo
alto
usa
object
effect
treatment
children
medulloblastoma
requir
function
team
adequ
neurosurg
neuroradiolog
patholog
radiotherapi
chemotherapi
facil
personnel
treat
center
also
capac
effect
screen
manag
treatment
associ
toxic
requir
made
difficult
mani
low
countri
lmic
centr
offer
cur
treatment
present
describ
manag
recommend
children
standard
risk
medulloblastoma
accord
level
facil
set
avail
method
auspic
siop
podc
group
multidisciplinari
write
group
compos
doctor
lmic
develop
countri
establish
produc
guidelin
assist
profession
work
lmic
treat
children
standard
risk
medulloblastoma
start
survey
conduct
amongst
doctor
lmic
establish
difficulti
encount
treat
children
medulloblastoma
respond
countri
follow
number
web
confer
guidelin
base
best
avail
evid
appropri
differ
set
grade
drawn
circul
profession
lmic
comment
use
enhanc
made
follow
comment
result
guidelin
use
standard
set
develop
overal
siop
podc
group
modif
appropri
treatment
medulloblastoma
set
recommend
treat
children
medulloblastoma
surgic
radiotherapi
chemotherapi
option
appropri
set
includ
guidelin
addit
suggest
investig
manag
potenti
toxic
includ
import
function
multidisciplinari
team
emphasis
conclus
guidelin
may
use
work
lmic
howev
import
appropri
consult
potenti
user
document
conduct
treatment
medulloblastoma
pnet
children
three
year
age
saudi
arabia
prospect
multicent
studi
abdullah
q
alharbi
alshahrani
mosleh
ali
balbaid
alkofid
n
alkhayat
ahm
e
bouffet
pediatr
hematolog
oncolog
king
fahad
medic
citi
riyadh
saudi
arabia
pediatr
hematolog
oncolog
king
abdulaziz
medic
guard
jeddah
saudi
arabia
pediatr
hematolog
oncolog
king
fahad
specialist
hospit
dammam
saudi
arabia
pediatr
hematolog
oncolog
princ
sultan
medic
militari
hospit
riyadh
saudi
arabia
pediatr
hematolog
oncolog
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
pediatr
hematolog
oncolog
hospit
sick
toronto
toronto
canada
object
treatment
children
medulloblastoma
saudi
heterogen
essenti
cooper
protocol
launch
tertiari
center
method
patient
year
medulloblastoma
pnet
receiv
postop
craniospin
radiat
accord
risk
group
concurr
oral
etoposid
receiv
six
cycl
chemotherapi
altern
cycl
cisplatin
day
etoposid
po
day
cycl
cycl
b
cyclophosphamid
day
vincristin
day
cycl
mainten
isotretinoin
given
month
result
patient
femal
enrol
patient
medulloblastoma
spnet
pinealoblastoma
median
age
year
patient
underw
gross
total
resect
subtot
partial
patient
underw
biopsi
patient
diseas
patient
treat
treat
radiat
start
median
interv
day
etoposid
well
toler
radiat
patient
experienc
hematolog
toxic
chemotherapi
patient
receiv
isotretinoin
toxic
death
occur
treatment
hear
assess
brock
scale
avail
patient
show
toxic
patient
median
month
patient
aliv
die
ar
patient
hr
patient
year
overal
surviv
os
project
year
os
conclus
although
still
earli
draw
conclus
surviv
approach
initi
result
encourag
show
mild
toxic
particular
term
hear
loss
medulloblastoma
children
year
report
treatment
result
king
faisal
specialist
hospit
research
centr
riyadh
saudi
arabia
alkofid
aya
e
alshail
hassounah
h
dababo
ana
siddiqui
khafaga
pediatr
hematolog
oncolog
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
neurosurgeri
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
patholog
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
radiat
oncolog
king
faisal
specialist
hospit
research
center
riyadh
saudi
arabia
object
medulloblastoma
common
malign
brain
tumor
seen
childhood
long
term
surviv
medulloblastoma
improv
past
decad
analyz
data
institut
children
medulloblastoma
method
elig
patient
identifi
result
male
median
age
diagnosi
year
rang
year
male
femal
tumor
confin
posterior
fossa
patient
spine
metastas
met
dissemin
diseas
within
brain
csf
metastas
pt
spine
met
symptom
present
headach
vomit
ataxia
one
patient
neurofibromatosi
surgic
intervent
perform
patient
gross
total
resect
subtot
resect
debulk
biopsi
pt
high
risk
diseas
residu
tumor
andor
standard
risk
therapeut
regimen
consist
full
dose
craniospin
high
risk
pt
reduc
dose
standard
risk
pt
concurr
weekli
vincristin
follow
cycl
cisplatinum
lomustin
vincristin
os
pt
overal
surviv
standard
risk
vs
high
risk
pt
vs
p
versu
metastat
diseas
vs
p
event
free
surviv
standard
risk
vs
high
risk
vs
p
vs
metastat
vs
p
conclus
outcom
analysi
high
risk
patient
good
compar
standard
risk
pt
may
possibl
refin
stratif
patient
util
molecular
marker
therebi
minim
use
potenti
harm
therapeut
modal
relaps
outcom
pattern
central
nervou
system
cn
secret
germ
cell
tumor
gct
treat
without
irradi
find
third
intern
cn
gct
studi
r
pruitt
n
saba
dasilva
cappellano
b
diez
gardner
j
allen
weinblatt
n
gottardo
g
dhall
jl
finlay
children
center
cancer
blood
diseas
children
hospit
lo
angel
lo
angel
usa
program
graacc
institut
pediatr
oncolog
sao
paolo
brazil
program
fundacion
para
la
lucha
contra
enfermedad
neurologica
de
la
infancia
bueno
air
argentina
hassenfeld
children
center
cancer
blood
diseas
new
york
univers
medic
center
new
york
usa
pediatr
hematologyoncolog
hospit
mineola
usa
pediatr
oncolog
princess
margaret
hospit
perth
australia
object
evalu
pattern
relaps
outcom
patient
cn
secret
mix
malign
gct
treat
initi
chemotherapi
without
irradi
intern
cn
gct
studi
iii
method
retrospect
chart
review
conduct
use
patient
enrol
intern
cn
gct
studi
iii
least
year
patient
detail
chemotherapi
regimen
publish
previous
dasilva
et
al
pediatr
blood
cancer
result
thirteen
patient
diagnosi
secret
cn
gct
patholog
tumor
marker
n
tumor
marker
alon
n
twelv
treat
chemotherapi
alon
one
receiv
focal
irradi
follow
chemotherapi
prior
relaps
six
patient
relaps
mean
month
rang
month
two
beyond
within
primari
site
alon
three
patient
relaps
earli
month
diagnosi
afp
elev
one
without
tumor
marker
assess
expir
progress
diseas
month
follow
initi
relaps
three
patient
relaps
late
month
without
afp
elev
one
germinoma
two
mild
chorion
gonadotropin
elev
fluid
patient
surviv
month
follow
addit
chemotherapi
irradi
conclus
patient
cn
secret
tumor
relaps
follow
regimen
display
two
distinct
pattern
recurr
outcom
patient
relaps
earli
appear
possess
secret
element
dismal
prognosi
patient
relaps
late
appear
pure
germinomat
element
excel
outcom
current
intern
cooper
group
studi
util
local
field
irradi
evalu
close
pattern
relaps
outcom
late
recurr
germinomat
element
might
avoid
initi
use
larger
field
irradi
whole
ventricular
craniospin
tumor
volum
primari
intracrani
germinoma
chang
dynam
chemoradiotherapi
n
kagawa
r
hirayama
fujimoto
chiba
kinoshita
koji
takano
eino
fukuya
f
yamamoto
k
nakanishi
n
hashimoto
hashii
j
hara
yoshimin
depart
neurosurgeri
osaka
univers
graduat
school
medicin
osaka
japan
depart
neurosurgeri
osaka
neurolog
institut
osaka
japan
depart
neurosurgeri
osaka
medic
center
cancer
cardiovascular
diseas
osaka
japan
depart
neurosurgeri
suita
manucip
hospit
osaka
japan
depart
development
midicin
osaka
univers
graduat
school
medicin
osaka
japan
depart
pediatr
hematologyoncolog
osaka
citi
gener
hospit
osaka
japan
object
spontan
regress
intracrani
germinoma
report
case
natur
histori
well
known
answer
part
question
retrospect
measur
tumor
volum
analyz
volumetr
chang
correl
clinic
paramet
method
case
primari
intracrani
germinoma
germinoma
treat
hospit
eight
plural
mri
scan
done
first
cours
chemotherapi
regimen
age
rang
year
endoscop
open
biopsi
perform
two
bifoc
type
tumor
volum
ten
lesion
analyz
volumetr
assess
base
mri
ratio
volumetr
chang
first
mri
admiss
scan
immedi
chemotherapi
defin
shrink
rate
ratio
volumetr
chang
influenc
first
cours
chemotherapi
defin
respons
rate
period
diseas
onset
first
chemotherapi
day
result
initi
tumor
volum
rang
cubic
centimet
mean
diagnost
radiat
dose
estim
msv
shrink
rate
rang
mean
case
shrink
rate
within
signific
relationship
diagnost
radiat
dose
shrink
rate
shrink
rate
correl
age
sex
respons
rate
shrink
rate
neg
influenc
initi
volum
p
conclus
studi
show
possibl
volum
intracrani
germinoma
chang
dynam
short
time
chemoradiotherapi
case
spontan
regress
part
volumetr
chang
inform
studi
need
give
light
biolog
natur
integr
analys
pediatr
high
grade
astrocytoma
reveal
similar
anaplast
astrocytoma
glioblastoma
n
gerg
haqu
kool
j
schwartzentrub
da
gayden
fontebasso
montpetit
shirinian
p
hauser
fauri
albrecht
sm
pfister
n
jabado
human
genet
mcgill
univers
montreal
canada
experiment
medicin
mcgill
univers
montreal
canada
pediatr
neurooncolog
german
cancer
research
center
heidelberg
germani
biotechnolog
wellcom
trust
sanger
institut
hinxton
unit
kingdom
sequenc
mcgill
univers
genom
innov
center
montreal
canada
intern
medicin
american
univers
beirut
beirut
lebanon
pediatr
semmelwei
univers
budapest
hungari
pediatr
montreal
children
hospit
research
institut
montreal
canada
patholog
montreal
children
hospit
montreal
canada
pediatr
mcgill
univers
mcgill
univers
health
center
research
institut
montreal
canada
object
brain
tumor
lead
caus
mortal
children
pediatr
astrocytoma
hga
includ
grade
iii
anaplast
astrocytoma
paa
grade
iv
glioblastoma
pgbm
rare
devast
brain
tumor
account
brain
tumor
children
paa
rare
consequ
investig
separ
entiti
pgbm
date
sever
subgroup
tumor
found
includ
relat
mutat
literatur
hga
often
studi
togeth
molecular
data
avail
paa
method
identifi
genet
differ
base
tumor
grade
children
investig
pediatr
hga
integr
data
whole
exom
sequenc
dna
methyl
gene
express
analys
result
result
demonstr
signific
segreg
two
tumor
group
neither
genom
epigenom
level
rna
express
level
gene
relat
cell
cycl
progress
dna
repair
apoptosi
inhibit
upregul
pgbm
compar
paa
ex
addit
gene
respons
growth
morpholog
differenti
cerebellar
neuron
downregul
fold
pgbm
rel
paa
pgbm
segreg
molecular
subgroup
base
underli
mutat
data
indic
molecular
subgroup
appli
paa
kaplan
meier
analys
show
signific
differ
overal
surviv
p
two
group
emphas
similar
clinic
cours
tumor
type
conclus
integr
analysi
indic
paa
may
distinct
entiti
pgbm
also
highlight
need
molecular
diagnost
criteria
pediatr
hga
propos
paa
pgbm
group
togeth
hope
treatment
tumor
group
improv
clinic
outcom
patient
multidisciplinari
treatment
role
system
chemotherapi
low
grade
glioma
fawzi
elhemali
awad
elbeltagi
zaghlol
hala
taha
elwakeel
nada
elkhatib
alaa
elhaddad
pediatr
oncolog
nation
cancer
institut
cairo
egypt
pediatr
oncolog
children
cancer
hospit
egypt
cairo
egypt
neurosurgeri
children
cancer
hospit
egypt
cairo
egypt
radiotherapi
children
cancer
hospit
egypt
cairo
egypt
surgic
patholog
children
cancer
hospit
egypt
cairo
egypt
radiodiagnosi
children
cancer
hospit
egypt
cairo
egypt
clinic
research
children
cancer
hospit
egypt
cairo
egypt
object
aim
studi
evalu
role
multidisciplinari
therapeut
approach
includ
surgeri
system
chemotherapi
outcom
pediatr
patient
differ
low
grade
glioma
lgg
subtyp
method
studi
patient
wereprospect
includ
patient
diagnos
lgg
betweenjuli
andjun
upfront
surgic
resect
attempt
tumor
optic
pathway
site
system
chemotherapi
given
accord
protocol
result
total
patient
enrol
onto
studi
male
femal
ratio
median
age
year
rang
yr
patient
year
old
pilocyt
astrocytoma
pa
frequent
encount
histolog
subtyp
cerebellar
site
predomin
optic
pathway
glioma
constitut
case
gross
totalnear
total
resect
feasibl
studi
patient
underw
subtot
resect
follow
adjuv
chemotherapi
big
residu
size
andor
symptomat
diseas
year
os
ef
entir
group
respect
compar
chemotherapi
patient
underw
surgic
tumor
resect
os
ef
versu
chemotherapi
patient
tumor
site
histolog
subtyp
extent
residu
tumor
significantli
associ
os
conclus
although
gtr
remain
standard
initi
treatment
lgg
yet
system
chemotherapi
compar
altern
surgeri
safe
accomplish
technic
feasibl
actual
treatment
strategi
infant
progress
hypothalam
chiasmat
glioma
azizi
ayn
meeteren
divis
neonatolog
pediatr
intens
care
neuropediatr
depart
pediatr
adolesc
medicin
medic
univers
vienna
vienna
austria
pediatr
oncolog
emma
children
hospit
academ
medic
center
amsterdam
netherland
object
treatment
infant
hypothalam
chiasmat
glioma
ihcg
challeng
sinc
children
progress
chemotherapi
despit
subsequ
treatment
year
overal
surviv
rate
studi
investig
treatment
strategi
current
appli
ihcg
method
webbas
questionnair
dillemma
treatment
ihcg
sent
member
siop
brain
tumor
group
well
low
grade
glioma
group
result
questionnair
answer
respond
paediatr
oncologist
profession
progress
diseas
first
line
therapi
would
treat
intensifi
chemotherapi
surgeri
plu
chang
chemotherapi
respond
compon
suggest
second
line
chemotherapi
vinblastin
cisplatin
cyclophosphamid
etoposid
compon
third
line
therapi
bevacizumab
consid
suitabl
respond
irinotecan
vinblastin
respect
experi
bevacizumab
ihcg
quit
common
median
treat
patient
age
mostli
combin
irinotecan
month
durat
effect
report
patient
least
stabl
diseas
sever
complic
rare
mention
proteinuria
hypertens
bleed
bevacizumab
would
avail
futur
protocol
patient
respond
radiotherapi
consid
treatment
option
failur
two
three
treatment
line
wide
rang
year
lower
age
limit
median
year
conclus
multipl
differ
cytostat
drug
regimen
appli
progress
ihcg
often
combin
surgeri
bevacizumab
often
use
satisfactori
level
third
line
combin
irinotecan
unravel
biolog
role
glioma
ms
pereira
f
pinto
f
pardal
j
amorim
pire
c
pinheiro
jm
lope
j
pimentel
c
jone
r
rei
life
health
research
institur
minho
univers
braga
portug
depart
patholog
hospit
de
braga
braga
portug
depart
oncolog
hospit
de
braga
braga
portug
depart
patholog
hospit
porto
portug
depart
neurosurgeri
hospit
porto
portug
depart
patholog
hospit
porto
portug
laboratori
neuropatholog
santa
maria
hospit
lisbon
portug
institut
cancer
research
institut
cancer
research
london
unit
kingdom
molecular
oncolog
research
center
barreto
cancer
hospit
barreto
brazil
object
tumor
suppressor
gene
codifi
protein
serin
proteas
involv
hgfmet
signal
pathway
demonstr
hypermethyl
varieti
cancer
includ
medulloblastoma
herein
intent
determin
clinic
relev
expressionhypermethyl
pediatr
adult
glioma
hgg
well
elucid
function
role
differ
transcript
pediatr
glioma
cell
line
method
cohort
adult
pediatr
primari
hgg
sampl
use
character
protein
express
immunohistochemistri
methyl
statu
pcr
moreov
glioblastoma
patient
tcga
use
evalu
mrna
express
methyl
level
plasmid
contain
transcript
construct
role
transcript
cell
migrat
viabil
evalu
mt
assay
result
observ
protein
frequent
absent
adult
hgg
pediatr
case
result
togeth
silico
analysi
demonstr
common
event
brain
tumor
found
associ
methyl
statu
promot
vitro
analysi
show
ectop
express
transcript
reduc
cell
migrat
capac
cell
metabol
viabil
furthermor
reveal
first
time
pronounc
effect
migrat
stronger
effect
cell
viabil
conclus
conclud
low
express
gene
hypermethyl
common
event
pediatr
adult
hgg
associ
higher
tumor
aggress
chromatin
architectur
pediatr
glioma
fontebasso
j
fraser
j
lambourn
jp
farmer
jl
mont
j
atkinson
pastinen
albrecht
j
dosti
n
jabado
experiment
medicin
montreal
children
hopsit
mcgill
univers
health
centr
montreal
canada
biochemistri
mcgill
univers
montreal
canada
human
genet
mcgill
univers
genom
quebec
innov
centr
montreal
canada
neurosurgeri
montreal
children
hospit
mcgill
univers
health
centr
montreal
canada
patholog
montreal
children
hospit
mcgill
univers
health
centr
montreal
canada
pediatr
human
genet
montreal
children
hopsit
mcgill
univers
health
centr
montreal
canada
object
epigenom
emerg
one
core
element
pediatr
glioma
key
facet
investig
context
begin
understood
human
cancer
spatial
organ
chromatin
influenc
regul
gene
express
cancer
cell
chromatin
landscap
influenc
gene
regul
even
promot
oncogen
alter
virtu
geograph
proxim
nucleu
method
effect
decid
explor
spatial
organ
chromatin
pediatr
glioma
focu
braf
locu
pilocyt
astrocytoma
pa
util
chromosom
conform
captur
technolog
patient
tumor
result
braf
alter
signific
proport
pa
tumor
form
tandem
duplic
chromosom
lead
fusion
notabl
predilect
tumor
aris
cerebellum
interestingli
analys
reveal
put
domain
tad
consist
across
tumor
within
cerebellum
studi
border
strikingli
braf
region
tad
appear
consist
across
cell
type
origin
hematolog
fibroblast
sourc
public
avail
dataset
conclus
best
confirm
tad
intend
profil
heterochromatin
mark
integr
data
gene
express
way
may
abl
elucid
structur
determin
may
favor
braf
fusion
pa
may
origin
inher
dna
conform
molecular
character
mapk
pathway
senesc
brazilian
cohort
pilocyt
astrocytoma
patient
ap
becker
w
menez
j
sheren
c
aisner
lt
bidinotto
l
neder
rm
rei
center
research
molecular
oncolog
barreto
cancer
hospit
barreto
brazil
cancer
center
univers
colorado
aurora
usa
patholog
barreto
cancer
hospit
barreto
brazil
patholog
univers
sao
paulo
ribeirao
preto
brazil
object
pilocyt
astrocytoma
pa
indol
glioma
case
progress
poorli
activ
mapk
main
molecular
pathway
may
trigger
senesc
oi
loss
express
mtap
describ
aggress
neoplasm
includ
glioma
data
concern
pa
publish
convers
overexpress
relat
senesc
neurodegen
diseas
aim
assess
relationship
express
mtap
immunohistochemistri
ihc
molecular
marker
mapk
activ
mutat
k
b
fusion
method
retrospect
studi
ihc
perform
antibodi
mtap
ffpe
tissu
microarray
platform
tma
avail
sampl
mutat
evalu
sanger
sequenc
k
b
fusion
custom
fluoresc
situ
hybrid
fish
probe
set
sampl
tma
valid
agil
acgh
assay
case
result
overal
sampl
patient
evalu
mf
median
age
year
cerebellum
main
locat
overexpress
mtap
patient
significantli
relat
cerebellar
locat
p
point
mutat
p
note
case
fusion
p
detect
sampl
adjac
cortex
case
astrocyt
weak
express
mtap
purkinj
neuron
strong
reaction
conclus
far
concern
first
studi
show
overexpress
mtap
pa
seem
reinforc
posit
relationship
constitut
activ
mapk
pathway
oi
phenomenon
one
mechan
respons
indol
behavior
pa
studi
larger
cohort
necessari
confirm
relationship
result
variou
method
treatment
childhood
anaplast
ependymoma
geludkova
borodina
korshunov
l
shishkina
ryzhova
kislyakov
yu
kushel
melikyan
shcherbenko
e
abbasova
v
emtsova
e
kumirova
gorbatyh
l
olhova
v
popov
l
privalova
mushinskaya
n
yudina
yu
punanov
popova
ozerov
v
ozerova
nechesnyuk
pediatr
oncolog
radiolog
russian
research
center
rentgenradiolog
moscow
russia
neurooncolog
russian
research
center
hematolog
oncolog
immunolog
moscow
russia
neuropathologisch
institut
pathologisch
heidelberg
germani
neuromorpholog
institut
neurosurgeri
moscow
russia
neuromorpholog
moscow
children
hospit
moscow
russia
pediatr
neurosurgeri
neurosurgeri
moscow
russia
ambulan
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
neurooncolog
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
oncolog
moscow
children
hospit
moscow
russia
oncolog
children
hospit
russia
oncolog
children
hospit
perm
russia
oncolog
children
hospit
voronezh
russia
oncolog
st
petersburg
russia
oncolog
volgograd
russia
surgeri
research
center
hematolog
oncolog
immunolog
moscow
russia
mri
neurosurgeri
moscow
russia
radiolog
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
present
standard
treatment
anaplast
ependymoma
method
evalu
treatment
result
children
ae
median
age
yo
patient
yo
male
femal
infratentori
tumor
pt
supratentori
pt
tumor
spinal
cord
pt
stage
metastas
detect
tumor
cell
patient
stage
known
pt
receiv
radiotherapi
accord
protocol
hit
receiv
radiotherapi
surgic
oper
patient
got
chemotherapi
pt
treat
use
surgic
intervent
patient
underw
total
n
subtot
n
tumor
resect
patient
extent
resect
evalu
result
pf
pf
median
pf
month
month
surviv
better
children
comparison
younger
yo
respect
surviv
among
femal
among
male
p
pf
better
supratentori
tumor
comparison
intratentori
respect
p
surviv
result
better
among
patient
stage
comparison
stage
respect
case
total
tumor
resect
surviv
better
case
subtot
resect
respect
p
pf
among
patient
receiv
chemoradiotherapi
radiotherapi
respect
among
patient
got
chemotherapi
tumor
resect
pf
surgeri
patient
recurr
p
conclus
chemotherapi
improv
result
treatment
anaplast
ependymoma
two
subsequ
aieop
protocol
childhood
adolesc
ependymoma
look
prognost
improv
massimino
v
biassoni
f
di
meco
ml
e
schiavello
sardi
l
genitori
bertin
e
viscardi
pg
modena
barra
g
scarzello
g
cinal
p
peretta
mussano
r
migliorati
mastronuzzi
f
giangaspero
antonelli
f
buttarelli
e
pecori
l
gandola
pediatr
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
neurosurgeri
fondazion
ircc
istituto
neurologico
carlo
besta
milano
itali
neurosurgeri
ircc
istituto
giannina
gaslini
genova
itali
pediatr
ospedal
pediatrico
meyer
firenz
itali
pediatr
ospedal
pediatrico
regina
margherita
torino
itali
pediatr
clinica
pediatrica
padova
itali
genet
ospedal
anna
como
itali
radiotherapi
istituto
dei
tumori
genova
itali
radiotherapi
istituto
oncologico
del
veneto
padova
itali
neurosurgeri
ospedal
santobono
napoli
itali
neurosurgeri
ospedal
pediatrico
regina
margherita
torino
itali
radiotherapi
azienda
ospedaliera
sanna
torino
itali
pediatr
ospedal
santobono
napoli
itali
pediatr
ospedal
pediatrico
bambino
roma
itali
neuropatholog
sapienza
roma
itali
radiotherapi
fond
ircc
istituto
nazional
dei
tumori
milano
itali
object
amelior
ependymoma
patient
prognosi
throuh
two
subsequ
italian
protocol
method
first
protocol
patient
given
focal
radiotherapi
hfrt
evid
diseas
ned
vec
chemotherapi
hfrt
residu
diseas
ed
hfrt
dose
gy
vec
vcr
ctx
gm
surgeri
recommend
studi
stratifi
pt
accord
two
prognost
factor
found
surgic
result
histolog
upfront
central
review
previous
childrenadolesc
age
yrbelow
tumor
focal
tumor
also
receiv
vec
irradi
ed
pt
receiv
possibl
irradi
plu
boost
fraction
surgic
residu
result
patient
respect
protocol
treat
activ
follow
year
first
second
protocol
respect
show
improv
ef
p
os
p
analyz
two
popul
first
seri
contain
significantli
whose
tumor
arous
posterior
fossa
second
contain
patient
grade
tumor
younger
one
year
first
seri
surgic
result
hydrocephalu
need
shunt
differ
multivari
analysi
posterior
fossa
origin
confirm
risk
factor
ef
os
treatment
accord
second
protocol
better
ef
p
os
p
conclus
aim
improv
treatment
strategi
seem
satisfi
even
longer
seri
need
confirm
benefit
cribriform
neuroepitheli
tumor
crinet
tumor
favor
prognosi
hasselblatt
v
ruland
k
bartelheim
p
johann
cr
pierson
c
hawkin
e
wide
sg
kim
kool
mc
w
paulu
institut
neuropatholog
univers
hospit
germani
swabian
children
cancer
center
children
hospit
augsburg
registri
work
group
augsburg
germani
divis
pediatr
neurooncolog
german
cancer
research
center
dkfz
heidelberg
germani
depart
patholog
laboratori
medicin
nationwid
children
hospit
ohio
state
univers
colleg
medicin
columbu
oh
usa
divis
patholog
hospit
sick
children
toronto
canada
dept
pediatr
oncolog
oslo
univers
hospit
rikshospitalet
oslo
norway
depart
patholog
keimyung
univers
dongsan
medic
center
daegu
korea
object
major
atyp
teratoidrhabdoid
tumor
atrt
character
inactiv
dismal
prognosi
children
harbor
unusu
tumor
term
cribriform
neuroepitheli
tumor
crinet
coin
record
anecdot
evid
suggest
rel
favor
prognosi
crinet
therefor
aim
investig
clinic
featur
prognosi
first
seri
rare
tumor
method
clinic
detail
neuropatholog
molecular
genet
data
well
inform
outcom
collect
children
harbor
crinet
data
surviv
surviv
compar
atrt
european
rhabdoid
tumor
registri
eurhab
result
median
age
male
femal
month
rang
month
major
crinet
locat
supratentori
often
midlin
neuropatholog
tumor
character
cribriform
strand
ribbon
epitheli
membran
surfac
tumor
stain
lost
mean
observ
time
month
one
child
die
due
respiratori
failur
earli
postop
phase
analysi
children
crinet
experienc
significantli
longer
surviv
compar
atrt
month
confid
interv
month
vs
month
month
p
overal
surviv
month
vs
month
p
conclus
crinet
rare
tumor
favor
prognosi
compar
atrt
prognost
factor
patient
atrt
central
nervou
system
geludkova
e
kumirova
borodina
korshunov
ryzhova
melikyan
kushel
l
olkhova
gorbatyh
v
popov
mushinskaya
n
popova
l
privalova
r
shammasov
scherbenko
e
abbasova
pediatr
oncolog
radiolog
research
center
rentgenradiolog
moscow
russia
neurooncolog
research
center
hematolog
oncolog
immunolog
moscow
russia
neuropathologi
pathologish
heidelberg
germani
neuromorpholog
neurosurgeri
moscow
russia
pediatr
neurosurgeri
neurosurgeri
moscow
russia
oncolog
moscow
children
hospit
moscow
russia
neurosurgeri
moscow
children
hospit
moscow
russia
oncolog
children
hospit
perm
russia
oncolog
children
hospit
volgograd
russia
oncolog
children
hospit
russia
oncolog
children
hospit
kazan
russia
oncolog
radiolog
research
center
rentgenradiolog
moscow
russia
object
atrt
malign
tumor
agress
behavior
method
evalu
prognost
factor
patient
atrt
patient
younger
year
old
patient
male
femal
respect
tumor
infratentori
patient
patient
infratentori
renal
tumor
patient
supratentori
tumor
stage
patient
patient
metastas
detect
tumor
cell
diagnosi
stage
precis
determin
patient
treatment
accord
protocol
administ
patient
protocol
cw
patient
patient
patient
got
treatment
result
patient
aliv
die
due
diseas
progress
due
chemotherapi
toxic
pf
os
median
surviv
time
month
median
observ
time
month
rang
month
surviv
rate
significantli
higher
among
patient
yo
comparison
younger
patient
respect
p
among
patient
total
tumor
resect
comparison
subtot
partial
resect
respect
p
among
patient
got
radiotherapi
comparison
local
radiotherapi
craniospin
radiat
radiotherapi
p
among
patient
stage
comparison
stage
respect
p
therapi
accord
protocol
led
better
surviv
rate
comparison
protocol
cw
p
conclus
factor
affect
prognosi
patient
age
extent
surgic
resect
chemotherapi
program
use
radiotherapi
presenc
metastas
prospect
studi
pediatr
patient
atyp
teratoid
rhabdoid
tumor
atrt
central
nervou
system
cn
j
chang
chang
confer
goldman
dunn
w
hartsel
radiat
oncolog
ann
robert
h
luri
children
hospit
chicago
chicago
usa
radiat
oncolog
oklahoma
citi
procur
proton
therapi
center
oklahoma
citi
usa
medic
oncolog
ann
robert
h
luri
children
hospit
chicago
chicago
usa
radiat
oncolog
proton
collabor
group
warrenvil
usa
object
atrt
rare
aggress
cn
tumor
usual
present
young
children
aggress
treatment
improv
outcom
strategi
includ
radiat
therapi
howev
young
age
short
long
term
radiat
toxic
preval
prospect
enrol
pediatr
cn
atrt
patient
onto
proton
collabor
group
registri
protocol
evalu
efficaci
toxic
proton
radiat
therapi
popul
method
consecut
pediatr
atrt
patient
treat
central
dupag
hospit
proton
center
oklahoma
citi
procur
proton
therapi
center
march
decemb
util
conform
proton
therapi
result
patient
evalu
year
age
younger
month
eight
patient
gross
total
resect
subtot
resect
along
anoth
document
nine
patient
receiv
multiag
intens
chemotherapi
per
dana
farber
cancer
institut
regimen
treatment
either
per
acn
protocol
intens
multiag
chemotherapi
along
stem
cell
transplant
radiat
local
field
patient
craniospin
irradi
mean
follow
month
rang
month
median
follow
month
last
follow
patient
aliv
without
evid
diseas
children
grade
toxic
acut
nausea
vomit
anorexia
radiat
therapi
respond
steroid
proton
therapi
abl
reduc
dose
cochlea
optic
chiasm
hippocampu
tempor
lobe
integr
whole
brain
conclus
initi
result
largest
prospect
seri
cn
atrt
patient
treat
proton
therapi
seem
favor
aggress
treatment
regimen
util
proton
beam
therapi
yield
proven
efficaci
improv
toxic
profil
critic
import
young
patient
popul
aggress
diseas
progress
declin
qualiti
life
among
survivor
brain
tumour
childhood
adolesc
r
barr
j
duckworth
nayiag
whitton
j
horsman
w
furlong
pediatr
mcmaster
univers
hamilton
canada
pediatr
hamilton
health
scienc
hamilton
canada
juravinski
cancer
centr
hamilton
health
scienc
hamilton
canada
na
health
util
inc
dunda
canada
object
trajectori
qualiti
life
hrql
assess
survivor
brain
tumour
childhood
adolesc
longitudin
studi
decad
method
incept
cohort
patient
compris
studi
sampl
least
year
complet
therapi
evid
progress
relaps
diseas
age
year
abl
commun
english
children
parent
proxi
respond
interview
use
item
questionnair
health
util
index
hui
mark
mark
hui
util
score
singl
attribut
domainsdimens
morbid
hrql
upper
limit
neg
score
hrql
repres
state
health
consid
wors
dead
subject
year
later
result
median
rang
score
hrql
time
point
correspond
score
differ
time
statist
signific
clinic
import
main
burden
morbid
attribut
sensat
emot
cognit
vision
cognit
pain
comparison
median
score
survivor
wilm
tumour
n
acut
lymphoblast
leukemia
n
neuroblastoma
treat
myeloabl
chemotherapi
stem
cell
rescu
n
conclus
year
studi
period
survivor
brain
tumour
childhood
adolesc
exhibit
progress
declin
overal
hrql
import
burden
morbid
numer
attribut
especi
cognit
find
identifi
need
intervent
minim
deterior
health
cohort
studi
cerebrovascular
diseas
radiat
therapi
craniopharyngioma
lo
f
howard
nichol
h
hasan
martin
h
manraj
k
goddard
radiat
oncolog
bc
cancer
agenc
vancouv
canada
school
popul
public
health
univers
british
columbia
vancouv
canada
radiolog
bc
cancer
agenc
vancouv
canada
radiolog
vancouv
gener
hospit
vancouv
canada
object
determin
preval
characterist
cerebrovascular
diseas
craniopharyngioma
patient
treat
radiotherapi
rt
method
craniopharyngioma
survivor
diagnos
age
treat
rt
british
columbia
elig
studi
elig
patient
patient
recruit
particip
patient
underw
clinic
assess
blood
work
magnet
reson
angiogram
mra
possibl
two
patient
comput
tomographi
angiogram
cta
metal
implant
preclud
mra
one
patient
exceed
equip
weight
limit
could
imag
fast
lipid
profil
obtain
patient
fast
glucos
hemoglobin
test
patient
result
median
age
year
diagnosi
rang
year
time
studi
rang
vascular
abnorm
detect
patient
angiogram
five
patient
histori
cva
abnorm
angiogram
remain
patient
one
could
imag
two
patient
histori
cva
abnorm
mra
remain
patient
normal
angiographi
histori
cva
time
studi
patient
hyperlipidemia
diabet
five
patient
bodi
mass
index
bmi
patient
bmi
conclus
young
patient
treat
rt
craniopharyngioma
high
preval
hyperlipidemia
cva
cerebrovascular
abnorm
imag
patient
undergo
care
monitor
aggress
modif
stroke
risk
factor
brain
tumour
impact
age
diagnosi
obes
pediatr
brain
tumor
survivor
k
strobel
p
simpson
p
donohou
firat
jogal
medic
student
medic
colleg
wisconsin
wauwatosa
usa
quantit
health
scienc
medic
colleg
wisconsin
wauwatosa
usa
pediatr
endocrinolog
children
hospit
wisconsin
wauwatosa
usa
radiat
oncolog
children
hospit
wisconsin
wauwatosa
usa
pediatr
hematologyoncolog
children
hospit
wisconsin
wauwatosa
usa
object
obes
morbid
children
diagnos
cn
tumor
bodi
mass
index
bmi
normal
declin
age
adipos
rebound
ar
increas
tumor
locat
radiat
therapi
surgeri
near
hypothalamu
increas
risk
obes
hypothes
hypothalam
involv
would
result
greater
bmi
diagnosistreat
ar
would
lead
greatest
bmi
method
retrospect
cohort
brain
tumor
survivor
diagnos
children
hospit
wisconsin
chart
review
extract
bmi
record
bmi
diagnosi
children
categor
six
group
base
age
diagnosi
hypothalam
involv
hi
consist
cdc
growth
curv
age
classifi
ar
month
ar
month
ar
month
old
bmi
compar
use
wilcoxon
sign
rank
test
result
children
bmi
z
score
diagnosi
similar
across
group
children
hi
higher
follow
bmi
z
score
diagnosi
ar
p
n
ar
p
n
group
without
hi
increas
bmi
z
score
two
year
follow
ar
n
ar
n
ar
n
ar
ar
cohort
hi
higher
bmi
z
score
follow
without
hi
p
ar
cohort
significantli
differ
without
hi
follow
conclus
children
cn
tumor
hypothalam
involv
increas
bmi
compar
without
hypothalam
involv
diagnosi
adipos
rebound
associ
greater
bmi
diagnosi
later
age
futur
studi
help
elucid
endocrin
caus
chang
assess
accuraci
death
record
clinic
diagnos
retrospect
chart
review
deceas
children
diagnos
brain
tumour
british
columbia
canada
h
hasan
g
hendson
f
howard
r
rassekh
j
hukin
c
dunham
ahm
lo
n
bradley
k
goddard
radiat
oncolog
bc
cancer
agenc
vancouv
canada
patholog
laboratori
medicin
bc
children
hospit
vancouv
canada
school
popul
public
health
univers
british
columbia
vancouv
canada
divis
oncologyhematologybmt
bc
children
hospit
vancouv
canada
divis
neurolog
oncolog
bc
children
hospit
vancouv
canada
pediatr
oncolog
group
ontario
network
inform
system
analyt
support
pediatr
oncolog
group
ontario
vancouv
canada
object
despit
advanc
diagnost
imag
techniqu
dispar
exist
diagnos
best
knowledg
current
studi
investig
relationship
diagnos
autopsi
find
children
diagnos
pediatr
brain
tumour
pbt
purpos
studi
determin
whether
discrep
exist
diagnos
provinci
cancer
registri
death
record
compar
autopsi
find
deceas
children
diagnos
pbt
method
retrospect
review
medic
record
autopsi
report
deceas
children
year
diagnos
pbt
british
columbia
canada
autopsi
perform
diagnos
compar
diagnos
classifi
base
major
minor
discrep
accord
goldman
criteria
concord
result
total
death
occur
studi
period
autopsi
patient
autopsi
patient
autopsi
avail
review
analysi
clinic
diagnos
case
reveal
minor
discrep
major
discrep
discrep
analysi
caus
death
british
columbia
cancer
registri
autopsi
find
determin
case
discord
concord
could
determin
due
miss
caus
death
inform
conclus
deceas
children
diagnos
pbt
autopsi
discrep
find
signific
proport
case
autopsi
provid
valuabl
inform
serv
educ
clinician
invalu
tool
provid
feedback
regard
accuraci
diagnost
appropri
patient
manag
small
proport
deceas
pbt
patient
autopsi
effort
made
increas
number
avoid
delay
diagnosi
uk
paediatr
cn
tumour
patient
retrospect
multicentr
audit
south
west
region
n
cork
carter
chandra
n
cohen
school
clinic
medicin
univers
cambridg
cambridg
unit
kingdom
depart
neurosurgeri
frenchay
hospit
bristol
unit
kingdom
depart
neuropatholog
frenchay
hospit
bristol
unit
kingdom
object
prompt
recognit
paediatr
central
nervou
system
cn
tumour
uncommon
unit
kingdom
uk
median
symptom
interv
si
first
symptom
onset
diagnosi
measur
month
compar
poorli
similar
nation
retrospect
multicentr
audit
aim
establish
common
clinic
present
si
achiev
recent
south
west
region
outlin
strategi
limit
systemat
delay
method
hospit
paediatr
patient
newli
diagnos
primari
cn
tumour
januari
novemb
identifi
approv
local
review
board
follow
data
retriev
clinic
note
date
birth
gender
ethnic
social
depriv
age
symptom
onset
diagnosi
clinic
featur
onset
diagnosi
date
locat
first
present
date
modal
first
imag
tumour
patholog
tumour
grade
tumour
locat
avail
referr
pathway
data
treatment
result
regardless
tumour
patholog
grade
locat
common
featur
onset
headach
motor
system
abnorm
nausea
andor
vomit
seizur
diagnosi
visual
system
abnorm
motor
system
abnorm
headach
nausea
andor
vomit
behaviour
chang
sign
symptom
increas
median
onset
median
diagnosi
median
si
month
tumour
significantli
associ
reduc
si
p
signific
associ
si
patient
gender
social
depriv
first
present
commun
hospit
conclus
visual
motor
system
abnorm
behaviour
chang
commonli
emerg
si
typic
bilater
papilloedema
diplopia
reduc
visual
acuiti
reduc
coordin
new
onset
lethargi
featur
within
otherwis
symptom
profil
prompt
urgent
clinic
reassess
si
consist
report
region
measur
restrict
si
uk
recommend
combat
combin
oral
metronom
biodifferenti
antiangiogen
treatment
therapi
poor
prognosi
pediatr
malign
brain
role
g
chinnaswami
prasad
v
dhamankar
vora
gupta
moiyadi
e
sridhar
banavali
r
jalali
p
kurkur
depart
pediatr
medic
oncolog
tata
memori
hospit
mumbai
india
depart
radiat
oncolog
tata
memori
hospit
mumbai
india
depart
neurosurgeri
tata
memori
hospit
mumbai
india
depart
patholog
tata
memori
hospit
mumbai
india
object
outcom
children
recurrenthigh
risk
malign
brain
tumor
continu
poor
convent
modal
therapi
metronom
therapi
combat
found
benefici
mani
dissemin
aggress
pediatr
solid
tumor
evalu
impact
efficaci
toxic
strategi
children
poor
prognosi
malign
brain
tumor
method
children
deem
poor
risk
malign
brain
tumor
histolog
site
metastat
statu
start
combat
regimen
complet
convent
therapi
relaps
high
grade
tumor
also
includ
treatment
strategi
consist
combat
regimen
includ
low
dose
temozolomid
etoposid
sodium
valproat
acid
administ
cycl
children
follow
monthli
interv
clinic
evalu
mr
imag
result
thirti
four
children
start
combat
therapi
year
avail
evalu
median
age
studi
popul
year
male
femal
ratio
among
patient
relapsedprogress
medulloblastoma
metastaticrecurr
pnet
supratentori
recurr
anaplast
ependymoma
diagnos
diffus
pontin
glioma
patient
show
respons
sdprcr
therapi
patient
continu
progress
respons
document
toxic
includ
grade
iiiiv
cytopenia
patient
patient
develop
myelodysplast
syndrom
isotretinoin
skin
toxic
note
major
manag
topic
intervent
final
analysi
patient
progress
median
time
progress
month
month
patient
shown
posit
sustain
respons
conclus
combat
regimen
feasibl
well
toler
effect
treatment
option
children
high
risk
metastat
brain
tumour
data
retrospect
analysi
henc
prospect
studi
evalu
strategi
systemat
warrant
tumor
cell
cerebrospin
fluid
low
grade
choroid
plexu
tumor
overtreat
ur
kord
benesch
hartung
k
petrasch
rutkowski
v
ruland
pietsch
hasselblatt
jea
wolff
pediatr
hematolog
oncolog
univers
medic
center
hamburg
eppendorf
hamburg
germani
divis
pediatr
hematgi
oncolog
depart
pediatr
adolesc
medicin
medic
univers
graz
graz
austria
institut
neuropatholog
univers
hospit
germani
institut
neuropatholog
brain
tumor
refer
center
bonn
univers
bonn
germani
depart
pediatr
hematolog
oncolog
cleveland
clinic
children
hospit
ohio
usa
object
cytomorpholog
cerebrospin
fluid
csf
remain
essenti
treatment
stratif
mani
embryon
brain
tumor
howev
incid
signific
posit
csf
choroid
plexu
tumor
cpt
well
understood
therefor
csf
evalu
studi
registri
method
chart
review
central
review
cytolog
lumbar
ventricular
csf
result
cytospin
prepar
patient
male
femal
median
age
diagnosi
year
low
grade
cpt
choroid
plexu
papilloma
cpp
n
atyp
choroid
plexu
papilloma
app
n
posit
n
highli
suspici
n
tumor
cell
posit
csf
detect
median
day
tumor
resect
rang
day
day
complet
resect
primari
tumor
achiev
patient
mri
show
leptomening
dissemin
patient
patient
irradi
nine
patient
observ
nine
patient
diagnos
receiv
mean
six
chemotherapi
cycl
two
patient
app
postop
residu
tumor
one
patient
primarili
unresect
cpp
three
patient
posit
csf
three
patient
prior
cpc
app
cpp
refer
histolog
one
patient
app
treat
system
intrathec
chemotherapi
stage
patient
aliv
without
relaps
progress
median
year
conclus
cytomorpholog
examin
csf
requir
complet
stage
cpt
differenti
plexu
papilloma
cell
normal
choroid
plexu
ependym
cell
challeng
persist
tumor
cell
longer
day
tumor
resect
innocu
find
low
grade
cpt
may
reflect
uniqu
properti
cell
deriv
choroid
plexu
deferr
chemotherapi
justifi
cpp
complet
resect
app
posit
csf
cytolog
cknowledg
fund
german
childhood
cancer
foundat
dkk
decreas
morbid
mortal
chemotherapi
autolog
hematopoet
rescu
children
malign
brain
tumor
head
start
consortium
trial
c
altshul
jl
finlay
k
haley
g
dhall
l
vasquez
r
sposto
l
ji
gardner
head
start
consortium
hematologyoncolog
children
hospit
lo
angel
lo
angel
usa
pediatr
oncolog
divis
nyu
langon
medic
center
new
york
usa
object
sinc
three
sequenti
prospect
clinic
trial
includ
particip
institut
conduct
head
start
consortium
young
children
malign
brain
tumor
improv
cure
rate
qualiti
surviv
avoid
method
overal
treatment
design
remain
unchang
throughout
prospect
trial
previous
report
five
day
cycl
induct
chemotherapi
cisplatin
vincristin
cyclophosphamid
etoposid
hsi
withwithout
methotrex
oral
etoposid
oral
temozolomid
hsiii
follow
patient
minim
residu
tumor
singl
cycl
thiotepa
etoposid
day
preced
carboplatin
day
bone
marrow
hsi
leukapheres
peripher
hematopoiet
cell
neupogen
stimul
obtain
follow
recoveri
first
andor
second
induct
cycl
radiotherapi
reserv
patient
residu
tumor
follow
complet
induct
result
total
children
enrol
consecut
hs
trial
primari
malign
brain
spinal
cord
tumor
underw
chemotherapi
day
toxic
mortal
steadili
declin
hsi
hsii
hsiii
grade
iv
oropharyng
mucositisstomatitispain
declin
hsi
hsiii
grade
iv
infect
declin
hsi
hsiii
conclus
increas
experi
chemotherapi
regimen
combin
improv
leukapheresi
support
care
techniqu
like
contribut
steadi
declin
morbid
mortal
patient
popul
contribut
toward
improv
overal
surviv
manag
pediatr
brain
tumor
report
moroccan
societi
pediatr
hematolog
oncolog
l
hessissen
f
el
midaoui
cherkaoui
benmiloud
el
kababri
kili
j
houdzi
qaddoumi
e
bouffet
karkouri
moham
v
univers
souissi
pediatr
center
rabat
morocco
medic
school
casablanca
pediatr
center
casablanca
morocco
medic
school
fez
pediatr
center
fez
morocco
medic
school
marrakech
pediatr
center
marrakech
morocco
st
jude
children
research
hospit
pediatr
center
memphi
usa
sick
children
hospit
pediatr
center
toronto
canada
medic
school
casablanca
patholog
center
casablanca
morocco
object
brain
tumor
bt
frequent
solid
tumor
children
inform
manag
low
incom
countri
lack
method
nation
multidisciplinari
group
children
bt
implement
februari
morocco
improv
commun
among
healthcar
provid
develop
adapt
protocol
decreas
referr
time
treatment
delay
improv
data
collect
group
includ
four
pediatr
oncolog
center
morocco
rabat
marrakech
fez
casablanca
intern
expert
st
jude
children
research
hospit
sick
children
hospit
toronto
commun
onlin
meet
via
http
web
site
use
discuss
patient
care
develop
protocol
administr
issu
plan
two
brain
tumor
workshop
morocco
result
januari
till
decemb
data
pediatr
bt
case
center
estim
treat
pediatr
cancer
morocco
avail
case
repres
approxim
rang
pediatr
cancer
treat
three
center
studi
period
malefemal
ratio
median
age
year
rang
month
year
patient
fossa
posterior
lesion
histolog
type
accord
classif
report
patient
astrocytoma
medulloblastomapnet
ependymoma
plexu
choroid
carcinoma
one
pineoblastoma
one
oligodendrogli
tumor
follow
data
avail
patient
aliv
complet
remiss
aliv
residu
diseas
progress
diseas
die
statu
unknown
lost
follow
abandon
referr
abroad
conclus
low
accrual
rate
poor
surviv
abandon
still
major
obstacl
face
bt
manag
morocco
hope
nation
bt
group
multidisciplinari
approach
collabor
intern
expert
overcom
obstacl
work
learn
fonseca
linar
sarmiento
k
scheinemann
pediatr
hematologyoncolog
hospit
sick
children
toronto
canada
pediatr
hematologyoncolog
universidad
nacion
de
colombiafundacion
hospit
la
misericordia
bogota
colombia
pediatr
hematologyoncolog
fundacion
hospit
la
misericordia
bogota
colombia
pediatr
hematologyoncolog
germani
object
collabor
canada
colombia
improv
manag
central
nervou
system
cn
tumor
start
begin
colombia
countri
estim
brain
tumor
diagnos
per
year
health
insur
individu
respons
case
bring
intrins
challeng
time
diagnosi
treatment
brain
tumor
method
monthli
teleconfer
tumor
board
use
platform
held
sinc
march
requir
comput
internet
access
particip
center
result
last
month
tumor
board
held
case
review
averag
case
per
session
averag
number
attende
center
present
tumor
board
center
present
session
held
center
multipl
citi
colombia
bogota
cartagena
neiva
particip
diagnos
review
includ
astrocytoma
medulloblastoma
ependymoma
pnet
cn
sarcoma
other
area
improv
identifi
uncommon
identifi
delay
referr
tertiari
center
adjuv
treatment
initi
surgic
intervent
unfortun
administr
healthcar
issu
neg
impact
time
manag
patient
brain
tumor
delay
acquisit
appropri
imag
intervent
frequent
nation
guidelin
manag
develop
conclus
collabor
project
establish
need
widespread
particip
multipl
center
appropri
impact
develop
nation
institut
treatment
guidelin
crucial
improv
time
treatment
guidelin
develop
prioriti
move
forward
manag
cn
tumor
colombia
metastat
rhabdoid
papillari
meningioma
braf
mutat
good
respons
person
therapi
oz
mordechai
postovski
e
vlodavski
eran
constantini
e
cagnano
ben
arush
pediatr
hematolog
oncolog
rambam
health
care
campu
haifa
israel
patholog
depart
rambam
health
care
campu
haifa
israel
radiolog
depart
rambam
health
care
campu
haifa
israel
pediatr
neurosurgeri
unit
tel
souraski
medic
center
tel
aviv
israel
patholog
depart
tel
souraski
medic
center
tel
aviv
israel
object
papillari
rhabdoid
meningioma
agress
histolog
variant
meningioma
account
meningioma
clinic
cours
agress
time
diseas
dissemin
csf
frequent
local
recurr
method
describ
case
year
old
femal
histori
headach
phonophobia
photophobia
brain
mri
demonstr
right
tempor
tumor
frontotempor
craniotomi
perform
tumor
macroscop
excis
histopatholog
examin
demonstr
diagnosi
papillari
rhabdoid
meningioma
spine
mri
csf
cytolog
exclud
metastasi
extern
radiat
therapi
deliv
cgi
three
month
later
develop
recurr
headach
photophobia
cn
imag
reveal
massiv
right
hemispher
recurr
leptomening
spread
child
neurolog
statu
deterior
rapidli
left
hemiplegia
anisocoria
grade
ii
coma
despit
urgent
craniospin
irradi
result
specimen
tumor
sent
comprehens
genom
profil
assay
reveal
activ
braf
mutat
therapi
braf
inhibitor
dabrafenib
initi
dose
mg
bid
one
month
mg
bid
clinic
condit
child
improv
progress
month
later
start
walk
without
help
ad
mek
inhibitor
trametinib
dose
mg
daili
mg
accord
pk
valu
patient
one
year
start
target
therapi
go
school
complet
recuper
right
hemiplegi
normal
neurolog
function
conclus
effect
strategi
build
upon
success
seen
dabrafenib
trabetinib
monotherapi
melanoma
combin
agent
goal
improv
respons
rate
delay
resist
role
braf
rearrang
tailor
therapi
pediatr
malign
need
research
larger
pediatr
popul
neurocytoma
cleveland
clinic
experi
tekautz
e
murphi
chao
v
recino
g
barnett
j
wolff
burkhardt
brain
tumor
center
cleveland
clinic
cleveland
usa
radiat
oncolog
cleveland
clinic
cleveland
usa
neurooncolog
center
cleveland
clinic
cleveland
usa
pediatr
neurosurgeri
cleveland
clinic
cleveland
usa
pediatr
hematologyoncolog
cleveland
clinic
cleveland
usa
object
neurocytoma
uncommon
tumor
need
postop
therapi
controversi
review
cleveland
clinic
experi
method
patient
histolog
diagnosi
neurocytoma
identifi
databas
clinic
tumor
treatment
factor
evalu
surviv
time
calcul
use
method
result
seventeen
patient
neurocytoma
treat
age
diagnosi
year
median
year
thirteen
patient
male
caucasian
common
present
symptom
headach
n
gait
disturb
n
sixteen
patient
intraventricular
lesion
patient
underw
surgeri
gross
total
resect
gtr
subtot
resect
str
three
patient
str
biopsi
underw
adjuv
radiat
fraction
rt
one
stereotact
radiosurgeri
median
event
free
surviv
ef
year
project
year
ef
overal
surviv
os
degre
resect
correl
ef
median
year
patient
without
evid
diseas
develop
recurr
diseas
subsequ
underw
gtr
patient
treat
adjuv
radiat
experi
diseas
recurr
n
twelv
patient
result
avail
diagnosi
median
result
recurr
invari
higher
present
median
predict
ef
os
conclus
cohort
patient
median
ef
year
suggest
possibl
benefit
adjuv
radiotherapi
select
case
excel
os
suggest
patient
benefit
salvag
therapi
combin
surgeri
radiat
prospect
molecular
analys
tumor
may
identifi
risk
factor
diseas
recurr
help
determin
would
benefit
aggress
upfront
therapi
radiat
choroid
plexu
carcinoma
patient
syndrom
bahar
j
wolff
pediatr
cleveland
clinic
cleveland
usa
pediatr
hematologyoncolog
cleveland
clinic
cleveland
usa
object
choroid
plexu
carcinoma
cpc
rare
pediatr
tumor
often
associ
syndrom
lf
germ
line
mutat
tumor
suppressor
gene
predispos
cancer
standard
care
controversi
studi
recommend
radiat
therapi
treatment
modal
use
literatur
analysi
evalu
hypothesi
radiat
therapi
avoid
patient
cpc
lf
method
expand
preexist
cpc
literatur
databas
ad
case
cpc
lf
identifi
pubm
end
compar
surviv
use
kaplan
meier
curv
log
rank
test
restrict
analysi
cpc
patient
identifi
presenc
dysfunct
phenotyp
characterist
lf
compar
overal
surviv
patient
receiv
radiat
therapi
patient
treat
without
radiat
therapi
result
patient
document
cpc
lf
ten
receiv
radiat
fifteen
receiv
radiat
therapi
median
overal
surviv
lf
cpc
patient
year
standard
error
surviv
patient
receiv
radiat
inferior
without
radiat
mo
year
versu
kaplan
meier
curv
cross
log
rank
test
suggest
differ
statist
signific
p
conclus
differ
previou
analys
find
surviv
disadvantag
patient
lf
cpc
receiv
radiat
versu
simpli
suggest
radiat
shorten
live
patient
sinc
chemotherapi
differ
two
patient
group
howev
find
provid
evid
pursu
treatment
approach
includ
radiat
patient
continu
develop
nation
brain
tumour
canadian
paediatr
experi
brown
r
sinha
strother
e
bouffet
saskatchewan
cancer
agenc
univers
saskatchewan
regina
canada
royal
univers
hospit
univers
saskatchewan
saskatoon
canada
alberta
children
hospit
univers
calgari
calgari
canada
hospit
sick
children
univers
toronto
toronto
canada
object
canadian
paediatr
oncologist
recogn
benefit
establish
protocol
central
nervou
system
cn
tumour
open
intern
studi
avail
spearhead
format
canadian
paediatr
brain
tumour
consortium
cpbtc
cpbtc
includ
paediatr
oncolog
center
canada
develop
collabor
conduct
clinic
studi
aim
improv
knowledg
brain
tumour
develop
effect
therapi
maxim
qualiti
life
also
establish
foster
research
support
encourag
young
investig
review
develop
challeng
success
group
past
year
method
cpbtc
meet
minut
public
review
result
first
cpbtc
teleconfer
held
novemb
center
attend
number
center
particip
teleconfer
peak
februari
collabor
studi
face
challeng
multipl
ethic
review
board
submiss
develop
contract
institut
fund
limit
alloc
preferenti
patholog
review
data
collect
princip
investig
activ
studi
repres
particip
center
public
abstract
intern
meet
complet
clinic
trial
prospect
research
paper
consortium
collabor
handbook
press
particip
consortium
comprehens
reflect
multidisciplinari
approach
manag
paediatr
brain
tumour
patient
preclin
clinic
studi
complement
children
oncolog
group
cog
intern
societi
paediatr
oncolog
siop
cooper
group
trial
conclus
cpbtc
facilit
complet
sever
nation
base
project
recogn
vehicl
collabor
research
futur
goal
includ
develop
nation
virtual
tumour
bank
advocaci
canadian
nation
ethic
review
board
academ
recognit
particip
contribut
websit
success
grant
applic
key
fund
futur
collabor
use
positron
emiss
tomographi
paediatr
brain
tumour
gilbert
shankar
f
fraioli
gaze
stoneham
j
bomanji
depart
paediatr
adolesc
oncolog
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
depart
nuclear
medicin
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
depart
clinic
oncolog
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
object
magnet
reson
imag
convent
use
imag
central
nervou
system
cn
tumour
signific
limit
evalu
respons
treatment
mr
imag
positron
emiss
tomographi
pet
wide
utilis
imag
cancer
howev
fdg
main
tracer
clinic
use
unsuit
brain
imag
glucos
primari
substrat
brain
metabol
investig
whether
simultan
fech
petmri
function
paramet
maxim
standard
uptak
valu
suvmaxmean
appar
diffus
coeffici
adc
max
mean
viabl
option
diagnosi
treatment
respons
assess
children
histolog
confirm
astrocyt
tumour
method
eleven
patient
biopsi
proven
astrocytoma
inject
mbq
imag
perform
minut
later
use
hybrid
petmri
scanner
pet
data
acquir
simultan
mr
sequenc
suvmax
suvmean
adc
max
mean
whole
tumour
region
interest
record
result
baselin
area
match
area
contrast
enhanc
restrict
diffus
neg
correl
trend
suvmax
adcmean
posit
correl
trend
suvmax
tumour
size
concord
reduct
tumour
size
reduct
suvmax
suvmean
four
children
three
adcmean
valu
increas
two
patient
although
anatom
tumour
size
remain
stabl
suvmax
suvmean
valu
increas
reduct
adcmean
valu
addit
two
children
mri
show
increas
tumour
size
well
increas
suvmax
reduct
adc
valu
conclus
result
suggest
fluoroethylcholin
pet
combin
function
mri
high
degre
sensit
specif
may
better
tool
respons
assess
compar
convent
cross
section
mri
alon
intramedullari
spinal
cord
tumor
adolesc
patient
j
sun
z
wang
neurosurg
depart
peke
univers
third
hospit
beij
china
object
prospect
analyz
clinic
featur
characterist
intramedullari
spinal
cord
tumor
adolesc
patient
method
studi
consecut
adolesc
patient
intramedullari
spinal
cord
tumor
recruit
underw
microsurgeri
tumor
use
posterior
approach
hospit
peke
univers
third
hospit
within
period
year
tumor
expos
dorsal
myelotomi
preoper
postop
neurolog
function
score
use
improv
joa
ijoa
grade
system
function
outcom
defin
postop
ijoa
score
minu
preoper
ijoa
score
patient
jan
result
male
femal
adolesc
patient
younger
year
mean
age
year
common
initi
symptom
sensori
disturb
includ
pain
andor
numb
follow
motor
disturb
includ
limb
weak
gait
deterior
pain
motor
disturb
well
fever
limb
deform
sphincter
dysfunct
respect
preoper
ijoa
score
patient
postop
ijoa
score
patient
commonli
involv
locat
cervicothorac
segment
follow
conu
terminali
cervic
region
thorac
region
lumbu
region
averag
involv
segment
frequent
tumor
neurodevelopment
tumor
includ
lipoma
epidermoid
cyst
teratoma
follow
astrocytoma
ependymoma
hemangioblastoma
glioblastoma
schwannoma
respect
conclus
adolesc
patient
intramedullari
spinal
cord
tumor
commonli
involv
locat
cervicothorac
segment
conu
terminali
frequent
tumor
neurodevelopment
tumor
astrocytoma
good
prognosi
adolesc
patient
observ
childhood
malign
diseas
associ
neurofibromatosi
type
hacettep
experi
varan
h
sen
b
aydin
b
yalcin
kutluk
c
akyuz
dept
pediatr
oncolog
hacettep
institut
oncolog
ankara
turkey
object
evalu
clinic
characterist
prognosi
patient
nf
malign
exclud
optic
glioma
method
patient
nf
follow
center
found
malign
diseas
optic
glioma
malign
disord
file
patient
analyz
retrospect
term
clinic
featur
treatment
result
result
male
femal
ratio
patient
age
diagnosi
nf
year
median
year
diagnosi
malign
age
year
median
respect
sixteen
patient
diagnos
malign
simultan
histolog
subtyp
soft
tissu
tumor
malign
peripher
nerv
sheath
tumor
mpnst
five
rhabdomyosarcoma
one
malign
fibrou
histiocytoma
brain
tumor
three
grade
astrocytoma
glioblastoma
four
astrocytoma
two
medulloblastoma
one
cervic
pilocyt
astrocytoma
two
neuroblastoma
one
lymphoma
diseas
locat
posterior
fossa
three
patient
brain
tumor
three
patient
high
grade
glioma
one
lymphoma
one
medulloblastoma
two
rhabdomyosarcoma
one
astrocytoma
die
diseas
progress
despit
treatment
five
patient
diagnosi
mpnst
die
diseas
one
patient
diagnos
age
year
follow
remiss
month
twelv
patient
still
aliv
conclus
five
percent
patient
develop
malign
diseas
prognosi
poor
despit
treatment
close
regular
crucial
earli
detect
malign
nf
estim
incid
acut
leukemia
children
western
kenya
review
malaria
blood
smear
pilot
feasibl
studi
f
njuguna
j
skile
moormann
r
mukhwana
vik
child
health
paediatr
moi
univers
colleg
health
scienc
school
medicin
eldoret
kenya
pediatr
indiana
univers
school
medicin
indianapoli
usa
pediatr
univers
massachusett
school
medicin
worcest
usa
object
retrospect
review
malaria
slide
undertaken
epidemiolog
studi
estim
incid
acut
leukemia
kenya
determin
feasibl
util
malaria
slide
improv
detect
acut
leukemia
method
one
year
malaria
slide
collect
kital
district
hospit
kenya
secondari
review
train
technologist
perform
review
slide
first
screen
potenti
posit
slide
identifi
use
follow
criteria
estim
white
blood
cell
wbc
count
less
neutrophil
seen
blood
smear
identifi
two
author
review
photograph
posit
slide
cell
count
differenti
done
posit
slide
clinic
data
slide
obtain
hospit
record
result
slide
identifi
show
sign
possibl
leukemia
includ
leukocytosi
sever
neutropenia
review
slide
clinic
data
slide
show
combin
find
make
highli
probabl
indic
leukemia
slide
show
definit
sign
leukemia
mani
neutrophilia
suggest
acut
infect
slide
neutropenia
infant
one
year
age
malaria
third
group
slide
screen
show
neutropenia
review
neutrophil
distort
neutropenia
present
conclus
studi
demonstr
feasibl
use
slide
made
screen
malaria
also
screen
leukemia
base
number
like
posit
slide
identifi
estim
incid
acut
leukemia
childrenyear
similar
countri
plan
prospect
trial
screen
slide
identifi
patient
earlier
referr
diagnosi
treatment
cknowledg
support
alex
lemonad
stand
foundat
landscap
pediatr
adolesc
young
adult
thyroid
cancer
ontario
j
pole
zuk
jd
wasserman
research
unit
pediatr
oncolog
group
ontario
toronto
canada
dalla
lana
school
public
health
univers
toronto
toronto
canada
divis
endocrinolog
hospit
sick
children
toronto
canada
object
describ
current
landscap
thyroid
carcinoma
tc
diagnos
demograph
ontario
among
children
adolesc
young
adult
eighteen
year
period
method
retrospect
cohort
assembl
data
extract
provinci
cancer
registri
administr
databas
direct
incid
rate
calcul
result
total
children
youth
less
year
age
diagnos
thyroid
cancer
provinc
ontario
canada
overal
thyroid
cancer
incid
rate
per
increas
ci
ci
sex
specif
incid
rate
tc
nearli
doubl
femal
male
ci
ci
ci
ci
respect
common
histolog
type
includ
follicular
document
case
anaplast
thyroid
carcinoma
cohort
tc
second
primari
malign
individu
patient
primari
thyroid
cancer
develop
subsequ
malign
neoplasm
major
tc
case
resid
urban
area
death
among
diagnos
tc
case
period
conclus
report
popul
rise
incid
tc
diagnos
time
though
extent
increas
appear
limit
elsewher
explan
rise
incid
well
observ
associ
multipl
primari
malign
well
outcom
merit
investig
childhood
leukemia
incid
surviv
southern
thailand
k
deman
h
sriplung
r
meza
ls
rozek
pj
lupo
scheurer
environment
health
scienc
univers
michigan
ann
arbor
usa
epidemiolog
unit
princ
songkla
univers
songkhla
thailand
epidemiolog
univers
michigan
ann
arbor
usa
pediatr
baylor
colleg
medicin
houston
usa
object
dispar
exist
childhood
leukemia
detect
diagnosi
treatment
develop
develop
countri
analyz
childhood
acut
myeloid
aml
acut
lymphoblast
leukemia
incid
surviv
trend
songkhla
thailand
point
refer
compar
result
childhood
leukemia
incid
unit
state
us
use
surveil
epidemiolog
end
result
seer
data
method
use
registri
data
songkhla
case
leukemia
diagnos
children
age
among
vital
statu
time
leukemia
subgroup
classifi
use
intern
classif
childhood
cancer
definit
seer
data
obtain
seer
stat
incid
comput
standard
use
standard
popul
incid
trend
analyz
use
joinpoint
regress
percent
surviv
comput
year
year
diagnosi
analyz
use
univari
linear
regress
result
aml
compos
leukemia
case
songkhla
respect
overal
incid
aml
case
per
respect
incid
increas
per
year
songkhla
p
lower
compar
us
p
aml
incid
increas
per
year
p
songhkla
decreas
p
us
aml
incid
higher
songkhla
compar
us
p
songkhla
median
surviv
year
aml
year
percent
surviv
improv
annual
p
conclus
incid
leukemia
increas
songkhla
proport
aml
case
higher
compar
us
surviv
improv
lower
us
tempor
chang
leukemia
incid
surviv
warrant
investig
novel
risk
factor
throughout
thailand
trend
hepatoblastoma
incid
among
children
adolesc
unit
state
racial
ethnic
dispar
r
amorim
r
nave
k
ribeiro
c
depart
social
medicin
faculdad
de
da
santa
casa
de
paulo
sao
paulo
brazil
pediatr
oncolog
children
cancer
blood
disord
center
boston
usa
object
low
birth
weight
lbw
associ
high
risk
develop
hepatoblastoma
preval
low
vlbw
lbw
significantli
increas
unit
state
last
decad
particularli
among
hispan
due
increas
special
deliv
neonat
health
care
aim
studi
evalu
trend
hepatoblastoma
incid
accord
sex
race
ethnic
method
retriev
data
nation
program
cancer
registri
npcr
databas
state
district
columbia
children
age
year
diagnos
hepatoblastoma
iccc
group
viia
includ
studi
incid
rate
asir
calcul
accord
sex
race
ethnic
use
segi
popul
trend
time
averag
annual
percent
chang
aapc
assess
use
joinpoint
regress
model
result
new
hepatoblastoma
case
regist
period
incid
significantli
higher
among
male
rate
ratio
ci
highest
lowest
incid
rate
observ
among
asian
asir
black
asir
respect
hispan
show
higher
incid
asir
compar
asir
differ
statist
signific
rr
ci
overal
signific
increas
incid
hepatoblastoma
observ
period
aapc
ci
howev
trend
statist
signific
male
aapc
ci
stratifi
analysi
ethnic
shown
per
year
increas
aapc
ci
larger
increas
observ
hispan
although
statist
signific
aapc
ci
largest
increas
trend
hepatoblastoma
incid
observ
among
black
aapc
ci
conclus
document
substanti
differ
incid
hepatoblastoma
among
differ
ethnic
racial
group
given
known
correl
hepatoblastoma
lbw
whether
differ
repres
ethnic
racial
variat
barrier
prenat
neonat
care
need
determin
use
trend
analysi
illustr
residu
cancer
dispar
surviv
childhood
embryon
tumor
p
friedrich
e
itriago
c
k
ribeiro
pediatr
oncolog
children
cancer
blood
disord
center
boston
usa
depart
social
medicin
faculdad
de
da
santa
casa
sao
paulo
brazil
object
trend
surviv
childhood
embryon
tumor
fulli
explor
perspect
cancer
dispar
studi
aim
assess
trend
identifi
residu
dispar
method
case
neuroblastoma
retinoblastoma
nephroblastoma
hepatoblastoma
rhabdomyosarcoma
germ
cell
tumor
gct
among
children
year
old
diagnos
retriev
data
data
raceethn
categori
includ
hispan
american
pacif
island
api
american
indianalaska
nativ
overal
surviv
obtain
use
kaplan
meier
method
annual
percentag
chang
apc
obtain
use
jointpoint
result
inclus
criteria
retriev
case
pairwis
comparison
raceethn
categori
recent
analyz
period
show
signific
differ
surviv
neuroblastoma
black
vs
white
vs
p
rhabdomyosarcoma
api
vs
white
vs
p
trend
analysi
cohort
show
signific
increas
apc
white
although
posit
signific
minor
hispan
black
api
posit
trend
achiev
signific
found
neuroblastoma
white
hispan
api
sinc
black
hispan
hepatoblastoma
nephroblastoma
show
neg
surviv
trend
achiev
signific
respect
white
show
signific
improv
surviv
hepatoblastoma
nephroblastoma
rel
flat
converg
trend
note
retinoblastoma
rhabdomyosarcoma
germ
cell
tumor
possibl
diverg
trend
note
neuroblastoma
nephroblastoma
hepatoblastoma
conclus
standard
surviv
analysi
use
pairwis
comparison
magnitud
specif
recent
time
interv
would
miss
dispar
identifi
although
number
case
rel
low
pediatr
oncolog
solid
tumor
trend
analysi
use
jointpoint
allow
better
illustr
possibl
residu
pediatr
cancer
surviv
dispar
spatial
cluster
cancer
children
young
peopl
northern
england
r
mcnalli
pw
jame
aw
craft
institut
health
societi
newcastl
univers
newcastl
upon
tyne
unit
kingdom
northern
institut
cancer
research
newcastl
univers
newcastl
upon
tyne
unit
kingdom
object
aetiolog
childhood
cancer
well
understood
genet
environment
factor
like
involv
spatial
cluster
occur
case
display
irregular
geograph
distribut
small
number
localis
area
larg
excess
larg
number
area
modest
excess
assess
whether
localis
environment
factor
may
play
role
aetiolog
test
spatial
cluster
address
birth
diagnosi
use
data
northern
england
method
extract
case
cancer
diagnos
children
young
peopl
age
year
period
northern
region
young
person
malign
diseas
registri
registri
includ
case
cancer
children
young
adult
resid
time
diagnosi
northern
england
popul
age
year
area
overal
cluster
analysi
perform
use
point
process
method
test
null
hypothesi
diseas
risk
vari
spatial
case
occur
independ
kulldorff
scan
statist
base
bernoulli
model
use
test
individu
cluster
result
base
address
birth
diagnosi
evid
overal
cluster
leukaemia
lymphoma
central
nervou
system
cn
tumour
sympathet
nervou
system
tumour
retinoblastoma
germ
cell
tumour
carcinoma
p
base
address
birth
evid
overal
spatial
cluster
soft
tissu
sarcoma
p
base
address
birth
kulldorff
scan
statist
detect
individu
spatial
cluster
cn
renal
bone
tumour
p
base
address
diagnosi
individu
spatial
cluster
carcinoma
p
conclus
studi
suggest
spatial
vari
environment
factor
may
implic
aetiolog
number
differ
cancer
racial
ethnic
dispar
pediatr
embryon
tumor
incid
unit
state
true
effect
confound
socioeconom
statu
p
friedrich
e
itriago
c
k
ribeiro
pediatr
oncolog
children
cancer
blood
disord
center
boston
usa
depart
social
medicin
faculdad
de
da
santa
casa
sao
paulo
brazil
object
racial
ethnic
dispar
incid
embryon
tumor
fulli
explor
exist
studi
often
address
racial
dispar
fail
incorpor
ethnic
control
socioeconom
statu
se
method
case
neuroblastoma
retinoblastoma
nephroblastoma
hepatoblastoma
rhabdomyosarcoma
germ
cell
tumor
gct
among
children
year
old
diagnos
retriev
databas
raceethn
categori
includ
hispan
american
pacif
island
api
american
indianalaska
nativ
incid
rate
rate
ratio
rr
obtain
counti
data
poverti
level
use
stratifi
analysi
se
result
hispan
present
lower
incid
neuroblastoma
compar
white
rr
p
effect
remain
signific
adjust
se
higher
incid
retinoblastoma
observ
among
hispan
rr
p
bilater
diseas
particular
rr
p
effect
dissip
control
se
compar
white
hispan
rr
p
api
rr
p
lower
risk
nephroblastoma
although
hispan
associ
lost
signific
low
se
group
risk
hepatoblastoma
lower
among
black
rr
p
effect
remain
signific
adjust
se
rhabdomyosarcoma
incid
lower
among
hispan
rr
p
effect
observ
control
se
incid
gct
higher
among
hispan
rr
p
lower
among
black
rr
p
api
rr
p
effect
hispan
api
modifi
se
conclus
ethnic
dispar
incid
tumor
document
use
data
particularli
neuroblastoma
hepatoblastoma
effect
modif
confound
se
observ
subgroup
analys
adequ
control
se
key
analyz
interpret
racial
ethnic
dispar
childhood
embryon
tumor
incid
inferior
surviv
among
aborigin
children
cancer
ontario
marjerrison
jd
pole
l
sung
divis
hematologyoncolog
mcmaster
children
hospit
hamilton
canada
research
divis
pediatr
oncolog
group
ontario
toronto
canada
divis
haematologyoncolog
hospit
sick
children
toronto
canada
object
pediatr
cancer
distribut
outcom
examin
canadian
aborigin
children
object
describ
distribut
surviv
overal
surviv
aborigin
children
malign
resid
ontario
compar
children
method
studi
includ
ontario
children
year
cancer
diagnos
case
identifi
pediatr
oncolog
group
ontario
network
inform
system
databas
aborigin
children
identifi
ethnic
postal
code
nativ
reserv
diagnosi
case
present
descript
statist
compar
use
fisher
exact
test
overal
surviv
probabl
calcul
aborigin
children
describ
curv
compar
test
result
identifi
aborigin
children
malign
distribut
malign
type
similar
signific
differ
baselin
characterist
presenc
metastat
diseas
treatment
approach
clinic
trial
standard
care
individu
protocol
group
surviv
standard
error
among
aborigin
children
vs
among
children
p
overal
surviv
vs
p
respect
caus
death
vari
aborigin
ethnic
conclus
surviv
significantli
inferior
among
aborigin
children
cancer
compar
children
cancer
ontario
futur
studi
requir
defin
etiolog
dispar
evalu
issu
nation
creat
intervent
improv
outcom
aborigin
children
genet
suscept
langerhan
cell
histiocytosi
pilot
associ
studi
use
triad
p
lupo
scheurer
j
belmont
tsavachidi
shih
simko
h
abhyankar
r
chakraborti
k
lim
k
mcclain
c
allen
pediatr
baylor
colleg
medicin
houston
usa
pediatr
baylor
colleg
medicin
houston
usa
object
langerhan
cell
histiocytosi
lch
inflammatori
myeloid
neoplasia
character
accumul
clonal
myeloid
dendrit
cell
lch
present
commonli
infant
children
incid
lch
estim
two
ten
case
per
million
children
year
age
younger
spite
clinic
complic
associ
lch
littl
known
genet
suscept
condit
character
germlin
genet
suscept
childhood
lch
perform
preliminari
associ
studi
gwa
use
triad
method
triad
studi
design
util
robust
popul
stratif
bia
baylor
colleg
medicin
institut
review
board
approv
studi
protocol
inform
consent
obtain
particip
lch
case
parent
recruit
texa
children
cancer
center
dna
sampl
triad
genotyp
laboratori
translat
genom
baylor
colleg
medicin
use
illumina
beadchip
singl
nucleotid
polymorph
snp
exclud
base
follow
criteria
genotyp
success
rate
minor
allel
frequenc
http
wwwbiostatharvardedufbatfbathtm
result
exclus
snp
includ
associ
analysi
eleven
snp
identifi
three
snp
identifi
specif
intron
intergen
snp
chromosom
p
x
chromosom
p
x
chromosom
p
x
associ
lch
risk
conclus
find
must
replic
independ
popul
suggest
inherit
genet
variat
may
relev
suscept
lch
current
expand
studi
plan
valid
find
expand
analys
methodolog
preliminari
assess
matern
genet
effect
childhood
acut
lymphoblast
leukemia
p
lupo
plon
ritter
wheeler
tsavachidi
r
zabriski
scheurer
pediatr
baylor
colleg
medicin
houston
usa
human
genom
sequenc
center
baylor
colleg
medicin
houston
usa
object
recent
evid
associ
studi
gwa
suggest
suscept
childhood
acut
lymphoblast
leukemia
influenc
sever
genet
loci
studi
focus
role
singl
nucleotid
polymorph
snp
carri
affect
individu
biolog
mechan
may
also
involv
may
aris
utero
one
mechan
involv
matern
genet
effect
specif
variat
matern
genom
could
affect
intrauterin
environ
essenti
normal
hematopoeisi
therefor
conduct
preliminari
assess
matern
genet
effect
risk
childhood
method
case
parent
recruit
texa
children
cancer
center
period
baylor
colleg
medicin
institut
review
board
approv
studi
protocol
inform
consent
obtain
particip
dna
sampl
complet
trio
genotyp
use
illumina
humancor
beadchip
appli
model
investig
whether
polymorph
matern
gene
influenc
risk
case
result
three
matern
snp
identifi
associ
p
x
specif
matern
genotyp
p
x
p
x
p
x
significantli
associ
childhood
risk
matern
genet
effect
independ
respect
genotyp
child
conclus
complet
evalu
matern
genet
effect
leukemia
risk
abl
identifi
snp
signific
effect
three
gene
implic
divers
physiolog
includ
previou
gwa
cardiovascular
trait
transmiss
allel
father
tumor
suppress
find
must
valid
suggest
matern
genet
effect
may
relev
risk
cknowledg
cancer
prevent
research
institut
texa
grant
number
improv
abandon
refus
therapi
pediatr
patient
cancer
guatemala
unidad
nacion
de
unop
e
alvarez
seppa
k
messacar
j
kurap
e
riva
bustamant
howard
b
efron
pediatr
hematologyoncologysctcanc
biolog
divis
stanford
univers
palo
alto
usa
depart
pediatr
infecti
diseas
univers
colorado
denver
usa
famili
medicin
hilo
bay
clinic
hilo
usa
pediatrica
unidad
nacion
de
pediatrica
guatemala
citi
guatemala
pediatr
oncolog
saint
jude
children
research
hospit
memphi
usa
depart
statist
biostatist
stanford
univers
palo
alto
usa
object
abandon
cancer
therapi
major
caus
therapeut
failur
histor
guatemala
high
rate
abandon
studi
examin
rate
abandon
time
guatemalan
children
identifi
factor
associ
increas
risk
abandon
method
retrospect
studi
children
cancer
age
seen
unop
guatemala
perform
patient
data
collect
pediatr
oncolog
network
databas
analyz
year
start
therapi
abandon
defin
laps
week
plan
treatment
refus
defin
failur
begin
treatment
cox
proport
hazard
analysi
identifi
effect
age
sex
year
diagnosi
distanc
ethnic
princip
diagnosi
abandon
therapi
outcom
measur
abandon
refus
result
chart
analyz
abandon
refus
therapi
time
rate
abandonmentrefus
decreas
greater
distanc
center
p
younger
age
p
earlier
year
diagnosi
p
associ
increas
risk
abandon
refus
indigen
ethnic
p
addit
associ
increas
risk
abandon
sex
cancer
diagnosi
signific
abandon
therapi
correl
decreas
surviv
patient
known
outcom
cumul
surviv
year
surviv
se
abandon
vs
complet
therapi
conclus
abandon
therapi
decreas
time
guatemala
correspond
establish
unop
central
pediatr
cancer
treatment
center
creation
psychosoci
team
target
famili
risk
abandon
research
need
investig
effect
socioeconom
factor
target
intervent
abandon
surviv
gap
children
cancer
incom
countri
lesson
king
hussein
cancer
center
jordan
sultan
r
rihani
f
madanat
sc
howard
pediatr
king
hussein
cancer
center
amman
jordan
pediatr
st
jude
children
research
hospit
memphi
usa
object
heterogen
outcom
children
cancer
around
world
standard
method
compar
outcom
children
cancer
need
use
open
access
databas
compar
surviv
children
center
method
depart
use
pediatr
oncolog
network
databas
pond
regist
patient
sinc
data
collect
includ
demograph
patholog
stage
risk
stratif
major
toxic
outcom
compar
distribut
case
outcom
regist
till
data
obtain
seer
databas
till
result
compar
patient
regist
pond
patient
regist
seer
mean
age
group
year
respect
p
diagnosi
distribut
similar
higher
percentag
patient
bone
tumor
retinoblastoma
center
significantli
better
surviv
seer
patient
compar
popul
seer
os
vs
pond
os
p
analysi
restrict
specif
diseas
surviv
patient
lymphoma
similar
record
seer
respect
hand
patient
aml
solid
tumor
cn
tumor
retinoblastoma
wors
outcom
popul
among
patient
outcom
jordanian
superior
particularli
patient
solid
tumor
compar
previou
report
center
notic
previou
public
bia
medulloblastoma
rhabdomyosarcoma
retinoblastoma
conclus
use
combin
prospect
databas
calcul
surviv
gap
popul
analysi
need
studi
reason
differ
particularli
patient
solid
tumor
brain
tumor
could
reflect
differ
referr
pattern
variat
manag
propos
method
easili
use
center
calcul
surviv
gap
accur
establish
incid
characterist
symptomat
venou
thrombot
event
pediatr
oncolog
patient
maritim
canada
popul
base
studi
k
kulkarni
mac
donald
v
price
c
fernandez
p
cox
j
berman
bernstein
b
crook
afzal
yhap
pediatr
hematolog
oncolog
iwk
health
centr
dalhousi
univers
halifax
canada
object
venou
thrombot
event
vte
recogn
import
complic
pediatr
cancer
patient
report
incid
characterist
vte
literatur
highli
variabl
due
vari
studi
methodolog
lack
popul
base
data
present
studi
done
establish
incid
characterist
symptomat
vte
pediatr
cancer
patient
maritim
provinc
nova
scotia
new
brunswick
princ
edward
island
receiv
central
oncolog
care
singl
tertiari
care
centr
method
pediatr
cancer
patient
maritim
manag
iwk
health
center
halifax
share
care
model
region
provinci
hospit
ethic
approv
case
record
cancer
patient
year
age
diagnos
manag
iwk
health
center
januari
march
retriev
data
multipl
databas
integr
includ
pediatr
oncolog
hospit
databas
ii
provinci
children
young
peopl
databas
iii
electron
medic
record
iv
pharmaci
databas
v
hospit
health
record
use
databas
patient
symptomat
vte
patient
signssymptom
directli
relat
vte
treat
anticoagul
identifi
data
analyz
use
spss
result
cancer
patient
diagnos
studi
period
n
symptomat
vte
mean
age
vte
diagnosi
month
year
male
femal
ratio
median
time
vte
cancer
diagnosi
day
within
month
approxim
second
vte
approxim
patient
vte
requir
central
venou
cathet
conclus
present
studi
one
first
establish
popul
base
incid
symptomat
vte
pediatr
oncolog
popul
addit
analysi
incorpor
larger
geograph
area
durat
need
valid
observ
rout
diagnosi
childhood
young
adult
cancer
within
inpati
hospit
care
servic
yorkshir
uk
c
lethabi
r
feltbow
kinsey
picton
van
laar
centr
biostatist
epidemiolog
leed
institut
genet
health
therapeut
leed
unit
kingdom
yorkshir
region
centr
paediatr
oncolog
haematolog
leed
teach
hospit
trust
leed
unit
kingdom
object
pathway
diagnosi
children
young
adult
cya
cancer
often
complex
develop
understand
pathway
vital
develop
effect
strategi
improv
time
diagnosi
studi
investig
admiss
rout
inpati
care
cya
diagnos
cancer
order
improv
understand
uniqu
cohort
access
healthcar
method
case
cancer
diagnos
age
year
yorkshir
identifi
yorkshir
specialist
registri
cancer
children
young
peopl
n
case
data
link
inpati
hospit
record
contain
code
clinic
data
admiss
rout
inpati
event
cancer
specif
alert
code
identifi
inpati
event
preced
coincid
date
definit
diagnosi
review
accept
uk
cya
cancer
awar
campaign
initi
admiss
rout
inpati
event
contain
alert
code
identifi
assess
children
year
young
adult
year
result
identifi
case
cancer
specif
alert
code
within
inpati
admiss
case
initi
admit
via
emerg
rout
emerg
rout
includ
admiss
via
accid
emerg
e
via
primari
care
via
outpati
care
categoris
emerg
rout
overal
proport
initi
emerg
admiss
rout
similar
children
young
adult
distribut
emerg
subgroup
also
similar
age
group
conclus
emerg
admiss
play
import
role
within
pathway
diagnosi
children
young
adult
cancer
predomin
e
admiss
within
initi
inpati
event
potenti
identifi
need
target
intervent
within
area
healthcar
structur
clinic
find
oncolog
emerg
diagnosi
iehara
k
tsuchiya
k
ouchi
miyachi
kuwahara
fumino
tajiri
h
hosoi
pediatr
kyoto
prefectur
univers
medicin
kyoto
japan
pediatr
surgeri
kyoto
prefectur
univers
medicin
kyoto
japan
object
oncolog
emerg
condit
requir
immedi
intervent
children
cancer
requir
emerg
respons
time
diagnosi
howev
requir
intens
care
manag
especi
need
rapid
diagnosi
control
aim
studi
clarifi
care
oncolog
emerg
case
examin
clinic
featur
first
visit
well
prognosi
method
retrospect
review
data
patient
cancer
treat
institut
period
seven
year
result
seventeen
children
exhibit
oncolog
emerg
first
visit
median
age
diagnosi
year
among
oncolog
emerg
patient
year
among
patient
averag
length
stay
picu
pediatr
intens
care
unit
among
emerg
patient
day
frequent
symptom
first
visit
hospit
dyspnea
due
acut
airway
obstruct
follow
cough
abdomin
pain
respect
frequent
oncolog
emerg
diseas
lymphoma
emerg
treatment
intub
surgeri
drainag
perform
respect
one
patient
experienc
death
acut
phase
within
day
first
visit
differ
overal
surviv
oncolog
emerg
case
overal
surviv
rate
respect
p
conclus
prognosi
children
oncolog
emerg
necessarili
poor
physician
understand
clinic
sign
provid
appropri
manag
percept
attitud
toward
genet
test
cancer
parent
children
cn
tumor
k
khaleifeh
u
tabbori
e
bouffet
n
amayiri
nurs
depart
king
hussein
cancer
center
amman
jordan
offic
scientif
affair
research
king
hussein
cancer
center
amman
jordan
pediatr
hematolog
oncolog
hospit
sick
children
toronto
canada
pediatr
king
hussein
cancer
center
amman
jordan
object
genet
predisposit
increasingli
accept
caus
childhood
cancer
aim
explor
percept
attitud
parent
children
cn
tumor
toward
genet
cancer
especi
import
countri
high
consanguin
cultur
factor
may
neg
impact
method
paper
valid
questionnair
administ
parent
regular
outpati
visit
pediatr
clinic
king
hussein
cancer
center
jordan
analyz
parent
demograph
knowledg
percept
genet
predisposit
attitud
toward
genet
test
result
questionnair
distribut
respons
rate
parent
report
famili
histori
cancer
rel
death
cancer
consanguin
found
famili
genet
predisposit
thought
caus
cancer
parent
half
parent
agre
consanguin
marriag
increas
risk
parent
believ
earli
detect
cancer
screen
improv
cure
rate
knowledg
genet
predisposit
may
contribut
surviv
half
parent
think
posit
genet
test
would
affect
neg
futur
live
children
howev
major
believ
pediatr
oncologist
inform
genet
predisposit
suspect
parent
would
genet
test
avail
want
know
posit
result
parent
inform
famili
member
posit
result
start
screen
improv
surviv
genet
test
posit
parent
compli
cancer
screen
investig
even
frequent
conclus
major
parent
want
genet
test
cancer
strongli
believ
cancer
screen
improv
surviv
encourag
oncologist
challeng
social
cultur
barrier
discuss
sensit
topic
famili
offer
genet
test
especi
commun
high
consanguin
clinic
characterist
patient
germlin
sufu
mutat
l
guillaudbatail
f
bourdeaut
puget
c
dufour
j
grill
b
bressac
e
sariban
c
vilain
b
isidor
l
mansuy
winship
delattr
valteau
couanet
l
brugier
gustav
roussi
villejuif
franc
genet
gustav
roussi
villejuif
franc
pediatri
institut
curi
pari
franc
pediatri
necker
univers
hospit
pari
franc
pediatri
gustav
roussi
villejuif
franc
pediatri
hopit
universitair
de
enfant
de
la
rein
fabiola
bruxel
belgium
pediatri
chu
nant
nant
franc
pediatri
chu
nanci
nanci
franc
genet
univers
melbourn
melbourn
australia
genet
institut
curi
pari
franc
object
germlin
mutat
sufu
gene
recent
describ
associ
medulloblastoma
case
describ
literatur
far
method
perform
retrospect
review
clinic
file
molecular
data
patient
germlin
sufu
mutat
diagnos
institut
gustav
roussi
institut
curi
genet
laboratori
result
patient
famili
diagnos
germlin
sufu
mutat
frameshift
splice
nonsens
larg
rearrang
one
missens
patient
diagnos
medulloblastoma
median
age
month
rang
desmoplast
extens
nodular
classic
indic
test
two
patient
presenc
famili
histori
medulloblastoma
criteria
gorlin
syndrom
basocellular
carcinoma
cbc
without
germlin
ptch
mutat
second
macrocrania
describ
patient
histori
medulloblastoma
sibl
describ
famili
mutat
inherit
patient
whose
parent
underw
genet
test
de
novo
case
overal
healthi
carrier
identifi
famili
second
malign
describ
medulloblastoma
patient
includ
multipl
cbc
ovarian
tumor
meningioma
thyroid
carcinoma
addit
sever
mutat
carrier
famili
member
diagnos
cancer
breast
cancer
meningioma
cbc
sarcoma
year
age
conclus
sufu
germlin
mutat
predispos
medulloblastoma
mostli
desmoplasticnodular
extens
nodular
subtyp
first
year
life
often
associ
macrocrania
patient
also
develop
basocellular
carcinoma
due
incomplet
penetr
genet
counsel
difficult
intern
collabor
necessari
order
better
defin
risk
associ
mutat
guidelin
surveil
retroperiton
teratoma
lesson
learn
case
helouri
nyo
king
nightingal
p
ferguson
md
leclair
pk
krishnan
urolog
royal
childrenshospit
melbourn
australia
pediatr
surgeri
monash
children
clayton
australia
pediatr
surgeri
nant
univers
hospit
nant
franc
pediatr
surgeri
singapor
singapor
object
retroperiton
teratoma
rpt
uncommon
tumor
children
purpos
paper
review
present
manag
outcom
children
rpt
method
retrospect
multi
centric
melbourn
children
hospit
nation
univers
hospit
singapor
nant
univers
hospit
review
children
rpt
encount
year
period
carri
age
present
sex
tumor
marker
level
oper
find
surgic
complic
histolog
outcom
evalu
result
thirteen
patient
femal
syndrom
patient
surgeri
year
age
patient
rais
afp
age
median
size
tumor
rang
surgic
resect
perform
patient
difficulti
resect
due
distort
vascular
anatomi
report
injuri
vessel
ivc
splenic
arteri
polar
renal
arteri
organ
remov
nephrectomi
complet
resect
achiev
patient
histolog
matur
teratoma
patient
immatur
teratoma
median
durat
follow
month
rang
month
year
recurr
immatur
teratoma
lung
iliac
bone
post
oper
complic
includ
intussuscept
requir
oper
reduct
one
splenic
arteri
thrombosi
one
persist
hypertens
conclus
rpt
uncommon
tumor
childhood
primarili
present
infant
major
tumor
benign
preoper
evalu
ct
scan
andor
mri
anatom
distort
mandatori
manag
complex
surgic
resect
complet
excis
cornerston
treatment
improv
surviv
extracrani
germ
cell
tumor
develop
countri
children
hospit
lahor
experi
ahmad
n
asghar
aw
rathor
faizan
ali
paediatr
oncolog
children
hospit
ich
lahor
pakistan
object
children
hospit
lahor
tertiari
govern
centr
provid
free
cancer
treatment
new
cancer
patient
per
year
purpos
studi
analyz
outcom
children
extracrani
gct
discuss
role
multidisciplinari
team
manag
social
support
improv
surviv
develop
countri
method
retrospect
review
patient
enrol
januari
januari
done
data
regard
age
site
stage
histopatholog
risk
stratif
afp
level
treatment
outcom
impact
mdt
approach
analyz
patient
treat
accord
ukccsg
gc
protocol
result
total
patient
age
rang
year
yr
includ
f
ratio
hpe
show
predomin
yolk
sac
tumor
follow
matur
teratoma
dysgerminoma
mmgct
jgcto
immatur
unspecifi
present
stage
stage
iii
stage
ii
gonad
common
site
follow
scct
abdomin
head
neck
thorax
afp
level
found
total
complet
treatment
treatment
lama
expir
due
metastat
progress
diseas
expiri
scct
group
two
patient
relaps
complet
event
note
stage
iv
patient
stage
iii
patient
effici
mdt
util
case
reduc
lama
rate
compar
siop
data
conclus
surviv
fair
whole
group
treat
group
mortal
reduc
earli
manag
infect
control
strategi
prognosi
significantli
improv
public
awar
seek
earli
treatment
establish
multidisciplinari
team
approach
effect
social
support
especi
scct
group
icccpo
parentsurvivor
nationwid
activ
intern
childhood
cancer
day
children
cancer
associ
japan
ccaj
kawaguchi
katayama
k
nonomura
k
okab
secretariat
children
cancer
associ
japan
tokyo
japan
object
children
cancer
associ
japan
ccaj
organ
found
desper
effort
two
parent
lost
children
due
cancer
around
intern
childhood
cancer
day
iccd
year
ccaj
nationwid
branch
implement
enlighten
campaign
togeth
let
ordinari
public
know
even
children
chanc
suffer
cancer
hand
campaign
card
includ
statement
earli
detect
import
save
children
cancer
show
earli
warn
sign
method
ccaj
defin
period
februari
march
date
campaign
tool
campaign
prepar
campaign
card
origin
blue
yellowish
logo
intern
childhood
cancer
day
distribut
exchang
donat
also
prepar
piec
origin
pocket
tissu
descript
ccaj
contact
list
ccaj
announc
campaign
iccd
specif
schedul
member
govern
offic
hospit
public
health
center
busi
corpor
mean
bulletin
websit
weblog
activ
campaign
also
releas
nation
local
media
result
tool
campaign
iccd
hand
campaign
card
piec
origin
pocket
tissu
distribut
conclus
could
strengthen
teamwork
ccaj
headquart
branch
activ
campaign
around
iccd
also
could
share
import
awar
childhood
cancer
branch
member
also
third
parti
involv
campaign
ie
govern
offic
hospit
public
health
center
busi
corpor
volunt
histor
focu
childhood
cancer
survivor
longev
awar
new
approach
r
rohrer
human
seton
hill
univers
greensburg
usa
object
construct
overview
histor
develop
childhood
cancer
survivorship
first
number
long
term
survivor
present
time
studi
explor
surviv
issu
chang
surviv
rate
increas
method
author
consult
archiv
nation
cancer
institut
nation
librari
medicin
nation
institut
health
librari
archiv
memori
sloan
ketter
cancer
center
person
account
childhood
cancer
survivor
famili
well
letter
articl
author
primari
sourc
studi
period
sinc
patient
famili
interview
also
key
sourc
result
present
focus
organ
proactiv
approach
taken
medic
psycho
social
team
provid
cure
whole
child
advanc
support
therapi
rehabilit
therapi
divers
late
effect
often
identifi
develop
countri
unit
state
focu
studi
emphasi
place
upon
role
internist
famili
physician
role
provid
follow
care
former
pediatr
cancer
patient
self
awar
long
term
effect
also
mission
children
oncolog
group
american
medic
associ
conclus
identif
long
term
effect
childhood
cancer
treatment
problem
came
success
therapi
first
childhood
leukemia
evolut
effect
multi
modal
therapi
cancer
children
still
great
need
support
childhood
cancer
survivor
age
adulthood
effort
continu
need
medic
assess
diseas
prevent
psycho
social
well
togeth
seri
therapeut
stori
children
famili
mccarthi
p
dearn
mors
k
peter
mcgowan
clinic
scienc
murdoch
children
research
institut
melbourn
australia
children
cancer
centr
royal
children
hospit
melbourn
australia
speech
patholog
royal
children
hospit
melbourn
australia
children
cancer
centr
royal
children
hospit
melbourn
australia
object
project
involv
develop
seri
children
book
design
assist
children
manag
physic
emot
impact
childhood
cancer
treatment
hospitalis
transit
period
follow
treatment
method
seri
five
stori
book
written
parent
young
child
undergo
leukaemia
treatment
assist
child
adapt
cancer
experi
particular
period
topic
includ
cope
hair
loss
address
fear
return
school
attempt
new
activ
adapt
fewer
hospit
visit
understand
parent
reaction
end
treatment
individu
stori
concept
seri
collabor
famili
therapist
speech
pathologist
play
therapist
author
addit
book
ad
children
write
stori
brief
sent
illustr
outlin
therapeut
intent
stori
formal
evalu
book
undertaken
particip
children
parent
grandpar
health
profession
psychologist
social
worker
teacher
book
evalu
relev
use
creativ
appeal
use
specif
develop
survey
result
overal
approv
rate
book
health
profession
parent
children
high
book
assess
relev
children
age
specif
comment
examin
edit
purpos
two
addit
book
directli
address
children
broader
experi
hospit
develop
result
philanthrop
fund
enabl
public
book
conclus
cancer
treatment
transit
end
treatment
well
recognis
highli
stress
time
children
famili
despit
resourc
particularli
young
children
limit
book
offer
creativ
relev
resourc
parent
enabl
help
child
adjust
potenti
find
stori
tell
percept
childhood
cancer
parent
assess
srivastava
thoma
b
singh
singh
sapra
r
seth
pediatr
india
institut
medic
scienc
delhi
india
object
aim
studi
assess
parent
psycholog
adjust
hospit
problem
behavior
chang
children
financi
problem
concern
child
health
hygien
method
sampl
studi
consist
parent
whose
children
age
undergo
treatment
acut
leukemia
questionnair
made
investig
local
languag
hindi
assess
parent
adjust
cancer
result
parent
unawar
cancer
prior
diagnosi
major
children
present
fever
parent
suffer
depress
anxieti
parent
found
difficult
get
investig
done
patient
face
financi
problem
mental
stress
seen
knowledg
govern
fund
scheme
problem
document
prepar
parent
concern
child
hygien
treatment
notic
child
behavior
chang
life
parent
also
chang
due
child
ill
sibl
patient
also
face
problem
parent
abl
give
proper
attent
famili
get
emot
financi
support
rel
conclus
studi
found
parent
experi
high
level
anxieti
depress
time
diagnosi
investig
hospit
affect
daili
routin
also
affect
sibl
donor
belov
brother
aaa
manullang
manullang
indonesian
anyo
foundat
yayasan
anyo
indonesia
jakarta
barat
indonesia
object
share
inspir
encourag
sibl
will
donor
brothersist
cancer
famili
method
name
andri
astarisanna
second
child
famili
brother
suffer
leukemia
sinc
year
old
volunt
donor
final
pass
away
year
old
found
blood
one
match
blood
therefor
chosen
donor
younger
sister
also
includ
candid
donor
end
best
option
give
stem
cell
brother
procedur
quit
hard
new
first
time
thought
go
take
bone
marrow
explain
achiev
new
method
howev
brave
strong
enough
end
procedur
result
parent
usual
look
candid
outsid
core
famili
donor
sometim
choos
anoth
sibl
donor
seem
sacrific
anoth
child
reason
easier
procedur
part
support
sibl
cancer
reduc
risk
error
also
creat
tighter
bond
famili
conclus
although
brother
still
go
inde
valuabl
memor
experi
help
desk
depart
croatian
children
hospit
l
vulet
pasa
oncolog
children
hospit
zagreb
zagreb
croatia
object
averag
diseas
occur
children
croatia
per
year
mean
child
diagnos
cancer
everi
day
around
children
treat
cancer
everi
year
children
hospit
zagreb
inadequ
access
inform
right
parent
children
regard
variou
field
dispers
unavail
inform
difficult
psycholog
emot
state
parent
know
ask
help
support
need
organ
singl
inform
point
support
parent
children
assist
right
well
activ
involv
help
parent
exercis
right
inform
child
treatment
cooper
support
hospit
profession
staff
method
set
point
provid
full
inform
regard
variou
issu
set
parent
meet
medic
staff
meet
person
variou
govern
institut
servic
essenti
exercis
mani
right
organ
group
support
parent
children
conduct
expert
creativ
educ
workshop
organ
carri
variou
activ
event
help
children
famili
difficult
time
result
rais
public
awar
mani
media
malign
diseas
facilit
work
medic
staff
rais
activ
life
qualiti
children
famili
provide
better
integr
children
teenag
reduc
abil
public
social
life
help
desk
user
conclus
unit
helpful
integr
problem
one
place
better
solut
solv
childhood
cancer
survivor
bone
tumor
sarcoma
increas
risk
hospit
c
gonzalez
l
randal
j
ying
kirchhoff
cancer
control
popul
scienc
research
program
univers
utah
huntsman
cancer
institut
salt
lake
citi
usa
depart
orthoped
sacroma
servic
univers
utah
huntsman
cancer
institut
salt
lake
citi
usa
famili
prevent
medicin
univers
utah
salt
lake
citi
usa
object
identifi
childhood
cancer
survivor
malign
bone
tumor
sarcoma
increas
risk
hospit
method
use
data
research
resourc
utah
identifi
childhood
adolesc
survivor
malign
bone
tumor
n
sarcoma
n
diagnos
year
diagnosi
select
birth
year
sex
match
comparison
cohort
n
hospit
exclud
pregnanc
deliveri
determin
discharg
record
multivari
cox
poisson
gamma
regress
use
evalu
risk
hospit
admiss
count
length
stay
survivor
versu
comparison
cohort
estim
bone
tumor
sarcoma
aggreg
sinc
regress
estim
similar
except
report
result
averag
sinc
survivor
year
sd
comparison
year
sd
p
hazard
ratio
hr
hospit
higher
survivor
comparison
cohort
hr
confid
interv
ci
survivor
experienc
higher
hospit
admiss
rate
rate
ratio
rr
ci
p
comparison
cohort
length
stay
longer
hospit
survivor
rr
ci
p
compar
cohort
sarcoma
bone
tumor
examin
separ
sarcoma
survivor
higher
rate
hospit
admiss
rr
ci
p
bone
tumor
survivor
experienc
even
higher
hospit
rate
rr
ci
p
refer
comparison
cohort
conclus
number
ofhospit
rate
admiss
length
stay
elev
among
childhood
cancer
survivor
bone
tumor
sarcoma
childhood
cancer
survivor
tend
receiv
less
health
care
diagnosi
effort
prevent
manag
sarcoma
bone
tumor
survivor
health
problem
outpati
set
could
help
reduc
hospit
risk
bone
fractur
pediatr
adolesc
survivor
childhood
cancer
report
project
reach
cancer
institut
dfci
lm
vrooman
je
blackmon
lb
kenney
lb
silverman
cj
reckliti
l
diller
pediatr
oncolog
cancer
institut
boston
usa
object
skelet
toxic
recogn
seriou
complic
therapi
childhood
cancer
occurr
bone
fractur
survivor
infrequ
describ
studi
assess
preval
risk
factor
develop
fractur
cohort
pediatr
adolesc
survivor
childhood
cancer
method
parent
particip
project
reach
prospect
cohort
studi
childhood
cancer
survivor
complet
questionnair
report
occurr
fractur
medic
record
review
treatment
health
outcom
data
cancer
diagnos
includ
acut
lymphoblast
leukemia
neuroblastoma
wilm
tumor
sarcoma
lymphoma
acut
myelogen
leukemiamyelodysplast
syndrom
hepatoblastoma
median
age
enrol
year
rang
median
time
sinc
diagnosi
year
rang
result
treatment
fractur
report
survivor
survivor
experienc
fractur
survivor
fractur
median
time
complet
therapi
first
fractur
year
rang
year
corticosteroid
exposur
associ
increas
frequenc
fractur
survivor
receiv
corticosteroid
experienc
fractur
compar
receiv
corticosteroid
ci
p
survivor
treat
dexamethason
higher
frequenc
fractur
compar
survivor
without
corticosteroid
exposur
p
fractur
occur
survivor
expos
steroid
includ
dexamethason
proport
significantli
differ
steroid
group
p
conclus
almost
quarter
ofchildhood
cancer
survivor
experienc
fractur
cancer
therapi
exposur
corticosteroid
associ
increas
frequenc
fractur
data
suggest
fractur
risk
may
extend
beyond
cancer
therapi
complet
electrocardiograph
abnorm
age
survivor
childhood
cancer
report
st
jude
lifetim
sjlife
cohort
studi
mulrooney
e
soliman
g
armstrong
v
joshi
green
k
srivastava
krasin
r
luepker
l
robison
hudson
k
ness
oncolog
epidemiologycanc
control
st
jude
children
research
hospit
memphi
usa
epidemiolog
cardiolog
research
center
wake
forest
univers
school
medicin
usa
epidemiolog
cancer
control
st
jude
children
research
hospit
memphi
usa
pediatr
univers
tennesse
health
scienc
center
memphi
usa
biostatist
st
jude
children
research
hospit
memphi
usa
radiolog
scienc
st
jude
children
research
hospit
memphi
usa
epidemiolog
commun
health
univers
minnesota
school
public
health
minneapoli
usa
purposeobject
electrocardiograph
ecg
abnorm
whether
major
minor
predict
poor
prognosi
provid
simpl
tool
cardiovascular
risk
assess
evalu
preval
determin
ecg
abnorm
among
adult
childhood
cancer
survivor
cc
materi
method
analysi
includ
particip
sjlife
cohort
male
mean
age
yr
diagnosi
yr
evalu
ecg
record
use
standard
method
central
review
ecg
core
laboratori
blind
medic
histori
abnorm
classifi
major
minor
per
minnesota
ecg
classif
frequenc
assess
regress
model
adjust
age
sex
race
bmi
smoke
use
estim
rel
risk
rr
confid
interv
ci
patient
treatment
characterist
result
least
one
ecg
abnorm
identifi
particip
major
minor
common
major
abnorm
major
isol
abnorm
evid
myocardi
infarct
left
ventricular
hypertrophi
strain
pattern
highest
frequenc
among
hodgkin
lymphoma
wilm
tumor
osteosarcoma
survivor
frequenc
major
minor
abnorm
treatment
chest
radiat
rt
anthracyclin
chest
rtanthracylin
adjust
model
risk
major
minor
abnorm
associ
chest
rt
rr
ci
rr
ci
male
sex
rr
rr
bmi
rr
rr
anthracyclin
exposur
rr
ci
rr
ci
increas
age
increment
associ
major
abnorm
rr
ci
conclus
ecg
abnorm
common
cc
nearli
least
one
abnorm
suggest
high
risk
cardiovascular
diseas
risk
highest
among
expos
chest
direct
rt
impact
radiat
cardiovascular
risk
factor
physic
activ
endotheli
progenitor
cell
among
childhood
cancer
survivor
k
pradhan
l
overmy
aranjo
j
mund
j
case
gupta
z
liu
j
renbarg
v
champion
pediatr
indiana
univers
school
medicin
indianapoli
usa
neonatolog
indiana
univers
school
medicin
indianapoli
usa
medicin
indiana
univers
school
medicin
indianapoli
usa
biostatist
indiana
univers
school
medicin
indianapoli
usa
nurs
research
indiana
univers
school
nurs
indianapoli
usa
object
atherosclerot
cardiovascular
diseas
acvd
elev
childhood
cancer
survivor
cc
secondari
caus
vascular
endotheli
impair
novel
biomark
endotheli
inflamm
analyz
peripher
blood
pb
may
aid
identifi
cc
risk
futur
acvd
biomark
includ
bona
fide
endotheli
progenitor
cell
term
endotheli
cell
ecfc
essenti
vascular
homeostasi
repair
well
apoptot
matur
circul
endotheli
cell
cec
purpos
studi
analyz
ecfc
cec
pb
cc
use
novel
protocol
method
studi
compar
cardiovascular
risk
factor
crf
qualiti
life
measur
diet
pa
dilat
fmd
measur
endotheli
function
ecfc
cec
cc
age
index
match
healthi
control
hc
addit
investig
effect
cancer
therapi
fmd
ecfc
cec
associ
measur
crf
pa
diet
result
enrol
cc
prior
diagnosi
leukemia
cc
significantli
lower
physic
function
pa
wors
diet
higher
fatigu
lower
cholesterol
compar
hc
p
differ
fmd
ecfc
cec
cc
hc
within
cc
cohort
radiotherapi
rt
significantli
lower
ecfc
cec
p
addit
signific
posit
correl
includ
fmd
pa
ecfc
signific
neg
correl
includ
systol
ecfc
p
conclus
studi
involv
cc
show
ecfc
affect
rt
worsen
crf
hypertens
inadequ
pa
alter
modifi
potenti
improv
vascular
health
prevent
futur
acvd
electroretinographi
visual
evok
potenti
childhood
brain
tumor
survivor
hl
lenko
koivisto
oja
r
korpela
depart
pediatr
rinnekoti
foundat
espoo
finland
depart
hematolog
cancer
center
helsinki
univers
central
hospit
helsinki
finland
depart
pediatr
tamper
univers
hospit
tamper
finland
tamper
school
public
health
univers
tamper
tamper
finland
depart
neurolog
hospit
tamper
finland
object
evalu
clinic
valu
electroretinographi
erg
visual
evok
potenti
vep
childhood
brain
tumor
survivor
method
total
primari
brain
tumor
patient
diagnos
year
age
treat
tamper
univers
hospit
survivor
potenti
elig
patient
invit
particip
studi
particip
examin
mean
age
year
rang
year
mean
time
year
year
flash
erg
checkerboard
revers
pattern
vep
flash
vep
done
result
abnorm
erg
one
bilater
delay
abnorm
vep
obtain
case
vep
abnorm
patient
chiasmat
hypophys
pineal
tumor
locat
patient
hypothalam
tumor
locat
tumor
locat
visual
pathway
associ
abnorm
respons
p
nine
patient
infratentori
tumor
locat
abnorm
vep
age
diagnosi
p
time
p
chemotherapi
p
radiotherapi
p
combin
therapi
p
hydrocephalu
p
shunt
revis
p
antiepilept
medic
p
associ
abnorm
vep
conclus
abnorm
erg
rare
observ
abnorm
vep
common
indic
damag
visual
pathway
fact
vep
bilater
delay
suggest
gener
toxicadvers
effect
visual
pathway
possibl
multifactori
erg
vep
test
may
clinic
scientif
valu
evalu
effect
childhood
brain
tumor
tumor
treatment
cknowledg
author
thank
particip
famili
personnel
depart
clinic
neurophysiolog
juha
md
phd
depart
ophthalmolog
tamper
univers
hospit
studi
support
foundat
pediatr
cancer
research
experiment
fertil
preserv
fp
intervent
pp
boy
cancer
report
prefer
teenag
cancer
survivor
parent
provid
lorenzo
r
donen
l
sung
k
boydel
stephen
c
portwin
pritchard
k
lo
gupta
urolog
univers
toronto
toronto
canada
pediatr
univers
toronto
toronto
canada
psychiatri
univers
toronto
toronto
canada
public
health
scienc
univers
toronto
toronto
canada
pediatr
mcmaster
univers
hamilton
canada
pediatr
univers
british
columbia
vancouv
canada
object
risk
infertil
cancer
therapi
sourc
great
distress
young
cancer
survivor
fp
challeng
pp
male
unabl
produc
bankabl
sperm
ejacul
sought
determin
factor
influenc
patient
parent
provid
prefer
testicular
biopsi
tbx
even
though
util
pp
tissu
fp
remain
experiment
method
oncolog
provid
parent
teenag
cancer
survivor
recruit
pediatr
center
canada
particip
interview
survey
hypothet
decis
made
tbx
tbx
willing
accept
complic
cost
risk
infertil
chanc
technolog
develop
desir
help
other
use
measur
strength
prefer
tbx
multipl
regress
use
associ
predictor
tbx
desir
score
risk
infertil
condit
result
proport
respond
prefer
tbx
vs
tbx
parent
provid
cancer
survivor
top
rank
factor
influenc
decis
group
risk
infertil
survivor
rank
rate
complic
cost
lower
desir
help
other
higher
compar
parent
p
group
similar
strength
prefer
tbx
compar
tbx
risk
infertil
chanc
technolog
develop
vari
child
age
type
cancer
ethnic
hospit
signific
factor
associ
prefer
tbx
parent
report
higher
incom
like
prefer
tbx
p
conclus
parent
survivor
provid
strongli
favor
tbx
rank
risk
infertil
import
parent
incom
predictor
prefer
risk
infertil
condit
address
cost
associ
fp
remain
import
focu
advoc
fp
ovarian
tissu
cryopreserv
pediatr
oncolog
gambl
futur
f
chambon
david
f
brugnon
jl
pouli
l
janni
gremeau
e
merlin
f
j
kanold
crctcp
chu
esta
franc
object
signific
improv
surviv
children
adolesc
cancer
fertil
preserv
major
concern
paediatr
oncologist
aim
studi
report
ovarian
tissu
cryopreserv
otc
case
order
specifi
interest
indic
method
studi
clinic
hormon
outcom
femal
method
septemb
septemb
femal
otc
center
eight
patient
malign
diseas
malign
diseas
inform
consent
surgic
ovarian
collect
consist
biopsi
third
ovari
laparoscopi
frozen
slow
cool
protocol
histolog
analysi
follicular
account
perform
result
among
patient
otc
indic
steril
chemotherapi
ovarian
tissu
harvest
perform
intraumbil
laparoscopi
use
laparoscop
two
trocar
use
major
postop
complic
occur
except
one
patient
sickl
cell
diseas
protein
defici
sever
haemorrhag
one
ovari
follow
chemotherapi
regimen
delay
start
median
rang
day
otc
anatomopatholog
analysi
show
primordi
malign
cell
ovarian
tissu
median
harvest
month
femal
aliv
complet
remiss
still
treatment
die
hormon
result
evalu
patient
median
age
yr
prematur
ovarian
failur
conclus
feasibl
otc
sampl
third
ovari
seem
appropri
method
transplant
consequ
therapeut
program
children
preserv
potenti
fertil
diseas
renal
function
bone
metabol
follow
treatment
cancer
studi
n
liuhto
n
malila
l
j
p
pediatr
turku
univers
hospit
turku
finland
faculti
medicin
univers
turku
turku
finland
epidemiolog
finnish
cancer
registri
helsinki
finland
biostatist
univers
turku
turku
finland
object
constant
progress
cancer
therapi
led
grow
number
cancer
survivor
prone
increas
morbid
owe
anticanc
therapi
aim
studi
investig
pediatr
young
adult
cancer
survivor
morbid
renal
diseas
diseas
bone
metabol
registri
set
level
method
patient
cohort
identifi
finnish
cancer
registri
consist
cancer
diagnos
age
sibl
without
cancer
identifi
central
popul
regist
use
control
cohort
inform
morbid
renal
diseas
diseas
bone
metabol
collect
nation
hospit
discharg
registri
use
assess
hazard
ratio
variou
outcom
patient
cohort
separ
two
age
group
pediatr
age
cancer
diagnosi
year
young
adult
age
cancer
diagnosi
year
result
significantli
elev
hazard
ratio
compar
control
observ
follow
outcom
scoliosi
hr
ci
osteoporosi
hr
ci
osteonecrosi
hr
ci
nephriti
hr
ci
kidney
failur
hr
ci
p
mention
hazard
ratio
significantli
elev
diagnost
age
group
hazard
ratio
obes
elev
pediatr
age
group
femal
hr
ci
survivor
cn
tumor
hr
ci
conclus
survivor
pediatr
cancer
increas
risk
sever
long
term
advers
outcom
must
taken
account
studi
provid
new
inform
cancer
survivor
morbid
renal
diseas
diseas
bone
metabol
renal
late
effect
treatment
unilater
wilm
tumor
kostel
bal
b
yalcin
h
susam
sen
b
aydin
varan
kutluk
c
akyuz
pediatr
oncolog
hacettep
univers
faculti
medicin
ankara
turkey
object
due
improv
prognosi
increas
surviv
rate
long
term
renal
consequ
wilm
tumor
patient
greater
concern
aim
investig
long
term
effect
treatment
survivor
unilater
wilm
tumor
method
total
unilater
nephrectom
survivor
wilm
tumor
treat
follow
center
enrol
studi
second
year
follow
cessat
treatment
glomerular
filtrat
rate
gfr
urinari
protein
excret
urinari
microglobulin
level
blood
pressur
assess
well
gener
health
statu
qualiti
life
result
analyz
correl
clinic
variabl
chemotherapi
radiotherapi
possibl
risk
factor
result
median
time
year
rang
year
none
patient
includ
studi
develop
renal
diseas
esrd
patient
renal
problem
hypertens
proteinuria
tubulopathi
none
patient
increas
urinari
microglobulin
level
compensatori
hypertrophi
observ
ultrasound
patient
median
maximum
bipolar
length
significantli
higher
patient
diagnos
age
month
patient
hypertens
time
diagnosi
studi
respect
median
gfr
valu
significantli
lower
time
diagnosi
although
time
studi
patient
normal
gfr
valu
longer
interv
especi
year
signific
declin
trend
gfr
observ
p
conclus
although
risk
develop
esrd
remark
low
unilater
wilm
tumor
group
less
seriou
progress
renal
dysfunct
concern
detail
analysi
renal
function
perform
long
term
regular
long
term
audiolog
outcom
children
treat
platinum
chemotherapi
k
knight
j
middaugh
r
fu
e
neuwelt
c
winter
pediatr
audiolog
oregon
health
scienc
univers
portland
usa
public
health
prevet
medicin
emerg
medicin
oregon
health
scienc
univers
portland
usa
neurolog
neurosurgeri
veteran
affair
medic
center
oregon
health
scienc
univers
portland
usa
oregon
clinic
translat
research
institut
oregon
health
scienc
univers
portland
usa
object
childhood
cancer
survivor
treat
platinum
chemotherapi
appear
risk
progress
hear
loss
treatment
purpos
studi
evalu
preval
sever
progress
hear
loss
evalu
time
cours
hear
chang
treatment
identifi
possibl
risk
factor
method
retrospect
cohort
studi
children
adolesc
treat
platinum
chemotherapi
oregon
health
scienc
univers
conduct
inclus
criteria
includ
treatment
cisplatin
andor
carboplatin
audiolog
evalu
within
month
final
platinum
treatment
least
one
long
term
hear
evalu
ltfu
month
complet
platinum
therapi
progress
hear
loss
defin
db
decreas
pure
tone
threshold
ltfu
rel
evalu
sever
hear
loss
grade
accord
siop
boston
hear
loss
grade
result
patient
variou
cancer
diagnos
met
inclus
criteria
treat
cisplatin
carboplatin
agent
also
receiv
cranial
radiat
prior
cisplatin
patient
ototox
hear
loss
complet
chemotherapi
mean
length
time
hear
evalu
recent
evalu
year
rang
patient
ototox
end
therapi
exhibit
progress
hear
loss
ltfu
three
medulloblastoma
patient
normal
hear
end
treatment
hear
loss
ltfu
variabl
includ
diagnosi
age
treatment
length
ltfu
cranial
radiat
platinum
dose
examin
explor
potenti
risk
factor
conclus
result
document
need
audiolog
monitor
manag
childhood
cancer
survivor
treat
platinum
agent
strategi
reduc
prevent
hear
loss
need
fatigu
childhood
cancer
survivor
report
project
reach
n
frederick
c
reckliti
pediatr
oncolog
dana
farber
cancer
institut
boston
usa
perini
famili
survivor
center
dana
farber
cancer
institut
boston
usa
object
better
understand
preval
etiolog
fatigu
adolesc
young
adult
survivor
childhood
cancer
factor
may
differ
older
childhood
cancer
survivor
method
particip
childhood
cancer
survivor
mean
age
yr
mean
age
dx
yr
femal
enrol
project
reach
longitudin
research
studi
fatigu
measur
use
pedsql
multidimension
fatigu
scale
valid
age
group
year
particip
standard
deviat
mean
standard
popul
classifi
significantli
fatigu
measur
also
includ
pedsql
result
particip
report
fatigu
significantli
differ
popul
norm
stratif
age
group
year
demonstr
similar
result
age
signific
predictor
fatigu
howev
trend
increas
fatigu
age
note
p
fatigu
case
associ
poor
qol
pedsql
p
poor
mental
health
function
popul
p
conclus
preval
fatigu
lower
expect
survivor
popul
fatigu
highli
correl
psychosoci
across
underscor
import
fatigu
assess
promot
optim
adjust
qol
fatigu
close
relat
number
chronic
condit
older
adult
seen
adolesc
young
adult
closer
treatment
find
may
reflect
advanc
cancer
care
aim
reduc
delay
onset
younger
survivor
ongo
cohort
evalu
help
better
elucid
evolut
fatigu
childhood
cancer
survivor
exercis
toler
energi
expenditur
among
adult
survivor
childhood
acut
lymphoblast
leukemia
report
st
jude
lifetim
cohort
studi
kk
ness
mm
hudson
karlag
ch
pui
w
chemaitilli
jq
lanctot
kc
hale
cl
wilson
robison
jp
delani
epidemiolog
cancer
control
st
jude
children
research
hospit
memphi
usa
oncolog
st
jude
children
research
hospit
memphi
usa
pediatr
divis
endocrinolog
st
jude
children
research
hospit
memphi
usa
medicin
endocrinolog
metabol
univers
pittsburgh
pittsburgh
usa
object
adult
survivor
childhood
less
activ
peer
lean
muscl
mass
deficit
problem
energi
expenditur
fit
may
explain
low
activ
level
aim
analysi
evalu
energi
expenditur
fit
among
survivor
compar
control
cancer
histori
method
evalu
total
daili
tdee
activ
aee
energi
expenditur
survivor
control
use
doubli
label
water
method
rest
energi
expenditur
ree
estim
indirect
calimetri
exercis
capac
cardiopulmonari
exercis
test
energi
expenditur
compar
group
gener
linear
model
adjust
total
bodi
mass
tbm
associ
fit
energi
expenditur
also
evalu
linear
model
adjust
tbm
result
survivor
male
white
median
age
year
median
year
age
diagnosi
surviv
median
year
survivor
similar
tbm
mean
sd
vs
kilogram
kg
p
shorter
vs
centimet
cm
lower
lean
mass
vs
kg
p
vs
milliliterskilogramminut
mlkgmin
p
control
adjust
fat
mass
differ
group
tdee
vs
kilocalori
kcal
aee
vs
kcal
ree
vs
kcal
among
survivor
mlkgmin
higher
associ
kcal
higher
aee
p
kcal
higher
tdee
p
associ
evid
among
control
conclus
adult
survivor
childhood
appear
deficit
energi
expenditur
tbm
taken
account
lower
expect
exercis
toler
may
explain
low
activ
among
survivor
whose
energi
expenditur
associ
obes
independ
influenc
gonad
function
adult
male
survivor
childhood
cancer
w
van
dorp
k
blijdorp
jse
laven
r
pieter
fh
de
jong
smf
pluijm
aj
van
der
leli
mm
van
den
negger
paediatr
oncologyhaematolog
obstetr
gynaecolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
paediatr
oncologyhaematolog
medicin
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
obstetr
gynaecolog
erasmu
univers
medic
center
rotterdam
netherland
paediatr
oncolog
haematolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
medicin
erasmu
univers
medic
center
rotterdam
netherland
paediatr
oncolog
haematolog
medicin
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
object
although
obes
associ
gonad
dysfunct
gener
popul
gonadotox
treatment
might
diminish
impact
obes
childhood
cancer
survivor
cc
aim
evalu
whether
alter
bodi
composit
associ
gonad
dysfunct
male
cc
independ
gonadotox
cancer
treatment
method
male
cc
includ
median
age
diagnosi
year
median
age
year
studi
totalfre
testosteron
sex
globulin
inhibin
b
fsh
potenti
determin
bmi
waist
circumfer
ratio
bodi
composit
measur
dual
energi
absorptiometri
result
free
testosteron
significantli
decreas
survivor
high
bmi
bmi
adjust
mean
nmoll
versu
nmoll
p
high
fat
percentag
versu
p
high
waist
circumfer
cm
versu
p
survivor
high
fat
percentag
significantli
lower
inhibin
bfsh
ratio
inhibin
b
fsh
ratio
p
conclus
obes
associ
gonad
dysfunct
male
cc
independ
irrevers
effect
previou
cancer
treatment
longitudin
studi
random
control
trial
requir
evalu
whether
weight
normal
diet
modif
physic
activ
bariatr
surgeri
could
improv
gonad
function
especi
obes
survivor
potenti
mechan
lifestyl
caus
obes
brain
statu
cognit
function
children
treat
acut
lymphoblast
leukemia
chemotherapi
alon
combin
reduc
cn
radiotherapi
pawlak
k
j
pilarczyk
k
derwich
j
wachowiak
depart
pediatr
oncolog
hematolog
transplantolog
poznan
univers
medic
scienc
poznan
poland
depart
neurolog
cerebrovascular
disord
poznan
univers
medic
scienc
poznan
poland
depart
neuroradiolog
poznan
univers
medic
scienc
poznan
poland
object
aim
studi
assess
long
term
consequ
cn
prophylaxi
children
treat
due
accord
chemotherapi
alon
vs
chemotherapi
combin
prophylact
cn
radiotherapi
reduc
gy
method
children
age
year
treat
studi
includ
chemotherapi
radiotherapi
treatment
control
group
assess
volumetr
measur
subcort
structur
respons
cognit
function
volumetr
mri
sequenc
use
neuropsycholog
assess
base
batteri
neuropsycholog
test
result
group
treat
due
without
cn
radiotherapi
significantli
smaller
volum
hippocampu
p
amygdala
p
putamen
p
globu
pallidu
p
comparison
control
group
found
addit
patient
treat
cn
irradi
significantli
lower
total
brain
volum
compar
control
group
p
patient
treat
lower
iq
level
verbal
p
perform
scale
p
measur
wechsler
intellig
scale
wors
memori
p
via
benton
visual
retent
test
memori
p
via
verbal
fluenci
test
level
execut
function
p
via
stroop
test
wisconsin
card
sort
test
compar
control
group
moreov
patient
receiv
cn
irradi
lower
learn
curv
p
via
rey
test
wors
process
speed
p
compar
patient
treat
chemotherapi
alon
control
group
conclus
children
treat
accord
reduct
subcort
structur
volum
observ
children
treat
without
cn
radiotherapi
cognit
deficit
domain
memori
execut
function
found
children
irradi
present
decreas
learn
process
probabl
caus
lower
process
speed
group
work
support
nation
scienc
centr
grant
radiotherapi
relat
prematur
arteri
age
young
adult
adolesc
survivor
high
risk
neuroblastoma
vatanen
sarkola
th
ojala
jahnukainen
turanlahti
um
k
jahnukainen
divis
stem
cell
transplant
children
hospit
univers
helsinki
helsinki
univers
central
hospit
finland
helsinki
finland
divis
cardiolog
children
hospit
univers
helsinki
helsinki
univers
central
hospit
finland
helsinki
finland
divis
transplant
children
hospit
univers
helsinki
helsinki
univers
central
hospit
finland
helsinki
finland
object
aim
studi
evalu
arteri
morpholog
function
finnish
nation
cohort
long
term
survivor
year
high
risk
neuroblastoma
nbl
treat
chemotherapi
autolog
hematopoiet
stem
cell
transplant
without
total
bodi
irradi
tbi
method
common
carotid
femor
brachial
radial
arteri
morpholog
assess
resolut
ultrasound
mhz
carotid
arteri
stiff
brachial
arteri
endotheli
function
evalu
convent
vascular
ultrasound
adult
pubert
age
year
rang
nbl
survivor
transplant
mean
age
year
compar
match
healthi
control
cardiovascular
risk
assess
includ
histori
index
fast
plasma
lipid
glucos
ambulatori
blood
pressur
bp
result
nbl
survivor
consist
smaller
arteri
lumen
increas
carotid
thick
imt
plaqu
format
n
carotid
stiff
compar
control
survivor
display
higher
plasma
triglycerid
cholesterol
level
increas
heart
rate
increas
systol
diastol
bp
multipl
regress
analysi
identifi
tbi
n
low
bodi
surfac
area
independ
predictor
decreas
arteri
lumen
size
increas
imt
plaqu
occur
among
survivor
receiv
tbi
conclus
adolesc
young
adult
high
risk
nbl
survivor
treat
tbi
display
sign
prematur
arteri
age
support
academ
need
pediatr
cancer
survivor
model
care
l
northman
morri
ross
n
ullrich
p
manley
psychosoci
oncolog
palli
care
cancer
institut
boston
usa
neurolog
boston
children
hospit
boston
usa
pediatr
oncolog
cancer
institut
boston
usa
object
studi
object
evalu
effect
model
psychoeduc
consult
advocaci
provid
school
liaison
program
slp
famili
school
children
whose
diagnosi
treatment
involv
central
nervou
system
compar
control
group
parent
children
risk
neurocognit
deficit
base
diagnosi
neurofibromatosi
type
receiv
servic
method
irb
approv
survey
complet
parent
children
demonstr
academ
difficulti
associ
medic
diagnosi
survey
sent
famili
pediatr
cancer
survivor
receiv
psychoeduc
consult
slp
control
group
famili
children
respons
intervent
slp
control
group
compar
use
wilcoxon
test
result
survey
return
slp
group
group
result
demonstr
differ
parent
belief
children
meet
academ
potenti
parent
receiv
slp
servic
report
greater
satisfact
child
progress
better
understand
learn
need
increas
abil
access
school
support
p
respect
addit
parent
children
longer
slp
involv
year
better
parent
understand
p
abil
advoc
p
parent
children
less
year
slp
servic
final
slp
clinician
came
patient
school
better
parent
understand
better
abil
advoc
less
difficulti
access
servic
greater
belief
child
abil
meet
academ
potenti
p
respect
conclus
consult
psychoeduc
parent
advocaci
train
provid
school
liaison
program
improv
knowledg
special
educ
support
satisfact
children
school
servic
increas
belief
children
meet
academ
potenti
risk
pattern
util
commun
care
mental
health
servic
among
childhood
adolesc
young
adult
cancer
survivor
british
columbia
canada
mcbride
li
k
goddard
pritchard
sr
rassekh
shep
cancer
control
research
british
columbia
cancer
agenc
vancouv
canada
divis
radiat
oncolog
british
columbia
cancer
agenc
vancouv
canada
divis
oncolog
hematolog
bone
marrow
transplant
british
columbia
children
hospit
vancouv
canada
school
popul
public
health
univers
british
columbia
vancouv
canada
object
cayac
childhood
adolesc
young
adult
cancer
survivorship
program
examin
multidimension
survivorship
issu
though
linkag
clinic
data
administr
databas
contain
outcom
inform
studi
describ
util
home
commun
care
hcc
mental
health
mh
servic
among
cohort
survivor
cancer
diagnos
age
british
columbia
canada
method
demograph
clinic
record
survivor
diagnos
age
year
identifi
provinci
cancer
registri
link
provinci
hcc
mh
servic
record
comparison
group
randomli
select
provinci
health
insur
plan
registri
birth
year
gender
frequenc
proport
servic
survivor
compar
calcul
compar
result
survivor
hcc
client
record
file
compar
compar
differ
survivor
show
higher
registr
rate
type
hcc
servic
direct
care
long
term
care
ltc
among
client
record
file
hcc
servic
util
type
vari
survivor
popul
compar
hcc
regist
survivor
receiv
direct
care
servic
compar
hcc
regist
compar
hcc
regist
survivor
receiv
ltc
care
advic
compar
hcc
regist
compar
util
mh
servic
show
differ
pattern
hcc
use
mh
servic
among
cancer
survivor
slightli
higher
peer
vs
conclus
cayac
survivor
show
much
higher
hcc
util
overal
peer
slightli
like
use
mh
servic
adult
survivor
childhood
aya
cancer
requir
continu
surveil
morbid
militari
servic
male
survivor
childhood
brain
solid
tumor
p
r
j
reme
k
parkkola
pediatr
hematolog
oncolog
turku
univers
hospit
turku
finland
pediatr
hematolog
oncolog
karolinska
hospitalet
stockholm
sweden
pediatr
turku
univers
hospit
turku
finland
pediatr
neurolog
oulu
univers
hospit
oulu
finland
finnish
defenc
forcesmerivoimien
esikunta
turku
finland
object
aim
studi
examin
accept
childhood
solid
brain
tumor
bt
survivor
still
mandatori
militari
servic
finland
conscript
perform
physic
cognit
test
servic
level
militari
educ
childhood
cancer
survivor
compar
healthi
control
method
male
survivor
childhood
bt
solid
tumor
born
aliv
age
year
age
n
identifi
finnish
cancer
registri
popul
registri
five
age
sex
place
resid
match
control
identifi
n
inform
decis
militari
servic
studi
subject
collect
databas
finnish
defenc
forc
result
enlist
frequenc
hodgkin
lymphoma
bt
neuroblastoma
malign
bone
tumor
soft
tissu
sarcoma
kidney
tumor
treatment
irradi
p
older
age
cancer
diagnosi
p
affect
militari
fit
categori
interrupt
servic
occur
extent
survivor
control
level
militari
educ
differ
group
averag
enlist
solid
tumor
survivor
manag
physic
test
train
similarli
control
perform
stand
long
jump
wors
p
enlist
bt
survivor
slightli
poorer
physic
perform
control
p
cooper
run
test
p
gener
muscl
strenght
p
solid
tumor
survivor
manag
well
cognit
test
bt
survivor
declin
test
cognit
skill
irradi
treatment
explain
find
conclus
frequenc
enlist
still
quit
low
cancer
survivor
proport
complet
servic
level
militari
educ
howev
resembl
control
data
give
valid
inform
discuss
cancer
survivor
prepar
militari
transit
childhood
cancer
survivor
adult
care
survey
pediatr
oncologist
lb
kenney
p
melvin
l
fishman
j
gs
sawicki
ziniel
l
diller
sm
fernand
pediatr
oncolog
cancer
institut
boston
usa
program
patient
safeti
qualiti
boston
children
hospit
boston
usa
depart
medicin
boston
children
hospit
boston
usa
depart
surgeri
boston
children
hospit
boston
usa
depart
pediatr
lucil
packard
children
hospit
stanford
palo
alto
usa
object
pediatr
oncologist
challeng
transit
adult
childhood
cancer
survivor
care
studi
describ
transit
practic
perceiv
barrier
transfer
identifi
potenti
area
intervent
method
electron
survey
us
member
children
oncolog
group
respond
met
elig
pediatr
oncologist
care
outpati
age
year
result
respond
male
median
year
practic
rang
practic
children
hospit
almost
care
patient
age
year
report
care
patient
age
year
age
year
oncologist
report
staff
provid
transit
educ
patient
report
also
provid
educ
patient
compar
care
adult
patient
year
like
endors
specif
criteria
transfer
includ
survivor
age
p
pregnanc
p
marriag
p
colleg
graduat
p
substanc
use
p
oncologist
identifi
barrier
transfer
includ
patientspar
attach
provid
lack
knowledg
adult
provid
cognit
delay
unstabl
social
situat
oncologist
care
patient
age
year
like
perceiv
parent
attach
provid
p
unstabl
social
situat
barrier
transfer
p
four
theme
emerg
respons
open
end
question
invit
input
transitiontransf
practic
import
standard
transit
practic
need
flexibl
transfer
criteria
lack
adult
provid
survivorship
expertis
lack
resourc
conclus
pediatr
oncologist
report
transfer
adult
childhood
cancer
survivor
adult
care
provid
transit
educ
patient
transit
practic
includ
educ
adult
provid
address
survivor
psychosoci
challeng
might
facilit
success
transfer
secondari
cancer
cancer
diagnosi
childhood
retrospect
cohort
studi
japan
ishida
qiu
maeda
j
fujimoto
h
kigasawa
r
kobayashi
sato
j
okamura
yoshinaga
rikiishi
h
shichino
c
kiyotani
k
kudo
k
asami
h
hori
h
kawaguchi
h
inada
adachi
manab
kuroda
pediatr
medic
center
ehim
prefectur
central
hospit
matsuyama
japan
drug
depend
research
nation
center
neurolog
psychiatri
tokyo
japan
pediatr
nippon
medic
school
tokyo
japan
epidemiolog
clinic
research
center
children
cancer
nation
center
child
health
develop
tokyo
japan
hematolog
kanagawa
children
medic
center
yokohama
japan
pediatr
sapporo
hokuyu
hospit
sapporo
japan
hematologyoncolog
osaka
medic
center
research
institut
matern
child
health
osaka
japan
pediatr
nation
kyushu
cancer
center
fukuoka
japan
research
center
radiat
protect
nation
institut
radiolog
scienc
chiba
japan
pediatr
tohoku
univers
school
medicin
sendai
japan
pediatr
child
health
nihon
univers
school
medicin
tokyo
japan
oncolog
nation
center
child
health
develop
tokyo
japan
hematolog
oncolog
shizuoka
children
hospit
shizuoka
japan
pediatr
niigata
cancer
center
niigata
japan
pediatr
mie
univers
graduat
school
medicin
mie
japan
pediatr
hiroshima
univers
hospit
hiroshima
japan
pediatr
kurum
univers
school
medicin
kurum
japan
human
health
scienc
kyoto
univers
school
medicin
kyoto
japan
pediatr
st
luke
intern
hospit
tokyo
japan
pediatr
surgeri
keio
univers
school
medicin
tokyo
japan
object
object
current
studi
assess
incid
risk
factor
secondari
cancer
sc
children
malign
nationwid
survey
japan
method
retrospect
cohort
studi
compris
children
cancer
treat
conduct
japanes
hospit
cumul
incid
rate
sc
calcul
use
compet
risk
death
compar
gray
method
standard
incid
rate
ratio
sir
defin
ratio
number
observ
divid
number
expect
cancer
use
region
cancer
registri
data
japan
risk
factor
analyz
use
cox
regress
analysi
result
sc
patient
identifi
cohort
median
year
month
year
total
observ
common
sc
acut
myeloid
leukemia
n
follow
myelodysplast
syndrom
n
brain
tumor
n
sarcoma
n
carcinoma
n
thyroid
cancer
n
lymphoid
malign
n
other
n
cumul
incid
rate
ci
year
ci
year
diagnosi
respect
sensit
analysi
limit
year
longer
durat
survivor
n
confirm
low
incid
rate
sir
sc
ci
cox
analysi
hazard
ratio
sc
retinoblastoma
ci
bone
soft
tissu
sarcoma
ci
allogen
stem
cell
transplant
ci
respect
conclus
cumul
incid
rate
sc
japan
high
sir
rel
high
allogen
stem
cell
transplant
retinoblastoma
sarcoma
primari
cancer
signific
risk
factor
sc
de
novo
mutat
monozygot
twin
hepatoblastoma
c
bozkurt
f
trippel
kanmaz
k
acarli
leuschner
g
sahin
schwarzmayr
von
schweinitz
tm
strom
r
kappler
pediatr
dr
sami
ulu
research
train
hospit
women
children
health
diseas
ankara
turkey
pediatr
surgeri
dr
von
hauner
children
hospit
munich
germani
organ
transplant
center
sisli
memori
hospit
istanbul
turkey
kielinstitut
paidopatholog
pediatr
tumor
registri
kiel
germani
pediatr
oncologydr
sami
ulu
research
train
hospit
women
children
health
diseas
ankara
turkey
institut
human
genet
helmholtz
zentrum
neuherberg
technisch
munich
germani
object
hepatoblastoma
hb
common
malign
liver
tumor
childhood
character
mutat
patient
howev
genet
basi
remain
case
still
remain
elus
aim
identifi
gene
caus
hb
develop
pair
monozygot
twin
lack
mutat
method
genom
dna
liver
tumor
tissu
peripher
blood
analyz
exom
sequenc
subsequ
sanger
verif
blood
parent
unaffect
brother
analyz
control
transcript
variant
disclos
revers
transcript
pcr
gel
electrophoresi
result
use
sequenc
found
heterozyg
singl
nucleotid
exchang
intron
retinoblastoma
gene
pair
monozygot
twin
develop
hb
age
month
mutat
detect
patient
tumor
blood
sampl
absent
parent
unaffect
brother
indic
de
novo
occurr
either
germ
cell
one
parent
fertil
egg
rna
level
mutat
gave
rise
transcript
skip
exon
andor
express
parallel
transcript
patient
aliv
diseas
free
eight
month
liver
transplant
close
monitor
retin
patholog
conclus
first
studi
report
point
mutat
affect
integr
hb
data
advoc
screen
hb
patient
mutat
intraop
detect
pulmonari
metastas
hepatoblastoma
use
indocyanin
green
fluoresc
imag
n
kitagawa
shinkai
k
mochizuki
h
usui
h
miyagi
tanaka
tanaka
h
goto
kusano
otsubo
depart
surgeri
kanagawa
children
medic
center
yokohama
japan
depart
patholog
kanagawa
children
medic
center
yokohama
japan
depart
surgeri
kushiro
rosai
hospit
kushiro
japan
depart
oral
maxillofaci
surgeri
kushiro
rosai
hospit
kushiro
japan
object
previous
demonstr
thorough
surgic
resect
pulmonari
metastat
lesion
improv
prognosi
patient
hepatoblastoma
introduc
intraop
indocyanin
green
icg
fluoresc
imag
visual
small
lesion
herein
present
use
modal
complet
thorough
resect
method
five
patient
hepatoblastoma
associ
multipl
lung
metastas
underw
metastasectomi
guid
method
age
rang
year
old
intraop
icg
fluoresc
imag
done
follow
icg
administ
intraven
hour
oper
thoracotomi
fluoresc
detector
combin
infrar
ray
radiat
photodynam
eyer
hamamatsu
photon
japan
use
visual
metastat
lesion
resect
lesion
examin
histopatholog
lesion
examin
fluoresc
microscop
specif
made
icg
fluoresc
observ
size
lesion
measur
microscop
result
lesion
total
detect
resect
among
lesion
diagnos
hepatoblastoma
histopatholog
smallest
diamet
lesion
hand
palpabl
lesion
also
resect
lesion
diagnos
benign
histolog
fluoresc
microscopi
reveal
fluoresc
observ
cytoplasm
tumor
cell
case
small
blood
thrombu
also
detect
origin
fluoresc
conclus
result
suggest
icg
fluoresc
imag
valuabl
identifi
pulmonari
lesion
pay
attent
possibl
fals
posit
origin
thrombu
histopatholog
studi
hepatoblastoma
focus
signific
cell
tanaka
yoshida
r
ijiri
h
goto
n
kitagawa
shinkai
tanaka
depart
diagnost
patholog
kanagawa
children
medic
center
yokohama
japan
depart
oncolog
kanagawa
children
medic
center
yokohama
japan
depart
surgeri
kanagawa
children
medic
center
yokohama
japan
object
compar
histopatholog
studi
hepatoblastoma
carri
suffici
degre
histolog
altern
differ
case
subset
hepatoblastoma
contain
call
cell
ilc
describ
zimmermann
consist
small
round
cell
mark
nuclear
express
low
prolif
activ
howev
signific
ilc
yet
clarifi
verifi
histopatholog
correl
properti
ilc
hepatoblastoma
method
fourteen
hepatoblastoma
biopsi
specimen
resect
specimen
collect
archiv
institut
histolog
subtyp
presenc
ilc
specimen
histolog
pattern
residu
tumor
ratio
necrosisfibrosisosteoid
specimen
review
immunohistochem
studi
perform
hepatocyt
specif
marker
afp
result
histolog
diagnosi
biopsi
specimen
includ
one
fetal
subtyp
eleven
combin
fetal
embryon
type
two
mix
epitheli
mesenchym
type
mem
among
case
biopsi
specimen
includ
two
mem
contain
foci
ilc
ilc
among
ilc
case
four
contain
osteoid
specimen
remain
one
show
extens
fibrosi
addit
foci
squamou
epithelia
observ
chemotherapi
ilc
case
osteoid
also
observ
case
ratio
necrosisfibrosisosteoid
area
tumor
chemotherapi
three
ilc
case
six
ilc
case
four
less
one
conclus
result
suggest
ilc
might
relat
histolog
altern
includ
mesenchym
differenti
andor
necrosisfibrosi
deviat
hepat
cell
improv
surviv
hepatoblastoma
dvelop
countri
case
seri
india
siddaiahgari
makadia
h
jayaram
c
vv
r
kancharla
pediatr
rainbow
children
hospit
hyderabad
india
pediatr
surgeri
rainbow
children
hospit
hyderabad
india
object
describ
overal
surviv
rate
children
manag
hepatoblastoma
tertiari
care
children
hospit
india
method
eighteen
children
diagnos
hepatoblastoma
age
group
month
year
octob
march
analys
year
prospect
nad
half
year
retrospect
descript
studi
result
major
patient
month
year
age
femal
common
present
symptom
abdomin
distent
two
case
pick
vaccin
visit
none
syndrom
associ
underw
ultrasound
initi
investig
follow
ct
abdomen
chest
along
bone
scan
renal
function
liver
function
clot
assess
along
alfa
fetoprotein
afp
level
afp
elev
case
rang
lakh
two
normal
afp
level
inoper
tumor
gone
surgeri
surgeri
receiv
cycl
chemotherapi
plado
cisplatin
doxorubicin
follow
tumor
excis
lobectomi
post
op
chemotherapi
cycl
given
per
afp
level
children
gone
surgic
resect
treatment
rang
yr
year
overal
surviv
children
inoper
tumor
one
child
aliv
year
chemotherapi
two
die
secondari
relaps
tumor
initi
respons
two
die
progress
tumor
conclus
hepatoblastoma
chemosensit
tumor
result
good
even
develop
countri
surgeri
combin
chemotherapi
good
support
care
rhabdoid
tumor
liver
report
pediatr
case
treat
singl
institut
cornet
g
de
lambert
f
v
fouquet
c
guettier
h
martelli
branchereau
pediatr
surgeri
bicetr
hospit
le
kremlin
bicetr
franc
pediatr
radiolog
bicetr
hospit
le
kremlin
bicetr
franc
patholog
bicetr
hospit
le
kremlin
bicetr
franc
object
rhabdoid
tumor
rt
liver
rare
aggress
malign
mainli
occur
first
year
life
definit
rt
histolog
reli
characterist
morpholog
inactiv
tumor
suppressor
gene
encod
subunit
swisnf
chromatin
remodel
complex
aim
studi
analyz
clinic
data
treatment
outcom
patient
method
report
retrospect
case
patient
treat
institut
rt
liver
januari
decemb
examin
variabl
includ
age
diagnosi
tumor
stage
variabl
treatment
surviv
result
median
age
diagnosi
month
rang
four
patient
diagnosi
percutan
biopsi
one
laparoscop
biopsi
patient
present
loss
express
normal
minim
increas
serum
afp
level
observ
patient
patient
present
metastasi
diagnosi
median
follow
month
rang
patient
receiv
chemotherapi
variabl
regimen
complet
surgic
treatment
two
patient
die
diseas
mistaken
non
secret
hepatoblastoma
diagnosi
recurr
shortli
complet
treatment
three
patient
survivor
receiv
multimod
therapi
includ
chemotherapi
accord
protocol
epssgnrst
doxorubicin
complet
surgic
remov
tumor
perform
within
month
diagnosi
one
patient
adjuv
radiotherapi
conclus
accord
result
search
mutat
non
secret
hepatoblastoma
mandatori
exclud
rt
chemotherapi
doxorubicin
aggress
earli
surgic
treatment
seem
justifi
improv
long
term
surviv
cell
pediatr
classic
hodgkin
lymphoma
associ
better
outcom
barro
p
segg
r
hassan
g
niedobitek
institut
patholog
unfallkrankenhau
berlin
berlin
germani
brazilian
nation
cancer
institut
bone
marrow
transplant
center
berlin
germani
object
classic
hodgkin
lymphoma
chl
character
neoplast
cell
background
inflammatori
cell
mani
studi
describ
cell
composit
tumour
microenviron
adult
case
demonstr
differ
pediatr
adult
chl
respect
two
studi
recent
describ
high
number
cell
associ
wors
surviv
adult
chl
receptor
express
cell
upon
activ
well
follicular
helper
cell
exhaust
cell
effector
memori
cell
object
studi
evalu
cell
paediatr
chl
case
median
method
cell
identifi
immunohistochemistri
number
cell
evalu
use
comput
assist
microscop
analysi
result
compar
popul
determin
previou
studi
case
result
median
observ
case
show
cell
direct
correl
observ
number
cell
p
well
cell
p
higher
number
cell
observ
case
cytotox
microenviron
profil
p
disclos
ratio
cell
number
cell
associ
age
group
case
higher
number
cell
associ
better
overal
surviv
p
conclus
result
suggest
major
cell
tumour
microenviron
paediatr
chl
may
contribut
immun
respons
neoplast
cell
detail
character
cell
progress
pathogenesi
paediatr
lymphoma
polycomb
protein
analysi
ramaglia
iannotta
v
dangelo
g
pecoraro
e
pota
c
fusco
di
martino
di
pinto
orest
c
indolfi
e
boccieri
p
indolfi
f
casal
women
child
gener
special
surgeri
second
univers
napl
napl
itali
object
polycomb
gene
set
epigenet
effector
multimer
repress
complex
catalyt
subunit
polycomb
repress
complex
methyl
histon
lysin
therebi
silenc
sever
gene
express
requir
bone
marrow
progress
cell
cell
therefor
genet
inactiv
lead
accumul
cell
stage
howev
inactiv
phase
addit
matur
step
hinder
suggest
function
earli
differenti
report
harbour
mutat
affect
exon
replac
tyrosin
residu
diffus
larg
lymphoma
dlbcl
follicular
lymphoma
fl
adult
patient
aim
studi
evalu
express
mutat
estim
role
paediatr
patient
lymphoma
method
analys
real
time
pcr
western
blot
express
level
lymph
node
biopsi
paediatr
patient
lymphoma
also
studi
mutat
sanger
sequenc
result
analysi
reveal
one
dlbcl
paediatr
sampl
heterozyg
mutat
furthermor
signific
increas
mrna
observ
patient
advanc
stage
hodgkin
lymphoma
protein
express
detect
sampl
particular
higher
level
express
sampl
mutat
conclus
preliminari
data
show
paediatr
lymphoma
date
yet
analys
seem
role
pathogenesi
cancer
investig
gain
better
insight
depend
cancer
growth
warrant
particularli
unravel
complex
protein
capac
induc
effect
serum
tarc
level
cohort
pediatr
patient
hodgkin
lymphoma
hl
promis
biomark
e
schiavello
terenziani
mazzocchi
catania
v
biassoni
podda
chiarav
n
puma
l
bergamaschi
casanova
ferrari
r
luksch
c
meazza
polastri
f
spreafico
massimino
depart
pediatr
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
unit
transfus
medicin
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
object
tarc
thymu
chemokin
express
hodgkin
cell
detect
serum
tarc
seem
correl
adult
hl
prognosi
data
publish
pediatr
method
tarc
serum
level
prospect
test
consecut
patient
consid
patholog
level
pgml
report
healthi
control
relaps
autolog
autosct
one
tarc
sampl
collect
diagnosi
cycl
treatment
end
everi
cycl
patient
characterist
median
age
year
rang
stage
bulki
diseas
extranod
involv
result
basal
tarc
level
median
high
rang
signific
higher
bulki
diseas
p
higher
signific
bsymptomsstag
patient
two
patient
normal
valu
diagnosi
stage
iib
nodularlymphocyt
predomin
varieti
stage
iia
classic
varieti
signific
declin
p
cycl
normal
persist
patient
stage
ivb
signific
decreas
without
reach
normal
ccr
two
primari
refractori
tarc
increas
pgml
relaps
compar
remiss
valu
two
monitor
tarc
reinduct
one
patient
pd
concomit
increas
tarc
tarc
normal
pr
subsequ
transplant
tarc
increas
radiolog
detect
relaps
primari
refractori
patient
tarc
decreas
correl
pr
statu
conclus
preliminari
studi
show
correl
tarc
clinic
risk
factor
radiolog
respons
first
pediatr
seri
need
valid
larger
cohort
confirm
clinic
applic
tarc
monitor
ibrutinib
significantli
alter
cell
prolifer
apoptosi
bl
pmbl
ibrutinib
may
potenti
adjuv
therapi
treatment
bl
andor
pmbl
oconnel
c
yin
barth
r
mile
j
ayello
l
harrison
c
van
de
ven
p
galardi
goldman
lim
hermiston
l
l
roth
perkin
lee
cairo
pediatr
new
york
medic
colleg
valhalla
usa
pediatr
univers
buffalo
buffalo
usa
patholog
univers
utah
salt
lake
citi
usa
pediatr
mayo
clinic
rochest
usa
pediatr
texa
oncolog
dalla
usa
patholog
univers
michigan
ann
arbor
usa
pediatr
univers
california
san
francisco
san
francisco
usa
pediatr
univers
pittsburgh
pittsburgh
usa
pediatr
patholog
laboratori
medicin
weill
cornel
medic
colleg
new
york
usa
object
bl
pmbl
two
common
subtyp
lymphoma
children
adolesc
milescairo
bjh
children
relaps
progress
bl
develop
diseas
rare
cure
salvag
therapi
cairo
et
al
jco
previous
report
signific
decreas
ef
among
pediatr
pmbl
patient
compar
stage
iii
pediatr
dlbcl
patient
follow
therapi
gerrardcairo
et
al
blood
bruton
tyrosin
kinas
btk
regul
normal
develop
compon
bcr
signal
chronic
activ
bcr
signal
btk
activ
inhibit
select
coval
btk
inhibitor
ibrutinib
recent
gain
fda
approv
adult
relaps
cll
mcl
hypothes
ibrutinib
may
therapeut
agent
treatment
bl
pmbl
method
raji
ramo
raji
bl
cell
cell
expos
ibrutinib
hour
evalu
cell
prolifer
raji
ramo
also
evalu
apoptosi
express
ibrutinib
gener
provid
janssen
pharmaceut
inc
result
ibrutinib
significantli
decreas
prolifer
raji
p
ramo
p
raji
p
p
cell
vs
control
signific
increas
caspas
activ
observ
raji
p
ramo
p
p
vs
control
signific
decreas
express
observ
raji
p
ramo
p
p
vs
control
conclus
ibrutinib
significantli
inhibit
cell
prolifer
raji
ramo
raji
increas
apoptosi
concomit
decreas
express
raji
ramo
ibrutinib
may
potenti
therapeut
agent
bl
pmbl
character
standard
uptak
valu
diagnost
petct
scan
accord
pediatr
lymphoma
subtyp
j
halparin
sr
rassekh
hr
nadel
pediatr
hematologyoncolog
bc
children
hospit
vancouv
canada
radiolog
bc
children
hospit
vancouv
canada
object
positron
emiss
tomographi
computer
tomographi
fdg
petct
use
increasingli
pediatr
lymphoma
diagnost
stage
assess
treatment
respons
identif
relaps
diseas
pet
ct
measur
tissu
metabol
activ
term
maximum
standard
uptak
valu
suv
max
whether
suv
max
diagnosi
relat
patholog
subtyp
lymphoma
unknown
purpos
studi
character
suv
max
fdg
petct
scan
pediatr
lymphoma
accord
patholog
subtyp
method
retrospect
chart
review
subject
includ
patient
diagnos
lymphoma
tertiari
children
hospit
petct
scan
time
diagnosi
data
collect
subject
includ
initi
suv
max
patholog
subtyp
lymphoma
descript
statist
use
summar
data
result
total
subject
includ
patholog
diagnos
hodgkin
lymphoma
hl
anaplast
larg
cell
lymphoma
alcl
burkitt
lymphoma
bl
diffus
larg
b
cell
lymphoma
dlbcl
lymphoma
bll
lymphoma
tll
result
follow
conclus
data
suggest
differ
subtyp
pediatr
lymphoma
character
differ
suv
max
fdg
petct
scan
howev
appear
signific
overlap
rang
initi
suv
max
across
subtyp
larger
prospect
studi
need
valid
data
investig
whether
suv
max
chang
suv
max
treatment
relat
outcom
pediatr
lymphoma
outcom
spanish
patient
outsid
hasenclev
echebarria
c
garrido
jl
vivanco
guibelald
rodriguez
coronado
behalf
sehop
pediatr
oncolog
unit
hospital
universitario
virgen
macarena
virgen
del
sevilla
spain
institut
medizinisch
informatik
statistik
epidemiologi
imis
leipzig
leipzig
germani
pediatr
unit
hospit
universitario
de
cruce
spain
pediatr
unit
hospit
universitario
gregorio
madrid
spain
pediatr
unit
hospit
universitario
doce
de
octubr
madrid
spain
pediatr
unit
hospit
universitario
miguel
servet
zaragoza
spain
pediatr
unit
hospit
universitario
son
espas
palma
de
mallorca
spain
radiotherapi
servic
hospit
universitario
la
paz
madrid
spain
nuclear
medicin
servic
hospit
universitario
la
paz
madrid
spain
sociedad
de
madrid
spain
object
spanish
hospit
start
accrual
trial
due
local
difficulti
complet
legal
requir
patient
differ
hospit
treat
outsid
trial
accord
standard
arm
benefit
nation
patholog
review
central
imag
review
hall
stage
earli
respons
assess
object
compar
outcom
spanish
patient
treat
outsid
trial
accord
standard
arm
trial
trial
method
patient
spanish
hospit
treat
insid
trial
standard
arm
trial
novemb
octob
descript
statist
event
free
surviv
estim
test
result
novemb
octob
spanish
patient
hospit
enter
trial
account
patient
spanish
patient
hospit
treat
accord
standard
arm
treatment
group
distribut
ef
month
similar
vs
p
ef
month
lower
vs
p
conclus
outcom
spanish
patient
regist
trial
similar
although
number
small
understag
may
explain
wors
outcom
trend
spanish
patient
treat
outsid
trial
particip
prospect
intern
random
trial
refer
patholog
central
imag
review
encourag
spanish
hospit
nation
region
author
parent
associ
must
made
awar
result
order
facilit
encourag
particip
clinic
trial
assess
treatment
outcom
among
childhood
endem
burkitt
lymphoma
jaramogi
oginga
odinga
teach
referr
hospit
kenya
gc
buckl
eo
mick
p
omollo
j
oyomb
omenah
ja
otieno
moormann
depart
pediatr
univers
massachusett
medic
school
worcest
usa
quantit
health
scienc
univers
massachusett
medic
school
worcest
usa
kenya
medic
research
institut
center
global
health
research
kisumu
kenya
pediatr
jaramogi
oginga
odinga
teach
referr
hospit
kisumu
kenya
object
evalu
clinic
characterist
treatment
outcom
children
diagnos
endem
burkitt
lymphoma
ebl
jaramogi
oginga
odinga
teach
referr
hospit
jootrh
region
referr
center
pediatr
oncolog
western
kenya
identifi
factor
associ
surviv
method
retrospect
analysi
conduct
children
diagnos
ebl
joorth
patient
treat
cytotox
regimen
includ
cyclophosphamid
vincristin
adriamycin
prednison
intrathec
methotrex
method
multivari
cox
proport
hazard
model
use
evalu
surviv
probabl
identifi
prognost
factor
age
gender
bodi
surfac
area
bsa
plasmodium
falciparum
malaria
infect
hemoglobin
level
tumor
stage
deviat
recommend
cytotox
dose
evalu
result
four
hundr
children
includ
analysi
male
mean
age
diagnosi
year
murphi
stage
distribut
stage
ii
iii
iv
cyclophosphamid
vincristin
methotrex
dose
deviat
recommend
dose
base
bsa
patient
respect
overal
surviv
averag
day
ward
tumor
stage
cyclophosphamid
dose
emerg
independ
factor
influenc
prognosi
tumor
stage
ii
higher
overdos
cyclophosphamid
associ
significantli
increas
risk
death
hazard
ratio
ci
p
ci
p
respect
conclus
find
suggest
advanc
stage
present
remain
barrier
improv
surviv
among
children
ebl
ii
lower
dose
cytotox
agent
may
better
toler
set
limit
support
care
iii
insuffici
pharmaci
nurs
support
may
contribut
treatment
failur
particularli
administr
complex
chemotherapeut
regimen
clinic
outcom
children
anaplast
larg
cell
lymphoma
underw
poland
allogen
autolog
haematopoiet
stem
cell
transplant
year
kulej
g
wrobel
n
adrianowska
daniluk
e
dudkiewicz
r
debski
k
drabko
e
gorczynska
e
grazynska
b
kazanowska
e
kamienska
koltan
kutrzeba
l
kapuscinska
j
rapala
ussowicz
j
wachowiak
wegner
woszczyk
spychala
k
kalwak
peadiatr
heamatolog
oncolog
bmt
medic
univers
wroclaw
poland
peadiatr
heamatolog
oncolog
medic
univers
lodz
poland
peadiatr
heamatolog
oncolog
children
memori
health
institut
warsaw
poland
peadiatr
heamatolog
oncolog
bmt
medic
univers
lublin
poland
peadiatr
heamatolog
oncolog
bmt
medic
univers
bydgoszcz
poland
peadiatr
heamatolog
oncolog
medic
univers
szczecin
poland
peadiatr
heamatolog
oncolog
bmt
american
institut
pediatr
jagiellonian
univers
krakow
poland
peadiatr
heamatolog
oncolog
medic
univers
gdansk
poland
peadiatr
surgeri
marciniak
hospit
wroclaw
poland
peadiatr
heamatolog
oncolog
bmt
medic
univers
poznan
poland
peadiatr
heamatolog
oncolog
medic
univers
chorzow
poland
object
risk
relaps
progress
diseas
children
anaplast
larg
cell
lymphoma
alcl
remain
high
report
clinic
characterist
outcom
patient
pt
relaps
alcl
underw
either
autolog
allogen
haematopoiet
stem
cell
transplant
hsct
method
pt
alcl
regist
polish
paediatr
leukemialymphoma
studi
group
pllsg
year
develop
relaps
line
treatment
clinic
stage
risk
group
relaps
pt
treat
accord
protocol
line
treatment
achiev
die
diseas
progress
dod
relaps
alcl
underw
transplant
autohsct
sibl
donor
msd
unrel
donor
mud
retranspl
due
relaps
transplant
center
poznan
lublin
bydgoszcz
median
age
year
sourc
stem
cell
bone
marrow
bm
n
peripher
blood
stem
cell
pbsc
n
primari
condit
regimen
transplant
procedur
beam
allogeneichsct
mudmsd
tbi
atg
use
mud
transplant
recipi
gvhdgraft
reject
prophylaxi
result
engraft
achiev
cr
relaps
underw
subsequ
allogen
hsct
outcom
hsct
die
due
renal
dysfunct
hsct
late
posttranspl
month
hsct
aspergillosi
hsct
remain
aliv
cr
hsct
complic
gvhd
liver
skin
pulmonari
aspergillosi
remain
aliv
cr
relaps
achiev
persist
cr
allogeneichsct
die
due
trm
conclus
risk
relaps
pediatr
alcl
high
use
allogeneichsct
seem
potenti
cur
option
reduct
toxic
lead
trm
essenti
improv
overal
result
allogen
hsct
anesthet
manag
children
anterior
mediastin
lymphoma
aml
narciso
c
tognon
pillon
todesco
r
alaggio
metrangolo
grazzini
n
zadra
g
cecchetto
p
dalligna
pediatr
surgeri
padua
padova
itali
pediatr
anesthesia
padua
padova
itali
pediatr
padua
padova
itali
pediatr
patholog
padua
padova
itali
object
children
aml
may
experi
seriou
complic
gener
anesthesia
due
compress
tracheabronchi
hearth
main
vessel
institut
specif
guidelin
anesthesia
use
sinc
recogn
three
group
patient
method
group
respiratori
symptom
compress
tracheahearthmain
vessel
patient
group
b
mild
respiratori
symptom
vascular
compress
tracheal
compress
patient
group
c
sever
respiratori
symptom
andor
vena
cava
syndrom
andor
tracheal
compress
patient
result
group
six
cooper
underw
biopsi
clnb
local
anesthesia
la
non
cooper
underw
clnb
use
mild
sedat
midazolam
ketamin
alfentanyl
underw
clnb
chamberlein
procedur
gener
anesthesia
ga
tracheal
intub
spontan
ventil
without
use
muscl
relax
drug
median
mmr
mediastin
mass
chest
diamet
ratio
group
b
two
underw
clnb
la
underw
chamberlein
procedur
clnb
ga
clnb
trucut
mass
la
anxiolyt
medic
midazolam
sinc
diagnosi
obtain
chamberlein
procedur
clnb
necessari
ga
median
mmr
group
c
four
underw
clnb
trucut
biopsi
mass
chamberlein
procedur
la
anxiolyt
medic
clnb
la
patient
treat
steroid
biopsi
case
mild
episod
cardiorespiratori
breakdown
occur
requir
chang
patient
posit
procedur
median
mmr
conclus
anesthesiolog
risk
patient
aml
alway
need
care
calcul
discuss
multidisciplinari
set
includ
children
parent
recent
experi
sinc
use
guidelin
combin
thorough
preoper
assess
less
invas
anesthesiolog
method
whenev
feasibl
possibl
rapid
surgic
procedur
could
obtain
correct
diagnosi
without
sever
complic
evalu
establish
treatment
relat
mortal
risk
score
follow
allogen
hematopoiet
stem
cell
transplant
children
singl
center
twenti
year
period
farrag
vraetz
amj
peter
yoshimi
p
noellk
cm
niemey
b
strahm
divis
pediatr
hematolog
oncolog
depart
pediatr
adolesc
medicin
univers
freiburg
freiburg
germani
object
matth
et
al
describ
risk
score
treatment
relat
mortal
hematopoiet
stem
cell
transplant
children
age
year
advanc
diseas
donor
match
sibl
donor
msd
character
risk
factor
evalu
risk
score
patient
transplant
year
period
center
refer
center
myelodysplasticmyeloprolif
syndrom
mdsmp
includ
juvenil
myelomonocyt
leukemia
jmml
method
data
consecut
patient
transplant
analyz
retrospect
result
median
age
transplant
year
diagnosi
includ
mpsmd
n
malign
n
disord
n
patient
receiv
myeloabl
prepar
regimen
match
unrel
donor
receiv
bone
marrow
graft
overal
surviv
occur
patient
patient
risk
score
respect
thu
demonstr
steadi
increas
increas
risk
score
howev
increas
accord
risk
score
compar
result
matth
earlier
time
period
observ
may
reflect
declin
patient
transplant
unrel
donor
due
better
due
center
special
sever
diagnos
like
jmml
advanc
md
overrepres
adapt
risk
score
consid
disord
advanc
diseas
score
system
work
well
conclus
score
matth
adjust
patient
subgroup
heavili
overrepres
cohort
studi
compar
refer
cohort
et
al
outcom
measur
pediatr
allogen
stem
cell
transplant
biol
blood
marrow
transplant
p
homozyg
haplotyp
untransl
region
associ
decreas
overal
surviv
childhood
acut
myeloid
leukemia
n
r
santo
rg
gome
aml
ramo
eav
marqu
tc
fonseca
gtn
diniz
f
pedrosa
eav
donadi
imunologia
centro
de
pesquisa
aggeu
recif
brazil
oncologia
instituto
de
medicina
integrl
professor
fernando
figueira
recif
brazil
de
computacionai
centro
de
pesquisa
aggeu
recif
brazil
de
imunologia
clinica
faculdad
de
medicina
de
preto
universidad
de
paulo
preto
brazil
object
major
histocompat
complex
class
molecul
exhibit
immunomodulatori
function
role
cancer
allotransplant
much
controversi
arisen
regard
role
leukemia
aim
evalu
possibl
associ
region
utr
allel
acut
myeloid
leukemia
aml
measur
solubl
level
bone
marrow
children
aml
assess
featur
childhood
aml
accord
overal
surviv
method
hundr
nine
consecut
unselect
children
aml
refer
instituto
de
medicina
integr
professor
fernando
figueira
recif
northeastern
brazil
studi
diagnosi
leukemia
character
blast
morpholog
phenotyp
genet
abnorm
polymorph
site
gene
investig
aml
healthi
unrel
children
gene
amplif
sequenc
allel
genotyp
frequenc
estim
use
genepop
arlekin
softwar
measur
leukemia
normal
bone
marrow
elisa
statist
analys
done
use
result
aml
patient
classifi
n
apl
n
secondari
aml
n
children
exhibit
diplotyp
show
worsen
overal
surviv
relat
exhibit
diplotyp
p
hazard
x
death
relat
patient
exhibit
heterozyg
diplotyp
p
hazard
x
death
major
aml
patient
exhibit
low
bone
marrow
level
mean
unitsml
median
unitsml
varianc
level
children
exhibit
homozyg
haplotyp
differ
compar
children
carri
haplotyp
p
conclus
regul
bone
marrow
might
involv
childhood
aml
pathogenesi
diseas
outcom
cytogenet
profil
acut
loblast
leukaemia
teenag
young
adult
singl
center
experi
n
khoubila
lamchaheb
n
hda
quachouh
rachid
madani
benchekroun
quessar
hematolog
pediatr
oncolog
august
hospit
ibn
rochd
univers
hospit
casablanca
morocco
biolog
analysi
laboratori
hda
casablanca
morocco
object
present
cytogenet
aberr
detect
time
acut
myeloblast
leukaemia
aml
diagnosi
constitut
common
basi
predict
clinic
outcom
minim
data
cytogenet
profil
aml
young
adult
countri
object
analyz
cytogenet
characterist
young
patient
novo
aml
method
elig
patient
age
year
old
de
novo
aml
includ
protocol
exclud
patient
acut
promyelocyt
leukemia
apl
secondari
aml
aml
cytogenet
analysi
done
diagnosi
separ
cytogenet
find
three
broad
prognost
categori
favour
intermedi
advers
treatment
includ
two
induct
two
consolid
result
patient
aml
follow
depart
patient
age
patient
exclud
apl
patient
de
novo
aml
includ
aml
subtyp
frequent
patient
karyotyp
done
patient
cytogenet
analysi
fail
case
patient
nt
cytogenet
studi
patient
cytogenet
analysi
result
elig
cytogenet
find
divid
three
group
favor
inv
intermedi
normal
advers
patient
treat
os
rate
among
favour
intermedi
advers
group
respect
conclus
cytogenet
profil
reveal
particular
high
rang
probabl
due
young
age
patient
major
intermedi
group
challeng
futur
studi
determin
prognosi
signific
normal
caryotyp
molecular
technic
somat
thrombopoietin
tpho
gene
mutat
childhood
myeloid
leukemia
houw
r
kersseboom
slm
goosken
ach
de
vri
reinhardt
j
stari
v
de
haa
rob
pieter
zwaan
mm
van
den
depart
pediatr
hematolog
oncolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
depart
clinic
genet
erasmu
univers
medic
center
rotterdam
netherland
depart
pediatr
oncologyhematolog
medic
school
hannov
germani
depart
pediatr
oncologyhematolog
charl
univers
univers
hospit
motol
pragu
czech
republ
dutch
childhood
oncolog
group
dutch
childhood
oncolog
group
hagu
netherland
depart
pediatr
hematolog
oncolog
prins
maxima
centererasmu
univers
medic
center
sophia
children
hospit
utrechtrotterdam
netherland
object
report
first
time
infant
myeloprolif
condit
harbor
germlin
hereditari
thrombopoietin
thpo
gene
mutat
patient
dutch
famili
g
c
mutat
splice
donor
site
thpo
gene
known
induc
famili
thrombocytosi
ft
increas
age
involv
regul
megakaryopoiesi
ft
gener
character
sustain
prolifer
megakaryocyt
result
elev
platelet
count
five
known
mutat
thpo
gene
locat
region
thpo
gene
mutat
lead
increas
translat
thpo
inhibit
remov
upstream
open
read
frame
uorf
monocyt
hyperprolifer
infant
age
patient
seem
occur
conjunct
germlinethpo
mutat
could
suggest
thpo
involv
hyperprolifer
monocyt
progenitor
lineag
recent
suggest
mutat
thpo
gene
might
predispos
adult
acut
myeloid
leukemia
myelofibrosi
multipl
myeloma
contrast
occurr
somat
thpo
mutat
sporad
pediatr
aml
patient
never
describ
method
perform
mutat
screen
repres
cohort
pediatr
aml
n
n
jmml
n
sampl
amplifi
region
thpo
result
screen
reveal
case
mutat
splice
site
c
g
aml
patient
conclus
conclud
somat
mutat
thpo
gene
seem
rare
sporad
childhood
myeloid
malign
nevertheless
germlin
thpo
mutat
may
consid
infant
diseas
without
dysmorph
featur
cytogenet
aberr
diagnosi
may
import
implic
clinic
cours
treatment
genet
counsel
intern
tandem
duplic
mutat
paediatr
aml
singl
centr
experi
v
gupta
bourn
n
bown
samarasingh
bailey
r
skinner
paediatr
adolesc
oncologybmt
great
north
children
hospit
newcastl
upon
tyne
hospit
nh
foundat
trust
newcastl
upon
tyne
unit
kingdom
northern
genet
servic
newcastl
upon
tyne
hospit
nh
foundat
trust
newcastl
upon
tyne
unit
kingdom
depart
heamatolog
oncolog
great
ormond
street
hospit
london
unit
kingdom
object
intern
tandem
duplic
itd
high
allel
ratio
associ
high
relaps
risk
aml
although
addit
mutat
may
reduc
risk
rel
littl
paediatr
data
treatment
outcom
avail
date
therapi
proven
benefit
inhibitor
sorafenib
haematopoet
stem
cell
transplant
hsct
treatment
option
present
experi
mutat
paediatr
aml
method
retrospect
data
analysi
carri
identifi
children
withwithout
mutat
clinic
profil
respons
chemotherapi
outcom
note
treatment
accord
uk
guidelin
result
mutat
evalu
paediatr
patient
age
year
aml
sinc
year
eight
patient
median
age
year
rang
year
identifi
give
frequenc
cohort
four
patient
enter
remiss
one
cours
ade
one
isol
skin
relaps
immedi
plan
hsct
second
remiss
achiev
clofaribin
daunoxom
sorafenib
follow
transplant
anoth
relaps
month
complet
chemotherapi
die
refractori
diseas
despit
sorafenib
three
patient
refractori
diseas
first
cours
ade
sorafenib
use
second
cours
one
patient
addit
mutat
pharyng
granulocyt
sarcoma
without
marrow
involv
respond
well
chemotherapi
six
patient
transplant
success
unrel
includ
one
doubl
cord
one
match
sibl
one
remain
remiss
median
day
rang
day
conclus
inspit
small
number
experi
consist
previou
report
children
itd
aggress
cours
aml
often
poor
respons
first
cours
chemotherapi
longer
follow
requir
see
whether
hsct
improv
diseas
control
overal
surviv
baselin
high
resolut
ct
scan
hrct
thorax
detect
respiratori
infect
patient
acut
myeloid
leukemia
aml
present
n
tandon
banavali
b
arora
kembhavi
medic
oncolog
tata
memori
hospit
mumbai
india
radiolog
tata
memori
hospit
mumbai
india
object
intens
chemotherapi
aml
increas
infecti
complic
especi
pulmonari
bacteri
fungal
lead
dismal
prognosi
aim
studi
assess
incid
baselin
pulmonari
infect
hrct
chest
aml
patient
start
induct
method
prospect
observ
singl
centr
studi
consecut
pediatr
year
aml
exclud
apml
patient
treat
tata
memori
centr
june
januari
elig
patient
underw
baselin
hrct
thorax
initi
induct
central
review
radiologist
result
patient
enrol
mean
age
year
male
fever
respiratori
symptom
abnorm
chest
examin
good
intermedi
poor
risk
cytogenet
mean
symptom
durat
month
twenti
two
patient
abnorm
hrct
thorax
among
possibl
bacteri
fungal
infect
miscellan
find
like
tuberculosi
pneumocysti
carinii
non
specif
nodul
univari
analysi
presenc
fever
p
respiratori
symptom
p
poor
risk
cytogenet
p
significantli
correl
abnorm
hrct
scan
howev
multivari
analysi
respiratori
symptom
poor
risk
cytogenet
statist
signific
p
conclus
hrct
chest
excel
imag
modal
aml
detect
baselin
pulmonari
infect
includ
diagnost
work
centr
signific
rate
infect
would
help
choos
antifung
prophylaxi
versu
treatment
therebi
improv
morbid
mortal
intens
aml
induct
underli
undiagnos
inherit
marrow
failur
syndrom
among
children
cancer
f
alabba
dror
r
grant
malkin
abla
weitzman
e
bouffet
hematolog
oncolog
hospit
sick
children
toronto
canada
object
determin
preval
children
cancer
underli
inherit
bone
marrow
failur
syndrom
ibfm
method
retrospect
review
medic
record
newli
diagnos
pediatr
cancer
patient
hospit
sick
children
june
may
conduct
clinic
laboratori
radiolog
paramet
extract
patient
chart
focus
particularli
find
suggest
possibl
underli
ibmf
tabl
find
suggest
underli
ibmf
newli
diagnos
cancer
patient
famili
histori
cancer
age
yearsassoci
physic
anomali
physic
radiolog
examin
histori
previou
cytopeniaelev
mcvelev
hemoglobin
fsever
toxic
chemotherapi
radiat
treatment
result
record
patient
review
five
candid
patient
identifi
three
present
acut
leukemia
two
present
kidney
malform
elev
mcv
elev
hemoglobin
f
seen
one
patient
one
patient
develop
grade
toxic
respons
chemotherapi
fourth
patient
present
brain
tumor
later
develop
sever
toxic
chemotherapi
prolong
pancytopenia
father
diagnos
nasopharyng
carcinoma
fifth
patient
present
wilm
tumor
congenit
anomali
elev
hemoglobin
f
conclus
data
suggest
small
fraction
patient
cancer
clinic
featur
indic
investig
rule
underli
ibmfss
care
evalu
indic
ibmfss
help
person
treatment
minim
toxic
provid
appropri
famili
counsel
prognosi
prospect
studi
necessari
accur
determin
preval
ibmfss
among
newli
diagnos
cancer
patient
lncrna
express
signatur
neuroblastoma
reveal
potenti
role
lncrna
contribut
neuroblastoma
pathogenesi
weitao
kuiran
c
ximao
l
gongbao
z
pediatr
surgeri
children
hospit
fudan
univers
shanghai
china
object
long
rna
lncrna
broadli
defin
transcrib
rna
molecul
greater
length
lack
open
read
frame
signific
length
less
animo
acid
purpos
studi
investig
differenti
express
lncrna
neuroblastoma
method
tumor
tissu
tissu
collect
store
past
two
year
studi
lncrna
microarray
human
lncrna
microarri
use
investig
differenti
express
lncrna
sampl
tumor
tissu
tissu
result
lncrna
mrna
differenti
express
tumor
tissu
tissu
tumor
vs
lncrna
mrna
lncrna
mrna
gene
ontolog
go
analysi
differenti
express
gene
involv
biolog
process
gene
fold
enrich
p
gene
involv
biolog
process
gene
fold
enrich
p
tumor
tissu
comprehens
analyz
lncrna
nearbi
code
gene
demonstr
express
differenti
meanwhil
fold
chang
p
especi
lncrna
fold
chang
p
nearbi
code
gene
synchron
fold
chang
p
tumor
tissu
find
comfirm
subsequ
pcr
result
neuroblastoma
sampl
tissu
conclus
experi
provid
list
differenti
express
lncrna
mrna
neuroblastoma
could
use
studi
novel
lncrna
mayb
play
import
role
neuroblastoma
pathogenesi
regul
nearbi
code
gene
copi
number
variat
cnv
defin
prognosi
neuroblastoma
patient
druy
e
shorikov
g
tsaur
tuponogov
popov
solodovnikov
l
saveliev
l
fechina
pediatr
oncolog
hematolog
center
region
children
hospitalresearch
institut
medic
cell
technolog
yekaterinburg
russia
pediatr
oncolog
hematolog
center
region
children
hospit
yekaterinburg
russia
pediatr
oncolog
hematolog
center
research
institut
medic
cell
technolog
yekaterinburg
russia
chair
laboratori
medicin
ural
state
medic
univers
yekaterinburg
russia
object
delet
mycn
amplif
mna
known
advers
prognost
marker
neuroblastoma
signific
mani
cnv
unclear
method
analyz
neuroblastoma
mlpa
loci
tumor
prognost
signific
estim
overal
os
surviv
ef
median
time
month
rang
month
result
patient
delet
reveal
prognost
impact
ef
vs
p
os
vs
p
gain
detect
patient
led
decreas
surviv
rate
ef
vs
p
os
vs
p
delet
gain
retain
prognost
signific
mycn
patient
gain
includ
mycn
observ
patient
show
prognost
signific
patient
year
ef
vs
p
gain
detect
patient
decreas
ef
patient
year
vs
p
gain
patient
led
reduc
ef
whole
group
vs
p
mycn
patient
vs
p
patient
delet
found
presenc
aberr
result
dramat
decreas
surviv
rate
ef
os
vs
correspondingli
p
p
multivari
analysi
os
perform
stage
age
mna
delet
gain
covari
patient
stage
iv
p
mna
p
delet
p
significantli
poor
surviv
conclus
cohort
patient
mna
delet
gain
demonstr
neg
prognost
signific
mna
delet
defin
independ
molecular
advers
factor
presenc
gain
led
decreas
ef
group
patient
year
role
neuroblastoma
initi
mainten
analysi
zebrafish
model
childhood
neuroblastoma
zhu
wood
g
yang
x
zhang
n
weichert
tao
oldridg
j
mari
look
depart
biochemistri
molecular
biolog
mayo
clinic
rochest
usa
divis
oncolog
center
childhood
cancer
research
children
hospit
philadelphia
philadelphia
usa
pediatr
oncolog
cancer
institut
boston
usa
object
neuroblastoma
embryon
tumor
peripher
sympathet
nervou
system
psn
account
childhood
cancer
death
recent
develop
robust
zebrafish
model
neuroblastoma
demonstr
activ
alk
synerg
mycn
inhibit
apoptot
respons
otherwis
induc
mycn
use
model
provid
evid
support
result
associ
studi
gwa
conduct
dr
john
mari
group
studi
reveal
inherit
common
singl
nucleotid
polymorph
snp
within
lim
gene
locu
highli
associ
develop
advanc
neuroblastoma
children
higher
risk
develop
neuroblastoma
overexpress
without
alter
code
sequenc
method
accordingli
develop
two
independ
transgen
line
human
gene
overexpress
psn
control
zebrafish
h
promot
line
bred
heterozyg
transgen
fish
overexpress
psn
control
h
promot
result
recent
result
show
overexpress
zebrafish
model
markedli
acceler
onset
increas
penetr
neuroblastoma
provid
vivo
evid
role
overexpress
initi
neuroblastoma
acceler
tumorigenesi
primarili
increas
prolif
rate
mycn
express
sympathet
neuron
progenitor
addit
found
coexpress
activ
alk
induc
neuroblastoma
first
time
neuroblastoma
induc
zebrafish
system
without
mycn
overexpress
conclus
thu
zebrafish
model
system
appear
ideal
function
genom
analysi
provid
vivo
evid
investig
mechan
pathway
underli
new
associ
emerg
gwa
tumor
genom
resequenc
technolog
current
intens
investig
human
cancer
protein
signatur
serum
patient
neuroblastoma
ragg
key
f
rankin
vik
hogarti
pediatr
indiana
univers
school
medicin
indianapoli
usa
pediatr
univers
pennsylvania
philadelphia
usa
object
neuroblastoma
heterogen
tumor
outcom
rang
excel
surviv
high
risk
failur
goal
develop
better
prognost
indic
children
oncolog
group
cog
collect
serum
sampl
larg
number
subject
time
diagnosi
sampl
use
character
protein
signatur
blood
indic
tumor
type
respons
therapi
relaps
post
treatment
method
measur
rel
concentr
low
abund
protein
custom
human
cytokin
antibodi
array
raybiotech
inc
subject
osteosarcoma
subject
wilm
tumor
subject
neuroblastoma
stage
favor
histolog
stage
mycn
amplifi
stage
sera
collect
diagnosi
local
cog
sampl
compar
sampl
healthi
subject
use
mix
effect
model
sever
standard
statist
learn
approach
use
classifi
serum
children
neuroblastoma
versu
healthi
control
result
comparison
healthi
control
sampl
protein
differenti
abund
sampl
subject
mycn
amplif
high
risk
neuroblastoma
protein
differenti
abund
sampl
subject
low
risk
neuroblastoma
sampl
subject
mycn
amplif
high
risk
neuroblastoma
contain
protein
differenti
abund
compar
sera
subject
wilm
tumor
osteosarcoma
protein
differenti
abund
uniqu
classif
result
consist
across
five
classif
algorithm
use
averag
specif
averag
sensit
conclus
studi
demonstr
multipl
low
abund
protein
form
accur
signatur
distinguish
healthi
diseas
subject
well
differ
cancer
type
bone
morphogenet
protein
receptor
ii
suppress
neuroblastoma
prolifer
vitro
vivo
x
cui
k
dong
jia
r
dong
k
li
x
xiao
w
yao
g
liu
pediatr
surgeri
children
hospit
fudan
univers
shanghai
china
shanghai
medic
colleg
fudan
univers
shanghai
china
object
bone
morphogenet
protein
receptor
ii
encod
member
bone
morphogenet
protein
receptor
famili
transmembran
serinethreonin
kinas
aim
studi
determin
whether
differ
express
affect
neuroblastoma
cell
prolifer
method
specimen
neuroblastoma
obtain
hospit
shrna
vector
transfect
nb
cell
line
overexpress
vector
transfect
nb
cell
line
effici
gene
silenc
overexpress
confirm
quantit
pcr
cell
prolifer
abil
measur
kit
coloni
format
assay
cell
inject
subcutan
nude
mice
tumor
size
quantifi
two
dimens
use
calip
immunohistochem
stain
use
express
statist
analysi
graphic
present
perform
use
graphpad
prism
result
quantit
pcr
immunohistochem
stain
show
express
level
neuroblastoma
higher
adren
tissu
p
assay
coloni
format
assay
show
disrupt
gene
express
posit
effect
prolifer
neuroblastoma
cell
contrari
overexpress
neg
effect
vivo
found
could
inhibit
neuroblastoma
cell
growth
mous
model
conclus
data
present
indic
signific
role
could
suppress
prolifer
neuroblastoma
vitro
vivo
involv
cell
surviv
differenti
jnk
pathway
neuroblastoma
sheikh
takatori
ms
hossain
mk
hasan
nakamura
nakagawara
children
cancer
research
center
chiba
cancer
center
research
institut
chiba
japan
object
neuron
repeat
protein
transmembran
protein
human
nlrr
gene
famili
nlrr
famili
associ
unfavor
prognosi
correl
favor
outcom
neuroblastoma
nb
howev
clinic
signific
function
nb
still
uncov
present
studi
interest
investig
function
transcript
regul
nb
method
evalu
express
tgw
cell
quantit
real
time
pcr
retino
acid
ra
use
induc
neuron
differenti
nb
cell
promot
activ
recruit
analyz
dual
luciferas
chip
assay
respect
cell
use
tumor
xenograft
studi
result
found
enforc
express
increas
nb
cell
growth
knockdown
significantli
reduc
nb
cell
growth
vitro
vivo
knockdown
cell
differenti
significantli
enhanc
ra
treatment
express
increas
correl
upregul
member
activ
famili
interestingli
treatment
jnk
inhibitor
reduc
express
promot
analysi
reveal
ra
treatment
enhanc
transcript
suppress
jnk
inhibitor
bind
site
identifi
promot
region
recruit
confirm
chip
assay
moreov
knockdown
reduc
express
suggest
induc
gene
regul
jnk
pathway
function
enhanc
nb
cell
surviv
inhibit
cell
differenti
conclus
accumul
evid
suggest
act
neg
feedback
regul
differenti
might
play
role
nb
drug
resist
could
give
us
possibl
therapeut
approach
treat
aggress
nb
compar
scintigraphi
patient
stage
neuroblastoma
investig
bone
bone
marrow
metastas
g
bleeker
smet
e
deurlo
b
van
h
caron
g
tytgat
depart
paediatr
oncolog
academ
medic
center
amsterdam
netherland
depart
radiolog
nuclear
medicin
academ
medic
center
amsterdam
netherland
object
compar
radionuclid
scintigraphi
magnet
reson
imag
mri
short
tau
invers
recoveri
stir
investig
bone
bone
marrow
metastas
neuroblastoma
method
diagnost
imag
patient
stage
neuroblastoma
evalu
assess
metastat
spread
skelet
segment
first
presenc
absenc
lesion
score
morpholog
characterist
lesion
compar
focal
sharpli
demarc
limit
one
locat
skelet
segment
diffus
indistinct
margin
dispers
throughout
skelet
segment
result
total
skelet
segment
evalu
modal
segment
lesion
visibl
segment
discrep
seen
lesion
morpholog
investig
reveal
show
focal
lesion
segment
diffus
combin
segment
show
focal
lesion
segment
diffus
combin
concord
morpholog
find
seen
segment
focal
diffus
segment
type
lesion
segment
morpholog
discord
find
found
lesion
focal
discord
diffus
lesion
segment
eight
affect
segment
patient
cortic
destruct
seen
lesion
diffus
type
diffus
type
focal
conclus
show
affect
skelet
segment
includ
patient
stage
find
affect
stage
discrep
also
morpholog
investig
indic
show
focal
diffus
lesion
feasibl
topotecan
therapi
follow
consolid
busulfan
melphalan
autolog
stem
cell
transplant
refractori
metastat
neuroblastoma
ferri
g
schleiermach
proust
p
chastagn
j
michon
oudoux
defachel
de
centr
oscar
lambret
lill
franc
de
institut
curi
pari
franc
de
institut
gustav
roussi
pari
franc
centr
hospitali
universitair
anger
franc
centr
hospitali
universitair
nanci
franc
de
institut
curi
pari
franc
de
centr
oscar
lambret
lill
franc
object
evalu
safeti
miitop
mibg
therapi
topotecan
follow
busulfan
melphalan
bumel
asct
patient
refractori
metastat
neuroblastoma
method
retrospect
analysi
toxic
data
patient
refractori
neuroblastoma
enrol
miitop
protocol
follow
bumel
assess
miitop
patient
receiv
activ
mcikg
combin
topotecan
vivo
dosimetri
use
calcul
second
activ
given
day
deliv
total
dose
gy
second
cours
topotecan
asct
perform
day
miitop
patient
without
progress
diseas
could
receiv
bumel
consist
iv
busulfan
day
accord
bodi
weight
strata
melphalan
day
asct
day
toxic
assess
miitop
result
seven
patient
complet
miitop
follow
bumelasct
median
interv
week
miitop
immedi
toler
miitop
good
grade
toxic
limit
two
patient
fever
unknown
origin
fuo
two
patient
develop
late
complic
grade
adren
insuffici
grade
hypothyroidi
bumel
two
patient
develop
bacteri
sepsi
five
fuo
grade
mucos
occur
five
patient
one
patient
develop
grade
sinusoid
obstruct
syndrom
recov
day
median
durat
neutropenia
thrombocytopenia
day
respect
one
patient
persist
thrombocytopenia
day
post
asct
end
treatment
one
complet
remiss
five
stabl
diseas
one
progress
diseas
conclus
bumel
safe
administ
week
miitop
therapi
mibg
mcikg
topotecan
refractori
metastat
neuroblastoma
impact
surviv
treatment
combin
evalu
phase
ii
trial
util
paediatr
neuroblastoma
comparison
scintigraphi
singl
institut
experi
v
dhull
p
sharma
c
patel
agarwala
v
bhatnagar
bakhshi
c
bal
r
kumar
nuclear
medicin
india
institut
medic
scienc
new
delhi
india
paediatr
surgeri
india
institut
medic
scienc
new
delhi
india
medic
oncolog
india
institut
medic
scienc
new
delhi
india
object
evalu
util
patient
paediatr
neuroblastoma
compar
result
scintigraphi
method
data
patient
male
femal
histopatholog
proven
neuroblastoma
underw
retrospect
evalu
scintigraphi
avail
patient
mean
interv
day
scintigraphi
imag
independ
evalu
two
nuclear
medicin
physician
separ
session
week
apart
minim
recal
bia
histopatholog
n
lesion
andor
clinicalimag
n
lesion
taken
refer
standard
result
patient
wise
sensit
specif
ppv
npv
accuraci
respect
total
lesion
lymph
bone
detect
patient
patient
undergo
modal
sensit
specif
ppv
npv
accuraci
respect
respect
patient
detect
lesion
lymph
bonebon
detect
lesion
lymph
bonebon
patient
wise
comparison
signific
differ
detect
lesion
differ
note
primari
lesion
significantli
better
scintigraphi
detect
lymph
nodal
bonebon
marrow
lesion
conclus
highli
accur
modal
patient
neuroblastoma
detect
lesion
compar
scintigraphi
patient
scintigraphi
imag
diagnos
neuroblastoma
cochran
diagnost
test
accuraci
review
g
bleeker
g
tytgat
j
adam
h
caron
l
hooft
l
kremer
e
van
dalen
depart
pediatr
oncolog
academ
medic
center
amsterdam
netherland
depart
nuclear
medicin
radiolog
academ
medic
center
amsterdam
netherland
dutch
cochran
centr
academ
medic
center
amsterdam
netherland
object
mani
studi
report
diagnost
accuraci
neuroblastoma
patient
heterogen
number
includ
patient
perform
imag
method
still
prognosi
treatment
respons
patient
base
therefor
assess
diagnost
accuraci
possibl
test
positron
emiss
tomographi
tomographi
pet
method
search
databas
medlinepubm
embaseovid
refer
list
relev
articl
review
confer
proceed
contact
expert
inclus
criteria
studi
compar
result
refer
standard
diagnost
design
children
year
old
neuroblastoma
stage
first
diagnosi
recurr
two
review
author
independ
select
studi
extract
data
assess
methodolog
qualiti
tabl
use
calcul
sensit
andor
specif
studi
possibl
forest
plot
gener
result
refer
includ
studi
elig
patient
pool
mean
sensit
confid
interv
predict
interv
patient
specif
lesion
patient
describ
one
studi
sensit
alon
compar
report
one
studi
specif
could
calcul
none
studi
provid
outcom
data
diagnost
accuraci
patient
neg
studi
methodolog
limit
conclus
pool
sensit
analysi
specif
difficult
one
studi
provid
data
fals
posit
true
neg
result
although
current
enough
evid
avail
possibl
test
neg
tumour
role
chest
comput
tomographi
ct
surveil
tool
children
neuroblastoma
sm
federico
sl
bradi
pappo
j
wu
mao
v
mcpherson
ra
kaufman
sc
kast
oncolog
st
jude
children
research
hospit
memphi
usa
object
amount
frequenc
imag
children
neuroblastoma
vari
among
institut
studi
examin
valu
chest
ct
cohort
pediatr
patient
neuroblastoma
method
medic
record
imag
patient
neuroblastoma
diagnos
st
jude
children
research
hospit
januari
decemb
review
surveil
imag
conduct
ten
patient
thorac
diseas
diagnosi
exclud
event
free
surviv
ef
overal
surviv
os
estim
use
method
kaplan
meier
size
specif
dose
estim
ct
scan
chest
abdomen
pelvi
use
estim
absolut
organ
dose
organ
organ
dosimetri
use
calcul
cohort
effect
dose
result
patient
underw
ct
includ
chest
abdomen
pelvi
scan
year
os
ef
respect
patient
progressedrecur
die
diseas
eleven
patient
develop
thorac
diseas
progressionrecurr
identifi
chest
ct
pulmonari
nodul
paraspin
mass
nodal
mibg
metaiodobenzylguanidin
scan
confirm
thorac
diseas
patient
five
normal
mibg
scan
chest
symptomat
diseas
asymptomat
normal
chest
mibg
scan
avid
bone
diseas
bonechest
pain
normal
mibg
abnorm
positron
emiss
tomographi
scan
estim
radiat
dose
save
gender
neutral
ct
surveil
without
chest
imag
calcul
rel
risk
reduct
conclus
neuroblastoma
progressionrecurr
chest
rare
often
present
symptom
identifi
use
imag
modal
patient
diagnos
neuroblastoma
lack
thorac
diseas
initi
omiss
chest
ct
imag
save
approxim
radiat
burden
without
compromis
diseas
detect
feasibl
therapeut
metaiodobenzylguanidin
mibg
previou
blood
stem
cell
collect
purg
vivo
neuroblastoma
hrnb
v
mta
almeida
c
buchpigel
amp
azambuja
csc
vinc
brumatti
nsh
neve
glf
batista
pt
maluf
jr
lmc
cristofani
oncologia
itaci
instituto
de
tratamento
infantil
sao
paulo
brazil
medicina
nuclear
icesp
instituto
de
estado
de
paulo
sao
paulo
brazil
hematologia
e
oncologia
hospit
israelita
albert
einstein
sao
paulo
brazil
oncologia
hospit
sao
paulo
brazil
object
estim
feasibl
mibg
purg
vivo
hrnb
method
start
asco
proceed
annual
meet
philadelphiapausa
children
hrnb
underw
chemotherapi
autolog
hematopoiet
stem
cell
support
ahsc
cell
collect
proceed
exposur
mibg
mcikg
data
relat
procedur
children
whose
follow
outpati
done
exclus
itaci
focus
mainli
feasibl
toxic
present
condit
regimen
includ
cbdcaetomel
bumel
children
result
peripher
blood
stem
cell
pbsc
suffici
allow
hematolog
recoveri
cell
x
obtain
children
requir
median
apheresi
whose
transplant
done
pbsc
support
addit
children
receiv
either
pbsc
marrow
support
ms
exclus
ms
stabl
anc
obtain
day
cell
reinfus
children
respect
achiev
stabl
platelet
count
day
independ
red
cell
transfus
day
ahsc
relev
immedi
toxic
death
secondari
sepsi
children
episod
sever
vod
late
toxic
includ
secondari
neoplasia
thyroid
carcinoma
fatal
abdomin
nhl
within
survivor
requir
thyroid
hormon
supplement
oral
iodin
given
time
mibg
exposur
consid
patient
whose
procedur
done
cell
collect
previou
mcikg
becam
routin
step
within
itaci
children
surviv
ef
neoplasia
conclus
therapeut
use
cell
collect
ahsc
feasibl
deserv
analysi
regard
potenti
use
treat
hrnb
charactert
imag
defin
risk
factor
idrf
patient
enrol
low
risk
protocol
japanes
neuroblastoma
studi
group
jnbsg
yoneda
tajiri
iehara
kitamura
nakazawa
h
takahashi
takimoto
nakagawara
pediatr
surgeri
osaka
medic
center
research
institut
matern
child
health
izumi
japan
pediatr
surgeri
kyoto
prefectur
univers
medicin
kyoto
japan
pediatr
kyoto
prefectur
univers
medicin
kyoto
japan
radiolog
nation
center
child
health
develop
tokyo
japan
patholog
nation
center
child
health
develop
tokyo
japan
clinic
trial
clinic
epidemiolog
tsukuba
univers
tsukuba
japan
clinic
research
nation
center
child
health
develop
tokyo
japan
biochemistri
innov
cancer
therapeut
chiba
cancer
center
research
institut
chiba
japan
object
japanes
neuroblastoma
studi
group
jnbsg
conduct
protocol
low
risk
patient
minim
treatment
complic
use
imag
defin
risk
factor
idrf
main
factor
treatment
decis
preliminari
report
analyz
idrf
result
protocol
order
clarifi
characterist
idrf
low
risk
neuroblastoma
nb
patient
method
idrf
evalu
diagnosi
well
time
cours
chemotherapi
protocol
registri
three
low
dose
chemotherapi
protocol
includ
studi
vcr
cpa
vcr
cpa
vcr
cpa
cbdca
idrf
present
patient
underw
surgeri
idrf
present
patient
underw
chemotherapi
idrf
result
local
nb
patient
enrol
collect
analyz
relationship
idrf
result
tumor
locat
well
inss
result
idrf
result
avail
patient
patient
identifi
idrf
present
onset
diseas
two
tumor
origin
neck
tumor
mediastinum
tumor
adren
gland
tumor
retroperiton
tumor
kidney
tumor
pelvi
idrf
diagnosi
none
inss
stage
tumor
stage
tumor
stage
tumor
stage
tumor
idrf
diagnosi
conclus
idrf
present
low
risk
patient
nb
diagnosi
tumor
origin
mediastinum
retroperitoneum
inss
stage
tumor
like
idrf
compar
tumor
origin
adren
grand
stage
tumor
systemat
review
literatur
reveal
uniform
definit
diagnost
imag
bone
bone
marrow
metastas
neuroblastoma
patient
g
bleeker
heijkoop
e
van
dalen
l
kremer
smet
b
van
e
deurlo
h
caron
g
tytgat
depart
paediatr
oncolog
academ
medic
center
amsterdam
netherland
radiolog
nuclear
medicin
academ
medic
center
amsterdam
netherland
object
sinc
presenc
bone
andor
bone
marrow
bm
metastas
correl
bad
prognosi
import
clear
uniform
definit
object
review
identifi
definit
bone
bm
metastas
use
imag
studi
determin
diagnost
accuraci
bone
andor
bm
metastas
imag
test
method
search
medlinepubm
embaseovid
bibliographi
relev
articl
studi
includ
report
diagnost
imag
patient
suspect
metastat
neuroblastoma
defin
bone
andor
bm
metastas
two
review
author
select
studi
extract
data
assess
methodolog
qualiti
disagr
resolv
discuss
sensit
andor
specif
calcul
use
data
result
thirti
identifi
studi
elig
inclus
main
exclus
reason
provid
definit
bone
andor
bm
metastas
n
includ
studi
defin
bone
defin
bm
defin
metastas
object
definit
bone
bm
metastas
vari
wide
includ
studi
bone
metastas
frequent
defin
focal
lesion
hotspot
scintigraphi
osteolyt
lesion
periost
reaction
radiographi
bm
metastas
diffus
lesion
mri
scintigraphi
without
focal
lesion
bm
metastas
mri
addit
defin
fourteen
studi
report
data
diagnost
accuraci
object
sensit
specif
valu
vari
enorm
studi
bone
bm
metastas
conclus
despit
fact
mani
studi
report
outcom
data
patient
bone
andor
bm
metastas
major
provid
definit
furthermor
studi
provid
definit
definit
diagnost
accuraci
vari
wide
conclus
drawn
pattern
relaps
neuroblastoma
patient
r
li
sridharan
w
london
lee
shusterman
k
marcu
depart
radiat
oncolog
brigham
women
hospit
boston
usa
depart
pediatr
oncolog
dana
farberboston
children
cancer
blood
disord
center
boston
usa
object
perform
retrospect
review
pediatr
patient
treat
neuroblastoma
identifi
whether
patient
relaps
origin
site
diseas
previous
site
particular
emphasi
impact
radiotherapi
metastat
site
method
patient
relaps
treatment
stage
iv
neuroblastoma
includ
cohort
site
diseas
defin
anatom
locat
mibg
avid
compar
diagnosi
first
relaps
fisher
exact
test
perform
determin
relationship
radiat
therapi
techniqu
relaps
previous
involv
site
result
patient
relaps
neuroblastoma
includ
patient
male
median
age
diagnosi
year
old
patient
treat
total
bodi
irradi
tbi
treat
without
tbi
instead
use
local
radiat
primari
site
without
focal
radiat
metastas
median
time
diagnosi
relaps
year
relaps
least
one
previous
mibg
avid
site
patient
relaps
previous
irradi
site
patient
involv
primari
site
relaps
group
radiat
techniqu
patient
treat
tbi
n
relaps
previous
involv
site
compar
patient
treat
without
tbi
n
p
conclus
overal
major
neuroblastoma
patient
relaps
least
one
site
previou
diseas
small
number
relaps
previous
irradi
locat
patient
receiv
tbi
significantli
like
relaps
previous
involv
diseas
site
qualiti
life
sampl
survivor
advanc
neuroblastoma
canada
c
portwin
c
rae
schecter
v
lewi
j
davi
mitchel
wall
p
teira
r
barr
pediatr
mcmaster
univers
hamilton
canada
depart
clinic
epidemiolog
biostatist
mcmaster
univers
hamilton
canada
hematolog
oncolog
transplant
hospit
sick
children
toronto
canada
hematolog
oncolog
transplant
alberta
children
hospit
calgari
canada
hematolog
oncolog
transplant
bc
children
hospit
vancouv
canada
hematolog
oncolog
transplant
montreal
children
hospit
montreal
canada
pediatr
hematolog
oncolog
transplant
univers
manitobacanc
care
manitoba
winnipeg
canada
pediatr
hematolog
oncolog
transplant
hopit
ste
justin
montreal
canada
object
examin
health
relat
qualiti
life
hrql
survivor
advanc
neuroblastoma
underw
intens
chemotherapi
follow
myeloabl
therapi
autolog
stem
cell
transplant
sct
method
nation
survey
conduct
survivor
treat
parent
survivor
complet
proxi
health
util
index
hui
questionnair
score
scale
compar
data
clinic
group
obtain
previou
studi
gener
popul
statist
canada
differ
overal
hrql
score
singl
attribut
score
consid
clinic
import
result
data
collect
pediatr
centr
includ
sct
centr
questionnair
return
complet
score
overal
mean
hrql
util
score
sd
significantli
less
children
year
age
gener
popul
p
signific
differ
p
mean
overal
hrql
survivor
treat
sct
mean
age
dx
treat
without
transplant
n
mean
age
dx
howev
clinic
import
differ
observ
attribut
hear
greater
morbid
report
sct
group
survivor
p
wilm
tumour
p
significantli
better
hrql
survivor
substanti
lower
morbid
attribut
hear
p
survivor
experienc
better
hrql
survivor
brain
tumour
differ
consid
clinic
import
conclus
survivor
hrql
wors
without
transplant
differenti
effect
hear
reflect
addit
exposur
chemotherapi
sct
group
survivor
enjoy
better
hrql
survivor
brain
tumour
poorer
hrql
survivor
wilm
tumour
valid
reliabl
risk
factor
local
neuroblastoma
report
territori
center
japan
fumino
k
kimura
iehara
n
motoki
n
satoaki
r
souzaki
nishi
taguchi
h
hosoi
tajiri
depart
pediatr
surgeri
kyoto
prefectur
univers
medicin
kyoto
japan
depart
pediatr
kyoto
prefectur
univers
medicin
kyoto
japan
depart
radiolog
kyoto
prefectur
univers
medicin
kyoto
japan
depart
pediatr
surgeri
kyushu
univers
fukuoka
japan
depart
clnical
radiolog
kyushu
univers
fukuoka
japan
object
japanes
neuroblastoma
studi
group
jnbsg
employ
protocol
use
risk
factor
idrf
local
neuroblastoma
minim
surgic
complic
sinc
howev
report
inrg
project
radiolog
supplement
descript
renal
vessel
even
isol
contact
consid
aim
studi
evalu
valid
reliabl
idrf
compar
previou
new
guidelin
method
medic
record
patient
local
neuroblastoma
treat
center
west
japan
retrospect
review
classifi
idrf
diagnosi
radiologist
indic
surgeri
base
surgeon
judgment
result
total
patient
enrol
median
age
month
primari
tumor
locat
abdomen
adren
gland
retroperitoneum
pelvi
mediastinum
site
idrf
present
use
previou
guidelin
pg
use
new
guidelin
ng
abdomin
neuroblastoma
idrf
present
usign
pg
use
ng
moreov
rate
increas
case
diagnos
mass
screen
case
complet
primari
resect
achiev
usign
pg
use
ng
one
major
surgic
complic
renal
atrophi
occur
case
use
either
guidelin
conclus
although
expect
rate
would
increas
resect
rate
would
decreas
accord
ng
idrf
could
use
predict
precis
surgic
risk
limit
seri
ng
might
overestim
surgic
risk
lead
unnecessari
chemotherapi
prolong
hospit
stay
recent
trend
dispar
neuroblastoma
surviv
unit
state
perspect
j
marron
k
ribeiro
lr
diller
pediatr
hematologyoncolog
children
cancer
blood
disord
center
boston
usa
social
medicin
santa
casa
school
medicin
sao
paulo
brazil
object
recent
chang
treatment
children
neuroblastoma
led
signific
increas
surviv
patient
receiv
full
complement
therapi
chemotherapi
radiat
surgeri
autolog
bone
marrow
transplant
immunotherapi
experi
surviv
nejm
use
publicli
avail
registri
data
examin
whether
outcom
improv
patient
month
age
consist
across
racial
ethnic
socioeconom
group
given
complex
new
treatment
modal
hypothes
access
limit
could
lead
dispar
surviv
gain
method
analyz
rel
surviv
neuroblastoma
patient
diagnos
month
age
cancer
registri
nation
cancer
institut
surveil
epidemiolog
end
result
seer
program
accord
individu
characterist
race
ethnic
measur
educ
incom
immigr
statu
result
surviv
rate
improv
analyz
popul
annual
percent
chang
apc
rel
surviv
per
year
p
gain
experienc
disproportion
popul
greater
surviv
improv
seen
counti
immigr
mani
immigr
apc
vs
p
counti
counti
apc
vs
p
counti
counti
apc
vs
p
dispar
also
found
accord
race
ethnic
metropolitan
resid
languag
isol
find
reach
statist
signific
conclus
recent
improv
surviv
children
neuroblastoma
diagnos
month
age
preferenti
benefit
racial
ethnic
socioeconom
group
may
due
disproportion
access
advanc
treatment
modal
patient
popul
care
children
cancer
becom
complex
address
dispar
access
requir
research
resourc
chyle
leak
follow
surgic
manag
neuroblastoma
underr
complic
e
rent
qureshi
p
rent
bhagat
n
singhal
surgic
oncolog
tata
memori
hospit
mumbai
india
public
health
tata
institut
social
scienc
mumbai
india
object
surgeri
mainstay
manag
neuroblastoma
children
incid
complic
like
infect
organ
dysfunct
document
literatur
chyle
leak
lack
attempt
fill
void
evalu
incid
risk
factor
implic
chyle
leak
follow
surgic
manag
neuroblastoma
method
retrospect
analys
prospect
collect
data
patient
underw
surgeri
neuroblastoma
period
ten
year
possibl
risk
factor
includ
stage
lymph
node
dissect
side
site
diseas
analys
determin
oncolog
implic
evalu
hospit
stay
delay
treatment
result
chyle
leak
document
patient
commonli
seen
lesion
aris
adren
gland
vs
higher
stage
diseas
previou
chemotherapi
left
side
diseas
vs
howev
none
reach
statist
signific
risk
factor
show
statist
signific
increas
chyle
leak
number
lymph
node
dissect
leak
rate
patient
less
lymph
node
sampl
lymph
node
sampl
p
patient
manag
conserv
durat
hospit
stay
prolong
day
compar
without
chyle
leak
howev
adjuv
chemotherapi
compromis
conclus
chylou
ascit
common
report
complic
follow
surgic
manag
neuroblastoma
settl
conserv
manag
compromis
oncolog
treatment
henc
deterr
aggress
surgeri
vigil
detect
howev
advis
immunotherapi
acut
leukemia
chimer
antigen
receptor
car
cytokin
induc
killer
cik
cell
sleep
beauti
system
cf
magnani
n
turazzi
f
benedicenti
tettamanti
gmp
giordano
attianes
e
montini
ljn
cooper
aiuti
biondi
e
biagi
centro
ricerca
tettamanti
clinica
pediatrica
milano
bicocca
osp
san
gerardofondazion
mbbm
monza
mb
itali
san
raffael
telethon
institut
gene
therapi
ospedal
san
raffael
milano
itali
univers
texa
md
anderson
cancer
center
houston
usa
object
cell
engin
car
recent
prove
effect
redirect
effector
activ
toward
leukem
blast
sinc
profil
efficaci
safeti
feasibl
cell
manufactur
gene
therapi
viral
vector
still
remain
major
concern
explor
use
sleep
beauti
sb
gene
transfer
cik
cell
target
acut
leukemia
method
optim
stimul
protocol
genet
modifi
cik
cell
express
two
distinct
car
specif
myelogen
leukemia
aml
acut
lymphoblast
leukemia
blast
result
nucleofect
minim
affect
phenotyp
cik
cell
optim
protocol
effect
induc
expans
fold
increas
suffici
translat
clinic
protocol
modifi
cik
cell
display
stabl
express
car
car
frequenc
n
n
respect
exert
effici
lysi
leukem
primari
blast
interestingli
car
trigger
antigen
express
leukem
cell
promot
specif
cytokin
secret
prolifer
restrict
modifi
fraction
cik
cell
loss
express
transposas
differenti
assess
assur
genom
stabil
cellular
product
absolut
quantif
final
preliminari
analysi
confirm
integr
genom
sb
system
correl
region
conclus
sb
system
togeth
optim
method
differenti
effici
expand
car
car
cik
cell
redirect
activ
toward
aml
cell
retain
safe
pattern
integr
genom
easi
adopt
cell
therapi
platform
base
innov
non
viral
method
gene
transfer
fundament
improv
rang
applic
immunotherapi
control
relaps
leukem
patient
phase
studi
pegcrisantaspas
administ
intraven
infus
adult
patient
relaps
refractori
hematolog
malign
g
sall
lepretr
le
gouill
f
c
haioun
balouet
corn
x
thoma
hospic
civil
de
lyon
claud
bernard
franc
centr
henri
becquerel
rouen
franc
cliniqu
centr
hospitali
universitair
de
nant
nant
franc
servic
centr
hospitali
universitair
de
toulous
toulous
franc
lymphoid
malign
unit
centr
hospitali
universitair
henri
mondor
franc
lymphoma
academ
research
organis
lysarc
centr
hospitali
franc
depart
clinic
oncolog
eusa
pharma
intern
divis
jazz
pharmaceut
plc
oxford
unit
kingdom
object
asparaginas
import
compon
chemotherapi
treat
acut
lymphoblast
leukemia
lymphoma
hypersensit
occur
patient
receiv
escherichia
asparaginas
often
necessit
switch
asparaginas
erwinia
chrysanthemi
due
short
asparaginas
erwinia
chrysanthemi
administ
time
week
improv
pharmacokinet
reduc
immunogen
recombin
pegyl
technolog
use
creat
new
erwinia
pegcrisantaspas
object
multicent
studi
determin
maximum
toler
dose
safeti
pharmacokinet
pegcrisantaspas
patient
relaps
refractori
hematolog
malign
method
patient
age
year
receiv
pegcrisantaspas
intraven
everi
week
initi
dose
dose
continu
diseas
progress
judg
appropri
investig
dose
escal
base
number
patient
experienc
toxic
dlt
within
day
first
infus
patient
activ
cn
diseas
previou
hypersensit
grade
asparaginas
erwinia
chrysanthemi
exclud
result
ten
patient
mean
age
year
enrol
date
patient
fail
multipl
therapi
regimen
six
patient
dose
respect
maintain
asparaginas
activ
iuml
day
three
patient
maintain
target
activ
week
follow
second
dose
one
dlt
observ
neutropenia
last
day
common
advers
event
diarrhea
anemia
hypoalbuminemia
decreas
antithrombin
iii
nausea
three
death
occur
follow
cerebr
hemorrhag
diseas
progress
diseas
progress
none
consid
studi
conclus
pegcrisantaspas
provid
effect
serum
asparaginas
activ
day
follow
intraven
infus
safeti
data
consist
known
safeti
profil
asparaginas
treatment
comorbid
diseas
progress
patient
popul
studi
fund
jazz
pharmaceut
plc
subsidiari
sfce
metronom
regimen
phase
ii
trial
pediatr
extracrani
solid
tumour
verschuur
aschero
p
petit
p
chastagn
p
leblond
aert
n
corradini
n
l
tessonni
n
pediatr
hematolog
oncolog
la
timon
children
hospit
marseil
franc
pediatr
radiolog
la
timon
children
hospit
marseil
franc
la
timon
children
hospit
marseil
franc
pediatr
oncolog
children
hospit
nanci
franc
pediatr
oncolog
centr
oscar
lambret
lill
franc
pediatr
oncolog
institut
curi
pari
franc
pediatr
adolesc
oncolog
hospit
nant
franc
chu
hautepierr
strasbourg
franc
biophys
nuclear
medicin
la
timon
univers
hospit
european
center
research
medic
imag
marseil
franc
object
investig
activ
metronom
therapi
mt
relapsingprogress
pediatr
extracrani
solid
tumour
est
primari
object
progress
cycl
therapi
method
patient
year
age
progress
est
adequ
organ
function
treatment
consist
cycl
oral
celecoxib
bid
weekli
vinblastin
oral
cyclophosphamid
qd
week
altern
oral
methotrex
twice
week
week
rest
maximum
treatment
year
chang
two
step
model
use
patient
first
stage
primari
object
reach
patient
addit
patient
includ
accord
group
neuroblastoma
nbl
sarcoma
st
bone
sarcoma
bs
miscellan
misc
irb
approv
obtain
result
patient
evalu
st
sd
mr
angiosarcoma
cycl
patient
metastat
hemangioendothelioma
stabil
current
month
therapi
misc
signific
stabil
observ
bs
osteosarcoma
ewe
progress
nbl
group
second
stage
open
current
patient
stabl
cycl
patient
sd
stop
mt
cycl
stabl
physician
choic
patient
remain
stabl
year
ten
patient
progress
cycl
yet
evalu
median
number
cycl
rang
treatment
interrupt
temporarili
patient
grade
toxic
hepat
andor
haematolog
conclus
mt
activ
bs
misc
limit
though
interest
activ
nbl
st
patient
stabl
year
studi
support
enfant
et
foundat
sfce
metro
metronom
regimen
activ
pediatr
glioma
verschuur
p
p
chastagn
p
leblond
aert
n
corradini
n
jc
gentet
n
pediatr
hematolog
oncolog
la
timon
children
hospit
marseil
franc
neuroradiolog
la
timon
children
hospit
marseil
franc
la
timon
children
hospit
marseil
franc
pediatr
oncolog
children
hospit
nanci
franc
pediatr
oncolog
centr
oscar
lambret
lill
franc
pediatr
oncolog
institut
curi
pari
franc
pediatr
adolesc
oncolog
hospit
nant
franc
chu
hautepierr
strasbourg
franc
depart
clinic
pharmaci
la
timon
children
hospit
marseil
franc
pediatr
hematolog
oncolog
la
timon
children
hospit
marseil
franc
object
investig
activ
metronom
regimen
relapsingprogress
pediatr
brain
tumour
bt
defin
surviv
pf
cycl
month
therapi
method
patient
year
age
progress
bt
adequ
organ
function
treatment
consist
cycl
oral
celecoxib
bid
daili
mg
accord
bw
weekli
iv
vinblastin
oral
cyclophosphamid
qd
week
altern
oral
methotrex
twice
week
week
rest
period
maximum
treatment
year
kepner
chang
model
use
patient
first
stage
primari
object
reach
patient
addit
patient
recruit
regimen
consid
efficaci
pf
cycl
alpha
beta
approv
obtain
irb
french
medic
agenc
result
patient
includ
medulloblastoma
mb
high
grade
glioma
hgg
dpig
low
grade
glioma
lgg
one
bsg
meningioma
one
patient
hgg
anaplast
oligodendroglioma
stabil
year
none
hgg
mb
stabil
patient
lgg
median
age
year
median
durat
ill
inclus
year
patient
receiv
vinblastin
previous
pr
observ
sd
pd
bsg
cycl
median
number
cycl
rang
four
patient
receiv
least
year
therapi
aliv
treatment
interrupt
temporarili
patient
grade
toxic
hepat
andor
hematolog
conclus
metronom
regimen
activ
patient
lgg
even
patient
receiv
vinblastin
previous
studi
support
enfant
et
foundat
nation
analysi
angiogen
marker
sfce
metronom
regimen
phase
ii
trial
pediatr
malign
progress
verschuur
l
arnaud
f
sabati
n
pediatr
hematolog
oncolog
la
timon
children
hospit
marseil
franc
laboratori
hematolog
vascular
biolog
la
concept
hospit
marseil
franc
la
timon
hospit
marseil
franc
object
circul
endotheli
cell
progenitor
suggest
biomark
indic
angiogen
activ
potenti
clinic
valu
monitor
metronom
chemotherapi
studi
investig
chang
angiogen
biomark
metronom
regimen
relapsingprogress
pediatr
solid
tumour
st
method
patient
year
age
adequ
organ
function
progress
st
treatment
consist
cycl
oral
celecoxib
bid
daili
weekli
iv
vinblastin
oral
cyclophosphamid
qd
week
altern
oral
methotrex
twice
week
week
rest
venou
blood
sampl
obtain
inclus
day
end
first
second
cycl
progress
endotheli
progenitor
cell
epc
enumer
use
flow
cytometri
circul
endotheli
cell
cec
count
vascular
endotheli
growth
factor
vegf
level
determin
use
separ
elisa
respect
irb
approv
obtain
patientspar
gave
inform
consent
result
patient
includ
brain
tumour
extracrani
tumour
epc
vegf
level
significantli
vari
metronom
regimen
baselin
cec
valu
wide
distribut
patient
high
cec
level
metronom
regimen
associ
trend
toward
cec
decreas
interestingli
cec
count
significantli
increas
progress
compar
valu
preced
time
cellsml
vs
cellsml
conclus
among
biomark
angiogenesi
chang
cec
may
reflect
impact
sfce
metronom
regimen
neovascular
sequenti
measur
cec
level
may
provid
tool
monitor
respons
treatment
andor
progress
studi
support
foundat
prognost
pediatr
oncolog
patient
enrol
phase
clinic
trial
design
adult
v
subbiah
f
ce
herzog
k
hess
pm
anderson
ww
huh
e
kleinerman
r
kurzrock
phase
program
ut
md
anderson
cancer
center
houston
usa
pediatr
ut
md
anderson
cancer
center
houston
usa
biostatist
ut
md
anderson
cancer
center
houston
usa
pediatr
oncologybmtcel
therapi
levin
children
hospitallevin
cancer
institut
houston
usa
ut
md
anderson
cancer
center
pediatr
houston
usa
divis
hematolog
oncolog
uc
san
diego
moor
cancer
center
san
diego
usa
object
pharmaceut
industri
sponsor
trial
excludepati
less
year
phase
clinic
trial
even
era
target
therapi
pediatr
patient
wait
phase
trial
complet
adult
enrol
clinic
trial
advanc
metastat
relaps
set
report
preliminari
analys
outcom
pediatr
patient
enrol
phase
studi
design
adult
major
cancer
center
method
review
medic
record
pt
year
treat
phase
trial
md
anderson
use
univari
multivari
analys
determin
baselin
clinicopatholog
characterist
includ
rmh
mdacc
score
associ
increas
decreas
overal
surviv
result
median
overal
surviv
durat
time
enrol
phase
trial
month
ci
month
multivari
analysi
age
independ
factor
predict
increas
overal
surviv
p
prior
therapi
p
predict
decreas
overal
surviv
median
surviv
durat
month
ci
month
multivari
analysi
independ
factor
predict
increas
surviv
age
year
p
prior
radiat
therapi
p
perform
statu
p
prior
therapi
p
predict
decreas
surviv
conclus
feasibl
conduct
phase
studi
pediatr
patient
base
adult
protocol
mortal
relat
phase
therapi
composit
score
use
larger
number
patient
need
develop
use
rmh
mdacc
score
futur
trial
era
target
therapi
trial
allow
pediatr
patient
earlier
drug
develop
especi
deem
safe
adult
earli
phase
trial
solid
tumor
childhood
display
specif
serum
microrna
profil
murray
kl
rabi
hk
saini
bailey
sv
wool
jm
tunnacliff
enright
jc
nicholson
n
coleman
depart
patholog
univers
cambridg
cambridg
unit
kingdom
european
molecular
biolog
laboratori
european
bioinformat
institut
cambridg
unit
kingdom
depart
paediatr
haematolog
oncolog
addenbrook
hospit
cambridg
unit
kingdom
object
current
diagnosi
childhood
solid
tumor
heavili
reliant
upon
histopatholog
find
avail
serum
biomark
would
improv
accuraci
timeli
diagnosi
reduc
need
invas
procedur
patient
tumor
hypothes
differenti
express
andor
releas
microrna
solid
tumor
childhood
may
detect
alter
serum
microrna
profil
method
undertook
global
quantit
polymeras
chain
reaction
microrna
profil
n
rna
extract
serum
sampl
repres
taken
patient
time
diagnosi
common
childhood
cancer
includ
neuroblastoma
wilm
tumor
sarcoma
hepatoblastoma
lymphoma
central
nervou
system
glioma
plu
refer
sampl
robust
qualiti
control
step
rna
extract
effici
use
rnadna
hemolysi
assess
next
perform
sampl
suitabl
full
profil
multipl
method
normal
global
data
assess
show
global
mean
approach
optim
gener
panel
six
stabl
microrna
suitabl
normal
microrna
pediatr
serum
sampl
result
serum
microrna
profil
identifi
tumor
type
select
microrna
underw
confirmatori
test
use
subset
tumor
four
control
sampl
profil
set
plu
four
independ
sampl
patient
neuroblastoma
strike
find
neuroblastoma
note
panel
microrna
highli
compar
tumor
control
group
includ
neuroblastoma
nb
differenti
diagnosi
panel
also
identifi
distinguish
abdomin
mass
wilm
tumor
vs
liver
mass
hepatoblastoma
vs
subtyp
sarcoma
lymphoma
conclus
studi
demonstr
feasibl
robust
diagnost
serum
microrna
profil
solid
tumor
childhood
identifi
candid
microrna
profil
test
larger
prospect
studi
chimer
superior
infect
glioblastoma
xenograft
cell
includ
glioma
stem
cell
physiolog
hypoxia
gk
friedman
l
nan
mc
haa
vm
kelli
ea
beierl
jm
markert
gy
gillespi
ka
cassadi
depart
pediatr
univers
alabama
birmingham
birmingham
usa
depart
surgeri
univers
alabama
birmingham
birmingham
usa
depart
neurosurgeri
univers
alabama
birmingham
birmingham
usa
object
oncolyt
engin
herp
simplex
virotherapi
emerg
promis
treatment
glioblastoma
howev
efficaci
similar
virus
previous
use
glioma
clinic
trial
reduc
physiolog
hypoxia
hallmark
glioblastoma
physiolog
hypoxia
support
maintain
glioma
stem
cell
gsc
phenotyp
vital
role
tumor
develop
invas
resist
chemotherapi
radiat
investig
abil
chimer
viru
contain
hcmv
gene
improv
late
viral
protein
synthesi
infect
kill
tumor
cell
includ
gsc
hypoxia
pediatr
glioblastoma
xenograft
fluoresc
protein
gfp
version
hsv
prepar
clinic
trial
method
tumor
maintain
flank
nude
mice
disaggreg
place
hypoxia
oxygen
maintain
neurospher
stem
medium
rel
infect
tumor
cell
gsc
unit
pfu
cell
quantifi
hour
fac
analysi
viru
recoveri
measur
limit
plaqu
dilut
cytotox
measur
alamarblu
assay
determin
hour
respect
result
hour
infect
cell
compar
cell
p
infect
significantli
cell
p
significantli
lower
dose
requir
kill
cell
pfucel
versu
p
viru
recov
p
conclus
chimer
viru
superior
infect
glioblastoma
xenograft
physiolog
hypox
condit
may
effect
target
pediatr
glioma
includ
chemotherapi
radiat
resist
gsc
natur
killer
cell
base
therapi
metastat
osteosarcoma
l
fernandez
j
l
pediatr
hospit
universitario
la
pazidipaz
universidad
autonoma
de
madrid
madrid
spain
clinic
research
group
cancer
nation
research
center
madrid
spain
pediatr
universitaria
de
navarra
madrid
spain
pediatra
centro
de
salud
de
carabanchel
alto
madrid
spain
object
metastat
osteosarcoma
dismal
prognosi
despit
convent
treatment
new
therapeut
approach
urgent
need
improv
surviv
natur
killer
nk
cell
lymphocyt
cytotox
activ
toward
malign
cell
crosstalk
nk
cell
receptor
tumour
cell
ligand
necessari
activ
present
studi
explor
vivo
feasibl
nk
therapi
primari
metastat
osteosarcoma
method
hla
class
fa
ligand
express
metastat
primari
osteosarcoma
nk
receptor
activ
expand
nk
nkae
cell
analyz
multiparametr
flow
cytometri
nkae
cell
obtain
co
cultur
peripher
blood
mononuclear
cell
pbmc
donor
patient
cell
line
rpmi
supplement
human
ab
serum
iuml
penicillin
streptomycin
perform
cytotox
nk
cell
receptor
block
antibodi
convent
releas
assay
explor
nk
cell
suscept
primari
osteosarcoma
lyse
nkae
addit
explor
differ
strategi
irradi
gemcitabin
spironolacton
increas
osteosarcoma
nk
cell
cytotox
suscept
result
found
fa
highli
express
ratio
mfi
primari
cell
line
specif
antibodi
blockad
shown
pathway
main
role
nk
cell
antitumor
activ
found
spironolacton
upregul
ligand
express
final
develop
vivo
orthotop
metastat
osteosarcoma
xenograft
explor
success
ex
vivo
therapi
conclus
ligand
fa
express
metastat
osteosarcoma
cell
although
tumour
shown
heterogen
nk
cell
lysi
fasfasl
pathway
respons
nk
cell
elimin
upregul
ligand
mediat
spironolacton
could
enhanc
nk
cell
mediat
lysi
ex
vivo
vivo
simpl
formula
base
cystatin
c
individu
carboplatin
dose
children
h
blufpand
aj
wilhelm
gjl
kasper
gj
peter
pediatr
oncologyhematolog
vu
univers
medic
center
amsterdam
netherland
clinic
pharmacolog
pharmaci
vu
univers
medic
center
amsterdam
netherland
medic
oncolog
vu
univers
medic
center
amsterdam
netherland
pediatr
nephrolog
vu
univers
medic
center
amsterdam
netherland
object
carboplatin
clearanc
linearli
relat
glomerular
filtrat
rate
principl
renal
dose
wide
accept
although
alway
practic
predict
carboplatin
clearanc
could
improv
ad
plasma
cystatin
c
patient
characterist
routin
use
dose
aim
evalu
use
cystatin
c
predictor
carboplatin
clearanc
children
develop
simpl
model
use
dose
method
perform
popul
pharmacokinet
analysi
clearanc
studi
perform
children
wide
spectrum
solid
tumor
use
mix
effect
model
influenc
six
covari
sex
age
bodi
weight
height
bmi
bsa
creatinin
cystatin
c
carboplatin
pharmacokinet
evalu
final
model
valid
use
bootstrap
analysi
result
model
fit
data
best
equat
carboplatin
clearanc
x
cystatin
x
bodi
clearanc
lh
cystatin
c
mgl
weight
kilogram
mean
paramet
obtain
bootstrap
run
almost
ident
estim
obtain
origin
dataset
indic
model
robust
observ
carboplatin
concentr
accur
predict
final
model
correl
observ
predict
clearanc
almost
perfect
p
bia
mpe
imprecis
mape
final
model
respect
conclus
model
base
cystatin
c
weight
give
best
predict
carboplatin
clearanc
children
simpl
model
use
individu
dose
carboplatin
carboplatin
dose
children
use
estim
glomerular
filtrat
rate
equat
matter
h
blufpand
gjl
kasper
aj
wilhelm
gj
peter
pediatr
oncologyhematolog
vu
univers
medic
center
amsterdam
netherland
clinic
pharmacolog
pharmaci
vu
univers
medic
center
amsterdam
netherland
medic
oncolog
vu
univers
medic
center
amsterdam
netherland
pediatr
nephrolog
vu
univers
medic
center
amsterdam
netherland
object
renal
carboplatin
dose
result
consist
drug
exposur
flat
dose
aim
valid
newel
dose
equat
use
estim
glomerular
filtrat
rate
gfr
studi
renal
function
marker
accur
predict
carboplatin
clearanc
children
method
children
wide
spectrum
solid
tumour
carboplatin
clearanc
valu
obtain
individu
fit
use
nonmem
observ
carboplatin
clearanc
compar
predict
clearanc
calcul
accord
newel
dose
equat
use
three
differ
gfr
estim
one
one
cystatin
one
base
creatinin
cystatin
c
bia
precis
predict
examin
result
ckid
equat
accur
bia
ci
ci
mlmin
respect
wherea
bia
significantli
differ
zero
ci
mlmin
gave
lowest
bia
imprecis
two
egfr
equat
show
overpredict
carboplatin
clearanc
reflect
neg
bia
higher
mean
predict
error
valu
proport
varianc
observ
clearanc
explain
predict
clearanc
lowest
schwartz
r
explain
varianc
ckid
equat
conclus
two
cystatin
ckid
equat
outperform
wide
use
schwartz
equat
predict
carboplatin
clearanc
recommend
use
estim
gfr
base
cystatin
c
carboplatin
dose
children
unless
gold
standard
gfr
measur
avail
associ
hemorrhag
cystiti
genotyp
pediatr
patient
receiv
busulfan
base
condit
regimen
prior
hematopoiet
stem
cell
transplant
cr
uppugunduri
rezgui
p
tyagi
j
rousseau
duval
h
bittencourt
krajinov
ansari
depart
pediatr
unit
cansearch
research
laboratori
univers
hospit
geneva
geneva
switzerland
depart
pediatr
chu
cancer
center
montreal
canada
object
one
complic
busulfan
bu
base
myeloabl
condit
regimen
especi
combin
cyclophosphamid
cy
children
prior
hematopoiet
stem
cell
transplant
hsct
occurr
hemorrhag
cystiti
hc
studi
explor
associ
genet
variant
involv
metabol
bu
cymetabolit
involv
format
sulfolan
activ
cy
enzym
detoxifi
cy
metabolit
relat
incid
hc
day
method
sixti
six
pediatr
patient
femal
male
recruit
st
justin
hospit
canada
retrospect
analyz
patient
genotyp
null
allel
hc
defin
presenc
hematuria
microscop
macroscop
week
initi
condit
regimen
day
patient
receiv
mesna
prophylaxi
hc
result
cumul
incid
hc
bk
viru
detect
hc
case
observ
higher
incid
hc
carrier
function
n
compar
carri
allel
either
gene
n
signific
correl
age
weight
incid
hc
also
seen
multivari
analysi
includ
condit
regimen
age
weight
gender
genotyp
bu
steadi
state
concentr
level
combin
cyp
genotyp
statu
independ
associ
hc
hazard
ratio
conclus
view
observ
hypothes
normal
function
indic
either
higher
format
sulfolan
bu
cy
toxic
metabolit
function
genotyp
indic
increas
format
gst
conjug
bu
intermediari
compound
simultan
might
deplet
gsh
level
avail
conjug
enzym
predominantli
involv
toxic
cy
metabolit
elimin
inappropri
carboplatin
exposur
children
flat
dose
hn
blufpand
gjl
kasper
pediatr
oncologyhematolog
vu
univers
medic
center
amsterdam
netherland
pediatr
nephrolog
vu
univers
medic
center
amsterdam
netherland
object
although
concept
renal
carboplatin
dose
children
dose
method
routin
practic
failur
correct
renal
function
result
variabl
carboplatin
exposur
risk
advers
effect
suboptim
treatment
set
determin
carboplatin
exposur
children
flat
dose
compar
target
exposur
method
children
wide
spectrum
solid
tumor
area
curv
auc
calcul
cours
carboplatin
use
nonmem
observ
auc
valu
compar
target
valu
calcul
mgmlmin
per
protocol
dose
bia
precis
accuraci
within
target
auc
calcul
result
median
observ
auc
percentag
target
auc
rang
auc
within
target
achiev
cours
figur
proport
slightli
lower
infant
older
children
p
infant
measur
fell
target
valu
oppos
underestim
older
children
p
figur
observ
auc
percentag
target
auc
infant
older
children
conclus
dose
base
bodi
surfac
area
bodi
weight
result
highli
variabl
carboplatin
exposur
particularli
infant
risk
toxic
well
lower
underscor
import
renal
carboplatin
dose
children
novel
formul
target
oxid
stress
preclin
model
retinoblastoma
r
brennan
e
pritchard
e
stewart
c
bradley
b
freeman
w
caufield
dyer
k
guy
oncolog
st
jude
children
research
hospit
memphi
usa
chemic
biolog
therapeut
st
jude
children
research
hospit
memphi
usa
development
neurobiolog
st
jude
children
research
hospit
memphi
usa
preclin
pk
share
resourc
st
jude
children
research
hospit
memphi
usa
object
overal
surviv
patient
intraocular
retinoblastoma
rb
excel
howev
globe
salvag
advanc
diseas
surviv
patient
metastat
diseas
remain
poor
whole
genom
sequenc
retinoblastoma
reveal
epigenet
deregul
essenti
tumor
develop
presenc
dna
break
transvers
indic
possibl
role
oxid
stress
tumorigenesi
congruent
find
target
drug
screen
retinoblastoma
cell
util
librari
agent
reveal
activ
histon
deacetylas
inhibitor
hdaci
studi
evalu
efficaci
hdaci
preclin
model
rb
optim
ocular
formul
character
pharmacokinet
toxic
profil
class
new
agent
retinoblastoma
arsen
method
panobinostat
vorinostat
select
character
develop
ocular
formul
use
fda
approv
adjuv
identifi
topic
intravitr
formul
ocular
deliveri
perform
pharmacokinet
compar
vitreal
penetr
system
dose
due
differ
epigenom
landscap
retinoblastoma
mous
model
compar
human
retinoblastoma
util
human
orthotop
xenograft
efficaci
studi
monitor
intraocular
pressur
iop
proxi
diseas
progress
eye
progress
diseas
underw
enucl
result
comprehens
preclin
test
follow
standard
approach
demonstr
signific
ocular
surviv
advantag
hdaci
compar
system
subconjunctiv
chemotherapi
topic
deliveri
panobinostat
result
improv
intraocular
penetr
compar
intravitr
subconjunctiv
system
dose
retin
toxic
follow
hdaci
administr
minim
conclus
panobinostat
hdaci
promis
target
therapi
retinoblastoma
topic
applic
effect
penetr
vitreou
may
use
protract
outpati
dose
regimen
pediatr
phase
test
oral
panobinostat
ongo
inform
futur
plan
clinic
trial
drug
retinoblastoma
patient
psychosoci
concern
express
childhood
cancer
survivor
accra
ghana
ca
adu
depart
child
health
korl
bu
teach
hospit
accra
ghana
object
studi
seek
determin
psychosoci
concern
express
childhood
cancer
survivor
intervent
institut
health
worker
help
address
issu
method
twenti
ghanaian
childhood
cancer
survivor
age
year
interview
consent
obtain
questionnair
administ
month
februari
march
result
twenti
five
percent
complet
treatment
less
year
ago
year
ago
knew
diagnosi
cancer
told
diagnosi
support
parent
famili
survivor
rememb
treatment
affect
abil
play
take
care
affect
financ
famili
mother
stay
home
look
felt
stigmat
friend
affect
school
social
life
children
rememb
friend
die
affect
survivor
concern
futur
abil
marri
children
feel
stronger
better
sibl
peer
fifti
percent
still
worri
return
cancer
express
optim
believ
complet
heal
felt
well
adjust
life
conclus
eas
financi
burden
famili
develop
countri
necess
clinic
psychologist
involv
help
children
cope
psychosoci
effect
includ
stigmat
measur
institut
pou
develop
countri
address
bereav
children
often
suffer
loss
friend
made
age
appropri
inform
made
avail
survivor
address
issu
relat
sexual
reproduct
health
club
survivor
interact
could
set
possibl
task
phd
nurs
time
great
turnov
nurs
pediatr
oncolog
af
sandeberg
pediatr
hematolog
oncolog
karolinska
univers
hospit
stockholm
sweden
object
overal
aim
meet
demand
evidencebas
childhood
cancer
care
promot
good
qualiti
care
patient
safeti
also
greater
job
satisfact
lower
turnov
nurs
method
posit
creat
pediatr
oncolog
center
appoint
phd
nurs
initi
qualiti
improv
project
supervis
bedsid
nurs
perform
result
number
project
perform
exampl
sinc
lidocain
given
togeth
hypoton
pain
inject
solut
despit
chang
isoton
solut
routin
continu
gener
feel
parent
staff
lidocain
caus
pain
result
studi
aim
compar
childrenspar
percept
intramuscular
given
without
local
anesthesia
lidocain
particip
n
prefer
continu
without
lidocain
longer
given
inject
anoth
project
start
due
discuss
nurs
physician
gastronomi
opinion
nurs
gastrostomi
offer
often
howev
physician
hesit
refer
high
risk
complic
retrospect
review
medic
record
identifi
gastrostomi
complic
children
adolesc
cancer
center
complic
common
sever
furthermor
ongo
project
aim
compar
milk
molass
enema
establish
enema
docus
sodium
sorbitol
regard
efficaci
constip
degre
discomfort
child
cancer
conclus
new
posit
enabl
scientif
approach
small
qualiti
improv
project
perform
bedsid
nurs
compet
phd
nurs
util
nurs
care
care
evidencebas
job
satisfact
bedsid
nurs
improv
infring
autonomi
ethic
concern
experienc
nurs
staff
c
bartholdson
k
k
blomgren
p
pergert
women
children
health
karolinska
institutet
stockholm
sweden
object
studi
regard
ethic
issu
way
deal
conduct
pediatr
cancer
care
ethic
issu
common
pediatr
care
aris
connect
valu
conflict
within
individu
andor
individu
concern
possibl
option
chosen
child
specif
situat
might
lead
disagr
treatment
care
furthermor
pediatr
care
children
grow
autonomi
consid
purpos
present
describ
one
ethic
concern
identifi
studi
experienc
nurs
staff
care
children
cancer
method
physician
regist
nurs
nurs
aid
work
children
hospit
sweden
answer
questionnair
qualit
content
analysi
appli
answer
result
infring
child
autonomi
give
child
chanc
decid
upon
care
relat
concern
herhimself
oppos
child
wish
perform
action
care
procedur
child
want
nurs
nurs
aid
particip
describ
children
autonomi
someth
violat
experienc
powerless
situat
inflict
suffer
limit
subcategori
infring
autonomi
conclus
health
care
profession
experi
ethic
concern
care
children
cancer
seem
produc
strong
feel
moral
confus
among
nurs
staff
want
inflict
suffer
child
feel
prevent
tell
truth
circumst
child
ill
exampl
nurs
care
respons
often
connect
medic
treatment
decis
experi
pediatr
procedur
sedat
analgesia
tertiari
care
hospit
pakistan
oncolog
patient
bhimani
haqu
h
jurair
z
fadoo
imran
day
care
oncolog
unit
aga
khan
univers
hospit
karachi
pakistan
pediatr
aga
khan
univers
hospit
karachi
pakistan
object
procedur
sedat
analgesia
psa
children
well
recogn
clinic
disciplin
develop
countri
aim
describ
experi
psa
resourc
limit
countri
method
collect
data
pediatr
psa
databas
januari
decemb
ketamin
propfofol
iv
use
success
sedat
defin
success
complet
procedur
complic
defin
hypoxia
puls
oximetri
less
apnea
sec
cardiac
arrest
hallucin
vomit
procedur
done
accord
asa
aap
guidelin
result
diagnost
therapeut
procedur
perform
psa
indic
bone
marrow
aspir
bone
marrow
aspir
tryfin
pic
line
insert
abdomin
mass
biopsi
median
dose
ketamin
propofol
procedur
success
perform
advers
event
occur
patient
complic
transient
resolv
increas
flow
reposit
airway
apnea
resolv
bag
mask
ventil
post
sedat
hallucin
record
sedat
failur
cardiac
arrest
need
endotrach
intub
conclus
small
dose
ketamin
propofol
found
safe
effect
children
requir
psa
life
preschool
age
child
cancer
sweden
l
darci
knutsson
k
child
school
health
scienc
sweden
object
major
children
receiv
cancer
diagnosi
year
age
group
surviv
rate
high
roughli
treatment
aggress
requir
long
frequent
hospit
admiss
caus
advers
side
effect
health
care
focu
shift
surviv
childhood
cancer
live
daili
basi
young
child
experi
crucial
provid
evid
base
care
aim
studi
explor
everyday
life
preschool
age
children
express
child
parent
first
year
post
diagnosi
method
interview
conduct
children
parent
connect
paediatr
oncolog
unit
southern
sweden
qualit
content
analysi
interview
data
three
time
point
shortli
diagnosi
six
month
one
year
post
diagnosi
made
result
dramat
chang
young
child
everyday
life
describ
experi
feel
like
stranger
attack
lone
experi
time
gain
control
make
normal
ill
treatment
feel
lone
describ
process
may
seen
strive
everyday
life
conclus
nurs
major
role
play
process
strive
child
goe
give
updat
inform
make
participari
care
assur
access
parent
peer
ongo
contact
preschool
vital
address
issu
updat
regularli
assist
young
child
transit
live
cancer
longitudin
studi
young
children
vital
captur
varieti
experi
cancer
trajectori
necessari
ensur
qualiti
care
effect
intervent
oral
mucos
hospit
peadiatr
oncolog
patient
system
review
j
chen
w
wu
hematolog
oncolog
depart
shanghai
children
research
hospit
shanghai
china
nurs
australlian
cathol
univers
brisban
australia
object
object
review
determin
best
avail
evid
vitamin
e
factor
oral
mucos
hospit
paediatr
oncolog
patient
method
databas
search
till
juli
databas
search
publish
studi
english
includ
academ
search
complet
cumul
index
nurs
alli
health
literatur
cinahl
cochran
central
regist
control
trial
ebsco
medlin
embas
pubm
scienc
direct
proquest
scopu
databas
proquest
dissert
these
two
review
use
standard
critic
apprais
instrument
joanna
brigg
institut
meta
analysi
statist
assess
review
instrument
independ
evalu
methodolog
valid
paper
result
review
includ
five
articl
publish
total
particip
five
includ
articl
four
rct
one
studi
averag
percentag
topic
appli
vitamin
e
three
studi
intervent
topic
applic
vitamin
e
lowest
proport
sever
oral
mucos
two
five
articl
present
result
number
particip
oral
mucos
three
articl
count
day
oral
mucos
result
durat
oral
mucos
compar
intervent
group
five
includ
studi
conclus
review
identifi
five
articl
test
topic
applic
system
applic
vitamin
e
oral
mucos
hospit
paediatr
oncolog
patient
demonstr
topic
applic
vitamin
e
effect
reliev
oral
pain
treat
sever
oral
mucos
caus
chemotherapi
narr
experi
childhood
cancer
systemat
review
critic
apprais
l
croal
la
jibb
v
cheung
jn
stinson
haematologyoncolog
hospit
sick
children
toronto
canada
leadership
sinai
centr
mount
sinai
hospit
toronto
canada
peter
gilgan
centr
research
learn
hospit
sick
children
toronto
canada
object
improv
childhood
cancer
outcom
come
increas
interest
experi
child
treatment
howev
analysi
qualit
literatur
across
institut
lack
sought
systemat
review
apprais
evid
describ
narr
experi
children
receiv
cancer
treatment
identifi
gap
understand
inform
intervent
improv
qualiti
life
qol
method
electron
search
conduct
psycinfo
medlin
embas
cinahl
databas
incept
june
primari
qualit
studi
articl
inclus
criteria
patient
popul
year
receiv
activ
cancer
treatment
cancer
experi
describ
patient
two
independ
review
assess
articl
relev
methodolog
qualiti
extract
data
result
articl
identifi
children
countri
includ
analysi
five
overarch
theme
identifi
famili
turn
upsid
chang
child
chang
famili
chang
trajectori
cope
strategi
social
support
normal
sustain
hope
spiritu
child
flux
awar
mortal
protector
love
one
need
autonomi
reorgan
prioriti
manag
treatment
inform
need
negoti
lifestyl
chang
negoti
treatment
effect
manag
hospit
fluctuat
realiti
prepar
worst
hope
best
celebr
amidst
fight
treatment
cancer
conclus
cancer
profound
impact
live
children
live
diseas
current
qualit
evid
suggest
life
interact
famili
development
trajectori
affect
qualit
research
relat
intim
relationship
live
uncertainti
need
broaden
understand
impact
cancer
children
innov
intervent
within
cultur
divers
primarili
treatment
environ
may
address
identifi
child
psychosoci
educ
need
improv
qol
intervent
focu
relationship
normal
child
experi
address
effect
better
direct
healthcar
provid
advanc
nurs
educ
practic
research
role
futur
direct
pediatr
oncolog
group
ontario
pogo
nurs
committe
ontario
canada
mj
de
courci
b
dimont
c
bennett
c
armstrong
mill
j
volp
j
lappan
p
bamburi
gibson
tsimicali
pediatr
hematologyoncolog
children
hospit
london
health
scienc
london
canada
nurs
pediatr
oncolog
group
ontario
toronto
canada
pediatr
hematologyoncolog
hospit
sick
children
toronto
canada
pediatr
hematologyoncolog
mcmaster
children
hospit
hh
hamilton
canada
children
outpati
clinic
grand
river
hospit
kitchen
canada
pediatr
oncolog
cancer
centr
southeastern
ontario
kingston
canada
ingram
school
nurs
mcgill
univers
montreal
canada
object
pogo
pediatr
oncolog
nurs
committe
form
address
issu
deliveri
childhood
cancer
care
facilit
profession
develop
activ
ongo
evalu
iter
aim
ensur
account
stimul
partnership
time
accomplish
goal
object
present
provid
overview
committe
activ
futur
direct
method
led
chair
committe
taskforc
meet
person
correspond
via
email
telephon
particip
variou
project
committe
reli
activ
particip
member
knowledg
exchang
share
local
resourc
member
may
lead
provid
feedback
committe
project
data
evalu
collect
current
committeetaskforc
member
well
select
pogo
staff
fellow
retrospect
review
nurs
role
meet
minut
email
commun
public
research
databas
result
date
nurs
serv
committe
member
collect
led
research
project
eg
workforc
telepractic
plan
educ
event
contribut
numer
clinic
project
eg
drug
safe
handl
symptom
manag
nurs
rolecurriculum
develop
committe
publish
peer
review
articl
develop
guidanc
document
present
peer
review
confer
committe
also
promot
research
opportun
present
nurs
award
phd
fellowship
seed
grant
produc
peer
review
public
nurs
taken
leadership
role
studi
relat
deliveri
care
futur
direct
includ
recruit
new
member
plan
implement
addit
project
strengthen
translat
effort
collabor
network
conclus
pogo
nurs
committe
instrument
advanc
role
nurs
ontario
collect
effort
may
serv
exampl
other
seek
optim
deliveri
childhood
cancer
care
nurs
manag
prevent
peripher
chemotherapeut
extravas
evalu
intervent
program
educ
outcom
nurs
care
oncolog
children
n
elsherif
pediatr
sham
univers
cairo
egypt
nurs
faculti
sham
univers
cairo
egypt
background
grow
understand
good
nurs
practic
cornerston
prevent
extravas
administr
chemotherapi
one
shortcom
lack
understand
practic
oncolog
nurs
caus
devast
complic
extravas
therefor
good
oncolog
nurs
care
children
close
monitor
complic
essenti
success
chemotherapi
studi
evalu
theoret
practic
requir
oncolog
nurs
clinic
implic
intervent
program
train
nurs
elimin
weak
point
relat
safe
administr
chemotherapi
prevent
extravas
method
studi
conduct
pediatr
oncolog
depart
children
hospit
sham
univers
hospit
cairo
egypt
use
experiment
research
design
prepost
intervent
assess
data
collect
use
questionnair
sheet
observ
checklist
prepost
format
develop
intervent
educ
program
nurs
manag
reduc
risk
chemotherapeut
extravas
oncolog
children
result
nurs
studi
sampl
age
group
less
year
major
nurs
school
diploma
nine
nurs
previous
attend
train
cours
program
signific
posit
impact
nurs
knowledg
perform
especi
relat
object
minim
extravas
type
chemotherapi
extravas
precaut
follow
convers
applic
program
meanwhil
statist
signific
increas
notic
score
knowledg
relat
recommend
document
extravas
conclus
studi
demonstr
implement
intervent
program
prevent
chemotherapi
extravas
led
higher
educ
practic
outcom
administr
prevent
measur
extravas
complic
chemotherapeut
administr
among
cancer
children
hospit
infantil
teleton
oncologia
hito
children
cancer
blood
disord
center
nurs
partner
improv
pediatr
oncolog
care
green
noriega
garcia
r
mintor
baraja
edid
espinoza
manjarr
l
morrissey
p
campillo
c
costello
l
camacho
estrada
c
nixon
varga
b
cuccovia
j
gouthro
ke
houlahan
p
branowicki
children
cancer
blood
disord
center
nurs
boston
usa
purposeobject
nurs
largest
workforc
health
care
signific
influenc
patient
outcom
research
demonstr
posit
associ
special
nurs
educ
lower
mortal
rate
among
children
cancer
nurs
partnership
collabor
hospit
infantil
teleton
oncologia
hito
children
cancer
blood
disord
center
dfbchcc
promot
optim
patient
care
special
nurs
educ
clinic
train
transfer
knowledg
nurs
hito
dfbchcc
via
observership
exchang
program
model
proven
effect
materi
method
ongo
collabor
nurs
staff
hito
dfbchcc
consist
formal
curriculum
tailor
role
nurs
leader
staff
nurs
specialti
nurs
hito
spent
three
month
dfbchcc
conduct
site
assess
observ
practic
throughout
key
area
prior
hito
open
decemb
nurs
staff
dfbchcc
travel
hito
provid
train
educ
nurs
special
oncolog
hematopoiet
stem
cell
transplant
intens
care
emerg
care
infect
control
surgeri
leadership
educ
partner
develop
program
meet
need
hito
staff
provid
teach
mentorship
result
data
collect
voluntari
survey
nurs
particip
collabor
sustain
train
educ
model
combin
onlin
teleconferenc
ongo
exchang
visit
conduct
conclus
educ
program
oncolog
nurs
throughout
develop
countri
improv
pediatr
cancer
care
build
capac
ongo
partnership
hito
dfbchcc
nurs
program
commit
continu
exchang
inform
pursu
initi
ensur
optim
nurs
care
refer
aiken
lh
clark
sp
cheung
rb
et
al
educ
level
hospit
nurs
surgic
patient
mortal
jama
role
nurs
care
manag
relaps
hodgkin
lymphoma
patient
high
dose
chemotherapi
autolog
stem
cell
singl
center
experi
pakistan
h
hamsar
h
khan
khan
pediatr
oncolog
nurs
shaukat
khanum
memori
cancer
hospit
research
center
lahor
pakistan
pediatr
oncolog
shaukat
khanum
memori
cancer
hospit
research
center
lahor
pakistan
object
main
object
studi
assess
nurs
care
issu
pediatr
patient
relaps
hodgkin
lymphoma
rhl
inpati
stay
high
dose
chemotherapi
hdc
autolog
stem
cell
transplant
asct
method
retrospect
review
nurs
note
pediatr
patient
rhl
treat
shaukat
khanum
memori
cancer
hospit
lahor
april
march
treat
beam
chemotherapi
bcnu
etoposid
cytarabin
melphalan
strict
protect
isol
observ
admiss
data
includ
age
gender
pay
statu
durat
hospit
stay
record
common
problem
encount
hospit
thoroughli
studi
result
patient
review
male
median
age
diagnosi
rhl
year
patient
except
one
receiv
free
treatment
patient
nurs
ratio
hospit
median
durat
hospit
stay
day
rang
day
symptom
persist
day
includ
diarrhea
oral
mucos
nausea
fever
oral
intak
markedli
reduc
patient
n
main
contribut
factor
oral
mucos
n
nauseavomit
n
abdomin
discomfort
n
dislik
hospit
food
n
consist
nurs
practic
includ
regular
oral
care
motiv
counsel
dietari
improv
psycholog
disturb
encount
patient
n
notabl
reason
isol
home
sick
fear
diseas
progress
side
effect
chemotherapi
frequent
counsel
session
attend
nurs
conduct
activ
listen
employ
play
therapi
n
provis
anim
movi
n
stori
book
n
conclus
studi
elabor
physic
psycholog
issu
face
pediatr
patient
undergo
hdc
asct
individu
assess
dedic
effort
nurs
staff
facilit
patient
cope
problem
encount
prolong
hospit
intens
chemotherapi
role
pediatr
oncolog
nurs
educ
anyo
hous
hous
shelter
educ
hanaratri
educ
develop
program
indonesian
anyo
foundat
tangerang
indonesia
object
pediatr
oncolog
nurs
knowledg
resourc
healthcar
provid
care
children
cancer
describ
pediatr
oncolog
nurs
educ
develop
program
indonesia
aim
provid
inform
stakehold
reinforc
import
compon
children
care
educ
program
import
element
child
pediatr
oncolog
treatment
method
sinc
june
monthli
formal
structur
learn
activ
design
execut
coordin
pediatr
oncolog
nurs
educ
free
educ
program
present
famili
children
cancer
member
health
sector
nurs
dietician
medic
student
pediatr
nurs
donor
educ
venu
rumah
anyo
anyo
hous
indonesian
anyo
foundat
speaker
repres
sever
disciplin
ie
medic
oncologist
dietician
pediatrician
gener
medicin
senior
oncolog
nurs
also
cancer
survivor
result
topic
includ
food
healthi
life
style
optim
earli
detect
child
develop
myth
fact
breast
milk
bio
energi
power
palli
care
effect
chemotherapi
children
cancer
optim
nutrit
children
receiv
cancer
treatment
teach
provid
hour
block
includ
lectur
discuss
question
question
answer
end
session
particip
complet
checklist
evalu
conclus
result
educ
session
nurs
coordin
guidelin
creat
consult
discuss
child
health
practition
manag
chemotherapi
side
effect
provid
good
nutrit
children
treatment
also
collabor
donor
develop
motiv
continu
educ
children
stay
rumah
anyo
remain
sever
famili
strategi
improv
develop
educ
program
special
commun
set
address
nurs
educ
home
care
program
children
cancer
develop
palli
care
home
h
hansson
k
schmiegelow
paediatr
adolesc
medicin
copenhagen
univers
hospit
rigshospitalet
copenhagen
denmark
depart
health
scienc
divis
nurs
faculti
medicin
lund
sweden
object
home
care
program
children
cancer
establish
develop
provid
medic
treatment
nurs
care
children
home
sinc
home
care
program
also
deliv
palli
care
includ
care
ensur
qualiti
continu
care
child
home
accord
famili
need
provid
palli
care
complex
challeng
task
purpos
describ
feasibl
deliv
palli
care
home
method
children
type
cancer
live
within
radiu
kilometr
hospit
elig
home
care
program
two
nurs
employ
depart
provid
home
visit
eg
intraven
chemotherapi
support
palli
care
descript
analysi
perform
hospit
record
result
januari
decemb
total
children
receiv
home
visit
femal
receiv
palli
care
home
median
age
year
rang
year
ten
children
brain
tumor
children
solid
tumor
one
child
number
home
visit
per
child
median
rang
last
minut
median
rang
minut
six
children
die
home
need
home
care
nurs
provid
home
visit
collabor
nurs
doctor
respons
child
treatment
pain
relief
evalu
perform
assess
quant
data
qualit
interview
famili
health
care
profession
conclus
feasibl
provid
palli
care
children
home
result
use
consid
provis
palli
care
base
hospit
depart
investig
analysi
special
nurs
knowledg
nurs
depart
pediatr
hematolog
oncolog
chines
hospit
h
lu
np
shen
hematolog
oncolog
shanghai
children
medic
center
shanghai
china
nurs
shanghai
children
medic
center
shanghai
china
object
investig
present
special
nurs
knowledg
nurs
depart
pediatr
hematolog
oncolog
chines
hospit
analyz
influenc
factor
method
research
design
investig
form
base
literatur
review
enrol
nurs
chines
hospit
conveni
sampl
collect
data
surveymonkey
onlin
investig
system
http
wwwsurveymonkeycom
result
averag
score
part
special
nurs
knowledg
higher
mean
less
understand
nurs
differ
experi
titl
demonstr
differ
level
respect
total
score
occup
nurs
knowledg
p
conclus
nurs
depart
pediatr
hematolog
oncolog
show
rel
lower
level
special
nurs
knowledg
especi
palli
knowledg
nurs
differ
background
demonstr
differ
acquisit
special
nurs
knowledg
research
suggest
pay
attent
import
special
nurs
knowledg
order
substanti
connot
nurs
elev
nurs
valu
promot
profession
care
children
hematolog
oncolog
nurs
consider
treatment
diffus
intrins
pontin
glioma
dipg
vinorelbin
nimotuzumab
p
hernandez
hernandez
alomso
p
garcia
prada
r
olaiz
campo
hematolog
pediatr
oncolog
unit
hospit
universitario
madrid
monteprincip
madrid
spain
object
brain
tumor
lead
caus
mortal
childhood
cancer
dipg
tumor
affect
brainstem
manifest
exclus
children
teenag
patient
surviv
rate
one
year
diagnosi
median
surviv
month
radiat
therapi
standard
palli
treatment
locat
surgic
manag
indic
without
radiotherapi
median
surviv
patient
week
objet
studi
evalu
toler
acut
side
effect
patient
suffer
dipg
ambulatori
treatment
nimotuzumab
vinorelbin
method
review
case
patient
treat
unit
nimotuzumab
vinorelbin
well
radiotherapi
result
concomit
use
nimotuzumab
plu
vinorelbin
along
radiotherapi
weekli
induct
treatment
everi
two
week
mainten
period
shown
decreas
number
hospit
admiss
increas
qualiti
life
surviv
rate
month
surviv
six
month
patient
conclus
combin
radiotherapi
nimotuzumab
plu
vinorelbin
well
toler
patient
administ
ambulatori
basi
without
need
hospit
admiss
due
neutropenia
fever
nausea
vomit
etc
complic
surgic
wound
heal
children
teenag
brain
tumor
treatment
bevacizumab
dexamethason
p
hernandez
hernandez
alonso
p
garcia
prada
r
olaiz
campo
hematolog
pediatr
oncolog
unit
hospit
universitario
madrid
monteprincip
madrid
spain
object
treatment
brain
tumor
surgeri
andor
radiotherapi
necessari
combin
drug
order
control
symptom
work
toward
erad
dexamethason
drug
frequent
use
deal
cerebr
edema
administr
produc
cush
syndrom
caus
increas
skin
fragil
new
therapi
look
inhibit
angiogenesi
tumor
bevacizumab
caus
regress
tumor
vascular
normal
residu
tumor
vasculatur
inhibit
tumor
neovascular
prevent
tumor
growth
heal
time
longer
object
studi
present
manag
result
nurseri
experi
complic
observ
heal
process
surgic
wound
three
patient
treat
unit
treat
dexamethason
time
method
case
patient
treat
dexamethason
regist
review
found
three
dehiscensia
surgic
wound
one
case
present
worn
septum
diagnos
diseas
dissemin
oligodendrogliomatosi
craniospin
progress
case
diffus
intrins
pontin
glioma
case
result
two
case
one
month
treatment
abdomin
dehiscensia
cathet
head
expos
treatment
silver
sulphadiazin
povidon
iodin
ointment
help
necessari
complet
heal
surgeri
closur
one
case
vacuum
assist
closur
use
consider
improv
success
anoth
patient
worn
septum
unabl
possibl
rebuild
tissu
conclus
bevacizumab
breakthrough
clinic
practic
effect
observ
short
time
singl
dose
treatment
use
well
accept
use
improv
neurolog
symptom
patient
although
free
signific
side
effect
biomark
oxid
stress
children
treat
leukemia
hockenberri
p
gundi
taylor
montgomeri
moor
nurs
duke
univers
durham
usa
nurs
univers
arizona
tuscon
usa
pediatr
baylor
colleg
medicin
houston
usa
object
central
nervou
system
cn
treatment
children
acut
lymphocyt
leukemia
necessari
prevent
diseas
recurr
brain
associ
cognit
problem
almost
survivor
cn
biomark
identifi
children
risk
could
increas
understand
neurotox
purpos
studi
investig
relationship
among
biomark
oxid
stress
two
oxid
glycerophospholipid
phosphatidylcholin
pc
phosphatidylinositol
pi
cerebr
spinal
fluid
csf
children
method
within
subject
repeat
measur
design
use
investig
relationship
among
csf
biomark
first
month
treatment
newli
diagnos
children
treat
children
oncolog
group
protocol
particip
csf
sampl
collect
lumbar
punctur
requir
per
protocol
intrathec
chemotherapi
result
isprostan
glycerophospholipid
increas
significantli
cn
treatment
compar
diagnost
csf
level
highest
concentr
induct
significantli
correl
highest
level
oxid
pc
r
p
treatment
phase
highest
concentr
significantli
correl
oxid
pc
r
p
oxid
pi
r
p
highest
concentr
continu
also
significantli
correl
oxid
pc
r
p
oxid
pi
r
p
conclus
signific
increas
oxid
pc
pi
provid
evid
use
measur
oxid
stress
brain
oxid
pc
pi
significantli
correl
isoprostan
establish
biomark
oxid
stress
futur
measur
may
becom
import
marker
underli
neurolog
injuri
portfolio
enhanc
resili
adolesc
young
adult
cancer
akiko
ishibashi
k
kamibeppu
depart
children
infant
nurs
japanes
red
cross
kyushu
intern
colleg
nurs
fukuoka
japan
depart
famili
nurs
graduat
school
health
scienc
nurs
tokyo
univers
hongo
tokyo
japan
purpos
purpos
studi
evalu
adolesc
young
adult
aya
cancer
view
use
portfolio
improv
resili
method
patient
portfolio
includ
two
sheet
find
self
project
goal
futur
exampl
portfolio
shown
get
idea
expect
one
author
support
work
question
section
built
content
portfolio
resili
scale
use
portfolio
result
total
patient
age
year
particip
found
middl
high
level
resili
half
increas
inner
resili
score
factor
person
hope
faith
confid
optim
found
portfolio
worthwhil
use
rest
particip
show
chang
low
level
resili
portfolio
conclus
use
portfolio
enabl
tool
pediatr
oncolog
nurs
help
aya
cancer
enhanc
resili
may
need
support
find
self
purpos
futur
studi
need
improv
valid
research
cknowledg
author
would
like
thank
okinawa
prefectur
nanbu
medic
center
children
medic
center
japanes
red
cross
kumamoto
hospit
thank
also
individu
particip
studi
deliv
end
life
care
children
young
peopl
rural
commun
r
jone
j
thoma
paediatr
oncolog
hywel
dda
univers
health
board
carmarthen
unit
kingdom
paediatr
palli
care
hywel
dda
univers
health
board
carmarthen
unit
kingdom
object
aim
develop
paediatr
palli
care
nurs
bank
ppcnb
deliv
end
life
care
children
young
peopl
die
malign
diseasea
previou
audit
shown
parent
care
die
child
hospit
set
would
taken
home
nurs
support
could
provid
initi
involv
develop
educ
train
nurs
bank
provid
fast
flexibl
respons
support
famili
wish
child
die
home
method
first
step
process
involv
explain
idea
senior
nurs
meet
gain
manag
support
interest
paediatr
nurs
recruit
order
develop
databas
staff
educ
train
consist
initi
seri
studi
day
follow
roll
programmm
continu
educ
debrief
session
enabl
staff
improv
knowledg
skill
palli
care
symptom
manag
result
servic
far
utilis
famili
care
die
child
home
feedback
famili
nurs
extrem
posit
famili
describ
feel
control
reassur
presenc
familiar
experienc
nurs
staff
train
element
develop
ensur
nurs
supplement
core
skill
skill
transferr
area
practic
conclus
vision
commit
children
young
peopl
famili
safe
access
sustain
high
qualiti
end
life
care
home
develop
ppcnb
uniqu
servic
rural
wale
improv
care
famili
vulner
time
increas
confid
knowledg
skill
nurs
staff
emot
experi
parent
care
children
cancer
c
kawakami
k
ideno
j
ogawa
r
amano
k
harada
n
morita
f
ishikawa
faculti
nurs
toho
univers
tokyo
japan
school
nurs
nutrit
shukutoku
univers
chiba
japan
pediatr
toho
univers
omori
medic
center
tokyo
japan
school
health
scienc
kyorin
univers
tokyo
japan
object
japanes
govern
decid
improv
relationship
pediatr
cancer
center
result
center
cooper
region
hospit
howev
system
start
almost
pediatr
cancer
patient
still
receiv
medic
examin
neighborhood
hospit
childhood
cancer
result
consider
stress
famili
stress
event
usual
unparallel
import
face
support
profession
essenti
famili
adapt
new
lifestyl
thu
purpos
studi
explor
emot
experi
parent
care
children
cancer
diagnosi
method
data
collect
interview
analyz
use
qualit
induct
method
particip
recruit
pediatr
oncolog
hospit
japan
local
ethic
committe
approv
studi
result
eleven
parent
women
men
interview
time
diagnosi
parent
commonli
experienc
strong
emot
feel
shock
disbelief
anger
loneli
powerless
difficult
parent
appreci
implic
child
diseas
immedi
howev
time
manag
grasp
realiti
child
health
condit
time
inform
deliv
parent
one
import
thing
consid
also
necessari
medic
profession
assess
parent
health
simultan
order
provid
care
child
famili
conclus
pediatr
nurs
import
role
play
provis
inform
need
vigil
regard
individu
need
parent
medic
profession
need
provid
comprehens
inform
meet
need
individu
concern
better
care
ill
children
need
accompani
last
relationship
parent
profession
job
analysi
oncolog
nurs
task
forc
plan
ambulatori
chemotherapi
unit
autom
chemotherapi
prepar
robot
technolog
use
karapinar
kebudi
vz
yenen
r
kebudi
f
yaman
agaoglu
oncolog
nurs
istanbul
univers
oncolog
institut
istanbul
turkey
student
advanc
placement
microeconom
hisar
school
high
school
istanbul
turkey
depart
busi
administr
divis
hospit
administr
beykent
univers
institut
social
scienc
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
oncolog
institut
istanbul
turkey
radiat
oncolog
istanbul
univers
oncolog
institut
istanbul
turkey
object
analys
time
spent
efficaci
nurs
procedur
ambulatori
chemotherapi
unit
establish
autom
chemotherapi
prepar
robot
technolog
method
chemotherapi
applic
perform
work
day
patientsday
ambulatori
chemotherapi
unit
istanbul
univers
institut
oncolog
sinc
juli
autom
chemotherapi
prepar
robot
technolog
use
eight
nurs
work
unit
june
differ
day
three
time
period
day
time
spent
nurs
procedur
assess
detail
variabl
two
independ
observ
use
chronomet
median
number
patient
reciev
ambulatori
chemotherapyday
studi
period
nurs
educ
procedur
previous
interview
result
use
robot
technolog
nurs
activ
involv
nurs
procedur
prior
robot
technolog
nurs
involv
prepar
chemotherapi
drug
activ
patient
procedur
median
time
spent
specif
nurs
procedur
chemotherapi
min
secpati
increas
median
hour
min
sec
advers
reaction
occur
exclud
lunchspecifi
break
nurs
expect
work
activ
h
minday
median
time
spent
nurs
patient
minut
patientsday
nurs
activ
work
hour
min
minut
expect
howev
extra
time
activ
work
less
prior
robot
technolog
conclus
robot
technolog
help
increas
safeti
accuraci
chemotherapeut
drug
increas
time
spent
nurs
activ
nurs
procedur
patient
led
better
satisfact
patient
multidisciplinari
pediatr
oncolog
train
botswana
kollar
j
hesselgrav
slone
p
semetsa
raletshegwana
w
oaits
mt
mokotedi
js
slone
ps
mehta
texa
children
cancer
hematolog
center
baylor
colleg
medicin
houston
usa
texa
children
cancer
hematolog
center
texa
children
hospit
houston
usa
paediatr
princess
marina
hospit
gaboron
botswana
paediatr
univers
botswana
gaboron
botswana
school
nurs
boitekanelo
colleg
gaboron
botswana
object
children
develop
cancer
live
low
middl
incom
countri
lmic
surviv
consider
less
set
major
challeng
treat
pediatr
cancer
lmic
lack
train
provid
baylor
colleg
medicin
bcm
texa
children
cancer
hematolog
center
txch
partnership
princess
marina
hospit
pmh
sinc
center
botswana
treat
children
cancer
pmh
full
time
pediatr
oncologist
care
coordin
bcmtxch
staff
includ
nurs
pharmacist
dietician
social
worker
receiv
littl
pediatr
train
method
conduct
multidisciplinari
workshop
improv
cancer
care
botswana
two
nurs
one
pediatr
resid
pmh
invit
bcmtxch
intens
train
prior
workshop
serv
instructor
along
pediatr
oncologist
care
coordin
local
nurs
instructor
two
visit
educ
txch
novel
curriculum
design
workshop
includ
overview
pediatr
cancer
treatment
support
care
chemotherapi
safeti
administr
pain
manag
care
palli
care
train
strategi
includ
case
studi
didact
lectur
open
forum
discuss
result
one
week
workshop
attend
particip
repres
eight
public
privat
institut
throughout
botswana
eight
disciplin
repres
includ
physician
surgeon
pathologist
nurs
social
worker
dietician
pharmacist
nurs
instructor
pre
demonstr
curriculum
effect
relay
key
principl
learner
particip
evalu
strongli
support
need
type
train
conclus
train
opportun
pediatr
oncolog
limit
lmic
standard
sustain
multidisciplinari
educ
vital
provid
highest
level
oncolog
care
curriculum
adapt
lmic
long
term
success
depend
local
capac
build
aspect
pediatr
cancer
care
cancer
life
chang
rule
richter
pediatr
hematolog
oncolog
univers
children
hospit
germani
object
diagnosi
cancer
immunosuppress
cancer
treatment
requir
thorough
chang
lifestyl
patient
famili
outsid
hospit
profession
provid
sens
secur
parent
need
know
protect
child
without
overli
restrict
everyday
life
hospit
staff
step
structur
instruct
program
design
provid
secur
care
patient
home
rais
awar
sign
potenti
emerg
situat
method
four
year
nurs
hospit
run
formal
instruct
session
nurs
clinic
attend
patient
discharg
hospit
first
stay
session
last
hour
need
instruct
may
also
arrang
outsid
clinic
hour
nurs
staff
train
integr
instruct
nurs
routin
result
program
well
accept
eg
total
newli
diagnos
patient
taken
advantag
nurs
clinic
repres
patient
system
chemotherapi
famili
declin
ideal
parent
take
part
instruct
session
quit
frequent
howev
one
parent
abl
attend
mostli
person
care
patient
home
pediatr
patient
tend
take
interest
nurs
clinic
older
get
usual
patient
year
older
decid
activ
particip
conclus
instruct
session
allow
parent
children
everyday
live
consequ
better
qualiti
life
home
moreov
heighten
awar
emerg
sign
assur
fast
intervent
situat
manag
home
eg
sever
febril
episod
neutropenia
situat
requir
direct
commun
treatment
center
children
cancer
guid
educ
creation
school
base
resourc
booklet
c
murphi
casey
dekker
hamalainen
haematologyoncolog
hospit
sick
children
toronto
canada
object
approxim
children
undergo
activ
cancer
treatment
ontario
canada
year
mani
children
school
age
cancer
diagnosi
present
uniqu
challeng
school
administr
educ
maintain
facilit
vital
aspect
child
life
part
role
pediatr
oncolog
group
ontario
pogo
interlink
commun
cancer
nurs
work
collabor
educ
famili
support
school
educ
children
cancer
supplement
enhanc
share
inform
program
specif
resourc
booklet
entitl
children
cancer
guid
educ
creat
method
literatur
regard
school
reintegr
review
content
well
establish
program
educ
support
provid
pogo
interlink
nurs
via
telephon
consult
school
meet
classroom
present
consid
consult
school
administr
educ
physician
nurs
contribut
content
booklet
result
booklet
school
base
resourc
outlin
gener
inform
childhood
cancer
treatment
practic
strategi
support
children
famili
throughout
cancer
experi
guid
educ
delin
phase
treatment
outlin
special
academ
social
consider
child
diagnos
cancer
child
return
school
event
child
cancer
recur
inform
emot
support
need
child
famili
sibl
classmat
faculti
address
colour
illustr
use
throughout
booklet
enhanc
content
clariti
conclus
pogo
interlink
nurs
began
distribut
resourc
booklet
enhanc
support
ontario
school
januari
although
formal
evalu
plan
anecdot
document
well
receiv
administr
educ
welcom
resourc
understand
facilit
educ
need
children
undergo
cancer
treatment
combin
morphin
ketamin
high
risk
neuroblastoma
patient
receiv
maximis
analgesia
minimis
side
effect
optimis
immunotherapi
deliveri
g
patton
c
reilli
canning
p
cuppl
moor
g
bell
rongh
j
sastri
murphi
oncolog
royal
hospit
sick
childrenyorkhil
glasgow
unit
kingdom
pain
team
royal
hospit
sick
childrenyorkhil
glasgow
unit
kingdom
object
obtain
optimum
pain
control
patient
receiv
antibodi
protocol
minim
side
effect
method
neuroblastoma
patient
receiv
antibodi
without
aldesleukin
monoclon
antibodi
bind
receptor
neuroblastoma
cell
induc
kill
tumour
cell
patient
immun
respons
treatment
significantli
toxic
patient
experi
sudden
onset
pain
administr
antibodi
therefor
concomit
pcanca
morphin
treatment
necess
pain
assess
score
identifi
patient
adequ
analgis
despit
signific
morphin
dose
escal
consequ
side
effect
antibodi
infus
interrupt
optimis
pain
manag
led
prolong
immunotherapi
infus
time
multidisciplinari
team
discuss
led
introduct
low
dose
ketamin
infus
adjunct
opioid
analgesia
ketamin
provid
good
analgesia
preserv
airway
patenc
ventil
cardiovascular
stabil
result
combin
morphin
ketamin
success
control
pain
far
fewer
side
effect
optim
pain
manag
allow
immunotherapi
deliveri
without
interrupt
ketamin
morphin
standard
patient
receiv
immunotherapi
conclus
combin
morphin
ketamin
increas
patient
pain
toler
antibodi
without
side
effect
high
dose
opiat
permit
substanti
increas
number
cycl
deliv
without
delay
break
maximis
therapeut
impact
immunotherapi
literatur
review
nurs
infant
retinoblastoma
famili
nagayoshi
hiros
school
medicinenurs
cours
yokohama
citi
univers
yokohama
japan
graduat
school
medicin
depart
nurs
yokohama
citi
univers
yokohama
japan
object
studi
aim
gain
insight
nurs
research
japan
literatur
review
nurs
care
abroad
infant
retinoblastoma
rare
eye
cancer
mother
treatment
retinoblastoma
develop
recent
year
method
pubm
cinahl
databas
explor
cover
last
two
decad
paper
select
review
base
literatur
map
develop
nurs
care
assess
result
first
paper
publish
zero
three
paper
identifi
year
thereaft
nurs
care
provid
classifi
three
topic
nurs
treatment
nurs
visual
impair
nurs
hereditari
cancer
nurs
treatment
brachytherapi
enucl
eye
chemotherapi
cover
studi
also
investig
nurs
prevent
psycholog
issu
effect
treatment
coordin
commun
school
children
cope
school
cure
rate
increas
particularli
case
hereditari
cancer
nurs
care
counsel
famili
import
conclus
surviv
rate
infant
retinoblastoma
continu
increas
hereditari
cancer
research
advanc
paper
discuss
support
problem
perspect
appear
result
suggest
signific
studi
continu
care
children
famili
retinoblastoma
visual
impair
famili
japan
improv
qualiti
life
treatment
appetit
sens
joy
life
nutrit
project
mm
nielsen
kristensen
c
thomsen
pediatr
oncolog
ward
aalborg
univers
hospit
aalborg
denmark
object
project
toward
children
admit
paediatr
oncolog
ward
aalborg
univers
hospit
purpos
project
ad
focu
nutrit
reduc
weight
loss
induc
chemotherapi
also
minim
need
tube
feed
formula
parenter
nutrit
intend
chang
hospitalis
child
percept
food
gener
new
knowledg
creat
set
meal
favour
children
need
wish
implement
paediatr
ward
method
project
interdisciplinari
project
oper
paediatr
oncolog
ward
hospit
kitchen
compani
unisan
parent
children
includ
project
interview
regard
wish
need
concern
children
diet
studi
children
nutrit
valu
threateneda
new
kitchen
build
famili
cook
new
food
concept
develop
better
content
excit
food
serv
addit
new
pamphlet
inspir
develop
food
shop
parent
children
cook
sens
coach
chef
unisan
part
project
food
shop
turn
everi
day
result
result
yet
calcul
conclud
number
success
criteria
fulfil
greater
fellowship
joy
eat
situat
children
want
cook
particip
social
gather
includ
food
children
teenag
becom
outgo
eat
food
serv
conclus
expect
project
help
improv
children
psychosoci
develop
futur
experi
project
use
design
new
eat
environ
paediatr
ward
parent
children
sickl
cell
anemia
sca
contempl
allogen
hematopoiet
stem
cell
transplant
hsct
n
noonan
bmt
children
hospit
research
center
oakland
oakland
usa
object
sickl
cell
diseas
common
inherit
blood
disord
unit
state
affect
estim
individu
despit
improv
support
care
past
year
hydroxyurea
chronic
transfus
known
cure
sca
hsct
hsct
sca
carri
mortal
risk
risk
associ
potenti
morbid
lack
studi
directli
compar
support
therapi
hsct
contribut
controversi
support
care
versu
hsct
sca
center
comprehens
hematologyoncologybmt
program
includ
pediatr
hemoglobinopathi
sinc
bmt
program
transplant
children
sca
os
df
although
consult
mani
famili
method
pubm
search
past
year
research
perform
identifi
sca
parentpati
interest
process
famili
contempl
hsct
therapi
aim
identifi
key
concept
relat
hsct
sca
interest
factor
educ
materi
need
option
improv
consult
servic
inform
consent
result
four
studi
survey
hbss
hb
patientsfamili
although
focu
vari
survey
assess
process
regard
treatment
choic
declin
patient
parent
attitud
toward
hsct
factor
associ
patientpar
interest
hsct
parent
attitud
toward
risk
accept
hsct
key
theme
identifi
provid
riskbenefit
inform
assess
parent
patient
interest
offer
hsct
conclus
conclus
limit
research
unansw
question
exist
regard
interest
sca
famili
regard
hsct
next
step
implement
either
survey
focu
group
captur
inform
specif
center
incorpor
find
hsctsca
educ
materi
hsct
consult
process
specif
interest
also
includ
role
referringprimari
physician
outreach
sca
commun
knowledg
attitud
nurs
team
treatment
pediatr
cancer
patient
medic
cannabi
r
ofir
yontanov
pediatr
hematolog
oncolog
rambam
health
care
campu
haifa
israel
object
late
increas
use
medic
cannabi
pediatr
cancer
patient
rambam
medic
center
start
use
cannabi
year
ago
request
parent
year
old
femal
end
life
order
allevi
pain
improv
mood
increas
appetit
use
cannabi
rais
ethic
issu
among
team
member
result
parent
request
need
improv
support
care
analyz
knowledg
attitud
nurs
staff
nurs
toward
cannabi
particular
relat
use
pediatr
cancer
patient
method
compos
questionnair
check
knowledg
attitud
toward
medic
cannabi
questionnair
consist
demograph
detail
question
knowledg
stanc
questionnair
given
without
prior
exposur
subject
part
staff
meet
team
heard
lectur
demonstr
medic
cannabi
benefit
month
afterward
questionnair
ii
answer
check
chang
knowledg
attitud
answer
questionnair
result
signific
chang
averag
staff
attitud
questionnair
questionnair
ii
found
question
attitud
use
cannabi
subject
support
idea
issu
knowledg
signific
differ
questionnair
ii
conclus
result
show
teach
staff
advantag
medic
cannabi
enrich
knowledg
chang
neg
attitud
knowledg
cannabi
increas
significantli
would
help
us
build
futur
medic
train
program
cannabi
children
cancer
year
focu
central
line
care
g
petersen
madsen
h
hansson
depart
pediatr
hematologyoncolog
copenhagen
univers
hospit
rigshospitalet
copenhagen
denmark
object
evalu
ten
year
focu
central
line
care
due
increas
number
central
line
infect
structur
educ
program
nurs
patient
parent
develop
program
evalu
show
decreas
number
central
venou
cathet
cvc
remov
due
infect
still
need
focu
follow
train
patient
parent
newli
employ
nurs
train
first
two
week
receiv
certif
within
first
month
employ
train
patient
parent
perform
certif
nurs
support
written
guidelin
photo
educ
document
checklist
patient
medic
record
method
certif
nurs
central
line
care
renew
everi
year
practic
theoret
test
train
patient
parent
evalu
audit
checklist
medic
record
interview
patient
parent
cvc
relat
infect
occur
result
almost
everi
recertif
nurs
habit
need
chang
ensur
guidelin
strictli
follow
recent
audit
educ
patient
parent
unfortun
still
show
lack
consist
follow
conclus
educ
nurs
patient
parent
import
need
ongo
constantli
improv
futur
plan
improv
educ
patient
parent
patient
cvc
booklet
develop
follow
patient
parent
train
schedul
whole
treatment
period
new
way
inform
video
app
also
new
way
educ
group
session
special
train
nurs
develop
individu
train
improv
share
respons
acut
pediatr
oncolog
scenario
train
p
roland
l
l
hjalgrim
lindequist
u
larsen
pediatr
haematholog
oncolog
rigshospitalet
copenhagen
univers
hospit
copenhagen
denmark
object
children
undergo
treatment
cancer
continu
risk
develop
complic
complic
may
develop
acut
within
minut
hour
earli
recognit
assess
treatment
complic
crucial
reduct
morbid
mortal
conduct
questionnair
doctor
nurs
target
knowledg
skill
emerg
situat
child
specif
address
abc
handl
teamwork
safe
commun
staff
express
great
uncertainti
lack
knowledg
handl
critic
ill
child
purpos
test
doctor
nurs
experienc
increas
skill
handl
critic
ill
child
special
emphasi
abc
algorithm
safe
commun
team
work
scenario
train
common
oncolog
emerg
situat
sepsi
anaphylact
reaction
method
prior
scenario
train
staff
lectur
use
abc
algorithm
team
work
safe
commun
real
time
scenario
train
conduct
depart
patient
room
situat
appear
authent
possibl
involv
one
doctor
three
nurs
complet
scenario
exercis
debrief
held
result
overal
particip
report
increas
averag
averag
skill
relat
abc
algorithm
teamwork
safe
combin
greatest
improv
skill
within
use
abc
algorithm
conclus
emerg
scenario
train
significantli
improv
skill
care
oncolog
child
common
standard
target
train
educ
implement
emerg
cart
emerg
tabl
improv
work
process
clear
role
commun
aim
futur
creat
scenario
train
program
earli
warn
sign
treatment
oncolog
emerg
test
staff
skill
prior
complet
program
impact
structur
educ
train
famili
staff
rate
infect
cvad
children
cancer
j
sastri
murphi
rongh
n
mcguir
b
gibson
e
chalmer
n
mcintosh
depart
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
depart
glasgow
univers
school
medicin
glasgow
unit
kingdom
object
introduct
central
venou
access
devis
cvad
central
modern
treatmentmanag
paediatr
cancer
patient
infect
seriou
potenti
life
threaten
complic
identifi
implement
structur
educ
guidanc
staff
famili
year
impact
infect
rate
identifi
cvad
care
maintain
longer
full
time
lead
person
respons
manag
cvad
sinc
januari
method
retrospect
studi
carri
period
januari
novemb
identifi
rate
infect
cvad
period
divid
two
one
jan
decemb
full
time
advanc
nurs
practition
anp
post
second
dec
nov
full
time
anp
longer
post
data
obtain
unit
cvad
microbiolog
theatr
data
base
evid
base
educ
method
train
programm
polici
guidanc
patient
inform
booklet
introduc
januari
result
studi
period
steadi
increas
number
cvad
situ
patient
per
year
decreas
rate
infect
studi
period
decreas
continu
second
period
full
time
anp
longer
post
conclus
audit
demonstr
implement
structur
educ
train
famili
staff
result
decreas
rate
infect
cvad
despit
increas
number
patient
cvad
declin
infect
rate
continu
absenc
full
time
anp
signifi
educ
train
packag
becom
cultur
unit
use
children
emot
manifest
scale
cem
pediatr
oncolog
hospit
patient
schiavetti
e
scardella
f
patriarchi
p
capelli
l
vapor
apollonio
md
pediatr
sapienza
univers
rome
rome
itali
school
nurs
sapienza
univers
rome
rome
itali
nurs
pediatr
oncolog
sapienza
univers
rome
rome
itali
nurs
coordin
pediatr
oncolog
sapienza
univers
rome
rome
itali
object
identifi
nurs
intervent
abl
improv
complianc
treatment
children
cancer
admit
method
use
children
emot
manifest
scale
cem
consid
variabl
facial
express
verbal
activ
interact
cooper
assign
item
score
one
five
total
score
rang
five
month
pt
evalu
cem
first
admiss
andor
subsequ
admiss
pt
divid
year
pt
year
pt
result
studi
show
score
differ
point
first
admiss
effect
intervent
sound
pt
year
play
pt
year
score
respect
second
admiss
effect
intervent
distract
pt
year
explan
procedur
listen
patient
request
pt
year
score
respect
conclus
studi
could
help
nurs
staff
better
manag
children
cancer
admit
engag
educ
studi
evalu
success
reduc
central
venou
bloodstream
infect
pediatr
cancer
r
secola
hematolog
oncolog
children
hospit
lo
angel
lo
angel
usa
object
central
venou
cathet
cvc
indispens
chronic
acut
ill
patient
requir
andor
complex
therapi
cvc
carri
high
level
mortal
morbid
directli
relat
risk
infect
substanti
stride
toward
reduc
cvc
associ
bloodstream
infect
bsi
effort
includ
implement
adher
cvc
insert
mainten
bundl
along
ongo
educ
monitor
treatment
children
adolesc
cancer
includ
use
cvc
despit
ubiquit
use
cvc
prospect
studi
conduct
address
infect
prevent
strategi
pediatr
oncolog
patient
purpos
present
provid
overview
cvc
type
select
infect
prevent
strategi
intervent
includ
engag
educ
frontlin
staff
children
hospit
lo
angel
well
intervent
consider
method
dedic
approach
engag
frontlin
staff
util
multipl
methodolog
educ
account
cvc
care
audit
observ
care
root
analys
cvc
associ
bsi
implement
reliabl
intervent
complet
pilot
studi
accomplish
result
remain
sustain
reduct
cvc
associ
bsi
rate
result
staff
engag
educ
cvc
care
bsi
evalu
implement
reliabl
intervent
furthermor
complet
cvc
infect
prevent
pilot
studi
highlight
key
risk
factor
studi
propos
valuabl
intervent
conclus
ongo
evalu
educ
monitor
random
observ
cvc
care
critic
analysi
cvc
associ
bsi
intervent
employ
necessari
sustain
improv
addit
rigor
studi
key
risk
factor
critic
mediat
pediatr
oncolog
patient
underli
malign
cvc
type
patient
acuityclin
indic
imper
strateg
intervent
dedic
cvc
team
chlorhexidin
bath
regimen
oral
care
bundl
effect
health
educ
parent
assess
kap
knowledg
attitud
practic
pediatr
oncolog
patient
thoma
srivastava
b
singh
singh
r
seth
pediatr
india
institut
medic
scienc
delhi
india
object
aim
studi
find
effect
health
educ
parent
attitud
care
pediatr
oncolog
patient
improv
knowledg
qualiti
care
effect
incid
febril
neutropenia
hospit
admiss
long
term
event
free
surviv
method
studi
sampl
consist
parent
pediatr
oncolog
patient
questionnair
made
local
languag
hindi
assess
parent
knowledg
attitud
practic
clean
food
clean
water
clean
environ
clean
hand
result
diagnosi
cancer
affect
life
parent
n
question
parent
prior
knowledg
diseas
come
patient
report
improv
understand
diseas
health
educ
patient
awar
import
clean
food
clean
water
clean
environ
parent
report
care
sibl
oncolog
patient
affect
child
diagnos
cancer
conclus
health
educ
import
part
holist
care
oncolog
patient
patient
low
socio
econom
statu
littl
knowledg
hygien
person
care
health
educ
improv
care
qualiti
life
oncolog
patient
decreas
rate
infect
need
hospit
influenc
school
reentri
support
relationship
adolesc
cancer
share
peer
teacher
soejima
sato
j
takita
k
koh
maeda
k
ida
k
kamibeppu
depart
famili
nurs
school
health
scienc
nurs
graduat
school
medicin
univers
tokyo
japan
depart
pediatr
graduat
school
medicin
univers
tokyo
japan
depart
hematologyoncolog
saitama
children
medic
center
japan
depart
pediatr
nippon
medic
school
japan
depart
pediatr
teikyo
univers
mizonokuchi
hospit
japan
object
support
relationship
peer
teacher
particularli
social
support
offer
relationship
especi
import
adolesc
cancer
purpos
studi
clarifi
form
school
reentri
support
adolesc
cancer
relat
perceiv
social
support
posit
adolesc
cancer
would
perceiv
support
relationship
peer
teacher
high
level
social
support
method
questionnair
survey
recruit
dyad
adolesc
cancer
guardian
questionnair
adolesc
question
perceiv
social
support
questionnair
guardian
question
demograph
inform
school
reentri
support
guardian
interview
supplement
result
questionnair
survey
complet
questionnair
result
questionnair
data
dyad
interview
data
guardian
analyz
questionnair
survey
reveal
peer
visit
understand
hospit
experi
interact
adolesc
cancer
relat
perceiv
social
support
peer
teacher
understand
physic
appear
academ
perform
hospit
experi
well
statu
liaison
hospit
school
relat
perceiv
social
support
peer
teacher
interview
survey
found
adolesc
cancer
could
establish
support
relationship
peer
teacher
school
reentri
support
led
adolesc
recognit
member
local
school
peer
teacher
understand
recoveri
process
adolesc
adolesc
awar
struggl
diseas
conclus
healthcar
profession
provid
inform
peer
teacher
emphas
adolesc
hospit
experi
also
encourag
adolesc
cancer
regard
cancer
experi
opportun
grow
would
help
adolesc
cancer
establish
support
relationship
peer
teacher
central
paediatr
oncolog
nurs
educ
netherland
increas
surviv
rate
c
van
den
bachelor
nurs
univers
appli
scienc
utrecht
netherland
object
netherland
approxim
children
annual
diagnos
cancer
children
diagnos
treat
paediatr
oncolog
centr
poc
centr
allogen
stem
cell
transplant
treatment
also
take
place
secondari
paediatr
unit
share
care
children
cancer
cure
sinc
educ
train
paediatr
oncolog
nurs
poc
share
care
accord
exist
recognis
compet
framework
train
job
method
far
sinc
major
develop
care
children
young
peopl
cancer
central
care
lead
hospit
one
nation
paediatr
oncolog
centr
princess
centr
method
studi
qualit
descript
design
result
current
educ
paediatr
oncolog
nurs
consist
year
bachelor
nurs
degre
bn
year
specialis
paediatr
nurs
train
job
paediatr
oncolog
nurs
provid
care
highest
level
nurs
highli
qualifi
educ
train
essenti
addit
central
care
central
educ
train
requir
paediatr
oncolog
nurs
princess
centr
share
carea
start
made
outflow
student
bn
paediatr
oncolog
profil
intens
cooper
necessari
studi
bn
internship
paediatr
nurs
paediatr
oncolog
nurs
conclus
one
paediatr
oncolog
centr
princess
centr
specialis
nurs
care
nurs
educ
train
brought
togeth
highest
level
ambit
increas
surviv
rate
realis
togeth
highest
possibl
qualiti
life
treatment
studi
japanes
literatur
grief
care
relat
pediatr
nurs
k
wada
fuchita
kato
suyama
nurs
tokai
univers
school
health
scienc
isehara
japan
nurs
tokai
univers
junior
colleg
nurs
technolog
hiratsuka
japan
nurs
tokai
univers
hospit
isehara
japan
object
review
japanes
studi
grief
care
relat
pediatr
nurs
past
year
ascertain
futur
direct
research
method
keyword
childhood
cancer
grief
care
hospic
use
search
articl
databas
japanes
medic
literatur
articl
mention
grief
care
categor
analyz
result
recipi
grief
support
often
famili
member
personnel
provid
grief
care
often
nurs
follow
medic
personnel
grief
care
involv
need
grief
care
difficulti
grief
care
train
grief
care
form
grief
care
griev
process
conclus
mani
studi
examin
care
bereav
famili
member
studi
examin
care
individu
nurs
children
cancer
surviv
rate
children
cancer
improv
futur
major
issu
need
address
mount
evid
need
grief
care
children
particularli
ward
children
die
pain
experienc
children
cancer
nurs
experi
resourc
limit
set
jw
wekesa
jebet
hematoncolog
ampathoncolog
eldoret
kenya
object
highlight
pain
experienc
children
cancer
highlight
challeng
encount
method
observ
qualit
studi
carri
practic
observ
interact
children
result
children
cancer
felt
pain
draw
blood
investig
children
also
felt
pain
fix
branular
administr
chemotherapi
receiv
inject
treatment
wound
dress
pain
cancer
especi
tumour
progress
challeng
lack
train
personnel
handl
children
cancer
lack
train
opportun
facil
care
paediatr
cancer
lack
equip
suppli
pott
cathet
chemotherapi
administr
conclus
manag
paediatr
oncolog
pain
reduc
cancer
suffer
improv
qualiti
life
expand
paediatr
oncolog
care
home
build
nurs
compet
confid
facilit
administr
subcutan
cytarabin
home
c
william
j
templeton
shelli
j
williamson
paediatr
integr
cancer
servic
royal
children
hospit
melbourn
australia
children
cancer
centr
monash
children
hospit
melbourn
australia
object
review
servic
provid
monash
children
home
commun
nurs
program
indic
mani
patient
would
benefit
expand
nurs
scope
practic
includ
administr
subcutan
cytarabin
treatment
acut
lymphoblast
leukaemia
gener
paediatr
nurs
indic
lack
confid
compet
deliv
chemotherapi
home
project
aim
expand
paediatr
outreach
servic
includ
deliveri
low
complex
chemotherapi
paediatr
patient
method
staff
attend
current
foundat
day
offer
oncolog
nurs
well
fit
purpos
train
modul
develop
specif
support
scope
practic
includ
train
chemotherapi
safe
handl
clinic
trial
cell
biolog
focus
agent
deliv
nurs
procedur
home
administr
cytarabin
develop
nurs
roster
oncolog
outpati
depart
compet
assess
result
fourteen
paediatr
commun
nurs
complet
compet
program
provid
sustain
level
care
nineteen
children
far
abl
cytarabin
deliv
home
result
hospit
bed
day
save
reduc
day
oncolog
admiss
negat
inpati
weekend
ward
admiss
travel
distanc
save
across
famili
estim
km
conclus
project
illustr
potenti
wide
rang
benefit
implement
small
localis
servic
improv
project
famili
staff
health
servic
increas
scope
practic
confid
staff
project
improv
care
pathway
children
famili
less
hospit
visit
time
home
health
servic
freed
bed
day
allow
servic
expand
level
care
commun
fit
purpos
model
train
also
encourag
particip
servic
outsid
oncolog
depart
physic
activ
survey
adolesc
cancer
j
withycomb
mc
hook
wright
l
gilchrist
k
sachs
j
danielson
k
kelli
children
cancer
blood
disord
center
palmetto
health
columbia
usa
school
nurs
univers
minnesota
minneapoli
usa
pediatr
oncolog
mcmaster
children
hospit
hamilton
canada
cancer
blood
disord
program
children
hospit
clinic
minnesota
minneapoli
usa
center
cancer
blood
disord
children
nation
medic
center
washington
usa
nurs
student
univers
minnesota
minnesota
usa
divis
pediatr
hematolog
oncolog
stem
cell
transplant
columbia
univers
medic
center
new
york
usa
object
decreas
physic
activ
well
document
childhood
cancer
patient
yet
littl
known
adolesc
desir
engag
physic
activ
treatment
perceiv
barrier
activ
survey
administ
identifi
exercis
activ
adolesc
perform
diagnosi
activ
interest
treatment
well
identifi
barrier
exercis
cancer
treatment
method
particip
n
enrol
across
six
pediatr
oncolog
center
unit
state
canada
particip
year
newli
diagnos
cancer
receiv
chemotherapi
plan
treatment
least
month
abl
independ
complet
written
survey
abl
provid
assentcons
enrol
particip
complet
amherst
health
activ
survey
describ
particip
physic
activ
diagnosi
month
treatment
well
physic
activ
would
interest
particip
therapi
result
adolesc
physic
activ
level
decreas
therapi
although
interest
remain
high
particip
calisthen
particip
therapi
express
interest
activ
walk
report
particip
rate
therapi
express
interest
basketbal
report
commonli
particip
team
sport
therapi
interest
express
particip
basketbal
laser
tag
volleybal
footbal
soccer
person
barrier
exercis
also
report
conclus
research
consist
shown
physic
activ
level
decreas
therapi
studi
found
although
activ
level
declin
mani
adolesc
still
report
interest
physic
activ
therapi
awar
adolesc
interest
physic
activ
well
perceiv
barrier
may
assist
healthcar
profession
engag
childhood
cancer
patient
maintain
activ
lifestyl
therapi
percept
cancerfightclub
interact
inform
social
network
platform
young
adult
cancer
v
wrzesien
tsimicali
c
loisel
ingram
school
nurs
mcgill
univers
montreal
canada
object
young
adult
cancer
increasingli
turn
onlin
resourc
meet
need
howev
research
need
explor
percept
onlin
resourc
cancer
survivorship
platform
cancerfightclub
cfc
creat
goal
provid
young
adult
cancer
onlin
access
support
resourc
studi
object
explor
extent
cfc
address
practic
psychosoci
inform
need
b
explor
cfc
could
enhanc
method
qualit
descript
studi
conduct
purpos
sampl
young
adult
treat
cancer
tertiari
hospit
montreal
quebec
canada
interview
complet
particip
data
transcrib
themat
analyz
result
twelv
particip
mix
age
rang
year
gender
femal
first
cancer
brain
tumor
lymphoma
testicular
breast
enter
studi
particip
express
great
interest
cfc
describ
cfc
import
definit
need
felt
reassur
know
alon
abl
connect
young
adult
cancer
commun
thu
appeas
feel
isol
cfc
addit
provid
space
particip
felt
could
find
inform
need
without
inform
want
avoid
opportun
enhanc
cfc
recommend
facilit
direct
peer
connect
initi
discuss
provid
support
famili
member
rais
awar
cfc
conclus
cfc
region
onlin
support
commun
might
contribut
toward
reduc
young
adult
feel
isol
provid
resourc
meet
need
posit
recept
cfc
help
champion
continu
develop
use
onlin
support
platform
young
adult
cancer
commun
made
awar
support
websit
order
refer
young
adult
patient
help
resourc
major
achiev
european
network
cancer
research
children
adolesc
encca
r
ladenstein
schrapp
k
chiucchiuini
essiaf
p
kearn
eggert
r
haupt
g
schreier
g
vassal
studi
statist
integr
research
children
cancer
research
institut
vienna
austria
depart
gener
pediatr
univers
medic
center
campu
kiel
kiel
germani
molecular
haematolog
cancer
biolog
unit
ucl
institut
child
health
great
ormond
street
hospit
nh
trust
london
unit
kingdom
grant
manag
research
support
children
cancer
research
institut
vienna
austria
siop
secretari
gener
siop
europ
european
societi
paediatrc
oncolog
brussel
belgium
crctu
birmingham
children
hospit
birmingham
unit
kingdom
onkologi
und
berlin
berlin
germani
uosd
epidemiologia
biostatistica
e
comitati
istituto
g
gaslini
genova
itali
safeti
secur
depart
ait
austrian
institut
technolog
gmbh
graz
austria
research
clinic
divis
institut
gustav
roussi
villejuif
franc
object
build
effect
european
research
arena
facilit
foster
coordin
region
nation
joint
european
pediatr
adolesc
oncolog
program
action
european
member
state
develop
virtual
european
pediatr
oncolog
po
institut
method
european
network
cancer
research
children
adolesc
encca
project
fund
european
union
program
encca
driven
lead
organ
countri
structur
work
packag
activ
interact
siop
commun
aim
resolv
fragment
translat
research
biobank
enhanc
drug
develop
improv
clinic
trial
framework
cancer
registri
address
special
need
patient
group
refer
age
given
cancer
diagnosi
includ
ethic
aspect
clinic
research
result
establish
european
clinic
research
council
integr
platform
leukemia
tumor
group
chair
presid
nation
po
group
togeth
european
parent
patient
advisori
committe
encca
help
siop
becom
uniqu
voic
european
stakehold
result
major
impact
new
european
clinic
trial
regul
encca
design
advanc
biomed
collabor
domain
encca
solut
european
virtual
institut
creat
roadmap
toward
feder
pediatr
cancer
biobank
resourc
eight
clinic
trial
embed
encca
addit
new
methodolog
approach
innov
trial
design
one
encca
highlight
develop
survivorship
passport
prototyp
survivor
encca
trigger
establish
new
link
po
commun
includ
patientspar
organ
industri
european
regul
ema
conclus
action
undertaken
far
basi
sustain
eu
virtual
institut
devot
improv
outcom
qualiti
treatment
pediatr
cancer
qualiti
life
survivor
radiat
oncolog
pro
improv
deliveri
safeti
proton
beam
therapi
j
buchsbaum
b
jyoti
v
simoneaux
r
reed
conley
radiat
oncolog
indiana
univeristi
school
medicin
bloomington
usa
object
proton
beam
therapi
product
secondari
neutron
contribut
risk
second
malign
debat
hypothes
could
improv
proton
safeti
decreas
neutron
product
simpl
method
minim
neutron
product
method
narrow
proton
beam
produc
acceler
need
later
spread
provid
coverag
target
use
passiv
activ
pencil
beam
method
achiev
amount
neutron
depend
amount
high
z
materi
intercept
path
beam
use
cm
snout
cm
circular
apertur
cm
rang
spread
bragg
peak
sobp
mu
neutron
read
taken
use
wide
energi
neutron
detect
instrument
neutron
detector
distanc
cm
snout
tip
cm
perpendicular
snout
tip
left
right
side
five
read
collect
per
side
variou
wobbl
field
size
snout
employ
compar
neutron
dose
wobbl
shape
size
compar
apertur
size
result
passiv
scan
averag
mr
activ
scan
averag
mr
wobbl
adjust
mimic
apertur
via
allow
cm
overlap
read
mr
analysi
wobbl
shape
show
decreas
neutron
measur
wobbl
size
decreas
real
pediatr
craniospin
field
treat
via
cm
nozzl
averag
wobbl
optim
wobbl
x
versu
x
respect
use
cm
deep
sobp
beam
neutron
read
fell
mr
mr
conclus
activ
scan
significantli
decreas
secondari
neutron
product
rel
passiv
scan
wobbl
size
directli
impact
neutron
product
possibl
minim
neutron
via
achiev
method
use
exist
hardwar
impact
radiat
therapi
igrt
pediatr
radiat
activ
j
francois
v
bogner
c
reinaud
l
padovani
x
muracciol
radiotherapi
hopit
de
la
timon
marseil
franc
object
determin
impact
radit
therapi
igrt
time
factor
associ
magnitud
displac
pediatr
popul
method
clinic
data
children
treat
institut
analyz
igrt
cbct
patient
without
igrt
control
time
session
calcul
group
setup
error
assess
displac
si
ap
ml
direct
divid
minor
mm
major
mm
result
session
deliv
imag
perform
igrt
group
session
realiz
cbct
irradi
versu
session
mean
time
per
session
minut
group
minut
igrt
group
children
mean
time
session
igrt
increas
compar
session
mv
contrast
mean
time
irradi
similar
whatev
irradi
modal
minor
displac
found
major
displac
respect
group
cbct
major
displac
found
case
control
realiz
twice
week
versu
daili
control
major
displac
concern
mainli
ap
direct
vs
si
ml
direct
children
year
old
conclus
pediatr
popul
igrt
control
induc
increas
time
treatment
result
show
use
daili
cbct
improv
detect
sensit
correct
residu
error
exceed
mm
especi
children
year
old
emot
psycholog
impact
radiat
therapist
treat
children
larg
region
cancer
centr
canada
l
grimard
b
smith
hamilton
radiat
oncolog
ottawa
hospit
ottawa
canada
radiat
medicin
ottawa
hospit
ottawa
canada
object
aim
studi
determin
psycholog
effect
difficulti
radiat
therapist
rt
experi
treat
children
studi
intend
provid
inform
order
assist
rt
occup
complement
spars
literatur
topic
method
survey
conduct
order
captur
data
emot
effect
opinion
rt
one
cancer
centr
questionnair
inspir
limit
literatur
around
issu
studi
converg
reaction
rt
children
receiv
radiat
treatment
impact
rt
emot
state
around
compon
practic
questionnair
distribut
electron
via
email
answer
provid
likert
scale
question
result
rt
complet
survey
question
questionnair
show
gender
age
play
major
role
rt
abil
cope
mental
half
rt
children
indic
children
made
somehow
difficult
cope
emot
paediatr
patient
rt
indic
emot
state
parent
care
giver
affect
children
play
key
role
anxieti
felt
child
treatment
percent
rt
state
treat
children
caus
higher
anxieti
level
treat
adult
final
survey
suggest
time
constraint
play
larg
part
rt
stress
level
treatment
conclus
overal
treat
children
caus
much
distress
treat
adult
also
result
survey
new
tool
rt
describ
cognit
stage
children
creat
order
help
rt
treat
paediatr
patient
proton
radiat
treatment
children
less
month
age
c
z
tochner
fisher
j
minturn
j
belasco
r
bagatel
n
balamuth
r
womer
reilli
p
phillip
ra
lustig
radiat
oncolog
univers
pennsylvania
school
medicin
children
hospit
philadelphia
usa
pediatr
neurooncolog
univers
pennsylvania
school
medicin
children
hospit
philadelphia
usa
pediatr
oncolog
univers
pennsylvania
school
medicin
children
hospit
philadelphia
usa
object
radiat
therapi
rt
may
delay
omit
reduc
dose
young
children
effort
reduc
toxic
proton
therapi
allow
spare
normal
tissu
may
improv
outcom
allow
multidisciplinari
treatment
deliveri
deliv
maxim
safeti
method
ten
patient
requir
rt
age
less
enrol
prospect
registri
radiat
deliv
induct
chemotherapi
andor
surgic
resect
indic
base
diagnosi
radiat
delay
due
age
radiat
plan
ct
simul
fusion
pre
imag
tumor
bed
clinic
target
volum
organ
risk
contour
eclips
plan
softwar
dose
report
absorb
dose
cgyrb
result
patient
popul
time
rt
rang
median
femal
six
patient
cn
tumor
medulloblastoma
atrt
ependymoma
pnet
diagnos
includ
neuroblastoma
undifferenti
sarcoma
rhabdoid
tumor
radiat
treatment
site
includ
infratentori
brain
abdomen
headneck
radiotherapi
deliv
use
passiv
scatter
proton
beam
patient
pencil
beam
scan
dose
rang
patient
receiv
daili
gener
anesthesia
patient
experienc
greater
grade
acut
toxic
maximum
month
rang
patient
aliv
one
diseas
recurr
outsid
radiat
field
patient
experienc
seriou
grade
toxic
relat
radiat
conclus
although
radiotherapi
young
children
must
undertaken
caution
proton
therapi
potenti
reduc
normal
tissu
dose
maxim
safeti
base
seri
proton
radiat
appear
safe
acut
set
even
extrem
young
children
may
improv
outcom
compar
paradigm
elimin
rt
monitor
late
effect
paramount
popul
feasibl
breast
spare
whole
lung
imrt
children
wilm
tumor
lung
metastasi
dosimetri
studi
j
kalapurak
v
sathiaseelan
gosiengfiao
j
reichek
walterhous
gopalakrishnan
radiat
oncolog
northwestern
memori
hospit
chicago
usa
pediatr
oncolog
ann
robert
luri
children
hospit
chicago
usa
object
demonstr
feasibl
dosimetr
advantag
whole
lung
imrt
children
sever
report
implic
whole
lung
irradi
wli
import
caus
higher
rate
secondari
breast
cancer
wilm
tumor
wt
survivor
conduct
dosimetri
studi
estim
breast
dose
femal
receiv
wli
method
wli
plan
use
standard
imrt
breast
spare
imrt
treatment
plan
perform
adac
system
use
femal
median
age
dose
breast
expans
lung
ptv
whole
heart
wh
right
ventricl
rv
left
ventricl
lv
compar
ptv
imrt
includ
entir
lung
volum
cm
margin
mediastinum
vertebra
heterogen
correct
appli
rt
dose
v
receiv
specif
rt
dose
gy
estim
compar
result
mean
breast
dose
imrt
respect
mean
dose
expans
imrt
respect
follow
mean
breast
dose
p
mean
expans
dose
p
mean
dose
coverag
lung
ptv
prescript
dose
imrt
respect
wh
lv
rv
imrt
wh
lv
rv
conclus
dosimetri
studi
demonstr
result
signific
spare
breast
tissu
femal
wt
without
compromis
improv
lung
volum
coverag
cardiac
protect
compar
may
consid
young
femal
limit
volum
lung
metastas
radiotherapi
childhood
rhabdomyosarcoma
experi
ege
univers
hospit
kamer
anacak
kantar
aksoylar
celik
n
cetingul
kansoy
radiat
oncolog
ege
univers
school
medicin
izmir
turkey
pediatr
oncolog
ege
univers
school
medicin
izmir
turkey
pediatr
surgeri
ege
univers
school
medicin
izmir
turkey
object
radiotherapi
rt
frequent
use
treatment
rm
contribut
control
plan
deliveri
rt
need
care
organ
order
obtain
maximum
control
minimum
late
effect
regard
small
age
patient
tumor
site
surround
critic
organ
need
high
radiat
dose
erad
rm
present
evalu
result
rt
children
rm
method
januari
octob
rt
use
case
rm
median
age
year
mf
ratio
histolog
subtyp
embryon
alveolar
botryoid
mixt
type
local
tumor
pelvic
case
paratesticular
head
neck
paramenengi
trunk
extrem
case
patient
treat
protocol
case
ir
use
case
rt
dose
gy
subclin
diseas
gy
macroscop
tumor
extern
rt
use
case
wherea
brachytherapi
alon
use
case
combin
extern
rt
brachytherapi
use
case
result
median
time
month
month
relaps
occur
distant
metastas
occur
patient
unfortun
patient
succumb
progress
diseas
diseas
free
surviv
rate
year
overal
surviv
rate
grade
iiiiv
late
effect
rt
detect
patient
growth
delay
bone
soft
tissu
renal
atrophi
one
azospermia
one
patient
conclus
rt
effect
treatment
modal
control
childhood
rm
care
plan
rt
extrem
import
maximum
benefit
late
effect
need
monitor
pediatr
age
group
experi
craniospin
irradi
manag
paediatr
medulloblastoma
patient
jl
lopez
guerra
p
cabrera
r
matut
j
peinado
marron
g
ramirez
jm
mj
ortiz
azinov
radiat
oncolog
hospit
virgen
del
rocio
sevilla
spain
radiat
oncolog
instituto
de
imo
madrid
spain
pediatr
oncolog
hospit
virgen
del
rocio
sevilla
spain
methodolog
andaluza
para
la
de
la
en
salud
de
sevilla
hospit
virgen
del
rocio
sevilla
spain
object
medulloblastoma
mb
common
malign
brain
tumor
childhood
craniospin
irradi
csi
central
manag
tumor
purpos
studi
assess
prognost
factor
surviv
mb
patient
treat
postop
csi
method
studi
conduct
patient
primari
mb
treat
csi
august
may
institut
inclus
criteria
includ
minimum
follow
month
patient
standard
risk
n
high
risk
n
met
criteria
median
csi
dose
fraction
gy
fraction
standard
high
risk
patient
respect
tumor
bed
receiv
gy
radiat
therapi
rt
techniqu
use
two
dimension
rt
n
three
dimension
rt
n
volumetr
modul
arc
therapi
vmat
n
tomotherapi
n
start
begin
csi
intent
patient
receiv
eight
weekli
dose
vincristin
high
risk
patient
underw
chemotherapi
rt
adjuv
chemotherapi
began
approxim
week
patient
complet
rt
result
median
age
diagnosi
year
rang
median
month
rang
overal
patient
die
two
overal
surviv
respect
relaps
two
surviv
respect
common
acut
toxic
hematolog
grade
case
univari
analysi
older
patient
year
old
associ
higher
risk
mortal
hr
p
high
risk
patient
associ
higher
risk
relaps
hr
p
conclus
older
patient
associ
higher
risk
mortal
high
risk
patient
associ
higher
risk
relaps
research
necessari
assess
better
treatment
approach
patient
order
improv
outcom
prepar
behavior
train
pediatr
patient
treat
proton
beam
therapi
mizumoto
k
ayuzawa
miyamoto
oshiro
okumura
fukushima
h
fukushima
h
ishikawa
koji
tsuboi
h
sakurai
radiat
oncolog
univers
tsukuba
tsukuba
japan
pediatr
univers
tsukuba
tsukuba
japan
object
sed
care
includ
anesthesia
often
administr
younger
children
proton
beam
therapi
pbt
howev
daili
sedat
contain
someth
problem
manpow
specialist
requir
anesthet
risk
fulli
elimin
treatment
time
becom
prolong
besid
radiotherapi
includ
pbt
associ
pain
daili
treatment
thing
patient
therefor
consid
pbt
without
anesthesia
possibl
even
pediatr
patient
commun
measur
tri
administr
treatment
train
prepar
pbt
use
anesthesia
method
april
decemb
pediatr
patient
treat
pbt
institut
patient
age
appli
prepar
train
pbt
follow
first
patient
look
treatment
room
treatment
fixat
made
whole
bodi
fixat
made
pediatr
patient
treatment
mask
prepar
necessari
treatment
plan
dosimetr
measur
patient
come
treatment
room
everi
day
simul
treatment
fixat
prepar
continu
start
pbt
result
fifteen
patient
could
success
receiv
pbt
without
sedat
median
age
patient
rang
sed
drug
administr
patient
first
becam
patient
daili
train
pbt
age
patient
rang
conclus
prepar
seem
use
perform
pbt
without
sedat
even
younger
pediatr
patient
gener
pbt
requir
longer
treatment
time
photon
radiotherapi
prepar
may
abl
appli
photon
radiotherapi
review
childhood
cancer
patient
treat
acceler
radiat
therapi
bach
mai
hospit
vietnam
juli
juli
khoa
mai
trong
p
pham
cam
nuclear
medicin
oncolog
center
bach
mai
hospit
hanoi
vietnam
object
review
clinic
epidemiolog
characterist
childhood
cancer
treat
acceler
radiat
therapi
nuclear
medicin
oncolog
center
bach
mai
hospit
vietnam
juli
juli
method
childhood
cancer
case
underw
radiat
therapi
nuclear
medicin
oncolog
center
bach
mai
hospit
vietnam
juli
juli
retrospect
studi
result
averag
age
year
old
youngest
oldest
ratio
malefemal
brain
tumor
wilm
tumor
bone
tumor
soft
tissu
sarcoma
leucemi
cn
infiltr
kind
tumor
less
common
clinic
symptom
vari
depend
cancer
type
intracrani
tumor
patient
headach
nausea
vomit
symptom
hemiplegia
cerebellar
syndrom
wilm
tumor
lumbar
pain
hematuria
abdomin
palpapbl
tumor
sarcoma
ischemia
syndrom
bone
pain
limit
movement
infect
syndrom
radiat
dose
chang
depend
natur
diseas
stage
risk
factor
radiat
side
effect
report
mainli
cours
treatment
headach
nausea
vomit
fatigu
anorexia
hair
loss
conclus
acceler
radiotherapi
combin
surgeri
chemotherapi
effect
safe
method
treatment
childhood
cancer
pediatr
patient
year
old
percentag
necrosi
influenc
decis
adjuv
radiotherapi
surgic
excis
ewe
sarcoma
puri
gulia
n
khanna
laskar
orthopaed
oncolog
tata
memori
hospit
mumbai
india
object
determin
indic
adjuv
radiotherapi
surgic
excis
ewe
sarcoma
method
consecut
patient
non
metastat
ewe
sarcoma
analys
patient
underw
appropri
surgic
resect
receiv
neoadjuv
chemotherapi
excis
specimen
analys
chemotherapi
induc
percentag
necrosi
divid
necrosi
post
oper
adjuv
radiotherapi
decid
case
case
basi
irrespect
percentag
necrosi
result
one
patient
involv
margin
necrosi
avail
patient
necrosi
patient
receiv
radiotherapi
patient
avail
follow
os
patient
year
current
patient
aliv
follow
rang
month
median
month
differ
os
patient
receiv
radiotherapi
p
case
necrosi
os
patient
receiv
radiotherapi
p
case
necrosi
os
patient
receiv
radiotherapi
p
conclus
data
suggest
decis
offer
adjuv
radiotherapi
surgic
excis
ewe
sarcoma
multifactori
independ
percentag
necrosi
chemotherapi
bevacizumab
treatment
necrosi
rin
pediatr
case
report
morici
c
riccheri
veron
pampin
muggeri
b
diez
pediatr
hospit
nacion
prof
posada
bueno
air
argentina
neurosurgeri
hospit
nacion
prof
posada
bueno
air
argentina
neurooncogi
fleni
bueno
air
argentina
background
rin
seriou
complic
radiat
treatment
brain
tumor
damag
result
local
cytokin
releas
increas
capillari
permeabl
extracellular
edema
loss
myelin
cover
neuron
allow
progress
radiat
necrosi
lead
small
vessel
occlus
diseas
bleed
friabl
small
vessel
chang
combin
caus
defin
worsen
patient
neurolog
sign
symptom
steroid
standard
care
treatment
brain
rin
despit
limit
efficaci
bevacizumab
use
adult
strategi
treat
cerebr
rin
purpos
describ
use
bevacizumab
child
complic
materi
method
old
male
present
histori
progress
increas
headach
vomit
left
faciobrachiocrur
paralysi
magnet
reson
imag
mri
show
supratentori
right
temporopariet
lesion
follow
complet
resect
tumor
histopatholog
examin
reveal
anaplast
ependymoma
receiv
convent
radiotherapi
cgi
cgi
fraction
month
radiat
therapi
patient
report
sever
neurocognit
impair
problem
urinari
incontin
mri
reveal
imag
suspect
rin
confirm
stereotact
biopsi
non
effect
steroid
treatment
bevacizumab
administ
cycl
mgkg
interv
result
child
show
clinic
neurolog
improv
mri
reveal
import
reduct
sequenc
analysi
conclus
bevacizumab
efficaci
treatment
cn
rin
adult
justifi
consider
treatment
option
children
suffer
rin
secondari
treatment
brain
tumor
daili
pediatr
radiotherapi
patient
reduc
risk
secondari
cancer
k
seiersen
j
hansen
depart
medic
physic
aarhu
univers
hospit
c
denmark
object
radiotherapi
igrt
allow
accur
setup
patient
treatment
case
daili
igrt
make
reduct
possibl
howev
daili
imag
also
add
integr
dose
deliv
patient
pediatr
case
mani
center
limit
igrt
due
risk
secondari
cancer
studi
demonstr
daili
combin
reduc
total
dose
patient
method
thorough
analysi
uncertainti
local
radiotherapi
process
shown
low
mm
use
small
cerebr
target
daili
appli
old
male
ependymoma
patient
plan
treat
gy
fraction
mm
second
plan
prepar
use
standard
mm
care
taken
obtain
similar
target
coverag
conform
index
increas
integr
dose
mm
margin
determin
compar
dose
result
use
tabul
data
vendor
publish
effect
dose
factor
children
find
one
deliv
effect
dose
msv
equal
msv
ad
dose
compar
two
dose
plan
plan
give
extra
effect
dose
msv
compar
margin
reduct
thu
reduc
effect
dose
time
entir
add
conclus
case
demonstr
treat
standard
radiotherapi
margin
without
daili
igrt
result
higher
total
effect
dose
thu
risk
secondari
cancer
reduc
margin
use
combin
daili
igrt
fraction
full
dose
radiotherapi
remain
standard
treatment
metastat
site
rhabdomyosarcoma
skamen
mitchel
abish
cr
freeman
radiat
oncolog
mcgill
univers
health
centr
montreal
canada
pediatr
hematolog
oncolog
mcgill
univers
health
centr
montreal
canada
object
current
standard
care
patient
metastat
rhabdomyosarcoma
includ
full
dose
radiotherapi
metastat
site
wish
question
practic
caus
often
logist
challeng
studi
pattern
failur
pediatr
teenag
patient
popul
method
mcgill
univers
health
centr
cancer
registri
queri
patient
diagnos
rhabdomyosaroma
age
less
januari
januari
patient
found
six
metastat
diseas
five
six
treat
standard
chemotherapi
togeth
radiotherapi
primari
metastat
site
dose
fraction
accord
site
gy
gy
fraction
gy
gy
fraction
whole
lung
radiotherapi
time
progress
calcul
end
radiotherapi
radiolog
patholog
evid
diseas
progress
result
median
age
five
patient
year
rang
three
femal
alveolar
histolog
unfavor
primari
site
median
number
metastat
site
treat
rang
three
patient
develop
progress
diseas
outsid
treat
field
one
patient
die
complic
without
evid
diseas
progress
median
time
progress
month
rang
one
five
patient
remain
month
post
radiotherapi
conclus
radiotherapi
metastat
diseas
site
prevent
progress
five
patient
metastat
alveolar
rhabdomyosarcoma
howev
failur
site
outsid
radiotherapi
volum
occur
patient
overal
surviv
poor
despit
aggress
treatment
site
diseas
radiotherapi
clearli
import
role
manag
patient
metastat
diseas
futur
studi
address
radiotherapi
dose
fraction
context
need
better
system
control
patient
popul
reduc
dose
pancrea
pediatr
abdomin
irradi
helic
tomotherapi
start
e
jouglar
g
delpon
l
campion
supiot
radiat
oncolog
institut
de
de
louest
herblain
franc
medic
physic
institut
de
de
louest
herblain
franc
object
children
irradi
pancrea
tail
shown
increas
likelihood
secondari
diabet
mellitu
compar
conform
radiotherapi
crt
helic
tomotherapi
ht
spare
pancrea
children
abdomin
irradi
method
select
children
abdomin
tumor
treat
institut
receiv
abdomen
treatment
plan
calcul
use
crt
xio
elekta
ht
tomotherapi
treatment
plan
system
order
reduc
dose
pancrea
low
possibl
maintain
ptv
coverag
organ
risk
oar
dosimetr
valu
compar
use
wilcoxon
test
result
consid
signific
level
result
dose
distribut
clinic
case
median
age
year
rang
calcul
differ
dose
ptv
medulloblastoma
nephroblastoma
tumor
boost
lymphnod
midlin
neuroblastoma
hodgkin
lymphoma
lymphnod
spleen
use
crt
ht
similar
target
coverag
obtain
dose
oar
similar
better
ht
ht
significantli
reduc
mean
dose
whole
pancrea
wp
pancreat
tail
pt
gener
wp
sd
crt
vs
sd
p
mean
dose
pt
reduc
patient
differ
rang
accord
tumor
locat
reach
signific
midlin
tumor
left
case
conclus
use
helic
tomotherapi
possibl
reduc
dose
pancrea
tail
maintain
good
ptv
coverag
oar
spare
children
abdomin
irradi
compar
studi
dose
distribut
proton
beam
therapi
conform
radiotherapi
radiotherapi
pediatr
brain
tumor
takizawa
mizumoto
yamamoto
muroi
fukushima
h
ishikawa
k
tsuboi
okumura
h
sakurai
radiat
oncolog
faculti
medicin
univers
tsukuba
tsukuba
japan
neurosurgeri
faculti
medicin
univers
tsukuba
tsukuba
japan
child
health
faculti
medicin
univers
tsukuba
tsukuba
japan
radiat
oncolog
faculti
medicin
univers
tsukuba
tsukuba
japan
object
purpos
studi
evalu
effect
proton
beam
therapi
pbt
pediatr
brain
tumor
compar
conform
radiotherapi
radiotherapi
imrt
method
pediatr
patient
brain
tumor
treat
pbt
institut
evalu
seven
patient
ependymoma
germinoma
local
irradi
whole
ventricl
irradi
perform
ependymoma
germinoma
respect
imrt
treatment
plan
gener
optim
use
practic
treatment
plan
ct
pbt
compar
dose
distribut
pbt
plan
target
volum
ptv
ident
among
pbt
imrt
patient
cover
line
plan
histogram
dvh
normal
brain
calcul
compar
result
local
irradi
case
pbt
could
reduc
median
normal
brain
dose
compar
median
compar
imrt
whole
ventricl
radiat
case
pbt
could
reduc
median
normal
brain
dose
compar
median
compar
imrt
conclus
pbt
could
reduc
dose
normal
brain
compar
imrt
proton
beam
irradi
childhood
first
experi
west
german
proton
therapi
centr
essen
wpe
b
timmermann
steffen
geismar
clinic
particl
therapi
west
german
proton
therapi
centr
essen
univers
hospit
essen
essen
germani
west
german
proton
therapi
centr
essen
univers
hospit
essen
essen
germani
object
proton
beam
therapi
pt
increas
interest
pediatr
oncolog
west
german
proton
therapi
centr
essen
wpe
start
treatment
may
septemb
registri
start
collect
prospect
data
children
year
pt
method
june
march
data
children
sixteen
male
femal
age
year
median
year
collect
diagnos
cn
n
sarcomat
tumor
n
respect
tumor
site
brainhead
neck
n
spine
n
pelvi
n
children
parallel
chemotherapi
appli
karnofski
perform
statu
ki
patient
first
present
total
pt
dose
rang
gy
median
gy
classifi
accord
common
terminolog
criteria
advers
event
ctcae
grade
system
result
median
fu
month
rang
month
major
children
grade
observ
erythema
fatigu
pain
nausea
fever
headach
patient
grade
pain
fever
observ
patient
present
grade
oral
mucos
end
pt
ki
score
children
late
evalu
patient
fu
day
one
present
grade
kerat
otherwis
mild
late
document
fatigu
focal
alopecia
skin
reaction
last
fu
patient
present
ki
patient
conclus
current
prospect
standard
data
wpe
registri
suggest
excel
feasibl
moder
earli
intens
local
pt
major
children
howev
longer
fu
time
larger
patient
cohort
need
defin
potenti
role
pt
pediatr
oncolog
earli
experi
advisori
centr
particl
therapi
pediatr
oncolog
germani
b
timmermann
frisch
steffen
geismar
clinic
particl
therapi
west
german
proton
therapi
centr
essen
univers
hospit
essen
essen
germani
west
german
proton
therapi
centr
essen
univers
hospit
essen
essen
germani
object
particl
therapi
pt
increas
interest
model
individu
oncolog
treatment
concept
childhood
number
particl
facil
continu
increas
worldwid
still
technic
equip
clinic
indic
treat
pt
diverg
wide
expert
field
rare
therefor
advis
pt
increas
demand
method
advisori
centr
pt
pediatr
oncolog
offer
support
refer
centr
treat
facil
affect
famili
support
provid
close
collabor
respect
radiat
refer
centr
multidisciplinari
trial
german
societi
pediatr
oncolog
hematolog
gpoh
ensur
adequ
treatment
modal
accord
studi
protocol
advis
given
defin
appropri
indic
implement
pt
new
protocol
push
financi
coverag
insur
pt
consid
interdisciplinari
treatment
protocol
result
januari
decemb
children
adolesc
year
male
femal
present
advisori
board
age
rang
year
diagnos
brain
tumor
sarcoma
miscellan
advic
request
radiat
refer
centr
hospit
patient
famili
member
pt
centr
institut
major
inquiri
pt
recommend
first
choic
howev
due
limit
avail
extern
photon
radiotherapi
propos
altern
exclus
treatment
option
propos
conclus
number
inquiri
show
high
demand
advisori
servic
concern
pt
effort
made
establish
pt
multidisciplinari
protocol
ensur
evalu
homogen
approach
pt
futur
advis
activ
continu
data
evalu
studi
group
accompani
pt
expert
refer
centr
support
german
children
cancer
foundat
clinic
result
proton
therapi
pediatr
oncolog
systemat
review
literatur
vennarini
l
vinant
b
rombi
amichetti
depart
proton
therapi
apss
trento
trento
itali
object
systemat
review
clinic
result
proton
therapi
pt
pediatr
oncolog
report
literatur
method
two
radiat
oncologist
search
independ
pubm
databas
articl
regard
pt
pediatr
oncolog
publish
key
word
use
combin
boolean
oper
andor
proton
therapi
pediatr
cancer
ependymoma
medulloblastoma
pnet
craniopharingioma
glioma
rhabdomyosarcoma
pediatr
sarcoma
ewe
sarcoma
germ
cell
tumor
osteosarcoma
atrt
retinoblastoma
neuroblastoma
hodgkin
lymphoma
articl
report
local
control
lc
overal
surviv
os
late
toxic
seri
patient
select
review
editori
congress
abstract
paper
english
languag
exclud
process
critic
review
two
research
result
fourteen
select
articl
consist
select
criteria
median
limit
month
four
articl
concern
chordoma
chondrosarcoma
two
soft
tissu
sarcoma
lc
os
one
ewe
sarcoma
one
medulloblastomapnet
one
ependymoma
one
craniopharingioma
lc
os
one
glioma
lc
os
one
atrt
lc
os
one
germ
cell
tumor
lc
os
one
neuroblastoma
late
toxic
usual
grade
intracrani
skull
base
malign
report
toxic
ototox
bone
asymmetri
major
event
brain
necrosi
cerebrovascular
problem
rare
cognit
function
remain
stabl
comparison
baselin
peripher
tumor
dermat
vertebr
asymmetri
frequent
side
effect
observ
conclus
evid
pt
efficaci
pediatr
oncolog
limit
clinic
result
report
confirm
pt
achiev
similar
lc
rate
histor
photon
cohort
late
toxic
appear
reduc
evid
consist
result
dosimetr
studi
suggest
potenti
clinic
advantag
techniqu
hemophagocyt
lymphohistiocytosi
children
tertiari
care
center
experi
india
agarw
n
radhakrishnan
thakkar
v
dinand
gupta
v
chinnabhandar
sachdeva
pediatr
hematooncolog
sir
ganga
ram
hospit
delhi
india
object
hemophagocyt
lymphohistiocytosi
hlh
although
rare
increasingli
diagnos
nowaday
discuss
clinic
profil
treatment
patient
diagnos
hlh
center
year
method
retrospect
analyz
patient
diagnos
hlh
base
hlh
criteria
januari
decemb
search
secondari
caus
perform
patient
patient
signific
famili
histori
evalu
famili
hlh
result
total
case
diagnos
male
femal
ratio
median
age
year
children
parent
consanguin
previou
sibl
death
present
featur
includ
fever
hepatosplenomegali
bleed
manifest
lymphadenopathi
skin
rash
shock
jaundic
cn
manifest
renal
failur
liver
failur
arthriti
pancytopenia
laboratori
paramet
includ
hemophagocytosi
bone
marrow
hyperferritinemia
hypertriglyceridemia
hypofibrinogenemia
secondari
caus
identifi
patient
infecti
caus
includ
ebv
typhoid
malaria
tuberculosi
juvenil
rheumatoid
arthriti
pseudomona
fungal
cmv
malign
caus
includ
hodgkin
lymphoma
anaplast
larg
cell
lymphoma
mutat
analysi
posit
children
evalu
children
perforin
griscelli
syndrom
week
old
child
heterozyg
munk
howev
sequenc
mutat
could
done
treatment
given
accord
hlh
protocol
receiv
steroid
receiv
cyclosporin
underw
stem
cell
transplant
umbil
cord
blood
match
sibl
bone
marrow
surviv
patient
succumb
secondari
complic
overal
patient
expir
surviv
lost
follow
rest
undergo
treatment
conclus
diagnosi
hlh
consid
patient
present
fever
hepatosplenomegali
pancytopenia
despit
earli
aggress
treatment
encount
mortal
patient
langerhan
cell
histiocytosi
singl
center
experi
k
mutafoglu
inc
e
buke
kizmazoglu
f
yenigurbuz
e
ozer
h
guleryuz
demir
olgun
n
olgun
dept
pediatr
oncolog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
dept
pediatr
oncolog
dokuz
eylul
univers
insitut
oncolog
izmir
turkey
dept
patholog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
dept
radiodiagnost
dokuz
eylul
univers
faculti
medicin
izmir
turkey
dept
radiat
oncolog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
dept
pediatr
surgeri
dokuz
eylul
univers
faculti
medicin
izmir
turkey
object
evalu
patient
langerhan
cell
histiocytosi
lch
diagnos
treat
center
method
medic
record
patient
lch
rewiev
clinic
characterist
treatment
detail
respons
analyz
retrospect
result
patient
lch
median
age
diagnosi
mf
ratio
complaint
mass
backlimb
pain
rash
atax
walk
lymphadenopathi
singl
system
involv
lch
involv
site
bone
skin
lymph
node
lung
surgeri
perform
chemotherapi
consist
vinblastin
prednisolon
methotrex
mercaptopurin
given
radiotherapi
rt
given
case
primari
relaps
occur
treat
rt
primari
relaps
occur
cr
achiev
cisplatin
interferon
vinblastin
median
time
week
os
rate
ef
rate
respect
multisystem
involv
lch
involv
site
bone
skin
lung
pituitari
gland
four
patient
lung
involv
riski
organ
ro
surgeri
perform
two
chemotherapi
consist
vinblastin
prednisolon
methotrex
mercaptopurin
given
rt
given
two
patient
refractori
diseas
primari
relaps
occur
three
patient
three
case
treat
cisplatin
interferon
vinblastin
prednisolon
cr
achiev
two
median
time
year
os
rate
ef
rate
conclus
group
age
tend
younger
group
patient
particularli
ro
involv
patient
need
intens
therapi
cisplatin
contain
chemotherapi
effect
treatment
option
relapserefractori
lch
patient
children
genet
mutat
adrenocort
tumor
western
cmcm
fiori
rosa
lf
feracini
hospit
cancer
uopeccan
cascavel
state
univers
west
unioest
cascavel
brazil
introduct
adrenocort
tumor
act
rel
rare
tumor
account
malign
despit
rariti
south
southeast
region
brazil
incid
act
time
higher
worldwid
approxim
incid
consid
endem
problem
southern
brazil
mainli
children
year
old
studi
conduct
dr
bonald
figueredo
genom
screen
newborn
possibl
identifi
genet
mutat
gene
newborn
sinc
risk
develop
tumor
patient
mutat
around
shown
penetr
studi
conduct
author
case
act
object
healthi
children
carri
germlin
mutat
act
refer
earli
center
children
oncolog
suspect
case
method
perform
children
studi
pequeno
research
institut
collect
blood
sampl
heel
prick
dna
specif
act
posit
result
genet
mutat
sinc
monitor
conduct
outpati
clinic
pediatr
univers
hospit
west
cascavel
result
children
femal
male
three
develop
tca
clinic
manifest
initi
hormon
level
compat
tumor
develop
conclus
clinic
healthi
children
genet
mutat
act
order
proceed
investig
earli
possibl
suspect
tumor
manifest
benefit
eventu
tumor
develop
increas
chanc
cure
function
inhibit
adrenocort
tumor
cell
promot
cellular
death
chang
gene
express
pathway
compon
ca
scride
rcp
lira
lf
leal
pf
fedatto
ce
martinelli
jr
castro
tucci
jr
l
neder
lnz
ramalho
ml
seiding
cardin
mj
mastellaro
ja
yune
sr
brandalis
lg
tone
srr
antonini
ca
scride
pediatr
preto
school
medicin
univers
paulo
preto
brazil
intern
medicin
preto
school
medicin
univers
paulo
preto
brazil
surgeri
preto
school
medicin
univers
paulo
preto
brazil
patholog
preto
school
medicin
univers
paulo
preto
brazil
pediatr
centro
infantil
boldrinist
univers
campina
campina
brazil
pediatr
preto
school
medicin
univers
paulo
preto
brazil
object
preview
analysi
pediatr
adrenocort
tumor
act
observ
signific
associ
high
level
tumor
relaps
metastasi
especi
weiss
score
interestingli
express
present
correl
import
gene
pathway
could
suggest
interact
pathway
aim
studi
evalu
function
adrenocort
carcinoma
cell
line
method
cell
treat
specif
inhibitor
perform
cell
prolifer
apoptosi
assay
addit
investig
gene
express
compon
igf
apc
pathway
treatment
quantit
result
treatment
significantli
decreas
cell
prolifer
concentr
nm
p
hour
reach
reduct
valu
nm
hour
nm
hour
apoptosi
rate
increas
manner
reach
dead
cell
nm
p
ic
addit
reduc
gene
express
p
p
p
respect
increas
p
hour
hour
observ
signific
low
level
p
p
conclus
treatment
adrenocort
carcinoma
cell
reduc
cell
prolifer
increas
apoptosi
rate
manner
suggest
potenti
therapeut
target
accord
correl
observ
pediatr
act
inhibit
function
induc
gene
express
chang
compon
suggest
associ
pathway
mening
sarcoma
children
survey
french
societi
pediatr
oncolog
sfce
l
mansuy
jc
gentet
frappaz
c
piguet
j
grill
e
schmitt
p
chastagn
pediatr
oncolog
children
univers
hospit
vandoeuvr
franc
pediatr
oncolog
children
univers
hospit
marseil
franc
pediatr
oncolog
institut
hop
lyon
franc
children
univers
hospit
children
univers
hospit
franc
pediatr
oncolog
children
univers
hospit
reim
franc
pediatr
oncolog
institut
g
roussi
villejuif
franc
neuroradiolog
nanci
univers
hospit
nanci
franc
object
describ
outcom
popul
mening
sarcoma
children
sfce
method
retrospect
studi
patient
harbor
mening
sarcoma
ms
base
french
registri
pediatr
tumor
pediatr
oncologist
questionnair
patient
characterist
treatment
collect
patholog
imag
central
review
result
pt
french
center
year
age
mean
treat
ms
mean
year
year
tumor
locat
frontal
pariet
tempor
occipit
thalam
pontocerebellar
angl
cerebellar
tentorium
cistern
ambient
metastas
observ
first
treatment
surgeri
case
chemotherapi
resect
total
case
partial
patholog
central
review
conclud
undifferenci
sarcoma
chondrosarcoma
fibrosarcoma
myxoid
desmoplast
tumor
patient
receiv
cours
chemotherapi
median
number
patient
aliv
equal
whatev
age
year
tumor
size
cm
pt
receiv
radiotherapi
aliv
versu
without
radiotherapi
ef
os
median
ef
case
total
resect
month
versu
case
partial
resect
conclus
short
seri
rare
cancer
age
tumor
size
seem
prognost
factor
total
resect
radiotherapi
seem
essenti
role
chemotherapi
unclear
inflammatori
myofibroblast
tumour
paediatr
solid
tumour
mir
gull
bhat
aejaz
shiekh
rashid
lone
medic
paediatr
oncolog
institut
medic
scienc
skim
srinagarjammu
kashmirindia
srinagar
india
object
inflammatori
myofibroblast
tumor
imt
rare
benign
lesion
often
seen
lung
young
adult
occur
children
variou
site
mimic
clinic
radiolog
malign
sarcoma
lymphoma
aim
review
clinic
radiolog
patholog
data
children
diagnosi
imt
reffer
depart
method
retrospect
studi
carri
depart
medic
paediatr
oncolog
region
cancer
centr
institut
medic
scienc
skim
srinagar
jammu
kashmir
india
januari
decemb
result
among
paediatr
solid
tumour
regist
studi
period
diagnosi
inflammatori
myofibroblast
tumour
male
femal
children
f
ratio
mean
age
year
rang
year
main
symptom
abdomin
distens
pain
case
breathless
cough
case
right
axillari
area
swell
case
comput
tomographi
chest
patient
mediastin
widen
impress
lymphoma
two
patient
label
retroperiton
sarcoma
patient
ileal
growth
impress
burkitt
lymphoma
one
patient
right
axillari
swell
lymphoma
suspect
patient
complet
surgic
excis
done
axillari
mass
abdomin
diseas
one
patient
retropritonel
mass
residu
diseas
receiv
chemotherapi
follow
complet
second
surgeri
case
mediastin
imt
surgeri
follow
local
radiotherapi
patient
initi
histopatholog
diagnos
imt
retroperiton
lesion
otherwis
review
immunohistochemitri
oncopathologist
diagnosi
inflammatori
myofibroblast
tumour
made
present
patient
diseas
free
patient
mediastin
imt
residu
progress
diseas
conclus
present
imt
constitut
formid
challeng
diagnosi
treatment
medic
treatment
capillari
hemangioma
young
children
e
unal
cabi
g
yavuz
n
tacyildiz
h
dincaslan
z
gordu
g
tanyildiz
fitoz
k
gundaz
pediatr
ankara
faculti
medicin
ankara
turkey
object
hemangioma
common
congenit
lesion
infant
children
benign
tumor
aris
island
angioblast
tissu
fail
connect
develop
vascular
system
capillari
hemangioma
young
children
difficult
treat
treatment
capillari
hemangioma
need
cosmet
medic
reason
includ
macer
eros
epidermi
infect
risk
occlus
amblyopia
locat
periocular
site
method
april
patient
whose
age
rang
day
year
capillari
hemangioma
follow
femal
male
f
result
among
patient
multipl
cutan
lesion
base
imag
studi
cranial
abdomin
site
detect
viscer
hemangioma
hemangioma
locat
head
neck
case
follow
trunk
upper
extrem
lower
extrem
perineum
respect
medic
manag
hemangioma
includ
observ
corticosteroid
system
beta
blocker
local
beta
blocker
interferon
alpha
sirolimu
respect
conclus
system
steroid
toler
well
treatment
interferon
alpha
expens
use
vision
threaten
hemangioma
resist
steroid
treatment
system
propranolol
effect
reduct
occur
radiograph
amblyogen
astigmast
treatment
potenti
complic
particularli
cardiac
patient
need
monitor
close
sirolimu
effect
sizabl
hemangioma
resist
steroid
system
propranolol
highli
recommend
patient
monitor
care
gastrointestin
cancer
children
adolesc
singl
institut
experi
daniluk
filipek
perek
b
brozyna
rutynowska
pediatr
oncolog
depart
children
memori
helath
institut
warsaw
poland
object
describ
type
clinic
cours
gastrointestin
cancer
children
adolesc
treat
institut
method
retrospect
analysi
medic
record
patient
gastrointestin
carcinoma
treat
perform
gender
age
tumor
type
stage
treatment
result
analyz
result
patient
treat
diagnos
gastrointestin
tumor
male
femal
age
yr
median
yr
distribut
tumor
follow
colorect
pt
pancrea
stomach
two
patient
fap
patient
ulcer
coliti
develop
colorect
carcinoma
patient
present
advanc
diseas
diagnosi
stage
iii
stage
iv
patient
underw
primari
surgeri
follow
adjuv
chemotherapi
adult
chemotherapi
regimen
specif
diseas
type
use
first
line
treatment
progressionrelaps
chemotherapi
modifi
individu
radiotherapi
implement
patient
target
therapi
patient
aliv
diseas
free
month
median
month
six
patient
die
diseas
time
death
rang
month
median
month
conclus
insidi
onset
advanc
stage
present
hallmark
digest
system
carcinoma
childhood
adolesc
earli
diagnosi
crucial
role
individu
risk
base
carcinoma
associ
condit
close
monitor
manag
follow
urotheli
neoplasm
bladder
children
report
trep
project
di
carlo
ferrari
g
cecchetto
k
perruccio
p
dangelo
ruggiero
r
alaggio
g
bisogno
depart
paediatr
univers
padua
padova
itali
paediatr
oncolog
unit
fondazion
ircc
istituto
nazional
tumori
milano
itali
divis
paediatr
surgeri
univers
padua
padova
itali
paediatr
oncolog
hematolog
section
santa
maria
della
misericordia
hospit
perugia
itali
paediatr
hematolog
oncolog
g
di
cristina
children
hospit
palermo
itali
paediatr
oncolog
unit
gemelli
hospit
roma
itali
institut
patholog
univers
padua
padova
itali
object
urotheli
neoplasm
bladder
unb
rare
found
paediatr
patient
part
trep
tumori
rari
pediatrica
project
italian
network
dedic
rare
tumour
present
nationwid
seri
patient
unb
aim
establish
treatment
follow
guidelin
method
patient
age
rang
year
unb
regist
accord
ptnm
system
tumour
classifi
pta
evid
subepitheli
invas
muscl
invas
invas
perives
tissu
invas
extravesc
organ
accord
grade
system
distinguish
papillari
urotheli
neoplasm
low
malign
potenti
grade
low
urotheli
carcinoma
grade
high
urotheli
carcinoma
grade
result
nine
case
ultrasound
show
area
polypoid
lesion
attach
intern
wall
bladder
maximum
diamet
cm
lesion
classifi
pta
consid
lesion
complet
resect
transurethr
resect
tur
children
singl
dose
intraves
chemotherapi
administ
one
child
recurr
one
year
diagnosi
treat
new
tur
intraves
mytomicin
patient
complet
remiss
median
fu
month
follow
perform
differ
patient
mostli
base
ultrasound
cystoscopi
month
year
interv
cytolog
conclus
show
absenc
defin
guidelin
manag
children
unb
heterogen
may
includ
unnecessari
potenti
toxic
treatment
consider
good
prognosi
follow
intens
number
cystoscopi
may
reduc
primari
pulmonari
tumor
children
year
experi
singl
center
cepelova
j
mali
b
frybova
rygl
v
mixa
kodetova
kyncl
j
stari
j
snajdauf
dpt
paediatr
haematolog
oncolog
faculti
medicin
charl
univers
univers
hospit
motol
pragu
czech
republ
dpt
paediatr
surgeri
faculti
medicin
charl
univers
univers
hospit
motol
pragu
czech
republ
dpt
anaesthesiolog
icm
faculti
medicin
charl
univers
univers
hospit
motol
pragu
czech
republ
dpt
patholog
molecular
medicin
faculti
medicin
charl
univers
univers
hospit
motol
pragu
czech
republ
dpt
radiolog
faculti
medicin
charl
univers
univers
hospit
motol
pragu
czech
republ
object
primari
pulmonari
tumor
children
rare
individu
singl
center
experi
therefor
limit
aim
studi
evalu
patient
primari
pulmonari
tumor
institut
period
year
method
treat
children
primari
pulmonari
tumor
retrospect
review
medic
record
histolog
materi
patient
result
patient
femal
male
treat
primari
pulmonari
tumor
median
age
time
diagnosi
year
rang
day
year
present
symptom
pneumonia
cough
fever
wheez
dyspnea
back
pain
due
bone
metastasi
failur
thrive
ct
scan
perform
patient
surgic
procedur
pneumonectomi
three
case
lobectomi
patient
segment
resect
four
biopsi
two
patient
nine
histolog
type
tumor
observ
twelv
benign
seven
inflammatori
myofibroblast
tumor
imt
two
hamartoma
one
invas
fibroblast
tracheobronchi
tumor
iftbt
one
cystic
histiocytoma
one
tumor
eight
neuroendocrin
tumor
typic
carcinoid
net
seven
malign
four
pleuropulmonari
blastoma
one
rhabdomyosarcoma
two
mucoepidermoid
carcinoma
patient
malign
tumor
receiv
combin
chemotherapi
median
year
rang
month
year
patient
aliv
without
sign
diseas
three
patient
die
one
patient
pleuropulmonari
blastoma
patient
initi
metastat
diseas
mukoepidermoid
carcinoma
carcinoid
conclus
primari
pulmonari
tumor
rare
histopatholog
heterogen
estim
incid
czech
republ
live
birth
prognosi
benign
tumor
complet
surgic
resect
excel
wherea
malign
tumor
still
associ
signific
mortal
univers
hospit
motol
particip
support
project
conceptu
develop
research
organ
mucoepidermoid
carcinoma
children
singl
instituit
experi
p
techavichit
j
hick
sarabia
h
saye
j
nuchtern
j
muscal
mf
okcu
chintagumpala
texa
children
cancer
hematolog
center
texa
children
hospit
houston
usa
patholog
texa
children
hospit
houston
usa
surgeri
texa
children
hospit
houston
usa
object
determin
clinicopatholog
featur
outcom
children
mucoepidermoid
carcinoma
method
retrospect
clinic
histopatholog
molecular
find
review
patient
mucoepidermoid
carcinoma
texa
children
cancer
center
result
femal
male
mean
age
year
rang
year
tumor
locat
submandibular
gland
case
parotid
gland
case
soft
hard
palat
case
tracheobronchi
case
patient
salivari
gland
palat
tumor
present
asymptomat
fluctuant
mass
patient
tracheobronchi
mass
present
persist
lower
respiratori
tract
infect
median
durat
symptom
four
month
among
eleven
patient
salivari
gland
palat
tumor
initi
tumor
biopsi
perform
six
case
five
patient
gross
total
remov
attempt
eight
eleven
patient
requir
addit
surgic
extirp
three
patient
requir
postop
radiat
therapi
posit
margin
case
mandibl
bone
marrow
involv
case
three
patient
tracheobronchi
tumor
underw
bronchoscopi
tissu
biopsi
prior
total
tumor
remov
pulmonari
lobectomi
histolog
grade
low
intermedi
high
nine
ten
inform
case
posit
fusion
transcript
death
metastasi
recurr
seri
mean
month
patient
treat
chemotherapi
conclus
children
adolesc
mec
femal
predilect
low
intermedi
histolog
grade
common
adult
complet
excis
treatment
choic
excel
outcom
role
radiotherapi
unclear
mayb
consid
patient
posit
surgic
margin
incomplet
resect
thymic
carcinoma
children
report
european
cooper
studi
group
pediatr
rare
tumor
expert
orbach
g
cecchetto
brecht
schneider
e
bien
synakiewicz
r
julien
ferrari
g
bisogno
depart
pediatr
hematolog
oncolog
medic
univers
gdansk
gdansk
poland
depart
pediatr
insitut
curi
pari
franc
pediatr
surgeri
unit
depart
woman
child
health
padova
univers
hospit
padova
itali
depart
pediatr
oncolog
univers
children
hospit
erlangen
germani
clinic
pediatr
municip
hospit
dortmund
germani
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
tumori
milano
itali
divis
depart
pediatr
univers
hospit
padova
padova
itali
object
thymic
carcinoma
belong
group
rare
thymic
epitheli
tumor
aris
anterior
mediastinum
constitut
malign
adult
tumor
extrem
rare
children
therapeut
guidelin
establish
method
clinic
data
therapeut
characterist
pediatr
patient
malign
thymic
tumor
treat
regist
expert
databas
cooper
nation
rare
pediatr
tumor
work
group
franc
itali
germani
unit
kingdom
poland
result
twenti
patient
thymic
carcinoma
median
age
year
enrol
studi
patient
year
old
four
children
present
autoimmun
paraneoplast
symptom
associ
tumor
presenc
myasthenia
gravi
polymyos
nephrit
syndrom
system
lupu
erythematosu
associ
hypertroph
pulmonari
osteoarthropathi
complet
primari
resect
perform
one
patient
resect
microscop
residu
made
case
incomplet
resect
macroscop
four
patient
chemotherapi
variou
regimen
administ
children
neoadjuv
chemotherapi
eight
receiv
addit
radiotherapi
fifteen
children
die
overal
surviv
patient
thymic
carcinoma
conclus
studi
confirm
poor
prognosi
pediatr
patient
thymic
carcinoma
independ
therapeut
manag
multidisciplinari
multicent
approach
necessari
order
make
common
assess
breast
mass
children
adolesc
yesil
karaman
c
bozkurt
hg
tanyildiz
mo
candir
toprak
karaman
g
sahin
pediatr
oncolog
dr
sami
ulu
pediatr
research
train
hospit
ankara
turkey
pediatr
surgeri
dr
sami
ulu
pediatr
research
train
hospit
ankara
turkey
object
overwhelm
major
breast
mass
children
adolesc
benign
varieti
etiolog
knowledg
clinic
sonograph
featur
allow
clinician
guid
appropri
manag
patient
paper
evalu
breast
mass
children
adolesc
method
children
less
year
diagnos
breast
mass
admit
center
march
march
analyz
age
gender
complaint
histori
malign
sonograph
patholog
find
diagnosi
retrospect
result
patient
femal
male
admit
breast
mass
within
last
two
year
mean
age
year
rang
eleven
patient
pain
patient
nippl
discharg
patient
bloodi
nippl
discharg
two
patient
famili
histori
breast
cancer
ultrasonographi
appli
patient
accord
breast
imag
report
data
system
classif
patient
categori
patient
categori
mass
four
patient
oper
mass
excis
two
patient
remain
two
patient
categori
furthermor
three
oper
patient
mass
cm
histopatholog
diagnosi
patient
juvenil
fibroadenoma
patholog
diagnosi
fourth
patient
malign
histori
pseudoangiomat
stromal
hyperplasia
patient
diagnosi
accord
clinic
sonograph
featur
fibroadenoma
patient
gynecomastia
patient
breast
abscess
patient
prematur
thelarch
patient
mammari
duct
ectasia
patient
accessori
breast
fibrocyst
chang
patient
adenosi
patient
patient
follow
ultrasound
none
develop
malignaci
conclus
preval
breast
cancer
pediatr
age
group
extrem
low
conserv
approach
clinic
sonograph
commonli
adopt
children
approach
identifi
gene
target
pancreatoblastoma
isob
seki
k
yoshida
shiraishi
k
chiba
h
tanaka
sato
kato
hama
tanaka
miyano
hayashi
ogawa
oka
j
takita
depart
pediatr
univers
tokyo
japan
depart
patholog
tumor
biolog
graduat
school
medicin
kyoto
univers
kyoto
japan
laboratori
dna
inform
analysi
human
genom
center
institut
medic
scienc
univers
tokyo
japan
depart
pediatr
nagoya
univers
graduat
school
medicin
nagoya
japan
divis
diagnost
patholog
kanagawa
children
medic
center
yokohama
japan
hematologyoncolog
gunma
children
medic
center
shibukawa
japan
object
pancreatoblastoma
pbl
unusu
malign
neoplasm
pediatr
pancrea
may
also
rare
affect
adult
somat
alter
pathway
includ
inactiv
mutat
apc
activ
mutat
loss
chromosom
alreadi
report
major
pbl
howev
mainli
due
rariti
littl
known
addit
genet
chang
respons
pathogenesi
pbl
explor
genet
alter
underli
pathogenesi
pbl
perform
whole
transcriptom
exom
analys
case
pbl
addit
case
pbl
use
valid
cohort
method
total
rna
dna
extract
fresh
frozen
tumor
pbl
patient
accord
manufactur
protocol
mrna
exon
captur
whole
transcriptomeexom
analys
use
illumina
hiseq
perform
dna
match
germlin
sampl
use
control
candid
fusion
somat
mutat
valid
sanger
sequenc
result
across
code
region
two
case
number
candid
mutat
sever
novel
fusion
gene
identifi
similar
pediatr
solid
tumor
recurr
mutat
almost
detect
pbl
except
mutat
mutat
confirm
somat
origin
interestingli
found
novel
fusion
transcript
associ
relat
gene
one
case
conclus
previous
report
result
reveal
alter
could
respons
pathogenesi
pbl
result
suggest
pathway
candid
therapeut
target
elucid
pathogenesi
pbl
search
pathway
enrich
mutat
possibl
involv
germlin
mutat
epigenet
regul
assess
treatment
experi
pediatr
langerhan
cell
histiocytosi
inc
b
demirag
erbay
r
ortac
kamer
oymak
g
ozek
yaman
carti
c
vergin
pediatr
hematolog
oncolog
clinic
dr
behcet
uz
children
hospit
izmir
turkey
dept
pediatr
oncolog
baskent
univers
faculti
medicin
adana
turkey
patholog
dr
behcet
uz
children
hospit
izmir
turkey
dept
radiat
oncolog
ege
univers
faculti
medicin
izmir
turkey
object
summar
treatment
experi
patient
langerhan
cell
histiocytosi
lch
method
medic
record
lch
patient
evalu
retrospect
clinic
featur
treatment
outcom
result
patient
lch
nine
singl
system
involv
ssi
lch
multisystem
involv
msi
lch
spontan
complet
remiss
cr
without
chemotherapi
observ
skin
involv
infant
patient
rosai
dorfman
treat
protocol
surgeri
perform
two
patient
bone
involv
one
also
receiv
rt
remain
patient
bone
involv
receiv
chemotherapi
one
given
addit
rt
primari
relaps
occur
three
case
cr
achiev
rt
two
patient
median
involv
site
skin
lung
bone
liver
spleen
cn
lymphadenopathi
gingiva
patient
riski
organ
ro
involv
cr
achiev
three
without
ro
involv
five
ro
involv
treat
treatment
two
die
within
one
month
due
progress
one
receiv
addit
rt
cr
pr
achiev
one
liver
transplant
propos
one
refus
treatment
month
remain
patient
pr
achiev
dal
protocol
cr
achiev
prednisolon
vinblastin
methotrex
cyclophosphamid
cr
achiev
protocol
remain
two
patient
primari
primari
relaps
occur
one
treat
contain
chemo
median
conclus
addit
infant
spontan
remiss
skin
involv
infant
die
earli
despit
treatment
pulmonari
liver
involv
affect
surviv
outcom
advers
multidisciplinari
new
treatment
approach
need
treatment
relaps
wilm
tumour
wt
patient
experi
topotecan
amc
mm
van
den
ga
tytgat
h
van
tinteren
g
vujan
k
l
howel
n
graf
c
bergeron
acha
f
spreafico
depart
pediatr
hematolog
oncolog
radboudumc
nijmegen
netherland
depart
pediatr
hematolog
oncolog
children
hospit
rotterdam
netherland
depart
pediatr
oncolog
emma
children
hospit
amsterdam
netherland
depart
statist
dutch
cancer
institut
amsterdam
netherland
depart
patholog
cardiff
univers
school
medicin
cardiff
unit
kingdom
institut
child
health
univers
colleg
london
london
unit
kingdom
depart
pediatr
oncolog
alder
hey
children
nh
foundat
trust
liverpool
unit
kingdom
pediatr
oncolog
hematolog
saarland
univers
homburg
unit
kingdom
pediatr
oncolog
hematolog
institut
et
doncologi
lyon
franc
depart
pediatr
oncolog
hospit
malaga
spain
pediatr
oncolog
unit
depart
hematolog
pediatr
oncolog
fondazion
ircc
istituto
nazional
dei
tumori
milaan
itali
object
topotecan
variabl
incorpor
treatment
patient
relaps
wt
previous
treat
three
four
drug
first
line
siop
chemotherapi
regim
howev
far
larg
seri
avail
describ
efficaci
topotecan
set
object
describ
outcom
retrospect
investig
potenti
role
topotecan
relaps
wt
patient
method
children
treat
topotecan
part
chemotherapeut
regimen
relapsedrefractori
wt
retrospect
identifi
includ
studi
patient
chart
review
gener
patient
characterist
histolog
stage
diagnosi
number
type
relaps
treatment
schedul
toxic
respons
treatment
outcom
result
children
median
age
relaps
year
rang
treat
topotecan
refractori
diseas
first
relaps
second
relaps
third
relaps
rest
partial
respons
topotecan
given
singl
agent
combin
convent
drug
eg
cyclophosphamid
etoposid
carboplatin
ifosfamid
sixteen
patient
siop
hr
histolog
diagnosi
includ
diffus
anaplast
tumour
die
within
month
progress
diseas
except
one
bilater
nephrectomi
partial
respons
topotecan
treatment
eleven
patient
ir
histolog
diagnosi
three
patient
display
object
respons
topotecan
overal
ir
patient
surviv
median
follow
year
three
stage
v
bilater
nephrectomi
topotecan
treatment
conclus
topotecan
show
effect
treatment
relaps
wt
patient
histolog
patient
histolog
role
topotecan
might
deserv
attent
prove
efficaci
surgeri
patient
liver
metastas
wilm
tumor
treat
siop
protocol
singl
surgic
center
experi
c
pasqualini
c
patt
v
fouquet
f
g
de
lambert
branchereau
h
martelli
f
gauthier
pediatr
surgeri
bicetr
hospit
le
kremlin
franc
pediatr
oncolog
institut
gustav
roussi
villejuif
franc
object
either
synchron
metachron
renal
tumor
liver
metastas
lm
less
frequent
lung
metastas
patient
wilm
tumor
wt
persist
lm
initi
chemotherapi
propos
excis
purpos
report
seri
patient
oper
lm
singl
pediatr
liver
surgic
center
method
patient
enrol
siop
studi
undergo
surgeri
lm
includ
retrospect
studi
follow
point
emphazis
synchron
slm
metachron
mlm
occurr
lm
person
data
side
local
stage
histolog
renal
tumor
vascular
involv
presenc
lung
metastas
diagnosi
number
locat
liver
lm
surgic
procedur
qualiti
resect
lm
outcom
patient
result
four
patient
sml
mlm
diagnos
month
averag
nephrectomi
identifi
two
predispos
syndrom
renal
tumor
right
kidney
patient
local
stage
iii
histolog
diagnosi
patient
caval
involv
sml
mlm
lung
metastas
surgeri
metastas
multipl
case
right
liver
remov
mean
wedg
resect
case
hepatectomi
case
eight
patient
complet
incomlet
microscop
resect
three
patient
one
two
lm
recurr
month
lm
surgeri
two
die
remain
patient
aliv
year
conclus
result
point
need
screen
wt
patient
lm
nephrectomi
major
role
aggress
surgeri
aim
microscop
complet
excis
lm
treatment
preliminari
treatment
outcom
util
siop
guidelin
novel
oncolog
care
model
wilm
tumor
rwanda
c
shyiramber
elmor
l
may
umuhizi
n
tapela
l
lehmann
mpunga
diseas
inshuti
mu
buzimapartn
health
rwanda
butaro
rwanda
medicin
harvard
medic
school
boston
usa
global
health
boston
children
hospit
boston
usa
butaro
cancer
center
excel
ministri
health
butaro
rwanda
clinic
pediatr
stem
cell
transplant
center
cancer
institut
boston
usa
object
wilm
tumor
wt
preval
pediatr
malign
butaro
cancer
center
excel
bccoe
partner
ministri
health
facil
rural
rwanda
wt
success
treat
urban
center
africa
current
report
rural
center
deliveri
protocol
care
via
clinician
first
report
preliminari
outcom
use
siop
wt
guidelin
set
method
patient
treat
wt
sinc
program
inaugur
juli
determin
use
electron
medic
record
paper
chart
patient
exclud
miss
imag
patholog
wt
confirm
extract
perform
use
excel
valid
paramet
descript
analys
comparison
perform
result
patient
treat
wt
femal
n
median
age
intak
month
n
present
local
unilater
mass
n
metastat
n
local
bilater
unknown
n
common
metastat
site
lung
n
liver
n
start
chemotherapi
n
n
n
surgeri
siop
stage
n
iii
n
iii
n
iv
n
v
n
indeterminatemiss
start
chemotherapi
n
n
n
die
median
time
day
n
treat
patient
lost
follow
n
patient
complet
treatment
n
evalu
evalu
show
clinic
remiss
median
month
conclus
wt
success
treat
rural
set
protocol
approach
util
clinician
loss
remain
low
rel
compar
set
treatment
vs
mortal
difficult
determin
though
conserv
analysi
indic
mortal
estim
within
report
rang
siop
podc
protocol
studi
determin
mortal
associ
risk
factor
need
patient
nephroblastoma
treat
siop
protocol
nation
hospit
pediatr
hanoi
vietnam
outcom
challeng
h
tran
oncolog
nation
hospit
pediatr
hanoi
vietnam
object
aim
replic
result
siop
protocol
hospit
test
applic
vietnam
situat
method
elig
patient
inclus
criteria
siop
protocol
enrol
studi
intermedi
risk
group
patient
stage
ii
treat
regimen
patient
stage
iii
treat
avd
rt
random
patient
enrol
studi
juli
decemb
follow
june
result
eighti
patient
enrol
studi
die
abandon
preoper
chemotherapi
diagnosi
preoper
chemotherapi
patient
diagnosi
nephroblastoma
full
treatment
lost
ceas
treatment
ef
last
examin
preoper
chemotherapi
tumor
volum
reduc
case
total
volum
tumor
reduc
tumor
stage
patient
follow
end
studi
patient
die
relaps
patient
event
free
surviv
overal
surviv
follow
time
month
mean
month
imag
diagnosi
correct
patholog
anatomi
case
much
lower
siop
data
discrep
may
due
less
experi
imag
specialist
compar
siop
institut
true
higher
incid
rare
tumor
vietnames
popul
experienc
higher
incid
clear
cell
sarcoma
rhabdoid
tumor
compar
report
siop
patholog
anatomi
diagnosi
difficult
work
rapid
central
review
avail
siop
institut
conclus
nation
hospit
pediatr
protocol
siop
appli
success
treatment
outcom
much
lower
siop
data
imag
patholog
anatomi
diagnos
big
challeng
wilm
tumor
retrospect
studi
case
center
tunisia
chabchoub
haj
mansour
f
zairi
n
kallala
h
zaghouani
l
ben
fatma
gharbi
hochlef
nouri
ben
ahm
medic
oncolog
farhat
hach
souss
tunisia
radiolog
farhat
hach
souss
tunisia
pediatr
surgic
farhat
hach
souss
tunisia
object
compar
result
siop
studi
method
studi
retrospect
children
wt
treat
depart
medic
oncolog
farhat
hach
hospit
januari
decemb
kaplan
meier
method
test
employ
surviv
analysi
result
mean
age
year
old
sex
ratio
eighti
percent
children
present
painless
abdomin
tumor
first
sign
tumor
mainli
unilater
right
ultrasound
comput
tomographi
show
heterogen
tumor
medium
size
cm
develop
lower
pole
kidney
venou
thrombosi
diagnos
wt
metastat
patient
receiv
preoper
chemotherapi
enlarg
nephrectomi
practic
postop
complic
postop
stage
ii
iii
respect
accord
siop
risk
classif
low
intermedi
high
histolog
risk
postop
chemotherapi
receiv
adjuv
radiotherapi
practic
overal
surviv
local
stage
metastat
stage
percent
relaps
averag
month
late
sequela
notic
conclus
studi
show
less
overal
surviv
siop
due
bigger
rate
metastat
form
late
diagnosi
difficulti
respect
time
schedul
protocol
siop
africapodc
collabor
wilm
tumour
project
challeng
progress
f
kouya
em
molyneux
pb
hessel
j
balagadd
v
paintsil
scanlan
l
hadley
l
burn
la
renner
israel
depart
paediatr
mbingo
baptist
hospit
mbingo
cameroon
depart
paediatr
colleg
medicin
blantyr
malawi
depart
paediatr
child
health
univers
stellenbosch
cape
town
south
africa
depart
paediatr
oncolog
uganda
cancer
institut
kampala
uganda
depart
paediatr
oncolog
komfo
anoky
teach
hospit
kumasi
ghana
depart
paediatr
oncolog
muhimbili
hospit
dar
es
salaam
tanzania
depart
paediatr
surgeri
univers
durban
south
africa
oper
manag
world
child
cancer
london
unit
kingdom
depart
paediatr
korl
bu
teach
hospit
accra
ghana
depart
paediatr
oncolog
outreach
program
vu
univers
medic
center
amsterdam
netherland
object
report
surviv
wilm
tumour
wt
patient
africa
challeng
includ
late
present
malnutrit
less
intens
support
care
facil
failur
complet
treatment
aim
improv
care
surviv
feasibl
sustain
fashion
method
region
collabor
group
establish
particip
eight
institut
five
countri
africa
institut
dedic
childhood
cancer
unit
establish
wilm
tumour
treatment
extern
fund
support
sever
year
siop
podc
adapt
treatment
guidelin
wilm
tumour
support
care
low
incom
countri
publish
includ
emphasi
diagnost
role
ultrasonographi
preoper
chemotherapi
reduc
dosag
malnourish
children
social
support
enabl
parent
complet
treatment
guidelin
implement
prospect
clinic
trial
expect
new
patient
per
year
research
question
includ
event
free
surviv
reason
treatment
failur
efficaci
toxic
preoper
chemotherapi
comparison
surgic
stage
local
patholog
central
review
patholog
stratifi
postop
chemotherapi
result
comprehens
uniform
treatment
protocol
uniform
data
collect
form
central
data
collect
tool
place
collabor
agreement
develop
sign
differ
particip
unit
local
irb
approv
sought
differ
unit
baselin
evalu
outcom
done
year
world
child
cancer
siop
agre
year
enrol
start
januari
project
websit
http
paedoncwixcomwilmsafricaproject
conclus
prospect
use
adapt
treatment
regimen
childhood
cancer
along
systemat
data
collect
among
region
partner
achiev
africa
hope
demonstr
futur
lead
improv
outcom
along
capac
build
result
trial
studi
treatment
nephroblastoma
singl
institut
develop
countri
c
cafferata
w
cacciavillano
rose
l
galluzzo
p
flore
p
zubizarreta
hospit
de
jp
garrahan
ciudad
de
bueno
air
argentina
patholog
hospit
de
jp
garrahan
ciudad
de
bueno
air
argentina
surgeri
hospit
de
jp
garrahan
ciudad
de
bueno
air
argentina
object
evalu
outcom
patient
wilm
tumor
wt
treat
accord
strategi
method
retrospect
analysi
consecut
patient
wt
diagnos
institut
decemb
perform
surviv
estim
overal
surviv
os
event
free
surviv
ef
calcul
result
patient
median
age
month
old
assess
analysi
fine
needl
aspir
initi
perform
patient
stage
distribut
stage
six
patient
stage
iii
tumor
spill
surgeri
eleven
patient
underw
initi
nephrectomi
patient
receiv
preoper
chemotherapi
poc
adjuv
chemotherapi
given
without
random
use
stage
ii
plu
radiotherapi
stage
iii
median
follow
month
os
ef
os
accord
stage
stage
p
signific
differ
ef
p
patient
intermedi
risk
patient
high
risk
compar
blastem
subtyp
subtyp
os
vs
p
ef
vs
p
ef
accord
tumor
volum
poc
tumor
respect
p
signific
differ
os
p
fifteen
patient
relaps
within
month
median
eight
patient
die
progress
diseas
death
conclus
guidelin
feasibl
appli
institut
excel
result
os
ef
seri
similar
report
lead
group
despit
small
number
patient
blastem
subtyp
show
better
outcom
treat
intensifi
regimen
outcom
wilm
tumor
treat
siop
wt
uk
version
guidelin
multicent
expereinc
pakistan
ashraf
sultan
b
ahm
aba
umar
saulat
sah
rizvi
pa
urolog
sindh
institut
urolog
transplant
karachi
pakistan
object
studi
outcom
children
wilm
tumor
treat
siop
uk
version
guidelin
method
retrospect
chart
review
case
wilm
tumor
regist
cch
siut
juli
octob
children
treat
immedi
nephrectomi
present
relaps
diseas
chemotherapi
exclud
children
receiv
pre
oper
chemotherapi
per
siop
wt
uk
version
guidelin
includ
outcom
analysi
done
respect
diseas
stage
present
local
metastat
bilater
post
stage
risk
group
caus
death
record
result
children
diagnos
wilm
tumor
biopsi
studi
period
age
rang
year
median
yr
male
femal
ratio
abdomin
mass
hematuria
common
present
present
local
metastat
bilater
diseas
seen
respect
overal
surviv
median
follow
year
whole
cohort
without
abandon
respect
overal
surviv
among
local
diseas
without
abandon
metastat
diseas
bilater
diseas
overal
surviv
accord
stage
local
diseas
stage
stage
ii
stage
iii
surviv
accord
risk
group
among
local
low
risk
intermedi
risk
high
risk
major
caus
death
relaps
inoper
tumor
poor
respons
chemotherapi
sepsi
abandon
treatment
major
advers
factor
conclus
treatment
wilm
tumor
siop
approach
karachi
shown
good
surviv
improv
reduct
abandon
toxic
death
better
complianc
protocol
wilm
tumour
malawi
surgic
stage
stratifi
postop
chemotherapi
es
borgstein
kamiza
g
vujan
pidini
bailey
tomoka
g
chagaluka
gjl
kasper
em
molyneux
israel
depart
surgeri
colleg
medicin
blantyr
malawi
depart
histopatholog
colleg
medicin
blantyr
malawi
depart
histopatholog
cardiff
univers
cardiff
unit
kingdom
depart
paediatr
colleg
medicin
blantyr
malawi
depart
paediatr
oncolog
sir
jame
spenc
institut
child
health
newcastl
unit
kingdom
depart
paediatr
oncolog
vu
univers
medic
center
amsterdam
netherland
paediatr
oncolog
vu
univers
medic
center
amsterdam
netherland
object
wilm
tumour
postop
chemotherapi
ideal
stratifi
accord
pathologist
assess
tumour
stage
risk
classif
tumour
type
africa
result
often
avail
time
influenc
therapi
malawi
surgic
stage
use
stratifi
postop
chemotherapi
compar
result
surgic
local
patholog
central
patholog
review
method
children
diagnos
wilm
tumour
blantyr
malawi
includ
nephrectomi
patholog
slide
avail
tumour
specimen
assess
three
differ
way
local
surgeon
document
surgic
stage
tumour
risk
classif
patholog
stage
assess
local
pathologist
siop
central
review
pathologist
europ
result
fifti
patient
complet
data
avail
includ
analys
tumour
risk
classif
differ
local
central
patholog
review
two
patient
use
central
patholog
review
gold
standard
patient
receiv
correct
postop
chemotherapi
treatment
base
surgic
stage
base
local
patholog
stage
risk
classif
conclus
local
patholog
capac
build
need
enabl
time
assess
report
epidemiolog
outcom
rare
renal
tumor
pediatr
popul
singl
tertiari
care
centr
india
n
pradhan
punatar
panda
gupta
prasad
g
narula
vora
g
chinnaswami
b
arora
banavali
p
kurkur
quereshi
medic
oncolog
tata
memori
hospit
mumbai
india
surgic
oncolog
tata
memori
hospit
mumbai
india
object
littl
data
exist
epidemiolog
outcom
renal
tumor
wilm
children
aim
studi
epidemiolog
profil
rare
renal
tumor
pediatr
popul
outcom
method
retrospect
analysi
year
data
januari
decemb
tata
memori
centr
mumbai
india
studi
includ
children
present
hospit
period
renal
mass
post
oper
histopatholog
pre
oper
biopsi
suggest
tumor
wilm
tumor
patient
receiv
standard
treatment
per
diagnosi
outcom
analyz
result
record
total
case
rare
renal
tumor
studi
case
clear
cell
sarcoma
kidney
ccsk
primit
neuroectoderm
tumor
pnet
rhabdoid
tumor
kidney
renal
cell
carcinoma
rcc
germ
cell
tumor
gct
transloc
associ
rcc
congenit
mesoblast
nephroma
synovi
sarcoma
metastat
diseas
present
found
total
case
case
ccsk
case
pnet
case
rhabdoid
tumor
patient
metastat
diseas
receiv
palli
support
care
four
patient
local
diseas
progress
treatment
rcc
rhabdoid
tumor
patient
ccsk
relaps
complet
therapi
eleven
patient
ccsk
pnet
rcc
transloc
associ
rcc
synovi
sarcoma
diseas
free
median
follow
year
eleven
patient
lost
follow
conclus
common
renal
tumor
wilm
tumor
patient
ccsk
follow
pnet
rhabdoid
tumor
approxim
patient
present
metastat
diseas
patient
local
diseas
reason
long
term
surviv
treat
standard
treatment
neoadjuv
therapi
advanc
wilm
tumor
year
experi
li
xu
tang
yong
huang
wu
q
shu
j
wang
lai
h
tang
divis
pediatr
surgic
oncolog
depart
pediatr
surgeri
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
divis
urolog
depart
pediatr
surgeri
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
depart
radiolog
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
depart
patholog
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
object
evalu
effect
neoadjuv
therapi
use
transcathet
arteri
chemoembol
tace
system
chemotherapi
treatment
advanc
wilm
tumor
method
januari
decemb
patient
male
femal
median
year
rang
year
unilater
advanc
wilm
tumor
treat
tace
system
chemotherapi
surgeri
characterist
patient
maxim
tumor
diamet
cm
involv
periaort
lymph
node
inferior
vena
cava
invas
distal
metastasi
tumor
anaplast
histolog
patient
subject
tace
selding
method
cathet
place
involv
renal
arteri
chemoembol
emuls
consist
cisplatin
pirarubicin
vindesin
iodiz
oil
ml
infus
intraven
chemotherapi
vindesin
week
actinomycin
gkg
daili
cours
administ
one
week
tace
surgic
resect
carri
week
tace
postop
therapi
accord
nwt
iv
protocol
result
cardiotox
renal
insuffici
hepat
dysfunct
found
patient
grade
marrow
suppress
develop
patient
tumor
volum
significantli
reduc
neoadjuv
therapi
complet
surgic
remov
tumor
achiev
patient
surgic
stage
stage
ii
stage
iii
patient
four
patient
clinic
stage
iv
diseas
present
histolog
result
classifi
fh
ah
case
gross
inspect
reveal
necrosi
tumor
variabl
extent
case
total
necrosi
tumor
observ
case
overal
surviv
surviv
respect
median
rang
month
conclus
neoadjuv
therapi
show
high
clinic
patholog
respons
rate
treatment
advanc
wilm
tumor
bilater
wilm
tumor
frequenc
manag
outcom
experi
children
cancer
hospit
egypt
w
zekri
e
moussa
h
monib
r
soliman
yone
el
shafi
zaghloul
h
taha
n
el
kinaai
refaat
pediatr
oncolog
children
cancer
hospit
egypt
cairo
egypt
research
children
cancer
hospit
egypt
cairo
egypt
surgeri
children
cancer
hospit
egypt
cairo
egypt
radiat
therapi
children
cancer
hospit
egypt
cairo
egypt
surgic
patholog
children
cancer
hospit
egypt
cairo
egypt
radiolog
children
cancer
hospit
egypt
cairo
egypt
object
success
treatment
wilm
tumor
requir
meticul
attent
correct
stage
tumor
good
commun
pediatr
oncologist
surgeon
radiodiagnosi
specialist
pathologyist
radiotherapist
combin
adjuv
therapi
surgeri
children
bwt
nearli
alway
technic
feasibl
complic
addit
believ
oper
intervent
done
earli
week
initi
chemotherapi
littl
signific
chang
tumor
size
like
import
determin
exact
tumor
histolog
aim
evalu
patient
diseas
characterist
assess
respons
complic
differ
treatment
modal
surviv
analysi
method
retrospect
studi
includ
patient
bilater
wilm
tumor
bwt
present
juli
march
children
cancer
egypt
follow
till
march
result
patient
select
time
period
age
rang
month
year
median
year
male
femal
ratio
case
bilater
synchron
renal
mass
record
case
metachron
bwt
use
cog
stage
system
local
stage
distribut
stage
iii
respect
initi
metastat
bwt
diagnos
case
repres
case
studi
median
follow
durat
month
year
os
rf
show
presenc
absenc
metastat
diseas
factor
statist
signific
effect
os
rf
conclus
treatment
bilater
wilm
tumor
requir
multimod
therapi
individu
decis
ensur
cure
preserv
much
renal
parenchyma
possibl
month
preoper
chemotherapi
allow
perform
renal
spare
surgeri
case
three
drug
chemotherapi
protocol
stage
wilm
tumor
practic
compromis
suboptim
stage
develop
countri
worth
safe
rastogi
qureshi
vora
g
chinnaswami
maya
prasad
laskar
n
khanna
ramadwar
medhi
p
kurkur
paediatr
solid
tumor
manag
group
tata
memori
hospit
mumbai
india
object
obstacl
manag
wt
tertiari
cancer
centr
develop
countri
india
lack
awar
among
caregiv
commun
regard
multidisciplinari
manag
wt
lead
delay
referr
adjuv
treatment
post
surgeri
without
adequ
surgic
patholog
detail
limit
appropri
stage
assign
overcom
obstacl
start
chemotherapi
protocol
use
anthracyclin
stage
method
wt
protocol
puls
intens
arm
studi
compris
vincristin
actinomycin
doxorubicin
wt
patient
regist
tata
memori
hospit
oct
dec
treat
wt
analys
univari
analysi
uva
relaps
free
surviv
rf
overal
surviv
os
perform
use
method
multivari
analysi
mva
perform
use
cox
proport
hazard
model
result
patient
wt
treat
protocol
octob
decemb
median
age
present
month
male
major
oper
outsid
refer
adjuv
therapi
patient
oper
upfront
wherea
receiv
anterior
chemotherapi
follow
surgeri
favor
histolog
fh
seen
ten
year
rf
os
respect
median
follow
month
age
group
month
p
histolog
p
signific
rf
uva
mva
histolog
p
statist
signific
uva
mva
oa
chf
occur
asymptomat
chang
chronic
hbv
skelet
abnorm
second
malign
hypertens
late
effect
conclus
chemotherapi
protocol
compris
three
drug
stage
wt
practic
compromis
compens
lacuna
stage
optim
therapeut
plan
asymptomat
late
anthracyclin
relat
cardiac
toxic
need
monitor
impact
qol
life
eye
implic
whole
child
famili
attempt
eye
salvag
unilater
sever
bilater
retinoblastoma
white
b
galli
one
retinoblastoma
world
daisi
eye
cancer
fund
oxford
unit
kingdom
ophthalmolog
hospit
sick
children
toronto
canada
object
primari
enucl
standard
care
unilater
retinoblastoma
intern
intraocular
retinoblastoma
classif
group
e
eye
children
bilater
diseas
often
cure
enabl
care
patholog
genet
test
evalu
risk
famili
physician
increasingli
select
innov
therapi
hope
save
eye
countri
limit
access
advanc
medic
care
famili
seek
intern
treatment
evalu
physic
psycholog
financi
impact
child
famili
primari
eye
salvag
unilater
sever
bilater
retinoblastoma
method
review
treatment
cours
event
free
surviv
psycholog
financi
impact
primari
reason
contact
among
famili
approach
daisi
eye
cancer
fund
assist
result
secondari
enucl
rate
high
particularli
among
intern
patient
children
unilater
retinoblastoma
two
case
parent
request
enucl
unilater
blind
eye
contest
multidisciplinari
team
lead
emot
trauma
extra
treatment
delay
surgeri
mortal
associ
poor
follow
due
financi
limit
resist
secondari
enucl
develop
countri
leptomening
metastasi
follow
intra
arteri
chemotherapi
children
bone
marrow
relaps
follow
intens
therapi
unilater
retinoblastoma
aliv
evid
diseas
year
follow
report
consist
post
traumat
stress
disord
frequent
children
parent
one
child
diagnos
ptsd
diagnosi
autism
spectrum
disord
frequent
financi
distress
common
mani
famili
unabl
pay
medic
bill
famili
seek
intern
treatment
experi
increas
poverti
return
home
rate
high
conclus
primari
enucl
unilater
advanc
bilater
retinoblastoma
save
live
signific
financi
psycholog
burden
eye
salvag
therapi
must
weigh
perceiv
treatment
benefit
inform
consent
process
especi
consult
famili
countri
one
rb
world
onlin
virtual
retinoblastoma
clinic
h
dimara
bl
galli
c
baik
lee
k
frasunkiewicz
ophthalmolog
vision
scienc
univers
toronto
toronto
canada
human
biolog
univers
toronto
toronto
canada
object
global
research
collabor
identifi
key
improv
outcom
retinoblastoma
first
retinoblastoma
clinic
practic
guidelin
publish
canada
optim
resourc
expertis
retinoblastoma
manag
outlin
serv
guid
inform
health
polici
nation
region
institut
level
subsequ
guidelin
adopt
kenyan
nation
retinoblastoma
strategi
group
countri
situat
analysi
key
treatment
center
inform
system
patient
referr
educ
capac
initi
predict
result
enhanc
patient
care
appli
approach
global
scale
onlin
virtual
retinoblastoma
clinic
method
conduct
survey
global
retinoblastoma
treatment
center
identifi
document
expertis
resourc
avail
care
children
retinoblastoma
worldwid
onlin
platform
develop
dissemin
inform
interact
format
result
virtual
clinic
connect
patient
famili
caregiv
document
data
center
countri
survey
function
allow
data
collect
updat
knowledg
retinoblastoma
children
manag
worldwid
provid
effici
rapid
path
parent
access
urgent
care
websit
indic
closest
expert
center
contact
path
referr
multicent
aim
keep
children
close
home
optim
access
advanc
therapi
need
estim
incid
vs
locat
capabl
treatment
centr
reveal
opportun
increas
capac
collabor
coverag
variou
region
conclus
one
retinoblastoma
world
virtual
clinic
connect
stakehold
strengthen
capac
care
global
retinoblastoma
popul
collabor
promot
global
standard
care
set
stage
multicent
clinic
trial
research
therebi
acceler
translat
result
lab
clinic
trilater
retinoblastoma
systemat
review
de
jong
wa
kor
p
de
graaf
ja
castelijn
ac
moll
radiolog
vu
univers
medic
center
amsterdam
netherland
pediatr
oncolog
vu
univers
medic
center
amsterdam
netherland
ophthalmolog
vu
univers
medic
center
amsterdam
netherland
object
rare
children
hereditari
retinoblastoma
rb
develop
trilater
retinoblastoma
trb
retinoblastoma
combin
histolog
ident
brain
tumor
commonli
locat
pineal
gland
unfortun
mani
surviv
object
studi
provid
overview
publish
case
analyz
surviv
method
search
medlin
embas
trb
case
publish
januari
februari
studi
perform
accord
prisma
statement
perform
surviv
data
result
one
hundr
trb
patient
studi
qualifi
patient
diagnos
trb
show
cumul
surviv
rate
csr
confid
interv
ci
period
csr
rose
ci
along
increas
use
chemotherapi
decreas
use
radiotherapi
brain
tumor
pineal
trb
show
csr
ci
ci
respect
wherea
trb
show
csr
ci
incalcul
ci
respect
restrict
activ
treat
patient
pineal
trb
show
csr
ci
ci
asymptomat
symptomat
diseas
respect
wherea
trb
show
csr
ci
ci
asymptomat
symptomat
diseas
respect
smaller
tumor
size
show
statist
signific
better
surviv
pineal
trb
trb
conclus
surviv
improv
consider
time
difficult
pinpoint
exact
reason
improv
mani
factor
chang
year
result
suggest
earli
detect
proper
treatment
subclin
tumor
key
success
especi
pineoblastoma
howev
patient
larger
tumor
clinic
symptom
also
chanc
surviv
especi
trb
baselin
central
nervou
system
magnet
reson
imag
retinoblastoma
singl
institut
experi
earli
detect
trilater
retinoblastoma
de
iori
p
valent
f
randisi
carai
r
cozza
f
del
bufalo
cacchion
romanzo
b
bernardi
mastronuzzi
hematologyoncolog
pediatr
hospit
bambino
gesu
roma
itali
ophtalmolog
pediatr
hospit
bambino
gesu
roma
itali
neuroradiolog
pediatr
hospit
bambino
gesu
roma
itali
neurosurgeri
pediatr
hospit
bambino
gesu
roma
itali
object
report
frequenc
well
clinic
imag
find
trilater
retinoblastoma
trb
retinobastoma
rb
seri
baselin
mri
adopt
routin
investig
patient
time
rb
diagnosi
method
rb
databas
check
order
identifi
patient
trb
diagnosi
januari
decemb
mri
review
studi
result
rb
patient
diagnos
year
regular
use
baselin
mri
screen
patient
unilater
rb
bilater
rb
mri
reveal
presenc
trb
three
patient
age
month
respect
one
patient
trb
metachron
patient
synchron
trb
occur
bilater
rb
one
famili
rb
trb
report
unilater
group
none
patient
receiv
prior
chemotherapeut
treatment
seven
benign
pineal
cyst
diagnos
period
conclus
trb
repres
rare
condit
occur
seri
rb
patient
frequenc
appear
higher
bilateralfamili
case
synchron
present
seem
frequent
baselin
mri
perform
brain
mri
recommend
perform
patient
rb
time
diagnosi
analysi
larg
seri
address
consid
treat
small
synchron
pineal
lesion
suggest
pineoblastoma
alter
mitochondri
complex
protein
human
retinoblastoma
l
singh
kashyap
n
pushker
tc
nag
sen
sharma
bakhshi
ocular
patholog
india
institut
medic
scienc
delhi
india
ophthalmolog
india
institut
medic
scienc
delhi
india
anatomi
india
institut
medic
scienc
delhi
india
ocular
microbiolog
india
institut
medic
scienc
delhi
india
medic
oncolog
india
institut
medic
scienc
delhi
india
object
mitochondria
critic
cellular
function
cancer
play
import
role
cell
differenti
surviv
defici
mitochondri
complex
import
factor
cancer
cell
purpos
studi
determin
express
mitochondri
complex
morpholog
chang
mitochondria
human
primari
retinoblastoma
tissu
method
express
mitochondri
complex
perform
case
immunohistochemistri
valid
western
blot
repres
case
morpholog
mitochondria
studi
transmiss
electron
microscopi
tem
case
result
defici
mitochondri
complex
found
case
immunohistochemistri
western
blot
perform
confirm
immunoreact
result
electron
microscopi
show
numer
degener
swollen
mitochondria
tumor
cell
statist
analysi
loss
mitochondri
complex
express
correl
significantli
poorli
differenti
retinoblastoma
tumor
invas
conclus
first
studi
show
express
mitochondri
complex
retinoblastoma
tumor
electron
microscopi
reveal
numer
morpholog
chang
mitochondria
may
due
chang
mitochondri
protein
express
correl
mitochondri
variat
express
complex
investig
investig
mtdna
alter
might
help
develop
biomark
manag
retinoblastoma
patient
histopatholog
analysi
cell
divis
cycl
phosphatas
protein
retinoblastoma
kashyap
l
singh
n
pushker
sen
sharma
b
chawla
ocular
patholog
india
institut
medic
scienc
delhi
india
ophthalmolog
india
institut
medic
scienc
delhi
india
ocular
microbiolog
india
institut
medic
scienc
delhi
india
object
retinoblastoma
common
childhood
intraocular
malign
tumor
develop
retina
cell
divis
cycl
phosphatas
essenti
regul
cell
cycl
machineri
function
posit
regul
activ
kinas
cdk
play
pivot
role
control
cell
prolifer
develop
tumorigenesi
overexpress
detect
number
tumor
impli
dysregul
malign
transform
howev
role
patient
retinoblastoma
still
unknown
method
prospect
analys
primari
enucl
retinoblastoma
case
period
one
year
jan
protein
express
investig
immunohistochemistri
formalin
fix
paraffin
embed
section
valid
western
blot
cytoplasm
stain
grade
weakneg
moder
strong
analysi
express
mrna
perform
pcr
express
correl
tumor
differenti
variou
histopatholog
high
risk
factor
result
total
poorli
differenti
retinoblastoma
well
differenti
retinoblastoma
necrosi
calcif
found
respect
massiv
choroid
invas
optic
nerv
invas
scleral
invas
found
case
respect
immunohistochemistri
show
express
total
case
western
blot
perform
confirm
immunoreact
result
repres
case
mrna
express
seen
case
express
show
statist
signific
correl
poor
tumour
differenti
tumor
invas
p
conclus
result
suggest
increas
express
play
import
role
pathogenesi
retinoblastoma
associ
invas
ocular
coat
poor
differenti
express
might
potenti
molecular
target
novel
drug
develop
tumor
biolog
possibl
role
hedgehog
pathway
ligand
desert
indian
rhabdomyosarcoma
j
roma
c
molist
p
velasco
vidal
mf
segura
soriano
l
jubierr
j
de
toledo
gallego
translat
research
paediatr
cancer
laboratori
vall
hebron
research
institut
barcelona
spain
paediatr
oncolog
hematolog
depart
hospit
vall
hebron
barcelona
spain
object
establish
mechan
activ
hedgehog
hh
pathway
rhabdomyosarcoma
rm
concret
elucid
role
hh
ligand
hh
shh
indian
hh
ihh
desert
hh
dhh
pathogenesi
neoplasia
method
pcr
western
blot
immunohistochemistri
use
determin
hh
ligand
level
rm
cell
line
tumor
sampl
genet
inhibit
ligand
perform
shrna
lentivir
vector
pgipz
function
assay
perform
order
determin
effect
genet
inhibit
hh
ligand
rm
cell
result
mrna
analysi
pcr
show
medium
high
ihh
dhh
express
sampl
analyz
convers
express
shh
shown
neglig
major
sampl
howev
approxim
patient
show
express
shh
western
blot
immunohistochem
analysi
coincid
result
obtain
pcr
shh
ihh
dhh
level
correl
express
shh
dhh
level
show
signific
direct
correl
express
ihh
tendenc
correl
observ
signific
correl
obtain
genet
inhibit
ihh
significantli
decreas
cell
prolifer
conclus
result
confirm
extrem
low
level
shh
express
major
rm
patient
approxim
interestingli
found
promin
express
ihh
dhh
ligand
rm
togeth
direct
correl
observ
two
ligand
one
target
hh
pathway
result
support
possibl
exist
autocrin
activ
hedgehog
pathway
neoplasia
result
suggest
develop
inhibitor
may
help
specif
inhibit
pathway
tumor
rm
therebi
provid
therapeut
altern
beyond
cyclopamin
deriv
influenc
polymorph
outcom
treat
rhabdomyosarcoma
pediatr
egyptian
patient
r
labib
yassin
e
elnadi
emam
research
children
cancer
cairo
egypt
clinic
patholog
children
cancer
cairo
egypt
pediatr
oncolog
children
cancer
cairo
egypt
clinic
pharmaci
faculti
pharmaci
beni
swef
egypt
object
cyclophosphamid
convent
use
rhabdomyosarcoma
rm
malign
highli
polymorph
suggest
major
contributor
cyclophosphamid
bioactiv
polymorph
enzym
may
affect
drug
bioactiv
henc
treatment
outcom
aim
work
investig
impact
snp
outcom
cyclophosphamid
treat
rm
patient
order
find
biomark
person
therapi
method
germ
line
dna
sampl
rm
patient
present
children
cancer
decemb
till
decemb
genotyp
rflp
snp
patient
enrol
protocol
base
cyclophosphamid
follow
till
march
clinic
data
surviv
demograph
patholog
chemotherapi
dose
clinic
respons
collect
examin
associ
genotyp
overal
surviv
failur
free
surviv
achiev
complet
respons
result
popul
tt
case
gt
gg
patient
gg
case
ag
aa
patient
tt
case
ct
cc
patient
failur
free
surviv
genotyp
gt
gg
genotyp
failur
free
surviv
higher
type
c
gg
c
compar
mutant
genotyp
yet
statist
signific
conclus
use
prognost
biomark
rhabdomyosarcoma
patient
receiv
cyclophosphamid
express
local
mhc
relat
chain
molecul
b
human
rhabdomyosarcoma
cell
uehara
kawatsu
k
nakahata
oue
n
usui
pediatr
surgeri
osaka
univers
hospit
osaka
japan
object
natur
killer
nk
cell
import
effector
cell
first
line
defens
tumor
interact
mhc
class
chain
molecul
b
micamicb
correspond
natur
killer
group
member
receptor
trigger
cytotox
effector
activ
natur
killer
cell
certain
subset
thu
presenc
micamicb
surfac
tumor
cell
contribut
tumor
immunosurveil
studi
investig
express
local
micamicb
human
rhabdomyosarcoma
rm
tumor
cell
line
method
immunohistochem
detect
micamicb
perform
use
paraffin
embed
sampl
obtain
surgeri
presenc
micamicb
mrna
protein
alveolar
embryon
rd
rm
cell
line
evalu
western
blot
analysi
surfac
express
level
micamicb
determin
flow
cytometri
result
immunohistochem
stain
show
clinic
tumor
sampl
posit
either
mica
micb
normal
striat
muscl
cell
neg
rm
cell
line
mica
mrna
detect
wherea
micb
mrna
detect
cell
western
blot
analysi
reveal
mica
protein
present
rm
cell
line
well
mrna
micb
protein
present
rd
cell
howev
surfac
express
mica
micb
limit
mica
detect
rd
cell
conclus
result
suggest
rm
cell
abil
produc
mica
micb
protein
wherea
rd
cell
express
mica
cell
surfac
therefor
sinc
lack
mic
express
surfac
rm
tumor
cell
may
lead
lack
tumor
recognit
nk
cell
modul
micamicb
express
may
help
activ
nk
cell
aldehyd
dehydrogenas
potenti
marker
cancer
cell
embryon
rhabdomyosarcoma
k
nakahata
uehara
oue
zenitani
n
usui
depart
pediatr
surgeri
osaka
univers
graduat
school
medicin
osaka
japan
object
recent
studi
demonstr
aldehyd
dehydrogenas
detect
marker
cancer
cell
csc
adult
cancer
pediatr
malign
tumor
howev
studi
regard
marker
csc
studi
hypothes
subpopul
cell
high
activ
cell
would
characterist
csc
rhabdomyosarcoma
rm
examin
characterist
cell
embryon
rm
method
use
human
embryon
rm
cell
line
rd
cultur
cell
sort
cell
subpopul
low
activ
cell
use
aldefluor
assay
kit
demonstr
cell
stronger
csc
characterist
cell
perform
assay
assay
vitro
assay
use
immunodefici
mice
vivo
result
cell
compris
cultur
rd
cell
aldefluor
assay
assay
document
cell
number
coloni
cell
higher
cell
vs
colonieswel
respect
regard
chemoresist
surviv
rate
cell
found
time
high
cell
follow
treatment
vincristin
surviv
rate
cell
compar
cell
cultur
cyclophosphamid
etoposid
respect
found
one
four
mice
inject
cell
two
three
mice
inject
cell
wherea
tumor
found
mice
inject
cell
either
cell
densiti
conclus
confirm
rd
cell
characterist
csc
includ
chemoresist
result
suggest
potenti
use
marker
csc
embryon
rm
novel
secondari
somat
mutat
ewe
sarcoma
desmoplast
small
round
cell
tumor
children
adolesc
young
adult
v
subbiah
jiang
f
janku
ja
ludwig
na
rs
benjamin
brown
pm
anderson
r
kurzrock
phase
program
ut
md
anderson
cancer
center
houston
usa
sarcoma
medic
oncolog
ut
md
anderson
cancer
center
houston
usa
phase
ut
md
anderson
cancer
center
houston
usa
patholog
ut
health
ut
houston
houston
usa
ped
hematologyoncologybmtcel
therapi
levin
children
hospitallevin
cancer
institut
charlott
usa
divis
hematolog
oncolog
uc
san
diego
moor
cancer
center
san
diego
usa
object
ewe
sarcoma
es
desmoplast
small
round
cell
tumor
dsrct
relat
small
round
blue
cell
tumor
driven
contain
ew
transloc
somat
mutat
report
es
none
identifi
dsrct
aim
studi
explor
potenti
action
mutat
es
dsrct
method
twenti
eight
patient
es
dsrct
tumor
tissu
avail
could
analyz
one
follow
method
exom
sequenc
platform
multiplex
pcrmass
spectroscopi
polymeras
chain
reaction
pcr
gene
mutat
screen
sanger
sequenc
result
action
somat
mutat
identifi
four
patient
advanc
es
two
patient
advanc
dsrct
six
kra
n
ptprd
n
n
n
n
one
patient
ptprd
mutat
one
mutat
achiev
complet
remiss
cr
insulin
like
growth
factor
receptor
inhibitor
base
treatment
one
patient
achiev
partial
remiss
pr
inhibitor
treatment
later
develop
resist
demonstr
kra
mutat
resist
tumor
tumor
suggest
rafrasmek
pathway
activ
progress
conclus
report
sever
differ
mutat
advanc
es
dsrct
direct
implic
target
therapi
technolog
agnost
approach
provid
initi
mutat
roadmap
use
path
toward
individu
combin
therapi
routin
imag
childhood
rhabdomyosarcoma
improv
patient
surviv
okcu
j
lin
p
guillerman
p
lupo
h
russel
pediatricshematolog
oncolog
texa
children
cancer
center
baylor
colleg
medicin
houston
usa
pediatr
baylor
colleg
medicin
houston
usa
pediatricsradiolog
baylor
colleg
medicin
houston
usa
object
routin
imag
often
obtain
surveil
diseas
relaps
respons
assess
children
rhabdomyosarcoma
evid
whether
imag
improv
patient
outcom
compar
surviv
patient
relaps
detect
basi
clinic
symptom
versu
routin
imag
method
children
relaps
rhabdomyosarcoma
treat
texa
children
hospit
identifi
overal
surviv
os
time
relaps
compar
two
group
patient
present
symptom
relat
relaps
patient
whose
relaps
initi
detect
imag
prior
symptom
differ
surviv
time
evalu
analysi
bivari
adjust
age
stage
clinic
group
histolog
diagnosi
result
children
relaps
rhabdomyosarcoma
treat
texa
children
hospit
identifi
overal
surviv
os
time
relaps
compar
two
group
patient
present
symptom
relat
relaps
patient
whose
relaps
initi
detect
imag
prior
symptom
differ
surviv
time
evalu
analysi
bivari
adjust
age
stage
clinic
group
histolog
diagnosi
conclus
result
suggest
routin
imag
surveil
relaps
diseas
children
rhabdomyosarcoma
associ
longer
patient
surviv
valid
result
larger
studi
limit
use
surveil
imag
could
reduc
medic
cost
radiat
exposur
without
compromis
patient
outcom
impact
respons
induct
chemotherapi
surviv
local
control
embryon
paramening
rhabdomyosarcoma
ladra
h
mandevil
niemierko
macdonald
friedmann
n
tarbel
yock
radiat
oncolog
massachusett
gener
hospit
boston
usa
radiat
oncolog
royal
marsden
hospit
london
unit
kingdom
pediatr
hematolog
oncolog
massachusett
gener
hospit
boston
usa
object
diseas
control
remain
challeng
pediatr
paramening
rhabdomyosarcoma
studi
set
identifi
predictor
failur
method
identifi
patient
local
embryon
age
year
without
surgic
resect
patient
complet
mri
imag
data
patient
treat
chemotherapi
follow
proton
therapi
median
dose
gyrb
gyrb
tumor
volum
determin
prior
initi
chemotherapi
prior
proton
therapi
induct
chemotherapi
dimens
tumor
measur
mri
ellipsoid
tumor
volum
calcul
use
formula
result
median
follow
year
actuari
ff
os
ci
ci
respect
local
failur
lf
predomin
seen
failur
cumul
incid
lf
ci
median
time
initi
ct
start
rt
week
patient
lf
greater
median
volum
compar
lc
vs
smaller
rel
percent
reduct
tumor
size
initi
chemotherapi
vs
tumor
volum
rel
percent
reduct
tumor
volum
significantli
associ
lf
p
p
respect
univari
cox
regress
ff
p
p
respect
factor
includ
age
sex
initi
tumor
volum
interv
ct
rt
intracrani
extens
associ
lf
ff
conclus
poor
respons
induct
chemotherapi
appear
associ
increas
risk
lf
ff
os
pediatr
embryon
result
japan
rhabdomyosarcoma
studi
group
protocol
use
vincristin
dactinomycin
cyclophosphamid
radiat
therapi
embryon
rhabdomyosarcoma
h
hosoi
h
hojo
h
okita
j
hata
h
masaki
nozaki
soejima
h
ikeda
k
horib
ohta
j
hara
takimoto
miyachi
k
tsuchiya
teramukai
morikawa
pediatr
kyoto
prefectur
univers
medicin
kyoto
japan
clinic
medicin
diagnost
patholog
aizu
medic
center
fukushima
medic
univers
aizu
japan
pediatr
hematolog
oncolog
research
nation
center
child
health
develop
tokyo
japan
central
institut
experiment
anim
kawasaki
japan
radiotherapi
kameda
medic
center
kamogawa
japan
radiolog
dokkyo
medic
univers
koshigaya
hospit
koshigaya
japan
radiat
oncolog
hyogo
cancer
center
akashi
japan
pediatr
surgeri
dokkyo
medic
univers
koshigaya
hospit
koshigaya
japan
innov
clinic
research
center
nation
hospit
organ
nagoya
medic
center
nagoya
japan
pediatr
shiga
univers
medic
scienc
seta
japan
pediatr
hematologyoncolog
children
medic
center
osaka
citi
gener
hospit
osaka
japan
clinic
epidemiolog
research
center
childhood
cancer
nation
center
child
health
develop
tokyo
japan
innov
clinic
research
center
kanazawa
univers
hospit
kanazawa
japan
pediatr
surgeri
intern
univers
health
welfar
ohtawara
japan
object
patient
local
grossli
resect
gross
residu
orbit
embryon
rhabdomyosarcoma
erm
surviv
ff
rate
overal
surviv
os
rate
use
intergroup
rhabdomyosarcoma
studi
group
protocol
iv
howev
protocol
prescrib
cyclophosphamid
caus
infertil
protocol
object
includ
reduc
cyclophosphamid
dose
could
keep
fertil
method
subgroup
patient
lowest
risk
erm
stage
group
iiia
stage
group
iii
orbit
stage
group
receiv
cycl
week
vincristin
dactinomycin
cyclophosphamid
therapi
patient
group
iiiii
receiv
radiotherapi
gy
stage
group
iia
patient
gy
group
iii
orbit
patient
result
pf
rate
ci
os
rate
subgroup
patient
n
median
year
among
five
group
iii
patient
three
patient
achiev
best
respons
cr
two
achiev
best
respons
pr
advers
event
includ
neutropenia
anemia
thrombocytopenia
nausea
stomat
peripher
neuropathi
constip
administr
vincristin
dactinomycin
reduc
two
case
develop
diseas
late
effect
orbit
primari
tumor
includ
cataract
three
case
ptosi
eye
movement
disord
two
case
bladder
wall
thicken
vesicoureter
reflux
hydronephrosi
observ
one
case
paratesticular
primari
tumor
cosmet
problem
aros
case
head
neck
primari
tumor
mortal
occur
conclus
signific
toxic
occur
use
cyclophosphamid
surviv
rate
similar
previou
protocol
studi
group
dosimetr
comparison
proton
radiotherapi
imrt
pediatr
rm
patient
enrol
phase
ii
proton
studi
ladra
edgington
moteab
mahajan
grosshan
macdonald
n
tarbel
yock
radiat
oncolog
massachusett
gener
hospit
boston
usa
radiat
oncolog
univers
texa
md
anderson
cancer
center
houston
usa
object
chemotherapi
radiat
pediatr
rhabdomyosarcoma
rm
highli
curabl
howev
cure
may
come
signific
radiat
relat
toxic
expos
develop
tissu
proton
therapi
pt
may
spare
excess
dose
normal
structur
potenti
reduc
incid
advers
effect
method
patient
enrol
prospect
phase
ii
trial
pt
pediatr
rm
intens
modul
radiat
therapi
imrt
plan
gener
comparison
clinic
pt
plan
clinic
target
normal
tissu
volum
held
constant
imrt
plan
optim
target
volum
coverag
normal
tissu
spare
accord
cog
protocol
guidelin
result
target
coverag
compar
pt
imrt
plan
mean
ctv
modal
p
howev
integr
dose
time
higher
imrt
rang
site
integr
dose
imrt
time
higher
h
n
pt
p
time
higher
gu
p
trunkextrem
pt
p
time
higher
orbit
pt
p
signific
spare
seen
pt
critic
structur
assess
mean
tempor
lobe
time
higher
mean
hypothalam
dose
time
higher
imrt
plan
h
n
orbit
site
p
case
len
dose
gy
seen
pt
patient
imrt
patient
p
mean
testicular
dose
gy
pt
gy
imrt
p
mean
ovarian
dose
gy
pt
gy
imrt
p
pelvic
growth
plate
pt
imrt
p
conclus
proton
radiat
lower
integr
dose
improv
normal
tissu
spare
compar
imrt
pediatr
rm
correl
clinic
outcom
necessari
profil
outcom
children
rhabdomyosarcoma
experi
pgimer
chandigarh
india
bansal
da
trehan
r
kapoor
sc
sharma
kln
rao
nk
panda
r
srinivasan
rajwanshi
n
kakkar
ks
sodhi
ak
saxena
rk
marwaha
pediatr
unit
dept
pediatr
advanc
pediatr
centr
postgradu
institut
medic
educ
research
chandigarh
india
radiotherapi
postgradu
institut
medic
educ
research
chandigarh
india
pediatr
surgeri
postgradu
institut
medic
educ
research
chandigarh
india
otolaryngolog
postgradu
institut
medic
educ
research
chandigarh
india
cytolog
postgradu
institut
medic
educ
research
chandigarh
india
histopatholog
postgradu
institut
medic
educ
research
chandigarh
india
radiodiagnosi
postgradu
institut
medic
educ
research
chandigarh
india
object
aim
retrospect
evalu
profil
outcom
children
rhabdomyosarcoma
rm
singl
center
method
case
record
children
rm
analyz
result
case
record
children
examin
median
age
present
year
interquartil
rang
iqr
f
ratio
mean
interv
month
iqr
infant
congenit
rm
frequent
site
involv
includ
headneck
genitourinari
unfavor
site
major
tumor
cm
patholog
embryon
patholog
treatment
includ
chemotherapi
surgic
excis
feasibl
follow
radiotherapi
residu
diseas
inoper
tumor
well
chemotherapi
low
risk
patient
given
vincristin
week
intermedi
high
risk
group
receiv
vincristin
cyclophosphamid
doxorubicin
etoposid
week
treatment
refus
abandon
major
concern
among
patient
opt
treatment
surgeri
perform
receiv
radiotherapi
evalu
patient
die
febril
neutropenia
progress
diseas
relaps
mean
time
relaps
month
iqr
survivor
free
diseas
follow
mean
durat
year
event
free
surviv
conclus
larg
studi
pediatr
rm
india
event
free
surviv
treatment
abandon
major
concern
particularli
earli
year
unit
strengthen
manag
strategi
initi
sever
remedi
measur
long
term
outcom
orbit
rhabdomyosarcoma
children
experi
institut
curi
h
boutroux
c
cellier
v
mosseri
helfr
c
levi
l
desjardin
c
plancher
p
freneaux
j
michon
orbach
pediatr
adolesc
young
adult
depart
institut
curi
pari
franc
depart
radiolog
institut
curi
pari
franc
depart
biostatist
institut
curi
pari
franc
radiotherapi
depart
institut
curi
pari
franc
ophthalmolog
depart
institut
curi
pari
franc
depart
patholog
institut
curi
pari
franc
object
local
rhabdomyosarcoma
associ
good
surviv
rate
consid
favor
site
primari
concern
orbit
orm
treatment
base
associ
best
local
therapi
sometim
surgeri
often
radiat
therapi
regard
initi
tumor
featur
tumor
respons
method
retrospect
monocentr
analyz
set
better
defin
outcom
patient
local
orm
paramening
treat
institut
curi
order
better
defin
patient
avoid
aggress
local
treatment
diagnosi
result
patient
analyz
median
age
diagnosi
year
rang
year
median
year
rang
month
year
paramening
extens
present
patient
irradi
therapi
part
primari
therapi
patient
year
ef
overal
surviv
os
respect
ef
similar
paramening
tumor
vs
p
wherea
os
significantli
better
tumor
vs
p
multivari
analysi
initi
tumor
size
remain
statist
signific
adjust
radiat
therapi
treatment
p
wherea
radiat
therapi
first
line
longer
statist
prognosi
factor
os
adjust
tumor
treatment
characterist
p
conclus
local
orm
remain
locat
favor
outcom
despit
actual
tendenc
reduc
agress
indic
local
therapi
sourc
ophthalmolog
structur
late
effect
patient
favor
pattern
strict
orm
treat
without
radiat
therapi
first
line
treatment
orm
paramening
extens
receiv
addit
radiotherapi
retrospect
analysi
outcom
patient
relaps
refractori
metastat
sarcoma
receiv
metronom
chemotherapi
kumar
dongr
b
arora
p
kurkur
g
chinnaswami
b
rekhi
laskar
kembhavi
puri
sd
banavali
medic
oncolog
tata
memori
hospit
mumbai
india
patholog
tata
memori
hospit
mumbai
india
radiat
oncolog
tata
memori
hospit
mumbai
india
radiolog
tata
memori
hospit
mumbai
india
surgic
oncolog
tata
memori
hospit
mumbai
india
object
studi
efficaci
toler
metronom
therapi
tamoxifen
etoposid
cyclophosphamid
refractori
relaps
metastat
soft
tissu
sarcoma
ewe
sarcoma
rhabdomyosarcoma
soft
tissu
sarcoma
method
retrospect
singl
institut
observ
studi
retrospect
review
data
patient
relaps
refractori
metastat
soft
tissu
sarcoma
st
ewe
sarcoma
es
rhabdomysarcoma
rm
st
treat
metronom
protocol
oral
tamoxifen
etoposid
cyclophosphamid
tec
period
april
septemb
approv
obtain
institut
review
board
waiver
consent
grant
patient
includ
analysi
relaps
primari
protocol
treat
metronom
tec
protocol
primari
refractori
metastat
diseas
rm
es
receiv
metronom
tec
therapi
result
patient
enrol
among
patient
diagnos
es
rm
st
whole
cohort
respons
rate
rr
clinic
benefit
rate
cbr
patient
studi
group
follow
subgroup
system
recurrentrelaps
diseas
n
metastat
diseas
present
n
local
diseas
refractoryrecurr
n
none
patient
requir
blood
platelet
support
admiss
support
care
median
pf
os
month
month
patient
respect
system
recurr
vs
month
month
respect
patient
primari
metastat
diseas
best
month
month
respect
patient
local
recurrentresidu
diseas
conclus
studi
provid
preliminari
evid
efficaci
toler
metronom
chemotherapi
poor
risk
es
rm
also
demonstr
low
cost
low
risk
treatment
patient
could
go
long
term
remiss
despit
high
diseas
burden
also
given
mainten
therapi
show
excel
long
term
outcom
synovi
sarcoma
relaps
children
adolesc
prognost
factor
treatment
outcom
f
sool
c
maupain
defachel
taqu
v
c
bergeron
de
ryck
orbach
pediatr
adolesc
young
adult
depart
institut
curi
pari
franc
patholog
depart
european
hospit
georg
pompid
pari
franc
pediatr
oncolog
depart
centr
oscar
lambret
lill
franc
pediatr
depart
hopit
sud
centr
hospitali
universitair
renn
franc
pediatr
depart
institut
gustav
roussi
villejuif
franc
pediatr
depart
institut
dhematologi
et
doncologi
pediatriqu
lyon
franc
biostatist
depart
institut
curi
pari
franc
object
patient
synovi
sarcoma
ss
relaps
appropri
treatment
experi
poor
outcom
patient
salvag
therapi
need
clearli
identifi
method
data
patient
treat
sfce
de
cancer
de
lenfant
center
initi
diagnosi
local
ss
age
year
treat
experienc
least
one
relaps
retriev
descript
analysi
statist
analysi
perform
determin
prognost
factor
result
patient
identifi
first
relaps
occur
median
interv
month
local
case
metastat
case
treatment
relaps
consist
new
surgeri
case
chemotherapi
case
radiotherapi
case
respons
rate
regimen
overal
patient
achiev
second
complet
remiss
median
surviv
overal
surviv
factor
significantli
correl
better
surviv
primari
tumor
involv
limb
age
less
year
diagnosi
absenc
chemotherapi
radiotherapi
initi
treatment
local
relaps
conclus
despit
poor
overal
outcom
relaps
synovi
sarcoma
sometim
remain
curabl
aggress
surgeri
possibl
combin
chemotherapi
radiotherapi
recommend
treatment
regimen
may
remain
effect
patient
relaps
ss
howev
altern
therapi
propos
patient
poor
prognost
factor
role
prognost
factor
soft
tissu
sarcoma
neurogen
origin
mpnst
children
treat
cw
protocol
e
bien
krawczyk
b
kazanowska
j
godzinski
e
e
p
czauderna
w
balwierz
kurylak
g
sobol
bm
w
jazdon
j
reich
urbanik
pediatr
hematolog
oncolog
medic
univers
gdansk
gdansk
poland
pediatr
hematolog
oncolog
bone
marrow
transplant
medic
univers
wroclaw
wroclaw
poland
pediatr
surgeri
marciniak
hospit
wroclaw
poland
laboratori
gener
patholog
neuropatholog
medic
univers
gdansk
gdansk
poland
surgeri
urolog
children
adolesc
medic
univers
gdansk
gdansk
poland
pediatr
oncolog
hematolog
jagiellonian
univers
collegium
medicum
krakow
poland
pediatr
hematolog
oncolog
nicolau
copernicu
univers
collegium
medicum
bydgoszcz
poland
oncolog
surgeri
children
youth
mother
child
institut
warszawa
poland
oncolog
hematolog
chemotherapi
medic
univers
silesia
katowic
poland
pediatr
oncolog
hematolog
diabetolog
medic
univers
lodz
lodz
poland
pediatr
surgeri
medic
univers
silesia
katowic
poland
pediatr
oncolog
hematolog
transplantolog
medic
univers
poznan
poznan
poland
pediatr
hematolog
oncolog
transplantolog
medic
univers
lublin
lublin
poland
object
aim
studi
assess
role
particular
clinic
prognost
factor
childhood
soft
tissu
sarcoma
neurogen
origin
mpnst
method
studi
includ
children
mpnst
mf
age
month
month
treat
cw
protocol
polish
center
pediatr
oncolog
result
neurofibromatosi
type
found
patient
children
present
extens
invas
tumor
diagnost
biopsi
primari
tumor
surgeri
made
cr
pr
respons
rate
cht
delay
surgeri
done
radiotherapi
rtx
ist
line
therapi
use
patient
recurr
occur
includ
mani
children
initi
qualifi
ir
ii
patient
die
pd
aliv
cr
fu
year
neg
prognost
factor
includ
tumor
locat
retroperiton
intern
organ
tumor
size
cm
coexist
failur
carri
complet
resect
tumor
stage
diseas
significantli
worsen
ef
os
respons
cht
depend
presenc
affect
significantli
conclus
high
rate
local
recurr
primari
surgeri
suggest
underestim
mpnst
stage
patient
primari
resect
requir
adjuv
local
therapi
surgic
andor
rtx
complet
resect
tumor
stage
diseas
aim
significantli
improv
prognosi
survivor
primari
secondari
resect
sustain
cr
cht
unlik
howev
cht
may
prevent
metastat
recurr
coexist
significantli
worsen
prognosi
children
mpnst
phase
studi
sunitinib
oral
tyrosin
kinas
inhibitor
subject
plexiform
neurofibroma
updat
c
shih
n
swigonski
j
case
k
robertson
c
dwight
c
ho
markel
f
yang
clapp
pediatr
indiana
univers
school
medicin
indianapoli
usa
purpos
sunitinib
malat
oral
bioavail
competit
inhibitor
vascular
endotheli
growth
factor
vegfr
growth
factor
pdgfr
tyrosin
kinas
phase
efficaci
trial
evalu
two
cohort
subject
adult
pediatr
clinic
signific
plexiform
neurofibroma
primari
respons
indic
tumor
respons
mri
imag
secondari
respons
indic
includ
volumetr
mri
imag
qualiti
life
measur
biomark
evalu
cytokin
endotheli
progenitor
cell
outcom
object
studi
assess
secondari
respons
indic
ie
pain
subject
least
month
method
frequenc
sever
pain
medic
usag
document
initi
enrol
visit
month
subject
sunitinib
data
patient
treat
imatinib
obtain
retrospect
chart
review
result
date
subject
enrol
evalu
consist
adult
pediatr
patient
two
subject
complet
studi
one
stabl
diseas
anoth
progress
diseas
two
subject
withdrew
studi
prior
evalu
patient
least
month
report
less
pain
decreas
pain
medic
util
patient
complain
either
increas
pain
pain
medic
usag
subject
report
increas
pain
use
pain
medic
compar
patient
treat
imatinib
patient
treat
sunitinib
report
statist
less
pain
p
less
pain
medic
usag
p
conclus
limit
patient
data
current
avail
respons
indic
pain
respons
secondari
indic
major
contributor
qualiti
life
daili
function
subject
trial
encourag
kaposi
sarcoma
children
open
randomis
trial
vincristin
oral
etoposid
combin
vincristin
bleomycin
g
chagaluka
e
molyneux
c
stanley
depani
israel
bailey
c
georg
paediatr
child
health
queen
elizabeth
central
hospit
blantyr
malawi
paediatr
child
health
colleg
medicin
blantyr
malawi
univers
malawi
chancellor
colleg
zomba
malawi
oncolog
royal
marsden
hospit
london
unit
kingdom
oncolog
vu
univers
medic
centr
amsterdam
netherland
oncolog
great
northern
hospit
newcastl
unit
kingdom
oncolog
queen
elizabeth
central
hospit
blantyr
malawi
object
introduct
kaposi
sarcoma
ks
common
childhood
cancer
place
hiv
endem
access
antiretrovir
therapi
art
delay
despit
randomis
trial
compar
assess
chemotherapeut
regimen
method
open
label
randomis
trial
compar
intraven
vincristin
alon
vincristin
bleomycin
oral
etoposid
carri
children
kaposi
sarcoma
queen
elizabeth
central
hospit
blantyr
malawi
hiv
infect
children
given
art
cours
chemotherapi
alreadi
treatment
neither
hiv
widespread
ks
curabl
treatment
aim
diseas
reduct
improv
qualiti
life
tumour
reduct
assess
measur
size
sentinel
ks
nodul
qualiti
life
qol
use
lanski
score
follow
death
one
year
result
children
enrol
art
hiv
neg
surviv
influenc
age
gender
better
oral
etoposid
vincristin
bleomycin
group
p
group
receiv
oral
etoposid
better
qualiti
life
toxic
signific
drop
haemoglobin
white
cell
count
could
causal
relat
hiv
infect
rather
cytotox
therapi
conclus
oral
etoposid
safe
effect
treatment
contain
ks
improv
qol
achiev
without
mani
visit
hospit
intraven
inject
health
care
util
cost
last
year
life
children
malign
p
ananth
p
melvin
jg
berri
j
wolf
pediatr
hematologyoncolog
children
cancer
blood
disord
center
boston
usa
program
patient
safeti
qualiti
boston
children
hospit
boston
usa
divis
gener
pediatr
boston
children
hospit
boston
usa
depart
psychosoci
oncolog
palli
care
cancer
institut
boston
usa
object
littl
known
children
malign
util
health
care
last
year
life
object
describ
durat
cost
admiss
last
year
life
children
malign
die
one
us
children
hospit
examin
hospit
resourc
use
termin
admiss
method
studi
children
malign
age
year
die
data
obtain
pediatr
health
inform
system
databas
malign
identifi
use
code
assess
hospit
day
total
intens
care
unit
hospit
cost
stratifi
class
malign
solid
vs
hematolog
last
year
life
also
character
hospit
day
intervent
receiv
termin
admiss
result
median
age
death
year
iqr
children
white
public
insur
last
year
life
children
malign
spent
median
day
hospit
iqr
day
icu
iqr
compar
children
solid
malign
children
hematolog
malign
n
higher
median
hospit
day
cost
median
hospit
day
iqr
median
cost
iqr
termin
admiss
children
unplan
hospit
children
spent
median
day
iqr
admit
median
icu
day
iqr
children
mechan
ventil
time
visit
oper
room
termin
admiss
conclus
children
malign
experi
lengthi
costli
hospit
last
year
life
undergo
invas
procedur
termin
admiss
children
hematolog
malign
appear
highest
cost
investig
may
reveal
whether
palli
care
intervent
children
might
improv
hospit
util
qualiti
life
assess
invis
financi
burden
face
famili
cancer
children
develop
countri
j
pulivadula
venkatasai
jx
scott
r
manipriya
ms
latha
rajendran
dept
pediatr
divis
sri
ramachandra
medic
colleg
research
institut
chennai
india
object
diagnosi
cancer
child
famili
crisi
cost
treatment
direct
medic
expens
also
expens
loss
pay
though
exist
financi
strain
well
known
studi
system
medic
literatur
especi
develop
countri
like
india
principl
object
studi
system
review
financi
burden
includ
invis
expens
incur
famili
children
cancer
social
perspect
method
famili
children
undergo
treatment
particip
studi
parentsguardian
interview
prepar
questionnair
session
studi
period
aug
result
patient
hematolog
malign
male
femal
mean
age
year
patient
household
annual
incom
rang
expens
account
monthli
household
incom
parent
rural
area
household
incom
urban
area
expens
food
travel
emerg
major
contribut
factor
sever
econom
effect
famili
patient
use
public
transport
like
train
buse
travel
treatment
invis
expens
loss
pay
seen
often
work
mother
father
household
multipl
children
restrict
need
sibl
provid
diseas
child
famili
borrow
money
money
lender
averag
interest
rate
push
state
debt
next
year
conclus
bring
financi
burden
experienc
famili
limelight
especi
invis
expens
issu
taken
seriou
consider
healthcar
plan
polici
make
aprepit
therapi
children
receiv
highli
emetogen
chemotherapi
random
doubl
blind
trial
bakhshi
batra
b
biswa
dhawan
r
paul
v
sreeniva
medic
oncolog
dr
bra
irch
aiim
delhi
india
biostatist
dr
bra
irch
aiim
delhi
india
object
aprepit
receptor
antagonist
combin
antagonist
dexamethason
recommend
adult
receiv
moder
highli
emetogen
chemotherapi
reduc
nausea
vomit
cinv
data
use
aprepit
children
limit
includ
guidelin
prevent
cinv
method
random
trial
conduct
singl
center
chemotherapi
children
year
receiv
highli
emetogen
chemotherapi
patient
receiv
intraven
ondanseteron
mgkg
dexamethason
mgkg
prior
chemotherapi
patient
randomli
assign
aprepit
arm
receiv
oral
aprepit
day
day
one
hour
chemotherapi
primari
outcom
measur
incid
acut
moder
sever
vomit
control
group
receiv
placebo
therapi
result
random
patient
three
exclud
analysi
patient
analyz
aprepit
arm
placebo
arm
acut
moder
sever
vomit
report
patient
receiv
placebo
patient
receiv
aprepit
p
acut
phase
assess
oral
intak
includ
fluid
food
significantli
decreas
control
group
compar
aprepit
arm
vs
p
vs
p
respect
major
advers
effect
note
conclus
first
doubl
blind
random
placebo
control
trial
unequivoc
show
aprepit
significantli
decreas
incid
acut
moder
sever
vomit
use
drug
ondanseteron
dexamethason
children
receiv
highli
emetogen
chemotherapi
http
clinicaltrialsgov
identifi
oral
vs
intraven
antibiot
low
risk
paediatr
febril
neutropenia
randomis
control
trial
vedi
rj
cohn
kid
cancer
centr
sydney
children
hospit
sydney
australia
object
sepsi
major
caus
morbid
mortal
paediatr
oncolog
patient
particularli
period
neutropenia
complic
immunosuppress
therapi
stratif
patient
low
categori
facilit
new
tailor
approach
empir
therapi
avail
oral
antimicrobi
drug
activ
common
pathogen
may
provid
attract
altern
aim
determin
whether
febril
neutropen
paediatr
popul
oral
antibiot
effect
intraven
antibiot
obtain
resolut
febril
neutropen
episod
method
comprehens
literatur
search
medlin
embas
central
identifi
prospect
randomis
control
trial
compar
oral
antibiot
intraven
antibiot
treatment
febril
neutropen
episod
paediatr
oncolog
patient
outcom
assess
mortal
rate
treatment
failur
length
febril
neutropen
episod
advers
event
random
effect
model
use
calcul
risk
ratio
rr
dichotom
data
mean
differ
standard
deviat
continu
data
result
seven
trial
includ
overal
analysi
includ
episod
febril
neutropenia
patient
age
month
year
overal
treatment
failur
rate
significantli
differ
oral
intraven
antibiot
rr
ci
p
conclus
care
select
febril
neutropen
children
empir
treatment
oral
antibiot
safe
effect
altern
intraven
antibiot
lower
cost
treatment
psychosoci
burden
children
famili
bacteri
spectrum
antimicrobi
suscept
pattern
blood
stream
infect
acut
lymphoblast
leukemia
children
febril
neutropenia
children
cancer
hospit
khatoon
f
zameer
r
punjwani
narijo
infect
control
children
cancer
hospit
karachi
pakistan
microbiolog
children
cancer
hospit
karachi
pakistan
nurs
educ
children
cancer
hospit
karachi
pakistan
medic
record
children
cancer
hospit
karachi
pakistan
object
bacteri
infect
major
caus
morbid
mortal
chemotherapi
induc
febril
neotropen
patient
regular
monitor
bacteri
epidemiolog
allow
evalu
antibacteri
strategi
purpos
studi
identifi
type
organ
antibiot
resist
pattern
necessari
know
categori
resist
organ
start
antibiot
method
data
retrospect
collect
medic
record
cch
patient
diagnos
chemotherapi
induc
febril
neutropenia
along
posit
cultur
januari
decemb
analyz
result
thirti
patient
studi
period
one
year
male
femal
median
age
year
patient
present
febril
neutropenia
induct
phase
patient
consolid
remain
induct
phase
treatment
acut
leukemia
major
caus
fn
hematolog
malign
children
cancer
hospit
accord
preliminari
analysi
pathogen
isol
organ
organ
fungi
popul
organ
isol
coagulas
neg
staphylococcu
follow
enterococcu
gram
neg
pseudomona
isol
major
coagulas
neg
staphylococcu
resist
oxacillin
levofloxacin
vancomycin
enteroccocu
resist
vancomycin
levofloxacin
amikcin
sensit
linezolid
pseudomona
mostli
sensit
antimicrobi
meronium
tazocin
levofloxacin
polymixin
b
amikcin
conclus
cougulas
neg
staph
mostli
found
studi
control
help
effect
infect
control
antibiot
cycl
neutropen
fever
implement
follow
extend
time
period
resist
remain
stabl
studi
necessari
clarifi
effect
cycl
antibiot
resist
patient
outcom
hospit
cost
preserv
varicella
serolog
titer
pediatr
oncolog
patient
follow
chemotherapi
p
de
gouveia
chiang
um
c
clarkston
r
ramphal
hematologyoncolog
children
hospit
eastern
ontario
ottawa
canada
object
pediatr
oncolog
patient
current
practic
includ
administ
immunoglobulin
vzig
prophylaxi
pep
viru
vzv
isol
patient
day
pediatr
oncolog
patient
immun
vzv
prior
cancer
diagnosi
repres
popul
like
preserv
immun
diseas
patient
popul
need
vzig
isol
poorli
valid
may
undu
health
care
cost
inconveni
patient
therefor
assess
vzv
serolog
marker
persist
immun
vzv
chemotherapi
method
approv
research
ethic
board
children
hospit
eastern
ontario
cheo
obtain
prior
studi
varicella
antibodi
titer
collect
pediatr
oncolog
patient
treat
cheo
patient
includ
studi
posit
titer
time
malign
diagnosi
vzv
antibodi
titer
treatment
result
elig
patient
posit
antibodi
titer
vzv
time
malign
diagnosi
patient
posit
neg
equivoc
post
chemotherapi
vzv
antibodi
titer
respect
moreov
varicella
breakthrough
diseas
develop
zoster
chemotherapi
prior
vzv
antibodi
titer
correl
age
tumour
type
preserv
vzv
antibodi
titer
conclus
major
pediatr
oncolog
patient
prior
vzv
antibodi
titer
preserv
vzv
immun
post
chemotherapi
consequ
popul
vzig
pep
isol
hospit
may
necessari
japan
unit
kingdom
acyclovir
use
altern
patient
vzv
seroposit
prior
malign
studi
determin
risk
factor
predispos
patient
breakthrough
diseas
may
identifi
subgroup
vzig
pep
necessari
role
parvo
viru
infect
caus
unexplain
complic
cancer
chemotherapi
children
commonli
unrecognis
problem
kumar
n
roy
moulik
n
verma
jain
p
jain
pediatr
king
georg
medic
univers
lucknow
india
virolog
king
georg
medic
univers
lucknow
india
object
children
cancer
cytopenia
transamin
inappropri
intens
chemotherapi
caus
treatment
delay
may
rais
concern
relaps
caus
often
remain
undetect
examin
role
parvo
viru
causat
unexplain
complic
method
children
cancer
chemotherapi
unexplain
cytopenia
andor
transamn
screen
parvoviru
infect
anti
igm
andor
dna
pcr
januari
decemb
clinic
cours
laboratori
paramet
respons
ivig
intraven
immunoglobulin
test
posit
describ
result
infect
detect
children
screen
leukemia
lymphoma
solid
tumor
posit
patient
isol
anemia
neutropenia
thrombocytopenia
seen
patient
respect
remain
patient
anemia
along
neutropenia
andor
thrombocytopenia
andor
posit
children
haematolog
malign
significantli
lower
haemoglobin
compar
solid
tumor
vs
gmdl
p
chemotherapi
interrupt
day
seen
higher
proport
children
haematolog
malign
compar
solid
tumor
posit
children
ivig
given
sever
ill
one
child
given
ivig
expir
report
avail
median
durat
recoveri
count
children
receiv
ivig
rang
day
thu
allow
earli
resumpt
chemotherapi
conclus
account
nearli
case
unexplain
complic
chemotherapi
seri
ill
sever
children
haematolog
malign
clinic
suspicion
earli
treatment
ivig
reduc
diseas
sever
durat
chemotherapi
interrupt
feasibl
new
screen
tool
optimis
manag
patient
chemotherapi
induc
peripher
neuropathi
cipn
p
loughnan
f
clinton
capra
depart
physiotherapi
ladi
children
hospit
dublin
ireland
depart
haematolog
oncolog
ladi
children
hospit
dublin
ireland
object
dublin
cipn
screen
tool
develop
enhanc
qualiti
pre
chemotherapi
examin
patient
receiv
vincristin
therebi
improv
detect
rate
cipn
facilit
appropri
onward
referr
method
retrospect
review
undertaken
highlight
limit
pre
chemotherapi
assess
patient
receiv
vincristin
tertiari
children
cancer
centr
dublin
cipn
screen
tool
consequ
develop
pilot
throughout
part
pre
chemotherapi
assess
patient
receiv
vincristin
prospect
review
evalu
qualiti
pre
chemotherapi
assess
cipn
detect
rate
subsequ
manag
cipn
complianc
screen
tool
user
satisfact
rate
also
evalu
result
introduct
dublin
cipn
screen
tool
tertiari
children
cancer
centr
result
increas
recognit
potenti
sign
symptom
cipn
versu
prompt
frequent
modif
vincristin
dose
versu
close
monitor
cipn
chang
allow
administr
higher
cumul
dose
vincristin
dose
modif
necessari
versu
staff
complianc
utilis
dublin
cipn
screen
tool
satisfact
rate
high
although
difficulti
examin
children
less
year
age
highlight
conclus
introduct
dublin
cipn
screen
tool
result
increas
detect
rate
cipn
time
recognit
sever
cipn
frequent
modif
vincristin
dose
tertiari
children
cancer
centr
recommend
dublin
cipn
screen
tool
minor
amend
adopt
routin
standard
care
centr
qualiti
life
hrql
fatigu
sleep
among
children
cancer
wakefield
ruiz
orsey
center
public
health
health
polici
univers
connecticut
health
center
farmington
usa
clinic
trial
unit
connecticut
children
medic
center
hartford
usa
hematologyoncolog
connecticut
children
medic
center
hartford
usa
object
investig
relationship
qualiti
life
hrql
fatigu
sleep
pediatr
patient
receiv
chemotherapi
andor
radiat
therapi
rt
cancer
method
pediatr
oncolog
patient
year
age
complet
studi
particip
receiv
chemotherapi
andor
rt
cancer
evalu
day
without
hospit
hrql
studi
particip
assess
use
pedsql
pedsql
cancer
modul
administ
children
cancer
parent
sleep
assess
object
actigraphi
sleep
time
wake
sleep
onset
waso
number
wake
bout
sleep
effici
sleep
assess
subject
sleep
diari
complet
particip
parent
determin
sleep
time
sleep
qualiti
morn
mood
fatigu
assess
use
fatigu
scale
child
adolesc
parent
result
studi
particip
consist
pediatr
patient
receiv
chemotherapi
andor
rt
cancer
male
femal
mean
age
year
hrql
score
significantli
correl
sleep
qualiti
p
fatigu
score
p
particip
report
signific
fatigu
also
report
lower
hrql
score
p
although
fatigu
correl
hrql
score
p
hrql
report
patient
higher
parent
assess
hrql
everi
hrql
domain
p
parent
teen
rate
children
procedur
treatment
anxieti
higher
parent
younger
children
p
conclus
hrql
significantli
associ
sleep
fatigu
although
proxi
report
parent
demonstr
correl
hrql
fatigu
discrep
particip
parent
report
warrant
investig
fatigu
sleep
may
modifi
factor
may
offer
mechan
improv
hrql
among
children
cancer
fulfil
vision
cancer
care
well
meet
support
care
need
adolesc
young
adult
aya
patient
drew
r
mcneil
mccarthi
dunt
l
orm
hotchkin
sawyer
centr
adolesc
health
depart
paediatr
royal
children
hospit
univers
melbourn
murdoch
children
research
institut
melbourn
australia
centr
adolesc
health
murdoch
children
research
institut
melbourn
australia
children
cancer
centr
royal
children
hospit
murdoch
children
research
institut
melbourn
australia
centr
health
polici
program
econom
univers
melbourn
melbourn
australia
ontrac
petermac
victorian
adolesc
young
adult
cancer
servic
children
cancer
centr
peter
maccallum
cancer
centr
royal
children
hospit
melbourn
australia
depart
paediatr
univers
melbourn
melbourn
australia
object
despit
global
interest
cancer
servic
reform
evid
best
practic
adolesc
young
adult
aya
care
scare
studi
investig
experi
ayaspar
inform
program
logic
model
psychosoci
support
care
method
stage
involv
qualit
telephon
interview
aya
n
parentpartn
carer
n
stage
involv
survey
nation
repres
sampl
aya
n
parent
n
survey
combin
question
need
survey
psychometr
measur
well
new
question
prompt
analysi
interview
topic
includ
psycholog
health
inform
need
social
support
practic
need
treatment
centr
dissemin
survey
paediatr
adult
result
littl
inform
experi
aya
even
less
experi
carer
project
describ
social
emot
financi
impact
cancer
treatment
percept
qualiti
interact
healthcar
staff
type
support
care
servic
access
barrier
present
focus
unmet
support
care
inform
need
treatment
soon
treatment
end
includ
area
mental
health
support
exercis
therapi
educ
vocat
support
genet
counsel
peer
support
access
inform
specif
design
age
group
also
illustr
way
issu
differ
across
differ
treatment
set
conclus
data
indic
consider
room
improv
mani
area
aya
support
care
sever
theme
previous
describ
literatur
result
show
valu
conceptu
ecolog
model
support
care
need
attend
aya
carer
individu
also
part
system
data
inform
articul
best
practic
model
aya
care
implic
find
health
care
deliveri
import
attend
patient
carer
support
care
need
address
pain
experi
adolesc
cancer
report
longitudin
electron
momentari
assess
studi
l
jibb
jn
stinson
c
nguyen
pc
nathan
maloney
dupui
jt
gerstl
hopyan
b
alman
c
strahlendorf
c
portwin
johnston
hematologyoncolog
hospit
sick
children
toronto
canada
child
health
evalu
scienc
hospit
sick
children
toronto
canada
gener
thorac
surgeri
hospit
sick
children
toronto
canada
orthopaed
surgeri
hospit
sick
children
toronto
canada
orthopaed
surgeri
duke
univers
school
medicin
durham
usa
hematologyoncolog
british
columbia
children
hospit
vancouv
canada
hematologyoncolog
mcmaster
children
hospit
hamilton
canada
hematologyoncolog
children
hospit
eastern
ontario
ottawa
canada
object
adolesc
cancer
report
pain
distress
element
diseas
treatment
neg
impact
qualiti
life
regardless
littl
known
daili
pain
experi
adolesc
especi
everyday
set
eg
home
school
studi
use
multidimension
smartphon
pain
assess
applic
understand
pain
experi
adolesc
cancer
method
longitudin
descript
studi
use
collect
momentari
pain
data
twice
daili
adolesc
recruit
pediatr
tertiari
care
center
adolesc
age
year
variou
cancer
diagnos
undergo
outpati
cancer
care
adolesc
complet
multidimension
pain
assess
smartphon
morn
even
intens
score
rate
cm
visual
analogu
scale
point
rank
pain
locat
captur
use
bodi
map
categor
data
relat
pain
durat
pain
manag
affect
pain
descriptor
record
result
pain
report
n
adolesc
period
eleven
adolesc
report
current
experienc
pain
everi
assess
current
pain
rate
sd
worst
pain
rate
sd
mean
pain
interfer
daili
activ
sd
adolesc
report
pain
occur
abdomen
head
low
back
adolesc
use
pharmacolog
intervent
pain
often
use
pain
medic
use
adolesc
also
use
rest
distract
deep
breath
manag
pain
pain
describ
tire
sicken
cruel
conclus
adolesc
cancer
report
pain
common
symptom
interfer
daili
live
despit
occurr
adolesc
frequent
manag
pain
home
set
may
benefit
intervent
provid
pain
manag
support
polysomnographi
multipl
sleep
latenc
test
find
children
craniopharyngioma
prior
proton
therapi
b
mandrel
v
crabtre
smith
wise
n
west
indelicato
merchant
divis
nurs
research
st
jude
children
research
hospit
memphi
usa
depart
psycholog
st
jude
children
research
hospit
memphi
usa
sleep
center
methodist
univers
hospit
memphi
usa
proton
center
univers
florida
gainesvil
usa
depart
radiat
oncolog
st
jude
children
research
hospit
memphi
usa
object
sleep
relat
problem
excess
daytim
sleepi
ed
common
pediatr
brain
tumor
patient
craniopharyngioma
patient
especi
risk
due
axi
tumor
locat
aggress
therapi
regimen
hypothalam
obes
common
result
tumor
treatment
may
contribut
sleep
disord
breath
daytim
sleepi
breath
pattern
yet
explor
popul
time
diagnosi
method
pediatr
craniopharyngioma
patient
n
underw
overnight
polysomnographi
multipl
sleep
latenc
test
mslt
prior
proton
therapi
assess
sleep
disord
daytim
sleepi
age
rang
year
sampl
primarili
femal
result
averag
particip
spent
minut
bed
sleep
averag
minut
sleep
effici
score
rang
mean
ahi
plm
result
mslt
indic
sampl
troublesom
rang
ed
sol
n
sorem
diagnos
clinic
signific
ed
found
sleep
disord
breath
conclus
craniopharyngioma
survivor
high
rate
clinic
signific
ed
work
demonstr
nearli
half
children
tumor
present
clinic
signific
ed
provid
evid
tumor
impair
alert
longitudin
assess
plan
cohort
describ
trajectori
sleepi
proton
therapi
intervent
popul
nutrit
statu
paediatr
cancer
patient
uk
prospect
cohort
studi
r
revuelta
iniesta
dc
wilson
paciarotti
jm
mckenzi
mfh
brougham
haematolog
oncolog
royal
hospit
sick
children
edinburgh
unit
kingdom
medicin
veterinari
medicin
child
life
health
univers
edinburgh
edinburgh
unit
kingdom
dietet
nutrit
biolog
scienc
queen
margaret
univers
edinburgh
unit
kingdom
haematolog
oncolog
royal
hospit
sick
children
edinburgh
unit
kingdom
object
investig
preval
malnutrit
undernutrit
overnutrit
pattern
chang
nutrit
statu
ns
potenti
factor
may
contribut
develop
malnutrit
paediatr
oncolog
patient
method
multicentr
prospect
perform
ns
assess
aug
use
anthropometri
bodi
composit
dietari
assess
childhood
cancer
categoris
four
group
solid
tumour
haematolog
malign
brain
tumour
associ
cancer
primari
outcom
malnutrit
defin
bodi
mass
index
bmi
accord
uk
growth
chart
centil
underweight
overweight
obes
ns
also
assess
arm
anthropometri
arm
circumfer
muac
tricep
skinfold
tsf
bodi
composit
muscl
ffm
fat
mass
fm
frisancho
percentil
use
establish
ns
arm
anthropometri
correl
independ
multilevel
analysi
perform
result
patient
studi
diagnosi
preval
undernutrit
overweight
obes
tsf
identifi
highest
preval
undernutrit
lowest
obes
bmi
p
ci
fm
p
ci
significantli
increas
month
remain
steadi
thereaft
whilst
ffm
p
ci
significantli
decreas
first
year
energi
intak
show
minor
correl
bmi
r
p
tsf
r
p
diagnosi
signific
differ
observ
diagnost
categori
first
year
howev
haematolog
malign
show
higher
bmi
p
ci
p
ci
month
p
ci
comparison
solid
tumour
conclus
undernutrit
particularli
preval
diagnosi
yet
overnutrit
increas
significantli
treatment
especi
children
diagnos
haematolog
malign
bodi
composit
chang
observ
emphasis
need
implement
target
strategi
improv
ns
paediatr
cancer
patient
olanzapin
treatment
prevent
acut
vomit
children
retrospect
review
j
flank
j
thackray
nielson
august
schechter
alexand
l
sung
dupui
lesli
dan
faculti
pharmaci
univers
toronto
toronto
canada
depart
pharmaci
memori
sloan
ketter
cancer
center
new
york
usa
depart
nurs
children
medic
center
dalla
usa
depart
pharmaci
children
merci
hospit
clinic
kansa
citi
usa
divis
haematologyoncolog
hospit
sick
children
toronto
canada
depart
pharmaci
hospit
sick
children
toronto
canada
object
addit
olanzapin
standard
antiemet
prophylaxi
improv
nausea
vomit
cinv
control
adult
publish
experi
children
cancer
lack
purpos
review
describ
safeti
efficaci
olanzapin
use
vomit
civ
control
children
method
children
year
old
receiv
olanzapin
acut
cinv
control
decemb
august
institut
identifi
patient
characterist
chemotherapi
antiemet
prophylaxi
olanzapin
dose
civ
control
liver
function
test
result
advers
event
abstract
health
record
complet
civ
control
defin
absenc
vomit
retch
throughout
acut
phase
toxic
grade
use
likelihood
toxic
attribut
olanzapin
assess
use
naranjo
scale
result
sixti
children
median
age
year
rang
receiv
olanzapin
chemotherapi
block
olanzapin
often
initi
due
histori
poorli
control
cinv
mean
initi
olanzapin
dose
rang
children
receiv
olanzapin
begin
first
day
chemotherapi
block
experienc
complet
civ
control
associ
olanzapin
dosekg
complet
civ
control
ci
p
sedat
report
chemotherapi
block
significantli
associ
increas
olanzapin
dose
ci
p
chemotherapi
block
alt
andor
ast
report
grade
elev
observ
mean
weight
chang
children
receiv
olanzapin
one
chemotherapi
block
rang
conclus
olanzapin
may
import
option
improv
civ
control
children
prospect
control
evalu
olanzapin
cinv
prophylaxi
children
warrant
central
line
placement
time
diagnosi
children
acut
leukemia
neutrophil
count
matter
p
vallanc
v
lewi
brindl
p
beaudri
u
amendi
strother
l
pediatr
hematolog
oncolog
bone
marrow
transplant
alberta
children
hospit
calgari
canada
pediatr
surgeri
alberta
children
hospit
calgari
canada
pediatr
diagnost
imag
alberta
children
hospit
calgari
canada
object
conflict
data
risk
infect
associ
earli
insert
central
venou
catheth
cvl
neutropen
patient
review
institut
practic
cvl
placement
children
newli
diagnos
leukemia
qualiti
assur
purpos
provid
evid
ongo
controversi
method
retrospect
review
consecut
children
institut
diagnos
leukemia
requir
cvl
placement
neutrophil
count
febril
episod
document
infect
mechan
complic
thrombosi
cvl
remov
within
first
day
treatment
record
result
patient
median
age
year
diagnos
leukemia
aml
cml
underw
cvl
placement
median
time
day
diagnosi
type
cvl
place
broviac
picc
time
cvl
insert
patient
neutrophil
count
median
anc
group
patient
neutropen
cvl
placement
episod
febril
neutropenia
describ
patient
among
document
infect
bacteremia
tunnel
infect
two
remov
document
infect
day
group
patient
line
placement
episod
febril
neutropenia
describ
patient
among
document
infect
bacteremia
one
picc
remov
thrombosi
day
signific
differ
group
term
number
line
remov
p
document
infect
p
febril
neutropen
episod
p
conclus
data
indic
differ
febril
neutropen
episod
line
complic
neutropen
patient
cvl
place
time
diagnosi
therefor
delay
broviac
insert
avoid
infect
line
complic
may
appear
indic
popul
number
infect
tunnel
infect
indic
vigil
requir
cvl
placement
signific
impact
treatment
subsidi
intensifi
counsel
strategi
therapi
abandon
children
acut
lymphoblast
leukemia
prospect
intervent
studi
n
roy
moulik
k
kulkarni
kumar
pediatr
king
georg
medic
univers
lucknow
india
pediatr
iwk
health
centr
halifax
canada
object
treatment
abandon
signific
impedi
improv
surviv
outcom
childhood
develop
nation
pauciti
studi
assess
impact
intervent
reduc
abandon
present
studi
design
assess
impact
treatment
subsidi
counsel
previous
high
abandon
rate
centr
method
case
record
patient
assess
intervent
evalu
intensifi
counsel
ii
treatment
subsidi
treatment
subsidi
includ
free
support
care
drugsantimicrobi
b
free
chemotherapyradiotherapi
c
free
investig
sinc
support
social
worker
data
manag
obtain
research
scheme
allow
improv
track
counsel
intensifi
structur
counsel
multidisciplinari
team
physician
alli
health
worker
disclosur
diagnosi
introduct
support
servic
therapi
plan
participatori
support
famili
centr
approach
period
group
counsel
session
includ
physician
social
worker
survivor
famili
children
undergo
treatment
introduc
earli
late
abandon
defin
abandon
complet
induct
respect
result
patient
abandon
therapi
rate
abandon
post
intervent
declin
significantli
p
compar
earlier
patient
present
compar
demograph
characterist
parent
attend
group
counsel
session
rate
usefula
moral
boost
fight
diseas
post
declin
signific
earli
p
well
late
abandon
p
conclus
present
studi
one
first
prospect
demonstr
signific
impact
subsidis
treatment
intensifi
counsel
well
group
counsel
reduc
earli
late
abandon
patient
function
fatigu
children
adolesc
cancer
earli
find
eo
bomfim
e
anatriello
mdr
nune
lc
lope
junior
rag
lima
lc
nascimento
depart
public
health
nurs
univers
sao
paulo
preto
brazil
object
persist
fatigu
crf
one
troubl
preval
cancer
tratement
evid
suggest
cytokin
might
play
role
etiolog
mechan
symptom
includ
fatigu
object
studi
evalu
associ
among
chemotherapi
proinflammatori
cytokin
fatigu
children
adolesc
cancer
method
questionnair
use
provid
inform
clinic
inform
phase
treatment
week
treatment
medic
use
level
hematocrit
hemoglobin
late
perform
pedsql
multidimension
fatigu
scale
use
measur
fatigu
pediatr
patient
blood
sampl
collect
flow
cytometri
use
evalu
interleukin
level
use
cytometr
bead
array
cba
flex
kit
bd
bioscienc
entir
procedur
perform
follow
instruct
indic
manufactur
result
total
blood
collect
perform
result
show
heterogen
among
differ
cancer
type
present
popul
chemotherapi
protocol
subject
clinic
characterist
fatigu
endpoint
mean
level
md
sd
regard
level
md
sd
weak
moder
correl
observ
among
level
differ
degre
fatigu
divers
type
chemotherapi
treatment
might
lead
vari
present
sever
fatigu
number
confound
factor
identifi
interfer
express
level
cytokin
subject
cancer
type
age
gender
psycho
cognit
characterist
sleep
pattern
conclus
result
suggest
role
proinflammatori
cytokin
fatigu
howev
due
sampl
size
conclus
limit
methodolog
recommend
propos
improv
futur
studi
issu
bring
chemotherapi
administr
daytim
improv
effici
patient
safeti
qualiti
improv
initi
k
mage
j
bate
nanji
b
gandhi
j
mclean
clark
z
swysten
alexand
oncolog
hospit
sick
children
toronto
canada
object
safeti
effici
chemotherapi
deliveri
paramount
care
pediatr
oncolog
patient
larg
tertiari
pediatr
oncolog
center
plan
chemotherapi
initi
day
admiss
concern
identifi
relat
late
day
initi
chemotherapi
includ
less
avail
healthcar
profession
address
chemotherapi
administr
relat
question
respond
reaction
well
addit
nurs
handoff
two
improv
process
initi
move
time
initi
chemotherapi
prior
method
first
initi
standard
rapid
hydrat
protocol
implement
literatur
review
consensu
build
second
initi
develop
follow
valu
stream
map
process
use
identifi
barrier
effici
admiss
initi
chemotherapi
streamlin
patient
admiss
process
gener
evalu
five
pdsa
cycl
result
pediatr
oncolog
program
hospit
sick
children
approxim
plan
chemotherapi
admissionsyear
baselin
data
found
children
plan
inpati
chemotherapi
initi
day
admiss
implement
rapid
hydrat
protocol
improv
five
sequenti
pdsa
cycl
design
evalu
improv
admiss
start
chemotherapi
process
demonstr
continu
improv
pdsa
cycl
includ
admiss
week
patient
chemotherapi
initi
analysi
length
stay
similar
chemotherapi
pre
post
implement
rapid
hydrat
earli
admiss
strategi
demonstr
averag
one
day
decreas
per
cycl
conclus
two
qi
initi
success
improv
percentag
patient
initi
chemotherapi
prior
success
initi
depend
engag
front
line
staff
design
implement
chang
prospect
track
patient
acut
lymphoblast
leukemia
abandon
therapi
parent
perspect
caus
implic
therapi
abandon
tertiari
cancer
care
centr
kumar
n
roy
moulik
k
kulkarni
n
verma
pediatr
king
georg
medic
univers
lucknow
india
pediatr
iwk
health
centr
halifax
canada
object
therapi
abandon
increasingli
recognis
major
contributor
inferior
surviv
outcom
develop
nation
limit
inform
avail
reason
outcom
treatment
abandon
current
studi
provid
insight
obtain
track
famili
patient
acut
lymphoblast
leukemia
abandon
therapi
larg
tertiari
care
cancer
center
india
method
case
record
children
manag
king
georg
medic
univers
abandon
therapi
retriev
ethic
approv
famili
abandon
therapi
subsequ
track
use
predesign
prestructur
telephon
interview
result
children
regist
januari
juli
abandon
refus
treatment
upfront
rest
abandon
variou
phase
chemotherapi
induct
consolid
mainten
rate
illiteraci
significantli
higher
mother
p
father
p
children
abandon
therapi
famili
could
track
telephon
expir
report
well
home
abandon
mainten
consolid
came
back
retreat
relaps
parent
cite
financi
constraint
common
reason
abandon
percept
incur
common
famili
abandon
complet
induct
abandon
later
thought
children
alreadi
cure
surviv
outcom
better
complet
induct
therapi
median
day
abandon
compar
day
p
test
conclus
abandon
rate
highest
complet
induct
follow
mainten
therapi
surviv
wors
children
abandon
therapi
complet
induct
illiteraci
financi
constraint
fals
percept
cure
contribut
abandon
major
short
term
effect
physic
fit
exercis
psychosoci
train
program
childhood
cancer
patient
k
braam
em
van
takken
veen
j
huisman
bier
jhm
merk
mm
van
den
eibrink
gjl
kasper
e
van
den
broeder
pediatr
oncologyhematolog
vu
univers
medic
center
amsterdam
netherland
medic
psycholog
vu
univers
medic
center
amsterdam
netherland
child
develop
exercis
center
wilhelmina
children
hospit
umc
utrecht
utrecht
netherland
medic
psycholog
wilhelmina
children
hospit
umc
utrecht
utrecht
netherland
pediatr
oncologyhematolog
wilhelmina
children
hospit
umc
utrecht
utrecht
netherland
pediatr
oncolog
emma
children
hospit
academ
medic
center
amsterdam
netherland
pediatr
oncologyhematolog
erasmu
mc
sophia
children
hospit
rotterdam
netherland
object
evid
exercis
train
intervent
childhood
cancer
patient
ccp
limit
studi
investig
physic
fit
effect
combin
physic
exercis
psychosoci
train
program
compar
usual
care
ccp
method
multicentr
random
control
trial
ccp
year
old
within
first
year
treatment
invit
particip
stratif
includ
age
sex
solid
tumourhaematolog
cancer
duringaft
treatment
physic
fit
determin
cardiopulmonari
exercis
test
peak
oxygen
uptak
baselin
shortli
intervent
period
result
ccp
age
year
male
includ
analys
n
treat
haematolog
malign
median
chang
score
treatment
group
correct
baselin
score
peak
oxygen
uptak
mlkgmin
significantli
differ
p
intervent
group
int
iqr
control
group
ctrl
iqr
n
int
score
standard
deviat
sd
dutch
paediatr
norm
valu
peak
oxygen
uptak
within
low
normal
rang
sd
ctrl
n
normal
rang
low
normal
rang
plu
one
mean
score
three
children
int
nine
ctrl
progress
normal
rang
low
normal
rang
int
chang
within
group
p
ctrl
chang
within
group
p
chang
group
p
conclus
treatment
group
show
littl
increas
maxim
cardiopulmonari
capac
contrast
expect
intervent
lead
improv
factor
analys
perform
assess
studi
result
plasma
supplement
paediatr
oncolog
patient
uk
cross
section
studi
mfh
brougham
dc
wilson
paciarotti
rfh
chin
c
brand
jm
mckenzi
r
revuelta
iniesta
haematolog
oncolog
royal
hospit
sick
children
edinburgh
unit
kingdom
medicin
veterinari
medicin
child
life
health
univers
edinburgh
edinburgh
unit
kingdom
dietet
nutrit
biolog
scienc
queen
margaret
univers
edinburgh
unit
kingdom
accid
emerg
royal
hospit
sick
children
edinburgh
unit
kingdom
object
assess
impact
micronutri
macronutri
supplement
plasma
oh
scottish
paediatr
oncolog
patient
method
time
seri
studi
perform
plasma
oh
measur
healthi
children
control
paediatr
oncolog
patient
case
children
age
year
diagnos
treat
cancer
se
scotland
includ
childhood
cancer
categoris
four
group
solid
tumour
haematolog
malign
brain
tumour
macronutri
nutrit
micronutri
vitamin
multivitamin
supplement
prescrib
accord
subject
global
assess
multidisciplinari
team
oh
defici
classifi
accord
endocrin
societi
clinic
practic
suboptim
insuffici
defici
plasma
oh
measur
use
autom
vitamin
immunoassay
glasgow
royal
infirmari
laboratori
descript
statist
wilcoxon
test
perform
result
plasma
oh
level
statist
differ
median
iqr
nmoll
patient
median
iqr
nmoll
diagnosi
children
diagnos
solid
tumour
highest
preval
oh
defici
insuffici
follow
haematolog
malign
patient
plasma
oh
measur
supplement
median
iqr
time
diagnosi
supplement
month
supplement
repeat
oh
measur
month
baselin
plasma
oh
suboptim
patient
insuffici
defici
receiv
macronutri
supplement
alon
remain
suboptim
median
iqr
oh
decreas
nmoll
convers
addit
supplement
micronutri
signific
improv
oh
median
iqr
increas
nmoll
p
howev
remain
suboptim
level
conclus
oh
defici
highli
preval
improv
follow
micronutri
supplement
optimis
oh
statu
popul
regular
monitor
alongsid
appropri
supplement
incorpor
clinic
practic
vincristin
induc
cranial
neuropathi
therapi
pediatr
malign
r
brennan
c
nickol
eftink
k
strachota
k
ness
qaddoumi
mw
wilson
j
thompson
oncolog
st
jude
children
research
hospit
memphi
usa
school
medicin
univers
citi
kansa
citi
usa
rehabilit
servic
st
jude
children
research
hospit
memphi
usa
epidemiolog
cancer
control
st
jude
children
research
hospit
memphi
usa
ophthalmolog
univers
tennesse
health
scienc
center
memphi
usa
neck
surgeri
univers
tennesse
health
scienc
center
memphi
usa
object
vincristin
wide
use
treat
pediatr
cancer
howev
incid
sever
cranial
neuropathi
jaw
pain
facial
weak
vocal
cord
dysfunct
dysphagia
dysphonia
optic
neuropathi
well
describ
method
retrospect
chart
review
patient
hematolog
solid
malign
expos
vincristin
therapi
evid
symptomat
cranial
neuropathi
grade
toxic
patient
cranial
neuropathi
diagnosi
receiv
cranial
radiat
exclud
result
elig
subject
experienc
cranial
neuropathi
toxic
common
among
solid
malign
fifteen
male
caucasian
median
age
year
rang
diagnos
includ
acut
lymphoblast
leukemia
n
ewe
sarcoma
n
rhabdomyosarcoma
n
retinoblastoma
n
wilm
tumor
n
primit
neuroectoderm
tumor
n
lymphoblast
lymphoma
n
dysphagia
jaw
pain
preval
vocal
cord
vc
dysfunct
note
seven
patient
one
requir
monitor
intens
care
unit
three
seven
patient
swallow
dysfunct
requir
intervent
dose
reduct
n
tube
n
liquid
n
speech
therapi
n
ten
patient
experienc
multipl
episod
toxic
vincristin
therapi
dose
vincristin
reduc
delay
omit
patient
cranial
neuropathi
jaw
pain
patient
recov
toxic
within
median
day
rang
conclus
review
limit
protocol
document
summar
report
incid
morbid
vincristin
induc
cranial
neuropathi
children
cancer
identif
patient
risk
earli
assess
symptomat
patient
essenti
therapi
modif
andor
clinic
intervent
amelior
ongo
toxic
prevent
control
strategi
implement
hepat
b
viru
outbreak
paediatr
haematolog
oncolog
unit
south
africa
buchner
nm
du
plessi
aven
fe
omar
j
vermeulen
mayaphi
af
haeri
mazanderani
dt
reynder
paediatr
oncolog
unit
univers
pretoria
pretoria
south
africa
paediatr
infecti
diseas
unit
univers
pretoria
pretoria
south
africa
depart
medic
virolog
univers
pretoria
pretoria
south
africa
object
hepat
b
remain
import
public
health
concern
south
africa
despit
introduct
hepat
b
vaccin
horizont
transmiss
hepat
b
play
import
role
develop
countri
occur
mainli
bodi
fluid
like
saliva
recent
nosocomi
hepat
b
viru
hbv
outbreak
involv
patient
occur
paediatr
haematolog
oncolog
unit
larg
tertiari
hospit
south
africa
possibl
breach
standard
infect
control
precaut
contamin
vial
transmiss
bodi
fluid
implic
describ
subsequ
infect
prevent
control
strategi
implement
method
seri
strategi
minimis
nosocomi
transmiss
hbv
implement
univers
infect
control
precaut
emphas
includ
strict
hand
wash
use
glove
polici
includ
elimin
use
vial
clean
disinfect
reusabl
equip
prevent
share
person
utensil
test
hbv
infect
immun
first
admiss
vaccin
patient
low
level
antibodi
put
practis
full
vaccin
schedul
initi
patient
titr
miuml
booster
hbv
vaccin
given
patient
titr
miuml
patient
attend
unit
routin
monitor
everi
month
declin
level
antibodi
vaccin
titr
fall
miuml
result
prevent
measur
introduc
reduc
incid
hbv
infect
significantli
one
new
case
hbv
infect
suspect
unrel
outbreak
occur
month
follow
implement
measur
conclus
outbreak
highlight
import
adequ
infect
prevent
control
strategi
prevent
nosocomi
transmiss
hbv
paediatr
haematolog
oncolog
unit
implement
polici
activ
surveil
hbv
infect
formul
clear
guidelin
prevent
control
thereof
laparoscop
oncolog
surgic
patholog
postop
pain
manag
intraperiton
local
anesthet
pediatr
patient
galant
univers
depart
anesthesia
intens
care
univers
hospit
ospedali
riuniti
foggia
itali
object
although
pain
laparoscop
surgeri
less
intens
open
surgeri
patient
still
experi
consider
discomfort
picu
postop
pain
laparoscop
oncolog
surgic
patholog
import
limit
factor
rapid
return
normal
activ
studi
demonstr
efficaci
safeti
intraperiton
administr
low
dose
local
anesthet
method
irb
approv
patient
asa
year
old
receiv
fashion
ml
normal
salin
solut
group
ropivacain
group
r
levobupivacain
group
l
standard
gener
anesthesia
perform
propofol
cisatracurium
mixtur
remifentanil
continu
infus
anesthet
solut
intraperiton
administ
end
laparoscop
procedur
repeat
picu
intraperiton
cathet
postop
pain
assess
first
end
surgeri
use
visual
analog
scale
va
anesthet
drug
postop
time
administ
also
record
result
pain
less
intens
group
l
particularli
rescu
analges
drug
consumpt
lower
group
respect
ropivacain
normal
salin
group
postop
pain
deep
inspir
higher
ropivacain
group
respect
levobupivacain
normal
salin
group
conclus
efficaci
safeti
intraperiton
administr
local
anesthet
well
demonstr
mani
studi
lack
consensu
regard
dose
concentr
laparoscop
oncolog
surgic
procedur
studi
show
use
lower
concentr
local
anesthet
led
significantli
lower
pain
score
particularli
concern
levobupivacain
refer
ioannidi
et
al
intraperiton
administr
local
anesthet
laparoscop
surgeri
pharmacolog
anatom
physiolog
pathophysiolog
consider
minerva
chir
varicella
zoster
viru
infect
chemotherapi
autolog
stem
cell
transplant
children
malign
l
f
roquet
c
dufour
c
pasqualini
g
goma
valteau
couanet
institut
gustav
roussi
villejuif
franc
statist
institut
gustav
roussi
villejuif
franc
pediatri
institut
gustav
roussi
villejuif
franc
object
varicella
zoster
viru
vzv
infect
frequent
complic
chemotherapi
hdc
follow
autolog
stem
cell
transplant
asct
children
conflict
data
publish
aim
determin
frequenc
consequ
risk
factor
vzv
infect
asct
larg
cohort
adapt
therapeut
manag
method
analyz
prospect
collect
data
children
treat
hdc
asct
pediatr
oncolog
depart
institut
gustav
roussi
compar
patient
develop
vzv
infect
intens
treatment
result
januari
juli
children
receiv
hdc
asct
without
vzv
prophylact
treatment
two
hundr
patient
develop
vzv
event
consist
varicella
herp
zoster
includ
doubl
event
median
time
vzv
infect
onset
day
post
asct
case
occur
within
first
year
evolut
simpl
aciclovir
treatment
patient
complic
resolv
treatment
consist
mainli
post
vzv
neuralgia
age
date
first
asct
p
underli
diseas
p
administr
sequenti
hdc
p
signific
factor
associ
vzv
infect
occurr
whole
popul
defin
fisher
test
logist
regress
model
singl
cours
hdc
asct
show
univari
multivari
analysi
age
year
date
first
graft
hodgkin
lymphoma
associ
occurr
vzv
infect
conclus
incid
vzv
infect
compar
found
literatur
favour
outcom
cur
treatment
aciclovir
confirm
absenc
benefit
prophylact
strategi
manag
children
receiv
hdc
follow
asct
risk
factor
develop
sever
infect
pediatr
oncolog
patient
febril
neutropenia
c
mata
b
santiago
garcia
b
hernandez
ruperez
r
herraiz
casa
fleca
u
sautu
c
garrido
colino
j
huerta
j
saavedra
lozano
hospit
gener
universitario
gregorio
madrid
spain
enfermedad
infecciosa
hospit
gener
universitario
gregorio
madrid
spain
lab
gripe
viru
respiratorio
instituto
salud
carlo
iii
madrid
spain
object
evalu
risk
factor
suffer
infect
myelosuppress
patient
febril
neutropenia
fn
episod
episod
classifi
febril
neutropenia
hrfn
febril
neutropenia
lrfn
differ
approach
taken
accordingli
method
studi
includ
children
prospect
enrol
fn
admit
hospit
octob
decemb
perform
patient
classifi
two
group
admiss
lrfn
hrfn
accord
previous
implement
protocol
base
physic
examin
laboratori
test
medic
social
background
bacteri
fungal
cultur
nasopharyng
wash
respiratori
virus
rv
use
test
result
one
hundr
thirti
fn
episod
evalu
patient
femal
median
age
year
among
classifi
treat
hrfn
lrfn
lrfn
episod
associ
higher
number
rv
infect
vs
hrfn
fewer
episod
gram
neg
bacteri
infect
vs
p
among
episod
evalu
final
diagnos
moder
sever
infect
mild
one
prophylaxi
associ
lower
incid
moder
sever
infect
vs
patient
receiv
prophylaxi
p
moder
sever
infectionswer
relat
higher
valu
pcr
mgdl
diagnosi
h
later
vs
mild
infect
p
higher
incid
arteri
hypotens
vs
p
higher
valu
procalcitonin
moder
sever
infect
vs
mild
infect
p
higher
incid
moder
sever
infect
leukaemia
lymphoma
compar
malign
p
conclus
respiratori
viral
infect
associ
lrfn
episod
higher
crp
pct
hypotens
chill
absenc
prophylaxi
may
predict
moder
sever
infect
therefor
need
hrfn
manag
seek
second
opinion
pediatr
oncolog
mordechai
tamir
pediatr
oncoloy
rambam
health
care
campu
haifa
israel
object
number
second
opinion
consult
pediatr
oncolog
increas
yet
ground
famili
decid
seek
second
opinion
littl
studi
goal
studi
identifi
patient
famili
factor
appear
contribut
second
opinion
sought
method
parent
jewish
origin
arab
origin
children
cancer
recent
treat
hematolog
oncolog
pediatr
depart
interview
questionnair
includ
epidemiolog
data
detail
diseas
time
second
opinion
consult
reason
seek
second
opinion
riskbenefit
consult
result
parent
sought
second
opinion
correl
higher
statu
p
number
educ
year
decis
go
second
opinion
p
parent
went
second
opinion
also
use
internet
data
sourc
use
internet
correl
decis
p
correl
age
parent
age
sick
child
famili
statu
live
place
urban
vs
rural
diseas
group
stage
diseas
use
cam
complementari
altern
integr
health
decis
go
second
opinion
parent
went
second
opinion
p
jewish
parent
go
second
opinion
versu
arab
parent
p
conclus
second
opinion
establish
part
health
care
caregiv
express
empathi
take
initi
discuss
parent
unmet
need
sometim
even
ther
success
commun
caregiv
recogn
scientif
evid
count
life
parent
child
cancer
deal
lifethreaten
diseas
psycholog
distress
causat
belief
among
caregiv
children
cancer
develop
countri
influenc
pathway
care
treatment
uptak
olagunju
aina
fadip
oyelohunnu
f
sarimiy
olagunju
depart
neuropsychiatri
psychooncolog
lago
univers
teach
hospitalcolleg
medicin
univers
lago
lago
nigeria
depart
radiotherapi
univers
colleg
hospit
ibadan
nigeria
hivinfecti
dises
hospit
health
servic
commiss
lago
nigeria
object
caregiv
children
cancer
often
play
signific
role
make
decis
pathway
care
treatment
relat
issu
treatment
relat
decison
may
influenc
caregiv
belief
cancer
causat
emot
wellb
studi
aim
investig
psycholog
distress
belief
causat
cancer
develop
context
method
studi
particip
made
one
hundr
caregiv
children
histolog
diagnos
cancer
attend
tertiari
health
facil
west
africa
elig
particip
gave
inform
consent
interview
design
questionnair
elicit
profil
treatment
relat
variabl
well
pathway
care
subsequ
follow
administr
gener
health
questionnair
ascertain
psycholo
distress
base
score
data
analys
done
use
result
mean
age
caregiv
femal
gender
predomin
caregiv
psycholog
distress
base
upto
report
posit
belief
preternaturalspiritu
causat
cancer
similarli
opt
one
form
altern
care
spiritu
deliver
prayer
herbal
prepar
among
other
present
hospit
good
treatment
uptak
correl
posit
level
educ
employ
good
social
support
famili
member
p
howev
financi
constraint
preternatur
causat
belief
correl
neg
good
treatment
uptak
p
conclus
care
children
cancer
significantli
impact
caregi
relat
factor
psychosoci
support
caregiv
promot
awar
campaign
target
cancer
educ
program
well
cancer
treatment
issu
indic
share
care
paediatr
oncolog
manag
negoti
partnership
tertiari
satellit
health
care
provid
punnett
greenberg
martimianaki
paediatr
haematologyoncolog
hospit
sick
children
toronto
canada
paediatr
hospit
sick
children
toronto
canada
object
vast
geographi
limit
human
health
resourc
dictat
need
collabor
care
manag
paediatr
cancer
patient
canada
lack
conceptu
empir
research
inform
best
practic
establish
enhanc
interprofession
collabor
gagliardi
particular
complex
relationship
within
profess
poorli
understood
damour
studi
sought
examin
natur
relat
dynam
establish
paediatr
oncolog
share
care
program
method
paediatr
oncolog
group
ontario
pogo
administ
formal
satellit
care
program
ontario
conduct
interview
purpos
sampl
tertiari
satellit
health
practition
examin
knowledg
skill
attitud
requir
success
collabor
care
program
interview
record
transcrib
induct
analyz
gener
emerg
theme
relat
percept
interprofession
interact
witz
model
profession
closur
strategi
use
explor
contextu
perceiv
relat
dynam
result
studi
approv
local
reb
particip
institut
interview
nurs
nurs
practition
physician
conduct
largest
tertiari
centr
sickkid
provinci
satellit
centr
unanim
commit
program
appear
pivot
navig
number
inher
tension
identifi
within
work
arrang
partnership
tertiari
satellit
centr
manag
negoti
establish
guidelin
necessari
overli
restrict
tertiari
provid
balanc
loss
control
evolv
job
profil
increas
access
tertiari
servic
satellit
provid
balanc
increas
job
satisfact
compet
respons
conflict
organiz
agenda
conclus
provid
within
share
care
program
navig
complex
profession
organiz
relationship
maintain
redefin
tradit
profession
boundari
ongo
manag
negoti
partnership
vial
success
longev
program
breast
milk
immun
thrombocytopen
mother
contain
anti
platelet
antibodi
associ
persist
thrombocytopenia
neonat
n
sharon
h
hauschner
n
rosenberg
u
seligsohn
r
mendelsohn
pediatr
laniado
hospit
netanya
israel
amalia
biron
research
institut
thrombosi
hemostasi
chaim
sheba
medic
center
tel
hashom
ramat
gan
israel
object
matern
immun
thrombocytopen
purpura
itp
account
case
pregnanc
associ
thrombocytopenia
common
caus
neonat
one
common
mechan
involv
transfer
igg
autoantibodi
platelet
receptor
found
blood
sampl
affect
patient
neonat
thrombocytopenia
usual
subsid
within
month
autoantibodi
often
igg
type
therefor
cross
placenta
caus
fetal
andor
neonat
thrombocytopenia
recent
observ
persist
neonat
itp
rapidli
disappear
follow
discontinu
breast
feed
aim
current
work
discern
whether
breast
milk
mother
itp
contain
antibodi
whether
antibodi
may
caus
persist
neonat
itp
method
breast
milk
sampl
collect
women
itp
seven
thrombocytopen
pregnanc
neonat
also
thrombocytopenia
remain
mother
histori
itp
current
pregnanc
neither
neonat
control
breast
milk
healthi
women
also
examini
presenc
antibodi
evalu
incub
wash
platelet
healthi
donor
breast
milk
extract
milk
ig
type
immun
globulin
defin
flow
cytometri
use
fluoresc
conjug
iga
igg
total
ig
antibodi
result
four
women
activ
itp
accompani
neonat
thrombocytopenia
high
level
iga
antibodi
observ
three
remain
women
activ
itp
histori
itp
minim
concentraion
antibodi
detect
antibodi
found
breast
milk
healthi
women
conclus
first
evid
transfer
antibodi
mother
itp
infant
via
breastfeed
associ
persist
thrombocytopen
neonat
role
primari
care
manag
teenag
young
adult
tya
cancer
preliminari
studi
steven
ridd
k
dixon
heawood
cameron
target
bristol
royal
hospit
children
bristol
unit
kingdom
social
commun
medicin
univers
bristol
bristol
unit
kingdom
tya
cancer
servic
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
object
cancer
tya
rare
primari
care
profession
may
unfamiliar
patient
need
improv
surviv
major
tya
return
primari
care
complet
treatment
limit
involv
famili
gener
practition
fp
tya
treatment
potenti
percept
diagnost
delay
may
impact
relationship
fp
patientfamili
creat
barrier
effect
aftercar
bristol
target
programm
show
tya
specif
want
inform
expect
fp
treatment
explor
fp
experi
tya
cancer
understand
barrier
inform
strategi
increas
involv
method
fp
recent
diagnos
year
old
cancer
invit
interview
topic
guid
develop
tya
clinician
interview
transcrib
verbatim
fp
contact
particip
interview
achiev
theme
satur
data
analys
use
constant
compar
method
result
analysi
show
fp
mostli
contribut
initi
referr
emot
support
care
medic
problem
lack
knowledg
prolong
period
hospit
treatment
incompleteineffect
commun
fp
fear
burden
patient
addit
input
common
reason
offer
limit
involv
especi
treatment
conclus
result
align
gener
find
cancer
survivorship
research
confirm
transit
specialist
cancer
care
care
fp
may
difficult
patient
fp
effect
commun
duringaft
treatment
inform
tya
cancer
fp
diagnosi
could
help
clarifi
expect
fp
patient
prevent
disrupt
patient
primari
care
relationship
assist
fp
contribut
care
partnership
tya
cancer
team
strategi
promot
engag
tya
fp
earli
diagnosi
develop
part
target
programm
surgeri
ipso
analysi
major
surgic
procedur
oncolog
pediatr
patient
coagul
disord
f
albanez
souza
e
mei
e
machado
ikeda
perini
coelho
favr
cortez
r
vianna
carvalho
pediatr
surgeri
instituto
nacion
de
rio
de
janeiro
brazil
coagul
committe
instituto
nacion
de
rio
de
janeiro
brazil
pediatr
oncolog
instituto
nacion
de
rio
de
janeiro
brazil
physic
therapi
servic
instituto
nacion
de
rio
de
janeiro
brazil
anesthesiolog
instituto
nacion
de
rio
de
janeiro
brazil
object
coagul
disord
found
mani
patient
neoplasm
risk
factor
bleed
andor
thrombosi
augment
patient
need
surgic
procedur
object
report
analyz
frequenc
risk
factor
preoper
manag
patient
abdomin
neoplasm
requir
major
surgic
treatment
method
retrospect
studi
patient
submit
major
surgic
abdomin
neoplasm
resect
nation
cancer
institut
period
year
old
patient
suspicion
coagul
disord
bleed
previou
histori
laboratori
coagul
disord
evalu
coagul
committe
non
hematolog
patient
enrol
studi
result
three
year
pediatr
oncolog
surgic
servic
perform
surgic
procedur
patient
evalu
coagul
committ
submit
major
surgic
treatment
histopatolog
diagnosi
neuroblastoma
wilm
tumor
germin
ewe
neoplasm
pnet
desmoplast
tumor
paraganglioma
hepatoblastoma
soft
tissu
sarcoma
patient
follow
special
coagul
team
surgic
procedur
initi
protocol
investig
coagul
committe
evalu
lupu
anticoagul
lac
protein
c
antithrombin
iii
v
vii
viii
ix
x
xi
factor
follow
institut
protocol
prevent
bleed
andor
thrombosi
specif
patient
major
postop
complic
occur
conclus
import
access
special
coagul
team
patient
coagul
disord
special
pediatr
oncolog
patient
adequ
manag
patient
major
complic
reduc
scf
express
associ
unfavor
prognosi
neuroblastoma
r
kapoor
agarwala
vk
iyer
sn
dwivedi
pp
chattopadhyay
ali
ak
dinda
bajpai
dk
gupta
v
bhatnagar
pediatr
surgeri
india
institut
medic
scienc
delhi
india
patholog
india
institut
medic
scienc
delhi
india
biostatist
india
institut
medic
scienc
delhi
india
biochemistri
india
institut
medic
scienc
delhi
india
molecular
genet
laboratori
nation
institut
immunolog
delhi
india
object
determin
preval
prognost
signific
scf
express
neuroblastoma
method
scf
express
investig
immunohistochemistri
univari
multivari
analysi
cox
regress
outcom
analysi
kaplan
meier
done
overal
surviv
os
surviv
ef
relat
scf
express
death
recurr
progress
consid
event
result
case
month
age
adren
histopatholog
upfront
done
unfavor
histolog
ufh
tumor
scf
express
observ
tumor
scf
express
commonli
observ
compar
vs
p
among
high
grade
low
grade
p
respons
progress
diseas
common
scf
express
ci
p
five
scf
express
die
event
give
poorer
os
vs
p
ef
vs
p
scf
express
patient
scf
express
adren
locat
die
event
give
poorer
os
p
ef
p
scf
express
among
patient
scf
express
among
die
event
give
poorer
os
p
ef
p
scf
express
thirteen
among
ufh
scf
express
among
die
event
ef
p
significantli
wors
ufh
scf
express
conclus
scf
express
neuroblastoma
express
independ
prognost
variabl
respons
shorter
surviv
ci
p
differ
outcom
especi
mark
age
adren
unfavour
histolog
tumor
clinic
applic
multiparamet
flow
cytometri
diagnost
screen
classif
pediatr
solid
tumor
c
c
milito
v
botafogo
fontana
l
thiago
e
oliveira
da
f
werneck
forni
dekermach
ap
azambuja
se
ferman
pa
silvestr
de
faria
land
orfao
e
sobral
da
costa
pediatr
depart
ippmg
feder
univers
rio
de
janeiro
rio
de
janeiro
brazil
depart
patholog
school
medicin
feder
univers
rio
de
janeiro
rio
de
janeiro
brazil
pediatr
hematolog
oncolog
brazilian
nation
cancer
institut
rio
de
janeiro
brazil
pediatr
hematolog
oncolog
servidor
estado
hospit
rio
de
janeiro
brazil
pediatr
surgeri
servidor
estado
hospit
rio
de
janeiro
brazil
pediatr
hematolog
oncolog
feder
univers
parana
curitiba
brazil
pediatr
oncolog
brazilian
nation
cancer
institut
rio
de
janeiro
brazil
flow
cytometri
servic
universidad
de
salamanca
salamanca
spain
object
multiparamet
flow
cytometri
mfc
immunophenotyp
proven
essenti
rapid
diagnosi
classif
monitor
therapi
hematolog
malign
includ
pediatr
leukemia
lymphoma
convers
remain
research
tool
pediatr
solid
tumor
evalu
mfc
panel
marker
diagnost
screen
classif
tumor
propos
strategi
aim
differenti
diagnosi
tumor
vs
reactiv
sampl
hematolog
vs
malign
subclassif
pediatr
solid
tumor
method
total
sampl
patient
suspici
pediatr
cancer
male
femal
analyz
mfc
panel
follow
gate
strategi
analysi
identif
suspici
tumor
cell
character
hematopoiet
vs
solid
tumor
establish
statist
signific
differ
observ
group
u
test
use
continu
variabl
spss
softwar
program
version
spss
inc
chicago
il
usa
result
patient
cancer
show
metastat
diseas
remain
children
inflammatoryreact
diseas
overal
concord
rate
mfc
analysi
histopatholog
exam
diagnost
sampl
agreement
reactiveinflammatori
fals
neg
case
diagnos
hodgkin
lymphoma
anaplast
lymphoma
metastat
nasopharyng
carcinoma
lymph
node
moreov
clear
discrimin
sampl
infiltr
hematopoiet
vs
tumor
cell
systemat
achiev
distinct
subtyp
solid
tumor
show
differ
protein
express
profil
allow
differenti
diagnosi
neuroblastoma
primit
neuroectoderm
tumor
wilm
tumor
cell
popul
rhabdomyosarcoma
carcinoma
germ
cell
tumor
eventu
hemangiopericytoma
conclus
summari
result
show
mfc
provid
fast
use
complementari
data
routin
histopatholog
diagnost
screen
classif
pediatr
cancer
acut
surgic
complic
abdomin
lymphoma
studi
among
egyptian
children
period
year
sadek
pediatr
surgeri
univers
alexandria
alexandria
egypt
object
report
studi
case
abdomin
lymphoma
present
acut
surgic
abdomen
method
children
abdomin
lymphoma
treat
pediatr
surgeri
pediatr
oncolog
depart
univers
alexandria
egypt
period
year
report
sudi
concern
demograph
data
clinic
present
patholog
varieti
stage
manag
modal
type
surgeri
surviv
record
result
total
number
case
abdomin
lymphoma
report
period
year
median
age
year
lymphoma
encount
case
lymphoblast
lymphoma
common
follow
burkitt
lymphoma
primari
intestin
lymphoma
encount
case
twenti
seven
present
acut
surgic
abdomen
follow
intussuscept
case
volvulu
case
intestin
perfor
case
case
treat
right
ileocaec
resect
case
ileal
resect
case
case
treat
chemotherapi
definit
therapi
two
year
surviv
case
correl
stage
follow
stage
stage
ii
stage
iii
stage
iv
conclus
primari
intestin
lymphoma
egyptian
children
special
entiti
abdomin
lymphoma
liabl
complic
present
acut
surgic
abdomen
surgey
indic
emerg
acut
surgic
abdomen
follow
chemotherapi
definit
therapi
role
ct
stage
pediatr
round
cell
tumor
elimin
need
bone
marrow
biopsi
n
singhal
qureshi
g
chinnaswami
kembhavi
v
rangarajan
desai
shah
p
kurkur
agraw
bhagat
surgic
oncolog
tata
memori
hospit
mumbai
india
pediatr
surgic
oncolog
tata
memori
hospit
mumbai
india
pediatr
oncolog
tata
memori
hospit
mumbai
india
radiolog
tata
memori
hospit
mumbai
india
nuclear
medicin
tata
memori
hospit
mumbai
india
patholog
tata
memori
hospit
mumbai
india
nuclear
medicin
tata
memori
hospit
mumbai
india
pediatr
surgeri
tata
memori
hospit
mumbai
india
object
evalu
efficaci
detect
bone
marrow
metastas
pediatr
round
cell
tumor
neuroblastoma
rhabdomyosarcoma
compar
gold
standard
method
bilater
bone
marrow
biopsi
also
compar
result
bilater
marrow
biopsi
unilater
biopsi
determin
whether
unilater
biopsi
suffici
detect
bone
marrow
metastas
method
prospect
observ
studi
includ
treatment
naiv
patient
histolog
confirm
diagnos
neuroblastoma
rhabdomyosarcoma
attend
pediatr
surgeri
outpati
depart
hospit
patient
underw
routin
stage
workup
along
evalu
result
unilater
versu
bilater
biopsi
find
right
side
biopsi
taken
baselin
comparison
patient
case
focal
marrow
posit
pet
show
posit
marrow
site
iliac
crest
discord
result
bone
marrow
biopsi
presenc
marrow
metastas
confirm
mri
scan
region
result
time
abstract
submiss
patient
evalu
case
rhabdomyosarcoma
case
neuroblastoma
evid
bone
marrow
metastas
patient
pet
scan
bone
marrow
biopsi
thu
neg
predict
valu
bone
marrow
metastas
studi
detect
marrow
metastas
patient
two
patient
also
posit
bone
marrow
biopsi
mri
done
one
patient
neg
bone
marrow
biopsi
confirm
find
pet
scan
two
patient
posit
bone
marrow
biopsi
one
patient
unilater
posit
bone
marrow
conclus
obviat
need
bone
marrow
biopsi
associ
morbid
also
potenti
singl
investig
stage
work
group
patient
outcom
ice
chemotherapi
surgic
resect
treatment
recurr
wilm
tumor
agarwala
bhatia
bakhshi
sriniva
bajpai
jana
thulkar
pathi
dk
gupta
v
bhatnagar
pediatr
surgeri
india
institut
medic
scienc
delhi
india
medic
oncolog
brairch
india
institut
medic
scienc
delhi
india
radiolog
brairch
india
institut
medic
scienc
delhi
india
radiotherapi
brairch
india
institut
medic
scienc
delhi
india
object
evalu
effect
ice
ifosphamidecarboplatinetoposid
salvag
therapi
recurr
wilm
tumor
rwt
method
prospect
maintain
data
patient
recurr
wilm
tumor
manag
pediatr
solid
tumor
clinic
august
decemb
analyz
efficaci
ice
salvag
regim
compar
regimen
use
statist
program
stata
signific
differ
taken
p
kaplan
meier
surviv
estim
overal
surviv
os
done
initi
stage
done
per
protocol
treatment
done
per
protocol
result
new
case
wt
treat
period
recur
favor
histolog
diffus
anaplasia
recurr
follow
treatment
stage
initi
treat
dactinomycinvincristin
stage
stage
stage
stage
follow
drug
dactinomycin
vincristin
doxorubicin
rt
recurr
bilater
local
metastat
opt
treatment
local
recurr
follow
treatment
bilater
diseas
receiv
altern
chemotherapi
ice
protocol
overal
patient
underw
surgic
resect
recurr
either
upfront
follow
chemotherapi
receiv
ice
aliv
give
os
among
group
surviv
os
odd
surviv
among
group
greater
seven
ice
group
receiv
protocol
achiev
diseas
free
statu
conclus
patient
opt
treatment
ice
salvag
regim
result
diseas
free
statu
far
less
frequent
protocol
achiev
os
intens
pretreat
patient
recurr
wilm
tumor
singl
center
seri
crocoli
serra
de
iori
md
de
pasqual
c
martucci
cacchion
f
diomedi
camassei
ae
tozzi
f
locatelli
ae
inserra
surgeri
bambino
children
hospit
ircc
rome
itali
hematologyoncolog
bambino
children
hospit
ircc
rome
itali
patholog
bambino
children
hospit
ircc
rome
itali
epidemiolog
bambino
children
hospit
ircc
rome
itali
object
wilm
tumor
wt
common
renal
tumor
children
excel
outcom
relaps
occur
gener
two
year
diagnosi
aim
studi
evalu
rate
characterist
recurr
ltr
singl
institut
experi
method
institut
wt
regist
check
order
identifi
patient
present
relaps
year
diagnosi
march
method
use
estim
overal
surviv
os
progress
free
surviv
pf
curv
patient
treat
accord
siop
siop
protocol
result
patient
diagnos
studi
period
year
os
pf
respect
relaps
occur
patient
median
time
month
diagnosi
rang
month
month
seri
bilater
kidney
involv
occur
patient
metastat
spread
recurr
occur
local
month
onset
two
ltr
occur
patient
bilater
diseas
onset
later
patient
present
monolater
wt
underw
surgeri
diagnosi
domin
polycyst
kidney
diseas
patient
present
second
local
recurr
month
third
metastat
spread
month
diagnosi
three
ltr
aliv
complet
remiss
month
diagnosi
conclus
ltr
rare
event
observ
less
popul
repres
relaps
mostli
local
often
associ
bilater
tumor
onset
notabl
seri
report
bilater
occurr
patient
analysi
may
confirm
increas
risk
ltr
bilater
diseas
suggest
experi
howev
prolong
follow
ultrasonograph
scan
recommend
bilater
diseas
diarrheal
neuroblastoma
diagnosi
treatment
h
wang
pediatr
surgic
oncolog
beij
children
hospit
cmu
beij
china
object
neuroblastoma
case
diarrhea
main
symptom
name
diarrheal
neuroblastoma
quit
rare
consequ
experi
diagnosi
treatment
diseas
limit
herebi
report
seri
case
diarrheal
neuroblastoma
institut
method
six
case
diarrheal
neuroblastoma
decemb
analys
retrospect
clinicopatholog
featur
summar
patholog
confirm
diagnosi
vasoact
intestin
peptid
vip
detect
immunohistochemistri
tumor
tissu
result
patient
age
month
period
diarrhea
begin
diagnosi
four
month
year
stool
loos
wateri
time
day
routin
faec
test
normal
diarrhea
first
symptom
last
perman
five
case
abdomin
tumor
found
ultrasound
final
two
case
underw
preoper
chemotherapi
diarrhea
stop
chemotherapi
one
surgeri
three
case
accept
upfront
surgeri
diarrhea
end
postoper
one
patient
persist
diarrhea
refractori
electrolyt
imbal
pass
away
end
one
patient
whose
preoper
serum
potassium
l
cure
normal
level
cardiac
arrest
happen
oper
exact
time
potassium
immunohistochem
stain
vip
show
posit
tumor
tissu
patient
conclus
persist
unreason
diarrhea
may
predict
neuroblastoma
metabol
disord
diarrheal
neuroblastoma
chronic
dehydr
intract
hypokalemia
chronic
malnutrit
growth
stagnat
even
preoper
serum
potassium
correct
normal
hypokalemia
would
still
occur
oper
could
lethal
role
surgeri
pediatr
neutropen
cancer
patient
present
gastrointestin
obstruct
perfor
g
ahm
yone
elshafiey
h
hafez
madeni
r
khedr
h
taha
n
elkinaai
surgeri
children
cancer
hospit
egypt
cairo
egypt
surgeri
nci
egypt
children
cancer
hospit
egypt
cairo
egypt
pediatr
oncolog
nci
egypt
children
cancer
hospit
egypt
cairo
egypt
patholog
nci
egypt
children
cancer
hospit
egypt
cairo
egypt
object
evalu
caus
impact
surgic
intervent
outcom
gastrointestin
obstruct
perfor
pediatr
neutropen
cancer
patient
post
chemotherapi
method
retrospect
studi
includ
neutropen
pediatr
patient
follow
chemotherapi
refer
surgeri
jan
dec
intestin
obstruct
perfor
unrel
primari
malign
clinic
radiolog
intraop
find
outcom
evalu
result
explor
done
nine
case
eight
leukemia
one
retinoblastoma
obstruct
seven
case
perfor
two
case
patholog
proven
mucormycosi
found
five
patient
three
intestin
obstruct
two
patient
stomach
perfor
explor
three
obstruct
case
patch
gangren
loop
adher
togeth
resect
anastomosi
done
case
gastric
perfor
edg
trim
edg
primari
repair
augment
oment
patch
done
one
case
partial
gastrectomi
case
remain
four
case
caus
obstruct
due
fibrou
band
two
patient
intussuscept
one
patient
inflamm
last
one
specif
clinic
radiolog
present
mucormycosi
two
five
case
die
progress
infect
inflamm
three
patient
recov
postop
mainten
antifung
therapi
conclus
earli
prompt
surgic
intervent
neutropen
pediatr
oncolog
patient
gastrointestin
obstruct
perfor
may
life
save
although
patient
gener
condit
may
render
riski
mucormycosi
uncommon
diagnosi
pediatr
neutopen
patient
gastrointestin
obstruct
perfor
thu
kept
mind
appropri
antifung
agent
start
earli
possibl
prevent
complic
laparoscop
resect
pancrea
children
solid
pseudopapillari
tumor
rybakova
p
kerimov
kazantcev
rubanski
children
oncolog
feder
state
budgetari
institut
nn
blokhin
russian
cancer
research
center
russian
academi
medic
scienc
moscow
russia
object
develop
ration
surgeri
solid
pseudopapillari
tumor
spt
pancrea
implement
endosurgeri
method
five
children
spt
oper
sinc
analyz
clinic
data
oper
option
result
treatment
result
patient
femal
age
year
median
cours
diseas
asymptomat
howev
observ
child
pain
epigastr
region
local
tumor
pancrea
tail
size
sm
sm
children
underw
laparoscop
distal
pancreatectomi
splenic
preserv
time
oper
min
bleed
complic
occur
patient
pancreat
pancreat
fistula
observ
period
patient
month
year
patient
aliv
without
evid
diseas
recurr
conclus
spt
pancrea
rare
diseas
children
usual
occur
femal
puberti
main
method
treatment
surgeri
use
endosurgeri
possibl
strictli
necessari
defin
indic
type
treatment
risk
postop
complic
manag
longterm
outcom
giant
mediastin
germ
cell
tumor
children
k
kumar
agarwala
bakhshi
sriniva
bajpai
ak
bisoi
ak
gupta
jana
dk
gupta
v
bhatnagar
pediatr
surgeri
india
institut
medic
scienc
delhi
india
medic
oncolog
brairch
india
institut
medic
scienc
delhi
india
cardiothorac
vascular
surgeri
india
institut
medic
scienc
delhi
india
radiodiagnosi
india
institut
medic
scienc
delhi
india
object
evalu
outcom
children
giant
mediastin
germ
cell
tumor
method
children
year
age
mediastin
germ
cell
tumor
gct
treat
hospit
evalu
tumor
size
malign
chemotherapi
surgeri
complic
outcom
result
twelv
mediastin
gct
includ
age
rang
month
year
year
year
age
except
one
male
averag
size
tumor
cm
x
cm
four
occupi
nearli
entir
hemithorax
displac
diaphragm
inferiorli
nine
benign
normal
fp
malign
elev
fp
benign
gct
resect
upfront
malign
one
receiv
cours
peb
cisplatinetoposidebleomycin
neoadjuv
chemotherapi
though
signific
reduct
size
notic
fp
level
decreas
three
patient
underw
complet
resect
tumor
thoracotomi
median
sternotomi
one
dumbel
shape
tumor
bochdelek
hernia
requir
laparotomi
well
diaphragmat
repair
complic
malign
one
complet
total
cours
peb
rang
month
mean
aliv
diseas
free
conclus
studi
group
mediastin
gct
bimod
age
distribut
male
predomin
tumor
older
children
giant
size
occupi
whole
neoadjuv
chemotherapi
elev
fp
decreas
size
tumor
even
though
fp
normal
complet
excis
led
minim
complic
ensur
long
term
diseas
free
surviv
rhabdoid
tumor
kidney
dismal
outcom
tertiari
care
center
develop
countri
v
khanna
agarwala
bakhshi
sriniva
thulkar
jana
bajpai
dk
gupta
v
bhatnagar
pediatr
surgeri
india
institut
medic
scienc
delhi
india
medic
oncolog
brairch
india
institut
medic
scienc
delhi
india
radiolog
brairch
india
institut
medic
scienc
delhi
india
object
evalu
outcom
children
rhabdoid
tumor
kidney
rtk
method
retrospect
review
record
children
rtk
enrol
present
chemotherapi
surgeryand
outcom
chemotherapi
vincristindactinomycinadriamycin
sinc
rtk
regim
carboplatinetoposidecyclophosphamid
result
among
renal
tumor
treat
period
werertk
age
rang
month
male
femal
ratio
present
abdomin
mass
also
hypertens
one
hadgross
hematuria
tumor
size
rang
centimet
mean
seven
children
stage
iiiand
stage
iv
diseas
metastasi
bilater
lung
one
bilater
lung
liver
anoth
four
receiv
neoadjuvantchemotherapi
regimen
could
resect
gross
complet
resect
die
progress
diseas
overal
patient
underw
surgeri
upfront
follow
neoadjuv
chemotherapi
gross
complet
resect
gross
residu
five
resect
tumor
spill
upfront
resect
two
die
soon
resect
remain
patient
receiv
adjuv
chemotherapi
receiv
radiotherapi
patient
underw
complet
excis
earli
local
recurr
rang
day
month
median
month
progress
diseas
follow
incomplet
resect
without
resect
patient
die
period
surviv
rang
month
diagnosi
median
month
conclus
rtk
rare
pediatr
renal
tumorof
young
children
high
incid
tumor
spill
upfront
resect
demonstr
earli
recurr
rapid
progress
death
within
median
month
diagnosi
despit
aggress
chemotherapi
complet
surgic
resect
paediatr
testicular
tumour
experi
fx
li
jhi
chua
kl
narasimhan
paediatr
sugeri
kk
women
children
hospit
singapor
singapor
object
describ
seri
paediatr
testicular
tumour
experi
surgeri
tss
method
follow
irb
approv
retrospect
clinic
chart
review
conduct
patient
primari
testicular
tumour
diagnos
januari
juli
data
clinic
present
demograph
investig
surgic
procedur
collat
analys
use
convent
statist
result
nineteen
tumour
analys
germ
cell
origin
median
age
diagnosi
month
common
present
painless
scrotal
swell
patient
underw
testicular
explor
via
inguin
approach
orchidectomi
perform
high
ligat
cord
select
case
benign
patholog
tss
done
nine
patient
benign
tumour
teratoma
epidermoid
cyst
lesion
malign
yolk
sac
tumour
yst
mix
malign
germ
cell
tumour
gct
follicular
lymphoma
rhabdomyosarcoma
gct
alphafetoprotein
elev
malign
subtyp
correct
age
except
one
malign
gct
stage
diagnosi
orchidectomi
alon
cur
surviv
month
last
patient
stage
yst
receiv
adjuv
chemotherapi
accord
bep
protocol
remain
year
tss
perform
benign
gct
ultrasound
demonstr
viabl
remain
testicular
tissu
least
child
undergon
puberti
demonstr
growth
remain
testicular
tissu
none
patient
benign
gct
tumour
recurr
median
month
conclus
major
paediatr
testicular
tumour
germ
cell
origin
tumour
excel
prognosi
even
advanc
diseas
delay
diagnosi
tss
therefor
feasibl
option
complet
orchidectomi
employ
case
recurr
close
imag
surveil
tss
perhap
also
offer
select
patient
malign
gct
periop
tumor
ruptur
confer
poor
surviv
wilm
tumor
k
svojgr
k
pycha
r
kodet
v
smelhau
j
koutecki
j
snajdauf
j
stari
j
mali
pediatr
hematolog
oncolog
charl
univers
faculti
medicin
univers
hospit
motol
pragu
czech
republ
pediatr
surgeri
charl
univers
faculti
medicin
univers
hospit
motol
pragu
czech
republ
patholog
molecular
medicin
charl
univers
faculti
medicin
univers
hospit
motol
pragu
czech
republ
object
wilm
tumor
wt
common
tumor
kidney
childhood
present
studi
focus
preoper
periop
ruptur
tumor
impact
surviv
method
patient
wt
treat
institut
event
free
surviv
ef
overal
surviv
os
analyz
use
stat
view
statist
program
result
patient
treat
accord
protocol
siop
patient
siop
siop
median
year
patient
treat
neoadjuv
cht
patient
underw
primari
nephrectomi
ef
os
patient
treat
neoadjuv
cht
primari
nephrectomi
differ
ef
versu
vs
p
os
vs
p
patient
suffer
tumor
ruptur
ef
os
differ
comparison
case
ef
vs
p
os
vs
p
preoper
tumor
spillag
diagnos
case
patient
underw
primari
nephrectomi
periop
tumor
spillag
occur
case
patient
suffer
tumor
spillag
primari
nephrectomi
patient
suffer
tumor
spillag
nephrectomi
perform
neoadjuv
cht
p
four
patient
periop
tumor
ruptur
metastat
diseas
diagnosi
comparison
patient
spontan
tumor
spillag
p
ef
patient
spontan
tumor
ruptur
comparison
periop
tumor
ruptur
p
os
vs
p
conclus
patient
suffer
periop
tumor
spillag
like
metastat
diseas
poor
prognosi
institut
find
confirm
multicent
studi
support
mhcz
dro
univers
hospit
motol
pragu
czech
republ
addit
topic
vancomycin
decreas
incid
surgic
site
infect
bone
tumor
puri
gulia
mb
suman
orthopaed
oncolog
tata
memori
hospit
mumbai
india
object
retrospect
audit
compar
consecut
group
patient
oper
bone
tumor
receiv
periop
antibiot
group
similar
group
addit
topic
vancomycin
sprinkl
wound
prior
closur
group
b
determin
addit
topic
vancomycin
decreas
incid
surgic
site
infect
ssi
method
patient
oper
jan
dec
group
patient
oper
april
dec
group
b
analys
patient
need
oper
intervent
wound
discharg
consid
infect
patient
one
year
follow
determin
incid
ssi
result
overal
rate
ssi
patient
group
group
b
patient
ssi
p
subgroup
analysi
patient
endoprosthet
reconstruct
group
patient
group
b
patient
ssi
similarli
group
patient
group
b
patient
intern
fixat
implant
plate
im
nail
ssi
conclus
addit
topic
vancomycin
prior
wound
closur
patient
oper
bone
tumor
decreas
incid
surgic
site
infect
ssi
longer
follow
may
determin
efficaci
reduc
incid
late
infect
earli
surgic
intervent
improv
chanc
surviv
neutropen
patient
clostridium
septicum
sepsi
zeinab
k
ampofo
k
korgenski
r
meyer
pediatr
oncolog
univers
utah
primari
children
hospit
salt
lake
citi
us
pediatr
infecti
univers
utah
primari
children
hospit
salt
lake
citi
us
pediatr
surgeri
univers
utah
primari
children
hospit
salt
lake
citi
us
purpos
due
identif
high
mortal
rate
neutropen
patient
clostridium
septicum
sepsi
sought
identifi
prognost
andor
intervent
measur
could
associ
improv
outcom
method
retrospect
review
patient
diagnos
c
septicum
infect
collect
prognost
intervent
measur
might
associ
outcom
result
six
patient
identifi
femal
median
age
infect
year
rang
year
three
acut
lymphoblast
leukemia
acut
myeloid
leukemia
one
rhabdoid
brain
tumor
receiv
myelosuppress
chemotherapi
patient
sever
neurtopen
yet
remiss
c
septicum
isol
cultur
patient
blood
biopsi
tissu
patient
present
septic
shock
clinic
featur
sever
enterocol
one
abdomin
wall
perirect
necrot
fasciiti
anoth
erector
spina
myonecrosi
patient
treat
broad
spectrum
antibiot
hospit
intens
care
surgeri
perform
patient
patient
underw
surgic
resectiondebrid
one
decompress
exploratori
laparotomi
compart
syndrom
two
patient
surviv
one
extens
erector
spina
myonecrosi
follow
extens
debrid
surgeri
resect
perfor
termin
ileum
remain
four
patient
die
within
hour
day
first
posit
c
septicum
cultur
conclus
immuncompromis
pediatr
oncolog
patient
c
septicum
infect
rapidli
highli
fatal
high
index
suspicion
particularli
patient
sever
abdomin
pain
septic
shock
togeth
prompt
therapeut
intervent
institut
antimicrobi
coverag
earli
surgic
intervent
critic
improv
chanc
surviv
toward
dyadic
understand
parent
coul
marit
satisfact
pediatr
cancer
context
w
burn
sultan
k
marcoux
p
robaey
chu
montreal
canada
psycholog
depart
de
montreal
canada
centr
de
recherch
chu
montreal
canada
object
context
pediatr
cancer
parent
variou
caregiv
support
role
child
rehabilit
hutchinson
et
al
long
marsland
thu
includ
conjug
vital
import
research
provid
dyadic
understand
martial
satisfact
mother
father
acut
lymphoblast
leukemia
patient
predictor
includ
individu
mood
perceiv
famili
method
coupl
complet
famili
assess
famili
profil
mood
form
mood
state
diagnosi
three
month
later
well
marit
adjust
scale
marit
satisfact
n
post
diagnosi
n
specif
data
come
cohort
parent
children
treat
chu
result
analys
base
interdepend
model
apim
kenni
et
al
demonstr
differ
marit
satisfact
predictor
mother
father
pediatr
cancer
patient
mother
marit
satisfact
post
diagnosi
predict
famili
variabl
diagnosi
actor
effect
wherea
father
marit
satisfact
predict
mood
actor
effect
partner
role
conflict
fatigu
diagnosi
partner
effect
conclus
research
find
indic
predictor
marit
satisfact
mother
father
children
leukemia
differ
suggest
import
use
dyadic
model
examin
relat
adjust
parent
coupl
account
potenti
partner
effect
gender
effect
thu
clinic
intervent
design
help
coupl
tailor
address
specif
need
continu
support
provid
throughout
cancer
trajectori
cknowledg
small
grant
fondat
chu
le
centr
de
recherch
interdisciplinair
sur
le
conjugaux
et
le
agress
sexuel
cripca
integr
assess
map
domain
base
holist
framework
j
cargil
v
gupta
cameron
p
beynon
dolbi
teenag
young
adult
cancer
servic
univers
hospit
bristol
nh
foundat
trust
bristol
unit
kingdom
teenag
young
adult
servic
teenag
cancer
trust
london
unit
kingdom
ontarget
programm
univers
hospit
bristol
nh
foundat
trust
bristol
unit
kingdom
psycholog
health
servic
univers
hospit
bristol
nh
foundat
trust
bristol
unit
kingdom
object
peer
review
standard
requir
patient
offer
holist
assess
need
within
teenag
yound
adult
tya
popul
seen
prioriti
given
rang
complex
need
south
west
tya
servic
oper
onlin
multidisciplinari
advisori
team
mdat
framework
captur
holist
need
tya
meet
guidanc
requir
method
collabor
approach
use
develop
integr
assess
map
iam
model
creat
provid
structur
ensur
tya
offer
assess
incorpor
impact
diagnosi
cancer
addit
treatment
within
framework
domain
use
iam
model
physic
impact
emot
impact
belief
spiritu
support
network
intim
relationship
fertil
educ
train
work
accommod
financ
score
system
develop
score
assign
domain
level
univers
addit
inputlevel
target
addit
inputlevel
specialist
signific
input
iam
complet
stage
throughout
pathway
allow
individu
track
profession
patient
tool
guid
servic
develop
result
intern
servic
evalu
complet
iam
use
consist
discuss
need
tya
via
onlin
advisori
team
mdat
meet
provision
data
examin
servic
develop
purpos
review
next
step
phase
begun
consid
valid
public
conclus
iam
provid
tya
servic
quantifi
measur
tya
support
need
variou
point
pathway
ensur
young
person
centr
care
plan
area
support
discuss
appropri
time
histori
relaps
diseas
pediatr
brain
tumor
survivor
psychosoci
outcom
qualiti
life
c
chow
c
liptak
p
manley
c
reckliti
depart
psychosoci
oncolog
palli
care
cancer
institut
boston
usa
depart
pediatr
oncolog
cancer
institut
boston
usa
object
advanc
medic
treatment
allow
improv
surviv
rate
pediatr
brain
tumor
patient
even
relaps
although
pediatr
brain
tumor
survivor
psychosoci
challeng
littl
known
relaps
histori
affect
psycholog
outcom
qualiti
life
studi
examin
associ
diseas
relaps
psycholog
function
qualiti
life
adolesc
young
adult
aya
survivor
pediatr
brain
tumor
method
particip
adolesc
age
complet
beck
youth
young
adult
age
complet
brief
symptom
parent
complet
child
adolesc
behavior
checklist
respect
age
group
clinician
rate
particip
global
assess
function
gaf
follow
clinic
interview
previous
establish
score
use
identifi
case
clinic
signific
distress
diseas
treatment
variabl
taken
medic
record
result
fourteen
percent
particip
experienc
relaps
relaps
particip
low
grade
glioma
clinic
signific
anxieti
significantli
common
survivor
relaps
histori
histori
relaps
vs
p
signific
relationship
relaps
histori
depress
qol
behavior
problem
clinician
gaf
rate
anxieti
significantli
relat
time
sinc
diagnosi
p
conclus
relaps
consid
risk
factor
clinic
elev
anxieti
aya
brain
tumor
survivor
anxieti
symptom
present
regardless
length
time
sinc
diagnosi
result
point
import
use
anxieti
measur
captur
distress
earli
identif
survivor
could
allow
implement
empir
valid
treatment
anxieti
particularli
low
grade
glioma
patient
may
experi
multipl
relaps
cknowledg
fund
children
brain
tumor
foundat
reckliti
brain
tumor
network
liptak
ethnic
differ
cope
social
support
qualiti
life
among
parent
children
cancer
de
paep
j
van
der
werff
ten
bosch
c
schott
pediatr
oncolog
uz
brussel
brussel
belgium
clinic
psycholog
uz
brussel
brussel
belgium
object
pediatr
cancer
wide
accept
drastic
impact
parent
qualiti
life
adapt
cope
skill
social
support
seen
import
protect
factor
eg
green
stoppelbein
despit
multicultur
societi
pediatr
cancer
research
ethnic
differ
parent
cope
social
support
scarc
current
studi
investig
mean
level
differ
cope
strategi
social
support
qualiti
life
caucasian
immigr
b
whether
impact
cope
social
support
qualiti
life
moder
ethnic
method
valid
questionnair
cope
social
support
qualiti
life
administ
two
match
sampl
parent
caucasian
north
african
result
differ
uncov
manova
analys
cope
immigr
found
score
higher
posit
reapprais
p
put
perspect
p
term
social
support
immigr
gener
report
receiv
equal
social
support
caucasian
p
time
also
report
lower
satisfact
social
support
well
p
also
immigr
seem
lower
qualiti
life
due
higher
incid
physic
complaint
pain
p
sleep
p
depress
symptom
p
linear
regress
analys
perform
investig
impact
cope
social
support
qualiti
life
degre
experienc
social
support
signific
predictor
yet
satisfact
social
support
found
import
predictor
qualiti
life
p
none
associ
moder
ethnic
conclus
conclus
current
childhood
cancer
investig
uncov
sever
import
ethnic
differ
parent
cope
especi
satisfact
social
support
profound
investig
larger
group
parent
warrant
order
guarante
support
tailor
need
person
regardless
ethnic
origin
attent
bia
modif
therapi
abmt
modern
techniqu
pain
manag
children
cancer
firoozi
depart
psycholog
univers
tehran
tehran
iran
introduct
purpos
attent
bia
modif
therapi
abmt
implicitli
shape
anxieti
relat
bias
attent
orient
continu
pain
problem
children
cancer
often
assum
excess
attent
symptom
refer
model
assum
fear
children
becom
increasingli
vigil
sign
bodili
threat
turn
lead
avoid
behavior
increas
disabl
maladjust
cancer
treatment
method
abmt
use
task
therapeut
tool
comput
program
potenti
applic
attent
bia
modif
abmt
acut
inject
pain
children
investig
studi
children
cancer
daili
inject
recruit
random
receiv
session
abmt
placebo
children
follow
month
later
result
particip
random
receiv
abmt
report
better
cope
inject
pain
p
adher
self
manag
program
control
pain
p
show
better
commun
nurs
inject
p
receiv
placebo
conclus
result
studi
show
potenti
applic
abmt
pain
condit
posit
effect
abmt
clinic
outcom
suggest
techniqu
worthi
futur
studi
intervent
pain
patient
psychosoci
profil
pediatr
brain
tumor
survivor
neurocognit
complaint
grootenhui
de
ruiter
meeteren
van
vuurden
h
c
gid
l
beek
b
granzen
j
oosterlaan
pediatr
psychosoci
depart
emma
children
hospit
academ
medic
centr
amsterdam
netherland
depart
pediatr
oncolog
emma
children
hospit
academ
medic
centr
amsterdam
netherland
depart
pediatr
vu
medic
center
amsterdam
netherland
depart
pediatr
oncologyhematolog
radboud
univers
medic
center
nijmegen
netherland
depart
medic
psycholog
wilhelmina
children
hospit
umc
utrecht
netherland
depart
pediatr
maastricht
univers
medic
centr
maastricht
netherland
depart
clinic
neuropsycholog
vu
univers
amsterdam
amsterdam
netherland
object
children
surviv
brain
tumor
neurocognit
consequ
tumor
andor
treatment
becom
appar
studi
psychosoci
function
grow
group
pediatr
brain
tumor
survivor
pbt
method
psychosoci
function
pbt
year
neurocognit
complaint
compar
norm
data
follow
domain
health
relat
qualiti
life
hrqol
function
execut
function
fatigu
sibl
control
group
independ
sampl
includ
questionnair
appropri
result
pbt
mean
age
year
sd
male
healthi
sibl
mean
age
sd
male
includ
pbt
report
decreas
physic
psycholog
gener
hrqol
ds
psd
pd
pd
psd
p
conclus
pbt
show
increas
psychosoci
problem
report
parent
teacher
small
larg
effect
size
better
understand
psychosoci
function
grow
group
pbt
neurocognit
complaint
help
provid
tailor
support
group
vulner
children
life
goal
patient
cancer
systemat
review
implic
adolesc
young
adult
patient
se
hullmann
sl
robb
kl
rand
school
nurs
indiana
univers
indianapoli
usa
depart
psycholog
indiana
univers
indianapoli
indianapoli
usa
object
one
characterist
adolescentyoung
adult
aya
develop
identif
pursuit
life
goal
unknown
cancer
affect
life
goal
development
stage
critic
examin
exist
research
need
establish
current
known
inform
subsequ
studi
design
purpos
systemat
review
identifi
theoret
model
use
examin
cancer
patient
life
goal
identifi
life
goal
construct
examin
assess
summar
known
impact
cancer
life
goal
method
systemat
review
examin
research
life
goal
patient
cancer
publish
inclus
criteria
cancer
popul
origin
research
articl
assess
life
goal
base
criteria
articl
screen
includ
final
review
theoret
model
goal
construct
assess
method
find
summar
inform
discuss
center
aya
life
goal
result
commonli
appli
theoret
model
nearli
half
use
theori
replic
studi
goal
construct
includ
life
goal
chang
life
goal
goal
disturbancehindr
goal
adjust
goal
assess
method
includ
valid
questionnair
questionnair
interview
review
studi
find
suggest
cancer
hinder
abil
achiev
goal
chang
life
prioriti
ie
greater
focu
social
goal
goal
adjust
relat
better
psychosocialphys
health
outcom
conclus
review
find
offer
theoret
framework
valid
questionnair
inclus
subsequ
research
cancer
neg
impact
patient
goal
achiev
intervent
target
goal
adjust
may
improv
patient
outcom
howev
represent
aya
review
studi
sampl
low
research
specif
aya
life
goal
need
elucid
impact
cancer
experi
patient
uniqu
development
stage
child
initi
parent
commun
die
child
death
l
jalmsel
kontio
stein
ji
henter
u
kreicberg
centr
research
ethic
bioethic
uppsala
univers
uppsala
sweden
women
child
care
sophiahemmet
univers
stockholm
sweden
women
child
care
karolinska
institutet
stockholm
sweden
object
open
honest
commun
identifi
import
factor
provid
good
palli
care
parent
lost
child
cancer
case
regret
talk
child
death
still
easi
solut
parent
die
child
commun
death
studi
report
parent
commun
death
die
child
method
questionnair
bereav
parent
lost
child
malign
period
sweden
parent
ask
commun
child
death
use
draw
film
music
activ
facilit
commun
addit
parent
ask
elabor
answer
written
comment
quantit
qualit
content
analys
use
result
parent
return
questionnair
use
fairi
tale
commonli
report
mean
commun
regardless
age
die
child
parent
children
younger
four
use
music
draw
commun
less
often
parent
older
children
parent
provid
comment
reveal
often
child
initi
commun
death
analysi
reveal
four
categori
commun
death
occur
commun
deathbi
use
narr
talk
friend
famili
die
death
talk
life
death
prepar
death
practic
prepar
conclus
mani
way
parent
commun
death
die
child
studi
mani
use
mean
facilit
commun
difficult
subject
provid
appropri
literatur
andor
movi
pediatr
ward
may
help
parent
children
commun
minim
risk
caus
harm
stabil
two
short
distress
measur
appli
parent
survivor
childhood
brain
solid
tumour
leclair
samson
carret
sultan
psycholog
depart
universit
de
montreal
outremont
canada
chu
montreal
canada
object
estim
stabil
distress
anxieti
depress
scale
edmonton
symptom
assess
parent
survivor
childhood
brain
tumour
solid
tumour
method
parent
complet
distress
questionnair
immedi
usual
appoint
child
month
later
parent
rate
children
hrqol
life
event
separ
scale
result
demontr
high
reliabl
stabl
clinic
situat
rs
chang
children
hrqol
life
event
associ
chang
distress
measur
score
associ
score
valid
distress
measur
rs
conclus
may
stabl
measur
parent
distress
result
support
use
instrument
caregiv
import
studi
correl
distress
measur
sinc
way
ascertain
reliabl
measur
evalu
summer
camp
children
cancer
famili
martiniuk
wu
amylon
faculti
medicin
univers
sydney
sydney
australia
faculti
medicin
univers
utah
utah
usa
faculti
medicin
pediatr
oncolog
stanford
univers
stanford
usa
object
children
surviv
childhood
cancer
children
cancer
famili
often
attend
special
summer
camp
therapeut
recreat
cancer
treatment
journey
evalu
program
emerg
recent
decad
previou
evalu
infrequ
use
standard
measur
typic
enrol
small
sampl
size
drawn
one
summer
camp
address
gap
studi
sought
use
standard
outcom
measur
enrol
larg
sampl
size
multipl
centr
enabl
stratif
outcom
method
studi
camp
north
america
use
evalu
summer
camp
children
cancer
sibl
outcom
measur
use
pediatr
camp
outcom
scale
pco
use
likert
scale
score
studi
approv
stanford
ethic
review
board
particip
sign
consent
form
result
total
camper
n
femal
enrol
studi
camper
patient
sibl
particip
patient
sibl
treatment
relaps
year
camp
mean
score
pco
emot
subscal
sd
social
subscal
sd
physic
subscal
sd
sd
pco
total
mean
score
sd
conclus
studi
use
standard
pco
tool
measur
outcom
children
attend
camp
allow
comparison
data
across
camp
across
specialti
camp
type
eg
cancer
diabet
etc
find
demonstr
camp
help
camper
feel
improv
emot
social
physic
function
help
children
improv
strongest
score
observ
emot
social
function
subscal
ultim
hope
increas
skill
gain
camp
help
build
cope
resili
children
diagnos
cancer
two
overlook
contributor
abandon
childhood
cancer
treatment
kenya
parent
social
network
experi
hospit
retent
polici
mostert
f
njuguna
sc
langat
ajm
slot
j
skile
mn
sitaresmi
pm
van
de
ven
j
musimbi
rc
vreeman
gjl
kasper
pediatr
vu
univers
medic
center
amsterdam
netherland
pediatr
moi
teach
referr
hospit
eldoret
kenya
pediatr
indiana
univers
school
medicin
indianapoli
usa
pediatr
dr
sardjito
hospit
yogyakarta
indonesia
epidemiolog
biostatist
vu
univers
medic
center
amsterdam
netherland
object
princip
reason
childhood
cancer
treatment
failur
countri
treatment
abandon
two
often
neglect
factor
may
contribut
abandon
lack
inform
guidanc
doctor
along
belief
surround
parent
increas
misconcept
regard
cancer
treatment
nation
polici
public
hospit
patient
retain
doctor
discharg
medic
bill
settl
studi
explor
parent
social
network
experi
hospit
retent
polici
kenyan
academ
hospit
method
conduct
interview
parent
childhood
cancer
patient
diagnos
abandon
treatment
result
retrospect
chart
review
reveal
childhood
cancer
patient
abandon
treatment
famili
could
reach
interview
commun
member
surround
parent
grandpar
rel
friend
villag
believ
child
bewitch
advis
parent
seek
altern
treatment
stop
medic
treatment
parent
discuss
parent
cancer
patient
child
life
god
hand
trauma
forc
hospit
stay
import
complet
treatment
financi
burden
treatment
incur
cancer
discuss
influenc
percept
cancer
treatment
use
famili
nineteen
parent
could
pay
medic
bill
allow
take
child
home
parent
felt
desper
powerless
sad
child
imprison
retent
period
parent
felt
hospit
retent
must
ceas
conclus
belief
surround
parent
may
influenc
percept
cancer
treatment
contribut
abandon
hospit
retent
polici
highli
distress
parent
may
contribut
treatment
delay
treatment
abandon
factor
jeopard
treatment
outcom
children
requir
attent
modif
examin
effect
childhood
cancer
parent
subsystem
n
moul
estefan
g
mccaffrey
tapp
strother
nurs
univers
calgari
calgari
canada
hematolog
oncolog
blood
marrow
transplant
program
alberta
children
hospit
calgari
canada
object
studi
investig
effect
childhood
cancer
parent
relationship
past
studi
report
childhood
cancer
neg
effect
relationship
other
even
strengthen
though
may
ever
known
whether
relationship
suffer
strengthen
littl
understood
cancer
experi
affect
relationship
parent
might
health
care
profession
support
relationship
method
unstructur
interview
conduct
total
particip
data
analyz
use
hermeneut
phenomenolog
method
interpret
particip
includ
parent
children
treat
cure
live
littl
side
effect
treat
live
long
term
effect
surviv
result
state
relationship
prior
cancer
mani
situat
import
implic
relationship
fare
cancer
experi
predictor
howev
challeng
relationship
thrive
repair
result
experi
strongest
find
studi
relationship
affect
intens
way
even
surpris
coupl
offer
advic
coupl
face
experi
particip
also
advic
offer
health
care
profession
thing
help
help
say
regard
support
coupl
conclus
relationship
parent
profound
effect
health
well
child
support
offer
area
prevent
healthcar
cknowledg
kid
cancer
care
foundat
chair
fund
alberta
children
hospit
foundat
detail
psychoaffect
statu
long
term
pediatr
acut
lymphoblast
leukemia
survivor
cohort
descript
predict
c
sinnett
sultan
psycholog
de
montreal
canada
chu
montreal
canada
object
survivor
pediatr
increas
risk
mental
health
difficulti
previou
research
suggest
emot
pattern
could
specif
popul
although
rate
broad
psychiatr
condit
studi
descript
individu
emot
symptom
offer
describ
psychoaffect
symptom
essenti
orient
treatment
object
studi
present
detail
descript
psychoaffect
statu
larg
pediatr
survivor
cohort
describ
posit
neg
emot
depress
anxieti
symptom
includ
concern
mental
qualiti
life
fatigu
method
present
sampl
consist
survivor
ongo
cohort
uhc
montreal
mean
age
rang
yr
questionnair
includ
distress
thermomet
depress
anxieti
modul
beck
youth
inventori
brief
symptom
assess
survivor
concern
pedsql
gener
scale
pedsql
fatigu
scale
describ
statist
use
effect
size
compar
sampl
extern
norm
result
minor
survivor
report
signific
distress
anxieti
frequent
report
depress
anxieti
affect
frequent
report
jitteri
nervou
anxiou
upset
scare
fatigu
particularli
high
sampl
survivor
report
fewer
concern
health
cancer
relaps
death
survivor
sampl
exploratori
result
suggest
risk
statu
treatment
histori
associ
symptom
anxieti
pattern
fatigu
conclus
result
suggest
symptomat
pattern
popul
could
mark
rel
high
number
anxieti
fatigu
symptom
fewer
depress
symptom
identifi
caus
miss
appoint
implement
intervent
real
time
increas
treatment
complianc
reduc
abandon
rate
childhood
cancer
el
salvador
c
salaverria
n
rossel
fuent
alabi
f
vasquez
hernandez
c
lam
r
ribeiro
pediatr
oncolog
vivirhospit
nacion
de
benjamin
bloom
san
salvador
el
salvador
depart
oncolog
intern
outreach
program
st
jude
children
research
hospit
memphi
usa
depart
oncolog
st
jude
children
research
hospit
memphi
usa
object
el
salvador
new
case
pediatr
cancer
diagnos
year
surviv
rate
approach
although
treatment
avail
cost
abandon
therapi
high
last
decad
reason
abandon
clear
procedur
design
detect
miss
appoint
regist
root
caus
interven
time
fashion
implement
method
absenc
medic
appoint
area
pediatr
oncolog
unit
inform
medic
team
daili
patient
demograph
reason
absenc
determin
regist
case
lymphoblast
leukemia
induct
therapi
contact
within
hour
notif
case
contact
within
hour
patient
complet
treatment
within
week
reason
absenc
obtain
telephon
person
interview
patient
fail
show
initi
contact
local
health
clinic
municip
contact
conduct
search
patient
law
enforc
use
last
resort
patient
first
line
treatment
good
prognosi
result
absenc
effici
regist
famili
reason
behind
absenc
detect
proper
intervent
conduct
categori
reason
absenc
establish
cultur
social
context
consid
abandon
rate
drop
institut
cost
reduc
conclus
relationship
adher
abandon
treatment
need
address
inform
first
might
shed
light
abandon
show
possibl
similar
well
differenec
two
analysi
impact
absente
surviv
need
explor
abandon
therapi
necessarili
result
studi
famili
psychosoci
function
recent
diagnosi
childhood
cancer
scheper
sm
sint
nicolaa
h
hn
caron
gjl
kasper
pm
hoogerbrugg
cm
verhaak
grootenhui
psychosoci
depart
academ
medic
center
amsterdam
netherland
depart
medic
psycholog
radboud
univers
medic
center
nijmegen
netherland
depart
pediatr
oncolog
academ
medic
center
amsterdam
netherland
depart
pediatr
oncolog
hematolog
vu
univers
medic
center
amsterdam
netherland
depart
pediatr
oncolog
radboud
univers
medic
center
nijmegen
netherland
object
diagnos
childhood
cancer
stress
event
entir
famili
put
risk
develop
psychosoci
problem
aim
determin
psychosoci
function
parent
patient
year
patient
year
sibl
year
recent
diagnosi
childhood
cancer
compar
score
healthi
popul
method
psychosoci
function
assess
onlin
one
month
n
famili
respons
rate
hospit
anxieti
depress
scale
had
use
parent
strength
difficulti
questionnair
sdq
use
patient
n
sibl
n
had
sdq
score
compar
dutch
refer
group
mean
percentag
clinic
rang
result
parent
children
cancer
score
significantli
higher
refer
group
p
anxieti
depress
percentag
parent
moder
sever
rang
higher
refer
group
p
anxieti
vs
depress
vs
signific
differ
found
mean
patient
sibl
compar
norm
one
fifth
patient
sibl
score
borderlin
clinic
rang
sdq
conclus
parentsreport
high
level
anxieti
depress
even
though
averag
patient
sibl
year
psychosoci
function
compar
norm
consider
proport
children
seem
struggl
structur
earli
attent
famili
problem
diagnosi
necessari
earli
prevent
intervent
possibl
psychosoci
alli
health
workforc
quantifi
workforc
ratio
paediatr
oncolog
servic
plan
futur
shelli
j
williamson
p
downi
hirst
paediatr
integr
cancer
servic
paediatr
integr
cancer
servic
melbourn
australia
sheila
hirst
consult
sheila
hirst
consult
melbourn
australia
object
manag
paediatr
oncolog
requir
extens
multidisciplinari
staf
recent
audit
activ
victorian
primari
treat
centr
period
reveal
signific
increas
usag
inpati
activ
chemotherapi
radiat
therapi
within
context
increas
servic
usag
togeth
increas
birth
rate
treatment
complex
surviv
project
undertaken
estim
patient
staff
ratio
psychosoci
alli
health
workforc
victorian
paediatr
oncolog
primari
treat
centr
method
workforc
ratio
estim
nine
psychosoci
alli
health
group
avail
ratio
inform
industri
award
guidelin
andor
model
care
profession
disciplin
identifi
task
requir
newli
diagnos
children
key
pathway
point
time
alloc
task
level
care
use
risk
adapt
approach
low
moder
high
riskne
result
methodolog
use
project
allow
calcul
ratio
newli
diagnos
children
per
annum
equival
fte
ratio
calcul
art
music
play
therapi
educ
play
therapi
dietet
mental
health
neuropsycholog
occup
therapi
pharmaci
physiotherapi
social
work
exampl
ratio
newli
diagnos
children
fte
neuropsychologist
recommend
mental
health
clinician
ratio
newli
diagnos
children
recommend
conclus
limit
nation
intern
model
avail
estim
paediatr
oncolog
psychosoci
alli
health
workforc
ratio
ratio
assist
primari
treat
centr
plan
meet
futur
workforc
need
victorian
children
adolesc
cancer
addit
methodolog
use
may
assist
state
australia
well
oversea
health
servic
plan
oncolog
psychosoci
alli
health
workforc
futur
commun
result
medic
imag
test
paediatr
oncolog
opinion
need
radiologist
survey
amjb
smet
ema
smet
ga
tytgat
hn
caron
j
stoker
grootenhui
radiolog
emma
childr
hospitalacadem
medic
center
amsterdam
netherland
medic
psycholog
emma
childr
hospitalacadem
medic
center
amsterdam
netherland
paediatr
oncolog
emma
childr
hospitalacadem
medic
center
amsterdam
netherland
paediatr
psycholog
emma
childr
hospitalacadem
medic
center
amsterdam
netherland
object
discov
malign
progress
recurr
malign
imag
test
stress
event
radiologist
radiologist
often
previou
relationship
patient
limit
time
build
rapport
hamper
commun
result
moreov
skill
break
bad
news
may
limit
commun
train
mandatori
radiolog
curriculum
conduct
survey
investig
opinion
attitud
need
regard
discuss
imag
result
parent
children
cancer
method
questionnair
present
member
european
societi
paediatr
radiolog
radiologist
children
cancer
among
patient
ask
anonym
answer
question
background
practic
opinion
need
regard
commun
result
parent
children
cancer
result
radiologist
interest
oncolog
repres
countri
respond
seventi
percent
respond
report
parent
pediatr
cancer
patient
frequent
ask
result
percent
respond
agre
role
discuss
result
directli
parent
percent
report
feel
comfort
discuss
worrisom
result
percent
respond
indic
never
receiv
train
commun
skill
percent
would
sign
train
commun
skill
avail
percent
report
unawar
polici
guidanc
disclos
result
within
depart
institut
conclus
parent
children
cancer
frequent
ask
radiologist
discuss
result
imag
test
mani
radiologist
agre
role
substanti
percentag
radiologist
feel
comfort
discuss
bad
news
report
lack
guidelin
find
suggest
room
need
guidelin
train
regard
commun
radiologist
patient
feasibl
test
help
onlin
inform
intervent
parent
share
inform
acut
lymphoblast
leukaemia
child
c
vindrola
g
bryan
g
macintyr
n
ranasingh
say
f
gibson
richardson
r
taylor
n
crichton
v
hard
children
nurs
london
south
bank
univers
london
unit
kingdom
parent
repres
user
paediatr
oncolog
cancer
servic
london
unit
kingdom
haematolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
children
nurs
london
south
bank
univers
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
faculti
health
scienc
univers
southampton
univers
hospit
southampton
nh
foundationtrust
southampton
unit
kingdom
children
nurs
univers
colleg
london
hospit
nh
foundat
trust
london
south
bank
univers
london
unit
kingdom
faculti
health
social
care
london
south
bank
univers
london
unit
kingdom
medic
illustr
univers
colleg
london
institut
child
health
london
unit
kingdom
object
previou
research
identifi
parent
children
acut
lymphoblast
leukaemia
felt
receiv
minim
support
facilit
acquisit
knowledg
diseas
especi
period
close
diagnosi
develop
onlin
intervent
name
help
harmonis
educ
leukaemia
parent
facilit
easi
access
inform
leukaemia
resourc
aim
parent
siop
present
earli
descript
intervent
might
look
like
siop
present
basi
help
explain
initi
develop
paper
focu
feasibl
test
valid
intervent
famili
health
profession
prior
evalu
second
phase
studi
method
develop
stage
feasibl
test
valid
took
place
five
sequenti
step
firstli
famili
advisori
group
provid
comment
content
look
feel
websit
next
group
clinician
parent
one
hospit
invit
use
help
provid
comment
thirdli
health
profession
four
site
review
intervent
provid
comment
advis
hospit
specif
chang
intervent
revis
reflect
comment
final
health
profession
review
intervent
valid
inform
result
feasibl
test
valid
intervent
lengthi
import
step
develop
help
trial
tribul
recruit
famili
treatment
busi
health
profession
take
part
research
discuss
final
version
help
present
conclus
second
phase
studi
help
test
prospect
two
group
studi
anticip
help
increas
parent
knowledg
confid
compet
decreas
stress
make
commun
profession
easier
explor
cancer
worri
predictor
adolesc
young
adult
survivor
childhood
cancer
r
wang
sy
p
nathan
r
barr
z
klassen
school
medicin
queen
univers
kingston
canada
health
research
methodolog
mcmaster
univers
hamilton
canada
pediatr
oncolog
hospit
sick
children
toronto
canada
depart
pediatr
mcmaster
univers
hamilton
canada
school
health
servic
manag
ryerson
univers
toronto
canada
object
experi
cancer
childhood
influenc
psychosoci
wellb
aya
adolesc
young
adult
survivor
report
worri
year
beyond
complet
treatment
cancer
worri
shown
import
barrierfacilit
transit
followup
care
also
impact
psychosoci
adjust
survivor
despit
import
lack
research
cancer
worri
popul
aim
studi
investig
relationship
patient
cancer
factor
cancer
worri
aya
childhood
cancer
survivor
method
juli
januari
aya
survivor
age
recruit
either
person
mail
three
canadian
pediatr
hospit
particip
respons
rate
complet
questionnair
booklet
includ
newli
develop
psychometr
sound
cancer
worri
scale
cw
select
predictor
cancer
worri
base
upon
review
literatur
guid
expert
opinion
univari
analysi
use
identifi
predictor
significantli
relat
cw
score
includ
multivari
regress
model
result
multivari
analysi
femal
aya
survivor
report
significantli
greater
cancer
worri
male
score
averag
point
lower
cw
p
ci
level
treatment
intens
also
signific
survivor
receiv
intens
therapi
significantli
worri
patient
receiv
least
intens
therapi
p
ci
predictor
contribut
good
fit
multivari
regress
model
p
conclus
studi
identifi
two
import
factor
associ
increas
cancer
worri
aya
popul
result
help
identifi
survivor
like
worri
direct
appropri
program
mitig
burden
cancer
worri
transit
process
overal
wellb
evalu
iron
overload
end
therapi
children
acut
lymphoblast
leukemia
acar
bayraktaroglu
th
karapinar
ay
oymak
b
demirag
inc
g
aydinok
c
vergin
pediatr
dr
uz
childen
hospit
izmir
turkey
radiolog
ege
univers
izmir
turkey
pediatr
ege
univers
izmir
turkey
object
aim
studi
determin
hepat
iron
overload
use
mri
evalu
influenc
hepat
iron
overload
liver
function
test
children
acut
lymphoblast
leukemia
method
medic
chart
patient
male
femal
diagnosi
record
age
diagnosi
time
mr
risk
group
treatment
protocol
amount
transfus
blood
product
note
patientsrecord
serum
iron
paramet
torch
hepatit
marker
end
therapi
note
patien
record
perform
mri
studi
first
month
therapi
evalu
liver
iron
burden
repeat
serum
iron
serun
ferritin
serum
transferrin
total
iron
bind
capac
month
end
treatment
patient
high
ferritin
result
twenti
patien
standart
risk
group
patient
intermedi
risk
group
patient
high
risk
group
patient
sever
hepat
iron
overload
eight
patient
mild
patient
moder
iron
everload
high
risk
group
highest
number
red
blood
cell
product
iron
overload
higher
patient
mlkg
red
blood
cell
product
transferrin
satur
ferritin
level
amount
transfus
per
year
posit
correl
amount
liver
iron
overload
repeat
ferritin
measur
mont
cessat
therapi
found
statist
decreas
patient
high
ferritin
level
abnorm
liver
function
test
found
conclus
patient
iron
overload
end
thrapi
correl
liver
iron
overload
liver
function
test
control
measur
ferritin
month
cessat
therapi
significantli
decreas
low
dose
rasburicas
treatment
prevent
tumour
lysi
syndrom
acut
lymphoblast
leukemia
singl
centr
experi
agarw
v
chinnabhandar
n
radhakrishnan
kumar
thakkar
tarangini
sachdeva
pediatr
hematooncolog
sir
ganga
ram
hospit
delhi
india
object
tumour
lysi
syndrom
tl
oncolog
emerg
requir
earli
recognit
intervent
rasburicas
use
wide
prevent
treatment
tl
dose
day
due
financi
constraint
difficult
administ
rasburicas
prescrib
dose
observ
effect
singl
dose
rasburicas
mgkg
use
center
manag
tl
method
retrospect
analysi
alllymphoma
patient
featur
tl
jan
done
biochem
marker
analyz
rasburicas
administr
result
patient
suffer
alllymphoma
develop
featur
tl
studi
period
rasburicas
use
children
financi
patient
ongo
tl
admiss
develop
chemotherapi
start
age
rang
year
dose
rang
weight
base
rang
uric
acid
rang
creatinin
baselin
median
ua
creatinin
level
respect
median
serum
ua
level
hour
rasburicas
administr
patient
signific
reduct
uric
acid
level
first
day
creatinin
phosphat
potassium
reduc
propotion
well
patient
undergo
hemodialysi
patient
given
rasburicas
due
rise
creatinin
howev
patient
undergo
hemodialysi
rasburicas
could
given
conclus
financi
constraint
develop
countri
pose
great
challeng
manag
cancer
cure
press
need
develop
cost
efficaci
yet
effect
modal
treatment
studi
suggest
singl
dose
rasburicas
effect
manag
tl
effect
reduc
need
renal
replac
therapi
compar
analysi
hdac
express
level
pediatr
acut
leukemia
patient
chemotherapi
compar
healthi
control
akin
aslar
mumcuoglu
u
ezer
e
kurekci
n
akar
cancer
research
genetik
laboratori
losev
foundat
children
leukemia
ankara
turkey
depart
pediatr
haematolog
gulhan
militari
medic
academi
ankara
turkey
depart
pediatr
clinic
hospit
ankara
turkey
object
hdac
involv
nucleosom
chang
chromatin
structur
remodel
import
gene
transcript
oncogenesi
regul
mutat
abnorm
express
hdac
observ
type
cancer
includ
haematolog
malign
studi
aim
evalut
mrna
express
hdac
childhood
leukemia
sampl
method
studi
popul
consist
patient
year
old
admit
hospit
diagnosi
acut
leukemia
rna
isol
perform
use
rna
isol
kit
express
data
analyz
use
relativebasicquantif
softwar
provid
result
interestingli
result
indic
differ
leve
hdac
express
among
patient
control
remain
rel
consist
sampl
show
lower
level
express
compar
control
except
two
patient
observ
dramat
increas
posttherapi
sampl
oppos
pretherapi
sampl
express
show
great
variant
express
sampl
express
high
compar
control
pre
therapi
sampl
decreas
control
level
postsampl
express
demonstr
signific
chang
either
preor
postsampl
except
one
patient
observ
low
level
express
sampl
experiment
time
point
one
patient
diagnos
myprebcel
cn
relaps
two
bone
marrow
transplant
show
unusu
high
express
pretherapi
sampl
anoth
patient
high
level
relaps
die
duringtreat
one
prebcel
patient
show
mll
transloc
high
level
anoth
patient
normal
karyotyp
show
high
express
posttherapi
high
express
pretherapi
sampl
lastli
prebcel
patient
show
high
express
pretherapi
conclus
studi
conduct
haematolog
malign
hdac
express
studi
analyz
express
chang
pediatr
leukemia
sampl
threapi
found
express
chang
import
pediatr
leukemia
sinc
gene
role
cell
differenti
angiogenesi
regul
pathway
reduc
side
effect
sever
asparaginas
reaction
anaphylaxi
possibl
role
use
methylen
blue
give
epinepherin
quickli
reduc
angioedema
hypotens
p
anderson
c
murphi
k
arnold
devin
j
kaplan
pediatr
carolina
healthcar
system
charlott
usa
object
effect
drug
acut
lymphoblast
leukemia
lymphoma
safeti
profil
includ
sever
allerg
reaction
usual
occur
repeat
dose
associ
symptom
includ
angioedema
hive
lip
mouth
throat
swell
hoars
wheez
difficulti
breath
hypotens
anaphylaxi
treatment
current
involv
administr
epinephrin
support
measur
rapidli
reduc
reaction
sever
start
use
addit
measur
methylen
blue
inhibit
angioedema
hypotens
method
review
literatur
show
mani
paper
support
use
methylen
blue
treat
anaphylaxi
methylen
blue
inhibit
guanylyl
cyclas
nitric
oxid
associ
vasoperm
methylen
commerci
suppli
mg
blue
liquid
ml
vial
contain
mgml
vial
cost
us
recommend
dose
given
rapid
iv
bolu
minut
time
epinephrin
given
result
input
pediatr
oncologist
nurs
pharmaci
emerg
depart
result
improv
pathway
care
reaction
character
skin
eg
hive
seriou
prompt
administr
epinephrin
team
care
start
skin
reaction
epinephrin
recommend
diphenhydramin
mgkg
iv
hydrocortison
iv
famotidin
mgkg
iv
given
sever
reaction
methylen
blue
bolu
infus
given
immedi
mgkg
im
epinephrin
addit
measur
done
includ
albuterol
nebul
oxygen
puls
oximetri
diphenhydramin
hydrocortison
famotidin
hospit
admiss
monitor
via
emerg
depart
also
encourag
parent
take
cell
phone
pictur
futur
caregiv
better
understand
sever
rash
andor
lip
face
swell
conclus
methylen
blue
inexpens
effect
mean
amelior
sever
asparaginas
reaction
demograph
diseas
respons
evalu
pediatr
high
risk
acut
lymphoblast
leukemia
patient
tertiari
care
centr
anwar
faizan
pa
hematologyoncolog
children
hospit
lahor
pakistan
object
main
object
studi
discuss
present
outcom
children
acut
lymphoblast
leukemia
method
present
retrospect
studi
look
demograph
outcom
children
present
hematolog
oncolog
depart
children
hospit
lahor
januari
decemb
children
bone
marrow
biopsi
proven
includ
data
regard
age
gender
risk
categor
outcom
record
analyz
children
stratifi
high
risk
year
age
factor
cn
diseas
mediastin
mass
present
lahor
group
protocol
acut
lymphoblast
leukemia
bfm
ukallxi
base
use
treatment
result
total
patient
includ
seventi
percent
male
major
year
age
patient
year
one
hundr
sixteen
high
risk
diseas
standard
risk
initi
wbc
bfm
risk
factor
patient
cn
diseas
mediastin
mass
present
seventi
eight
patient
complet
treatment
left
medic
advic
die
twenti
nine
relaps
among
relaps
treatment
conclus
high
risk
diseas
common
present
children
centr
initi
high
wbc
count
massiv
organomegali
male
predomin
abandon
anoth
major
factor
affect
overal
surviv
rate
howev
overal
surviv
almost
treat
patient
safeti
nalbuphin
neural
tissu
rat
efficaci
treatment
acut
herpet
pain
pediatr
acut
lymphoblast
leukemia
j
attia
kamel
r
yousef
anesthesia
icu
faculti
medicin
minia
egypt
pharmacolgi
depart
faculti
medicin
minia
egypt
patholog
depart
faculti
medicin
minia
egypt
object
acut
lymphoblast
leukemia
previous
shown
caus
sever
impair
immun
turn
make
children
suscept
viral
infect
especi
herp
zoster
manifest
sever
pain
main
purpos
studi
evalu
firstli
safeti
nalbuphin
experiment
neural
tissu
rat
secondli
efficaci
caudal
inject
nalbuphin
minim
dose
oral
paracetamol
analges
pediatr
patient
suffer
acut
herpet
pain
method
two
studi
perform
studi
evalu
safeti
nalbuphin
hcl
neural
tissu
experiment
rat
treat
group
inject
nalbuphin
mgkg
intrathec
one
day
day
longitudin
section
cerebellum
transvers
section
spinal
cord
excis
anim
histolog
examin
studi
studi
conduct
children
nalbuphin
inject
caudal
dose
mg
dose
everi
h
period
day
paracetamol
administr
dose
mgkg
everi
hour
result
result
reveal
nalbuphin
show
patholog
chang
cerebellum
spinal
cord
hand
protect
effect
nalbuphin
minim
dose
paracetamol
associ
signific
analges
effect
children
analges
effect
assess
facial
pain
scale
fp
behavior
pain
assess
bpa
motor
block
effect
assess
bromag
score
conclus
find
show
nalbuphin
caudal
inject
induc
proper
analges
effect
minim
dose
paracetamol
acut
herpet
pain
pediater
patient
toxic
high
dose
methotrex
children
acut
lymphoblast
leukemia
b
choneska
jovanova
glamochanin
k
martinova
z
trajkova
antevska
kocheva
jovanovska
hematolog
oncolog
univers
clinic
children
diseas
skopj
macedonia
object
intensif
system
chemotherapi
inclus
high
dose
methotrex
mtx
contribut
improv
event
free
surviv
children
acut
lymphoblast
leukemia
help
reduc
cranial
radiat
mostli
patient
despit
benefit
agent
might
caus
seriou
toxic
even
life
treat
event
treatment
predict
earli
detect
manag
toxic
effect
therapi
high
dose
mtx
still
great
challeng
everi
pediatr
oncologist
aim
studi
evalu
incid
toxic
effect
chemotherapi
high
dose
mtx
compar
toxic
applic
lower
dose
mtx
method
retrospect
record
review
done
children
standard
risk
treat
depart
forti
five
treat
treat
histor
group
toxic
regist
accord
protocol
acut
toxic
part
bfm
protocol
result
toxic
high
dose
mtx
predomin
group
treat
signific
toxic
effect
hepatotox
versu
p
oral
mucos
versu
p
myelosupres
anemia
gradu
present
versu
trombopenia
gr
versu
patient
studi
group
experienc
episod
neutropenia
versu
bacteri
viral
infect
predomin
studi
group
due
sever
myelosupres
conclus
studi
toxic
effect
common
studi
group
due
applic
higher
dose
mtx
variation
toxic
patient
studi
group
probabl
due
genet
differ
drug
metabol
current
research
dedic
discov
marker
abl
predict
risk
appear
mtx
toxic
molecular
cytogenet
abnorm
children
acut
lymphoblast
tertiari
care
center
north
india
yr
chopra
ramzan
r
sharma
katewa
yadav
pediatr
hematolog
oncolog
bone
marrow
transplant
unit
forti
memori
research
institut
gurgaon
india
object
aim
studi
determin
frequenc
cytogenet
abnorm
childhood
patient
come
tertiari
care
hospit
develop
countri
method
retrospect
studi
inclus
criteria
patient
age
age
multiplex
revers
transcriptas
polymeras
chain
reaction
multiplex
rt
pcr
analysi
convent
cytogenet
perform
detect
chromosom
abnorm
result
cytogenet
analysi
done
children
rest
could
done
view
financi
constraint
twenti
b
cell
cell
normal
cytogenet
twenti
clonal
chromosom
abnorm
numer
imbal
consist
hypodiploid
chromosom
case
hyperdiploid
chromosom
b
cell
cell
pseudodiploidi
chromosom
case
b
cell
chromosom
transloc
detect
multiplex
rt
pcr
observ
patient
five
children
posit
mll
rearrang
present
infant
complex
cytogenet
seen
children
ten
children
relaps
bfm
protocol
cytogenet
could
done
normal
cytogenet
standard
risk
high
risk
conclus
cytogenet
could
perform
complet
risk
stratif
hinder
six
children
relaps
cytogenet
known
confound
factor
risk
stratif
manag
prognosi
aim
everi
patient
mtor
relat
protein
express
childhood
k
neme
z
dept
pediatr
semmelwei
univers
budapest
hungari
dept
patholog
experimet
cancer
re
semmelwei
univers
budapest
hungari
object
improv
treatment
childhood
may
depend
develop
target
therapi
mtor
kinas
central
mediat
sever
signal
pathway
recent
attract
remark
attent
potenti
target
pediatr
howev
limit
data
exist
activ
mtor
method
present
studi
amount
mtor
activ
depend
character
elisa
human
leukemia
cell
line
lymphoblast
childhood
patient
n
express
measur
chemotherapi
relaps
leukemia
cell
line
exhibit
increas
mtor
activ
indic
ribosom
protein
phosphoryl
eukaryot
initi
factor
bind
protein
elev
protein
level
detect
sampl
diagnosi
efficaci
chemotherapi
follow
decreas
mtor
activ
depend
protein
phosphoryl
optic
densiti
od
elisa
significantli
higher
patient
poor
prognosi
diagnosi
sampl
relaps
patient
result
result
suggest
measur
mtor
activ
relat
elisa
may
help
identifi
patient
poor
prognosi
treatment
detect
earli
relaps
conclus
determin
mtor
activ
leukem
cell
may
also
use
tool
select
patient
may
benefit
futur
rapalog
treatment
support
otka
analysi
advers
event
children
acut
lymphoblast
leukaemia
treat
protocol
ic
bfm
retrospect
studi
k
derwich
p
baranska
j
wachowiak
pediatr
oncolog
hematolog
transplantolog
poznan
univers
medic
scienc
poznan
poland
object
aim
studi
retrospect
analysi
advers
event
children
treat
protocol
ic
bfm
depart
method
accord
ic
bfm
criteria
patient
femal
male
year
age
med
yr
classifi
group
remiss
time
achiev
patient
median
month
rang
month
result
treatment
analys
pef
prf
result
among
advers
event
relaps
observ
within
month
med
month
diagnosi
earli
earli
late
relaps
bm
sr
ir
cn
sr
testi
hr
mediastinum
hr
mix
relaps
sr
ir
hr
ir
sr
death
earli
death
due
treatment
complic
cr
ir
hr
ii
cr
due
leukaemia
relapseprogress
car
accid
patient
cr
ii
cr
conclus
analysi
shown
bm
cn
mix
relaps
seen
high
proport
patient
sr
ir
group
high
rate
death
mainli
hr
group
patient
notic
due
treatment
complic
profil
acut
lymphoblast
leukemia
children
experi
jammu
india
digra
ss
slathia
r
harish
pediatr
govern
medic
colleg
jammu
india
object
studi
profil
children
present
method
children
hospit
depart
pediatr
govern
medic
colleg
jammu
period
year
includ
retrospect
studi
clinic
hematolog
profil
analyz
detail
result
total
patient
diagnos
male
femal
ratio
major
children
less
year
age
patient
patient
less
year
age
fever
pallor
bleed
manifest
lymphadenopathi
gener
weak
weight
loss
bone
pain
present
respect
patient
hemoglobin
less
gm
hemoglobin
gm
respect
patient
decreas
increas
mean
cell
volum
mean
cell
hemoglobin
increas
total
leucocyt
count
seen
patient
count
seen
patient
leucopenia
seen
patient
rest
normal
count
patient
thrombocytopenia
lymphoblast
atyp
cell
peripher
blood
film
conclus
found
region
fab
common
age
year
fever
anemia
bleed
manifest
lymphadenopathi
commonest
present
featur
major
leukocytosi
thrombocytopenia
time
present
bone
marrow
express
vascular
endotheli
growth
factor
vegf
vegf
pediatr
acut
lymphoblast
leukemia
v
dinand
sharma
n
rao
kalra
p
gupta
preeti
n
radhakrishnan
sachdeva
pediatr
hematolog
oncolog
bmt
sir
ganga
ram
hospit
delhi
india
research
depart
sir
ganga
ram
hospit
delhi
india
histopatholog
depart
sir
ganga
ram
hospit
delhi
india
object
angiogenesi
play
import
role
hematolog
malign
vascular
endotheli
growth
factor
vegf
promot
angiogenesi
via
interact
vegf
blood
level
vegf
receptor
shown
prognost
signific
pediatr
acut
lymphoblast
leukemia
assess
signific
svegf
bone
marrow
bm
express
vegf
method
children
newli
diagnos
children
relaps
remiss
complet
therapi
prospect
enrol
control
includ
healthi
children
normal
bm
biopsi
svegf
level
measur
present
new
relaps
time
remiss
induct
end
therapi
immunochemistri
vegf
done
bm
biopsi
time
point
result
untreat
leukemia
bm
sampl
n
show
strong
vegf
express
blast
cell
convers
normal
bm
n
moder
vegf
express
mononuclear
cell
express
moder
leukem
sampl
blast
cell
contrast
normal
sampl
show
strong
express
hematopoiet
cell
remiss
induct
n
end
treatment
n
immunochemistri
result
compar
bm
control
median
interquartil
rang
svegf
significantli
lower
untreat
relaps
case
compar
control
old
case
enrol
treatment
complet
p
conclus
bm
express
vegf
strong
blast
mainli
express
normal
mononuclear
cell
overexpress
reduc
hematolog
remiss
predictor
acut
toxic
children
b
n
krstovski
janic
j
l
dokmanov
malcic
j
lazic
p
rodic
depart
pediatr
hematolog
oncolog
children
hospit
banja
luka
banja
luka
bosnia
herzegovina
depart
pediatr
hematolog
oncolog
univers
children
hospit
belgrad
belgrad
serbia
object
success
treat
childhood
acut
lymphoblast
leukemia
achiev
mainli
due
intensif
cytotox
therapi
analyz
possibl
predictor
acut
toxic
popul
method
short
studi
review
medic
record
children
age
year
diagnos
treat
accord
allic
bfm
protocol
two
academ
medic
center
decemb
may
clinic
biolog
characterist
diseas
characterist
diagnosi
intens
chemotherapi
patient
analyz
possibl
predictor
toxic
result
retrospect
studi
includ
patient
averag
age
year
median
year
toxic
data
patient
least
one
toxic
complic
treatment
age
p
sex
p
bodi
mass
index
p
initi
leukocyt
count
p
organomegali
p
cn
statu
p
diagnosi
imunophenotyp
p
molecular
p
cytogenet
p
featur
leukemia
associ
higher
toxic
presenc
central
venou
cathet
associ
total
toxic
well
infect
common
complic
p
p
chemotherapi
associ
higher
incid
entir
toxic
p
particularli
infect
p
cycl
chemotherapi
patient
group
hr
cytarabin
methotrex
significantli
associ
higher
toxic
p
conclus
sampl
shown
intens
chemotherapi
predictor
toxic
patient
group
intens
chemotherapi
higher
rate
total
toxic
particularli
infect
group
patient
requit
increas
intens
support
care
correl
diagnosi
delay
risk
stratif
acut
lymphoblast
leukemia
children
dwinata
e
supriyadi
juffri
faculti
medicin
universita
gadjah
mada
yogyakarta
indonesia
depart
pediatr
rsup
dr
sardjito
yogyakarta
indonesia
object
understand
correl
diagnosi
delay
risk
stratif
children
method
fifti
eight
patient
diagnos
precursor
b
pediatr
depart
rsup
dr
sardjito
yogyakarta
indonesia
observ
result
among
medic
record
analyz
patient
classifi
standard
risk
patient
classifi
high
risk
mean
diagnosi
delay
day
analysi
use
mean
delay
show
signific
correl
p
odd
ratio
ci
conclus
time
increas
risk
becom
high
risk
day
delay
studi
bigger
sampl
size
conduct
confirm
result
preval
cmv
infect
patient
ehsani
karahroudi
aa
rahabarimanesh
aghajani
z
jalilitahmasebi
e
shahgholi
ap
meisami
mehrvar
tashvighi
pediatr
hematolog
oncolog
tehran
univers
medic
scienc
tum
tehran
iran
commun
medicin
tehran
univers
medic
scienc
tum
tehran
iran
pediatr
hematolog
oncolog
mahak
chariti
hospit
tehran
iran
object
cmv
opportunist
infect
may
lethal
immunocomprim
patient
method
patient
admit
bahrami
hospit
tum
tehran
iran
march
march
prospect
follow
elig
patient
previou
diagnosi
treat
protocol
patient
least
one
year
chemotherapi
includ
none
patient
receiv
hematopoiet
sct
patient
posit
result
cmv
viremia
accord
pcr
clinic
laboratori
find
suggest
cmv
diseas
treat
oral
valganciclovir
mgkg
twice
daili
week
discharg
hospit
first
follow
week
complet
cours
treatment
four
week
complet
treatment
patient
clinic
improv
repeat
pcr
cmv
serolog
perform
time
initi
diagnosi
cmv
infect
patient
viremia
without
evid
cmv
diseas
receiv
treatment
patient
follow
close
test
fisher
exact
test
need
use
compar
proport
group
p
valu
consid
statist
signific
result
total
patient
male
median
rang
age
year
includ
median
rang
valu
hb
wbc
platelet
alt
ast
gdl
ul
ul
respect
two
patient
hepatosplenomegali
total
patient
cmv
viremia
p
male
femal
compris
virem
patient
respect
p
conclus
studi
igm
sensit
specif
ppv
suitabl
test
screen
detect
infect
earli
complic
outcom
children
leukem
hyperleukocytosi
experi
develop
countri
asb
sy
z
fadoo
haq
ashraf
alam
khan
pediatr
hematolog
oncolog
aga
khan
univers
hospit
karachi
pakistan
karachi
pakistan
pediatr
hematolog
oncolog
children
cancer
hospit
karachi
pakistan
object
studi
present
clinic
laboratori
featur
earli
complic
outcom
children
acut
leukemia
hyperleukocytosi
diagnos
treat
two
medic
center
karachi
januari
decemb
method
descript
observ
retrospect
analysi
result
hyperleukocytosi
found
patient
diagnos
acut
leukemia
precursor
cell
precursor
b
cell
acut
myeloid
leukemia
chronic
myeloid
leukemia
age
group
year
patient
year
common
among
male
half
symptom
day
seventeen
patient
cn
involv
therapeut
intervent
hydrationallopurinol
patient
leukapheresi
done
patient
one
expir
median
hemoglobin
gdl
rang
gdl
gdl
median
total
leukocyt
count
rang
median
platelet
count
rang
median
ldh
iul
rang
iul
iul
median
uric
acic
mgdl
rang
mgdl
mgdl
median
phosphat
mgdl
rang
mgdl
mgdl
bcr
abl
transloc
posit
patient
patient
expir
first
admiss
major
caus
death
infect
respiratori
complic
infect
cn
respiratori
complic
infect
renal
complic
conclus
earli
death
complic
prevent
earli
referr
time
appropri
antibiot
manag
tumor
lysi
syndrom
time
use
icu
modal
leukapheresi
whenev
requir
rna
new
field
pharmacogenet
pediatr
acut
lymphoblast
leukemia
e
j
uriz
navaja
p
genet
physic
anthropolog
anim
physiolog
univers
basqu
countri
leioa
spain
depart
paediatr
hospit
donosti
san
sebastian
spain
depart
oncohaematolog
hospit
cruce
bilbao
spain
depart
oncohaematolog
hospit
la
paz
madrid
spain
object
acut
lymphoblast
leukemia
treatment
produc
sever
toxic
last
year
pharmacogenet
studi
perform
order
search
marker
toxic
pediatr
howev
date
tpmt
marker
clinic
guidelin
drug
dose
major
studi
focus
code
region
entir
genom
promis
field
pharmacogenet
region
codifi
protein
may
regulatori
function
rna
ncrna
alter
ncrna
express
function
associ
drug
respons
differ
cancer
alter
ncrna
could
due
genet
polymorph
aim
present
studi
evalu
whether
polymorph
ncrna
lead
drug
respons
method
analyz
blood
sampl
pediatr
patient
complet
remiss
treat
lalshop
protocol
select
snp
describ
maf
snp
long
non
code
rna
lncrna
dysregul
cancer
use
veracod
goldeng
genotyp
assay
illumina
result
preliminari
studi
includ
snp
mirna
patient
found
first
time
associ
polymorph
toxic
take
account
result
extend
studi
increas
number
patient
snp
total
snp
lncrna
obtain
promis
result
conclus
genet
variant
ncrna
could
new
toxic
marker
treatment
pediatr
project
support
retic
upvehu
ufi
basqu
govern
new
suscept
marker
pediatr
acut
lymphoblast
leukemia
non
code
rna
e
n
garcia
de
andoin
navaja
p
carbon
genet
physic
anthropolog
anim
physiolog
univers
basqu
countri
leioa
spain
depart
paediatr
univers
hospit
donostia
san
sebastian
spain
depart
oncohaematolog
univers
hospit
cruce
bilbao
spain
depart
oncohaematolog
univers
hospit
la
paz
madrid
spain
depart
oncohaematolog
univers
hospit
miguel
servet
zaragoza
spain
object
evid
inherit
genet
risk
pediatr
acut
lymphoblast
leukemia
provid
sever
studi
focus
code
region
howev
region
repres
entir
genom
express
non
code
rna
ncrna
specif
microrna
mirna
long
non
code
rna
lncrna
shown
dysregul
suggest
may
role
risk
chang
ncrna
function
may
occur
genet
variant
therefor
aim
studi
evalu
whether
polymorph
ncrna
contribut
predisposit
childhood
method
analyz
blood
sampl
patient
complet
remiss
healthi
control
studi
select
snp
describ
maf
snp
dysregul
lncrna
cancer
use
veracod
goldeng
genotyp
assay
illumina
result
preliminari
studi
patient
healthi
control
snp
mirna
found
first
time
associ
polymorph
suscept
take
account
result
increas
number
patient
number
snp
select
snp
gene
snp
cover
code
rna
conclus
result
suggest
snp
rna
may
affect
suscept
may
repres
novel
marker
suscept
project
support
retic
upvehu
ufi
basqu
govern
therapeut
potenti
dasatinib
acut
lymphoblast
leukemia
h
goto
goto
n
miyagawa
sarashina
yokosuka
f
iwasakai
hamanou
k
fukuda
h
shimbo
j
nagai
divis
medicin
kanagawa
children
medic
center
yokohama
japan
object
src
recent
suggest
therapeut
target
neg
acut
lymphoblast
leukemia
investig
therapeut
potenti
effect
dasatinib
surviv
cell
studi
method
cytotox
imatinib
dasatinib
childhood
clinic
sampl
n
includ
cell
line
n
includ
studi
assay
clinic
sampl
cell
defin
sensit
surviv
cell
day
incub
drug
lower
express
psrc
pakt
analyz
phosflow
assay
combin
effect
dasatinib
drug
evalu
improv
isobologram
assay
result
clinic
sampl
sensit
imatinib
dasatinib
respect
two
clinic
sampl
sensit
drug
cell
line
respond
dasatinib
valu
vari
nm
none
cell
line
respond
imatinib
dasatinib
reduc
psrc
express
follow
subsequ
decreas
pakt
cell
level
reduct
psrc
pakt
correl
among
cell
line
among
drug
clofarabin
show
synergist
effect
dasatinib
sever
differ
concentr
ratio
cell
conclus
dasatinib
suggest
therapeut
role
combin
use
drug
clofarabin
might
enhanc
effect
dasatinib
prospect
random
trial
asparaginas
versu
prednisolon
prevent
tumor
lysi
syndrom
acut
lymphoblast
leukemia
patient
hyperleucocytosi
gulia
b
arora
g
narula
g
chinnaswami
pg
subramamanium
sd
banavali
pediatr
oncolog
tata
memori
hospit
mumbai
india
tata
memori
hospit
mumbai
india
object
patient
withacut
leukaemia
present
hyperleucocytosi
develop
life
threaten
complic
although
leukapheresi
standard
care
prevent
complic
expens
wide
avail
rapid
cytoreduct
patient
use
steroid
significantli
increas
risk
tumor
lysi
syndrom
tl
view
need
safe
cost
effect
cytoreduct
method
manag
hyperleucocytosi
minim
occurr
tl
hypothes
caus
adequ
cytoreduct
minim
tl
compar
prednisolon
acut
leukemia
patient
hyperleucocytosi
method
prospect
random
trial
patient
hyperleucocytosi
wbc
count
age
group
year
random
receiv
either
altern
day
prednisolon
medic
continu
till
wbc
enrol
whichev
earlier
less
fall
blood
count
hour
studi
patient
taken
studi
patient
receiv
standard
tl
prophylaxi
measur
primari
outcom
variabl
incid
laboratoryclin
tl
secondari
outcom
variabl
rate
cytoreduct
result
patient
includ
random
receiv
receiv
prednisolon
median
age
year
year
median
wbc
count
present
x
patient
arm
develop
laboratori
tl
note
patient
receiv
prednisolon
p
one
patient
prednisolon
arm
develop
clinic
tl
none
note
group
hour
patient
prednisolon
arm
achiev
adequ
cytoreduct
wbc
baselin
compar
arm
conclus
interim
analysi
studi
show
differ
incid
laboratori
tl
prednisolon
patient
hyperleucocytosi
basal
cell
carcinoma
treatment
childhood
acut
lymphoblast
leukemia
concis
review
literatur
f
gumruk
unal
cetin
divis
pediatr
hematolog
hacettep
univers
medic
school
ankara
turkey
object
cumul
incid
secondari
malign
relat
treatment
childhood
report
depend
differ
treatment
durat
herein
report
two
patient
develop
basal
cell
carcinoma
bcc
within
previou
radiat
field
pediatr
treatment
review
literatur
bcc
follow
childhood
leukemia
method
computer
literatur
search
electron
embas
identifi
publish
studi
subject
start
date
databas
februari
gener
search
structur
electron
databas
childhood
synonym
basal
cell
carcinoma
secondari
patient
primari
diagnosi
leukemia
includ
literatur
review
electron
search
result
case
woman
develop
bcc
scalp
year
success
treatment
childhood
patient
diagnos
age
year
treat
chemotherapi
intrathec
treatment
cgi
prophylact
cranial
radiotherapi
day
develop
bcc
age
year
case
present
hyperpig
macul
cm
diamet
age
latenc
period
year
initi
diagnosi
previous
receiv
prophylact
cranial
radiat
treatment
leukemia
patholog
evalu
confirm
bcc
literatur
patient
develop
bcc
subsequ
leukemia
treatment
besid
among
ccss
data
childhood
malign
develop
bcc
subsequ
includ
leukemia
primari
malign
conclus
basal
cell
carcinoma
secondari
malign
follow
rare
may
occur
often
among
patient
previous
receiv
radiat
therapi
pharmacolog
effect
inhibitor
pediatr
acut
lymphoblast
leukaemia
iannotta
ramaglia
lombardi
v
dangelo
caraglia
mc
affinita
c
fusco
di
martino
di
pinto
orest
c
indolfi
p
indolfi
f
casal
women
child
gener
special
surgeri
second
univers
napl
napl
itali
biochemistri
biophys
gener
patholog
second
univers
napl
napl
itali
object
polycomb
group
pcg
protein
highli
conserv
epigenet
effector
maintain
silenc
state
gene
involv
critic
biolog
process
evid
suggest
histon
metil
transferasi
enhanc
zest
homologu
strongli
associ
haematolog
cancer
progress
poor
outcom
dznep
first
molecular
inhibitor
studi
pharmacolog
effect
dznep
convent
chemotherap
agent
daunoblastina
dnb
pediatr
acut
lymphoblast
leukaemia
method
jurkat
cell
line
blast
cell
pediatr
grown
rpmi
treat
dnb
dznep
singl
combin
cell
viabil
analyz
mtt
trypan
blu
assay
apoptot
cell
death
cell
cycl
analyz
stain
pi
fluoresc
procaspas
analyz
western
blot
assay
result
data
demonstr
synergist
effect
biosoft
calcusyn
softwar
jurkat
growth
inhibit
dnbdznep
decreas
peak
presum
due
apoptosi
parallel
increas
cell
phase
result
confirm
annexin
analysi
increas
earli
apoptosi
moreov
found
decreas
procaspas
express
singl
treatment
dznep
combin
dnb
respect
therefor
observ
complet
decreas
protein
respect
singl
treatment
dnb
sampl
treat
dnbdznep
evidenc
inhibit
conclus
inhibit
may
offer
opportun
novel
treatment
approach
could
consid
combin
convent
chemotherapi
erad
stem
cell
better
understand
complex
epigenet
regulatori
network
control
express
target
gene
would
facilit
design
novel
therapeut
intervent
unravel
childhood
leukemia
genet
bottleneck
phenomenon
relat
postul
mathemat
model
ivanovski
djuric
p
ivanovski
institut
mother
child
healthcar
medic
faculti
univers
belgrad
belgrad
serbia
institut
epidemiolog
medic
faculti
univers
belgrad
belgrad
serbia
univers
children
hospit
medic
faculti
univers
belgrad
belgrad
serbia
object
childhood
leukemia
prevent
method
comprihens
brows
articl
lead
leukemia
research
journal
etiolog
childhood
leukemia
construct
view
leukemia
bottleneck
etiolog
result
form
prenat
newborn
one
child
hundr
children
born
gene
develop
leukemia
bottleneck
phenomenon
word
hundr
children
born
one
child
risk
leukemia
develop
mean
inevit
suffici
overt
leukemia
stringent
requir
second
genet
abnorm
leukemia
develop
case
leukemia
transloc
complement
loss
normal
tel
gene
involv
transloc
contralater
loss
normal
tel
gene
ie
loss
heterozygos
loh
occur
postnat
mitot
prolifer
cell
mitot
cross
mco
process
mco
rare
event
frequenc
rate
kb
region
sinc
minim
delet
region
alway
affect
least
part
tel
transcript
framework
follow
report
frequenc
mco
kb
locu
valid
mco
frequenc
cell
conclus
explor
identif
environment
exposur
caus
prolifer
cell
approxim
mitos
gener
caus
ie
tel
delet
andor
introduct
mitot
cross
inhibitor
may
contribut
childhood
leukemia
prevent
analysi
prognost
risk
factor
pediatr
acut
leukemia
fungemia
j
jiang
hematolog
oncolog
center
bei
jing
children
hopspit
beij
china
object
investig
epidemiolog
fungemia
provid
evid
clinic
therapi
method
retrospect
survey
done
case
fungemia
hospit
jan
jan
result
case
candida
fungemia
account
fugemia
main
pathogen
agent
albican
candida
fungemia
candida
albican
candida
parapsilosi
candida
glabrata
candida
tropicali
uneffect
case
account
analysi
show
neutropenia
time
day
antibiot
use
time
day
fungal
infect
histori
correl
bad
prognosi
studi
also
show
chemotherapi
regiment
includ
hormon
combin
organ
fungal
infect
albican
risk
factor
bad
prognosi
conclus
main
pathogen
agent
fungimia
candida
especi
albican
neutropenia
time
day
antibiot
use
time
day
fungal
infect
histori
correl
bad
prognosi
neurolog
complic
due
chemotherapi
pediatr
acut
lymphoblast
leukemia
patient
treat
ic
bfm
singl
center
experi
jovic
micic
kuzmanov
jovanov
r
kravljanac
gazikalov
depart
pediatr
hematolog
mother
chile
health
care
institut
belgrad
serbia
depart
neurolog
mother
chile
health
care
institut
belgrad
serbia
depart
radiolog
mother
chile
health
care
institut
belgrad
serbia
object
studi
present
retrospect
analys
acut
lymphoblast
leukemia
patient
develop
neurolog
complic
due
chemotherapi
method
april
februari
diagnosi
establish
patient
among
patient
whose
age
rang
month
year
develop
complic
diagnosi
made
upon
follow
procedur
comput
tomographi
ct
patient
magnet
reson
imag
mri
patient
eeg
patient
lumbar
punctur
lp
patient
mthfr
mutat
patient
biochem
analysi
includ
screen
hemostasi
perform
patient
result
common
clinic
manifest
seizur
occur
patient
episod
sagitt
sinu
thrombosi
diagnos
one
acut
encephalopathi
notic
two
patient
two
year
old
male
induct
treatment
three
year
old
femal
due
hypoglycemia
provok
mainten
therapi
posterior
revers
encephalopathi
syndrom
diagnos
one
femal
acut
onset
hemiparesi
peculiar
complic
observ
two
year
old
male
develop
persist
chemic
arachnoid
first
lumbar
punctur
mainten
therapi
prophylact
lumbar
punctur
acut
ataxia
right
side
hemiparesi
occur
ct
scan
show
multifoc
parenchim
calcif
mri
confirm
presenc
calcif
massiv
edema
basal
ganglia
investig
homozyg
mthfr
mutat
conclud
case
methotrex
toxic
complet
recoveri
achiev
patient
two
patient
develop
neurolog
sequel
delay
speech
develop
mild
hemiparesi
conclus
neurolog
complic
due
chemotherap
patient
rare
better
diagnosi
close
follow
effect
treatment
underli
caus
morbid
mortal
complic
decreas
cn
complic
childhood
leukemia
role
mri
diagnosi
manag
kakkar
p
sobti
c
kakkar
k
saggar
paediatr
dayanand
medic
colleg
ludhiana
india
paediatr
christian
medic
colleg
ludhiana
india
radiodiagnosi
dayanand
medic
colleg
ludhiana
india
object
illustr
mri
pattern
variou
cn
complic
childhood
leukemia
method
mri
studi
children
acut
leukemia
present
seizur
alter
sensorium
focal
neurolog
deficit
review
children
divid
two
categori
first
group
includ
children
complic
relat
leukemia
second
group
therapi
relat
complic
result
children
children
complic
directli
relat
leukemia
includ
leukem
infiltr
n
microinfarct
n
stroke
n
cortic
venou
thrombosi
n
limbic
enceph
paraneoplast
manifest
n
second
group
includ
chemotherapi
induc
leucoencephalopathi
n
vascul
n
posterior
revers
encephalopathi
syndrom
n
infect
n
thrombot
microangiopathi
n
conclus
wide
rang
abnorm
affect
brain
central
nervou
system
leukem
child
mri
play
substanti
role
earli
diagnosi
manag
condit
induct
relat
mortal
morbid
children
treat
acut
lymphoblast
leukaemia
singl
center
experi
lower
middl
incom
countri
khan
shahzad
riaz
f
naz
rashid
pediatr
oncolog
shaukat
khanum
memori
cancer
hospit
research
center
lahor
pakistan
object
outcom
induct
phase
therapi
ip
acut
lymphoblast
leukemia
reduc
develop
countri
resourc
poor
set
morbid
mortal
ip
still
high
main
object
studi
review
outcom
children
ip
treat
shaukat
khanum
memori
cancer
hospit
lahor
method
medic
record
newli
diagnos
childhood
patient
jan
june
retrospect
review
first
clinic
visit
till
start
consolid
abandon
death
patient
characterist
detail
diagnosi
chemotherapi
cours
ill
bone
marrow
morpholog
complic
therapi
record
die
caus
death
assess
thorough
data
review
result
case
review
median
age
present
year
male
femal
ratio
precursor
b
diagnos
wherea
patient
precursor
diseas
bulk
diseas
present
case
standard
high
risk
patient
treat
drug
induct
respect
mortal
rate
ip
n
caus
death
attribut
infecti
etiolog
patient
n
death
occur
week
ip
hypocellular
marrow
report
patient
assess
day
n
success
complet
ip
n
common
reason
admiss
febril
neutropenia
diarrhea
oral
mucos
pneumonia
sepsi
sever
malnutrit
bulk
diseas
found
statist
signific
factor
respect
conclus
infect
commonest
caus
morbid
mortal
ip
therapi
better
infect
control
strategi
support
care
improv
outcom
nutrit
rehabilit
sever
malnourish
children
chemotherapi
modif
ip
may
consider
express
prospect
marker
predict
minim
residu
diseas
mrd
level
day
children
acut
lymphoblast
leukemia
khvedelidz
shengelaia
javakhadz
hematologyoncolog
children
central
hospit
tbilisi
georgia
object
address
predict
valu
receptor
express
cell
initi
diagnosi
context
minim
residu
diseas
monitor
day
children
method
nine
newli
diagnos
children
assess
mrd
level
day
remiss
induct
arbitrarili
assign
patient
either
rel
high
low
base
percentag
posit
event
initi
diagnosi
phenotyp
perform
agreement
recommend
use
flow
cytometri
acquisit
number
least
nucleat
cell
per
tube
mrd
cellular
event
consid
posit
result
among
studi
subject
four
male
five
femal
averag
age
ci
median
percentag
posit
cell
low
group
defin
interquartil
rang
iqr
iqr
high
group
gate
cell
comparison
group
reveal
statist
signific
differ
minim
residu
diseas
level
day
p
median
percentag
mrd
high
group
iqr
median
residu
leukem
cell
iqr
observ
low
group
correl
analys
reveal
signific
posit
correl
receptor
express
mean
fluoresc
intens
diagnosi
p
percentag
posit
cell
also
posit
correl
leukocyt
count
initi
diagnosi
p
conclus
studi
show
receptor
express
initi
diagnosi
might
exercis
surrog
marker
predict
mrd
level
day
children
although
larger
cohort
studi
need
address
question
associ
immunophenotyp
prognosi
children
acut
lymphoblast
leukemia
f
genel
n
oymak
yaman
g
inc
c
vergin
pediatr
hematolog
oncolog
dr
uz
childen
hospit
izmir
turkey
pediatr
immunolog
dr
uz
childen
hospit
izmir
turkey
pediatr
oncolog
dr
uz
childen
hospit
izmir
turkey
object
acut
lymphoblast
leukemia
common
malign
childhood
immunophenotyp
becom
import
determin
subgroup
aim
determin
featur
subgroup
accord
immunophenotyp
correl
clinic
laboratori
effect
prognosi
retrospect
method
male
forti
femal
receiv
bfm
includ
studi
result
mean
age
year
distribut
common
b
cortic
matur
higher
rate
compar
literatur
male
gender
domin
cell
compar
b
cell
group
cell
seen
frequent
group
patient
older
year
age
leukocyt
count
higher
diagnosi
common
cell
group
lymphadenopathi
larger
cm
common
cell
group
compar
common
b
cell
group
mediastin
involv
high
cell
compar
common
b
cell
group
found
case
statist
differ
subgroup
determin
common
marker
show
neg
effect
relat
myeloid
antigen
term
clinic
medic
prognosi
found
overal
relaps
rate
death
rate
relaps
group
respect
wbc
count
organomegali
lymphadenopathi
prednison
respons
day
marrow
day
relaps
risk
subgroup
signific
impact
overal
surviv
wbc
count
higher
factor
influenc
surviv
multivari
analysi
conclus
immunophenotyp
flow
cytometri
import
diagnosi
determin
immunophenotyp
subgroup
risk
group
plan
therapi
improv
outcom
children
adolesc
acut
lymphoblast
leukemia
last
decad
report
slovak
republ
kolenova
makohusova
z
subova
e
bubanska
oravkinova
j
horakova
v
mrazova
sejnova
e
kaiserova
depart
pediatr
hematolog
oncolog
comeniu
univers
medic
school
univers
children
hospit
bratislava
slovakia
depart
chemistri
univers
ss
cyril
methodiu
trnava
slovakia
depart
pediatr
hematolog
oncolog
univers
children
hospit
bratislava
slovakia
depart
pediatr
hematolog
oncolog
univers
children
hospit
banska
bystrica
slovakia
depart
pediatr
hematolog
oncolog
univers
children
hospit
kosic
slovakia
depart
pediatr
hematolog
oncolog
univers
children
hospit
bratislava
slovakia
object
analyz
ef
overal
surviv
os
among
children
adolesc
acut
lymphoblast
leukemia
treat
intern
bfm
intercontinent
trial
ic
therapi
slovak
republ
method
total
children
adolesc
age
year
treat
ic
bfm
base
therapi
divid
two
period
patient
activ
enrol
trial
trial
close
patient
treat
therapi
without
random
result
ef
os
rate
respect
similar
result
obtain
trial
basi
ic
bfm
therapi
ef
p
os
p
significantli
better
prior
slovak
experi
surviv
improv
standard
intermedi
risk
group
includ
male
femal
age
year
older
immunophenotyp
also
excel
transloc
hyperdiploidi
good
respons
peripher
blood
day
bone
marrow
day
rate
death
induct
cumul
incid
death
complet
remiss
relaps
decreas
howev
outcom
suboptim
patient
high
risk
goup
conclus
current
ef
os
rate
children
adolesc
slovak
republ
approach
obtain
western
europ
result
clinic
trial
particip
gain
clinic
experi
intens
bfm
type
treatment
favor
prognosi
precursor
acut
lymphoblast
leukemia
kourti
athanassiad
lambrou
tapark
v
sidi
k
stamatopoulo
koliouska
pediatr
oncolog
depart
hippokr
gener
hospit
thessaloniki
greec
hematolog
hsct
depart
papanikola
gener
hospit
thessaloniki
greec
first
pediatr
depart
aristotl
univers
thessaloniki
thessaloniki
greec
object
high
hyperdiploidi
heh
chromosom
pediatr
precursor
acut
lymphoblast
leukemia
gener
associ
favor
prognosi
perform
retrospect
analysi
patient
heh
treat
depart
last
year
cytogenet
analysi
avail
method
prettreat
bone
marrow
sampl
cultur
analyz
standard
cytogenet
method
total
children
femal
male
display
karyotyp
chromosom
also
inform
molecular
studi
includ
analysi
result
frequent
gain
chromosom
x
tripl
trisomi
identifi
case
tripl
case
median
chromosom
rang
wherea
neg
case
median
chromosom
rang
high
hyperdiploidi
identifi
case
none
heh
case
evid
extramedullari
central
nervou
system
mediastin
mass
test
leukemia
diagnosi
median
age
diagnosi
year
rang
year
median
rang
case
stratifi
patient
prednison
poor
respond
minim
residu
diseas
mrd
bone
marrow
day
day
achiev
complet
remiss
mrd
patient
continu
complet
remiss
overal
surviv
conclus
result
consist
literatur
heh
largest
cytogenet
subgroup
childhood
associ
favor
clinic
featur
impact
tripl
trisomi
context
high
hyperdiploidi
warrant
investig
relaps
acut
lymphoblast
leukemia
singl
center
experi
develop
world
kumar
v
chinnabhandar
gupta
n
radhakrishnan
sachdeva
pediatr
bone
marrow
transplant
centr
sir
ganga
ram
hospit
delhi
india
object
data
relaps
lack
develop
world
analys
centr
relaps
data
see
pattern
treatment
outcom
method
retrospect
data
analysi
done
among
patient
treat
modifi
xi
protocol
relaps
defin
presenc
blast
cell
bone
marrow
bm
histolog
cytolog
document
blast
em
site
achiev
complet
remiss
base
time
relaps
categor
earli
within
month
diagnosi
earli
month
within
month
complet
therapi
late
month
complet
therapi
result
patient
relaps
among
patient
median
age
year
rang
male
preponder
seen
major
b
cell
type
among
one
case
cn
diaseas
diagnosi
present
initi
high
tlc
molecular
work
show
n
n
mll
n
hyperdiploidi
n
respect
isol
bm
cn
relaps
one
testicular
ocular
combin
bm
cn
relaps
combin
bm
testicular
opt
therapi
treat
patient
aliv
median
follow
year
year
relaps
rate
cr
achiev
die
relaps
patient
lost
follow
die
year
os
year
ef
conclus
feasibl
treat
children
relaps
develop
world
sepsi
treatment
abadon
barrier
improv
surviv
incid
hyperglycemia
remiss
induct
chemotherapi
paediatr
hospit
base
studi
r
laila
islam
bhuiya
k
nahar
saha
paediatr
unit
hospit
dhaka
bangladesh
paediatr
haematlog
oncolog
bangabandhu
sheikh
mujib
medic
univers
dhaka
bangladesh
nephrolog
birdem
dhaka
bangladesh
paediatr
bangabandhu
sheikh
mujib
medic
univers
dhaka
bangladesh
object
see
incid
hyperglycemia
remiss
induct
phase
chemotherapi
treatment
case
children
method
prospect
observ
studi
newli
diagnos
patient
age
rang
year
studi
studi
period
month
hyperglycemia
defin
random
glucos
determin
mgldl
first
day
induct
phase
chemotherapi
result
patient
develop
hyperglycemia
remiss
induct
signific
differ
notic
two
group
hyperglycem
group
non
hyperglycem
group
regard
age
distribut
p
bodi
weight
p
hyperglycemia
mostli
experienc
second
week
patient
third
week
patient
condit
persist
day
patient
patient
conclus
around
patient
induct
remiss
phase
chemotherapi
experienc
hyperglycemia
recov
drug
like
l
corticosteroid
withdrawn
patient
longer
long
term
advers
eflect
outcom
prognost
factor
posit
acut
lymphoblast
leukemia
korean
children
singl
institut
studi
jw
lee
ps
jang
ng
chung
dc
jeong
b
cho
hk
kim
pediatr
cathol
univers
korea
seoul
korea
object
fusion
frequent
genet
abnorm
children
acut
lymphoblast
leukemia
associ
favor
outcom
howev
incid
differ
accord
patient
ethnic
prognost
relev
may
also
differ
method
studi
studi
outcom
prognost
featur
patient
diagnos
depart
pediatr
cathol
univers
korea
may
june
independ
variabl
studi
includ
patient
age
wbc
count
diagnosi
minim
residu
diseas
posit
end
remiss
induct
mrd
cytogenet
featur
includ
presenc
complex
karyotyp
addit
transloc
invers
besid
abnorm
result
median
patient
age
diagnosi
year
rang
patient
diagnos
age
year
median
wbc
count
diagnosi
rang
complex
karyotyp
found
frequent
diagnosi
eight
patient
relaps
median
month
diagnosi
rang
includ
bm
patient
isol
cn
relaps
surviv
patient
bm
relaps
receiv
allogen
transplant
subsequ
relaps
die
diseas
progress
five
year
overal
surviv
univari
studi
wbc
count
p
mrd
end
induct
p
abnorm
p
predict
relaps
multivari
studi
abnorm
signific
factor
relaps
p
conclus
signific
portion
cohort
relaps
note
relaps
occur
rel
earli
diagnosi
contrast
western
studi
report
tendenc
late
relaps
consid
extrem
poor
prognosi
relaps
occur
studi
undertaken
clarifi
addit
genet
lesion
patient
predict
poor
prognosi
clinic
signific
dynam
monitor
minim
residu
diseas
childhood
b
lineag
acut
lymphoblast
leukemia
h
li
hemotologyoncolog
children
hospit
shanghai
shanghai
china
object
studi
clinic
signific
dynam
monitor
minim
residu
diseas
mrd
use
flow
cytometr
detect
abnorm
immunophenotyp
childhood
b
lineag
acut
lymphoblast
leukemia
method
patient
enrol
research
januari
decemb
mrd
target
filter
preliminarili
flow
cytometri
dynam
monitor
specifi
time
overal
treatment
plan
refer
shanghai
children
leukemia
cooper
group
protocol
divid
patient
low
middl
high
risk
group
depend
risk
factor
includ
day
level
data
analyz
spss
result
patient
belong
low
risk
patient
middl
risk
higher
risk
five
year
ef
respect
signific
statist
differ
low
high
risk
group
p
patient
achiev
complet
remiss
induct
therapi
surviv
ef
patient
mrd
target
patient
without
ef
respect
univari
analysi
confirm
mrd
target
significantli
differ
group
p
mrd
detect
day
mrd
patient
year
relaps
free
surviv
rf
mrd
case
rf
p
patient
mrd
day
turn
normal
day
relaps
still
abnorm
relaps
signific
statist
differ
two
group
p
conclus
prognosi
low
risk
patient
signific
better
middl
high
risk
group
patient
year
ef
patient
mrd
marker
higher
without
mrd
marker
import
clinic
signific
dynam
monitor
mrd
adjust
treatment
time
mrd
day
import
prognost
factor
patient
prognosi
mrd
continu
posit
poor
prognost
factor
treatment
outcom
pediatr
intermedi
high
risk
review
case
q
kai
l
yang
pediatr
hematologyoncolog
sun
memori
hospit
sun
univers
guangzhou
china
object
evalu
prognost
factor
therapeut
effect
case
pediatr
intermedi
risk
ir
high
risk
hr
treat
three
variou
chemotherapeut
regimen
includ
sum
lymphoblast
method
patient
depart
retrospect
studi
evalu
patient
overal
surviv
os
rate
surviv
ef
rate
recurr
rate
mortal
rate
analysi
compar
patient
os
ef
differ
surviv
curv
test
data
process
spss
result
among
case
os
ef
mll
gene
neg
case
n
mll
gene
posit
case
n
vs
vs
respect
case
whose
ldh
first
visit
n
whose
ldh
level
n
os
ef
vs
vs
respect
among
case
os
ef
prednison
good
respons
pgr
n
prednison
poor
respons
ppr
n
case
vs
day
induct
chemotherapi
os
ef
n
n
case
vs
vs
respect
case
classifi
ir
n
hr
n
os
ef
vs
vs
respect
median
month
month
os
ef
respect
conclus
mll
gene
posit
ldh
first
visit
ppr
bone
marrow
show
remiss
day
induct
chemotherapi
higher
risk
degre
poor
prognost
factor
result
lower
surviv
rate
success
screen
risk
factor
benefit
design
prognost
analyt
model
choos
optim
solut
patient
immunogen
intraven
asparaginas
erwinia
chrysanthemi
patient
acut
lymphoblast
leukemia
lymphoblast
lymphoma
b
benson
lu
eller
clincial
develop
jazz
pharmaceut
inc
palo
alto
ca
usa
biostatist
jazz
pharmaceut
inc
palo
alto
ca
usa
research
clinic
develop
jazz
pharmaceut
inc
palo
alto
ca
usa
object
asnas
import
compon
multiag
chemotherapi
pediatr
acut
lymphoblast
leukemia
like
larg
protein
asnas
induc
host
respons
stimul
develop
antibodi
implic
immunogen
therapi
rang
effect
alter
pharmacokinet
pk
efficaci
andor
safeti
profil
object
analysi
character
immunogen
profil
patient
receiv
erwinia
asnas
follow
hypersensit
escherichia
asnas
method
patient
receiv
erwinia
asnas
intraven
time
weekli
combin
chemotherapi
serum
sampl
antibodi
test
collect
trough
asnas
activ
level
predos
hour
postdos
evalu
antidrug
antibodi
ada
screen
assay
elisa
confirmatori
assay
competit
inhibit
sampl
posit
confirmatori
assay
test
neutral
antibodi
nab
result
thirti
patient
age
year
mean
year
enrol
complet
studi
discontinu
due
advers
event
patient
male
seven
patient
screen
posit
ada
ada
confirm
posit
none
confirm
ada
patient
test
posit
nab
comparison
pk
ada
ada
neg
patient
limit
fact
pk
sampl
taken
patient
becam
antibodi
posit
trough
asparaginas
activ
level
low
ten
patient
experienc
hypersensit
reaction
studi
ada
six
ada
patient
discontinu
follow
hypersensit
reaction
fourth
ada
patient
experi
hypersensit
reaction
refus
treatment
conclus
ada
patient
presenc
asnas
antibodi
commonli
associ
hypersensit
reaction
although
mani
patient
experienc
hypersensit
reaction
asnas
antibodi
studi
fund
jazz
pharmaceut
plc
subsidiari
pair
genotyp
untransl
region
associ
pediatr
cell
lymphoblast
leukemia
rs
almeida
rg
gome
aml
ramo
eav
marqu
tc
fonseca
ea
donadi
f
pedrosa
n
imunologia
centro
de
pesquisa
aggeu
recif
brazil
oncologia
instituto
de
medicina
integr
professor
fernando
figueira
recif
brazil
imunologia
universidad
de
paulo
faculdad
de
medicina
de
preto
preto
brazil
object
antigen
modul
immun
respons
health
diseas
presenc
polymorph
site
region
utr
gene
seem
involv
antigen
express
cancer
express
associ
wors
outcom
lesser
known
leukemia
investig
genet
variabl
gene
segment
children
lineag
acut
lymphoblast
leukemia
possibl
prognost
marker
method
children
refer
pediatr
oncolog
instituto
de
medicina
integr
professor
fernando
figueira
recif
northeastern
brazil
studi
diagnosi
blast
bone
marrow
character
morpholog
immunophenotyp
minim
residu
diseas
mrd
investig
use
flow
cytometri
day
polymorph
site
determin
vitro
gene
amplif
sequenc
allel
genotyp
frequenc
estim
genepop
softwar
compar
data
healthi
children
use
prism
softwar
result
children
year
proport
male
femal
twelv
die
within
day
mrd
measur
children
present
valu
blast
day
none
posit
day
pair
bp
genotyp
p
overrepres
children
p
underrepres
compar
children
die
aliv
proport
complet
remiss
x
case
relaps
x
differ
differ
age
p
leucocyt
count
x
p
presenc
mediastin
mass
hepat
spleen
enlarg
p
genotyp
frequenc
also
group
conclus
genotyp
associ
children
diseas
outcom
end
induct
therapi
outcom
children
acut
lymphoblast
leukemia
ethiopia
celik
pediatr
tikur
anbessa
hospit
addi
ababa
ethiopia
object
examin
data
induct
therapi
acut
lymphoblast
leukemia
children
tikur
anbessa
hospit
order
determin
outcom
variabl
determin
method
children
present
new
relaps
includ
examin
april
februari
incomplet
record
exclud
result
fifti
nine
evalu
children
age
year
median
year
receiv
induct
chemotherapi
occas
newli
diagnos
relaps
end
induct
patient
aliv
patient
die
patient
abandon
respect
mortal
abandon
rate
induct
n
respect
patient
aliv
end
induct
mortal
rate
abandon
rate
receiv
induct
n
patent
aliv
end
induct
among
high
risk
patient
n
surviv
mortal
abandon
rate
patient
receiv
induct
n
receiv
induct
n
respect
infect
bleed
primari
reason
mortal
similar
rate
group
averag
infect
bleed
socioeconom
constraint
hopeless
primari
reason
abandon
somehow
higher
among
consid
standard
risk
conclus
intens
chemotherapi
lead
significantli
lower
surviv
rate
children
ethiopia
observ
underlin
import
make
honest
assess
set
ascertain
proper
support
care
make
therapeut
decis
low
middl
incom
countri
clinic
analysi
three
case
fungal
esophag
children
acut
lymphoblast
leukemia
h
mai
h
cai
dai
bai
q
yang
x
yuan
c
li
hematolog
oncolog
shenzhen
children
hospit
shenzhen
china
object
summar
experi
diagnosi
treatment
fungal
esophag
children
acut
lymphoblast
leukemia
method
retrospect
review
clinic
manifest
diagnosi
treatment
fungal
esophag
three
children
acut
lymphoblast
leukemia
chemotherapi
result
three
patient
symptom
epigastr
pain
vomit
discomfort
precordi
area
chemotherapi
diagnos
fungal
esophag
gastroscopi
one
case
fever
neutropenia
regimen
chemotherapi
patient
includ
dexamathason
case
given
antifung
drug
includ
fluconazol
micafungin
itraconazol
two
four
week
recov
base
endoscopi
result
conclus
gastroscopi
perform
make
diagnosi
fungal
esophag
patient
symptom
epigastr
pain
discomfort
precordi
chemotherapi
gastroscopi
use
way
find
site
fungal
infect
patient
febril
neutropen
antifung
drug
effect
fungal
esophag
flowcytomytr
pattern
prognost
signific
cell
surfac
phenotyp
acut
lymphoblast
leukemia
paediatr
retrospect
analysi
region
cancer
centr
kashmir
india
mir
aejaz
shiekh
medic
paediatr
oncolog
institut
medic
scienc
skim
srinagarjammu
kashmirindia
srinagar
india
object
acut
lymphoblast
leukemia
heterogen
diseas
biolog
clinic
distinct
subset
immunophenotyp
leukem
cell
diagnosi
reflect
level
differenti
achievd
clone
aim
studi
review
flowcytometr
pattern
prognost
sigfnific
paediatr
patient
method
retrospect
studi
carri
depart
medic
paediatr
oncolog
region
cancer
centr
institut
medic
scienc
srinagar
jammu
kashmir
india
clinic
hematolog
flowcytometr
data
patient
review
four
year
period
januari
decemb
result
patient
regist
studi
period
paediatr
patient
adult
flowcytometri
avail
children
male
femal
children
constitut
earli
pre
b
cell
common
follow
pre
b
cell
matur
b
cell
among
b
cell
phenotyp
cell
phenotyp
matur
cell
common
follow
pre
cell
mix
phenotyp
present
calla
posit
present
phve
earli
pre
b
cell
favour
prognosi
complet
respons
rate
follow
pre
b
cell
cell
matur
cell
complet
respons
rate
follow
pre
cell
treatment
failur
rate
higher
cell
type
compar
b
cell
phenotyp
conclus
immunophenotyp
play
central
role
determin
clinic
relev
subset
although
intens
therapi
may
blur
prognost
distinct
consider
toxicityefficaci
ratio
persist
defin
group
requir
continu
use
immunophenotyp
diagnosi
classif
success
treatment
dasatinib
case
relaps
novel
fusion
gene
n
miyagawa
sarashina
yokosuka
k
fukuda
f
iwasaki
hamanou
k
kobayashi
h
gotou
divis
medicin
kanagawa
children
medic
center
yokohama
japan
pediatr
hematolog
oncolog
research
nation
research
institut
child
health
develop
tokyo
japan
object
posit
acut
lymphoblast
leukemia
poor
respons
prognosi
convent
chemotherapi
howev
outcom
improv
addit
first
second
gener
tyrosin
kinas
inhibitor
recent
new
high
risk
subtyp
neg
identifi
similar
express
profil
posit
genet
alter
activ
kinas
signal
includ
rearrang
platelet
deriv
growth
factor
receptor
pdgfrb
report
first
patient
receiv
allogen
stem
cell
transplant
treatment
dasatinib
method
male
achiev
first
complet
remiss
cr
convent
chemotherapi
suffer
first
bone
marrow
bm
relaps
b
cell
precursor
mainten
therapi
chromosom
karyotyp
analysi
relaps
blast
cell
show
xy
use
sampl
relaps
perform
mrna
sequenc
analysi
vitro
drug
test
assay
result
mrna
sequenc
analysi
identifi
transcript
fuse
exon
exon
pdgfrb
furthermor
vitro
drug
test
reveal
sensit
dasatinib
style
chemotherapi
could
provid
reason
efficaci
therefor
alter
ecm
therapi
etoposid
cytarabin
mitoxantron
result
second
achiev
cycl
therapi
still
detect
bm
revers
transcript
polymeras
chain
reaction
subsequ
perform
allel
mismatch
cord
blood
neutrophil
recov
bm
show
donor
type
treatment
dasatinib
start
day
posit
bm
bm
decreas
dasatinib
final
becam
undetect
day
conclus
dasatinib
may
effect
relaps
pdgfrb
rearrang
philadelphia
posit
acut
lymphoblast
leukemia
children
experi
singl
centrein
india
r
moham
c
yogiraj
rajat
k
satyendra
satya
prakash
pediatr
hematolog
oncolgi
bmt
unit
forti
memori
research
institut
gurgaon
india
object
philadelphia
posit
acut
lymphoblast
leukemia
phve
aggress
diseas
poor
prognosi
children
object
determin
outcom
phve
allin
childhood
northern
india
method
sixti
one
case
pediatr
acut
lymphoblast
leukemia
studi
retrospect
result
phve
found
five
case
patient
three
male
two
werefemal
median
age
year
month
year
four
treat
protocol
one
ukallxi
protocol
imatinib
mesyl
start
daili
time
diagnosi
went
remiss
later
achiev
complet
molecular
remiss
howev
mainten
therapi
patient
start
rise
valu
quantit
valu
month
month
month
diagnosi
children
sibl
match
unrel
donor
avail
three
imatinib
stop
take
inform
consent
parent
dasatanib
start
dose
two
divid
dose
mainten
therapi
oral
methotrex
continu
patient
achiev
reduct
quantit
pcr
month
molecular
remiss
month
start
dasatinib
one
patient
stop
dasatinibaft
month
start
herbal
medicin
molecular
remiss
one
isol
cn
relaps
rest
two
patient
imatinib
molecular
remiss
two
patient
dasatinib
acquir
whimsyndrom
therapi
one
patient
imatinib
fractur
excess
callu
format
humeru
four
patient
growth
delay
short
statur
age
conclus
dasatanib
use
altern
drug
imatinib
resist
phve
side
effect
need
monitor
care
patient
dasatinib
imatinib
collabor
among
differ
oncolog
center
middl
incom
countri
improv
risk
stratif
children
acut
lymphoblast
leukemia
muwakkit
el
trabulsi
salman
r
mahfouz
p
noun
h
khalif
r
farah
g
gemayel
n
kabbara
n
yassin
n
sbeiti
r
saab
abboud
h
depart
pediatr
adolesc
medicin
american
univers
beirut
beirut
lebanon
depart
patholog
laboratori
medicin
american
univers
beirut
beirut
lebanon
depart
pediatr
geitaoui
lebanes
hospit
beirut
lebanon
depart
pediatr
rafic
hariri
government
gener
hospit
beirut
lebanon
depart
pediatr
saint
georg
hospit
univers
medic
center
beirut
lebanon
depart
pediatr
makass
gener
hospit
beirut
lebanon
depart
pediatr
adolesc
medicin
american
univers
beirut
beirut
lebanon
object
acut
lymphoblast
leukemia
common
cancer
childhood
optim
treatment
strategi
differ
among
differ
risk
case
children
cancer
center
lebanon
american
univers
beirut
offer
newli
diagnos
lebanes
children
chanc
get
treatment
provid
analysi
bone
marrow
bm
flow
cytometri
molecular
cytogenet
test
cost
cover
fund
rais
nation
level
method
identifi
patient
younger
year
diagnos
retrospect
chart
review
conduct
collect
patient
laboratori
data
review
includ
lebanes
patient
newli
diagnos
treat
lebanes
hospit
result
patient
identifi
male
patient
year
age
year
year
initi
wbc
patient
dna
index
metaphas
cytogenet
reveal
normal
karyotyp
chromosom
chromosom
chromosom
rest
fail
cytogenet
test
molecular
studi
done
patient
conclus
high
karyotyp
failur
rate
attribut
long
wait
time
bm
perform
deliveri
cytogenet
lab
futur
plan
includ
perform
day
mrd
studi
patient
well
use
uniform
treatment
protocol
offer
examin
bm
lebanes
pediatr
patient
import
risk
stratif
patient
order
offer
therapi
thu
best
chanc
cure
experi
serv
good
model
middl
countri
collabor
implement
uniform
treatment
protocol
hope
improv
surviv
children
treatment
relat
death
relaps
childhood
acut
lymphoblast
leukemia
oskarsson
j
arvidson
e
foresti
frandsen
n
carlsen
hellebostad
glomstein
p
heyman
pediatr
oncolog
karolinska
univers
hospit
stockholm
sweden
pediatr
oncolog
uppsala
univers
hospit
uppsala
sweden
pediatr
oncolog
univers
hospit
sweden
pediatr
oncolog
rigshospitalet
univers
hospit
copenhagen
denmark
pediatr
oncolog
odens
univers
hospit
odens
denmark
pediatr
oncolog
hospit
oslo
norway
pediatr
oncolog
rikshospitalet
univers
hospit
oslo
norway
pediatr
oncolog
turku
univers
hospit
turku
finland
object
patient
relaps
acut
lymphoblast
leukemia
suscept
advers
effect
leukemia
therapi
accumul
organ
specif
toxic
intens
relaps
treatment
addit
higher
proport
patient
undergo
stem
cell
transplant
sct
second
complet
remiss
prolong
sever
immunosuppress
diseas
gvhd
increas
risk
life
threaten
event
aim
studi
investig
incid
risk
factor
treatment
relat
death
trd
patient
relaps
childhood
method
retrospect
studi
analyz
data
children
relaps
common
upfront
treatment
accord
nordic
societi
paediatr
haematolog
oncolog
nopho
protocol
patient
immunophenotyp
year
year
diagnosi
undergo
sct
first
complet
remiss
exclud
studi
patient
data
export
nopho
registri
case
incomplet
registr
request
sent
treat
clinic
result
identifi
patient
trd
among
patient
includ
studi
eleven
patient
die
reach
treat
chemotherapi
patient
undergo
sct
infect
common
caus
death
independ
risk
factor
trd
high
risk
clinic
profil
relaps
unfavor
cytogenet
find
signific
gender
age
differ
conclus
treatment
relat
death
approxim
three
time
common
relaps
treatment
primari
treatment
infect
common
reason
trd
patient
stratifi
high
risk
relaps
patient
unfavor
cytogenet
monitor
close
treat
promptli
suspect
infect
endocrin
side
effect
chemotherapi
patient
acut
lymphoblast
leukemia
b
uysal
oymak
k
demir
hilkay
karapinar
ay
gozmen
b
demirag
carti
g
ozek
b
tatli
gune
e
albudak
ozcan
e
toret
inc
c
vergin
pediatr
hematolog
oncolog
dr
behcet
uz
chidren
hospit
izmir
turkey
pediatr
endocrinolog
dr
behcet
uz
chidren
hospit
izmir
turkey
object
focu
cancer
therapi
childhood
becom
crucial
import
exposur
chemotherapi
young
age
increas
vulner
treatment
induc
sequela
also
contribut
radiat
may
increas
advers
sequela
method
aim
evalu
endocrin
side
effect
patient
mf
acut
lymphoblast
leukemia
year
treatment
patient
screen
endocrin
side
effect
growth
blood
glucos
metabol
lipid
metabol
abnorm
sexual
develop
thyroid
metabol
bone
miner
densiti
adren
insuffici
result
mean
age
patient
year
patient
least
one
endocrin
complic
detect
one
patient
height
percentil
patient
obes
forteen
patient
insulin
resist
three
patient
igf
level
sd
two
patient
high
level
one
patient
subclin
hypothyroidi
one
patient
posit
thyroid
antibodi
twenti
patient
low
level
cortisol
six
patient
subclin
vitamin
defici
two
patient
subclin
hyperparathyroidi
three
patient
isol
hypercalcemia
insulin
resist
rate
higher
patient
aplli
rt
nt
aplli
rt
conclus
studi
endocrin
side
effect
seen
two
year
therapi
patient
appli
chemotherapi
rt
treatment
close
endocrinolog
side
effect
earli
diagnosi
treatment
perform
endocrinolog
disas
may
develop
later
life
interact
model
natur
kill
cell
leukem
cell
firt
goal
preliminari
data
jf
pascual
mv
galera
blanquer
blanquer
minguela
pura
mm
salina
jl
fuster
soler
jm
moraleda
paediatr
oncolog
haematolog
servic
hospit
universitario
virgen
de
la
arrixaca
murcia
spain
immunolog
servic
hospit
universitario
virgen
de
la
arrixaca
murcia
spain
haematolog
cell
therapi
transplant
unit
hospit
universitario
virgen
de
la
arrixaca
murcia
spain
biobank
imib
servic
hospit
universitario
virgen
de
la
arrixaca
murcia
spain
object
acut
leukaemia
common
malign
patholog
contemporari
chemotherapi
protocol
achiev
overal
surviv
result
improv
last
sever
year
new
treatment
approach
repres
immun
mediat
inher
alloreact
nk
cell
nkc
need
know
role
interact
nkc
leukem
cell
start
prospect
trial
octob
clarifi
trial
goal
describ
match
mismatch
nkc
receptor
kir
leukem
cell
cytotox
role
serum
cytokin
progress
transplant
patient
method
preliminari
result
present
review
includ
acut
lymphoblast
mieloblast
leukaemia
octob
till
januari
one
patient
exclud
refus
sing
consent
collect
data
male
eight
femal
median
year
old
age
rang
year
old
time
store
sera
leukem
cell
previou
treatment
result
got
free
event
surviv
mortal
sampl
three
children
alm
thirteen
b
three
transplant
six
watch
dispar
around
kir
receptor
conclus
conclus
show
ab
genotyp
common
genotyp
relaps
patient
next
step
studi
test
cytotox
complet
remiss
patient
end
treatment
link
result
kir
hla
genotyp
gene
express
multi
drug
resist
protein
multi
drug
relat
protein
mrp
lung
resist
protein
lrp
pediatr
acut
lymphoblast
leukemia
case
b
prateek
masih
rani
n
varma
j
binota
bansal
rk
marwaha
pediatr
pgimer
chandigarh
india
molecular
diagnsot
laboratori
mdr
laboratori
chandigarh
india
hematolog
pgimer
chandigarh
india
pediatr
pgimer
chandigarh
india
introduct
approxim
children
present
diseas
recurr
treatment
failur
due
either
pharmacokinet
resist
cell
resist
antineoplast
drug
aim
object
studi
gene
express
multi
drug
resist
protein
multi
drug
relat
protein
mrp
lung
resist
protein
lrp
pediatr
correl
earli
respons
chemotherapi
clinic
laboratori
variabl
method
prospect
studi
pediatr
case
enrol
rel
quantif
mrna
mrp
lrp
done
real
time
pcr
assay
use
dye
high
express
defin
fold
control
cell
result
case
male
femal
mean
age
year
base
tlc
age
standard
risk
intermedi
high
risk
categori
rest
case
abnorm
cytogenet
note
day
check
marrow
statu
case
high
express
lrp
note
case
mrp
case
signific
associ
note
slow
earli
respons
statu
four
fold
higher
lrp
gene
express
p
one
case
diseas
relaps
also
fold
high
lrp
express
conclus
post
induct
death
sepsi
relat
three
high
express
lrp
gene
note
studi
et
valera
et
al
also
found
posit
associ
increas
lrp
express
poor
event
free
surviv
larger
prospect
studi
need
correl
drug
relat
gene
express
overal
survivaloutcom
better
understand
clinic
relev
platelet
microparticl
pediatr
patient
leukemia
solid
tumor
g
mokhtar
tantawi
ragab
r
radwan
pediatr
depart
univers
cairo
egypt
clinic
patholog
depart
univers
cairo
egypt
object
contribut
platelet
progress
cancer
emerg
area
research
interest
studi
aim
assess
level
platelet
microparticl
pmp
childhood
malign
relat
respons
therapi
method
prospect
case
control
studi
includ
newli
diagnos
patient
malign
acut
lymphoblast
leukemia
n
acut
myeloid
leukemia
aml
n
stage
iv
neuroblastoma
n
pmp
assess
diagnosi
complet
remissionor
good
partial
respons
compar
healthi
match
control
result
signific
differ
found
level
pmp
patient
control
group
diagnosi
signific
differ
median
initi
pmp
patient
aml
neuroblastoma
p
respect
signific
differ
pre
post
induct
pmp
patient
p
aml
p
signific
rise
pmp
found
patient
neuroblastoma
phase
p
group
signific
correl
found
platelet
count
pmp
r
p
chemotherapi
r
p
signific
posit
correl
found
platelet
count
pmp
chemotherapi
r
p
aml
group
neuroblastoma
group
mean
platelet
count
pmp
level
significantli
increas
chemotherapi
signific
correl
found
platelet
count
pmp
chemotherapi
r
p
higher
pmp
level
diagnosi
found
patient
die
induct
phase
conclus
conclud
platelet
microparticl
rose
induct
phase
children
aml
neuroblastoma
suggest
interpret
absolut
pmp
count
caution
patient
thrombocytopenia
rather
use
pmpplatelet
count
ratio
yet
conclus
need
cautious
interpret
small
sampl
size
establish
clinic
research
limit
resourc
set
acut
lymphoblast
leukemia
model
w
rash
ezzat
research
children
cancer
cairo
egypt
object
establish
research
team
childhood
acut
lymphoblast
leukemia
limit
resourc
countri
like
egypt
challeng
challeng
increas
increas
number
patient
receiv
everi
year
averag
case
method
research
depart
establish
first
time
egypt
introduc
concept
form
team
diseas
multidisplenari
team
form
result
mention
step
marvel
impact
childhood
initi
genet
epidemiolog
grant
fund
obtain
base
result
grant
appli
anoth
grant
genom
wide
associ
studi
gwa
get
fund
complet
research
identifi
caus
egyptian
popul
success
obtain
million
egyptian
pound
presenc
databas
statist
analysi
surviv
allow
hold
collabor
st
jude
research
hospit
special
risk
protocol
allow
check
qualiti
flow
cytometri
result
cytogent
result
enhanc
qualiti
allow
rapid
consult
complic
case
presenc
hospit
registri
suppli
biobank
sampl
help
futur
research
rapid
statist
number
relaps
patient
die
induct
relaps
addit
product
patient
educ
booklet
educ
materi
treatment
protocol
futur
plan
make
strategi
becom
mandatori
identifi
genet
caus
relaps
analysi
patient
die
induct
complet
remiss
plan
make
translat
research
individu
treatment
educ
illiter
famili
kid
via
simpl
materi
conclus
presenc
clinic
research
impact
childhood
patient
staff
institut
signific
day
bone
marrow
acut
lymphoblast
leukemia
bone
marrow
day
absenc
mrd
n
bukhari
riaz
ahm
pediatr
oncolog
shaukat
khanum
memori
cancer
hospit
research
centr
lahor
pakistan
object
acut
lymphoblast
leukemia
common
hematolog
malign
among
pediatr
popul
differ
protocol
like
ukal
cog
use
manag
protocol
suggest
bone
marrow
biopsi
day
day
induct
phase
day
minimum
residu
diseas
mdr
statu
usual
advis
develop
countri
facil
mdr
avail
patient
treat
accord
protocol
bone
marrow
biopsi
advis
day
day
hypothesi
day
bone
marrow
remiss
signific
day
bone
marrow
absenc
mrd
facil
method
patient
admit
form
jan
dec
surviv
induct
includ
induct
therapi
accord
standard
arm
ukal
given
bone
marrow
biopsi
done
day
depend
upon
regimen
day
patient
mdr
avail
result
total
patient
includ
male
femal
ratio
age
rang
month
year
seventeen
patient
yr
patient
cell
pre
b
seventeen
patient
bone
marrow
bone
marrow
day
none
residu
leukemia
day
patient
bone
marrow
remiss
day
none
evid
residu
leukemia
day
bone
marrow
conclus
absenc
mrd
facil
signific
day
bone
marrow
day
bone
marrow
remiss
surviv
analysi
children
adolesc
acut
lymphoblast
leukemia
treat
onco
hematolog
center
childhood
cetohi
brazil
souza
mnayarji
r
basegio
departamento
de
oncologia
centro
de
tratamento
onco
hematologico
infantil
cetohi
hospit
region
campo
grand
brazil
background
public
institut
children
de
novo
acut
lymphoblast
leukemia
treat
januari
decemb
accord
brazilian
childhood
cooper
gbtli
bfm
protocol
aim
evalu
experi
tese
protocol
treatment
result
accord
risk
group
method
children
age
year
old
stratifi
risk
group
low
group
result
one
hundr
seventh
nine
children
enter
studi
ratio
averag
age
year
month
median
age
year
month
children
low
risk
group
overal
complet
remiss
rate
children
die
induct
overal
surviv
patient
low
risk
group
group
averag
age
follow
year
month
median
year
month
patient
still
first
complet
clinic
remiss
children
aliv
relaps
patient
relaps
surviv
patient
low
risk
group
group
conclus
treatment
outcom
children
acut
lymphoblast
leukemia
improv
remark
last
decad
children
suffer
acut
lymphoblast
leukemia
could
cure
protocol
result
patient
public
institut
compar
result
achiev
servic
brazil
countri
three
case
childhood
matur
lymphoblast
leukemia
morpholog
sarashina
h
goto
n
miyagawa
yokosuka
k
fukuda
f
iwasaki
hamanou
h
iwabuchi
takachi
saito
c
imai
divis
kanagawa
children
medic
center
yokohama
japan
depart
pediatr
niigata
univers
graduat
school
medic
dental
scienc
niigata
japan
object
matur
typic
associ
morpholog
rearrang
myc
gene
howev
report
show
rare
case
morpholog
chimer
gene
express
matur
immunophenotyp
may
repres
distinct
subset
mostli
rapid
aggress
clinic
cours
report
case
matur
discuss
clinic
genet
immunophenotyp
featur
context
previous
report
case
method
patient
femal
infant
patient
femal
respect
bone
marrow
smear
diagnosi
show
morpholog
patient
immunophenotyp
posit
sigm
evid
myc
rearrang
detect
case
fish
analysi
mll
rearrang
detect
fish
confirm
result
achiev
complet
remiss
convent
chemotherapi
underw
hematopoiet
stem
cell
transplant
high
risk
patient
infantil
mll
rearrang
other
mll
rearrang
hyperleukocytosi
wbc
diagnosi
patient
receiv
bone
marrow
transplant
sibl
patient
receiv
cord
blood
transplant
unrel
donor
respect
patient
maintain
complet
remiss
year
sinc
transplant
patient
remain
complet
remiss
month
initi
diagnosi
conclus
previou
report
surviv
patient
character
matur
b
immunophenotyp
morpholog
poor
especi
relaps
accumul
case
featur
clarifi
clinic
signific
uniqu
phenotyp
childhood
retrospect
analysi
cohort
pediatr
acut
lymphoblast
leukemia
case
singl
tertiari
care
center
india
r
sharma
chopra
ramzaan
katewa
sp
yadav
pediatr
hematolog
oncolog
bmt
forti
memori
research
institut
gurgaon
india
object
pediatr
character
vari
clinic
present
recurr
numer
structur
chromosom
abnorm
thought
specif
associ
diagnosi
risk
stratif
treatment
respons
prognosi
method
children
upto
diagnos
period
jan
analyz
retrospect
result
total
b
cell
tcell
patient
evalu
mean
age
present
yr
yr
yr
f
nation
cancer
institut
risk
stratif
standard
high
high
treat
bfm
protocol
uk
xi
lost
follow
ltfu
median
month
month
refus
treatment
relaps
patient
evalu
final
outcom
analysi
aliv
variou
phase
chemotherapi
mean
follow
month
aliv
complet
treatment
mean
follow
month
relaps
median
month
relaps
earli
earli
late
relaps
except
standard
risk
relaps
high
high
risk
categori
start
relaps
protocol
rez
bfm
refus
treatment
given
chemotherapi
underw
bone
marrow
transplant
allogen
aliv
follow
expir
entir
cohort
event
free
surviv
ef
overal
surviv
os
mean
follow
conclus
cytogenet
studi
could
done
signific
number
patient
due
resourc
constraint
signific
number
ltfu
patient
need
address
lmic
set
somat
mutat
chines
patient
relaps
pediatr
acut
lymphoblast
leukemia
liu
c
gao
zg
li
rd
zhang
wj
li
l
cui
wu
hy
zheng
hematolog
oncolog
center
beij
children
hospit
beij
china
object
children
relaps
acut
lymphoblast
leukemia
carri
poor
prognosi
owe
intrins
drug
resist
howev
biolog
pathway
mediat
chemotherapi
resist
remain
unknown
mutat
gene
recent
identifi
childhood
aim
present
studi
investig
frequenc
clinic
impact
mutat
chines
pediatr
patient
relaps
method
studi
enrol
patient
relaps
includ
cell
sequenc
exon
gene
result
mutat
detect
relaps
cell
patient
novel
mutat
map
activ
site
enzym
detect
relaps
patient
mutat
heterozyg
locat
exon
clinic
patient
carri
mutat
relaps
earli
within
month
initi
diagnosi
although
differ
signific
p
conclus
find
suggest
mutat
recurr
event
novel
mutat
expand
mutat
spectrum
cknowledg
work
partial
support
nation
natur
scienc
foundat
china
key
scientif
technolog
project
beij
municip
educ
commiss
nation
scienc
technolog
major
project
plan
unusu
manifest
non
sinopulmonari
fungal
infect
children
acut
lymphoblast
leukemia
siddaiahgari
b
jillela
pediatr
oncolog
rainbow
children
hospit
hyderabad
india
pediatr
oncolog
rainbow
children
hospit
hyderabad
india
object
fungal
infect
caus
signific
morbid
moratl
increas
econom
pscycholog
burden
acut
lymphoblast
leukemia
children
describ
differ
type
non
sinopulmonari
fungal
infect
outcom
children
method
identifi
interest
case
children
differ
type
fungal
infect
manifest
differ
form
result
year
male
calla
posit
b
cell
week
induct
present
cm
hyperpig
lesion
medial
aspect
right
foot
pancytopenia
lesion
respond
antibiot
antifung
requir
debrid
identifi
exserohilum
rostratum
fungal
cultur
lesion
resolv
week
iv
amphotericin
b
debrid
case
unus
fungal
infect
well
child
rais
suspicion
malign
year
male
present
fever
day
initi
manag
enter
fever
iv
antibiot
abscess
cannula
site
notic
cultur
grew
rhizopu
aerhizu
cbp
reveal
hb
gm
wbc
lyphocyt
platelet
lakh
bone
marrow
aspir
confirm
calla
posit
b
respond
amphotericin
b
case
year
old
male
standard
risk
calla
posit
induct
present
histori
right
eye
swell
chemosi
even
week
induct
neutropenia
cell
right
eye
vitreou
biopsi
done
endophthalm
intravitr
amphotericin
given
cultur
vitreal
fluid
isol
aspergillu
fumigatu
antifung
given
week
control
fungal
infect
case
year
femal
calla
posit
cn
neg
standard
count
genet
consolid
develop
skin
fungal
infect
axilla
identifi
mucormycsi
requir
debrid
skin
lesion
along
week
iv
liposom
amphotericin
b
conclus
awar
earli
recognit
differ
fungal
infect
children
import
prevent
mortal
morbid
peg
asparginas
induc
superior
sagit
sinu
thrombosi
acut
lymphoblast
leukemia
children
report
case
siddaiahgari
makadia
l
lingappa
pediatr
rainbow
children
hospit
hyderabad
india
pediatr
neurolog
rainbow
children
hospit
hyderabad
india
object
identifi
caus
cerebr
sinoven
thrombosi
csvt
children
induct
therapi
acut
leukemia
method
two
children
identifi
csvt
treat
octob
decemb
eighteen
receiv
pegasparginas
remain
l
asparginas
result
case
year
old
male
standard
risk
develop
left
focal
seizur
evolv
statu
epilepticu
left
hemiparesi
day
consolid
week
post
second
dose
pegasparginas
induct
given
use
dexamethason
vincristin
intrathec
methotrex
cvst
predominantli
right
side
mri
brain
start
weight
heparin
lmwh
levetriacetam
left
hemiparesi
improv
fulli
ambulatori
within
week
consolid
chemotherapi
continu
smoothli
concomit
use
lmwh
intrathec
methotrex
omit
temporarili
subsequ
restart
continu
lmwh
month
post
reinduct
pegasparginas
part
shedul
repeat
mr
angiogram
reveal
partial
recan
thrombophilia
work
initi
show
low
protein
antithrombin
iii
becam
normal
month
post
cvst
procoagul
work
parent
complet
normal
case
year
old
femal
present
statu
epilepticu
left
hemiparesi
week
induct
week
first
dose
pegasparginas
siimilar
cours
case
except
requir
antiepilept
control
seizur
also
normal
thrombophilia
work
even
time
episod
low
molecular
weight
heparin
continu
similar
fashion
till
reinduct
show
good
respons
therapi
without
residu
neurolog
disabl
conclus
case
illustr
strong
correl
rare
thrombot
complic
cvst
hypercoagul
statu
secondari
combin
asparaginas
corticosteroid
earli
vigil
recognit
prompt
anticoagul
prevent
neurolog
damag
lipid
profil
induct
chemotherapi
bangladeshi
children
acut
lymphoblast
leukemia
r
siddiqu
cy
jamal
karim
f
yasmin
smr
rahman
b
yamin
islam
pediatr
hematolog
oncolog
bangabandhu
sheikh
mujib
medic
univers
dhaka
bangladesh
object
evalu
chang
lipid
profil
asparaginas
complet
induct
chemotherapi
method
observ
analyt
studi
carri
march
novemb
depart
pediatr
hematolog
oncolog
bsmmu
view
evalu
chang
lipid
profil
due
induct
chemotherapi
protocol
ukal
modifi
newli
diagnos
children
age
rang
year
includ
studi
fast
hour
serum
total
cholesterol
tg
hdl
ldl
fast
blood
glucos
alt
creatinin
done
treatment
complet
asparaginas
induct
complet
risk
stratif
patient
done
age
report
cbc
bone
marrow
examin
result
mean
sd
age
children
studi
year
age
group
year
male
current
studi
treatment
mean
total
cholesterol
tg
hdl
ldl
valu
mgdl
complet
tg
ldl
declin
significantli
hdl
increas
significantli
complet
induct
chemotherapi
mean
valu
total
cholesterol
hdl
ldl
level
increas
p
p
p
respect
tg
decreas
p
also
observ
patient
receiv
dexamethason
significantli
increas
cholesterol
level
comparison
receiv
conclus
induct
chemotherapi
total
cholesterol
hdl
ldl
level
increas
tg
level
decreas
increas
cholesterol
valu
probabl
due
steroid
rather
rhinocerebr
mucormycos
child
acut
lymphoblast
leukemia
skoric
g
milosev
laban
depart
hematolog
oncolog
children
univers
hospit
belgrad
serbia
depart
microbiolog
children
univers
hospit
belgrad
serbia
object
mucormycosi
rare
fungal
diseas
affect
immunocompromis
patient
rhinocerebr
mucormycosi
common
form
high
mortal
rate
method
present
case
rhinocerebr
mucormycosi
pediatr
acut
lymphoblast
leukemia
patient
result
femal
diagnos
present
febril
neutropenia
third
time
induct
phase
first
second
line
antibiot
introduc
without
success
dark
discolor
hard
palat
periorbit
edema
note
caspofungin
administ
due
suspicion
aspergillosi
posit
serum
galactomannan
assay
due
aggrav
gener
condit
patient
transfer
picu
two
day
later
dark
discolor
skin
note
base
nose
endocrani
ct
reveal
hyperdens
fluid
paranas
sinus
nasal
caviti
endoscop
examin
nasal
caviti
revel
perfor
nasal
septum
necrosi
maxillari
ethmoid
sinus
day
infect
colloid
dispers
amphothericin
b
introduc
therapi
due
suspicion
mucormycosi
tissu
sampl
taken
histopatholog
cultur
confirm
diagnosi
progress
local
find
deterior
gener
condit
continu
lead
respiratori
failur
local
surgic
intervent
consid
perform
due
progress
process
cerebr
parenchyma
seen
mri
patient
develop
pulmonari
hemorrhag
ard
lead
fatal
outcom
day
infect
conclus
late
recognit
aggress
infect
inabl
perform
radic
surgic
debrid
led
fatal
outcom
first
case
mucormycosi
institut
rhinocerebr
mucormycosi
rare
rapidli
progress
diseas
high
mortal
rate
earli
diagnosi
resolut
predispos
factor
aggress
surgic
intervent
time
use
adequ
antifung
agent
cornerston
success
treatment
nevertheless
mortal
still
high
effort
must
made
improv
outcom
mucormycosi
methylenetetrahydrofolatereductas
glutathion
tranferas
gene
polymorph
secondari
leukemia
skoric
joksic
radic
simic
g
milosev
depart
hematolog
oncolog
children
univers
hospit
belgrad
serbia
depart
genet
clinic
gynecolog
obstetr
narodni
front
belgrad
serbia
institut
medic
clinic
biochemistri
faculti
medicin
univers
belgrad
belgrad
serbia
object
leukemia
clinic
syndrom
occur
late
complic
patient
treat
cytotox
therapi
herein
present
result
analysi
common
gene
polymorph
methylenetetrahydrofolatereductas
mthfr
gluthatoin
transferas
gst
gene
male
develop
rare
type
cancer
acut
biphenotyp
leukemia
six
year
treatment
acut
lymphoblast
leukemia
method
studi
mthfr
gene
polymorph
assess
role
herit
factor
develop
rare
type
childhood
secondari
leukemia
result
analysi
mthfr
gene
polymorph
show
patient
homozyg
heterozyg
result
lower
enzym
activ
among
gst
genotyp
test
lower
express
b
gene
variant
togeth
homozig
delet
found
absenc
protein
well
express
activ
could
result
lower
detoxif
potenti
toward
anticanc
drug
conclus
analysi
mthfr
gene
polymorph
show
patient
homozyg
heterozyg
result
lower
enzym
activ
could
confer
increas
risk
develop
secondari
malign
sever
way
result
accord
higher
frequenc
null
genotyp
secondari
hematolog
malign
patient
treatment
cyclophosphamid
seem
reason
asumm
null
lower
activ
b
genotyp
result
enhanc
chemotherapi
induc
oxid
dna
damag
could
lead
mutat
secondari
leukemia
express
bid
bak
childhood
acut
lymphoblast
leukemia
panagouli
g
martimianaki
pesmatzogl
e
athanassopoulo
e
stiakaki
pediatr
univers
hospit
heraklion
heraklion
crete
greec
object
quantit
determin
express
level
molecul
bak
bid
bone
marrow
bm
children
acut
lymphoblast
leukemia
diagnosi
remiss
children
solid
tumour
st
without
bone
marrow
involv
method
twenti
eight
children
male
median
age
year
children
diagnosi
alld
remiss
achiev
allr
solid
tumor
diagnosi
without
bone
marrow
involv
studi
total
rna
isol
bone
marrow
mononuclear
cell
mrna
level
correspond
bak
bid
quantifi
polymeras
chain
reaction
pcr
analysi
use
gapdh
normalis
reaction
perform
duplic
quantif
gene
standard
curv
made
serial
dilut
refer
line
cdna
tanou
result
express
level
determin
signific
higher
blast
diagnosi
compar
remiss
p
well
st
p
express
level
bid
determin
low
diagnosi
high
enough
remiss
statist
signific
differ
p
result
accord
apoptot
role
high
level
also
observ
st
without
bm
involv
p
concern
express
apoptot
bak
gene
level
found
statist
signific
higher
alld
compar
remiss
p
similar
high
level
determin
solid
tumor
statist
signific
differ
compar
allr
p
conclus
diagnosi
seem
suppress
induct
treatment
remiss
achiev
express
bid
amplifi
remiss
molecul
stimul
apoptosi
role
bak
level
diagnosi
remiss
respect
function
warrant
investig
traumat
lumbar
punctur
lead
greater
relaps
acut
lymphoblast
leukemia
outcom
singl
center
india
totadri
trehan
r
srinivasan
bansal
rk
marwaha
pediatr
hematolog
oncolog
postgradu
institut
medic
educ
research
chandigarh
india
cytolog
postgradu
institut
medic
educ
research
chandigarh
india
object
thorn
success
stori
treatment
acut
lymphoblast
leukemia
remain
relaps
patient
relaps
despit
risk
adapt
therapi
studi
done
address
whether
traumat
lumbar
punctur
tlp
contribut
relaps
method
children
treat
januari
decemb
analyz
tlp
diagnosi
subsequ
therapi
evalu
outcom
result
children
treat
per
ukal
protocol
median
age
year
first
diagnost
lumbar
punctur
tlp
tlp
patient
got
extra
intrathec
methotrex
induct
overal
relaps
cn
relaps
patient
tlp
relaps
cn
tlp
diagnosi
correl
increas
incid
overal
relaps
p
cn
relaps
p
signific
differ
overal
surviv
os
event
free
surviv
ef
children
tlp
os
ef
total
administ
rate
traumat
lp
averag
number
tlp
per
child
receiv
oper
characterist
curv
gener
predict
relaps
base
tlp
entir
treatment
offer
poor
sensit
auc
ci
cn
relaps
asymptomat
detect
routin
csf
examin
confirm
cell
count
flow
cytometri
conclus
traumat
lp
diagnosi
associ
increas
risk
relaps
possibl
extra
intrathec
amelior
effect
tlp
one
traumat
lp
treatment
increas
risk
relaps
howev
routin
csf
malign
cytolog
surveil
role
detect
cn
relaps
onset
symptom
profil
outcom
acut
lymphoblast
leukemia
develop
countri
experi
udgir
k
jain
b
agarw
mudaliar
swami
n
shah
desai
pediatr
hematolog
oncolog
bj
wadia
hospit
parel
mumbai
mumbai
india
object
acut
lymphoblast
leukemia
common
hematolymphoid
malign
children
advent
new
chemotherapeut
protocol
good
support
care
highli
curabl
aim
studi
give
comprehens
overview
clinic
haematolog
present
event
therapi
outcom
signific
problem
occur
patient
data
lack
develop
countri
method
retrospect
data
analysi
patient
period
treat
follow
centr
infant
treat
interinf
protocol
other
hongkong
singapor
hksg
prtotocol
result
children
age
group
analys
median
age
children
infant
male
preponder
major
bcell
type
patient
joint
bleed
pallor
abdomin
distens
diagnosi
patient
high
wbc
count
hemoglobin
platelet
count
patient
cn
diseas
diagnosi
cytogenet
molecular
analysi
show
children
receiv
steroid
day
prior
diagnosi
accord
risk
stratif
fall
standard
intermedi
risk
high
risk
achiev
complet
remiss
cr
resist
diseas
remain
patient
referr
follow
induct
cn
event
occur
patient
sagitt
sinu
patient
relaps
among
patient
achiev
bcell
type
tcell
earli
late
relaps
natur
relaps
isol
bm
bm
cn
cn
orbit
conclus
common
type
preb
type
patient
receivi
steroid
prior
diagnosi
result
delay
diagnosi
impair
prognost
therefor
requir
better
awar
among
doctor
regard
use
steroid
cytolog
analysi
reveal
trisomi
common
follow
cn
complic
frequent
event
therapi
requir
rapid
detect
prompt
treatment
limit
perman
damag
outcom
pediatr
acut
lymphoblast
leukemia
patient
present
hyperleukocytosi
unal
ozsurekci
aytac
b
kuskonmaz
b
tavil
tuncer
yetgin
gurgey
f
gumruk
cetin
divis
pediatr
hematolog
hacettep
univers
medic
school
ankara
turkey
divis
pediatr
hacettep
univers
medic
school
ankara
turkey
object
patient
hyperleukocytosi
diagnosi
pediatr
acut
lymphoblast
leukemia
constitut
patient
knowledg
manag
patient
limit
method
retrospect
studi
patient
present
hyperleukocytosi
diagnosi
includ
result
cohort
receiv
st
jude
total
xi
group
receiv
total
xiii
group
receiv
total
xv
protocol
group
median
age
diagnosi
month
patient
receiv
iv
alkalin
hydrat
least
twice
daili
fluid
mainten
patient
initi
methylprednisolon
mpz
mgkgday
decreas
wbc
hour
vincristin
administ
cytoreduct
treatment
leukopheresi
exchang
transfus
appli
symptomat
patient
group
cytoreduct
treatment
appli
patient
group
group
group
patient
except
one
unrespons
mpz
vincristin
dose
treat
lekopheresi
group
leukopheresi
appli
patient
eight
patient
group
receiv
rasburicas
patient
group
develop
either
icb
pulmonari
leukostasi
ef
group
respect
p
os
group
p
four
patient
group
group
deceas
induct
treatment
death
induct
observ
group
conclus
initi
lower
dose
sequenti
chemotherapi
seem
ration
instead
initi
treatment
protocol
time
current
practic
appli
cytoreduct
treatment
oftenli
earli
mortal
morbid
lesser
type
approach
individu
dose
switch
acut
lymphoblast
leukemia
number
neeed
treat
analysi
kf
villa
f
di
trapani
b
nejadnik
biostatist
jazz
pharmaceut
inc
palo
alto
ca
usa
medic
inform
commun
medic
affair
jazz
pharmaceut
inc
palo
alto
ca
usa
oncolog
jazz
pharmaceut
inc
palo
alto
ca
usa
object
import
compon
chemotherapi
pediatr
acut
lymphoblast
leukemia
surviv
ef
recent
publish
studi
vrooman
jco
significantli
higher
patient
random
individu
dose
id
initi
dose
adjust
maintain
nadir
serum
asparaginas
activ
nsaa
within
iuml
vs
fd
escherichia
coli
object
compar
number
need
treat
nnt
associ
id
vs
fd
treatment
strategi
method
nnt
calcul
reciproc
absolut
risk
reduct
arr
equal
control
minu
experiment
event
rate
compar
nnt
prevent
one
event
relaps
death
id
vs
fd
also
calcul
nnt
switch
asparaginas
prepar
silent
inactiv
si
defin
id
patient
nsaa
iuml
success
determin
despit
dose
adjust
coupl
antibodi
posit
nnt
compar
pediatr
oncolog
intervent
conduct
literatur
search
identifi
random
control
trial
rct
intervent
pediatr
hematolog
solid
malign
report
past
year
result
ef
fd
id
group
respect
nnt
id
vs
fd
fd
patient
level
iuml
never
switch
prepar
ef
vs
id
patient
switch
prepar
si
nnt
id
switch
si
vs
fd
switch
five
rct
pediatr
cancer
outcom
measur
nnt
rang
conclus
nnt
valu
id
switch
asparaginas
prepar
base
evid
si
resembl
oncolog
treatment
highlight
valu
monitor
prospect
identifi
suboptim
asparaginas
activ
si
analysi
fund
jazz
pharmaceut
plc
subsidiari
new
transcript
childhood
xw
wang
hh
liang
lx
ding
bs
li
jy
tang
hematolog
oncolog
shanghai
children
medic
center
shanghai
china
object
research
transcript
method
childhood
tumor
cell
method
mutat
found
case
childhood
tumor
cell
whole
exom
sequenc
cours
experi
transcript
report
could
nt
clone
might
new
transcript
variant
childhood
tumor
cell
design
primer
gsp
use
rna
children
revers
transcript
pcr
smarter
race
cdna
amplif
kit
obtain
complet
sequenc
new
transcript
sequenc
result
use
smarter
race
cdna
amplif
kit
obtain
first
strand
reaction
product
accord
experiment
correspond
step
prepar
master
mix
ad
first
strand
reaction
product
mixtur
race
univers
primer
upm
relev
control
sampl
pcr
tube
pcr
amplif
specif
band
obtain
pcr
product
process
gel
extract
clone
transform
plasmid
deliveri
plasmid
genom
sequenc
sequenc
complet
sequenc
new
transcript
obtain
complet
upm
sequenc
complet
upm
sequenc
poli
new
transcript
exon
report
yet
new
locat
transcript
new
locat
transcript
new
correspond
transcript
conclus
new
transcript
method
exist
childhood
tumor
cell
analysi
therapeut
effect
high
dose
cytarabin
plu
children
acut
lymphoblast
leukemia
mrd
j
yang
hemotologyoncolog
shanghai
children
hospit
shanghai
china
object
analyz
therapeut
effect
safeti
high
dose
cytarabin
combin
minim
residu
diseas
mrd
childhood
acut
lymphoblast
leukemia
method
four
color
fluoresc
antibodi
label
method
use
monitor
dynam
chang
mrd
children
total
case
patient
case
high
risk
case
moder
risk
case
low
rise
consid
mrd
posit
remiss
includ
male
case
femal
case
averag
age
month
rang
month
patient
treat
combin
chemotherapi
cytarabin
dexamethason
efficaci
surviv
time
advers
event
patient
statist
analyz
use
spss
result
level
mrd
patient
test
one
month
chemotherapi
turn
neg
decreas
yet
still
posit
patient
follow
dec
relaps
die
recurr
rate
year
probabl
surviv
overal
surviv
respect
toxic
includ
grade
diarrhea
nausea
grade
neutropenia
associ
fever
case
grade
liver
function
damag
death
conclus
show
high
dose
cytarabin
combin
effect
improv
prognosi
childhood
posit
mrd
advers
event
could
well
toler
rare
complic
dasanitib
acut
lymphoblast
leukemia
case
hemorrhag
cystiti
coliti
g
tanyildiz
mo
candir
yesil
c
bozkurt
g
sahin
pediatr
oncolog
dr
sami
ulu
pediatr
research
train
hospit
ankara
turkey
object
dasanitib
new
gener
tyrosin
kinas
inhibitor
use
high
risk
childhood
acut
lymphoblast
leukemia
case
philadelphia
chromosom
fusion
gene
literatur
side
effect
associ
dasanitib
treatment
commonli
report
adult
case
report
child
diagnos
acut
lymphoblast
leukemia
present
hemorrhag
cystiti
coliti
dasanitib
treatment
method
year
old
child
diagnos
resist
imitanib
treatment
enrol
dasanitib
therapi
result
hour
initi
dasanitib
therapi
hemorrhag
diarrhea
start
stool
cultur
result
neg
term
pathogen
agent
hemoglobin
level
detect
grdl
dasanitib
therapi
stop
steroid
treatment
start
hematolog
paramet
clinic
statu
improv
hour
cessat
dasanitib
therapi
therefor
low
dose
dasanitib
restart
follow
period
blastic
white
cell
count
decreas
progress
dosag
dasanitib
increas
dysuria
present
massiv
haematuria
develop
adjust
dosag
renal
function
normal
thrombocytopenia
coagulopathi
defin
urinari
system
ultrasonographi
urin
sampl
result
normal
patenc
urinari
system
tract
ensur
cathater
bladder
haematuria
improv
complet
day
discontinu
dasanitib
treatment
conclus
dasanitib
new
tyrosin
kinas
inhibitor
use
case
resist
imitanib
treatment
acut
lymphoblast
leukemia
gastrointestin
system
side
effect
associ
dasanitib
treatment
relat
infiltr
cell
epitheli
surfac
benefici
effect
steroid
treatment
side
effect
dasanitib
mayb
consid
result
cell
activ
although
imitanib
substrat
p
glycoprotein
dasanitib
properti
dasanitib
import
factor
develop
drug
resist
term
kinas
famili
clinician
keep
mind
potenti
side
effect
dasanitib
usag
essenti
express
signific
children
acut
leukemia
liu
miao
shi
qingzhao
tang
rong
j
yi
paediatr
renmin
hospit
wuhan
univers
wuhan
china
object
examin
express
bone
marrow
cell
children
acut
leukemia
al
detect
relationship
classif
clinic
featur
therapeut
effect
prognosi
al
method
use
sabc
method
immunohistochem
stain
express
bone
marrow
cell
case
al
detect
result
express
initi
treatment
refractori
relaps
relief
group
obvious
higher
control
group
p
signific
differ
express
acut
lymphoblast
leukemia
acut
nonlymphoblast
leukemia
anll
group
p
express
complet
remiss
cr
group
lower
initi
treatment
group
p
express
refractori
relaps
group
higher
initi
treatment
group
p
howev
high
express
occur
initi
treatment
group
refractori
relaps
group
signific
differ
p
pearson
rank
correl
analysi
indic
posit
correl
express
r
p
statist
analysi
show
cr
rate
patient
neg
express
remark
higher
posit
express
p
conclus
express
play
role
onset
progress
prognosi
al
two
may
act
synergist
onset
develop
al
outcom
relaps
acut
lymphoblast
leukemia
modifi
bfm
protocol
china
x
zhai
h
wang
jun
li
hui
miao
x
qian
hematolog
depart
children
hospit
fudan
univers
shanghai
china
object
acut
lymphoblast
leukemia
commonest
childhood
malign
modern
treatment
achiev
steadi
improv
surviv
nevertheless
approxim
patient
would
experi
relaps
diseas
remain
major
caus
treatment
failur
method
start
new
relaps
acut
lymphoblasticleukemia
treatment
protocol
base
modifi
bfm
protocol
aim
improv
treatment
outcom
chines
children
patient
first
relaps
childhood
includ
patient
stratifi
four
risk
group
treatment
consist
intens
chemotherapi
follow
allogen
hematopoiet
stem
cell
transplant
hsct
indic
result
patient
recruit
median
age
diagnosi
rang
year
median
time
initi
diagnosi
relaps
rang
year
risk
group
standard
risk
group
intermedi
group
high
risk
rate
initi
diagnos
patient
nineteen
patient
achiev
second
complet
remiss
rate
group
respect
overal
surviv
os
os
patient
respect
conclus
alert
standard
risk
group
patient
initi
diagnosi
relaps
children
relaps
risk
group
could
well
treat
intensifi
treatment
protocol
hsct
could
improv
surviv
rate
group
group
need
innov
approach
improv
treatment
outcom
surviv
pediatr
patient
osteosarcoma
result
pediatr
hematolog
oncolog
group
toluca
valley
xico
l
arac
tejocot
laffont
pediatr
oncolog
hospit
materno
infantil
issemym
toluca
mexico
pediatr
oncolog
hospit
para
el
del
imiem
toluca
mexico
object
object
studi
assess
surviv
pediatr
patient
osteosarcoma
treat
two
hospit
toluca
valley
mexico
well
factor
relat
method
studi
cours
clinic
prognosi
patient
diagnosi
osteosarcoma
evalu
characterist
demograph
clinic
paraclin
diseas
factor
risk
well
clinic
featur
time
surviv
medic
treatment
surgic
well
possibl
factor
relat
type
use
analysi
result
period
march
march
diagnost
oseosarcoma
patient
age
year
male
frequent
site
follow
proxim
humeru
distal
femur
metastat
diseas
diagnosi
patient
candid
preserv
limb
five
patient
die
earli
surviv
patient
metastat
diseas
month
diseas
metastat
month
patient
receiv
neoadjuv
chemotherapi
doxorubicin
cyclophosphamid
etoposid
adjuv
cisplatino
one
patient
diseas
metastat
diagnosi
also
mifamurtida
conclus
advanc
chemotherapi
treatment
well
use
biolog
therapi
achiev
signific
increas
surviv
pediatr
patient
osteosarcoma
howev
develop
countri
late
diagnost
decreas
exponenti
surviv
due
mainli
high
tumor
burden
diagnosi
limit
access
limb
preserv
surgeri
well
use
biolog
therapi
carri
train
staff
first
contact
earli
detect
cancer
childhood
whose
impact
surviv
measur
year
ice
regimen
relapsedrefractori
bone
soft
tissu
sarcoma
b
aydin
h
susam
sen
kutluk
varan
b
yalcin
c
akyuz
pediatr
oncolog
hacettep
institut
oncolog
ankara
turkey
object
patient
recurr
refractori
sarcoma
dismal
prognosi
studi
respons
treatment
outcom
children
recurrentrefractori
sarcoma
treat
ice
regimen
retrospect
evalu
method
patient
relapsedrecurr
bone
soft
tissu
sarcoma
treat
ice
regimen
select
demograph
clinic
characterist
treatment
result
analyz
ice
regimen
given
ifosfamid
day
carboplatin
day
etoposid
day
result
patient
male
femal
evalu
respons
treatment
median
age
diagnosi
rang
tumor
type
rhabdomyosarcoma
n
ewe
sarcoma
n
osteosarcoma
n
ppnet
n
undifferenti
sarcoma
n
total
patient
metastat
diseas
diagnosi
ice
regimen
given
median
month
diagnosi
due
relapsedrefractori
diseas
patient
receiv
median
cycl
rang
orr
complet
respons
good
partial
respons
partial
respons
stabl
diseas
median
durat
respons
os
ice
month
month
ef
os
rate
os
rate
significantli
increas
respond
vs
p
ef
rate
rhabdomyosarcoma
ewe
sarcoma
osteosarcoma
ppnet
p
conclus
treatment
relaps
refractori
sarcoma
remain
challeng
orr
os
rate
significantli
improv
patient
respons
treatment
rhabdomyosarcoma
ice
regimen
result
show
ice
valuabl
therapeut
option
relapsedrefractori
sarcoma
system
region
hemodynam
children
adolesc
bone
sarcoma
begun
r
tarasevich
function
diagnost
belarusian
research
center
pediatr
oncolog
hematolog
immunolog
minsk
region
belaru
object
studi
hemodynam
lower
extrem
take
account
cardiac
output
volum
tumor
patient
bone
sarcoma
method
analysi
data
obtain
initi
ultrasound
examin
patient
age
year
morpholog
proven
bone
sarcoma
lower
extrem
perform
estim
cardiac
output
co
volum
blood
flow
main
femor
arteri
q
mlmin
indic
resist
pulsat
ri
pi
well
size
percentag
deviat
affect
limb
compar
contralater
q
ri
pi
result
system
note
chang
cardiac
output
increas
tumor
volum
r
p
system
effect
tumor
background
interdepend
volum
blood
flow
main
arteri
affect
healthi
limb
r
p
herewith
neg
correl
index
valu
q
blood
flow
healthi
limb
q
r
p
confirm
one
compon
hemodynam
chang
redistribut
blood
flow
establish
correl
volum
malign
ri
pi
r
p
decreas
region
vascular
tone
affect
limb
conclus
patholog
mechan
hemodynam
support
affect
limb
may
includ
system
increas
co
region
chang
vascular
tone
background
redistribut
certain
volum
blood
healthi
affect
limb
role
thromboprophylaxi
pediatr
sarcoma
patient
literatur
review
focus
epidemiolog
risk
factor
outcom
thromboembol
sarcoma
patient
md
bhatt
u
athal
ak
chan
pediatr
hematologyoncolog
mcmaster
children
hospit
hamilton
canada
object
thromboembol
te
common
complic
cancer
children
includ
sarcoma
te
caus
signific
morbid
mortal
patient
popul
current
thromboprophylaxi
recommend
pediatr
sarcoma
patient
psp
review
literatur
describ
epidemiolog
risk
factor
outcom
te
psp
evalu
thromboprophylaxi
practic
psp
method
english
languag
articl
search
pubm
use
term
sarcoma
thrombosi
sarcoma
thromboembol
time
period
studi
describ
epidemiolog
risk
factor
outcom
andor
thromboprophylaxi
psp
adult
sarcoma
patient
asp
te
review
case
report
exclud
result
among
four
review
studi
averag
incid
te
psp
fold
higher
describ
adult
audino
describ
lower
incid
psp
howev
limit
inpati
central
venou
cathet
cvc
dysfunct
statist
signific
risk
factor
describ
psp
athal
trend
toward
clinic
signific
describ
metastat
diseas
import
adult
risk
factor
hipthigh
diseas
studi
psp
mortal
though
infrequ
report
signific
morbid
includ
cvc
remov
recurr
te
syndrom
delay
cancer
treatment
use
week
low
molecular
weight
heparin
thromboprophylaxi
children
bone
sarcoma
n
none
develop
te
howev
studi
lack
control
group
recent
survey
oncologist
includ
medic
surgic
publish
crocco
describ
use
mechan
andor
chemic
prophylaxi
respond
conclus
incid
te
psp
higher
asp
despit
age
lifestyl
relat
risk
factor
yet
thromboprophylaxi
recommend
asp
surgeri
evid
thromboprophylaxi
psp
limit
henc
larger
studi
urgent
requir
defin
role
time
thromboprophylaxi
select
psp
skip
metastas
osteosarcoma
st
jude
children
research
hospit
experi
mw
bishop
ah
loh
bahrami
mb
mccarvil
mao
j
wu
md
neel
pappo
bn
rao
oncolog
st
jude
children
research
hospit
memphi
usa
surgeri
st
jude
children
research
hospit
memphi
usa
patholog
st
jude
children
research
hospit
memphi
usa
radiolog
scienc
st
jude
children
research
hospit
memphi
usa
biostatist
st
jude
children
research
hospit
memphi
usa
object
presenc
synchron
region
bone
metastas
known
skip
metastas
osteosarcoma
histor
associ
poor
clinic
outcom
studi
describ
experi
osteosarcoma
skip
metastas
period
method
retrospect
review
conduct
patient
treat
st
jude
children
research
hospit
newli
diagnos
osteosarcoma
januari
decemb
radiograph
andor
histopatholog
evid
skip
metastasi
data
evalu
includ
clinic
characterist
surgic
medic
treatment
histolog
respons
clinic
outcom
surviv
ef
overal
surviv
os
estim
clinic
patholog
factor
correl
outcom
result
skip
metastas
identifi
patient
median
age
year
rang
year
patient
present
addit
metastat
site
pulmonari
nodul
locoregion
lymph
node
patient
receiv
neoadjuv
chemotherapi
evalu
histolog
respons
patient
good
respons
greater
necrosi
develop
recurr
lung
nodul
locallung
diseas
one
local
relaps
posit
margin
site
skip
metastasi
patient
aliv
median
time
month
rang
month
activ
diseas
year
ef
se
os
se
tumor
necrosi
greater
approach
signific
os
p
patient
without
metastat
site
diagnosi
aliv
compar
present
pulmonari
nodul
sampl
size
larg
enough
determin
differ
group
conclus
skip
metastas
occur
rare
osteosarcoma
outcom
may
suboptim
compar
local
osteosarcoma
without
skip
lesion
even
absenc
diseas
site
histolog
respons
chemotherapi
may
still
predict
likelihood
surviv
uniqu
subset
patient
propos
function
rehabilit
physic
therapi
patient
undergo
total
intern
hemipelvectomi
type
iv
bonatelli
al
stellet
e
boldrini
sarri
ge
martin
lf
lope
ea
toller
pediatr
cancer
center
barreto
barreto
brazil
orthopaed
cancer
center
barreto
barreto
brazil
physioterapi
cancer
center
barreto
barreto
brazil
phd
medic
director
cancer
center
barreto
barreto
brazil
object
malign
primari
bone
tumor
rare
mainli
affect
children
young
adult
may
occur
anywher
bodi
emerg
effect
drug
treatment
technic
improv
surgeon
intern
hemipelvectomi
ih
surgic
remov
hemipelvi
part
preserv
limb
conduct
gener
challeng
rehabilit
patient
ih
consist
resect
bone
affect
tissu
pelvic
girdl
limb
salvag
ennek
classif
demonstr
function
outcom
rehabilit
total
ih
type
iv
method
first
postop
physic
therapi
evalu
perform
consid
muscular
strength
rang
motion
lung
capac
sit
balanc
postur
bed
vascular
direct
global
cinesioterapia
chang
posit
balanc
train
sit
posit
kinet
respiratori
maneuv
posit
affect
limb
discharg
patient
refer
outpati
physiotherapi
follow
aspect
evalu
muscular
strength
rang
motion
balanc
propriocept
gait
evalu
perform
global
cinesioterapia
stretch
strengthen
russian
current
gait
train
without
support
partial
full
weight
bear
workout
static
dynam
balanc
without
support
partial
full
weight
bear
balanc
train
static
limb
result
averag
month
physic
therapi
patient
ambul
support
crutch
excel
balanc
without
support
type
prosthesi
arthrodesi
reconstruct
pelvi
extens
fibrosi
allow
patient
weight
bear
affect
limb
despit
shorten
conclus
function
outcom
patient
total
intern
hemipelvectomi
specif
intens
physic
therapi
rehabilit
posit
influenc
qualiti
life
result
intens
chemotherapi
regimen
without
methotrex
treatment
pediatr
osteosarcoma
experi
instituto
nacion
de
xico
h
j
instituto
nacion
de
mexico
citi
mexico
de
instituto
nacion
de
mexico
citi
mexico
de
instituto
mexicano
del
seguro
social
mexico
citi
mexico
object
mexico
pediatr
osteosarcoma
hgo
occupi
fifth
place
pediatr
cancer
repres
present
high
incid
metastat
pulmonari
diseas
larg
primari
tumor
volum
diagnosi
result
poor
surviv
describ
result
recent
cohort
treat
system
chemotherapi
regimen
without
methotrex
instituto
nacion
de
pediatria
mexico
citi
method
retrospect
longitudin
clinic
studi
perform
januari
januari
patient
younger
year
extrem
hgo
prior
chemotherapi
treatment
includ
patient
receiv
chemotherapi
regimen
without
methotrex
base
neoadjuv
chemotherapi
regimen
cisplatin
plu
doxorubicin
adjuv
treatment
cyclophosphamid
cours
given
two
therapeut
arm
total
dose
non
metastat
patient
gradual
climb
dose
cours
metastat
bad
respond
patient
arm
plu
etoposid
cours
result
pulmonari
metastas
present
diagnosi
osteoblast
histolog
prevail
underw
amput
procedur
limb
disarticul
surgeri
good
respond
patient
overal
surviv
os
patient
metastat
patient
p
surviv
ef
metastat
patient
p
os
good
respond
bad
respond
p
import
toxic
second
malign
report
point
follow
conclus
intens
short
chemotherapi
regimen
without
methotrex
rel
advers
event
improv
outcom
os
mainli
abl
achiev
similar
outcom
ef
current
seri
report
ef
patient
local
extrem
osteosarcoma
long
term
follow
ewe
sarcoma
patient
memori
sloan
ketter
experi
k
chastain
j
chou
r
adsuar
c
moskowitz
j
candela
p
meyer
l
wexler
chou
wolden
k
oeffing
pediatr
univers
citi
kansa
citi
usa
epidemiolog
biostatist
memori
sloan
ketter
cancer
center
new
york
usa
medicin
memori
sloan
ketter
cancer
center
new
york
usa
pediatr
memori
sloan
ketter
cancer
center
new
york
usa
radiat
oncolog
memori
sloan
ketter
cancer
center
new
york
usa
medicin
pediatr
memori
sloan
ketter
cancer
center
new
york
usa
object
aim
determin
overal
surviv
os
character
second
malign
neoplasm
smn
cohort
patient
diagnos
ewe
sarcoma
es
treat
singl
institut
method
preform
retrospect
chart
review
elig
es
patient
irb
approv
obtain
prior
review
individu
exclud
least
month
therapi
time
review
receiv
chemotherapi
mskcc
overal
surviv
confid
interv
ci
assess
estim
cox
proport
hazard
regress
mortal
evalu
cumul
incid
function
account
compet
risk
result
assess
outcom
patient
femal
racialethn
minor
treat
consecut
primari
site
bone
soft
tissu
median
age
diagnosi
year
rang
median
interv
cancer
diagnosi
last
contact
year
rang
relaps
occur
patient
occur
within
year
diagnosi
total
smn
solid
tumor
melanoma
skin
cancer
os
ci
death
relat
relapsedprogress
es
cumul
incid
death
due
es
year
death
due
caus
multivari
model
racialethn
minor
es
patient
like
poor
os
white
patient
ci
older
age
diagnosi
also
associ
poor
os
everi
year
increas
age
hazard
ratio
ci
conclus
overal
surviv
smn
risk
remain
suboptim
patient
ewe
sarcoma
highlight
need
new
target
therapeut
zoledron
acid
treatment
children
refactori
giant
cell
tumor
jaw
chien
l
mascarenha
r
venkatramani
depart
pediatr
keck
school
medicin
univers
southern
california
lo
angel
usa
divis
hematolog
oncolog
bmt
children
hospit
lo
angel
lo
angel
usa
object
approv
system
therapi
current
exist
treatment
pediatr
giant
cell
tumor
jaw
gct
central
giant
cell
granuloma
although
bisphosphon
zoledron
acid
za
use
success
adult
use
pediatr
limit
due
concern
effect
bone
health
growth
arrest
review
outcom
pediatr
gct
treat
za
institut
method
data
collect
retrospect
chart
review
patient
gct
treat
za
children
hospit
lo
angel
januari
decemb
mg
max
dose
za
administ
intraven
everi
week
result
four
patient
femal
male
age
month
year
treat
za
patient
month
old
femal
incomplet
resect
maxillari
gct
receiv
za
primari
treatment
due
unaccept
risk
interferon
treatment
achiev
tumor
remiss
cours
remiss
one
year
follow
therapi
patient
b
c
receiv
za
therapi
recurr
surgic
resect
interferon
therapi
recurr
lesion
surgic
resect
follow
cours
za
patient
b
diseas
free
four
year
patient
c
develop
local
tumor
recurr
two
year
treatment
success
resect
patient
underli
diagnosi
osteoglophosi
dwarfism
refractori
gct
result
administr
multipl
regimen
includ
za
experienc
diseas
progress
follow
cours
side
effect
za
includ
symptom
electrolyt
abnorm
includ
hypocalcemia
hypophosphotemia
mild
asymptomat
effect
project
anthropometr
growth
paramet
note
conclus
result
demonstr
therapi
za
reason
option
children
relaps
refractori
gct
though
larger
studi
need
demonstr
efficaci
predictor
infect
proxim
tibia
allograft
composit
reconstruct
sa
swaim
federico
c
sampson
anderson
mc
gebhardt
orthoped
surgeri
boston
children
hospit
boston
usa
oncolog
boston
children
hospit
boston
usa
plastic
surgeri
boston
children
hospit
boston
usa
object
reconstruct
proxim
tibia
wide
resect
challeng
advoc
argu
advantag
includ
bone
preserv
biolog
reconstruct
facilit
reattach
extensor
mechan
structur
metal
prosthesi
use
delay
distal
femor
growth
plate
preserv
complic
numer
infect
common
believ
infect
correl
poor
coverag
seen
area
investig
evalu
experi
patient
analyz
incid
manag
infect
method
patient
male
femal
averag
age
year
old
underw
allograft
proxim
tibia
reconstruct
evalu
occurr
infect
potenti
predictor
infect
categor
pre
periop
factor
analyz
term
risk
develop
allograft
infect
result
patient
osteosarcoma
remain
patient
ewe
sarcoma
reconstruct
osteoarticular
allograft
fifti
percent
patient
flap
coverag
index
procedur
allograft
surviv
rate
year
allograft
infect
rate
two
patient
convert
metal
endoprosthesi
new
allograft
knee
disarticul
common
complic
wound
dehisc
allograft
fractur
predictor
infect
could
identifi
trend
lower
wbc
note
patient
develop
infect
howev
statist
signific
patient
develop
infect
previou
wound
dehisc
wound
dehisc
posit
bacteri
cultur
howev
progress
allograft
infect
conclus
despit
unabl
identifi
predictor
infect
recommend
nutrit
immunolog
optim
patient
surgeri
low
threshold
flap
coverag
index
surgeri
wound
dehisc
common
complic
aggress
surgic
treatment
recommend
avoid
progress
allograft
infect
allograft
infect
reduct
rate
high
attain
approach
use
mifamurtid
steroid
patient
osteosarcoma
chronic
renal
failur
secondari
cisplatin
j
pediatr
oncolog
cecan
chihuahua
chihuahua
mexico
pediatr
instituto
mexicano
del
seguro
social
mexico
citi
mexico
object
case
report
male
osteoblast
osteosarcoma
present
method
patient
present
may
refer
pain
right
leg
secondari
contus
respond
analges
increas
extrem
volum
claudic
tumor
lesion
right
tibia
comput
tomographi
ct
magnet
reson
imag
mri
show
cm
lesion
involv
adipos
tissu
adjac
muscl
thorac
ct
neg
metastasi
bone
scan
show
singl
focal
well
delimit
concentr
augment
proxim
metaphys
area
chemotherapi
cisplatin
plu
doxorrubicin
day
altern
cisplatin
result
cycl
present
sever
emesi
dehydr
acut
renal
failur
arf
creatinin
bun
urea
oliguria
urem
encephalopathi
partial
improv
creatinin
bun
urea
steroid
puls
initi
continu
prednison
mainten
renal
ultrasound
show
bilater
glomerulonephr
bilater
renal
scan
reveal
defici
renograph
curv
phase
mainli
excretori
high
depth
activ
suggest
chronic
renal
failur
crf
right
kidney
function
effect
renal
plasma
flow
erpf
left
kidney
function
erpf
month
creatinin
chemotherapi
continu
without
cisplatin
steroid
ct
show
tumor
cm
limb
salvag
novemb
adjuv
cycl
etoposid
cicl
mifamurtid
initi
one
month
surgeri
total
dose
dose
steroid
treatment
vigil
start
februari
last
thorac
ct
bone
scan
neg
follow
month
conclus
cisplatin
highli
effect
chemotherapeut
agent
one
limit
side
effect
nephrotox
may
lead
crf
report
venkatakrishnan
et
al
renal
impair
alter
clinic
pharmacokinet
pharmacodynam
mifamurtid
dose
modif
appear
necessari
patient
case
steroid
also
seem
interact
mifamurtid
new
show
associ
risk
osteosarcoma
critic
studi
n
z
ascaiturrieta
granado
k
goricar
v
dolzan
genet
physic
anthropolog
anim
physiolog
univers
basqu
countri
leioa
spain
laboratori
pediatr
univers
clinic
navarra
pamplona
spain
faculti
medicin
institut
biochemistri
ljubljana
slovenia
object
recent
systemat
review
osteosarcoma
conclud
two
murin
doubl
minut
polymorph
impact
diseas
risk
howev
author
detect
sever
weak
studi
inaccuraci
analys
perform
therefor
aim
present
studi
analyz
whether
polymorph
increas
risk
osteosarcoma
method
first
studi
effect
two
differ
osteosarcoma
popul
spain
n
slovenia
n
correspond
control
n
n
respect
second
perform
studi
perform
far
includ
two
previou
popul
result
result
two
popul
analyz
allow
conclud
two
polymorphim
analyz
statist
increas
risk
osteosarcoma
contrast
previou
data
discuss
result
compar
previou
also
shown
conclus
increas
risk
osteosarcoma
project
support
retic
upvehu
ufi
basqu
govern
non
code
rna
new
marker
suscept
osteosarcoma
n
e
v
dolzan
genet
physic
anthropolog
anim
physiolog
univers
basqu
countri
leioa
spain
laboratori
pediatr
univers
clinic
navarra
pamplona
spain
faculti
medicin
institut
biochemistri
ljubljana
slovenia
object
osteosarcoma
common
primari
malign
bone
cancer
children
young
adult
suscept
osteosarcoma
due
complex
multipl
genet
factor
non
code
rna
ncrna
specif
long
non
code
rna
lncrna
microrna
mirna
shown
deregul
divers
kind
cancer
includ
osteosarcoma
show
import
diseas
alter
ncrna
express
level
function
attribut
genet
polymorph
fact
recent
studi
found
associ
polymorph
osteosarcoma
risk
aim
studi
evalu
role
snp
suscept
osteosarcoma
method
analyz
blood
sampl
osteosarcoma
patient
two
differ
popul
spain
n
slovenia
n
correspond
control
n
n
respect
total
snp
mirna
snp
lncrna
genotyp
use
veracod
goldeng
genotyp
assay
illumina
result
previou
result
group
show
snp
process
gene
mirna
associ
risk
osteosarcoma
therefor
decid
extend
studi
analyz
two
differ
popul
increas
number
sampl
polymorph
preliminari
result
show
polymorph
ncrna
associ
osteosarcoma
result
confirm
conclus
result
suggest
snp
non
code
rna
may
affect
osteosarcoma
suscept
project
support
retic
upvehu
ufi
basqu
govern
radiofrequ
ablat
epiphys
chondroblastoma
children
emerg
new
modal
treatment
gulia
puri
kulkarni
orthoped
oncolog
surgic
oncolog
tata
memori
hospit
mumbai
india
depart
radiolog
tata
memori
hospit
mumbai
india
object
chondroblastoma
treat
curettag
bone
graft
risk
injuri
articular
surfac
growth
plate
minim
invas
techniqu
like
percutan
radiofrequ
ablat
rfa
attempt
altern
surgic
intervent
present
studi
done
demonstr
safeti
efficaci
rfa
novel
altern
surgeri
chondroblastoma
also
evalu
function
oncolog
outcom
method
januari
januari
treat
case
chondroblastoma
rfa
male
mean
age
year
rang
year
case
primari
involv
proxim
femur
case
proxim
tibia
proxim
humeru
distal
femur
case
procedur
done
comput
tomographi
guidanc
lesion
biopsi
confirm
frozen
treat
rfa
set
clinic
symptom
rang
movement
radiograph
mst
score
assess
hour
week
everi
month
procedur
result
signific
relief
symptom
note
immedi
post
procedur
day
patient
singl
session
rfa
patient
requir
repeat
procedur
surgic
curettag
patient
complet
relief
symptom
need
medic
assist
first
follow
week
patient
avail
final
evalu
median
follow
month
rang
month
recurr
treatment
relat
complic
patient
return
pre
diseas
activ
level
averag
mst
score
last
conclus
percutan
rfa
safe
effect
less
morbid
minim
invas
altern
surgeri
manag
epiphys
chondroblastoma
extrem
oncolog
outcom
pediatr
extrem
skelet
chondrosarcoma
tertiari
sarcoma
treatment
centr
gulia
puri
v
ramanujan
orthoped
oncolog
surgic
oncolog
tata
memori
hospit
mumbai
india
object
chondrosarcoma
third
common
primari
bone
tumour
late
recurr
lead
surviv
rate
uncommon
children
present
studi
done
analys
outcom
chondrosarcoma
pediatr
popul
method
case
musculoskelet
chondrosarcoma
treat
ten
patient
year
includ
studi
patient
underw
pre
surgic
stage
site
diseas
humeru
pelvi
one
tibia
clavicl
scapula
femur
patient
primari
diseas
secondari
enchondromatosi
multipl
osteochondroma
mean
durat
follow
month
rang
month
month
result
case
wasmetastat
present
lung
two
patholog
fractur
nine
limb
salvag
amput
margin
free
microscop
posit
final
histopatholog
mesenchym
chondrosarcoma
de
differenti
chondrosarcoma
clear
cell
grade
ii
chondrosarcoma
grade
iii
chondrosarcoma
one
patient
patient
de
differenti
chondrosarcoma
receiv
adjuv
chemotherapi
patient
loss
follow
patient
aliv
diseas
free
three
patinet
develop
distant
metastasi
scum
diseas
conclus
chondrosarcoma
rare
pediatr
popul
account
chondrosarcoma
hospit
surgic
resect
wide
margin
treatment
choic
de
differenti
mesenchym
subtyp
associ
poorer
prognosi
non
oper
manag
aneurysm
bone
cyst
percutan
scleros
inject
children
earli
result
prospect
observ
studi
gulia
puri
v
ramanujan
orthoped
oncolog
surgic
oncolog
tata
memori
hospit
mumbai
india
object
evalu
result
treat
primari
aneurysm
bone
cyst
abc
intralesion
scleros
inject
method
februari
novemb
treat
primari
aneurysm
bone
cyst
serial
intralesion
scleros
inject
lesion
treat
ulna
scapula
median
follow
month
case
diagnost
biopsi
femal
male
age
rang
year
median
year
polidocanol
inject
percutan
lesion
imag
guidanc
outpati
procedur
heal
assess
serial
radiograph
symptomat
improv
observ
patient
opacif
lesion
increas
cortic
thicken
taken
evid
heal
inject
repeat
maximum
interv
week
lesion
show
evid
heal
result
lesion
show
evid
heal
one
lesion
periacetabular
area
show
evid
heal
inject
oper
curretag
bone
graft
anoth
proxim
humeru
leision
fail
heal
inject
subsequ
underw
surgeri
year
old
child
need
surgeri
subsequ
progress
varu
deform
develop
site
lesion
case
heal
singl
inject
inject
inject
inject
requir
inject
session
angioembolistaion
first
evid
radiolog
heal
seen
week
median
week
complic
conclus
though
longer
follow
mandat
rule
develop
recurr
earli
result
inexpens
non
invas
method
manag
aneurysm
bone
cyst
promis
mifamurtid
children
osteosarcoma
turkish
experi
r
kebudi
ilhan
kantar
fb
cakir
e
guler
n
olgun
celkan
pediatr
hematolog
oncolog
istanbul
univers
oncolog
institut
istanbul
turkey
pediatr
hematolog
oncolog
ankara
oncolog
train
research
hospit
ankara
turkey
pediatr
hematolog
oncolog
ege
univers
school
medicin
izmir
turkey
pediatr
hematolog
oncolog
bezmi
alem
vakif
univers
istanbul
turkey
pediatr
hematolog
oncolog
antalya
univers
medic
faculti
antalya
turkey
pediatr
hematolog
oncolog
dokuz
eylul
univers
medic
faculti
izmir
turkey
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
istanbul
turkey
object
mifamurtid
liposom
muramyl
tripeptid
activ
macrophag
provid
antitumor
effect
lung
mifamurtidechemotherapi
improv
surviv
nonmetastat
osteosarcoma
patient
phase
iii
studi
ema
approv
mifamurtid
nonmetastat
osteosarcoma
could
use
approv
ministri
health
patient
basi
turkey
multicentr
studi
aim
evalu
demograph
characterist
advers
effect
outcom
ad
mifamurtid
chemotherapi
children
osteosarcoma
turkey
method
septemb
nonmetastat
metastat
metastasectomi
osteosarcoma
patient
mifamurtid
ad
chemotherapi
surgeri
center
turkey
chemotherapi
regimen
use
epirubicinifosfamidecisplatin
istanbul
univers
oncolog
mayopilotii
euramo
ice
etc
mifamurtid
given
twice
weekli
week
follow
weekli
week
result
median
age
year
year
total
dose
mifamurtid
administ
major
side
effect
chill
fever
initi
frequent
median
time
month
nonmetastat
patient
year
ef
os
nonmetastat
patient
complet
mifamurtid
evid
diseas
ned
median
mo
mo
relaps
median
month
die
awd
continu
treatment
metastat
patient
die
month
nonmetastat
patient
center
iuoi
compar
histor
control
reciev
chemotherapi
median
fu
mo
relaps
present
wherea
histor
case
relaps
median
month
conclus
multicentr
studi
mifamurtid
could
administ
safe
major
side
effect
experi
mifamurtid
patient
nonmetastat
osteosarcoma
promis
longer
follow
need
make
conclus
surviv
benefit
polylactid
bioabsorb
strut
chest
wall
reconstruct
pediatr
patient
makarawo
ra
reynold
ml
cullen
gener
surgeri
provid
hospit
southfield
usa
orthoped
surgeri
st
john
hospit
medic
center
gross
point
usa
pediatr
surgeri
st
john
hospit
medic
center
gross
point
usa
object
chest
wall
reconstruct
follow
pediatr
tumor
resect
challeng
children
uniqu
characterist
relat
growth
prosthet
materi
reconstruct
must
chosen
care
pla
bioabsorb
prosthet
materi
use
plate
form
reconstruct
follow
tumor
resect
children
recent
develop
pla
strut
success
use
reconstruct
pediatr
chest
wall
deform
first
descript
use
pla
rib
strut
reconstruct
chest
wall
defect
pediatr
chest
wall
tumor
resect
method
present
case
femal
present
back
pain
due
x
cm
chest
wall
mass
confirm
ewe
sarcoma
eighth
rib
patient
elect
surgic
resect
tumor
via
right
posterior
thoracotomi
chest
wall
resect
rib
perform
reconstruct
perform
use
pla
rib
replac
strut
resect
rib
replac
strut
sutur
transvers
process
spine
posteriorli
boni
compon
nativ
rib
anteriorli
two
addit
strut
place
vertic
axillari
line
five
strut
use
vertic
horizont
connect
vertic
strut
join
normal
rib
defect
allow
synchron
vertic
rib
movement
chest
tube
place
tenth
intercost
space
result
patient
made
unev
recoveri
discharg
home
drain
remov
seventh
day
patient
month
stabl
chest
wall
symmetr
appear
conclus
rib
strut
stabl
physiolog
advantag
method
reconstruct
chest
wall
malign
tumor
resect
bioabsorb
particularli
advantag
grow
pediatr
chest
wall
osteosarcoma
skull
case
report
review
literatur
maza
medina
l
vasquez
ponc
oscanoa
gutierrez
g
mejia
sanchez
avila
j
geronimo
meza
pediatr
oncolog
unit
edgardo
rebagliati
martin
hospit
lima
peru
patholog
edgardo
rebagliati
martin
hospit
lima
peru
object
osteosarcoma
skull
rare
primari
tumor
repres
tumor
skull
due
rariti
tumor
present
case
primari
osteosarcoma
skull
review
case
report
literatur
date
method
describ
young
primari
osteosarcoma
skull
clinic
present
histolog
featur
clinic
outcom
examin
pubmedmedlin
search
perform
collect
case
primari
osteosarcoma
skull
result
year
oldpati
present
histori
month
historyof
painless
headach
nausea
skull
radiographi
evidenc
larg
lesion
sun
radiat
pattern
initi
mri
show
mass
x
cm
periost
reaction
infiltr
adjac
brain
parenchyma
patholog
evid
osteogen
sarcoma
distant
lesion
evid
start
neoadjuv
chemotherapi
ct
ifosfamid
vincristin
adriamycin
methotrex
week
show
poor
tumor
respons
perform
left
craniectomi
en
bloc
resect
bone
tumor
histopatholog
confirm
find
osteosarcoma
cerebr
parenchym
infiltr
commit
edg
present
favor
postop
cours
continu
chemotherapi
radiotherapi
patient
progress
diseas
die
month
diagnosi
least
pediatr
case
osteosarcoma
skull
describ
literatur
clinic
case
report
small
seri
due
rariti
diseas
larg
prospect
studi
entiti
conclus
skull
osteosarcoma
rare
tumor
hard
manag
wors
prognosi
surgeri
neg
margin
primari
lesion
import
prognost
chemotherapi
adjuv
neoadjuv
may
increas
surviv
report
case
pediatr
osteosarcoma
skull
make
character
entiti
possibl
therapeut
strategi
role
scan
evalu
bone
sarcoma
children
young
adult
n
mittal
p
kent
ibrahim
pediatr
hematolog
oncolog
univers
illinoi
rush
stroger
hospit
fellowship
program
chicago
us
ppediatr
hematolog
oncolog
rush
univers
medic
center
chicago
us
diagnost
radiolog
rush
univers
medic
center
chicago
us
object
positron
emiss
tomographi
pet
recommend
initi
bone
sarcoma
workup
cog
nccn
compar
convent
imag
scanctmri
pet
shown
superior
detect
soft
tissu
metastas
bone
skelet
metastas
insensit
small
lung
metastas
detect
occult
metastas
incorrect
identif
metastas
may
chang
treatment
decis
object
describ
institut
experi
pet
scan
evalu
primari
relaps
bone
sarcoma
children
young
adult
method
retrospect
evalu
petct
convent
imag
mri
ct
chest
bone
scan
find
patient
male
age
year
primari
relaps
bone
sarcoma
diagnos
past
year
center
lung
metastas
mm
size
exclud
nine
patient
osteosarcoma
metastat
ewe
sarcoma
metastat
total
pet
scan
lesion
met
inclus
criteria
result
sensitivityspecif
detect
bone
primari
overal
sensitivityspecif
detect
metastas
three
confirm
lung
metastas
metastasi
cm
bone
lesion
skull
pet
neg
figur
four
lesion
bone
infecti
pet
posit
positiveneg
predict
valu
ppvnpv
metastat
bone
tumor
sensitivityspecificityppvnpv
lung
metastas
bone
lesion
boni
lesion
figur
conclus
cohort
pet
use
adjunct
could
replac
convent
imag
diagnosi
stage
bone
sarcoma
case
pet
alon
would
miss
metastas
diseas
influenc
treatment
decis
studi
need
evalu
role
diagnosi
stage
bone
sarcoma
children
young
adult
oral
vp
relapsedrefractori
ewe
sarcoma
experi
fondazion
ircc
istituto
nazional
dei
tumori
milan
podda
r
luksch
polastri
n
puma
c
meazza
terenziani
ferrari
casanova
f
spreafico
l
gandola
v
biassoni
e
schiavello
massimino
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
radiotherapi
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
object
evalu
efficaci
low
dose
oral
vp
relapsedrefractori
ewe
sarcoma
secondarili
evalu
toxic
method
record
patient
treat
relapsedrefractori
ewe
sarcoma
receiv
oral
vp
depart
analyz
dose
consecut
day
everi
day
respons
evalu
whenev
possibl
cycl
accord
recist
criteria
result
receiv
least
cycl
suspend
treatment
cycl
due
rapidli
progress
diseas
diagnosi
median
age
metastat
patient
receiv
intens
program
includ
vp
iv
first
n
second
line
n
receiv
myeloabl
regimen
pbsc
rescu
allogen
transplant
oral
vp
prescrib
ii
iii
iv
line
patient
respect
total
number
cycl
administ
median
mean
rang
evalu
accord
recist
criteria
respons
pr
vgpr
stabil
record
mean
respons
durat
month
hematolog
toxic
evalu
cycl
record
cycl
hemoglobin
leukocyt
platelet
respect
respons
patient
decid
voluntarili
stop
therapi
due
gastriti
note
case
pneumonia
one
hzv
reactiv
record
secondari
leukemia
patient
receiv
cycl
conclus
low
dose
oral
vp
may
suitabl
palli
set
accept
toxic
conclus
efficaci
warrant
prospect
studi
risk
secondari
leukemia
line
report
literatur
pool
shrna
screen
identifi
tumour
cell
specif
therapeut
target
ewe
sarcoma
c
schaefer
c
schleithoff
b
lechtap
h
u
dirksen
j
potratz
paediatr
haematologyoncolog
univers
children
hospit
germani
gener
paediatr
univers
children
hospit
germani
object
improv
prognosi
reduc
treatment
toxic
patient
ewe
sarcoma
novel
therapeut
target
treatment
approach
need
ewe
sarcoma
fusion
protein
provid
uniqu
specif
target
principl
effect
target
remain
unsolv
challeng
identif
protein
synthet
lethal
express
may
alon
present
altern
approach
toward
specif
target
promot
understand
oncogen
transform
object
therefor
identifi
protein
method
shrna
technolog
provid
function
ie
approach
identif
protein
ie
potenti
molecular
target
recent
advanc
pool
screen
approach
combin
sequenc
facilit
screen
appli
technolog
ewe
sarcoma
cell
line
model
stabl
knockdown
endogen
control
offon
aim
identifi
novel
specif
target
synthet
lethal
express
result
stabl
shrna
transduct
cell
establish
optim
gipz
shrnamir
lentivir
system
thermoscientif
adjust
achiev
integr
shrna
per
cell
suffici
target
knockdown
shrna
integr
confirm
mrna
protein
level
use
laminac
shrna
sequenc
defin
test
pool
shrna
util
confirm
dna
recoveri
pcr
amplif
shrna
sequenc
develop
quantifi
shrna
recov
defin
pool
therebi
simul
valid
establish
pool
screen
protocol
principl
conclus
establish
pool
shrna
screen
protocol
ewe
sarcoma
cell
line
model
presenceabs
subsequ
shrna
screen
contribut
identif
novel
specif
target
understand
oncogen
function
cknowledg
transarnet
project
support
bmbf
cell
line
model
kindli
provid
lessnick
univers
utah
intramedullari
extens
periost
osteosarcoma
portend
aggress
biolog
puri
gulia
desai
chorg
orthopaed
oncolog
tata
memori
hospit
mumbai
india
object
evalu
intramedullari
extens
periost
osteosarcoma
indic
aggress
biolog
behaviour
term
poorer
overal
surviv
method
retrospect
analysi
case
periost
osteosarcoma
treat
januari
decemb
carri
male
femal
mean
age
present
year
rang
year
tibia
femur
common
site
seen
patient
sixteen
patient
receiv
chemotherapi
limb
spare
resect
one
amput
one
rotationplasti
result
surgic
margin
free
patient
histopatholog
intramedullari
involv
found
patient
patient
avail
follow
median
follow
month
rang
month
pulmonari
metastasi
subsequ
occur
case
intramedullari
involv
seen
case
fourteen
patient
current
aliv
continu
diseas
free
median
follow
survivor
month
month
diseas
free
surviv
year
overal
surviv
patient
without
marrow
involv
better
overal
surviv
year
compar
patient
marrow
involv
vs
p
conclus
intramedullari
involv
may
suggest
aggress
diseas
biolog
intermedi
grade
tumor
differ
studi
statist
signific
could
reflect
small
number
chemotherapi
induc
necrosi
prognost
marker
osteosarcoma
need
rais
bar
puri
gulia
crasto
orthopaed
oncolog
tata
memori
hospit
mumbai
india
object
studi
co
relat
chemotherapi
induc
percentag
necrosi
overal
surviv
os
method
consecut
patient
non
metastat
osteosarcoma
analys
patient
underw
appropri
surgic
resect
receiv
neoadjuv
chemotherapi
excis
specimen
analys
chemotherapi
induc
percentag
necrosi
patient
divid
base
percentag
necrosi
result
necrosi
avail
patient
necrosi
necrosi
necrosi
patient
avail
follow
current
patient
aliv
follow
rang
month
median
month
os
patient
year
differ
os
group
tradit
necrosi
use
necrosi
necrosi
respect
p
chang
necrosi
os
necrosi
necrosi
respect
p
conclus
data
suggest
tradit
cut
necrosi
may
true
represent
poor
good
respond
may
better
stratifi
patient
necrosi
prognosi
trial
evalu
post
surgeri
chemotherapi
chang
chemotherapi
induc
necrosi
prognost
marker
ewe
sarcoma
need
rais
bar
puri
gulia
bhanupriya
n
khanna
laskar
g
chinna
swami
vora
orthopaed
oncolog
tata
memori
hospit
mumbai
india
object
studi
co
relat
chemotherapi
induc
percentag
necrosi
overal
surviv
os
method
consecut
patient
non
metastat
ewe
sarcoma
analys
patient
underw
appropri
surgic
resect
receiv
neoadjuv
chemotherapi
excis
specimen
analys
chemotherapi
induc
percentag
necrosi
patient
divid
base
percentag
necrosi
patient
receiv
adjuv
radiotherapi
result
necrosi
avail
patient
necrosi
necrosi
necrosi
patient
avail
follow
current
patient
aliv
follow
rang
month
median
month
os
patient
year
differ
os
group
necrosi
necrosi
respect
p
compar
necrosi
necrosi
group
os
necrosi
necrosi
respect
p
conclus
data
suggest
tradit
cut
necrosi
may
true
represent
poor
good
respond
necrosi
group
behav
similar
necrosi
group
may
better
stratifi
patient
necrosi
prognosi
evalu
decis
relat
treatment
outcom
childhood
ewe
sarcoma
famili
tumour
treat
two
consecut
protocol
year
experi
univers
malaya
medic
centr
kuala
lumpur
r
rajagop
yap
lum
azura
vivek
krishnan
wan
ariffin
h
ariffin
paediatr
univers
malaya
medic
centr
kuala
lumpur
malaysia
orthopaed
univers
malaya
medic
centr
kuala
lumpur
malaysia
object
review
demograph
data
clinic
featur
treatment
outcom
patient
ewe
sarcoma
famili
tumour
esft
till
univers
malaya
medic
centr
ummc
method
retrospect
analysi
medic
record
patient
diagnos
esft
age
less
year
treat
two
consecut
chemotherapeut
regimen
mkscc
protocol
subsequ
protocol
onward
use
unit
result
patient
f
seen
year
studi
period
ten
present
metastat
diseas
lung
bone
bone
marrow
combin
site
primari
tumour
appendicular
skeleton
axial
skeleton
rib
skull
patient
gross
total
resect
gtr
median
time
month
initi
therapi
median
time
year
combin
overal
surviv
rate
treatment
arm
local
diseas
metastat
diseas
relaps
occur
median
time
month
rang
month
mainli
long
bone
one
refractori
diseas
relaps
rate
patient
esft
metastat
diseas
local
diseas
relaps
patient
die
within
month
mean
month
despit
variou
salvag
therapi
induct
toxic
death
protocol
common
side
effect
observ
septic
shock
tubulopathi
patient
default
henc
diseas
statu
uncertain
conclus
cohort
overal
surviv
rate
consecut
patient
treat
two
protocol
relaps
seen
local
metastat
patient
occur
within
one
year
relaps
ewe
sarcoma
associ
dismal
prognosi
despit
variou
salvag
therapi
evalu
overal
surviv
os
surviv
ef
paediatr
sarcoma
patient
west
scotland
experi
rongh
murphi
j
sastri
p
donnelli
macdonald
f
cowi
r
jone
r
duncan
paediatr
oncolog
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
clinic
oncolog
beatson
west
scotland
cancer
centr
glasgow
unit
kingdom
orthoped
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
object
evalu
os
ef
paediatr
sarcoma
patient
interest
compar
metastat
case
case
compil
statist
treatment
method
method
retrospect
observ
studi
sarcoma
patient
identifi
unit
databas
contain
inform
diagnosi
treatment
prognost
indic
outcom
patient
result
osteosarcoma
male
age
rang
median
os
ef
primari
site
diseas
femur
tibia
humeru
scapula
metastat
rate
os
ewe
sarcoma
male
age
rang
median
os
ef
primari
site
diseas
pelvi
femur
paraspin
chest
wall
tibia
metastat
rate
os
ef
alveolar
patient
os
ef
metastat
rate
os
ef
embryon
rhabdomyosarcoma
patient
os
ef
metastat
rate
conclus
result
reflect
access
experienc
innov
paediatr
sarcoma
servic
close
link
nation
sarcoma
multidisciplinari
team
data
fall
line
studi
term
age
onset
locat
primari
tumour
metastat
rate
site
metastas
prognosi
cancer
type
limb
salvag
surgeri
greatli
favour
amput
osteosarcoma
ewe
sarcoma
femal
favour
prognosi
osteosarcoma
slightli
poorer
prognosi
ewe
sarcoma
overal
surviv
rate
current
better
statist
three
four
tumour
examin
prognost
impact
express
profil
hypoxia
relat
gene
vegf
osteosarcoma
ewe
sarcoma
ca
scride
ee
engel
rgp
l
neder
vk
suazo
bo
mori
lg
tone
ca
scride
pediatr
preto
school
medicin
univers
paulo
preto
brazil
orthoped
preto
school
medicin
univers
paulo
preto
brazil
patholog
preto
school
medicin
univers
paulo
preto
brazil
object
osteosarcoma
os
ewe
sarcoma
es
common
primari
malign
bone
tumor
children
adolesc
hypoxia
relat
gene
shown
import
prognost
marker
associ
chemoresist
differ
human
cancer
studi
conduct
primari
bone
cancer
aim
studi
analyz
express
profil
hypoxia
relat
gene
tumor
method
analyz
gene
express
profil
hypoxia
relat
gene
vegf
consecut
microdissect
sampl
osteosarcoma
n
ewe
sarcoma
n
diagnosi
use
taqman
probe
ct
method
test
use
assess
correl
gene
express
clinicalbiolog
variabl
surviv
analyz
plot
test
result
patient
osteosarcoma
present
higher
level
p
compar
ewe
sarcoma
osteosarcoma
found
signific
associ
lower
degre
tumor
necrosi
post
neoadjuv
chemotherapi
huvo
score
iii
higher
express
level
vegf
p
p
patient
ewe
sarcoma
gene
express
level
higher
median
signific
higher
year
event
free
surviv
versu
p
conclus
data
suggest
prognost
impact
hypoxia
relat
gene
pediatr
osteosarcoma
e
ewe
sarcoma
function
studi
analysi
great
number
case
necessari
confirm
find
osteosarcoma
children
year
age
experi
singl
institut
j
palacio
j
shalkow
leon
hernandez
surgic
oncolog
nation
institut
pediatr
mexico
citi
mexico
feder
director
pediatr
cancer
program
nation
center
pediatr
adolesc
health
mexico
citi
mexico
object
osteosarcoma
common
malign
bone
tumor
children
adolesc
prognosi
children
year
age
dismal
describ
herein
treatment
outcom
patient
year
age
osteosarcoma
method
review
case
children
year
age
treat
osteosarcoma
nation
institut
pediatr
mexico
citi
result
patient
median
age
year
common
primari
site
femur
follow
humeru
tibia
fibula
cranium
axial
skeleton
common
histolog
type
osteoblast
patient
receiv
neoadjuv
chemotherapi
accord
nation
protocol
time
diagnosi
surgeri
primari
tumor
includ
wide
local
excis
patient
amput
five
patient
accept
radic
surgeri
propos
despit
multimod
therapi
success
complet
surgic
resect
patient
remain
aliv
children
die
conclus
patient
year
age
diagnosi
osteosarcoma
carri
dismal
prognosi
seem
higher
rate
tumor
newer
treatment
strategi
possibl
includ
tailor
treatment
need
group
patient
prognost
factor
childhood
osteosarcoma
singl
institut
experi
peru
l
vasquez
j
geronimo
maza
oscanoa
f
tarrillo
jm
silva
l
sialer
quinonez
pediatr
oncolog
rebagliati
hospit
lima
peru
traumatolog
rebagliati
hospit
lima
peru
patholog
rebagliati
hospit
lima
peru
object
determin
prognost
factor
influenc
surviv
pediatr
patient
osteosarcoma
extrem
method
retrospect
analysi
patient
osteosarcoma
extrem
treat
rebagliati
hospit
januari
decemb
perform
patient
sex
age
primari
tumor
site
serum
alkalin
phosphatas
lactat
dehydrogenas
level
distant
metastasi
onset
presenc
patholog
fractur
histolog
respons
type
surgeri
analyz
overal
surviv
os
surviv
ef
determin
method
result
patient
high
grade
osteosarcoma
extrem
identifi
median
age
year
rang
year
common
site
primari
tumor
distal
femur
patient
metastat
diseas
onset
local
group
patient
conserv
surgeri
type
surgeri
conserv
vs
radic
patient
affect
surviv
p
patient
receiv
neoadjuv
adjuv
chemotherapi
rais
serum
alkalin
phosphatas
p
poor
histolog
respons
chemotherapi
necrosi
less
p
show
signific
correl
wors
prognosi
age
histolog
subtyp
patholog
fractur
site
primari
tumor
affect
surviv
estim
os
ef
patient
local
group
respect
estim
os
ef
patient
metastat
group
respect
median
month
conclus
rais
serum
alkalin
phosphatas
poor
histolog
respons
chemotherapi
associ
wors
prognosi
patient
high
grade
osteosarcoma
need
improv
stratif
intensifi
treatment
especi
patient
metastat
diseas
clinic
outcom
toxic
surviv
patient
ewe
sarcoma
treat
nation
protocol
nation
institut
pediatr
mexico
l
r
r
l
l
oncolog
instituto
nacion
de
mexico
citi
mexico
object
analyz
surviv
patient
ewe
sarcoma
es
treat
nation
treatment
protocol
singl
institut
method
includ
consecut
patient
es
januari
januari
tumor
consist
evalu
primari
site
mri
high
resolut
ct
lung
bone
marrow
biopsi
petct
patient
receiv
treatment
vincristin
day
doxorubicin
convent
day
pegyl
day
cyclophosphamid
day
altern
ifosfamid
day
etoposid
day
number
cours
establish
accord
presenc
metastas
complet
resect
tumor
result
studi
patient
median
age
year
male
mean
time
onset
symptom
start
treatment
month
present
axial
metastat
diseas
patient
treat
convent
doxorubicin
pegyl
doxorubicin
cycl
chemotherapi
administ
present
toxic
overal
surviv
patient
local
patient
metastat
diseas
p
surviv
patient
axial
diseas
locat
p
patient
die
due
toxic
due
progress
tumor
patient
metastat
diseas
underw
autolog
hematopoyet
stem
cell
transplant
surviv
conclus
nation
treatment
protocol
well
toler
patient
es
similar
surviv
report
intern
despit
surviv
patient
metastat
diseas
low
need
explor
andor
expand
therapeut
option
includ
stem
cell
transplant
consolid
altern
proceed
chemotherapi
new
agent
andor
combin
therapi
includ
radiotherapi
osteosarcoma
mandibl
mo
multidisciplinari
manag
cooper
studi
rare
cancer
network
gettecrefcor
sfce
focus
patient
c
verit
j
thariat
brouchet
h
reychler
auvrignon
frappaz
p
p
lutz
h
pacquement
l
pediatr
medic
oncolog
children
hospit
bordeaux
franc
radiat
oncolog
cancer
center
nice
franc
patholog
center
hospitali
universitair
toulous
franc
medic
oncolog
center
hospitali
universitair
louvain
franc
pediatr
medic
oncolog
center
hospitali
universitair
pari
franc
pediatr
medic
oncolog
cancer
center
lyon
franc
pediatr
medic
oncolog
center
hospitali
universitair
strasbourg
franc
pediatr
medic
oncolog
cencer
center
curi
pari
franc
pediatr
medic
oncolog
cancer
center
igr
pari
franc
object
mo
except
children
adolesc
method
retrospect
studi
conduct
case
mo
diagnos
franc
aim
determin
impact
chemotherapi
radiat
therapi
surgeri
outcom
identifi
prognost
factor
report
focuss
patient
year
old
result
patient
less
year
old
median
age
rang
male
patient
mo
second
even
third
primari
malign
previou
histori
head
neck
cancer
treat
radiotherapi
li
fraumeni
syndrom
tnm
stage
patholog
grade
high
one
low
neoadjuv
chemotherapi
includ
methotrex
ifosfamideetoposid
doxorubucin
cisplatin
carri
one
patient
progress
first
line
therapi
surgeri
die
surgeri
carri
pt
resect
histolog
respons
poor
viabl
tumor
cell
resect
specimen
patient
good
known
case
post
chemotherapi
perform
patient
andpost
op
radiotherapi
last
follow
aliv
yr
patient
experienc
death
primari
progress
one
aliv
diseas
relaps
local
metastatiqu
aliv
metachron
osteosarcoma
pt
li
fraumeni
syndrom
entir
cohort
wide
surgeri
clear
margin
strongest
prognost
factor
neoadjuv
chemotherapi
improv
surviv
conclus
mo
remain
rare
highli
malign
tumor
demand
aggress
therapi
surgeri
mainstay
treatment
margin
import
factor
local
control
surviv
medulloblastoma
age
year
treatment
prognost
factor
ahm
e
eldebawi
n
elkhateeb
awaad
zaghloul
radiotherapi
children
cancer
hospit
egypt
cche
giza
egypt
radiotherapi
children
cancer
hospit
egypt
cche
nation
cancer
institut
cairo
univers
egypt
cairo
egypt
statist
children
cancer
hospit
egypt
cche
cairo
egypt
medic
oncolog
children
cancer
hospit
egypt
cche
cairo
egypt
object
investig
treatment
medulloblastoma
year
old
determin
factor
affect
prognosi
method
twenti
five
children
age
year
treat
children
cancer
hospitalegypt
period
juli
oct
gross
total
resect
perform
children
subtot
excis
biopsi
one
patient
seventeen
children
metastat
eight
children
receiv
infantil
medulloblastoma
chemotherapi
protocol
receiv
chemotherapi
protocol
metastat
children
receiv
craniospin
irradi
csi
nine
patient
receiv
posterior
fossa
pf
irradi
receiv
csi
age
year
result
year
os
children
ef
nonmetastat
respect
infantil
chemotherapi
protocol
patient
led
os
compar
protocol
os
csi
compar
conform
pf
irradi
os
gtr
less
gtr
respect
two
patient
csi
group
develop
cn
relaps
two
patient
spinal
relaps
relaps
patient
receiv
pf
irradi
non
detect
differ
statist
signific
children
toler
treatment
minim
immedi
toxic
late
effect
aggress
treatment
conclus
non
metastat
statu
medulloblastoma
age
year
carri
better
oa
ef
metastat
categori
irrespect
treatment
protocol
histon
deacetylas
inhibitor
show
inhibit
cell
prolifer
clonogen
surviv
pediatr
glioblastoma
cell
pv
andrad
af
andrad
rg
de
paula
queiroz
ca
scride
lg
tone
et
valera
depart
pediatr
ribeirao
preto
medic
school
usp
preto
paulo
brazil
depart
genet
ribeirao
preto
medic
school
usp
preto
paulo
brazil
object
studi
aim
evalu
therapeut
potenti
hdaci
pediatr
gbm
line
prolifer
clonogen
surviv
assay
method
prolifer
assay
resazurin
dye
perform
plate
use
cell
per
well
cell
treat
differ
drug
concentr
clonogen
surviv
assay
cell
seed
plate
cell
per
dish
cell
treat
increas
drug
concentr
cultur
medium
replac
cell
cultur
addit
day
individu
coloni
cell
per
coloni
fix
methanol
stain
crystal
violet
subsequ
count
statist
analysi
made
anova
bonferoni
result
cell
line
sensit
toward
treatment
display
inhibit
prolifer
treatment
p
cell
line
strongest
effect
observ
dose
growth
inhibit
approxim
cell
line
show
time
depend
inhibit
prolifer
treatment
strongest
effect
observ
growth
inhibit
approxim
clonogen
assay
coloni
format
treatment
show
great
sensibl
gbm
cell
treatment
conclus
primari
data
demonstr
induc
inhibit
cell
prolifer
clonogen
surviv
gbm
cell
addit
show
potenti
hdaci
treatment
pediatr
gbm
experi
perform
assess
abil
hdaci
modul
cellular
respons
ioniz
radiat
financi
support
fapesp
process
clival
chordoma
childhood
kutluk
b
aydin
b
bilgin
n
akalan
f
soylemezoglu
f
zorlu
b
yalcin
varan
c
akyuz
pediatr
oncolog
hacettep
institut
oncolog
ankara
turkey
neurosurgeri
hacettep
faculti
medicin
ankara
turkey
patholog
hacettep
faculti
medicin
ankara
turkey
radiat
oncolog
hacettep
institut
oncolog
ankara
turkey
object
clivu
chordoma
rare
local
aggress
neoplasm
bone
treat
primarili
surgeri
seri
consist
small
number
children
suggest
standard
treatment
algorithm
total
surgeri
seri
patient
review
characterist
cours
diseas
method
file
patient
clivu
chordoma
diagnos
retrospect
analyz
result
seven
patient
diagnos
diagnosi
chordoma
clival
local
median
age
femal
male
year
symptom
headach
patient
diplopia
patient
sleep
apnea
dysphagia
hemiparesi
motor
dysfunct
arm
ataxia
one
patient
median
month
patient
follow
median
month
month
first
medic
intervent
surgeri
three
five
patient
subtot
resect
local
recur
need
three
patient
recurr
tumor
receiv
radiotherapi
two
receiv
chemotherapi
also
one
receiv
vac
regimen
ifosfamid
etoposid
imatinib
resect
third
patient
refus
chemotherapi
still
aliv
progress
brain
metastas
first
patient
given
vac
regimen
die
progress
diseas
first
cours
conclus
clivu
chordoma
problemat
total
resect
achiev
addit
radiotherapi
help
improv
overal
surviv
chemotherapi
ifosfamid
etoposid
might
benefit
recurr
tumor
research
need
defin
role
chemotherapi
target
therapi
stabil
regress
chordoma
pediatr
tectal
plate
glioma
h
susam
sen
b
yalcin
b
bilgin
k
karli
oguz
b
aydin
varan
kutluk
n
akalan
c
akyuz
pediatr
oncolog
hacettep
univers
faculti
medicin
ankara
turkey
neurosurgeri
hacettep
univers
faculti
medicin
ankara
turkey
radiolog
hacettep
univers
faculti
medicin
ankara
turkey
object
tectal
glioma
distinct
form
brain
stem
tumor
gener
astrocytoma
unusu
benign
behavior
treatment
includ
observ
lesion
shunt
divers
cerebrospin
fluid
csf
reliev
associ
hydrocephalu
aim
investig
clinic
characterist
manag
approach
patient
tectal
plate
glioma
method
file
children
treat
hospit
diagnos
tectal
plate
glioma
review
retrospect
clinic
characterist
treatment
result
result
identifi
femal
male
tectal
plate
glioma
whose
age
rang
year
median
common
present
symptom
headach
vertigo
tremor
hand
gaze
palsi
one
patient
find
neurofibromatosi
type
median
durat
delay
onset
symptom
definit
diagnosi
month
month
magnet
reson
imag
mri
size
primari
tumor
rang
cm
contrast
enhanc
case
median
month
month
four
patient
underw
procedur
form
ventriculoperiton
shunt
endoscop
third
ventriculostomi
one
patient
underw
tumor
resect
due
progress
diseas
month
one
patient
observ
intervent
three
patient
need
least
one
procedur
median
month
conclus
sinc
lesion
capabl
growth
either
without
new
neurolog
symptom
close
monitor
essenti
interven
prior
develop
irrevers
debilit
neurolog
sequela
tumor
size
cm
contrast
enhanc
mri
scan
might
relat
tumor
progress
children
find
hydrocephalu
undergo
mri
tectal
plate
glioma
consid
differenti
diagnosi
util
idh
express
childhood
adolesc
age
group
glioma
across
northern
india
babu
singhai
l
gupta
n
husain
chandra
sagar
patholog
king
georg
medic
univers
lucknow
india
patholog
rml
institut
medic
scienc
lucknow
india
neuro
surgeri
king
georg
medic
univers
lucknow
india
object
paediatr
glioma
heterogen
group
glioma
encompass
tumor
differ
histolog
clinic
util
idh
express
well
establish
adulthood
glioma
howev
paediatr
data
quit
scanti
consid
idh
express
util
tool
manag
paediatr
glioma
present
studi
attempt
reflect
answer
concern
method
total
case
year
paediatr
glioma
differ
histolog
enrol
period
year
parallel
arm
case
constitut
adulthood
glioma
age
patient
rang
year
mean
year
case
pilocyt
astrocytoma
ependymoma
mix
glioma
oligodendroglioma
common
site
involv
follow
posterior
fossa
increas
intracrani
tension
accompani
vari
degre
motor
paralysi
common
clinic
featur
durat
rang
month
case
look
express
per
protocol
result
case
express
present
case
oligoastrocytoma
case
diffus
astrocytoma
oligodendroglioma
show
grade
ii
grade
iii
regard
age
distribut
posit
case
year
parallel
arm
involv
adult
posit
case
seen
earli
mid
adulthood
year
comparison
statist
signific
accompani
paramet
viz
site
symptom
durat
express
concord
group
conclus
conclud
emphas
util
idh
express
earli
childhood
glioma
limit
howev
earli
adolesc
age
group
beyond
shown
concord
result
consid
diagnost
tool
glioma
present
older
pediatr
popul
combin
multipl
chemotherapi
posterior
fossa
radiotherapi
infant
nonmetastat
medulloblastoma
l
baroni
f
lubieniecki
f
fiandrino
martinez
alderet
oncolog
hospit
garrahan
bueno
air
argentina
patholog
hospit
garrahan
bueno
air
argentina
radiotherapi
hospit
garrahan
bueno
air
argentina
radiotherapi
vidt
centro
medico
bueno
air
argentina
object
new
radiotherapi
modal
radiat
therapi
crt
imrt
allow
includ
radiotherapi
treatment
patient
younger
medulloblastoma
aim
evalu
result
protocol
chemotherapi
infant
nonmetastat
medulloblastoma
method
octob
decemb
infant
patient
medulloblastoma
treat
institut
metastat
nonmetastat
patient
evalu
studi
median
age
diagnosi
month
initi
surgeri
children
receiv
cycl
induct
chemotherapi
includ
vincritin
cisplatin
cyclophosphamid
etoposid
follow
mainten
chemotherapi
carboplatin
vincristin
cyclophosphamid
etoposid
oral
patient
whith
gross
residu
tumor
receiv
hd
metrotex
induct
posterior
fossa
bed
tumor
imrt
withwithout
temozolamid
indic
induct
achiv
month
old
result
histolog
subtyp
classic
meduloblastoma
desmoplasticnodular
extens
nodular
four
patient
gross
residu
tumor
thirteen
patient
receiv
median
time
resect
radiotherapi
median
age
two
pt
receiv
crt
die
induct
extens
nodular
median
follow
year
surviv
overal
surviv
probabl
respect
four
pt
relaps
supratentori
metastasi
intraventicular
relaps
leptomening
dissemin
spinal
space
median
time
diagnosi
relaps
conclus
result
obtain
particular
group
patient
encourag
consid
similar
result
group
patient
old
use
craneoespin
radiotherapi
respons
intraventricular
topotecan
itv
oral
temozolamid
etoposid
children
relaps
medulloblastoma
experi
alderet
l
baroni
f
lubieniecki
f
fiandrino
f
auad
ml
gonzalez
w
cardena
p
pacheco
oncolog
hospit
garrahan
bueno
air
argentina
patholog
hospit
garrahan
bueno
air
argentina
radiotherapi
hospit
garrahan
bueno
air
argentina
neurosurgeri
hospit
garrahan
bueno
air
argentina
object
patient
relaps
medulloblastoma
unlik
cure
new
effect
treatment
strategi
need
method
retrospect
review
case
relaps
medulloblastoma
jun
oct
treat
palli
care
criteria
ivt
temozolamid
oral
etoposid
oral
ommaya
reservoir
implant
ivt
administr
twice
week
weekli
other
twice
month
sinc
surgeri
perform
one
site
affect
improv
patient
symptom
respons
assess
mri
everi
initi
diagnosi
median
age
six
high
risk
receiv
craniospin
radiotherapi
respect
respect
posterior
fossa
follow
adjuv
chemotherapi
use
cisplatin
vincristin
lomustin
andor
ciclophosphamid
adapt
cog
strategi
one
younger
treat
babi
protocol
includ
posterior
fossa
radiotherapi
relaps
median
age
median
time
diagnosi
relaps
five
isol
intraventricular
relaps
leptomening
dissemin
supratentori
mening
metastasi
result
four
underw
surgic
resect
gross
resect
subtot
resect
evalu
tumor
seen
respons
chemotherapi
seen
case
complet
remiss
partial
respons
stabl
diseas
median
follow
eight
remain
aliv
without
progress
two
show
mri
progress
one
relaps
die
respect
treatment
grade
thrombocytopenia
observ
lead
decreas
temozolamid
conclus
combin
itv
oral
temozolamid
etoposid
produc
object
respons
minim
toxic
children
relaps
medulloblastoma
strategi
allow
pt
live
normal
possibl
residu
life
treatment
strategi
children
supratentori
glioma
z
bekic
g
tasic
j
bokun
tufegdz
skender
pediatr
oncolog
dept
institut
oncolog
radiolog
serbia
belgrad
serbia
brain
tumour
dept
clinic
neurosurgeri
clinic
center
serbia
belgrad
serbia
pediatr
oncolog
dept
institut
oncolog
radiolog
serbia
belgrad
serbia
brain
tumour
dept
institut
patolog
medic
faculti
belgrad
belgrad
serbia
object
aim
studi
evalu
result
treatment
analyz
prognost
factor
patient
supratentori
glioma
method
treat
pt
median
age
rang
year
gross
total
resect
perform
pt
subtot
pt
partial
pt
anaplast
astrocytoma
aa
found
pt
glioblastoma
multiform
gbm
pt
surgeri
patient
treat
local
radiotherapi
primari
site
rang
gy
chemotherapi
chemotherapi
regimen
vcr
ccnu
group
pt
regimen
group
pt
vcr
ccnu
cddp
group
pt
result
month
period
overal
surviv
signific
prognost
factor
patohistolog
type
aa
vs
gbm
extent
surgeri
signific
differ
chemotherapi
regimen
group
vs
group
vs
conclus
patohistolog
type
extent
tumor
resect
predictor
better
prognosi
among
chemotherapi
regimen
appli
differ
overal
surviv
proteom
chang
inhibit
transcript
factor
nordihydroguaiaret
acid
glioblastoma
cell
af
andrad
vk
suazo
hj
laur
c
izumi
jc
rosa
lg
tone
pediatr
univers
paulo
preto
brazil
genet
univers
paulo
preto
brazil
protein
chemistri
center
molecular
cell
biolog
univers
paulo
preto
brazil
object
nordihydroguaiaret
acid
global
transcript
repressor
gene
depend
transcript
factor
affect
apoptosi
drug
resist
prolifer
respons
gene
radiat
resist
recent
demonstr
antineoplast
effect
induc
apoptosi
act
synergist
deregul
gene
survivin
glioblastoma
gbm
cell
howev
global
impact
inhibit
transcriptom
proteom
cell
unknown
method
gbm
cell
line
treat
cell
prolifer
assay
use
test
protein
extract
obtain
western
blot
assay
label
isobar
tag
rel
absolut
quantit
itraq
technolog
line
strong
cation
exchang
chromatographi
scx
line
revers
phase
lc
coupl
use
identifi
peptid
determin
protein
differenti
express
statist
analysi
perform
use
scaffold
softwar
result
treatment
reduc
prolifer
deregul
protein
express
survivin
cell
line
investig
quantit
proteom
analysi
identifi
protein
least
peptid
identifi
protein
identif
probabl
cell
line
thirteen
six
protein
deregul
treatment
cell
respect
gene
ontolog
analysi
demonstr
deregul
protein
particip
import
cell
metabol
process
carbohydr
metabol
conclus
found
evid
inhibit
treatment
alter
significantli
express
protein
relat
metabol
process
gbm
cell
studi
investig
molecular
chang
gbm
cell
mainli
transcriptom
field
order
achiev
better
understand
inhibit
provid
new
insight
gbm
biolog
financi
support
fapesp
process
number
chemotherapi
irresect
low
grade
glioma
combin
servic
south
africa
davidson
figaji
k
pillay
kilborn
l
padayachi
hendrick
van
eyssen
j
park
paediatr
child
health
univers
cape
town
cape
town
south
africa
paediatr
neurosurgeri
univers
cape
town
cape
town
south
africa
paediatr
patholog
univers
cape
town
cape
town
south
africa
paediatr
radiolog
univers
cape
town
cape
town
south
africa
radiat
oncolog
univers
cape
town
cape
town
south
africa
object
assess
role
chemotherapi
manag
low
grade
glioma
combin
servic
univers
cape
town
method
retrospect
analysi
perform
folder
patient
diagnos
red
cross
children
hospit
groot
schuur
hospit
result
children
age
year
median
forti
six
tumour
grade
grade
ii
includ
fibrillari
astrocytoma
pilomyxoid
astrocytoma
one
pleomorph
xanthoastrocytoma
commonest
site
cerebellum
hypothalamu
cerebrum
optic
tract
fourteen
patient
manag
expectantli
includ
neurocutan
syndrom
thirti
two
patient
underw
surgeri
diagnosi
form
debulk
gross
total
resect
patient
requir
surgeri
recurr
progress
fifteen
patient
receiv
radiotherapi
first
line
treatment
thirteen
patient
irresect
diseas
median
age
treat
chemotherapi
vincristin
carboplatin
first
line
regimen
eleven
tumour
involv
optic
tract
hypothalamu
ten
juvenil
pilocyt
astrocytoma
pilomyxoid
astrocytoma
one
patient
progress
three
show
stabl
diseas
nine
respond
reduc
volum
median
estim
overal
surviv
os
whole
group
tumour
ii
tumour
estim
progress
free
surviv
pf
whole
group
patient
treat
chemotherapi
os
pf
conclus
chemotherapi
vital
part
multidisciplinari
manag
low
grade
glioma
low
middl
incom
set
glioblastoma
multiform
singl
institut
experi
belo
horizontebrazil
ap
dutra
jc
aguirr
neto
jl
sousa
filho
b
silva
costa
pediatr
oncolog
santa
casa
de
belo
horizont
belo
horizont
brazil
neurosurgeri
santa
casa
de
belo
horizont
belo
horizont
brazil
object
goal
studi
determin
epidemiolog
clinic
present
treatment
outcom
pediatr
glioblastoma
multiform
singl
center
institut
method
clinic
data
patient
year
age
brain
tumor
decemb
decemb
review
santa
casa
de
belo
horizontemina
result
six
patient
diagnosi
glioblastoma
multiform
femal
male
averag
age
year
analyz
rang
year
diagnosi
patient
supratentori
tumor
posterior
fossa
tumor
common
sign
symptom
associ
intracrani
hypertens
five
patient
headach
somnol
vomit
papilledema
three
patient
seizur
hemiparesi
one
patient
present
posterior
fossa
tumor
brainstem
paralysi
multipl
cranial
pair
intracrani
hypertens
ataxia
parcial
resect
perform
five
patient
one
brainstem
stereotat
biopsi
patient
treat
radiotherapi
associ
chemotherapi
one
patient
use
temozolamid
surviv
seven
month
median
overal
surviv
month
rang
month
children
die
due
diseas
progress
conclus
glioblastoma
occur
rare
pediatr
patient
glioblastoma
symptom
durat
month
prior
diagnosi
dismal
prognosi
glioblastoma
tendenc
recur
dissemin
despit
treatment
surgeri
chemotherapi
radiat
poor
outcom
seen
tumor
suggest
optim
treatment
strategi
yet
elucid
much
work
need
done
brain
tumor
experi
year
belo
horizontebrazil
dutra
jc
aguirr
neto
jl
sousa
filho
b
silva
costa
dellaretti
filho
pediatr
oncolog
santa
casa
de
belo
horizont
belo
horizont
brazil
neurosurgeri
santa
casa
de
belo
horizont
belo
horizont
brazil
object
goal
studi
determin
epidemiolog
clinic
present
associ
factor
patholog
fictur
treatment
outcom
pediatr
brain
tumor
singl
center
institut
method
clinic
data
patient
year
age
brain
tumor
decemb
decemb
review
santa
casa
de
belo
horizontemina
result
one
hundr
eight
children
femal
male
median
age
year
analyz
diagnosi
patient
intracrani
hypertens
seizur
patient
posterior
fossa
tumor
medulloblastoma
brain
stem
tumor
supratentori
tumor
present
children
low
grade
glioma
six
patient
glioblastoma
multiform
four
supratentori
none
aliv
total
resect
perform
patient
parcial
resect
stereotat
biopsi
patient
aliv
without
tumor
die
due
tumor
progress
infect
lost
segment
conclus
singl
center
institut
limit
resourc
patient
die
tumor
progress
infect
necessari
improv
support
care
develop
new
treatment
strategi
increas
overal
surviv
weekli
vinblastin
pediatr
low
grade
glioma
f
gachi
n
zehani
c
louni
k
ezzian
trabzi
k
bouzid
bakhti
mahiou
c
tayeb
pediatr
oncolog
pierr
mari
curi
center
algier
algeria
neurosurgeri
mustapha
bacha
hospit
algier
algeria
radiat
oncolog
pierr
mari
curi
center
algier
algeria
radiat
oncolog
militari
hospit
algier
algeria
object
assess
efficacyand
toxic
weekli
vinblastin
low
grade
glioma
children
method
conduct
prospectivestudi
involv
children
treat
incomplet
resect
unresect
lgg
vinblastin
administ
weekli
progress
diseas
unaccept
toxic
maximum
year
therapi
result
patient
median
age
year
sex
ratio
enrol
studi
respons
rate
median
follow
month
rang
month
overal
surviv
year
year
surviv
year
year
toxic
mostli
hematolog
manag
conclus
glioma
chronic
diseas
treatment
less
aggress
possibl
vinblastin
effect
therapeut
good
toler
eas
use
low
cost
would
interest
altern
contri
could
use
first
line
multidisciplinari
approach
visual
acuiti
treat
case
optic
pathway
glioma
astigarraga
echebarria
j
r
r
adan
r
mj
navaja
pediatr
oncohematolog
unit
depart
pediatr
hospit
universitario
cruce
barakaldo
spain
depart
ophtalmolog
hospit
universitario
cruce
barakaldo
spain
pediatr
neurolog
unit
depart
pediatr
hospit
universitario
cruce
barakaldo
spain
object
within
pediatr
brain
tumor
optic
pathway
glioma
opg
specif
group
requir
special
handl
review
experi
therapi
respons
visual
prognosi
opg
method
review
low
grade
glioma
lgg
involv
visual
pathway
last
year
analyz
epidemiolog
clinic
radiolog
histolog
data
diagnosi
focus
multidisciplinari
approach
therapi
visual
acuiti
diagnosi
evolut
result
among
lgg
patient
refer
pediatr
oncolog
unit
involv
optic
pathway
time
diagnosi
women
averag
age
year
year
case
presenc
neurofibromatosi
confirm
one
patient
isol
unilater
optic
nerv
involv
region
cn
extens
initi
biopsi
perform
patient
progress
mri
characterist
analyz
differ
specialist
involv
manag
pediatr
oncologist
neurologist
neuroradiologist
geneticist
radiotherapist
neurosurgeon
endocrinologist
ophthalmologist
otolaryngologist
nephrologist
case
treatment
administ
chemotherapi
radiotherapi
surgeri
mean
month
two
patient
die
due
tumor
progress
one
oligodendroglioma
spinal
dissemin
visual
acuiti
follow
highli
impair
slightli
impair
stabl
rest
one
improv
chemotherapi
conclus
despit
advanc
brain
tumor
manag
optic
pathway
glioma
remain
challeng
although
vital
prognosi
favor
nowaday
still
lack
consensu
regard
therapi
poor
visual
outcom
occur
mani
case
close
import
precis
visual
assess
manag
multidisciplinari
team
remain
essenti
optim
care
patient
glioblastoma
multiform
rehabilit
case
dg
gasperini
bm
e
boldrini
nlg
suarez
ms
murra
bonatelli
mga
constantino
mlpc
ceb
cavalcant
lf
lope
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
nutrit
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
physiotherapi
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
speech
therapi
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
occup
therapi
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
radiolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
phd
medic
diretor
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
object
glioblastoma
multiform
grade
iv
astrocytoma
repres
intracrani
tumor
childhood
method
patient
year
old
femal
admit
headach
vomit
paralysi
right
arm
day
ago
develop
right
facial
paralysi
mild
dysphagia
foi
function
oral
intak
scale
function
classif
base
kp
karnofski
perform
statu
scale
independ
activ
daili
live
katz
score
mri
brain
lesion
central
necrosi
perilesion
hematoma
measur
cm
left
frontal
region
compress
pre
central
gyru
divert
midlin
right
made
frontal
pariet
craniotomi
subtot
resect
patient
develop
cerebr
edema
done
dural
repair
cranial
bone
place
subcutan
tissu
abdomen
result
intens
care
unit
glasgow
without
sedat
kp
rehabilit
care
nutrit
enter
nutrit
pasti
bland
gener
support
supplement
physiotherapi
motor
respiratori
cinesiotherapi
workout
sit
postur
balanc
orthostat
function
neuro
electrostimul
speech
therapi
passiv
activ
orofaci
exercis
cold
thermal
stimul
workout
swallow
breath
decannul
tracheostomi
occup
therapi
guidanc
posit
treatment
adher
encourag
relationship
use
adapt
recreat
activ
express
activ
outsid
hospit
day
function
independ
measur
fim
made
conform
radiotherapi
g
temozolomid
current
foi
kp
fim
score
last
mri
stabl
diseas
current
use
temod
day
cycl
cranioplasti
schedul
conclus
although
know
potenti
malign
glioma
recidiv
clear
case
patient
may
benefit
surgeri
radiotherapi
chemotherapi
good
rehabilit
work
antitumor
activ
alon
combin
histon
deacetylas
inhibitor
saha
medulloblastoma
cell
line
l
geron
vk
suazo
af
andrad
ks
borg
ca
scride
lg
tone
genet
school
philosophi
scienc
letter
preto
ffclrpusp
preto
brazil
pediatr
preto
medic
school
preto
brazil
genet
preto
medic
school
preto
brazil
object
medulloblastoma
mb
common
malign
childhood
brain
tumor
aurora
kinas
essenti
cell
divis
primarili
activ
mitosi
follow
identif
potenti
target
cancer
chemotherapi
mani
aurora
kinas
inhibitor
discov
current
develop
recent
combin
aurora
kinas
inhibitor
iaurk
histon
deacetylas
inhibitor
ihdac
shown
potenti
antitumor
effect
signific
biolog
effect
preclin
cancer
model
evalu
effect
kinas
inhibitor
amg
alon
combin
histon
deacetylas
inhibitor
saha
pediatr
mb
cell
line
method
cell
prolifer
clonogen
apoptosi
assay
perform
triplic
result
amg
caus
inhibit
cell
prolifer
diminut
clonogen
capac
increas
apoptosi
rate
cell
line
p
valu
nm
nm
cell
respect
synergist
effect
combin
evidenc
inhibit
cell
prolifer
cell
line
especi
sequenti
drug
treatment
moreov
combin
drug
reach
inhibit
coloni
format
synergist
effect
treatment
increas
express
alter
one
cell
line
conclus
result
show
inhibit
aurora
kinas
amg
lead
antineoplast
effect
pediatr
mb
cell
line
combin
ihdac
promis
effect
treatment
tumor
financi
support
fapesp
process
herbi
studi
phase
ii
open
label
random
multicent
studi
therapi
pediatr
patient
newli
diagnos
glioma
hgg
j
grill
p
varlet
jaspan
dr
hargrav
massimino
e
bouffet
aa
azizi
f
saran
g
vassal
pediatr
oncolog
institut
gustav
roussi
pari
franc
neuropatholog
hospit
pari
franc
divis
neuroradiolog
univers
hospit
nottingham
unit
kingdom
pediatr
oncolog
great
ormond
street
hospit
london
unit
kingdom
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
hospit
sick
children
toronto
canada
pediatr
oncolog
unit
hu
la
fe
valencia
spain
depart
pediatr
kinder
und
jugendheilkund
vienna
austria
pediatr
oncolog
royal
marsden
nh
trust
sutton
unit
kingdom
clinic
translat
research
divis
institut
gustav
roussi
villejuif
franc
behalf
european
innov
therapi
children
cancer
itcc
consortium
european
societi
paediatr
oncolog
brain
tumour
group
australian
children
cancer
trial
group
object
despit
recent
therapeut
advanc
outcom
pediatr
hgg
remain
poor
phase
studi
et
al
j
clin
oncol
indic
bevacizumab
well
toler
children
refractori
solid
tumor
yield
pharmacokinet
data
support
studi
bevacizumab
childhood
cancer
method
total
elig
patient
age
year
newli
diagnos
local
supratentori
infratentori
cerebellar
peduncular
histolog
confirm
world
health
organ
grade
hgg
central
independ
histolog
confirm
random
week
concomit
temozolomid
local
radiotherapi
follow
temozolomid
treatment
break
week
adjuv
temozolomid
bevacizumab
everi
week
children
age
month
year
includ
young
patient
cohort
relaps
patient
receiv
temozolomid
bevacizumab
without
radiotherapi
patientspar
provid
written
inform
consent
per
local
institut
review
board
primari
end
point
surviv
defin
time
earliest
occurr
tumor
progressionrecurr
central
independ
assess
per
respons
assess
criteria
secondari
malign
death
secondari
end
point
includ
overal
surviv
respons
rate
safeti
feasibl
toler
random
patient
follow
year
futil
analysi
perform
first
random
patient
follow
year
primari
analysi
perform
patient
follow
year
updat
analys
perform
year
last
patient
random
result
herbi
conduct
clinic
site
countri
first
patient
random
octob
among
patient
screen
date
random
enrol
young
patient
cohort
conclus
complet
studi
expect
pediatr
malign
brain
tumor
treat
bevacizumab
b
herrero
martinez
villa
c
rubio
j
valero
duqu
b
pediatr
hematolog
oncolog
unit
hm
hospital
madrid
spain
radiat
therapi
hm
hospital
madrid
spain
neuroradiolog
hm
hospital
madrid
spain
object
bevacizumab
human
monoclon
antibodi
recogn
block
vascular
endotheli
growth
factor
evalu
malign
brain
tumor
children
report
experi
bevacizumab
tumor
pediatr
oncolog
unit
method
retrospect
studi
patient
malign
brain
tumor
treat
bevacizumab
may
februari
undertaken
bevacizumab
administ
dose
along
chemotherapi
irinotecan
progress
result
patient
diagnos
malign
brain
tumor
treat
bevacizumab
present
dipg
patient
treat
diagnosi
right
radiat
therapi
patient
treat
relaps
progress
ganglioglioma
anaplast
ependymoma
medulloblastoma
pnet
oligodendrogliomatosi
atyp
teratoid
rhabdoid
tumor
mean
age
diagnosi
year
old
treatment
administ
mean
time
month
quit
well
toler
minim
toxic
bleed
wound
heal
problem
lead
temporarili
treatment
interrupt
three
patient
treatment
stop
one
patient
parent
decis
present
time
patient
continu
complet
remiss
patient
stabl
diseas
patient
aliv
tumor
progress
die
tumor
progress
two
sever
complic
high
blood
pressur
massiv
stroke
may
acceler
death
within
context
tumor
progress
conclus
bevacizumab
well
toler
drug
use
combin
antineoplast
stabil
tumor
growth
result
like
influenc
use
drug
second
line
patient
progress
diseas
wors
basal
statu
clinic
experi
nimotuzumab
children
diagnos
diffus
intrins
pontin
glioma
dipg
b
herrero
martinez
villa
j
valero
duqu
j
hinojosa
b
pediatr
hematolog
oncolog
unit
hm
hospital
madrid
spain
radiat
therapi
hm
hospital
madrid
spain
neuroradiolog
hm
hospital
madrid
spain
neurosurgeri
hm
hospital
madrid
spain
neurosurgeri
hospit
quiron
madrid
spain
object
nimotuzumab
human
monoclon
antibodi
target
epiderm
growth
factor
receptor
egfr
evalu
malign
brain
tumor
children
experi
nimotuzumab
dipg
present
method
retrospect
studi
patient
dipg
diagnos
treat
nimotuzumab
march
march
unit
undertaken
nimotuzumab
administ
dose
weekli
radiotherapi
six
week
thereaft
tumor
progress
toxic
result
took
care
patient
diagnos
dipg
treat
nimotuzumab
three
year
five
femal
mean
age
year
rang
receiv
nimotuzumab
combin
radiotherapi
seven
patient
receiv
also
vinorelbin
radiotherapi
five
patient
treat
also
bevacizumab
six
patient
receiv
also
dexamethason
nimotuzumab
administ
month
mean
month
nimotuzumab
well
toler
case
mean
follow
month
half
patient
die
two
progress
diseas
two
stabl
diseas
conclus
dipg
poor
prognosi
radiat
therapi
imrt
standard
treatment
upon
diagnosi
nimotuzumab
recombin
monoclon
igg
antibodi
recogn
human
egfr
block
bind
ligand
lead
inhibit
cell
prolifer
signal
decreas
vascular
endotheli
growth
factor
vegf
product
nimotuzumab
repres
new
tool
treat
dipg
along
radiat
therapi
prove
less
effect
chemotherapi
administ
along
drug
toxic
group
patient
nimotuzumab
experi
pediatr
glial
tumour
kantar
onen
kamer
aksoylar
n
cetingul
anacak
pediatr
oncolog
ege
univers
school
medicin
izmir
turkey
radiat
oncolog
ege
univers
school
medicin
izmir
turkey
object
nimotuzumab
nmz
monoclon
antibodi
tumor
cell
becom
widespreadli
use
pediatr
oncolog
studi
share
experi
nimotuzumab
glioma
method
use
nimotuzumab
combin
vinorelbin
vnr
dipg
one
glioblastoma
multiform
one
recurr
anaplast
ependymoma
dipg
group
median
age
femal
male
diagnosi
dipg
made
mrg
case
except
one
biopsi
result
irradi
diagnosi
tmz
use
patient
prior
cours
start
irradi
upon
clinic
radiolog
progress
combin
start
median
month
median
time
use
month
one
patient
receiv
tmz
still
aliv
month
three
patient
die
progress
diseas
one
diseas
still
aliv
month
also
use
patient
gbm
treat
surgeri
irradi
plu
tmz
progress
month
use
combin
month
unfortunet
fail
stop
progress
patient
last
patient
anaplast
ependymoma
relaps
year
inial
diagnosi
second
surgeri
combin
start
month
combin
stay
howev
later
progress
die
diseas
conclus
nimotuzumab
well
toler
nimotuzumab
plu
vinorelbin
combin
seem
benefit
glioma
result
two
patient
encourag
children
need
clinic
trial
target
therapi
glioma
recurr
glioma
pinealoblastoma
r
kebudi
b
koc
f
yaman
agaoglu
gorgun
j
wolff
bay
kapu
kebudi
e
darendelil
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
oncolog
institut
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
oncolog
institut
istanbul
turkey
radiat
oncolog
istanbul
univers
oncolog
institut
istanbul
turkey
pediatr
hematolog
oncolog
cleveland
clinic
children
ohio
usa
oncolog
surgeri
maltep
univers
medic
faculti
istanbul
turkey
object
pinealoblastoma
pbl
rare
tumor
central
nervou
system
common
children
object
studi
evalu
demograph
data
outcom
children
pbl
singl
center
method
file
children
diagnos
pinealoblastoma
istanbul
univers
oncolog
institut
evalu
retrospect
demograph
data
treatment
long
term
outcom
result
children
male
femal
median
age
year
year
diagnos
pinealoblastoma
istanbul
univers
oncolog
institut
time
interv
patient
year
old
diagnos
malign
central
nervou
system
cn
tumor
center
thu
pinealoblastoma
constitut
cn
tumor
three
subot
resect
three
underw
biopsi
diagnosi
one
spinal
seed
mri
cerebrospin
fluid
cytolog
reciev
craniospin
radiotherapi
chemotherapi
patient
year
old
reciev
neoadjuv
chemotherapi
first
median
follow
year
year
two
patient
aliv
year
one
total
thyroidectomi
papillari
thyroid
cancer
second
malign
year
other
die
median
year
due
progress
diseas
conclus
conclus
pbl
aggress
tumor
necessit
intens
treatment
strategi
includ
surgeri
craniospin
radiotherapi
chemotherapi
patient
folow
long
term
side
effect
second
malign
neurocognit
evalu
long
term
survivor
atyp
teratoid
rhabdoid
tumor
atrt
canadian
registri
experi
johnston
l
janzen
guger
k
scheinemann
fleme
c
fryer
mabbott
huang
e
bouffet
l
pediatr
hematolog
oncolog
bone
marrow
transplant
alberta
children
hospit
calgari
canada
pediatr
oncolog
children
hospit
east
ontario
ottawa
canada
pediatr
oncolog
hospit
sick
children
toronto
canada
pediatr
oncolog
mc
master
univers
hospit
hamilton
canada
pediatr
oncolog
montreal
children
hospit
montreal
canada
pediatr
oncolog
bristish
columbia
women
children
hospit
vancouv
canada
object
atrt
rare
diseas
infanc
carri
grim
prognosi
focu
long
term
outcom
especi
neurocognit
remain
limit
new
era
multimod
therapi
patient
long
term
survivor
method
review
neuropsycholog
np
statu
survivor
canadian
atrt
registri
result
among
patient
diagnos
survivor
formal
np
assess
avail
patient
five
patient
could
test
young
blind
significantli
impair
lost
follow
addit
patient
special
educ
class
grade
one
receiv
educ
assist
grade
one
met
academ
expect
grade
patient
comprehens
np
median
age
diagnosi
month
four
tumor
infratentori
metastat
four
patient
underw
complet
resect
patient
receiv
post
oper
sequenti
high
dose
chemotherapi
carpoplatinthiotepa
five
patient
receiv
intrathec
chemotherapi
two
patient
underw
radiat
median
age
time
np
year
full
scale
intellectu
quotient
fsiq
rang
median
simpl
express
recept
languag
appear
rel
preserv
low
averag
superior
three
recent
diagnos
patient
median
time
assess
post
diagnosi
year
averag
high
averag
score
fsiq
academ
visual
spatial
skill
visual
verbal
memori
four
diagnos
earlier
test
median
time
year
fsiq
rang
median
one
patient
preexist
genet
syndrom
condit
extrem
low
function
fsiq
approxim
score
impair
rang
conclus
whether
find
suggest
declin
overtim
reflect
improv
overal
manag
recent
diagnos
patient
remain
unclear
nevertheless
cohort
infant
appear
significantli
impair
school
age
despit
absenc
systemat
radiotherapi
larger
seri
focus
neurocognit
definit
need
embrac
adjuv
radiotherapi
standard
care
late
morbid
survivor
childhood
brain
tumor
nationwid
base
studi
finland
p
gunn
j
mo
arola
n
malila
pediatr
hematolog
oncolog
turku
univers
hospit
turku
finland
pediatr
neurolog
turku
univers
hospit
turku
finland
pediatr
turku
univers
hospit
turku
finland
pediatr
hematolog
oncolog
tamper
univers
hospit
turku
finland
cancer
epidemiolog
finnish
cancer
registri
helsinki
finland
object
popul
survivor
childhood
brain
tumor
bt
grow
survivor
organ
structur
way
earlier
research
morbid
bt
survivor
suffer
small
sampl
size
hand
larger
studi
often
base
possibl
recal
select
bia
method
patient
diagnos
neuroepitheli
bt
age
year
finland
identifi
finnish
cancer
registri
new
diagnos
year
cancer
diagnosi
assess
use
hospit
discharg
registri
contain
data
hospit
outpati
visit
specialist
health
care
sibl
bt
patient
identifi
control
patient
via
popul
registri
result
survivor
childhood
bt
significantli
increas
hazard
ratio
endocrin
diseas
hr
mental
behavior
disord
hr
mental
retardationdisord
psycholog
develop
hr
diseas
nervou
system
hr
disord
vision
hear
hr
diseas
circulatori
system
hr
compar
sibl
control
group
outcom
also
increas
preval
year
primari
diagnosi
irradi
treatment
explain
excess
morbid
survivor
embryon
tumor
kidney
problem
group
femal
survivor
higher
hazard
ratio
mental
circulatori
problem
compar
sibl
male
survivor
conclus
systemat
long
term
support
measur
essenti
due
numer
late
effect
among
childhood
brain
tumor
survivor
even
health
relat
qualiti
life
survivor
might
improv
late
sequela
recogn
taken
care
adequ
energi
expenditur
white
adipos
tissu
activ
respons
brain
tumour
growth
c
lam
l
robinson
symond
b
coyl
children
brain
tumour
research
centr
univers
nottingham
nottingham
unit
kingdom
academ
divis
child
health
obstetr
gynaecolog
univers
nottingham
nottingham
unit
kingdom
object
brain
tumour
common
solid
tumour
children
pathway
frequent
activ
tumourigenesi
delet
tumour
suppressor
phosphatas
tensin
homolog
pten
contrast
pathway
may
also
inhibit
increas
pten
express
adipos
tissu
result
increas
uncoupl
protein
ucp
express
metabol
protect
tumourigenesi
intrins
protect
thought
aris
interscapular
brown
adipos
tissu
ibat
may
also
occur
beig
inguin
white
adipos
tissu
iwat
aim
studi
see
associ
exist
express
adipos
tissu
paediatr
brain
tumour
growth
elev
pten
level
method
two
type
medulloblastoma
wnt
n
group
n
ependymoma
n
tumour
cell
orthotop
xenograft
mice
ibat
iwat
sampl
extract
tumour
bear
mice
n
examin
pten
express
western
blot
haematoxylin
eosin
stain
antibodi
immunohistochemistri
ihc
also
use
determin
bat
depot
thermogen
activ
adipos
tissu
indirectli
measur
thermal
imag
mice
result
iwat
ependymoma
mice
evid
beig
increas
abund
histolog
ihc
express
ibat
remain
high
mice
increas
gene
express
thermogenesi
observ
mice
spinal
metastasi
pten
express
relat
express
conclus
data
indic
mice
implant
aggress
tumour
increas
iwat
though
pten
involv
pathway
like
pathway
explor
due
associ
tumourigenesi
express
wat
conclus
pilot
studi
suggest
rapidli
grow
metastat
brain
tumour
may
stimul
metabol
protect
via
increas
express
iwat
impact
high
dose
chemotherapi
regimen
children
high
risk
cn
tumor
lassaletta
r
robl
n
del
toro
l
moreno
r
urabayen
j
l
madero
diaz
pediatr
hematolog
oncolog
hospit
madrid
spain
object
unclear
whether
specif
high
dose
chemotherapi
hdc
regimen
autolog
rescu
ascr
children
recurr
cn
tumor
superior
studi
evalu
outcom
differ
hdc
regimen
children
cn
tumor
method
clinic
characterist
outcom
toxic
children
cn
tumor
treat
hdc
follow
ascr
retrospect
review
primari
endpoint
overal
surviv
os
event
free
surviv
ef
toxic
secondari
endpoint
result
patient
male
median
age
rang
evalu
diagnos
medulloblastoma
glioma
atrt
locat
infratentori
diseas
statu
prior
hdc
complet
remiss
cr
hdc
regimen
busulfanmelphalan
busulfanthiotepa
carboplatinetoposidethiotepa
median
number
rang
median
day
admiss
rang
percent
patient
develop
mucos
grade
iv
engraft
syndrom
mortal
year
os
ef
respect
os
patient
receiv
busulfanmelphalan
regimen
respect
p
ef
patient
receiv
busulfanmelphalan
regimen
respect
p
patient
cr
prior
hdc
achiev
ef
vs
cr
p
conclus
although
hdc
ascr
well
toler
incorpor
routin
practic
overal
result
remain
disappoint
singl
hdc
regimen
show
superior
children
cn
tumor
diseas
statu
prior
hdc
remain
strongest
predictor
surviv
studi
intellectu
function
children
treat
brain
tumor
j
lemier
vercruyss
jacob
haer
k
vandenabeel
geuen
v
labarqu
van
gool
paediatr
uzleuven
leuven
belgium
object
averag
intellectu
function
perform
iq
affect
verbal
iq
find
children
treat
brain
tumor
howev
studi
make
difficult
evalu
evolut
intellectu
function
disentangl
tumor
specif
treatment
factor
present
studi
investig
evolut
iq
perform
two
diagnosi
treatment
method
total
children
diagnos
brain
tumor
univers
hospit
leuven
test
twice
wechsler
scale
first
assess
conduct
soon
possibl
diagnosi
initi
andor
radiotherapi
second
assess
perform
year
diagnosi
mean
age
diagnosi
year
local
infratentori
children
diagnos
medulloblastoma
receiv
ventricular
drainag
underw
surgeri
baselin
test
underw
cranial
irradi
treatment
result
baselin
total
iq
perform
iq
significantli
norm
averag
p
p
perform
iq
significantli
lower
verbal
iq
p
similar
pattern
found
second
assess
repeat
measur
analysi
tumor
type
factor
use
radiotherapi
covari
demonstr
signific
interact
effect
differ
score
f
p
discrep
verbal
perform
iq
increas
iq
point
time
children
medulloblastoma
conclus
result
demonstr
discrep
intellig
profil
alreadi
present
newli
diagnos
children
pattern
remain
present
year
diagnosi
discrep
becam
pronounc
children
medulloblastoma
specif
neuropsycholog
test
diagnosi
recommend
refin
cognit
profil
larger
group
need
evalu
potenti
predictor
cognit
outcom
children
treat
brain
tumor
signal
critic
target
among
signal
transduct
pathway
human
medulloblastoma
cell
j
liu
lj
yu
q
wang
wen
ml
wu
xy
chen
qy
kong
h
li
liaon
lab
cancer
genet
epigenet
dalian
medic
univers
dalian
china
object
medulloblastoma
frequent
brain
malign
childhood
character
rapid
growth
earlier
intracrani
dissemin
frequent
recurr
although
combin
oper
craniospin
radiat
andor
chemotherapi
adapt
clinic
set
outcom
medulloblastoma
remain
poor
due
difficulti
remov
tumor
radic
convent
adjuv
therapi
sever
signal
pathway
activ
medulloblastoma
play
pivot
role
tumor
develop
progress
resveratrol
polypheno
compound
possess
multifacet
biolog
activ
show
inhibitori
effect
medulloblastoma
cell
howev
underli
mechan
resveratrol
remain
unclear
studi
aim
address
issu
method
influenc
resveratrol
status
pathway
mediat
wnt
notch
sonic
hedgehogshh
medulloblastoma
cell
analyz
multipl
experiment
approach
result
resveratrol
suppress
wnt
notch
sonic
hedgehogshh
activ
well
express
downstream
gene
signal
enhanc
resveratrol
select
inhibit
directli
commit
cell
apoptosi
without
induct
differenti
select
inhibit
wnt
notch
sonic
hedgehogshh
activ
littl
effect
growth
medulloblastoma
cell
singl
dose
effect
inhibit
activ
lead
treat
cell
growth
arrest
apoptosi
conclus
multipl
signal
pathway
concurr
inhibit
resveratrol
inactiv
critic
event
import
signal
surviv
medulloblastoma
cell
signal
regard
molecular
target
resveratrol
promis
agent
manag
medulloblastoma
fatti
acid
inhibit
medulloblastoma
growth
vitro
vivo
l
ljungblad
j
johnsen
p
kogner
h
gleissman
dept
women
children
health
karolinska
institutet
stockholm
sweden
object
docosahexaeno
acid
dha
eicosapentaeno
acid
epa
fatti
acid
antitumor
effect
sever
cancer
type
dha
also
protect
neural
cell
apoptosi
import
mainten
normal
brain
develop
function
includ
cognit
function
medulloblastoma
common
malign
brain
tumor
childhood
highli
invas
embryon
tumor
aris
cerebellum
brainstem
multimod
treatment
necessari
includ
surgeri
radiotherapi
chemotherapi
howev
treatment
often
result
signific
neurolog
sequela
risk
resist
relaps
signific
neuroprotect
antitumor
properti
could
therefor
great
benefit
method
cytotox
activ
dha
epa
studi
cell
viabil
assay
panel
medulloblastoma
cell
line
molecular
mechan
character
use
molecular
biolog
techniqu
mice
human
medulloblastoma
xenograft
treat
fatti
acid
prophylact
therapeut
tumor
growth
monitor
result
dha
epa
induc
medulloblastoma
cell
toxic
valu
rang
six
medulloblastoma
cell
line
dha
inhibit
prostaglandin
product
indic
possibl
mechan
action
vivo
supplement
result
significantli
delay
establish
xenograft
tumor
signific
inhibit
tumor
growth
establish
tumor
treat
vivo
treatment
conclus
medulloblastoma
cell
highli
sensit
induc
toxic
vitro
vivo
dhaepa
therefor
good
candid
improv
current
therapi
act
sword
shield
kill
cancer
cell
protect
healthi
neuron
toxic
promot
cognit
function
survivor
thu
potenti
tumor
growth
inhibitor
well
reduc
sequela
tumor
histolog
accord
tumor
locat
childhood
central
nervou
system
tumor
singl
center
studi
mehrvar
aa
hedayati
asl
tashvighi
faranoush
n
mehrvar
alebouyeh
oncolog
mahak
pediatr
cancer
treatment
research
center
tehran
iran
research
mahak
pediatr
cancer
treatment
research
center
tehran
iran
object
central
nervou
system
tumor
account
second
common
childhood
malign
first
caus
mortal
children
cancer
patient
receiv
multimod
treatment
accord
patholog
tumor
area
improv
treatment
modal
lead
increas
surviv
rate
patient
studi
examin
patholog
type
childhood
brain
tumor
base
tumor
locat
patient
refer
mahak
pediatr
cancer
treatment
research
center
mpctrc
tehran
iran
treatment
method
retrospect
review
children
less
year
old
cn
histolog
proven
tumor
present
mpctrc
april
april
perform
data
analyz
spss
version
result
male
children
elig
studi
major
tumor
infratentori
n
supratentori
n
spinal
n
mean
age
per
tumor
locat
year
supratentori
year
infratentori
year
spinal
tumor
tumor
histolog
accord
infratentori
locat
medulloblastoma
low
grade
glioma
high
grade
glioma
ependymoma
atrt
germ
cell
tumor
respect
accord
supratentori
locat
low
grade
glioma
high
grade
glioma
ependymoma
pnet
atrt
germ
cell
tumor
craniopharyngioma
primari
cn
malign
lymphoma
histiocytosi
respect
time
analysi
death
lost
conclus
hospit
base
studi
rate
commonest
type
cn
tumor
similar
report
data
benchmark
increas
understand
childhood
cn
tumor
iran
small
molecul
tolfenam
acid
inhibit
marker
angiogenesi
medulloblastoma
cell
via
target
specif
protein
transcript
factor
j
murray
ut
sankpal
l
tabor
felini
wp
bowman
r
basha
hematolog
oncolog
center
cook
children
health
care
system
fort
worth
usa
depart
pediatr
univers
north
texa
health
scienc
center
fort
worth
usa
depart
obstetricsgynecolog
univers
north
texa
health
scienc
center
fort
worth
usa
object
medulloblastoma
mb
requir
aggress
multimod
therapi
survivor
frequent
suffer
numer
therapi
object
studi
explor
novel
strategi
enhanc
optim
therapeut
effect
current
mb
treatment
specif
protein
sp
transcript
factor
known
regul
survivin
inhibitor
apoptosi
protein
associ
poor
prognosi
resist
treatment
sp
protein
also
modul
express
vascular
epitheli
growth
factor
vegf
regul
angiogenesi
small
molecul
tolfenam
acid
ta
inhibit
mb
cell
prolifer
tumor
growth
mice
xenograft
target
sp
protein
survivin
evalu
effect
ta
express
vegf
compar
chang
key
transcript
factor
phosphoryl
microrna
regul
repressor
method
human
mb
cell
line
daoy
treat
vehicl
dmso
ta
cell
viabil
monitor
hour
use
celltiterglo
kit
mithramycin
use
control
experi
express
survivin
actin
determin
western
blot
analysi
microrna
express
measur
use
taqman
small
rna
assay
result
ta
caus
dose
inhibit
gml
hour
cell
viabil
decreas
express
survivin
vrgf
totalphospho
ta
gml
hour
caus
decreas
express
conclus
result
demonstr
ta
target
key
regul
mb
tumor
growth
mediat
via
sp
molecular
mechan
includ
candid
involv
angiogenesi
research
focu
epidemiolog
studi
evalu
associ
sp
protein
mb
along
dedic
molecular
profil
better
understand
underli
mechan
intraop
mri
facilit
aggress
brain
tumor
resect
infant
children
adolesc
j
murray
r
robert
dj
donahu
c
guajardo
j
honeycutt
hematolog
oncolog
center
cook
children
health
care
system
fort
worth
usa
neurosci
center
cook
children
health
care
system
fort
worth
usa
object
prognosi
children
oper
brain
tumor
correl
degre
resect
regardless
benign
versu
malign
histolog
use
adjuv
chemotherapi
andor
radiat
therapi
critic
initi
tumor
resect
remain
paramount
applic
diagnost
qualiti
intraop
magnet
reson
imag
imri
recent
introduc
pediatr
neurosurgeri
design
implement
uniqu
imri
imri
oper
room
suit
whose
mobil
tesla
siemen
magnet
glide
diagnost
suit
oper
suit
present
first
consecut
imri
brain
tumor
resect
method
februari
dedic
imri
oper
room
suit
hous
anesthesia
equip
standard
oper
room
equip
intraop
mobil
oper
microscop
robust
safeti
protocol
imri
room
engag
epilepsi
chiari
surgeri
vascular
malform
brain
tumor
resect
result
employ
imri
oper
room
tumor
extirp
case
year
period
patient
rang
age
infanc
late
adolesc
mean
age
year
posterior
fossa
tumor
account
resect
neoplasm
repres
averag
intraop
mri
scan
per
procedur
mean
scan
time
minut
intraop
scan
prompt
addit
tumor
resect
case
complic
increas
incid
infect
one
patient
anesthesia
problem
next
day
rate
go
back
neurosurgeri
next
day
due
unseen
unresect
tumor
zero
conclus
imri
facilit
aggress
brain
tumor
resect
infant
children
adolesc
low
complic
rate
technolog
safe
result
unanticip
go
back
reoper
next
day
histor
occur
prior
case
imri
tumor
resect
surgeri
becom
standard
practic
institut
children
cn
tumor
experi
singl
institut
nakano
nakamura
k
yamasaki
c
nitani
k
okada
h
fujisaki
osugi
j
hara
depart
pediatr
hematolog
oncolog
children
medic
center
osaka
citi
gener
hospit
osaka
japan
object
use
methotrex
power
tool
control
cn
leukemia
standard
treatment
howev
procedur
leukoencephalopathi
concern
combin
radiat
therapi
cn
tumor
aim
studi
exam
incid
leukoencephalopathi
correl
mtx
method
retrospect
review
medic
record
pediatr
patient
cn
tumor
treat
institut
sinc
till
result
patient
age
year
treat
patient
diagnos
germ
cell
tumor
medulloblastoma
ependyoma
atrt
mtx
mg
given
via
lumber
punctur
singl
mg
mtx
given
via
ommaya
reservoir
singl
three
four
consecut
day
newli
diagnos
patient
receiv
combin
system
chemotherapi
n
without
n
radiotherapi
mainli
local
irradi
germinoma
local
craniospin
irradi
medulloblastoma
patient
relaps
tumor
receiv
combin
radiotherapi
n
present
patient
surviv
month
four
patient
receiv
cours
two
develop
asymptomat
leukoencephalopathi
two
patient
receiv
itiv
mtx
recurr
diseas
line
treatment
irradi
system
chemotherapi
conclus
studi
develop
leukoencephalopathi
limit
patient
recurr
diseas
newli
diagnos
patient
itiv
mtx
seem
treatment
develop
futur
retrospect
multicent
analysi
children
low
grade
glioma
result
japanes
pediatr
brain
tumor
consortium
osugi
c
kiyotani
h
sakamoto
yanagisawa
kanno
h
moritak
kosaka
j
hirado
takimoto
nakazawa
j
hara
depart
pediatr
nation
hospit
organizaiton
osaka
nation
hospit
osaka
japan
depart
solid
tumor
oncolog
child
cancer
center
nation
center
child
health
develop
tokyo
japan
depart
pediatr
neurosurgeri
osaka
citi
gener
hospit
osaka
japan
depart
saitama
medic
univers
intern
medic
center
saitama
japan
depart
pediatr
yamagata
univers
hospit
yamagata
japan
divis
pediatr
depart
reproduct
development
medicin
univers
miyazaki
miyazaki
japan
depart
hematologyoncolog
hyogo
children
hospit
hyogo
japan
clinic
depart
patholog
gunma
univers
hospit
gunma
japan
divis
data
analysi
child
cancer
center
nation
center
child
health
develop
tokyo
japan
depart
patholog
child
cancer
center
nation
center
child
health
develop
tokyo
japan
depart
pediatr
hematologyoncolog
osaka
citi
gener
hospit
osaka
japan
object
retrospect
investig
histori
children
glioma
lgg
diagnos
center
japan
method
children
mean
age
year
rang
one
year
studi
tumor
locat
cerebrum
cerebellum
optic
pathwaythalamu
midbrain
other
assess
patient
tumor
total
remov
histolog
grade
grade
pilocyt
astrocytoma
grade
ii
diffus
pilomixoid
lgg
no
six
patient
histolog
examin
done
result
initi
receiv
chemotherapi
receiv
radiotherapi
patient
follow
median
month
month
diagnosi
present
patient
complet
remiss
stabl
diseas
recurr
observ
among
seven
patient
die
diseas
one
malign
transform
diseas
observ
year
diagnosi
lgg
os
pf
os
pf
pa
da
lgg
no
respect
among
pa
pf
optic
pathway
inferior
cerebellum
patient
residu
tumor
surgeri
year
pf
wors
patient
whose
tumor
total
remov
patient
suffer
recurr
year
diagnosi
sequela
epilepsi
hydrocephalu
lost
vision
seen
endocrin
problem
need
therapi
need
support
live
one
second
malign
conclus
lgg
especi
pa
clinic
benign
appear
incid
malign
transform
low
patholog
diagnosi
tumor
locat
resect
extent
influenc
outcom
diseas
also
need
follow
late
effect
sequel
medulloblastoma
risk
peri
hippocamp
diseas
progress
l
padovani
geoffray
c
dufour
f
doz
j
gentet
boll
c
carri
x
muracciol
radiotherapi
la
timon
children
hospit
marseil
franc
radiolog
lenval
hospit
nice
franc
medic
oncolog
gustav
roussi
institut
villejuif
franc
medic
oncolog
curi
institut
pari
franc
medic
oncolog
la
timon
children
hospit
marseil
franc
medic
oncolog
gustav
roussi
institut
villejuif
franc
radiotherapi
leon
berard
center
lyon
franc
object
report
natur
histori
medulloblastoma
mb
incid
hippocamp
area
metastas
method
children
treat
hr
mb
major
includ
pnet
hr
metastasi
time
relaps
review
distribut
metastat
locat
axial
mri
central
review
report
use
identifi
metastasi
hippocampu
clinic
radiograph
analyz
term
nodular
leptomening
infiltr
distanc
peri
hippocamp
hippocamp
region
divid
three
group
mt
hippocamp
near
hippocamp
mm
hippocampu
distanc
divid
hippocamp
area
anterior
posterior
area
result
patient
analyz
initi
imb
time
relaps
tor
hr
spinal
locat
diagnosi
treat
craniospin
irradi
csi
gy
low
risk
diagnosi
imb
group
sustentori
metastas
diagnosi
intra
later
ventricular
nodul
leptomening
infiltr
metastasi
includ
infiltr
patient
tor
group
develop
sustentori
locat
intra
later
ventricular
nodul
includ
hr
patient
leptominig
infiltr
contact
hippocamp
area
nh
mt
near
anterior
area
conclus
result
underlin
high
risk
mb
patient
relaps
low
risk
respect
develop
sustentori
locat
metastasi
underw
hippocamp
area
diagnost
progress
present
metastas
near
hippocamp
area
studi
still
go
defin
group
patient
low
risk
hippocamp
progress
propos
partial
csi
ependymoma
treat
clinic
set
south
africa
j
park
davidson
figaji
k
pillay
kilborn
l
padaychi
hendrick
van
eyssen
radiat
oncolog
univers
cape
town
cape
town
south
africa
radiat
oncolog
groot
schuur
hospit
univers
cape
town
servic
depart
paediatr
child
health
red
cross
children
hospit
cape
town
south
africa
paediatr
neurosurgeri
red
cross
children
hospit
univers
cape
town
cape
town
south
africa
paediatr
patholog
red
cross
children
hospit
univers
cape
town
cape
town
south
africa
paediatr
radiolog
red
cross
children
hospit
univers
cape
town
cape
town
south
africa
object
review
demograph
outcom
paediatr
ependymoma
patient
refer
combin
paediatr
servic
univers
cape
town
method
retrospect
analysi
perform
children
age
year
less
diagnos
ependymoma
red
cross
children
hospit
rcch
groot
schuur
hospit
gsh
result
children
seen
age
year
median
year
patient
data
avail
exclud
analysi
patient
brain
tumour
infratentori
supratentori
one
known
patient
spinal
tumour
patient
localis
patient
advanc
metastat
diseas
patient
stage
inform
patient
gross
total
resect
tumour
patient
subtot
resect
patient
biopsi
remaind
patient
extent
surgeri
document
ten
patient
receiv
chemotherapi
patient
receiv
radiotherapi
receiv
craniospin
radiotherapi
receiv
proton
therapi
estim
relaps
free
surviv
rf
patient
overal
surviv
os
n
brain
tumour
n
rf
grade
tumour
n
rf
wherea
anaplast
tumour
n
rf
infratentori
tumour
n
rf
supratentori
n
tumour
patient
treat
year
os
conclus
manag
ependymoma
difficult
best
done
team
even
environ
manag
strategi
evolv
year
studi
outcom
improv
qualit
evalu
craniospin
irradi
techniqu
plan
set
pediatr
patient
medulloblastoma
mb
perez
de
antueno
j
barro
l
rafailovici
l
filomia
j
chiozza
skuman
martinez
radiotherapi
vidt
medic
center
sa
bueno
air
argentina
object
craniospin
irradi
histor
becam
mainstay
therapi
mb
introduc
cooper
group
adjuv
chemotherapi
treatment
mb
lead
improv
surviv
subsequ
reduct
rt
dosag
irradi
treatment
achiev
dose
reduct
kind
treatment
offer
better
neurocognit
result
clinic
outcom
patient
averag
risk
concept
support
import
develop
adequ
techniqu
dose
deliveri
rt
purpos
paper
document
qualiti
rt
deliv
pediatr
patient
mb
implement
techniqu
propos
task
group
method
present
techniqu
plan
patient
set
mb
treatment
pediatr
patient
chemotherapi
scheme
treat
depart
period
mean
age
year
yr
surgeri
rt
treatment
deliv
conform
rt
crt
differ
devic
use
patient
immobil
individu
set
up
vari
prone
supin
accord
patient
clinic
statu
rt
dose
critic
structur
record
plan
patient
result
techniqu
allow
us
deliv
highli
reproduc
treatment
low
rate
relaps
secondari
goal
inmobil
devic
improv
comfort
patient
reduc
margin
error
set
field
conclus
manag
pediatr
patient
mb
strategi
reduc
rt
dose
craniospin
axi
must
includ
accur
plan
verif
dose
deliv
risk
organ
ptv
treatment
experi
crt
consist
set
day
treatment
crucial
propos
techniqu
good
way
achiev
evalu
effect
treatment
brain
tumor
intracrani
diseas
children
rotat
gamma
knife
rgk
bach
mai
hospit
vietnam
p
pham
cam
khoa
mai
trong
ha
tran
dinh
dai
le
chinh
nuclear
medicin
oncolog
center
bach
mai
hospit
hanoi
vietnam
purpos
assess
effect
treat
brain
tumor
well
intracrani
diseas
rotat
gamma
knife
rgk
bach
mai
hospit
vietnam
method
materi
prospect
clinic
intervent
patient
year
diagnos
brain
tumor
intracrani
diseas
treat
rotat
gamma
knife
juli
juli
bach
mai
hospit
vietnam
result
averag
age
year
old
age
time
radiosurgeri
rang
youngest
oldest
malefemal
ratio
studi
patient
includ
arterioven
malform
avm
pineal
tumor
astrocytoma
cavernoma
ependynoma
clinic
symptom
headach
nausea
vomit
convuls
hemiplegia
cerebellar
syndrom
tumor
locat
frontal
tempor
side
intraventricular
brainstem
median
tumor
size
cm
rang
cm
median
prescrib
dose
vari
depend
natur
posit
tumor
min
max
group
arterioven
malform
low
grade
astrocytoma
good
respons
craniopharyngioma
poorli
respons
far
patient
improv
obvious
clinic
symptom
reduc
headach
nausea
tumor
size
patient
die
due
progress
tumor
treatment
conclus
radiosurgeri
treat
brain
tumor
intracrani
diseas
rotat
gamma
knife
safe
effect
children
treatment
outcom
children
medulloblastoma
experi
singl
institut
malaysia
r
rajagop
yap
lum
krishnan
hani
ariffin
wan
ariffin
paediatr
univers
malaya
medic
centr
kuala
lumpur
malaysia
object
review
outcom
children
medulloblastoma
treat
univers
malaya
medic
centr
ummc
till
method
clinic
prognost
indic
patient
medulloblastoma
retrospect
analyz
children
age
year
treat
ccg
protocol
less
year
ukccsg
cn
headstart
onward
protocol
use
risk
stratif
base
chang
stage
classif
result
male
patient
median
age
diagnosi
year
median
durat
symptom
week
vomit
n
headach
n
unsteadi
gait
n
diplopia
n
common
present
patient
exclud
review
refus
treatment
surgeri
default
transfer
hospit
remain
patient
treat
per
protocol
base
risk
stratif
n
metastat
diseas
diagnosi
residu
tumour
distant
metastasi
present
associ
high
relaps
rate
respect
cohort
age
diagnosi
gender
durat
present
symptom
delay
imag
delay
radiotherapi
significantli
influenc
outcom
analysi
histopatholog
result
exclud
due
lack
descript
detail
percent
n
patient
die
relat
treatment
associ
complic
due
diseas
recurr
progress
median
time
recurr
month
die
within
year
none
respond
salvag
chemotherapi
overal
surviv
rate
median
time
year
abnorm
commonest
side
effect
conclus
result
demonstr
dismal
prognosi
medulloblastoma
due
advanc
stage
diseas
diagnosi
high
rate
treatment
refus
abandon
observ
centr
studi
tert
mechanist
relat
molecul
medulloblastoma
r
rei
gc
almeida
jn
staval
malheiro
j
pimentel
c
clara
molecular
oncolog
research
center
barreto
cancer
hospit
barreto
brazil
life
health
research
institur
minho
univers
braga
portug
depart
patholog
barreto
cancer
hospit
barreto
brazil
depart
patholog
feder
univers
paulo
paulo
brazil
laboratori
neuropatholog
santa
maria
hospit
lisbon
portug
depart
neurosurgeri
barreto
cancer
hospit
lisbon
portug
object
hotspot
activ
mutat
tert
promot
region
recent
describ
sever
tumor
type
mutat
lead
enhanc
express
telomeras
respons
telomer
mainten
allow
continu
cell
divis
addit
atrx
mutat
altern
telomer
mainten
mechan
associ
histon
mutat
respons
disrupt
histon
code
affect
regul
transcript
altern
affect
histon
regul
inactiv
mutat
absenc
result
microsatellit
instabl
msi
investig
clinic
relev
mechanist
relat
molecul
medulloblastoma
method
cohort
paraffin
embed
medulloblastoma
age
year
use
investig
hotspot
mutat
tert
promot
region
use
sanger
sequenc
deregul
analyz
protein
level
immunohistochemistri
msi
statu
msi
target
gene
studi
multiplex
pcr
follow
genotyp
result
success
sequenc
tert
medulloblastoma
identifi
total
mutat
case
mutat
detect
respect
sampl
similarli
previou
report
tert
mutat
frequent
older
patient
p
found
patient
younger
year
age
addit
tert
mutat
tumor
frequent
recurr
p
tert
mutat
significantli
enrich
tumor
locat
right
cerebellar
hemispher
p
clinicopatholog
data
avail
found
statist
signific
mutat
found
msi
phenotyp
seen
analyz
sampl
express
current
patholog
evalu
conclus
tert
promot
mutat
frequent
medulloblastoma
associ
older
patient
tumor
prone
recurr
aris
right
cerebellar
hemispher
hand
msi
phenotyp
histon
mutat
rare
event
medulloblastoma
medulloblastoma
childhood
tunisian
exp
rienc
mhamdi
aissi
h
rifi
n
chraiet
l
kochbati
mezlini
salah
azaiz
tuni
tunisia
medic
oncolog
salah
azaiz
tuni
tunisia
mdical
oncolog
salah
azaiz
tuni
tunisia
rdiotherapi
salah
azaiz
tuni
tunisia
object
medulloblastoma
common
brain
embryon
tumour
children
aim
retrospect
studi
evalu
clinic
radiolog
therapeut
prognost
featur
diseas
method
seventi
seven
children
medulloblastoma
treat
depart
clinic
present
domin
sign
intracrani
pressur
gait
instabl
alter
eye
movement
diplopia
tumour
locat
fourth
ventricl
vermian
ventricular
shunt
resect
perform
increas
intracrani
pressur
resect
complet
patient
four
patient
leptomeneg
dissemin
sixti
eight
patient
postop
radiotherapi
rt
preced
initi
chemotherapi
ct
case
exclus
case
follow
ct
case
averag
dose
craniospin
axi
gy
rang
boost
posterior
fossa
total
dose
gy
rang
gy
exclus
ct
recommend
patient
ct
protocol
commonli
use
carboplatin
bbsfop
result
median
age
year
sex
ratio
median
follow
month
patient
complet
remiss
patient
present
local
recurr
requir
reoper
ct
alon
two
patient
lost
follow
initi
resect
conclus
medulloblastoma
curabl
signific
proport
patient
diseas
initi
diagnosi
delay
diagnosi
qualiti
excis
remain
import
factor
influenc
prognosi
radiat
therapi
treatment
tumor
children
russo
n
isa
rey
pediatr
radiotherapi
nation
cancer
institut
santiago
chile
introduct
due
locat
tumor
trunk
tt
present
high
surgic
risk
diagnosi
usual
made
imag
chile
case
treat
accord
pinda
program
nation
treatment
guid
pediatr
tumor
patient
receiv
radiotherapi
rt
diagnosi
aim
studi
evalu
treatment
result
tt
nation
cancer
institut
nci
patient
method
retrospect
review
patient
diagnos
tt
nci
conduct
patient
popul
symptom
treatment
receiv
overal
surviv
describ
prognost
factor
result
novemb
decemb
children
refer
possibl
rt
actual
receiv
median
age
diagnosi
year
old
march
patient
due
diseas
progress
median
surviv
patient
receiv
rt
patient
month
end
treatment
surviv
rate
year
univari
analysi
show
surviv
affect
mrn
high
resolut
imag
p
hr
diffus
tumor
pattern
p
hr
multivari
analysi
show
surviv
affect
mrn
high
resolut
imag
p
hr
higher
dose
rt
protector
p
hr
conclus
poor
obtain
treatment
tt
rt
inc
similar
report
center
explor
regard
treatment
option
base
combin
therapi
use
rt
need
chemotherapi
improv
surviv
pediatr
diffus
intrins
pontin
glioma
dipg
z
gokc
samar
c
faur
conter
c
carri
l
claud
c
chabert
frappaz
pediatr
institut
et
doncologi
lyon
franc
radiotherapi
institut
et
doncologi
lyon
franc
radiolog
institut
et
doncologi
lyon
franc
oncolog
institut
et
doncologi
lyon
franc
object
median
surviv
rare
exce
month
standard
treatment
dipg
focal
radiotherapi
bsg
protocol
prospect
trial
frontlin
chemotherapi
aim
delay
radiat
time
clinic
progress
os
result
encourag
frappaz
neuro
oncolog
protocol
propos
routin
cancer
center
dipg
patient
particip
anoth
prospect
studi
current
abstract
deal
new
cohort
method
protocol
consist
frontlin
chemotherapi
cycl
includ
three
cours
deliv
monthli
first
cours
second
third
methotrex
standard
radiotherapi
deliv
either
time
progress
elect
month
contemporari
comparison
cohort
patient
receiv
experiment
treatment
contain
least
local
radiat
therapi
serv
control
initi
monthli
mri
retrospect
central
review
special
confirm
diagnosi
dipg
accord
publish
criteria
result
patient
treat
accord
bsg
protocol
two
patient
underw
one
cycl
patient
two
cycl
one
patient
three
cycl
nine
patient
four
cycl
one
patient
go
third
cycl
finish
yet
three
patient
experienc
sever
iatrogen
infect
ten
patient
requir
platelet
transfus
median
surviv
increas
significantli
patient
treat
accord
protocol
compar
contemporari
control
month
vs
month
p
median
pf
longer
respect
vs
month
p
median
radiat
free
surviv
month
conclus
bsg
strategi
confirm
one
effect
current
treatment
dipg
may
serv
control
arm
random
trial
explor
innov
treatment
may
propos
parent
children
reluct
biopsi
salvag
chemotherapi
associ
recurrentrefractori
brain
tumor
children
schiavetti
g
varrasso
g
real
de
grazia
e
ferrara
paiano
clerico
pediatr
sapienza
univers
rome
rome
itali
object
date
current
standard
care
treatment
recurrentrefractori
brain
tumor
major
patient
succumb
diseas
novel
treatment
strategi
explor
use
agent
combin
cytotox
cht
investig
studi
report
report
phase
ii
studi
seri
consecut
case
recurrentrefractori
brain
tumor
method
eight
children
male
femal
median
age
initi
diagnosi
month
rang
affect
relaps
medulloblastoma
glioblastoma
pnet
glioma
pt
treat
bevacizumab
irinotecan
associ
five
also
receiv
temozolamid
pt
receiv
two
previou
cht
line
median
age
start
treatment
month
rang
pt
receiv
treatment
follow
bevacizumab
mgkg
iv
irinotecan
iv
everi
week
temozolamid
po
daili
five
consecut
day
everi
day
total
cours
administ
rang
two
pt
still
treatment
result
two
pt
mb
start
treatment
radic
surgic
remain
cr
respect
month
one
still
treatment
one
progress
month
therapi
stop
five
pt
mb
pnet
gb
maintain
sd
median
month
rang
one
pt
lgg
obtain
pr
month
still
treatment
pf
month
observ
pt
treatment
well
toler
good
qualiti
life
toxic
includ
allergi
pt
grade
thrombocytopenia
pt
conclus
small
seri
pt
associ
temozolamid
show
encourag
result
studi
larger
popul
pediatr
pt
brain
tumor
need
overexpress
medulloblastoma
inhibit
abl
reduc
prolifer
increas
methyl
level
cell
line
model
ca
scride
gav
cruzeiro
mbf
rei
ak
eterov
da
moreno
l
neder
rs
oliveira
aguiar
ja
yune
sr
brandalis
lg
tone
et
valera
pediatr
preto
school
medicin
univers
paulo
preto
brazil
genet
preto
school
medicin
univers
paulo
preto
brazil
system
biolog
md
anderson
cancer
center
houston
usa
genet
preto
school
medicin
univers
paulo
preto
brazil
patholog
preto
school
medicin
univers
paulo
preto
brazil
surgeri
preto
school
medicin
univers
paulo
preto
brazil
pediatr
centro
infantil
boldrinist
univers
campina
campina
brazil
pediatr
preto
school
medicin
univers
paulo
preto
brazil
object
medulloblastoma
mb
common
malign
brain
tumor
childhood
sever
studi
correl
hypoxia
gene
tumor
progress
chemoradioresist
human
cancer
known
gene
mb
aim
studi
analyz
express
profil
hypoxia
relat
gene
mb
method
studi
evalu
gene
express
profil
hypoxia
relat
gene
vegf
pediatr
medulloblastoma
comparison
fetal
cerebellum
sampl
use
taqman
probe
addit
analyz
effect
hypoxia
normoxia
level
condit
pediatr
medulloblastoma
cell
line
gene
express
effect
silenc
sirna
cell
prolifer
xtt
assay
methyl
level
gene
relat
hypoxia
apoptosi
pyrosequenc
result
lower
express
level
p
p
vegf
p
higher
express
level
p
observ
mb
sampl
compar
fetal
cerebellum
analyz
test
cell
line
hypoxia
condit
result
regul
gene
vegf
knockdown
protein
silenc
effici
analyz
western
blot
found
decreas
cell
prolifer
p
anova
reduct
express
gene
vegf
inhibit
caus
signific
increas
pattern
methyl
gene
conclus
except
gene
lower
express
hypoxia
relat
gene
observ
mb
compar
fetal
cerebellum
silenc
pediatr
mb
cell
line
abl
decreas
significantli
cell
prolifer
suggest
could
potenti
therapeut
target
gene
mb
effect
treatment
child
supratentori
primit
neuroectoderm
tumor
shaverskyi
orlov
v
zyabchenko
p
plavskyi
paediatr
romodanov
institut
neurosurgeri
kiev
ukrain
object
supratentori
primit
neuroectoderm
tumor
children
rel
rare
one
malign
brain
tumor
method
work
base
result
retrospect
analysi
treatment
children
primit
supratentori
neuroectoderm
brain
tumor
undergon
treatment
institut
patient
consist
male
femal
children
mean
age
surgeri
year
rang
month
year
case
infant
result
total
resect
perform
case
subtot
case
partial
case
two
children
biopsi
oper
mortal
case
tumor
classifi
neuroblastoma
case
ganglioneuroblastoma
presenc
tumor
cell
csf
found
case
metastasi
part
brain
diagnos
case
metastas
spinal
cord
case
extraneur
dissemin
two
case
patient
underw
chemotherapi
patient
radiat
therapi
data
month
year
avail
patient
averag
surviv
rate
month
signific
wors
surviv
younger
children
signific
differ
found
surviv
accord
patient
sex
tumor
patholog
stage
diseas
time
diagnosi
conclus
complex
surgeri
applic
radiat
therapi
chemotherapi
affect
surviv
rate
overal
qualiti
life
patient
aggress
surgic
approach
associ
postop
low
mortal
long
surviv
inclus
complex
treatment
radiat
chemotherapi
prolong
surviv
intracrani
tumor
newborn
babi
shaverskyi
orlov
p
plavskyi
paediatr
romodanov
institut
neurosurgeri
kiev
ukrain
object
report
retrospect
studi
brain
tumor
diagnos
neonat
period
treat
institut
neurosurgeri
nam
ukrain
till
method
year
case
newborn
babi
brain
tumor
observ
institut
neurosurgeri
make
children
brain
tumor
treat
pediatr
depart
mention
period
ten
male
five
femal
histolog
analysi
tumor
confirm
observ
benign
tumor
diagnos
case
plexu
papilloma
atyp
plexu
pailloma
hemangiopericytoma
matur
teratoma
lipoma
malign
tumor
found
case
anaplast
astrocytoma
neuroblastoma
immatur
teratoma
medulloblastoma
spnet
histostructur
identifi
case
result
total
patient
underw
oper
tumor
remov
complement
shunt
procedur
two
case
total
tumor
remov
perform
patient
subtot
tumor
remov
case
biopsi
one
case
mortal
tumor
remov
patient
follow
averag
life
expect
year
year
conclus
modern
diagnost
techniqu
make
possibl
diagnos
congenit
brain
tumor
earli
stage
life
prenat
though
treatment
outcom
surviv
rate
remain
poor
certain
categori
children
show
quit
satisfactori
period
outcom
qualiti
life
leptin
concentr
nutrit
statu
cours
treatment
children
brain
tumour
g
k
musiol
w
stolpa
h
wo
depart
pediatr
oncolog
haematolog
chemotherapi
medic
univers
silesia
upper
silesia
children
care
heatlh
centr
katowic
poland
object
assess
nutrit
statu
children
malign
brain
tumour
cours
treatment
correl
concentr
leptin
method
studi
involv
children
treat
cn
tumour
bodi
mass
index
leptin
valu
analys
three
time
begin
treatment
mainten
treatment
complet
result
initi
sd
bmi
similar
control
group
valu
paramet
sd
bmi
decreas
therapi
complet
treatment
sd
bmi
valu
increas
therapi
increas
concentr
leptin
decreas
complet
therapi
observ
conclus
children
brain
tumour
quantit
disord
nutrit
statu
correl
period
treatment
correl
concentr
leptin
nutrit
statu
children
brain
tumour
confirm
investig
vdr
gene
polymorph
pediatr
patient
brain
cancer
b
yilmaz
g
tokuc
pediatr
hamatolog
oncolog
marmara
univers
istanbul
turkey
object
vitamin
steroid
structur
intracellularli
bound
special
receptor
play
import
role
cell
prolifer
inflamm
recent
year
also
believ
vitamin
may
play
protect
role
cancer
type
certain
region
vdr
gene
may
show
genet
differ
structur
frequent
polymorph
gene
region
cancer
associ
vdr
gene
polymorph
like
colorect
ca
breast
ca
prostat
ca
adult
review
medic
literatur
studi
done
children
far
method
investig
three
common
gene
polymorph
vdr
gene
childhood
brain
tumour
healthi
children
result
couldt
find
relationship
childhood
brain
tumor
vdr
gene
polimorph
region
conclus
children
relationship
vdr
gene
polimorph
vitamin
statu
pediatr
solid
tumour
need
evalu
larger
seri
patient
pencil
beam
scan
proton
therapi
without
concomit
chemotherapi
children
atyp
teratoidrhabdoid
tumor
paul
scherrer
institut
experi
dc
weber
r
malyapa
f
albertini
u
kliebsch
l
mikroutsiko
p
morach
c
are
r
schneider
center
proton
therapi
paul
scherrer
institut
villigen
switzerland
object
atyp
teratoidrhabdoid
tumor
atrt
cn
rare
extrem
aggress
embryon
neoplasm
earli
childhood
mean
report
survivorship
young
atrt
children
rang
month
unlik
convent
radiotherapi
proton
therapi
pt
allow
optim
dose
distribut
ad
benefit
exit
dose
assess
clinic
result
pencil
beam
scan
pb
pt
treatment
atrt
patient
method
fifteen
children
male
n
treat
pb
pt
may
januari
mean
age
diagnosi
month
local
infratentori
type
supratentori
patient
respect
gross
total
resect
primari
tumor
achiev
patient
median
dose
administ
focal
sedat
gy
rbe
patient
receiv
concomit
chemotherapi
respect
acut
toxic
assess
accord
ctcae
version
result
median
time
month
rang
patient
present
local
failur
lf
distant
brain
failur
dbf
spinal
failur
sf
respect
combin
treatment
failur
lf
dbf
n
dbf
sf
n
observ
patient
six
patient
die
tumor
progress
median
overal
surviv
os
reach
local
failur
db
surviv
os
rate
respect
age
p
local
p
type
resect
p
prognost
os
pt
well
toler
grade
acut
toxic
observ
one
grade
anoth
grade
impair
motor
function
observ
patient
conclus
pb
pt
effect
treatment
young
children
atrt
pt
without
concomit
chemotherapi
median
os
reach
seri
acut
toxic
manag
surviv
two
young
children
relaps
atyp
teratoidrhabdoid
tumor
h
yamada
sakaguchi
j
fujimura
h
tamaichi
kurimoto
saito
kondo
saito
shimizu
pediatr
juntendo
univers
faculti
medicin
tokyo
japan
neurosurgeri
juntendo
univers
faculti
medicin
tokyo
japan
object
atyp
teratoidrhabdoid
tumor
atrt
highli
malign
embryon
central
nervou
system
tumor
primarili
occur
children
less
three
year
age
median
surviv
less
month
approxim
patient
eventu
relaps
despit
aggress
treatment
treatment
option
patient
relaps
diseas
particularli
limit
method
conduct
retrospect
chart
review
two
patient
treat
relaps
atrt
result
case
patient
diagnos
posterior
fossa
atrt
age
three
month
initi
treatment
consist
gross
total
tumor
resect
chemotherapi
patient
local
relaps
six
month
complet
chemotherapi
underw
gross
total
tumor
resect
four
cours
intens
multidrug
chemotherapi
patient
aliv
without
evid
diseas
year
initi
diagnosi
case
patient
diagnos
posterior
fossa
atrt
age
month
initi
treatment
consist
gross
total
tumor
resect
chemotherapi
follow
craniospin
irradi
patient
metastat
relaps
anterior
cranial
fossa
month
complet
treatment
subtot
tumor
resect
week
multidrug
chemotherapi
initi
stereotact
radiosurgeri
use
cyberknif
perform
residu
tumor
chemotherapi
patient
aliv
year
initi
diagnosi
conclus
prognosi
patient
relaps
atrt
extrem
poor
howev
multimod
approach
includ
chemotherapi
surgeri
stereotact
radiotherapi
may
prolong
surviv
maintain
qualiti
life
chemotherapi
childhood
intracrani
ependymoma
yokosuka
n
miyagawa
sarashina
k
fukuda
f
iwasaki
hamanou
h
goto
ito
n
aida
tanaka
depart
medicin
kanagawa
children
medic
center
yokohama
japan
depart
neurosurgeri
kanagawa
children
medic
center
yokohama
japan
depart
radiolog
kanagawa
children
medic
center
yokohama
japan
depart
patholog
kanagawa
children
medic
center
yokohama
japan
object
standard
therapi
childhood
intracrani
ependymoma
maxim
tumor
resect
follow
irradi
although
use
routin
chemotherapi
produc
object
respons
ependymoma
recurr
infant
undertook
clinic
trial
chemotherapi
children
intracrani
ependymoma
kanagawa
children
medic
center
investig
potenc
chemotherapi
method
children
newli
diagnos
ependymoma
treat
institut
patient
could
receiv
chemotherapi
sever
brainstem
compress
tumor
enrol
studi
children
non
metastat
ependymoma
median
age
year
year
primari
site
infratentori
supratentori
patient
gross
total
resect
gtr
achiev
patient
subtot
resect
str
achiev
patient
grade
ii
grade
iii
tumor
respect
result
children
receiv
chemotherapi
vincristin
etoposid
x
day
cyclophosphamid
x
day
cisplatin
x
day
follow
surgeri
focal
irradi
fourteen
children
complet
cycl
chemotherapi
median
year
rang
year
entir
group
year
overal
surviv
os
surviv
ef
respect
three
patient
experienc
diseas
recurr
eventu
die
year
os
grade
ii
grade
iii
tumor
p
year
os
patient
underw
str
versu
underw
gtr
p
conclus
result
suggest
primari
chemotherapi
strategi
import
role
treatment
children
intracrani
ependymoma
patient
str
inferior
outcom
despit
respons
chemotherapi
consid
surgeri
prior
irradi
pediatr
ependymoma
italian
experi
verrico
l
quaglietta
r
migliorati
g
scimon
di
gennaro
v
donofrio
p
de
antonelli
zollo
g
cinal
pediatr
univers
napl
federico
ii
napl
itali
children
hospit
napl
itali
radiotherapi
san
giovanni
di
dio
e
ruggi
daragona
salerno
itali
patholog
children
hospit
napl
itali
centro
di
ingegneria
genetica
e
biotecnologia
avanz
ceing
napl
itali
medicina
molecolar
e
biotecnologi
medich
univers
napl
federico
ii
napl
itali
neurosurgeri
children
hospit
napl
itali
object
ependymoma
constitut
primari
central
nervou
system
tumor
children
year
surviv
pf
best
report
experi
method
children
diagnosi
ependymoma
confirm
central
neuropatholog
review
attend
neurosurgeri
unit
children
hospit
enrol
result
consecut
children
median
age
year
rang
year
studi
male
femal
ratio
percent
tumor
intracrani
occur
posterior
fossa
pf
supratentori
spinal
local
associ
age
older
year
imag
ependymoma
heterogen
contain
cyst
calcif
occasion
hemorrhag
irregular
enhanc
dissemin
case
diagnosi
pf
ependymoma
infiltr
brainstem
case
project
cerebellopontin
angl
upper
spinal
canal
case
percent
children
pf
ependymoma
receiv
complet
surgic
resect
histopatholog
variant
cellular
clear
cell
papillari
anaplast
follow
surgeri
patient
receiv
addit
therapi
radiotherapi
chemotherapi
year
pf
median
pf
year
rang
year
pf
children
supratentori
tumor
slightli
better
children
pf
tumor
correl
anaplast
histolog
higher
rate
diseas
recurr
vs
recurr
occur
tumor
bed
case
also
metastat
patient
receiv
surgeri
progress
recurr
rate
significantli
lower
radiotherapi
pair
surgeri
year
pf
independ
extent
resect
seem
advantag
pf
patient
receiv
chemotherapi
conclus
tumor
collect
use
sourc
molecular
studi
aim
identifi
gene
relev
recurr
epidemiolog
childhood
cancer
western
african
region
assess
gender
differ
adetokunboh
divis
commun
health
stellenbosch
univers
cape
town
south
africa
object
wide
believ
male
suscept
develop
cancer
femal
counterpart
except
type
site
cancer
also
appli
childhood
cancer
littl
differ
male
femal
global
know
gender
suscept
give
import
clue
aetiolog
cancer
studi
seek
assess
gender
differ
among
children
cancer
western
african
region
method
secondari
data
analys
conduct
use
globocan
dataset
incid
childhood
cancer
exclud
skin
cancer
analys
fifteen
countri
western
african
region
examin
pair
data
analysi
conduct
determin
differ
among
male
femal
cancer
patient
analysi
carri
use
stata
ic
result
region
record
new
case
africa
burden
male
mean
ci
femal
mean
ci
p
nigeria
highest
number
among
male
femal
respect
cape
verd
lowest
number
case
conclus
western
african
region
signific
gender
differ
new
case
childhood
cancer
male
much
femal
unlik
initi
believ
region
analysi
total
implant
venou
access
port
paediatr
oncolog
favr
g
santana
e
machado
de
matto
guaraldi
c
martin
moura
junior
superti
f
ferreira
f
albanez
souza
r
carvalho
pediatr
surgeri
instituto
nacion
de
rio
de
janeiro
brazil
pediatr
oncolog
nurs
instituto
nacion
de
rio
de
janeiro
brazil
coagul
committe
instituto
nacion
de
rio
de
janeiro
brazil
corynebacterium
diphtherium
laboratori
universidad
estado
rio
de
janeiro
pgcm
rio
de
janeiro
brazil
infect
control
committe
instituto
nacion
de
rio
de
janeiro
brazil
laboratori
microbiolog
instituto
nacion
de
rio
de
janeiro
brazil
nurs
research
instituto
nacion
de
rio
de
janeiro
brazil
object
venou
access
challeng
pediatr
oncolog
order
overcom
barrier
venou
tunnel
cathet
creat
wide
use
pediatr
adult
patient
undergo
chemotherapi
object
studi
evalu
complic
total
implant
venou
access
port
tivap
pediatr
oncolog
patient
method
retrospect
analyz
patient
year
old
treat
chemotherapi
januari
decemb
submit
tivap
insert
follow
cathet
protocol
contempl
oper
room
insert
manipul
care
control
specif
cathet
ambulatori
expert
surgeon
nurs
case
infect
supervis
hospit
infect
control
committe
patient
suspicion
thrombosi
submit
doppler
scan
confirm
case
cathet
remov
initi
thrombolyt
therapi
result
pediatr
patient
cathet
patient
tivap
statist
gender
differ
follow
cathet
ambulatori
tumor
hematolog
patient
patient
complic
cathet
still
use
remov
complet
chemotherapi
protocol
complic
caus
cathet
remov
infect
bacteri
infect
fungal
infect
thrombosi
thrombosi
infect
four
patient
die
treatment
cathet
relat
complic
conclus
use
long
term
cathet
pediatr
oncolog
safe
provid
good
adhes
treatment
result
show
infect
rate
compar
literatur
import
follow
patient
tivap
special
team
cathet
ambulatori
delay
diagnosi
children
third
care
center
special
pediatr
oncolog
mexico
citi
low
incom
countri
f
arreguin
pared
zapata
b
almazan
paez
j
figueroa
pediatr
oncolog
centro
medico
nacion
de
noviembr
issst
mexico
citi
mexico
pediatr
oncolog
instituto
nacion
de
pediatria
mexico
citi
mexico
pediatr
oncolog
centro
medico
nacion
de
noviembr
issst
mexico
citi
mexico
pediatr
oncolog
mexican
institut
social
secur
mexico
citi
mexico
object
develop
countri
delay
referr
patient
special
medic
center
pediatr
cancer
treatment
thu
worsen
prognosi
aim
describ
time
begin
symptom
sign
ill
final
definit
diagnosi
cancer
method
medic
record
pediatr
patient
cancer
treat
last
ten
year
depart
oncolog
centro
medico
nacion
de
noviembr
issst
mexico
citi
review
result
diagnosi
distribut
similar
one
report
literatur
consult
medic
doctor
within
first
five
day
first
symptom
averag
referr
first
doctor
cancer
unit
day
delay
cancer
unit
final
diagnosistook
day
averag
number
doctor
patient
consult
pediatr
oncologist
conclus
import
delay
referr
sick
children
cancer
center
must
consid
better
educ
medic
administr
peopl
order
improv
surviv
incid
surviv
among
adolesc
carcinoma
israel
year
l
berkun
r
rabinovicz
barchana
liphshiz
linn
b
futerman
ben
arush
pediatr
hematolog
oncolog
rambam
health
care
campu
haifa
israel
pediatr
depart
shneider
children
hospit
tel
aviv
israel
epidemiolog
univers
haifa
haifa
israel
epidemiolog
ministri
health
jerusalem
israel
epidemiolog
rambam
health
care
campu
haifa
israel
object
goal
describ
adolesc
carcinoma
incid
surviv
israel
identifi
demograph
epidemiolog
variat
among
adolesc
carcinoma
method
use
data
israel
nation
cancer
registri
order
examin
incid
surviv
adolesc
cancer
isra
adolesc
age
year
diagnos
year
case
analyz
accord
sex
ethnic
compar
popul
children
diagnos
age
year
old
estim
surviv
probabl
updat
decemb
calcul
surviv
new
case
end
result
among
new
case
cancer
children
age
year
old
adolesc
carcinoma
diagnos
median
age
jewish
children
arab
children
incid
rate
per
million
jewish
children
arab
children
incid
children
diagnos
age
per
million
carcinoma
locat
thyroid
gland
case
testi
case
nasopharynx
case
bladder
case
parotid
gland
case
colon
case
ovari
case
unknown
primari
site
case
overal
surviv
year
jewish
children
arab
popul
p
comparison
seer
data
incid
adolesc
carcinoma
higher
israel
conclus
studi
may
add
inform
investig
genet
environment
factor
caus
adolesc
cancer
israel
well
delin
genet
basi
ethnic
origin
dispar
surviv
psycholog
factor
mediat
relat
physic
fit
qualiti
life
children
cancer
k
braam
em
van
lm
buffart
e
van
den
broeder
takken
j
huisman
jhm
merk
mm
van
den
eibrink
gjl
kasper
veen
pediatr
oncologyhematolog
vu
univers
medic
center
amsterdam
netherland
medic
psycholog
vu
univers
medic
center
amsterdam
netherland
epidemiologyand
biostatist
vu
univers
medic
center
emgo
institut
health
care
research
amsterdam
netherland
child
develop
exercis
center
wilhelmina
children
hospit
umc
utrecht
utrecht
netherland
medic
psycholog
wilhelmina
children
hospit
umc
utrecht
utrecht
netherland
pediatr
oncolog
emma
children
hospit
academ
medic
center
amsterdam
netherland
pediatr
oncologyhematolog
erasmu
mc
sophia
children
hospit
rotterdam
netherland
pediatr
oncologyhematolog
vu
univers
medic
center
amsterdam
netherland
object
children
cancer
decreas
physic
fit
qol
studi
aim
investig
relat
physic
fit
qol
whether
mediat
psycholog
factor
method
analys
base
baselin
qlim
qualiti
life
motion
studi
data
random
control
trial
evalu
effect
physic
exercis
psychosoci
intervent
physic
function
fit
among
children
age
year
old
longer
one
year
post
cancer
treatment
data
children
male
age
sd
year
analys
treat
haematolog
malign
cardiorespiratori
fit
crf
assess
maximum
cardiopulmonari
exercis
test
psycholog
function
assess
questionnair
pedsqol
qol
physic
function
fatigu
child
depress
inventori
depress
symptom
youth
self
report
behavior
problem
seri
linear
regress
analys
conduct
examin
associ
crf
qol
crf
mediat
variabl
mediat
variabl
qol
control
age
sex
mediat
effect
examin
use
product
coeffici
method
bootstrap
calcul
confid
interv
result
crf
posit
associ
qol
b
ci
associ
mediat
fatigu
mediat
effect
ci
depress
symptom
ci
intern
behavior
problem
ci
mediat
effect
account
respect
conclus
crf
score
significantli
associ
qol
associ
mediat
fatigu
depress
intern
behaviour
problem
order
increas
qol
childhood
cancer
patient
intervent
focu
improv
crf
sinc
may
reduc
fatigu
distress
improv
qol
futur
longitudin
studi
confirm
find
beyond
burkitt
lymphoma
wide
spectrum
pediatr
malign
curabl
despit
resourc
limit
public
tertiari
hospit
lilongw
malawi
n
mtete
mutai
r
mlotha
h
g
liomba
r
krysiak
g
fedoriw
gopal
kim
p
mehta
p
kazemb
pediatr
new
york
medic
colleg
valhalla
usa
paediatr
kamuzu
central
hospit
lilongw
malawi
patholog
kamuzu
central
hospit
lilongw
malawi
medicin
univers
north
carolina
lilongw
malawi
patholog
univers
north
carolina
chapel
hill
usa
pediatr
baylor
colleg
medicin
children
lilongw
malawi
pediatr
baylor
colleg
medicin
houston
usa
object
burkitt
lymphoma
bl
common
pediatr
malign
africa
herein
describ
experi
treat
varieti
childhood
cancer
lilongw
malawi
method
retrospect
analyz
record
pediatr
oncolog
patient
diagnosi
usual
clinic
howev
fine
needl
aspir
biopsi
perform
routin
start
patient
receiv
transport
reimburs
plu
extens
counsel
result
children
diagnos
cancer
male
femal
diagnos
includ
lymphoma
kaposi
sarcoma
ks
solid
tumor
abdomen
major
wilm
tumor
sarcoma
leukemia
hodgkin
lymphoma
nhl
nhl
jaw
jaw
node
jaw
abdomin
mass
jaw
cn
cranial
nerv
palsi
andor
spinal
cord
compress
probabl
bl
diagnos
also
possibl
bl
nhl
lymphoblast
lymphoma
diffus
larg
lymphoma
base
upon
patholog
andor
clinic
characterist
seven
nhl
patient
primari
mediastin
mass
probabl
lymphoblast
lymphoma
altogeth
children
present
abdomin
lymphoma
pediatr
nhl
murphi
stage
reveal
stage
iii
stage
iii
stage
iv
cn
presum
bone
marrow
involv
patient
hiv
nhl
endem
ks
patient
overal
complet
treatment
regimen
lost
children
achiev
overal
surviv
three
patient
cn
bl
achiev
complet
remiss
chop
chemotherapi
plu
intrathec
conclus
bl
account
childhood
cancer
lymphoma
altogeth
account
major
lymphoma
present
stage
iiiiv
abdomin
mass
common
primari
site
prompt
diagnosi
care
intens
chemotherapi
result
cur
outcom
despit
signific
resourc
limit
epidemiolog
surviv
analysi
egyptian
children
solid
tumor
singl
center
experi
n
elsherif
altawil
el
desouki
ahm
moham
refaat
pediatr
sham
univers
cairo
egypt
epidemiolog
biostatist
nation
cancer
institut
cairo
egypt
pediatr
sham
univers
cairo
egypt
object
total
incid
solid
tumor
among
children
overal
surviv
solid
tumor
year
reach
respect
result
continu
improv
increas
efficaci
treatment
studi
evalu
aspect
surviv
analysi
solid
tumor
among
children
treat
singl
pediatr
oncolog
center
last
year
method
retrospect
data
analysi
children
solid
tumor
diagnos
period
januari
januari
pediatr
oncolog
unit
children
hospit
sham
univers
cairo
egypt
result
patient
diagnos
solid
tumor
total
patient
diagnos
cancer
period
includ
male
femal
frequenc
distribut
newli
diagnos
patient
solid
tumor
heterogen
period
year
highest
year
lowest
year
throughout
year
period
exclud
cn
tumor
neuroblastoma
common
wilm
tumor
came
next
frequenc
retinoblastoma
follow
germ
cell
tumor
hepatoblastoma
osteosarcoma
ewe
sarcoma
rhabdomyosarcoma
overal
surviv
os
patient
solid
tumor
male
patient
patient
without
famili
histori
malign
oper
upon
significantli
higher
year
os
year
os
patient
retinoblastoma
highest
osteosarcoma
lowest
os
conclus
center
incid
pediatr
solid
tumor
rise
frequenc
differ
type
vari
year
year
past
year
os
rate
improv
result
implement
intern
approv
optim
treatment
regimen
base
risk
factor
molecular
marker
factor
influenc
parent
consent
particip
clinic
research
involv
children
egypt
fouda
n
nasef
pediatr
mansoura
univers
children
hospit
mansoura
egypt
object
factor
affect
parent
decis
involv
children
clinic
research
studi
cultur
background
aim
explor
attitud
belief
influenc
parent
decis
involv
children
clinic
research
mansoura
egypt
method
studi
design
sampl
parent
legal
author
repres
children
admit
inpati
depart
mansoura
univers
children
hospit
mansoura
egypt
januari
decemb
elig
studi
parent
guardian
approach
within
hour
child
admiss
ask
complet
questionnair
explor
factor
would
influenc
decis
involv
child
clinic
research
result
famili
approach
flled
questionnair
parent
consent
involv
child
clinic
research
children
consent
significantli
older
refus
sd
versu
sd
year
factor
favour
consent
research
bene
child
enough
explan
benefit
learn
child
condit
factor
favour
refus
use
new
drug
vaccin
invas
procedur
parent
rate
consent
posit
correl
research
belief
research
benefit
child
neg
correl
belief
refus
may
neg
affect
care
provid
child
conclus
hospit
egypt
minim
invas
research
clear
benefit
child
clear
explan
research
process
staff
import
motiv
parent
consent
involv
children
clinic
research
pediatr
osteosarcoma
niamey
first
result
niger
cancer
registri
mamoud
garba
h
hami
h
mahamad
zaki
soulaymani
h
nouhou
quyou
laboratori
genet
biometri
faculti
scienc
ibn
univers
kenitra
morocco
laboratori
patholog
anatomi
cytolog
faculti
health
scienc
abdou
moumouni
univers
niamey
niger
object
worldwid
estim
children
diagnos
cancer
year
incid
case
per
children
less
year
age
children
cancer
live
develop
countri
access
inform
earli
detect
effect
treatment
care
often
poor
studi
aim
investig
epidemiolog
characterist
osteosarcoma
pediatr
patient
past
year
niamey
method
descript
retrospect
studi
pediatr
osteosarcoma
case
report
niger
cancer
registri
establish
faculti
health
scienc
abdou
moumouni
univers
niamey
result
studi
period
children
age
year
diagnos
osteosarcoma
niamey
account
pediatr
malign
collect
period
nearli
case
male
ratio
averag
age
diagnosi
year
rang
year
nearli
case
diagnos
children
age
year
common
site
osteosarcoma
initi
diagnosi
long
bone
lower
limb
preval
ethnic
group
conclus
recent
estim
childhood
cancer
incid
mortal
world
reveal
sharp
differ
develop
developingcountri
possibl
relat
miss
opportun
earli
diagnosi
incomplet
report
childhood
cancer
africa
colorect
carcinoma
pediatr
age
epidemiolog
paradigm
jain
r
mathur
b
lahoti
sharma
depart
surgic
oncolog
divis
pediatr
oncolog
tata
memori
centr
mumbai
india
depart
surgeri
divis
pedaitr
surgeri
mgm
medic
colleg
hospit
govt
cancer
hospit
indor
india
object
colorect
cancer
rare
diseas
pediatr
age
group
annual
incid
case
per
million
children
spectrum
colorect
cancer
includ
pediatr
popul
also
usual
present
advanc
stage
unfavor
histolog
ultim
poor
prognosi
difficult
differenti
diagnosi
delay
present
aggress
biolog
behavior
lead
poor
outcom
method
retrospect
analysi
pediatr
colorect
cancer
patient
present
divis
pediatr
surgeri
june
june
includ
studi
specif
design
audit
form
devis
captur
relev
inform
regard
clinic
present
patholog
factor
treatment
outcom
prognost
factor
follow
result
studi
period
year
june
june
case
pediatr
colorect
cancer
report
median
age
year
rang
five
patient
present
featur
intestin
obstruct
diagnos
emerg
laparotomi
common
site
involv
rectum
transvers
colon
next
common
site
adenocarcinoma
histolog
type
patient
patient
die
within
year
rest
patient
receiv
treatment
conclus
colorect
cancer
rare
diseas
pediatr
age
group
diagnost
dilemma
difficult
differenti
diagnosi
delay
present
treatment
advanc
stage
poor
histolog
featur
contribut
poor
prognosi
diseas
pediatr
age
group
compar
adult
adult
colorect
cancer
earli
detect
stage
stratif
multidisciplinari
treatment
plan
particip
prospect
clinic
trial
help
improv
prognosi
outcom
pediatr
patient
demograph
clinic
surviv
featur
childhood
cancer
istanbul
univers
oncolog
institut
r
kebudi
uludag
iu
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
oncolog
institut
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
istanbul
turkey
pediatr
hematolog
oncolog
radiat
oncolog
divis
istanbul
univers
oncolog
institut
istanbul
turkey
object
aim
studi
identifi
demograph
clinic
surviv
featur
childhood
cancer
admit
istanbul
univers
oncolog
institut
pediatr
year
method
chart
patient
year
admit
evalu
retrospect
age
gender
birth
date
date
diagnosi
place
birthresid
famili
histori
concomin
diseas
primari
diagnosi
primari
site
stage
present
symptom
durat
date
last
examinationdeath
istanbul
univers
cerrahpasa
medic
faculti
clinic
trial
ethic
committe
result
children
cancer
enrol
median
age
year
yr
male
femal
distrubut
age
group
year
year
year
year
year
five
year
surviv
patient
distrubut
diseas
group
year
surviv
central
nervou
system
cn
tumor
n
malign
bone
tumor
n
lymphoma
n
soft
tissu
sarcoma
n
retinoblastoma
n
neuroblastoma
n
leukemia
n
germ
cell
tumor
n
carcinoma
n
renal
tumor
n
hepat
tumor
n
number
patient
diagnos
earli
stage
increas
p
whole
group
year
surviv
rate
patient
diagnos
earli
stage
year
surviv
rate
patient
advanc
stage
diseas
p
conclus
common
solid
tumor
similar
develop
countri
cn
tumor
frequenc
retinoblastoma
bone
tumor
high
refer
center
surviv
patient
diagnos
earli
stage
significantli
higher
advanc
stage
promis
futur
cancer
registri
countri
develop
recent
year
registri
major
cent
help
obtain
detail
data
epidemiolog
clinic
characterict
cancer
patient
may
help
organ
health
care
program
current
statu
servic
childhood
cancer
survivor
turkish
pediatr
oncolog
center
k
mutafoglu
inc
kutluk
dept
pediatr
oncolog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
dept
pediatr
oncolog
hacettep
univers
cancer
institut
ankara
turkey
object
aim
describ
survivorship
servic
provid
turkish
pediatr
oncolog
center
includ
extent
servic
provid
resourc
barrier
servic
develop
method
institut
turkey
pediatr
oncolog
program
invit
particip
survey
order
defin
pediatr
cancer
survivor
servic
particip
rate
result
number
new
cancer
case
center
percent
center
treat
leukemia
solid
tumor
other
treat
cancer
except
leukemia
major
institut
report
provid
survivorship
care
howev
survivor
follow
servic
given
within
routin
pediatr
oncolog
outpati
clinic
practic
attend
pediatr
oncolog
doctor
center
one
centr
report
survivor
clinic
multidisciplinari
team
pediatr
oncolog
clinic
staf
pediatr
oncologist
pediatrician
oncolog
fellow
nurs
oncolog
nurs
social
worker
psychologist
dietitian
nine
institut
keep
survivor
age
treat
institut
center
feel
readi
transit
keep
indefinit
nine
center
report
standard
follow
guidelin
center
report
standard
clinic
assess
form
copi
care
plan
given
survivor
center
evalu
need
servic
provid
consult
center
day
appoint
anoth
day
preval
barrier
insuffici
qualifi
staff
lack
dedic
time
program
develop
lack
physic
space
lack
fund
conclus
survivorship
servic
need
improv
turkey
government
attempt
requir
overcom
defin
barrier
develop
survivorship
program
institut
environment
health
indic
incid
childhood
cancer
pernambuco
northeastern
brazil
role
urban
lnv
basto
jc
silveira
jr
cf
luna
n
centro
de
pesquisa
aggeu
recif
brazil
imunologia
centro
de
pesquisa
aggeu
recif
brazil
object
evalu
impact
environment
health
indic
incid
childhood
cancer
pernambuco
state
northeastern
brazil
method
base
autor
report
chemotherapi
radiotherapi
author
provid
state
health
secretari
pernambuco
new
case
childhood
cancer
age
year
analyz
term
gender
age
diagnosi
municip
origin
popul
estim
whole
period
base
offici
popul
count
health
environment
indic
drive
forc
gini
index
popul
growth
rate
urban
rate
human
develop
index
pressur
number
vehicl
agricultur
establish
extract
manufactur
industri
per
capita
situat
basic
health
unit
per
capita
provid
offici
sourc
empir
bayesian
estim
moran
global
local
index
estim
multipl
regress
use
evalu
associ
health
indic
cancer
incid
result
analyz
new
case
cancer
year
month
diagnos
pernambuco
averag
crude
incid
rate
case
per
million
peopl
increas
rate
ratio
male
femal
except
children
year
leukemialymphoma
predomin
case
central
nervou
system
tumor
correspond
remain
solid
tumor
account
case
mean
averag
incid
rate
municip
group
upper
quartil
bayesian
method
casesmillion
counti
bottom
quartil
casesmillion
p
moran
local
index
identifi
municip
spatial
autocorrel
bivari
analysi
identifi
posit
correl
cancer
urban
p
confirm
multipl
regress
model
p
conclus
adjust
averag
incid
rate
cancer
show
group
municip
high
rate
eastern
state
habit
chang
due
urban
might
increas
exposur
cancer
promot
agent
casual
relat
though
complex
effect
exposur
synthesi
hemoglobin
preschool
children
l
pediatr
second
affili
hospit
shantou
univers
medic
colleg
shantou
china
object
guiyu
major
recycl
town
china
primari
purpos
studi
measur
effect
exposur
synthesi
hemoglobin
hb
preschool
children
method
two
hundr
children
age
exposur
group
live
guiyu
town
children
age
control
group
live
pollut
town
chosen
test
blood
lead
hb
ferritin
folat
vitamin
level
hemoglobinopathi
fill
parent
result
order
better
access
effect
environment
toxic
synthesi
hemoglobin
signific
differ
level
ferritin
folat
vitamin
exposur
control
group
children
exclud
thalassemia
blood
lead
level
bll
rate
bll
exposur
group
signifcantli
higher
control
group
p
three
group
divid
accord
bll
group
group
b
group
c
seen
level
hb
decreas
along
elev
bll
significantli
exposur
group
f
p
howev
shown
control
group
f
p
furthermor
preval
rate
anemia
along
bll
exposur
group
signific
higher
control
group
versu
p
preval
rate
anemia
without
bll
iron
defici
exposur
group
signific
higher
control
group
versu
p
conclus
differ
gener
environ
lead
exposur
area
might
aggrav
inhibit
synthesi
hb
potenti
toxic
might
also
respons
comparison
retinoblastoma
incid
among
children
republ
kyrgyzstan
kazakhstan
e
makimbetov
g
abdualieva
surgeri
slavon
univers
bishkek
kyrgyz
republ
epidemiolog
kazakh
institut
oncolog
radiolog
almati
kazakhstan
object
studi
descript
epidemiolog
retinoblastoma
among
children
central
asian
republ
kyrgyzstan
andkazakhstan
method
studi
cover
period
data
regist
case
retinoblastoma
provid
special
hospit
countri
calcul
retinoblastoma
incid
rate
age
group
geograph
region
gender
ethnic
report
crude
rate
asr
calcul
use
world
refer
popul
result
averag
annual
type
childhood
cancer
incid
per
one
million
kyrgyzstan
kazakhstan
studi
period
total
children
malign
tumor
eye
regist
kazakhstan
correspond
regist
childhood
malign
countri
total
new
case
pediatr
malign
tumor
regist
kyrgyzstan
among
childhood
cancer
retinoblastoma
eighth
common
malign
averag
annual
crude
incid
rate
per
one
million
kazakhstan
male
femal
male
femal
kyrgyzstan
incid
rate
rang
kazakhstan
asr
higher
kyrgyzstan
kazakhstan
age
group
high
incid
rate
retinoblastoma
found
among
uzbek
ethnic
compar
ethnic
group
kyrgyz
russian
kyrgyzstan
incid
rate
slightli
higher
among
rural
region
urban
region
rr
ci
signific
differ
retinoblastoma
incid
found
ethnic
kazakhstan
conclus
incid
rate
retinoblastoma
central
asian
countri
rel
low
compar
level
diseas
countri
asia
africa
south
america
find
support
idea
need
popul
base
childhood
eye
cancer
surveil
etiolog
research
studi
cancer
incid
seven
major
hospit
nepal
k
pradhananga
cancer
prevent
control
research
b
p
koirala
memori
cancer
hospit
bharatpur
nepal
object
studi
give
overview
reliabl
inform
cancer
incid
nepal
year
period
help
make
prevent
control
plan
polici
clinician
polici
maker
give
prioriti
cancer
prevent
control
activ
method
descript
type
studi
case
collect
medic
record
section
seven
collabor
hospit
data
analysi
breakdown
incid
year
age
gender
analys
age
standard
incid
common
cancer
age
specif
rate
tabul
result
total
case
includ
studi
know
burden
cancer
patient
major
hospit
nepal
cancer
diagnos
treat
studi
femal
case
diagnos
male
overal
common
cancer
site
male
lung
stomach
leukemia
femal
cancer
cervix
uteru
breast
lung
cancer
case
seen
femal
male
found
broad
age
group
year
young
age
leukemia
lymphoma
common
replac
lung
oral
stomach
cancer
middl
age
old
age
lung
stomach
cancer
found
male
femal
breast
cancer
young
cervix
uteru
cancer
middl
follow
lung
cancer
older
age
conclus
type
studi
first
time
nepal
know
burden
across
greater
proport
cancer
major
hospit
coverag
may
repres
whole
countri
cancer
patient
diagnos
bpkm
cancer
hospit
popul
base
cancer
registri
yet
establish
difficult
reflect
burden
cancer
impact
mortal
trend
childhood
cancer
midwest
brazil
compar
seer
data
usa
f
ramo
rezend
mp
curado
health
scienc
feder
univers
brazil
health
scienc
feder
univers
prevent
research
institut
brazil
object
global
trend
increas
incid
decreas
mortal
pediatr
tumor
aim
studi
analyz
incid
rate
trend
mortal
childhood
cancer
midwest
brazil
compar
trend
usa
seer
method
incid
data
obtain
cancer
registri
cuiaba
brasilia
campo
grand
mortal
data
obtain
mortal
inform
system
datasusm
standard
rate
calcul
accord
us
std
popul
analyz
mortal
trend
use
logist
regress
model
poisson
join
point
softwar
result
adjust
incid
rate
midwest
region
brazil
childhood
tumor
per
men
per
women
mortal
higher
male
per
femal
per
trend
reduct
mortal
childhood
cancer
gender
significantli
male
year
apc
p
incid
rate
usa
lower
brazil
male
higher
rate
per
femal
per
mortal
rate
per
male
per
femal
period
usa
incid
trend
usa
seer
increas
significantli
apc
p
mortal
decreas
apc
p
conclus
trend
mortal
pediatr
cancer
midwest
brazil
develop
countri
similar
usa
reduct
mortal
although
incid
mortal
rate
brazil
higher
analys
incid
trend
midwest
possibl
due
lack
long
time
seri
epidemiolog
pediatr
malign
india
p
rent
qureshi
e
rent
puri
gulia
bhagat
moiyadi
g
chinnaswami
b
arora
banavali
public
health
tata
institut
social
scienc
mumbai
india
surgic
oncolog
tata
memori
hospit
mumbai
india
medic
oncolog
tata
memori
hospit
mumbai
india
object
much
known
regard
epidemiolog
childhood
cancer
third
world
countri
may
signific
differ
incid
differ
malign
develop
countri
due
differ
genet
environment
factor
data
regard
diseas
pattern
build
block
form
public
health
strategi
countri
studi
attempt
studi
epidemiolog
childhood
malign
third
world
countri
method
retrospect
analysi
undertaken
use
data
tertiari
cancer
centr
india
collect
jan
dec
case
patient
age
group
year
taken
consider
case
distribut
individu
malign
evalu
also
analys
age
present
individu
malign
result
hematolog
malign
common
leukemia
form
lymphoma
total
case
among
solid
tumor
top
five
cn
pnet
osteosarcoma
neuroblastoma
gct
occurr
malign
analyz
across
differ
age
group
see
retinoblastoma
found
year
age
group
similarli
lung
case
age
group
age
group
case
colorect
case
age
group
case
group
conclus
trend
pediatr
cancer
differ
india
develop
countri
higher
rate
pnet
osteosarcoma
lower
rate
cn
malign
public
health
programm
strategi
frame
use
countri
specif
epidemiolog
data
prevent
earli
detect
treatment
diseas
cancer
egyptian
children
epidimiolog
surviv
incid
sadek
pediatr
surgeri
pediatr
oncolog
univers
alexandria
alexandria
egypt
object
report
clarifi
preval
differ
type
mailgnanc
among
egyptian
children
well
incid
surviv
method
retrospect
studi
incid
differ
type
cancer
children
admit
treat
pediatr
oncolog
pediatr
surgeri
depart
univers
alexandria
egypt
pariod
year
done
incid
overal
yera
surviv
analys
report
compar
western
countri
possibl
caus
low
surviv
studi
analys
result
total
number
case
cancer
children
report
period
year
alexandria
univers
hospit
egypt
treat
pediatr
oncolog
pediatr
surgeri
depart
rel
incid
follow
leukemia
brain
tumor
lymphoma
bone
tumor
wilm
tumor
neuroblastoma
sftt
tissu
tumor
germ
cell
tumor
liver
tumor
overal
five
year
surviv
rate
much
lower
compar
western
countri
prove
conclus
egyptian
cancer
children
higher
incid
lymphoma
report
uk
usa
seri
also
higher
incid
wilm
tumor
lower
incid
soft
tissu
tumor
cancer
children
egypt
lower
incid
surviv
compar
report
western
countri
among
import
caus
low
surviv
delay
present
consequ
delay
diagnosi
delay
treatment
well
lack
special
center
pediatr
oncolog
diagnost
delay
childhood
malign
hospit
base
studi
v
sondhi
r
kapoor
p
suresh
dharmesh
chaterje
v
manu
r
tewari
v
sharma
v
nair
pediatr
arm
forc
medic
colleg
pune
india
hematolog
command
hospit
pune
india
medic
oncolog
command
hospit
pune
india
immunohematolog
arm
forc
medic
colleg
pune
india
patholog
arm
forc
medic
colleg
pune
india
radiodiagnosi
arm
forc
medic
colleg
pune
india
dean
arm
forc
medic
colleg
pune
india
object
time
diagnosi
follow
effect
treatment
essenti
manag
childhood
malign
howev
diagnosi
childhood
tumor
often
get
delay
due
earli
symptom
rariti
diseas
object
studi
investig
diagnost
process
childhood
malign
emphasi
time
onset
symptom
start
treatment
method
retrospect
studi
conduct
tertiari
care
referr
hospit
india
studi
period
feb
children
diagnos
malign
studi
chronicl
event
initi
symptom
final
diagnosi
treatment
current
statu
patient
diseas
treatment
delay
defin
time
first
symptom
onset
treatment
result
acut
lymphoblast
leukemia
commonest
malign
diagnos
children
follow
brain
tumor
rhabdomyosarcoma
account
patient
aml
hodgkin
lymphoma
neuroblastoma
pnet
wilm
tumor
account
three
patient
lymphoma
hepatoblastoma
diagnosi
two
children
osteosarcoma
langerhan
cell
histiocytosi
contribut
one
patient
median
delay
treatment
entir
studi
group
day
rang
median
delay
among
children
rang
day
compar
rang
day
among
children
brain
tumor
p
treatment
delay
day
three
week
associ
poor
hazard
ratio
hr
ci
p
acut
leukemia
hr
note
ci
p
brain
tumor
determin
ci
p
conclus
long
delay
onset
symptom
treatment
initi
associ
poor
outcom
high
index
suspicion
earli
initi
diagnost
test
may
aid
earli
diagnosi
reduc
time
onset
treatment
descript
studi
establish
dedic
paediatr
oncolog
servic
low
incom
countri
ghana
south
africa
uganda
j
van
heerden
b
neethl
v
paintsil
j
g
fadhil
paediatr
haematolog
oncolog
servic
pietermaritzburg
metropolitan
complex
hospit
pietermaritzburg
south
africa
paediatr
oncolog
unit
child
health
director
komfo
anoky
teach
hospit
kumasi
ghana
paediatr
oncolog
unit
uganda
cancer
institut
kampala
uganda
object
descript
studi
evalu
logist
clinic
social
educ
challeng
establish
paediatr
oncolog
servic
africa
method
retrospect
chart
review
conduct
children
month
period
respect
kumasi
ghana
pietermaritzburg
south
africa
kampala
uganda
three
newli
establish
dedic
paediatr
haematolog
oncolog
servic
studi
conduct
demograph
vari
countri
determin
burden
diseas
natur
histolog
present
abil
treat
children
malign
evalu
infrastructur
servic
resourc
treat
children
result
kumasi
pietermaritzburg
kampala
unit
respect
servic
million
million
million
children
respect
catchment
area
ratio
million
children
per
specialist
preval
diagnosi
ghana
uganda
endem
burkitt
lymphoma
whilst
south
africa
hodgkin
lymphoma
nephroblastoma
stage
diseas
domin
three
servic
malnutrit
rate
ghana
hiv
rate
amongst
oncolog
patient
whilst
uganda
south
africa
hiv
case
haematolog
malign
malaria
common
diseas
equatori
countri
complic
treatment
neutropen
fever
pietermaritzburg
children
start
establish
protocol
wherea
kumasi
kampala
modifi
protocol
use
due
drug
unavail
toxic
paediatr
servic
compet
adult
servic
resourc
conclus
burden
diseas
outweigh
current
staff
medic
resourc
avail
deliv
comprehens
servic
variou
diseas
prevent
initi
standard
chemotherapi
protocol
caus
frequent
modif
treatment
treatment
goal
mainli
palli
futur
train
paediatr
oncologist
includ
interpret
applic
standard
treatment
modal
regard
diseas
treatment
limit
miss
data
surviv
analysi
central
nervou
system
tumour
amongst
children
adolesc
yorkshir
uk
van
laar
greenwood
stark
rg
feltbow
divis
epidemiolog
biostatist
univers
leed
leed
unit
kingdom
st
jame
institut
oncolog
leed
teach
hospit
nh
trust
leed
unit
kingdom
object
sever
cancer
diagnosi
poorli
record
medic
record
often
result
case
miss
prognost
factor
exclud
analys
complet
case
analysi
cca
creat
potenti
bia
investig
surviv
trend
central
nervou
system
cn
tumour
use
multipl
imput
mi
imput
miss
valu
grade
ethnic
method
children
adolesc
year
diagnos
cn
tumour
identifi
cancer
regist
n
miss
valu
imput
use
logist
regress
age
sex
diagnosi
year
depriv
relaps
treatment
predictor
perform
imput
hazard
ratio
hr
cox
regress
model
pool
compar
cca
result
miss
data
occur
case
surviv
analysi
mi
show
increas
risk
death
compar
white
ethnic
increas
risk
death
grade
ii
iii
iv
tumour
compar
grade
surviv
improv
per
year
studi
period
effect
ethnic
grade
similar
cca
howev
improv
time
observ
mi
reduc
standard
error
coeffici
averag
compar
cca
conclus
mi
minimis
bia
enhanc
precis
surviv
worsen
exponenti
increas
grade
tumour
poorer
compar
white
ethnic
surviv
improv
significantli
studi
period
importantli
effect
observ
use
standard
cca
method
cancer
diagnosi
adolesc
emerg
room
nation
institut
health
r
l
l
r
oncolog
instituto
nacion
de
mexico
citi
mexico
object
mexico
diagnosi
cancer
adolesc
late
associ
poor
prognosi
aim
studi
describ
clinic
characterist
diagnost
adolesc
cancer
method
realiz
descript
retrospect
studi
includ
patient
year
moment
cancer
diagnosi
januari
decemb
analyz
clinic
characterist
stratifi
two
group
patient
diagnos
emerg
room
outpati
clinic
result
includ
patient
diagnos
oncolog
emerg
relat
male
femal
main
oncolog
diagnosi
osteosarcoma
follow
acut
lymphoblast
leukemia
central
nervou
system
tumor
reason
visit
emerg
room
pain
headach
tumor
pallor
associ
diagnosi
emerg
room
mortal
statist
signific
conclus
adolesc
diagnos
frequent
emerg
room
advanc
stage
diseas
medic
urgenc
relev
establish
earli
detect
program
popul
order
reduc
diagnosi
delay
comparison
gonad
extragonad
extracrani
local
germ
cell
tumor
children
multicent
studi
poland
e
jezierska
e
w
balwierz
chybicka
j
kowalczyk
j
peregud
pogorzelski
g
j
wachowiak
wysocki
j
stefanowicz
k
polczynska
l
chelmecka
hanusiewicz
wieczorek
karpinska
e
leszczynska
j
nurzynska
flak
k
peszynska
szczepanski
pobudejska
pieniazek
rychlowska
pruszynska
sokol
jezewska
w
mlynarski
j
trelinska
urasinski
k
wachowiak
szajdak
paediatr
hematolog
oncolog
medic
univers
gdansk
gdansk
poland
patholog
neuropatholog
medic
univers
gdansk
gdansk
poland
pediatr
oncolog
hematolog
ju
medic
colleg
krakow
krakow
poland
pediatrictransplantolog
hematolog
oncolog
medic
univers
wroclaw
wroclaw
poland
pediatr
hematolog
oncolog
medic
univers
lublin
lublin
poland
pediatr
hematolog
oncolog
pomeranian
medic
univers
szczecin
szczecin
poland
pediatr
silesian
medic
univers
katowic
katowic
poland
pediatr
hematolog
oncolog
transplantolog
univers
medic
scienc
poznan
poznan
poland
pediatr
hematolog
oncolog
nicola
copernicu
medic
univers
bydgoszcz
bydgoszcz
poland
pediatr
hematolog
oncolog
medic
univers
gdansk
gdansk
poland
hematolog
oncolog
pediatr
oncolog
center
chorzow
chorzow
poland
paediatr
hematolog
oncolog
medic
univers
bialystok
bialystok
poland
paediatr
hematolog
oncolog
medic
univers
lublin
lublin
poland
paediatr
hematolog
oncolog
nicola
copernicu
medic
univers
bydgoszcz
bydgoszcz
poland
paediatr
hematolog
oncolog
silesian
medic
univers
katowic
zabrz
poland
pediatr
oncolog
surgeri
mother
child
institut
warsaw
warsaw
poland
paediatr
hematolog
oncolog
diabetolog
medic
univers
lodz
lodz
poland
paediatr
hematolog
oncolog
pomeranian
medic
univers
szczecin
szczecin
poland
pediatr
hematolog
oncolog
transplantolog
univers
medic
scienc
poznan
poznan
poland
object
compar
clinic
characterist
histolog
treatment
result
gonad
extragonad
extracrani
local
malign
germ
cell
tumor
mgct
children
method
retrospect
analysi
clinic
histolog
featur
regard
outcom
two
group
patient
group
extragonad
eg
group
ii
gonad
gn
mgct
result
patient
polish
paediatr
oncolog
centresdiagnos
evalu
treat
accord
protocol
includ
group
eg
tumor
group
ii
gn
tumor
patient
gn
tumor
older
median
age
year
month
patient
eg
tumor
median
age
year
month
group
femal
predomin
group
ii
male
size
tumor
bigger
group
evalu
serum
marker
indic
increas
afp
group
group
ii
increas
hcg
reveal
group
group
ii
high
level
ldh
normal
valu
found
adequ
urem
acid
increas
vs
patient
group
group
ii
qualifi
high
risk
group
frequent
recogn
histolog
type
teratoma
yolk
sac
tumor
yst
group
group
ii
yst
dysgerminomaseminoma
relaps
note
patient
everi
group
primari
resist
observ
gn
tumor
third
line
therapi
use
patient
group
group
ii
unsatisfactori
outcom
seen
patient
conclus
signific
differ
clinic
histolog
featur
document
studi
need
explain
prognost
factor
gonad
extragonad
tumor
testicular
paratesticular
tumor
childhood
adolesc
b
aydin
h
susam
sen
varan
b
yalcin
kutluk
c
akyuz
pediatr
oncolog
hacettep
institut
oncolog
ankara
turkey
object
testicular
paratesticular
tumor
rare
childhood
differ
characterist
adult
counterpart
review
experi
testicular
cancer
children
adolesc
center
method
clinic
characterist
outcom
children
treat
retrospect
evalu
result
median
age
patient
primari
testicular
paratesticular
tumor
year
rang
histopatholog
diagnos
yolk
sac
tumor
teratoma
mix
malign
germ
cell
tumor
leydig
cell
tumor
granulosa
cell
tumor
paratesticular
rabdomyosarcoma
three
patient
diagnos
primari
testicular
lymphoma
one
patient
metastat
paratesticular
wilm
tumor
common
clinic
present
painless
scrotal
mass
initi
surgeri
patient
radic
inguin
orchiectomi
patient
stage
higher
germ
cell
tumor
receiv
bep
regimen
cisplatin
day
etoposid
day
bleomycin
day
patient
follow
median
month
year
ef
os
stage
respect
patient
rhabdomyosarcoma
stage
diseas
os
year
patient
paratesticular
rhabdomyosarcoma
conclus
frequent
testi
tumor
yolk
sac
tumor
childhood
bep
effect
regimen
testicular
germ
cell
tumor
stage
tumor
excel
prognosi
regardless
histolog
pure
gonadoblastoma
karyotyp
xx
xy
chimer
neg
girl
case
report
gasperini
g
martin
e
silva
n
suarez
v
kremer
neto
luiz
lope
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
patholi
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
oncolog
pediatr
surgeon
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
cytogeneticist
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
phd
medic
director
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
object
gonadoblastoma
germ
cell
tumor
intim
mix
stromal
circumscrib
nest
usual
hyalin
basal
membran
focal
diffus
calcif
despit
metastat
gonadoblastoma
tumor
type
germ
cell
tumor
associ
invad
stroma
especi
combin
disgerminoma
other
usual
appear
patient
dysgenet
gonad
phenotyp
femal
sexual
somat
abnorm
often
karyotyp
observ
individu
absenc
chromosom
karyotyp
xx
structur
abnorm
x
xx
del
true
hermaphrodit
method
report
case
infant
pure
gonadoblastoma
femal
month
old
without
gonad
dysgenesi
karyotyp
neg
xy
chimer
admit
hospit
palpabl
mass
pelvi
discov
surgeri
correct
right
inguin
hernia
afp
human
chorion
gonadotropin
hcg
normal
ultrasonograph
examin
reveal
larg
solid
expans
train
adnex
right
heterogen
partial
accur
lobul
contour
measur
x
x
cm
volum
laparotomi
found
extens
tumor
left
ovari
right
ovari
tape
perform
left
biopsi
right
ovari
histolog
examin
show
gonadoblastoma
left
ovari
absenc
neoplasia
structur
analyz
immunohistochem
examin
calretinin
inhibin
posit
help
diagnos
gonadoblastoma
result
current
follow
exam
ultrasonagraphi
collect
afp
hcg
monthli
control
possibl
relaps
conclus
case
literatur
review
done
discuss
treatment
approach
addit
research
germ
cell
induc
human
umbil
cord
mesenchym
induc
pluripot
stem
cell
l
wang
chen
pediatr
second
affili
hospit
shantou
univers
medic
colleg
shantou
china
pediatr
capit
institut
pediatr
beij
china
pediatr
guangdong
matern
child
health
care
hospit
guangzhou
china
object
reprogramm
induc
pluripot
stem
ip
cell
human
umbil
cord
mesenchym
cell
humsc
induc
ip
cell
germ
cell
method
nanog
transfect
humsc
lentiviru
reprogram
humsc
ip
cell
morpholog
observ
alkalin
phosphatas
stain
karyotyp
analysi
immunofluoresc
stain
tumor
format
vivo
embryniod
bodi
format
vitro
perform
examin
pluripot
ip
cell
line
induc
one
ip
cell
line
germ
cell
gene
express
measur
day
germ
specif
protein
vasa
meiosi
specif
protein
assesss
immunofluoresc
stain
result
obtain
two
ip
cell
line
complet
reprogram
express
germ
cell
marker
dazl
protamin
undifferenti
state
upregul
germ
cell
marker
differ
time
point
highli
spontan
differenti
upregul
dazl
vasa
modestli
day
howev
gene
downregul
day
vasa
immunofluoresc
stain
indic
high
vasa
express
induc
group
contrast
low
express
spontan
group
day
meanwhil
modest
fluoresc
induc
group
contrast
immunofluores
spontan
group
conclus
nanog
reprogram
humsc
ip
cell
effect
differenti
earli
germ
cell
spontan
germ
cell
induc
enter
meiosi
outcom
extracrani
germ
cell
tumour
children
nation
hospit
pediatr
hanoi
vietnam
ha
nguyen
n
bui
oncolog
nation
hospit
pediatr
ha
noi
vietnam
object
germ
cell
tumour
gct
account
approxim
childhood
cancer
benign
malign
aim
studi
evalu
outcom
extracrani
gct
children
nhp
patient
treat
accord
germ
cell
iii
protocol
method
retrospect
review
children
extracrani
gct
treat
nhp
result
treatment
recurr
death
overal
surviv
os
event
free
surviv
ef
year
analyz
result
patient
matur
teratoma
underw
surgeri
alon
recurr
death
patient
immatur
teratoma
recurr
die
patient
yolk
sac
tumour
underw
excis
tumour
surgic
biopsi
follow
chemotherapi
recurr
death
patient
die
patient
recurr
mortal
recurr
rate
high
sacrococcyg
mediastin
tumour
mix
malign
gct
caus
death
respiratori
failur
coma
due
metastas
overal
surviv
os
whole
patient
group
surviv
ef
year
patient
gonad
gct
os
ef
higher
extragonad
os
p
ef
p
patient
sacrococcyg
mediastin
tumour
os
ef
lower
gonad
retroperiton
gct
os
p
ef
p
patient
immatur
teratoma
yolk
sac
tumour
highest
probabl
os
ef
complic
infect
disord
defec
urin
oper
tumour
sacrococcyg
conclus
prognosi
gct
quit
good
especi
gonad
gct
characterist
extracrani
germ
cell
tumour
children
nation
hospit
pediatr
hanoi
vietnam
ha
nguyen
n
bui
oncolog
nation
hospit
pediatr
ha
noi
vietnam
object
aim
studi
evalu
characterist
extracrani
gct
children
nhp
method
retrospect
review
children
extracrani
gct
treat
nhp
patholog
age
sex
primari
tumour
metastas
stage
analyz
result
children
year
old
studi
malefemal
clinic
sign
could
includ
big
testi
abdomin
distens
touch
abdomin
tumour
sacrococcyg
defec
urin
difficulti
gonad
gct
hold
almost
tumour
extragonad
sacrococcyg
tumour
matur
teratoma
found
ovari
sacrococcyg
mediastinum
tumour
testi
almost
yolk
sac
tumour
children
year
old
usual
tumour
testi
sacrococcyg
children
year
old
usual
tumour
ovari
mediastinum
tumour
imag
sound
mix
heterogen
afp
normal
patient
matur
teratoma
afp
increas
immatur
teratoma
almost
yolk
sac
tumour
mix
malign
gct
teratoma
found
frequent
matur
immatur
follow
yolk
sac
tumour
n
mix
malign
gct
n
dysgerminoma
n
embryon
carcinoma
n
gct
locat
site
testi
n
ovari
n
sacrococcyg
n
mediastinum
n
retroperitoneum
n
abdomin
caviti
n
neck
n
shin
n
miscellan
n
patient
stage
patient
stage
ii
patient
stage
iii
patient
stage
iv
patient
oper
hospit
could
classifi
conclus
extracrani
gct
children
variabl
patholog
primari
locat
patient
admit
earli
stage
extracrani
germ
cell
tumor
thirteen
year
experi
kanti
children
hospit
k
sah
oncolog
kanti
children
hospit
kathmandu
nepal
object
evalu
treatment
outcom
children
extra
cranial
germ
cell
tumor
gct
treat
center
method
retrospect
analysi
treatment
outcom
children
extracrani
germ
cell
tumor
regist
center
march
march
case
undergon
surgic
remov
mass
biopsi
done
post
oper
chemotherapi
follow
tumor
marker
rais
receiv
jeb
carboplatin
etoposid
bleomycin
chemotherapi
weekli
tumor
marker
normal
cycl
ad
thereaft
stage
tumor
matur
gct
normal
tumor
marker
kept
regular
follow
result
childhood
cancer
gct
median
age
group
year
rang
day
yr
f
base
histolog
find
common
tumor
type
yolk
sac
tumor
immatur
teratoma
matur
teratoma
mix
gct
embryon
carcinoma
common
site
sacrococcyg
follow
gonad
mediastin
tumor
common
stage
ii
forti
case
receiv
chemotherapi
kept
close
follow
start
chemotherapi
complet
treatment
end
thirteen
year
aliv
regular
follow
die
lost
follow
conclus
extracrani
germcel
tumour
gct
common
gct
surviv
rate
primari
thymic
germinoma
boy
low
syndrom
takezo
watanab
genma
ohsumi
mori
r
horikawa
k
matsuoka
shimizu
migita
takahashi
ohno
k
sato
fuchimoto
kanamori
depart
pediatr
surgeri
nation
center
child
health
develop
tokyo
japan
depart
oncolog
nation
center
child
health
develop
tokyo
japan
depart
endocrinolog
metabol
nation
center
child
health
develop
tokyo
japan
depart
patholog
nation
center
child
health
develop
tokyo
japan
object
mediastin
germ
cell
tumor
rel
rare
among
thymic
germinoma
extrem
rare
tumor
report
case
thymic
germinoma
associ
low
syndrom
knowledg
first
case
report
thymic
germinoma
complic
low
syndrom
method
case
report
result
male
diagnos
low
syndrom
follow
outpati
clinic
patient
low
syndrom
follow
sign
symptom
renal
tubular
acidosi
congenit
cataract
intellectu
disabl
year
month
old
secondari
sexual
characterist
appear
rapidli
week
serum
high
pgml
chest
mri
show
cystic
tumor
thymu
although
difficult
clarifi
whether
tumor
malign
tumor
function
decid
resect
tumor
tumor
first
biopsi
turn
germinoma
prompt
intraop
diagnosi
perform
extend
thymectomi
mediastin
lymph
node
dissect
oper
treat
four
cours
jeb
carboplatin
etoposid
bleomycin
chemotherapi
dose
reduc
consid
deterior
renal
function
follow
outpati
clinic
shown
recurr
conclus
report
first
case
thymic
germinoma
complic
low
syndrom
imag
featur
matur
immatur
teratoma
pediatr
age
group
youssef
abd
al
karim
ahm
rafaat
el
shafi
h
taha
el
wakil
zaki
diagnost
imag
nation
cancer
institut
cairo
univers
cairo
egypt
surgeri
nation
cancer
institut
cairo
univers
cairo
egypt
pediater
nation
cancer
institut
cairo
univers
cairo
egypt
diagnost
imag
nation
cancer
institut
cairo
univers
cairo
egypt
patholog
nation
cancer
institut
cairo
univers
cairo
egypt
object
teratoma
frequent
germ
cell
tumor
accept
theori
origin
suggest
due
abnorm
differenti
embryon
germ
cell
aris
fetal
yolk
sac
normal
cell
migrat
gonad
yet
migrat
abnorm
locat
gondal
extra
gondal
teratoma
teratoma
rang
benign
matur
immatur
poorli
differenti
lesion
solid
compon
malign
transform
prognosi
clinic
outcom
risk
recurr
report
relat
degre
tumor
matur
object
demonstr
radiolog
featur
teratoma
evalu
potenti
accuraci
imag
find
differenti
matur
immatur
teratoma
method
seventi
pediatr
male
patholog
proven
teratoma
present
hospit
past
four
year
includ
studi
age
rang
day
year
retrospect
review
radiolog
studi
done
correl
patholog
result
result
gondal
tertoma
found
case
ovarian
n
two
bilater
testicular
n
sacrocogg
locat
commonest
site
extragond
teratoma
n
follow
reteroperotin
n
intraperotin
lesion
n
intraspin
n
intracrani
n
neck
n
orbit
n
penil
n
patholog
diagnosi
show
matur
teratoma
immatur
teratoma
matur
teratoma
show
fat
calcif
cystic
solid
compon
wherea
immatur
lesion
usual
lake
one
compon
mostli
fat
compon
conclus
teratoma
common
gondal
one
pediatr
unlik
adult
awar
imag
featur
lesion
especi
immatur
teratoma
import
proper
manag
improv
patient
outcom
malign
histiocytosi
report
two
case
abdullahi
u
abdulsalam
ibrahim
hg
dalhat
paediatr
bayero
universityaminu
kano
teach
hospit
kano
nigeria
haematolog
bayero
universityaminu
kano
teach
hospit
kano
nigeria
background
malign
histiocytosi
rare
disord
character
system
prolifer
morpholog
atyp
histiocyt
clinic
present
vari
greatli
rang
mild
life
threaten
object
draw
attent
clinician
particularli
develop
countri
rare
disord
easili
confus
acut
leukemia
case
report
two
male
age
year
respect
admit
aminu
kano
teach
hospit
present
recurr
fever
month
bilater
neck
swell
period
repeat
blood
transfus
examin
two
underweight
signific
cervic
enlarg
gener
petechiael
haemorrhag
initi
suspect
acut
leukemia
howev
bone
marrow
aspir
biopsi
reveal
diagnosi
malign
histiocytosi
treat
cyclophosphamid
oncovin
doxorubicin
prednisolon
parent
first
child
abandon
cours
chemotherapi
day
first
cours
patient
die
home
day
leav
hospit
second
patient
complet
six
cycl
chemotherapi
repeat
bone
marrow
aspir
biopsi
full
blood
count
first
cours
show
signific
improv
patient
still
follow
patient
bone
marrow
infiltr
histiocyt
engulf
matur
immatur
haemopoiet
cell
patient
patient
chest
radiograph
diagnosi
patient
complet
treatment
patient
chest
radiograph
complet
treatment
conclus
histiocytosi
rare
suspect
differenti
diagnosi
patient
signific
lymph
node
enlarg
recurr
anaemia
repeat
blood
transfus
hematopoiet
stem
cell
transplant
langerhan
cell
histiocytosi
experi
ege
univers
turkey
n
aksoylar
kansoy
kantar
b
demirag
b
akinci
pediatr
oncolog
ege
univers
school
medicin
izmir
turkey
object
langerhan
cell
histiocytosi
lch
character
heterogen
lesion
includ
langerhan
cell
system
involv
risk
organ
andor
patient
younger
year
diagnosi
consid
particularli
devast
carri
potenti
fatal
prognosi
despit
treatment
intensif
mortal
rate
approxim
patient
wiht
refractori
patient
multipl
reactiv
present
challeng
cladribin
cladribin
arabinosid
combin
clofarabin
use
salvag
therapi
method
report
refractori
langerhan
cell
histiocytosi
patient
treat
success
hematopoet
stem
cell
transplant
use
non
myeloabl
condit
regimen
result
conclus
orbit
eosinophil
granuloma
clinic
patholog
studi
r
fan
sun
patholog
indiana
univers
school
medicin
indianapoli
usa
ophthalmolog
indiana
univers
school
medicin
indianapoli
usa
object
orbit
eosinophil
granuloma
aka
unifoc
langerhan
cell
histiocytosi
rel
rare
entiti
among
orbit
tumor
mani
uniqu
clinic
patholog
featur
challeng
current
larg
scale
clinicopatholog
studi
miss
method
retrospect
collect
case
nine
case
institut
file
nine
case
medic
literatur
case
either
electron
microscop
confirm
birbeck
granul
immunohistochemistri
find
andor
posit
clinic
inform
select
radiolog
imag
histopatholog
case
institut
review
result
patient
age
rang
year
old
mean
year
male
predomin
mf
lesion
equal
distribut
right
left
side
case
side
almost
patient
superior
later
orbit
lesion
eye
lid
forehead
swell
proptosi
common
symptom
vision
unimpair
mildli
affect
conclus
decad
present
male
predomin
predilect
eosinophil
granuloma
superior
later
orbit
frequent
remark
adjac
bone
destruct
narrow
differenti
diagnosi
significantli
contrast
rhabdomyosarcoma
orbit
commonli
happen
superomedi
quadrant
embryon
variant
inferior
alveolar
variant
neuroblastoma
though
prefer
metastat
locat
age
characterist
lower
spectrum
accompani
higher
frequenc
bilater
hypertens
caus
catecholamin
secret
pathologist
perspect
spars
langerhan
cell
present
andor
mixtur
inflammatori
infiltr
inconspicu
eosinophil
frozen
section
major
challeng
secondari
hemophagocyt
lymphohistiocytosi
children
malign
undergo
intens
chemotherapi
r
kebudi
b
cakir
gorgun
dogan
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
istanbul
turkey
pediatr
hematolog
oncolog
bezmialem
vakif
univers
medic
faculti
istanbul
turkey
patholog
istanbul
univers
istanbul
medic
faculti
istanbul
turkey
object
hemophagocyt
lymphohistiocytosi
hlh
condit
uncontrol
immun
dysfunct
induc
hyperinflammatori
respons
secondari
hemophagocyt
lymphohistiocytosi
may
associ
system
viral
bacteri
fungal
parasit
infect
individu
underli
immunolog
disord
malign
aim
document
characterist
secondari
hlh
children
malign
point
earli
diagnosi
treatment
method
characterist
hlh
induc
factor
treatment
outcom
femal
male
children
cancer
secondari
hlh
evalu
result
children
acut
lymphoblast
leukemia
infect
relaps
neuroblastoma
infect
anaplast
larg
cell
lymphoma
diagnosi
fever
hepatosplenomegali
anemia
thrombocytopenia
increas
liver
function
test
high
ferritin
level
high
triglycerid
level
hemophagocytosi
bone
marrow
diagnos
secondari
hlh
infecti
etiolog
cytomegaloviru
cmv
cmv
probabl
invas
aspergillu
staphylococcu
aureu
infect
malign
treatment
hemophagocyt
lymphohistiocytosi
consist
corticosteroid
andor
intraven
immunoglobulin
along
appropri
antimicrobi
therapi
chemotherapi
patient
one
patient
second
reactiv
hlh
intens
chemotherapi
due
concomit
cmv
fungal
infect
symptom
sign
regress
gradual
conclus
secondari
hlh
diagnos
patient
malign
may
life
threaten
patient
high
fever
liver
dysfunct
investig
marrow
aspir
sampl
care
observ
detect
hemophagocytosi
earlier
diagnosi
treatment
may
decreas
high
mortal
rate
patient
impact
outcom
modifi
langerhan
cell
histiocytosi
lch
protocol
intensifi
high
risk
induct
augment
prolong
singl
institut
experi
g
narula
ba
wanv
b
arora
sd
banavali
medic
oncolog
pediatr
divis
tata
memori
hospit
mumbai
india
object
relaps
lch
mortal
high
risk
remain
problemat
diseas
progress
earli
reassess
necessit
expens
salvag
option
includ
transplant
etoposid
show
modest
benefit
prolong
mainten
reduc
recurr
earlier
studi
methotrex
prove
equivoc
shorter
mainten
strategi
discontinu
lch
trial
regim
metronom
etoposid
prolong
mainten
includ
methotrex
devis
reduc
need
salvag
patient
accru
year
analyz
method
lch
record
year
jan
studi
singl
system
ss
multisystem
low
risk
receiv
weekli
vinblastin
dose
prednisolon
week
taper
continu
weekli
puls
till
week
puls
till
week
puls
continu
mainten
hr
month
respect
addit
vinblastin
daili
mercaptopurin
weekli
methotrex
given
throughout
mainten
also
receiv
daili
etoposid
everi
day
cycl
one
year
respons
evalu
month
end
therapi
result
patient
evalu
median
age
month
ss
five
lost
follow
first
revalu
improv
activ
better
activ
diseas
intermedi
respons
first
reassess
progress
risk
organ
manag
hr
relaps
within
month
requir
salvag
median
follow
month
evalu
patient
aliv
sequela
conclus
induct
mainten
augment
metronom
etoposid
prolong
mainten
addit
methotrex
shown
promis
reduc
mortal
relaps
respect
avoid
expens
salvag
treatment
case
secondari
hemophagocyt
lymphohistiocytosi
hlh
follow
incomplet
kawasaki
diseas
kd
import
distinguish
recurr
kd
hlh
b
oflaz
sozmen
r
kebudi
dindar
f
gurakan
devecioglu
pediatr
hematolog
oncolog
koc
univers
american
hospit
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
american
hospit
istanbul
turkey
pediatr
cardiolog
istanbul
univers
medic
faculti
american
hospit
istanbul
turkey
pediatr
gastroenterolog
american
hospit
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
medic
faculti
istanbul
turkey
object
hemophagocyticlymphohistiocytosi
hlh
potenti
life
threaten
disord
character
sever
system
inflamm
caus
immun
dysregul
secondari
hlh
seen
variou
infect
rheumatolog
disord
malign
method
report
patient
secondari
hlh
develop
kawasaki
diseas
kd
result
previous
healthi
one
year
old
male
initi
admit
hospit
prolong
unremit
fever
diffus
maculopapular
rash
diagnos
incomplet
kd
echocardiogram
show
dilat
left
coronari
arteri
treat
intraven
immunoglobulin
ivig
aspirin
initi
respons
five
day
hospit
discharg
week
initi
therapi
start
fever
worsen
rash
develop
hepatosplenomegali
cytopenia
hemoglobin
gdl
platelet
ferritin
triglycerid
level
elev
respect
bone
marrow
aspir
biopsi
perform
reveal
hemophagocytosi
level
elev
uml
perforin
mutat
neg
diagnos
secondari
hlh
start
ivig
dexamethason
per
hlh
protocol
rapid
respons
treatment
improv
gener
statu
resolut
fever
cytopenia
decreas
ferritin
triglycerid
level
conclus
hlh
may
secondari
kd
differenti
recurr
kd
secondari
hlh
may
difficult
import
recogn
clinic
laboratori
criteria
hlh
quit
earli
initi
treatment
accordingli
avoid
mortal
morbid
due
hlh
central
nervou
system
imag
childhood
lch
l
porto
jurcoan
e
hattingen
lehrnbech
neuroradiolog
univers
children
hospit
frankfurt
main
germani
object
langerhan
cell
histiocytosi
lch
system
diseas
variabl
impact
central
nervou
system
cn
aim
studi
evalu
cerebr
abnorm
mr
imag
children
lhc
method
two
experienc
neuroradiologist
retrospect
review
mr
examin
avail
children
adolesc
lch
typic
cerebr
patholog
lch
record
rate
regard
signal
intens
imag
imag
result
common
locat
visibl
structur
chang
osseou
follow
respect
pineal
enhanc
enlarg
pituitari
stalkmass
white
matter
hyperintens
dentat
nucleu
parenchym
enhanc
hippocampu
mening
enhanc
agreement
lowest
agreement
found
pineal
region
dentat
nucleu
conclus
common
site
manifest
lch
bone
system
part
cn
cerebellum
white
matter
may
also
involv
indic
initi
neurodegener
childhood
late
present
predict
endocrin
dysfunct
patient
langerhan
cell
histiocytosi
lch
retrospect
analysi
west
scotland
lch
servic
rongh
coyt
murphi
j
sastri
f
ahm
g
shaikh
paediatr
oncolog
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
paediatr
endocrinolog
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
object
langerhan
cell
histiocytosi
lch
rare
condit
primarili
affect
paediatr
popul
characteris
clonal
prolifer
langerhan
cell
diseas
sever
depend
type
number
organ
involv
addit
focal
diseas
aetiolog
still
remain
unclear
aim
record
incid
characterist
west
scotland
lch
patient
focu
predict
factor
endocrin
dysfunct
method
consecut
diagnos
lch
royal
hospit
sick
children
glasgow
januari
decemb
select
patient
note
use
collect
inform
age
sex
postcod
scottish
index
depriv
depriv
ethnic
system
involv
sign
symptom
present
diseas
progress
treatment
current
statu
result
patient
diagnos
lch
median
age
diagnosi
year
rang
year
n
femal
half
patient
n
simd
score
popul
caucasian
south
asian
mix
origin
head
common
site
present
mortal
cohort
common
symptom
present
includ
skin
rash
lump
musculoskelet
pain
patient
high
risk
organ
involv
spleen
liver
hematopoiet
system
lung
femal
endocrin
dysfunct
diabet
insipidu
common
seen
n
n
diagnos
diabet
insipidu
alon
patient
endocrin
dysfunct
longer
symptom
interv
compar
without
endocrin
dysfunct
n
diagnos
month
compar
n
without
endocrin
dysfunct
p
conclus
depriv
associ
increas
incid
lch
femal
like
develop
high
risk
organ
diseas
third
paediatr
lch
patient
develop
endocrin
dysfunct
patient
longer
symptom
interv
studi
requir
sever
dissemin
cn
juvenil
xanthogranuloma
present
brainstem
dysfunct
coma
siddaiahgari
makadia
l
lingappa
pediatr
oncolog
rainbow
children
hospit
hyderabad
india
pediatr
neurolog
rainbow
children
hospit
hyderabad
india
object
see
outcom
juvenil
xanthogranulomatosi
jxg
present
brainstem
dysfunct
coma
method
year
child
present
coma
hemiparesi
secondari
non
langerhan
cell
histiocytosi
treat
lch
protocol
result
three
year
male
present
nodular
lesion
face
sinc
month
age
gradual
progress
trunk
back
extrem
abnorm
birth
histori
polyuria
polydipsia
month
age
frontal
headach
vomit
month
weak
left
half
bodi
pool
secret
month
prior
present
examin
diffus
xanthogranulomat
lesion
skin
eye
mouth
normal
organomegali
cn
examin
reveal
gc
swallow
difficulti
restrict
horizont
gaze
left
hemiparesi
power
grade
right
facial
palsi
cbp
crp
electrolyt
bichemistri
lipid
profil
normal
cxr
usg
abdomen
echo
normal
mri
brain
show
diffus
circumscrib
lesion
cerebrum
cerebellum
subcortex
ependym
region
larg
lesion
right
cp
angl
caus
compress
ivth
ventricl
mild
hydrocephalu
distort
brain
stem
skin
brainbiopsi
report
reveal
juvenil
xanthogranuloma
immunohistochemistri
demonstr
histiocyt
cell
posit
neg
combin
result
confirm
histiocyt
cell
light
clinic
histolog
find
diagnosi
jxg
made
start
chemotherapi
per
lch
iii
protocol
treat
diabet
insipidu
desmopressin
bulbar
dysfunct
hemiparesi
conscious
improv
within
week
skin
lesion
gradual
improv
mri
show
near
total
resolut
lesion
mainten
extend
year
per
neuroimag
find
current
treatment
month
well
conclus
sever
dissemin
cn
diseas
jxg
respond
chemotherapi
signific
neurolog
improv
near
total
mri
skin
lesion
resolut
vincristin
prednisolon
treatment
children
ms
lch
respond
first
line
treatment
experi
tertiari
care
hospit
india
singh
g
pai
l
dawman
r
seth
pediatr
india
institut
medic
scienc
new
delhi
india
object
purpos
studi
find
treatment
outcom
patient
treat
c
steroid
protocol
failur
first
line
treatment
method
medic
record
patient
diagnosi
lch
examin
find
treatment
respons
first
line
protocol
steroid
vbl
treatment
refractori
lch
subsequ
cours
surviv
late
sequela
follow
outcom
assess
result
multisystem
lch
seen
patient
durat
symptom
rang
year
mean
month
multisystem
lch
seen
patient
patient
refractoryrecurr
lch
one
patient
low
risk
recurr
lch
respond
steroid
patient
treat
arac
vcr
protocol
three
receiv
cladribin
base
therapi
group
treat
cladribin
arac
vcr
show
compar
respons
radiolog
clinic
advers
reaction
episod
febril
neutropenia
less
arac
vcr
protocol
risk
organ
affect
liver
patient
multisystem
diseas
residu
lesion
activ
diseas
conclus
arac
vcr
base
treatment
refractori
lch
good
altern
cladribin
base
protocol
cost
benefit
less
myelosuppress
advantag
cladribin
low
risk
recurr
lch
treat
less
cytotox
regim
treatment
refractori
lch
present
challeng
treatment
protocol
need
decid
base
risk
organ
involv
organ
dysfunct
respons
less
intens
protocol
treatment
relaps
langerhan
cell
histiocytosi
accord
lch
iii
protocol
prevent
subsequ
relaps
singl
center
experi
k
svojgr
h
mottl
kyncl
r
kodet
v
smelhau
j
stari
j
mali
pediatr
hematolog
oncolog
charl
univers
faculti
medicin
univers
hospit
motol
pragu
czech
republ
radiolog
charl
univers
faculti
medicin
univers
hospit
motol
pragu
czech
republ
patholog
molecular
medicin
charl
univers
faculti
medicin
univers
hospit
motol
pragu
czech
republ
object
langerhan
cell
histiocytosi
lch
rare
diseas
character
accumul
malign
dendrit
cell
studi
analyz
outcom
patient
lch
treat
lch
iii
protocol
method
patient
lch
treat
institut
eventfre
surviv
ef
overal
surviv
os
analyz
use
stat
viewstatist
program
result
patient
lch
treat
lch
iii
protocol
patient
treat
diagnosi
patient
underw
primari
local
therapi
osteolyt
bone
lesion
first
relaps
median
month
protocol
use
subsequ
salvag
therapi
ss
lch
diagnos
patient
bone
skin
lung
pericardium
lch
patient
bone
skin
lymph
node
thymu
lung
liver
pituitari
gland
risk
organ
affect
patient
lung
liver
median
age
diagnosi
year
median
follow
year
tree
patient
stratifi
therapeut
group
patient
group
group
ss
multifoc
bone
central
nervou
system
ef
patient
os
ef
p
therapeut
group
patient
relaps
group
relaps
group
patient
relaps
p
ef
patient
treat
lch
progress
comparison
primari
treat
patient
p
conclus
patient
lch
treat
lch
iii
protocol
excel
prognosi
institut
hand
lch
iii
protocol
prevent
subsequ
progress
use
salvag
treatment
relaps
lch
primari
local
therapi
larg
number
patient
need
confirm
find
support
mhcz
dro
univers
hospit
motol
pragu
czech
republ
stem
cell
transplant
primari
hemophagocyt
lymphohistiocytosi
experi
tertiari
care
centr
india
thakkar
n
radhakrishnan
kalra
gupta
v
dinand
sachdeva
pediatr
bmt
unit
sir
ganga
ram
hospit
new
delhi
india
object
hemophagocyt
lymphohistiocytosi
hlh
primari
secondari
primari
hlh
refractori
secondari
hlh
hematopoiet
stem
cell
transplant
hsct
cur
treatment
method
retrospect
review
hsct
data
done
patient
underw
hsct
hlh
patient
diagnos
hlh
base
hlh
criteria
genet
workup
done
whenev
feasibl
result
f
month
old
femal
diagnos
hlh
underw
match
sibl
donor
msd
hsct
brother
match
condit
fludarabin
melphalan
globulin
peripher
blood
stem
cell
dose
x
kg
neutrophil
engraft
day
gvhd
skingut
respond
immunosuppres
present
aliv
post
hsct
month
old
male
abnorm
nk
cell
activ
mutat
underw
doubl
umbil
cord
blood
ucb
hsct
post
condit
campath
fludarabin
melphalan
cord
match
nucleat
cell
nc
dose
x
cord
b
match
nc
dose
x
post
transplant
cmv
reactiv
die
month
post
transplant
acut
renal
failuren
year
old
male
munc
mutat
underw
unrel
ucb
hsct
match
condit
busalphan
cyclophosphamid
etoposid
post
transplant
complic
bk
viru
cystiti
skin
gut
gvhd
hypertens
encephalopathi
vision
impair
neutrophil
platelet
engraft
day
respect
die
cardiogen
shock
day
post
transplant
conclus
patient
hlh
undergo
hsct
mani
need
intric
manag
success
rate
transplant
patient
improv
evolv
experi
multisystem
langerhan
cell
histiocytosi
lch
case
seri
review
literatur
india
thakkar
n
radhakrishnan
kalra
agarw
tarangini
v
dinand
sachdeva
pediatr
bmt
unit
sir
ganga
ram
hospit
new
delhi
india
object
outcom
lch
children
vari
excel
respons
diseas
poor
respons
multisystem
diseas
analyz
patient
diagnos
multisystem
lch
center
compar
outcom
publish
literatur
india
method
retrospect
analysi
patient
diagnos
lch
centr
done
patient
stratifi
manag
per
protocol
result
patient
diagnos
lch
f
ratio
median
age
present
year
patient
multisystem
diseas
involv
patient
anemia
hb
anemia
thrombocytopenia
present
featur
includ
fever
n
breath
difficulti
n
hepatomegali
n
splenomegali
n
skin
rash
n
bone
lesion
n
diarrhoea
n
rectal
bleed
n
bleed
ear
n
neck
swell
n
seizur
n
patient
receiv
cours
induct
prednisolon
vinblastin
mainten
chemotherapi
given
patient
patient
switch
salvag
protocol
relaps
activ
diseas
patient
complet
treatment
remiss
treatment
expir
abandon
treatment
lost
follow
identifi
case
seri
indian
literatur
describ
outcom
chidren
lch
bansal
report
lch
patient
year
multisystem
involv
treat
prednisolon
vinblastin
etoposid
week
fatal
outcom
case
seri
singh
report
patient
lch
year
multisystem
diseas
receiv
treatment
one
remiss
one
relaps
die
conclus
multisystem
involv
seen
pediatr
patient
present
lch
outcom
patient
seri
well
report
subcontin
continu
poor
cytosin
arabinosid
combin
chemotherapi
treatment
refractori
recurr
langerhan
cell
histiocytosi
urbieta
garcia
lombardi
g
rey
oncolog
unit
hospit
de
r
gutierrez
ciudad
de
bueno
air
argentina
object
children
langerhan
cell
histiocytosi
lch
may
becom
refractori
standar
therapi
present
repeat
recurr
report
indic
cytosin
arabinosid
combin
chemotherapi
effect
case
purpos
review
describ
experi
unit
method
retrospect
analysi
record
patient
admit
januari
decemb
patient
confirm
diagnosi
lch
recur
sever
time
respond
standard
therapi
patient
given
dose
daili
day
plu
concurr
day
profilact
filgrastim
total
cours
program
cours
repeat
everi
week
result
patient
lch
admit
refer
period
patient
use
scheme
plu
multipl
reactiv
progress
diseas
median
age
diagnosi
month
rang
month
year
patient
initi
involv
organ
central
nervou
system
cn
mass
patient
complet
cours
chang
per
progress
two
cours
one
discontinu
sever
grade
liver
toxic
first
dose
first
cours
one
myelosuppress
main
toxic
even
patient
complet
cours
grade
three
patient
free
activ
diseas
month
complet
cours
chemotherapi
high
risk
organ
invol
patient
one
cn
mass
refractori
patient
patient
liver
toxic
aliv
conduct
line
treatment
conclus
patient
refractori
lch
multipl
subsequ
reactiv
standard
therapi
high
chanc
achiev
remiss
combin
scheme
report
literatur
accept
toxic
clinic
studi
treatment
efficaci
case
malign
eosinophil
granuloma
orbit
children
huang
zhang
w
zhang
pediatr
beij
tongren
hospit
capit
medic
univers
beij
china
object
studi
clinic
charact
analysi
efficaci
orbit
malign
eosinophil
granuloma
first
symptom
orbit
mass
children
method
total
patient
orbit
malign
eosinophil
granuloma
children
diagnos
use
patholog
hospit
apr
apr
case
male
case
femal
median
age
year
old
case
case
chemotherapi
use
mvp
project
methylamin
vincristin
v
prednison
p
case
chemotherapi
use
project
etoposid
prednison
vinblastin
case
treat
use
surgeri
chemotherapi
case
treat
use
singl
chemotherapi
statist
analysi
clinic
charact
efficaci
prognosi
case
malign
orbit
eosinophil
granuloma
children
result
first
symptom
case
orbit
mass
extrud
eyebal
case
strabismu
diminut
vision
eye
pain
fever
patient
eye
diseas
come
right
orbit
case
account
left
orbit
case
account
follow
octob
median
time
month
case
follow
nidus
case
complet
absorb
nidus
case
absorb
case
patient
relaps
five
patient
strabismu
diminut
vision
eye
pain
recov
chemotherapi
function
obstruct
conclus
malign
orbit
eosinophil
granuloma
children
insidi
onset
atyp
clinic
manifest
pay
attent
differenti
diagnosi
orbit
eosinophil
granuloma
children
sensit
chemotherapi
focu
absorpt
rate
comprehens
treatment
higher
icccpo
parentsurvivor
late
effect
radiat
therapi
power
neuroplast
l
cadogan
pediatr
oncolog
bc
children
hospit
vancouv
canada
object
descript
late
effect
radiat
therapi
bear
adult
surviv
cancer
children
impact
qualiti
life
present
includ
current
research
person
struggl
face
childhood
cancer
survivor
inform
differ
methodsprogram
promot
neuroplast
rehabilit
childhood
cancer
collabor
effort
srcc
child
develop
ccd
tata
memori
hospit
tmh
cancer
survivor
support
group
jha
e
goswami
v
dhamankar
prasad
p
kurkur
r
jalali
nagrulkar
joshi
garwar
survivorship
cancer
societi
mumbai
india
pediatr
oncolog
tata
memori
hospit
mumbai
india
neuro
oncolog
tata
memori
hospit
mumbai
india
rehabilit
child
develop
ccd
mumbai
india
object
rehabilit
young
cancer
patient
whose
psycholog
locomotor
function
affect
due
treatment
provid
therapi
session
collabor
ccd
rehabilit
centr
method
tmh
collabor
multi
specialti
rehabilit
therapi
centr
mumbai
offer
therapi
young
cancer
patient
disturb
psycholog
locomotor
function
cancer
survivor
support
group
survivorship
programm
indian
cancer
societi
respons
implement
execut
administr
ugam
childhood
cancer
survivor
charg
facilit
collabor
centr
conduct
physiotherapi
occup
therapi
speech
therapi
educ
therapi
session
evalu
patient
patient
given
rate
good
fair
poor
base
aforesaid
evalu
monthli
report
sent
hospit
give
detail
assess
recommend
follow
patient
may
may
advis
follow
give
due
consider
hisher
sensori
activ
daili
live
adl
psycholog
locomotor
function
evalu
evalu
done
free
cost
result
total
patient
median
age
rang
beneficiari
brain
tumor
non
brain
tumor
receiv
cranial
irradi
resid
mumbai
outsid
mumbai
parent
feedback
regard
session
good
fair
patient
shown
overal
improv
activ
daili
live
therapi
session
conclus
taken
except
step
rehabilit
activ
cancer
patient
session
boon
patient
parent
also
treat
oncologist
abl
deliv
holist
care
patient
expect
sever
elig
cancer
patient
get
benefit
ongo
collabor
long
term
toler
whole
irradi
children
cancer
v
martin
v
n
oberlin
jl
habrand
h
martelli
boll
radiat
oncolog
institut
gustav
roussi
villejuif
franc
pediatr
oncolog
institut
gustav
roussi
villejuif
franc
pediatr
mignot
le
chenay
franc
pediatr
oncolog
institut
gustav
roussi
villejuif
franc
radiat
oncolog
centr
bacless
caen
franc
pediatr
surgeri
necker
enfant
malad
pari
franc
pediatr
surgeri
du
le
franc
radiat
oncolog
institut
gustav
roussi
villejuif
franc
object
analys
sequela
children
receiv
whole
irradi
wapi
cancer
method
patient
longer
year
treat
childhood
cancer
multimod
approach
includ
wapi
gustav
roussi
review
data
collect
medic
technic
file
toxic
grade
ctcae
result
children
treat
wapi
mean
age
time
irradi
year
year
histolog
wilm
tumor
patient
desmoplas
tumor
clear
cell
sarcoma
seminoma
tumor
rhabdomyosarcoma
mesoblast
nephroma
wapi
deliv
dose
gy
anterior
posterior
field
boost
case
residu
tumor
contralater
kidney
protect
gy
median
year
year
long
term
renal
failur
concern
patient
grade
grade
iii
grade
iii
also
receiv
nephrotox
chemotherapi
digest
disord
occur
patient
grade
grade
ii
grade
iii
femal
need
treatment
induc
puberti
still
prepubert
age
endocrin
disord
report
male
short
statur
defin
height
ds
age
sex
occur
patient
scoliosi
observ
patient
secondari
tumor
occur
twice
one
urotheli
carcinoma
one
chondrosarcoma
ilium
within
radiat
field
conclus
sequela
wapi
limit
except
growth
troubl
secondari
tumor
loss
ovarian
function
femal
thu
patient
need
close
prolong
ovarian
tissu
cryopreserv
least
futur
vitro
oocyt
matur
may
appropri
femal
underw
wapi
receiv
give
support
german
concept
work
f
mauersberg
deutsch
kinderkrebsstiftungdlfh
german
childhood
cancer
foundat
deutsch
kinderkrebsstiftungdlfh
german
childhood
cancer
foundat
hall
germani
object
present
concept
receiv
give
support
deutsch
kinderkrebsstiftung
german
childhood
cancer
foundat
main
goal
concept
good
mixtur
give
support
young
adult
get
back
experi
initi
support
concern
youth
method
young
adult
receiv
special
medic
social
law
support
give
includ
tour
rainbow
handsid
support
seminar
camp
differ
topic
cours
teach
young
adult
result
cancer
young
adult
difficult
experi
concept
want
gain
multidimension
view
possibl
achiev
experi
thing
learn
cancer
spread
impress
other
conclus
aim
concept
young
adult
cancer
get
platform
exchang
receiv
invest
time
experi
support
concern
youth
give
support
person
support
like
strengthen
idea
present
survey
project
fate
moroccan
childhood
cancer
survivor
f
msefer
alaoui
n
benaicha
el
khattabi
l
hessissen
childhood
cancer
associ
lavenir
rabat
morocco
epidemiolog
clinic
research
chu
hassan
ii
fe
morocco
survivor
associ
lavenir
rabat
morocco
pediatr
oncolog
children
hospit
rabat
rabat
morocco
object
present
survey
object
establish
databas
moroccan
childhood
cancer
survivor
gather
inform
current
statu
meet
need
treatment
prevent
strategi
monitor
term
prevent
earli
detect
treatment
support
method
survey
target
moroccan
patient
treat
complet
partial
rabat
childhood
cancer
diagnosi
put
least
year
ago
data
collect
includ
civil
statu
diagnosi
cancer
characterist
treatment
evolut
current
medic
social
statu
order
reach
survivor
use
sever
mean
includ
phone
email
social
network
postal
mail
questionnair
would
complet
survivor
parent
physician
hire
project
coordin
fellow
epidemiologist
write
thesi
survey
subject
project
durat
expect
month
includ
survey
prepar
distribut
collect
questionnair
analysi
result
write
publish
survey
find
project
budget
includ
coordin
salari
train
meet
expens
would
financ
terri
fox
run
took
place
rabat
morocco
februari
intern
childhood
cancer
day
event
result
path
hope
associ
found
moroccan
childhood
cancer
survivor
attend
meet
gave
inform
phone
mail
mani
well
other
suffer
medic
educ
behavior
problem
conclus
conclus
survey
crucial
establish
databas
moroccan
childhood
cancer
survivor
order
monitor
system
includ
key
referenti
inform
medic
social
support
nation
level
lavenir
associ
year
support
children
cancer
morocco
f
msefer
alaoui
f
chraibi
l
hessissen
childhood
cancer
associ
lavenir
rabat
morocco
object
develop
countri
parent
group
creat
enhanc
research
well
children
develop
countri
associ
famili
rare
first
aim
provid
financi
resourc
treatment
method
lavenir
associ
one
first
parent
children
cancer
associ
develop
countri
establish
caregiv
parent
cancer
patient
time
state
mani
problem
face
infecti
nutriti
diseas
sinc
creation
lavenir
get
stronger
effici
servic
provid
numer
drug
equip
school
entertain
hous
awar
earli
diagnosi
train
financi
support
develop
partnership
st
jude
research
children
hospit
improv
educ
diagnosi
care
paediatr
oncolog
lavenir
work
hospit
caregiv
cancer
organ
state
depart
set
local
section
fe
initi
group
survivor
path
hope
lavenir
built
parent
hous
provid
accommod
famili
nt
live
rabat
soften
treatment
condit
decreas
treatment
follow
abandon
la
maison
de
lavenir
spaciou
bedroom
kitchen
dine
room
live
room
playroom
provid
meal
famili
pay
usd
day
per
adult
sinc
open
famili
spent
day
day
time
year
time
hous
run
lavenir
organ
fund
rais
event
result
la
maison
de
lavenir
significantli
allow
decreas
treatment
abandon
contribut
strongli
cure
children
cancer
conclus
parent
friend
group
develop
countri
achiev
remark
result
improv
social
medic
condit
patient
hayim
children
cancer
israel
associ
servic
children
cancer
israel
orren
hayim
associ
ramat
gan
israel
object
hayim
associ
found
parent
children
cancer
voluntari
organ
activ
children
oncolog
ward
throughout
israel
goal
assist
reduc
suffer
children
famili
improv
qualiti
health
care
associ
oper
medic
center
nationwid
part
oncolog
ward
associ
member
icccpo
method
main
activ
support
israel
medic
associ
pediatr
hematolog
oncolog
gather
coordin
medic
inform
child
cancer
purchas
sophist
equip
improv
diagnosi
treatment
ie
pfax
earli
diagnosi
leukemia
refriger
store
stem
cell
etc
fund
studi
develop
sophist
method
improv
diagnos
direct
optim
care
improv
profession
standard
medic
paramed
psychosoci
personnel
fund
particip
local
intern
convent
seminar
foster
improv
children
welfar
support
surround
support
famili
financi
problem
due
child
diseas
fund
transport
treatment
fund
support
group
better
cope
diseas
arrang
trip
fun
day
children
famili
israel
abroad
monthli
fun
flight
children
assist
class
play
corner
hospit
individu
tuition
children
treatment
grant
scholarship
children
rehabilit
result
associ
achiev
includ
assist
establish
night
care
ward
children
cancer
first
kind
israel
rabin
medic
center
assist
set
bone
marrow
transplant
ward
children
schneider
hospit
first
israel
standard
medic
psychosoci
care
among
variou
center
israel
improv
child
welfar
hospit
condit
conclus
much
must
done
overview
pediatr
adolesc
malign
scope
challeng
nepal
panthe
ks
sharma
na
children
cancer
foundat
bharatpur
nepal
object
find
occurr
type
pediatr
malign
estim
cancer
burden
facil
requir
treat
method
collect
data
hospit
base
nation
cancer
registri
nepal
divis
pediatr
oncolog
b
p
koirala
memori
cancer
hospit
bpkmch
data
analyz
occurr
rel
frequenc
pediatr
cancer
nepal
result
new
pediatr
cancer
report
hbcr
new
case
report
bpkmch
divis
pediatr
oncolog
bpkmch
leukemia
lymphoma
bone
sarcoma
brain
tumor
retinoblastoma
germ
cell
tumor
wilm
tumor
skin
epithelia
neoplasm
hepatoblastoma
neuroblastoma
ent
other
nation
wide
hbcr
leukemia
lymphoma
bone
sarcoma
brain
tumor
retinoblastoma
gct
neuroblastoma
epitheli
neoplasm
hepatoblastoma
other
million
children
year
age
censu
averag
incid
childhood
cancer
new
case
year
conclus
pediatr
oncologist
bed
avail
within
nepal
much
insuffici
present
bed
capac
oncologist
ca
nt
cure
patient
year
larg
number
patient
treatment
access
due
inadequ
human
recours
facil
give
cancer
treatment
care
new
case
bed
pediatr
oncologist
along
support
subspecialti
expert
resourc
cure
pediatr
cancer
low
cost
save
almost
life
year
psychosoci
need
servic
survivor
age
yr
schmid
deutsch
kinderkrebsstiftung
bonn
germani
object
today
major
children
cancer
becom
survivor
howev
survivorship
often
come
differ
psychosoci
problem
besid
medic
side
effect
cancer
treatment
even
adult
survivor
childhood
cancer
risk
variou
social
psycholog
sequela
therefor
need
servic
especi
steadili
increas
group
present
psychosoci
need
survivor
age
yr
show
servic
deutsch
kinderkrebsstiftung
german
childhood
cancer
foundat
survivor
method
deutsch
kinderkrebsstiftung
german
childhood
cancer
foundat
own
waldpiratencamp
camp
childhood
cancer
patient
survivor
famili
camp
heidelberg
also
camp
especi
adult
survivor
childhood
cancer
sinc
one
seminar
yearli
cancer
survivor
year
arisen
urgent
question
survivor
tell
peopl
especi
malefriendfemalefriend
cancer
survivor
peopl
go
think
anyon
want
date
okay
sex
birth
control
pill
etc
open
frank
discuss
sensit
topic
may
prevent
unnecessari
hurt
stress
result
older
childhood
cancer
survivor
need
younger
one
seminar
exclus
adult
year
alway
fulli
book
conclus
servic
especi
survivor
age
year
essenti
youth
futur
guidanc
workforc
childhood
cancer
survivor
austria
c
schneider
kienesberg
vienna
austria
object
former
childhood
cancer
patient
often
face
difficulti
enter
workforc
deal
cognit
impair
other
cope
reduc
capac
mani
patient
problem
commun
gap
cv
due
recent
cancer
treatment
case
patient
also
deal
prejud
employ
stigmat
former
childhood
cancer
patient
underestim
abil
urgent
need
initi
support
former
patient
way
enter
workforc
method
look
suitabl
solut
former
patient
austria
long
time
final
appropri
project
found
munich
germani
run
success
sinc
therefor
use
german
model
base
austrian
intervent
result
austria
project
youth
futur
start
begin
cooper
local
hospit
austrian
childhood
cancer
organ
acco
die
berat
lead
consult
focus
coach
train
context
collabor
three
institut
adopt
differ
role
hospit
recommend
former
patient
acco
fund
project
consult
provid
base
mani
year
experi
individu
support
client
amongst
thing
servic
includ
person
develop
clarif
physic
psycholog
abil
career
advic
applic
coach
conclus
austrian
childhood
cancer
organ
feel
oblig
support
former
childhood
cancer
patient
also
medic
treatment
especi
former
brain
tumor
patient
need
profession
support
find
place
world
workforc
patient
fix
traine
posit
regular
work
condit
great
import
mean
gain
econom
independ
financi
secur
stronger
posit
within
societi
work
togeth
win
battl
cancer
live
better
life
give
back
commun
wan
mutual
support
littl
life
warrior
societi
hong
kong
hong
kong
china
object
carri
vision
work
togeth
win
battl
cancer
live
better
life
give
back
commun
method
ever
sinc
establish
littl
life
warrior
societi
llw
grown
rel
modest
basic
run
voluntari
helper
uniqu
model
provid
mutual
support
servic
cancer
children
parent
commun
llw
provid
platform
cancer
children
parent
get
support
famili
go
experi
llw
regist
chariti
societi
hong
kong
home
littl
life
warrior
offici
open
cancer
centr
provid
comfort
area
patient
famili
member
rest
play
wait
outpati
treatment
also
tutori
class
arrang
help
children
catch
schoolwork
result
gener
help
mani
support
decad
littl
life
warrior
societi
rais
public
awar
childhood
cancer
reach
mainland
china
intern
stage
number
member
peopl
nine
littl
life
warrior
societi
mainland
china
establish
impact
work
mani
childhood
cancer
patient
famili
conclus
year
vision
littl
life
warrior
societi
remain
solid
small
warrior
grown
big
warrior
becom
volunt
societi
serv
childhood
cancer
patient
hospit
use
home
littl
life
warrior
refer
set
children
cancer
patient
resourc
centr
hong
kong
children
hospit
put
servic
fight
spirit
conquer
cancer
zakaria
foundat
indonesian
childhood
cancer
foundat
yoai
jakarta
indonesia
object
survivor
would
like
motiv
cancer
patient
spirit
patient
diagnos
mani
new
goal
want
complet
life
want
help
friend
suffer
cancer
give
support
think
support
one
thing
need
keep
spirit
nt
give
middl
treatment
method
obviou
medic
treatment
time
felt
sad
even
depress
sister
ask
write
someth
like
journal
help
feel
better
honest
nt
think
write
would
realli
final
began
write
coupl
day
sinc
love
sing
think
nt
make
write
someth
everyon
enjoy
start
write
coupl
song
base
experi
diari
write
gather
song
wrote
made
album
result
help
famili
abl
produc
album
made
thought
sell
album
donat
incom
cancer
patient
indonesian
childhood
cancer
foundat
yoai
fact
would
love
abl
donat
children
cancer
throughout
world
foundat
conclus
present
still
write
song
english
indonesian
time
distribut
album
sever
friend
abl
give
sever
album
foundat
icccpo
confer
hongkong
wish
idea
inspir
cancer
patient
risk
factor
associ
anthracyclin
induc
cardiac
dysfunct
pediatr
patient
shaikh
mm
alam
saleem
ahm
pediatr
child
health
aga
khan
univers
hospit
karachi
pakistan
object
anthracyclin
signific
impact
outcom
mani
pediatr
chemotherapi
protocol
therefor
remain
mainstay
treatment
aim
studi
identifi
risk
factor
anthracyclin
induc
cardiac
dysfunct
pediatr
oncolog
patient
method
perform
prospect
cohort
studi
juli
jun
aga
khan
univers
hospit
pakistan
pediatr
oncolog
patient
age
year
receiv
anthracyclin
chemotherapi
remain
regular
follow
least
year
post
chemotherapi
includ
final
analysi
result
patient
male
mean
age
month
n
common
primari
diagnosi
follow
lymphoma
n
aml
n
doxorubicin
alon
combin
use
n
patient
cumul
dose
p
mode
deliveri
p
also
found
statist
signific
conclus
anthracyclin
induc
cardiac
dysfunct
mostli
relat
cumul
dose
radiat
therapi
sepsi
regular
long
term
follow
cardiologist
key
point
earli
diagnosi
therapi
long
term
surviv
anthracyclin
induc
acut
earli
onset
myocardi
dysfunct
childhood
malign
shaikh
mm
alam
saleem
mohsin
ahm
pediatr
child
health
aga
khan
univers
hospit
karachi
pakistan
object
anthracyclin
ie
doxorubicin
daunorubicin
backbon
chemotherapi
childhood
malign
well
known
cardiotox
includ
cardiomyopathi
systol
andor
diastol
dysfunct
arrhythmia
pericardi
effus
object
studi
identifi
anthracyclin
induc
acut
earli
onset
chronic
progress
cardiotox
variou
childhood
malign
method
children
receiv
anthracyclin
chemotherapi
three
echocardiograph
evalu
baselin
one
month
year
aga
khan
univers
karachi
juli
june
prospect
analyz
cardiac
dysfunct
statist
analysi
across
systol
diastol
dysfunct
baselin
month
year
made
repeat
measur
analysi
varianc
anova
result
among
studi
male
mean
age
month
major
acut
lymphoblast
leukemia
doxorubicin
alon
use
combin
therapi
use
fifteen
children
develop
cardiac
dysfunct
month
children
within
year
isol
diastol
dysfunct
respect
combin
systol
diastol
dysfunct
month
year
echocardiographi
respect
seven
patient
expir
due
sever
cardiac
dysfunct
eight
children
receiv
doxorubicin
show
dysfunct
mostli
relat
higher
cumul
dose
p
conclus
studi
report
high
incid
anthracyclin
induc
cardiotox
presenc
high
cumul
dose
doxorubicin
alon
combin
daunorubicin
patient
trisomi
aml
ewe
sarcoma
identifi
high
risk
evalu
iron
overload
acut
lymphoblast
leukemia
end
treatment
k
arjmandi
rafsanjani
l
rohani
hematolog
oncolog
iran
univers
medic
scienc
tehran
iran
md
tehran
univers
medic
scienc
tehran
iran
object
leukemia
common
malign
children
treatment
diseas
caus
bone
marrow
suppress
necessit
excess
blood
transfus
aim
studi
evalu
iron
overload
assess
serum
ferritin
level
acut
lymphoblast
leukemia
correl
number
blood
transfus
children
year
age
method
studi
patient
refer
oncolog
depart
children
hospit
known
enrol
serum
level
ferritin
serum
iron
tibc
transferin
satur
end
treatment
month
month
treatment
evalu
patient
sign
infect
inflamm
exclud
end
data
analyz
spss
version
softwar
result
patient
evalu
male
femal
mean
serum
iron
mean
tibc
transferin
satur
mean
valu
ferritin
end
treatment
month
month
treatment
mean
number
transfus
signific
correl
serum
level
ferritin
number
transfus
conclus
present
studi
show
treatment
serum
level
ferritin
high
compar
normal
valu
number
blood
transfus
prove
determin
factor
iron
overload
feasibl
pilot
studi
set
fertil
clinic
survivor
childhood
cancer
treatment
india
p
arora
r
misra
mehrotra
sharma
p
bagai
r
arora
reproduct
medicin
nova
ivi
fertil
clinic
new
delhi
india
medic
oncolog
medanta
medic
gurgaon
india
parent
support
group
new
delhi
india
medic
oncolog
max
hospit
new
delhi
india
object
cancer
children
treatment
implic
futur
fertil
hitherto
studi
fertil
preserv
infertil
manag
patient
india
studi
pilot
initi
address
gap
method
childhood
cancer
survivor
either
work
whose
parent
work
invit
attend
clinic
focuss
fertil
dec
mar
survivor
seen
paediatr
oncologist
reproduct
medicin
specialist
result
survivor
male
median
age
year
rang
year
treatment
median
year
rang
year
seen
origin
diagnosi
includ
relaps
aml
nhl
retinoblastoma
wilm
bone
sarcoma
gonad
gct
alkyl
agent
exposur
seen
survivor
commonli
cyclophosphamid
median
dose
rang
radiotherapi
exposur
seen
cranial
radiotherapi
testicular
radiat
one
one
survivor
gonad
surgeri
ovarian
dysgerminoma
one
hsct
base
clinic
treatment
variabl
survivor
classifi
low
risk
infertil
medium
risk
high
risk
except
one
year
old
achiev
puberti
hormon
semen
analysi
request
appropri
none
plan
start
famili
none
receiv
counsel
fertil
preserv
time
diagnosi
conclus
fertil
clinic
survivor
childhood
cancer
treatment
india
feasibl
part
overal
survivor
clinic
resourc
limit
appropri
risk
group
identifi
children
benefit
fertil
preserv
need
earli
intervent
cancer
treatment
complet
insight
biomark
obes
survivor
acut
leukemia
batra
r
shrivastava
tyagi
dhawan
l
ramakrishnan
bakhshi
medic
oncolog
dr
bra
irch
aiim
new
delhi
india
cardiac
biochemistri
india
institut
medic
scienc
new
delhi
india
object
acut
lymphoblast
lymphoma
survivor
predispos
obes
consequ
increas
risk
death
due
cardiovascular
diseas
exact
mechan
obes
known
although
attribut
steroid
cranial
irradi
consequ
hypothalam
disturb
studi
done
assess
preval
potenti
biomark
obes
survivor
acut
leukaemia
patient
method
studi
conduct
india
institut
medic
scienc
survivor
acut
myeloid
leukaemia
aml
complet
treatment
atleast
one
year
enrol
studi
preval
obes
studi
determin
bodi
mass
index
bmi
bmi
percentil
classifi
overweight
obes
potenti
biomark
studi
assess
serum
leptin
resistin
adiponectin
level
elisa
compar
obes
leukaemia
survivor
result
acut
leukaemia
aml
patient
enrol
studi
median
follow
month
post
treatment
median
age
rang
year
patient
male
preval
overweightobes
acut
leukaemia
survivor
compar
normal
healthi
control
mean
serum
leptin
resistin
level
similar
obes
leukemia
survivor
vs
pgml
p
vs
ngml
p
howev
mean
serum
adiponectin
level
significantli
lower
obes
leukaemia
survivor
compar
leukaemia
survivor
vs
gml
p
conclus
preval
obes
higher
acut
leukaemia
survivor
lower
level
adiponectin
obes
leukem
survivor
may
one
mechan
predisposit
survivor
acut
leukaemia
qualiti
life
function
outcom
childrenadolesc
survivor
malign
bone
tumor
p
berlanga
salom
v
castel
cancer
clinic
translat
research
group
instituto
de
investigacion
sanitaria
la
fe
valencia
spain
pediatr
orthoped
unit
hospit
la
fe
valencia
spain
pediatr
oncolog
unit
hospit
la
fe
valencia
spain
object
qualiti
life
hrql
import
outcom
measur
due
increas
surviv
rate
although
hrql
long
pediatr
cancer
mostli
compar
gener
popul
bone
tumor
hrql
rel
poor
compar
cancer
survivor
aim
assess
hrql
function
perform
survivor
order
establish
individu
program
promot
earli
detect
chronic
health
problem
method
prospect
studi
cohort
malign
bone
tumor
survivor
year
old
diagnosi
one
year
therapi
evid
diseas
inclus
studi
patient
interview
pediatr
oncologist
orthoped
surgeon
health
util
index
use
measur
hrql
musculoskelet
tumor
societi
score
mst
assess
physic
disabl
bone
tumor
hrql
compar
match
leukemialymphoma
survivor
data
analyz
use
spss
result
fifteen
osteosarcoma
eleven
ewe
sarcoma
patient
includ
median
age
diagnosi
evalu
rang
year
rang
fourteen
male
twelv
femal
seven
patient
undergon
amput
bone
tumor
survivor
rate
health
state
goodveri
goodperfect
compar
leukemialymphoma
group
p
score
bone
tumor
group
significantli
lower
vs
p
well
ambul
pain
score
vs
p
vs
p
respect
median
mst
score
rang
conclus
malign
bone
tumor
survivor
poorer
overal
hrql
compar
match
leukemialymphoma
survivor
howev
consid
health
state
goodveri
goodperfect
focus
adequ
pain
control
rehabilit
group
patient
need
utilis
requir
manag
approach
integr
user
profession
view
design
teenag
young
adult
tya
cancer
survivorship
servic
p
beynon
l
hartley
j
cheshir
cameron
dolbi
badger
c
p
spencer
e
fynn
steven
target
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
tya
cancer
servic
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
psycholog
health
servic
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
object
intervent
appli
earli
cancer
diagnosi
may
effect
way
help
tya
patient
treatment
inform
patientprofession
experi
integr
view
deliveri
patient
care
demand
structur
approach
collect
prioritis
data
requir
manag
rm
system
engin
process
use
evalu
develop
region
tya
clinic
servic
method
data
sought
postal
questionnaireinterviewfocu
group
patient
n
familyfriend
n
onlin
questionnaireinterview
profession
n
data
item
extract
summaris
find
assess
underli
requir
chang
caredeliveri
servic
exampl
patient
find
exercis
go
public
gym
would
nt
comfort
fear
exposedjudg
gener
two
differ
possibl
requir
patient
need
access
sportshealth
facil
afford
sens
privacyprotect
public
patient
offer
psycholog
support
help
deal
feel
differ
andor
percept
judg
neg
requir
deriv
way
evalu
factor
reflect
health
polici
practic
applic
includ
benefit
achiev
term
qualityinnovationproductivitypreventionpersonalis
care
qippp
difficulti
easi
prioriti
mustshouldcouldwould
benefit
servic
benefit
patient
result
individu
find
gener
requir
reduc
uniqu
requir
prioritis
select
consid
easiest
achiev
high
direct
benefit
patient
use
design
intervent
modifyenh
patient
care
area
physic
psycholog
wellb
work
mentor
staff
train
conclus
rm
use
tool
support
servic
develop
base
userprofession
view
use
larg
volum
data
appli
alongsid
methodolog
accur
respond
user
need
audit
trail
link
find
final
step
servic
chang
use
fatigu
thermomet
screen
adolesc
young
adult
brain
tumor
survivor
brand
c
chorda
c
liptak
p
manley
c
reckliti
psychosoci
oncolog
cancer
institut
boston
usa
pediatr
oncolog
cancer
institut
boston
usa
object
cancer
relat
fatigu
crf
one
common
distress
symptom
experienc
adolesc
young
adult
aya
cancer
survivor
may
disproportion
affect
brain
tumor
survivor
nation
guidelin
recommend
screen
crf
routin
data
support
specif
screen
measur
limit
object
studi
assess
valid
fatigu
thermomet
ft
measur
assess
fatigu
aya
brain
tumor
survivor
method
survivor
age
median
time
sinc
diagnosi
year
rang
year
complet
fatigu
thermomet
ft
multidimension
fatigu
scale
mf
singl
clinic
visit
result
survivor
identifi
clinic
fatigu
mf
roc
analysi
indic
good
concord
ft
rate
mf
criterion
auc
ft
score
reliabl
identifi
survivor
elev
mf
score
identifi
low
ft
score
good
sensit
poor
specif
higher
ft
cutoff
score
good
specif
miss
mani
case
fatigu
identifi
mf
sensit
ft
cutoff
score
met
studi
criteria
screen
accuraci
sensit
specif
conclus
result
studi
indic
ft
screen
measur
fatigu
abl
identifi
clinic
signific
fatigu
aya
brain
tumor
survivor
result
discuss
context
research
screen
measur
well
clinic
research
implic
find
anticanc
chemotherapi
development
anomali
teeth
children
e
brozyna
b
dental
surgeri
clinic
children
children
memori
helath
institut
warsaw
poland
pediatr
oncolog
depart
children
memori
helath
institut
warsaw
poland
depart
pediatr
dentistri
medic
univers
warsaw
warsaw
poland
object
anticanc
treatment
childhood
carri
risk
dental
anomali
denticl
aim
correl
development
anomali
teeth
type
anticanc
drug
administ
chemotherapi
relat
earli
complic
method
sixti
patient
complet
anticanc
treatment
median
yr
treatment
complet
healthi
children
age
year
assess
clinic
radiolog
evalu
perform
includ
assess
enamel
anomali
anomali
number
size
tooth
structur
medic
record
review
data
collect
tumor
type
age
diagnosi
treatment
chemotherapi
durat
typedos
anitcanc
agent
emesi
mucos
treatment
sever
accord
ctcae
v
criteria
statist
analysi
perform
use
u
mann
spearman
test
result
children
treat
chemotherapi
statist
higher
incid
enamel
anomali
teeth
agenesi
microdontia
root
shorten
taurodont
denticl
compar
health
control
administr
vincristin
total
dose
correl
everi
type
tooth
anomali
cyclophosphamid
ifosfamid
doksorubicin
hypodontia
microdontia
root
shorten
enamel
anomali
etoposid
cisplatin
microdontia
root
shorten
enamel
anomali
methotrex
teniposid
root
shorten
carboplatin
denticl
enamel
anomali
mucosisti
emesi
potenti
root
shorten
microdontia
enamel
anomali
conclus
chemotherapi
earli
complic
emesi
mucosisti
result
develop
dental
anomali
vincristin
cyclophosphamideifosfamid
doxorubicin
anticanc
agent
like
greatest
impact
incid
complic
mucos
emesi
add
sever
anomali
health
outcom
childhood
medulloblastomapnet
one
center
result
b
brozyna
drogosiewicz
e
swieszkowska
filipek
tarasinska
j
korzeniewska
perek
pediatr
oncolog
depart
children
memori
helath
institut
warsaw
poland
object
assess
health
outcom
survivor
childhood
medulloblastomapnet
mbpnet
method
mbpnet
patient
male
femal
least
yr
median
yr
treatment
complet
examin
median
patient
age
mbpnet
diagnosi
yr
assess
yr
patient
treat
surgeri
irradi
chemotherapi
clinic
health
problem
assess
grade
accord
ctc
ae
v
criteria
result
follow
health
problem
record
decreas
physic
activ
patient
neurolog
fatigu
iq
averag
short
statur
renal
hear
requir
hear
dental
cari
dental
musculoskelet
skin
bmi
second
malign
among
patient
advers
health
event
nineti
patient
demonstr
least
health
problem
median
health
problem
one
patient
sever
ctc
four
patient
develop
second
malign
pt
pt
md
conclus
survivor
childhood
mbpnet
high
risk
develop
variou
multipl
chronic
acut
health
condit
due
complex
observ
advers
health
problem
lifelong
care
children
cure
mbpnet
essenti
health
problem
survivor
childhood
solid
tumor
brozyna
b
daniluk
rutynowska
drogosiewicz
pediatr
oncolog
children
memori
helath
institut
warsaw
poland
object
evalu
health
statu
consecut
present
children
treatment
solid
tumor
exclud
cn
tumor
method
patient
male
femal
median
age
examin
yr
tumor
diagnosi
examin
least
year
elaps
sinc
treatment
complet
survivor
nhl
hodgkin
soft
tissu
sarcoma
st
bone
sarcoma
wilm
hepatoma
mix
germ
cell
treatment
follow
tumor
specif
protocol
patient
examin
physician
health
statu
assess
grade
accord
ctc
ae
result
among
survivor
children
genet
syndrom
pt
nutrit
statu
normal
short
statur
observ
patient
present
least
one
follow
health
issu
endocrinopathi
nephropathi
skin
abnorm
bone
skelet
deform
osteoporosi
immunolog
hematolog
neurolog
gastrolog
cardiolog
disord
hear
sight
impair
dental
cari
psychosoci
psychiatr
problem
two
patient
histori
second
malign
neoplasm
ewe
patient
present
least
one
diseas
therapi
relat
health
problem
requir
treatment
close
conclus
diseas
treatment
relat
complic
common
survivor
childhood
malign
due
wide
spectrum
observ
health
problem
children
cure
solid
tumor
follow
lifetim
transit
adult
care
specif
recommend
given
medic
psychosoci
assist
second
malign
neoplasm
smn
report
one
center
b
brozyna
filipek
drogosiewicz
w
grajkowska
pediatr
oncolog
depart
children
memori
helath
institut
warsaw
poland
patholog
depart
children
memori
helath
institut
warsaw
poland
object
second
malign
neoplasm
smn
seriou
complic
anticanc
treatment
sinc
childhood
malign
cure
rate
sinc
grow
number
patient
smn
assess
risk
condit
mandatori
aim
studi
review
patient
smn
treat
depart
method
clinic
featur
patient
smn
gender
age
primari
diagnosi
treatment
first
diseas
time
primari
tumor
smn
smn
type
treatment
outcom
analyz
patholog
primari
smn
review
result
among
patient
treat
children
femal
male
age
yr
yr
median
yr
diagnos
smn
patient
primari
diagnosi
cn
tumor
tissu
sarcoma
st
tumor
wt
case
osteosarcoma
hepatoblstoma
germ
cell
tumor
patient
radiotherapi
primari
tumor
cn
prophylaxi
receiv
chemotherapi
time
diagnosi
primari
diseas
smn
rang
month
year
year
follow
smn
diagnos
hematolog
malign
pt
pt
malign
brain
osteosarcoma
thyroid
cancer
wt
clear
cell
sarcoma
renal
cell
carcionoma
ovarian
cancer
patient
smn
occur
irradi
field
pt
cn
pt
thyroid
seven
pt
primari
cn
tumor
develop
aml
md
smn
patient
aliv
year
month
year
median
year
conclus
observ
confirm
risk
smn
children
cure
cancer
long
latenc
period
smn
warrant
lifelong
surveil
condit
pulmonari
complic
term
survivor
childhood
adolesc
cancer
n
f
ergin
e
demir
kantar
h
alper
aksoylar
sayin
kansoy
pediatr
oncolog
ege
univers
school
medicin
izmir
turkey
pediatr
radiyolog
ege
univers
school
medicin
izmir
turkey
chest
ege
univers
school
medicin
izmir
turkey
object
pulmonari
complic
among
common
seriou
sequela
seen
childhood
cancer
survivor
ccss
cancer
type
age
diagnosi
thorac
involv
pulmonari
metastasi
diagnosi
type
treatment
modal
chemotheraphi
pulmonarythorac
radiotheraphi
surgeri
affect
pulmonari
complic
method
studi
examin
pulmonari
complic
cancer
patient
year
old
whose
treatment
complet
remiss
least
year
physic
examin
chest
pulmonari
function
test
pft
spyrometr
test
dlco
evalu
ege
univers
depart
pediatr
oncolog
also
healthi
within
age
rang
children
young
adult
evaul
control
group
result
patient
acut
leukemia
lymphoma
bone
soft
tissu
sarcoma
cn
tumor
solid
tumor
surviv
patient
disord
pft
found
small
airway
diseas
diffus
disord
combin
disord
restrict
disord
disord
control
group
disord
pft
diagnos
cancer
year
age
increas
risk
restrict
disord
small
airway
diseas
p
bone
soft
tissu
sarcoma
increas
risk
small
airway
diseas
sad
solid
tumor
observ
especi
disord
p
receiv
high
dose
alkil
agent
increas
risk
restrict
disord
also
pulmonarythorac
rt
increas
risk
impair
pft
saw
follow
time
caus
variabl
impair
pft
conclus
pulmonari
disfunct
ccss
prevel
diagnost
age
pulmonari
rtsurgeri
high
dose
alkil
agent
import
risk
factor
ccss
follow
late
pulmonari
function
impair
complic
second
neoplasm
singl
center
experi
sa
c
bozkurt
g
sahin
n
yuksek
si
yesil
g
tanyildiz
mo
candir
toprak
au
ertem
pediatr
dr
sami
ulu
woman
health
children
educ
research
hospit
ankara
turkey
pediatr
medic
school
univers
ecevit
ankara
turkey
pediatr
konya
research
train
hospit
ankara
turkey
object
despit
improv
childhood
cancer
patient
surviv
time
second
cancer
anoth
problem
radiotheraphi
epipodophyllotoxin
alkyl
agent
respons
factor
unit
state
secondari
malign
percentag
percentag
increas
diagnosi
hodgkin
lymphoma
aim
studi
evalu
second
neoplasm
affect
factor
center
method
file
patient
diagnos
second
neoplasm
evalu
retrospect
mostli
diagnosi
patient
perform
regular
follow
diagnosi
two
patient
perform
adult
oncolog
center
first
diagnosi
patient
includ
seven
acut
leukemia
six
acut
lymphoblast
leukemia
one
mixt
type
leukemia
two
wilm
tumor
two
lymphoma
one
hodgkin
lymphoma
one
ganglioneuroblastoma
one
langerhan
cell
histiocytosi
respect
result
period
total
childhood
cancer
patient
diagnos
center
fourteen
second
neoplasm
diagnos
period
eight
fourteen
patient
male
median
period
cessationof
theraphi
initi
diseas
diagnosi
secondari
neoplasm
month
month
two
patient
develop
second
malign
treatment
first
diagnosi
six
aml
three
soft
tissu
sarcoma
one
osteoblastoma
one
paraganglioma
one
hodgkin
lymphoma
one
squamoou
cell
carcinoma
tongu
one
papillari
type
carcinoma
thyroid
respectivli
four
patient
diagnos
acut
myeloid
leukemia
aml
die
three
patient
treatment
conclus
seri
epipodophyllotoxin
alkyl
agent
radiotheraphi
seem
risk
factor
second
neoplasm
result
second
aml
dismal
number
second
cancer
like
estim
insuffici
number
follow
childhood
cancer
patient
need
regular
follow
lifetim
triptorelin
preserv
fertil
adolesc
treat
chemotherapi
cancer
meli
caruso
la
spina
l
lo
nigro
p
samperi
damico
f
bellia
v
miraglia
g
russo
di
cataldo
pediatr
hematolog
oncolog
univers
catania
catania
itali
pediatr
endocrinolog
univers
catania
catania
itali
object
triptorelin
gnrh
agonist
analogu
may
administ
femal
cancer
receiv
chemotherapi
order
obtain
menstrual
suppress
decreas
hemorrhag
risk
due
thrombocytopenia
object
evalu
triptorelin
administr
also
protect
role
gonadotox
chemoterapeut
drug
method
retrospect
observ
analysi
includ
femal
receiv
chemotherapi
cancer
unit
age
alreadi
menarch
inform
consent
receiv
monthli
depot
intramuscular
triptorelin
dose
mg
report
includ
patient
conclud
treatment
sinc
least
one
year
still
aliv
evalu
ovarian
function
look
clinic
sign
symptom
ovarian
damag
amenorrhea
menstrual
chang
also
search
possibl
pregnanc
abort
made
laboratori
dose
serum
fsh
lh
prl
progesteron
ovarian
ultrasound
result
patient
evalu
accord
elig
criteria
lymphoma
leukemia
pnet
ewe
sarcoma
rhabdomyosarcoma
four
receiv
chemotherapi
hdct
patient
receiv
hdct
one
develop
amenorrhea
other
maintain
normal
ovarian
function
clinic
laboratori
ultrasound
evalu
three
achiev
spontan
physiolog
pregnanc
gave
birth
healthi
babi
three
patient
made
hdct
develop
prematur
ovarian
failur
pof
conclus
hdct
seem
triptorelin
abl
preserv
ovarian
function
case
could
recommend
triptorelin
follow
cryopreserv
ovarian
tissu
oocyt
studi
suggest
chemotherapi
may
prevent
pof
patient
treat
without
hdct
indic
appropri
need
prospect
random
trial
larger
popul
long
term
childhood
cancer
survivor
lebanon
r
farah
r
kouzi
p
kiwan
r
bejjani
c
saddi
j
pediatr
st
georg
hospit
univers
medic
center
beirut
lebanon
faculti
health
scienc
american
univers
beirut
beirut
lebanon
faculti
medicin
univers
balamand
beirut
lebanon
chanc
children
cancer
associ
beirut
lebanon
object
despit
high
surviv
rate
pediatr
cancer
evalu
medic
psychosoci
effect
survivor
lebanon
scarc
method
children
treat
variou
type
cancer
cure
year
diagnosi
three
major
hospit
lebanon
identifi
data
collect
base
chart
review
extens
questionnair
administ
parent
patient
excel
sheet
fill
data
analyz
result
elig
cancer
survivor
identifi
averag
period
year
rang
yr
patient
includ
initi
survey
mean
age
rang
yr
femal
male
leukemia
lymphoma
sarcoma
rest
variou
malign
common
physic
symptom
report
weight
problem
chronic
fatigu
emot
manifest
includ
anxieti
felt
adventur
confid
patient
complain
treatment
affect
educ
repeat
academ
year
troubl
continu
educ
drop
patient
attend
colleg
one
smoker
none
drug
abus
survivor
knew
truth
previou
cancer
posit
insight
medic
treatment
hospit
team
famili
support
therapi
conclus
studi
first
lebanon
look
outcom
childhood
cancer
survivor
although
mani
success
lead
normal
life
signific
number
whose
health
overal
educ
affect
medic
psycholog
critic
reintegr
societi
program
lack
countri
need
develop
pulmonari
function
treatment
embryon
brain
tumor
includ
craniospin
irradi
green
te
merchant
c
billup
dc
stoke
bronisc
u
bartel
chintagumpala
te
hassal
gururangan
gb
mccowag
ja
heath
rj
cohn
mj
fisher
srinivasan
gw
robinson
gajjar
epidemiolog
cancer
control
st
jude
children
research
hospit
memphi
usa
radiolog
scienc
st
jude
children
research
hospit
memphi
usa
biostatist
st
jude
children
research
hospit
memphi
usa
pediatr
univers
tennesse
school
medicin
memphi
usa
oncolog
st
jude
children
research
hospit
memphi
usa
haematolog
oncolog
hospit
sick
children
toronto
canada
pediatr
medicin
texa
children
hospit
houston
usa
haematolog
oncolog
royal
children
hospit
brisban
australia
pediatr
preston
robert
tisch
brain
tumor
center
duke
univers
medic
center
durham
usa
pediatr
children
hospit
westmead
sydney
australia
oncolog
royal
children
hospit
melbourn
australia
clinic
oncolog
sydney
children
hospit
sydney
australia
oncolog
children
hospit
philadelphia
philadelphia
usa
bone
marrow
transplant
cellular
therapi
st
jude
children
research
hospit
memphi
usa
object
treatment
children
embryon
brain
tumor
ebt
includ
craniospin
irradi
limit
data
regard
effect
radiat
therapi
rt
pulmonari
function
method
protocol
enrol
patient
year
age
ebt
pulmonari
function
test
pft
forc
expiratori
volum
one
second
forc
vital
capac
fvc
spirometri
total
lung
capac
tlc
plethysmographi
diffus
capac
lung
carbon
monoxid
correct
hemoglobin
dlcocorr
obtain
differ
pft
obtain
follow
complet
rt
month
act
compar
use
exact
wilcoxon
sign
rank
test
result
elig
patient
spine
dose
cgi
cgi
proton
beam
n
enrol
june
march
least
one
pft
median
age
diagnosi
year
rang
year
median
spinal
rt
dose
gy
rang
gy
median
cyclophosphamid
dose
g
rang
month
complet
treatment
dlco
predict
evalu
evalu
predict
evalu
evalu
fvc
predict
evalu
evalu
tlc
predict
evalu
evalu
patient
dlco
significantli
decreas
median
differ
md
predict
p
month
act
md
predict
p
compar
end
rt
conclus
dlco
significantli
decreas
month
complet
spinal
rt
compar
immedi
tlc
margin
decreas
month
act
p
continu
monitor
cohort
plan
preval
hypertens
among
childhood
cancer
survivor
e
guler
n
araz
buyukcelik
balat
pediatr
oncolog
akdeniz
univers
school
medicin
antalya
turkey
pediatr
gaziantep
univers
school
medicin
gaziantep
turkey
pediatr
nephrolog
gaziantep
univers
school
medicin
gaziantep
turkey
object
limit
number
studi
regard
preval
hypertens
among
childhood
cancer
survivor
aim
studi
determin
preval
hypertens
relationship
obes
method
patient
treat
follow
least
two
year
without
relaps
second
malign
includ
studi
patient
ambulatori
blood
pressur
monitor
perform
h
use
microlif
oscillometr
devic
hypertens
defin
systol
blood
pressur
andor
diastol
blood
pressur
percentil
weight
measur
bioelectr
imped
analysi
bia
bia
determin
tanita
tbf
bodi
composit
devic
obes
defin
indic
intern
obes
task
forc
intern
standart
diagnost
crietaria
intern
diabet
foundat
respect
result
averag
age
patient
femalemal
year
time
therapi
rang
month
median
diagnosi
patient
hematolog
malignaci
wilm
tumor
solid
tumor
thirti
six
patient
normotens
patient
hypertens
hypertens
preval
patient
wilm
tumor
solid
tumor
hematolog
malign
respect
forti
three
patient
standart
weight
wherea
overweight
obes
fourteen
patient
abdomin
obes
particularli
high
hematolog
malign
relationship
hypertens
obes
waist
circumfer
found
p
conclus
childhood
cancer
survivor
increas
risk
develop
obes
abdomin
obes
hypertens
hypertens
preval
patient
wilm
tumor
higher
patient
malign
result
might
point
import
follow
earli
diagnosi
hypertens
especi
wilm
tumor
survivor
pattern
predictor
accompani
adult
survivor
childhood
cancer
routin
clinic
visit
k
hain
hr
mitchel
l
balsamo
j
rotatori
ns
pediatr
yale
univers
school
medicin
new
usa
object
mani
adult
survivor
childhood
cancer
difficulti
transit
health
care
independ
indic
patient
depend
determin
pattern
attend
clinic
other
associ
predictor
among
survivor
method
studi
survivor
childhood
cancer
age
year
attend
first
routin
yale
hero
survivor
clinic
visit
presenc
famili
member
companion
routin
ascertain
part
standard
evalu
elig
patient
frequenc
attend
clinic
other
calcul
overal
stratifi
patient
diseas
characterist
potenti
predictor
attend
clinic
other
analyz
logist
regress
result
particip
mean
age
year
diagnosi
femal
histori
leukemialymphoma
cn
tumor
sarcoma
solid
tumor
age
year
rang
overal
patient
year
attend
clinic
parent
spousesignific
rel
friend
categori
mutual
exclus
patient
age
like
year
attend
anoth
vs
p
parent
spousessignific
other
compris
companion
respect
age
group
histori
cn
tumor
significantli
associ
attend
survivor
clinic
accompani
p
age
diagnosi
gender
insur
type
significantli
associ
attend
clinic
other
conclus
found
high
percentag
adult
childhood
cancer
survivor
particularli
cn
tumor
accompani
other
routin
survivor
care
visit
research
need
evalu
role
famili
companion
childhood
cancer
survivor
health
care
assist
young
adult
patient
transit
independ
manag
health
survivorship
passport
care
childhood
cancer
survivor
initi
european
network
research
cancer
children
adolesc
encca
r
haupt
c
dellacasa
karner
l
kremer
c
bergeron
caruso
saraceno
v
morsellino
r
skinner
l
hjorth
epidemiolog
biostatist
unit
g
gaslini
institut
genoa
itali
health
care
system
cineca
bologna
itali
project
manag
icccpo
vienna
austria
pediatr
oncolog
emma
children
hospit
academ
medic
center
amsterdam
netherland
pediatr
hematologyoncolog
centr
leon
berard
lyon
franc
epidemiolog
biostatist
unit
g
gaslini
institut
genoa
itali
paediatr
adolesc
haematolog
oncolog
great
north
children
hospit
royal
victoria
infirmari
newcastl
upon
tyne
unit
kingdom
paediatr
haematolog
oncolog
lund
univers
lund
sweden
object
young
peopl
cancer
surviv
least
half
reach
enter
adulthood
essenti
health
system
abl
inform
survivor
relev
stakehold
possibl
risk
late
effect
cancer
treatment
receiv
method
partnership
among
profession
survivor
parent
expert
establish
encca
network
creat
survivorship
passport
paper
document
design
given
patient
plan
end
treatment
contain
simpl
cancer
histori
therapi
inform
passport
includ
recommend
indivualis
base
clinic
guidelin
develop
within
pancaresurfup
project
intern
guidelin
harmon
group
ighg
facilit
prevent
earli
detect
treatment
potenti
late
effect
result
intern
ballot
involv
expert
clinician
held
defin
passport
templat
passport
gener
secur
platform
access
multipl
languag
type
user
integr
nationalhospit
clinic
trial
databas
linkag
guidelin
screen
relev
possibl
late
complic
secondari
breast
cancer
cardiomyopathi
prematur
ovarian
insuffici
establish
new
guidelin
implement
soon
becom
public
conclus
survivorship
passport
aim
harmon
former
cancer
patient
across
europ
promot
homogen
criteria
guidelin
clinic
practic
prevent
earli
detect
treatment
physic
psychosoci
late
advers
effect
age
person
medicin
simpl
access
tool
enhanc
healthcar
address
individu
patient
issu
specif
pediatr
cancer
survivor
possibl
lead
import
breakthrough
monitor
cure
childhood
cancer
survivor
contribut
optim
qualiti
life
survivor
centralis
long
term
clinic
childhood
cancer
survivor
mani
survivor
attend
jk
mcloon
j
jone
ce
wakefield
k
johnston
rj
cohn
school
women
children
health
unsw
medicin
univers
new
south
wale
sydney
australia
australian
new
zealand
haematologyoncolog
group
institut
medic
research
clayton
australia
kid
cancer
centr
sydney
children
hospit
randwick
australia
behaviour
scienc
unit
kid
cancer
centr
sydney
children
hospit
randwick
australia
object
childhood
cancer
survivor
remain
elev
riskof
chronic
diseas
complet
cancer
treatment
long
term
follow
ltfu
care
recommend
earli
detectionintervent
howev
mani
childhood
cancer
survivor
ccss
remain
engag
ltfu
servic
decad
complet
nation
studi
assess
ccss
perceiv
benefit
barrier
attend
specialis
ltfu
care
method
childhood
cancer
survivor
year
diagnosi
includ
adult
ccss
parent
ccss
year
age
four
paediatr
oncolog
hospit
complet
mail
questionnair
data
analys
use
result
n
male
adult
survivor
mean
age
sd
mean
time
sinc
diagnosi
sd
parent
mean
age
child
sd
mean
time
sinc
diagnosi
sd
mani
ccss
current
attend
ltfu
clinic
despit
dissatisfact
altern
care
current
receiv
dissatisfi
versu
ltfu
clinic
attende
recognis
ltfu
clinic
attend
import
import
learn
learn
screeningdiagnost
test
check
develop
second
cancer
ccss
also
report
unmet
inform
need
area
late
effect
second
cancer
care
receiv
howev
lack
awar
regard
avail
ltfu
clinic
promptsremind
attend
disengag
report
key
barrier
attend
ltfu
conclus
current
model
centralis
ltfu
care
meet
need
ccss
futur
research
design
engag
empow
survivor
seek
receiv
care
altern
ltfu
care
pathway
includ
multidisciplinari
primari
care
clinic
commun
health
servic
overcom
barrier
receiv
care
meet
need
critic
preval
abnorm
gonad
hormon
young
male
cancer
survivor
krawczuk
rybak
plonowski
j
sadowska
j
wachowiak
chybicka
e
malinowska
matysiak
koltan
wysocki
szczepanski
b
przybyszewski
w
badowska
perek
j
kowalczyk
pediatr
oncolog
hematolog
medic
univers
bialystok
bialystok
poland
pediatr
oncolog
hematolog
hematopoiet
stem
cell
transplant
medic
univers
poznan
poznan
poland
pediatr
oncolog
hematolog
bone
marrow
transplant
medic
univers
wroclaw
wroclaw
poland
pediatr
pediatr
oncolog
hematolog
medic
univers
gdansk
gdansk
poland
pediatr
pediatr
oncolog
hematolog
medic
univers
warsaw
warsaw
poland
pediatr
oncolog
hematolog
collegium
medicum
nicolau
copernicu
univers
bydgoszcz
poland
pediatr
oncolog
hematolog
medic
univers
silesia
zabrz
poland
pediatr
oncolog
hematolog
children
state
hospit
olsztyn
poland
pediatr
oncolog
children
memori
health
institut
warsaw
poland
pediatr
hematolog
oncolog
medic
univers
lublin
lublin
poland
object
gonad
function
affect
chemotherapi
radiat
pelvic
head
area
total
bodi
irradi
lead
temporari
perman
oligospermia
deleteri
chang
sperm
qualiti
male
anticanc
protocol
includ
cytostat
exert
variou
effect
gonad
frequent
pediatr
cancer
divid
three
group
accord
gonadotox
treatment
high
hr
middl
mr
low
lr
risk
studi
gonad
pituitari
hormon
analyz
young
cancer
survivor
method
evalu
gonad
function
young
mean
age
year
year
end
treatment
cancer
survivor
control
measur
level
gonadotropin
fsh
lh
testosteron
inhibin
b
result
entir
cohort
cancer
survivor
independ
risk
group
compar
control
group
lower
mean
inhibin
b
ngl
vs
ngl
p
higher
fsh
vs
p
lh
vs
iul
p
testosteron
level
compar
control
abnorm
level
inhibin
b
found
survivor
lr
group
mr
hr
group
elev
fsh
level
observ
survivor
mr
hr
group
inhibin
b
fsh
ratio
lower
risk
group
profoundli
hr
group
take
consider
age
treatment
well
time
pass
sinc
treatment
termin
survivor
compar
risk
group
present
similar
hormon
abnorm
conclus
anticanc
treatment
risk
gonad
damag
increas
particularli
high
risk
group
patient
parent
inform
possibl
lower
reproduct
function
pretreat
semen
cryopreserv
sould
recommend
adolesc
young
adult
aya
survivor
childhood
challeng
complet
therapi
act
clinic
p
kurkur
prasad
v
dhamankar
goswami
n
dalvi
act
oncolog
tata
memori
hospit
mumbai
india
object
assess
evolu
late
effect
childhood
cancer
survivor
transit
aya
age
group
longitudin
follow
act
clinic
tata
memori
hospit
mumbai
method
act
clinic
databas
analyz
childhood
cancer
survivor
attain
yr
age
last
follow
demograph
grade
late
effect
impact
qol
result
childhood
cancer
survivor
yr
therapi
diseas
free
regist
act
clinic
survivor
aya
group
mf
hematolymphoid
solid
tumour
mumbai
non
mumbai
base
median
age
diagnosi
current
median
age
median
durat
follow
sinc
act
clinic
registr
yr
rang
yr
registr
late
effect
gradei
gradeii
gradeiii
gradeiv
late
effect
increas
last
follow
mainli
due
recurr
second
neoplasia
death
due
late
effect
due
medic
reason
accid
low
risk
develop
potenti
late
effect
intermedi
risk
fell
high
risk
categori
requir
least
annual
follow
nearli
survivor
regist
first
decad
stop
follow
compar
regist
subsequ
decad
p
conclus
aya
survivor
childhood
cancer
form
major
group
long
term
follow
clinic
increas
incid
life
threaten
late
effect
longitudin
follow
combin
statist
signific
increas
trend
stop
follow
period
time
sinc
act
registr
alarm
call
innov
approach
maintain
good
follow
approach
use
base
commun
format
support
group
like
ugam
preval
monitor
compon
metabol
syndrom
adolesc
survivor
childhood
cancer
lee
h
shin
h
kang
yang
pediatr
hanyang
univers
seoul
hospit
seoul
korea
pediatr
hallym
univers
kangdong
sacr
heart
hospit
seoul
korea
object
compon
metabol
syndrom
ms
tend
increas
associ
cardiovascular
risk
survivor
childhood
cancer
investig
preval
compon
ms
adolesc
survivor
childhood
cancer
tri
monitor
period
method
investig
adolesc
survivor
childhood
cancer
median
age
year
rang
year
median
time
elaps
year
rang
year
measur
bodi
mass
index
bmi
systol
diastol
blood
pressur
triglycerid
tg
lipoprotein
hdl
fast
glucos
fatti
liver
evalu
ultrasound
examin
period
result
survivor
demonstr
ms
compon
howev
survivor
abnorm
compon
abnorm
compon
respect
frequenc
compon
increas
bmi
elev
blood
pressur
elev
tg
level
low
hdl
cholesterol
elev
fast
glucos
among
compon
increas
tg
level
highli
preval
survivor
gener
popul
p
fatti
liver
identifi
survivor
sixteen
survivor
receiv
least
repeat
examin
annual
twelv
survivor
abnorm
compon
initi
examin
number
metabol
compon
shown
decreas
persist
increas
survivor
three
survivor
compon
ms
initi
examin
show
least
abnorm
compon
conclus
observ
high
incid
increas
tg
level
adolesc
survivor
childhood
cancer
detect
abnorm
compon
ms
period
lifestyl
intervent
period
monitor
would
need
reduc
metabol
risk
childhood
cancer
survivor
behaviour
among
childhood
cancer
survivor
marjerrison
e
hendershot
p
nathan
divis
hematologyoncolog
mcmaster
children
hospit
hamilton
canada
divis
haematologyoncolog
hospit
sick
children
toronto
canada
object
survivor
pediatr
cancer
risk
late
effect
therapi
may
exacerb
smoke
alcohol
drug
use
undertook
literatur
determin
whether
survivor
childhood
cancer
engag
behaviour
rate
differ
peer
method
medlin
embas
psychinfo
cctr
examin
studi
compar
engag
behaviour
cancer
survivor
sibl
match
peer
control
two
review
assess
studi
inclus
extract
data
independ
studi
combin
forrest
plot
review
manag
use
invers
varianc
weight
random
effect
model
determin
odd
ratio
incid
rate
behavior
survivor
compar
control
risk
bia
assess
health
evid
bulletin
wale
critic
apprais
observ
studi
tool
result
studi
identifi
met
criteria
inclus
twelv
studi
assess
smoke
rate
bing
drink
drug
use
compar
sibl
childhood
cancer
survivor
less
like
smoke
confid
interv
bing
drink
similarli
like
use
drug
compar
match
peer
survivor
less
like
smoke
use
drug
equal
like
bing
drink
among
survivor
smoke
bing
drank
use
drug
studi
includ
gener
low
risk
bia
conclus
survivor
childhood
cancer
gener
engag
similar
lower
rate
sibl
peer
futur
studi
examin
youth
engag
behaviour
use
inform
focu
intervent
strategi
minim
activ
among
survivor
subsequ
neoplasm
childhood
cancer
experi
hospit
infantil
de
mexico
federico
gomez
em
jj
hematolog
oncolog
hospit
infantil
de
mexico
federico
gomez
mexico
citi
mexico
patholog
hospit
infantil
de
mexico
federico
gomez
mexico
citi
mexico
object
assess
patient
characterist
outcom
subsequ
neoplasm
sn
survivor
pediatr
cancer
institut
method
review
record
patient
develop
sn
treatment
childhood
cancer
clinic
characterist
leukemia
subtyp
histolog
latenc
treatment
outcom
record
result
total
malign
neoplasm
diagnos
januari
decemb
patient
develop
sn
cumul
incid
occur
mean
age
diagnosi
primari
neoplasm
year
common
primari
retinoblastoma
follow
acut
lymphoblast
leukemia
langerhan
cell
histiocytosi
brain
tumor
lymphoma
germ
cell
tumor
soft
tissu
sarcoma
st
osteosarcoma
genet
suscept
could
identifi
case
averag
interv
diagnosi
first
second
malign
year
patient
genet
predisposit
second
malign
includ
aml
st
brain
tumor
osteosarcoma
thyroid
carcinoma
ewe
sarcoma
hepatocellular
carcinoma
gastric
carcinoma
nonmelanomat
skin
cancer
lymphoma
retinoblastoma
patient
develop
aml
third
malign
eight
secondari
aml
case
receiv
high
dose
etoposid
cyclophosphamid
platinum
compound
treatment
first
neoplasm
secondari
solid
tumor
receiv
radiotherapi
nine
patient
aliv
diseas
free
die
due
second
malign
risk
die
higher
among
patient
develop
aml
conclus
found
low
cumul
incid
sn
differ
type
primari
secondari
neoplasm
respect
seri
ten
year
ago
abandon
higher
mortal
rate
consequ
patient
die
develop
sn
associ
cogstat
computer
test
cognit
state
standard
achiev
test
score
survivor
childhood
cancer
mitchel
l
balsamo
n
pediatr
hematolog
oncolog
yale
univers
school
medicin
new
usa
object
childhood
cancer
survivor
risk
impair
neurocognit
function
impact
educ
perform
screen
neuropsychologist
costli
sought
determin
cogstat
batteri
computer
measur
neurocognit
function
associ
academ
achiev
method
patient
histori
chemotherapi
cranial
radiat
neurosurgeri
cn
tumor
year
least
year
diagnosi
administ
cogstat
comput
batteri
task
measur
neurocognit
function
see
tabl
yale
pediatr
oncolog
clinic
connecticut
state
standard
assess
math
read
achiev
obtain
perform
categor
atabov
vs
goal
result
particip
male
median
rang
year
old
year
diagnosi
overal
goal
math
read
achiev
particip
respect
reveal
signific
associ
achiev
score
cogstat
test
cognit
see
tabl
student
goal
math
perform
significantli
wors
problem
solvingreason
test
goal
read
perform
significantli
wors
process
speed
attent
work
memori
test
effect
size
associ
moder
larg
conclus
result
suggest
cogstat
comput
batteri
signific
predictor
academ
achiev
larg
suggest
wors
perform
least
cogstat
test
may
help
identifi
children
vulner
academ
difficulti
bone
toxic
evalu
brazilian
patient
treat
two
consecut
studi
gbtli
gbtli
pcc
molinari
mlm
lee
emm
caran
pediatr
oncolog
instituto
de
oncologia
paulo
brazil
object
evalu
impact
therapi
bone
miner
densiti
bmd
acut
lymphoblast
leukemia
survivor
treat
accord
brazilian
cooper
childhood
protocol
gbtli
method
bmd
dual
energi
absorptiometri
perform
treat
patient
studi
valu
evalu
accord
clinic
treatment
characterist
bodi
composit
correl
bmd
valu
variabl
test
use
test
fisher
exact
test
likelihood
ratio
test
signific
level
result
sixti
patient
femal
white
current
mean
age
year
patient
treat
accord
gbtli
accord
gbtli
twenti
patient
receiv
cranial
radiotherapi
nutrit
diagnosi
overweight
obes
observ
fractur
osteonecrosi
assess
bone
toxic
group
younger
year
age
three
patient
low
bmd
risk
valu
low
bmd
group
lower
lumbar
spine
p
total
bodi
p
bmd
compar
group
normal
valu
moreov
group
lower
lean
bodi
mass
p
group
older
year
age
ten
patient
osteopenia
older
group
bmd
normal
valu
p
conclus
character
risk
group
low
bmd
compris
present
signific
low
valu
bmd
studi
suggest
group
need
better
attent
monitor
bone
loss
may
benefit
prevent
action
avoid
bone
loss
promot
good
habit
life
furthermor
encourag
develop
protocol
longitudin
monitor
patient
hepat
focal
nodular
hyperplasia
patient
previous
treat
pediatr
solid
tumor
c
moscheo
casanova
terenziani
c
morosi
podda
c
meazza
e
schiavello
v
biassoni
chiarav
n
puma
l
bergamaschi
g
gotti
massimino
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
radiolog
depart
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
radiolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
object
focal
nodular
hyperplasia
fnh
benign
condit
liver
may
occur
patient
previous
treat
malign
aetiopathogen
mechan
underli
fnh
poorli
understood
method
institut
fnh
diagnos
patient
male
femal
previous
treat
pediatr
cancer
patient
treat
neuroblastoma
ewe
sarcoma
medulloblastoma
wilm
tumor
osteosarcoma
hepatoblastoma
malign
mesothelioma
median
age
time
origin
cancer
diagnosi
year
rang
month
year
patient
receiv
chemotherapi
underw
regimen
busulphan
melphalan
thiotepa
also
receiv
radiotherapi
result
median
age
fnh
diagnosi
year
rang
median
interv
diagnosi
cancer
fnh
year
rang
case
radiolog
find
includ
mri
scan
inconclus
liver
biopsi
perform
four
patient
singl
liver
lesion
patient
fnh
multifoc
median
maximum
nodul
diamet
largest
lesion
case
multifoc
time
diagnosi
mm
rang
median
month
rang
median
diamet
mm
rang
driven
case
increas
size
increas
linear
time
median
increas
mmyear
rang
interestingli
case
singl
lesion
fnh
becam
multifoc
patient
receiv
surgic
treatment
patient
remain
activ
conclus
experi
consist
concept
focal
nodular
hyperplasia
benign
condit
biopsi
improv
diagnost
accuraci
case
radiolog
find
conclus
regard
treatment
recommend
conserv
wait
see
approach
nutrit
statu
dietari
intak
physic
activ
childhood
cancer
survivor
murphi
l
lockwood
hallahan
psw
davi
children
nutrit
research
centr
queensland
children
medic
research
institut
univers
queensland
brisban
australia
divis
oncolog
children
health
queensland
royal
children
hospit
brisban
australia
divis
oncolog
children
health
queensland
royal
children
hospit
queensland
children
medic
research
institut
univers
queensland
brisban
australia
object
nutrit
relat
late
effect
import
consider
childhood
cancer
survivor
cc
aim
studi
examin
nutrit
statu
dietari
intak
physic
activ
level
cc
method
studi
involv
cc
n
solid
tumor
measur
includ
bodi
mass
index
bmi
bodi
cell
mass
index
bcmi
via
measur
total
bodi
potassium
percent
fat
fat
via
energi
intak
physic
activ
level
pal
three
day
diet
physic
activ
diari
result
popul
mean
sd
age
year
mean
sd
time
sinc
activ
treatment
year
mean
height
weight
bmi
z
score
fell
within
rang
base
upon
bmi
patient
obes
two
classifi
thin
howev
fat
measur
consid
obes
male
femal
bcm
measur
consid
malnourish
bcmi
z
score
percent
cc
consum
estim
energi
requir
mean
sd
pal
group
subject
classifi
sedentarylightli
activ
lifestyl
pal
posit
relationship
bcmi
z
score
pal
r
p
neg
relationship
fat
pal
r
p
conclus
malnutrit
nutrit
problem
cc
recogn
assess
bmi
childhood
cancer
survivor
appear
dietari
intak
similar
gener
popul
sedentari
lifestyl
decreas
bcmi
increas
fat
relat
decreas
activ
level
recommend
physic
activ
intervent
combin
dietari
guidanc
focu
cancer
treatment
minim
level
malnutrit
seen
cc
rel
differ
risk
neuropsycholog
outcom
post
proton
radiat
infratentori
versu
supratentori
pediatr
brain
tumor
paltin
ce
ra
lustig
je
minturn
jb
belasco
ka
cole
pc
phillip
aj
waander
mj
fisher
child
adolesc
psychiatri
behavior
scienc
children
hospit
philadelphia
philadelphia
usa
radiat
oncolog
hospit
univers
pennsylvania
philadelphia
usa
pediatr
children
hospit
philadelphia
philadelphia
usa
object
describ
neuropsycholog
np
outcom
proton
radiat
prt
infratentori
supratentori
pediatr
brain
tumor
patient
method
patient
complet
np
evalu
patient
complet
evalu
year
infrantentori
n
male
median
age
year
rang
supratentori
n
male
median
age
year
rang
cumul
tumor
bed
dose
rang
neuropsycholog
measur
includ
adapt
behavior
assess
behavior
assess
system
development
test
integr
behavior
rate
inventori
execut
function
california
verbal
learn
purdu
pegboard
test
rey
complex
figur
test
wechsler
iq
measur
result
baselin
iq
rang
impair
superior
infratentori
n
rang
mean
sd
supratentori
n
rang
mean
sd
group
struggl
integr
fine
motor
function
infratentori
group
perform
measur
attent
inhibit
visual
verbal
memori
problem
solv
organ
execut
function
averag
superior
supratentori
group
consist
demonstr
averag
abil
variabl
impair
task
visual
organ
infratentori
group
demonstr
low
averag
superior
intellig
rang
mean
sd
supratentori
group
demonstr
averag
high
averag
intellig
rang
mean
sd
group
evidenc
age
expect
fine
motor
dexter
list
learn
visual
organizationmemori
averag
report
execut
function
infratentori
group
inhibit
visual
verbal
memori
abil
declin
averag
rang
low
averag
adapt
function
supratentori
group
perform
remain
averag
continu
integr
weak
conclus
supratentori
mean
group
perform
stabl
despit
strong
perform
younger
infratentori
group
declin
greater
variabl
group
member
subset
infratentori
popul
uniqu
vulner
earli
prt
cognit
symptomat
osteonecrosi
children
undergo
chemotherapi
acut
lymphoblast
leukemia
e
papakonstantin
lambrou
athanasiadi
n
lalioti
v
sidi
anastasi
de
koliouska
paediatr
oncolog
hippokr
gener
hospit
thessaloniki
greec
object
osteonecrosi
increasingli
document
pediatr
acut
lymphoblast
leukemia
result
joint
dysfunct
subsequ
impair
activ
daili
live
among
survivor
risk
factor
includ
age
year
femal
sex
use
dexamethason
report
incid
symptomat
osteonecrosi
children
treat
acut
lymphoblast
leukemia
depart
method
retrospect
assess
incid
symptomat
total
patient
acut
lymphoblast
leukemia
treat
protocol
bfm
allic
symptomat
diagnos
patient
male
femal
median
age
year
rang
patient
identifi
base
clinic
symptom
persist
bone
pain
limp
limit
motion
joint
osteonecrosi
confirm
diagnost
imag
studi
magnet
reson
imag
mri
result
cumul
incid
diagnos
median
treatment
week
rang
commonli
affect
joint
bone
hip
joint
knee
joint
two
patient
exhibit
multipl
lesion
patient
underw
weight
bear
restrict
pain
manag
one
patient
need
surgic
intervent
median
time
month
rang
clinic
outcom
follow
amelior
stabl
diseas
deterior
conclus
signific
number
patient
develop
treatment
childhood
joint
commonli
affect
clinic
screen
patient
especi
within
year
diagnosi
necessari
earli
recognit
scar
childhood
cancer
survivor
moalem
melam
e
krivoy
n
arad
postovski
ben
barak
zaidman
weyl
pediatr
rambam
health
care
campu
haifa
israel
school
behavior
scienc
tel
academ
colleg
tel
aviv
israel
object
childhood
cancer
survivor
cope
scar
least
one
chest
scar
central
venou
cathet
cvc
scar
caus
esthet
discomfort
visual
remind
diseas
impact
scar
cancer
survivor
qol
rare
investig
evalu
cope
scar
effect
bodi
self
imag
qol
survivor
pediatr
cancer
method
survivor
childhood
cancer
age
year
femal
male
ltfu
complet
questionnair
concern
demograph
detail
diseas
treatment
scar
number
length
cm
local
psycholog
impact
scar
esthet
aspect
self
affect
social
life
qol
statist
analysi
variant
perform
spss
method
result
patient
show
scar
one
chest
scar
cvc
percent
least
two
scar
one
solid
tumor
resect
one
chest
cvc
averag
scar
length
cm
rang
cm
survivor
ignor
hid
scar
even
found
influenc
self
activ
social
life
survivor
scar
origin
health
concern
cope
scar
hide
scar
found
relat
statist
signific
self
bodi
imag
p
conclus
percent
childhood
cancer
patient
least
two
scar
survivor
cope
scar
ambival
hide
scar
decreas
neg
impact
esthet
amelior
self
bodi
imag
affect
social
qol
remain
health
concern
pediatr
hematopoiet
cell
transplat
cancer
survivor
n
arad
postovski
ben
barak
r
elhasid
german
weyl
zaidman
pediatr
rambam
health
care
campu
haifa
israel
pediatr
souraski
medic
center
tel
aviv
israel
pediatr
endocrinolog
rambam
health
care
campu
haifa
israel
object
increas
number
hematopoiet
cell
transplant
hct
autolog
well
allogen
perform
greater
number
survivor
purpos
studi
review
late
effect
secondari
treatment
exposur
hct
hct
condit
therapi
method
subject
includ
childhood
cancer
survivor
ltfu
hct
patient
autolog
allogen
hct
result
median
age
diagnosi
year
rang
median
age
ltfu
rang
median
year
ltfu
rang
male
femal
ratio
found
late
effect
survivor
late
effect
cancer
patient
chemotherapi
radiotherapi
hct
late
effect
cancer
patient
chemotherapi
hct
without
radiotherapi
late
effect
found
patient
patient
hct
late
effect
hemianopsi
hemiparesi
convuls
disord
post
acut
dissemin
encephalomyel
attent
deficit
disord
dental
problem
avascular
necrosi
leg
length
discrep
hypothyroid
cardiac
valv
insuffici
chronic
hepat
primari
ovari
failur
second
cancer
osteoporosi
femal
failur
thrive
obes
survivor
receiv
radiotherapi
late
effect
mainli
disord
hypothyroid
cataract
second
cancer
osteoporosi
report
femal
infertil
rate
almost
equal
gender
case
metabol
syndrom
hyperlipidemia
diabet
mellitu
report
conclus
conclus
studi
report
late
effect
childhood
cancer
survivor
treat
radiotherapi
cardiovascular
late
effect
report
may
explain
median
ltfu
high
risk
late
effect
hct
survivor
warrant
lifelong
structur
ltfu
musculoskelet
sequela
solid
tumour
cancer
rehabilit
children
treat
intens
chemotherapi
surgeri
radiat
therapi
petrichenko
e
bukreeva
n
ivanova
sharoev
prityko
oncolog
child
health
care
research
clinic
moscow
russia
rehabilit
child
health
care
research
clinic
moscow
russia
director
child
health
care
research
clinic
moscow
russia
object
recommend
screen
prevent
manag
survivor
method
studi
includ
children
adolesc
mean
age
year
solid
tumour
treat
year
followup
month
patient
metastas
patient
solitari
metastas
treatment
consist
chemotherapi
radiotherapi
oncolog
surgeri
includ
procedur
common
late
effect
observ
scoliosi
case
muscular
hypoplasia
osteopenia
discrep
spite
usag
grow
endoprosthesi
deform
chest
wall
limb
patholog
fractur
poor
joint
movement
neurolog
disturb
lymphedema
deform
osteoarthrosi
case
patient
late
effect
patient
underw
individu
combin
rehabilit
program
patient
underw
cours
postop
inpati
physic
therapi
studi
evalu
short
chang
physic
fit
child
childhood
malign
use
individu
rehabilit
program
consist
combin
physic
exercis
kinesiotherapi
aquat
rehabilit
implement
shortli
treatment
train
perform
individu
supervis
experienc
paediatr
physic
therapist
result
suggest
usag
individu
rehabilit
program
decreas
pain
improv
muscl
strength
rang
motion
joint
increas
suppli
blood
muscl
higher
muscl
metabol
circul
limb
improv
tissu
nutrit
help
heal
process
conclus
surviv
possibl
even
patient
metastat
diseas
survivor
childhood
cancer
attend
special
therapi
rehabilit
clinic
thyroid
carcinoma
treatment
childhood
adolesc
malign
experi
fondazion
ircc
istituto
nazional
dei
tumori
milan
podda
terenziani
l
gandola
n
pizzi
c
meazza
r
luksch
ferrari
casanova
f
spreafico
polastri
e
schiavello
v
biassoni
massimino
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
pediatr
radiotherapi
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
otolaryngolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
object
describ
natur
histori
therapeut
approach
histopatholog
secondari
thyroid
cancer
individu
malign
diseas
childhood
adolesc
method
conduct
retrospect
analysi
patient
treat
institut
develop
thyroid
neoplasm
treat
malign
pediatr
age
result
patient
secondari
cancer
thyroid
identifi
primari
cancer
hodgkin
lymphoma
patient
receiv
radiotherapi
first
malign
total
thyroidectomi
perform
case
lymphadenectomi
hemithyroidectomi
lymphadenectomi
patient
receiv
radiometabol
therapi
therapi
histolog
diagnos
papillari
follicular
carcinoma
os
pf
year
respect
none
patient
die
thyroid
diseas
nodal
involv
onset
factor
correl
recurr
surgic
sequela
occur
patient
underw
total
thyroidectomi
conclus
surviv
depend
aggress
surgeri
data
confirm
good
prognosi
secondari
thyroid
cancer
prompt
us
encourag
minimalist
approach
treatment
particular
patient
wherev
possibl
valu
high
sensit
troponin
survivor
childhood
cancer
treat
anthracyclin
pourier
l
kapusta
van
gennip
jpm
j
loonen
l
bellersen
amc
depart
pediatr
hematolog
oncolog
radboud
univers
nijmegen
medic
centr
nijmegen
netherland
children
heart
centr
radboud
univers
nijmegen
medic
centr
nijmegen
netherland
depart
cardiolog
radboud
univers
nijmegen
medic
centr
nijmegen
netherland
object
cardiac
biomark
play
import
role
earli
detect
subclin
heart
failur
studi
aim
obtain
valu
high
sensit
cardiac
troponin
survivor
childhood
cancer
investig
potenti
role
biomark
detect
subclin
cardiotox
method
natriuret
peptid
measur
survivor
childhood
cancer
electrocardiographi
echocardiographi
perform
evalu
cardiac
function
result
mean
period
year
rang
year
survivor
clinic
asymptomat
histori
heart
failur
immedi
treatment
anthracyclin
electrocardiographi
avail
survivor
show
sign
myocardi
injuri
relat
ischemia
abnorm
qtc
echocardiographi
perform
survivor
mean
left
ventricular
shorten
fraction
sf
rang
mean
eject
fraction
ef
rang
seven
survivor
mildli
decreas
ef
normal
level
detect
survivor
rang
ngl
concentr
differ
among
differ
anthracyclin
dosag
group
yet
survivor
elev
level
rang
pgml
survivor
one
mildli
abnorm
ef
ef
sf
ecg
find
normal
survivor
conclus
concentr
normal
survivor
childhood
cancer
even
subpopul
elev
andor
mildli
decreas
ef
indic
sensit
marker
late
onset
subclin
anthracyclin
induc
cardiotox
late
effect
longterm
survivor
childhood
hodgkin
lymphoma
singl
centr
experi
prasad
v
dhamankar
goswami
n
dalvi
b
arora
g
narula
sd
banavali
p
kurkur
act
clinic
paediatr
oncolog
tata
memori
hospit
mumbai
india
paediatr
haematolymphoid
dmg
tata
memori
hospit
mumbai
india
object
assess
spectrum
late
effect
survivor
childhood
hodgkin
lymphoma
hl
treat
combin
radiat
therapi
rt
method
retrospect
analysi
survivor
hl
regist
complet
therapi
act
clinic
paediatr
oncolog
depart
record
analys
demograph
well
late
effect
possibl
caus
factor
result
total
survivor
regist
diagnosi
hl
median
age
diagnosi
age
last
followup
median
followup
disproportion
male
enrol
f
ratio
note
patient
treat
receiv
chemotherapi
doxorubicin
alkyl
agent
receiv
rt
although
patient
complic
act
complic
last
patient
multipl
signific
issu
common
problem
cohort
includ
impair
growth
chronic
hepatitisb
complic
hypothyroid
detect
test
significantli
associ
rt
neck
p
conclus
childhood
hl
high
cure
rate
therefor
longterm
survivor
potenti
late
effect
high
incid
late
effect
especi
older
modal
treatment
impetu
therapi
less
intens
toxic
treatment
protocol
renal
tumour
singl
institut
studi
schiavetti
f
patriarchi
g
varrasso
g
megaro
l
de
luca
p
versacci
pediatr
sapienza
univers
rome
rome
itali
object
late
morbid
mortal
renal
tumor
rt
treat
follow
five
consecut
siop
protocol
method
retrospect
cohort
studi
assess
rt
survivor
diagnos
mortal
subsequ
malign
neoplasm
cardiac
function
musculoskelet
effect
fertil
pregnanc
renal
function
pt
rcc
cc
wt
synchron
bwt
die
diseas
renal
failur
wagr
accid
mean
fu
yr
os
survivor
previous
treat
unilater
nephrectomi
nephrectomi
one
side
partial
nephrectomi
one
nephron
spare
surgeri
local
rt
lung
rt
whole
abdomen
rt
twenti
pt
receiv
anthracyclin
cardioxan
associ
result
survivor
particip
short
fu
exclud
mean
age
yr
evalu
second
neoplasm
case
present
osteosarcoma
colon
carcinoma
respect
irradi
site
cardiac
function
fe
rang
case
borderlin
fs
rang
case
borderlin
fertil
pregnanc
femal
success
pregnanc
male
abort
malform
infertil
whole
abdomen
irradi
case
musculoskelet
effect
irradi
case
scoliosi
flank
hypotrophi
renal
function
uncompl
uninefrectom
case
present
egfr
stage
chronic
kidney
diseas
ckd
one
bwt
case
stage
ckd
one
nss
case
egfr
conclus
seri
pt
long
fu
second
tumor
main
problem
rt
survivor
contrast
similar
report
found
good
cardiac
function
advers
event
local
treatment
head
neck
rhabdomyosarcoma
survivor
extern
beam
radiotherapi
amor
treatment
ra
schoot
slater
cm
roncker
ah
zwinderman
ajm
balm
b
hartley
van
de
brekel
gupta
p
saeed
e
gajdosova
br
pieter
mn
gaze
hc
mandevil
r
davila
fajardo
chang
sd
stracke
dunaway
c
abela
c
mason
le
smeel
jc
chisholm
g
levitt
lcm
kremer
grootenhui
h
ca
stiller
p
hammond
hn
caron
jhm
merk
depart
paediatr
oncolog
emma
children
hospit
academ
medic
centr
amsterdam
amsterdam
netherland
depart
paediatr
oncolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
depart
clinic
epidemiolog
academ
medic
centr
amsterdam
netherland
depart
head
neck
oncolog
surgeri
netherland
cancer
institut
amsterdam
netherland
depart
otorhinolaryngolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
orbit
centr
depart
ophthalmolog
academ
medic
centr
amsterdam
netherland
depart
ophthalmolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
depart
radiat
oncolog
academ
medic
centr
amsterdam
netherland
depart
oncolog
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
depart
radiotherapi
royal
marsden
nh
foundat
trust
sutton
unit
kingdom
depart
plastic
reconstruct
hand
surgeri
academ
medic
centr
amsterdam
netherland
dental
maxillofaci
depart
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
depart
oral
maxillofaci
surgeri
academ
medic
centr
amsterdam
netherland
children
young
peopl
depart
royal
marsden
hospit
sutton
unit
kingdom
paediatr
psychosoci
depart
emma
children
hospit
academ
medic
centr
amsterdam
netherland
childhood
cancer
research
group
depart
paediatr
univers
oxford
oxford
unit
kingdom
molecular
medicin
unit
ucl
institut
child
health
london
unit
kingdom
object
major
head
neck
rhabdomyosarcoma
hnrm
patient
need
radiotherapi
achiev
local
control
radiotherapi
caus
advers
event
ae
reduc
ae
innov
local
treatment
develop
emma
children
hospit
amsterdam
abl
surgeri
mould
brachytherapi
surgic
reconstruct
amor
aim
determin
preval
ae
hnrm
survivor
compar
ae
survivor
treat
intern
standard
extern
beam
radiotherapi
london
survivor
treat
amor
feasibl
otherwis
ebrt
amsterdam
method
hnrm
survivor
treat
london
amsterdam
januari
decemb
n
aliv
year
elig
n
predefin
list
ae
assess
multidisciplinari
clinic
grade
accord
common
terminolog
criteria
advers
event
result
eighti
hnrm
survivor
attend
clinic
median
year
experienc
grade
event
ae
grade
survivor
treatment
experienc
significantli
frequent
sever
ae
survivor
treatment
p
p
respect
five
year
overal
surviv
sourc
popul
treatment
treatment
p
conclus
studi
baselin
new
method
local
control
use
futur
assess
ae
caus
novel
local
treatment
modal
local
treatment
result
similar
overal
surviv
reduct
ae
secondari
local
treatment
hear
loss
survivor
childhood
head
neck
rhabdomyosarcoma
r
schoot
ear
theunissen
slater
lopez
yurda
cl
zuur
mn
gaze
chang
hc
mandevil
je
gain
k
rajput
br
pieter
r
davila
fajardo
r
talwar
hn
caron
ajm
balm
wa
dreschler
jhm
merk
depart
paediatr
oncolog
emma
children
hospit
academ
medic
centr
amsterdam
amsterdam
netherland
depart
head
neck
oncolog
surgeri
netherland
cancer
institut
amsterdam
netherland
depart
paediatr
oncolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
depart
epidemiolog
biostatist
netherland
cancer
institut
amsterdam
netherland
depart
oncolog
univers
colleg
london
hospit
nh
foundat
trust
london
unit
kingdom
depart
radiotherapi
royal
marsden
nh
foundat
trust
sutton
unit
kingdom
depart
audiolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
depart
radiat
oncolog
academ
medic
centr
amsterdam
netherland
depart
otorhinolaryngolog
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
depart
audiolog
academ
medic
centr
amsterdam
netherland
object
major
children
head
neck
rhabdomyosarcoma
hnrm
need
radiotherapi
achiev
maintain
local
control
howev
radiotherapi
region
caus
signific
advers
event
especi
young
patient
preval
hear
loss
advers
event
popul
survivor
unknown
therefor
assess
hear
statu
hnrm
survivor
clinic
furthermor
compar
hear
loss
survivor
extern
beam
radiotherapi
ebrt
local
treatment
survivor
local
treatment
amor
innov
local
treatment
consist
abl
surgeri
mold
techniqu
afterload
brachytherapi
surgic
reconstruct
amor
method
prospect
analysi
conduct
hear
threshold
low
high
frequenc
obtain
pure
tone
audiometri
differ
hear
threshold
treatment
group
assess
use
repeat
measur
linear
regress
analys
clinic
relev
hear
loss
defin
deterior
db
pta
khz
khz
result
survivor
includ
median
year
found
clinic
relev
hear
loss
survivor
pure
tone
averag
khz
conduct
mix
type
hear
loss
fewer
survivor
experienc
clinic
relev
hear
loss
treatment
compar
treatment
versu
p
multivari
regress
analysi
show
survivor
treat
treatment
paramening
tumor
significantli
hear
impair
compar
survivor
treatment
tumor
conclus
found
clinic
relev
hear
loss
hnrm
survivor
furthermor
studi
show
trend
toward
less
hear
loss
treatment
compar
local
treatment
ebrt
hnrm
survivor
impair
bone
health
children
treatment
polychemotherapi
retinoblastoma
earli
childhood
subtl
mm
pk
hauffa
sc
goretzki
j
bauer
w
sauerwein
n
bornfeld
bp
hauffa
c
grasemann
pediatr
hematolog
oncolog
univers
hospit
essen
essen
germani
radiotherapi
univers
hospit
essen
essen
germani
ophtalmolog
univers
hospit
essen
essen
germani
pediatr
endocrinolog
diabetolog
univers
hospit
essen
essen
germani
object
impair
bone
health
survivor
childhood
cancer
occur
frequent
retinoblastoma
rb
malign
eye
tumor
young
children
enucl
usual
cur
howev
chemoreduct
eye
spare
treatment
attempt
appli
increasingli
chemotherapi
commonli
combin
local
treatment
modal
conduct
cross
section
studi
analyz
impact
chemotherapi
retinoblastoma
bone
health
method
studi
approv
local
ethic
committe
patient
femal
age
diagnosi
recruit
regular
visit
essen
patient
unilater
bilater
rb
patient
underw
polychemotherapi
either
enucl
melphalan
brachytherapi
percutan
radiat
combin
therapi
polychemotherapi
consist
cyclophosphamid
etoposid
vincristin
carboplatin
clinic
biochem
paramet
growth
pubert
develop
bone
health
obtain
histori
fractur
bone
pain
assess
age
depend
paramet
calcul
sd
height
weight
bmi
pubert
stage
assess
use
age
appropri
norm
bone
specif
alkalin
phosphatas
bap
osteocalcin
oc
result
mean
chronolog
age
height
sd
bmi
sd
sd
testicular
volumebreast
develop
defici
vd
ngml
observ
hyperparathyroid
pth
pgml
patient
bap
elev
report
bone
pain
experienc
fractur
conclus
impair
bone
health
treatment
chemotherapi
rb
subtl
howev
children
present
bone
pain
alter
paramet
bone
health
sinc
identif
children
risk
difficult
recommend
long
term
monitor
supplement
vitamin
late
morbid
among
survivor
childhood
cancer
experi
tertiari
care
cancer
hospit
n
shaheen
f
naz
raiz
ms
khan
ahm
paediatr
oncolog
shaukat
khanum
memori
cancer
hospit
research
center
lahor
pakistan
object
studi
cohort
characterist
late
effect
variou
treatment
modal
childhood
cancer
survivor
centerto
organ
health
screen
guidelin
among
childhood
cancer
survivor
method
children
age
year
diagnosi
cancer
jan
dec
skmch
fulfil
follow
inclus
criteria
enrol
studi
treatment
center
chemotherapi
andor
radiat
andor
surgeryf
year
post
primari
diagnosi
follow
long
term
follow
clinic
ltf
data
analyz
retrospect
determin
candid
clinic
demograph
characterist
detail
treatment
toxic
evalu
tailor
accord
specif
therapeut
exposur
frequenc
toxic
attribut
chemoradi
agent
calcul
result
three
hundr
patient
studi
male
femal
ratio
time
diagnosi
year
year
year
year
age
current
median
age
year
rang
year
hodgkin
lymphoma
common
diagnosi
follow
acut
leukemia
nhl
gct
retinoblastoma
respect
durat
surviv
year
less
year
patient
regard
treatment
modal
receiv
chemotherapi
xrt
chemo
surgeri
chemo
surgeri
radiat
surgeri
toxic
evalu
azospermia
common
late
effect
follow
oligospermia
patient
hypothyroid
develop
ototox
impair
dlco
low
bone
densiti
cardiomyopathi
conclus
studi
confirm
high
preval
persist
toxic
chemoradi
exposur
among
survivor
childhood
cancer
need
implement
risk
base
exposur
relat
guidelin
life
long
follow
cancer
survivor
long
term
risk
cardiac
morbid
irradi
sharma
b
sarkar
agraw
n
hazarika
ganesh
munshi
bk
mohanti
radiat
onclog
forti
memori
research
institut
gurgaon
india
paediatr
onclog
forti
memori
research
institut
gurgaon
india
object
evalu
long
term
risk
cardiac
morbid
patient
treat
radiotherapi
csi
approx
odd
ratio
develop
cardiac
morbid
non
radiat
medulloblastoma
method
studi
includ
six
medulloblastoma
patient
simul
supin
posit
immobil
use
thermoplast
cast
target
delin
includ
ctvbrain
encompass
whole
brain
tissu
ctvspine
includ
entir
spinal
canal
extend
caudal
till
lower
end
thecal
sac
ctvboost
encompass
posterior
fossa
addit
mm
margin
gener
respect
ptv
csi
dose
wk
low
risk
diseas
high
risk
diseas
posterior
fossa
boost
dose
organ
risk
delin
includ
heart
lung
thyroid
esophagu
eye
cochlea
axi
kidney
liver
patient
plan
either
imrt
vmat
either
xio
moanco
v
patient
plan
sad
techniqu
plan
use
systemat
junction
shift
imrtvmat
use
junction
dose
gradient
techniqu
evalu
late
cardiac
morbid
dmax
dmean
volum
heart
record
patient
odd
radio
develop
late
long
term
cardiac
morbid
calcul
formula
mean
dose
receiv
heart
valu
use
equat
result
median
age
present
year
yr
four
patient
standard
risk
medullblastoma
wherea
two
high
risk
categori
median
volum
heart
rang
dmax
heart
gy
rang
wherea
dmean
receiv
heart
rang
odd
radio
develop
late
long
term
cardiac
morbid
csi
rang
conclus
risk
late
long
term
cardiac
morbid
csi
higher
medulloblastoma
patient
care
cancer
relat
commun
provid
among
young
adult
survivor
childhood
cancer
transfer
adult
care
szalda
w
hobbi
j
ginsberg
l
brumley
wasik
l
schwartz
oncolog
children
hospit
philadelphia
philadelphia
usa
object
approxim
childhood
cancer
survivor
receiv
care
recommend
howev
studi
assess
engag
perceiv
qualiti
adult
survivorship
care
follow
formal
transfer
pediatr
adult
care
studi
describ
rate
satisfact
care
transfer
young
adult
survivor
ya
commun
adult
primari
care
provid
pcp
method
ya
transfer
survivorship
program
adult
provid
within
year
complet
onlin
measur
data
collect
ongo
final
n
confer
result
particip
n
yo
male
caucasian
patient
report
see
healthcar
provid
past
year
n
report
attend
adult
survivorship
clinic
n
report
see
pcp
survivorship
care
past
year
qualiti
cancer
care
perceiv
good
excel
patient
attend
survivorship
clinic
patient
attend
primari
care
ya
saw
pcp
survivorship
care
report
discuss
regard
endors
prior
diagnosi
treatment
risk
late
effect
screen
late
effect
patient
report
receiv
survivorship
care
n
saw
pcp
reason
case
follow
survivor
report
discuss
prior
diagnosi
treatment
risk
late
effect
screen
late
effect
conclus
almost
half
transfer
ya
seek
care
past
year
ya
receiv
survivorship
care
pcp
report
margin
better
rate
commun
seek
care
pcp
reason
result
highlight
need
better
understand
barrier
seek
adult
survivorship
care
improv
compet
pcp
provid
optim
survivorship
care
relationship
cisplatin
administr
develop
ototox
g
tokuc
pediatr
hamatolog
oncolog
marmara
univers
istanbul
turkey
object
ototox
import
side
effect
purpos
determin
audiolog
toxic
associ
cisplatin
pediatr
oncolog
patient
method
perform
audiometr
analysi
pediatr
oncolog
patient
receiv
cisplatin
therapi
januari
januari
treat
cisplatin
diagnosi
neuroblastoma
medulloblastoma
osteosarcoma
germ
cell
tumour
hepatoblastoma
result
median
age
time
diagnosi
rang
year
male
femal
underli
diseas
neuroblastoma
case
medulloblastoma
case
osteosarcoma
case
germ
cell
tumor
case
hepatoblastoma
case
median
individu
dose
median
cumul
dose
sixteen
patient
receiv
cranial
radiotherapi
patient
develop
hear
loss
lead
overal
incid
logist
regress
analys
show
age
treatment
p
cumul
dose
cisplatin
p
signific
risk
factor
predict
hear
loss
children
treat
cisplatin
neither
improv
aggrav
patient
hear
loss
month
conclus
cumul
dose
cisplatin
younger
age
treatment
year
mainli
import
risk
factor
ototox
patient
treat
cisplatin
serial
audiometr
evalu
need
patient
risk
factor
cisplatin
treatment
thyroid
dysfunct
follow
treatment
hodgkin
diseas
g
tokuc
pediatr
hamatolog
oncolog
marmara
univers
istanbul
turkey
object
thyroid
dysfunct
import
morbid
therapi
hodgkin
diseas
well
recogn
doctor
patient
aim
investig
thyroid
dysfunct
incid
among
hodgkin
lymphoma
patient
treatment
method
forti
eight
pediatr
patient
less
year
old
diagnosi
treat
chemotherapi
radiotherapi
diagnosi
hodgkin
diseas
period
evalu
thereaft
patient
irradi
neck
other
irradi
region
accord
involv
diseas
first
diagnosi
result
median
age
diagnosi
year
median
durat
follow
year
patient
irradi
neck
region
develop
biochem
hypothyroid
median
time
develop
hypothyroid
year
transient
hyperthyroid
develop
two
patient
month
treatment
hodgkin
diseas
among
patient
irradi
region
neck
none
develop
thyroid
disfunct
four
patient
although
normal
thyroid
function
hypoecho
nodul
diagnos
thyroid
ultrasonographi
nodul
show
histolog
multinodular
goiter
singl
colloid
nodul
conclus
high
risk
thyroid
diseas
develop
follow
neck
radiat
therapi
hodgkin
diseas
reinforc
import
need
continu
clinic
biochem
evalu
patient
follow
electroejacul
method
fertil
preserv
boy
diangos
cancer
experi
review
literatur
mc
adank
w
van
dorp
smit
nj
van
casteren
jse
laven
r
pieter
mm
van
den
paediatr
oncolog
haematolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
paediatr
oncolog
haematolog
obstetr
gynaecolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
urolog
erasmu
univers
medic
center
rotterdam
netherland
obstetr
gynaecolog
erasmu
univers
medic
center
rotterdam
netherland
object
evalu
feasibl
electroejacul
perform
semen
cryopreserv
pubert
male
gonadotox
therapi
review
literatur
topic
method
perform
retrospect
cohort
studi
review
literatur
retrospect
studi
perform
academ
children
hospit
includ
male
diagnos
cancer
sperm
cryopreserv
offer
start
gonadotox
therapi
studi
outcom
electroejacul
includ
patient
characterist
hormon
level
semen
paramet
result
semen
sampl
obtain
masturb
male
cancer
adequ
preserv
male
electroejacul
offer
appear
adequ
preserv
review
report
electroejacul
case
children
cancer
literatur
case
success
testosteron
level
higher
patient
success
sperm
yield
obtain
electroejacul
testosteron
median
nmoll
success
versu
median
nmoll
unsuccess
harvest
conclus
semen
cryopreserv
offer
pubert
male
masturb
fail
electroejacul
consid
use
option
semen
cryopreserv
lead
adequ
materi
cryopreserv
half
case
slip
capit
femor
epiphysi
total
bodi
irradi
vedi
k
nevil
saravanja
k
johnston
rj
cohn
kid
cancer
centr
sydney
children
hospit
sydney
australia
endocrin
depart
sydney
children
hospit
sydney
australia
orthopaed
depart
sydney
children
hospit
sydney
australia
object
significantli
increas
risk
slip
capit
femor
epiphysi
scfe
recent
identifi
survivor
childhood
cancer
treat
recombin
growth
hormon
rhgh
receiv
total
bodi
irradi
tbi
condit
hematopoiet
stem
cell
transplant
hsct
method
identifi
case
femal
scfe
cohort
children
receiv
tbi
condit
prior
hsct
past
year
rhgh
time
present
result
children
present
year
tbi
condit
autolog
hsct
present
atyp
compar
idiopath
younger
age
year
prepubert
one
overweight
bmi
two
bilater
present
three
four
patient
present
uncommon
valgu
variant
scfe
overal
time
symptom
onset
radiolog
diagnosi
month
child
present
scfe
unilater
whilst
rhgh
year
old
femal
unreplac
hypogonad
diagnos
month
commenc
rhgh
though
experienc
neg
transient
hip
pain
month
prior
upon
review
origin
radiograph
yngve
subtl
evid
valgu
slip
conclus
conclud
tbi
alon
signific
risk
factor
scfe
delay
diagnosi
due
atyp
clinic
radiolog
present
valgu
slip
frequent
subacut
present
standard
radiolog
inadequ
yngve
criteria
sensit
method
screen
initi
radiograph
children
hip
symptom
howev
standard
radiolog
techniqu
neg
equivoc
modal
ultrasound
andor
mri
must
consid
earli
orthopaed
referr
mandatori
furthermor
rhgh
therapi
frequent
consid
popul
risk
develop
scfe
must
care
consid
clinician
clearli
discuss
famili
embark
rhgh
therapi
pediatr
young
adult
patient
germ
cell
tumor
treat
peb
chomotherapi
regimen
vervaek
gosiengfiao
b
lockart
walterhous
j
reichek
k
k
dilley
j
toia
j
woodman
pediatr
ann
robert
h
luri
children
hospit
chicago
chicago
usa
hematolog
oncolog
stem
cell
transplant
ann
robert
h
luri
children
hospit
chicago
chicago
usa
object
incid
sever
peb
regimen
report
children
treat
germ
cell
tumor
gct
purpos
studi
evalu
incid
sever
audiolog
reproduct
renal
pulmonari
toxic
pediatr
young
adult
patient
gct
patient
treat
peb
method
perform
retrospect
chart
review
audiolog
renal
pulmonari
reproduct
toxic
patient
year
age
gct
diagnos
treat
ann
robert
h
luri
children
hospit
chicago
januari
decemb
patient
receiv
radiat
chemotherapi
agent
exclud
result
patient
receiv
cycl
peb
median
month
measur
hear
loss
ctcae
grade
hear
loss
requir
hear
aid
follow
treatment
patient
requir
hear
aid
receiv
cisplatin
other
hear
loss
receiv
standard
dose
patient
data
avail
assess
kidney
function
normal
kidney
function
stage
chronic
kidney
diseas
ckd
gfr
none
requir
electrolyt
supplement
patient
pulmonari
function
test
perform
treatment
normal
exclud
patient
obstruct
diseas
prior
treatment
patient
test
normal
fsh
lh
estradiol
testosteron
valu
one
becam
pregnant
conclus
seri
suggest
signific
proport
pediatr
patient
receiv
peb
gct
audiolog
renal
pulmonari
reproduct
toxic
hear
loss
usual
requir
hear
aid
reduc
gfr
qualifi
stage
ckd
frequent
establish
paediatr
long
term
transit
clinic
tertiari
adult
health
care
sector
skinner
r
harrap
k
egan
j
williamson
p
downi
long
term
follow
program
paediatr
integr
cancer
servic
melbourn
australia
paediatr
integr
cancer
servic
paediatr
integr
cancer
servic
melbourn
australia
object
number
new
patient
refer
paediatr
long
term
ltf
program
addit
exist
ltf
patient
requir
ongo
review
exce
current
clinic
capac
method
long
term
program
ltfp
collabor
establish
transit
clinic
two
tertiari
adult
health
care
provid
support
process
transit
enhanc
transfer
adolescentyoung
adult
aya
tertiari
adult
health
care
sector
result
three
year
month
prior
june
patient
transit
tertiari
adult
health
care
provid
averag
patient
per
year
transit
clinic
implement
juli
period
juli
decemb
month
total
patient
transit
tertiari
adult
health
care
provid
averag
patient
per
year
addit
patient
plan
transit
june
averag
patient
per
year
conclus
follow
implement
formalis
transit
clinic
transit
aya
tertiari
adult
health
servic
increas
patient
refer
ltfp
transit
increas
patient
per
year
patient
per
year
creat
capac
within
ltfp
new
referr
reduc
wait
list
time
implement
formalis
transit
clinic
support
aya
patient
receiv
personalis
support
transit
reduc
number
aya
patient
bounc
back
paediatr
sector
provid
opportun
adult
health
care
sector
receiv
face
face
hand
complex
patient
optimis
follow
children
brain
tumour
wong
william
h
green
l
salisburi
depart
paediatr
haematologyoncolog
cambridg
univers
hospit
nh
foundat
trust
addenbrook
hospit
cambridg
unit
kingdom
object
aim
project
optimis
follow
children
brain
tumour
recognis
group
children
often
multipl
sequela
diseas
treatment
includ
growth
endocrin
neurolog
neuropsycholog
sequela
ongo
rehabilit
need
attend
multipl
appoint
interfer
school
parent
work
commit
comprehens
manag
plan
often
difficult
achiev
method
identifi
patient
attend
clinic
mani
addit
ongo
rehabilit
need
produc
clinic
proforma
summaris
diagnosi
treatment
given
complic
includ
prompt
address
medic
issu
school
neuropsycholog
need
potenti
transit
plan
septemb
one
clinic
establish
bring
multiprofession
team
togeth
provid
holist
review
children
team
meet
establish
fulli
discuss
patient
includ
rehabilit
issu
famili
move
room
key
worker
one
clinic
nurs
specialist
team
ensur
aspect
address
repeat
unnecessarili
clinic
comprehens
clinic
letter
produc
summaris
medic
need
rehabilit
review
school
futur
manag
plan
patient
carer
local
share
care
hospit
alli
health
profession
gener
practition
result
three
clinic
run
far
patient
staff
feedback
posit
particularli
relat
fewer
appoint
holist
approach
review
conclus
children
brain
tumour
multipl
sequela
diseas
treatment
benefit
dedic
specialist
clinic
address
medic
holist
need
one
stop
clinic
also
provid
opportun
patientpar
educ
around
medic
neurolog
neuropsycholog
issu
use
varieti
differ
tool
function
impact
peripher
neuropathi
children
youth
treat
acut
lymphoblast
leukemia
multidimension
assess
wright
twose
j
gorter
pediatr
mcmaster
children
hospitalmcmast
univers
hamilton
canada
pediatr
mcmaster
children
hospit
hamilton
canada
object
describ
function
assess
chemotherapi
induc
peripher
neuropathi
cipn
relat
impair
activ
limit
particip
restrict
childrenyouth
treat
acut
lymphoblast
leukemia
method
particip
purpos
sampl
childrenyouth
treatment
vari
degre
cipn
multidimension
assess
outlin
result
instrument
gait
analysi
conduct
analys
descript
norm
valu
provid
context
result
fourteen
particip
assess
median
age
year
rang
male
receiv
mainten
therapi
treatment
mean
time
month
rang
data
present
mean
standard
deviat
rang
norm
pediatr
modifi
total
neuropathi
minut
walk
test
metr
test
motor
profici
run
speed
agil
subtest
standard
score
oxford
foot
ankl
questionnair
physic
school
play
emot
shoe
wear
gross
motor
function
stand
walk
run
jump
pediatr
outcom
data
collect
instrument
transfer
basic
mobil
sport
physic
function
pain
comfort
edinburgh
gait
scale
common
kinemat
gait
characterist
includ
knee
hyperextens
decreas
dorsiflexion
delay
heelris
decreas
ankl
plantarflexion
pre
swing
stanc
decreas
ankl
dorsiflexion
compensatori
hip
knee
motion
swing
tempor
spatial
data
show
reduc
step
length
correspond
reduct
veloc
kinet
demonstr
decreas
ankl
momentspow
gener
push
tibiali
anterior
gastrocnemiu
electromyographi
show
time
amplitud
abnorm
conclus
function
assess
childrenyouth
particip
treat
demonstr
variabl
impair
activ
limit
particip
restrict
relat
cipn
measur
potenti
inform
clinic
decis
make
regard
vincristin
dose
exercis
orthot
facilit
evalu
time
provid
tool
research
impact
cipn
follow
treatment
recal
fertil
discuss
adolesc
femal
cancer
patient
zarnegar
gosiengfiao
rademak
rl
casey
kh
albritton
pediatr
ann
robert
h
luri
children
hospit
chicago
chicago
usa
pediatr
hematolog
oncolog
stem
cell
transplant
ann
robert
h
luri
children
hospit
chicago
chicago
usa
depart
prevent
medicin
feinberg
school
medicin
northwestern
univers
chicago
usa
children
hospit
colorado
aurora
usa
hematolog
oncolog
cook
children
health
care
system
fort
worth
usa
object
current
clinic
guidelin
emphas
oncologist
discuss
risk
infertil
preserv
option
start
therapi
purpos
studi
determin
whether
femal
adolesc
cancer
patient
ann
robert
h
luri
children
hospit
chicago
rememb
discuss
fertil
preserv
option
initi
treatment
plan
whether
satisfi
inform
receiv
method
survey
femal
year
old
cancer
diagnosi
month
year
diagnosi
enrol
regard
initi
treatment
plan
current
feel
includ
mental
health
statu
demograph
result
subject
survey
recal
discuss
decreas
fertil
potenti
side
effect
therapi
b
recal
discuss
preserv
option
subject
satisfi
inform
receiv
diagnosi
contrast
satisfact
b
p
present
subject
remain
satisfi
compar
b
half
subject
report
make
joint
medic
decis
parent
compar
b
subject
look
forward
futur
pregnanc
cancer
diagnosi
recal
discuss
fertil
overal
subject
anticip
difficulti
becom
pregnant
treatment
one
woman
believ
abl
becom
pregnant
conclus
major
subject
recal
discuss
infertil
preserv
option
young
women
satisfi
inform
receiv
recal
discuss
fertil
share
may
import
factor
recal
discuss
non
hepatoblastoma
liver
tumor
children
singl
centr
experi
bhagat
qureshi
kembhavi
ramadwar
desai
g
chinnaswami
vora
laskar
n
khanna
pediatr
surgeri
oncolog
tata
memori
hospit
mumbai
india
dept
radiolog
tata
memori
hospit
mumbai
india
dept
patholog
tata
memori
hospit
mumbai
india
pediatr
medic
oncolog
tata
memori
hospit
mumbai
india
radiat
oncolog
tata
memori
hospit
mumbai
india
object
aim
studi
review
clinic
featur
manag
outcom
children
diagnos
non
hepatoblastoma
liver
tumor
nhlt
method
pediatr
patient
nhlt
manag
institut
includ
studi
biopsi
perform
serum
tumor
marker
normal
radiolog
featur
suggest
hepatoblastoma
age
less
month
year
lesion
stage
retrospect
per
pretext
stage
system
clinic
find
imag
surgic
detail
intraop
postop
complic
relaps
surviv
detail
analyz
chemotherapi
radiotherapi
util
indic
result
total
liver
lesion
benign
hemangioendothelioma
mesenchym
hamartoma
hemangioma
adenoma
focal
nodular
fnh
primari
liver
tumor
hepatocellular
carcinoma
hcc
synovi
sarcoma
three
metastat
lesion
primari
metastat
patient
ovarian
germ
cell
tumor
gct
pancreaticoblastoma
wilm
tumor
pretext
distribut
ii
iii
iv
right
hepatectomi
perform
four
left
later
sectorectomi
ll
three
non
anatom
resect
nar
seven
median
blood
loss
ml
rang
median
intraop
time
hour
hour
patient
neg
margin
except
one
fnh
intraop
postop
complic
mean
month
local
recurr
patient
aliv
diseas
free
conclus
nhlt
often
low
pretext
stage
safe
surgeri
feasibl
without
morbid
associ
good
outcom
treatment
outcom
children
hepatoblastoma
b
demirag
inc
celik
erbay
hosgor
g
diniz
oymak
yaman
g
ozek
c
vergin
pediatr
hematolog
oncolog
clinic
dr
behcet
uz
children
hospit
izmir
turkey
pediatr
surgeri
dept
ege
univers
faculti
medicin
izmir
turkey
pediatr
hematolog
oncolog
dept
baskent
univers
faculti
medicin
adana
turkey
pediatr
surgeri
dept
dr
behcet
uz
children
hospit
izmir
turkey
patholog
dr
behcet
uz
children
hospit
izmir
turkey
object
evalu
treatment
result
patient
hepatoblastoma
hb
method
medic
record
patientswith
hb
diagnos
treat
review
retrospect
result
patient
diagnosi
hb
elig
two
patient
refus
treatment
median
age
diagnosi
month
patient
age
mf
ratio
stage
distribut
two
patient
pulmonari
metastasi
median
afp
level
ngml
histopatholog
examin
reveal
epitheli
hb
primari
total
resect
perform
four
case
diseas
male
afp
cr
achiev
primari
total
tumor
resect
risk
chemotherapi
protocol
twelv
patient
receiv
chemotherapi
accord
siopel
protocol
four
patient
delay
surgeri
perform
dextrazoxan
provid
three
patient
receiv
protocol
delay
surgeri
result
microscop
residu
two
patient
diseas
one
two
patient
relaps
pulmonari
metastas
month
relaps
primari
tumor
site
month
liver
transplant
perform
patient
primari
relaps
median
time
surviv
analysi
done
patient
treat
accord
siopel
protocol
ef
rate
ef
rate
os
rate
earli
late
chemothearpi
toxic
conclus
perform
surgeri
experienc
center
import
hepatoblastoma
treatment
death
relat
chemotherapi
toxic
surgeri
surviv
rate
accept
siopel
protocol
found
applic
success
condit
liver
mass
clinic
radiolog
differenti
diagnosi
report
case
admit
singl
month
gasperini
e
boldrini
c
cavalcant
n
suarez
e
silva
luiz
lope
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
radiologist
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
patholog
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
phd
medic
director
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
object
paper
report
four
case
liver
mass
children
admit
hospit
august
method
age
rang
month
year
male
abdomin
distens
palpabl
liver
mass
chief
complaint
associ
sign
symptom
weight
loss
respiratori
distress
cough
dyspnea
jaundic
achol
stool
dark
urin
two
elev
afp
two
abnorm
liver
enzym
one
hyperbilirubinemia
underw
examin
biopsi
three
malign
two
hepatoblastoma
rhabdomyosarcoma
biliari
tract
one
mesenchym
hamartoma
result
hepatoblastoma
common
liver
tumor
childhood
often
age
three
male
femal
ratio
associ
cirrhosi
mass
usual
larg
singl
often
increas
afp
biliari
rhabdomyosarcoma
rare
tumor
common
caus
malign
obstruct
jaundic
age
group
occur
around
age
jaundic
achol
stool
dark
urin
hepatomegali
increas
bilirubin
liver
enzym
mesenchym
hamartoma
frequent
children
year
congenit
benign
lesion
present
palpabl
abdomin
mass
abdomin
distens
painless
without
alter
liver
function
afp
common
radiolog
find
hepatoblastoma
well
circumscrib
may
appear
lobul
septa
rabdomiassarcoma
biliari
present
dilat
bile
mesenchym
hamartoma
pathway
appear
cystic
liver
injuri
multilocular
thin
intern
septa
conclus
ultrasound
excel
screen
test
suspect
liver
mass
ioniz
radiat
need
sedat
confirm
hepat
mass
ct
scan
mri
perform
guid
biopsi
surgeri
subsequ
hepatoblastoma
clinic
characterist
outcom
patient
inc
k
mutafoglu
e
buke
f
yenigurbuz
kilic
olgun
c
arikan
e
ozer
h
guleryuz
n
olgun
dept
pediatr
oncolog
dokuz
eylul
univers
institut
oncolog
izmir
turkey
liver
transplant
team
kent
hospit
izmir
turkey
dept
pediatr
surgeri
dokuz
eylul
univers
faculti
medicin
izmir
turkey
dept
patholog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
dept
radiodiagnost
dokuz
eylul
univers
faculti
medicin
izmir
turkey
dept
pediatr
oncolog
dokuz
eylul
univers
insitut
oncolog
izmir
turkey
object
evalu
clinic
featur
treatment
result
patient
hepatoblastoma
hb
depart
method
medic
record
children
diagnos
treat
hb
analyz
retrospect
result
children
hb
median
diagnosi
age
mf
ratio
stage
distribut
pretext
iv
pretext
ii
pretext
iii
pretext
ii
patient
median
afp
level
histopatholog
examin
reveal
epitheli
hb
fetal
mix
fetalembryon
epithelialmesenchym
hb
hb
specifi
patient
pretext
hb
primari
delay
surgeri
perform
without
residu
chemotherapi
given
accordingli
one
four
patient
femal
relaps
primari
site
month
die
progress
month
case
without
diseas
median
time
pretext
hb
patient
chemotherapi
schema
delay
surgeri
perform
patient
liver
transplant
done
six
surgic
magrin
tumor
posit
one
residu
tumor
thrombu
remain
one
patient
relaps
die
progress
first
one
primari
relaps
month
die
month
second
one
relaps
primari
site
month
die
month
median
time
ef
os
conclus
oldest
patient
poor
outcom
despit
residu
tumor
liver
transplant
result
earli
relaps
death
two
case
multidisciplinari
treatment
perform
surgeri
experienc
center
essenti
manag
hb
manag
pediatr
hepatocellular
carcinoma
multimod
approach
kohorst
dm
warad
dk
frees
jm
matsumoto
v
rodriguez
aa
nageswara
rao
pediatr
adolesc
medicin
mayo
clinic
rochest
usa
pediatr
adolesc
medicinedivis
pediatr
hematologyoncolog
mayo
clinic
rochest
usa
pediatr
adolesc
medicinedivis
pediatr
gastroenterolog
mayo
clinic
rochest
usa
pediatr
adolesc
medicinedivis
pediatr
radiolog
mayo
clinic
rochest
usa
object
pediatr
hepatocellular
carcinoma
hcc
exceedingli
rare
account
childhood
tumor
surviv
rate
primari
unresect
hcc
dismal
cisplatin
doxorubicin
plado
regimen
demonstr
event
free
overal
surviv
respect
adjunct
sorafenib
shown
favor
result
adult
littl
promis
data
children
furthermor
hepat
arteri
chemoembol
hace
proven
effect
treatment
strategi
achiev
resect
minim
system
toxic
liver
transplant
may
consid
unresect
hcc
object
describ
multimod
approach
manag
unresect
hcc
method
case
report
literatur
review
result
femal
present
abdomin
pain
firm
hepatomegali
elev
ngml
rang
mri
abdomen
reveal
larg
liver
mass
involv
section
left
portal
vein
liver
biopsi
show
poorli
differenti
hcc
angiolymphat
invas
fibrosi
metastat
neg
underw
cycl
plado
sorafenib
follow
hace
doxorubicin
mitomycin
decreas
tumor
burden
level
declin
dramat
reduct
liver
size
allow
complet
tumor
resect
orthotop
liver
transplant
explant
liver
demonstr
tumor
viabil
sorafenib
restart
discontinu
month
due
signific
syndrom
trial
sirolimu
mtor
inhibitor
immunosuppress
initi
ad
benefit
recurr
risk
reduct
howev
develop
mild
acut
reject
result
restitut
tacrolimu
current
month
remiss
perform
score
conclus
limit
pediatr
literatur
exist
hcc
manag
especi
unresect
case
multimod
treatment
involv
chemotherapi
plado
sorafenib
hace
time
liver
transplant
mtor
inhibitor
period
may
help
improv
outcom
prolong
surviv
pediatr
patient
unresect
hcc
studi
clinic
characterist
prognost
factor
case
hepatoblastoma
z
lu
hemotologyoncolog
shanghai
children
hospit
shanghai
china
object
investig
clinic
characterist
surviv
analysi
childhood
hepatoblastoma
prognost
factor
method
februari
septemb
case
hepatoblastoma
diagnos
shanghai
children
hospit
includ
studi
male
femal
median
age
month
rang
month
follow
median
time
month
month
patient
stage
refer
pretext
stage
oper
surgeri
chemotherapi
use
accord
differ
stage
evalu
correl
surviv
rate
stage
treatment
strategi
result
accord
pretext
stage
number
case
stage
ii
iii
iv
overal
surviv
os
stage
ii
iii
iv
p
ef
p
case
receiv
tumor
complet
excis
first
diagnosi
cure
case
receiv
chemotherapi
tumor
biopsi
second
tumor
resect
given
tumor
shrinkag
case
relaps
case
cure
conclus
onset
age
pediatr
hepatoblastoma
younger
surgic
resect
combin
preoper
postop
chemotherapi
main
way
improv
surviv
rate
stage
complet
resect
may
risk
factor
children
hepatoblastoma
pediatr
hepatoblastoma
thailand
experi
singl
institut
k
phuakpet
k
sanpakit
n
vathana
p
tanaanunmongkol
laohapansang
chuangsuwanich
depart
pediatr
faculti
medicin
siriraj
hospit
mahidol
univers
bangkok
thailand
depart
surgeri
faculti
medicin
siriraj
hospit
mahidol
univers
bangkok
thailand
depart
patholog
faculti
medicin
siriraj
hospit
mahidol
univers
bangkok
thailand
object
assess
treatment
outcom
surviv
df
children
hepatoblastoma
treat
institut
method
retrospect
review
medic
record
hepatoblastoma
patient
year
old
diagnos
treat
siriraj
hospit
thailand
june
decemb
demograph
data
investig
result
treatment
approach
treatment
outcom
collect
analyz
result
patient
diagnos
hepatoblastoma
studi
period
median
age
diagnosi
year
old
rang
year
old
patient
follow
children
oncolog
group
cog
stage
ii
iii
iv
seven
patient
initi
lung
metastasi
thirteen
patient
resect
tumor
underw
upfront
surgeri
follow
adjuv
chemotherapi
remain
patient
receiv
neoadjuv
chemotherapi
patient
achiev
total
tumor
remov
later
common
chemotherapi
regimen
continu
doxorubicin
plu
either
carboplatin
cisplatinum
eighteen
patient
hematolog
toxic
cardiotox
report
patient
achiev
complet
remiss
patient
subsequ
local
relaps
median
durat
year
rang
year
eleven
patient
die
diseas
median
time
year
rang
year
df
cog
stage
ii
iii
iv
respect
df
significantli
better
achiev
total
tumor
remov
p
significantli
wors
metastat
diseas
p
conclus
treatment
outcom
hepatoblastoma
develop
countri
compar
develop
countri
total
tumor
remov
key
treatment
success
neoadjuv
chemotherapi
rather
attempt
surgeri
suggest
complet
resect
unlik
begin
total
tumor
remov
eventu
achiev
case
lead
favor
outcom
howev
intens
treatment
need
metastat
diseas
papillari
thyroid
carcinoma
chemotherapi
liver
transplant
hepatoblastoma
k
watanab
h
hiramatsu
k
umeda
okamoto
e
ogawa
dept
pediatr
kyoto
univers
kyoto
japan
dept
pediatr
surgeri
kyoto
univers
kyoto
japan
object
hepatoblastoma
rare
childhood
malign
may
present
famili
cancer
famili
adenomat
polyposi
fap
howev
associ
papillari
thyroid
carcinoma
hepatoblastoma
rare
report
method
describ
femal
papillari
thyroid
carcinoma
treatment
hepatoblastoma
result
patient
diagnos
pretext
iii
hepatoblastoma
old
age
underw
preoper
chemotherapi
cisplatinpirarubicin
ifosfamidepirarubicinetoposidecarboplatin
follow
live
donor
liver
transplant
mother
receiv
postop
three
cours
irinotecan
follow
ct
scan
accident
reveal
thyroid
mass
fine
needl
aspir
biopsi
led
diagnosi
papillari
carcinoma
nine
year
old
total
thyroidectomi
cervic
lymph
node
dissect
perform
diseas
diagnos
stage
papillari
carcinoma
pex
lymph
node
metastasi
extrathyroid
extens
lymph
node
metastasi
radioiodin
ablat
perform
prevent
recurr
conclus
papillari
thyroid
carcinoma
rare
childhood
report
associ
radiat
exposur
associ
hepatoblastoma
papillari
thyroid
carcinoma
might
relat
fap
howev
patient
histori
radiat
exposur
famili
histori
suggest
fap
patholog
thyroid
cancer
cribriform
pattern
typic
fap
fap
mutat
analysi
current
underway
primari
immunodefici
diseas
pid
present
lymphoma
treat
hematopoiet
stem
cell
transplant
hsct
descript
patient
k
aabideen
v
gupta
z
nademi
slatter
hambleton
genneri
flood
abinum
cant
bone
marrow
transplant
great
north
children
hospit
newcastl
upon
tyne
unit
kingdom
object
pid
one
risk
factor
lymphoma
children
manag
strategi
lymphoma
due
pid
still
evolv
hsct
treatment
choic
mani
pid
present
patient
underw
hsct
present
lymphoma
due
pid
method
retrospect
review
clinic
detail
outcom
six
patient
pid
present
lymphoma
result
year
old
male
diagnos
ebv
driven
lymphoprolif
diseas
lpd
resembl
hodgkin
diseas
confirm
interleukin
induc
cell
kinas
itk
defici
brother
itk
defici
therefor
confirm
itk
defici
birth
wait
transplant
develop
ebv
driven
lpd
similar
diffus
larg
b
cell
lymphoma
dlbl
year
old
male
diagnos
malt
lymphoma
found
combin
immun
defici
cid
year
old
male
diagnos
ebv
neg
dlbl
confirm
cid
patient
one
year
old
male
diagnos
cid
due
cell
activ
disord
develop
multipl
lymphadenopathi
confirm
ebv
posit
lpd
year
old
femal
famili
histori
famili
histori
undiagnos
pid
develop
nodular
scleros
classic
hodgkin
diseas
subsequ
confirm
cid
patient
success
hsct
lymphoma
resolv
patient
patient
surviv
differ
post
transplant
follow
period
month
respect
patient
conclus
pid
rule
atyp
chemotherapi
resist
relaps
case
lymphoma
chemotherapi
unlik
effect
lymphoma
due
pid
hsct
treatment
choic
sever
pid
hsct
cur
lymphoma
due
pid
intracardiac
lymphoma
treatment
challeng
outcom
resourc
limit
set
adefehinti
uu
onakpoya
ao
komolaf
oo
adeodu
durosinmi
paediatr
unit
depart
paediatr
obafemi
awolowo
univers
teach
hospit
nigeria
cardiothorac
surgeri
unit
depart
surgeri
obafemi
awolowo
univers
teach
hospit
nigeria
depart
morbid
anatomi
forens
medicin
obafemi
awolowo
univers
teach
hospit
nigeria
unit
depart
paediatr
obafemi
awolowo
univers
teach
hospit
nigeria
depart
haematolog
immunolog
obafemi
awolowo
univers
teach
hospit
nigeria
object
highlight
need
earli
recognit
diagnosi
challeng
involv
treatment
intracardiac
lymphoma
method
malign
lymphoma
present
intracardiac
mass
rare
morbid
mortal
may
high
associ
pericardi
effus
cardiac
tamponad
without
time
interventon
old
femal
present
children
emerg
ward
clinic
featur
pericardi
effus
cardiac
tamponad
report
echocardiographi
confirm
massiv
pericardi
effus
huge
mass
attach
anterior
tricuspid
valv
imped
diastol
flow
right
ventricl
dilat
right
atrium
interatri
shift
left
almost
collaps
left
atrial
wall
emerg
pericardiostomi
pericardi
biopsi
done
cytolog
histolog
report
pericardi
fluid
biopsi
confirm
lymphoma
posit
cd
cd
neg
cd
cd
immunohistochemistri
peripher
blood
bone
marrow
free
blast
cylophosphamid
oncovin
prednisolon
cop
one
week
follow
cylophosphamid
oncovin
cytosin
arabinosid
prednisolon
coap
regimen
receiv
two
six
cycl
coap
financi
reason
serial
follow
echocardiographi
end
cop
end
cycl
coap
confirm
signific
reduct
intracardiac
mass
aliv
well
one
year
later
becam
symptomat
die
result
none
conclus
intracardiac
lymphoma
rare
associ
pericardi
effus
cardiac
tamponad
cost
treatment
enorm
challeng
resourc
limit
set
nodular
lymphocyt
predomin
hodgkin
lymphoma
experi
singl
institut
argentina
e
alfaro
c
sanchez
la
rosa
guitter
rose
w
caccavillano
l
galluzzo
felic
p
zubizarreta
hospit
de
prof
dr
juan
p
garrahan
bueno
air
argentina
object
nodular
lymphocyt
predomin
hodgkin
lymphoma
nlphl
repres
hodgkin
lymphoma
hl
distinct
featur
overal
good
prognosi
treatment
strategi
base
protocol
hl
select
patient
treat
surgeri
alon
aim
describ
clinic
characterist
manag
outcom
patient
nlph
method
januari
patient
f
median
age
rang
year
consecut
diagnos
institut
initi
chemotherapi
schedul
abvd
doxorubicin
bleomycin
vinblastin
dacarbazin
coppabvd
adriamycinvincristineprednisonecyclophosphamid
respons
partial
null
addit
chemotherapi
administ
anti
andor
hdcasct
strategi
lymph
node
complet
surgeri
use
two
case
strategi
becam
trustworthi
result
eleven
patient
show
nodal
compromis
cervic
local
frequent
ten
patient
present
local
diseas
stage
ia
stage
advanc
diseas
stage
stage
one
patient
b
symptom
two
ia
stage
case
complet
node
resect
five
patient
receiv
cycl
abvd
one
patient
receiv
coppabvd
three
patient
receiv
cycl
one
patient
receiv
cycl
plu
dose
rituximab
one
patient
present
progress
diseas
cycl
abvd
addit
chemotherapi
administ
hdcasct
three
receiv
plu
chemotherapi
one
patient
still
treatment
respons
treatment
cr
pt
pt
nr
pt
median
follow
rang
month
patient
remain
cr
conclus
although
manag
nlphl
uniform
retrospect
analysi
result
excel
tailor
therapi
accord
stage
diseas
respons
seem
good
strategi
set
differ
type
malign
child
differ
time
period
life
yr
chopra
ramzan
r
sharma
katewa
yadav
pediatr
hematolog
oncolog
bone
marrow
transplant
unit
forti
memori
research
institut
gurgaon
india
object
cancer
survivor
higher
risk
new
primari
cancer
anoth
organ
gener
popul
describ
case
yr
old
male
present
multipl
malign
year
age
method
pediatr
case
report
result
year
old
male
born
birth
order
marriag
strong
famili
histori
malign
patern
uncl
die
unknown
reason
elder
brother
die
neuroblastoma
stage
iv
year
age
sibl
die
glioblastoma
multiform
year
age
one
year
old
femal
sibl
diagnos
stage
ii
ileocec
burkitt
lymphoma
surgic
resect
follow
cycl
copad
chemotherapi
asymptomat
till
year
age
featur
suggest
superior
vena
cava
syndrom
cect
chest
show
anterior
mediastin
mass
cect
abdomen
bone
marrow
csf
normal
trucut
biopsi
suggest
unclassifi
lymphoma
treat
cycl
chop
chemotherapi
repeat
cect
cycl
show
margin
shrinkag
receiv
cycl
ice
chemotherapi
went
cr
underw
autolog
stem
cell
transplant
follow
beam
condit
regimen
asymptomat
till
day
abdomin
lump
cect
abdomen
reveal
diffus
mesenter
lymphadenopathi
conglomer
necrot
mass
encas
sma
biopsi
flowcytometri
mass
reveal
featur
cell
malign
lymphoma
genet
studi
could
perform
due
monitori
problem
unfortun
due
econom
constraint
parent
opt
palli
care
conclus
three
malign
childhood
rare
event
famili
member
scrutin
detail
includ
genet
studi
avascular
necrosi
pediatr
patient
hodgkin
diseas
king
hussein
cancer
center
r
deebajah
tawfiq
f
bazzeh
pediatr
king
hussein
cancer
center
amman
jordan
nurs
king
hussein
cancer
center
amman
jordan
pediatr
king
hussein
cancer
center
amman
jordan
object
limit
data
incid
avascular
necrosi
avn
bone
adolesc
children
hl
review
institut
experi
higher
incid
avn
report
method
conduct
retrospect
analysi
children
year
hodgkin
lymphoma
develop
avn
treatment
present
decemb
june
patient
characterist
treatment
regimen
steroid
cumul
dose
treatment
modal
avn
analyz
result
identifi
patient
femal
develop
avn
treatment
hl
median
age
diagnosi
year
rang
eight
treat
high
risk
beacopp
regimen
one
intermedi
risk
cycl
abvd
cycl
copp
mri
lower
limb
request
therapi
due
symptom
cumul
dose
steroid
rang
one
patient
receiv
radiotherapi
field
involv
femor
head
two
patient
underw
joint
decompress
rest
patient
n
treat
conserv
manag
conclus
observ
higher
expect
number
patient
hl
develop
avn
may
reflect
genuin
increas
risk
popul
condit
other
care
clinic
follow
warrant
detect
earli
sign
avn
adolesc
hl
autolog
hematopoiet
stem
cell
transplant
relapsedrefractori
lymphoma
childhood
singl
center
experi
f
erbey
atay
akbiyik
g
pediatr
hematologyoncolog
pediatr
bmt
unit
bahcelievl
medicalpark
hospit
istanbul
turkey
object
evalu
treatment
outcom
patient
relapsedrefractori
lymphoma
receiv
autolog
stem
cell
transplant
asct
childhood
method
retrospect
analyz
outcom
patient
done
asct
januari
decemb
result
median
age
year
rang
year
male
femal
lymphoma
nhl
hodgkin
lymphoma
hl
patient
seven
patient
receiv
beam
bcnu
etoposid
melphalan
patient
receiv
bumel
busulfan
melphalan
support
asct
time
studi
patient
aliv
patient
die
due
progress
diseas
mortal
overal
surviv
os
diseas
free
surviv
df
median
month
rang
month
patient
respect
differ
efficaci
condit
regimen
found
conclus
asct
effect
treatment
patient
relapsedrefractori
lymphoma
signific
differ
outcom
observ
beam
bumel
condit
regimen
comparison
two
treatment
regimen
non
hodgkin
lymphoma
patient
singl
institut
experi
children
hospit
lahor
faizan
anwar
n
asghar
shabbir
ali
tajfrom
podc
cclg
paediatr
hematologyoncolog
children
hospit
institut
child
health
lahor
pakistan
paediatr
lahor
gener
hospit
lahor
pakistan
paediatr
hematologyoncolog
royal
marsden
hospit
london
unit
kingdom
object
children
hospit
lahor
tertiari
care
pediatr
hospit
pakistan
bed
hematologyoncolog
unit
report
experi
treat
non
hodgkin
lymphoma
nhl
use
regimen
guidelin
protocol
patient
method
fifti
consecut
biopsi
proven
patient
nhl
burkitt
diffus
larg
b
cell
lymphoma
includ
studi
first
patient
treat
accord
cclg
guidelin
contain
high
dose
next
accord
less
intens
consist
cyclophosphamid
adriamycin
vincristin
etoposid
ifosfamid
low
dose
methotrex
result
total
patient
thirti
seven
patient
male
major
patient
year
age
major
present
abdomin
symptom
abdomin
mass
intussuscept
intestin
obstruct
present
complaint
patient
one
patient
nasopharyng
mass
symptom
obstruct
uropathi
major
present
stage
iii
stage
iv
none
present
stage
ii
group
receiv
treatment
accord
cclg
guidelin
overal
surviv
abandon
without
expir
left
medic
advic
lama
caus
mortal
high
dose
methotrex
mtx
toxic
sepsi
document
chart
overal
surviv
abandon
without
abandon
patient
treat
protocol
relaps
expir
due
sepsi
lama
conclus
high
dose
mtx
toxic
major
caus
mortal
patient
receiv
treatment
accord
cclg
guidelin
mcp
involv
low
dose
mtx
better
toler
patient
therapi
offer
mostli
outdoor
basi
better
outcom
develop
countri
need
adopt
protocol
demand
limit
support
care
facil
toler
studi
case
primari
bone
lymphoma
n
suarez
paula
gasperini
c
cavalcant
e
silva
luiz
lope
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
radiolog
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
patholog
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
object
hodgkin
lymphoma
repres
approxim
tumor
children
year
bone
present
rare
children
diffus
larg
lymphoma
frequent
method
report
case
lymphoma
bone
primari
site
admit
decemb
februari
result
femal
male
age
year
patient
bone
pain
main
symptom
associ
claudic
paresthesia
time
onset
symptom
five
month
year
diagnos
confirm
biopsi
accord
histolog
clinic
aspect
lymphoma
b
left
acetabulum
stage
iv
lymphoma
right
tibia
stage
iii
larg
lymphoma
left
humeru
stage
iii
larg
lymphoma
right
iliac
bone
involv
pubi
ischium
bodi
stage
iii
immunohistochem
exam
case
tdt
cd
cd
posit
confirm
diagnosi
conclus
clinic
radiolog
bone
destruct
lytic
area
sclerot
variabl
involv
entir
bone
extens
soft
tissu
histolog
diffus
infiltr
small
round
cell
specif
bone
lymphoma
mandatori
extend
immunohistochem
panel
includ
tdt
cd
cd
done
case
avoid
possibl
error
diagnosi
conclud
bone
lymphoma
includ
differenti
diagnosi
bone
tumor
clinic
characterist
treatment
outcom
pediatr
hodgkin
lymphoma
children
hospit
benghazi
libya
n
gheriani
l
ballo
alshkteria
hematolog
oncolog
unit
children
hospit
benghazi
benghazi
libya
commun
medicin
depart
benghazi
univers
benghazi
libya
object
lymphoma
third
common
childhood
malign
howev
littl
data
avail
lymphoma
develop
countri
present
work
perform
identifi
clinic
characterist
treatment
outcom
pediatr
hodgkin
lymphoma
hl
center
method
retrospect
studi
patient
diagnos
hl
use
chemotherapeut
regimen
abvd
copp
stage
iv
beacopp
bleomycin
etoposid
adriamycin
cyclophosphamid
vincristin
procarbazin
prednisolon
vvac
vinblastin
arac
cisplatin
ad
patient
receiv
radiotherapi
ann
arbor
hl
stage
criteria
appli
stage
rye
system
use
histopatholog
examin
treatment
outcom
evalu
use
method
differ
outcom
test
use
logrank
test
result
male
femal
male
femal
ratio
median
age
year
year
bulki
diseas
b
symptom
found
patient
respect
stage
distribut
patient
stage
ii
iii
iv
respect
patient
present
stage
iii
iv
histopatholog
subtyp
nodular
sclerosi
mix
cellular
lymphocyt
predomin
lymphocyt
deplet
respect
death
relaps
mix
cellular
patient
complet
remiss
relaps
cure
relaps
die
overal
surviv
os
surviv
ef
rate
respect
median
follow
year
os
rate
bulki
diseas
without
p
os
rate
b
symptom
without
p
histopatholog
stage
relaps
effect
os
rate
p
p
p
respect
conclus
stage
histopatholog
relaps
statist
signific
predict
factor
os
rate
patient
commonli
present
advanc
stage
studi
requir
evalu
caus
paediatr
plasmablast
lymphoma
singl
unit
experi
natal
south
africa
goga
r
thejpal
k
moodley
n
moonsami
b
neethl
paediatr
haematolog
unit
dept
paediatr
child
health
nelson
r
mandela
school
medicin
univers
natal
durban
south
africa
object
describ
patient
characterist
treatment
respons
surviv
patient
plasmablast
lymphoma
singl
centr
method
retrospect
chart
review
patient
plasmablast
lymphoma
diagnos
januari
decemb
result
five
patient
diagnos
plasmablast
lymphoma
male
predomin
patient
black
three
patient
stage
diseas
two
patient
stage
diseas
patient
present
maxillarynas
mass
abdomin
maxillari
diseas
femal
patient
present
multipl
boni
lesion
none
patient
cn
involv
patient
hiv
posit
haart
highli
activ
diseas
naiv
diagnosi
count
avail
patient
patient
count
count
patient
patient
treat
cytoreduct
therapi
cyclophospomid
vincristin
prednison
cop
follow
hybrid
vincristin
doxorubicin
cyclophosphomid
prednison
altern
bleomycin
methotrex
vincristin
patient
treat
use
bfm
base
copadm
protocol
conclus
plasmablast
lymphoma
rare
hiv
associ
malign
predilect
nasal
maxillari
area
low
count
predict
surviv
treatment
protocol
poorli
defin
role
scan
manag
matur
b
cell
pediatr
lymphoma
cche
experi
hani
abdelrahman
hamoda
sedki
emad
moussa
iman
attia
raafat
ayda
youssef
w
omar
hassanein
alaa
elhadad
pediatr
oncolog
nation
cancer
institut
cairo
univers
fom
elkalig
cairo
egypt
pediatr
oncolog
nation
research
center
cairo
egypt
pediatr
oncolog
elmounofia
univers
cairo
egypt
radiodiagnosi
nation
cancer
institut
cairo
univers
fom
elkalig
cairo
egypt
nuclear
medicin
nation
cancer
institut
cairo
univers
fom
elkalig
cairo
egypt
object
evalu
sensit
specif
predict
valu
pet
scan
manag
pediatr
lymphoma
nhl
method
retrospect
studi
enrol
pediatr
patient
nhl
children
cancer
hospit
egypt
cche
period
juli
till
end
june
done
inclus
criteria
includ
diagnosi
matur
b
cell
nhl
pet
addit
convent
ct
done
stage
treatment
blind
revis
pet
ct
scan
specif
done
studi
result
pediatr
nhl
patient
pet
ct
scan
done
median
age
year
rang
year
male
femal
one
hundr
twenti
six
scan
done
burkitt
lymphoma
patient
scan
done
dlbc
nineteen
examin
done
start
chemotherapi
time
evalu
follow
patient
sensit
pet
convent
ct
p
specif
pet
ct
p
burkitt
lymphoma
sensit
pet
ct
p
specif
pet
ct
respect
p
conclus
pet
scan
significantli
sensit
convent
ct
manag
aggress
matur
b
cell
pediatr
nhl
clinic
review
lymphoprolif
disord
ptld
case
aris
young
liver
transplant
recipi
huang
k
chiang
oncolog
depart
beij
children
hospit
beij
china
oncolog
depart
queen
mari
hospit
hong
kong
hong
kong
china
object
make
clinician
better
understand
ptld
young
children
reduc
delay
diagnosi
earli
stage
explor
feasibl
mean
prophylaxi
treatment
method
retrospect
analysi
clinicopatholog
featur
treatment
outcom
consecut
case
ptld
liver
transplant
januari
decemb
initi
symptom
delay
diagnosi
time
ebv
cmv
statu
complet
blood
count
lft
patholog
result
imag
result
treatment
outcom
review
respect
result
six
case
diagnos
clinic
major
symptom
snore
derang
lft
median
time
initi
symptom
onset
ptld
diagnosi
month
case
histopatholog
diagnos
initi
symptom
variou
among
differ
patholog
subtyp
mononorph
lpd
case
system
aggress
case
interv
initi
symptom
onset
final
diagnosi
also
variou
delay
diagnosi
due
organ
involv
especi
clinic
manifest
ptld
treatment
consist
reduc
stop
immunosuppress
follow
rituximab
chemotherapi
requir
case
remiss
cr
pr
two
die
ptld
relat
multipl
organ
failur
episod
liver
reject
case
os
ef
respect
conclus
delay
diagnosi
ptld
young
children
common
due
variou
clinic
manifest
among
differ
patholog
subtyp
time
diagnosi
treatment
essenti
prognosi
rituximab
efficaci
drug
ptld
sinc
high
incid
ptld
liver
transplant
reject
episod
relaps
diseas
possibl
alway
essenti
keep
low
dose
immunosuppress
possibl
monitor
patient
treatment
ptld
necessari
clinic
review
mediastin
lymphoma
pediatr
patient
singl
center
experi
china
huang
zhang
l
jin
oncolog
depart
beij
children
hospit
beij
china
object
clinic
featur
treatment
outcom
mediastin
beij
children
hospit
studi
method
retrospect
examin
clinic
featur
treatment
outcom
mediastin
within
period
decemb
case
bone
marrow
involv
case
bone
marrow
involv
rest
case
bone
marrow
involv
use
modifi
bfm
lbl
protocol
result
newli
diagnos
case
median
age
year
patient
b
symptom
bulki
mediastin
mass
diamet
cm
case
superior
vena
cava
syndrom
svc
case
upper
airway
obstruct
case
acut
tumor
lysi
syndrom
atl
among
median
time
initi
symptom
onset
final
diagnosi
studi
group
n
stage
iii
n
stage
iv
n
case
elev
uric
acid
ua
elev
lactat
dehydrogenas
ldh
among
case
case
case
die
chemotherapi
dead
diseas
progress
relaps
dead
sever
infect
estim
overal
surviv
os
event
free
surviv
ef
respect
conclus
bulki
mass
common
mostli
caus
svc
upper
airway
obstruct
atl
advanc
diseas
stage
iv
common
depend
poor
prognost
factor
singl
center
clinic
analysi
childhood
non
hodgkin
lymphoma
j
hui
z
lu
j
yang
j
shao
hong
li
hemotologyoncolog
shanghai
children
hoapitalshanghai
jiao
tong
univers
shanghai
china
object
retrospect
analyz
clinic
efficaci
childhood
non
hodgkin
lymphoma
nhl
accord
world
health
organ
classif
tumor
method
januari
decemb
patient
newli
diagnos
nhl
verifi
clinic
imag
cell
morpholog
immun
phenotyp
histopatholog
classif
patient
total
receiv
treatment
male
averag
age
year
rang
year
year
accord
st
jude
stage
classif
case
divid
stage
ii
case
stage
iii
case
stage
iv
chemotherapi
regimen
base
phenotyp
pathologicali
clinic
stage
precursor
lymphoblast
lymphoma
receiv
treatment
acut
lymphoblast
leukemia
result
among
case
burkittsburkitt
like
lymphoma
anaplast
larg
cell
lymphoma
alcl
diffus
larg
lymphoma
dlbcl
precursor
lymphoblast
lymphoma
case
cell
case
b
cell
estim
surviv
ef
patient
burkittsburkitt
like
lymphoma
alcl
dlbcl
precursor
lymphoblast
lymphoma
differ
ef
burkittsburkitt
like
lymphoma
alcl
signific
p
differ
alk
posit
alcl
p
ef
stage
ii
stage
iii
stage
iv
p
conclus
correct
cell
phenotyp
pathologicali
diagnosi
nhl
key
step
prognosi
nhl
burkittsburkitt
like
lymphoma
good
prognosi
child
though
aggress
current
treatment
effect
safe
childhood
nhl
pattern
failur
outcom
pediatr
patient
relaps
progress
hodgkin
lymphoma
c
karadeniz
oguz
okur
fg
pinarli
isik
f
tekkesin
n
akyurek
h
bora
pediatr
oncolog
gazi
univers
school
medicin
ankara
turkey
object
studi
present
clinic
characterist
failur
pattern
outcom
pediatr
patient
hodgkin
lymphoma
hl
treat
chemotherapi
dose
involv
field
radiotherapi
singl
institut
method
retrospect
analysi
compris
patient
hl
treat
institut
receiv
four
six
cycl
abvdcopp
altern
chemotherapi
base
stage
follow
ifrt
gy
result
patient
nine
recurr
progress
month
diagnosi
median
month
month
progress
recurr
mean
age
diagnosi
year
five
patient
local
stage
iia
iib
four
patient
advanc
diseas
stage
iiib
iv
diagnosi
two
patient
progress
diseas
first
line
chemotherapi
one
respond
high
dose
chemotherapi
hdct
autolog
hematopoiet
stem
cell
transplant
hsct
die
diseas
patient
lost
diseas
two
patient
earli
five
patient
late
relaps
one
patient
earli
relaps
die
diseas
month
salvag
therapi
patient
earli
relaps
receiv
hdct
allogen
hsct
aliv
month
without
diseas
five
patient
late
relaps
achiev
complet
remiss
autolog
hsct
two
second
line
chemotherapi
aliv
without
diseas
month
recurr
three
patient
local
two
patient
distant
two
patient
local
distant
relaps
lung
parenchyma
common
extralymphat
site
involv
patient
relaps
progress
diseas
conclus
seen
local
distant
relaps
almost
equal
number
patient
outcom
patient
earli
relaps
progress
diseas
poor
pediatr
larg
lymphoma
clinic
featur
treatment
outcom
kirov
lone
divis
oncolog
choc
children
hospit
orang
california
usa
depart
patholog
laboratori
medicin
univers
california
lo
angel
lo
angel
california
usa
object
larg
lymphoma
tcrlbcl
subtyp
diffus
larg
lymphoma
dlbcl
character
small
number
scatter
larg
numer
reactiv
pediatr
tcrlbcl
uncommon
well
understood
goal
preliminari
studi
character
clinic
featur
pediatr
tcrlbcl
primari
diagnosi
treatment
outcom
method
three
pediatr
patient
tcrlbcl
evalu
clinic
featur
treatment
respons
therapi
outcom
result
clinic
featur
includ
age
year
male
femal
murphi
stage
axilla
ii
cervic
tonsil
nasopharynx
iii
abdomen
pelvi
spleen
spineepidur
elev
lactat
dehydrogenas
treatment
accord
protocol
two
patient
stage
ii
follow
arm
patient
advanc
diseas
stage
iii
follow
arm
patient
achiev
complet
respons
cr
subsequ
relaps
remain
remiss
ten
year
diagnosi
conclus
pediatr
tcrlbcl
occur
adolesc
may
present
lymph
node
extranod
site
local
advanc
diseas
treatment
current
pediatr
lymphoma
regimen
patient
achiev
cr
durabl
remiss
latent
infect
immunolog
statu
host
pediatr
hodgkin
lymphoma
singl
center
studi
klekawka
w
balwierz
depart
pediatr
oncolog
hematolog
institut
pediatr
jagiellonian
univers
med
colleg
krakow
poland
object
associ
latent
viru
ebv
infect
associ
hodgkin
lymphoma
hl
well
document
howev
scanti
data
host
immunolog
statu
aspect
ebv
latent
infect
hodgkin
cell
avail
pediatr
patient
method
assess
impact
latent
ebv
infect
immunolog
statu
patient
analysi
hl
case
age
median
year
perform
hiv
infect
inherit
immun
defici
syndrom
exclud
ebv
statu
neoplast
cell
determin
situ
hybrid
immonohistochem
protein
detect
respect
case
posit
well
serum
iga
igm
igg
concentr
data
collect
case
lymphocyt
subpopul
studi
avail
case
lymphocyt
transform
test
perform
case
immunolog
test
result
compar
express
statu
eber
statu
well
result
differ
group
patient
found
iga
igg
serum
concentr
igm
serum
concentr
significantli
lower
p
posit
neg
group
median
gl
respect
differ
group
also
found
serum
immunoglobulin
concentr
refer
valu
also
trend
toward
slightli
lower
igm
concentr
case
p
observ
differ
lymphocyt
subpopul
respect
eber
statu
found
trend
toward
higher
mitogen
respons
index
pwm
observ
p
group
differ
lymphocyt
transform
test
found
respect
eber
statu
conclus
relat
ebv
statu
found
except
igm
concentr
larger
group
analyz
identifi
differ
host
immunolog
statu
ebv
latenc
hl
condit
moment
diagnosi
lymphoma
children
l
kozlowska
n
niedzwiecki
szalewska
e
g
wrobel
pediatr
hematolog
oncolog
medic
univers
gdansk
gdansk
poland
pediatr
oncolog
hematolog
bone
marrow
transplant
wroclaw
medic
univers
wroclaw
poland
object
lymphoma
nhl
third
common
malign
children
although
prognosi
good
year
surviv
rate
delay
diagnosi
may
lead
condit
without
give
patient
chanc
react
treatment
aim
studi
show
patient
newli
diagnos
nhl
present
condit
method
among
patient
diagnos
lymphoma
depart
pediatr
hematolog
oncolog
medic
univers
gdansk
year
patient
present
condit
moment
diagnosi
result
among
patient
children
anaplast
nhl
observ
condit
children
anaplast
nhl
children
nhl
present
vena
cava
inferior
syndrom
patient
cholestasi
pancreat
ileu
pleural
effus
patient
malign
show
vena
cava
superior
syndrom
patient
cardiac
tamponad
almost
patient
nhl
present
acut
tumor
lysi
syndrom
atl
patient
symptom
success
treat
chemotherapi
histopatholog
diagnosi
made
due
emerg
conclus
nhl
aggress
malign
high
mitot
index
may
lead
condit
short
time
chemotherapi
even
without
histopatholog
diagnosi
may
need
order
increas
chanc
surviv
clinic
characterist
prognosi
lymphoprolif
disord
singl
institut
experi
japan
miyamura
hashii
n
fukushima
minami
kogaki
ueno
h
kondo
h
yoshida
e
miyashita
n
nakagawa
k
ozono
depart
pediatr
osaka
univers
graduat
school
medicin
osaka
japan
depart
cardiovascular
surgeri
osaka
univers
graduat
school
medicin
osaka
japan
depart
gener
thorac
surgeri
osaka
univers
graduat
school
medicin
osaka
japan
depart
pediatr
surgeri
osaka
univers
graduat
school
medicin
osaka
japan
object
lymphoproliferart
disord
ptld
caus
barr
viru
ebv
recent
recogn
seriou
complic
variou
organ
transplant
investig
clinic
featur
ptld
retrospect
singl
institut
japan
method
evalu
period
juli
februari
seven
patient
ptld
male
femal
diagnos
ptld
blood
examin
lymph
node
histolog
ebv
viral
load
result
ptld
associ
variou
organ
transplant
heart
lung
liver
institut
patient
post
heart
transplant
six
post
lung
transplant
fifti
patient
post
liver
transplant
median
age
onset
year
old
rang
six
patient
aliv
remiss
one
patient
die
toxic
median
time
onset
ptld
transplant
month
rang
six
patient
recipi
donor
abdomin
lymph
node
involv
detect
case
sever
abdomin
symptom
includ
intestin
perfor
bone
marrow
cn
invas
detect
reduct
immunosuppress
agent
chemotherapi
combin
rituximab
perform
patient
result
remiss
patient
disappear
lesion
discontinu
immunosuppress
agent
conclus
although
reduct
immunosuppress
agent
may
effect
treatment
ptld
difficult
reduc
dose
risk
reject
mani
case
patient
one
statu
could
one
factor
develop
ptld
gastrointestin
lesion
detect
case
import
select
treatment
care
establish
appropri
treatment
strategi
accord
prognost
factor
distinct
charact
ptld
accumul
case
pediatr
hodgkin
lymphoma
experi
children
cancer
center
lebanon
ten
year
r
farhat
eid
b
youssef
r
saab
h
abboud
muwakkit
depart
pediatr
adolesc
medicin
american
univers
beirut
beirut
lebanon
depart
radiat
oncolog
american
univers
beirut
beirut
lebanon
object
describ
experi
hybrid
chemotherapeut
regimen
consist
copp
abv
children
hodgkin
lymphoma
hl
method
patient
treat
patient
classifi
group
diseas
stage
iia
group
stage
iv
group
patient
belong
either
result
median
age
year
rang
f
patient
non
classic
hl
patient
bulki
diseas
bd
b
symptom
activ
diseas
cycl
patient
stage
iv
diseas
present
patient
group
diseas
treat
cycl
coppabv
receiv
radiotherapi
rt
none
relaps
group
diseas
receiv
cycl
abvcopp
b
symptom
bd
icr
cycl
chemotherapi
receiv
rt
patient
stage
iv
treat
cours
intens
chemotherapi
b
symptom
bd
icr
cycl
receiv
rt
recur
patient
receiv
rt
relaps
patient
recur
stage
iv
diseas
among
b
symptom
icr
cycl
bone
marrow
involv
bd
patient
stage
ii
bd
b
symptom
achiev
cr
cycl
receiv
rt
howev
recur
outsid
rt
field
os
ef
pubert
male
develop
azoospermia
therapi
conclus
major
lebanes
children
hl
diseas
despit
excel
os
ef
protocol
associ
azoospermia
patient
stage
iv
diseas
b
symptom
bulki
diseas
achiev
cr
cycl
recur
regardless
rt
burkitt
lymphoma
challeng
resourc
limit
rural
commun
j
ngwang
e
ngwa
paediatr
unit
calmef
health
centr
tiko
cameroon
object
burkitt
lymphoma
bl
preval
children
cancer
cameroon
lethal
treat
curabl
lone
cyclophosphamid
cpd
therapi
combin
methrotrex
huge
palli
care
respons
challeng
support
need
especi
paediatr
oncolog
health
profession
exist
compel
june
june
commun
studi
ascertain
paediatr
palli
care
support
need
challeng
also
altern
approach
meet
need
method
survey
use
questionnair
base
aspect
palli
care
relat
cultur
view
tradit
belief
commun
special
attent
paediatr
oncolog
need
care
support
provid
ascertain
palli
care
need
possibl
practic
intervent
result
much
differ
exist
western
palli
care
support
approach
commun
ther
uniqu
super
attach
cultur
view
belief
compat
typic
modern
approach
death
rate
much
result
late
diagnosi
lack
health
unit
inaccess
treatment
product
conclus
poverti
primit
cultur
note
main
hurdl
access
bl
care
treatment
also
palli
care
support
henc
studi
outcom
guid
new
guidelin
draft
implement
difficult
copi
past
modern
approach
palli
care
support
though
startl
studi
result
portray
review
paediatr
palli
care
support
guidelin
consider
probabl
improvis
guidelin
resourc
limit
commun
may
benefici
success
enhanc
qualiti
life
famili
cancer
requir
palli
care
support
evalu
convent
imag
techniqu
pediatr
hodgkin
lymphoma
patient
singl
center
oguz
f
tekkesin
fg
pinarli
c
karadeniz
lo
kapucu
boyunaga
okur
pediatr
oncolog
gazi
univers
ankara
turkey
nuclear
medicin
gazi
univers
ankara
turkey
radiolog
gazi
univers
ankara
turkey
object
aim
evalu
role
diagnosi
stage
respons
therapi
children
adolesc
hodgkin
lymphoma
compar
convent
imag
techniqu
method
retrospect
evalu
convent
imag
find
patient
hodgkin
lymphoma
diagnos
januari
gazi
univers
depart
pediatr
oncolog
result
mean
age
patient
hodgkin
lymphoma
time
diagnosi
rang
fm
ratio
primari
involv
area
head
neck
region
patient
mediastinum
head
neck
mediastinum
axillari
region
bone
patient
patient
receiv
altern
coppabvd
frontlin
chemotherapi
plu
involv
field
radiotherapi
median
time
month
rang
patient
perform
patient
time
diagnosi
interim
patient
end
therapi
patient
convent
imag
techniqu
diagnosi
compar
statist
signific
differ
determin
stage
p
sensit
specif
evalu
advanc
stage
hodgkin
lymphoma
respect
wherea
posit
predict
valu
ppv
neg
predict
valu
npv
respect
sensit
specif
convent
imag
techniqu
ppv
npv
patient
partial
regress
interim
petct
one
relaps
month
patient
accept
refractori
patient
normal
interim
one
relaps
month
conclus
could
find
statist
signific
differ
convent
imag
techniqu
patient
group
larger
number
patient
need
evalu
express
childhood
matur
lymphoma
oguz
uslan
n
akyurek
f
pinarli
c
karadeniz
okur
pediatr
oncolog
gazi
univers
school
medicin
ankara
turkey
pediatri
gazi
univers
school
medicin
ankara
turkey
patholog
gazi
univers
school
medicin
ankara
turkey
object
differenti
germin
center
like
gcb
lymphoma
nhl
type
immun
phenotyp
analysi
evalu
amount
express
effect
prognosi
main
object
studi
method
paraffin
tissu
block
patient
age
year
matur
nhl
examin
express
evalu
immunohistochemistri
stain
method
transloc
evalu
fish
result
express
burkitt
lymphoma
bl
n
respect
gcb
phenotyp
present
case
bl
case
diffus
larg
lymphoma
dlbcl
n
express
marker
respect
three
case
dlbcl
gcb
phenotyp
case
phenotyp
although
statist
signific
p
immun
phenotyp
group
prognosi
dlbcl
found
overal
os
event
free
surviv
ef
higher
gcb
patient
gcb
phenotyp
phenotyp
express
bl
dlbcl
respect
transloc
posit
bl
case
transloc
found
dlbcl
accord
result
statist
signific
correl
pearson
r
p
transloc
express
matur
nhl
conclus
studi
correl
found
transloc
express
matur
nhl
need
futur
studi
larger
number
patient
immun
phenotyp
classif
order
show
impact
prognosi
posttranspl
lymphoprolif
disord
experi
three
patient
n
olgun
k
mutafoglu
inc
e
buke
kizmazoglu
kilic
c
arikan
e
ozer
l
doganay
h
guleryuz
dept
pediatr
oncolog
dokuz
eylul
univers
insitut
oncolog
izmir
turkey
liver
transplant
team
kent
hospit
izmir
turkey
patholog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
radiolog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
object
present
treatment
experi
posttranspl
lymhoprolif
disord
ptld
method
medic
record
patient
diagnosi
ptld
review
oncolog
treatment
detail
treatment
respons
summar
result
three
patient
ptld
liver
transplant
lt
caus
lt
biliari
atresia
two
chronic
liver
diseas
one
male
appli
fever
abdomin
pain
distens
month
lt
multipl
abdomin
enlarg
lymph
node
hepat
nodul
bilater
renal
infiltr
detect
ct
bone
marrow
examin
reveal
lymphoblast
eber
posit
lymphoma
ptld
diagnos
gancyclovir
cours
chemotherapi
prednisolon
vcr
cyc
doxo
mtx
given
follow
without
diseas
year
male
appli
fever
abdomin
mass
month
lt
multipl
enlarg
abdomin
lymph
node
thicken
intestin
wall
detect
ct
gastrointestin
gi
endoscop
biopsi
reveal
b
cell
ptld
cd
admiss
ebv
dna
cmv
dna
posit
acyclovir
gancyclovir
cours
chemotherapi
prednisolon
cycrituximab
given
follow
without
diseas
one
month
month
old
femal
appli
diarrhea
month
transplantaion
endoscop
gi
biopsi
reveal
ptld
cd
hpylori
like
microorgan
stomach
sirolimu
cours
chemotherapi
prednisolon
cycrituximab
given
follow
without
diseas
month
conclus
ptld
may
relat
ebv
cmv
h
pylori
endoscop
biopsi
may
helpful
diagnosi
complet
remiss
achiev
antivir
treatment
reduc
intens
chemotherapi
rituximab
effect
agent
cd
ptld
patient
undergo
solid
organ
transplant
symptom
care
evalu
term
ptld
complex
vizual
diagnosi
renal
involv
pediatr
lymphoma
panferova
valiev
kaminskaya
e
mikchailova
n
koshechkina
radiolog
dpt
institut
pediatr
oncolog
haematolog
nnblokhin
cancer
research
cent
moscow
russia
hematolog
dpt
institut
pediatr
oncolog
haematolog
nnblokhin
cancer
research
cent
moscow
russia
object
renal
involv
children
lymphoma
nhl
specifi
analyz
assess
role
ultrasound
us
comput
tomographi
ct
magnet
reson
tomographi
mri
data
children
nhl
renal
involv
method
analyz
result
complex
examin
us
ct
mri
pediatr
patient
age
year
old
nhl
renal
involv
statist
perform
program
result
found
follow
type
renal
lesion
base
ultrasound
comput
magnet
reson
tomographi
data
infiltr
small
focal
medium
focal
nodular
common
type
infiltr
focal
p
medium
focal
type
associ
burkitt
lymphoma
bl
p
patient
lymphoma
found
small
focal
type
lesion
p
nodular
type
found
patient
lymphoma
primaryh
mediastin
lymphoma
bl
p
conclus
found
correl
renal
lesion
type
base
complex
visual
diagnosi
morpholog
immunolog
nhl
variant
modifi
beacopp
regimen
hodgkin
lymphoma
indian
children
toxic
outcom
jayabos
k
rathnam
v
kasi
sr
vignesh
arthi
jx
scott
pediatr
hematolog
hemato
oncolog
meenakshi
mission
hospit
research
centr
madurai
india
pediatr
hematolog
hemato
oncolog
kanchikamakoti
child
trust
hospit
chennai
india
chennai
india
object
studi
use
adriamycin
bleomycin
vincristin
etoposid
prednison
cyclophosphamid
modifi
beacopp
regimen
treatment
intermedi
risk
hodgkin
lymphoma
hl
patient
regard
toxic
outcom
method
high
risk
patient
receiv
cycl
modifi
beacop
bleomycin
etoposid
doxorubicin
cyclophoshamid
vincristin
procarbazin
prednison
day
plu
cycl
abvd
intermedi
risk
patient
receiv
cycl
doxorubicin
bleomycin
vincristin
etoposi
prednison
cyclophosphamied
plu
cycl
abvd
result
period
patient
receiv
cycl
receiv
cycl
cours
respect
thrombocytopenia
occur
vs
signific
anemia
hb
gmdl
vs
neutropenia
anc
febril
neutropenia
vs
mean
durat
hospit
vs
day
respect
one
episod
local
infect
hepat
abscess
cours
none
episod
bacteremia
sepsi
either
regimen
two
patient
requir
addit
chemotherapi
involv
field
radiat
therapi
achiev
complet
remiss
cr
patient
cr
well
median
month
rang
relaps
thu
relaps
free
event
free
surviv
conclus
like
caus
cytopenia
regimen
well
toler
accept
toxic
profil
indian
children
thu
use
institut
adequ
facil
optimum
support
care
two
regimen
offer
remiss
relaps
free
surviv
intermedi
hodgkin
lymphoma
patient
clinic
profil
chemotherapi
respons
children
hodgkin
lymphoma
tertiari
care
centr
r
seth
p
singh
k
puri
r
da
pediatr
india
institut
medic
scienc
new
delhi
india
object
optim
treatment
strategi
children
hodgkin
lymphoma
hl
still
remain
controversi
especi
advanc
diseas
review
clinic
profil
pediatr
hl
tertiari
care
centr
evalu
efficaci
chemotherapi
ct
alon
treatment
modal
childhood
hl
method
retrospect
evalu
case
record
children
treat
hl
five
year
teriari
center
india
done
result
children
male
femal
median
age
year
rang
studi
year
old
late
stage
diseas
stage
iii
iv
present
bulki
mediastin
diseas
spleen
involv
case
none
bone
marrow
involv
histolog
type
nodular
sclerosi
mix
cellular
lymphocyt
predomin
unclassifi
patient
patient
receiv
abvdcopp
abvd
regimen
two
patient
need
beacopp
due
progress
diseas
patient
need
involv
field
radiotherapi
rt
mean
sd
extend
month
patient
relaps
one
lost
treat
chemotherapi
child
die
due
diseas
two
patient
asymptomat
mild
restrict
pulmonari
function
test
pattern
patient
develop
hypothyroid
radiotherapi
associ
advers
prognost
factor
surviv
conclus
system
ct
alon
effect
therapi
childhood
hodgkin
lymphoma
avoid
potenti
organ
dysfunct
secondari
malign
associ
radiotherapi
may
use
salvag
therapi
clinicopatholog
studi
pediatr
hodgkin
lymphoma
treatment
outcom
year
experi
resourc
limit
set
bpkmch
bharatpur
chitwan
nepal
ks
sharma
mehta
misra
head
pediatr
oncolog
divis
b
p
koirala
memori
cancer
hospit
bharatpur
nepal
medic
offic
pediatr
oncolog
divis
b
p
koirala
memori
cancer
hospit
bharatpur
nepal
medic
offic
pediatr
oncolog
divis
b
p
koirala
memori
cancer
hospit
bharatpur
nepal
object
know
clinicopatholog
profil
childhood
hodgkin
lymphoma
chemotherapi
effect
outcom
follow
resourc
limit
set
method
analyz
patient
record
come
divis
pediatr
oncolog
suspici
lymphoma
record
major
clinic
detail
histopatholog
report
pretreat
assess
done
stage
hematolog
biochem
radiolog
bone
marrow
examin
diagnos
patient
treat
standard
chemotherapi
protocol
doxorubicin
bleomycin
vinblastin
dacarbazin
radiotherapi
recommend
residu
diseas
patient
advic
follow
result
total
patient
diagnos
hodgkin
lymphoma
period
number
children
start
recommend
chemotherapi
children
year
children
year
age
children
year
number
patient
male
children
primari
diseas
cervic
area
site
inguin
abdomin
waldey
ring
axillari
percent
patient
present
within
month
ill
present
month
present
beyond
month
histolog
type
mix
cellular
lymphocyt
predomin
nodular
sclerosi
children
present
stage
iii
stage
ii
stage
stage
iv
percent
patient
complet
cure
primari
diseas
percent
patient
drop
due
financi
constrain
children
regular
follow
organ
involv
includ
spleen
liver
lung
without
bone
marrow
involv
conclus
hodgkin
lymphoma
common
male
year
cervic
lymphadenopathi
commonest
present
present
month
ill
mix
cellular
commonest
type
present
stage
iii
hodgkin
lymphoma
cure
patient
present
follow
without
signific
side
effect
lymphoma
childhood
clinicopatholog
featur
therapi
outcom
two
egyptian
center
l
sherief
u
e
abdelkhalek
youssef
n
kamal
pediatr
hematolog
oncolog
zagazig
univers
zagazig
egypt
pediatr
zagazig
univers
zagazig
egypt
pediatr
cairo
univers
cairo
egypt
object
describ
epidemiolog
clinicopatholog
characterist
treatment
outcom
lymphoma
nhl
treat
two
egyptian
center
method
studi
data
collect
retrospect
review
medic
record
children
nhl
admit
oncolog
unit
period
februari
februari
result
abdomin
involv
common
present
burkitt
lymphoma
common
nhl
subtyp
major
patient
diagnos
advanc
diseas
murphi
stage
iii
iv
diseas
year
os
ef
patient
respect
none
clinic
epidemiolog
patholog
characterist
signific
associ
probabl
surviv
conclus
nhl
occur
younger
age
higher
incid
burkitt
lymphoma
advanc
diseas
outcom
nhl
two
center
satisfactori
approach
intern
percentag
outcom
treatment
anaplast
larg
cell
lymphoma
alcl
protocol
patient
tawfiqu
islam
k
islam
pediatr
hematolog
oncolog
squar
hospit
ltd
dhaka
bangladesh
patholog
squar
hospit
ltd
dhaka
bangladesh
pediatr
surgeri
squar
hospit
ltd
dhaka
bangladesh
object
present
outcom
treatment
alcl
protocol
chemotherapi
method
seri
case
case
includ
purpos
seri
diagnos
clinic
nhl
histopatholog
biopsi
tumor
mass
suggest
anaplast
larg
cell
varieti
nhl
immunohistochemistri
confirm
diagnosi
alcl
posit
stain
cd
along
neg
stain
cd
result
short
seri
four
case
diagnos
alcl
found
immunohistochemistri
two
present
system
manifest
two
system
cutan
manifest
case
treat
protocol
alcl
complet
schedul
chemotherapi
regim
alreadi
past
year
event
free
surviv
conclus
protocol
specif
case
alcl
found
effect
treatment
alcl
abvd
without
consolid
radiotherapi
rt
complet
remiss
cr
pediatr
hodgkin
lymphoma
hl
preliminay
result
pilot
studi
terenziani
e
schiavello
f
crippa
g
cefalo
l
gandola
e
pecori
casanova
ferrari
r
luksch
c
meazza
polastri
f
spreafico
catania
v
biassoni
podda
chiarav
n
puma
massimino
pediatr
oncolog
unit
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
depart
nuclear
medicin
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
depart
pediatr
ospedal
san
paolo
milan
itali
radiotherapi
fondazion
ircc
istituto
nazional
dei
tumori
milan
itali
object
children
hl
good
surviv
treatment
bring
appreci
morbid
minim
sequela
design
studi
abvd
stage
includ
b
symptom
without
rt
cr
patient
reduc
rt
volum
dose
pr
patient
method
onward
consecut
children
hl
yr
stage
b
symptom
treat
chemotherapi
consist
cours
abvd
follow
rt
patient
pr
gy
pr
site
cr
defin
basi
clinic
imag
assess
earli
respons
regularli
perform
abvd
result
pt
achiev
cr
ct
stage
stage
ii
stage
iii
children
irradi
one
introduct
number
irradi
patient
differ
stage
iii
p
ns
presenc
b
symptom
patient
ccr
median
follow
year
seven
patient
relaps
median
time
month
ct
previous
uninvolv
involv
node
ctrt
within
rt
field
outsid
three
primari
refractori
intensifi
six
patient
cr
three
pt
die
aliv
diseas
observ
two
second
malign
one
osteosarcoma
outsid
one
lung
adjac
radiat
field
month
diagnosi
median
year
pf
ef
os
respect
conclus
signific
number
pt
could
cure
without
rt
stage
poor
respond
may
deserv
intensifi
treatment
systemat
use
pet
improv
respons
evalu
reduc
number
irradi
patient
treat
hodgkin
diseas
resourc
poor
set
problem
outcom
n
verma
kumar
n
moulik
pediatr
king
georg
medic
univers
lucknow
india
object
assess
problem
encount
manag
children
hodgkin
diseas
hd
resourc
poor
indian
set
describ
clinic
profil
outcom
children
method
case
record
previous
untreat
children
age
diagnos
hd
center
review
children
consent
take
treatment
center
refus
treatment
abandon
treatment
clinic
characterist
treatment
offer
outcom
children
analyz
result
male
femal
median
age
percent
children
came
rural
area
children
malnourish
anemia
hypoalbuminemia
median
durat
symptom
prior
treatment
month
rang
month
children
advanc
diseas
stage
present
mix
cellular
common
histolog
subtyp
children
experienc
complic
treatment
derang
liver
function
fever
anemia
children
acquir
hepat
b
hepat
c
treatment
children
die
treatment
death
due
chemotherapi
relat
toxic
due
advanc
diseas
unrel
death
due
cn
tuberculosi
children
complet
treatment
relaps
children
experienc
delay
chemotherapi
due
variou
reason
derang
liver
children
surviv
free
diseas
median
follow
rang
conclus
children
hd
come
center
tend
delay
present
advanc
diseas
abandon
rate
high
children
get
infect
hepat
b
c
cours
treatment
complic
common
treatment
lead
therapi
delay
factor
respons
poor
outcom
compar
develop
countri
rituximab
childhood
matur
lymphoma
report
singl
center
china
h
wang
x
zhai
f
lu
l
hu
j
li
h
miao
x
qian
x
zhu
yu
hematolog
children
hospit
fudan
univers
shanghai
china
object
evalu
efficaci
safeti
rituximab
childhood
matur
lymphoma
method
treat
children
progress
lymphoma
combin
rituximab
data
patient
analyz
result
fourteen
stage
iii
stage
iv
sixteen
patient
diagnos
burkitt
lymphoma
dlbl
rest
b
cell
lymphoma
seventeen
patient
initi
treat
rituximab
rest
treat
replac
among
patient
rituximab
initi
therapi
ldh
ldh
ul
three
patient
experienc
relaps
die
mean
follow
durat
month
ef
five
patient
relaps
lymphoma
die
death
studi
cohort
relat
rituximab
treatment
conclus
seriou
advers
effect
observ
initi
therapi
rituximab
might
improv
prognosi
lymphoma
children
heavi
tumor
load
simultan
present
acut
myeloid
leukemia
burkitt
lymphoma
case
report
review
literatur
f
arreguin
v
flore
l
merino
j
trejo
pediatr
oncolog
centro
medico
nacion
de
noviembr
issst
mexico
citi
mexico
pediatr
hematolog
centro
medico
nacion
de
noviembr
issst
mexico
citi
mexico
object
perform
case
report
review
literatura
simultan
present
two
hematolog
malign
burkitt
lymphoma
acut
myeloid
leukemia
child
pediatr
servic
centro
medico
nacion
de
noviembr
issst
mexico
citi
method
patholog
flow
citometr
cytogenet
assay
perform
certifi
clinic
laboratorio
use
standard
techniqu
inmunohistochemistri
perform
antibodi
sigm
tdt
result
paper
report
year
old
child
burkitt
lymphoma
stage
iii
cytogenet
abnorm
found
veb
infect
discard
receiv
copadm
scheme
four
month
treatment
present
leukocytosi
cephalea
bilater
proptosi
bone
marrow
aspir
show
myloblast
cn
infiltr
involv
optic
neve
mening
receiv
treatment
accord
acut
myeloid
leukemia
high
risk
protocol
achiev
complet
remiss
find
dono
bone
marrow
transplant
month
relaps
burkitt
lymphoma
final
die
conclus
case
show
patient
acut
myeloid
leukemia
burkitt
lymphoma
patient
short
respons
treatment
earli
relaps
poor
prognosi
pediatr
myelodysplast
syndrom
experi
singl
center
cetin
unal
bayhan
aytac
b
kuskonmaz
b
tavil
tuncer
f
gumruk
divis
pediatr
hematolog
hacettep
univers
medic
school
ankara
turkey
object
pediatr
myelodysplast
syndrom
md
group
heterogen
clonal
disord
lesser
frequenc
compar
adult
addit
much
rare
data
pediatr
age
group
relat
present
find
treatment
method
clinic
laboratori
data
addit
therapeut
intervent
outcom
patient
singl
diagnos
summar
result
median
age
studi
group
year
common
complaint
present
includ
fever
fatigu
bleed
abdomin
distent
addit
rare
present
complaint
includ
pallor
rash
vomit
irrit
jaundic
stridor
abdomin
pain
easi
bruis
underli
disord
establish
neurofibromatosi
syndrom
secondari
prior
chemotherapi
pnet
fanconi
anemia
jacobsen
syndrom
klinefelt
final
diagnosi
md
jmml
hypoplast
md
chemotherapi
relat
md
median
hb
wbc
thrombocyt
count
present
gdl
respect
mutat
studi
relat
md
patient
posit
common
common
cytogenet
abnorm
chromosom
relat
abnorm
patient
aliv
aliv
patient
aliv
subsequ
hematpoiet
stem
cell
transplant
hsct
conclus
patient
pediatr
md
may
present
variou
complaint
may
underli
genet
diseas
caus
propens
md
surviv
better
among
patient
underw
hsct
success
manag
case
granulocyt
sarcoma
concurr
hemophagocyt
lympho
histiocytosi
yr
chopra
ramzan
katewa
yadav
pediatr
hematolog
oncolog
bone
marrow
transplant
unit
forti
memori
research
institut
gurgaon
india
object
granulocyt
sarcoma
gs
rare
extra
medullari
tumor
usual
associ
acut
myelogen
leukaemia
aml
hemophagocyt
lympho
histiocytosi
hlh
rare
report
child
present
gs
describ
success
manag
gs
concurr
hlh
method
medic
record
institut
review
result
year
old
admit
us
complaint
pain
right
frontal
region
swell
right
eye
receiv
oral
antibiot
week
ophthalmologist
thought
cellul
view
improv
evalu
found
mass
visibl
right
nasal
caviti
mri
brain
paranas
sinus
done
reveal
mass
posterior
aspect
nasal
caviti
extend
nasal
choana
biopsi
mass
suggest
gs
subsequ
bma
flow
cytometri
consist
diagnosi
blast
transloc
posit
treat
per
modifi
uk
amlxii
protocol
seizur
first
lumbar
punctur
caus
found
first
induct
develop
persist
fever
diagnos
hlh
caus
hlh
could
identifi
meticul
treat
chemotherapi
aml
dexamethaon
hlh
conclus
high
suspicion
necessari
diagnos
gs
children
earli
diagnosi
immedi
initi
treatment
mandatori
overcom
condit
clinic
data
describ
clinic
cours
manag
children
mah
warrant
cytogenet
pediatr
acut
myeloid
leukemia
singl
centr
experi
chowdhri
rn
makroo
sharma
priyanka
mishra
thakur
singh
mahajan
molecular
biolog
transplant
immunolog
indraprastha
apollo
hospit
delhi
delhi
india
object
acut
myeloid
leukemia
aml
clinic
genet
heterogen
diseas
account
childhood
leukemia
current
classif
hematolog
malign
defin
distinct
entiti
myeloid
disord
base
presenc
recurr
cytogenet
abnorm
cytogenet
abnorm
divid
follow
three
prognost
group
use
risk
stratif
treatment
favor
risk
inv
advers
risk
monosomi
long
arm
chromosom
del
monosomi
abnorm
complex
karyotyp
intermedi
risk
chang
aml
rare
children
true
prognost
signific
individu
chromosom
abnorm
age
group
remain
unclear
present
studi
undertaken
determin
cytogenet
abnorm
pediatr
aml
prognost
signific
method
bone
marrow
sampl
collect
pediatr
aml
patient
cultur
hour
without
stimul
agent
sampl
treat
colcemid
follow
hypoton
treatment
fixat
karyotyp
analyz
use
gtg
band
techniqu
describ
accord
intern
system
human
cytogenet
nomenclatur
result
aml
patient
male
femal
median
age
patient
year
cytogenet
abnormalati
detect
patient
normal
karyotyp
favor
prognost
categori
case
case
case
accompani
structur
abnorm
either
loss
sex
chromosom
structur
abnorm
unfavour
prognost
categori
trisomi
found
case
hyperdiploidi
complex
karyotyp
conclus
larger
studi
kind
may
provid
inform
prognost
signific
cytogenet
abnorm
pediatr
aml
maintain
therapi
acut
myeloid
leukemia
experi
develop
countri
k
jain
udgir
mudaliar
swami
n
shah
desai
b
agarw
oncolog
bj
wadia
hospit
children
mumbai
india
object
object
studi
determin
addit
maintain
therapi
mt
would
improv
surviv
children
acut
myeloid
leukemia
aml
compar
treat
without
mt
method
retrospect
analysi
case
year
diagnos
patient
demograph
therapi
regimen
induct
follow
denver
protocol
onward
current
patient
treat
follow
high
dose
cytarabin
addit
mt
result
total
patient
patient
diagnos
complet
treatment
secondari
infect
follow
patient
receiv
mt
patient
surviv
relaps
remiss
period
survivor
wbc
unfavour
cytogenet
delet
patient
achiev
complet
remiss
cr
induct
wbc
unfavour
complex
achiev
cr
induct
dysplast
chang
bone
marrow
probabl
need
bone
marrow
transplant
children
treat
without
mt
relaps
surviv
last
follow
median
remiss
period
relaps
patient
cytogenet
achiev
cr
induct
survivor
followup
wbc
achiev
cr
cytogenet
analysi
done
conclus
impress
progress
treatment
aml
major
patient
still
die
diseas
compar
diseas
free
remiss
period
aml
improv
centr
use
mt
howev
initi
chemotherapi
induct
consolid
support
care
financi
help
also
better
may
ad
factor
improv
use
modifi
protocol
acut
myeloblast
leukemia
indian
children
jayabos
kasi
viswanathan
sr
vignesh
r
priya
k
rathnam
pediatr
meenakshi
mission
hospit
research
centr
madurai
india
object
analyz
result
treatment
aml
modifi
protocol
assess
toxic
regimen
method
studi
retrospect
analysi
consecut
aml
patient
treat
period
year
male
femal
ratio
median
live
patient
month
patient
denovo
aml
patient
md
phase
two
patient
acut
promyelocyt
leukemia
six
one
invers
eight
patient
two
evid
aml
bone
marrow
modif
mrc
protocol
includ
reduc
number
instead
cytarabin
dose
etoposid
dose
instead
induct
dose
mitoxantron
instead
intensif
patient
receiv
cycl
oral
mainten
therapi
etoposid
daili
x
everi
day
patient
receiv
treatment
without
risk
stratif
result
six
patient
die
infecti
complic
induct
five
patient
fail
induct
patient
achiev
complet
remiss
four
patient
fail
induct
therapi
seven
patient
die
sepsi
infect
six
patient
relaps
month
two
relaps
patient
aliv
month
relaps
three
patient
develop
signific
cardiac
dysfunct
three
die
infecti
complic
remiss
estim
overal
surviv
surviv
conclus
modifi
regimen
poorli
toler
indian
children
unaccept
high
mortal
induct
remiss
requir
reduct
treatment
intens
induct
consolid
especi
patient
cytogenet
profil
acut
myeloblast
leukemia
children
adolesc
case
n
khoubila
lamchahab
n
hda
cherkaoui
madani
benchekroun
quessar
depart
oncolog
hospit
august
casablanca
morocco
object
determin
cytogenet
profil
children
adolesc
aml
evalu
prognost
impact
cytogenet
abnorm
method
conduct
retrospect
studi
march
march
includ
patient
de
novo
aml
age
year
diagnosi
confirm
cytolog
fab
classif
immunophenotyp
children
treat
moroccan
protocol
karyotyp
perform
diagnosi
sampl
bone
marrow
cytogenet
studi
made
rhg
band
hour
cultur
cytogenet
abnorm
found
classifi
prognost
group
favor
intermedi
unfavor
result
case
aml
diagnos
karyotyp
perform
patient
includ
cultur
failur
male
femal
sex
ratio
mf
median
age
year
year
cytolog
type
common
type
karyotyp
perform
patient
acquir
clonal
abnorm
note
case
cultur
failur
patient
treat
nation
protocol
continu
complet
remiss
mcr
group
favor
intermedi
unfavor
respect
declin
month
distribut
prognost
group
follow
favor
group
patient
case
case
invers
chromosom
one
case
intermedi
group
patient
normal
karyotyp
case
delet
band
unfavor
group
patient
abnorm
karyotyp
monosomi
one
patient
conclus
result
enabl
us
identifi
cytogenet
profil
patient
guid
therapeut
strategi
includ
better
manag
pediatr
case
gene
acut
myeloid
leukemia
w
lin
xuan
zhou
wu
w
li
hematologyoncolog
center
beij
children
hospit
beij
china
object
recent
report
reveal
epigenet
chang
dna
methyl
import
caus
leukemia
although
mutat
rare
pediatr
aml
patient
remain
import
diagnost
prognost
factor
patient
commonli
screen
report
pediatr
case
aml
posit
gene
mutat
onset
diagnosi
method
male
first
present
scalp
lump
upon
examin
suggest
myeloid
sarcoma
lump
disappear
treatment
evid
suggest
presenc
leukemia
except
gene
five
month
later
male
present
testicular
swell
result
diagnosi
aml
result
eventu
patient
diagnos
acut
monocyt
leukemia
testicular
leukemia
central
nervou
system
leukemia
chemotherapi
success
elimin
bone
marrow
cell
although
child
also
receiv
hematopoiet
stem
cell
transplant
relaps
testicular
leukemia
receiv
radiotherapi
conclus
gene
mutat
import
prognosi
earli
diagnosi
pediatr
aml
preliminari
report
diagnost
studi
pet
detect
extramedullari
diseas
emd
pediatr
acut
myeloid
leukemia
aml
matsui
j
yamanaka
h
uryu
n
sato
k
kubota
matsushita
pediatr
nation
center
global
health
medicin
shinjyuku
japan
radiologist
nation
center
global
health
medicin
shinjyuku
japan
object
primari
purpos
studi
assess
diagnost
use
pet
detect
emd
pediatr
aml
diagnosi
secondari
purpos
includ
assess
use
evalu
remiss
statu
induct
therapi
analyz
relationship
find
pet
clinic
outcom
studi
consecut
experienc
children
aml
emd
consid
signific
import
find
decid
present
select
case
report
case
method
patient
enrol
studi
undergo
pet
scan
immedi
diagnosi
prior
start
induct
therapi
preval
emd
detect
pet
scan
convent
assess
compar
second
scan
perform
prior
consolid
therapi
evalu
respons
chemotherapi
judg
fdg
uptak
chang
emd
area
bone
marrow
bm
correl
pet
find
clinic
outcom
analys
accumul
data
case
result
first
case
male
diagnos
aml
fab
inv
fusion
gene
second
case
male
diagnos
aml
fab
fusion
gene
first
pet
demonstr
emd
lesion
case
case
standard
diagnost
examin
detect
lesion
case
achiev
complet
remiss
cr
induct
therapi
convent
criteria
second
scan
could
confirm
cr
reduc
uptak
fdp
emd
bm
patient
conclus
present
two
case
childhood
aml
emd
perform
pet
scan
case
demonstr
use
pet
diagnos
emd
assess
treatment
respons
emd
bm
cytogenet
molecular
genet
abnorm
evalu
pediatr
acut
myeloblast
leukemia
mehrvar
tashvighi
aa
hedayati
asl
faranoush
j
saberi
nejad
ramyar
n
mehrvar
l
kuchakzadeh
f
kompani
ms
rahiminejad
oncolog
mahak
pediatr
cancer
treatment
research
center
tehran
iran
pediatr
children
center
hospit
tehran
iran
pediatr
children
center
hospit
tehran
iran
research
mahak
pediatr
cancer
treatment
research
center
tehran
iran
object
genet
abber
underli
acut
myeloblast
leukemia
aml
import
landmark
better
manag
pathogenesi
diseas
two
main
referr
center
childhood
malign
tehran
capit
citi
iran
mahak
pediatr
cancer
treatment
research
center
mpctrc
children
center
hospit
children
less
year
old
kind
childhood
malign
admit
two
center
diagnosi
therapi
patient
part
iran
refer
main
goal
studi
evalu
genet
abnorm
patient
aml
better
manag
diseas
futur
method
enrol
patient
refer
part
iran
two
referr
childhood
malign
center
tehran
iran
mpctrc
children
center
hospit
april
april
uniqu
check
list
patient
impli
basic
data
sex
age
date
dead
bone
marrow
aspir
pediatr
aml
case
analyz
techniqu
karyotyp
real
transloc
final
data
analys
spss
version
result
male
enrol
patient
mean
age
patient
year
immunophenotyp
result
show
n
n
group
major
phenotyp
respect
twenti
patient
genet
abnorm
n
invers
n
mosaic
delet
n
hyperdiploidi
mosaic
transloc
mosaic
monosomi
trisomi
gene
delet
n
patient
die
studi
surviv
rate
conclus
analysi
literatur
review
reveal
preval
abnorm
author
suggest
comprehens
studi
larger
patient
seri
confirm
evalu
focus
cytogenet
abnorm
consid
prognost
signific
patient
aml
affect
treatment
plan
imatinib
mesyl
induc
bone
marrow
aplasia
need
extra
vigil
rare
complic
r
moham
c
yogiraj
rajat
k
satyendra
c
ritu
satya
prakash
pediatr
hematolog
oncolgi
bmt
unit
forti
memori
research
institut
gurgaon
india
depart
patholog
forti
memori
research
institut
gurgaon
india
object
imatinib
mesyl
signal
transduct
inhibitor
molecul
revolution
manag
ofchron
phase
chronic
myelogenousleukemia
cml
drug
gener
well
toler
severebon
marrow
bm
aplasia
rare
report
method
male
child
present
novemb
histori
fever
day
fatigu
examin
hadgood
gener
condit
mild
pallor
without
organomegali
rest
system
examinationwa
within
normal
limit
haemoglobin
hb
gdl
whiteblood
cell
count
wbc
x
x
differenti
count
bone
marrow
studi
confirm
diagnosi
chronic
phase
cml
cytogenet
studi
reveal
metaphas
result
start
mgday
novemb
weekli
monitor
count
toler
drug
welland
requir
dose
modif
visit
foundto
pancytopenia
hbwa
gdl
wbc
x
platelet
count
x
quantit
method
repeat
cbc
januari
show
hb
gdl
wbc
x
andplatelet
count
x
imatinib
discontinu
bone
marrow
aspir
hemodilut
biopsi
show
sever
hypoplast
marrow
cellular
increasein
blast
mild
increas
fibrosi
reticulin
stain
cbc
feb
feb
show
hb
wbc
platelet
count
x
respect
quantit
method
zero
restart
low
dose
imatinib
conclus
imatinib
induc
sever
bone
marrow
aplasia
rare
complic
cml
patient
imatinib
therapi
need
close
monitor
acut
erythroleukemia
cytogenet
featur
e
papakonstantin
tapark
n
gompaki
f
vadikolia
athanasiad
p
anagnostopoul
athanasiadi
vrani
kourti
de
koliouska
paediatr
oncolog
hippokr
gener
hospit
thessaloniki
greec
object
erythroleukemia
rare
disord
character
uncontrol
prolifer
erythroblast
myeloblast
compris
acut
myeloid
leukemia
french
american
british
fab
classif
leukemia
aml
gener
seen
old
age
case
pediatr
erythroleukemia
report
literatur
compris
less
pediatr
leukemia
method
one
rare
de
novo
case
present
pediatr
erythroleukemia
patient
present
depart
clinic
morpholog
immunophenotyp
cytogenet
featur
patient
review
purpos
studi
correl
bone
marrow
morpholog
immunophenotyp
karyotyp
neoplast
cell
result
patient
present
thrombopenia
peripher
blood
examin
show
anemia
hb
thrombocytopenia
x
l
blast
multipl
cervic
lymph
node
present
measur
cm
free
mobil
multipl
purpur
spot
present
bodi
bone
marrow
bm
aspir
show
predominantli
erythroid
popul
scant
moder
amount
pale
blue
cytoplasm
round
oval
nuclei
mani
coalesc
vacuol
erythroblast
show
posit
period
acid
schiff
pa
myeloperoxidas
mpo
neg
flow
cytometri
demonstr
blast
popul
express
myeloid
marker
blast
express
monocyt
marker
hladr
megakaryocyt
marker
immunophenotyp
pretreat
bone
marrow
show
chromosom
analysi
reveal
abnorm
karyotyp
xy
patient
first
complet
remiss
cycl
protocol
search
compat
donor
bone
marrow
transplant
bmt
conclus
prognosi
erythroleukemia
poor
patient
good
respond
aml
induct
regimen
surviv
could
achiev
bmt
first
complet
remiss
relat
allel
haplotyp
patient
acut
myeloblast
leukemia
patiroglu
hh
akar
depart
pediatr
hematolog
oncolog
erciy
univers
faculti
medicin
kayseri
turkey
depart
pediatr
immmunolgi
erciy
univers
faculti
medicin
kayseri
turkey
object
previou
studi
demonstr
signific
differ
hla
allel
frequenc
leukem
patient
normal
subject
purpos
studi
evalu
frequenc
hla
class
b
class
ii
allel
acut
myeloblast
leukemia
compar
unrel
healthi
control
method
investig
relat
hla
allel
acut
myeloblasticleukemia
aml
patient
unrel
normal
subject
method
use
luminex
technolog
result
allel
frequenc
higher
patient
aml
compar
control
p
p
contrari
allel
frequenc
lower
control
p
conclus
result
suggest
allel
may
play
presumpt
predispos
factor
aml
addit
allel
found
neg
associ
aml
intens
consolid
compar
consolid
mainten
therapi
adolesc
young
adult
acut
myeloid
leukemia
semochkin
tn
tolstykh
ss
kulikova
eg
arshanskaya
vv
lunin
ai
lukina
ag
rumiantsev
pediatr
oncolog
hematolog
radiat
therapi
pirogov
russian
nation
research
medic
univers
moscow
russia
adolesc
young
adult
hematolog
feder
scientif
clinic
centr
pediatr
hematolog
oncolog
immunolog
moscow
russia
hematolog
citi
clinic
hospit
na
sp
botkin
moscow
russia
director
centr
feder
scientif
clinic
centr
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
examin
efficaci
intens
consolid
without
mainten
versu
consolid
plu
mainten
therapi
adolesc
young
adult
acut
myeloid
leukemia
aml
method
total
patient
median
age
year
rang
de
novo
aml
enrol
non
randomli
trial
patient
assign
receiv
cycl
induct
daunorubicin
day
cytarabin
everi
hour
day
consolid
cycl
follow
mainten
chemotherapi
also
cycl
year
patient
treat
cycl
induct
plu
ham
cytarabin
per
day
mitoxantron
day
complet
respons
cr
document
first
cycl
cycl
consolid
hidac
per
day
without
follow
mainten
result
cr
document
intens
consolid
consolid
follow
mainten
therapi
patient
median
overal
surviv
os
year
versu
year
hr
ci
p
median
surviv
patient
year
respect
os
vs
p
test
howev
os
rate
vs
p
due
high
frequenc
late
relaps
longer
track
time
group
vs
p
intens
consolid
compar
consolid
accompani
higher
frequenc
advers
event
iiiiv
degre
includ
neutropenia
vs
p
conclus
concept
therapi
adolesc
young
adult
aml
demonstr
equival
clinic
efficaci
acut
myeloid
leukemia
children
experi
tertiari
care
facil
india
r
seth
r
seth
singh
seth
pediatr
india
institut
medic
scienc
delhi
india
cardiolog
india
institut
medic
scienc
delhi
india
object
document
demograph
profil
outcom
children
acut
myeloid
leukemia
aml
treat
tertiari
center
india
method
retrospect
review
case
record
children
diagnos
treat
aml
done
patient
diagnos
two
year
result
averag
age
present
male
common
present
featur
fever
pallor
follow
bleed
hyperleukocytosi
seen
patient
cn
diseas
present
patient
cytogenet
profil
patient
declin
treatment
diagnosi
soon
initi
treatment
patient
patient
undergo
treatmentcomplet
treatment
averag
durat
follow
rang
month
reason
expiri
includ
febril
neutropenia
myocardi
dysfunct
fungal
sepsi
emerg
import
caus
febril
neutropenia
conclus
outcom
pediatr
aml
inferior
seen
western
countri
howev
patient
recept
initi
treatment
aml
mortal
high
need
sensit
toward
import
support
care
infect
control
manag
childhood
aml
improv
surviv
rate
acut
myeloid
leukemia
develop
countri
use
protocol
siddaiahgari
b
jillella
manikyam
pediatr
rainbow
children
hospit
hyderabad
india
object
look
outcom
children
acut
myeloid
leukemia
aml
use
aml
protocol
method
year
prospect
retrospect
observ
studi
done
teritiari
care
center
month
children
januari
decemb
result
total
children
identifi
year
femal
common
present
symptom
fever
respect
subcutan
deposit
one
leukemia
cuti
sever
anemia
gm
notic
case
six
hyperleucocytosi
case
platelet
less
blast
peripher
blood
common
type
aml
aml
acut
promyelocyt
leukemia
apml
notic
respect
cytogenet
perform
apml
posit
one
one
one
inv
one
one
one
one
case
mll
posit
karyotyp
note
one
case
cn
posit
facial
nerv
palsi
csf
posit
cerebr
deposit
receiv
chemotherapi
per
uk
aml
went
remiss
induct
except
case
post
treatment
relaps
within
month
treatment
die
progress
diseas
relaps
one
one
normal
genet
one
cn
posit
diseas
one
one
normal
genet
two
expir
febril
neutropenia
overal
aliv
well
year
treatment
year
conclus
good
support
care
overal
surviv
rate
aml
improv
even
develop
countri
orbit
myeloid
sarcoma
acut
myeloid
leukemia
experi
tertiari
care
centr
india
j
srirambhatla
kannan
sinha
r
parimkayala
medic
oncolog
mnj
institut
oncolog
rcc
hyderabad
india
object
orbit
myeloid
sarcoma
rare
pediatr
malign
woould
like
review
clinico
epidemiolog
profil
children
present
orbit
myeloid
sarcoma
diagnosi
anted
leukemia
method
clinico
epidemiolog
data
children
diagnosi
orbit
myeloid
sarcoma
regist
centr
jan
dec
collect
retrospect
result
orbit
myeloid
sarcoma
amongst
new
case
acut
myeloid
leukemia
leukocytosi
note
acut
myeloid
leukemia
aml
occur
concurr
anted
aml
aml
aml
one
aml
undifferenti
note
complet
remiss
achiev
progress
note
relaps
leukemia
note
children
within
end
children
aliv
conclus
aml
commonli
associ
orbit
myeloid
sarcoma
children
outcom
childhood
acut
myeloid
leukemia
malaysia
kh
teh
ej
abdul
rahman
b
menon
h
mohd
ibrahim
moham
paediatr
kuala
lumpur
hospit
kuala
lumpur
malaysia
object
aim
studi
review
treatment
outcom
children
diagnos
acut
myeloid
leukemia
aml
treat
modifi
uk
mrc
aml
protocol
middl
incom
countri
method
retrospect
review
patient
diagnos
aml
till
treat
hospit
kuala
lumpur
made
patient
less
year
old
exclud
patient
syndrom
chronic
myeloid
leukemia
acut
myeloid
blast
crisi
transient
myelodysplasia
syndrom
juvenil
myelomonocyt
leukemia
exclud
result
patient
identifi
one
patient
refus
treatment
four
patient
die
sever
bleed
treatment
one
patient
abandon
treatment
default
follow
first
cours
patient
receiv
treatment
achiev
remiss
ten
patient
die
within
day
diagnosi
six
due
sever
sepsi
four
due
uncontrol
bleed
fifteen
patient
die
sepsi
remiss
relaps
estim
year
event
free
surviv
ef
overal
surviv
os
respect
segreg
patient
differ
time
period
period
period
b
period
c
show
improv
ef
introduct
amsacrin
period
c
estim
year
ef
period
period
b
period
c
respect
differ
partial
explain
differ
septic
death
period
period
b
period
c
autolog
allogen
haematopoiet
stem
cell
transplant
hsct
perform
patient
enhanc
surviv
conclus
surviv
children
aml
improv
follow
adopt
regim
use
develop
countri
improv
support
care
result
treatment
children
newli
diagnos
acut
promyelocyt
leukemia
singl
experi
rap
teixeira
vmg
jardini
wo
sanglard
cr
costa
ta
tele
mm
silva
pediatria
centro
de
tratamento
infantojuvenil
fabiana
macedo
de
morai
do
campo
brazil
object
describ
result
treatment
children
newli
diagnos
acut
promyelocyt
leukemia
method
twenti
newli
diagnos
children
acut
promylocyt
leukemia
apl
treat
centro
de
tratamento
infanto
juvenil
fabiana
macedo
de
mora
median
age
month
analyz
pcr
cytogenet
regard
presenc
posit
two
neg
isochromosom
initi
treat
acid
atra
first
day
maintain
throughout
initi
day
idarrubicin
ida
dose
ad
fibrinogen
level
becam
stabl
without
hemorrhag
manifest
intensif
ida
mitoxantron
plu
addit
year
mainten
mercaptopurinemethotrex
backbon
atra
everi
month
result
median
leukocyt
count
diagnosi
median
platelet
count
high
risk
patient
leukocyt
platelet
die
earli
hemorrhag
event
one
thromboembol
complic
diagnosi
due
refractori
leukemia
one
earli
relaps
death
high
risk
group
two
patient
isochromosom
treat
initi
atra
respond
one
pmrara
posit
patient
respons
atra
ida
resist
even
use
arsen
trioxid
ato
die
sepsi
pulmonari
bleed
conclus
hemorrhag
disturb
remain
particular
advers
event
initi
treatment
apl
patient
high
leucocyt
count
low
platelet
level
wors
prognosi
prompt
introduct
atra
apl
suspicion
crucial
better
outcom
final
want
point
two
patient
isochromosom
pmlrara
neg
gene
fusion
respond
atra
induct
treatment
result
nation
protocol
acut
myeloid
leukemia
nation
institut
pediatr
mexico
r
l
r
oncolog
instituto
nacion
de
mexico
citi
mexico
object
result
treatment
children
acut
myeloid
leukemia
aml
challeng
low
incom
countri
toxic
regimen
main
caus
death
present
promis
result
cohort
patient
treat
singl
institut
method
longitudin
clinic
studi
perform
januari
septemb
nineteen
case
patient
aml
includ
patient
receiv
ade
induct
therapi
cytarabin
dose
daunorubicin
day
etoposid
day
medic
research
council
mrc
mainten
four
cycl
aml
treat
atra
mrc
protocol
result
median
age
month
two
patient
two
two
one
extramedular
infiltr
diagnosi
three
patient
need
one
cycl
remiss
ten
need
two
cycl
three
remiss
rate
patient
one
infecti
event
none
fatal
one
patient
abandon
two
die
hemorrhag
one
septic
shock
four
patient
bone
marrow
relaps
rescu
progenitor
cell
transplant
analyz
patient
overal
surviv
month
conclus
oncolog
depart
select
bia
almost
half
patient
extramedular
infiltr
howev
ade
induct
therapi
show
improv
result
overal
surviv
compar
standard
regimen
regimen
use
develop
countri
differ
somat
mutat
gene
express
blast
transient
leukemia
acut
myeloid
leukemia
syndrom
j
chen
f
yousif
beck
j
mcpherson
j
hitzler
development
stem
cell
biolog
hospit
sick
children
toronto
canada
informat
ontario
institut
cancer
research
toronto
canada
hematologyoncolog
hospit
sick
children
toronto
canada
object
transient
leukemia
tl
occur
newborn
syndrom
ds
typic
resolv
spontan
approxim
infant
tl
go
develop
acut
myeloid
leukemia
ds
within
first
four
year
life
blast
tl
harbour
somat
mutat
object
studi
identifi
genet
event
associ
progress
tl
method
leukem
blast
tl
normal
lymphocyt
sort
blood
bone
marrow
sampl
five
patient
success
develop
disord
addit
blast
one
patient
subsequ
relaps
analyz
gene
express
mutat
spectrum
determin
rnaseq
exom
sequenc
result
tl
blast
harbor
fewer
mutat
mutat
cohesin
ra
pathway
gene
identifi
subset
tl
patient
relaps
differ
cohesin
gene
mutat
detect
initi
diagnosi
aml
relaps
minor
clone
present
initi
diagnosi
aml
emerg
predomin
clone
relaps
differenti
gene
express
predominantli
higher
tl
blast
compar
includ
gene
encod
chemokin
relat
tgf
signal
latter
result
consist
occurr
frequent
fatal
organ
fibrosi
tl
conclus
pathogen
sequenc
culmin
initi
uniqu
event
children
ds
somat
mutat
contrast
event
associ
transform
tl
resembl
progress
factor
also
found
aml
acetyl
l
carnitin
interfer
antitumor
effect
cisplatin
akta
z
altun
pamukoglu
e
kolatan
p
ercetin
dursun
e
serinan
b
demir
yilmaz
n
olgun
institut
oncolog
dokuz
eylul
univers
izmir
turkey
institut
health
scienc
dokuz
eylul
univers
izmir
turkey
object
alcar
well
known
antioxid
previou
studi
show
protect
effect
alcar
cisplatin
induc
neuro
oto
nephrotox
vitro
vivo
experiment
model
aim
studi
investig
whether
alcar
interfer
antitumor
effect
cisplatin
neuroblastoma
method
atym
male
nude
mice
gram
week
age
anim
per
group
subcutan
inject
million
neuroblastoma
cell
studi
consist
four
group
control
alcar
cisplatin
alcarcisplatin
group
tumor
size
reach
cm
day
intraperiton
inject
isoton
solut
control
group
cisplatin
mgkg
alcar
combin
time
appli
anim
sacrifi
day
antitumor
activ
evalu
gross
measur
tumor
microscob
evalu
tumor
necrobiyosi
apoptosi
evalu
result
control
alcar
tumor
group
agent
given
tumor
cell
aliv
minim
necrosi
apoptosi
promin
mitosi
cisplatin
group
tumor
show
promin
necrosi
necrobiosi
promin
apoptosi
alcarcisplatin
group
tumor
show
lesser
necrosi
compar
cisplatin
group
conclus
anim
model
vivo
studi
show
alcar
given
time
cisplatin
interfer
antitumor
activ
neuroblastoma
use
alcar
protect
agent
cisplatin
induc
toxic
well
question
cknowledg
studi
support
turkish
societi
pediatr
oncolog
molecular
profil
neuroblastoma
turkey
behalf
turkish
societi
pediatr
oncolog
akta
b
demir
p
ercetin
z
altun
n
olgun
institut
oncolog
dokuz
eylul
univers
izmir
turkey
object
neuroblastoma
common
pediatr
neuroendocrin
tumor
aris
neural
crest
sympathet
nervou
system
neuroblast
tumor
exhibit
extrem
heterogen
affect
outcom
therapi
differ
neuroblastoma
mainli
categor
three
risk
level
low
intemedi
high
molecular
evalu
come
promin
determin
risk
categori
patient
studi
result
molecular
analysi
perform
within
scope
tpog
turkish
societi
pediatr
oncolog
protocol
evalu
method
compil
molecular
analysi
patient
neuroblastoma
oncolog
center
turkey
variou
govern
univers
privat
hospit
analys
nmyc
amplif
loh
del
gain
statu
patient
pcr
analysi
dna
ploidi
index
flow
cytomet
result
molecular
analysi
patient
evalu
age
interv
patient
month
averag
age
percentag
posit
loh
del
gain
percentag
posit
respect
dna
ploidi
index
dpi
analys
sampl
posit
correl
nmyc
amplif
loh
found
p
correl
found
among
delet
gain
nmyc
amplif
sampl
neg
four
genet
paramet
conclus
result
show
exist
posit
correl
nmyc
amplif
loh
consist
sever
previou
studi
almost
sampl
shown
posit
gain
mostli
seen
abber
among
sampl
evalu
surgic
complic
outcom
abdomin
neuroblastoma
singl
institut
studi
l
ali
f
branchereau
g
de
lambert
c
baujard
l
chevret
f
gauthier
h
martelli
pediatr
surgeri
bicetr
hospit
pari
franc
anesthesia
bicetr
hospit
pari
franc
object
anatom
relat
surgic
excis
abdomin
neuroblastoma
pvan
challeng
procedur
aim
studi
evalu
complic
outcom
patient
oper
tumour
singl
institut
method
patient
oper
neuroblastoma
encas
abdomin
aorta
main
abdomin
arteri
renal
pedicl
preoper
chemotherapi
given
patient
accord
current
ongo
protocol
accord
intern
neuroblastoma
risk
group
inrg
classif
patient
metastat
ms
assess
periop
outcom
result
median
age
surgeri
year
two
patient
underw
stage
procedur
excis
complet
patient
perform
plan
nephrectomi
oper
complic
consist
vascular
advers
event
patient
includ
accident
injuri
superior
sma
inferior
mesenter
arteri
spasm
injuri
renal
arteri
spasm
hepat
arteri
injuri
renal
vein
complic
occur
patient
die
mesenter
ischemia
accident
injuri
sma
patient
kidney
atrophi
patient
thrombosi
celiac
trunk
renal
vein
respons
hemodynam
instabl
acut
liver
ischem
necrosi
renal
insuffici
final
recov
without
sequela
five
patient
develop
temporari
asciti
bowel
obstruct
median
month
patient
aliv
patient
die
local
recurr
initi
resect
macroscop
incomplet
die
metastat
recurr
conclus
surgeri
perivascular
abdomin
neuroblastoma
challeng
bear
potenti
life
threaten
complic
mainli
vascular
could
prevent
andor
revers
appropri
peri
manag
hemodynam
chang
hing
laminoplasti
use
techniqu
urgent
decompress
neuroblastoma
caus
spinal
cord
compress
appropri
select
case
h
bishop
g
anichini
r
vashu
p
bhatt
paediatr
oncolog
royal
aberdeen
children
hospit
aberdeen
unit
kingdom
neurosurgeri
aberdeen
royal
infirmari
aberdeen
unit
kingdom
object
highlight
util
safeti
hing
laminoplasti
techniqu
urgent
decompress
neuroblastoma
caus
spinal
cord
compress
scc
appropri
select
case
method
month
period
children
present
paediatr
oncolog
servic
royal
aberdeen
children
hospit
diagnosi
neuroblastoma
scc
first
age
month
month
histori
grade
weak
lower
limb
urgent
hing
laminoplasti
high
dose
dexamethason
emerg
carboplatin
etoposid
second
age
month
day
histori
grade
weak
lower
limb
constip
emerg
carboplatin
etoposid
dexamethason
follow
urgent
hing
laminoplasti
follow
day
third
age
week
present
abdomin
mass
mri
reveal
scc
constip
weak
treatment
emerg
carboplatin
etoposid
dexamethason
result
first
patient
month
diagnosi
remiss
walk
frame
power
lower
limb
second
month
diagnosi
remiss
neurolog
deficit
third
month
diagnosi
remain
treatment
neurolog
deficit
conclus
neuroblastoma
scc
associ
rel
good
prognosi
oncolog
neurolog
prognosi
vari
sever
motor
deficit
concern
symptomat
deterior
scoliosi
compromis
abil
deliv
chemotherapi
caus
earli
decompress
fall
favour
show
appropri
select
case
hing
laminoplasti
effect
approach
urgent
decompress
need
compromis
compromis
chemotherapi
deliveri
also
carri
smaller
risk
refer
thorsten
et
al
dev
med
chil
neurol
hh
et
al
pediatr
neurosurg
role
human
neuroblastoma
tumourigenesi
l
prasad
robert
chowdhuri
l
lau
charlton
henwood
n
graf
arbuckl
catchpool
histopatholog
depart
children
hospit
westmead
westmead
australia
tumour
bank
children
cancer
research
unit
children
hospit
westmead
westmead
australia
object
cytokin
neurotroph
effect
develop
embryon
nerv
cell
lead
neuron
differenti
michaelson
etal
development
biolog
sequenc
variat
pathogen
neurolog
disord
multipl
sclerosi
ms
neuroblastoma
nb
common
extracrani
childhood
solid
tumour
show
remark
heterogen
respect
neuron
differenti
microarray
studi
indic
significantli
increas
express
good
prognosi
nb
tumour
treatment
outcom
present
sever
line
evid
implic
alter
signal
nb
develop
method
express
receptor
downstream
signal
protein
analys
use
immunohistochemistri
stroma
poor
nb
tumour
stroma
rich
ganglioneuroma
gn
express
correl
level
stromal
marker
neuroblast
marker
neg
marker
result
protein
express
posit
exclus
schwannian
stroma
favour
unfavour
histolog
tumour
specialis
digit
imag
analysi
determin
express
increas
gn
compar
nb
express
found
significantli
reduc
p
stroma
poor
nb
compar
gn
like
undifferenti
tumour
nb
cell
line
panel
demonstr
uniform
express
low
express
absenc
partner
deplet
two
cell
line
ion
torrent
next
gener
sequenc
code
region
key
signal
pathway
gene
nb
cell
line
identifi
sequenc
variat
known
associ
ms
eg
zhang
etal
molecular
biolog
report
conclus
find
implic
within
schwannian
stroma
tumour
architectur
paracrin
signal
effect
neighbour
neuroblast
turn
vari
capac
differenti
respons
vivo
effect
sanguinarin
neuroblastoma
e
cecen
akta
pamukoglu
e
kolatan
p
ercetin
b
demir
yilmaz
n
olgun
pediatr
oncolog
adnan
mender
univers
school
medicin
aydin
turkey
basic
oncolog
dokuz
eylul
univers
institut
oncolog
izmir
turkey
laboratori
anim
scienc
dokuz
eylul
univers
school
medicin
izmir
turkey
pediatr
oncolog
dokuz
eylul
univers
institut
oncolog
izmir
turkey
object
neuroblastoma
among
common
extracrani
solid
cancer
children
origin
primordi
crest
approxim
half
patient
neuroblastoma
diagnos
poor
prognosi
diseas
novel
therapi
need
sanguinarin
benzophenanthridin
alkaloid
properti
previous
show
antitumor
effect
sanguinarin
neuroblastoma
cell
cultur
studi
aim
studi
determin
vivo
effect
sanguinarin
neuroblastoma
method
atym
male
nude
mice
mean
weight
g
week
age
anim
per
group
subcutan
inject
million
neuroblastoma
cell
studi
consist
three
group
control
sanguinarin
cisplatin
tumor
size
reach
cm
day
intraperiton
inject
isoton
solut
control
group
cisplatin
mgkg
sanguinarin
appli
anim
sacrifi
day
antitumor
activ
evalu
gross
measur
tumor
microscob
evalu
tumor
necrobiosi
apoptosi
evalu
result
control
tumor
group
agent
given
tumor
cell
aliv
minim
necrosi
apoptosi
promin
mitosi
cisplatin
group
tumor
show
promin
necrosi
necrobiosi
promin
apoptosi
sanguinarin
group
tumor
reveal
necrosi
apoptosi
much
promin
compar
cisplatin
group
conclus
anim
model
vivo
studi
demonstr
sanguinarin
compar
cisplatin
antitumor
activ
neuroblastoma
studi
need
determin
inhibitori
effect
sanguinarin
tumor
growth
experiment
tumor
model
studi
suggest
sanguinarin
like
candid
evalu
neuroblastoma
treatment
role
pathway
neuroblastoma
chemoresist
b
cuglievan
f
hernandez
g
de
angulo
vanni
r
graham
pediatr
miami
children
hospit
miami
usa
pediatr
hematolog
oncolog
md
anderson
cancer
center
houston
usa
pediatr
hematolog
oncolog
miami
children
hospit
miami
usa
neurosurgeri
depart
univers
miami
miami
usa
neurosurgeri
univers
miami
miami
usa
object
chemoresist
major
obstacl
success
treatment
neuroblastoma
nb
sirtuin
sirt
nad
depend
deacetylas
activ
period
stress
lead
cellular
protect
cancer
activ
sirt
larg
depend
nad
salvalg
pathway
nampt
key
enzym
inhibit
nad
metabol
downstream
target
may
repres
novel
way
enhanc
cancer
chemotherapeut
object
determin
therapeut
potenti
sirt
nampt
inhibit
novel
method
increas
nb
chemosensit
akt
pathway
inhibit
method
cell
viabil
determin
mt
ldh
assay
cell
signal
pathway
evalu
western
blot
analysi
nb
cell
treat
perifosin
everolimu
inhibit
pathway
result
sirtinol
inhibitor
nampt
inhibitor
induc
dose
depend
nb
cell
death
combin
sirt
akt
pathway
inhibit
induc
parp
cleavag
cell
death
viabil
vehicl
sirtinol
perifosin
sirtinolperifosin
everolimu
sirtinoleverolimu
inhibit
sirt
target
nad
product
also
significantli
increas
nb
cell
death
respons
akt
pathway
inhibitor
conclus
data
indic
sirt
regul
cell
surviv
follow
chemotherapeut
insult
sirt
inhibitor
trial
howev
nampt
inhibitor
clinic
trial
could
potenti
use
inhibit
sirt
therebi
enhanc
therapeut
effect
akt
pathway
inhibitor
well
chemotherapeut
agent
provid
novel
insight
role
sirt
nb
suggest
new
therapeut
regimen
cancer
minim
surviv
persist
metaiodobenzylguanidin
mibg
spot
long
term
metastat
neuroblastoma
year
age
de
iori
mc
garganes
md
de
pasqual
pizzoferro
crocoli
f
del
bufalo
serra
mastronuzzi
castellano
f
locatelli
hematologyoncolog
pediatr
hospit
bambino
gesu
roma
itali
nuclear
medicin
pediatr
hospit
bambino
gesu
roma
itali
surgeri
pediatr
hospit
bambino
gesu
roma
itali
object
metaiodobenzylguanidin
mibg
scintigraphi
use
tool
diagnosi
stage
evalu
respons
treatment
neuroblastoma
nb
aim
studi
report
featur
implic
residu
uptak
metastat
nb
survivor
method
retrospect
review
seri
metastat
nb
year
age
enrol
two
consecut
local
protocol
least
year
medic
record
review
check
patient
persist
mibg
spot
mibg
scan
review
result
metastat
nb
patient
treat
juli
august
enrol
studi
one
posit
diseas
diagnosi
survivor
patient
present
persist
stabl
uptak
month
sinc
diagnosi
respect
three
patient
younger
month
diagnosi
none
mycn
amplif
achiev
partial
responseveri
good
partial
respons
end
induct
phase
high
dose
chemotherapi
conclus
residu
persist
mibg
uptak
report
metastat
nb
patient
younger
month
without
mycn
amplif
impact
surviv
spot
may
reflect
residu
differenti
diseas
analys
larg
seri
need
clarifi
implic
residu
uptak
metastat
nb
modul
treatment
mibg
time
treatment
neuroblastoma
topotecan
regimen
k
dong
x
cui
kai
li
x
xiao
lian
chen
surgeri
children
hospit
fudan
univers
shanghai
china
patholog
children
hospit
fudan
univers
shanghai
china
object
summar
experi
treatment
neuroblastoma
topotecan
regimen
method
newli
diagnos
patient
neuroblastoma
includ
studi
januari
decemb
age
patient
day
month
diagnosi
made
imageolog
bone
marrow
biopsi
postop
patholog
diagnosi
stage
patient
determin
inss
system
follow
case
stage
stage
ii
stageiii
stage
iv
stage
iv
treatment
scheme
accord
protocol
topotecan
regimen
result
remiss
rate
new
assist
chemotherapi
gross
total
resect
rate
group
overal
surviv
rate
year
group
respect
overal
surviv
rate
year
patient
gross
total
resect
respect
year
surviv
rate
year
surviv
rate
age
ef
surviv
roc
receiv
oper
characterist
curv
analysi
show
best
discrimin
threshold
day
sensit
specif
respect
area
curv
conclus
studi
show
treatment
neuroblastoma
accord
america
cog
protocol
better
japanes
studi
group
protocol
patient
low
risk
group
mycn
amplif
undergo
surgeri
alon
achiev
favor
prognosi
case
patient
age
ef
roc
curv
analysi
obtain
best
discrimin
threshold
day
much
longer
data
use
stage
iv
neuroblastoma
experi
tertiari
care
center
india
durugappa
nita
radhakrishnan
thakkar
aggarw
kalra
sachdeva
pediatr
hematolog
oncolog
sir
gangaram
hospit
new
delhi
india
object
stage
iv
neuroblastoma
system
diseas
requir
multimod
intens
treatmentour
object
studi
clinic
profil
outcom
stage
iv
neuroblastoma
diagnos
institut
method
retrospect
analysi
data
patient
diagnos
stage
iv
neuroblastoma
period
year
patient
treat
uniform
induct
protocol
consist
cycl
opecojec
chemotherapi
cycl
evid
metastat
diseas
primari
surgic
amen
resectiondebulk
attempt
end
induct
therapi
myeloabl
chemotherapi
autolog
stem
cell
rescu
follow
local
therapi
given
acid
given
patient
complet
treatment
result
total
patient
stage
iv
neuroblastoma
patient
diagnos
major
male
n
mean
age
diagnosi
year
rang
fever
abdomin
distens
common
present
symptom
patient
primari
tumour
supraren
region
retroperiton
region
posterior
mediastinum
skin
involv
seen
patient
bone
marrow
common
metastat
site
follow
liver
bone
urinari
vma
elev
patient
n
myc
done
patient
mibg
scan
done
pet
ct
done
children
underw
abmt
one
expir
therapi
cn
relaps
expir
total
children
expir
lost
follow
children
abandon
treatment
children
receiv
treatment
present
conclus
surviv
patient
stage
iv
neuroblastoma
dismal
stem
cell
rescu
improv
surviv
recent
time
yet
support
strong
evid
indian
scenario
indian
data
neuroblastoma
stage
iv
outcom
lack
need
studi
neuron
leucin
rich
repeat
suppress
ngftrka
signal
neuroblastoma
fukuda
takatori
nakamura
nakagawara
children
cancer
research
center
chiba
cancer
center
research
institut
chiba
japan
divis
innov
cancer
therapeut
chiba
cancer
center
research
institut
chiba
japan
object
type
transmembran
protein
highli
express
unfavor
neuroblastoma
nb
previous
report
acceler
egf
igf
signal
enhanc
cell
prolifer
nb
howev
function
role
receptor
tyrosin
kinas
includ
trka
elus
trka
associ
favor
outcom
nb
enhanc
cell
surviv
differenti
upon
nerv
growth
factor
ngf
treatment
nb
cell
present
studi
investig
function
interact
trka
method
mrna
express
trka
evalu
quantit
pcr
qpcr
primari
nb
sampl
ngftrka
signal
investig
western
blot
analysi
nb
cell
result
nb
clinic
sampl
found
mrna
express
trka
invers
correl
express
test
p
express
cell
cell
growth
medium
reduc
compar
control
cell
upon
ngf
treatment
level
phosphoryl
trka
erk
one
downstream
molecul
trka
decreas
express
cell
conclus
data
suggest
trka
show
mutual
exclus
express
pattern
nb
clinic
sampl
contribut
aggress
nb
part
suppress
trka
signal
decreas
treatment
neuroblastoma
multidisciplinari
care
h
halalsheh
ismael
k
ghandour
alboheisi
sultan
pediatr
king
hussein
cancer
center
amman
jordan
pediatr
surgeri
king
hussein
cancer
center
amman
jordan
nurs
king
hussein
cancer
center
amman
jordan
object
treatment
low
intermedi
risk
lir
neuroblastoma
need
judici
use
differ
modal
group
patient
typic
treat
care
scatter
report
experi
emphasi
role
multidisciplinari
care
also
propos
algorithm
manag
countri
limit
resourc
method
conduct
retrospect
analysi
children
lir
nb
present
patient
characterist
treatment
modal
outcom
analyz
case
discuss
multidisciplinari
clinic
includ
least
pediatr
oncologist
radiologist
pediatr
surgeon
radiat
oncologist
result
identifi
patient
male
present
lir
nb
center
lr
median
age
diagnosi
month
rang
stage
distribut
follow
stage
stage
ii
stage
iii
stage
iv
patient
mycn
amplifi
patient
stage
gross
macroscop
resect
achiev
surgeri
chemotherapi
given
patient
patient
receiv
cycl
ef
os
three
patient
die
two
relaps
month
diagnosi
die
diseas
third
patient
die
hemorrhag
renal
shut
surgeri
anoth
patient
develop
progress
residu
mass
month
diagnosi
lost
follow
conclus
children
risk
neuroblastoma
develop
countri
possibl
treatment
reduct
good
outcom
treatment
modifi
multidisciplinari
team
discuss
propos
countri
limit
resourc
minim
treatment
provid
patient
neuroblastoma
unless
advanc
therapi
avail
includ
stem
cell
transplant
immunotherapi
synergist
antitumor
interact
panobinostat
neuroblastoma
cell
hanmod
g
wang
h
edward
buck
ge
j
taub
z
wang
divis
pediatr
hematolog
oncolog
children
hospit
michigan
detroit
usa
depart
pediatr
wayn
state
univers
school
medicin
detroit
usa
depart
oncolog
wayn
state
univers
school
medicin
detroit
usa
object
despit
recent
advanc
treatment
regimen
patient
neuroblastoma
surviv
rate
resist
current
agent
continu
one
main
reason
treatment
failur
progress
diseas
among
group
patient
therefor
new
agent
urgent
need
improv
treatment
outcom
patient
neuroblastoma
studi
util
inhibitor
combin
panobinostat
determin
antitumor
interact
underli
molecular
mechan
method
vitro
cytotox
panobinostat
clinic
achiev
concentr
either
alon
combin
evalu
neuroblastoma
cell
line
use
mtt
assay
mechan
antitumor
activ
investig
use
propidium
iodid
pi
stain
flow
cytometri
analysi
determin
apoptosi
well
western
blot
assess
express
phosphoryl
result
treatment
neuroblastoma
cell
line
nm
caus
growth
arrest
apoptosi
minim
effect
cell
line
combin
panobinostat
result
synergist
antitumor
interact
three
cell
line
test
treatment
cell
induc
increas
level
could
decreas
addit
panobinostat
accompani
increas
dna
damag
apoptosi
select
inhibitor
potent
synergist
enhanc
prolifer
inhibit
cell
support
play
import
role
mediat
synergist
antitumor
interact
panobinostat
conclus
combin
panobinostat
synergist
antitumor
activ
neuroblastoma
cell
line
hold
promis
potenti
effect
treatment
strategi
manag
neuroblastoma
patient
adher
uk
children
cancer
leukaemia
group
guidelin
manag
low
intermedi
risk
neuroblastoma
f
herd
k
wheeler
da
morgenstern
da
tweddl
depart
paediatr
oncolog
great
north
children
hospit
newcastl
unit
kingdom
paediatr
oncolog
oxford
children
hospit
oxford
unit
kingdom
depart
paediatr
oncolog
great
ormond
street
hospit
london
unit
kingdom
depart
paediatr
oncolog
northern
institut
cancer
research
newcastl
univers
newcastl
unit
kingdom
object
evalu
uk
children
low
lr
intermedi
risk
ir
neuroblastoma
manag
compar
nation
cclg
guidelin
august
base
siopen
low
intermedi
risk
neuroblastoma
line
trial
method
cclg
centr
ask
follow
guidelin
lr
ir
neuroblastoma
august
patient
number
genet
test
includ
mycn
segment
chromosom
abnorm
sca
outcom
data
specif
subgroup
collect
result
cclg
centr
repli
describ
case
lr
ir
princip
centr
adher
guidelin
case
test
mycn
amplif
sca
either
local
via
central
refer
facil
newcastl
lr
patient
biopsi
due
need
emerg
chemotherapi
primari
surgeri
antenat
diagnos
adren
mass
lr
tumour
sca
gain
commonest
patient
diseas
without
life
threaten
symptom
sca
receiv
cycl
chemotherapi
patient
month
age
localis
unresect
tumour
sca
chemotherapi
follow
surgeri
case
one
surgeri
alon
patient
aliv
one
die
diseas
progress
ir
tumour
sca
commonest
gain
patient
month
old
undifferenti
tumour
sca
receiv
chemotherapi
surgeri
radiotherapi
retino
acid
one
child
still
treatment
one
progress
die
remaind
first
remiss
conclus
studi
show
cclg
centr
broadli
follow
guidelin
depth
analysi
specif
subgroup
show
variabl
adher
import
captur
data
current
line
trial
open
uk
tumor
histolog
follow
induct
chemotherapi
andor
chemotherapi
impact
outcom
patient
neuroblastoma
hishiki
h
hori
higashimoto
k
yotsumoto
komatsu
okimoto
h
kakuda
taneyamai
h
yoshida
j
iwai
depart
pediatr
surgeri
chiba
children
hospit
chiba
japan
depart
patholog
chiba
children
hospit
chiba
japan
depart
hematolog
oncolog
chiba
children
hospit
chiba
japan
depart
pediatr
surgeri
chiba
univers
graduat
school
medicin
chiba
japan
object
recent
year
japan
increas
number
patient
neuroblastoma
nb
treat
delay
local
treatment
dl
polici
undergo
surgeri
complet
chemotherapi
hematopoiet
stem
cell
rescu
hdc
review
histopatholog
find
oper
includ
patient
treat
dl
method
patient
nb
underw
second
look
oper
follow
chemotherapi
surgeri
perform
induct
chemotherapi
case
std
wherea
case
complet
induct
chemotherapi
hdc
undergo
tumor
resect
dl
treatment
effect
measur
amount
necrosi
degre
differenti
assess
accord
intern
neuroblastoma
patholog
classif
inpc
result
percent
tumor
show
necrosi
specimen
two
dl
case
show
complet
disappear
viabl
tumor
cell
contrarili
seven
contain
viabl
neuroblast
variou
proport
howev
amount
necrosi
affect
prognosi
patient
within
entir
cohort
hand
degre
differenti
within
viabl
tumor
compon
evalu
inpc
impact
surviv
patient
tumor
immatur
phenotyp
ie
undifferenti
poorli
differenti
nb
oper
extrem
poor
outcom
conclus
result
support
previou
report
advoc
tumor
sustain
unfavor
histolog
chemotherapi
behav
aggress
thereaft
knowledg
first
report
focus
histolog
characterist
tumor
resect
complet
chemotherapi
hematopoiet
stem
cell
transplant
result
appli
strategi
see
wait
children
suspect
neurogen
tumor
hizhnikov
kazantsev
p
kerimov
rubanski
kapkova
rubanskaya
rybakova
pediatr
oncolog
n
n
blokhin
cancer
research
center
russian
academi
medic
scienc
moscow
russia
object
determin
role
dynam
monitor
children
suspect
neurogen
tumor
method
patient
age
month
monitor
see
wait
strategi
research
institut
pediatr
oncolog
hematolog
children
neoplasm
local
adren
gland
child
posterior
mediastinum
child
pelvi
patient
tumor
child
neoplasm
neoplasm
found
prenat
period
child
aliv
without
evid
diseas
progress
children
progress
diseas
note
increas
tumor
size
month
start
observ
result
children
underw
surgic
treatment
due
diseas
progress
aliv
momment
without
evid
diseas
progress
observ
period
month
adrenalectomi
tumor
remov
posterior
mediastinum
tumor
remov
pelvi
perform
children
receiv
surgic
treatment
morpholog
molecular
genet
proven
neuroblastoma
conclus
children
suspect
neurogen
tumor
locat
recommend
perform
surgeri
determin
diagnosi
strategi
treatment
genet
predisposit
syndrom
children
neuroblastoma
kachanov
g
muftahova
shamanskaya
shevcov
olshanskaya
n
semenova
g
novichkova
varfolomeeva
clinic
oncolog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
laboratori
cytogenet
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
genet
citi
clinic
hospit
citi
clinic
hospit
pediatr
name
nil
filatov
moscow
russia
clinic
oncolog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
etiolog
neuroblastoma
nb
fulli
understood
aim
studi
analyz
incid
natur
cancer
predisposit
syndrom
cohort
patient
neuroblastoma
method
period
month
children
nb
treat
diagnosi
nb
made
accord
intern
criteria
patient
stratifi
risk
group
treat
accord
protocol
cytogenet
analys
tumor
tissu
done
fish
mycn
statu
karyotyp
perform
infant
year
patient
famili
histori
collect
patient
clinic
examin
search
clinic
abnorm
patient
clinic
abnorm
consult
medic
genet
chromosom
microarray
analysi
done
necessari
result
cancer
predisposit
syndrom
diagnos
patient
case
femal
left
adren
neuroblastoma
stage
turner
syndrom
diagnosi
confirm
karyotyp
case
old
male
right
adren
neuroblastoma
stage
diagnos
microdelet
syndrom
malform
includ
heart
abnorm
deaf
case
male
diagnos
left
adren
neuroblastoma
stage
soto
syndrom
age
day
child
oper
congenit
sacroccocyg
teratoma
multipl
malform
observ
includ
heart
abnorm
hydrohephalu
myoton
syndrom
case
cancer
predisposit
syndrom
confirm
chromosom
microarray
analys
fish
analys
show
unfavor
abnorm
patient
phenotyp
featur
typic
syndrom
case
presenc
genet
syndrom
suspect
diagnosi
cancer
done
conclus
genet
predisposit
neuroblastoma
rare
genet
consult
includ
karyotyp
chromosom
microarray
analysi
indic
patient
malform
bilater
adren
neuroblastoma
singl
center
experi
kachanov
g
muftahova
shamanskaya
r
moiseenko
usychkina
olshanskaya
e
andreev
g
tereschenko
v
roschin
likar
varfolomeeva
clinic
oncolog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
laboratori
cytogenet
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
surgeri
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
radiolog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
patholog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
nuclear
medicin
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
bilater
adren
involv
neuroblastoma
nb
rare
event
extent
surgic
procedur
matter
debat
purpos
studi
analys
clinic
featur
outcom
cohort
patient
treat
singl
center
russia
method
period
month
children
nb
treat
diagnosi
confirm
accord
intern
criteria
stage
assign
accord
inss
patient
stratifi
risk
group
treat
accord
protocol
cytogenet
analys
tumor
tissu
done
fish
mycn
statu
morpholog
verif
recommend
patient
age
month
older
result
bilater
adren
involv
diagnos
patient
median
age
month
rang
male
femal
ratio
initi
diagnosi
base
clinic
data
histolog
patient
stage
distribut
stage
stage
stage
site
distant
metastasi
includ
liver
patient
liver
bone
marrow
patient
oper
age
month
cytogenet
analysi
show
lack
unfavor
abnorm
studi
case
patient
primari
tumor
liver
metastasi
extent
surgic
procedur
gross
total
resect
subtot
resect
biopsi
patient
bilater
adrenalectomi
patient
receiv
chemotherapi
patient
abdomin
irradi
patient
observ
show
tumor
regress
median
month
rang
outcom
patient
aliv
archiv
complet
respons
patient
stage
die
due
massiv
hepatomegali
conclus
data
confirm
favor
featur
neuroblastoma
patient
bilater
involv
associ
stage
aggress
surgeri
warrant
case
concurr
extraren
nephroblastoma
neuroblastoma
infant
r
kebudi
c
buyukun
b
oflaz
sozmen
karaca
kurugoglu
dervisoglu
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
american
hospit
istanbul
turkey
pediatr
surgeri
istanbul
univers
cerrahpasa
medic
faculti
american
hospit
istanbul
turkey
pediatr
koc
univers
american
hospit
istanbul
turkey
pediatr
surgeri
izmir
univers
school
medicin
izmir
turkey
radiolog
istanbul
univers
cerrahpasa
medic
faculti
istanbul
turkey
patholog
istanbul
univers
cerrahpasa
medic
faculti
istanbul
turkey
object
nephroblastoma
common
malign
renal
tumor
children
extraren
nephroblastoma
rare
concurr
extraren
nephroblastoma
neuroblastoma
extrem
rare
report
month
old
femal
extraren
nephroblastoma
present
inguin
mass
surren
mass
investig
nephroblastoma
method
case
report
result
previous
month
oldinf
born
vitro
fertil
refer
us
diagnos
extraren
nephroblastoma
good
health
month
age
parent
notic
left
side
inguin
mass
ultrasound
show
mm
solid
mass
afp
ferritin
ldh
level
cbc
within
normal
limit
seen
pediatr
surgeon
anoth
medic
center
underw
total
resect
patholog
consist
nephroblastoma
anaplasia
comput
tomographi
chest
abdomen
show
lung
metastasi
lesion
aris
kidney
left
supraren
mass
nse
slightli
elev
underw
total
excision
supraren
mass
lymph
node
sampl
instituit
patholog
revela
neuroblastoma
lymphat
involv
bone
scan
bone
marrow
biopsi
show
metastat
diseas
diagnos
total
excis
stage
neuroblastoma
stage
favor
histolog
extraren
nephroblastoma
start
chemotherapi
per
protocol
day
second
surgeri
conclus
extraren
nephroblastoma
neuroblastoma
extrem
rare
diagnost
metastat
workup
rare
tumor
caseof
anoth
mass
detail
investig
done
order
stage
properli
decid
therapi
correl
one
vitro
fertil
two
tumor
also
studi
larger
popul
infant
prognost
signific
delet
gene
express
neuroblastoma
neg
mycn
gene
statu
n
khranovska
g
klymnyuk
n
svergun
skachkova
e
shaida
pavlyk
inomistova
n
ionkina
research
laboratori
experiment
oncolog
nation
cancer
institut
mph
ukrain
kiev
ukrain
research
depart
pediatr
oncolog
nation
cancer
institut
mph
ukrain
kiev
ukrain
object
high
clinic
heterogen
neuroblastoma
reflect
complex
genom
abnorm
character
tumor
role
mycn
gene
amplif
neuroblastoma
pathogenesi
first
establish
earli
due
associ
high
risk
tumor
low
patient
surviv
current
prognost
signific
sever
genet
abnorm
neuroblastoma
consider
purpos
studi
determin
prognost
signific
delet
gene
express
neuroblastoma
neg
mycn
gene
statu
method
seventi
two
children
diagnos
stage
neuroblastoma
age
month
year
enrol
studi
patient
assign
treatment
basi
age
tumor
mycn
statu
tumor
cell
ploidi
investig
delet
mycn
gene
amplif
tumor
cell
perform
fish
method
gene
express
studi
perform
tumor
cell
ploidi
studi
use
flow
cytometri
result
shown
neg
statu
mycn
found
neuroblastoma
case
unfavor
diseas
cours
chromosom
loss
found
tumor
assum
tumor
case
transcript
function
control
protein
high
gene
express
level
tumor
associ
poor
respons
chemotherapi
regardless
gene
mycn
statu
reveal
delet
chromosom
tumor
cell
occur
investig
neuroblastoma
tumor
case
associ
mycn
gene
amplif
patient
neg
statu
mycn
gene
delet
chromosom
associ
diseas
progress
conclus
delet
elev
level
gene
express
import
prognosi
neuroblastoma
could
recommend
replenish
genet
compon
risk
group
stratif
complex
treatment
standard
high
risk
patient
group
neuroblastoma
one
centr
expiri
pavlyk
g
klymnyuk
e
shaida
pediatr
nation
cancer
institut
ukrain
kiev
ukrain
object
histor
neuroblastoma
patient
surviv
probabl
less
advent
comprehens
treatment
approach
includ
intens
induct
chemotherapi
myeloabl
consolid
therapi
stem
cell
rescu
target
therapi
os
rate
improv
howev
current
surviv
rate
remain
unaccept
come
expens
substanti
immedi
morbid
method
patient
neuroblastoma
sr
patient
hr
patient
receiv
treatment
scienc
research
depart
pediatr
oncolog
nation
cancer
institut
enrol
patient
receiv
treatment
accord
protocol
hr
patient
cure
chemotherapi
hdct
autolog
stem
cell
support
patient
cure
tandem
hdct
result
overal
surviv
os
sr
patient
hr
patient
follow
unfavor
prognost
factor
neuroblastoma
use
studi
child
age
time
make
diagnosi
stage
amplif
depend
child
age
os
patient
year
age
os
patient
age
year
also
analyz
surviv
rate
hr
patient
base
whether
patient
amplif
os
neg
subject
posit
subject
current
os
patient
treat
tandem
hdht
autolog
stem
cell
support
conclus
depend
therapeut
program
use
os
hr
patient
result
treatment
hr
patient
receiv
tandem
hdht
autolog
steam
cell
support
encourag
tandem
peripher
blood
stem
cell
transplant
children
neuroblastoma
g
klymnyuk
pavlyk
e
shayda
n
khranovska
pediatr
nation
cancer
institut
ukrain
kiev
ukrain
experiment
oncolog
nation
cancer
institut
ukrain
kiev
ukrain
object
base
result
recent
investig
applic
autolog
stem
cell
tandem
transplant
tt
could
improv
treatment
result
patient
malign
solid
tumor
nowaday
tt
investig
medulloblastoma
germ
cell
tumor
neuroblastoma
nevertheless
effect
convinc
result
nt
obtain
method
year
depart
pediatr
oncolog
nation
cancer
institut
carri
tandem
transplant
children
neuroblastoma
patient
age
year
pt
primari
neuroblastoma
got
tt
chemotherapi
protocol
pt
consolid
relaps
therapi
first
part
tandem
chemotherapi
bumel
patient
ten
patient
regimen
second
part
tandem
transplant
three
patient
cem
regimen
time
interv
part
tandem
month
autolog
transplant
use
peripher
stem
cell
patient
receiv
retino
acid
convent
treatment
result
patient
success
complet
first
chemotherapi
wbc
count
recov
l
day
plt
count
recov
day
pbsc
one
patient
observ
neurotox
like
short
clonic
tonic
seizur
second
chemotherapi
chemotherapi
cancel
immedi
patient
receiv
dose
cyclophosphamid
topotecan
full
dose
neutropenia
thrombocytopenia
rate
oral
mucos
differ
degre
sever
patient
wbc
count
recov
l
day
plt
count
recov
day
current
patient
cr
patient
earli
relaps
continu
treatment
die
pd
period
accomplish
tt
month
conclus
applic
tt
children
neuroblastoma
result
surviv
rate
overal
surviv
rate
surgic
approach
thorac
inlet
tumor
aris
symphathet
chain
children
singl
institut
experi
qw
lee
hy
chua
depart
pediatr
surgeri
kandang
kerbau
women
children
hospit
singapor
singapor
object
neuroblastoma
nb
commonest
pediatr
solid
tumor
singapor
nb
aris
thorac
inlet
may
carri
better
prognosi
despit
challeng
surgic
access
area
examin
center
experi
tumor
method
irb
approv
clinic
chart
patient
thorac
inlet
tumor
fulfil
intern
classif
diseas
oncolog
neuroblastoma
ganglioneuroblastoma
ganglioneuroma
manag
center
review
result
femal
male
median
age
month
old
month
month
age
three
patient
neuroblastoma
one
ganglioneuroblastoma
one
ganglioneuroma
amongst
neuroblastoma
stage
diseas
boni
metastas
stage
diseas
enlarg
neck
mass
one
neck
abscess
follow
chemotherapi
anterior
thoracotomi
perform
first
patient
thoracoscop
assist
resect
perform
one
upfront
resect
perform
ganglioneuroblastoma
resect
use
da
vinci
robot
perform
ganglioneuroma
patient
horner
syndrom
improv
time
one
patient
phrenic
resolv
asid
child
stage
nb
patient
well
residu
diseas
mean
month
month
month
one
child
succumb
refractori
bone
marrow
diseas
conclus
thorac
inlet
pose
challeng
resect
nb
site
matur
element
tumor
may
lend
favour
prognosi
minim
invas
approach
allow
superior
visual
anatomi
anterior
thoracotomi
facilit
dissect
around
critic
structur
three
case
report
pediatr
atyp
neuroblastoma
li
l
liu
pediatr
hematologyoncolog
sun
memori
hospit
sun
univers
guangzhou
china
object
show
clinic
characterist
atyp
neuroblastoma
three
chines
pediatr
patient
method
retrospect
analysi
made
three
case
atyp
neuroblastoma
result
atyp
neuoblastoma
refer
primari
onset
neuroblastoma
without
detect
mass
common
site
bone
marrow
orand
metastasi
part
infrequ
occurr
present
three
unusu
case
chines
atyp
neuroblastoma
extramedullari
substanti
mass
found
moreov
three
case
present
typic
neuroblastoma
cell
form
rosett
bone
marrow
smear
diagnosi
neuroblastoma
establish
markedli
elev
vanillylmandel
acid
vma
urin
serum
enolas
nse
neuroblastoma
mrd
level
peripher
blood
amplif
bone
marrow
absent
noteworthi
first
case
show
part
tumor
infiltr
addit
bone
marrow
second
case
third
case
involv
neurobalstoma
bone
marrow
bone
three
patient
treat
nine
cours
induct
chemotherapi
neuroblastoma
protocol
includ
cav
cyclophosphamidepirarubicinvincristin
pvp
cisplatinum
etoposid
ct
cyclophosphamidetopotecan
although
first
patient
achiv
complet
remiss
child
free
recurr
half
year
due
lack
consolid
chemotherapi
second
case
contrast
complet
remiss
obtain
abandon
treatment
econom
reason
third
case
achiev
partial
remiss
entir
induct
chemotherapi
experi
consolid
chemotherapi
present
conclus
case
atyp
neuroblastoma
chemotherapi
might
effect
firstlin
treatment
absens
visibl
solid
mass
limit
experi
seem
patient
atyp
neuroblastoma
unfavor
prognosi
convent
intens
chemotherapi
especi
presenc
bone
involv
effect
arsen
trioxid
convent
chemotherapeut
drug
express
human
neuroblastoma
cell
line
l
liu
li
pediatr
hematologyoncolog
sun
memori
hospit
sun
univers
guangzhou
china
object
aim
studi
investig
effect
arsen
trioxid
convent
chemotherapeut
drug
apoptosi
express
neuroblastoma
cell
method
chang
express
level
measur
western
blot
cell
incub
variou
drug
includ
cisplatin
ddp
etoposid
flow
cytometri
annexin
stain
use
monitor
abil
induc
cell
apoptosi
result
previou
studi
found
may
potent
agent
human
neuroblastoma
cell
line
result
determin
find
report
previous
shown
toxic
effect
cell
via
induct
apoptosi
treatment
found
western
analysi
show
express
began
decreas
micromolar
rang
exposur
decreas
exposur
express
reduc
mostli
rapidli
howev
express
cell
increas
treat
ddp
drug
concentr
effect
time
increas
conclus
show
exert
effect
cell
via
induct
apoptosi
find
western
analysi
provid
experiment
evid
low
dose
reduc
express
human
neuroblastoma
cell
line
contrari
convent
chemotherapeut
drug
increas
express
taken
togeth
propos
probabl
substrat
extrud
cell
reduc
cellular
express
multidisciplinari
treatment
high
risk
neuroblastoma
beij
children
hospit
result
x
jin
dw
zhang
mq
qin
b
wang
x
zhou
hm
wang
h
qin
cj
zhou
q
zeng
hematolog
oncolog
center
beij
children
hospit
capit
medic
univers
beij
china
oncolog
surgeri
beij
children
hospit
capit
medic
univers
beij
china
patholog
depart
beij
children
hospit
capit
medic
univers
beij
china
thorac
surgeri
beij
children
hospit
capit
medic
univers
beij
china
object
beij
children
hospit
bch
establish
multidisciplinari
program
neuroblastoma
nb
sinc
earli
summar
nb
bch
result
method
retrospect
review
medic
record
children
present
clinic
andor
histolog
confirm
nb
apr
march
must
year
age
stage
iii
unresect
iv
patient
tumour
genom
copi
number
irrespect
stage
age
elig
multimod
treatment
protocol
includ
intens
chemotherapi
surgeri
radiat
therapi
local
control
follow
autolog
haematopoiet
stem
cell
transplant
consolid
therapi
also
isotretinoin
mainten
treatment
total
cours
children
follow
dec
result
total
children
femal
median
age
month
primari
postmediastin
tumor
retroperiton
pelvic
tumor
patient
fulli
known
biolog
featur
case
nb
nb
chemotherapi
chang
case
ganglioneuroblastoma
one
ganglioneuroma
gene
amplif
fish
children
treat
regularli
median
time
month
follow
occur
event
relaps
stop
treatment
median
month
tumor
progress
patient
die
sever
infect
use
analysi
show
expect
overal
surviv
rate
conclus
prognosi
far
lower
common
childhood
leukemia
lymphoma
import
role
multidisciplinari
treatment
order
improv
children
surviv
rate
moreov
still
possibl
recurr
relaps
stop
treatment
year
follow
necessari
compar
studi
pet
mibg
diagnosi
manag
neuroblastoma
e
moussa
mf
fawzi
ah
hamouda
az
zaher
oh
hassanain
sa
azmi
clinic
oncolog
menoufia
univers
cairo
egypt
pediatr
oncolog
nation
cancer
institut
cairo
egypt
nuclear
medicin
nation
cancer
institut
cairo
egypt
research
children
cancer
hospit
cairo
egypt
object
convent
radiopharmaceut
imag
neuroblastoma
diagnosi
sensit
specif
nearli
although
neuroblastoma
cell
concentr
sever
conflict
result
pet
scan
evalu
neuroblastoma
report
purpos
studi
prospect
evalu
diagnost
signific
petct
imag
compar
diagnost
prognost
valu
scintigraphi
patient
neuroblastoma
differ
phase
diseas
method
total
patient
male
femal
less
year
diagnos
treat
children
cancer
accord
cog
high
risk
patient
cog
intermedi
risk
patient
pet
scan
within
month
diagnosi
differ
point
manag
result
scan
mibg
pet
examin
patient
differ
manag
stage
comparison
ct
scan
primari
tumor
site
bone
scan
bone
involv
bone
marrow
biopsi
result
bone
marrow
infiltr
pet
scan
posit
scan
primari
site
bone
involv
bone
marrow
infiltr
wherea
mibg
scan
posit
primari
site
bone
bone
marrow
infiltr
pet
scan
sensit
mibg
detect
primari
tumor
pet
versu
mibg
detect
bone
metastas
pet
versu
mibg
bone
marrow
involv
pet
versu
mibg
incorpor
modal
lead
better
treatment
decis
conclus
author
recommend
use
petct
evalu
primari
tumor
either
diagnosi
differ
stage
therapi
although
extend
doubl
blind
studi
need
neuroblastoma
patient
month
singl
institut
experi
argentina
rossa
w
cacciavillano
rose
cadario
j
lopez
marti
g
chantada
p
zubizarreta
hematologia
oncologia
hospit
jp
garrahan
ciudad
de
bueno
air
argentina
cirugia
hospit
jp
garrahan
ciudad
de
bueno
air
argentina
hospit
jp
garrahan
ciudad
de
bueno
air
argentina
object
evalu
outcom
patient
month
diagnos
neuroblastoma
method
april
octob
consecut
patient
retrospect
review
result
mean
age
month
month
frequent
site
adren
gland
n
paravertebr
n
site
involv
n
cervic
n
mediastin
n
histopatholog
diagnosi
poorli
differenti
neuroblastoma
n
differenti
n
metastat
neuroblastoma
n
intermix
ganglioneuroblastoma
n
neuroblastoma
uncharacter
n
biopsi
n
amplif
detect
patient
studi
delet
patient
without
evalu
aberr
one
patient
patient
studi
accord
inrg
pretreat
classif
schema
patient
belong
categori
receiv
chemotherapi
n
surgeri
n
chemotherapysurgeri
n
observ
n
nine
patient
categori
receiv
chemotherapi
surgic
treatment
surgerychemotherapi
amplifi
seven
patient
stage
amplif
one
one
aberr
amplif
receiv
treatment
n
group
n
three
patient
classifi
stage
ms
one
receiv
treatment
intermedi
group
median
month
month
month
ef
patient
se
os
se
signific
differ
found
os
ef
patient
stage
ms
vs
stage
ef
stage
se
ms
vs
se
p
os
se
ms
vs
se
p
conclus
although
os
ef
result
similar
report
intern
studi
improv
obtain
result
biolog
prognost
factor
warrant
accur
stage
consequ
appropri
treatment
retrospect
evalu
clinic
characterist
outcom
patient
neuroblastoma
treat
children
cancer
institut
lebanon
f
saad
r
nader
akel
abboud
muwakkit
h
el
solh
r
saab
pediatr
adolesc
medicin
american
univers
beirut
beirut
lebanon
intern
medicin
american
univers
beirut
beirut
lebanon
surgeri
american
univers
beirut
beirut
lebanon
object
evalu
clinic
characterist
outcom
patient
neuroblastoma
treat
children
cancer
institut
lebanon
method
clinic
data
patient
diagnos
april
decemb
singl
multidisciplinari
center
retrospect
analyz
risk
stratif
base
children
oncolog
group
cog
studi
result
patient
diseas
median
age
diagnosi
year
rang
year
ratio
median
month
rang
month
base
intern
neuroblastoma
stage
system
patient
stage
iv
diseas
amplifi
test
tumor
patient
treat
per
protocol
n
achiev
complet
respons
cr
n
progress
diseas
therapi
pd
sixteen
patient
underw
autolog
transplant
asct
consolid
therapi
rest
qualifi
due
poor
respons
n
relaps
consolid
n
thirteen
patient
receiv
radiotherapi
part
local
control
reason
receiv
radiotherapi
includ
pd
n
death
toxic
n
current
n
patient
aliv
median
time
year
eight
patient
two
eleven
patient
die
eight
due
tumor
progress
due
toxic
consolid
cn
toxoplasmosi
failur
engraft
sinusoid
obstruct
syndrom
respect
conclus
overal
surviv
neuroblastoma
lebanon
seem
compar
develop
countri
multimod
therapi
given
multidisciplinari
set
improv
like
depend
avail
novel
therapi
yet
easili
access
develop
countri
european
clinic
trial
direct
impact
trial
implement
line
behalf
siopen
cooper
group
v
segura
alpash
dicataldo
g
schleiermach
jd
v
mosseri
v
papadaki
k
wheeler
r
ladenstein
paediatr
oncolog
instituto
de
investigacion
sanitaria
la
fe
valencia
spain
studi
statist
integr
research
project
st
anna
kinderkrebsforschung
viena
austria
pediatr
hematolog
oncolog
univers
catania
catania
itali
depart
pediatr
oncolog
institut
curi
pari
franc
departamento
de
universidad
de
valencia
valencia
spain
servic
de
biostatistiqu
institut
curi
pari
franc
depart
pediatr
aghia
sophia
children
hospit
athen
greec
depart
paediatr
haematolog
oncolog
oxford
children
hospit
oxford
unit
kingdom
unidad
de
hospit
universitario
la
fe
valencia
spain
object
european
low
intermedi
risk
neuroblastoma
line
eudract
http
clinicaltrialsgov
identifi
intern
siopen
clinic
trial
framework
encca
project
european
network
cancer
research
children
adolesc
line
stratifi
patient
treatment
accord
biolog
clinic
marker
order
minim
treatment
burden
patient
previou
studi
shown
excel
outcom
ii
intensifi
treatment
patient
biolog
unfavour
mycn
amplifi
neuroblastoma
improv
outcom
method
line
includ
ten
separ
therapeut
group
one
randomis
case
regist
databas
monitor
qualiti
prospect
enter
stage
data
includ
real
time
central
review
biolog
histolog
neonat
adren
mass
nam
infant
month
also
regist
observ
without
initi
surgeri
result
line
iislaf
first
launch
spain
site
juli
open
itali
site
austria
site
denmark
site
franc
site
norway
site
israel
site
belgium
site
author
switzerland
ireland
slovenia
new
zeeland
expect
author
come
month
summari
expect
particip
countri
open
recruit
patient
enrol
group
low
risk
intermedi
risk
nam
last
year
conclus
sinc
european
clinic
trial
direct
implement
difficult
launch
academ
pediatr
cancer
trial
due
high
cost
addit
nation
requir
bureaucraci
delay
clinic
trial
initi
hope
new
clinic
trial
regul
bring
process
harmonis
shorten
timelin
across
europ
cknowledg
encca
grant
ganglioneuroma
singl
center
experi
russia
shamanskaya
kachanov
g
muftahova
olshanskaya
e
andreev
v
roschin
likar
varfolomeeva
clinic
oncolog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
laboratori
cytogenet
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
surgeri
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
patholog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
nuclear
medicin
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
ganglioneuroma
rare
benign
tumor
sympathet
nervou
system
standard
care
includ
indic
surgeri
radiat
therapi
rare
condit
determin
aim
studi
analyz
clinic
featur
outcom
cohort
patient
singl
center
russia
method
patient
sympathet
nervou
tumor
treat
period
initi
includ
ctmri
primari
site
tumor
marker
mibg
scintigraphi
bone
marrow
evalu
patholog
diagnosi
done
accord
intern
neuroblastoma
patholog
classif
patient
stratifi
treat
accord
protocol
surgeri
treatment
choic
patient
without
risk
factor
result
ganglioneuroma
confirm
histolog
case
primari
gn
diagnos
patient
secondari
patient
oper
cycl
chemotherapi
ratio
patient
older
year
median
age
month
rang
patient
primari
gn
symptomat
time
diagnosi
mild
pain
common
symptom
distribut
patient
primari
site
retpoperitoneum
posterior
mediastinum
presacr
elev
enolas
level
upper
limit
patient
tumor
extent
surgeri
gross
total
resect
macroscop
residu
tumor
biopsi
surgeri
limit
biopsi
major
vessel
involv
patient
presacr
retroperitoneum
local
median
month
rang
patient
aliv
without
evid
diseas
progress
two
patient
biopsi
show
progress
tumor
symptom
conclus
surgic
treatment
depend
presenc
risk
factor
case
risk
factor
benefit
surgeri
balanc
risk
sever
morbid
analysi
short
term
efficaci
case
children
neuroblastoma
j
shao
hemotologyoncolog
shanghai
children
hospit
shanghai
china
object
retrospect
analysi
case
children
neuroblastoma
nb
correl
short
term
efficaci
prognost
factor
method
total
newli
diagnos
nb
patient
juli
june
divid
low
risk
lr
medium
risk
mr
high
risk
hr
group
depend
age
clinic
stage
chemotherapi
acid
andor
second
tumor
resect
use
end
treatment
refer
differ
risk
group
result
accord
inss
number
case
stage
ii
iii
iv
iv
respect
follow
dec
case
achiev
complet
remiss
cr
partial
remiss
pr
overal
surviv
os
stage
ii
iii
iv
iv
ef
p
os
ef
lr
mr
hr
p
case
diagnos
patholog
diagnosi
whose
differ
histopatholog
subtyp
stroma
mitosi
karyorrhexi
index
mki
statist
signific
surviv
year
os
ef
obvious
higher
patient
favor
histolog
fh
one
unfavor
histolog
uh
p
univari
statist
analysi
show
factor
significantli
correl
prognosi
age
stage
risk
group
p
age
bone
marrow
metastasi
diagnosi
risk
group
import
event
nb
patient
p
conclus
stage
risk
group
age
import
prognost
factor
nb
absenc
data
month
divid
line
prognosi
patient
histolog
categori
combin
age
mki
patholog
favor
predict
prognosi
nb
patient
diagnost
implic
oncogen
amplif
unilater
pediatr
renal
tumor
case
report
sharma
rn
makroo
chowdhri
p
srivastava
mishra
singh
thakur
molecular
biolog
transplant
immunolog
indraprastha
apollo
hospit
new
delhi
india
object
renal
tumor
childhood
occasion
exhibit
histopatholog
clinic
featur
prevent
accur
diagnosi
molecular
cell
cultur
techniqu
may
help
better
character
case
method
case
report
fish
use
examin
unusu
renal
tumor
month
old
femal
establish
accur
assess
tumor
stratifi
risk
group
fish
test
perform
formalin
fix
paraffin
embed
tissu
supraren
area
use
commerci
avail
probe
result
histopatholog
evalu
right
kidney
show
featur
wilm
tumor
predomin
epitheli
compon
resect
margin
uret
capsul
free
tumor
also
mass
right
supraren
area
histopatholog
show
featur
suggest
undifferenti
neuroblastoma
three
lymph
node
isol
hilar
area
show
deposit
wilm
tumor
fish
analys
supra
renal
mass
reveal
amplif
gene
thu
favour
neuroblastoma
conclus
although
histopatholog
featur
could
clearli
distinguish
wilm
tumor
neuroblastoma
gene
amplif
strongli
suggest
neoplasm
would
behav
aggress
neuroblastoma
fish
analys
therefor
contribut
revis
diagnosi
neuroblastoma
effect
approach
case
dilemma
occur
treatment
outcom
neuroblastoma
treat
accord
german
nb
protocol
e
shorikov
druy
tuponogov
lemesheva
popova
zaichikov
chusovitin
vyatkin
g
tsaur
popov
l
saveliev
l
fechina
pediatr
oncolog
hematolog
region
children
hospitalresearch
institut
medic
cell
technolog
yekaterinburg
russia
pediatr
oncolog
hematolog
region
children
hospit
yekaterinburg
russia
pediatr
oncolog
hematolog
ural
state
medic
academi
yekaterinburg
russia
object
retrospectiveevalu
treatment
outcom
patient
observ
og
mrg
group
protocol
method
among
children
primari
neuroblastoma
treat
accord
hospit
decemb
till
octob
patient
stratifi
og
one
refer
mrg
median
age
ogmrg
patient
month
rang
year
patient
distribut
stage
follow
stage
children
stage
ii
iii
iv
iv
diagnos
patient
respect
median
follow
period
month
result
patient
og
stage
iii
stage
iv
chemotherapi
start
immedi
diagnosi
huge
size
primari
tumor
symptom
patient
mrg
treat
accord
arm
present
time
patient
aliv
aliv
without
progress
unfavor
event
regist
case
among
relaps
case
progress
diseas
death
patient
die
tumor
progress
ef
whole
group
os
ef
os
patient
og
mrg
differ
significantli
vs
p
vs
p
respect
worst
prognosi
patient
stage
iv
comparison
children
ef
vs
p
os
vs
p
correspondingli
worst
outcom
patient
stage
iv
comparison
children
ef
vs
p
os
vs
p
correspondingli
conclus
prognosi
children
neuroblastoma
excel
exist
protocol
criteria
patient
stratif
demonstr
effect
major
case
allow
reduc
treatment
intens
local
abdomin
neuroblastoma
present
rare
associ
siddaiahgari
makadia
pediatr
rainbow
children
hospit
hyderabad
india
object
describ
rare
associ
local
abdomin
neuroblastoma
chylothorax
method
year
old
male
present
respiratori
distress
secondari
chylothorax
found
abdomin
neuroblastoma
result
year
male
present
one
month
fever
abdomin
pain
distent
develop
breath
difficulti
day
prior
present
greenish
discolor
left
upper
chest
day
tachycard
tachypn
retractio
ns
along
reduc
air
entri
left
side
chest
abdomen
distend
left
upper
quadrant
palpabl
mass
initi
hemogram
show
hb
gm
paramet
normal
chest
show
left
pleural
effus
usg
abdomen
show
larg
well
defin
lobul
solid
mass
cm
lesion
area
necrosi
left
supraren
region
compress
renal
vessel
encas
pleural
fluid
tap
analyz
milki
white
fluid
specif
graviti
leukocyt
count
l
lymphocyt
triglycerid
cholesterol
content
mgdl
respect
lipoprotein
electrophoresi
fluid
show
chylomicron
band
conclus
chylothorax
usg
guid
biopsi
abdomin
mass
hpe
immunohistochemistri
suggest
neuroblastoma
nse
chromogrannin
posit
initi
stabil
patient
start
chemotherapi
rapid
cojec
start
octreotid
continu
week
control
chylothorax
symptomat
reaccumul
rapidli
post
tap
post
rapid
cojec
mass
resect
follow
autolog
stem
cell
therapi
n
myc
amplifi
conclus
thorac
neuroblastoma
produc
chylothorax
due
either
extrins
compress
infiltr
thorac
duct
caus
increas
intraduct
pressur
case
interestingli
abdomin
neuroblastoma
present
chylothorax
describ
earlier
resolv
week
chemotherapi
octreotid
improv
trend
surviv
outcom
high
risk
neuroblastoma
singapor
sy
soh
chan
tan
paediatr
haematologyoncolog
servic
kk
women
children
hospit
singapor
singapor
object
neuroblastoma
patient
singapor
treat
chemotherapi
surgeri
myeloabl
therapi
mat
radiat
acid
mainten
retrospect
review
characterist
treatment
practic
outcom
patient
seen
kk
women
children
hospit
kkh
largest
pediatr
unit
singapor
method
studi
approv
singhealth
central
institut
review
board
includ
patient
inss
stage
diagnosi
stage
treat
kkh
year
exclud
patient
came
second
opinion
surgeri
divid
patient
earlier
cohort
later
cohort
cohort
comparison
result
patient
cohort
cohort
median
age
diagnosi
month
rang
month
year
male
major
stage
diseas
stage
diseas
chang
manag
identifi
nmyc
statu
avail
patient
cohort
cohort
chemotherapi
opecojec
modifi
mat
condit
consist
cisplatin
teniposid
doxorubicin
melphalan
withwithout
tbi
modifi
tbi
omit
patient
underw
mat
cohort
cohort
patient
cohort
cohort
die
diseas
two
die
sepsi
overal
surviv
cohort
cohort
conclus
although
number
small
trend
encourag
could
explain
multipl
factor
regim
surgeri
support
care
dedic
team
uniform
practic
hope
result
continu
improv
avail
futur
immunotherapi
mibg
therapi
novel
agent
modal
role
pathway
abnorm
neuroblastoma
prognosi
n
svergun
g
klymnyuk
n
khranovska
skachkova
inomistova
pavlyk
shaida
experiment
oncolog
depart
nation
cancer
institut
mph
ukrain
kiev
ukrain
children
oncolog
depart
nation
cancer
institut
mph
ukrain
kiev
ukrain
object
abnorm
pathway
present
neuroblastoma
nb
case
diagnosi
occur
predominantli
hyperexpress
inactiv
aim
studi
estim
role
pathway
abnorm
neuroblastoma
prognosi
method
case
group
compris
patient
histolog
confirm
nb
median
age
month
rang
month
stage
stage
tumor
patient
treat
accord
risk
group
intern
standard
protocol
primari
tumor
tissu
obtain
patient
diagnosi
use
analysi
delet
mycn
gene
amplif
detect
fish
method
gene
express
level
analyz
taqman
real
time
result
delet
observ
one
case
nb
express
level
increas
proport
stage
diseas
p
maximum
valu
stage
iv
express
level
higher
tumor
without
mycn
amplif
p
primari
resist
tumor
significantli
higher
level
gene
express
compar
chemotherapi
sensit
tumor
p
roc
analysi
reveal
express
level
import
marker
associ
surviv
ef
primari
childhood
nb
patient
se
sp
auc
p
tumor
categor
two
group
high
low
express
base
cutoff
point
optim
criterion
determin
roc
analysi
high
express
associ
reduc
ef
nb
patient
ef
rate
nb
patient
high
express
compar
patient
low
express
p
conclus
result
suggest
possibl
involv
clinic
behavior
nb
inhibit
restor
activ
sensit
nb
cell
apoptosi
clinic
featur
treatment
outcom
neuroblastoma
patient
singl
center
experi
turkey
f
akici
tugcu
g
aydogan
z
salcioglu
akcay
h
sen
gokc
g
keskindemirci
b
bilgic
sander
pediatr
kanuni
sultan
suleyman
train
research
hospit
istanbul
turkey
patholog
istanbul
univers
istanbul
medic
school
istanbul
turkey
pediatr
surgeri
kanuni
sultan
suleyman
train
research
hospit
istanbul
turkey
object
neuroblastoma
common
extracrani
solid
tumor
childhood
prognost
factor
age
stage
cytogenet
profil
use
risk
stratif
treatment
assign
method
studi
demograph
data
clinic
outcom
neuroblastoma
case
evalu
within
therapeut
result
treat
ipog
tpog
protocol
compar
result
median
age
month
month
primari
local
abdomen
patient
local
surren
mediastinum
cervic
paraspin
accord
inss
system
patient
classifi
stage
stage
ii
stage
iii
stage
iv
stage
iv
frequent
site
metastasi
bone
marrow
bone
liver
patient
advanc
stage
receiv
chemotherapi
patient
modifi
chemotherapi
patient
opec
patient
turkish
pediatr
oncolog
protocol
patient
chemotherapi
radiotherapi
five
year
gener
surviv
found
diseas
free
surviv
month
month
relaps
detect
patient
year
gener
surviv
yr
ef
icog
group
tpog
group
event
free
surviv
month
old
upper
month
old
signific
diferanti
two
group
p
surviv
differ
accord
stage
ten
year
gener
surviv
stage
iii
iv
respect
ten
year
surviv
stage
iii
iv
respect
conclus
conclus
surviv
rate
neuroblastoma
improv
last
decad
center
simul
spectmr
attenu
correct
demonstr
potenti
uptak
quantif
neuroblastoma
hj
wallac
ms
bradnam
aa
bolster
j
foster
watt
gj
irwin
h
kaur
rongh
j
sastri
murphi
depart
clinic
physic
bioengin
greater
glasgow
clyde
health
board
univers
glasgow
glasgow
unit
kingdom
radiolog
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
oncolog
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
object
neuroblastoma
extrem
heterogen
cancer
requir
multitud
diagnost
test
includ
imag
scintigraphi
mri
audit
rhsc
mibg
clinic
report
suggest
quantif
radionuclid
uptak
would
use
case
one
major
confound
accur
uptak
quantif
photon
attenu
correct
use
attenu
correct
ac
deriv
spectct
howev
ct
introduc
addit
radiat
burden
altern
approach
would
deriv
ac
mri
data
petmr
sequenc
enabl
segment
soft
tissu
lack
abil
discrimin
cortic
bone
purpos
studi
simul
evalu
mrac
spect
use
readili
avail
spectct
dataset
adult
bone
scan
method
eleven
sequenti
bone
spectct
scan
select
gri
nuclear
medicin
databas
ct
dataset
segment
five
tissu
type
air
lung
soft
tissu
water
adipos
tissu
cortic
bone
adipos
tissu
water
assign
popul
averag
hounsfield
unit
valu
cortic
bone
assign
valu
water
simul
morpholog
fill
process
mrac
spect
reconstruct
compar
correspond
ctac
spect
visual
assess
voxel
valu
analysi
result
visual
assess
identifi
clinic
signific
chang
mrac
spect
dataset
voxel
valu
analysi
show
spect
uptak
reduc
averag
compar
ctac
conclus
mrac
produc
qualit
similar
spect
imag
ctac
averag
reduct
radionuclid
uptak
quot
petmr
literatur
threshold
clinic
signific
practic
use
sophist
approach
enabl
averag
voxel
error
improv
base
studi
mrac
feasibl
spect
reconstruct
provid
superior
baselin
spect
scan
quantif
neuroblastoma
without
addit
patient
dose
local
advanc
cervic
neuroblastoma
present
prenat
period
weismil
cullen
j
haouilou
lorenzana
gener
surgeri
provid
hospit
medic
center
southfield
usa
pediatr
surgeri
st
john
hospit
medic
center
detroit
usa
vascular
surgeri
st
john
hospit
medic
center
detroit
usa
pediatr
hematologyoncolog
st
john
hospit
medic
center
detroit
usa
object
describ
local
advanc
neonat
cervic
neuroblastoma
first
detect
antenat
ultrasound
method
congenit
cervic
neuroblastoma
extrem
rare
repres
less
one
percent
neonat
neonat
case
stage
stage
small
abdomin
primari
describ
congenit
cervic
neuroblastoma
identifi
antenat
ultrasound
week
gestat
ultim
proven
stage
result
postnat
urinari
vma
vanillylmandel
acid
high
mgg
normal
mgg
uhva
homovanil
acid
mgg
normal
mgg
postnat
ultrasound
show
cm
solid
mass
calcif
mri
show
mass
extend
thorac
inlet
base
skull
mass
compress
involv
surround
structur
includ
carotid
arteri
trachea
thyroid
parotid
gland
figur
complet
resect
lymphadenectomi
perform
tumor
complet
effac
partial
encas
common
carotid
arteri
greater
percent
carotid
bifurc
intern
extern
jugular
vein
percent
displac
compress
trachea
medial
elev
parotid
gland
superiorli
vagu
nerv
encas
preserv
capsular
incis
meticul
neurolysi
five
lymph
node
posit
mki
mitot
karyorrhet
index
low
dna
index
greater
one
postop
mibg
scan
reveal
asymmetr
uptak
left
neck
felt
repres
salivari
gland
rather
metastat
diseas
tumor
classifi
low
risk
infant
follow
serial
lab
examin
conclus
repres
uniqu
case
local
advanc
neonat
cervic
neuroblastoma
success
treat
surgic
excis
without
need
chemotherapi
irinotecan
temozolamid
effect
schedul
progress
therapi
resist
neuroblastoma
experi
polish
pediatr
solid
tumor
group
wieczorek
stypinska
hennig
wieczorek
zubowska
k
g
ussowicz
w
balwierz
pediatr
oncologyhematolog
institut
pediatr
jagiellonian
univers
med
colleg
krakow
poland
pediatr
oncolog
children
memori
health
institut
warsaw
poland
pediatr
hematolog
oncolog
medic
univers
gdansk
gdansk
poland
pediatr
oncolog
chorzow
center
pediatr
oncolog
chorzow
poland
pediatr
oncolog
hematolog
bone
marrow
transplant
medic
univers
poznan
poland
oncolog
hematolog
diabetolog
medic
univers
lodz
poland
pediatr
hematolog
oncolog
nicolau
copernicu
univers
torun
collegium
medicum
bydgoszcz
bydgoszcz
poland
pediatr
oncolog
hematolog
chemotherapi
medic
univers
silesia
upper
silesia
children
care
health
centr
katowic
poland
bone
marrow
transplant
pediatr
oncolog
hematolog
medic
univers
wroclaw
poland
object
irinotecantemozolamid
chemotherapi
kushner
evalu
possibl
therapi
schedul
progress
therapi
resist
neuroblastoma
nbl
patient
treat
center
polish
pediatr
solid
tumor
group
endpoint
studi
best
respons
overal
surviv
os
pf
side
effect
qualiti
life
method
patient
treat
includ
n
therapi
failur
diagnos
employ
patient
stage
stage
stage
stage
stage
diagnosi
age
month
diagnosi
patient
treat
previou
chemotherapi
seven
patient
primari
resist
diseas
first
least
second
therapi
failur
four
patient
addit
vincristin
exclud
object
respons
observ
patient
cr
pr
sd
result
number
cycl
respond
patient
median
patient
aliv
cr
pr
sd
receiv
addit
chemotherapi
patient
receiv
hsct
autolog
allogen
case
mibg
therapi
radiotherapi
ra
cycl
one
immunotherapi
mean
os
month
pf
employ
month
month
advers
event
observ
case
diarrhea
present
patient
cure
loperamid
case
atropin
necessari
hematolog
toxic
patient
requir
modif
drug
dosag
frequenc
heavili
bone
marrow
involv
conclus
chemotherapi
accept
patient
parent
gener
patient
requir
hospit
cycl
found
effect
therapeut
option
intens
palli
treatment
clinic
featur
prognost
factor
chines
children
neuroblastoma
xy
yuan
x
z
tan
q
sheng
q
zhang
mw
jiang
ym
wu
pediatr
hematologyoncolog
xinhua
hospit
affili
shanghai
jiaotong
univers
school
medicin
shanghai
china
dept
oncologyradiotherapi
xinhua
hospit
affili
shanghai
jiaotong
univers
school
medicin
shanghai
china
dept
pediatr
surgeri
xinhua
hospit
affili
shanghai
jiaotong
univers
school
medicin
shanghai
china
object
explor
clinic
featur
prognost
factor
chines
children
neuroblastoma
nb
method
one
hundr
three
nb
patient
regist
hospit
jan
dec
clinic
data
prognost
factor
retrospect
analys
use
surviv
analysi
result
newli
diagnos
nb
children
enrol
studi
median
age
onset
month
month
male
femal
ratio
median
time
month
month
overal
surviv
os
surviv
ef
total
fourteen
recurr
case
observ
median
interv
initi
diagnosi
relaps
month
month
os
relaps
patient
whose
recurr
time
later
month
diagnosi
higher
relaps
within
month
vs
p
among
death
lead
caus
sever
chemotherapi
infect
follow
death
due
tumor
progress
univari
analysi
reveal
inss
stage
iii
stage
iv
ldh
ul
bone
metastas
amplif
neg
prognost
factor
multivari
analysi
suggest
inss
stage
amplif
independ
prognost
factor
conclus
inss
stage
amplif
independ
prognost
factor
chines
children
nb
death
caus
sever
infect
paid
attent
patient
relaps
within
month
diagnosi
inferior
prognosi
patient
stage
ii
recurr
situ
could
acquir
surviv
treat
time
report
stage
neuroblastoma
zhang
jy
tang
c
pan
qd
ye
zhou
j
chen
cy
luo
jm
wang
yj
tang
hl
xue
sh
shen
hematologyoncolog
shanghai
children
medic
center
medic
colleg
shanghai
jiaotong
univers
shanghai
china
object
evalu
outcom
childhood
stage
neuroblastoma
nb
correl
prognost
factor
method
comprehens
protocol
includ
tumor
resect
intens
chemotherapi
radiotherapi
abmt
design
put
practic
total
nb
stage
patient
shanghai
children
medic
center
collect
june
decemb
treat
accord
comprehens
protocol
clinic
featur
therapeut
effect
differ
period
outcom
prognost
factor
analyz
result
among
patient
patient
nt
complet
treatment
parent
decis
although
patient
turn
becom
better
rest
complet
protocol
case
achiev
verygood
partial
remiss
vgpr
achiev
partial
remiss
pr
anoth
case
progress
treatment
effici
rate
includ
vgprpr
treatment
median
period
month
case
patient
lost
median
month
year
event
free
surviv
ef
patient
respect
age
month
poor
cur
effect
fail
achiev
vgpr
end
treatment
high
level
ldh
normal
valu
bone
marrow
involv
poor
prognost
factor
chi
p
multivari
estim
hazard
age
poor
cur
effect
high
level
ldh
associ
wors
surviv
p
brain
metastasi
predict
wors
outcom
death
rate
compar
tradit
chemotherapi
topotecan
includ
chemotherapi
could
improv
effici
vs
p
outcom
year
ef
vs
p
stage
nb
conclus
prognosi
neuroblastoma
stage
remain
poor
age
month
poor
cur
effect
high
level
ldh
normal
valu
bone
marrow
infiltr
associ
wors
prognosi
brain
metastasi
predict
worst
death
rate
topotecan
includ
chemotherapi
could
prove
effect
studi
clinic
efficaci
analysi
case
infant
neuroblastoma
zhang
w
zhang
huang
pediatr
beij
tongren
hospit
capit
medic
univers
beij
china
object
purpos
paper
analysi
clinic
characterist
clinic
efficaci
nb
less
old
method
case
infant
nb
confirm
diagnosi
use
patholog
imag
februari
august
case
male
case
femal
median
age
case
stage
case
stage
case
special
stage
combin
chemotherapi
oper
statist
analysi
primari
site
first
symptom
characterist
level
serum
nse
chemotherapi
efficaci
prognosi
result
case
less
month
old
account
case
month
old
account
case
month
old
account
patient
case
middl
risk
group
account
case
high
risk
group
account
case
higher
normal
diagnosi
reach
median
level
serum
nse
treatment
case
slightli
higher
normal
account
case
decreas
significantli
account
case
decreas
normal
level
account
follow
februari
except
case
treat
case
case
case
achiev
complet
remiss
cr
account
achiev
partial
remiss
pr
account
overal
surviv
rate
conclus
infant
nb
sensit
chemotherapi
diseas
incid
rate
stage
infant
nb
high
remisson
rate
prognosi
infant
nb
comprehens
treatment
high
chromosom
analysi
neuroblastoma
children
q
zhao
zhang
center
beij
children
hospit
beij
china
object
studi
clinic
featur
prognosi
children
neuroblastoma
acorrd
chromosom
statu
hospit
analyz
relationship
chromosom
statu
characterist
cur
effect
improv
understand
neuroblastoma
chromosom
abnorm
method
clinic
characterist
treatment
surviv
statu
children
neuroblastoma
retrospect
analys
review
literatur
result
total
patient
chromosom
abnorm
among
case
adopt
hospit
includ
case
gain
case
gain
delet
abnorm
found
rest
tumor
marker
case
chromosom
abnorm
elev
differ
rang
serum
nse
higher
neuroblastoma
children
normal
chromosom
case
chromosom
abnorm
mycn
gain
treatment
case
lost
case
progress
case
die
rest
one
gain
delet
complet
remiss
regular
chemotherapi
surgeri
autolog
peripher
blood
stem
cell
transplant
month
differ
ef
rate
found
patient
differ
chromosom
statu
ef
rate
higher
normal
chromosom
group
abnorm
group
p
valu
conclus
base
case
relev
literatur
show
gain
delet
risk
factor
neuroblastoma
certain
clinic
signific
diagnosi
evalu
prognosi
neuroblastoma
research
posit
rate
abnorm
chromosom
convent
detect
method
lower
previou
report
consid
relat
methodolog
need
improv
level
clinic
signific
cytokin
serum
children
neuroblastoma
w
zhao
hematolog
depart
beij
children
hospit
capit
medic
univers
beij
china
object
studi
level
children
neuroblastma
nb
relat
clinic
stage
provid
basi
immunomodutatori
support
therapi
nb
chemotherapi
method
studi
enrol
children
new
nb
patient
treat
hospit
novemb
decemb
level
type
cytokin
includ
tumor
necrosi
includ
cytokin
serm
detect
flow
fluorensc
immunmicrobead
assay
ffia
children
high
risk
children
low
medium
risk
nb
result
level
type
cytokin
significantli
lower
patient
high
risk
low
medium
risk
nb
p
lower
patient
high
risk
low
medium
risk
nb
statist
signific
differ
p
level
signific
higher
low
medium
risk
nb
patient
p
level
type
cytokin
higher
patient
high
risk
low
medium
risk
nb
statist
signific
differ
p
p
level
patient
signific
higher
low
medium
risk
nb
patient
p
conclus
imbal
children
nb
type
cytokin
inhibit
type
cytokin
rel
enhanc
shift
increas
risk
trend
obviou
serum
level
th
subset
may
relat
immun
functiong
lung
cancer
patient
good
sign
prognosi
effect
zebularin
alon
combin
histon
deacetylas
inhibitor
saha
medulloblastoma
cell
af
andrad
ks
borg
vk
suazo
ca
scride
lg
tone
genet
preto
medic
school
usp
preto
brazil
pediatr
preto
medic
school
usp
preto
brazil
object
medulloblastoma
mb
aggress
grow
tumor
aris
cerebellum
common
malign
one
children
current
treatment
cure
reach
patient
howev
approxim
children
experi
tumor
recurr
die
diseas
thu
new
approach
urgent
need
drug
combin
use
inhibitor
dna
methyltransferas
idnmt
histon
deacetylas
ihdac
shown
antineoplast
effect
differ
tumor
zebularin
zb
block
dna
methyl
inhibit
dna
methyltransferas
activ
exhibit
minim
cytotox
vitro
vivo
howev
effect
mb
previous
report
studi
aim
investig
efficaci
zb
alon
combin
saha
vitro
use
mb
cell
line
method
effect
zb
alon
combin
evalu
cell
viabil
clonogen
apoptosi
assay
mb
cell
e
analys
conduct
accord
principl
establish
chou
talalay
drug
combin
analyz
use
two
differ
schedul
administr
simultan
sequenti
perform
statist
analysi
perform
anova
bonferoni
result
zb
decreas
cell
prolifer
clonogen
capac
cell
line
manner
respect
p
drug
increas
apoptosi
rate
combin
index
valu
zb
saha
treatment
greater
indic
two
agent
induc
antagonist
effect
mb
cell
independ
schedul
use
conclus
administ
alon
zb
saha
exert
activ
vitro
mb
cell
zb
saha
combin
treatment
produc
antagonist
rather
synergist
effect
studi
conduct
differ
drug
combin
schedul
aim
better
character
effect
combin
financi
support
fapesp
process
sirolimu
treatment
vascular
anomali
c
akyuz
h
susam
sen
b
aydin
b
oguz
kutluk
b
yalcin
varan
pediatr
oncolog
hacettep
institut
oncolog
ankara
turkey
radiolog
hacettep
faculti
medicin
ankara
turkey
object
vascular
anomali
va
heterogen
group
benign
diseas
requir
multidisciplinari
treatment
approach
mammalian
target
rapamycin
mtor
inhibitor
sirolimu
recent
use
treatment
va
success
result
report
studi
clinic
characterist
outcom
patient
va
treat
sirolimu
evalu
method
file
patient
va
treat
sirolimu
analyz
retrospect
clinic
featur
treatment
result
patient
diagnos
either
radiolog
histolog
biopsi
result
median
age
male
femal
diagnosi
year
rang
day
year
patient
given
sirolimu
median
age
rang
month
year
venolymphat
malform
lymphangioma
vascular
malform
venou
malform
gorham
stout
syndrom
blue
rubber
bleb
nevu
syndrom
patient
patient
receiv
least
one
previou
treatment
sirolimu
given
month
median
month
frequent
clinic
respons
improv
pain
feed
exercis
capac
reduct
hospit
tracheostomi
closur
extub
clinic
radiolog
respons
patient
less
patient
respons
patient
radiolog
five
patient
oral
aphthou
lesion
patient
hyperlipidemia
treatment
side
effect
mild
revers
conclus
sirolimu
use
effect
reliabl
patient
va
refractori
previou
therapi
accept
toxic
promis
use
sirolimu
prolif
disord
chan
sy
soh
k
chang
tan
paediatr
subspecialti
kk
women
children
hospit
singapor
singapor
patholog
kk
women
children
hospit
singapor
singapor
object
mammalian
target
rapamycin
mtor
signal
stimul
cell
growth
inhibit
rapamycin
natur
occur
antifung
compound
first
discov
easter
island
rapamycin
sirolimu
use
immunosuppress
kidney
transplant
also
known
recent
reduc
prolif
tumour
harmartoma
syndrom
refractori
vascular
anomali
seriou
advers
side
effect
describ
experi
use
sirolimu
varieti
prolif
disord
method
five
patient
put
sirolimu
accord
institut
protocol
june
latest
patient
recruit
januari
diagnos
gorham
diseas
metastat
haemangioendothelioma
lymphangiomatosi
extens
inflammatori
myofibroblast
tumour
imt
patient
fail
varieti
therapi
offer
sirolimu
monthli
sirolimu
blood
level
kept
ngml
monthli
full
blood
count
renal
panel
liver
function
fast
lipid
urinari
total
protein
monitor
prophylact
cotrimoxazol
given
result
patient
metastat
haemangioendothelioma
show
near
complet
respons
gorham
show
good
respons
gorham
show
stabl
diseas
extens
imt
show
possibl
partial
respons
latest
patient
recruit
assess
yet
age
rang
year
time
treatment
interestingli
patient
imt
also
chronic
itp
respond
sirolimu
platelet
normalis
month
two
patient
transient
hypercholesterolaemia
transient
proteinuria
one
patient
mucos
togeth
cost
issu
caus
stop
treatment
month
treatment
otherwis
well
toler
februari
durat
treatment
rang
month
conclus
sirolimu
show
promis
result
treatment
prolif
disord
refractori
therapi
well
toler
howev
long
term
effect
young
children
determin
antitumor
activ
novel
antagonist
mh
li
r
swenson
hla
l
shapiro
f
ferrer
center
vascular
biolog
univers
connecticut
health
center
farmington
usa
drug
discoveri
arroyo
bioscienc
llc
princeton
usa
depart
patholog
laboratori
medicin
weill
medic
colleg
cornel
univers
new
york
usa
depart
surgerycent
vascular
biolog
connecticut
children
medic
centerunivers
connecticut
health
center
hartfordfarmington
usa
object
bioactiv
lipid
receptor
play
critic
role
mani
patholog
process
includ
cancer
axi
becom
potenti
therapeut
target
literatur
standard
antagonist
potenti
instabl
vivo
structur
modif
tri
develop
specif
stabl
analog
method
flipr
assay
conduct
assess
agonismantagon
analog
pharmacokinet
analysi
perform
detect
blood
concentr
mice
differ
time
migrat
assay
glioblastoma
gb
neuroblastoma
nb
xenograft
model
util
compar
biolog
efficaci
analog
western
blot
pcr
perform
compar
efficaci
modul
express
downstream
molecul
vegf
ctgf
result
one
analog
exhibit
better
antagon
effect
compar
nm
versu
nm
intraven
pharmacokinet
show
blood
concentr
mice
remain
higher
hour
indic
better
stabil
slower
clearanc
vivo
migrat
assay
gb
show
potent
either
revers
cell
migrat
inhibit
cell
enhanc
cell
migrat
cell
nb
cell
line
display
least
potenc
revers
inhibit
inhibit
activ
inhibit
vegf
ctgf
express
xenograft
tumor
model
display
stronger
tumor
inhibit
effect
compar
conclus
improv
potenc
intraven
pharmacokinet
better
cellular
activ
display
stronger
activ
compar
nb
may
enhanc
clinic
applic
databas
overview
inform
retriev
express
level
bric
gene
tumor
neuroblastoma
medulloblastoma
rhabdomyosarcoma
leukemia
j
kapelushnik
manor
plaschk
v
caspi
pediatr
hemato
oncolog
ben
gurion
univers
negev
israel
genet
ben
gurion
univers
negev
sorka
medic
center
israel
genet
ben
gurion
univers
negev
bioinformat
core
fciliti
israel
object
newcastl
diseas
viru
ndv
avian
paramyxoviru
potenti
select
oncolyt
effect
human
tumor
shown
newcastl
viru
replic
viru
overcom
resist
apoptosi
melanoma
primari
cultur
express
livin
protein
contrast
melanoma
tumor
cell
express
livin
rel
resist
treatment
potent
induc
apoptosi
overcom
antiapoptot
effect
livin
allow
cleavag
livin
proapoptot
tlivin
express
live
protein
tumor
predict
oncolysi
effect
newcastl
viru
protein
method
search
gene
express
databas
geo
microarray
experi
descript
contain
name
one
request
cancer
type
neuroblastoma
medulloblastoma
rhabdomyosarcoma
retriev
experi
search
gene
gene
express
profil
either
taken
geo
profil
avail
calcul
visual
use
tool
result
medulloblastoma
children
age
year
express
gene
background
high
express
neuroblastoma
cell
line
one
cell
line
express
brich
gene
glioblastoma
gbm
express
gene
rhabdomyosarcoma
mice
express
gene
ewe
sarcoma
famili
express
gene
leukemia
children
patient
check
gene
children
good
risk
leukemia
higher
express
gene
conclus
higher
express
bric
gene
brain
tumor
frequent
gbm
tumor
higher
express
result
good
prognosi
leukemia
current
investig
gene
express
children
contract
newcastl
viru
vector
drug
demonstr
higher
preclin
activ
neuroblastoma
pediatr
glioma
cell
line
first
data
pediatr
oncolog
p
leblond
e
boulet
c
pillon
kruczynski
n
guilbaud
c
bailli
e
lartigau
lansiaux
meignan
pediatr
oncolog
centr
oscar
lambret
inserm
lill
franc
antitumor
pharmacolog
laboratori
centr
oscar
lambret
inserm
ircl
lill
franc
research
develop
center
pierr
fabr
toulous
franc
radiotherapi
centr
oscar
lambret
lill
franc
object
prognosi
children
high
grade
glioma
hgg
high
risk
neuroblastoma
remain
poor
despit
aggress
multidisciplinari
therapeut
approach
combin
epipodophyllotoxin
topoisomeras
ii
spermin
moieti
introduc
cell
deliveri
vector
spermin
moieti
facilit
select
uptak
tumor
cell
via
polyamin
transport
system
pt
reinforc
topoisomeras
ii
poison
method
evalu
three
pediatr
hgg
four
neuroblastoma
cell
line
pt
activ
specif
evalu
confoc
microscopi
flow
cytometri
use
fluoresc
probe
contain
spermin
moieti
cytotox
alon
associ
cisplatin
carboplatin
melphalan
effect
investig
vitro
antitumor
activ
assess
vivo
use
bioluminesc
neuroblastoma
model
result
activ
pt
evidenc
test
pediatr
cell
line
provid
specif
rapid
transfer
compound
cell
nuclei
assess
three
neuroblastoma
cell
line
competit
experi
spermin
confirm
essenti
role
pt
cell
uptak
cytotox
cytotox
appear
greater
neuroblastoma
compar
hgg
cell
seem
independ
pt
activ
level
interestingli
present
signific
higher
cytotox
effect
etoposid
lack
spermin
chain
vivo
evalu
confirm
import
prolong
antitumor
effect
neuroblastoma
combin
cisplatin
carboplatin
found
often
synergist
combin
melphalan
appear
variou
final
demonstr
signific
potenti
kelli
cell
line
conclus
appear
effect
etoposid
pediatr
tumor
cell
line
higher
efficaci
neuroblastoma
cell
synergist
effect
observ
platinum
compound
radiosensit
effect
could
lead
great
potenti
develop
pediatr
oncolog
resveratrol
induc
apoptosi
medulloblastoma
cell
without
affect
astrocyt
neuron
xh
shu
xx
sun
h
li
x
song
wang
shi
j
liu
liaon
laboratori
cancer
genet
epigenet
depart
cell
biolog
dalian
medic
univers
dalian
china
object
medulloblastoma
lethal
pediatr
brain
malign
due
aggress
growth
frequent
recurr
adjuv
therapi
employ
prevent
cancer
relaps
caus
long
term
side
effect
resveratrol
induc
differenti
lead
medulloblastoma
cell
growth
arrest
apoptosi
studi
aim
prove
practic
valu
resveratrol
evalu
effect
resveratrol
normal
brain
cell
method
glial
cell
neuron
isol
fetal
rat
brain
get
permiss
experiment
anim
warfar
committe
dalian
medic
univers
separ
cultur
optim
condit
day
treat
resveratrol
hour
morpholog
treat
cell
check
hour
interv
cell
bear
coverslip
collect
observ
point
immunocytochem
mtt
tunel
analys
medulloblastoma
cell
cite
control
result
unlik
cell
rat
glial
cell
neuron
littl
respons
resveratrol
treatment
prolifer
rate
andor
morpholog
cell
similar
normal
cultur
counterpart
express
glial
cell
neuron
lack
nuclear
transloc
level
alter
resveratrol
nuclear
label
evidenc
cell
becom
diminish
upon
resveratrol
treatment
accompani
extens
apoptosi
conclus
safeti
effect
dose
resveratrol
rat
glial
cell
neuron
confirm
presum
due
inactiv
statu
resveratrol
target
signal
cell
therefor
compound
would
use
clinic
treatment
medulloblastoma
cknowleg
work
support
grant
natur
scienc
foundat
china
no
research
fund
phd
supervisor
educ
depart
china
dhmeq
pediatr
medulloblastoma
cell
line
pmm
ramo
ja
pezuk
ca
scride
k
umezawa
lg
tone
genet
preto
medic
school
usp
preto
brazil
pediatr
preto
medic
school
usp
preto
brazil
molecular
target
medicin
screen
aichi
medic
univers
aichi
japan
object
medulloblastoma
pediatr
cancer
central
nervou
system
highli
invas
embryon
origin
locat
cerebellum
common
treatment
surgeri
chemotherapi
radiotherapi
tochildren
older
year
old
due
side
effect
b
key
transcript
factor
regul
immun
respons
inflamm
process
involv
transcript
regul
larg
number
gene
relat
tumorigenesi
process
constitut
activ
mani
type
cancer
import
potenti
therapeut
target
dhmeq
dehidroximetilepoxiquinomicina
drug
inhibit
transloc
b
cytoplasm
nucleu
thu
inhibit
activ
transcript
activ
sever
studi
shown
antineoplast
effect
dhmeq
numer
tumor
type
howev
survey
test
effect
medulloblastoma
method
present
studi
evalu
effect
dhmeq
pediatr
medulloblastoma
cell
line
prolifer
clonogen
capac
apoptosi
invas
migrat
assay
besid
drug
combin
radio
sensit
assay
result
prolifer
test
result
demonstr
signific
decreas
cell
growth
strongli
inhibit
clonogen
capac
migrat
cell
invas
three
medulloblastoma
cell
line
addit
increas
level
apoptosi
synergist
combin
chemotherapeut
agent
combin
point
radiosensit
strongli
three
cell
line
conclus
result
congruent
potenti
antitumor
effect
dhmeq
point
clearli
possibl
use
new
therapeut
agent
medulloblastoma
treatment
role
pathway
therapi
relat
myeloid
neoplasm
delet
new
therapeut
target
n
mittal
seba
z
qian
pediatr
hematolog
oncolog
univers
illinoi
chicago
us
medicin
divis
hematologyoncolog
univers
illinoi
chicago
us
medicin
univers
illinoi
chicago
us
object
success
therapi
pediatr
malign
led
rise
incid
aml
del
recur
cytogenet
abnorm
approxim
pediatr
current
therapi
yr
surviv
del
associ
apc
gene
hematopoiet
stem
cell
hsc
lead
diseas
mice
apc
regul
function
hsc
depend
mechan
object
show
effect
wnt
pathway
blockad
del
leukemia
method
express
higher
human
myeloid
leukemia
cell
line
del
versu
reh
lymphoid
line
without
del
treat
reh
cell
indomethacin
lentivir
particl
express
control
empti
backbon
target
inhibitori
shrna
transduc
reh
knockdown
achiev
cell
analyz
effect
growth
cell
cycl
apoptosi
vitro
coloni
form
assay
perform
result
cell
show
signific
growth
inhibit
compar
reh
indomethacin
p
inhibit
treatment
confirm
cell
transduc
shrna
show
growth
inhibit
compar
control
vector
contrast
reh
demonstr
compar
growth
control
shrna
transduc
cell
decreas
fraction
increas
apoptosi
p
cell
inhibit
compar
control
reh
show
differ
distribut
similar
frequenc
apoptosi
inhibit
control
cell
decreas
coloni
format
observ
cell
inhibit
conclus
chromosom
del
lead
blockad
wnt
pathway
suppress
cell
growth
induc
apoptosi
myeloid
leukemia
cell
line
del
discoveri
pave
way
new
therapeut
strategi
target
improv
surviv
del
decitabin
enhanc
cytotox
effect
agent
synergist
acut
lymphoblast
leukemia
cell
line
k
sakaguchi
h
takahashi
depart
pediatr
hamamatsu
univers
school
medicin
hamamatsu
japan
object
examin
combin
effect
decitabin
dac
agent
clofarabin
clo
etoposid
eto
acut
lymphoblast
leukemia
cell
line
method
measur
vitro
drug
sensit
dac
clo
eto
dacclo
daceto
use
mtt
assay
combin
index
ci
produc
softwar
also
assay
detect
apoptosi
use
cell
examin
mrna
express
level
gene
bak
bid
bax
bad
bim
puma
atm
noxa
well
gene
xiap
express
level
target
gene
calcul
normal
gapdh
analyz
methyl
statu
gene
hour
incub
without
dac
result
eto
etodac
clo
clodac
respect
ci
etodac
clodac
observ
greater
activ
dac
clo
dac
eto
clo
eto
observ
dac
increas
mrna
express
level
bax
noxa
decreas
bak
bid
puma
atm
xiap
methyl
statu
bak
noxa
xiap
incub
dac
respect
incub
without
dac
respect
conclus
result
show
dac
synergist
enhanc
clo
eto
cytotox
cytotox
effect
depend
activ
found
dac
decreas
gene
bak
bid
puma
atm
result
show
dac
demethyl
cpg
bak
noxa
xiap
thu
dac
must
demethyl
cpg
gene
nevertheless
mani
gene
involv
apoptosi
remain
unclear
gene
demethyl
dac
antitumor
activ
indisulam
pediatr
adult
glioblastoma
cell
line
xenograft
tumor
ca
scride
sa
teixeira
ja
pezuk
af
andrad
ms
brassesco
vk
suazo
ca
carlotti
jr
em
rego
cla
silva
rpq
gome
lg
tone
ca
scride
pediatr
preto
school
medicin
univers
paulo
preto
brazil
genet
preto
school
medicin
univers
paulo
preto
brazil
surgeri
preto
school
medicin
univers
paulo
preto
brazil
intern
medicin
preto
school
medicin
univers
paulo
preto
brazil
object
glioblastoma
gbm
aggress
form
brain
cancer
dismal
prognosi
children
adult
carbon
anhydras
isoform
highli
overexpress
mani
type
cancer
includ
gbm
aim
studi
evalu
effect
inhibit
ca
indisulam
novel
anticanc
drug
potent
inhibit
ca
vitro
vivo
model
method
studi
investig
effect
inhibit
indisulam
cell
surviv
pediatr
adult
gbm
cell
line
cell
line
cultur
condit
hypoxia
prolifer
cell
cycl
apoptosi
evalu
vivo
antitumor
effect
indisulam
assess
swiss
nude
mice
n
group
inocul
gbm
cell
line
indisulam
administ
differ
treatment
approach
tumor
growth
potenti
treatment
toxic
monitor
result
ca
inhibit
vitro
significantli
reduc
prolifer
depend
p
arrest
compar
control
increas
apoptosi
upon
hypoxia
exposur
moreov
concurr
combin
temozolamid
tmz
inhibit
cell
growth
cell
line
determin
prolifer
result
anim
test
use
human
tumor
xenograft
indic
indisulam
significantli
reduc
growth
tumor
p
pretreat
indisulam
equal
sensit
cell
chemotherapi
tmz
lead
reduct
xenograft
tumor
volum
p
differ
observ
tmz
alon
compar
control
conclus
studi
provid
evid
therapeut
potenti
indisulam
agent
tumor
cell
might
therefor
attract
treatment
strategi
gbm
success
manag
lymphat
malform
tongu
use
sirolimu
yesil
c
bozkurt
g
tanyildiz
mo
candir
toprak
g
sahin
pediatr
oncolog
dr
sami
ulu
pediatr
research
train
hospit
ankara
turkey
object
lymphat
malform
congenit
malform
lead
signific
disfigur
soft
tissu
hypertrophi
skelet
overgrowth
boni
abnorm
andor
infect
treatment
remov
includ
surgic
resect
varieti
scleros
agent
report
present
novel
approach
treatment
lymphat
malform
tongu
use
sirolimu
method
one
year
old
femal
admit
complaint
macroglossia
born
term
year
old
woman
vagin
deliveri
birth
weight
gram
macroglossia
nt
signific
antenat
matern
medic
famili
histori
physic
examin
scab
ridg
tongu
dimens
tongu
diffus
elev
could
nt
chew
fed
liquid
nutrient
mr
imag
reveal
heterogen
hypervascular
solidcyst
mass
unclear
border
mainli
local
anterior
tongu
chest
abdomen
usg
normal
laboratori
examin
includ
chromosom
microarray
test
test
metabol
disord
also
normal
result
patient
began
treatment
sirolimu
mammalian
target
rapamycin
inhibitor
initi
dose
administ
oral
twice
daili
subsequ
dose
adjust
made
order
maintain
goal
drug
trough
level
ngml
continu
therapeut
dose
sirolimu
nine
month
without
advers
effect
abl
close
mouth
eat
everyth
conclus
sirolimu
therapi
offer
promis
treatment
option
lymphat
malform
children
polyamid
target
induc
apoptosi
wilm
tumor
cell
line
yoshizawa
k
sugito
ishizuka
r
hoshi
watanab
uekusa
h
kawashima
koshinaga
k
fujiwara
h
nagas
pediatr
surgeri
nihon
univers
school
medicin
tokyo
japan
gener
medicin
nihon
univers
school
medicin
tokyo
japan
divis
cancer
genet
chiba
cancer
center
research
institut
chiba
japan
object
kvdmr
one
imprint
control
region
assign
chromosom
human
sinc
kvdmr
locat
promot
genom
alter
region
delet
patern
upd
matern
allel
lead
rna
known
suppress
circumjac
gene
includ
tumor
suppressor
gene
accompani
report
sever
tumor
kvdmr
frequent
observ
syndrom
bw
around
bw
patient
develop
embryon
tumor
wilm
tumor
hepatoblastoma
base
fact
hypothes
suppress
could
show
effect
method
polyamid
pip
small
synthet
chemic
compos
aromat
amino
acid
recogn
specif
dna
sequenc
pip
design
transcript
factor
bind
site
suppress
express
downstream
gene
gener
pip
target
promot
investig
effect
human
bw
fibroblast
result
clearli
shown
pcr
express
level
significantli
reduc
treat
pip
compar
control
cell
induct
cell
treatment
withpip
detect
western
blot
assay
reveal
cell
treat
pip
show
significantli
lower
viabil
control
cell
found
higher
number
cell
undergo
apoptosi
pip
treat
group
control
group
fac
analysi
conclus
current
data
strongli
suggest
pip
induc
apoptosi
suppress
express
follow
protein
believ
pip
target
possibl
new
therapeut
agent
tumor
harbor
island
promot
support
women
survivor
childhood
cancer
literatur
review
tomioka
maru
health
care
scienc
tokyo
medic
dental
univers
tokyo
japan
object
cure
rate
childhood
cancer
continu
improv
survivor
live
late
effect
treatment
support
women
survivor
childhood
cancer
suffici
studi
thu
far
particularli
regard
women
childbear
age
therefor
conduct
literatur
review
clarifi
current
statu
women
survivor
childhood
cancerand
support
receiv
method
medlin
cinahl
search
articl
publish
adult
childhood
cancer
survivor
includ
studi
focus
issu
specif
women
survivor
childhood
cancer
compar
women
male
counterpart
result
women
survivor
childhood
cancer
lower
qualiti
life
male
counterpart
higher
risk
posttraumat
stress
disord
women
concern
reproduct
health
felt
uncertainti
futur
conclus
result
indic
support
need
childhood
cancer
survivor
particularli
women
role
interleukin
predict
tumor
aggress
respons
therapi
pediatr
malign
abd
elmoneim
z
alhawsawi
zolali
e
abd
elmoneim
pediatr
depart
sohag
univers
sohag
egypt
pediatr
depart
matern
children
hospit
almadinah
almounourah
saudi
arabia
pediatr
depart
taibah
univers
almadinah
almounourah
saudi
arabia
object
upon
contact
tumor
cell
vitro
human
monocyt
becom
unrespons
demonstr
decreas
product
enhanc
secret
clinic
deregul
serum
level
reciproc
balanc
state
mani
cancer
hand
dampen
directli
tumor
growth
vitro
vivo
inhibit
tumor
cell
prolifer
induct
apoptosi
aim
studi
detect
pretreat
serum
level
ratio
pediatr
hematolog
malign
well
solid
tumor
correl
chemotherapi
respons
method
pre
treatment
serum
level
detect
blood
sampl
children
diagnos
differ
type
malign
healthi
peer
use
elisa
correl
serum
level
interleukin
diseas
sever
patient
respons
chemotherapi
conduct
result
median
level
significantli
higher
cancer
diseas
children
healthi
control
median
level
significantli
decreas
elev
ratio
decreas
correl
histolog
poor
respons
therapi
relaps
death
cancer
conclus
serum
level
balanc
children
cancer
may
valu
addit
prognost
tool
predict
respons
therapi
analysi
potenti
theori
anti
tumor
effect
possibl
use
candid
novel
drug
resist
malign
assess
myocardi
function
children
autolog
peripher
blood
stem
cell
transplant
hala
mattar
r
sarhan
pediatr
mansoura
univers
children
hospit
mansoura
egypt
object
interest
focus
advers
effect
bone
marrow
transplant
subclin
cardiac
involv
appear
common
adult
report
concern
pediatr
patient
method
prospect
studi
perform
children
normal
cardiac
function
undergo
autolog
hematopoiet
stem
cell
transplant
hsct
tissu
doppler
imag
tdi
echocardiograph
measur
obtain
accord
guidelin
american
societi
echocardiographi
result
lateralmitralannulu
hsct
show
signific
reduc
mitral
systol
annular
veloc
p
earli
diastol
annular
veloc
p
late
diastol
annular
veloc
prolong
volumetr
relax
time
p
comparison
control
signific
reduc
mitral
systol
annular
veloc
p
earli
diastol
annular
veloc
emam
ratio
higher
late
diastol
annular
veloc
prolong
ict
irt
hsct
observ
studi
later
tricuspid
annulu
show
nearli
similar
result
lateralmitralannulu
lv
rv
tei
indic
found
higher
hsct
comparison
control
remain
higher
hsct
conclus
tdi
could
detect
subtl
abnorm
systol
diastol
function
hsct
impli
condit
regimen
may
affect
cardiac
function
activ
drug
concentr
gener
vincristin
formul
southeast
asia
ap
alcasaba
ym
khoo
ae
yeoh
hs
lee
tc
quah
paediatr
philippin
gener
hospit
manila
philippin
pharmacolog
nation
univers
singapor
singapor
singapor
paediatr
khoo
teck
univers
children
medic
institut
singapor
singapor
object
avail
gener
drug
aid
rise
cost
healthcar
especi
develop
countri
afford
innov
product
howev
public
percept
may
inferior
qualiti
establish
guidelin
ensur
pharmaceut
qualiti
mani
countri
resourc
implement
asia
numer
case
fake
substandard
gener
medicin
studi
evalu
gener
chemotherapi
formul
low
activ
drug
level
contamin
increas
toxic
report
old
agent
vincristin
gener
brand
avail
asia
purpos
studi
determin
activ
drug
concentr
vincristin
among
differ
brand
avail
southeast
asia
method
gener
vincristin
formul
obtain
southeast
asian
countri
includ
india
transport
cold
storag
nation
univers
singapor
vincristin
level
measur
use
high
perform
liquid
chromatographi
compar
vincristin
lab
standard
sigma
modifi
us
pharmacopeia
methodolog
result
ten
gener
vincristin
formul
obtain
malaysia
sri
lanka
vietnam
indonesia
india
philippin
singapor
two
brand
sampl
brand
sampl
brand
sampl
manufactur
india
south
korea
netherland
hungari
within
prescrib
shelf
life
mean
vincristin
level
obtain
per
brand
fell
control
valu
rang
conclus
select
gener
vincristin
formul
southeast
asia
india
accept
activ
drug
level
lab
standard
presenc
quantiti
impur
may
clinic
signific
test
studi
child
tumor
african
environ
difficulti
manag
advocaci
health
screen
care
alumeti
n
luhiriri
b
cikwanin
k
nfundiko
f
itek
birindwa
c
guhanika
bahala
l
ahuka
ona
depart
surgeri
specialti
gener
refer
panzi
hospit
bukavu
democrat
republ
congo
introduct
childhood
cancer
complex
aim
studi
discuss
difficulti
manag
children
cancer
eastern
dr
congo
bring
awar
problem
advoc
polici
chang
patient
method
studi
conduct
citi
bukavu
eastern
dr
congo
questionnair
administ
caregiv
work
variou
health
care
facil
result
wilm
tumor
common
follow
leukemia
retinoblastoma
malign
lymphoma
clinic
diagnosi
support
ultrasound
histopatholog
treatment
howev
limit
high
cost
middl
cost
usa
lack
inventori
cyclophosphamid
methotrex
prednisolon
avail
drug
use
two
gener
refer
hospit
bukavu
meet
criteria
manag
childhood
cancer
mean
presenc
qualifi
staff
pediatrician
surgeon
pathologist
laboratori
capabl
determin
tumor
marker
pharmaci
capabl
provid
anticanc
drug
conclus
childhood
cancer
seriou
problem
eastern
dr
congo
current
challeng
diagnosi
treatment
unit
capabl
care
childhood
cancer
essenti
also
begin
address
popular
misconcept
childhood
cancer
alway
end
cemeteri
abdomin
tumor
congoles
children
difficulti
manag
case
alumeti
n
luhiriri
k
nfundiko
b
cikwanin
bahala
l
malekera
lotin
muka
b
kampimba
j
kitumaini
l
ahuka
ona
depart
surgeri
specialti
gener
refer
panzi
hospit
bukavu
democrat
republ
congo
introduct
abdomin
tumor
children
mani
diagnost
therapeut
challeng
especi
develop
countri
dr
congo
aim
studi
determin
frequenc
abdomin
tumor
children
describ
therapeut
modal
countri
limit
resourc
patient
method
retrospect
studi
five
year
depart
pediatr
surgeri
children
year
old
present
hospit
abdomin
mass
follow
epidemiolog
clinic
therapeut
paramet
document
analyz
result
femal
made
higher
percentag
children
present
abdomin
mass
averag
age
year
age
group
affect
clinic
diagnosi
support
ultrasound
wilm
tumor
common
tumor
follow
genit
tumor
neuroblastoma
pancreat
tumor
case
underw
surgeri
postop
cours
unev
death
howev
children
releas
palli
care
conclus
abdomin
tumor
children
repres
childhood
tumor
diagnosi
primarili
clinic
howver
ultrasound
import
tool
surgic
treatment
must
compliment
chemotherapi
howev
alway
avail
commun
role
parent
group
awar
creation
childhood
cancer
f
aveh
j
ahenkorah
opoku
l
renner
account
univers
profession
studi
accra
ghana
medic
school
univers
ghana
accra
ghana
parent
group
ghana
parent
associ
childhood
cancer
accra
ghana
object
rais
awar
childhood
cancer
ghana
method
high
profil
launch
ghana
parent
associ
childhood
cancer
ghapacc
public
challeng
face
children
affect
cancer
famili
awar
creation
fundrais
walk
organis
intern
childhood
cancer
day
coverag
nation
tv
need
children
affect
cancer
parent
made
public
articl
nation
daili
paper
member
parent
group
particip
radio
televis
talk
show
famili
funfair
organis
easter
use
avenu
awar
creation
septemb
media
meet
organis
ghapacc
media
hous
involv
dissemin
earli
warn
sign
televis
radio
print
media
result
nationwid
public
childhood
cancer
ongo
poster
distribut
ghapacc
includ
school
church
sever
organis
made
substanti
contribut
directli
toward
childhood
cancer
treatment
mani
ngo
sprung
result
current
launch
project
construct
bed
hostel
famili
children
admiss
hospit
conclus
level
awar
childhood
cancer
ghana
improv
need
done
superstiti
belief
stigmat
societi
hindranc
earli
report
case
health
facil
educ
media
would
effect
way
continu
awar
help
get
better
access
care
improv
outcom
childhood
cancer
improv
stage
infect
risk
children
febril
neutropenia
multiplex
viral
pcr
cytokin
determin
b
santiago
c
mata
b
r
c
garrido
l
mm
santo
c
e
cela
j
huerta
casa
j
navarro
molecular
immunobiolog
depart
pedaitr
infecti
diseas
unit
hospit
gener
universitario
gregorio
madrid
spain
pediatr
oncohematolog
depart
hospit
gener
universitario
gregorio
madrid
spain
infecti
diseas
depart
hospit
gener
universitario
gregorio
madrid
spain
molecular
immunobiolog
depart
hospit
gener
universitario
gregorio
madrid
spain
pediatr
infecti
diseas
unit
hospit
gener
universitario
gregorio
madrid
spain
influenza
respiratori
viru
laboratori
instituto
de
salud
carlo
iii
madrid
spain
object
respiratori
viral
infect
rvi
common
caus
febril
neutropenia
fn
episod
children
cancer
present
cohort
children
fn
evalu
rvi
conjunct
cytokin
profil
order
describ
incid
clinic
outcom
potenti
earli
biomark
rvi
method
children
fn
admit
hospit
prospect
enrol
admiss
children
evalu
rv
nasopharyng
wash
cytokin
profil
determin
blood
flow
citometri
children
rvi
compar
children
bacteri
infect
bi
analyz
risk
stage
admiss
clinic
outcom
laboratori
paramet
cytokin
profil
result
total
episod
fn
children
enrol
femal
median
age
year
admiss
classifi
low
risk
bi
lrbi
accord
protocol
overal
microbiolog
confirm
obtain
rv
identifi
episod
mix
bi
detect
rhinoviru
common
viru
n
follow
parainfluenza
n
rsv
n
coronaviru
n
influenza
b
n
adenoviru
n
rv
common
children
lrbi
compar
high
risk
vs
p
admiss
children
rvi
present
lower
median
pct
vs
p
vs
p
tnfa
vs
p
compar
children
bi
outcom
children
whose
isol
rv
favor
regardless
risk
establish
admiss
conclus
cohort
children
fn
rv
infecti
agent
frequent
isol
earli
detect
rv
conjunct
low
pct
tnfa
level
admiss
may
enhanc
identif
patient
improv
risk
stage
children
fn
clostridium
diarrhea
children
hematolog
malign
f
begum
islam
r
haqu
chowdhuri
mia
f
yasmin
begum
lr
molla
z
ara
doherti
pediatr
hematolog
oncolog
bangabandhu
sheikh
mujib
medic
univers
dhaka
bangladesh
parasitolog
laboratori
icddrb
dhaka
bangladesh
pediatr
hematolog
oncolog
bangabandhu
sheikh
mujib
medic
univers
dhaka
bangladesh
medic
educ
centr
medic
educ
dhaka
bangladesh
pediatr
palli
care
children
hospit
eastern
ontario
ottawa
canada
object
clostridium
difficil
associ
diarrhea
cdad
consid
one
commonest
caus
nosocomi
diarrhea
worldwid
infect
form
diarrhea
dysenter
ill
lead
caus
infect
pediatr
oncolog
patient
bsmmu
dhaka
bangladesh
studi
conduct
see
frequenc
clostridium
difficil
infect
eia
among
diarrheal
children
hematolog
malign
bsmmu
method
prospect
observ
studi
conduct
april
march
see
rate
clostridium
difficil
infect
children
hematolog
malign
total
diarrheal
episod
experienc
children
differ
hematolog
malign
consecut
includ
develop
diarrhea
point
hospit
fecal
sampl
sent
icddrb
laboratori
eia
c
difficil
aerob
cultur
common
bacteria
pcr
common
parasit
infect
result
among
total
diarrheal
episod
sampl
posit
sampl
neg
gdh
antigen
eia
test
none
fecal
sampl
posit
toxin
andor
b
eia
potenti
pathogen
bacteria
isol
sampl
aerob
stool
cultur
differ
parasit
identifi
sampl
pcr
frequent
identifi
protozoa
giardia
lamblia
episod
children
neutropen
sever
neutropenia
signific
corerel
gdh
posit
usag
imipenem
high
dose
cytosar
omeprazol
signific
correl
gdh
posit
diarrheal
episod
conclus
studi
found
colon
rate
clostridium
dificil
none
toxigen
among
diarrheal
children
hematolog
malign
parasit
infect
seen
frequent
children
malign
malign
infant
implement
metastat
potenti
tumor
reach
peak
growth
rate
begun
krasko
aleinikova
function
diagnost
belarusian
research
center
pediatr
oncolog
hematolog
immunolog
minsk
region
belaru
bioinformat
unit
institut
informat
problem
minsk
belaru
manag
belarusian
research
center
pediatr
oncolog
hematolog
immunolog
minsk
region
belaru
object
rate
kinet
characterist
growth
embryon
tumor
relat
term
implement
metastat
potenti
primari
tumor
method
retrospect
analysi
primari
malign
ultrasound
diagnosi
children
age
day
sex
nephroblastoma
retroperiton
neuroblastoma
neuroblastoma
adren
gland
hepatoblastoma
made
point
maximum
veloc
inflect
point
gompertz
model
calcul
base
vanish
second
deriv
gompertz
use
determin
threshold
age
diseas
goe
prognost
unfavor
stage
result
median
actual
volum
abdomin
tumor
primari
imag
obtain
spearman
rank
correl
p
tumor
volum
time
initi
diagnosi
age
base
evalu
gompertz
model
paramet
calcul
point
maximum
rate
tumor
growth
tmax
valu
correspond
day
sinc
birth
indic
critic
chang
growth
rate
malign
first
four
month
life
accord
result
found
threshold
exceed
age
chanc
malign
diagnosi
advanc
stage
sick
infant
increas
fold
ci
threshold
day
specif
ci
sensit
ci
auc
ci
conclus
thu
clinic
data
cohort
infant
model
situat
first
month
life
occur
greatest
intensif
process
malign
growth
realiz
metastat
potenti
reach
peak
growth
rate
investig
hepat
b
immun
children
present
paediatr
haematolog
oncolog
unit
south
africa
buchner
fe
omar
j
vermeulen
dt
reynder
paediatr
oncolog
unit
univers
pretoria
pretoria
south
africa
object
hepat
b
import
public
health
issu
south
africa
hepat
b
vaccin
introduc
south
african
expand
programm
immunis
epi
without
programm
durat
protect
hepat
b
vaccin
unknown
wane
immun
leav
children
risk
hepat
b
infect
set
preval
high
horizont
transmiss
like
aim
studi
assess
immun
hepat
b
patient
first
present
paediatr
oncolog
unit
method
retrospect
audit
done
new
patient
seen
unit
januari
decemb
none
patient
receiv
previou
immunosuppress
therapi
total
patient
result
avail
review
patient
classifi
immun
anti
hb
low
immun
anti
hb
immun
anti
hb
result
patient
includ
median
age
year
immun
hepat
b
despit
presum
vaccin
part
epi
schedul
six
patient
test
posit
hepat
b
core
antigen
consist
previou
infect
patient
activ
hepat
b
infect
hepat
b
surfac
antigen
posit
patient
hiv
infect
immun
conclus
signific
number
children
immun
hepat
b
despit
vaccin
part
south
african
epi
revaccin
consid
oncolog
haematolog
patient
opportun
exist
exposur
hepat
b
viru
consider
also
given
offer
booster
vaccin
popul
whole
water
qualiti
character
children
hospit
santiago
chile
zubieta
j
busto
e
vogel
r
rabagliati
mt
ulloa
p
research
depart
nuestro
hijo
santiago
chile
infecti
diseas
specialist
medic
center
medicin
faculti
cathol
univers
chile
santiago
chile
microbiolog
mycolog
program
faculti
medicin
univers
chile
santiago
chile
transplant
unit
lui
calvo
mackena
hospit
santiago
chile
object
good
water
qualiti
hospit
critic
mitig
risk
children
order
understand
realiti
santiago
chile
metropolitan
area
conduct
investig
local
hospit
water
suppli
pinda
nation
antineoplast
drug
children
program
center
sampl
taken
santiago
chile
metropolitan
area
month
april
juli
novemb
januari
method
microbiolog
mycolog
program
faculti
medicin
univers
chile
conduct
analys
bacteriolog
fungal
parasitolog
presenc
conduct
statist
analys
employ
test
respons
variabl
microbiolog
load
hospit
result
identifi
presenc
least
one
microorgan
locat
test
microsporidia
spp
preval
presenc
sampl
decreas
order
identifi
follow
organ
pseudomona
fluores
enterobact
cloaca
pseudomona
aeruginosa
pseudomona
oleovoran
pseudomona
putida
stenotrophomona
maltophilia
pseudomona
stutzeri
alcaligen
faecali
faecali
also
unidentifi
bacterium
gram
neg
non
ferment
bacilli
fungu
although
quantit
analys
show
presenc
microorgan
consist
enough
presenc
sampl
detect
statist
differ
p
among
hospit
test
conclus
discov
gener
water
qualiti
defici
test
hospit
thu
hospit
treat
immunocompromis
patient
present
data
suggest
necessari
take
specif
measur
ensur
health
child
treat
hospit
santiago
chile
metropolitan
area
role
pediatr
surgeon
oncologist
acut
pancreat
children
leukemia
treat
acut
lymphoblast
l
asparaginas
experi
nation
institut
pediatr
v
carrasquel
valecillo
j
palacio
acosta
leon
hernandez
hernandez
arrazola
pediatr
surgic
oncolog
instituto
nacion
de
mexico
citi
mexico
object
pancreat
inflammatori
diseas
exocrin
pancrea
tissu
enzym
aim
paper
evalu
role
de
oncolog
pediatr
surgeon
manag
acut
pancreat
method
retrospect
studi
analyz
case
patient
acut
pancreat
induc
l
treat
nation
institut
pediatr
inp
depart
surgic
oncolog
period
year
order
establish
role
pediatr
surgeon
oncologist
manag
patient
acut
pancreat
l
asp
clinic
record
patient
admit
surgic
oncolog
acut
pancreat
period
patient
acut
pancreat
induc
l
asp
review
clinic
biochem
data
ultrasound
comput
tomographi
treatment
complic
intens
care
stay
analyz
result
patient
acut
pancreat
l
asp
mean
age
year
gender
found
ratio
male
patient
femal
patient
abdomin
pain
nausea
vomit
elev
pancreat
enzym
lipas
amylas
ct
pancreat
necrosi
found
patient
patient
underw
periton
drainag
cathet
patient
tenchkoff
perform
necrosectomi
die
patient
one
due
toxic
pancrea
conclus
l
asp
effect
drug
treatment
toxic
requir
close
monitor
due
main
complic
pancreat
order
start
treatment
soon
possibl
surgeri
acut
pancreat
limit
remov
infect
necrot
pancreat
tissu
role
surgeon
paramount
import
determin
window
opportun
time
manag
poem
pediatr
oncolog
exercis
manual
knowledg
synthesi
improv
awar
physic
activ
benefit
childhood
cancer
c
chamorro
vina
keat
wurz
n
health
well
lab
faculti
kinesiolog
univers
calgari
canada
school
health
human
perform
divis
kinesiolog
dalhousi
univers
canada
depart
psychosoci
resourc
tom
baker
cancer
centr
alberta
health
servic
calgari
canada
depart
oncolog
faculti
medicin
univers
calgari
canada
purpos
promot
physic
activ
pa
children
cancer
therebi
improv
overal
qualiti
life
qol
pediatr
oncolog
exercis
manual
poem
websit
distribut
among
clinician
fit
profession
educ
cfe
well
famili
specif
project
seek
increas
awar
benefit
pa
cancer
treatment
equip
cfe
famili
tool
resourc
inform
method
conven
intern
spain
germani
netherland
usa
canada
acclaim
panel
expert
pediatr
oncolog
develop
first
worldwid
pa
manual
children
cancer
manual
develop
profession
lay
version
highlight
topic
includ
gener
evid
benefit
pa
cancer
recommend
precaut
survivor
experienc
poem
distribut
along
educ
session
onlin
platform
creat
evalu
qualiti
poem
b
provid
ongo
resourc
c
foster
ongo
intern
collabor
develop
onlin
train
creat
global
capac
area
result
dissemin
poem
across
alberta
begin
spring
plan
expans
nation
throughout
canada
intern
contributor
countri
final
plan
dissemin
poem
countri
develop
dissemin
manual
track
along
use
websit
resourc
survey
result
analyz
incorpor
yearli
qualiti
improv
cycl
ensur
best
translat
occur
conclus
creation
poem
along
onlin
support
enhanc
awar
role
pa
pediatr
oncolog
econom
sustain
manner
increas
pa
level
result
enhanc
qol
pediatr
cancer
survivor
diminish
risk
develop
comorbid
condit
survivorship
cknowledg
canadian
institut
health
research
alberta
children
hospit
poem
contributor
development
delay
child
autoimmun
lymphoprolif
syndrom
yr
chopra
ramzan
r
sharma
katewa
yadav
pediatr
hematolog
oncolog
bone
marrow
transplant
unit
forti
memori
research
institut
gurgaon
india
object
autoimmun
lymphoprolif
syndrom
alp
inherit
lymphoid
disord
attribut
defect
apoptosi
character
lymphoprolifer
autoimmun
cytopenia
rais
circul
doubl
neg
cell
dnt
development
delay
dd
report
condit
describ
femal
alp
development
delay
method
detail
analysi
child
histori
examin
laboratori
investig
along
review
literatur
two
condit
done
result
femal
present
intermitt
fever
repeat
hospit
last
year
physic
examin
splenohepatomegali
development
delay
evalu
infect
malaria
leukaemia
lymphoma
inborn
error
metabol
glycogen
storag
disord
connect
tissu
disord
investig
reveal
neutropenia
hypergammaglobulinemia
chest
x
ray
normal
mantoux
neg
almost
infecti
caus
rule
serolog
test
ana
neg
bone
marrow
examin
normal
view
persist
neutropenia
month
non
non
splenohepatomegali
possibl
alp
thought
flow
cytometri
done
reveal
doubl
neg
cell
confirm
alp
resolut
neutropenia
start
prednisolon
also
start
sirolimu
decreas
organomegali
though
improv
occur
development
mileston
conclus
alp
suspect
child
isol
persist
neutropenia
organomegali
common
caus
like
infect
malign
autoimmun
rule
best
knowledg
development
delay
report
alp
report
make
paediatr
oncologist
awar
rare
associ
deficit
clinic
trial
enrol
among
adolesc
young
adult
cancer
treat
academ
medic
center
c
collin
dr
freyer
pediatr
hematologyoncolog
children
hospit
lo
angel
lo
angel
usa
object
improv
surviv
adolesc
young
adult
aya
age
cancer
wors
compar
children
older
adult
trend
may
partli
due
poor
accrual
clinic
trial
determin
clinic
trial
enrol
academ
medic
center
compar
proport
aya
enrol
children
older
adult
institut
within
center
method
california
cancer
registri
provid
data
patient
diagnos
cancer
treat
univers
southern
california
usc
cancer
center
institut
usc
oncolog
care
deliv
set
children
hospit
adult
cancer
hospit
facil
provid
care
children
adult
patient
identifi
registri
match
institut
databas
track
trial
enrol
differ
enrol
determin
test
result
overal
children
enrol
therapeut
clinic
trial
compar
aya
adult
p
enrol
among
aya
higher
children
hospit
compar
either
adult
cancer
hospit
p
counti
facil
p
howev
within
children
hospit
proport
aya
enrol
therapeut
trial
significantli
lower
compar
children
p
frequent
aya
diagnos
clinic
trial
avail
compar
children
adult
conclus
proport
aya
adult
enrol
therapeut
trial
low
suggest
administr
barrier
enrol
within
children
hospit
lower
enrol
among
aya
suggest
barrier
trial
avail
may
also
contribut
howev
reason
routin
captur
prevent
analysi
caus
low
enrol
document
prospect
across
treatment
set
cystein
cathepsin
cystatin
c
vegf
tumor
vasculogenesi
n
dementieva
surgeri
oncolog
region
children
hospit
dnipropetrovsk
dnipropetrovsk
ukrain
object
studi
activ
cystein
proteas
cathepsin
b
l
h
endogen
inhibitor
cystatin
c
vascular
endotheli
growth
factor
vegf
blood
serum
children
infantil
hemangioma
compar
control
method
studi
activ
cathepsin
b
l
h
concentr
cystatin
c
vegf
blood
serum
healthi
children
children
infantil
hemangioma
treat
propranolol
group
good
respons
group
relaps
discontinu
propranolol
use
standard
method
result
serum
level
activ
vegf
cathepsin
b
l
h
patient
hemangioma
significantli
higher
serum
healthi
children
vegf
serum
concentr
higher
group
compar
control
p
gradual
normal
cours
treatment
vegf
concentr
differ
control
group
activ
cathepsin
b
l
h
group
treatment
compar
control
group
reach
level
healthi
children
sever
involut
hemangioma
pattern
level
cystatin
cconcentr
conclus
unfavor
aggress
cours
hemangioma
associ
elev
concentr
vegf
activ
cathepsin
b
l
h
blood
serum
understand
role
cystein
proteas
cathepsin
b
l
h
endogen
inhibitor
cystatin
c
vascular
endotheli
growth
factor
vegf
tumor
vasculogenesi
could
lead
develop
efficaci
therapi
untangl
cord
polici
analysi
nation
public
umbil
cord
blood
bank
canada
denburg
j
abelson
haematologyoncolog
hospit
sick
children
toronto
canada
centr
health
econom
polici
analysi
mcmaster
univers
toronto
canada
object
recognit
valu
cord
blood
prompt
widespread
effort
collect
bank
privat
publicli
recent
canada
group
countri
without
nation
public
cord
blood
bank
explan
canada
rel
delay
develop
nation
cord
blood
bank
cbb
program
unclear
receiv
almost
scholarli
attent
method
data
analysi
deriv
search
publish
grey
literatur
cbb
sourc
data
includ
academ
articl
government
document
media
sourc
organiz
industri
websit
onlin
media
map
determin
cbb
polici
canada
employ
analyt
framework
develop
jonathan
loma
consid
manner
inform
valu
institut
configur
context
polici
result
analysi
highlight
predomin
institut
structur
determin
polici
stasi
cbb
structur
blood
system
govern
condit
use
valu
inform
influenc
problem
definit
cbb
canada
diffus
role
hamper
earli
sustain
stewardship
cbb
polici
disjunctur
polit
respons
ambit
nation
cbb
polici
slow
develop
nation
cord
blood
bank
conclus
analysi
suggest
locat
greater
respons
fund
feder
level
would
facilit
coordin
nation
respons
polici
challeng
emerg
stem
cell
scienc
evolv
explicit
framework
policymak
cord
blood
rapidli
evolv
area
blood
system
polici
would
provid
transpar
blueprint
formal
effort
public
consult
delib
process
otherwis
could
help
plait
public
percept
evolv
scientif
evid
align
broadli
held
moral
intuit
ethic
principl
justifi
polici
choic
outcom
acut
gut
gvhd
post
stem
cell
transplant
children
import
nutrit
statu
dhamija
v
khandelw
choudhari
sharma
n
gupta
hemato
oncolog
bmt
blk
super
special
hospit
new
delhi
india
object
acut
diseas
agvhd
allogen
hematopoiet
cell
transplant
associ
consider
morbid
mortal
gut
agvhd
remain
difficult
manag
morbid
mortal
increas
malnutrit
studi
undertaken
report
outcom
gut
agvhd
children
tertiari
care
center
india
effect
malnutrit
morbid
mortal
method
retrospect
observ
studi
report
outcom
patient
age
year
gut
agvhd
grade
iv
steroid
refractori
nine
children
malnourish
time
start
condit
regimen
weight
age
less
centil
cdc
standard
result
nine
children
match
sibl
donor
match
unrel
haploident
relat
one
antigen
mismatch
relat
donor
respect
sourc
stem
cell
peripher
blood
patient
bone
marrow
five
mean
cell
dose
mean
time
appear
symptom
day
mortal
cohort
common
immedi
caus
death
gram
neg
sepsi
secondari
immunosuppress
four
patient
steroid
refractori
gut
gvhd
surviv
p
five
malnourish
children
succumb
p
conclus
come
children
malnutrit
gut
agvhd
wors
steroid
refractori
gut
agvhd
hold
poor
outcom
breast
diseas
children
adolesc
risk
factor
breast
cancer
dragomir
c
comsa
badoi
e
gruber
voinea
blidaru
c
radu
pediatr
oncolog
institut
oncolog
bucharest
romania
surgeri
depart
institut
oncolog
bucharest
romania
endocrinolog
institut
oncolog
bucharest
romania
object
analyz
breast
diseas
children
adolesc
estim
risk
factor
breast
cancer
method
patient
includ
year
age
breast
diseas
treat
surgeri
treatment
institut
oncolog
bucharest
look
risk
factor
breast
cancer
famili
histori
breast
ovarian
malignanaci
diet
outcom
diseas
surgic
treatment
pt
lumpectomi
tumorectomi
pt
receiv
drug
therapi
case
small
tumor
cm
choic
expect
result
case
male
patient
highest
incid
year
old
type
breast
tumor
phyllod
tumor
ductal
papilloma
mammari
disord
fibrocyst
chang
sign
symptom
physiolog
swell
tender
pt
nodular
pt
breast
pain
pt
palpabl
breast
lump
pt
famili
histori
event
found
patient
mother
rel
benign
mammari
lesion
breast
andor
ovarian
cancer
pt
symptomat
high
serum
estrogen
level
menstruat
disord
ovarian
cyst
earli
menarch
excess
carbohydr
diet
overweight
obes
present
case
year
follow
small
tumor
cm
reveal
becam
smaller
kept
size
becam
larger
conclus
signific
number
children
adolesc
breast
benign
tumor
fibrocyst
chang
risk
factor
breast
cancer
effect
accur
counsel
adolesc
parent
regard
breast
cancer
prevent
routin
compon
prevent
health
work
togeth
ethic
ethic
deliber
involv
profession
well
patient
parent
repres
lesson
result
encca
project
jck
dupont
karner
f
doz
kienesberg
k
paediatr
oncolog
depart
institut
curi
pari
franc
vienna
austria
institut
child
health
univers
colleg
london
london
unit
kingdom
object
ethic
european
network
cancer
research
children
adolesc
encca
use
valid
methodolog
ethic
evalu
deliber
aim
make
state
art
review
relev
ethic
issu
paediatr
oncolog
research
balanc
perspect
profession
patient
parent
repres
method
european
repres
intern
confeder
childhood
cancer
parent
organ
icccpo
profession
involv
encca
invit
particip
ethic
deliber
clinic
trial
deliber
conceiv
mean
get
stakehold
expert
conclus
ethic
issu
make
particip
game
give
ask
reason
justifi
stanc
sound
argument
abil
di
agre
stakehold
becam
scorekeep
game
ethic
deliber
fulli
inclus
view
result
fromth
scope
natur
di
agreement
three
kind
result
could
distil
name
eg
valu
research
particip
ralli
eg
commun
equipois
clinic
trial
discrep
eg
voluntari
particip
exclus
membership
encca
partner
found
deliber
meaning
scope
exercis
allow
design
ethic
intervent
identif
empir
norm
research
avenu
relev
paediatr
oncolog
commun
whole
profession
lay
peopl
conclus
ethic
deliber
process
preclud
disagr
therefor
import
develop
exhaust
balanc
perspect
two
answer
made
question
one
relat
valu
plural
biomed
research
ethic
knowledg
anoth
consist
present
patient
repres
valu
encca
experi
ethic
jeneec
place
home
away
home
famili
stay
undergo
medic
treatment
j
edroff
board
director
jeneec
edroff
societi
victoria
canada
object
purpos
build
home
famili
need
place
stay
victoria
undergo
medic
treatment
home
would
provid
warm
safe
invit
environ
pediatr
famili
hope
elimin
stress
stay
also
rais
approxim
year
oper
cost
elimin
need
fundrais
earli
year
oper
method
use
person
stori
overcom
medic
challeng
past
histori
rais
million
dollar
penni
varieti
children
chariti
secur
recognit
support
notabl
partner
telu
children
health
foundat
norgaard
foundat
corpor
sponsor
donat
larg
amount
money
rest
donat
island
commun
secur
donat
kind
contractor
secur
figur
donat
variou
local
corpor
sponsor
name
room
help
us
achiev
goal
short
period
time
media
coverag
paramount
result
first
shovel
ground
finish
jeneec
place
built
month
squar
foot
home
accommod
famili
rais
project
goal
built
jeneec
place
significantli
budget
due
kind
donat
contractor
first
time
accomplish
year
old
young
ladi
conclus
jeneec
place
open
year
serv
famili
famili
visit
jeneec
place
come
vancouv
island
golf
island
come
far
away
franc
serv
purpos
help
bc
famili
protocol
abdomin
comput
tomographi
reduct
ioniz
radiat
pediatr
oncolog
patient
ce
cavalcant
r
rossini
lederman
carvalho
l
lope
diagnost
imag
radiolog
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
diagnost
imag
radiolog
unifesp
universidad
feder
de
paulo
paulo
brazil
medic
director
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
object
dose
reduct
ioniz
radiat
pediatr
oncolog
patient
chang
protocol
comput
tomographi
scan
stage
intraven
contrast
earli
portal
phase
describ
method
patient
select
underw
comput
tomographi
ct
examin
upper
abdomen
lower
abdomen
total
period
novemb
august
describeb
old
protocol
group
patient
underw
ct
period
septemb
januari
describ
new
protocol
group
total
dose
averag
total
dose
equival
done
group
result
base
averag
equival
dose
ct
reduct
radiat
dose
patient
new
protocol
group
compar
old
protocol
group
moreov
protocol
chang
caus
damag
diagnost
imag
conclus
princip
object
work
verifi
result
reduct
total
equival
dose
ct
examin
within
possibl
limit
base
principl
alara
radiat
safeti
manual
univers
washigton
radiat
safeti
misdiagnosi
referr
patient
disord
pediatr
oncolog
unit
farrag
ghazali
pediatr
oncolog
depart
south
egypt
cancer
institut
assiut
univers
assiut
egypt
depart
pediatr
faculti
medicin
assiut
univers
assiut
egypt
object
evalu
patient
wrongli
misdiagnos
refer
pediatr
oncolog
unit
initi
suspicion
cancer
evalu
size
problem
one
larg
cancer
institut
develop
countri
method
retrospect
analysi
perform
patient
refer
pediatr
oncolog
depart
south
egypt
cancer
institut
seci
result
avail
data
patient
admit
seci
suffer
malign
tumor
referredescapedlost
full
diagnosi
die
earli
admiss
reach
final
diagnosi
prove
diseas
benign
tumor
benign
hematolog
diseas
infect
inflammatori
case
metabol
diseas
differ
diagnos
conclus
misdiagnosi
cancer
children
problem
exclud
start
therapi
pediatr
oncolog
unit
especi
develop
countri
diagnost
facil
restrict
strategi
prevent
treatment
abandon
childhood
cancer
rio
de
janeiro
brazil
ferman
f
lima
suzuki
c
lage
l
portela
b
de
camargo
r
ribeiro
pediatr
oncolog
depart
instituto
nacion
de
rio
de
janeiro
brazil
pediatr
hematolog
oncolog
program
instituto
nacion
de
rio
de
janeiro
brazil
pediatr
oncolog
depart
st
jude
children
research
hospit
memphi
usa
object
abandon
treatment
childhood
cancer
consid
one
major
limit
achiev
high
cure
rate
develop
countri
aim
studi
describ
impact
simpl
strategi
prevent
treatment
abandon
method
studi
period
patient
younger
year
diagnos
treat
solid
tumor
instituto
nacion
de
rio
de
brazil
prospect
monitor
adher
appoint
daili
one
health
care
profession
regist
patient
miss
schedul
oncolog
consult
famili
member
contact
within
hour
miss
appoint
phone
call
andor
telegram
primari
physician
inform
well
multidisciplinari
team
intervent
address
lack
resourc
travel
expens
lodg
transport
food
basket
provid
famili
abandon
defin
week
miss
appoint
activ
treatment
result
studi
period
patient
schedul
oncolog
consult
patient
miss
least
one
famili
contact
data
manag
number
absenc
diagnost
investig
treatment
number
absenc
pt
n
n
n
n
n
n
pt
one
hundr
five
pt
return
treatment
pt
abandon
treatment
despit
effort
absenc
occur
pt
treatment
conclus
monitor
miss
appoint
earli
intervent
address
issu
associ
provid
resourc
help
famili
treatment
associ
low
abandon
rate
earli
diagnosi
childhood
cancer
challeng
develop
countri
cmcm
fiori
rosa
cg
santo
sc
buettner
miaa
melo
ry
sakurada
hospit
cancer
uopeccan
cascavel
state
univers
west
unioest
cascavel
brazil
introduct
develop
countri
cure
rate
cancer
children
exce
realiti
far
achiev
brazil
main
reason
difficulti
health
profession
diagnos
diseas
earli
cancer
hospit
cascavel
uopeccan
partnership
ronald
mcdonald
institut
earli
diagnosi
cancer
children
adolesc
program
train
profession
health
pediatr
municip
object
train
profession
health
pediatrician
contribut
earli
identif
cancer
children
adolesc
reduc
time
onset
sign
symptom
diagnosi
special
center
provid
increas
probabl
cure
methodolog
health
profession
citi
train
april
receiv
basic
inform
children
cancer
adolesc
epidemiolog
sign
symptom
suspicion
care
need
attent
children
adolesc
cancer
group
form
profession
hour
cours
result
profession
doctor
nurs
technician
nurs
assist
commun
health
agent
upper
level
profession
auxiliari
comment
among
diagnos
case
cancer
children
brasil
mani
refer
treatment
center
diseas
advanc
stage
one
goal
campaign
encourag
educ
prevent
action
becom
known
peopl
symptom
sign
diseas
program
perform
brazilian
citi
show
reduct
time
cours
week
arriv
children
referr
center
region
train
shorten
time
suspicion
cancer
earli
diagnosi
treatment
certainli
contribut
increas
expect
cure
develop
countri
dilut
pediatr
oncolog
guidelin
practic
applic
l
fruit
p
leblond
sakji
h
sudour
g
marliot
c
lervat
mercier
delbey
defachel
clinic
pharmaci
depart
oscar
lambret
center
lill
franc
pediatr
oncolog
unit
oscar
lambret
center
lill
franc
object
sinc
case
accident
intrathec
inject
report
worldwid
respons
sever
irrevers
neurolog
disord
order
avoid
advers
event
sever
health
author
publish
recommend
among
dilut
chemotherapi
produc
pediatr
unit
among
prepar
purpos
studi
feasibl
implement
guidelin
method
analyz
intern
recommend
franc
usa
canada
england
ireland
spain
australia
hong
kong
use
mainli
recommend
n
adult
pediatr
four
guidelin
recommend
use
syring
pediatr
pediatr
oncolog
unit
prescrib
vinblastin
vincristin
vinorelbin
work
togeth
pediatrician
dilut
chemotherapi
result
manag
dilut
vinorelbin
minibag
main
issu
total
administ
volum
dilut
flush
infusor
sometim
larg
smaller
children
consequ
could
nt
vincristin
vinblastin
shorter
administr
time
dilut
larg
syring
implement
aim
kind
prepar
reduc
probabl
accident
intrathec
administr
larger
volum
short
period
could
lead
cardiovascular
advers
effect
conclus
pediatr
oncolog
recommend
made
secur
use
difficult
appli
still
use
luer
syring
prepar
way
effici
secur
use
would
use
devic
intrathec
inject
yet
avail
franc
spread
devic
would
major
step
identif
instrument
use
evalu
symptom
children
adolesc
cancer
systemat
review
geronutti
murra
lf
lope
bs
paiva
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
hospit
director
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
research
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
object
systemat
literatur
review
identifi
instrument
use
assess
symptom
children
adolesc
cancer
method
review
carri
pubm
databas
use
keyword
questionnair
mesh
scale
instrument
questionnair
inventori
symptom
assess
mesh
pain
pain
mesh
fatigu
mesh
fatigu
weak
lack
energi
tired
depress
mesh
depress
sad
sleepi
sleep
stagescompl
mesh
dyspnea
mesh
dyspnoea
dyspnea
lack
air
nausea
vomit
anxieti
mesh
anxieti
constip
constip
mesh
drowsi
neoplasm
mesh
cancer
tumor
tumor
neoplasm
pediatr
inclus
criteria
titl
abstract
english
portugues
spanish
without
restrict
period
address
singl
multipl
symptom
scale
questionnair
pediatr
instrument
result
articl
initi
identifi
exclud
review
address
instrument
qualiti
life
symptom
complet
treatment
scale
mucos
dealt
theme
popul
thu
articl
exclud
analyz
delet
occur
adult
follow
relat
critic
instrument
one
commun
systemat
review
patholog
side
effect
address
intervent
improv
qualiti
life
report
experi
patient
undergo
cancer
treatment
discuss
pharmacolog
intervent
pain
percept
parent
staff
treatment
thu
studi
analyz
conclus
possibl
identifi
shortag
instrument
assess
symptom
pediatr
patient
likewis
happen
pediatr
oncolog
therefor
necessari
develop
valid
instrument
assess
symptom
children
cancer
use
interact
play
children
world
countri
access
school
disrupt
diagnosi
subsequ
treatment
govend
kleinenberg
ngo
choc
childhood
cancer
foundat
sa
durban
south
africa
object
base
premis
ubuntu
provid
basic
interact
play
hospitalis
young
person
allow
opportun
interact
well
adult
learn
new
skill
ultim
reintegr
societi
limit
school
owe
age
circumst
choc
fill
gap
interact
play
whilst
treatment
method
power
point
present
discuss
interact
pack
prepar
deleg
order
achiev
activ
result
creat
person
experi
duplic
countri
diminish
resourc
conclus
advoc
interact
play
replac
school
interact
play
fulfil
social
emot
cognit
interact
function
role
close
gap
child
cancer
reintegr
societi
painlessli
learnt
skill
incorpor
school
want
impart
tri
test
skill
microbiolog
profil
infect
children
solid
tumor
receiv
anticanc
treatment
one
center
k
semczuk
b
k
j
styczynski
pediatr
oncolog
children
memori
helath
institut
warsaw
poland
depart
clinic
microbiolog
immunolog
children
memori
helath
institut
warsaw
poland
depart
pediatr
hematolog
oncolog
collegium
medicum
nicolau
copernicu
univers
bydgoszcz
poland
object
one
common
complic
anticanc
treatment
infect
neutropenia
mucos
prolong
hospit
central
venou
cathet
main
risk
factor
chang
pattern
microbiolog
agent
respons
seriou
infect
grow
antibiot
resist
warrant
continu
epidemiolog
microbiolog
monitor
aim
studi
assess
type
frequenc
etiolog
agent
infecti
complic
children
solid
tumor
treat
singl
institut
method
year
chemotherapi
relat
hospit
treatment
complic
regist
depart
year
children
age
year
age
treat
blood
urin
stool
specimen
collect
cultur
case
neutropen
fever
non
neutropen
patient
site
correspond
symptom
infect
analysi
type
microbiolog
agent
resist
antibiot
perform
result
microbiolog
studi
perform
microbiolog
posit
correl
clinic
symptom
infect
gastrointestin
infect
common
episod
clostridium
difficil
identifi
rotavir
infect
bacteri
central
venou
infect
confirm
episod
gram
posit
agent
gram
neg
common
gram
posit
bacteria
staphylococcu
spp
episod
candidaemia
cvc
episod
candida
spp
cultur
urin
specimen
conclus
materi
etiolog
agent
identifi
specimen
clostridium
difficil
frequent
identifi
attribut
broad
spectrum
antibiot
administ
children
undergo
anticanc
treatment
case
fever
target
treatment
often
possibl
cultur
usual
neg
gram
posit
agent
remain
frequent
etiolog
infect
result
parent
support
group
health
profession
survey
knowledg
access
essenti
medicin
lowmiddl
incom
countri
lmic
e
grynszpancholc
j
wernikowski
r
barr
presid
dafn
flexer
ciudad
de
bueno
air
argentina
clinic
pharmacist
paediatr
paediatr
haematologyoncolog
mcmaster
children
hospita
hamilton
canada
depart
pediatr
patholog
medicin
mcmaster
univers
mcmaster
children
hospit
hamilton
canada
object
gaug
knowledg
identifi
barrier
access
drug
essenti
medicin
list
health
profession
parent
method
two
survey
deliv
last
year
one
siop
member
intern
confeder
childhood
cancer
parent
organ
icccpo
member
result
siop
respond
n
low
low
middl
incom
countri
respond
knew
essenti
medicin
list
eml
certain
govern
use
eml
guid
purchas
drug
respond
said
drug
sourc
combin
govern
ngo
past
year
respond
delay
cancel
treatment
due
drug
unavail
experienc
weekli
monthli
basi
percent
felt
drug
cost
alway
barrier
felt
sometim
barrier
access
percent
felt
price
charg
famili
drug
signific
barrier
icccpo
respond
n
low
low
middl
incom
countri
respond
believ
problem
shortag
delay
countri
shortag
problem
pronounc
countri
delay
medic
due
larg
much
bureaucraci
countri
main
reason
patientsdoctor
request
medic
health
insur
compani
govern
suppli
medic
respond
llmic
budget
purchas
medicinesdrug
respond
hic
provid
medic
conclus
access
medicin
remain
signific
concern
lmic
costpric
unavail
beaurocraci
major
barrier
deliv
treatment
support
system
childhood
cancer
survivor
difficulti
hayashi
fumiko
ishida
manag
npo
project
niigata
citi
japan
manag
npo
chiba
citi
japan
pediatr
medic
center
ehim
prefectur
central
hospit
matsuyama
citi
japan
object
mani
childhood
cancer
survivor
ccss
launch
variou
field
increas
cure
rate
ccss
howev
struggl
hardship
work
although
govern
deliv
disabl
certif
social
welfar
servic
handicap
peopl
quit
ccss
problem
cover
even
case
brain
tumor
ccss
higher
brain
dysfunct
cover
handicap
person
employ
law
give
opportun
disabl
peopl
find
employ
appli
almost
ccss
may
face
difficulti
start
project
improv
circumst
method
sent
questionnair
ccss
grasp
employ
situat
answer
found
ccss
even
late
twenti
forti
financi
depend
famili
result
last
april
open
tearoom
hire
ccss
aim
ultim
goal
get
hire
busi
societi
futur
learn
commun
peopl
work
tearoom
waiterswaitress
simpl
paper
work
comput
well
also
opportun
learn
someth
want
like
get
certifi
special
skill
also
assign
keep
daili
work
descript
find
good
overcom
conclus
pass
year
sinc
open
tearoom
hire
ccss
confid
posit
member
societi
pay
tax
one
got
marri
expect
babi
soon
one
got
hire
compani
start
new
life
clofarabin
children
relaps
acut
leukemia
istanbul
experi
z
karaka
b
sirin
koc
karaman
anak
unuvar
e
uysalol
l
agaoglu
g
ozturk
devecioglu
pediatr
hematologyoncolog
istanbul
univers
istanbul
medic
faculti
istanbul
turkey
object
although
clofarabin
known
effect
novel
agent
relaps
acut
leukemia
optimum
combin
time
use
remain
challeng
aim
studi
evalu
clofarabin
base
protocol
children
acut
leukemia
method
retrospect
analyz
data
twelv
children
treat
clove
protocol
third
greater
bone
marrow
relaps
acut
leukemia
seven
patient
aml
patient
relaps
treat
one
two
cure
flag
perform
rez
protocol
relaps
aml
treat
two
cure
flag
mrc
protocol
case
respons
least
two
relaps
protocol
receiv
clove
protocol
one
two
cure
result
clofarabin
effect
induc
remiss
six
patient
half
hematopoiet
stem
cell
transplant
hsct
tabl
relaps
hsct
one
also
relaps
second
hsct
although
clofarabin
effect
induc
remiss
overal
surviv
poor
studi
overal
surviv
rate
start
clove
protocol
respect
common
advers
event
prolong
neutropenia
although
one
patient
die
sever
infect
patient
sever
bacteri
invas
fungal
infect
also
observ
elev
liver
enzym
patient
one
patient
refractori
aml
need
pediatr
intens
care
due
sever
hepatotox
vod
clofarabin
therapi
conclus
patient
except
one
die
relapsedrefractori
leukemia
even
though
four
hsct
although
provid
longer
lifetim
use
clove
multipl
relaps
acut
leukemia
subsequ
patient
die
uncontrol
leukemia
therefor
suggest
clofarabin
use
first
relaps
leukemia
mrd
determin
obtain
better
result
main
question
remain
better
outcom
could
obtain
earlier
clofarabin
base
chemotherapi
infect
respiratori
virus
children
cancer
istanbul
r
kebudi
bay
kapu
b
oflaz
sozmen
ciblak
gorgun
b
zulfikar
badur
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
oncolog
institut
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
oncolog
institut
istanbul
turkey
pediatr
hematolog
oncolog
koc
univers
american
hospit
istanbul
turkey
microbiolog
istanbul
univers
medic
faculti
istanbul
turkey
object
respiratori
viru
rv
infect
caus
signific
morbid
mortal
pediatr
cancer
patient
aim
studi
identifi
rv
infect
children
cancer
present
sign
symptom
respiratori
tract
infect
method
children
cancer
present
sign
symptom
respiratori
tract
infect
assess
rv
algorithm
molecular
techniqu
suggest
cdc
refer
virolog
laboratori
istanbul
univers
result
sampl
episod
children
cancer
evalu
follow
rv
identifi
episod
influenza
influenza
b
respiratori
syncyti
viru
rhinoviru
coronaviru
metapneumoviru
bocaviru
five
patient
lower
respiratori
tract
infect
influenza
rsv
patient
coronaviru
also
pleural
effus
fever
cough
nasal
discharg
sore
throat
common
symptom
system
antibiot
also
given
febril
neutropen
episod
patient
influenza
treat
oseltamivir
except
rhinoviru
metapneumonia
parainfluenza
requir
hospit
recov
specif
andor
support
treatment
chemotherapi
delay
day
episod
conclus
kept
mind
virus
major
caus
respiratori
tract
infect
children
cancer
oseltamivir
effect
treatment
influenza
children
cancer
sinc
effect
antivir
agent
respiratori
virus
precautionari
infect
control
earli
diagnosi
import
prevent
infect
spread
case
hospit
support
care
need
reduc
morbid
avoid
mortal
improv
outcom
invas
fungal
diseas
pediatr
cancer
patient
local
institut
experi
year
khattab
w
jastaniah
k
abdullah
k
hanif
mufti
asseri
abrar
princ
noorah
oncolog
center
king
abdulaziz
medic
cityn
guard
hospit
jeddah
saudi
arabia
background
increas
incid
invas
fungal
diseas
ifd
due
increas
intens
variou
chemotherapi
ifd
common
caus
morbid
mortal
immunocompromis
patient
avail
mani
antifung
agent
impact
outcom
object
find
type
cancer
infect
ifd
type
ifd
studi
outcom
pediatr
cancer
patient
ifd
impact
surviv
method
retrospect
review
pediatr
cancer
hematolog
malign
develop
ill
proven
probabl
ifd
report
asco
abstract
overal
surviv
mortal
due
cancer
due
ifd
report
type
cancer
type
fungal
diseas
overal
surviv
mortal
whether
due
primari
diseas
ifd
result
period
patient
regist
relaps
aml
nhl
nbl
rm
wt
os
lch
hd
chediak
higashi
synd
mbl
aplast
anemia
es
cml
hlh
pt
proven
aspergillosi
surviv
die
primari
diseas
ifd
pt
candidiasi
surviv
die
primari
di
fungal
sepsi
pt
consid
probabl
ifd
surviv
die
primari
diseas
mucormycosi
surviv
die
primari
diseas
cure
cutan
pulmonari
mucormycosi
die
mucormycosi
overal
surviv
mortal
primari
diseas
mortal
ifd
conclus
compar
previou
abstract
show
local
improv
outcom
ifd
due
proper
time
start
empir
antifung
c
fungal
diagnost
approach
surgic
debrid
cutan
lesion
sinus
lung
lesion
indic
choos
appropri
antifung
agent
accord
patient
clinic
function
statu
measur
oral
mucos
children
cancer
ij
jenei
k
gyurina
j
c
kiss
depart
restor
dentistri
univers
debrecen
debrecen
hungari
depart
biostatist
epdemiolog
univers
debrecen
debrecen
hungari
depart
pediatr
univers
debrecen
debrecen
hungari
object
aim
studi
evalu
administr
oral
mucos
symptom
prom
scale
among
pediatr
cancer
patient
compar
data
dental
surgeon
assess
oral
health
measur
establish
advers
impact
om
qualiti
life
qol
method
children
cancer
male
femal
age
yr
investig
januari
decemb
hungarian
version
prom
scale
use
particip
fill
questionnair
accord
sever
symptom
item
visual
analogu
scale
admiss
weekli
day
sum
item
score
gave
total
prom
score
om
diagnoz
dental
surgeon
use
score
cariolog
periodont
condit
wbc
anticanc
drug
antiinfect
support
therapi
regist
result
om
observ
patient
total
prom
score
increas
gradual
day
follow
transient
decreas
day
peak
day
contrast
patient
largest
homogen
subgroup
patient
exhibit
monoton
decreas
tendenc
total
prom
score
day
ie
conclud
induct
therapi
found
signific
associ
p
prom
item
score
om
score
compon
signific
correl
p
observ
item
total
prom
score
wbc
signific
associ
cariolog
periodont
indic
total
prom
score
item
score
conclus
prom
questionnair
suitabl
measur
om
pediatr
patient
character
incid
sever
om
prom
may
allow
develop
comprehens
program
reduc
highli
distress
cancer
treatment
children
studi
support
otka
project
relationship
express
vincristin
neurotox
turkish
children
malign
u
kocak
h
kayilioglu
dk
karaer
ep
percin
okur
c
karadeniz
pediatr
hematolog
gazi
univers
school
medicin
ankara
turkey
genet
gazi
univers
school
medicin
ankara
turkey
pediatr
oncolog
gazi
univers
school
medicin
ankara
turkey
object
vincristin
wide
use
chemotherapeut
agent
treatment
childhood
malign
neuropathi
combin
onset
peripher
progress
motor
sensori
autonom
compon
common
advers
effect
vincristin
treatment
also
lead
caus
dose
modif
howev
vincristin
dose
caus
neuropathi
particular
patient
decis
anticip
enzym
cytochrom
enzym
system
respons
vincristin
metabol
common
allel
encod
abnorm
splice
mrna
prematur
stop
codon
result
decreas
express
common
allel
peopl
provid
high
express
rate
fast
metabol
vincristin
lead
lesser
neurotox
studi
distribut
allel
among
turkish
children
malign
relat
genotyp
neurotox
rate
sever
durat
neuropathi
total
vincristin
dose
investig
method
file
patient
age
year
treat
vincristin
consist
chemotherapi
protocol
retrospect
review
neurotox
genotyp
analyz
neurotox
grade
accord
nation
cancer
institut
common
terminolog
criteria
advers
event
scale
result
neurotox
occur
patient
combin
sensori
motor
neuropathi
common
form
although
found
occur
frequent
dose
vincristin
rate
higher
low
dose
vincristin
group
suggest
contribut
factor
neurotox
rate
genotyp
genotyp
differ
statist
signific
p
conclus
conclus
studi
suggest
vincristin
relat
neurotox
genotyp
caus
factor
occurr
neurotox
patient
cost
lead
financi
crisi
famili
children
cancer
could
avoid
provis
basic
financi
support
j
lamont
candlelight
childhood
cancer
support
program
ottawa
ontario
canada
famili
children
cancer
experi
numer
expens
creat
addit
emot
stress
financi
challeng
seem
insurmount
provis
basic
financi
assist
lessen
financi
burden
famili
help
reduc
number
face
financi
crisi
econom
implic
input
feedback
ongo
dialogu
famili
healthcar
provid
consist
identifi
area
need
park
fee
ga
cost
meal
expens
incur
parent
hospit
childcar
address
candlelight
provis
program
genuin
impact
famili
financi
situat
survey
conduct
februari
evalu
signific
program
childhood
cancer
journey
percent
survey
report
experienc
financi
hardship
result
child
cancer
respond
famili
benefit
candlelight
initi
report
famili
would
experienc
financi
crisi
without
candlelight
assist
financi
crisi
defin
need
request
addit
financi
assist
beyond
provid
famili
candlelight
survey
respond
report
believ
everi
famili
child
diagnos
cancer
regardless
race
religion
cultur
socioeconom
statu
elig
basic
fund
knowledg
addit
fund
could
access
base
addit
need
percent
feel
enough
financi
assist
avail
famili
larg
part
due
servic
provid
candlelight
avoid
inevit
cost
result
child
diagnos
cancer
provid
much
need
financi
support
everyday
expens
result
stabl
financi
situat
posit
effect
famili
overal
financi
posit
cope
childhood
cancer
result
track
wilm
tumor
patient
kenya
j
libe
f
njuguna
j
musimbi
k
patel
h
lovvorn
pediatr
vanderbilt
univers
nashvil
usa
pediatr
moi
teach
referr
hospit
eldoret
kenya
immunolog
moi
teach
referr
hospit
eldoret
kenya
pediatr
surgeri
vanderbilt
univers
children
hospit
nashvil
usa
object
review
kenyan
wilm
tumor
wt
registri
trace
call
reveal
estim
year
overal
surviv
os
percent
patient
diagnos
due
mortal
treatment
abandon
report
preliminari
result
track
effort
wt
patient
moi
teach
referr
hospit
method
januari
train
research
nurs
call
parent
abandon
treatment
therapi
follow
children
determin
vital
statu
encourag
return
therapi
track
patient
previous
newli
diagnos
miss
visit
result
patient
diagnos
wt
n
percent
mortal
rate
percent
mortal
rate
treatment
abandon
abandon
rate
percent
percent
aliv
one
patient
return
therapi
percent
contact
percent
die
nine
percent
patient
lost
follow
termin
treatment
one
patient
return
trace
call
os
estim
percent
patient
diagnos
n
still
therapi
preliminarili
percent
mortal
rate
one
patient
abandon
treatment
return
trace
call
conclus
result
preliminari
due
document
lag
time
time
short
year
mortal
remain
high
track
miss
visit
result
potenti
less
treatment
abandon
fals
belief
financi
constraint
still
exist
standard
treatment
protocol
support
care
educ
financi
support
crucial
improv
surviv
wt
kenya
shut
shut
shut
caregiv
paediatr
brain
tumor
survivor
lymberi
doctor
student
educ
leadership
polici
univers
british
columbia
vancouv
canada
object
weblog
caregiv
paediatr
brain
tumor
pbt
survivor
contribut
current
state
knowledg
caregiv
work
might
onlin
blog
address
silenc
isol
caregiv
experi
learn
need
lifestyl
way
inform
unpaid
work
constrain
qualiti
life
health
caregiv
impact
given
decad
unpaid
work
childyouthadult
materi
pbt
survivor
live
adulthood
unabl
gain
employ
maintain
friendship
given
health
social
vulner
requir
daili
support
provid
parent
particularli
mother
past
year
caregiv
son
malign
inoper
pnet
brain
tumor
diagnos
age
radiotherapi
calcifi
invas
tumor
effect
continu
disabl
progress
declin
typic
demograph
hear
sight
loss
impair
speech
endocrin
issu
mobil
factor
cognit
speed
stroke
research
research
subject
new
weblog
project
creat
knowledg
interconnect
canadian
caregiv
pbt
survivor
method
use
anonym
weblog
data
hope
assess
current
state
caregiv
knowledg
pbt
survivor
includ
unmet
need
qualit
narr
inquiri
standpoint
theori
help
assess
issu
social
isol
invis
silenc
econom
loss
research
project
ethic
approv
process
result
venu
help
inform
caregiv
new
canadian
project
pbt
survivor
caregiv
doctor
student
conclus
hope
research
identifi
person
social
econom
barrier
face
caregiv
pbt
survivor
also
hope
theme
futur
advocaci
work
also
identifi
chemotherapi
medic
error
pediatr
oncolog
clinic
nation
cancer
institut
colombia
nm
carreno
ahumada
c
casa
j
lago
ozaeta
pediatr
oncolog
nation
cancer
institut
bogota
dc
colombia
clinic
investig
group
nation
cancer
institut
bogota
dc
colombia
pharmaci
nation
cancer
institut
bogota
dc
colombia
pediatr
oncolog
nation
cancer
institut
bogota
dc
colombia
object
establish
classifi
chemotherapi
medic
error
outpati
clinic
worldwid
potenti
increas
number
error
relat
prescript
due
increas
new
drug
market
clinic
practic
well
know
medic
error
oncolog
servic
mani
caus
kind
lesion
patient
like
disabl
lesion
even
death
mani
case
error
go
unobserv
start
prescript
prepar
administr
patient
method
cross
section
studi
establish
sampl
size
analyz
chemotherapi
prescript
oncolog
pediatr
servic
care
review
chemotherapi
order
nation
cancer
pediatr
oncolog
outpati
clinic
period
six
month
juli
decemb
error
type
classifi
use
nation
coordin
council
medic
error
report
prevent
index
categor
medic
error
result
six
month
period
chemotherapi
prescript
oncolog
hematolog
pediatr
oncolog
pediatr
oncolog
sampl
size
found
medic
error
frequent
error
mainli
relat
dosag
omiss
medic
nt
death
disabl
secondari
medic
error
conclus
analysi
period
none
error
led
disabl
death
patient
therefor
nt
know
futur
nt
know
mani
error
potenti
mani
error
relat
prescript
mani
correct
administr
time
introduct
new
medic
clinic
practic
necessari
develop
program
avoid
error
relat
prescript
dosag
identif
patient
adolesc
young
adult
aya
program
barreto
brazil
sm
volc
lf
lope
ca
danta
pereira
sv
serrano
fm
carcano
clinicalpediatr
oncolog
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
pediatr
oncolog
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
clinic
oncolog
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
object
adolesc
young
adult
oncolog
ongo
scienc
nci
recogn
popul
rang
year
old
characterist
demand
age
group
underrepres
clinic
trial
could
reason
lack
improv
surviv
rate
last
year
differ
organ
model
drive
pediatr
oncolog
medic
oncolog
adult
cancer
resist
chemotherapi
exactli
opposit
seen
pediatr
oncolog
receiv
differ
model
care
current
opinion
say
train
pediatr
medic
oncologist
skill
need
manag
multidisciplinari
aya
treatment
strategi
best
way
method
sever
attempt
aya
comprehens
program
develop
world
one
take
place
barreto
cancer
hospit
brazil
order
improv
commun
cooper
pediatr
oncologist
medic
oncologist
design
integr
model
care
pediatr
oncologist
compos
adult
sarcomamelanoma
team
approach
taken
place
patient
forti
enter
pediatr
clinic
team
pediatr
clinic
oncologist
train
recogn
specif
demand
result
aya
program
barreto
brazil
inici
recent
good
accept
conclus
pediatr
adult
oncolog
group
come
differ
background
differ
prioriti
even
deal
similar
diseas
differ
practic
tend
homogen
model
care
improv
institut
treatment
total
patient
year
old
treat
institut
repres
almost
total
patient
popul
number
express
differenti
model
care
came
answer
specif
question
demand
aya
patient
pediatr
oncolog
network
databas
pond
use
adjunct
set
new
pediatr
unit
cancer
registri
develop
world
r
moham
c
yogiraj
rajat
k
satyendra
satya
prakash
pediatr
hematolog
oncolgi
bmt
unit
forti
memori
research
institut
gurgaon
india
object
nationwid
registri
lack
paediatr
cancer
patient
india
pediatr
oncolog
network
databas
pond
use
adjunct
creat
supplement
cancer
registri
free
onlin
databas
provid
st
jude
children
hospit
usa
pediatr
oncologist
develop
countri
describ
usefullnessof
pond
regist
data
newpati
first
one
year
set
newpediatr
pho
bone
marrow
transplant
bmt
unit
method
new
patient
regist
pho
unit
first
one
year
includ
data
regard
diagnosi
treatment
outcom
prospect
enter
experienc
data
base
manag
pond
result
new
patient
regist
unit
blood
cancer
disord
data
enter
pond
malign
patient
acut
lymphoblast
acut
myeloid
chronic
myeloid
hodgkin
solid
patient
brain
wilm
adrenocort
rhabdoid
ewe
benign
hematolog
patient
immun
thrombocytopen
aplast
sickl
cell
hemolyt
megaloblast
pure
red
cell
hemophagocyt
lymoho
primari
congenit
dyserythropeit
sideroblast
congenit
protein
c
other
hematopoet
stem
cell
transplant
hsct
perform
autolog
allogen
aplast
thalasemia
sickl
cell
primari
myelodysplat
conclus
pond
use
adjunct
maintain
patient
databas
recommend
pho
unit
india
creat
registri
beaba
patient
transform
agent
inform
medic
desmystifi
cancer
mozzilli
r
j
boechat
e
sassi
directorcr
instituto
beaba
sao
paulo
brazil
object
oncolog
world
particular
univers
child
famili
debut
environ
impact
new
experi
complex
term
mean
frighten
mission
demystifi
environ
present
inform
cancer
treatment
way
clear
object
optimist
method
beaba
nonprofit
organ
compos
young
patient
doctor
creativ
entrepreneur
differ
design
methodolog
young
patient
one
respons
creat
brief
pinpoint
everyth
bother
frighten
unknown
data
collect
proceed
discuss
former
patient
also
give
suggest
opinion
come
doctor
respons
knowledg
assess
valid
everyth
inform
hand
creativ
team
figur
best
strategi
meet
littl
patient
need
approv
entrepreneur
execut
idea
materi
produc
rang
wide
varieti
product
etiquett
manual
societi
learn
treat
cancer
patient
person
workshop
small
patient
teach
newcom
result
result
increas
young
patient
addit
feel
import
respons
entiti
activ
realiz
actual
becam
role
model
children
littl
patient
turn
passiv
individu
activ
one
coordin
learn
process
innumer
children
thu
promot
exponenti
growth
beaba
conclus
inform
still
best
way
save
live
whether
use
earli
diagnosi
reliev
symptom
eas
fear
relax
invigor
littl
cancer
patient
symptomat
thrombosi
lebanes
children
cancer
treat
tertiari
care
center
muwakkit
n
hashw
k
charafeddin
e
abdelrahman
chan
r
saab
h
tamim
abboud
h
el
traboulsi
depart
pediatr
adolesc
medicin
american
univers
beirut
beirut
lebanon
depart
patholog
laboratori
medicin
american
univers
beirut
beirut
lebanon
depart
pediatr
mcmaster
univers
hamilton
canada
depart
intern
medicin
american
univers
beirut
beirut
lebanon
pediatr
fellow
children
cancer
center
lebanon
american
univers
beirut
medic
center
beirut
lebanon
object
studi
preval
potenti
risk
factor
thromboembol
te
children
cancer
method
retrospect
chart
review
children
year
develop
symptomat
te
result
patient
treat
cccl
period
year
central
venou
line
cvl
patient
develop
symptomat
te
mean
age
year
rang
year
male
patient
evid
cvl
dysfunct
patient
either
die
aliv
recurr
diseas
remain
aliv
diseas
free
adf
patient
develop
te
cn
te
occur
receiv
steroid
concomitantli
remain
aliv
receiv
anticoagul
nine
patient
sarcoma
te
tumor
cm
six
metastat
lung
diseas
seven
develop
diseas
recurr
adf
eleven
lymphoma
patient
develop
te
bulki
mediastin
diseas
three
die
adf
patient
brain
tumor
develop
symptomat
te
die
aml
patient
te
adf
patient
neuroblastoma
infant
month
old
adf
children
solid
tumor
thrombosi
wors
outcom
without
thrombosi
patient
test
inherit
thrombophilia
heterozyg
factor
ii
mutat
heterozyg
factor
v
leiden
conclus
preval
symptomat
te
patient
lymphoma
sarcoma
respect
patient
te
older
compar
children
cancer
diagnosi
cvl
dysfunct
one
third
patient
te
die
reach
end
stage
recurr
diseas
factor
v
leiden
preval
durat
anticoagul
variabl
mean
monthspati
brain
tumor
patient
low
incid
thrombosi
solid
tumor
patient
thrombosi
wors
outcom
correl
imag
guid
biopsi
result
children
nihayah
shamma
r
vali
b
connolli
depart
diagnost
imag
hospit
sick
children
toronto
canada
object
evalu
earli
experi
correl
imag
guid
biopsi
igbx
result
pediatr
popul
better
understand
role
may
play
method
singl
centr
retrospect
case
seri
patient
underw
igbx
pet
ct
scan
januari
decemb
analyz
inclus
criteria
whose
igbx
occur
within
week
scan
prior
post
biopsi
clinic
demograph
imag
patholog
report
collect
use
redcap
correl
descript
statist
employ
result
patient
male
femal
includ
age
year
median
year
known
malign
coaxial
techniqu
use
ultrasound
guidanc
ct
fluoroscopi
biopsi
involv
soft
tissu
bone
minor
major
complic
bleed
requir
transfus
pet
scan
posit
pet
scan
neg
posit
scan
biopsi
show
malign
diagnosi
benign
diagnosi
nfectioninflamm
normal
tissu
inadequ
neg
pet
scan
benign
diagnosi
found
malign
interv
chemotherapi
given
concord
result
biopsi
pet
obtain
discord
result
obtain
sensit
pet
ppv
conclus
play
valuabl
role
direct
imag
guid
biopsi
children
chemotherapi
administr
pediatr
oncolog
dilut
solut
f
normand
p
leblond
sakji
h
sudour
g
marliot
c
lervat
mercier
delbey
defachel
clinic
pharmaci
depart
oscar
lambret
center
lill
franc
pediatr
oncolog
unit
oscar
lambret
center
lill
franc
object
due
young
age
pediatr
patient
chemotherapi
administr
high
volum
short
time
could
respons
advers
effect
mainli
cardiovascular
dilut
volum
associ
chemotherapi
rins
volum
design
problemat
pediatr
oncologist
aim
reduc
volum
optim
medicin
treatment
method
consult
protocol
use
hospit
identifi
differ
dose
prescrib
anticanc
drug
cooper
pediatr
oncologist
took
care
factor
affect
term
dilut
weight
dose
rout
administr
peripher
central
line
infus
risk
extravas
physicochem
stabil
molecul
link
final
concentr
infus
rate
base
research
anticanc
drug
thesauru
n
result
adapt
anticanc
drug
dilut
volum
done
pediatr
anticanc
drug
prescrib
protocol
drug
dose
determin
accord
patient
weight
accord
bodi
surfac
area
decid
defin
three
subgroup
patient
less
kg
summari
tabl
made
approv
pediatr
oncologist
sum
dilut
volum
subgroup
patient
anticanc
drug
dilut
case
volum
less
equal
ml
patient
less
infus
volum
less
case
conclus
multidisciplinari
approach
succeed
reduc
volum
infus
children
adapt
practic
pediatr
specif
improv
optim
care
patient
due
overfil
industri
use
empti
bag
promot
case
percept
elderli
peopl
big
challeng
hivaid
mitig
high
risk
urban
slum
africa
k
odor
r
opara
health
promot
univers
ibadan
nigeria
ibadan
nigeria
age
care
gertrud
nurs
home
sydney
australia
object
hivaid
continu
pose
public
health
challeng
africa
pandem
border
affect
everi
age
group
includ
old
person
despit
engag
riski
sexual
activ
increas
hivaid
infect
howev
limit
attent
paid
mitig
pandem
studi
therefor
examin
perceiv
hivaid
infect
among
old
peopl
africa
method
studi
design
sampl
procedur
use
select
questionnair
develop
use
inform
obtain
focu
group
discuss
fgd
use
collect
inform
fgd
data
analyz
themat
questionnair
data
analyz
use
descript
statist
result
percent
particip
sex
sinc
attain
elderli
age
howev
among
subgroup
sex
use
condom
male
femal
use
condom
last
extramarit
sex
low
level
attribut
condom
worthwhil
opinion
condom
made
elderli
moreov
fgd
particip
view
sex
could
lead
pregnanc
major
posit
patron
tradit
healer
use
herbsconcuss
could
prevent
hivaid
similarli
use
due
confid
tradit
herb
perceiv
protect
sti
includ
hivaid
conclus
engag
riski
activ
among
elderli
grow
hivaid
challeng
misconstru
probabl
due
knowledg
gap
without
urgent
measur
enabl
protect
develop
effort
jeopardi
invest
geriatr
srh
intervent
mitig
hivaid
pandem
malign
primari
immunedefici
singl
center
experi
patiroglu
hh
akar
ozdemir
e
unal
karakukcu
patiroglu
depart
pediatr
hematolog
oncolog
erciy
univers
faculti
medicin
kayseri
turkey
depart
pediatr
immmunolgi
erciy
univers
faculti
medicin
kayseri
turkey
depart
patholog
erciy
univers
faculti
medicin
kayseri
turkey
object
overal
risk
develop
malign
children
primari
immunodefici
pid
estim
lymphoma
predomin
account
case
pid
known
associ
increas
incid
malign
common
variabl
immunodefici
cvid
iga
defici
dna
repair
disord
recent
year
type
also
includ
sever
combin
immunodefici
scid
wiskott
aldrich
syndrom
aim
studi
histopatholog
characterist
malign
pid
report
result
singl
refer
center
middl
anatolia
turkey
method
present
eight
patient
male
femal
pid
evalu
pediatr
depart
medic
faculti
erciy
univers
age
diagnosi
pid
age
diagnosi
malign
histopatholog
characterist
malign
clinic
cours
patient
analyz
result
studi
period
patient
malign
associ
pid
patient
rang
year
age
mean
age
year
sd
year
diagnosi
malign
histopatholog
five
patient
diffus
larg
b
cell
lymphoma
idiopath
defici
dna
repair
immunodefici
nijmegen
breakag
syndrom
remain
patient
hodgkin
lymphoma
osteosarcoma
bloom
syndrom
gastric
signet
ring
carcinoma
respect
conclus
want
underlin
pid
genet
disord
predispos
patient
malign
well
sever
infect
autoimmun
meet
need
sibl
pediatr
hematopoiet
stem
cell
transplant
hsct
patient
r
pentz
white
k
hendershot
aldef
dixon
w
pelleti
k
stegenga
p
hind
school
medicin
emori
univers
atlanta
usa
school
medicin
emori
univers
wiship
cancer
institut
atlanta
usa
center
healthcar
deliveri
scienc
nemoursalfr
dupont
hospit
children
wilmington
usa
hematologyoncologytranspl
program
alberta
children
hospit
calgari
canada
nurs
research
children
merci
hospit
clinic
kansa
citi
usa
divis
nurs
children
nation
medic
center
washington
usa
object
sibl
pediatr
cancer
hsct
patient
report
lack
inform
lack
inclus
famili
separ
addit
respons
famili
transplant
experi
although
resourc
current
exist
help
sibl
children
may
benefit
person
attent
inform
purpos
studi
identifi
strategi
help
sibl
propos
novel
implement
certifi
child
life
specialist
method
conduct
secondari
semant
analysi
qualit
interview
complet
famili
member
pediatr
hsct
patient
code
data
strategi
famili
use
cancer
experi
also
interview
hsct
healthcar
team
member
regard
current
resourc
sibl
suggest
addit
intervent
result
famili
interview
code
healthcar
worker
interview
includ
certifi
child
life
specialist
ccl
inpati
nurs
midlevel
provid
psychologist
social
worker
physician
frequent
use
strategi
meet
member
healthcar
team
share
inform
child
use
phone
call
skype
commun
often
parent
split
time
hospit
home
attend
sibl
support
group
workshop
give
sibl
special
role
sibl
visit
hospit
special
day
event
sibl
twelv
healthcar
worker
express
concern
sibl
distress
address
current
support
requir
travel
lack
sibl
inclus
lack
inform
nomin
ccl
interven
sibl
via
skype
address
need
felt
sibl
conclus
exist
resourc
inadequ
meet
need
sibl
children
undergo
hsct
children
may
benefit
person
inform
support
deliv
varieti
strategi
famili
member
healthcar
worker
novel
ccl
virtual
intervent
may
help
allevi
siblingsunmet
need
use
rasburicas
children
hematolog
malign
experi
pediatr
hemato
oncolog
centr
southern
india
k
rathnam
j
somasundaram
v
kasi
r
priya
sr
vinesh
rajeswari
dept
pediatr
hematolog
oncolog
meenakshi
mission
hospit
research
centr
madurai
india
object
rasburicas
rapidli
reduc
plasma
uric
acid
pua
thu
markedli
decreas
risk
renal
failur
tumor
lysi
syndrom
tl
howev
limit
data
use
india
limit
use
due
studi
analys
use
rasburicas
resourc
limit
set
method
retrospect
studi
look
efficaci
safeti
rasburicas
children
hematolog
malign
treat
period
month
male
femal
laboratori
tl
risk
tl
diagnos
nhl
case
rasburicas
given
dose
mg
kg
one
screen
defici
result
initi
pua
median
mgdl
rang
six
creatinin
level
mgdl
peak
phosphat
level
mgdl
one
patient
requir
dialysi
dose
rasburicas
use
median
rang
median
reduct
pua
hour
rang
need
one
dose
need
dose
two
need
dose
none
die
tl
none
develop
anaphylaxi
signific
hemolysi
conclus
rasburicas
safe
effect
even
lower
dose
rang
mgkg
markedli
reduc
risk
renal
failur
tl
indian
children
hematolog
malign
etoposid
reaction
pediatr
oncolog
patient
rayar
l
dupui
atkinson
f
shaikh
taylor
ross
alexand
hematologyoncolog
hospit
sick
children
toronto
canada
allergyimmunolog
hospit
sick
children
toronto
canada
object
etoposid
common
chemotherapi
agent
use
treat
childhood
cancer
past
year
rate
etoposid
associ
reaction
perceiv
higher
expect
institut
prompt
review
natur
reaction
method
retrospect
chart
review
conduct
singl
institut
patient
age
year
receiv
iv
etoposid
octob
june
elig
studi
result
patient
receiv
etoposid
studi
period
patient
met
inclus
criteria
patient
reaction
etoposid
averag
rate
infus
etoposid
differ
patient
experienc
reaction
reaction
occur
shortli
start
etoposid
infus
mean
time
advers
event
minut
rang
minut
reaction
occur
patient
second
dose
etoposid
rang
reaction
associ
varieti
symptom
includ
mucocutan
n
respiratori
n
gastrointestin
n
hypotens
n
patient
display
reaction
toler
subsequ
etoposid
dose
given
premed
antihistamin
orand
steroid
andor
infus
slower
rate
remain
patient
complet
therapi
two
patient
experienc
subsequ
reaction
first
patient
develop
lip
swell
second
experienc
persist
vomit
patient
abl
toler
dose
premed
conclus
reaction
rate
etoposid
observ
although
exact
mechan
event
unclear
natur
histori
consist
type
hypersensit
reaction
patient
develop
reaction
safe
rechalleng
etoposid
given
premed
investig
possibl
etiolog
reaction
includ
examin
infus
devic
ongo
use
chang
methodolog
improv
patient
flow
bed
usag
effect
alter
methotrex
assay
servic
l
roe
norton
j
patel
barker
moor
heap
mw
english
oncolog
birmingham
children
hospit
birmingham
unit
kingdom
haematolog
birmingham
children
hospit
birmingham
unit
kingdom
pharmaci
birmingham
children
hospit
birmingham
unit
kingdom
clinic
chemistri
birmingham
children
hospit
birmingham
unit
kingdom
object
delay
discharg
outsid
work
hour
frustrat
children
famili
mean
less
safe
effect
use
bed
delay
treatment
identifi
delay
receiv
methotrex
assay
anoth
hospit
contribut
problem
method
plan
hous
assay
serum
methotrex
level
set
flexibl
agre
produc
result
time
manner
without
overburden
lab
servic
regular
meet
pharmacist
doctor
nurs
laboratori
scientist
address
issu
develop
sever
step
old
system
elimin
batch
specimen
transfer
courier
process
differ
hospit
telephon
result
offic
hour
result
check
complaint
miss
result
disappear
patient
receiv
high
dose
methotrex
hdm
discharg
safe
level
reach
includ
acut
lymphoblast
leukaemia
patient
osteosarcoma
compar
length
stay
lo
chang
assay
osteosarcoma
admiss
reduct
length
stay
hdm
patient
discharg
day
p
day
osteosarcoma
p
note
differ
found
patient
prolong
excret
methotrex
either
group
would
expect
importantli
half
patient
discharg
offic
hour
introduct
local
assay
conclus
act
expens
set
new
assay
servic
offset
improv
discharg
plan
undertak
valu
stream
map
identifi
aspect
admiss
prolong
stay
occur
use
pdca
cycl
help
elimin
delay
also
go
use
patient
level
cost
measur
econom
benefit
realis
futur
chang
select
venou
access
system
profession
involv
instal
rykov
v
polyakov
gener
oncolog
institut
pediatr
oncolog
hematolog
n
n
blokhin
moscow
russia
object
treatment
cancer
imposs
without
venou
access
must
respons
choic
direct
provis
integr
approach
involv
oncologist
surgeon
anesthetist
method
year
conduct
train
select
instal
venou
access
doctor
variou
specialti
oncologist
anesthesiologist
intervent
radiologist
train
includ
practic
oper
theatr
demonstr
subclavian
venou
cathet
venou
port
instal
techniqu
togeth
theoret
cours
theoret
exercis
addit
analyz
experi
oncolog
clinic
russia
approach
provid
venou
access
result
physician
fulli
master
techniqu
major
intervent
radiologist
physician
anesthetist
surgeon
seven
clinic
problem
choic
venou
access
consid
clinic
peripher
vein
use
chemotherapi
provis
seriou
complic
began
appli
subclavian
cathet
clinic
subclavian
cathet
use
begin
treatment
clinic
insert
subclavian
cathet
involv
anesthesiologist
case
due
complic
caus
incorrect
instal
oper
subclavian
cathet
cancer
treatment
program
interrupt
conclus
comprehens
target
train
doctor
directli
field
venou
access
necessari
doctor
exist
special
necessari
skill
procedur
anesthesiologist
difficulti
section
sutur
tissu
surgeon
intervent
radiologist
punctur
blood
vessel
optim
train
specialist
among
intervent
radiologist
profici
gener
surgic
skill
also
abl
use
intraop
fluoroscopi
effect
modern
russia
heritor
ancient
tradit
babylon
tragic
stori
central
venou
catheter
rykov
gener
oncolog
institut
pediatr
oncolog
hematolog
n
n
blokhin
moscow
russia
object
lot
health
problem
russia
given
attent
clinic
countri
popul
million
peopl
pay
attent
vascular
access
method
russia
cancer
pt
record
oncologist
pt
doctor
cancer
clinic
among
clinic
practic
implant
venou
port
system
treatment
pt
remain
pt
clinic
pt
undergo
central
vein
catheter
least
time
period
treatment
commonli
peripher
vein
use
thrombophleb
pneumothorax
routin
complic
oncologist
peopl
awar
exist
venou
port
know
method
implant
russian
clinic
includ
one
surgic
oper
theatr
reason
imposs
widespread
introduct
port
system
result
ten
thousand
pt
live
ruin
action
illiter
health
worker
reason
totalitarian
regim
lack
educ
lack
adequ
health
care
financ
pervas
corrupt
penetr
sphere
daili
life
mani
complic
consequ
neglig
howev
taken
inevit
exact
number
complic
associ
error
provis
vascular
access
cathet
associ
bloodstream
infect
taken
account
accord
conserv
estim
least
central
venou
catheter
accompani
develop
sever
complic
level
cathet
associ
bloodstream
infect
less
conclus
ancient
babylon
author
execut
patient
medic
servic
russian
feder
often
risk
factor
central
venou
cathet
cvc
complic
children
disord
sakoda
kawano
hosoya
h
yoshiwara
hirabayashi
hasegawa
ozawa
h
matsufuji
manab
takahashi
pediatr
surgeri
st
luke
intern
hospit
tokyo
japan
pediatr
st
luke
intern
hospit
tokyo
japan
center
clinic
epidemiolog
st
luke
life
scienc
institut
tokyo
japan
object
identifi
risk
factor
cvc
complic
understand
optim
cvc
manag
method
complic
analyz
retrospect
cathet
implant
patient
june
februari
st
luke
intern
hospit
complic
includ
centrallin
associ
blood
stream
infect
clabsi
obstruct
disloc
andruptur
multivari
logist
regress
conduct
adjust
sever
potenti
confound
result
total
number
cvc
day
overal
rate
complic
cvc
day
age
cvc
insert
doubl
lumen
cathet
betadineskin
prepar
vs
chlorhexidin
signific
predictor
cvc
complic
p
conclus
cvc
complic
rate
decreas
dramat
use
chlorhexidin
instead
betadin
proper
asept
techniqu
stuff
recommend
progress
young
patient
also
requir
doubl
lumen
cathet
incid
febril
neutropenia
acut
leukemia
children
india
use
uk
protocol
siddaiahgari
manikyam
hambir
b
jillella
pediatr
rainbow
children
hospit
hyderabad
india
object
asses
febril
neutropenia
episod
mortal
relat
acut
leukemia
children
india
use
ukal
aml
protocol
method
prospect
studi
perform
tertiari
care
children
hospit
march
may
children
month
year
result
total
children
male
remain
femal
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
calla
b
cell
cell
total
episod
febril
neutropenia
fn
observ
patient
aml
fn
episod
commonli
observ
consolid
follow
induct
aml
fn
episod
commonli
observ
month
follow
month
chemotherapi
respiratori
complaint
seen
episod
follow
genitourinari
gastrointestin
fever
without
focu
cultur
posit
episod
common
site
isol
urin
follow
blood
gram
neg
bacteria
commonli
seen
follow
gram
posit
escherichia
coli
common
case
among
gram
neg
follow
pseudomona
aeruginosa
klebsiella
sensit
amoxyclav
piperacillin
tazobactum
carbepenem
gram
posit
staphylococcu
common
follow
pneumococcu
episod
respond
first
line
antibiot
time
cefipim
amikacin
episod
need
upgrad
antibiot
antifung
use
case
treat
empir
percent
evid
fungal
infect
mean
durat
hospit
stay
children
die
studi
relaps
due
febril
neutropenia
conclus
wth
good
support
care
western
protocol
use
develop
countri
without
increas
febril
neutropenia
relat
mortal
morbid
vari
spectrum
neurolog
complic
relat
diseas
therapi
childhood
malign
siddaiahgari
makadia
l
lingappa
n
shah
b
jillela
r
varma
pediatr
oncolog
rainbow
children
hospit
hyderabad
india
pediatr
neurolog
rainbow
children
hospit
hyderabad
india
pediatr
rainbow
children
hospit
hyderabad
india
pediatr
neuroradiolog
rainbow
children
hospit
hyderabad
india
object
describ
neurolog
complic
children
cancer
short
term
outcom
method
neurolog
problem
present
featur
part
therapi
relat
complic
childhood
malign
identifi
review
novemb
decemb
year
prospect
month
retrospect
pre
exist
neurolog
problem
cn
tumor
post
chemotherapi
cognit
dysfunct
exclud
result
children
month
year
age
neurolog
problem
acut
lymphoblast
leukemia
neuroblastoma
opsoclonu
myoclonu
syndrom
neurolog
problem
ewingspnet
seen
histiocyt
disord
cn
deposit
case
four
acut
myeloid
leukemia
aml
one
hodgkin
lymphoma
one
diffus
larg
b
cell
lymphoma
one
germ
cell
tumour
one
rhabdomyosarcoma
tumor
relat
neurolog
problem
seen
directli
relat
tumor
paraneoplast
opsoclonu
myoclonu
secondari
neuroblastoma
cord
germ
cell
hodgkin
five
present
seizur
two
encephalopathi
seizur
aml
two
facial
nerv
palsi
tumor
infiltr
present
featur
one
amlon
dlbl
one
ptosi
intracrani
neuroblastoma
extens
primari
hlh
present
head
ach
vomit
secondari
cn
deposit
therapi
relat
problem
seen
case
stroke
like
present
seen
methotrex
seizur
post
cortic
venou
thrombosi
secondari
peg
asparganis
one
ventricul
induct
one
child
post
mtx
chemic
mening
one
posterior
revers
encephalopathi
syndrom
secondari
hypertens
steroid
one
vincristin
induc
acut
flaccid
paralysi
two
case
diseas
relat
group
treatment
relat
mild
neurolog
disabl
conclus
therapi
relat
neurolog
complic
seen
children
spinal
cord
compress
common
neurolog
present
featur
earli
recognit
neurolog
complic
either
diseas
treatment
relat
essenti
control
mortal
morbid
invas
fungal
infect
children
cancer
g
k
musiol
w
stolpa
h
wo
depart
pediatr
oncolog
haematolog
chemotherapi
medic
univers
silesia
upper
silesia
children
care
heatlh
centr
katowic
poland
object
assess
clinic
cours
ifi
neoplast
children
accord
diagnost
therapeut
difficulti
base
institut
experi
method
studi
enrol
children
cancer
diagnos
ifi
analyz
clinic
cours
ifi
base
initi
symptom
diagnost
difficulti
therapi
clinic
cours
ifi
diagnost
difficulti
therapi
treatment
result
result
pt
develop
ifi
deep
neutropenia
period
characterist
persist
fever
pt
ifi
locat
lung
pt
additionari
cn
pt
liver
diagnos
fungi
patogen
candida
albican
candida
tropicali
aspergillu
pt
pathogen
identifi
group
ifi
diagnos
probabl
possibl
pt
proven
infect
conclus
invas
fungal
infect
seriou
cancer
treatment
complic
ofth
diagnost
therapeut
difficulti
subsequ
result
delay
therapi
deep
neutropenia
play
funament
role
develop
ifi
cost
chidhood
cancer
treatment
africa
stefan
van
zyl
stone
paediatr
child
health
stellenbosch
univers
cape
town
south
africa
paediatr
child
health
free
state
univers
bloemfontein
south
africa
object
annual
african
children
suffer
cancer
inform
cost
care
childhood
cancer
africa
miss
make
imposs
polici
maker
adopt
afford
intervent
aim
studi
estim
health
system
cost
cancer
care
africa
propos
effect
approach
investig
treatment
common
cancer
method
cost
cancer
estim
use
administr
data
differ
period
time
differ
african
unit
deriv
direct
indirect
financi
econom
cost
health
system
perspect
cost
includ
drug
personnel
annuit
capit
cost
diseas
analys
includ
nephroblastoma
retinoblastoma
burkitt
lymphoma
hiv
associ
malign
kaposi
sarcoma
nhl
result
cost
treat
nephroblastoma
vari
eur
stage
time
stage
eur
treat
one
patient
nephroblastoma
avert
dali
cost
treat
bl
euro
group
b
group
c
first
line
treatment
ks
cost
eur
paclitaxel
salvag
regimen
eur
retinoblastoma
cost
estim
less
eur
advanc
diseas
conclus
treat
childhood
cancer
africa
cost
effect
key
polici
point
research
need
recognit
childhood
cancer
health
problem
african
govern
improv
awar
earli
diagnosi
adapt
protocol
local
resourc
limit
condit
afford
treatment
bloodstream
infect
predictor
morbid
mortal
among
children
live
cancer
rural
set
uganda
j
suvada
meciakova
bartosova
c
kiyaga
r
iriso
e
namagala
nh
russel
e
kaiserova
v
kr
cmeri
hia
health
care
project
st
john
paul
ii
st
elizabeth
univers
public
health
social
scienc
kampala
uganda
dept
microbiolog
central
public
health
laboratori
kampala
uganda
pediatr
depart
baylor
colleg
medicin
kampala
uganda
children
care
ministri
health
kampala
uganda
hope
ward
intern
hospit
kamapala
kampala
uganda
children
hematolog
oncolog
children
teach
hospit
kampala
uganda
clinic
microbiolog
st
elizabeth
univers
public
health
social
scienc
bratislava
slovakia
object
bloodstream
infect
bsi
common
caus
admiss
morbid
mortal
among
pediatr
patient
malign
worldwid
impact
antibiot
resist
eg
hiv
infect
tb
treatment
outcom
mani
rural
develop
set
well
known
method
conduct
prospect
multicent
studi
evalu
incid
bsi
risk
factor
among
children
treat
due
cancer
rural
set
uganda
observ
consecut
admiss
children
sign
system
infecti
diseas
blood
taken
serolog
test
cultur
malaria
microscopi
indic
record
data
clinic
find
underli
diseas
antimictobi
drug
use
admiss
microbi
agent
find
outcom
result
incid
laboratori
confirm
bloodstreem
infect
admit
children
system
infecti
sing
patient
receiv
prior
admiss
least
one
cours
antimicrobi
therapi
antimari
therapi
prior
blood
cultur
frequent
isol
klebsiella
spp
e
coli
salmonella
enterococci
staphylococcu
aureu
streptococcu
spp
pediatr
patient
malaria
hiv
infect
tubercuosi
children
laboratori
confirm
bloodstream
infect
die
comparison
clinic
present
infect
file
evalu
microbi
agent
confirm
resist
least
one
common
antibiot
agent
conclus
bloodstream
infect
less
common
malaria
set
respons
death
among
children
cancer
frequent
use
antimicrobi
drug
prior
blood
cultur
may
crucial
impact
detect
antibiot
test
suscept
commonli
use
antibiot
find
antimicrobi
resist
malnutrit
predict
fatal
outcom
call
renew
effort
recommend
nation
also
local
level
effect
mode
financi
aid
support
treatment
pediatr
cancer
patient
resourc
poor
set
thakkar
n
radhakrishnan
kalra
gupta
sachdeva
pediatr
bmt
unit
sir
ganga
ram
hospit
new
delhi
india
object
treatment
form
cancer
children
pose
signific
financi
burden
famili
resourc
poor
countri
like
india
circumst
abandon
treatment
common
event
financi
aid
govern
well
organ
ngo
help
patient
complet
treatment
attempt
analys
effect
variou
mode
financi
aid
avail
famili
help
continu
treatment
method
retrospect
analysi
patient
acut
lymphoblast
leukemia
diagnos
centr
jan
carri
patient
treat
per
bfm
protocol
sourc
financ
treatment
patient
assess
questionnair
result
studi
period
patient
diagnos
centr
patient
lost
follow
patient
opt
treatment
altern
centr
remain
patient
patient
sought
financi
assist
complet
treatment
patient
parent
patient
complet
treatment
child
help
insur
avail
employ
agenc
patient
sought
monetari
aid
prime
minist
relief
fund
govern
support
also
got
support
ngo
form
free
cost
medicin
patient
patient
also
receiv
aid
support
group
form
parent
children
treat
past
conclus
resourc
poor
countri
like
india
mani
patient
diagnos
need
financi
assist
treatment
financi
constrain
famili
insur
grant
parent
employ
agenc
ascertain
financi
aid
govern
play
major
role
decreas
rate
treatment
abandon
febril
neutropenia
pediatr
malign
patient
akbarzad
g
tokuc
koc
b
yilmaz
pediatr
hamatolog
oncolog
marmara
univers
istanbul
turkey
object
aim
studi
determin
clinic
featur
microbiolog
pattern
antimicrobi
suspect
febril
neutropenia
children
cancer
method
isol
microorgan
antimicrobi
suscept
febril
neutropen
episod
patient
hospit
depart
pediatrichematolog
oncolog
august
evalu
retrospect
studi
result
patient
episod
fn
report
primari
malign
wereleucemia
episod
solid
tumor
episod
mean
absolut
neutrophil
count
mean
durat
hospit
day
mean
fever
time
day
episod
microbiolog
document
common
site
clinic
document
mucosa
skin
isol
microorgan
bacilli
cocci
candidaspp
ecoli
staphylococci
common
isol
among
bacteria
respect
antimicrobi
suscept
test
among
isol
microorgan
resist
found
cefepim
frequent
use
antimicrobi
agent
empir
therapi
cephoperazon
resist
identifieda
total
febril
neutropen
episod
improv
antimicrobi
therapi
modif
requir
episod
leucemia
durat
fever
discharg
hospit
longer
crp
higher
solid
tumor
total
death
conclus
suitabl
rationalist
approach
decreas
mortal
morbid
start
rapidli
empir
therapi
febril
neutropen
patient
accord
result
frequenc
suscept
pattern
isol
microorgan
local
epidemiolog
data
necessari
make
modif
therapi
accord
cultur
result
clinic
situat
incid
sever
advers
reaction
associ
anthracyclin
paediatr
patient
j
varga
neri
castelan
martinez
r
riva
ruiz
g
hernandez
p
clark
peralta
pharmacolog
centro
de
investigacion
de
estudio
avanzado
del
ipn
mexico
citi
mexico
clinic
research
centro
medico
nacion
siglo
xxi
del
imss
mexico
citi
mexico
clinic
epidemiolog
hospit
infantil
de
mexico
federico
gomez
mexico
citi
mexico
object
determin
incid
sever
advers
reaction
associ
anthracyclin
paediatr
patient
method
retrospect
cohort
patient
treat
anthracyclin
treat
children
hospit
mexico
federico
gomez
pediatr
hospit
centro
medico
nacion
siglo
xxi
identifi
advers
reaction
intens
pharmacovigil
method
perform
analysi
causal
perform
use
naranjo
test
sever
advers
reaction
determin
accord
offici
mexican
standard
call
instal
oper
pharmacovigil
result
total
patient
includ
studi
found
total
advers
event
associ
anthracyclin
incid
advers
reaction
associ
anthracyclin
neutropenia
fever
vomit
mucos
thrombocytopenia
anemia
cardiotox
respect
accord
sever
advers
reaction
associ
anthracyclin
sever
mild
moder
conclus
anthracyclin
high
rate
advers
event
even
fatal
intens
pharmacovigil
effect
method
determin
incid
advers
event
necessari
time
identif
potenti
risk
patient
cancer
first
pediatr
oncolog
hospit
mexico
new
model
care
l
g
escamilla
aguilar
elizald
direccion
medica
hospit
infantil
teleton
de
oncologia
mexico
oncolog
hospit
infantil
teleton
de
oncologia
mexico
radiolog
hospit
infantil
teleton
de
oncologia
mexico
object
report
plan
open
first
hospit
special
design
children
cancer
mexico
method
review
process
plan
design
hospit
innov
model
care
result
construct
hospit
infantil
teleton
de
hito
start
finish
novemb
medic
model
base
axi
diagnost
accuraci
modern
treatment
prevent
complic
qualiti
life
hous
teleton
hous
teleton
foundat
design
campu
hospit
teleton
hous
treat
children
cancer
integr
model
health
care
exclus
children
suffer
cancer
conclus
new
model
pediatr
oncolog
care
propos
chang
health
care
focu
special
need
cancer
patient
expect
solv
main
problem
affect
result
chemotherapi
surveil
cancer
patient
nation
institut
pediatr
mexico
l
r
r
oncolog
instituto
nacion
de
mexico
citi
mexico
object
chemotherapi
surveil
fundament
tool
pediatr
oncolog
evalu
long
term
follow
efficaci
secur
treatment
aim
describ
sever
advers
event
sae
secondari
chemotherapi
oncolog
depart
nation
institut
pediatr
method
realiz
prospect
studi
regist
grade
sae
accord
world
health
organ
februari
februari
analyz
diagnosi
outcom
accord
naranjo
algorithm
result
includ
patient
present
sae
frequent
grade
neutropenia
anemia
thrombocytopenia
neutropen
coliti
mucos
anaphylact
shock
frequent
diagnosi
acut
lymphoblast
leukemia
acut
myeloid
leukemia
osteosarcoma
ewe
sarcoma
retinoblastoma
medulloblastoma
germ
cell
tumor
ifosfamid
frequent
chemotherapeut
agent
associ
sae
mortal
conclus
chemotherapi
surveil
pediatr
oncolog
must
systemat
action
order
establish
causal
assess
secur
chemotherapi
gener
new
strategi
reduc
sever
mortal
sae
experi
haploident
hematopoiet
stem
cell
transplant
acquir
sever
aplast
anemia
develop
countri
like
india
k
vipin
mayank
c
dharma
g
nitin
sanjeev
haematooncolog
bmt
blk
superspeci
hospit
delhi
india
object
ass
role
haploident
hematopoiet
stem
cell
transplant
hhct
acquir
sever
aplast
anemia
saa
altern
match
unrel
donor
mud
transplant
resourc
limit
countri
like
india
method
studi
design
retrospect
studi
studi
period
januari
februari
set
b
l
kapur
superspeci
hospit
delhi
inclus
criteria
two
children
age
year
show
respons
immunotherapi
includ
condit
regimen
includ
fludarabin
cyclophosphamid
mgkg
day
tbi
prophylaxi
gvhd
cyclophosphamid
mgkg
day
tacrolimu
mycophenol
mofetil
absolut
viabl
posit
cell
count
vari
x
x
per
kg
recipi
bodi
weight
result
one
patient
experienc
earli
graft
reject
receiv
second
hhct
achiev
sustain
engraft
one
patient
develop
acut
gvhd
grade
ii
manag
steroid
children
sustain
complet
donor
chimer
normal
peripher
blood
count
conclus
hhct
use
post
transplant
cyclophosphamid
cell
deplet
reason
treatment
option
children
acquir
saa
feasibl
develop
countri
limit
avail
match
unrel
donor
skin
protect
regimen
manag
diaper
skin
compromis
pediatr
oncolog
patient
c
braeutigam
pyle
c
baker
pearson
visscher
cancer
blood
diseas
institut
cincinnati
children
hospit
medic
center
cincinnati
usa
skin
scienc
plastic
surgeri
cincinnati
children
hospit
medic
center
cincinnati
usa
object
sever
diaper
dermat
extrem
challeng
side
effect
treatment
among
infant
leukemia
like
due
multipl
factor
includ
chemotherapi
lead
chemic
burn
hyper
hydrat
increas
urin
stool
output
looser
stool
suspect
higher
concentr
enzym
decreas
immun
function
decreas
heal
capac
result
sever
morbid
institut
current
practic
liquid
barrier
film
topic
barrier
cream
suffici
effect
object
determin
effect
regimen
consist
substant
liquid
skin
protect
plu
ointment
daili
sitz
bath
frequent
diaper
chang
minimizeprev
irrit
diaper
dermat
throughout
multipl
chemotherapi
cycl
method
infant
receiv
high
dose
chemotherapi
eg
doxorubicin
cyclophosphamid
vincristin
prednison
intrathec
therapi
methotrex
cytarabin
diaper
patient
receiv
methotrex
alkalin
hyperhydr
enrol
upon
hospit
irb
approv
studi
liquid
protect
appli
diaper
region
upon
resolut
open
wound
evalu
daili
reappli
necessari
throughout
multipl
chemotherapi
recoveri
cycl
zinc
ointment
appli
liber
everi
diaper
chang
skin
assess
erythema
rash
use
valid
scale
standard
digit
imag
taken
quantifi
area
involv
erythema
absolut
neutrophil
count
urin
stool
output
frequenc
medic
track
skin
grade
imag
time
result
twenti
patient
enrol
follow
day
sever
diaper
dermat
mild
perin
irrit
observ
multipl
chemotherapi
cycl
despit
neutropen
multipl
antibiot
fever
delay
chemotherapi
due
sever
skin
breakdown
conclus
regimen
effect
delay
lessen
skin
compromis
among
infant
receiv
chemotherapi
rel
hospit
standard
care
develop
servic
capabl
framework
guid
health
servic
provid
care
children
adolesc
cancer
c
william
shelli
j
williamson
p
downi
f
mechinaud
g
wheeler
ashley
k
whitfield
paediatr
integr
cancer
servic
royal
children
hospit
melbourn
australia
children
cancer
centr
monash
children
hospit
melbourn
australia
children
cancer
centr
royal
children
hospit
melbourn
australia
paediatr
late
effect
peter
maccallum
cancer
centr
melbourn
australia
cancer
servic
barwon
health
geelong
australia
cancer
reform
strategi
victorian
depart
health
melbourn
australia
object
achiev
best
outcom
paediatr
cancer
care
requir
coordin
time
multidisciplinari
approach
activ
collabor
health
servic
support
approach
paediatr
integr
cancer
servic
develop
servic
capabl
scf
state
victoria
australia
purpos
defin
minimum
requir
provid
sustain
coordin
safe
paediatr
oncolog
care
across
varieti
health
network
includ
region
urban
set
method
literatur
review
undertaken
gather
evid
guid
rational
recommend
within
scf
expert
steer
group
establish
wider
consult
disciplin
scf
endors
victorian
paediatr
tertiari
referr
centr
well
victorian
state
govern
risk
manag
insur
group
result
scf
present
four
level
care
health
servic
particip
includ
algorithm
risk
factor
may
escal
level
care
requir
level
defin
accord
complex
care
patient
critic
mass
level
paediatr
oncolog
servic
avail
servic
vari
across
victoria
outreach
centr
provid
support
care
specialist
tertiaryquaternari
referr
centr
level
also
defin
across
critic
time
point
patient
care
support
clinic
decis
make
referr
process
level
describ
necessari
infrastructur
workforc
educ
research
qualiti
clinic
govern
servic
network
requir
framework
also
describ
minimum
requir
special
area
clinic
trial
laboratori
servic
imag
multidisciplinari
team
meet
nurs
pharmaci
psychosoci
care
radiat
oncolog
surgeri
manag
late
effect
conclus
scf
support
health
servic
plan
develop
paediatr
cancer
servic
within
agre
scope
practic
scf
support
health
servic
deliv
level
care
meet
need
local
commun
whilst
maintain
patient
safeti
efficaci
confid
refer
share
care
beta
blocker
treatment
hemangioma
experi
case
singl
institut
n
yazici
f
sarialioglu
erbay
erdogan
p
kiper
misirlioglu
pediatr
oncolog
baskent
univers
adana
turkey
pediatr
cardiolog
baskent
univers
adana
turkey
pediatr
baskent
univers
adana
turkey
object
efficaci
safeti
beta
blocker
especi
propranolol
approv
infantil
hemangioma
aim
studi
analys
efficaci
safeti
system
topic
beta
blocker
larg
popul
preliminari
experi
institut
method
septemb
januari
medic
record
patient
diagnos
hemangioma
retrospect
investig
baskent
univers
depart
pediatr
oncolog
basal
complet
blood
count
serum
biochemistri
obtain
patient
system
beta
blocker
treatment
cardiac
evalu
made
patiet
echocardiographi
select
one
start
dose
propranolol
rang
mgkgday
steroid
ad
propranolol
major
case
local
timolol
ointment
use
minor
case
tini
cuten
hemangioma
treatment
respons
record
earli
late
respons
criteria
group
retrospect
record
vital
sign
initi
treatment
record
advers
event
examin
lesion
secondari
treatment
also
evalu
result
femal
median
age
month
month
gestat
age
week
indic
treatment
rapid
growth
ulcer
infect
cosmet
issu
bleed
breath
feed
ocular
problem
compart
syndrom
earli
respons
seen
case
respons
end
treatment
advers
event
result
interrupt
cessat
treatment
detect
case
favor
result
obtain
sever
locat
phenotyp
variant
hemangioma
local
treatment
timolol
limit
use
conclus
experi
hemangioma
reveal
satisfactori
result
sever
case
specif
locat
phenotyp
variant
believ
earli
use
beta
blocker
would
associ
less
complic
cours
benign
disord
propranolol
tumor
except
infantil
hemangioma
present
four
case
f
sarialioglu
n
yazici
erbay
demir
alkan
ne
kocer
uckan
pediatr
oncolog
baskent
univers
faculti
medicin
ankara
turkey
pediatr
oncolog
baskent
univers
faculti
medicin
adana
turkey
radiolog
baskent
univers
faculti
medicin
adana
turkey
patholog
baskent
univers
faculti
medicin
adana
turkey
oral
surgeri
baskent
univers
faculti
dentistri
adana
turkey
object
debat
use
propranolol
infantil
hemangioma
question
efficaci
vascular
lesion
like
tuft
angioma
kasabach
merrit
syndrom
hemangioendothelioma
hand
improv
surviv
publish
adult
cancer
incident
use
beta
blocker
indic
herein
four
case
lesion
infantil
hemangioma
present
beta
blocker
treatment
interest
result
method
femal
metastat
hemangioendothelioma
liver
bone
male
noonan
syndrom
progress
hypothalam
chiasmat
low
grade
glioma
femal
giant
retroorbit
plexiform
neurofibroma
neurofibromatosi
type
femal
recurr
giant
cell
granuloma
jaw
present
parent
patient
metastat
hemangioendothelioma
progress
glioma
refus
standard
treatment
relaps
recurr
giant
cell
tumor
lesion
inoper
three
oper
steroid
inject
treatment
offer
period
procur
calcitonin
health
care
system
patient
propranolol
mgkg
prednisolon
mgkg
use
inform
consent
obtain
prednisolon
durat
differ
patient
result
patient
metastat
hemangioendothelioma
respond
well
propranolol
prednisolon
failur
free
surviv
month
relaps
patient
progress
glioma
show
promin
neurocognit
develop
radiolog
regress
tumor
case
plexiform
neurofibroma
mri
display
regress
retroorbit
mass
first
three
month
treatment
stabil
cours
thereaft
giant
cell
tumor
respond
treatment
approxim
three
week
third
relaps
side
effect
detect
prolong
use
conclus
probabl
mechan
four
differ
case
borderlin
tumor
accept
respons
treatment
propranolol
achiev
abdomin
inflammatori
myofibroblast
tumor
great
mimick
imag
help
diagnosi
youssef
madney
el
wakil
el
shafi
iman
zaki
diagnost
imag
nation
cancer
institut
cairo
univers
cairo
egypt
pediater
nation
cancer
institut
cairo
univers
cairo
egypt
surgeri
nation
cancer
institut
cairo
univers
cairo
egypt
diagnost
imag
nation
cancer
institut
cairo
univers
cairo
egypt
object
inflammatori
myofibroblast
tumor
imt
quasineoplast
lesion
commonli
involv
lung
orbit
report
occur
nearli
everi
site
bodi
imt
report
mainli
children
young
adult
variat
clinic
present
imt
confound
diagnosi
imt
rariti
lesion
often
mimic
sarcoma
lymphoma
metastasi
imt
often
clinic
misdiagnos
malign
tumor
featur
imt
imag
studi
variabl
manifest
often
soft
tissu
mass
object
evalu
imag
featur
patholog
confirm
ten
case
imt
method
retrospect
review
imag
studi
ten
case
patholog
confirm
imt
region
result
ten
patient
male
femal
imt
studi
age
rang
one
year
mesenteri
commonest
locat
n
follow
liver
n
urinari
bladder
n
us
ten
patient
review
show
soft
tissu
mass
lesion
definit
specif
sonograph
criteria
imt
ct
ten
patient
review
show
heterogen
hypo
dens
mass
evid
enhanc
calcif
encount
one
case
small
cyst
note
within
case
mesenter
lesion
caus
secondari
effect
ie
intestin
obstruct
mri
review
case
one
hepat
urinari
bladder
case
signific
featur
hypointens
signal
imt
mass
conclus
imt
rare
usual
benign
neoplasm
mimic
sever
malign
tumor
radiolog
clinic
radiologist
familiar
entiti
present
facilit
accur
diagnosi
help
avoid
unnecessari
radic
surgic
resect
initi
implement
art
craft
activ
child
life
servic
depart
underprivileg
pediatr
oncolog
patient
improv
qualiti
life
ali
psycho
oncolog
children
cancer
hospit
karachi
pakistan
object
child
life
servic
cl
offshoot
depart
creat
improv
qualiti
life
hospit
children
view
parent
concern
regard
loss
normalci
child
life
due
long
hospit
stay
chemo
cancer
treatment
art
craft
project
initi
children
intervent
base
belief
creativ
process
involv
make
art
heal
life
enhanc
method
volunt
initi
train
basic
childclient
center
therapi
art
work
sent
engag
children
differ
art
craft
activ
ie
hand
face
paint
collag
origami
cut
past
draw
color
work
group
children
approx
children
age
rang
year
daycar
unit
observ
studi
method
use
volunt
provid
written
observ
pre
post
activ
along
feedback
hospit
staff
parent
result
respons
intervent
observ
staff
parent
volunt
yield
similar
result
intervent
help
allevi
mood
stress
children
creat
respons
group
work
enthusiasm
interest
share
releas
boredom
help
produc
complianc
food
medicin
also
aid
distract
invas
procedur
conclus
emot
health
wellb
children
suffer
cancer
crucial
child
develop
well
treatment
implement
intervent
underprivileg
chariti
organ
challeng
due
scarciti
limit
materi
well
human
resourc
also
famili
unswerv
unfound
belief
faith
healer
compound
problem
face
doctor
treat
patient
qualiti
life
perspect
pediatr
cancer
patient
survivor
good
thing
bad
thing
anthoni
e
selkirk
dix
r
klaassen
l
sung
klassen
pediatr
mcmaster
univers
hamilton
canada
pediatr
bc
children
hospit
vancouv
canada
pediatr
children
hospit
eastern
ontario
ottawa
canada
pediatr
hospit
sick
children
toronto
canada
object
systemat
assess
qualiti
life
qol
necessari
within
pediatr
oncolog
research
clinic
practic
research
intervent
initi
requir
theoret
framework
found
clearli
defin
construct
qol
howev
given
multidimension
natur
qol
remain
unclear
domain
concept
import
children
cancer
purpos
studi
inform
theoret
underpin
qol
perspect
pediatr
cancer
patient
survivor
qualit
studi
guid
interpret
descript
method
studi
particip
recruit
four
canadian
academ
pediatr
hospit
data
collect
complet
interview
transcript
examin
common
theme
pattern
review
continu
interpret
understand
consid
within
context
clinic
practic
current
knowledg
field
theme
refin
team
consensu
satur
reach
result
total
children
particip
femal
diagnos
vari
cancer
type
identifi
cancer
survivor
median
age
rang
year
particip
acknowledg
presenc
posit
neg
aspect
within
cancer
experi
express
necessari
take
good
bad
perspect
illumin
across
three
promin
theme
one
abl
alway
one
want
feel
isol
within
new
close
famili
friend
develop
posit
amidst
anger
sad
linger
worri
conclus
explor
theme
highlight
particip
interwoven
experi
qol
demonstr
potenti
dynam
within
contextu
variabl
futur
step
includ
consid
whether
qol
instrument
repres
assess
qol
experienc
within
pediatr
popul
cancer
develop
theoret
framework
refin
within
context
current
find
longitudin
chang
hope
parent
children
cancer
poor
prognosi
effect
diagnosi
di
battista
l
beaun
e
buffet
nichola
barrera
psycholog
hospit
sick
children
toronto
canada
hematologyoncolog
hospit
sick
children
toronto
canada
pediatr
hospit
sick
children
toronto
canada
faculti
social
work
univers
calgari
edmonton
canada
object
date
studi
use
standard
instrument
prospect
document
parent
hope
child
treat
cancer
poor
prognosi
object
use
standard
instrument
longitudin
examin
parent
hope
first
year
effect
cancer
diagnosi
hope
method
parent
children
diagnos
cancer
poor
prognosi
larg
pediatr
cancer
centr
particip
institut
approv
obtain
studi
particip
sign
consent
particip
parent
complet
hearth
hope
index
hhi
refer
child
condit
upon
enrol
month
post
diagnosi
month
six
month
nine
month
month
later
hhi
standardard
adult
chronic
advanc
diseas
base
child
diagnosi
parent
stratifi
three
group
leukemialymphoma
solid
tumor
st
brain
tumor
bt
analys
repeat
measur
anova
conduct
effect
size
present
result
overal
parent
score
hope
significantli
higher
norm
data
time
interv
assess
significantli
hope
bt
group
st
group
compar
st
group
bt
group
parent
hope
significantli
increas
st
group
hope
significantli
decreas
hope
alter
time
group
conclus
fluctuat
parent
hope
time
seem
relat
child
diagnosi
like
depend
child
respons
treatment
result
suggest
import
address
parent
hope
child
treatment
part
psychosoci
care
assess
continu
impact
holist
care
provid
st
jude
india
childcar
centr
child
return
home
treatment
bilgrami
b
sanadhya
develop
st
jude
childcar
centr
mumbai
india
former
develop
manag
st
jude
childcar
centr
mumbai
india
object
understand
impact
st
jude
qualiti
life
famili
analyz
problem
famili
face
home
measur
impact
famili
chang
agent
commun
use
find
support
famili
improv
model
method
pilot
studi
conduct
famili
centr
establish
paramet
studi
random
select
famili
return
home
agre
particip
studi
interview
photograph
home
complet
checklist
complet
item
observ
result
chang
better
entir
famili
daili
routin
cleanli
home
eat
habit
chang
famili
manag
keep
hous
clean
children
learn
good
habit
pass
other
famili
mani
famili
tri
improv
way
live
home
renov
home
provid
proper
facil
famili
reloc
better
home
school
condit
home
differ
substanti
centr
tabl
show
somedetail
find
conclus
famili
agre
learnt
cleanli
disciplin
control
daili
life
live
harmoni
commun
posit
think
feel
empower
confid
explor
psychosoci
aspect
paediatr
oncolog
person
lifebook
initi
illustr
psychosoci
experi
patient
famili
paediatr
cancer
singapor
j
choo
p
tan
choo
cm
ho
yl
chiu
tc
quah
yong
loo
lin
school
medicin
nation
univers
singapor
singapor
singapor
raffl
institut
raffl
institut
singapor
singapor
depart
psycholog
medicin
nation
univers
singapor
singapor
singapor
depart
social
work
nation
univers
singapor
singapor
singapor
divis
paediatr
nation
univers
hospit
singapor
singapor
object
lifebook
therapeut
tool
review
elderli
dementia
termin
ill
yet
children
process
explor
experi
mean
facilit
reflect
hold
potenti
tremend
psychosoci
benefit
especi
pertin
acut
lymphoblast
leukemia
patient
famili
despit
increas
rate
remiss
still
face
mani
psychosoci
challeng
lifebook
also
serv
inspir
provid
advic
other
help
cope
mechan
famili
child
surviv
method
patient
famili
recruit
base
willing
lifebook
inform
consent
done
formal
interview
conduct
audiotap
transcrib
transcript
storylin
patient
famili
involv
much
possibl
encourag
contribut
content
design
idea
provid
materi
like
photo
draft
creat
publish
compani
review
famili
social
worker
complimentari
print
copi
given
patient
famili
result
product
lifebook
ongo
project
current
recipi
healthcar
profession
found
benefici
therapeut
children
cancer
foundat
ccf
singapor
key
organ
support
children
cancer
famili
support
project
aim
eventu
benefit
nation
univers
hospit
nuh
paediatr
oncolog
patient
famili
conclus
besid
therapeut
full
spectrum
experi
narrat
lifebook
uniqu
supplement
perspect
healthcar
profession
futur
direct
includ
compil
advic
booklet
publish
compil
lifebook
book
creat
lifebook
librari
nuh
wardsclin
launch
lifebook
onlin
platform
project
promis
shed
light
improv
paediatr
oncolog
psychosoci
care
singapor
asian
set
help
cancer
survivor
regain
face
challeng
therapeut
adventur
expedit
leblanc
f
dufour
expedit
tip
toe
foundat
chicoutimi
canada
object
adolesc
live
cancer
threaten
physic
integr
often
affect
qualiti
life
relationship
famili
friend
sinc
tip
toe
foundat
organ
outdoor
therapeut
adventur
young
cancer
survivor
year
old
across
canada
mission
help
young
peopl
live
cancer
regain
overcom
new
challeng
contact
natur
part
group
individu
problemat
purpos
present
explain
approach
tip
toe
foundat
specif
program
object
help
particip
surpass
becom
awar
strength
develop
sens
autonomi
respons
creat
experi
base
social
inclus
go
sick
treatment
adventur
program
allow
holist
heal
process
remiss
period
method
powerpoint
use
present
organ
program
result
pictur
trip
short
video
present
result
preliminari
result
five
year
studi
impact
therapeut
expedit
qualiti
life
adolesc
live
cancer
paquett
l
univers
quebec
chicoutimi
present
conclus
present
give
better
understand
approach
program
develop
tip
toe
foundat
result
adolesc
balanc
grief
surviv
experi
children
brain
tumour
parent
c
eaton
russel
e
bouffet
j
beaton
lolli
max
beatric
wolf
children
centr
temmi
latner
centr
palli
care
mt
sinai
hospit
toronto
canada
hospit
sick
children
toronto
canada
famili
relat
appli
nutrit
univers
guelph
guelph
canada
object
research
explor
mani
import
aspect
live
childhood
cancer
includ
multitud
strain
famili
member
reaction
littl
known
experi
children
brain
tumour
parent
end
research
team
conduct
qualit
studi
guid
ground
theori
method
explor
uniqu
share
element
experi
childhood
brain
tumour
perspect
children
parent
method
interview
conduct
twelv
children
brain
tumour
age
year
one
parent
total
particip
result
woven
throughout
stori
express
grief
uncertainti
relat
tumour
effect
live
children
parent
describ
effort
strategi
use
tri
maintain
posit
outlook
sens
normalci
order
cope
adapt
struggl
chang
live
conclus
substant
theori
balanc
grief
surviv
develop
offer
len
view
children
parent
complex
experi
struggl
cope
strategi
integr
dynam
process
present
introduc
particip
theori
illustr
quot
insight
share
children
parent
implic
futur
research
clinic
practic
also
discuss
singl
session
group
intervent
griev
rel
j
espinosa
l
fuent
l
psycholog
unidad
nacion
de
guatemala
guatemala
object
purpos
intervent
giveemot
tool
strategi
particip
healthi
elabor
oftheir
grief
process
method
intervent
rel
patient
whodi
oncolog
diseas
gather
nation
unit
pediatriconcolog
unop
take
part
seri
activ
led
thepsycholog
depart
aid
social
work
child
life
paliativecar
group
activ
focus
develop
emot
skillsfor
particip
cope
loss
someon
close
result
end
theactiv
particip
secur
environ
emot
catharsisand
name
least
conduct
introduc
everyday
lifefor
appropri
griev
process
conclus
interventionoff
opportun
particip
guid
emotionalresourc
healthi
resolut
griev
process
cognit
function
children
acut
lymphoblast
leukemia
undergo
chemotherapi
develop
countri
perspect
v
gupta
singh
tb
singh
sk
upadhyaya
pediatr
banara
hindu
univers
varanasi
india
divis
biostatist
banara
hindu
univers
varanasi
india
object
studi
cognit
function
patient
acut
lymphoblast
leukemia
therapi
major
studi
focus
long
term
survivor
data
develop
countri
even
scarcer
emphasi
still
cure
rather
qualiti
life
complet
therapi
present
studi
carri
assess
cognit
function
children
still
treatment
method
cognit
function
children
mainten
phase
chemotherapi
assess
use
malin
intellig
scale
indian
children
adapt
weschler
intellig
scale
children
divid
standard
high
risk
group
base
age
diagnosi
initi
white
cell
count
immunophenotyp
cytogenet
high
risk
group
receiv
intens
chemotherapi
includ
cranial
irradi
children
chronic
diseas
serv
control
result
median
age
patient
year
children
score
iq
less
control
group
mean
iq
score
studi
control
group
respect
p
patient
poor
score
area
statist
signific
area
inform
comprehens
arithmet
digit
span
pictur
complet
block
design
code
subgroup
analysi
mean
iq
score
high
risk
standard
risk
group
respect
p
high
risk
patient
score
lower
comprehens
arithmet
block
design
object
assembl
code
conclus
children
undergo
chemotherapi
lower
score
verbal
perform
overal
iq
differ
mark
high
risk
group
earli
identif
risk
patient
poor
outcom
help
better
rehabilit
patient
psycholog
problem
healthi
sibl
pediatr
oncolog
guseva
e
barchina
g
tseitlin
rehabilit
autonom
organ
rehabilit
children
cancer
children
moscow
russia
psychotherapi
institut
practic
psycholog
psychoanalysi
moscow
russia
moscow
russia
rehabilit
dmitri
rogachev
feder
research
centr
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
childhood
cancer
significantli
affect
entir
famili
make
consider
impact
daili
function
emot
condit
healthi
sibl
particularli
vulner
compet
deal
famili
crisi
studi
purpos
explor
psycholog
problem
cope
resourc
healthi
sibl
particip
compris
children
age
pediatr
oncolog
patient
remiss
healthi
sibl
griev
loss
elder
sister
leukemia
method
studi
conduct
rehabilit
camp
citi
famili
club
two
year
includ
diagnost
therapi
individu
sibl
pair
group
diagnost
project
test
famili
diagnost
therapi
method
guid
phantasi
v
oakland
play
therapi
td
sandplay
result
outcom
reveal
healthi
sibl
less
often
emot
behavior
problem
sick
brotherssist
healthi
sibl
low
diffid
passiv
vital
posit
high
lack
earli
adult
statu
feel
flood
complic
emot
anger
offenc
fear
death
jealousi
guilt
sad
abandon
coexist
care
concern
sick
lead
emot
conflict
high
anxieti
respons
sibl
demonstr
behavior
syndrom
known
defens
mechan
maladapt
cope
autoaggress
close
act
dependentdevi
behavior
hyperact
retard
school
failur
psychosomat
disord
depress
etc
healthi
sibl
suffer
loss
could
openli
acknowledg
mourn
parent
love
safeti
confid
futur
usual
way
life
etc
possibl
loss
cancer
sibl
conclus
healthi
sibl
involv
rehabilit
program
right
cancer
diagnos
brothersist
famili
system
therapi
core
element
rehabilit
program
famili
help
healthi
children
cope
share
inform
feel
care
sick
love
attent
rehabilit
camp
program
guseva
g
tseitlin
rehabilit
autonom
organ
rehabilit
children
cancer
ano
children
moscow
russia
rehabilit
rogachev
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
russian
camp
program
conduct
moscow
twice
year
sinc
ano
children
scientif
methodolog
support
rogachev
feder
research
center
pediatr
hematolog
oncolog
immunolog
purpos
attain
rehabilit
adapt
disabl
children
healthi
sibl
help
overcom
social
depriv
promot
famili
effect
social
integr
method
children
age
receiv
care
within
program
sibl
receiv
mainten
chemotherapi
camp
program
base
follow
principl
sibl
accept
hospit
treatment
brotherssist
restrict
number
arriv
child
work
camp
leader
assist
children
program
individu
group
psychotherapi
core
element
camp
program
multidisciplinari
special
educ
team
oncologist
psychologist
art
therapist
teacher
camp
leader
work
camp
result
camp
program
children
cancer
highli
effect
rehabilit
technolog
pediatr
oncolog
rehabilit
effect
depend
sever
condit
camp
independ
complimentari
program
citi
famili
club
children
involv
long
period
program
staff
conclus
camp
program
essenti
element
rehabilit
system
children
cancer
parent
healthi
sibl
entir
famili
experi
show
perman
develop
camp
program
result
effect
collabor
organ
parent
club
feder
center
commerci
structur
analysi
qualiti
life
survivor
childhood
cancer
studi
turkey
v
hazar
erol
guney
pediatr
hematologyoncolog
bmt
unit
istanbul
medipol
univers
faculti
medicin
istanbul
turkey
depart
pediatr
akdeniz
univers
faculti
medicin
antalya
turkey
object
evalu
health
relat
qualiti
life
hrqol
turkish
childhood
cancer
survivor
assess
influenc
demograph
medic
characterist
hrqol
method
studi
conduct
cancer
survivor
whose
age
begin
treatment
treatment
stop
least
year
ago
healthi
control
characterist
term
age
gender
condit
pediatr
qualiti
life
inventori
pedsql
tm
gener
core
scale
use
survivor
age
year
parent
qualiti
survey
appli
survivor
age
result
comparison
total
score
survivor
control
age
reveal
lower
point
hrqol
score
survivor
p
survivor
older
year
time
diagnosi
report
significantli
wors
hrqol
score
p
control
survivor
age
group
wors
score
hrqol
physic
social
subscal
p
p
respect
evalu
physic
subscal
score
survivor
among
paramet
walk
p
run
p
exercis
p
daili
hous
work
p
fatigu
p
found
lower
control
group
similarli
score
survivor
group
among
social
paramet
other
want
friend
p
abl
thing
other
p
keep
play
kid
p
found
lower
control
group
work
capac
concentr
score
wors
survivor
older
year
old
control
group
p
p
respect
conclus
studi
provid
crucial
clue
hrqol
pediatr
cancer
survivor
clue
lead
rehabilit
jordan
river
villag
camp
program
children
cancer
israel
g
hertzel
shternin
z
zihar
oz
mordechai
ben
arush
pediatr
hematolog
oncolog
haemek
medic
center
afula
israel
jordan
river
villag
jordan
river
villag
galil
israel
pediatr
hematolog
oncolog
rambam
health
care
campu
haifa
israel
object
cancer
diagnosi
treatment
caus
signific
stress
leav
children
increas
risk
psycholog
problem
jordan
river
newest
member
newman
chain
camp
locat
lower
galile
region
israel
camp
kind
middl
east
method
jordan
river
villag
seek
kid
chronic
ill
broader
middl
east
enrich
live
jewish
muslim
christian
children
region
result
villag
open
two
year
ago
children
chronic
diseas
came
israel
palestin
without
parent
diagnos
cancer
age
year
old
mean
year
staff
includ
volunt
physician
nurs
therapist
counselor
clown
social
worker
program
offer
medic
supervis
week
swim
drama
sport
art
set
upper
galile
children
constant
supervis
one
counselor
arab
hebrew
languag
assign
everi
two
camper
attend
need
day
sleep
room
night
special
train
staff
overse
daili
activ
staff
doctor
nurs
well
mani
volunt
medic
personnel
provid
necessari
medic
supervis
lead
hospit
voluntari
organ
partner
jordan
river
villag
recogn
import
villag
benefit
thousand
children
conclus
creat
free
fill
memor
medic
safe
camp
experi
jordan
river
villag
one
best
model
therapeut
recreat
program
children
cancer
give
opportun
independ
independ
cultur
differ
recent
employ
trend
childhood
cancer
survivor
japan
survey
ishida
hayashi
f
inou
ozawa
pediatr
medic
center
ehim
prefectur
central
hospit
matsuyama
japan
herat
link
work
project
niigata
japan
member
herat
link
work
project
chiba
japan
pediatr
st
luke
intern
hospit
tokyo
japan
object
previou
research
shown
adult
childhood
cancer
survivor
ccss
experienc
employ
difficulti
howev
actual
employ
statu
ccss
japan
studi
method
particip
select
membership
directori
heart
link
health
insur
recruit
childhood
cancer
patient
network
conduct
survey
questionnair
employ
via
postal
mail
commun
link
internet
websit
explor
associ
characterist
ccss
requir
disabl
qualif
experienc
unemploy
adjust
odd
ratio
or
factor
outcom
interest
estim
logist
regress
analysi
result
total
ccss
indic
disabl
qualif
signific
independ
factor
relat
need
disabl
qualif
late
effect
confid
interv
ci
brain
tumor
ci
high
school
graduat
ci
unemploy
rate
among
ccss
exclud
homemak
student
approxim
unemploy
ccss
late
effect
report
experienc
job
difficulti
childhood
cancer
independ
factor
relat
unemploy
late
effect
ci
drop
school
ci
brain
tumor
ci
seventi
four
unemploy
ccss
report
want
work
employ
understood
ccss
better
conclus
unemploy
rate
high
japan
ccss
need
extend
disabl
qualif
independ
factor
relat
unemploy
late
effect
drop
school
unemploy
ccss
like
seek
work
despit
health
problem
father
suvivor
retreat
explor
fathersurvivor
role
commun
relationship
aya
brain
tumor
commun
w
iwata
wagner
social
work
children
brain
tumor
foundat
new
york
usa
object
research
indic
father
also
experi
increas
distress
level
treatment
survivorship
sloper
clinic
intervent
design
address
distress
father
level
distress
greater
impact
vulner
child
feel
mother
distress
level
child
robinson
et
al
father
survivor
less
like
connect
other
similar
situat
mother
peer
mentor
commun
build
shown
reduc
distress
sloper
p
predictor
distress
parent
children
cancer
prospect
studi
journal
pediatr
psycholog
robinson
k
e
gerhardt
c
vannatta
k
noll
r
b
parent
famili
factor
associ
child
adjust
pediatr
cancer
journal
pediatr
psycholog
method
address
relationship
commun
issu
father
survivor
pilot
weekend
intervent
explor
father
focu
group
conduct
determin
program
object
indic
concern
around
commun
age
appropri
development
marker
career
relationship
independ
survivor
also
survey
interest
father
survivor
indic
desir
team
build
activ
activ
discuss
group
creat
meet
research
identifi
need
result
famili
recruit
area
twelv
brain
tumor
survivor
father
attend
three
day
retreat
increas
level
commun
father
survivor
seen
increas
father
involv
commun
event
held
children
brain
tumor
foundat
conclus
poster
discuss
program
creation
implement
outcom
retreat
impact
fathersurvivor
relationship
commun
look
well
futur
implic
step
evalu
effect
intervent
pediatr
enhanc
connect
parent
intervent
mother
children
cancer
b
jone
f
lewi
f
phillip
school
social
work
ut
austin
austin
usa
school
nurs
univers
washington
seattl
usa
object
parent
children
cancer
face
incred
demand
includ
disrupt
normal
function
anxieti
trauma
depress
neg
psychosoci
outcom
therapeut
intervent
need
help
parent
cope
ongo
stress
enhanc
resili
respons
child
diagnosi
purpos
studi
evalu
feasibl
adapt
enhanc
connect
program
manual
educ
counsel
program
mother
breast
cancer
school
age
children
pediatr
enhanc
connect
pec
program
mother
children
acut
phase
child
cancer
diagnosi
treatment
method
qualit
interview
use
inquir
modifi
intervent
reson
mother
n
experi
child
cancer
themat
analysi
data
involv
identif
common
thread
repres
particip
experi
theme
identifi
describ
reaction
mother
intervent
materi
perceiv
intervent
meet
need
famili
result
result
indic
desir
support
specif
uniqu
experi
parent
child
cancer
mother
describ
avail
psychosoci
support
children
lack
support
emot
need
specif
parent
concern
mother
describ
feel
guilt
lack
confid
parent
skill
regard
child
ill
mother
express
desir
parent
similar
situat
final
mother
describ
barrier
face
relat
self
care
conclus
mother
children
cancer
clear
suggest
adapt
intervent
meet
need
find
suggest
need
parent
intervent
mother
face
childhood
cancer
cancer
children
socioeconom
resourc
parent
non
government
organ
support
famili
kebudi
h
akcay
e
aysoy
gonen
r
kebudi
student
hisar
school
volunt
childhood
cancer
love
solidar
societi
coksev
istanbul
turkey
bt
director
fleet
corp
volunt
childhood
cancer
love
solidar
societi
coksev
istanbul
turkey
vice
presid
volunt
childhood
cancer
love
solidar
societi
coksev
istanbul
turkey
secretari
volunt
childhood
cancer
love
solidar
societi
coksev
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
cerrahpasa
medic
faculti
oncolog
institut
presid
coksev
istanbul
turkey
object
cancer
children
influenc
entir
famili
parent
work
situat
may
affect
method
parent
children
cancer
evalu
regard
number
sibl
live
environ
parent
employ
hospit
medic
children
reimburs
govern
result
ten
famili
home
istanbul
stay
hous
rel
two
three
famili
live
hous
time
two
room
per
hous
twenti
famili
two
sibl
twelv
father
regular
job
either
unemploy
quit
job
care
child
thirti
low
incom
mother
housewif
tri
gain
incom
famili
housework
clean
hospit
medic
children
reimburs
govern
nevertheless
famili
extra
financi
need
transportationto
hospit
food
cloth
conclus
addit
psycholog
burden
cancer
children
poor
socioeconom
resourc
famili
increas
burden
famili
non
government
organ
ngo
may
provid
support
famili
develop
pediatr
psycho
oncolog
environ
limit
resourc
z
ke
cman
bmt
unit
laboratori
cryobiolog
depart
treatment
hematolog
oncolog
diseas
mother
child
health
care
institut
serbia
dr
vukan
cupic
belgrad
serbia
object
serbia
around
children
diagnos
cancer
yearli
most
treat
depart
mother
child
health
care
institut
serbia
dr
vukan
cupic
mchci
serbia
formal
educ
program
hospit
volunt
great
support
matter
given
local
childhood
cancer
parent
organ
zvoncica
ccpo
profession
practic
start
introduct
ward
juli
sever
unsuccess
attempt
period
recogn
need
children
famili
adequ
met
method
psycholog
support
provid
form
individu
interview
children
famili
play
therapi
medic
play
psycholog
counsel
psychotherapi
result
approxim
six
hundr
psycholog
intervent
provid
approxim
one
hundr
children
first
six
month
children
famili
feedback
show
help
necessari
life
qualiti
improv
long
term
hospit
treatment
conclus
experi
show
pediatr
support
continu
exist
futur
effort
develop
provid
better
profession
support
improv
profession
skill
order
meet
children
famili
psycholog
social
develop
goal
contribut
children
recoveri
preserv
patient
famili
mental
health
help
get
challeng
cancer
treatment
order
continu
live
hospit
medic
staff
recognit
necess
profession
psycholog
support
close
cooper
ccpo
right
track
achiev
develop
implement
depart
children
cancer
hospit
use
integr
medicin
multidisciplinari
approach
e
khan
ghazi
children
cancer
hospit
karachi
pakistan
object
order
meet
psychosoci
need
pediatr
popul
children
cancer
hospit
depart
start
januari
includ
child
life
spiritu
counsel
servic
method
model
care
govern
western
australia
depart
health
use
benchmark
practic
assess
distress
thermomet
symptom
measur
human
figur
draw
test
comprehens
interview
schedul
use
tier
intervent
model
hutchison
steginga
dunn
use
individu
group
therapi
spike
protocol
deliv
unpleas
inform
employ
intervent
play
art
music
assist
therapi
integr
medicin
practic
medit
aromatherapi
reiki
touch
dream
work
mind
base
stress
reduct
use
address
distress
cognit
disturb
legaci
project
initi
eas
die
process
condol
visit
arrang
give
emot
support
famili
child
life
specialist
employ
art
play
therapi
ensur
optimum
qualiti
life
patient
spiritu
counselor
train
cognit
behavior
therapi
address
patient
famili
existenti
crise
result
psychosoci
care
avail
throughout
cancer
journey
ensur
better
qualiti
life
treatment
complianc
patient
reduct
stressdistress
associ
ill
till
six
thousand
session
given
depart
patient
famili
conclus
challeng
resourc
limit
includ
human
space
technolog
languag
barrier
poverti
lack
educ
awar
patient
famili
regard
diseas
psychosoci
impact
anoth
challeng
stigma
associ
get
psycholog
help
train
requir
field
special
pakistan
pertain
benefit
function
activ
toy
recreat
therapi
children
cancer
j
koppling
dan
mornar
design
udoo
planet
creation
ltd
surrey
canada
oncologyhematologybmt
program
british
columbia
children
hospit
vancouv
canada
object
function
activ
toy
posit
effect
patient
qualiti
life
use
recreat
therapi
children
cancer
method
udoo
produc
therapeut
play
product
also
function
cloth
item
newdo
hat
simul
activ
hair
style
fun
creativ
way
fleec
dread
braid
tie
knot
worn
hat
come
four
differ
color
mimic
natur
hair
blond
brunett
red
black
rang
hair
accessori
ad
boodo
hat
make
easi
fun
chang
rearrang
featur
hat
express
differ
fantasi
face
puppmittz
function
mitten
keep
hand
warm
four
differ
charact
mitten
children
caregiv
flip
mitt
flop
top
reveal
differ
look
emot
puppmittz
tell
stori
kid
express
experi
feel
charact
function
activ
toy
use
interact
live
theatr
perform
bc
children
hospit
vancouv
canada
function
activ
also
ad
show
base
result
udoo
planet
ltd
creat
line
function
activ
product
particularli
suitabl
recreat
therapi
result
result
promis
patient
exhibit
high
level
involv
product
peer
kid
delight
play
act
like
kid
clear
posit
impact
children
particip
engag
felt
better
conclus
udoo
product
enthusiast
receiv
facilit
focu
group
twenti
children
bc
children
hospit
vancouv
bright
color
tactil
fabric
engag
children
encourag
creativ
experi
parent
paediatr
patient
acut
lymphoblast
leukemia
two
month
complet
treatment
lucchetta
b
muskat
h
jone
w
shama
zupanec
social
work
hospit
sick
children
toronto
canada
nurs
hospit
sick
children
toronto
canada
object
complet
pediatr
cancer
treatment
consid
difficult
anxieti
produc
time
famili
transit
activ
care
believ
exceedingli
stress
famili
spent
year
live
demand
uncertainti
cancer
treatment
despit
grow
recognit
famili
emot
stress
uncertainti
vulner
decreas
health
relat
qualiti
life
exist
pauciti
research
parent
experi
crucial
time
explor
parent
experi
transit
need
purpos
studi
captur
live
experi
parent
pediatr
patient
two
month
complet
cancer
therapi
ultim
object
examin
need
end
treatment
post
treatment
support
method
open
exploratori
studi
experi
relat
child
ill
treatment
well
linger
effect
health
care
experi
treatment
deliveri
qualit
methodolog
employ
use
mccracken
interview
method
well
interview
guid
contain
question
interview
audio
tape
transcrib
verbatim
transcript
enter
nvivo
analyz
use
long
interview
method
qualit
data
analysi
result
find
analysi
identifi
rang
theme
includ
elat
guilt
fear
relaps
sens
decreas
prioriti
abrupt
end
treatment
uncertainti
deal
new
normal
lack
prepared
transit
activ
care
also
identifi
result
suggest
greater
understand
sensit
experi
famili
essenti
conclus
result
studi
highlight
need
signific
chang
current
practic
therapi
complet
better
promot
posit
psychosoci
cope
adjust
next
step
formul
implement
consist
comprehens
end
therapi
plan
posit
impact
cancer
survivor
mother
provid
support
pediatr
cancer
patient
mother
makhoul
khouri
g
yaqub
poling
r
gagin
pediatr
hematolog
oncolog
rambam
health
care
campu
haifa
israel
object
research
show
mother
pediatr
cancer
patient
involv
daili
basi
child
treatment
cours
therefor
influenc
rest
famili
cope
ill
frank
et
al
adolesc
diagnos
cancer
often
lose
hope
easili
success
stori
surviv
peer
may
help
improv
mental
state
bring
hope
life
method
research
involv
qualit
questionnair
check
posit
influenc
support
mother
children
surviv
cancer
give
famili
first
stage
treatment
ask
experi
feel
insight
met
mother
surviv
children
help
deal
ongo
treatment
result
mother
support
mother
till
individu
meet
mother
whose
children
recov
mother
whose
children
receiv
treatment
interview
mother
children
treatment
report
satisfact
meet
felt
encourag
understood
possibl
deal
difficult
period
treatment
also
felt
support
mother
abl
pinpoint
weak
spot
empath
survivor
support
patient
till
individu
meet
survivor
adolesc
patient
interview
conduct
adolesc
patient
report
feel
hope
optim
said
listen
success
stori
given
energi
continu
battl
felt
survivor
understood
felt
close
even
peer
conclus
outcom
interview
point
project
import
necessari
promot
feel
optim
hope
among
patient
marit
resili
parent
coupl
face
stem
cell
transplant
hsct
children
cancer
j
martin
duval
mf
vachon
sultan
chu
montreal
canada
object
research
effect
childhood
cancer
parent
coupl
show
conflict
result
neg
posit
effect
describ
order
articul
previou
result
focu
new
model
marit
resili
combin
two
core
element
common
coupl
ident
collabor
behavior
model
necessari
help
reinforc
parent
coupl
order
support
futur
famili
rehabilit
purpos
studi
describ
experi
coupl
face
hsct
cancer
child
order
identifi
perceiv
factor
coupl
resili
method
collect
qualit
data
twelv
coupl
experienc
hsct
child
follow
cancer
parent
ask
talk
coupl
gener
react
marit
unit
cancer
hsct
child
interview
code
open
code
agenda
group
concept
retriev
previou
research
subject
code
scale
usual
use
coupl
therapi
measur
partner
individu
sens
ident
coupl
also
code
sens
intimaci
inclus
self
scale
result
parent
identifi
sever
factor
major
import
marit
resili
includ
cohes
within
coupl
capac
work
team
face
advers
open
commun
result
support
idea
experi
major
predictor
resili
conclus
import
collabor
within
coupl
especi
mainten
develop
commun
emot
support
parent
suggest
resili
could
encourag
result
translat
set
recommend
appli
practic
transplant
team
strengthen
parent
coupl
psychosoci
risk
brazilian
famili
children
cancer
two
moment
treatment
motta
f
caprini
genelhu
bortolini
program
psycholog
feder
univers
espirito
santo
brazil
social
development
psycholog
depart
feder
univers
espirito
santo
brazil
servic
hospit
estadu
infantil
nossa
senhora
da
brazil
object
psychosoci
risk
associ
cancer
diagnosi
must
impact
adjust
children
adolesc
treatment
besid
futur
adapt
research
aim
describ
psychosoci
risk
famili
children
cancer
moment
diagnosi
time
two
month
begin
treatment
time
method
nine
patient
age
year
attend
servic
children
hospit
espirito
santo
brazil
includ
studi
parent
provid
inform
psychosoci
risk
portugues
languag
version
psychosoci
assess
tool
pat
social
econom
level
brazilian
econom
classif
criteria
clinic
characterist
obtain
patient
medic
document
data
analyz
descript
statist
consid
tool
standard
result
patient
receiv
diagnosi
leukemia
lymphon
present
high
risk
graviti
cancer
socioeconom
level
famili
indic
vulner
aspect
patient
famili
maintain
psychosoci
risk
classif
level
clinic
target
famili
exibit
univers
classif
subscal
analysi
show
famili
problem
problem
children
highlight
sourc
risk
domain
stress
reaction
show
great
averag
risk
conclus
psychosoci
risk
found
remain
two
month
show
famili
impact
cancer
diagnosi
even
treatment
goe
recogn
famili
must
assess
recent
diagnosi
continu
time
direct
intervent
propos
promot
adapt
outcom
cancer
cours
children
surviv
parent
support
requir
healthi
sibl
pediatr
cancer
patient
nagao
ozawa
ogawa
takei
e
takeuchi
manab
suzuki
depart
prevent
psychiatrydepart
research
manag
graduat
school
medicin
tohoku
universityst
luke
intern
hospit
sendai
japan
depart
pediatr
st
luke
intern
hospit
tokyo
japan
graduat
school
human
scienc
waseda
univers
saitama
japan
faculti
medicinedepart
research
manag
univers
miyazaki
hospitalst
luke
intern
hospit
saitama
japan
object
sibl
pediatr
cancer
patient
higherrisk
develop
emot
problem
especi
patient
hospit
sibl
would
receiv
less
attent
mother
investig
thesupport
mother
sibl
identifi
support
requir
byth
sibl
method
participantswer
mother
pediatr
cancer
patient
patient
sibl
mother
ask
complet
support
scalewhich
measur
much
support
mother
provid
sibl
thesibl
answer
anoth
support
scale
measur
muchsupport
receiv
mother
result
test
indic
signific
differencesbetween
mother
thesibl
tell
sibl
mother
treatmentwil
work
patient
go
holiday
mother
conclus
result
suggest
thatth
sibl
requir
inform
patient
treatment
pain
may
singular
suffer
plural
qualit
analysi
impact
childhood
cancer
senegales
famili
ndiay
sm
ndiay
ac
dieng
mt
sagna
c
moreira
mn
diouf
fb
diagn
pediatr
oncolog
univers
hospit
aristid
le
dantec
dakar
seneg
psychiatri
hopit
princip
de
dakar
dakar
seneg
object
assum
diagnosi
childhood
cancer
agit
famili
aim
explor
numer
famili
testimoni
understand
experi
find
undergo
method
qualit
analysi
thirti
focu
group
parent
hospit
children
address
journey
reach
pediatr
oncolog
unit
hardship
hospit
strain
famili
equilibrium
discuss
resourc
mobil
manag
cancer
experi
result
parent
report
delay
diagnosi
wast
time
seek
tradit
treatment
suitabl
refer
medic
system
discuss
financi
burden
treatment
fee
mostli
struggl
balanc
cost
live
hospit
expens
home
parent
report
feel
powerless
frustrat
inform
suffici
medic
team
child
health
degrad
mother
testifi
distress
lack
understand
spous
blame
voluntarili
stay
hospit
regardless
parent
grate
qualiti
care
reassur
improv
child
health
also
valu
support
parent
medic
team
member
mostli
impress
strength
emot
resourc
mobil
children
never
knew
possess
conclus
intrus
cancer
child
disturb
famili
homeostasi
parent
fragil
sinc
separ
support
reorgan
structur
mobil
spars
resourc
report
highli
stress
period
must
resili
persever
support
children
overwhelm
lone
yet
fight
give
child
never
option
nordic
platform
clinic
ethic
pediatr
oncolog
p
pergert
castor
p
wendtland
edslev
h
glosli
h
haug
lehtinen
g
petersen
l
obot
nophonobo
work
group
ethic
women
children
health
karolinska
institutet
stockholm
sweden
pediatr
depart
aarhu
univers
hospit
aarhu
denmark
depart
pediatr
oncologyhematolog
skane
univers
hospit
lund
sweden
depart
pediatr
oncologyhematolog
children
hospit
reykjavik
iceland
depart
pediatr
medicin
oslo
univers
hospit
oslo
norway
depart
pediatr
oulu
univers
hospit
oulu
finland
depart
pediatr
adolesc
medicin
rigshospitalet
copenhagen
univers
hospit
copenhagen
denmark
pediatr
clinic
univers
hospit
sweden
nordic
societi
pediatr
oncolog
nurs
nobo
nordic
societi
paediatr
haematolog
oncolog
nopho
nordic
countri
sweden
object
purpos
present
present
develop
activ
achiev
nophonobo
work
group
ethic
wge
method
joint
work
group
ethic
consist
pediatr
oncolog
nurs
physician
constitut
nophonobo
annual
meet
intent
creat
nordic
compet
group
address
ethic
question
within
pediatr
oncolog
wge
member
nurs
physician
least
two
repres
nordic
countri
group
meet
yearli
two
one
meet
organiz
educ
member
educ
intern
cours
confer
clinic
ethic
train
facilit
moral
case
deliber
result
wge
member
particip
initi
formal
clinic
ethic
project
pediatr
depart
hospit
region
countri
clinic
project
provid
deliber
ethic
difficult
case
regular
basi
integr
part
daili
work
pediatr
oncolog
ten
member
activ
local
clinic
ethic
committe
two
member
initi
supervis
research
project
ethic
matter
two
member
teach
ethic
nurs
medic
student
one
board
member
nation
societi
clinic
ethic
conclus
best
knowledg
wge
repres
first
special
work
group
ethic
within
framework
intern
studi
group
pediatr
oncolog
nopho
first
joint
work
group
nopho
nobo
prove
benefici
combin
pediatr
oncolog
nurs
physician
differ
countri
work
collabor
educ
creat
common
nordic
platform
develop
clinic
appli
ethic
importantli
wge
inspir
enabl
member
initi
engag
activ
project
local
region
nation
thu
increas
focu
clinic
ethic
caregiv
financi
expenditur
pediatr
cancer
adapt
establish
instrument
j
pole
cj
longo
zuk
l
sung
research
unit
pediatr
oncolog
group
ontario
toronto
canada
degroot
school
busi
mcmaster
univers
hamilton
canada
haematologyoncolog
hospit
sick
children
toronto
canada
object
adapt
caregiv
financi
expenditur
instrument
use
pediatr
cancer
context
use
measur
longitudin
financi
burden
among
caregiv
pediatr
cancer
patient
identifi
characterist
financi
burden
method
focu
group
methodolog
use
evalu
face
valid
understand
pediatr
cancer
individu
invit
review
current
instrument
meet
particip
includ
divers
group
health
care
profession
parent
children
diagnos
cancer
advanc
focu
group
particip
evalu
item
regard
import
item
relat
cost
understand
focu
group
independ
facilit
work
probe
particip
regard
essenti
natur
concept
understand
face
valid
appropri
use
exampl
revis
provid
addit
comment
particip
result
invit
particip
provid
evalu
total
particip
attend
meet
focu
group
respons
provid
clariti
three
main
area
recal
timefram
concept
clariti
need
overal
explan
specif
exampl
restructur
introduct
describ
focu
section
along
definit
use
throughout
gener
question
revis
focu
recal
past
week
format
word
exampl
question
revis
base
feedback
conclus
util
focu
group
help
adapt
establish
instrument
new
uniqu
popul
provid
invalu
insight
focu
group
particip
drove
thought
instrument
ultim
result
instrument
focus
easier
understand
provid
clear
instruct
exampl
measur
level
medic
traumat
stress
parent
children
cancer
recent
complet
treatment
quinn
gozman
v
kanwar
pediatr
hematolog
oncolog
albani
medic
center
albani
usa
object
transit
stress
event
parent
andor
primari
caregiv
henceforth
refer
parent
children
cancer
psychosoci
need
parent
therapi
receiv
limit
attent
unit
state
publish
quantit
studi
largest
parent
small
academ
center
without
formal
program
want
investig
address
need
recruit
transit
care
coordin
tcc
quantit
screen
parent
end
therapi
develop
support
intervent
method
inform
consent
standard
questionnair
psychosoci
assess
tool
pat
administ
parent
therapi
complet
month
later
tcc
provid
univers
intervent
famili
end
therapi
binder
contain
treatment
summari
roadmap
inform
late
effect
survivor
scholarship
base
pat
score
parent
provid
intervent
specif
symptom
target
intervent
refer
behavior
health
specialist
clinic
intervent
result
pat
administ
parent
women
n
score
higher
men
n
parent
experienc
worri
anxieti
sadnessdepress
addit
report
stress
symptom
hypervigil
substanti
proport
found
warrant
target
clinic
intervent
psychosoci
need
facilit
tcc
conclus
pilot
studi
initi
octob
small
academ
center
use
tcc
pat
screen
tool
emerg
statist
suggest
greater
stress
mother
therapi
substanti
proport
parent
symptom
ptss
therapi
anticip
gather
data
parent
confirm
find
link
commun
resourc
support
adher
treatment
appoint
reduc
abandon
childhood
cancer
el
salvador
n
rossel
c
salaverria
hernandez
alabi
r
vasquez
bonilla
c
lam
r
ribeiro
r
rei
oncolog
depart
benjamin
bloom
children
hospit
santa
tecla
el
salvador
intern
outreach
program
st
jude
children
research
hospit
memphi
usa
depart
oncolog
st
jude
children
research
hospit
memphi
usa
depart
od
public
health
commun
care
leiden
univers
medic
center
leiden
netherland
object
abandon
treatment
major
caus
treatment
failur
death
children
cancer
develop
countri
purpos
gain
insight
reason
salvadoran
parent
miss
appoint
abandon
abl
establish
need
support
studi
form
part
newli
introduc
track
system
earli
detect
improv
adher
treatment
appoint
result
substanti
decreas
abandon
rate
method
nearli
patient
miss
one
appoint
track
qualit
data
gather
interview
vari
short
phone
convers
interview
hospit
result
reason
absenc
practic
local
resourc
health
clinic
municip
patient
commun
contact
assist
support
famili
adher
treatment
consist
mostli
money
transport
attend
appoint
confirm
parent
decis
make
depend
medic
consider
regard
risk
benefit
treatment
also
practic
resourc
also
ask
parent
experi
support
receiv
answer
suggest
ad
import
benefit
track
intervent
result
give
practic
support
direct
daili
environ
patient
reduc
feel
isol
helpless
thu
posit
influenc
predisposit
parent
toward
treatment
children
conclus
hospit
reach
patient
commun
impact
decis
treatment
put
togeth
resourc
readi
use
patient
daili
environ
particip
commun
institut
brought
econom
relief
famili
cancer
program
propos
unexpect
social
emot
benefit
help
enhanc
effect
intervent
word
analysi
weblog
post
parent
children
cancer
k
ruccion
j
gilberto
gantan
gordon
divis
hematolog
oncolog
bone
marrow
transplant
children
hospit
lo
angel
lo
angel
usa
institut
creativ
technolog
univers
southern
california
lo
angel
usa
object
identifi
need
parent
children
cancer
distil
naturalist
blog
post
internet
method
blog
post
identifi
use
storyupgrad
program
search
weblog
post
use
fiction
prototyp
stori
sought
post
time
point
diagnosi
activ
treatment
treatment
complet
use
famili
adjust
adapt
respons
faar
model
conceptu
framework
team
content
expert
independ
review
blog
entri
code
review
code
differ
resolv
discuss
achiev
consensu
result
analysi
post
blog
key
theme
previous
identifi
focu
group
structur
interview
patterson
et
al
miedema
et
al
verifi
strain
often
note
ill
relat
treatment
strong
emot
loss
normal
lifeact
child
strong
emot
loss
normal
famili
life
famili
resourc
frequent
mention
child
strength
child
religi
belief
parent
compet
extend
famili
support
famili
support
parent
commun
competentcar
doctor
support
nursessoci
worker
health
care
system
cope
strategi
often
cite
positivemaintain
hope
religi
faith
pride
childstrength
child
live
focus
present
normalseek
normal
balanc
famili
need
advoc
child
organizedplan
ahead
seek
inform
cancer
humorfuncelebr
seekinggiv
support
blog
analysi
also
discov
sever
theme
previous
identifi
pain
strain
gratitud
altruism
cope
gener
commun
support
tangibl
support
resourc
conclus
weblog
analysi
yield
confirmatori
new
evid
parent
need
support
use
internet
research
find
may
use
guid
clinic
care
foster
access
vet
resourc
eg
http
searchhopechlaorg
base
parent
collect
live
wisdom
cknowledg
partial
fund
support
provid
chase
famili
foundat
experi
use
sick
card
patient
educ
materi
improv
outcom
childhood
cacr
r
seth
r
seth
singh
thoma
srivastava
b
singh
pediatr
india
institut
medic
scienc
delhi
india
object
parent
children
undergo
treatment
childhood
cancer
stress
extrem
anxieti
mani
distant
place
aim
provid
detail
diseas
side
effect
treatment
inform
care
children
cancer
opportun
avail
govern
non
government
sourc
treatment
famili
also
construct
sick
card
carri
inform
regard
patient
diseas
medic
common
ailment
dose
first
line
manag
febril
neutropenia
made
local
languag
besid
english
method
questionnair
parent
provid
base
assess
understand
patient
educ
materi
result
parent
awar
variou
form
patient
educ
materi
prepar
detail
provid
help
abil
understand
diseas
better
detail
variou
laboratori
investig
room
provid
found
sick
card
particulrli
use
carri
informationof
intraven
drug
may
use
first
line
treatment
febril
neutropenia
telephon
contact
number
e
mail
support
group
made
parent
children
undergo
cancer
treatment
detail
support
groupsambhav
e
diacuss
conclus
patient
educ
materi
play
import
role
toward
impov
treatment
outcom
camp
trillium
cancer
camp
children
cancer
famili
ontario
canada
martiniuk
execut
director
camp
trillium
hamilton
canada
faculti
medicin
univers
sydney
sydney
australia
object
year
camp
trillium
provid
camp
experi
children
cancer
famili
summer
camp
program
popular
children
cancer
famili
ontario
recent
find
suggest
camp
program
help
children
famili
cope
childhood
cancer
help
improv
qualiti
life
aim
describ
scope
program
number
camper
attend
program
offer
camp
trillium
increas
awar
exist
camp
trillium
consid
leader
oncolog
camp
activ
involv
collabor
nation
intern
program
enhanc
cancer
camp
experi
method
qualit
approach
taken
includ
gather
histor
current
document
camp
trillium
interview
current
staff
board
member
camp
trillium
result
summer
famili
particip
camp
program
famili
activ
cancer
treatment
cancer
treatment
bereav
famili
camp
trillium
work
pediatr
treatment
centr
summer
famili
patient
hospit
sick
kid
toronto
patient
children
hospit
western
ontario
london
mcmaster
children
hospit
hamilton
children
hospit
eastern
ontario
ottawa
kingston
region
cancer
centr
kingston
unknown
clinic
interact
board
director
year
staff
conclud
mission
camp
trillium
demonstr
posit
impact
famili
children
cancer
conclus
abstract
aim
rais
awar
camp
trillium
oncolog
camp
program
support
children
cancer
famili
canadian
model
cancer
camp
movement
nation
collabor
oncolog
camp
best
practic
robertson
treasur
canadian
associ
pediatr
oncolog
camp
hamilton
canada
chair
canadian
associ
pediatr
oncolog
camp
toronto
canada
object
canadian
associ
pediatr
oncolog
camp
form
ensur
cancer
camp
pediatr
oncologist
refer
patient
safe
clinic
director
across
canada
encourag
leader
cancer
camp
examin
oncolog
camp
program
canada
result
set
guidelin
adopt
develop
baselin
best
standard
practic
implement
annual
standard
review
process
led
member
camp
across
canada
given
gold
star
practic
highest
level
aim
describ
evolut
role
canadian
associ
pediatr
oncolog
camp
capoc
increas
awar
exist
need
best
practic
camp
program
method
qualit
approach
taken
includ
gather
histor
current
document
capoc
interview
current
board
member
capoc
result
togeth
board
director
medic
committe
capoc
work
develop
comprehens
set
guidelin
oncolog
camp
sever
resourc
network
opportun
alreadi
exist
includ
peer
peer
visit
occur
everi
three
year
result
gold
star
membership
visit
allow
member
see
camp
action
share
idea
verifi
camp
commit
safe
camp
oper
conclus
abstract
aim
rais
awar
capoc
therefor
enabl
futur
work
around
develop
pediatr
oncolog
camp
guidelin
resourc
share
best
practic
oncolog
camper
requir
attent
expert
knowledg
need
prior
camp
experi
safest
cancer
camp
consid
medic
psychosoci
supervis
suppli
need
care
sick
child
well
meet
exceed
provinci
camp
standard
ensur
camp
contribut
posit
experi
child
address
psychosoci
need
hospit
child
role
child
life
program
ns
jose
child
life
program
kyth
foundat
inc
quezon
citi
philippin
object
kyth
foundat
inc
philippin
base
organ
establish
child
life
program
clp
address
psychosoci
need
chronic
ill
patient
provid
development
appropri
intervent
minim
stress
anxieti
experienc
assur
continu
optim
growth
develop
kyth
undertook
studi
look
role
clp
play
lower
neg
emot
experienc
chronic
ill
children
method
studi
conduct
hematolog
oncolog
depart
philippin
children
medic
center
adapt
clp
decemb
evid
valu
clp
children
draw
child
draw
hospit
clatworthi
instrument
design
measur
emot
statu
hospit
children
obtain
pediatr
patient
age
year
old
prior
implement
clp
instrument
administ
six
month
implement
clp
ascertain
whether
chang
children
draw
seen
statistician
hire
analyz
data
result
result
show
signific
differ
score
pretest
posttest
draw
indic
allevi
neg
emot
experienc
children
conclus
child
life
program
integr
hospit
set
focu
social
emot
impact
ill
hospit
children
strive
promot
posit
hospit
experi
goal
minim
stress
anxieti
much
possibl
provid
environ
children
gain
better
understand
hospit
ill
medic
treatment
work
teenag
young
adult
tya
cancer
develop
better
approach
care
approach
steven
cameron
j
cheshir
p
spencer
p
beynon
e
fynn
c
neck
j
cargil
target
bristol
royal
hospit
children
bristol
unit
kingdom
tya
cancer
servic
univers
hospit
bristol
nh
trust
bristol
unit
kingdom
object
servic
user
questionnair
use
clinic
servic
evaluationimprov
often
repres
knowledgeinsight
profession
construct
respons
solut
also
tend
lie
profession
servic
around
rather
patient
methodolog
shift
focu
profession
deliv
care
one
patient
becom
central
servic
also
continu
develop
better
health
experiencesoutcom
like
success
approach
tya
popul
unknown
method
conveni
sampl
patient
attend
region
tya
centr
invit
particip
exploratori
work
base
around
develop
patient
questionnair
express
interest
fulli
engag
combin
techniqu
interview
email
exchang
focu
group
use
period
sever
month
ascertain
view
construct
questionnair
content
designfac
valid
commun
prefer
distribut
larger
patient
cohort
respond
valid
ensur
congruenc
team
record
patient
experienceperspect
result
unanim
agreement
reach
area
inclus
physic
wellbeinghealth
peer
support
inform
provis
psychologicalemot
support
familyfriend
educationemploy
educationtrain
tya
cancer
other
along
design
suggest
idea
ongo
commun
tya
patient
questionnair
subsequ
distribut
tya
patient
team
prior
contact
return
indic
interest
continu
work
team
conclus
use
patient
engag
creativ
develop
tya
friendli
questionnair
satisfactori
respons
rate
subsequ
work
involv
tya
prioritis
theme
servic
develop
intervent
base
questionnair
find
particip
includ
agre
content
deliveri
wellb
day
select
mentor
work
mentor
programm
defin
content
design
function
psycholog
support
websit
adolesc
cancer
six
month
studi
first
year
diagnosi
e
sulker
j
fleer
brinksma
pf
roodbol
wa
kamp
wje
tiss
r
sanderman
umcg
school
nurs
health
univers
groningen
univers
medic
center
groningen
groningen
netherland
depart
health
scienc
health
psycholog
section
univers
groningen
univers
medic
center
groningen
groningen
netherland
depart
pediatr
oncologyhematolog
beatrix
children
hospit
univers
groningen
univers
medic
center
groningen
groningen
netherland
object
despit
fact
bf
promot
one
potenti
mechan
underli
resili
adjust
pediatr
oncolog
studi
examin
bf
youth
cancer
furthermor
research
bf
earli
phase
cancer
trajectori
almost
absent
studi
aim
investig
tempor
dynam
time
onset
pattern
chang
time
impact
bf
psycholog
outcom
adolesc
cancer
first
year
method
newli
diagnos
adolesc
cancer
mean
age
sd
femal
type
cancer
chanc
surviv
complet
measur
bf
anxieti
depress
qualiti
life
month
result
six
month
adolesc
experienc
bf
least
degre
bf
sd
differ
significantli
bf
month
sd
p
bf
significantli
posit
associ
physic
function
qualiti
life
subscal
anxieti
depress
aspect
qualiti
life
bf
unrel
outcom
p
conclus
find
patient
report
similarli
high
level
bf
assess
point
suggest
bf
alreadi
occur
within
first
month
diagnosi
futur
research
longer
determin
whether
level
bf
remain
stabl
decreas
surviv
phase
bf
associ
psycholog
outcom
measur
studi
thu
question
whether
bf
adapt
youth
cancer
requir
investig
predictor
bacteri
infect
among
pediatr
cancer
patient
singl
center
experi
j
suvada
plesko
e
kaiserova
l
perdochova
zuzulova
n
kulkova
children
hematolog
oncolog
st
elizabeth
univers
public
health
social
scienc
bratislava
slovakia
children
hematolog
oncolog
children
teach
hospit
bratislava
slovakia
clinic
microbiolog
hpl
bratislava
slovakia
dept
biochemistri
immunolog
oncolog
insitut
st
elizabeth
bratislava
slovakia
dept
microbiolog
st
elizabeth
univers
public
health
social
scienc
bratislava
slovakia
object
children
cancer
undergo
chemotherapi
develop
mani
common
complic
bacteri
infect
bi
especi
blood
stream
infect
bsi
usual
commonli
observ
treatment
cours
present
differ
case
case
without
neutropenia
fever
clinic
sign
sepsi
method
conduct
prospect
studi
identifi
predictor
invas
bacteri
infect
cultur
neg
sepsi
children
cancer
patient
slovakia
enrol
patient
met
inclus
criteria
taken
sampl
investig
bacteri
inflam
eg
tnf
alpha
procalcitonin
protein
presepsin
independ
predictor
clinic
present
analyz
use
multipl
regress
model
result
patient
median
age
year
underli
diagnosi
leukemia
independ
predictor
bacteri
infect
anc
less
temperatur
present
central
venou
cathet
insers
underli
diagnosi
marker
except
crp
procalcitonin
correl
predict
bacteri
infect
highest
valu
observ
among
develop
blood
stream
infect
seriou
bacteri
invas
infect
common
infect
conclus
studi
identifi
predictor
infectioncompl
confirm
predict
valu
new
marker
pediatr
patient
bacteri
infect
work
highlight
import
new
inflam
marker
whoch
success
use
differ
cancer
pediatr
patient
predict
model
warrant
prospect
valid
explor
psychosoci
aspect
paediatr
oncolog
qualit
studi
psycholog
social
emot
experi
patient
paediatr
cancer
singapor
p
tan
j
choo
choo
tc
quah
cm
ho
yl
chiu
yong
loo
lin
school
medicin
nation
univers
singapor
singapor
singapor
raffl
institut
raffl
institut
singapor
singapor
divis
paediatr
nation
univers
hospit
singapor
singapor
depart
psycholog
medicin
nation
univers
singapor
singapor
singapor
depart
social
work
nation
univers
singapor
singapor
singapor
object
acut
lymphoblast
leukemia
commonest
childhood
cancer
dismal
surviv
rate
howev
extens
biomed
advanc
enter
complet
remiss
cure
yet
countless
physic
emot
psychosoci
implic
childhood
cancer
question
whether
qualiti
match
quantiti
life
remain
unansw
studi
aim
identifi
collat
analyz
classifi
signific
psychosoci
issu
patient
improv
holist
care
educ
lay
good
foundat
research
method
seventeen
interview
done
pair
caregiv
patient
interview
kept
convers
use
seidman
interview
techniqu
transcrib
analyz
use
smith
interpret
phenomenolog
analysi
ipa
subject
relapsestranspl
protocol
result
organ
hierarchi
conceptu
logic
encompass
psychosoci
issu
rais
subject
mani
theme
subthem
signific
one
advers
impact
academ
pursuit
deterior
relationship
peer
sibl
fear
medic
set
personnel
procedur
attribut
impress
caregiv
healthcar
profession
increas
matur
child
conclus
import
psychosoci
issu
highlight
studi
help
guid
healthcar
profession
provid
psychosoci
care
patient
caregiv
research
could
delv
deeper
reason
ramif
issu
exact
signific
quantifi
qualiti
life
children
follow
cancer
preliminari
find
qualit
studi
parent
oncologist
badarau
colita
dragomir
b
elger
kuehn
miron
f
niggli
k
ruhe
wangmo
pediatr
ethic
institut
biomed
ethic
basel
switzerland
pediatr
oncolog
fundeni
clinic
institut
bucharest
romania
pediatr
oncolog
prof
dr
al
trestioreanu
oncolog
institut
bucharest
romania
pediatr
oncolog
haematolog
univers
children
hospit
basel
switzerland
pediatr
oncolog
sf
maria
clinic
emerg
hospit
iasi
romania
pediatr
oncolog
univers
children
hospit
switzerland
object
investig
decis
make
process
children
undergo
cur
cancer
treatment
perspect
parent
oncologist
method
interview
conduct
separ
dyad
parent
oncologist
switzerland
romania
studi
approv
research
ethic
committe
countri
written
inform
consent
obtain
particip
start
interview
particip
ask
discuss
experi
time
child
cancer
diagnosi
treatment
interview
transcrib
verbatim
themat
code
maxqda
use
elicit
major
topic
result
parent
describ
time
child
diagnosi
overwhelm
catastroph
identifi
myriad
constraint
limit
abil
make
decis
regard
treatment
lack
medic
knowledg
understand
time
pressur
unfamiliar
hospit
set
inform
overload
emot
turmoil
henc
time
follow
physician
lead
decis
make
feel
equal
respons
decis
parent
highlight
loss
control
somewhat
regain
focus
start
treatment
immedi
physician
report
grappl
need
gear
discuss
toward
start
treatment
also
custom
inform
parent
reaction
interact
parent
physician
tend
seek
complianc
treatment
perceiv
follow
best
interest
child
conclus
decis
make
pediatr
oncolog
around
time
diagnosi
complex
partial
understood
process
better
understand
parent
need
difficult
situat
facilit
commun
diagnosi
address
constrain
factor
imping
decis
make
percept
young
adult
cancer
ventur
pack
program
sourc
tangibl
support
l
wazneh
tsimicali
cg
loisel
purden
edward
ingram
school
nurs
mcgill
univers
montreal
canada
ingram
school
nurs
faculti
medicin
mcgill
univers
montreal
canada
christin
herschel
victorhop
cope
chair
psychosoci
oncolog
depart
oncolog
ingram
school
nurs
jewish
gener
hospit
mcgill
univers
montreal
canada
adolesc
young
adult
aya
oncolog
ventur
beyond
cancer
foundat
montreal
canada
object
within
cancer
commun
young
adult
ya
cancer
increasingli
recogn
distinct
group
unmet
support
care
need
ventur
beyond
cancer
commun
agenc
commit
provid
ya
tangibl
support
servic
address
need
one
servic
call
ventur
pack
program
provid
backpack
contain
three
resourc
kit
help
ya
throughout
cancer
journey
studi
object
explor
need
ya
newli
diagnos
cancer
b
discuss
extent
help
meet
practic
psychosoci
inform
need
c
explor
could
enhanc
method
qualit
descript
studi
conduct
purpos
sampl
ya
treat
cancer
tertiari
hospit
montreal
quebec
canada
interview
conduct
transcrib
code
themat
analyz
result
overal
ya
posit
perceiv
welcom
time
packag
meet
need
hospit
comfort
kit
seen
hand
resourc
help
comfort
hospit
stay
ventur
kit
view
catalyst
connect
similar
other
offer
complimentari
outing
friend
lara
inform
kit
commend
relev
dispatch
import
support
resourc
particip
recommend
deliveri
two
month
diagnosi
broader
awar
dissemin
program
conclus
enhanc
program
increas
awar
promot
network
among
ya
cancer
critic
meet
need
systemat
dissemin
program
one
would
add
overarch
goal
provid
comprehens
cancer
care
underserv
segment
cancer
popul
existenti
anxieti
growth
children
cancer
r
woodgat
c
west
k
tailor
faculti
nurs
univers
manitoba
winnipeg
canada
counselor
educ
counsel
psycholog
marquett
univers
milwauke
usa
object
date
minim
research
detail
experi
children
diagnos
cancer
existenti
predica
purpos
present
describ
find
speak
existenti
challeng
experienc
children
live
cancer
method
interpret
descript
qualit
research
design
use
thirteen
children
year
undergo
treatment
cancer
particip
studi
two
main
sourc
data
collect
util
first
children
opportun
journal
experi
via
comput
diari
creat
first
author
addit
comput
diari
draw
tool
children
express
feel
second
sourc
data
involv
children
take
part
individu
interview
data
analysi
occur
concurr
data
collect
use
constant
compar
method
data
analysi
result
within
cancer
world
children
move
feel
anxieti
gener
existenti
worri
existenti
long
existenti
vacuum
existenti
growth
children
work
within
draw
tool
portal
inner
world
open
allow
explor
anxieti
draw
mani
children
draw
intim
connect
physic
symptom
emot
defin
existenti
challeng
clearli
evid
connect
physic
symptom
emot
defin
existenti
challeng
clearli
evid
conclus
research
provid
evid
activ
engag
children
imagin
use
tool
may
signific
therapeut
valu
assist
children
cancer
explor
understand
manag
physic
suffer
well
associ
anxieti
live
use
symbol
form
commun
includ
draw
offer
profession
new
possibl
enhanc
therapeut
convers
interact
ill
children
famili
case
report
malign
small
round
cell
tumour
unknown
histogenesi
diagnost
dilemma
agarw
thakkar
taringini
nita
radhakrishnan
sachdeva
pediatr
hematooncolog
sir
ganga
ram
hospit
delhi
india
object
malign
small
round
cell
tumor
extens
necrosi
histogenesi
could
delin
rare
lesion
occasion
report
india
exact
incid
etiolog
histogenesi
tumor
unknown
rariti
method
report
patient
abdomin
mass
despit
comprehens
evalu
tumor
defin
histopatholog
immunocytochem
ultrastructur
cytogenet
featur
could
identifi
result
year
old
femal
present
day
durat
mass
per
day
difficulti
day
usg
show
larg
retroperiton
heterogen
mass
lesion
area
hypoechogen
suggest
necrosi
cect
show
mass
c
loop
duodenum
head
pancrea
defin
lesion
evalu
pet
scan
done
reveal
larg
lobul
fdg
avid
peripher
enhanc
solid
cystic
mass
lesion
area
suggest
hemorrhag
abut
liver
gall
bladder
duodenum
underw
exploratori
laparotomi
frozen
section
histopatholog
found
necros
viabl
tumor
cell
avail
report
repeat
attempt
obtain
tissu
also
reveal
necrot
tissu
verifi
multipl
center
india
ihc
low
ki
activ
neg
lca
synaptophysin
cd
mpo
ck
plap
given
vac
regimen
follow
tumor
shrunk
size
make
amen
surgic
resect
underw
whippl
procedur
isol
loop
reveal
extens
ischem
necrosi
outlin
round
cell
tumor
howev
patient
stabl
without
recurr
month
follow
conclus
diagnost
nightmar
due
non
avail
viabl
tumour
peculiar
find
case
howev
respond
standard
treatment
modal
exact
natur
tumor
still
mysteri
spectrum
yet
unidentifi
categori
tumor
system
symptom
angiomatoid
fibrou
histiocytoma
caus
excess
product
akiyama
yamaoka
j
yoshizawa
ikegami
k
matsumoto
pediatr
jikei
univers
school
medicin
tokyo
japan
pediatr
surgeri
jikei
univers
school
medicin
tokyo
japan
patholog
jikei
univers
school
medicin
tokyo
japan
allergi
immunolog
nation
reserch
institut
child
health
develop
tokyo
japan
object
angiomatoid
fibrou
histiocytoma
afh
rare
soft
tissu
neoplasm
intermedi
biolog
potenti
often
aris
extrem
children
young
adult
howev
etiopathogenesi
afh
remain
unclear
studi
describ
japanes
femal
tumor
left
upper
extrem
appear
magnet
reson
imag
heterogen
lobul
mass
low
intens
imag
high
intens
imag
low
enhanc
contrast
measur
x
x
mm
moreov
patient
system
symptom
weight
loss
continu
intermitt
fever
laboratori
data
show
anemia
thrombocytosi
high
level
inflammatori
reactiv
marker
complet
resect
tumor
patient
gener
condit
laboratori
data
markedli
improv
studi
molecular
etiopathogenesi
afh
method
resect
tumor
studi
immunopatholog
molecular
genet
blood
sampl
obtain
oper
subject
cytokin
analysi
use
multiplex
assay
laboratori
result
tumor
diagnos
afh
basi
patholog
find
fusion
gene
detect
fluoresc
hybrid
polymeras
chain
reaction
direct
sequenc
product
show
exon
ew
gene
fuse
exon
gene
cytokin
profil
serum
sampl
demonstr
postop
decreas
chemokin
superfamili
fractalkin
immunopatholog
studi
show
resect
afh
cell
posit
phosphoryl
conclus
fusion
gene
lead
continu
activ
gene
result
product
excess
product
might
play
pivot
role
etiopathogenesi
afh
result
therefor
provid
rational
develop
target
therapi
afh
olfactori
neuroblastoma
childhood
c
akyuz
h
susam
sen
b
aydin
varan
b
yalcin
kutluk
pediatr
oncolog
hacettep
institut
oncolog
ankara
turkey
object
olfactori
neuroblastoma
estesioneuroblastoma
rare
slow
grow
local
aggress
tumor
deriv
olfactori
neuroepitheli
tissu
symptom
promin
tumor
reach
bigger
size
total
surgic
resect
mainstay
treatment
literatur
support
combin
treatment
approach
surgeri
neoadjuv
chemotherapi
radiotherapi
studi
aim
evalu
clinic
characterist
treatment
result
patient
diagnos
olfactori
neuroblastoma
depart
method
olfactori
neuroblastoma
estesioneuroblastoma
rare
slow
grow
local
aggress
tumor
deriv
olfactori
neuroepitheli
tissu
symptom
promin
tumor
reach
bigger
size
total
surgic
resect
mainstay
treatment
literatur
support
combin
treatment
approach
surgeri
neoadjuv
chemotherapi
radiotherapi
studi
aim
evalu
clinic
characterist
treatment
result
patient
diagnos
olfactori
neuroblastoma
depart
result
three
patient
age
diagnos
olfactori
neuroblastoma
nasal
obstruct
diagnosi
three
tumor
sinonas
region
bone
destruct
intracrani
intraorbit
extens
also
present
patient
stage
iii
diseas
accord
kadish
stage
system
endoscop
tumor
excis
perform
patient
neoadjuv
chemotherapi
first
patient
die
due
metastat
diseas
second
patient
follow
remiss
year
third
patient
craniotomi
partial
tumor
excis
craniotomi
adjuv
radiotherapi
chemotherapi
third
patient
follow
remiss
year
conclus
best
treatment
approach
surgeri
olfactori
neuroblastoma
howev
difficult
perform
total
resect
tumor
local
literatur
support
chemosensit
tumor
combin
surgeri
neoadjuv
chemotherapi
radiotherapi
might
increas
resect
outcom
histiocyt
sarcoma
femal
case
report
bastandji
f
bernard
yaich
n
bouchair
kharoubi
j
donadieu
jf
emil
cliniqu
infantil
ste
chu
ibn
rochd
annaba
nbk
hospit
koweit
citi
koweit
servic
orl
chu
dorban
annaba
servic
centr
de
de
histiocytos
hopit
trousseau
pari
franc
servic
de
pathologi
universitair
ambrois
pari
franc
object
histiocyt
sarcoma
hs
exceedingli
rare
tumor
especi
children
aggress
malign
neoplasm
show
morpholog
immunophenotyp
evid
histiocyt
differenti
vast
major
previous
report
hss
recogn
initi
misdiagnosi
method
describ
pediatr
patient
hs
present
lymphadenopathi
pulmonari
nodul
tumor
progress
chemotherapi
design
langerhan
cell
histiocytosi
lch
sarcoma
result
healthi
femal
experienc
isol
fibroelast
lymph
node
left
inguin
region
lymph
node
measur
less
mm
largest
measur
mm
biopsi
made
result
suggest
lch
node
volum
quickli
increas
evolv
larg
vascular
swell
bleed
contact
therapi
start
condit
deterior
new
biopsi
perform
morpholog
immunohistochem
alter
compat
hs
immunophenotyp
confirm
histiocyt
lineag
posit
express
cd
lysozym
neg
melan
ema
alk
chemotherapi
accord
sarcoma
protocol
start
treatment
ct
scan
show
evolut
mediastin
lymph
node
pulmonari
nodul
diseas
spread
poor
respons
therapi
patient
receiv
ice
chemotherapi
condit
deterior
child
die
conclus
report
bona
fide
hs
exist
mostli
involv
adult
describ
unusu
clinic
present
diagnosi
mainli
base
immunohistochem
techniqu
molecular
genet
method
exclud
malign
epitheli
melanocyt
lymphoid
phenotyp
poor
prognosi
common
find
diseas
spread
poor
respons
therapi
report
similar
poor
respons
chemotherapi
rariti
hs
continu
make
manag
recommend
therapi
challeng
young
children
malign
solid
tumor
children
syndrom
report
three
case
discuss
jm
eguiguren
leon
g
sanchez
e
villanueva
j
acebo
e
eguiguren
ega
c
pediatr
hospit
metropolitano
solca
universidad
san
francisco
de
quito
e
internacion
del
ecuador
quito
ecuador
pediatr
hospit
solca
quito
quito
ecuador
pediatr
st
joseph
children
hospit
paterson
usa
object
children
syndrom
ds
decreas
incid
solid
tumor
report
three
patient
two
rhabdomyosarcoma
one
periost
osteosarcoma
method
descript
three
recent
case
ds
seen
solca
hospit
ae
male
trisomi
metastat
embryon
rhabdomyosarcoma
relaps
refer
anoth
hospit
two
year
diagnosi
histori
hematuria
bladder
tumor
receiv
chemotherapi
relaps
treatment
hospit
found
pelvic
bladder
tumor
pulmonari
hepat
metastasi
receiv
chemotherapi
develop
renal
failur
tumor
progress
went
palli
care
male
ds
agenesi
right
kidney
present
month
age
peduncul
perian
lesion
largest
x
cm
diamet
also
inguin
metastasi
biopsi
confirm
embryon
rhabdomyosarcoma
undergo
chemotherapi
frequent
infecti
complic
yn
femal
ds
month
histori
slowli
grow
left
tibial
mass
mri
left
leg
show
x
cm
tumor
soft
tissu
involv
ct
scan
thorax
disclos
multipl
metastasi
bone
biopsi
diagnost
periost
osteosarcoma
receiv
two
cycl
cisplatin
doxorubicin
resolut
lung
metastasi
local
therapi
accept
parent
abandon
therapi
result
occurr
solid
tumor
specif
rhabdomyosarcoma
osteosarcoma
unusu
patient
ds
report
embryon
bone
tumor
record
medic
literatur
conclus
specul
tumor
supressor
gene
increas
level
b
protein
decreas
hormon
endostatin
serum
level
protect
children
ds
solid
tumor
treatment
relat
toxic
constitut
formid
challeng
case
biliari
rhabdomyosarcoma
rare
tumor
childhood
case
report
dg
gasperini
rzm
silva
nlg
suarez
ceb
cavalcant
eca
silva
lf
lope
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
radiologist
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
pathologist
oncolog
pediatr
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
phd
medic
director
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
object
rhabdomyosarcoma
malign
tumor
mesenchym
origin
often
occur
children
adolesc
correspond
cancer
children
common
site
head
neck
genitourinari
tract
retroperitoneum
biliari
locat
rare
common
caus
malign
obstruct
jaundic
age
group
averag
age
present
year
present
obstruct
jaundic
case
accompani
fecal
acholia
hepatomegali
pain
nausea
vomit
fever
uncommon
histolog
biliari
tract
embryon
type
current
treatment
includ
surgic
resect
radiotherapi
chemotherapi
usual
highli
chemosensit
tumor
commonli
use
medic
actinomycin
vincristin
cyclophosphamid
ifosfamid
without
doxorubicin
method
rariti
report
case
child
male
year
month
old
admit
abdomin
distens
jaundic
achol
stool
choluria
hepatomegali
hyperbilirubinemia
elev
liver
enzym
neg
hepat
serolog
normal
abdomin
ultrasound
tc
scan
adbomen
show
larg
mass
liver
heterogen
limit
locat
segment
iii
iva
ivb
v
viii
involv
portal
hepat
vessel
caus
mild
dilat
bile
duct
measur
x
x
cm
percutan
biopsi
histolog
examin
show
biliari
embryon
rhabdomyosarcoma
immunohistochem
examin
posit
vimentin
desmin
myogenin
confirm
diagnosi
result
chemotherapi
vincristin
dactinomycin
cyclophosphamid
made
week
patient
develop
progress
diseas
even
chemotherapi
rescu
irinotecan
vincristin
tumor
refractori
patient
die
conclus
conclus
patient
unfavor
outcom
compar
report
literatur
cervic
spine
rhabdoid
tumor
case
report
literatur
review
chabchoub
haj
mansour
gargoura
f
zairi
ayadi
khanfir
n
bouaouina
ben
ahm
h
krifa
frikha
medic
oncolog
farhat
hach
souss
tunisia
medic
oncolog
habib
bourguiba
sfax
tunisia
radiotherapi
farhat
hach
souss
tunisia
neurosurgeri
sahloul
souss
tunisia
object
report
retrospect
case
atyp
spinal
malign
rhabdoid
tumor
mrt
year
old
femal
method
retrospect
case
report
spinal
pediatr
rhabdoid
tumor
sprt
year
old
femal
famili
past
histori
first
degre
consanguin
marriag
result
patient
present
first
cervicobrachi
neuralgia
rapidli
progress
tetraparesi
mri
show
right
tumor
local
right
scalenu
lodg
level
vertebr
invas
spinal
canal
extens
surgeri
perform
residu
diseas
immunohistochemistri
tumor
cell
posit
ema
pan
ck
vimentin
nse
neg
lca
desmin
myogenin
practic
avail
despit
postop
radiotherapi
follow
chemotherapi
obtain
stabil
tumor
patient
die
month
initi
diagnosi
conclus
prognosi
psrt
remain
poor
case
need
determin
effect
treatment
success
use
sorafenib
progress
pulmonari
metastas
pediatr
papillari
thyroid
carcinoma
hein
n
graf
rohrer
nn
dept
pediatr
oncologyhematolog
univers
children
hospit
pediatr
oncolog
homburg
germani
dept
pediatr
endocrinolog
univers
children
hospit
pediatr
oncolog
homburg
germani
dept
radiolog
univers
hospit
radiolog
homburg
germani
object
sorafenib
studi
adult
patient
advanc
thyroid
cancer
prolong
surviv
report
use
substanc
pediatr
popul
scarc
object
ist
present
young
femal
progress
pulmonari
metastas
due
ptc
achiev
stabl
diseas
use
year
far
sorafenib
adult
dose
x
mg
method
twelv
year
old
femal
diagnos
ptc
year
previous
tnm
pul
underw
thyreoidectomi
neck
dissect
cours
radioact
iodin
final
cours
retinoid
pulmonari
metastas
progress
thyreoglobulin
increas
sign
pulmonari
insuffici
develop
use
sorafenib
initi
mg
daili
increas
twice
mg
month
hematolog
minim
also
cutan
mild
grade
handfoot
syndrom
due
cramp
diarrhea
weight
loss
therapi
decreas
daili
mg
year
increas
full
dose
month
theraft
minor
reduct
dose
necessari
month
one
year
patient
toler
full
dose
mg
hardli
therapi
calcium
calcitriol
therapi
continu
result
one
month
initi
sorafenib
extens
pulmonari
metastas
show
mild
reduct
theraft
futher
declin
observ
mri
ct
also
progress
thyreoglobulin
level
thyreoglobulin
antibodi
remain
elev
without
signific
decreas
due
fluctuat
valu
thyreoglobulin
ngml
conclus
case
pediatr
ptc
progress
pulmonari
metastas
rai
option
sorafenib
help
stabil
diseas
given
adult
dose
x
mg
without
sever
children
ret
protooncogen
codon
mutat
inc
b
kadioglu
e
buke
oymak
h
unver
oz
karaku
f
hazan
e
ozer
k
mutafoglu
n
olgun
pediatr
oncolog
dokuz
eylul
univers
institut
oncolog
izmir
turkey
pediatr
hematolog
oncolog
clinic
dr
behcet
uz
children
hospit
izmir
turkey
pediatr
oncolog
dokuz
eylul
univers
insitut
oncolog
izmir
turkey
pediatr
endocrinolog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
pediatr
surgeri
dokuz
eylul
univers
faculti
medicin
izmir
turkey
genet
dr
behcet
uz
children
hospit
izmir
turkey
patholog
dokuz
eylul
univers
faculti
medicin
izmir
turkey
object
would
like
present
treatment
experi
children
ret
protooncogen
codon
mutat
method
medic
record
patient
summar
result
year
old
femal
admit
center
without
complaint
medic
histori
unremark
mother
year
old
pregnanc
mother
diagnos
medullari
thyroid
carcinoma
mtc
treat
six
year
ago
heterozyg
mutat
ret
g
detect
mother
histori
malign
mother
famili
father
year
old
sister
healthi
ret
protooncogen
analysi
normal
year
old
sister
ret
protooncogen
analysi
show
heterozyg
mutat
g
also
patient
physic
examin
unremark
thyroid
ultrasonographi
reveal
abnorm
thyroid
function
test
result
normal
tsh
iuml
serum
level
antimycrosom
antithyroglobulin
antibodi
normal
iuml
anti
tg
iuml
serum
calcitonin
level
found
minim
elev
two
time
calcitonin
pgml
pgml
parathormon
pth
pgml
carcinoembrion
antigen
ngml
level
normal
prophylact
thyroidectomi
sampl
cervic
lymph
node
perform
histopatholog
examin
thyroid
reveal
hyperplasia
c
cell
examin
lymph
node
reveal
reactiv
lymphadenopathi
mtk
conclus
risk
mtc
report
life
patient
ret
mutat
prophylact
tyhroidectomi
propos
patient
report
particularli
patient
mutat
risk
occur
metastat
progressiverecurr
mtc
rather
patient
mutat
prophylact
thyroidectomi
cervic
lymph
node
dissect
propos
patient
mutat
primari
pulmonari
pnetew
sarcoma
adren
metastasi
b
jindal
b
dubashi
b
naredi
raju
ramesh
halnayak
depart
pediatr
surgeri
jawaharl
institut
postgradu
medic
educ
research
pondicherri
india
depart
medic
oncolog
jawaharl
institut
postgradu
medic
educ
research
pondicherri
india
depart
patholog
jawaharl
institut
postgradu
medic
educ
research
pondicherri
india
depart
radiolog
jawaharl
institut
postgradu
medic
educ
research
pondicherri
india
depart
nuclear
medicin
jawaharl
institut
postgradu
medic
educ
research
pondicherri
india
object
extraskelet
ewe
sarcoma
except
rare
tumor
primaryextraskelet
ewe
sarcomapnet
lung
even
rarer
caseshav
report
literatur
retrospect
studi
extraoss
pnet
describ
case
primari
pulmonari
pnet
lung
adren
metastasisin
year
femal
child
method
studi
clinic
patholog
radiolog
profil
primari
pulmonari
pnet
review
literatur
result
total
case
extraoss
ewe
sarcoma
treat
one
case
primari
pulmonari
pnet
detect
adren
boni
metastasi
conclus
primari
pulmonarypnet
rare
tumor
usual
poor
outcom
especi
case
present
metastasi
emphasis
import
earli
evalu
metastasi
surgeri
option
result
treatment
children
solid
pseudopapillari
tumor
pancrea
p
kerimov
rybakova
kazantcev
rubanski
children
oncolog
feder
state
budgetari
institut
nn
blokhin
russian
cancer
research
center
russian
academi
medic
scienc
moscow
russia
object
solid
pseudopapillari
tumor
spt
pancrea
rare
neoplasm
low
malign
potenti
first
describ
franz
less
tumor
extrem
rare
children
method
scientif
research
institut
children
oncolog
hematolog
children
diagnosi
solid
tumor
pancrea
oper
analys
clinicodiagnost
data
oper
volum
result
treatment
observ
time
result
patient
femal
age
year
median
rule
diseas
asymptomat
discov
incident
two
children
experienc
pain
epigastr
region
patient
nausea
vomit
accord
studi
patient
tumor
locat
tail
pancrea
bodi
head
maximum
size
tumor
cm
locat
head
pancrea
children
underw
laparoscop
distal
pancreatectomi
gastropancreatoduoden
resect
case
perform
distal
subtot
resect
pancrea
enucl
tumor
resect
wall
duodenum
resect
bodi
pancrea
complic
occur
patient
case
postop
pancreatonecrosi
pancreat
fistula
bleed
pancreat
branch
splenic
arteri
pneumonia
observ
period
patient
month
year
patient
aliv
without
evid
diseas
recurr
conclus
solid
pseudopapillari
tumor
spt
pancrea
rare
diseas
children
usual
occur
femal
pubertatni
age
main
method
treatment
surgeri
howev
high
risk
complic
tumor
local
surgic
treatment
pancreat
tumor
one
centr
experi
shchepotin
g
klymnyuk
lukashenko
ijovskyi
abdomin
oncolog
nation
cancer
institut
mph
ukrain
kiev
ukrain
pediatr
oncolog
nation
cancer
institut
mph
ukrain
kiev
ukrain
object
solid
pancreat
tumor
rare
patholog
young
age
surgic
treatment
group
patient
technic
complic
surgic
treatment
experi
suffici
advanc
modern
literatur
method
patient
femal
male
given
surgic
treatment
pancreat
tumor
last
year
averag
age
patient
year
children
till
year
old
follow
oper
carri
one
patient
receiv
pancreat
tumor
enucl
two
patient
distal
pancreatomi
four
patient
radic
antegrad
modular
pancreatosplenectomi
one
patient
radic
antegrad
modular
pancreatosplenectomi
left
adrenalectomi
two
patient
pancreaticoduodenectomi
pancreatojejunostomi
author
method
total
isol
pancreaticobiliari
tract
reconstruct
microjejunostomi
microgostomi
patient
age
year
old
result
patholog
conclus
oper
materi
shown
follow
four
case
tumor
verifi
solid
pseudopapilloma
pancrea
cancer
femal
patient
three
case
malign
neuroendocrinolog
tumor
one
case
malign
paraganglioma
next
one
adenocarcinoma
anoth
one
matur
teratoma
involv
head
pancrea
averag
time
surgeri
min
averag
hemorrhag
ml
max
ml
postop
period
one
patient
abscess
success
treat
via
us
drainag
three
patient
treat
adjuv
chemotherapi
one
patient
die
metastat
recurr
nine
patient
still
aliv
without
sign
diseas
conclus
surgic
treatment
solid
pancreat
tumor
complic
method
provid
long
term
surviv
produc
right
adrenocort
adenoma
old
boy
case
report
migita
watanab
k
sato
ono
takahashi
takahashi
takezo
shimizu
fuchimoto
kanamori
mori
pediatr
surgeri
nation
center
child
health
develop
tokyo
japan
oncolog
nation
center
child
health
develop
tokyo
japan
object
report
case
adrenocort
adenoma
elev
level
serum
afp
method
case
report
result
patient
male
consult
famili
doctor
diarrhea
abdomin
pain
incident
right
adren
gland
tumor
diagnos
ultrasonographi
refer
hospit
treatment
adrenocort
function
normal
blood
test
tumor
marker
neg
except
serum
afp
ngml
abdomin
ct
show
tumor
mass
right
upper
retroperitoneum
size
tumor
x
x
mm
homogen
textur
ct
index
low
around
radiolog
find
strongli
suggest
tumor
adrenocort
carcinoma
patient
underw
right
adrenectomi
lymph
node
swell
around
tumor
detect
final
patholog
diagnosi
adrenocort
adenoma
serum
afp
decreas
normal
level
oper
conclus
adrenocort
tumor
rare
children
furthermor
afp
produc
adren
tumor
extrem
rare
one
adult
case
report
english
literatur
first
pediatr
case
afp
produc
adrenocort
adenoma
malign
atyp
rhabdoid
tumor
pelvi
cure
still
distant
dream
r
moham
c
yogiraj
k
satyendra
arvind
bk
satya
prakash
pediatr
hematolog
oncolgi
bmt
unit
forti
memori
research
institut
gurgaon
india
object
extra
renal
extra
cranial
malign
rhabdoid
tumor
highli
lethal
rare
tumor
poor
prognosi
incid
per
million
children
definit
treatment
defin
describ
cours
outcom
malign
atyp
rhabdoid
tumor
matrt
child
method
seven
year
old
femal
admit
us
view
bleed
per
vaginum
week
durat
rest
gener
system
examin
normal
evaluationmri
pelvi
show
mass
x
x
mm
pelvi
without
metastasi
suggest
rhabdomyosarcoma
histopatholog
report
transrect
trucut
biopsi
mass
show
high
grade
poorli
differenti
malign
tumor
pelvi
immunohistochem
stain
posit
vimentin
neg
desmin
myogenin
final
diagnos
matrt
scan
show
fdg
avid
heterogen
enhanc
cystic
mass
local
topelvi
withno
fdg
avid
distal
metastasi
result
repeat
mri
whole
abdomen
contrast
week
vac
vincristin
actinomycin
cyclophosphamid
show
mass
almost
size
underw
surgeri
gross
total
resect
colostomi
histopatholog
immunohistochemistri
compat
viabl
matrt
express
ema
vimentin
neg
desmin
myogenin
receiv
cours
altern
vdcie
chemotherapi
vincristin
doxorubicin
cyclophosphamid
ifosphamid
etoposid
concomit
radiotherapi
gy
cours
ievdc
repeat
mri
pet
scan
show
evid
diseas
six
cycl
mention
chemotherapi
relaps
occur
given
high
dose
methotrex
cyclophosphamideto
reliev
symptom
plan
autolog
stem
cell
transplant
final
die
home
conclus
cure
still
distant
dream
atrt
newer
aggress
multimod
approach
requir
near
futur
cure
fatal
diseas
neonat
solid
tumor
year
experi
ricardo
gutierrez
children
hospit
oncolog
depart
nana
garcia
lombardi
r
rohr
p
robledo
detoni
g
rey
oncolog
hospit
de
r
gutierrez
ciudad
de
bueno
air
argentina
object
neonat
solid
tumor
nst
rare
neoplasm
children
histolog
low
incid
tumor
behavior
respons
treatment
differ
tumor
found
older
children
describ
clinic
epidemiolog
featur
histolog
type
treatment
outcom
nst
method
retrospect
descript
studi
patient
p
nst
admit
oncolog
depart
ricardo
gutierrez
children
hospit
result
n
p
histolog
benign
malign
prenat
ultrasound
diagnosi
sign
symptom
birth
tumor
type
neuroblastoma
nbt
low
grade
fibrosarcoma
myofibromatosi
retinoblastoma
rtb
bilater
hepatoblastoma
mesoblast
nephroma
primit
neuroectoderm
tumor
teratoma
matur
central
nervou
system
cn
sacrococcig
cn
tumor
anaplast
ependymoma
low
grade
glioma
papyloma
adrenocort
tumor
diagnosi
requir
biopsi
nbt
clinic
imag
diagnosi
rtb
ocular
fundu
brainstem
glioma
imag
metatat
diagnosi
nbt
myofibromatosi
treatment
receiv
chemotherapi
requir
surgeri
alon
rest
combin
therapi
rtb
receiv
local
radiotherapi
achiev
complet
remiss
relaps
bilater
rtb
die
nbt
due
surgeri
complic
rest
tumor
progress
sequela
conclus
major
p
evalu
malign
diseas
frequent
tumor
type
nbt
quarter
p
present
symptom
birth
prenat
diagnosi
surgeri
import
mainstay
treatment
high
rate
complet
remiss
observ
low
relaps
rate
mortal
data
obtain
similar
report
world
literatur
novel
alk
rearrang
neonat
fetal
lung
interstiti
tumor
onoda
kanno
h
sato
n
takahashi
h
izumino
h
ohta
emura
h
katoh
h
ohizumi
h
ohtak
h
asao
lp
dehner
ad
hill
k
hayasaka
mitsui
depart
pediatr
yamagata
univers
faculti
medicin
yamagata
japan
second
depart
surgeri
yamagata
univers
faculti
medicin
yamagata
japan
depart
patholog
yamagata
univers
faculti
medicin
yamagata
japan
depart
immunolog
yamagata
univers
faculti
medicin
yamagata
japan
depart
patholog
immunolog
patholog
pediatr
washington
univers
st
loui
st
loui
usa
divis
patholog
children
nation
medic
center
washington
dc
usa
object
fetal
lung
interstiti
tumor
flit
patholog
type
congenit
lung
lesion
compris
solid
cystic
compon
patholog
featur
includ
uniqu
interstiti
cell
prolifer
differ
neoplasm
repres
pleuropulmonari
blastoma
congenit
peribronchi
myofibroblast
tumor
flit
extrem
rare
profil
yet
report
first
report
novel
chromosom
rearrang
result
anaplast
lymphoma
kinas
alk
gene
fusion
patient
flit
method
tumor
specimen
review
pathoimmunohistochem
examin
identifi
tumour
specif
transloc
use
fluoresc
situ
hybrid
fish
amplif
cdna
end
result
tumor
cell
contain
transloc
mesenchym
origin
eg
inflammatori
myofibroblast
tumor
suggest
involv
alk
case
flit
fish
demonstr
chromosom
rearrang
alk
use
identifi
novel
transcript
fuse
exon
exon
alk
correspond
chimer
gene
subsequ
confirm
sequenc
includ
genom
breakpoint
intron
alk
respect
conclus
discoveri
novel
alk
fusion
partner
togeth
involv
alk
provid
new
insight
pathogenesi
flit
suggest
potenti
new
therapeut
strategi
base
alk
inhibitor
extraren
rhabdoid
tumor
rare
clinician
scare
pai
qureshi
n
singhal
banavali
ramdwar
g
chinnaswami
prasad
vora
b
aurora
g
narula
pediatr
oncolog
tata
memori
hospit
mumbai
india
pediatr
surgic
oncolog
tata
memori
hospit
mumbai
india
surgic
oncolog
tata
memori
hospit
mumbai
india
patholog
tata
memori
hospit
mumbai
india
object
malign
rhabdoid
tumor
rare
central
nervou
system
commonest
extra
renal
site
report
extra
renal
extra
cranial
site
extrem
rare
isol
case
report
literatur
keep
scarciti
literatur
prospect
report
experi
case
seri
aim
provid
greater
insight
manag
rare
entiti
method
retrospect
audit
patient
histolog
confirm
diagnosi
extraren
rhabdoid
tumor
present
pediatr
divis
hospit
year
done
patient
complet
follow
detail
treat
hospit
includ
review
result
patient
studi
male
femal
site
origin
includ
axilla
cervicothorac
liver
groin
patient
less
year
age
time
diagnos
loss
found
case
ihc
vincristin
adriamycin
base
chemotherapi
given
patient
found
effect
none
patient
benefit
radiotherapi
two
patient
succumb
diseas
within
month
diagnos
one
patient
recurr
diseas
local
site
post
treatment
die
within
month
diseas
recurr
two
patient
aliv
diseas
metronom
therapi
conclus
rariti
tumor
make
imposs
institut
gain
solid
experi
formul
manag
guidelin
therebi
make
imper
clinician
review
literatur
avail
form
case
seri
deriv
appropri
infer
guid
treatment
improv
dismal
prognosi
rare
scari
tumor
use
vandetanib
metastat
medullari
carcinoma
thyroid
paediatr
patient
multipl
endocrin
neoplasia
rongh
v
narayanan
f
macgregor
n
bradshaw
r
davidson
n
reed
g
shaikh
paediatr
oncolog
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
paediatr
endocrinolog
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
paediatr
ent
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
medic
genet
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
clinic
oncolog
beatson
west
scotland
cancer
centr
glasgow
unit
kingdom
object
aim
present
first
case
paediatr
patient
multipl
endocrin
neoplasia
men
unresect
metastat
medullari
carcinoma
thyroid
mtc
treat
vandetanib
togeth
posit
respons
treatment
vandetanib
novel
tyrosin
kinas
inhibitor
select
target
transfect
ret
gene
vascular
endotheli
receptor
epiderm
mediat
signal
method
year
old
male
present
local
advanc
metastat
inoper
mtc
associ
genet
studi
confirm
mutat
rearrang
transfect
ret
gene
start
vandetanib
mg
daili
result
demonstr
good
clinic
respons
fall
calcitonin
level
ngl
ngl
within
month
reduct
size
primari
thyroid
malign
lymph
node
pulmonari
metastas
repeat
ct
scan
vandetanib
month
stabl
diseas
calcitonin
level
conclus
vandetanib
role
treatment
patient
includ
children
inoper
local
advanc
metastat
medullari
carcinoma
thyroid
inform
need
use
children
long
term
outcom
nasopharyng
carcinoma
childhood
report
three
case
discuss
g
jm
eguiguren
e
villanueva
j
acebo
ega
v
pediatr
solca
hospit
quito
ecuador
object
past
seven
year
treat
three
adolesc
nasopharyng
carcinoma
npc
servic
pediatr
oncolog
tumor
rare
children
therefor
manag
deriv
adult
treatment
protocol
method
review
medic
record
three
patient
npc
treat
analysi
result
male
present
cervic
pain
fever
weight
lost
dysphagia
ct
scan
report
cm
mass
obliter
nasopharynx
npc
stage
iii
diagnos
receiv
radiat
therapi
rt
gy
chemotherapi
cisplatin
relaps
year
receiv
second
line
chemotherapi
gemcitabin
carboplatin
complet
remiss
second
patient
male
present
weight
loss
fever
bilater
cervic
supraclavicular
lymphadenopathi
ct
scan
show
mediastin
mass
initi
misdiagnos
germ
cell
tumor
receiv
bep
excel
respons
patholog
review
npc
stage
iv
confirm
start
cisplatin
progress
diseas
partial
respons
obtain
chemotherapi
third
patient
male
month
histori
cervic
lymphadenopathi
suspicion
tuberculosi
biopsi
report
npc
stage
iii
receiv
radiotherapi
gy
eight
cycl
chemotherapi
cisplatin
remain
remiss
month
complet
therapi
result
evid
male
predomin
advanc
stage
system
symptom
weight
loss
fever
diagnosi
establish
lymph
node
biopsi
initi
two
patient
complet
respons
follow
relaps
three
patient
aliv
conclus
nasopharyng
carcinoma
rare
children
male
sex
predomin
complet
explain
known
risk
factor
cooper
studi
need
order
standard
treatment
option
malign
pleural
mesothelioma
child
j
scharf
gm
lee
cm
sergi
surgeri
univers
alberta
edmonton
canada
patholog
univers
alberta
edmonton
canada
object
herein
describ
success
treatment
malign
pleural
mesothelioma
child
scarc
bodi
literatur
pertain
childhood
mesothelioma
practic
guid
data
adult
literatur
object
add
paediatr
literatur
order
improv
outcom
treatment
childhood
entiti
method
eight
year
old
child
found
right
side
chest
mass
measur
roughli
x
x
cm
basi
report
inconclus
needl
biopsi
open
lung
biopsi
done
unfortun
frozen
section
specimen
inconclus
review
boston
vancouv
diagnosi
malign
pleural
mesothelioma
epithelioid
type
made
decid
surgic
resect
tumour
found
tumour
appear
origin
viscer
pleura
horizont
obliqu
fissur
extend
lung
parenchyma
involv
three
lobe
right
lung
right
pneumonectomi
perform
unfortun
child
develop
right
chest
wall
recurr
chest
wall
includ
rib
four
eight
resect
follow
surgeri
child
underw
cycl
chemotherapi
pemetrex
cisplatin
result
child
month
pneumonectomi
month
chest
wall
excis
appear
complet
respons
therapi
definit
recurr
diseas
function
child
well
abl
attend
school
conclus
childhood
malign
pleural
mesothelioma
extrem
rare
tumour
paediatr
popul
cari
dismal
prognosi
although
addit
work
need
develop
standard
care
diseas
document
success
treatment
pneumonectomi
follow
chest
wall
excis
chemotherapi
pemetrex
cisplatin
amg
aurora
kinas
inhibitor
enhanc
chemosensit
topoisomeras
ii
inhibitor
modul
gene
express
adrenocort
tumor
cell
line
ca
scride
ks
borg
af
andrad
vs
silveira
da
marco
antonio
ejr
vasconcelo
srr
antonini
ce
martinelli
jr
castro
lg
tone
ca
scride
pediatr
preto
school
medicin
univers
paulo
preto
brazil
genet
preto
school
medicin
univers
paulo
preto
brazil
bioinformat
preto
school
medicin
univers
paulo
preto
brazil
seatl
biomed
research
institut
seatl
biomed
research
institut
seatl
usa
pediatr
preto
school
medicin
univers
paulo
preto
brazil
intern
medicin
preto
school
medicin
univers
paulo
preto
brazil
object
pediatr
adrenocort
tumor
act
rare
malign
advanc
diseas
treatment
small
impact
overal
surviv
previou
studi
group
suggest
aurka
aurkb
overexpress
pediatr
act
may
relat
aggress
diseas
gene
involv
mainten
genom
integr
cell
cycl
divis
consid
new
target
cancer
treatment
present
studi
show
result
effect
new
aurora
kinas
inhibitor
amg
associ
standard
chemotherapeut
agent
adrenocort
carcinoma
cell
line
method
cell
prolifer
assess
giemsa
stain
apoptosi
perform
flow
cytometri
drug
combin
analysi
made
basi
method
hormon
dosag
assay
perform
evalu
effect
aurora
kinas
inhibitor
hormon
secret
microarray
experi
carri
use
agil
human
microarray
result
treatment
amg
caus
inhibit
prolifer
increas
apoptosi
sensit
cell
topoisomeras
ii
inhibitor
doxorubicin
etoposid
wherea
combin
cisplatin
led
antagonist
respons
addit
amg
reduc
hormon
synthesi
modul
express
gene
involv
activ
final
aurora
kinas
inhibit
alter
express
gene
associ
cell
cycl
phase
regul
affect
notch
signal
pathway
target
gene
conclus
data
suggest
aurora
kinas
inhibit
amg
may
new
therapeut
approach
adrenocort
carcinoma
treatment
malign
rhabdoid
tumor
children
singl
institut
experi
hy
shin
cr
hong
hj
kang
hy
ju
jy
lee
h
kim
kd
park
hs
ahn
pediatr
seoul
nation
univers
children
hospit
seoul
korea
object
malign
rhabdoid
tumor
mrt
rare
highli
aggress
tumor
affect
young
children
due
extrem
rariti
avail
data
base
retrospect
case
seri
add
current
knowledg
diseas
review
patient
treat
mrt
institut
method
retrospect
medic
record
review
done
children
treat
patholog
confirm
mrt
seoul
nation
univers
children
hospit
januari
may
result
eleven
children
male
femal
diagnos
mrt
median
age
month
old
six
patient
renal
mrt
soft
tissu
mrt
subment
paraspin
retrostern
coccyg
area
ten
patient
evalu
loss
patient
loss
stain
patient
whose
specimen
retain
stain
show
late
present
adolesc
five
patient
metastasi
diagnosi
entir
cohort
receiv
chemotherapi
patient
underw
addit
high
dose
chemotherapi
autolog
stem
cell
rescu
hdct
ascr
melphalan
etoposid
carboplatin
mecb
eight
patient
surgeri
patient
receiv
therapeut
radiotherapi
five
patient
progress
relaps
overal
surviv
cohort
median
durat
month
rang
month
event
free
surviv
median
durat
month
rang
month
conclus
mrt
still
highli
aggress
tumor
young
children
improv
surviv
cohort
promis
surgic
resect
therapeut
radiotherapi
hdct
ascr
mecb
may
promis
treatment
option
colorect
carcinoma
children
adolesc
singl
center
experi
sumerau
k
svojgr
kodetova
puchmajerova
l
po
kyncl
z
link
zapotocki
j
stari
depart
pediatr
hematolog
oncolog
faculti
hospit
motol
pragu
czech
republ
depart
patholog
molecular
medicin
faculti
hospit
motol
pragu
czech
republ
depart
biolog
medic
genet
faculti
hospit
motol
pragu
czech
republ
depart
pediatr
surgeri
faculti
hospit
motol
pragu
czech
republ
depart
radiolog
faculti
hospit
motol
pragu
czech
republ
depart
oncolog
faculti
hospit
motol
pragu
czech
republ
object
colorect
carcinoma
crc
one
common
tumor
adult
extrem
rare
childhood
studi
retrospect
report
group
six
patient
year
old
treat
depart
pediatr
hematolog
oncolog
pragu
czech
republ
method
femal
male
among
childrenadolesc
crc
median
age
year
rang
unfavor
crc
histiotyp
signet
cell
mucin
adenocarcinoma
advanc
diseas
stage
iib
stage
iiib
stage
iv
time
diseas
onset
initi
surgic
resect
complet
case
patient
receiv
postop
chemotherapi
xelox
folfox
withwithout
target
therapi
tumor
predisposit
syndrom
confirm
two
patient
lynch
sy
sy
result
four
patient
tumor
progress
relaps
die
tumor
overal
surviv
os
year
two
patient
aliv
one
stage
iib
crc
long
term
survivor
year
time
diseas
diagnosi
conclus
studi
confirm
rariti
advanc
stage
aggress
biolog
poor
prognosi
crc
children
adolesc
surgeri
remain
mainstay
treatment
chemotherapi
target
therapi
impact
diseas
control
metastat
childhood
crc
support
project
conceptu
develop
research
organ
pediatr
malign
solitari
fibrou
tumor
kidney
case
report
review
literatur
tugcu
f
akici
atay
g
aydogan
z
salcioglu
gokc
g
keskindemirci
h
sen
u
guvenc
sander
dervisoglu
pediatr
kanuni
sultan
suleyman
train
research
hospit
istanbul
turkey
pathholog
kanuni
sultan
suleyman
train
research
hospit
istanbul
turkey
pediatr
surgeri
kanuni
sultan
suleyman
train
research
hospit
istanbul
turkey
patholog
istanbul
univers
cerrahpasa
medic
school
istanbul
turkey
object
renal
solitari
fibrou
tumor
unusu
spindl
cell
neoplasm
orgin
mesenchym
cell
orgin
discov
pleura
method
ten
year
old
male
previous
healthi
admit
hospit
macroscob
hematuria
dysuria
low
grade
fever
abdomin
pain
without
palpabl
mass
normal
blood
pressur
laboratori
test
show
mildli
elev
white
blood
cell
count
normal
renal
function
test
urin
analysi
show
numer
white
red
blood
cell
normal
cultur
result
result
abdomen
ultrasonographi
reveal
lobul
soft
tissu
mass
right
kidney
hyperecho
appear
measur
mm
enhanc
ct
scan
abdomen
reveal
mm
hyperdens
mass
locat
within
pelvi
right
kidney
focal
ectasia
radic
right
nephrectomi
perform
macroscop
specimen
measur
cm
locat
pelvi
renal
parenchym
infiltr
without
hemorrhag
necrosi
microscop
cell
nuclei
round
oval
spindli
hyperchromat
eosinophil
cytoplasma
mild
coars
chromatin
tumor
cell
frequent
mitos
per
high
power
field
tumor
classifi
malign
group
due
hypercelluler
cytolog
atypia
mytot
activ
histopatholog
neoplast
cell
diffus
posit
vimentin
show
rare
posit
sma
neg
protein
ema
desmin
cd
pancytoceratin
nuclear
posit
detect
cell
conclus
total
resect
tumor
nt
recurr
metastasi
within
month
without
chemotherapi
knowledg
first
report
case
malign
solitari
fibrou
tumor
kidney
pediatr
age
clinic
trial
need
malign
form
tumor
clarifi
benefit
chemotherapi
denosumab
treatment
tumor
maxilla
girl
g
yavuz
e
unal
cabi
n
tacyildiz
h
dincaslan
e
pekpak
b
aksoy
berberoglu
z
siklar
z
gordu
f
asarcikli
pediatr
ankara
faculti
medicin
ankara
turkey
object
tumor
bone
gctb
primarili
seen
young
adult
compris
primari
bone
tumor
gct
rare
seen
childhood
case
gctb
usual
benign
tumor
frequent
recur
local
surgic
resect
metastat
diseas
present
uncommon
femal
present
march
facial
mass
caus
swell
left
side
famili
histori
reveal
father
diagnos
gctb
year
age
brother
diagnos
gct
maxilla
age
success
treat
intralesionar
steroid
calcitonin
center
method
patient
treat
intralesionar
steroid
calcitonin
develop
cellul
hospit
broad
spectrum
antibiot
surgic
drainag
curettag
discharg
lost
follow
year
final
admit
februari
left
maxillari
huge
mass
complet
fill
oral
caviti
dacryocyst
fistula
put
subcutan
everi
day
imatinib
mesyl
oral
two
month
later
seen
outpati
clinic
maxillofaci
surgeon
perform
intralesionar
steroidsweekli
month
everi
month
may
denosumab
treatment
plan
satisfactori
regress
tumor
subsequ
start
denosumab
induct
dose
subcutaneouslyweekli
week
follow
mg
denosumab
subcutaen
per
month
result
current
month
treatment
patient
requir
iuday
oral
vitamin
elementari
calcium
supplement
develop
hypocalcemia
decreas
bone
turnov
treatment
recent
calcium
level
tumor
show
shrinkag
reconstruct
surgeri
plan
conclus
first
pediatr
patient
treat
denosumab
gctb
turkey
thyroid
cancer
increas
young
adolesc
e
unal
cabi
n
tacyildiz
g
yavuz
h
dincaslan
g
tanyildiz
berberoglu
z
siklar
aydi
yagmurlu
e
erden
kir
pediatr
ankara
faculti
medicin
ankara
turkey
object
believ
incid
rare
tumor
differenti
thyroid
cancer
children
increas
follow
chernobyl
nuclear
catastroph
common
present
find
thyroid
cancer
thyroid
nodul
cervic
lymphadenopathi
posit
famili
histori
neck
irradi
risk
factor
develop
thyroid
carcinoma
method
februari
case
thyroid
carcinoma
diagnos
sixteen
femal
male
age
rang
year
one
cranial
rt
one
neck
irradi
hd
one
patient
live
kiev
famili
histori
parent
histopatholog
case
differenti
papillari
thyroid
carcinoma
papillari
thyroid
variant
follicular
medullari
thyroid
carcinoma
case
thyroid
nodul
result
follow
surgeri
lymph
node
infiltr
one
case
wherea
one
distant
lung
metastasi
three
patient
experienc
hypoparathyroid
one
case
vocal
chord
problem
patient
receiv
adjuv
radioact
iodin
therapi
put
thyroid
hormon
replac
therapi
mutat
studi
carri
case
ad
target
therapi
ie
sorafenib
metastat
recurr
case
patient
monitor
measur
serum
human
tg
level
ultrasound
recurr
conclus
although
treatment
modal
children
thyroid
cancer
still
controversi
total
thyroidectomi
togeth
lymph
node
sampl
dissect
repres
domin
method
surgic
treatment
enabl
success
rate
rai
therapi
provid
longer
diseas
free
surviv
aggress
fibromatosi
children
singl
center
experi
varan
c
akyuz
b
aydin
f
yildiz
barista
b
yalcin
kutluk
dept
pediatr
oncolog
hacettep
institut
oncolog
ankara
turkey
dept
radiat
oncolog
hacettep
institut
oncolog
ankara
turkey
dept
medic
oncolog
hacettep
institut
oncolog
ankara
turkey
object
determin
clinic
featur
treatment
result
children
aggress
fibromatosi
treat
singl
institut
method
record
patient
aggress
fibromatosi
treat
analyz
retrospect
demograph
characterist
tumor
locat
record
possibl
surgeri
perform
radiotherapi
rt
andor
chemotherapi
use
treatment
tamoxifen
interferon
rocaltrol
vinblastinemethotrex
regimen
use
accord
relaps
diseas
condit
result
three
male
eight
femal
median
age
year
rang
year
tumor
locat
lower
limb
n
upper
limb
n
gluteal
region
n
neck
n
largest
tumor
diamet
rang
cm
median
cm
five
patient
undergon
subtot
resect
time
diagnosi
six
undergon
biopsi
seven
patient
progress
diseas
without
treatment
surgeri
two
patient
receiv
rt
achiev
stabl
diseas
without
need
treatment
two
patient
receiv
rt
chemotherapi
one
rocaltrol
case
also
stabl
diseas
requir
treatment
patient
progress
treat
rt
andor
chemotherapi
three
treat
rt
one
receiv
rt
rocaltrol
two
receiv
rocaltrol
one
receiv
vinblastinemethotrex
one
patient
treat
rt
rocaltrol
one
treta
rt
achiev
stabl
diseas
anoth
treat
rt
alon
develop
progress
diseas
conclus
agress
fibromatosi
rare
tumor
treatment
problemat
although
seri
small
conclud
rt
may
enabl
stabl
diseas
cours
patient
paraovarian
endometroid
cystoadenocarcinoma
infant
proteu
syndrom
case
report
review
literatur
l
vasquez
maza
oscanoa
j
geronimo
tello
latorr
pediatr
oncolog
rebagliati
hospit
lima
peru
patholog
rebagliati
hospit
lima
peru
object
ovarian
paraovarian
malign
neoplasm
uncommon
children
mainli
germ
cell
tumor
least
frequent
epitheli
tumor
associ
genit
tract
tumor
proteu
syndrom
rare
sporad
ad
progress
entiti
character
postnat
overgrowth
sever
tissu
mosaic
pattern
caus
mutat
akt
gene
method
describ
infant
proteu
syndrom
develop
paraovarian
cystoadenocarcinoma
clinic
present
histolog
featur
clinic
outcom
examin
pubmedmedlin
search
perform
collect
case
adnex
mass
proteu
syndrom
result
asymptomat
femal
proteu
syndrom
diagnos
unilater
paraovarian
mass
routin
ultrasound
classic
criteria
syndrom
like
connect
tissu
nevu
disproportion
overgrowth
limb
finger
found
evid
distant
metastasi
onset
underw
complet
resect
tumor
take
sampl
omentum
lymph
node
peritoneum
patholog
endometroid
cystoadenocarcinoma
stage
ic
receiv
adjuv
chemotherapi
paclitaxel
infus
day
carboplatin
auc
day
cycl
evid
diseas
seven
month
total
nine
patient
describ
tumor
femal
tract
proteu
syndrom
mostli
includ
bilater
ovarian
cystoadenoma
benign
mass
conclus
paraovarian
neoplasm
extrem
rare
children
could
includ
criterion
proteu
syndrom
youngest
patient
rare
syndrom
malign
adnex
tumor
far
report
intern
literatur
stage
treatment
tumor
well
standard
howev
author
conclud
neoplasm
must
treat
ovarian
counterpart
small
cell
lung
cancer
male
yano
hebiguchi
k
kodama
takahashi
depart
pediatr
akita
univers
hospit
akita
japan
object
small
cell
lung
cancer
sclc
exceedingli
rare
children
method
herein
report
pediatr
case
sclc
result
male
admit
depart
histori
cough
thorac
ct
mri
show
two
larg
mass
one
cm
primari
tumor
close
right
middl
lobe
bronchu
cm
subcarin
lymph
node
system
reveal
multipl
bone
metastas
serolog
analys
level
releas
peptid
enolas
high
pgml
normal
pgml
ngml
normal
ngml
respect
diagnos
patient
sclc
base
histopatholog
find
biopsi
specimen
obtain
endoscop
tumor
partial
expos
bronchial
wall
start
treat
cisplatin
irinotecan
pi
combin
therapi
one
recommend
regimen
adult
patient
first
cours
pi
combin
therapi
reduct
tumor
volum
decreas
level
biomark
therefor
plan
administ
sever
cours
pi
therapi
conclus
prognosi
adult
sclc
patient
gener
poor
even
desir
initi
treatment
respons
obtain
order
improv
prognosi
new
trial
agent
topotecan
amrubicin
perform
bevacizumab
endotheli
growth
factor
vegf
monoclon
antibodi
effect
intrigu
candid
molecular
target
drug
evalu
sclc
valu
vegf
present
patient
plasma
high
consid
earli
administr
bevacizumab
combin
effect
pi
therapi
may
intens
treatment
patient
may
improv
prognosi
pediatr
neuroendocrin
tumor
hepat
metastas
yesil
c
bozkurt
g
tanyildiz
h
kirimlioglu
tekgunduz
candir
g
sahin
pediatr
oncolog
dr
sami
ulu
pediatr
research
train
hospit
ankara
turkey
patholog
univers
acibadem
istanbul
turkey
object
neuroendocrin
tumor
net
heterogen
group
malign
aris
neuroendocrin
system
net
pediatr
popul
extrem
rare
primarili
involv
gastrointestin
tract
lung
tumor
either
tumor
symptom
relat
mass
effect
malign
tumor
diseas
function
tumor
specif
hormon
secret
induc
specif
clinic
syndrom
although
major
tumor
malign
rel
neoplasm
net
classifi
tumor
due
tumor
histolog
metastat
tumor
frequent
local
net
often
present
liver
metastasi
paper
aim
present
pediatr
net
hepat
metastas
initi
diagnosi
method
thirteen
year
old
male
admit
complaint
abdomin
pain
physic
examin
erythemat
erupt
face
neck
trunk
also
epigastr
mass
radiolog
examin
reveal
solid
mass
segment
liver
cystic
necrot
compon
patholog
report
biopsi
liver
reveal
diagnosi
neuroendocrin
tumor
grade
level
acid
urin
collect
elev
gastrointestin
system
endoscopi
biopsi
normal
somatostatin
receptor
scintigraphi
reveal
liver
lesion
octreotid
everolimu
treatment
given
one
year
sever
tricuspid
valv
regurgit
develop
treatment
discontinu
somatostatin
radionuclid
therapi
administ
two
month
ago
side
effect
observ
result
system
treatment
option
child
neuroendocrin
liver
metastas
candid
surgic
resect
rather
limit
patient
symptom
resolv
liver
lesion
regress
combin
somatostatin
analog
everolimu
termin
therapi
sever
cardiac
side
effect
due
everolimu
conclus
somatostatin
radionuclid
therapi
offer
promis
treatment
option
net
children
manag
challeng
young
child
three
tumor
complex
case
syndrom
zanett
deang
gerstl
g
somer
malkin
hematologyoncolog
hospit
sick
children
toronto
canada
opthalmolog
hospit
sick
children
toronto
canada
gener
surgeri
hospit
sick
children
toronto
canada
pediatr
laboratori
medicin
hospit
sick
children
toronto
canada
object
lf
autosom
dominantli
inherit
cancer
predisposit
syndrom
associ
heterozyg
germlin
mutat
gene
cancer
gener
occur
children
young
adult
survivor
increas
risk
multipl
primari
cancer
knowledg
genet
statu
gene
patient
critic
due
increas
risk
malign
also
therapeut
implic
sinc
higher
rate
secondari
tumour
patient
observ
method
describ
year
old
child
lf
harbour
matern
inherit
heterozyg
germlin
mutat
affect
three
synchron
malign
age
anaplast
alveolar
rhabdomyosarcoma
rm
right
orbit
diagnos
age
mnth
right
adrenocort
carcinoma
acc
age
mth
right
orbit
low
grade
osteosarcoma
os
age
mth
radiolog
treatment
surveil
program
adjust
accord
recommend
lf
patient
result
treat
per
children
oncolog
group
cog
protocol
rm
order
avoid
radiat
local
control
achiev
orbit
exonter
routin
lf
surveil
acc
orbit
low
grade
osteosarcoma
diagnos
follow
two
cycl
chemotherapymitotan
per
cog
complet
resect
acc
achiev
optim
manag
strategi
os
evalu
conclus
manag
tumour
treatment
option
patient
lf
complex
due
theoret
actual
risk
de
novo
secondari
tumor
concurr
present
three
distinct
cancer
case
highlight
challeng
manag
potenti
develop
cancer
even
therapi
import
surveil
imag
presymptomat
tumor
detect
desmoplast
small
round
cell
tumor
case
report
thakkar
n
radhakrishnan
kalra
agarw
tarangini
sachdeva
pediatr
bmt
unit
sir
ganga
ram
hospit
new
delhi
india
object
desmoplast
small
round
cell
tumor
dsrct
rare
diseas
age
group
less
case
report
worldwid
till
present
infanc
rare
rariti
diseas
littl
known
optim
treatment
outcom
tri
present
find
cours
ill
patient
diagnos
dsrct
institut
method
step
wise
approach
identifi
etiolog
ill
adopt
patient
present
symptom
abdomin
distens
result
month
old
male
child
present
progress
increas
abdomin
distens
sinc
month
histori
alter
bowel
habit
fever
bleed
jaundic
loss
weight
hematuria
afp
level
normal
ct
scan
reveal
retroperiton
larg
heterogen
soft
tissu
mass
lesion
subsequ
biopsi
done
reveal
malign
small
round
cell
tumour
srct
exact
natur
diseas
could
delin
view
lack
specif
diagnosi
repeat
biopsi
done
show
malign
round
cell
tumor
express
mic
epithelioid
marker
cytokeratin
ema
focal
occasion
cell
express
desmin
also
tumor
cell
immunoneg
synaptophysin
lca
myogenin
thu
confirm
dsrct
diagnosi
child
given
inj
vincristin
cyclophosphamid
doxorubicin
howev
respons
could
assess
parent
abandon
treatment
post
cycl
chemotherapi
lack
resourc
conclus
dsrct
rare
tumor
requir
high
index
suspicion
multidisciplinari
approach
inspit
rariti
occurr
tumor
dsrtc
kept
mind
differenti
diagnosi
infant
present
mass
prognost
signific
vascular
endotheli
growth
factor
vegf
express
wilm
tumor
relev
express
abdallah
e
abdelzah
g
khedr
h
elleithi
patholog
alexandria
faculti
medicin
alexandria
egypt
oncolog
alexandria
faculti
medicin
alexandria
egypt
object
angiogenesi
play
import
role
wilm
tumor
progress
metastat
spread
vascular
endotheli
growth
factor
vegf
angiogen
factor
found
genitourinari
neoplasm
vegf
direct
target
gene
method
vegf
express
determin
immunohistochem
wilm
tumor
specimen
result
case
express
vegf
signific
posit
correl
detect
vegf
express
signific
neg
correl
detect
express
tumor
stage
signific
associ
found
poor
outcom
one
hand
advanc
tumor
stage
high
risk
patholog
group
hand
conclus
express
advanc
tumor
stage
high
risk
patholog
group
poor
prognost
factor
wilm
tumor
vegf
signific
posit
correl
implic
tumorogenesi
support
postul
regulatori
influenc
vegf
express
nephroblastoma
infilter
tricuspid
valv
yr
old
boy
oa
adewuyi
mda
kyaw
paediatr
medunsa
pretoria
south
africa
virolog
medunsa
pretoria
south
africa
introduct
nephroblastoma
commonest
childhood
renal
cancer
spread
heart
without
pulmonari
involv
unusu
method
old
male
refer
month
histori
dyspnoea
progress
abdomin
mass
weight
loss
anorexia
weak
cough
contact
tb
patient
examin
dysmorph
wast
muscl
stunt
growth
whz
haz
dyspnoeic
tachypno
rr
pallor
mild
dehydr
gener
lymphadenopathi
splinter
haemorrhag
normal
eye
temperatur
bp
ascit
well
hepatomegali
cm
hard
mass
right
lumber
region
cross
midlin
extend
superiorli
right
hemi
thorax
normal
bowel
sound
apex
beat
locat
ic
anterior
axillari
line
psm
audibl
llsbcxr
show
cardiomegali
ratio
right
lower
lobe
collaps
lung
also
note
echocardiogram
detect
presenc
tricuspid
veget
extend
pulmonari
valv
area
haematuria
proteinuria
observ
urin
dipstick
blood
cultur
bacteria
neg
haemoglobin
gdl
alt
normal
blood
urea
creatinin
normal
moll
respect
ldh
level
high
ul
vma
hva
nse
neg
mibg
neg
ct
abdomen
reveal
huge
right
renal
mass
invad
inferior
vena
cava
para
aortic
lymph
node
stage
iv
nephroblastoma
diagnos
tricuspid
valv
involv
heart
failur
chemotherapi
nephrectomi
got
chemo
radiotherapi
valvular
lesion
regress
residu
tumor
plan
remov
cardiothorac
surgic
unit
collaps
die
await
cardiac
oper
result
see
imag
conclus
prognosi
nephroblastoma
cardiac
involv
children
appear
alter
neg
especi
poor
resourc
countri
implement
strong
social
support
improv
surviv
renal
tumor
develop
countri
children
hospit
lahor
experi
ahmad
n
asghar
aw
rathor
faizan
mahmood
sheikh
paediatr
oncolog
children
hospit
ich
lahor
pakistan
paediatr
surgeri
jinnah
hospit
lahor
lahor
pakistan
paediatr
surgeri
children
hospit
ich
lahor
pakistan
object
children
hospit
lahor
tertiari
govern
centr
receiv
new
cancer
patient
pakistan
across
border
per
year
purpos
studi
analyz
manag
outcom
children
renal
tumor
discuss
role
effect
social
support
improv
surviv
patient
method
retrospect
review
patient
enrol
januari
done
data
regard
age
stage
histopatholog
risk
stratif
treatment
outcom
impact
social
support
analyz
patient
treat
accord
ukccsg
wt
protocol
result
total
patient
age
rang
year
mean
age
includ
f
ratio
present
advanc
stage
iv
stage
iii
stage
ii
wilm
tumor
cc
round
blue
cell
tumor
total
complet
treatment
treatment
got
lama
expir
due
metastat
progress
diseas
receiv
preoper
chemotherapi
upfront
nephrectomi
done
preoper
chemotherapi
four
patient
relaps
cours
therapi
travel
km
day
care
father
monthli
incom
mom
primari
patient
malnutrit
provid
social
support
patient
track
system
lama
rate
decreas
treat
patient
increas
compar
siop
data
pub
conclus
surviv
patient
significantli
improv
strengthen
social
support
servic
public
awar
seek
earli
complet
treatment
mortal
reduc
earli
diagnosi
treatment
effect
infect
control
practic
abandon
rate
decreas
effici
track
servic
day
care
center
growth
rate
renal
tumor
infant
begun
papkevich
function
diagnost
belarusian
research
center
pediatr
oncolog
hematolog
immunolog
minsk
region
belaru
object
establish
growth
rate
malign
kidney
tumor
infant
method
twenti
infant
survey
median
age
month
malign
tumor
kidney
establish
prospect
nephroblastoma
rhabdoid
prenat
diagnosi
term
week
gestat
fetu
ultrasonographi
infant
suspect
malign
tumor
kidney
complet
result
patient
diagnos
kidney
tumor
prenat
diagnosi
data
nevertheless
postnat
volum
tumor
ml
ml
primari
diagnosi
time
point
explain
establish
volum
tumor
ml
consist
embryon
doubl
accord
publish
data
rate
doubl
cell
cultur
nephroblastoma
day
henc
fetal
tumor
growth
volum
begin
ml
form
day
week
given
start
time
favorit
excretori
system
determin
gestat
age
visual
refer
week
howev
controversi
find
found
group
sick
infant
tumor
grew
least
month
differ
speed
number
doubl
stage
tumor
infant
stage
diseas
doubl
time
tumor
day
age
day
much
less
group
v
stage
day
p
conclus
natur
histori
tumor
growth
remain
poorli
understood
possibl
possibl
isol
case
continu
track
growth
nativ
human
tumor
receiv
data
requir
studi
pathophysiolog
aspect
tumor
growth
establish
screen
interv
ultrason
test
infant
apprais
effect
appli
chemotherapi
regiment
pediatr
tough
wilm
tumor
cao
jie
yan
h
wang
padiatr
oncolog
tianjin
medic
univers
cancer
institut
hospit
tianjin
china
object
preliminari
effect
appli
cog
chemotherapi
regiment
pediatr
tough
wilm
tumor
hospit
recent
year
summar
analyz
method
refer
nwtsg
standard
diagnosi
synthet
apprais
stage
textur
pathologicalpattern
preliminari
summari
analysi
done
appli
cog
chemotherapi
regiment
synthet
radioact
therapi
tough
children
wilm
tumor
hospit
april
may
result
patient
kept
contact
month
surviv
overal
surviv
os
rate
surviv
rate
df
respect
seriou
reaction
occur
except
acut
myelosuppress
comparison
previou
overal
surviv
rate
surviv
treatment
iv
stage
metastasi
recurr
wilm
tumor
respect
os
df
unfavour
prognosi
patholog
pattern
ufhccskrtk
conclus
appli
chemotherapi
regiment
pediatr
tough
wilm
tumor
safe
significantli
effect
multilocular
cystic
nephroma
rare
benign
renal
neoplasm
l
chen
z
ling
w
xu
g
wang
k
dong
patholog
children
hospit
fudan
univers
shanghai
china
depart
urolog
zhongshan
hospit
fudan
univers
shanghai
china
depart
surgeri
children
hospit
ofl
fudan
univers
shanghai
china
object
multilocular
cystic
nephroma
mlcn
rel
rare
benign
tumor
uncertain
etiolog
increas
awar
type
renal
tumor
method
two
children
underw
radic
nephrectomi
due
left
renal
mass
present
characterist
imag
histopatholog
featur
differenti
diagnosi
treatment
altern
discus
result
ct
scan
reveal
circumscrib
exophyt
mass
consist
cystic
element
contrast
hold
septat
aris
outer
border
left
kidneya
radic
nephrectomi
final
perform
microscop
examin
cyst
line
cuboid
epitheli
cell
arrang
hobnail
pattern
separ
cellular
spindl
cell
stroma
adjunct
therapi
administ
patient
complet
asymptomat
free
recurr
metastasi
conclus
mlcn
manag
radic
nephrectomi
due
suspicion
renal
cell
carcinoma
case
surgeri
kept
mind
mass
solitari
local
unilater
smaller
cm
also
surgeri
becom
import
patient
solitari
kidney
contralater
renal
patholog
wilm
tumour
singl
centr
studi
singapor
kt
chan
tan
sy
soh
paediatr
haematolog
oncolog
kk
women
children
hospit
singapor
singapor
object
wilm
tumour
common
malign
renal
tumour
childhood
retrospect
review
clinic
profil
outcom
wilm
tumour
case
kk
women
children
hospit
kkh
singapor
method
studi
approv
singhealth
central
institut
review
board
includ
patient
malign
renal
tumour
seen
kkh
year
result
patient
wilm
tumour
studi
period
eight
male
femal
male
femal
ratio
median
age
diagnosi
year
rang
year
abdomin
mass
common
present
n
either
isol
togeth
symptom
abdomin
pain
fever
poor
feed
vomit
hypertens
haematuria
one
patient
hypospadia
bilater
cryptorchid
two
present
gross
painless
haematuria
two
patient
tumour
diagnos
screen
one
underli
aniridia
hemihypertrophi
umbil
hernia
anoth
child
diagnos
incident
workup
diabet
ketoacidosi
fever
unilater
diseas
one
patient
nephroblastomatosi
contralater
kidney
stage
accord
nwt
seven
stage
five
stage
ii
seven
stage
iii
two
stage
iv
lung
metastasi
treat
nwt
protocol
except
one
siop
one
patient
unfavour
histolog
diffus
anaplasia
median
follow
time
year
aliv
diseas
recurr
conclus
abdomin
mass
common
present
seen
spectrum
present
surviv
outcom
excel
even
stage
iv
diseas
multidisciplinari
treatment
standard
protocol
vital
optim
care
malign
rhabdoid
tumor
childhood
report
case
treat
singl
institut
c
duan
xl
jin
dw
zhang
heamatologyoncolog
beij
children
hospit
beij
china
object
malign
rhabdoid
tumor
mrt
rare
malign
renal
extraren
organ
mrt
extraren
organ
mostli
affect
liver
central
nervou
system
pelvi
soft
tissu
caviti
treatment
patient
renal
tumor
remain
challeng
method
children
mrt
age
month
year
diagnos
singl
institut
result
patient
diagnos
renal
mrt
patient
diagnos
extraren
mrt
includ
patient
central
nervou
system
mrt
patien
caviti
mrt
patient
soft
tissu
mrt
time
month
year
median
time
month
seven
patient
subsequ
receiv
radiotherapi
patient
recurr
tumor
within
year
patient
die
progress
diseas
one
die
oper
mortal
median
surviv
time
patient
month
one
year
old
male
recurr
soft
tissu
mrt
receiv
aggress
chemotherapi
radiotherapi
diseas
remain
stabl
month
conclus
malign
rhabdoid
tumor
mrt
rare
malign
tumor
wors
prognosi
surgic
oper
treatment
combin
radiotherapi
aggress
chemotherapi
may
help
allevi
diseas
clinic
characterist
treatment
outcom
unilater
wilm
tumor
egypt
report
prospect
cohort
analysi
w
zekri
zaghloul
youn
e
el
desouki
e
ebeid
paediatr
oncolog
nation
cancer
institut
cairo
univers
children
cancer
hospit
egypt
radiat
oncolog
nation
cancer
institut
cairo
univers
children
cancer
hospit
egypt
surgic
oncolog
nation
cancer
institut
cairo
univers
children
cancer
hospit
egypt
cancer
epidemiolog
biostatist
nation
cancer
institut
cairo
univers
egypt
paediatr
oncolog
nation
cancer
institut
cairo
univers
egypt
object
huge
progress
made
treatment
wilm
tumor
wt
result
outcom
exceed
modern
era
studi
aim
evalu
demograph
diseas
characterist
treatment
outcom
unilater
wt
patient
treat
nation
cancer
institut
cairo
univers
children
cancer
hospit
egypt
method
prospect
cohort
studi
includ
elig
patient
newli
diagnos
nephroblastoma
period
januari
decemb
patient
treat
accord
unilater
renal
tumor
protocol
ccherentul
base
cog
protocol
patient
follow
till
decemb
result
among
patient
male
mean
age
diagnosi
year
patient
metastat
present
post
surgeri
patient
stage
iii
tumor
patient
stage
patient
stage
ii
diseas
anaplasia
seen
patient
patient
n
favor
histolog
wt
fhwt
median
follow
period
month
rang
month
overal
os
surviv
ef
rate
fhwt
patient
respect
patient
anaplast
wt
os
ef
rate
respect
earli
tumor
stage
iii
associ
significantli
improv
ef
compar
stage
iii
stage
iv
ef
versu
versu
respect
p
regard
os
statist
signific
differ
found
stage
iii
stage
iii
howev
significantli
better
compar
stage
iv
diseas
os
versu
versu
respect
p
conclus
studi
outcom
earli
stage
wt
compar
result
western
group
metastat
wt
significantli
wors
outcom
compar
group
wilm
tumor
outcom
adolesc
young
adult
patient
ann
robert
h
luri
children
hospit
chicago
c
higham
walterhous
gosiengfiao
j
reichek
e
morgan
e
perlman
j
woodman
pediatr
hematologyoncolog
ann
robert
h
luri
children
hospit
chicago
chicago
usa
patholog
ann
robert
h
luri
children
hospit
chicago
chicago
usa
object
histor
adult
wilm
tumor
inferior
outcom
compar
pediatr
patient
recent
studi
suggest
adult
wilm
tumor
patient
treat
pediatr
protocol
fare
better
patient
treat
pediatr
protocol
year
surviv
ef
respect
purpos
studi
determin
outcom
adolesc
young
adult
aya
wilm
tumor
patient
treat
luri
children
identifi
factor
may
affect
outcom
method
perform
retrospect
chart
review
patient
year
old
diagnos
complet
therapi
wilm
tumor
luri
children
result
nine
patient
age
year
identifi
stage
distribut
stage
stage
ii
stage
iii
stage
iv
patient
unfavor
histolog
ef
overal
surviv
median
month
median
time
relaps
month
second
complet
respons
rate
median
time
present
treatment
day
deceas
patient
day
present
treatment
patient
relaps
month
diagnosi
aliv
n
patient
relaps
prior
month
deceas
n
one
patient
signific
delay
treatment
due
toxic
avail
tumor
test
loss
heterozygoz
loss
n
loss
n
gain
n
patient
loss
gain
aliv
without
relaps
month
follow
patient
gain
die
diseas
progress
conclus
outcom
cohort
aya
patient
wilm
tumor
wors
expect
patient
treat
pediatr
protocol
tumor
biolog
appear
explain
poorer
outcom
delay
initi
referr
start
treatment
may
contribut
inferior
outcom
result
treatment
children
bilater
nephroblastoma
rubanski
kazantsev
p
kerimov
rubanskaya
rybakova
hizhnikov
kapkova
pediatr
oncolog
n
n
blokhin
cancer
research
center
russian
academi
medic
scienc
moscow
russia
object
improv
result
treatment
children
bilater
nephroblastoma
method
period
institut
oncolog
hematolog
examin
treat
children
bilater
nephroblastoma
patient
diagnosi
confirm
morpholog
main
peak
incid
bilater
nephroblastoma
account
period
age
year
surgic
treatment
children
four
children
receiv
surgic
treatment
due
progress
diseas
background
treatment
children
surgic
treatment
carri
two
stage
first
least
affect
kidney
tumor
contralater
organ
patient
surgeri
perform
one
step
result
median
patient
month
median
surviv
month
month
group
patient
receiv
surgic
treatment
two
stage
patient
figur
month
respect
group
patient
receiv
surgic
treatment
one
stage
patient
month
respect
overal
surviv
patient
bilater
nephroblastoma
surviv
overal
surviv
children
bilater
nephroblastoma
underw
surgic
treatment
two
stage
respect
group
patient
surgeri
perform
simultan
total
surviv
rate
conclus
correct
diagnost
modern
strategi
therapi
improv
overal
surviv
children
bilater
nephroblastoma
manag
treatment
childhood
wilm
tumor
three
year
hospit
base
studi
mehrvar
tashvighi
aa
hedayati
asl
faranoush
n
mehrvar
r
gholami
alebouyeh
oncolog
mahak
pediatr
cancer
treatment
research
center
tehran
iran
research
mahak
pediatr
cancer
treatment
research
center
tehran
iran
medic
unit
islam
azad
univers
tehran
iran
object
wilm
tumor
curabl
childhood
malign
develop
healthi
child
sinc
surviv
rate
tumor
purpos
topic
evalu
pediatr
cancer
treatment
epidemiolog
treatment
children
wilm
tumor
refer
mahak
research
center
method
cohort
studi
compli
children
less
year
old
favor
wilm
tumor
patholog
report
refer
mahak
pediatr
cancer
treatment
research
center
sinc
jan
jan
standard
checklist
contain
addit
inform
fill
individu
result
enrol
patient
case
femal
mean
age
year
old
time
diagnosi
stage
patient
iii
iv
ii
v
respect
tumor
involv
right
left
kidney
common
symptom
patient
mass
abdomen
hematuria
patient
nephrectomi
surgeri
earli
diagnosi
twelv
case
relaps
treatment
mean
relaps
time
month
enrol
patient
treatment
six
dead
lost
five
year
surviv
three
year
surviv
rate
studi
conclus
literatur
review
determin
children
wilm
tumor
cure
renal
problem
multimod
therapi
surgeri
radiotherapi
result
excel
tumor
control
rate
achiev
highest
surviv
rate
children
wilm
tumor
monitor
surveil
program
earli
detect
manag
therapi
relat
toxic
malign
renal
tumour
children
studi
hospic
africa
uganda
nandaula
nandaula
nakimbugw
palli
care
hospic
africa
uganda
kampala
uganda
research
assist
hospic
africa
uganda
kampala
uganda
object
review
frequenc
mode
present
histolog
pattern
children
malign
renal
tumour
method
year
retrospect
review
renal
tumour
folder
institut
result
children
qualifi
studi
malefemal
ratio
mean
age
year
peak
age
fifth
birth
day
patient
present
late
renal
cell
cancer
commonest
tumour
type
commonest
mode
present
abdomin
mass
pain
conclus
malign
renal
tumour
present
late
environ
patient
hesit
accept
avail
treatment
option
surgeri
need
increas
patient
awar
high
index
suspicion
clinician
particularli
imag
procedur
would
significantli
enhanc
earli
detect
patient
wilm
tumor
experi
case
treat
singl
centr
okur
f
pinarli
c
karadeniz
oguz
poyraz
h
bora
pediatr
oncolog
gazi
univers
medic
school
ankara
turkey
patholog
gazi
univers
medic
school
ankara
turkey
radiat
oncolog
gazi
univers
medic
school
ankara
turkey
object
illustr
clinic
experi
children
wilm
tumor
method
medic
record
children
wilm
tumor
diagnos
depart
pediatr
oncolog
gazi
univers
medic
school
review
clinic
radiolog
patholog
surviv
data
collect
analysi
perform
use
spss
version
result
femalemal
ratio
mean
age
diagnosi
month
clinic
manifest
includ
abdomin
mass
abdomin
pain
hematuria
one
patient
beckwith
wiedemann
syndrom
anoth
patient
hemihypertrophi
patient
stage
diagnosi
four
case
bilater
two
patient
extraren
wilm
tumor
patient
receiv
chemotherapi
patient
also
receiv
radiat
therapi
blastem
predomin
histolog
elicit
case
focal
diffus
anaplasia
found
case
late
complic
observ
patient
includ
proteinuria
patient
bronchiectasi
patient
secondari
malign
patient
pulmonari
alveolar
proteinosi
patient
chronic
renal
failur
patient
mean
time
month
one
patient
aliv
remiss
without
diseas
fifteen
patient
experienc
recurr
progress
diseas
nine
patient
die
treatment
event
free
surviv
overal
surviv
respect
event
free
surviv
overal
surviv
respect
one
patient
chronic
kidney
diseas
patient
die
due
electrolyt
disturb
two
patient
secondari
malign
one
rhabdomyosarcoma
patient
acut
myeloid
leukemia
conclus
wilm
tumor
well
treatabl
diseas
howev
signific
number
patient
present
advanc
stage
advanc
stage
present
presenc
anaplasia
requir
aggress
manag
result
complic
higher
mortal
rate
ten
year
retrospect
audit
manag
treatment
outcom
children
wilm
tumor
tertiari
center
p
maturi
e
rogena
g
kitonyi
hematolog
blood
transfusionpediatr
oncolog
univers
nairobi
nairobi
kenya
object
object
studi
review
clinic
present
manag
children
wilm
tumor
factor
influenc
outcom
kenyatta
nation
referr
teach
hospit
knh
find
studi
form
basi
revis
treatment
design
patient
diagnos
nephroblastoma
knh
method
record
wt
patient
age
less
year
treat
kenyatta
nation
hospit
kenya
period
januari
decemb
review
manag
protocol
follow
scheme
us
nation
wilm
tumor
studi
group
nswtg
result
thirteen
case
diagnos
stage
stage
ii
stage
iii
stage
iv
two
case
bilater
diseas
stage
v
stage
tumor
kidney
overal
surviv
os
event
free
surviv
ef
rate
respect
univari
analysi
test
reveal
statist
signific
associ
os
nodal
statu
valu
manifest
gross
hematuria
tumor
size
centimet
multivari
analysi
found
nodal
statu
independ
associ
os
hazard
ratio
eight
stage
case
stage
iii
case
relaps
surviv
significantli
poorer
outcom
found
case
earli
relaps
within
day
enrol
conclus
childhood
wilm
tumor
present
late
set
consequ
manag
challeng
need
educ
populac
primari
healthcar
provid
benefit
earli
diagnosi
treatment
condit
overemphas
larg
tumor
size
gross
hematuria
associ
risk
poorer
outcom
manag
bilater
wilm
tumor
experi
bv
raghunath
bc
gowrishankar
narendra
babu
ramesh
j
vinay
j
deepak
jayalakshmi
kl
aravind
ravindra
pediatr
surgeri
indira
gandhi
institut
child
health
bangalor
india
object
manag
bilater
wilm
tumor
particularli
challeng
consid
chanc
recurr
long
term
renal
function
affect
patient
aggress
surgic
resect
prevent
recurr
must
balanc
desir
preserv
renal
function
evalu
experi
manag
bilater
wilm
tumor
stress
challeng
encount
decis
make
role
nephron
spare
surgeri
nss
limit
resourc
set
method
four
children
present
bilater
wilm
tumor
evalu
appropri
stage
given
standard
chemotherapi
per
nwt
guidelin
tumor
consid
good
respons
chemotherapi
suffici
tumor
shrinkag
observ
renal
hilum
seen
free
tumor
nss
consid
perform
feasibl
follow
complet
adjuv
chemotherapi
patient
follow
serial
ultrasound
scan
monthli
cect
abdomen
yearli
blood
urea
serum
creatinin
hypertens
proteinuria
assess
follow
visit
result
children
receiv
chemotherapi
per
guidelin
result
summar
follow
tabl
child
present
await
right
partial
nephrectomi
follow
line
chemotherapi
second
child
follow
yr
well
conclus
manag
bilater
wilm
tumor
challeng
nss
consid
patient
bilater
wilm
tumor
favour
histolog
even
preoper
imag
studi
suggest
lesion
unresect
pulmonari
hypertens
patient
wilm
tumor
rayar
h
tilman
g
taylor
l
abbott
r
grant
hematologyoncolog
hospit
sick
children
toronto
canada
critic
care
medicin
hospit
sick
children
toronto
canada
paediatr
laboratori
medicin
hospit
sick
children
toronto
canada
object
patient
metastat
wilm
tumor
wt
requir
multimod
treatment
surgeri
chemotherapi
radiat
achiev
optim
outcom
therapi
may
result
toxic
recent
clinic
trial
high
risk
renal
tumor
encount
lung
toxic
includ
pulmonari
arteri
hypertens
ph
describ
develop
success
treatment
ph
patient
stage
iv
wt
method
femal
present
stage
iv
favour
histolog
wt
involv
left
kidney
extens
proxim
inferior
vena
cava
liver
lung
metastas
treatment
includ
surgic
resect
primari
tumor
chemotherapi
doxorubicin
dactinomycin
vincristin
irradi
lung
liver
boost
poorli
respond
lesion
upper
left
lung
field
four
month
treatment
develop
persist
tachycardia
respiratori
distress
subsequ
decreas
cardiac
function
without
evid
hypoxia
spiral
ct
reveal
evid
pulmonari
embol
although
initi
present
thought
cardiac
pulmonari
natur
echocardiogram
subsequ
cardiac
catheter
consist
ph
lung
biopsi
show
preserv
lung
parenchyma
patchi
eccentr
mostli
concentr
fibrointim
hyperplasia
medial
hypertrophi
note
small
pulmonari
arteri
pulmonari
vein
unremark
find
consist
ph
result
treat
supplement
oxygen
therapi
puls
intraven
dose
steroid
oral
sildenafil
month
maxim
pulmonari
vascular
dilat
normal
echo
cardiac
function
underw
gradual
withdraw
ph
direct
therapi
remain
asymptomat
month
ph
therapi
conclus
cardiac
pulmonari
toxic
describ
metastat
wt
patient
attribut
radiat
anthracyclin
administr
patient
present
isol
ph
revers
treatment
ph
must
consid
earli
symptomat
wt
patient
order
implement
appropri
therapi
wilm
tumor
treatment
result
pediatr
popul
russo
n
isa
rey
pediatr
radiotherapi
nation
cancer
institut
santiago
chile
object
introduct
wilm
tumor
wt
common
form
malign
kidney
tumor
childhood
pinda
protocol
treatment
includ
depend
stage
present
earli
surgeri
rt
chemotherapi
ct
object
work
review
result
patient
nation
cancer
institut
nci
condit
method
patient
method
retrospect
review
patient
diagnos
wt
nci
conduct
patient
popul
rt
treatment
receiv
surviv
result
describ
prognost
factor
search
result
septemb
decemb
children
treat
rt
median
age
diagnosi
year
old
median
month
rt
march
total
patient
follow
die
due
diseas
progress
death
occur
within
three
year
treatment
overal
surviv
year
old
respect
multivari
analysi
show
day
surgeri
without
start
rt
chanc
surviv
decreas
p
conclus
wt
treatment
excel
prognosi
surviv
year
stabil
without
present
complic
regardless
group
patient
belong
among
prognost
factor
patient
rt
prescript
radiat
start
earli
close
surgeri
possibl
ureter
thrombu
wilm
pgimer
chandigarh
experi
r
samujh
n
peter
p
menon
bawa
chhabra
pediatr
surgeri
postgradu
institut
medic
educ
research
chandigarh
india
object
ureter
thrombu
wilm
tumour
rare
occurr
wilm
tumour
present
experi
patient
manag
modifi
siop
protocol
method
record
children
ureter
extens
tumor
review
period
two
year
present
symptom
diagnost
histopatholog
studi
oper
perform
outcom
record
result
patient
oper
wilm
tumor
period
two
year
patient
ureter
thrombu
patient
receiv
standard
preoper
chemotherapi
femal
male
mean
age
year
left
side
tumour
common
l
r
ratio
one
patient
present
hematuria
rest
asymptomat
abdomin
mass
one
patient
follow
wagr
syndrom
preoper
ultrasound
ct
scan
show
ureter
involv
patient
patient
show
degre
hydronephrosi
patient
success
underw
nephrouretectomi
case
could
get
tumor
thrombu
divid
uret
centimetr
thicken
uret
last
patient
entir
uret
thicken
right
uretroves
junction
patient
receiv
adjuv
chemotherapi
event
free
mean
month
post
oper
conclus
incidenceof
ureter
thrombu
common
previous
report
preoper
suspicion
patient
gross
hematuria
hydronephrosi
accur
imag
help
preoper
plan
profil
outcom
retinoblastoma
patient
philippin
nation
referr
center
alcasaba
gv
mercado
medina
p
fajardo
r
hernand
e
domingo
em
melendr
dy
dy
paediatr
philippin
gener
hospit
manila
philippin
ophthalmolog
philippin
gener
hospit
manila
philippin
object
retinoblastoma
rb
high
incid
philippin
per
million
children
year
expect
number
new
case
year
mani
children
refer
nation
referr
center
philippin
gener
hospit
review
case
seen
ophthalmolog
pediatr
oncolog
chariti
servic
method
record
retinoblastoma
patient
januari
decemb
review
result
case
unilater
bilater
jan
dec
mean
age
month
unilater
rb
month
bilater
initi
present
leukocoria
n
mass
n
strabismu
n
eye
red
n
blind
n
dilat
pupil
n
stage
base
patholog
report
n
n
miss
data
n
record
metastat
lack
patient
treat
upfront
enucl
two
refus
treatment
one
transfer
care
adjuv
chemotherapi
includ
vincristin
carboplatin
etoposid
two
patient
receiv
radiat
outcom
patient
aliv
children
treat
enucl
alon
abandon
therapi
die
lost
follow
abandon
therapi
n
stop
adjuv
chemotherapi
n
chemotherapi
n
radiat
n
radiat
caus
death
intracrani
extens
n
record
n
conclus
advanc
diseas
abandon
major
caus
poor
outcom
earli
detect
campaign
establish
referr
system
facilit
time
diagnosi
treatment
prospect
studi
need
identifi
specif
barrier
care
monitor
impact
intervent
impact
implement
retinoblastoma
program
public
tertiari
hospit
resourc
limit
set
ap
alcasaba
k
caranto
c
mw
wilson
cg
lam
g
sundar
tc
quah
mc
dolendo
section
hematologyoncolog
depart
pediatr
philippin
gener
hospit
manila
philippin
depart
pediatr
children
cancer
blood
diseas
unit
southern
philippin
medic
center
davao
philippin
pediatr
oncolog
dana
farber
cancer
institut
boston
usa
depart
surgeri
divis
ophthalmolog
patholog
st
jude
children
research
hospit
memphi
usa
depart
intern
outreach
program
st
jude
children
research
hospit
memphi
usa
depart
ophthalmolog
nation
univers
singapor
singapor
singapor
section
pediatr
khoo
teck
univers
children
medic
institut
singapor
singapor
object
retinoblastoma
high
incid
philippin
per
million
children
year
major
patient
present
late
extens
reason
delay
diagnosi
includ
financi
constraint
inaccess
care
misdiagnosi
mindanao
philippin
new
case
expect
yearli
yet
fewer
seen
govern
referr
center
address
multifacet
program
establish
may
southern
philippin
medic
center
involv
educ
healthcar
provid
local
health
center
govern
hospit
earli
warn
sign
retinoblastoma
establish
referr
system
develop
treatment
regimen
team
format
capac
build
includ
dedic
retinoblastoma
patient
coordin
specialist
clinic
interdisciplinari
case
discuss
method
data
retinoblastoma
patient
prospect
collect
part
routin
clinic
care
may
compar
retrospect
data
prior
program
implement
treatment
includ
enucl
radiat
chemotherapi
vincristin
carboplatin
etoposid
result
may
februari
patient
seen
unilater
bilater
mean
age
year
lag
time
diagnosi
month
median
rang
irss
stage
stage
n
stage
n
stage
n
stage
n
stage
n
four
patient
refus
stage
overal
surviv
rate
year
year
respect
nine
patient
abandon
treatment
compar
baselin
estim
mean
annual
referr
increas
present
drop
conclus
develop
effect
public
health
educ
referr
system
retinoblastoma
establish
center
excel
local
intern
collabor
increas
patient
referr
decreas
present
rate
sustain
model
need
impact
outcom
oncogen
human
papilloma
viru
isol
eye
retinoblastoma
prospect
studi
north
indian
children
r
aggarw
j
naru
u
singh
nk
mangat
n
kakkar
rk
marwaha
bansal
immunopatholog
postgradu
institut
medic
educ
research
chandigarh
india
ophthalmolog
advanc
eye
center
postgradu
institut
medic
educ
research
chandigarh
india
histopatholog
postgradu
institut
medic
educ
research
chandigarh
india
pediatr
unit
dept
pediatr
advanc
pediatr
centr
postgradu
institut
medic
educ
research
chandigarh
india
object
risk
factor
retinoblastoma
poorli
understood
incid
retinoblastoma
higher
develop
countri
report
describ
human
papilloma
viru
hpv
retinoblastoma
tumor
tissu
aim
investig
preval
hpv
retinoblastoma
tumor
tissu
compar
control
method
studi
prospect
case
includ
eye
enucl
retinoblastoma
control
donor
eye
obtain
dna
isol
normal
retin
tissu
tumor
tissu
eye
retinoblastoma
pcr
hpv
perform
hpv
genotyp
array
kit
hybribio
ltd
hong
kong
util
consensu
primer
simultan
amplifi
genotyp
follow
hybrid
respect
probe
embed
membran
fiber
hpv
type
probabl
type
type
result
studi
enrol
retinoblastoma
normal
retin
tissu
diseas
bilater
three
patient
famili
histori
retinoblastoma
tumor
tissu
infect
hpv
subtyp
isol
none
control
eye
famili
case
hpv
posit
conclus
isol
eye
retinoblastoma
none
control
famili
case
hpv
posit
greater
number
though
signific
hpv
posit
case
vagin
deliveri
belong
low
background
link
hpv
retinoblastoma
explor
prevent
strategi
develop
countri
fund
parent
institut
impact
optic
nerv
resect
length
surviv
retinoblastoma
bhagat
qureshi
ramadwar
n
shetti
g
chinnaswami
vora
p
kurkur
pediatr
surgeri
oncolog
tata
memori
hospit
mumbai
india
object
enucl
cure
patient
uniocular
retinoblastoma
howev
patient
present
extraocular
relaps
enucl
mani
high
risk
factor
scleral
involv
choroid
invas
post
laminar
optic
nerv
involv
diseas
free
optic
nerv
length
impact
surviv
howev
due
overal
good
surviv
rate
impact
tumor
free
optic
nerv
length
surviv
studi
exhaust
studi
done
determin
resect
length
optic
nerv
impact
surviv
guid
surgeon
optimum
surgeri
therebi
improv
outcom
method
retrospect
analysi
prospect
maintain
data
databas
patient
undergon
surgeri
retinoblastoma
septemb
septemb
includ
data
analys
use
spss
assess
impact
optic
nerv
tumor
free
resect
margin
surviv
delin
variou
prognost
factor
affect
surviv
retinoblastoma
result
total
case
includ
studi
median
length
optic
nerv
obtain
cm
rang
cm
case
wherein
involv
optic
nerv
n
n
laminar
involv
n
cut
margin
found
posit
one
case
histolog
factor
unfavor
patient
residu
tumor
two
favor
rest
event
free
surviv
better
patient
optic
nerv
length
cm
patient
optic
nerv
length
cm
p
conclus
better
event
free
surviv
seen
cm
resect
optic
nerv
length
thu
optim
surgeri
includ
least
cm
tumor
free
length
optic
nerv
improv
outcom
diencephal
tumor
retinoblastoma
patient
rare
coincid
de
iori
sg
colafati
f
randisi
carai
p
valent
r
cozza
romanzo
mg
cefalo
b
bernardi
mastronuzzi
hematologyoncolog
pediatr
hospit
bambino
gesu
roma
itali
neuroradiolog
pediatr
hospit
bambino
gesu
roma
itali
neurosurgeri
pediatr
hospit
bambino
gesu
roma
itali
ophtalmolog
pediatr
hospit
bambino
gesu
roma
itali
object
retinoblastoma
rb
patient
present
high
risk
develop
second
malign
neoplasm
smn
epeci
children
hereditari
rb
diencephal
tumor
rare
paediatr
age
report
three
case
diencephal
tumor
occur
rb
patient
method
clinic
imag
find
three
patient
review
rb
databas
check
order
identifi
patient
similar
diencephal
lesion
diagnos
januari
sinc
decemb
result
rb
patient
diagnos
year
three
patient
present
diencephal
tumour
period
none
present
famili
rb
histori
alter
identifi
two
patient
bilater
rb
diencephal
lesion
occur
month
rb
diagnosi
without
symptom
biopsi
perform
one
patient
histolog
show
low
grade
glioma
period
stabl
diseas
lesion
progress
first
two
patient
first
patient
receiv
radiotherapi
gy
later
one
chemotherapi
base
bevacizumab
plu
irinotecan
three
patient
aliv
month
month
year
cn
tumour
diagnosi
conclus
diencephal
tumour
previous
treat
rb
patient
seem
peculiar
smn
consid
site
short
time
interv
tumour
absenc
risk
factor
clearli
associ
smn
altern
pathogenet
mechan
suppos
analys
larg
seri
need
clarifi
entiti
angiogenesi
retinoblatoma
revis
assess
therapeut
suggest
de
iori
r
de
vito
p
valent
spagnoli
tomaselli
r
rota
gallo
r
cozza
mastronuzzi
f
locatelli
hematologyoncolog
pediatr
hospit
bambino
gesu
roma
itali
patholog
pediatr
hospit
bambino
gesu
roma
itali
ophtalmolog
pediatr
hospit
bambino
gesu
roma
itali
object
retinoblastoma
rtb
vascular
tumor
assess
express
angiogen
marker
rtb
patient
explor
possibl
associ
clinic
patholog
paramet
therapeut
consider
address
accord
result
method
primari
rtb
sampl
analyz
immunohistochemistri
cell
prolifer
potenti
determin
stain
express
smooth
muscl
actin
vegf
evalu
indic
angiogen
tumor
featur
tumour
necrosi
also
measur
clinic
histolog
data
age
later
clinic
stage
accord
intern
retinoblastoma
stage
system
irss
classificaton
system
intraocular
retinoblastoma
review
coroid
scleral
nerv
involv
evalu
accord
irss
anterior
chamber
involv
correl
marker
express
result
smooth
muscl
actin
express
differ
level
rtb
specimen
vegf
respect
posit
tumor
necrosi
present
sampl
smooth
muscl
actin
express
bilater
case
sampl
patient
anterior
chamber
involv
express
sampl
rtb
patient
primari
enucl
chemotherapi
treatment
p
wherea
differ
seen
express
vegf
conclus
data
show
express
major
resist
rtb
result
suggest
anti
treatment
could
propos
theoret
effect
probabl
bilater
case
patient
resist
standard
antiblast
drug
could
benefit
approach
develop
clinic
cancer
genet
servic
resourc
limit
countri
case
retinoblastoma
kenya
h
dimara
l
l
njambi
jm
nyamori
e
nyenz
k
kimani
matend
h
rono
v
njom
retinoblastoma
genet
task
forc
ophthalmolog
vision
scienc
univers
toronto
toronto
canada
human
biolog
univers
toronto
toronto
canada
ophthalmolog
univers
nairobi
nairobi
kenya
pediatr
lighthous
eye
centr
mombasa
kenya
kital
eye
centr
kital
kenya
ophthalmolog
coast
provinci
hospit
mombasa
kenya
kenyan
nation
retinoblastoma
strategi
group
nairobi
kenya
object
clinic
cancer
genet
integr
part
cancer
control
manag
yet
develop
essenti
medic
servic
hinder
mani
countri
report
experi
develop
clinic
cancer
genet
servic
retinoblastoma
kenya
method
genet
task
forc
creat
within
membership
exist
kenyan
nation
retinoblastoma
strategi
group
task
forc
engag
multipl
telephon
discuss
offer
experi
opinion
suggest
retinoblastoma
genet
servic
discuss
record
themat
categor
develop
strategi
design
implement
nation
retinoblastoma
clinic
genet
servic
result
discuss
among
retinoblastoma
genet
task
forc
support
develop
comprehens
genet
servic
rest
three
pillar
patient
famili
counsel
commun
involv
medic
educ
conclus
coordin
nation
retinoblastoma
genet
task
forc
led
creation
uniqu
relev
approach
deliv
comprehens
accur
genet
care
kenyan
retinoblastoma
patient
task
forc
aim
stimul
innov
approach
cancer
genet
research
educ
knowledg
translat
take
advantag
uniqu
opportun
offer
african
context
ident
triplet
retinoblastoma
illustr
spectrum
therapi
optim
outcom
b
galli
c
ngo
z
noubari
tennant
f
shaikh
h
chan
e
ophthalmolog
vision
scienc
hospit
sick
children
toronto
canada
ophthalmolog
univers
alberta
edmonton
canada
depart
pediatr
hematolog
oncolog
hospit
sick
children
toronto
canada
ophthalmolog
vision
scienc
hospit
sick
children
toronto
canada
object
describ
treatment
choic
optim
outcom
ident
triplet
affect
retinoblastoma
method
digit
imag
shape
pupil
one
eye
triplet
male
reveal
leukocoria
examin
anaesthesia
reveal
five
six
eye
retinoblastoma
tumor
eye
vari
degre
minor
iri
coloboma
result
treatment
child
eye
depend
size
locat
tumor
degre
involv
eye
triplet
eye
intern
intraocular
retinoblastoma
classif
group
tumor
visual
retcam
imag
eye
group
c
macular
tumor
adjac
vitreou
seed
one
peripher
tumor
treat
nm
laser
peripher
tumor
subtenon
topotecan
intravitr
melphalan
triplet
group
b
eye
threat
vision
five
ten
tumor
invis
detect
optic
coher
tomographi
oct
eight
tumor
treat
laser
confirm
correct
oct
invis
tumor
peripher
tumor
treat
cryotherapi
triplet
group
eye
group
eye
macular
larg
tumor
overhang
optic
nerv
inferior
retin
detach
subretin
seed
extens
discuss
parent
famili
evalu
child
interest
salvag
right
eye
would
requir
invas
treatment
repeat
monitor
least
year
anaesthet
ongo
risk
simpl
enucl
group
eye
would
avoid
invas
extend
intervent
enucl
perform
immedi
placement
temporari
prosthet
eye
conclus
three
children
avoid
initi
system
therapi
children
excel
visual
prognosi
one
year
age
oct
regularli
use
detect
treat
earli
tini
visual
threaten
tumor
pathologyc
risk
factor
estim
risk
relaps
retinoblastoma
instituto
nacion
de
brazil
n
grigorovski
kuyven
l
portela
psp
almeida
mm
garab
mm
brochado
pa
faria
soar
cc
mattosinho
e
lucena
se
ferman
pediatr
oncolog
instituto
nacion
de
rio
de
janeiro
brazil
patholog
instituto
nacion
de
rio
de
janeiro
brazil
ophathalmolog
instituto
nacion
de
rio
de
janeiro
brazil
object
unilater
retinoblastoma
account
case
advanc
intraocular
diseas
diagnosi
requir
enucl
adjuv
chemotherapi
avoid
risk
relaps
base
patholog
evalu
describ
histopatholog
studi
intraocular
unilater
rb
groupvirc
primarili
enucl
without
adjuv
therapi
accord
patholog
risk
factor
correl
outcom
method
retrospect
studi
primarili
enucl
advanc
rb
patient
rb
previou
treatment
one
enucl
admiss
hospit
exclud
analysi
eye
review
experienc
pathologist
access
choroid
andor
optic
nerv
involv
accord
patholog
guidelin
intern
retinoblastoma
stage
work
group
classif
group
minim
choroid
invas
andor
prelaminar
absenc
optic
nerv
involv
massiv
choroid
invas
andor
intraor
retrolaminar
involv
group
scleral
invas
andor
tumor
cut
end
optic
nerv
outcom
assess
case
result
twenti
outof
patholog
find
choroid
invas
optic
nerv
involv
optic
nerv
involv
lamina
cribrosa
observ
treatment
given
aliv
without
evid
diseas
seven
isol
choroid
invas
focal
n
massiv
n
receiv
adjuv
chemotherapi
aliv
without
evid
diseas
one
massiv
invas
develop
bone
bone
marrow
relaps
treat
intens
chemotherapi
aliv
evid
diseas
eight
featur
invas
optic
nerv
beyond
lamina
cribosa
receiv
chemotherapi
two
aliv
one
develop
cn
relaps
die
progress
diseas
pd
two
risk
factor
observ
case
receiv
n
aliv
conclus
accur
histopatholog
assess
enucl
crucial
indic
adjuv
therapi
graduat
intens
approach
surviv
excel
group
group
indic
need
chemotherapi
intensif
bilater
retinoblastoma
conserv
modal
case
report
chabchoub
haj
mansour
aert
h
zaghouani
n
cassoux
levi
h
bouguila
ben
ahm
j
michon
medic
oncolog
farhat
hach
souss
tunisia
pediatr
oncolog
curi
pari
franc
radiolog
farhat
hach
souss
tunisia
ophtalmolog
hedi
rai
ophtalmolog
institut
tuni
tunisia
object
report
case
one
year
old
bilater
retinoblastoma
treat
success
preoper
chemotherapi
locoregion
treatment
method
case
report
one
year
old
bilater
retinoblastoma
result
one
year
old
femal
famili
past
histori
present
right
leukocoria
clinic
examin
mri
conclud
retinoblastoma
reis
v
right
reis
iii
left
cerebr
second
locat
receiv
cours
chemotherapi
cev
carboplatin
etoposid
vincristin
well
toler
reduc
much
left
tumor
volum
right
onea
collabor
curi
institut
consid
offer
chanc
preserv
right
eye
avoid
tumor
spread
delay
child
receiv
cev
coursesa
favor
respons
notic
persist
calcifi
format
mm
eye
right
eye
one
left
eye
patient
laser
session
cryotherapi
right
eye
laser
combin
plaqu
radiotherapi
left
eye
month
relaps
neither
sequela
notic
conclus
combin
modal
first
line
chemotherapi
eye
laser
cryotherapi
plaqu
radiotherapi
good
strategi
avoid
enucl
especi
bilater
retinoblastoma
clinic
analysi
case
bilater
intraocular
retinoblastoma
jin
j
zhao
zhang
g
yu
q
wu
cui
x
hematologyoncolog
center
beij
children
hospit
capit
medic
univers
beij
china
beij
tongren
eye
centr
beij
tong
ren
hospit
capit
medic
univers
beij
china
depart
ophthalmolog
beij
children
hospit
capit
medic
univers
beij
china
object
retinoblastoma
rb
common
primari
malign
intraocular
tumor
children
studi
analyz
clinic
characterist
diagnosi
treatment
patient
bilater
intraocular
retinoblastoma
method
clinic
document
case
bilater
intraocular
retinoblastoma
confirm
hospit
decemb
februari
retrospect
analyz
result
median
age
primari
diagnosi
month
younger
unilater
rb
patient
time
patient
leucocoria
common
manifest
primari
diagnosi
rate
base
symptom
case
intraocular
retinoblastoma
group
group
b
group
c
group
group
e
patient
enucl
group
e
enucl
rate
chemoreduct
signific
differ
p
among
patient
dead
patient
complic
caus
chemoreducton
patient
occur
transient
hear
loss
hear
loss
recov
fellow
sum
percent
sick
eye
preserv
preserv
eye
percentag
group
e
group
group
c
group
c
group
b
group
enucl
case
conclus
chemoreduct
combin
local
ophthalm
therapi
effect
treatment
intraocular
retinoblastoma
system
chemotherapi
reduc
enucl
without
signific
system
toxic
mutat
south
african
children
retinoblastoma
kruger
rd
wainwright
de
la
rey
ej
van
rensburg
paediatr
child
health
stellenbosch
univers
cape
town
south
africa
paediatr
child
health
univers
witwatersrand
johannesburg
south
africa
genet
univers
pretoria
pretoria
south
africa
object
retinoblastoma
common
intraocular
tumour
children
caus
mutat
tumour
suppressor
gene
aim
studi
screen
children
retinoblastoma
treat
two
treatment
center
south
africa
mutat
method
total
blood
sampl
ffpe
tumour
sampl
rb
famili
famili
affect
individu
sporad
bilater
sporad
unilater
case
screen
larg
mlpa
analysi
small
sequenc
chang
sscp
direct
sequenc
result
total
mutat
consist
larg
genom
deletionsinsert
nonsens
missens
one
delet
one
promotor
mutat
detect
small
mutat
frequent
larg
deletionsinsert
less
common
two
larg
genom
delet
somat
mutat
sporad
unilater
case
wherea
six
chang
one
famili
duplic
exon
five
bilater
sporad
case
delet
vari
size
nonsens
mutat
frequent
small
mutat
mutat
exon
common
recurr
n
nonsens
mutat
herit
case
sporad
bilater
famili
case
mutat
detect
rate
sporad
unilater
case
also
mutat
somat
mutat
detect
sporad
unilater
case
unidentifi
mutat
bilater
proband
may
due
presenc
mosaic
detect
screen
method
eight
unilater
sporad
case
appear
mutat
may
due
epigenet
chang
conclus
first
report
mutat
south
african
children
import
genet
counsel
life
style
paramet
patern
sperm
dna
health
role
sporad
retinoblastoma
sb
kumar
b
chawla
r
dada
dept
anatomi
india
institut
medic
scienc
new
delhi
india
retinoblastoma
clinic
rpc
india
institut
medic
scienc
new
delhi
india
object
compar
somat
cell
oocyt
sperm
vulner
oxidt
stress
due
minim
cytosol
oxid
stress
damag
sperm
nuclear
mitochondri
dna
therefor
plan
analyz
sperm
dna
integr
free
radic
level
oxid
dna
base
father
children
sporad
retinoblastoma
correl
paramet
life
style
habit
father
method
total
case
sporad
retinoblastoma
control
men
recruit
tertiari
referr
centr
india
semen
sampl
collect
father
rb
patient
analyz
semen
paramet
per
guidelin
biolog
marker
sperm
dna
damag
dna
fragment
assay
dfi
scsa
elisa
reactiv
oxygen
speci
ro
level
chemiluminisc
assay
measur
mutat
analysi
qpcr
sequenc
rb
gene
inherit
rule
blood
dna
parent
logist
binari
regress
use
comput
odd
ratio
rb
result
among
case
control
signific
differ
experiment
paramet
ro
p
dfi
p
p
observ
or
smoker
p
ci
pesticid
expos
alcohol
ci
ci
p
ci
p
respect
conclus
major
sperm
dna
damag
repair
oocyt
threshold
beyond
sperm
dna
damag
may
repair
accumul
ethenonucleosid
type
dna
lesion
sperm
may
inhibit
nucleotid
excis
repair
mechan
mutat
load
thu
carri
embryo
fertil
high
level
dna
damag
influenc
dna
repair
capac
oocyt
thu
accumul
sperm
dna
damag
may
result
sporad
rb
smoke
pesticid
exposur
alcohol
intak
advers
affect
dna
qualiti
thu
life
style
intervent
significantli
improv
dna
health
plasma
novel
potenti
biomark
retinoblastoma
detect
q
liu
pediatr
gener
hospit
chines
peopl
arm
polic
forc
beij
china
object
studi
aim
investig
whether
express
candid
mirna
show
differ
plasma
rb
patient
healthi
control
quantit
polymeras
chain
reaction
also
discuss
relationship
plasma
mirna
clinic
characterist
rb
patient
evalu
valu
plasma
mirna
distinguish
rb
patient
healthi
control
method
studi
collect
plasma
sampl
rb
patient
anoth
sampl
healthi
peopl
control
microrna
level
measur
via
quantit
polymeras
chain
reaction
rel
retinoblastoma
test
statist
data
analysi
receiv
oper
characterist
roc
curv
result
plasma
patient
sampl
auc
rang
combin
classifi
less
conclus
plasma
mirna
level
show
import
rb
diagnos
regard
novel
diagnos
biomark
especi
present
outcom
retinoblastoma
rb
develop
countri
experi
singl
institut
f
naz
mir
khan
h
saeed
pediatr
oncolog
shaukat
khanum
memori
cancer
hospit
research
centr
lahor
pakistan
object
pakistan
incid
rb
children
limit
inform
outcom
object
studi
review
present
featur
outcom
rb
tertiari
care
cancer
center
pakistan
method
conduct
retrospect
review
patient
treat
skmch
rc
rb
januari
demograph
present
featur
treatment
detail
outcom
collect
analyz
use
spss
result
patient
studi
n
unilater
diseas
median
age
present
year
male
femal
ratio
median
time
present
month
common
present
symptom
leukocoria
forti
percent
n
report
loss
vision
time
present
almost
half
patient
underw
upfront
enucl
extraocular
diseas
present
distant
metastas
cut
end
optic
nerv
involv
patient
scleral
involv
show
choroid
involv
anterior
chamber
involv
lamina
cribrosa
invas
twelv
percent
n
abandon
initi
therapi
requir
chemotherapi
wherea
other
treat
cycl
chemotherapi
carboplatinvincristineetoposid
half
patient
intraocular
diseas
eye
salvag
possibl
overal
surviv
year
event
free
surviv
significantli
better
p
patient
without
cut
end
involv
vs
term
global
surviv
patient
unilater
diseas
underw
enucl
case
bilater
diseas
lost
one
eye
wherea
underw
bilater
enucl
conclus
global
overal
surviv
patient
much
lower
report
literatur
may
relat
advanc
stage
advers
histolog
featur
due
delay
present
retinoblastoma
indian
children
clinic
profil
predictor
metastasi
r
seth
singh
b
chawla
thoma
pediatr
india
institut
medic
scienc
delhi
india
ophthalmolog
india
institut
medic
scienc
delhi
india
object
retinoblastoma
common
primari
intraocular
malign
children
tumor
highli
curabl
intraocular
develop
countri
rate
ocular
salvag
patient
surviv
low
sinc
diagnosi
delay
object
determin
burden
clinic
profil
retinoblastoma
tertiari
center
india
ascertain
risk
factor
metastasi
retinoblastoma
common
primari
intraocular
malign
children
tumor
highli
curabl
intraocular
develop
countri
rate
ocular
salvag
patient
surviv
low
sinc
diagnosi
delay
object
determin
burden
clinic
profil
retinoblastoma
tertiari
center
india
ascertain
risk
factor
metastasi
method
retrospect
analysi
case
record
newli
diagnos
patient
retinoblastoma
period
month
done
clinic
profil
ascertain
reason
delay
present
risk
factor
metastasi
identifi
result
patient
retinoblastoma
diagnos
studi
period
patient
eye
extraocular
retinoblastoma
non
metastat
major
children
eorb
year
age
bilater
involv
seen
case
f
ratio
major
belong
low
socio
econom
strata
famili
histori
seen
case
case
bilater
involv
leukocoria
commonest
present
follow
squint
proptosi
conclus
extraocular
involv
seen
case
children
year
age
major
present
proptosisexopyt
mass
children
eorb
bilater
diseas
develop
metastat
diseas
delay
diagnosi
risk
factor
metastasi
ignor
behalf
parent
delay
referr
behalf
gener
practitionerpediatrician
refus
medic
advic
lead
delay
diagnosi
poor
treatment
outcom
correl
high
mobil
group
protein
histopatholog
high
risk
factor
retinoblastoma
mk
singh
kashyap
l
singh
n
pushker
sen
sharma
ocular
patholog
india
institut
medic
scienc
delhi
india
ophthalmolog
india
institut
medic
scienc
delhi
india
ocular
microbiolog
india
institut
medic
scienc
delhi
india
object
retinoblastoma
malign
tumor
compos
embryon
tumor
cell
retinoblast
neuroepitheli
origin
import
chromatin
protein
protein
organ
dna
regul
transcript
associ
cell
prolifer
differenti
neoplast
transform
howev
role
still
unclear
retinoblastoma
method
prospect
analys
primari
enucl
retinoblastoma
case
period
one
year
includ
express
perform
immunohistochemistri
ihc
formalin
fix
retinoblastoma
specimen
mrna
express
perform
revers
transcriptas
pcr
result
total
eye
taken
eye
bilater
involv
age
rang
case
report
poorli
differenti
tumor
wherea
case
necrosi
calcif
respect
histopatholog
massiv
choroid
invas
optic
nerv
invas
case
sclera
ciliari
bodi
invas
strong
express
seen
case
perform
case
case
show
mrna
express
express
statist
signific
poor
differenti
p
optic
nerv
invas
p
hrf
p
conclus
express
frequent
found
poorli
differenti
tumor
histopatholog
high
risk
factor
could
serv
poor
prognost
marker
retinoblastoma
understand
molecular
mechan
underli
function
could
yield
novel
therapeut
approach
strategi
evalu
cerebrospin
fluid
retinoblastoma
use
cytolog
immunocytolog
molecular
marker
sobrero
v
laurent
j
rossi
torbidoni
c
romero
c
sampor
eandi
g
chantada
hemato
oncolog
hospit
de
prof
dr
juan
p
garrahan
bueno
air
argentina
hemato
oncolog
hospit
de
pediatria
prof
dr
juan
p
garrahan
bueno
air
argentina
hemato
oncolog
conicet
bueno
air
argentina
object
evalu
role
immunocytolog
gangliosid
synthas
cone
transcript
factor
crx
confirm
malign
minim
dissemin
md
method
csf
evalu
done
diagnosi
children
irss
stage
trilater
diseas
high
risk
stage
case
extraocular
relaps
clinic
suspect
morpholog
evalu
csf
done
immunocytolog
done
confirm
case
pleocytosi
abnorm
cell
morpholog
examin
result
posit
csf
detect
children
high
risk
stage
md
one
cn
relaps
occur
child
neg
md
nineteen
children
stage
cn
relaps
occur
md
patient
stage
ivb
trilater
diseas
relaps
minim
diseas
one
patient
stage
cn
relaps
delay
enucl
problem
complianc
overal
posit
diagnost
csf
examin
obtain
moment
csf
relaps
symptomat
patient
nine
posit
cytolog
confirm
immunocytolog
inconclus
cytolog
posit
immunocytolog
evalu
crx
children
molecular
detect
md
preced
cn
relaps
conclus
case
posit
inconclus
csf
examin
use
immunocytolog
pcr
crx
may
improv
diagnost
accuraci
md
may
detect
children
advanc
diseas
correl
increas
risk
csf
relaps
predict
valu
tnm
classif
intern
classif
stage
retinoblastoma
likelihood
high
risk
patholog
featur
yousef
sultan
hijja
jaradat
mehyar
r
deebajah
k
rawashdeh
khurma
nawaiseh
depart
surgeri
king
hussein
cancer
center
amman
jordan
depart
patholog
king
hussein
cancer
center
amman
jordan
depart
pediatr
king
hussein
cancer
center
amman
jordan
depart
radiotherapi
king
hussein
cancer
center
amman
jordan
object
evalu
predict
valu
edit
american
joint
committe
cancerth
union
intern
cancer
control
ajccuicc
tnm
classif
intern
classif
icrb
stage
retinoblastoma
rb
likelihood
high
risk
patholog
featur
hrf
eye
treat
primari
enucl
method
retrospect
observ
case
seri
eye
patient
patholog
confirm
rb
enucl
primari
therapi
review
medic
record
patholog
report
imag
main
outcom
measur
includ
demograph
later
tnm
stage
icrb
group
stage
choroid
invas
optic
nerv
invas
anterior
chamber
invas
scleral
invas
result
median
age
enucl
month
patient
male
patient
bilater
rb
hrf
mandat
adjuv
chemotherapi
seen
eye
eye
p
icrb
group
c
eye
group
eye
group
e
eye
p
stage
tumor
higher
incid
hrf
upstag
eye
twenti
patient
receiv
adjuv
chemotherapi
hrf
median
follow
month
singl
case
metastasi
dead
conclus
higher
ajccuicc
stage
diseas
advanc
iirc
group
present
associ
higher
incid
hrf
case
stage
system
larg
tumor
occupi
globe
consid
icrb
group
e
rather
group
b
sinc
higher
incid
hrf
paclitaxel
relaps
refractori
pediatr
bone
soft
tissu
sarcoma
b
aydin
c
akyuz
kutluk
varan
b
yalcin
pediatr
oncolog
hacettep
institut
oncolog
ankara
turkey
object
given
poor
outcom
relapsedrefractori
soft
tissu
bone
sarcoma
retrospect
review
result
paclitaxel
cyclophosphamid
carboplatin
pcc
regimen
evalu
effect
outcom
method
file
children
diagnos
rhabdomyosarcoma
n
ewe
sarcoma
n
malign
mesenchym
tumor
n
treat
pcc
regimen
relapsedrefractori
diseas
retrospect
result
median
age
male
femal
year
rang
median
ef
first
event
month
pcc
regimen
use
patient
patient
regimen
patient
patient
receiv
median
cours
either
pcc
patient
altern
reduc
dose
vac
regimen
vincristin
dactinomycin
cyclophosphamid
patient
object
respons
rate
cr
vgpr
sd
five
patient
progress
diseas
median
ef
os
pcc
month
month
month
month
ef
os
rate
patient
median
ef
pcc
altern
regimen
month
p
conclus
relaps
refractori
soft
tissu
bone
sarcoma
dismal
prognosi
paclitaxel
might
altern
patient
although
patient
number
low
conclud
pcc
altern
reduc
dose
vac
might
better
respons
rate
studi
warrant
treatment
outcom
genitourinari
rhabdomyosarcoma
year
experi
fadel
kamal
yousef
hanoo
pediatr
oncolog
faculti
medicin
alexandria
egypt
pediatr
urolog
faculti
medicin
alexandria
egypt
object
genitourinari
rhabdomyosarcoma
special
entiti
need
complex
treatment
algorithm
chemotherapi
surgeri
radiotherapi
impact
diseas
control
long
term
outcom
aim
retrospect
review
genitourinari
rhabdomyosarcoma
outcom
limit
resourc
countri
method
retrospect
review
made
clinic
record
patient
younger
age
year
diagnos
genitourinari
rm
treat
alexandria
univers
hospit
period
year
primari
outcom
examin
overal
surviv
secondari
outcom
local
recurr
progress
free
surviv
rate
calcul
toxic
advers
effect
follow
treatment
evalu
nation
cancer
toxic
criteria
version
result
twenti
patient
histolog
confirm
gu
rm
age
present
vari
month
year
median
year
male
femal
median
follow
entir
group
approxim
year
rang
initi
therapi
common
primari
tumor
site
bladder
prostat
patient
paratesticular
retroperotineum
uteru
cervix
vagina
patient
present
ir
group
iii
diseas
patient
treat
accord
siop
mmt
protocol
remain
patient
treat
accord
irsg
protocol
iv
end
studi
patient
show
evid
diseas
case
show
recurr
grade
toxic
diarrhea
febril
case
die
one
case
die
due
sever
febril
neutropenia
die
advanc
diseas
conclus
result
limit
resourc
countri
close
publish
data
multimod
treatment
appli
surviv
factor
affect
outcom
synovi
sarcoma
children
adolesc
h
hafiz
e
elnadi
h
taha
youn
ms
zaghloul
elwakeel
ahm
g
taha
r
labib
pediatr
oncolog
children
cancer
cairo
egypt
surgic
patholog
children
cancer
cairo
egypt
surgeri
children
cancer
cairo
egypt
radiotherapi
children
cancer
cairo
egypt
radiodiagnosi
children
cancer
cairo
egypt
research
children
cancer
cairo
egypt
object
evalu
impact
clinicopatholog
featur
diagnosi
treatment
given
outcom
synovi
sarcoma
children
adolesc
method
retrospect
analysi
patient
year
old
diagnos
synovi
sarcoma
treat
children
cancer
hospit
egypt
cche
juli
may
clinic
characterist
patholog
inform
treatment
modal
surviv
data
review
result
seventeen
patient
includ
median
age
diagnosi
year
common
affect
primari
site
extrem
n
tumor
size
less
equal
cm
case
initi
surgic
excis
feasibl
patient
patient
underw
surgic
excis
respons
preoper
chemotherapi
two
patient
unresect
tumor
show
respons
chemotherapi
receiv
radiotherapi
local
control
therapi
adjuv
radiotherapi
given
patient
patient
receiv
chemotherapi
without
local
radiotherapi
patient
receiv
modal
estim
overal
surviv
failur
free
surviv
rate
entir
group
respect
ff
better
patient
underw
complet
surgic
excis
either
initi
post
chemotherapi
versu
gross
microscop
residu
also
failur
free
surviv
versu
smaller
equal
cm
larger
cm
respect
conclus
tumor
size
complet
surgic
excis
import
prognost
factor
though
statist
insignific
preoper
chemotherapi
help
delay
excis
patient
present
initi
unresect
tumor
local
rhabdomyosarcoma
head
neck
retrospect
analysi
patient
treat
tertiari
care
centr
india
n
iqbal
thakar
agarwala
dn
sharma
mc
sharma
bakhshi
medic
oncolog
india
institut
medic
scienc
delhi
india
ent
india
institut
medic
scienc
delhi
india
pediatr
surgeri
india
institut
medic
scienc
delhi
india
radiat
oncolog
india
institut
medic
scienc
delhi
india
patholog
india
institut
medic
scienc
delhi
india
object
rhabdomyosarcoma
rm
common
sarcoma
children
howev
rare
adult
head
neck
site
account
rm
studi
aim
retrospect
review
factor
treatment
outcom
prognost
factor
patient
local
rm
head
neck
treat
centr
method
data
pertain
patient
report
databas
local
rm
head
neck
diagnos
may
dec
retriev
factor
evalu
age
histolog
site
tumor
size
stage
risk
intergroup
rhabdomyosarcoma
studi
ir
group
surviv
estim
determin
use
surviv
time
end
point
event
death
caus
result
median
age
year
median
symptom
durat
month
male
constitut
femal
male
femal
ratio
primari
site
tumor
orbit
paramening
median
tumor
size
cm
rang
cm
common
histolog
embryon
case
percent
patient
stage
iii
intermedi
risk
ir
group
iii
percent
patient
receiv
year
ef
os
respect
univari
surviv
analysi
found
intermedi
risk
group
patient
wors
ef
compar
vs
p
stage
iii
tumor
tumor
size
cm
trend
toward
poor
ef
p
valu
respect
none
factor
affect
overal
surviv
conclus
singl
center
experi
unselect
patient
surviv
cohort
less
compar
publish
data
west
intermedi
risk
significantli
associ
poor
ef
perhap
rel
larg
tumor
contribut
higher
failur
rate
malign
rhabdoid
tumor
soft
tissu
singl
center
experi
russia
kachanov
teleshova
usychkina
r
moiseenko
g
muftahova
mitrofanova
shamanskaya
varfolomeeva
clinic
oncolog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
patholog
feder
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
object
aim
studi
analyz
clinic
data
therapi
result
cohort
patient
malign
rhabdoid
tumor
soft
tissu
mrt
treat
feder
cancer
center
russian
feder
method
eight
patient
includ
analysi
treat
feder
research
center
pediatr
hematolog
oncolog
immunolog
period
analyz
age
diagnosi
primari
tumor
locat
stage
diseas
accord
intergroup
rhabdomyosarcoma
studi
criteria
diagnosi
establish
histopatholog
examin
confirm
lack
nuclear
express
patient
treat
accord
european
rhabdoid
tumor
registri
recommend
result
median
age
diagnosi
month
month
diagnosi
verifi
year
life
patient
case
day
life
f
ratio
topographi
primari
tumor
includ
liver
case
deep
soft
tissu
neck
case
abdomin
caviti
case
orbit
case
test
case
mutat
gene
identifi
patient
local
diseas
patient
distant
metastas
clinic
group
distribut
accord
ir
iii
patient
iv
case
initi
tumor
ruptur
case
intraop
tumor
ruptur
patient
outcom
patient
aliv
complet
therapi
undergo
therapi
patient
die
due
earli
progress
due
refractori
diseas
conclus
data
confirm
present
diseas
case
first
year
life
demonstr
unfavor
prognosi
due
advanc
stage
diseas
poor
respons
therapi
soft
tissu
sarcoma
clinic
analysi
three
case
rhabdomyosarcoma
bone
marrow
metastasi
x
li
hemotolog
center
bei
jing
children
hopspit
beij
china
object
investig
violat
children
rhabdomyosarcoma
bone
marrow
metastasi
clinic
characterist
treatment
outcom
method
retrospect
analyz
three
case
children
rhabdomyosarcoma
bone
marrow
metastasi
januari
decemb
result
three
patient
male
mean
age
year
year
month
year
old
novemb
accord
us
rhabdomyosarcoma
studi
group
ir
stage
criteria
patient
stage
iv
stage
clinic
group
group
primari
head
neck
two
case
primari
pelvic
caviti
retroperiton
area
buttock
mass
partial
occupi
oppress
caus
oliguria
anuria
patient
confirm
biopsi
immunohistochem
stain
confirm
histolog
type
includ
case
alveolar
type
one
case
embryon
clinic
manifest
mainli
tumor
tissu
mass
oppress
caus
invas
carri
strictli
accord
treatment
children
ir
instal
us
oncolog
research
center
use
group
cog
rhabdomyosarcoma
chemotherapi
one
case
tumor
progress
treatment
month
one
case
treatment
one
year
chemotherapi
surgeri
radiotherapi
autolog
stem
cell
transplant
relaps
one
case
accept
chemotherapi
year
later
recurr
current
surviv
one
case
conclus
children
bone
marrow
involv
rhabdomyosarcoma
earli
diagnosi
difficult
gener
poor
specif
clinic
featur
often
misdiagnos
hematolog
malign
complic
often
associ
renal
failur
variou
seriou
infect
poor
prognosi
surviv
rate
low
chemotherapi
combin
surgeri
radiotherapi
stem
cell
transplant
combin
therapi
effect
treatment
control
diseas
treatment
scheme
requir
discuss
success
treatment
scleros
rhabdomyosarcoma
patient
duchenn
muscular
dystrophi
r
mehrotra
smith
f
j
panick
pediatr
univers
kansa
medic
center
kansa
citi
usa
object
year
old
male
duchenn
muscular
dystrophi
dmd
clinic
stage
iii
scleros
rhabdomyosarcoma
srm
success
treat
surgeri
chemotherapi
radiat
method
patient
present
one
month
histori
pain
thigh
mass
stage
studi
show
heterogen
mass
cm
within
left
rectu
femori
muscl
local
region
node
involv
tumor
biopsi
sentinel
node
dissect
show
scleros
rhabdomyosarcoma
treatment
consist
week
vincristin
cyclophosphamid
actinomycin
cardiac
monitor
picu
tumor
resect
follow
radiat
tumor
bed
nodal
site
addit
chemotherapi
total
week
anthracyclin
avoid
due
underli
cardiac
dysfunct
result
week
chemotherapi
tumor
mass
show
metabol
activ
pet
scan
compar
suv
present
resect
tumor
cm
show
excel
patholog
respons
chemotherapi
less
viabl
tumor
cell
patient
toler
therapi
well
episod
fever
neutropenia
need
parenter
nutrit
blood
product
support
experi
signific
deterior
neuromuscular
cardiac
function
treatment
conclus
patient
dmd
develop
rm
success
treatment
accomplish
coordin
treatment
plan
oncologist
oncolog
surgeon
picu
radiat
therapi
occid
mexico
rhabdomyosarcoma
rm
experi
slight
improv
lot
work
xa
j
fa
servicio
de
oncologia
hematologia
pediatrica
hospit
civil
de
guadalajara
guadalajara
mexico
object
identifi
clinic
characterist
event
free
surviv
global
surviv
patient
occid
mexico
rm
method
studi
review
children
electron
chart
rm
institut
treat
intergroup
rhabdomyosarcoma
studi
group
irsg
iii
iv
regimen
result
median
age
diagnosi
year
rang
year
geograph
characterist
patient
jalisco
mexico
accord
irsg
classif
stage
lr
ir
hr
unknown
patient
primari
site
tumor
trunk
retroperitoneum
n
head
neck
n
paramening
n
orbit
n
genitourinari
n
paratesticular
n
extrem
n
histopatholog
n
embrionari
alveolar
n
bothroyd
n
anaplast
n
unknown
n
irsg
group
local
diseas
microscop
residu
diseas
group
ii
group
iii
incomplet
resect
biopsi
macroscop
residu
group
iv
distant
metastas
receiv
radiotherapi
n
radiotherapi
n
time
studi
aliv
activ
aliv
without
activ
die
diseas
die
differ
caus
abandon
transfer
anoth
unit
diseas
risk
group
year
event
free
surviv
ef
lr
group
diseas
surviv
month
ir
hr
global
surviv
gs
lr
month
ir
hr
conclus
comparison
ef
slight
improv
outcom
patient
rm
occid
mexico
improv
come
togeth
cooper
group
provid
best
care
improv
commun
multidisciplinari
team
collabor
wilm
tumor
treatment
outcom
multidisciplinari
pediatr
cancer
center
lebanon
w
rabeh
akel
muwakkit
abboud
h
el
solh
r
saab
children
cancer
institut
american
univers
beirut
beirut
lebanon
depart
surgeri
american
univers
beirut
beirut
lebanon
object
approach
treatment
wilm
tumor
wt
differ
european
school
advoc
neoadjuv
chemotherapi
north
american
school
favor
upfront
tumor
resect
children
cancer
institut
lebanon
approach
wt
follow
north
american
protocol
sinc
use
multidisciplinari
approach
diagnosi
treatment
plan
review
clinic
outcom
patient
wt
identifi
prognost
determin
outcom
method
irb
approv
retrospect
review
clinic
record
patient
wt
treat
hospit
april
june
result
studi
includ
children
male
femal
ratio
mean
age
year
eight
patient
stage
diseas
stage
ii
diseas
stage
iii
diseas
stage
iv
diseas
stage
v
tumor
treatment
per
north
american
nwt
protocol
upfront
resect
done
case
biopsi
perform
stage
v
tumor
n
tumor
associ
ivc
thrombu
n
local
extens
tumor
deem
unresect
n
patient
subtot
resect
prior
referr
n
time
analysi
patient
free
diseas
median
month
diagnosi
rang
month
four
patient
relaps
median
time
month
rang
month
four
initi
metastat
diseas
one
patient
develop
chronic
renal
failur
treatment
conclus
nwt
protocol
result
favor
outcom
children
wilm
tumor
set
multidisciplinari
approach
therapi
observ
rel
high
incid
patient
bilater
find
suggest
need
studi
genet
molecular
level
group
patient
lymphocyt
reconstitut
prognost
factor
sarcoma
sobrino
c
mata
e
ruiz
de
leon
j
cayrol
r
herrainz
cristob
c
gonzalez
sansegundo
j
huerta
e
cela
de
c
garrido
colino
c
bielez
pediatr
depar
hospit
gener
universitario
gregorio
madrid
spain
object
lymphocyt
reconstitut
identifi
prognost
factor
malign
tri
determin
earli
lymphocyt
recoveri
predictor
surviv
cohort
paediatr
patient
type
sarcoma
receiv
chemotherapi
method
children
diagnos
sarcoma
treat
chemotherapi
institut
retrospect
evalu
chemotherapi
appli
accord
intern
protocol
current
demograph
hematolog
relat
treatment
data
collect
result
data
pediatr
sarcoma
patient
analyz
median
age
male
femal
diagnosi
ewe
sarcomapnet
osteosarcoma
rhabdomyosarcoma
non
tissu
sarcoma
six
metastat
diagnosi
surgeri
done
receiv
type
radiotherapi
includ
intraop
radiotherapi
five
year
overal
surviv
aliv
deceas
good
histolog
respons
time
resect
found
patient
poor
histolog
respons
patient
classifi
patient
two
group
accord
threshold
absolut
lymphocyt
count
day
start
chemotherapi
patient
cell
l
l
although
differ
statist
signific
p
analyz
separ
tumor
data
rhabdomyosarcoma
l
aliv
year
diagnosi
l
die
diseas
p
conclus
despit
limit
small
studi
support
role
lymphocyt
recoveri
paediatr
sarcoma
potenti
use
risk
stratif
initi
therapi
addit
need
inmun
reconstitut
treatment
strategi
soft
tissu
sarcoma
nrst
studi
singapor
e
tan
p
iyer
sy
soh
paediatr
haematologyoncolog
kkh
singapor
singapor
object
soft
tissu
sarcoma
nrst
repres
childhood
cancer
though
use
adult
data
directli
translat
children
paediatr
entiti
shown
differ
biolog
treatment
respons
outcom
report
experi
nrst
largest
public
paediatr
hospit
singapor
method
retrospect
analysi
children
nrst
diagnos
conduct
data
patient
demograph
tumour
characterist
treatment
surviv
statu
obtain
singapor
children
cancer
registri
review
case
record
studi
approv
institut
review
board
result
median
age
diagnosi
year
rang
year
male
femal
ratio
differ
type
tumour
seen
infantil
fibrosarcoma
n
malign
peripher
nerv
sheath
tumour
mpnst
n
fibrou
histiocytoma
n
leiomyosarcoma
n
alveolar
soft
part
sarcoma
asp
n
hemangioblastoma
n
spindl
cell
sarcoma
n
myofibroblast
sarcoma
n
rhabdoid
tumour
n
embryon
sarcoma
n
angiosarcoma
n
stage
done
accord
irsg
except
one
describ
seven
stage
four
stage
seven
stage
three
stage
patient
underw
tumour
resect
nine
chemotherapi
three
patient
receiv
neoadjuv
chemotherapi
five
receiv
radiotherapi
median
year
three
patient
relaps
within
first
year
time
analysi
sixteen
patient
surviv
seven
stage
four
stage
three
stage
two
stage
diseas
six
patient
mpnst
myofibroblast
sarcoma
malign
rhabdoid
tumour
hemangioblastoma
spindl
cell
sarcoma
conclus
spectrum
nrst
seen
show
great
heterogen
histolog
surviv
outcom
good
multidisciplinari
treatment
uniform
approach
vital
treat
heterogen
group
tumour
epithelioid
angiosarcoma
colon
rare
case
report
infant
rap
teixeira
jq
rh
baroni
rz
filippi
j
oba
pediatria
instituto
da
tratamento
infantil
hc
sao
paulo
brazil
cirurgia
hospit
albert
einstein
sao
paulo
brazil
radiologia
hospit
albert
einstein
sao
paulo
brazil
de
patologia
hospit
albert
einstein
sao
paulo
brazil
gastroenterologia
hospit
albert
einstein
sao
paulo
brazil
object
epithelioid
angiosarcoma
ea
rare
tumor
affect
children
usual
occur
liver
extrem
mesenter
angiosarcoma
occur
infant
rare
report
report
case
colon
ea
affect
femal
child
emphas
clinic
featur
difficult
manag
brief
review
literatur
method
femal
present
histori
intestin
bleed
associ
pale
inadequ
weight
gain
perin
dermat
initi
dairi
allergi
consid
howev
intestin
bleed
persist
infant
hospit
investig
result
imag
find
us
ct
show
mass
cecum
extend
mesenteri
small
liver
lung
nodul
also
found
surgeri
perform
complet
resect
tumor
anatomopatholog
result
show
x
x
cm
hemorrhag
tumor
involv
colon
necrosi
classifi
high
grade
sarcoma
surgic
margin
ea
confirm
immunohistochemistri
strong
reactiv
endothelium
marker
neg
marker
tumor
infant
undergon
four
chemotherapi
cycl
ifosfamid
adriamycin
disappear
pulmonari
node
sign
tumor
found
surgeri
also
liver
node
biopsi
two
equal
chemotherapi
cycl
month
therapi
excel
recoveri
normal
ct
imag
without
sign
relaps
conclus
angiosarcoma
rare
tumor
vascular
endothelium
cell
origin
may
occur
anywher
bodi
occurr
gastrointestin
tract
quit
uncommon
case
report
medic
literatur
unfavor
outcom
best
knowledg
first
report
case
child
bellow
one
year
age
good
respons
nation
treatment
protocol
pediatr
patient
soft
tisu
sarcoma
nation
institut
pediatr
mexico
experi
r
cardena
l
velasco
j
shalkow
zapata
melchor
gonzalez
r
oncolog
nation
institut
pediatr
mexico
citi
mexico
feder
director
pediatr
cancer
program
nation
center
pediatr
adolesc
health
mexico
citi
mexico
research
nation
institut
pediatr
mexico
citi
mexico
head
divis
oncolog
nation
institut
pediatr
mexico
citi
mexico
object
soft
tisu
sarcoma
nrmsst
infrequ
malign
tumor
children
treatment
depend
histolog
biolog
behaviour
stage
mexico
implement
nation
treatment
protocol
entiti
seven
year
ago
present
herein
result
obtain
nation
institut
pediatr
method
studi
cohort
patient
nrmsst
januari
januari
patient
categor
high
low
risk
accord
clinic
histolog
featur
depend
risk
stratif
treatment
includ
surgeri
radiotherapi
without
cycl
ifosfamid
doxorrubicin
result
patient
median
age
year
male
ratio
median
time
first
symptom
arriv
depart
month
frequent
histolog
type
peripher
nerv
sheath
tumor
pnst
sinovi
sarcoma
ss
everi
patient
underw
surgic
resect
primari
tumor
receiv
radiotherapi
sixteen
patient
categor
thu
reciv
chemotherapi
overal
surviv
howev
group
surviv
compar
surviv
rate
group
p
tabl
conclus
nrmsst
heterogen
group
neoplasm
prognosi
depend
histolog
stage
patient
surgeri
radiotherapi
alon
offer
good
chanc
surviv
howev
patient
prognosi
remain
dismal
spite
multimod
therapi
new
treatment
strategi
requir
group
patient
malign
rhabdoid
tumor
posterior
bladder
sever
local
relaps
mo
candir
c
bozkurt
yesil
g
tanyildiz
toprak
g
sahin
pediatr
oncolog
dr
sami
ulu
pediatr
research
train
hospit
ankara
turkey
object
malign
rhabdoid
tumor
gener
characteris
aggres
overal
surviv
approxim
sugic
resect
one
supressor
gene
exon
mutat
delet
could
found
kind
tumor
tissu
central
nervou
urinari
system
frequent
involv
involv
could
seen
thorax
liver
cervic
region
axilla
multimod
therapi
combin
surgic
resect
best
treatment
option
method
present
case
diagnos
malign
rhabdoid
tumor
posterior
bladder
repres
renal
failur
year
old
year
old
local
relaps
five
time
exprienc
sever
surgic
intervent
result
rhabdomyosarcoma
protocol
firstli
initi
vincristin
adriamicyn
topotecan
protocol
vinorelbin
cytarabin
protocol
oral
etoposid
protocol
use
last
relaps
surgeri
total
cgi
dosag
radiotherapi
appli
follow
end
firstli
use
rhabdomyosarcoma
protocol
patholog
immunhistochem
examin
tumor
tissu
resect
materi
reveal
mutat
conclus
case
remiss
repeat
eight
cure
gemcitabin
combin
docetaxel
therapi
surgeri
compar
studi
pediatr
adult
patient
rhabdomyosarcoma
q
zhao
jf
wang
zy
li
depart
pediatr
oncolog
tianjin
medic
univers
cancer
institut
hospit
tianjin
china
object
compar
prognost
factor
clinic
differ
pediatr
adult
rhabdomyosarcoma
method
review
clinic
data
patient
diagnos
rm
patholog
complet
data
januari
hospit
pediatr
patient
adult
patient
result
surviv
rate
pediatr
group
respect
signific
statist
differ
show
pediatr
group
adult
group
factor
histolog
subtyp
primari
site
distant
metastasi
test
conclus
prognosi
adult
rhabdomyosarcoma
significantli
wors
pediatr
tumor
differ
histolog
subtyp
primari
site
distant
metastas
two
group
respons
outcom
patient
solid
tumor
first
event
nassan
awadi
sultan
pediatr
king
hussien
cancer
center
amman
jordan
object
limit
public
avail
regard
outcom
pediatr
patient
solid
tumor
first
event
recogn
outcom
group
patient
help
select
patient
may
benefit
treatment
improv
util
palli
care
method
retrospect
chart
review
patient
regist
pond
databas
king
hussein
cancer
center
till
event
defin
relaps
progress
refractori
diseas
patient
death
first
event
exclud
result
among
patient
solid
tumor
femal
experienc
event
median
month
rang
diagnosi
median
age
relaps
year
rang
common
diseas
categori
bone
tumor
neuroblastoma
soft
tissu
sarcoma
renal
tumor
overal
surviv
whole
group
overal
surviv
differ
diseas
categori
follow
bone
tumor
neuroblastoma
soft
tissu
sarcoma
renal
tumor
find
signific
differ
patient
receiv
receiv
multiag
chemotherapi
term
surviv
andth
last
report
pain
score
patient
receiv
chemotherapi
like
spend
less
time
hospit
earlier
placement
dnr
order
conclus
find
studi
import
highlight
import
earli
palli
care
group
patient
burden
treatment
famili
unit
justifi
case
open
clinic
trial
avail
pediatr
palli
program
implement
home
care
jordan
nassan
sh
awadi
ih
mezher
jmean
wawi
hmood
sultan
pediatr
king
hussien
cancer
center
amman
jordan
object
pediatr
palli
care
decreas
pain
suffer
children
cancer
famili
also
decreas
burden
busi
unit
allow
treat
patient
home
care
essenti
extens
import
servic
method
start
home
care
servic
attach
pediatr
palli
care
program
driver
nurs
social
worker
made
daili
visit
prepar
list
patient
vist
vari
durat
hour
base
patient
need
frequenc
individu
patient
vari
accord
specif
need
month
start
home
care
visit
data
collect
visit
nurs
use
data
collect
sheet
data
collect
includ
demograph
diseas
data
home
care
issu
famili
social
issu
result
patient
includ
analysi
femal
patient
cn
tumor
solid
tumor
major
refer
patient
referr
major
patient
pain
well
control
n
use
one
medic
emerg
room
visit
median
per
patient
hospit
admiss
day
median
minim
reflect
satisfact
home
care
six
patient
need
enter
feed
nasogastr
peg
tube
two
patient
need
intens
wound
care
deep
ulcer
three
patient
refer
back
center
palli
procedur
tracheostomi
vp
shunt
placement
note
famili
repres
typic
social
statu
jordan
median
incom
jd
us
per
month
median
famili
size
conclus
home
care
essenti
even
countri
enhanc
servic
palli
care
limit
resourc
abl
demonstr
success
implement
servic
impact
qualiti
life
patient
home
minim
util
servic
center
composit
advers
event
outcom
prolong
febril
neutropen
pediatr
cancer
patient
mm
alam
naqvi
belgumi
z
fadoo
pediatr
child
health
aga
khan
univers
hospit
karachi
pakistan
pediatr
hematologyoncolog
sick
kid
toronto
canada
pediatr
hematologyoncolog
kfsh
rc
riyadh
saudi
arabia
pediatr
hematologyoncolog
aga
khan
univers
hospit
karachi
pakistan
object
pediatr
cancer
patient
pcp
prolong
neutropenia
increas
risk
sever
recurr
new
bacteri
fungal
infect
advers
outcom
aim
studi
identifi
risk
factor
associ
advers
outcom
group
method
studi
retrospect
analysi
clinic
data
pcp
prolong
febril
neutropenia
pfn
tertiari
health
care
center
pakistan
result
analyz
hospit
pcp
pfn
mean
age
year
male
mean
durat
day
day
acut
leukemia
common
diagnosi
follow
lymphoma
solid
tumor
caus
neutropenia
identifi
patient
bsi
pneumonia
fungal
infect
infecti
diarrhea
uti
patient
sever
myelosuppress
composit
advers
event
outcom
observ
patient
mortal
occur
picu
admiss
occur
inotrop
support
requir
logist
regress
analysi
cancer
type
aml
aor
confid
interv
p
cm
aor
ci
p
platelet
count
cm
aor
ci
p
bsi
aor
ci
p
fungal
infect
aor
ci
p
found
independ
risk
factor
associ
develop
composit
ae
outcom
pcp
pfn
conclus
aml
sever
myelosuppress
blood
stream
infect
fungal
infect
identifi
risk
factor
associ
develop
advers
event
outcom
pcp
pfn
prospect
studi
larg
cooper
trial
may
benefici
evalu
risk
factor
febril
neutropenia
pediatr
cancer
patient
experi
tertiari
health
care
facil
pakistan
mm
alam
qureshi
r
matloob
channa
n
mushtaq
z
fadoo
pediatr
child
health
aga
khan
univers
hospit
karachi
pakistan
object
febril
neutropenia
fn
common
complic
therapi
among
children
cancer
aim
studi
describ
demograph
clinic
featur
laboratori
data
manag
outcom
fn
pediatr
cancer
patient
method
studi
retrospect
analysi
clinic
data
pediatr
cancer
patient
febril
neutropenia
tertiari
health
care
facil
pakistan
result
analyz
hospit
pediatr
cancer
patient
fn
mean
age
studi
popul
year
male
femal
n
common
diagnosi
follow
aml
n
lymphoma
n
sarcoma
n
caus
neutropenia
identifi
patient
urti
n
bsi
n
pneumonia
n
infecti
diarrhea
n
uti
n
age
less
year
p
aml
p
patient
receiv
chemotherapi
within
week
fn
p
sever
neutropenia
anc
cm
p
platelet
count
cm
p
fungal
infect
p
day
pediatr
cancer
patient
total
patient
requir
picu
admiss
overal
patient
expir
outcom
variabl
statist
signific
regard
picu
admiss
vs
p
mortal
rate
vs
p
patient
prolong
fn
versu
fn
respect
conclus
younger
age
aml
sever
myelosuppress
fungal
infect
pneumonia
identifi
risk
factor
associ
prolong
fn
outcom
regard
picu
admiss
mortal
wors
patient
prolong
fn
prolong
febril
neutropenia
risk
factor
outcom
pediatr
oncolog
patient
mm
alam
qureshi
r
matloob
z
fadoo
pediatr
child
health
aga
khan
univers
hospit
karachi
pakistan
object
pediatr
cancer
patient
febril
neutropenia
fn
increas
risk
sever
recurr
new
bacteri
fungal
infect
although
prompt
initi
empir
antibacteri
antibiot
lead
substanti
improv
morbid
mortal
infecti
complic
still
persist
aim
studi
describ
demograph
clinic
featur
laboratori
data
risk
factor
outcom
fn
pediatr
cancer
patient
method
studi
retrospect
analysi
clinic
data
pediatr
cancer
patient
fn
tertiari
health
care
center
pakistan
result
analyz
hospit
pediatr
cancer
patient
fn
mean
age
studi
popul
year
male
femal
common
diagnosi
follow
aml
lymphoma
sarcoma
caus
neutropenia
identifi
patient
urti
bsi
pneumonia
infecti
diarrhea
uti
addit
median
neutrophil
count
platelet
count
reveal
profound
myelosuppress
case
age
less
year
p
aml
p
patient
receiv
chemotherapi
within
week
fn
p
sever
neutropenia
anc
cm
p
platelet
count
cm
p
fungal
infect
p
day
pediatr
cancer
patient
total
patient
requir
picu
admiss
overal
patient
expir
outcom
variabl
statist
signific
regard
picu
admiss
mortal
rate
patient
prolong
fn
versu
fn
respect
conclus
younger
age
aml
sever
myelosuppress
fungal
infect
pneumonia
identifi
risk
factor
associ
develop
prolong
fn
outcom
regard
picu
admiss
mortal
wors
patient
prolong
fn
adren
insuffici
children
cancer
present
fever
neutropenia
bank
ce
teuffel
p
agyeman
g
hofer
k
leibundgut
ra
ammann
depart
pediatr
univers
bern
bern
switzerland
depart
pediatr
institut
infecti
diseas
univers
bern
bern
switzerland
object
detect
whether
children
cancer
suffici
adren
function
present
fever
neutropenia
fn
method
set
prospect
observ
studi
serum
sampl
pediatr
patient
cancer
present
fn
store
cortisol
concentr
measur
commerci
avail
elisa
correl
differ
clinic
characterist
includ
cumul
dose
past
corticosteroid
therapi
cortisol
concentr
nmoll
consid
insuffici
stress
fn
situat
studi
approv
institut
review
board
patient
abl
judg
legal
guardian
gave
written
inform
consent
prior
studi
entri
result
serum
sampl
avail
fn
episod
patient
age
year
patient
characterist
outcom
compar
patient
without
serum
sampl
freez
time
significantli
associ
cortisol
median
cortisol
nmoll
iqr
rang
concentr
nmoll
exact
ci
cumul
dose
corticosteroid
therapi
within
one
month
preced
fn
tendenti
associ
cortisol
spearman
rho
ci
p
earlier
dose
cortisol
significantli
associ
patient
characterist
temperatur
present
outcom
advers
event
durat
hospit
intraven
antimicrobi
therapi
conclus
present
fn
one
half
pediatr
patient
cancer
insuffici
adren
stress
respons
associ
past
corticosteroid
therapi
larger
prospect
studi
adren
respons
fn
warrant
influenc
differ
fever
definit
rate
fever
neutropenia
diagnos
children
cancer
ra
ammann
teuffel
p
agyeman
n
amport
k
leibundgut
depart
pediatr
univers
bern
bern
switzerland
depart
pediatr
institut
infecti
diseas
univers
bern
bern
switzerland
object
temperatur
limit
defin
fever
tldf
base
scarc
evid
studi
aim
determin
rate
fever
neutropenia
fn
episod
addit
diagnos
lower
versu
standard
tldf
method
singl
center
use
high
tldf
tympan
temperatur
limitstandard
pediatr
patient
treat
chemotherapi
cancer
observ
prospect
result
temperatur
measur
cbc
record
applic
lower
tldf
limitlow
rang
versu
limitstandard
simul
silicon
studi
approv
institut
review
board
patient
abl
judg
legal
guardian
gave
written
inform
consent
prior
studi
entri
result
patient
temperatur
measur
cbc
record
month
chemotherapi
virtual
appli
limitstandard
result
fn
diagnos
limitlow
addit
fn
record
poisson
rate
ratioadditionalstandard
lower
confid
bound
lower
limitlow
led
earlier
diagnosi
major
fn
median
hour
ci
addit
fn
diagnos
spontan
defervesc
without
specif
therapi
observ
realiti
conclus
lower
tldf
led
mani
addit
fn
diagnos
impli
overtreat
spontan
defervesc
observ
vast
major
question
high
tldf
efficaci
well
safe
remain
open
posaconazol
salvag
therapi
immunocompromis
children
malign
immun
defici
preliminari
report
anak
somer
sutcu
e
uysalol
bulut
hancerli
torun
karaman
n
salman
unuvar
z
karaka
pediatr
hematolog
oncolog
medipol
univers
medic
faculti
istanbul
turkey
pediatr
infecti
diseas
istanbul
univers
istanbul
medic
faculti
istanbul
turkey
pediatr
hematolog
oncolog
istanbul
univers
istanbul
medic
faculti
istanbul
turkey
pediatr
istanbul
univers
istanbul
medic
faculti
istanbul
turkey
object
posaconazol
extend
spectrum
triazol
invivo
invitro
activ
aspergillu
mainli
use
prophylaxi
immunocompromis
children
malign
present
five
case
refractori
andor
relaps
invas
pulmonari
aspergillosi
ipa
treat
posaconazol
salvag
therapi
method
five
patient
either
relaps
leukemia
chronic
granulomat
diseas
cgd
age
year
median
rang
treat
posaconazol
tid
po
ipa
resist
voriconazol
combin
therapi
day
month
till
radiolog
regress
andor
resolv
galactomannan
initi
diagnosi
base
clinic
symptom
weekli
galactomannan
survey
andor
radiolog
find
sever
immunocompromis
due
diseas
agress
treatment
includ
bmt
result
two
three
relaps
leukemia
patient
expir
day
month
initi
posaconazol
mainli
progress
underli
diseas
one
patient
respons
current
treatment
ipa
sinc
month
two
patient
cgd
respons
still
treatment
month
drug
well
toler
without
ant
conclus
antifung
posaconazol
might
effici
altern
salvag
therapi
pediatr
patient
resist
ipa
although
safe
drug
children
efect
depend
factor
like
state
underli
diseas
drug
absorbt
metabol
iv
formul
might
solv
problem
near
futur
support
care
chemotherapi
radiat
swish
swallow
glutamin
disaccharid
nutrit
supplement
reduc
mucos
improv
enter
nutrit
p
anderson
pediatr
levin
cancer
institut
charlott
usa
object
two
common
support
care
question
parent
patient
ask
food
diet
help
fight
cancer
recommend
nutrit
supplement
prior
evid
shown
glutamin
disaccharid
suspens
reduc
mucos
toxic
glutamin
supplement
diet
may
also
associ
less
cancer
growth
facilit
improv
lymphocyt
prolifer
immun
function
howev
time
write
prescript
glutamin
disaccharid
suspens
pharmaci
compound
tast
sucros
vehicl
cake
refriger
conveni
product
need
therefor
powder
contain
glutamin
sucros
trehalos
suspend
agent
orang
grape
flavor
healio
develop
method
glutamin
powder
http
healiosproductscom
scoop
contain
gm
glutamin
disaccharid
ad
water
swish
second
swallow
twiceday
chemotherapi
radiat
involv
mouth
throat
esophagu
result
rapid
facilit
uptak
glutamin
disaccharid
reach
peak
uptak
within
second
glutamin
suspend
water
poor
cellular
uptak
glutamin
disaccharid
suspens
success
reduc
mucos
toxic
cancer
therapi
pilot
differ
random
placebo
trial
includ
children
glutamin
suspens
need
also
complet
radiat
least
addit
day
probabl
facilit
heal
residu
damag
conclus
glutamin
disaccharid
supplement
develop
high
patient
accept
use
chemotherapi
andor
radiat
high
likelihood
caus
stomat
pharyng
andor
esophag
enter
nutrit
concern
care
provid
consid
recommend
safe
inexpens
nutrit
supplement
ration
support
care
measur
reduc
amelior
mucos
toxic
cancer
therapi
promot
better
enter
nutrit
chemotherapi
andor
radiat
establish
paediatr
palli
care
unit
noninadequ
facil
exist
challeng
opportun
p
bagai
l
crack
ahuja
h
ani
r
arora
qualiti
care
research
impact
new
delhi
india
medic
oncolog
max
hospit
new
delhi
india
object
kid
support
children
famili
time
diagnosi
cancer
treatment
surviv
reintegr
bereav
centr
across
india
children
access
palli
care
within
cancer
centr
india
order
address
need
cankid
set
dedic
palli
care
servic
children
delhi
vision
develop
model
cost
effect
paediatr
palli
care
support
pan
india
method
inpati
facil
open
new
delhi
august
close
major
cancer
centr
easi
access
public
transport
accommod
care
children
plu
attend
parent
creat
child
friendli
hygien
environ
essenti
order
nurs
children
undergo
chemotherapi
increas
risk
infect
educ
support
activ
programm
togeth
counsel
psycholog
support
physic
therapi
consid
core
compon
servic
provid
free
charg
result
first
year
oper
admiss
bed
occup
rang
around
admiss
less
day
children
need
stay
longer
month
male
femal
admit
support
sad
realiti
femal
neglect
even
end
life
conclus
cankid
palli
care
centr
fill
gap
cancer
center
inadequ
palli
care
facil
need
provid
hour
access
suitabl
train
medic
nurs
staff
compli
nurs
home
regul
palli
care
standard
prove
major
challeng
like
limit
develop
inpati
servic
favour
nurs
led
doctor
support
outpatientday
care
model
dissemin
pan
india
survey
immunis
practic
children
cancer
india
prabha
p
bagai
r
arora
qualiti
care
research
impact
new
delhi
india
medic
oncolog
max
hospit
new
delhi
india
object
children
cancer
treatment
immunosuppress
risk
infect
live
vaccin
mount
adequ
protect
respons
inactiv
vaccin
henc
immun
treatment
requir
special
consider
want
identifi
immun
practic
children
india
method
clinician
attend
indian
pediatr
oncolog
initi
meet
indian
pediatr
oncolog
group
meet
pediatr
section
indian
cancer
congress
invit
complet
questionnair
result
respond
institut
citi
public
sector
annual
caseload
new
patient
advis
inactiv
live
vaccin
advis
vaccin
cancer
treatment
child
recommend
hepat
b
vaccin
public
hospit
privat
hospit
p
annual
influenza
vaccin
public
hospit
privat
hospit
p
child
undergo
treatment
recommenc
vaccin
month
complet
treatment
revaccin
form
booster
continu
normal
schedul
continu
normal
schedul
repeat
entir
immun
schedul
measur
antibodi
level
decid
conclus
heterogen
immun
practic
children
cancer
develop
dissemin
immunis
guidelin
specif
india
children
undergo
complet
cancer
treatment
would
use
standard
practic
qualiti
life
children
cancer
treat
palli
care
qualit
studi
profession
percept
j
lahay
v
parent
duval
n
humbert
sultan
hemato
oncolog
chu
montreal
canada
hemato
oncolog
catholiqu
de
louvain
belgium
psycholog
de
sherbrook
longueuil
canada
hemato
oncolog
chu
de
montreal
canada
palli
care
chu
de
montreal
canada
object
steer
commite
canadian
cancer
societi
estim
peopl
age
diagnos
cancer
close
die
partli
due
deterior
health
statu
children
clinic
ethic
literatur
rais
question
valid
definit
qualiti
life
qol
children
palli
care
abil
profession
defin
evalu
qol
key
make
appropri
decis
trajectori
children
issu
although
concept
behind
adult
qol
palli
care
clarifi
subject
measur
case
pediatr
palli
care
object
describ
main
dimens
qol
context
pediatr
palli
care
base
profession
view
method
interview
conduct
profession
chu
depart
interview
guid
inspir
question
use
hind
al
qualit
studi
assess
children
cancer
perceiv
qol
interview
profession
ask
represent
qol
children
cancer
receiv
palli
care
base
past
experi
interview
data
analyz
use
themat
analysi
code
use
qdamineur
result
analysi
identifi
dimens
qol
context
follow
element
promin
aspect
social
relationship
physic
psycholog
health
statu
autonomi
unmet
need
pain
verbal
descript
profession
insist
preserv
abil
posit
behavior
emot
smile
play
etc
conclus
represent
profession
qol
context
mark
maintain
abil
includ
social
one
like
chang
time
make
possibl
develop
appropri
measur
evalu
qol
ill
children
patient
febril
neutropenia
upper
respiratori
tract
infect
identifi
viral
isol
nasopharyng
aspir
prospect
observ
studi
north
india
k
ananta
rao
sarkar
bansal
rk
ratho
trehan
rk
marwaha
pediatr
unit
dept
pediatr
advanc
pediatr
centr
postgradu
institut
medic
educ
research
chandigarh
india
virolog
postgradu
institut
medic
educ
research
chandigarh
india
object
aim
identifi
virus
nasopharyng
aspir
children
hematolog
malign
febril
neutropenia
upper
respiratori
tract
infect
method
hospit
children
treatment
hematolog
malign
febril
neutropenia
clinic
evid
upper
respiratori
tract
infect
rhinorrhea
andor
cough
enrol
patient
lower
respiratori
tract
infect
exclud
nasopharyng
aspir
obtain
patient
qualit
polymeras
chain
reaction
virus
respiratori
syncyti
viru
influenza
b
human
parainfluenza
human
metapneumoviru
result
studi
includ
children
receiv
antibiot
mean
age
year
rang
major
admiss
durat
fever
rang
day
mean
platelet
count
x
patient
mean
durat
hospit
day
rang
virus
isol
patient
common
identifi
viru
influenza
b
posit
case
follow
rsv
hmpv
two
coinfect
age
p
anc
p
phase
chemotherapi
p
durat
hospit
p
influenc
viral
posit
patient
posit
viral
isol
winterspr
compar
rest
year
p
none
influenza
virus
isol
summerautumn
procedur
nasopharyng
aspir
well
toler
transient
epistaxi
bacteri
organ
isol
blood
cultur
patient
complicationsdeath
conclus
children
febril
neutropenia
upper
respiratori
tract
infect
identifi
viral
isol
nasopharyng
aspir
along
steril
blood
cultur
trial
need
conduct
would
explor
option
earli
cessat
antibiot
select
group
patient
report
outcom
clinic
trial
randomis
clinic
trial
children
receiv
palli
end
life
care
c
barton
l
brook
paediatr
oncolog
alder
hey
children
hospit
liverpool
unit
kingdom
paediatr
palli
care
alder
hey
children
hospit
liverpool
unit
kingdom
object
purpos
studi
identifi
publish
research
describ
use
patient
report
outcom
pro
clinic
randomis
clinic
trial
children
receiv
care
explor
medic
condit
health
care
domain
clinic
trend
describ
method
literatur
search
conduct
use
medlin
cinahl
embas
psychinfo
search
term
cross
referenc
thesauru
databas
result
limit
english
languag
result
total
articl
identifi
psychinfo
embas
cinahl
medlin
defin
pro
report
statu
child
health
condit
came
directli
patient
without
interpret
clinician
articl
includ
none
describ
pro
relev
measur
tool
manual
literatur
internet
search
identifi
relev
articl
databas
includ
pro
search
term
within
thesauru
low
consist
definit
ie
scope
index
basic
search
term
eg
end
life
referenc
thesauru
databas
conclus
despit
increas
interest
use
develop
patient
report
outcom
develop
health
care
servic
use
primari
even
secondari
outcom
clinic
trial
within
paediatr
palli
care
research
remain
limit
best
perhap
greatest
barrier
lack
develop
fit
purpos
valid
outcom
measur
signific
amount
research
need
done
pro
use
measur
evalu
benefit
potenti
treatment
end
life
children
preval
outcom
multidrug
resist
bacteri
sepsi
children
chemotherapi
bhattacharyya
krishnan
dalvi
mitra
r
tiwari
ghosh
ferdousi
v
saha
bhattacharya
paediatr
oncolog
tata
medic
center
kolkata
india
microbiolog
tata
medic
center
kolkata
india
object
multidrug
resist
mdr
gram
neg
sepsi
associ
high
mortal
children
undergo
chemotherapi
report
preval
outcom
mdr
bacteri
sepsi
children
tertiari
cancer
centr
india
method
posit
blood
cultur
obtain
jan
review
mdr
gram
neg
bacteria
defin
produc
carbapenemas
extend
spectrum
beta
lactamas
esbl
resist
multipl
broad
spectrum
antibiot
patient
admit
febril
neutropenia
initi
receiv
cefepim
empir
chang
meropenem
esbl
organ
isol
patient
carbapenemas
produc
organ
receiv
colistin
addit
result
blood
cultur
sent
studi
period
posit
blood
cultur
obtain
patient
mean
age
year
rang
year
forti
seven
patient
hematolog
malign
solid
tumor
blood
cultur
identifi
probabl
isol
remain
mdr
organ
identifi
esbl
carbapenemas
produc
mdr
obtain
patient
thu
patient
hematolog
malign
respect
mdr
organ
isol
blood
cultur
three
patient
hematolog
malign
carbapenemas
produc
organ
succumb
infect
prolong
intraven
antibiot
success
clear
mdr
other
conclus
experi
mdr
organ
isol
third
posit
blood
cultur
obtain
children
cancer
undergo
therapi
half
carbapenemas
produc
mdr
mdr
also
like
isol
patient
hematolog
malign
earli
identif
prompt
intervent
decreas
mortal
associ
mdr
organ
nevertheless
effect
antibiot
carbapenemas
resist
organ
requir
especi
emerg
colistin
resist
assess
nutrit
statu
newli
diagnos
pediatr
patient
mayo
clinic
experi
b
bidadi
al
nofal
p
marri
lamprecht
c
arndt
pediatr
adolesc
medicin
mayo
clinic
rochest
usa
object
children
newli
diagnos
cancer
high
risk
develop
weight
loss
caus
includ
treatment
relat
advers
effect
diseas
relat
reason
despit
high
preval
malnutrit
pauciti
data
appropri
manag
review
nutrit
statu
pediatr
cancer
patient
receiv
chemotherapi
andor
radiat
diagnos
treat
institut
method
retrospect
chart
analysi
patient
older
year
younger
year
exclud
result
cohort
includ
patient
male
femal
mean
age
diagnosi
year
patient
receiv
chemotherapi
thirti
receiv
radiat
therapi
diagnos
includ
leukemia
n
lymphoma
n
central
nervou
system
tumor
n
sarcoma
n
wilm
tumor
n
tumor
n
patient
weight
loss
n
weight
loss
n
weight
loss
n
median
time
nadir
weight
loss
month
patient
metastas
n
higher
median
percent
weight
loss
rang
patient
rang
patient
osteosarcoma
greatest
median
weight
loss
eight
week
rang
eighteen
patient
receiv
either
nasogastr
n
gastrostomi
tube
feed
n
patient
receiv
nasogastr
gastrostomi
feed
median
percent
weight
loss
time
feed
start
median
time
tube
insert
month
conclus
cohort
high
preval
weight
loss
especi
patient
osteosarcoma
metastat
diseas
patient
tend
weight
loss
within
eight
week
initi
therapi
result
highlight
need
earli
nutrit
intervent
newli
diagnos
cancer
patient
symptom
suffer
percept
end
life
cancer
children
impact
caregiv
e
boldrini
pediatr
barreto
cancer
hospit
barreto
brazil
object
littl
known
symptom
suffer
end
life
children
cancer
face
assess
percept
parent
symptom
suffer
children
underw
end
life
presenc
mood
disord
grief
reaction
parent
correl
method
casuist
compris
parent
whose
children
admit
barreto
cancer
hospit
cancer
diagnosi
die
patient
year
old
administ
questionnair
sent
mail
brazil
econom
classif
criteria
symptom
scale
hospit
anxieti
depress
scale
had
texa
revis
inventori
grief
trig
use
result
caregiv
report
averag
symptom
leukemialymphoma
central
nervou
system
tumour
patient
averag
symptom
solid
tumour
patient
consider
disagr
questionnair
compar
doctor
report
even
regard
presenc
pain
kappa
regard
caregiv
present
symptom
anxieti
present
symptom
depress
regard
grief
present
accut
grief
present
moder
grief
present
delay
grief
present
prolong
grief
statist
signific
among
educ
p
econom
statu
p
delayedprolong
grief
well
associ
had
anxieti
p
depress
p
delayedprolong
grief
conclus
presenc
symptom
last
week
life
child
show
associ
complic
grief
trig
statist
signific
among
educ
p
econom
statu
p
delayedprolong
grief
well
associ
had
anxieti
p
depress
p
bioelectr
imped
vector
analysi
biva
children
adolesc
cancer
undergo
hematopoiet
stem
cell
transplant
sao
paulo
brazil
g
bouchabki
k
viani
jm
nabarret
acl
silva
v
oliveira
nutrit
instituto
de
tratamento
infantil
instituto
da
hospit
da
faculti
medicin
univers
sao
paulo
sao
paulo
brazil
object
hematopoiet
stem
cell
transplant
hsct
repres
increas
nutrit
risk
pediatr
oncolog
patient
consid
nutrit
statu
prognost
factor
hsct
nutrit
assess
procedur
essenti
bioelectri
imped
vector
analysi
biva
use
screen
monitor
nutrit
hydrat
statu
phase
angl
pa
consid
prognost
nutrit
statu
indic
estim
bodi
cell
mass
aim
studi
investig
whether
confid
ellips
mean
vector
pa
assess
bioimped
analysi
bia
techniqu
differ
group
children
adolesc
cancer
three
differ
moment
hsct
method
prospect
studi
carri
pediatr
oncolog
patient
undergo
hsct
resist
reactanc
pa
assess
day
hsct
biva
softwar
use
construct
confid
ellips
mean
vector
spss
conduct
relat
sampl
wilcoxon
sign
rank
test
pa
result
begin
studi
patient
n
age
year
old
femal
due
clinic
condit
patient
exclud
second
analysi
n
third
analysi
n
confid
ellips
mean
vector
graph
show
similar
three
hsct
moment
phase
angl
statist
analysi
p
p
p
day
day
day
hsct
respect
conclus
although
statist
differ
biva
pa
three
analyz
moment
found
studi
trend
decreas
paramet
observ
howev
studi
larger
sampl
take
place
order
better
understand
behavior
variabl
hsct
evalu
physician
knowledg
attitud
paediatr
palli
care
ppc
chan
rt
chin
df
chuang
pl
koh
paediatr
subspecialti
kk
women
children
hospit
singapor
singapor
yong
loo
lin
school
medicin
nation
univers
singapor
singapor
singapor
paediatr
nation
univers
hospit
singapor
singapor
object
mani
children
ill
refer
late
ppc
particularli
ill
paediatrician
knowledg
attitud
import
primari
gatekeep
aim
evalu
physician
knowledg
attitud
ppc
specif
refer
barrier
face
method
anonymis
questionnair
studi
result
seventi
paediatrician
recruit
major
kk
women
children
hospit
nation
univers
hospit
equal
proport
generalist
subspecialist
even
spread
senior
although
awar
ppc
avail
major
feel
inadequ
knowledg
skill
role
ppc
clear
consensu
refer
believ
parent
decid
whether
involv
sick
child
barrier
referr
identifi
includ
difficulti
match
appropri
servic
patient
need
lack
resourc
parent
factor
like
denial
commun
difficulti
fear
give
physician
factor
like
lack
knowledg
prognost
paralysi
rare
barrier
interestingli
feel
burnout
common
griev
health
care
profession
remain
hidden
feel
inadequ
grief
support
agre
ppc
need
integr
mainstream
practic
paediatrician
equip
basic
palli
skill
conclus
identifi
barrier
use
set
direct
ppc
educ
servic
provis
integr
mainstream
practic
possibl
children
given
option
palli
care
regardless
stage
diseas
effect
strong
opioid
inflammatori
complic
hematopoiet
stem
cell
transplant
children
cho
iguchi
sato
j
ohshima
terashita
sugiyama
ariga
pediatr
hokkaido
univers
hospit
sapporo
japan
object
use
strong
opioid
increas
pediatr
field
educ
support
care
precondit
hematopoiet
stem
cell
transplant
hsct
often
bring
patient
sever
mucos
result
need
strong
opioid
howev
strong
opioid
rais
risk
intestin
bacteri
transloc
system
inflamm
suppress
intestin
motil
especi
strongli
immunocompromis
patient
furthermor
system
inflamm
sometim
induc
complic
purpos
research
estim
associ
use
strong
opioid
inflammatori
complic
hsct
children
method
consecut
hsct
patient
younger
year
old
octob
analyz
retrospect
strong
opioid
use
within
period
start
precondit
engraft
sed
use
exclud
analyt
factor
includ
hsct
modal
opioid
dosag
stool
frequenc
fever
durat
crp
blood
cultur
result
one
hundr
nineteen
hsct
pediatr
patient
done
year
strong
opioid
use
hsct
autolog
pbsct
relat
allogen
bmt
relat
allogen
pbsct
unrel
allogen
bmt
unrel
allogen
cbsct
sever
pain
control
nsaid
weak
opioid
continu
intraven
fentanyl
given
case
morphin
opioid
provid
enough
effect
decreas
stool
frequenc
observ
start
strong
opioid
patient
howev
statist
signific
use
strong
opioid
kind
opioid
durat
fever
maximum
crp
conclus
data
suggest
strong
opioid
use
safe
pain
control
hsct
children
effect
use
glutamin
hydroxymethyl
butyr
gastrointestin
mucos
due
use
methotrex
rat
c
citak
alakaya
kaya
sn
yilmaz
gd
kulekci
aa
ozcimen
myb
cimen
pediatr
oncolog
mersin
univers
faculti
medicin
mersin
turkey
pediatr
oncolog
mersin
univers
faculti
medicin
mersin
turkey
histolog
embriolog
mersin
univers
faculti
medicin
mersin
turkey
biolog
mersin
univers
faculti
scienc
letter
mersin
turkey
medic
biochemistri
mersin
univers
faculti
medicin
mersin
turkey
object
studi
glutamin
gln
hmb
use
combin
one
one
prevent
intestin
mucos
made
comparison
efficaci
either
method
method
fifti
wistar
albino
rat
divid
group
studi
group
got
mgkg
mtx
intraperiton
third
day
third
day
experi
mlkg
distil
water
given
nasogastr
rout
day
first
group
placebo
third
group
mtx
gln
group
given
gkg
gln
day
mtx
hmb
group
group
given
mgkg
hmb
day
mtx
gln
hmb
combin
use
fifth
group
given
gln
mgkg
hmb
day
fifth
day
experi
blood
intestin
tissu
sampl
obtain
form
group
result
compar
degre
intestin
cript
deepest
mtx
group
p
despit
group
shown
better
score
p
park
score
system
erythrocyt
reproduct
index
appli
group
higher
score
among
five
studi
group
tissu
inspect
coat
apopitosi
highest
mtx
group
percentag
apopitosi
lowest
group
express
gene
highest
mtx
group
p
lowest
group
signific
differ
p
conclus
research
show
combin
gln
hmb
use
effect
seper
use
chemic
evalu
prophylaxi
vomit
children
f
puglisi
dambra
la
spina
l
lo
nigro
p
samperi
damico
f
bellia
meli
di
cataldo
g
russo
pediatr
hematolog
oncolog
univers
catania
catania
itali
object
lack
specif
scheme
nausea
vomit
children
may
lead
inadequ
manag
emesi
unit
chose
adapt
pediatr
popul
guidelin
design
adult
patient
includ
combin
ondansetron
dexamethason
aprepit
scheme
appli
patient
accord
administ
chemotherapi
age
weight
child
effect
assess
medic
record
data
opinion
parent
patient
method
data
collect
perform
patient
age
year
receiv
chemotherapi
malign
consid
data
nausea
vomit
report
nurs
record
carri
inform
consent
structur
interview
parent
ask
opinion
effect
antiemet
final
request
child
opinion
method
braf
scale
result
evalu
cours
chemotherapi
differ
degre
emet
risk
high
moder
low
low
medic
record
show
total
control
nausea
vomit
case
absenc
vomit
occasion
episod
nausea
among
parent
rate
treatment
effect
consid
effect
data
collect
concern
braf
scale
show
children
select
cartoon
equival
state
littl
nausea
without
vomit
conclus
data
indic
nurs
parent
children
express
concord
evalu
effect
prophylaxi
therefor
method
assess
appear
suffici
reliabl
schedul
use
efficaci
patient
therefor
effort
need
pursu
order
improv
stratif
patient
accord
emet
risk
subsequ
select
intensif
anti
emet
strategi
pediatr
palli
care
tertiari
oncolog
depart
bangladesh
doherti
islam
pediatr
hematologyoncolog
bangabandhu
sheikh
mujib
medic
univers
dhaka
bangladesh
object
pediatr
palli
care
servic
unavail
major
children
bangladesh
pediatr
hematologyoncolog
depart
bangabangu
sheikh
mujib
medic
univers
cancer
treatment
facil
provid
pediatr
palli
care
consult
children
cancer
object
describ
palli
care
servic
provid
children
tertiari
care
hospit
dhaka
bangladesh
method
retrospect
chart
review
pediatr
palli
care
record
children
treat
depart
januari
march
perform
palli
care
encount
document
electron
onlin
patient
databas
use
standard
data
collect
tool
result
patient
palli
care
encount
uniqu
patient
specifi
time
period
median
number
encount
per
patient
twenti
patient
treat
physic
symptom
children
pain
gastrointestin
symptom
children
physic
symptom
medic
prescrib
includ
paracetamol
morphin
lax
medic
emot
intervent
includ
play
therapi
art
therapi
support
counsel
provid
occas
eight
occas
palli
care
team
ask
assist
discuss
child
incur
diseas
statu
famili
member
meet
famili
also
taught
provid
basic
end
life
care
home
conclus
major
children
cancer
bangladesh
signific
palli
care
need
previou
studi
depart
found
famili
refus
discontinu
treatment
child
diagnosi
train
oncolog
care
provid
physician
nurs
address
physic
psycholog
social
emot
need
children
cancer
improv
palli
care
children
bangladesh
indic
assess
qualiti
palli
care
children
cancer
jk
duc
ka
widger
e
bouffet
friedrichsdorf
greenberg
husain
liben
jd
pole
h
siden
j
whitlock
j
wolf
rapoport
depart
paediatr
hospit
sick
children
toronto
canada
faculti
nurs
univers
toronto
toronto
canada
depart
haematologyoncolog
hospit
sick
children
toronto
canada
depart
pain
medicin
palli
care
integr
medicin
children
hospit
clinic
minnesota
minnesota
usa
temmi
latner
centr
palli
care
mount
sinai
hospit
toronto
canada
palli
care
program
montreal
children
hospit
montreal
canada
depart
research
pediatr
oncolog
group
ontario
toronto
canada
faculti
medicin
univers
british
columbia
vancouv
canada
pediatr
advanc
care
team
boston
children
hospit
boston
usa
object
purpos
systemat
literatur
review
identifi
potenti
structur
process
outcom
indic
qualiti
palli
care
peolc
children
cancer
famili
identifi
reliabl
valid
method
measur
indic
method
conduct
search
use
electron
databas
cinahl
medlin
embas
combin
follow
key
term
neoplasm
palli
care
terminalhospic
care
advanc
care
plan
outcom
assess
qualiti
life
result
limit
studi
children
publish
english
sinc
book
chapter
these
exclud
iter
process
use
screen
articl
titl
abstract
relev
review
select
full
articl
two
review
involv
level
review
result
remov
duplic
titl
abstract
screen
relev
full
articl
obtain
review
mani
articl
exclud
children
year
constitut
less
sampl
articl
retain
final
review
common
indic
identifi
qualiti
life
child
sibl
parent
number
potenti
tool
measur
avail
indic
includ
reduct
pain
fatigu
symptom
nevertheless
major
indic
identifi
relat
structur
process
care
rather
outcom
conclus
number
indic
associ
measur
assess
qualiti
peolc
children
cancer
howev
work
requir
identifi
addit
outcom
indic
peolc
comprehens
summari
key
qualiti
indic
associ
measur
provid
basi
assess
impact
intervent
design
improv
qualiti
peolc
children
cancer
blood
transfus
paediatr
oncolog
patient
report
audit
tertiari
care
hospit
india
durugappa
p
malhotra
thakkar
nita
radhakrishnan
kalra
sachdeva
aggarw
pediatr
hematolog
oncolog
sir
gangaram
hospit
new
delhi
india
object
transfus
therapi
key
success
manag
children
cancer
hematolog
diseas
recepi
hsct
observ
pattern
blood
product
requir
patient
diagnos
center
method
paediatr
oncolog
patient
receiv
blood
product
period
analys
age
gender
primari
diagnosi
treatment
protocol
phase
therapi
blood
product
receiv
patient
given
blood
transfus
per
bcsh
guidelin
result
total
patient
receiv
episod
transfus
studi
period
among
major
male
n
mean
age
year
month
year
mean
hemoglobin
gmdl
platelet
observ
patient
acut
lymphoblast
leukemia
receiv
transfus
often
episod
among
major
follow
neuroblastoma
stage
iv
among
patient
patient
protocol
receiv
maximum
number
transfus
follow
patient
protocol
major
patient
requir
transfus
reconsolid
phase
platelet
transfucion
requir
often
prbc
episod
requir
episod
requir
prophylact
prbc
transfus
prophylact
platelet
transfus
conclus
red
cell
platelet
concentr
frequent
use
paediatr
oncolog
patient
chemotherapi
patient
acut
lymphoblast
leukemia
reconsolid
phase
requir
episod
transfus
oncolog
emerg
need
intens
care
diagnosi
children
cancer
astigarraga
echebarria
r
adan
r
j
j
j
navaja
pediatr
oncohematolog
unit
depart
pediatr
hospit
universitario
cruce
barakaldo
spain
pediatr
intens
care
unit
hospit
universitario
cruce
depart
pediatr
barakaldo
spain
object
onset
oncolog
process
condit
need
manag
intens
care
unit
icu
aim
studi
analys
experi
manag
sever
complic
observ
confirm
malign
diagnosi
method
retrospect
studi
children
need
critic
care
diagnosi
januari
decemb
epidemiolog
data
tumour
characterist
site
type
complic
treatment
mortal
review
statist
analysi
perform
spss
result
emerg
present
symptom
observ
new
cancer
patient
requir
admiss
icu
diagnosi
male
median
age
diagnos
rang
complic
intracrani
airway
hyperleukocytosi
tumor
lysi
syndrom
arteri
hypertens
cardiac
tamponad
hypercalcemia
superior
vena
cava
syndrom
urinari
obstruct
frequent
diagnos
brain
acut
rhabdoid
malign
locat
bone
therapi
includ
ventriculoperiton
shunt
surgeri
ventilatori
support
extern
ventricular
drainag
ventriculostomi
death
rate
reach
cancer
diagnosi
conclus
earli
identif
symptom
situat
onset
suspect
malign
admiss
icu
crucial
improv
prognosi
sever
case
innov
way
educ
commun
health
profession
recognis
warn
sign
symptom
cancer
essenti
improv
earli
detect
ensur
prompt
referr
specialist
medic
care
collabor
among
physician
icu
oncolog
unit
import
manag
children
cancer
support
need
therapi
special
tertiari
hospit
tumour
lysi
syndrom
childhood
malign
tertiari
hospit
nigeria
call
increas
visibl
supportivepalli
care
gk
eke
na
akani
ie
yarher
depart
paediatr
univers
port
harcourt
teach
hospit
upth
port
harcourt
nigeria
introduct
tumour
lysi
syndrom
emerg
due
metabol
derang
secondari
tumour
cell
necrosi
earli
detect
metabol
disturb
imper
avert
complic
promptli
initi
treatment
thu
improv
manag
outcom
primari
diseas
object
determin
preval
tumour
lysi
syndrom
among
children
treat
malign
univers
port
harcourt
teach
hospit
upth
evalu
impact
primari
diseas
manag
materi
method
retrospect
studi
review
case
childhood
malign
admit
paediatr
oncolog
unit
upth
two
year
period
januari
decemb
clinic
profil
patient
uric
acid
level
serum
calcium
phosphat
potassium
bicarbon
outcom
treatment
review
also
retriev
durat
diseas
present
diagnosi
mode
therapi
data
analys
use
spss
version
p
valu
signific
less
result
children
treat
malign
laboratori
paramet
suggest
tl
half
children
identifi
prior
chemotherapi
whilst
half
commenc
chemotherapi
develop
tl
five
tl
present
within
week
onset
ill
present
metastat
diseas
nephroblastoma
top
list
term
diagnosi
case
follow
hepatoblastoma
hyperuricaemia
hyperkalemia
low
serum
calcium
mortal
record
case
perform
statu
also
correl
outcom
conclus
preval
tl
patient
quit
high
sinc
presenc
tl
delay
specif
therapi
primari
diseas
creat
opportun
spread
worsen
outcom
need
advoc
intensif
support
manag
palli
care
mani
care
giver
may
give
earli
patient
poor
clinic
pictur
patient
tl
may
present
cknowledg
resid
paediatr
oncolog
unit
staff
nurs
children
medic
ward
incid
outcom
infecti
complic
among
pediatr
cancer
patient
relat
perman
central
venou
cathet
elhemali
hamoda
pediatr
oncolog
nation
cancer
institut
cairo
egypt
object
ass
incid
perman
cathet
morbid
includ
blood
stream
infect
cathet
relat
septicemia
system
infect
toxic
endocard
toxic
myocard
among
immunocompromis
pediatr
patient
final
outcom
portcath
infect
regard
salvalgibilti
line
mortal
relat
central
line
infect
method
studi
done
pediatr
cancer
patient
age
year
insert
portcath
microbiolog
document
perment
central
line
infect
period
octob
till
end
march
episod
analyz
regard
caus
organ
morbid
relat
septicemia
toxic
myocard
endocard
caus
remov
central
line
mortal
relat
central
line
infect
result
total
number
episod
portcath
infect
gram
organ
gram
organ
final
candida
common
organ
coagulas
staph
among
patient
gram
organ
patient
normal
echo
four
patient
septic
myocard
two
patient
impair
contractil
valvular
affect
veget
valvular
regurg
regard
patient
gram
organ
episod
patient
normal
echo
three
patient
septic
myocard
final
two
patient
impair
contractil
valvular
affect
veget
cath
remov
patient
due
failur
steril
sepsi
patient
portcath
salvag
patient
die
central
line
infect
gram
isol
patient
die
gram
isol
patient
conclus
gram
pathogen
common
caus
permen
central
line
portacath
infect
requir
better
infect
control
high
mortal
rate
relat
portcath
system
infect
enforc
us
select
patient
urgent
need
portcath
inset
delay
present
earli
death
pediatr
oncolog
unit
singl
center
experi
develop
countri
farrag
mh
ghzalli
pediatr
oncolog
depart
south
egypt
cancer
institut
assiut
univers
assiut
egypt
depart
pediatr
faculti
medicin
assiut
univers
egypt
object
evalu
patient
die
earli
first
admiss
pediatr
oncolog
unit
center
locat
develop
countri
method
follow
data
collect
retrospect
review
report
newli
admit
patient
pediatr
oncolog
unit
south
egypt
cancer
institut
seci
assiut
univers
egypt
die
earli
admiss
reach
final
diagnosi
sex
symptom
time
interv
initi
symptom
first
time
admiss
pediatr
oncolog
depart
admiss
death
caus
death
result
avail
data
patient
admit
seci
patient
male
femal
die
earli
present
unit
mean
day
admiss
mean
durat
sinc
initi
symptom
till
first
visit
pediatr
oncolog
unit
day
initi
symptom
abdomin
swell
n
fever
n
head
neck
swell
n
hemorrhag
n
pallor
n
main
caus
death
due
pulmonari
complic
n
tumor
lysi
syndrom
acut
renal
failur
n
septicemia
n
mediastin
syndrom
n
anem
heart
failur
n
hemorrhag
n
conclus
special
problem
childhood
tumor
manag
develop
countri
one
initi
late
present
patient
advanc
diseas
lead
earli
death
appropri
manag
nausea
vomit
children
receiv
high
dose
methotrex
without
vincristin
j
flank
sr
lavorator
h
vol
taylor
e
zelunka
pc
nathan
maloney
dupui
pharmaci
hospit
sick
children
toronto
canada
haematologyoncolog
hospit
sick
children
toronto
canada
nurs
hospit
sick
children
toronto
canada
object
nausea
vomit
cinv
neg
influenc
qualiti
life
children
receiv
chemotherapi
littl
known
sever
cinv
experienc
children
receiv
iv
methotrex
purpos
studi
describ
preval
acut
delay
phase
cinv
children
receiv
vincristin
method
children
age
year
receiv
particip
prospect
observ
studi
nausea
sever
time
emet
episod
administr
antiemet
record
diari
begin
immedi
administr
hour
achiev
threshold
mtx
concentr
acut
phase
addit
day
delay
phase
nausea
sever
assess
children
use
valid
tool
penat
children
receiv
antiemet
order
primari
care
team
complet
cinv
control
defin
vomit
retch
maximum
nausea
assess
score
result
thirti
children
mean
age
sd
year
male
receiv
plu
vincristin
alon
particip
antiemet
prophylaxi
consist
ondansetron
granisetron
without
dexamethason
eleven
patient
receiv
cinv
prophylaxi
consist
antiemet
guidelin
two
patient
experienc
complet
cinv
control
acut
delay
phase
respect
patient
experienc
complet
vomit
control
acut
delay
phase
experienc
complet
nausea
control
vs
children
receiv
acut
cinv
prophylaxi
none
experienc
complet
six
experienc
partial
acut
cinv
control
conclus
acut
delay
phase
cinv
control
follow
administr
emetogen
rank
reconsid
light
find
attent
also
focus
provis
cinv
prophylaxi
optim
mucos
prevent
protocol
decreas
local
infect
children
adolesc
undergo
hematopoiet
stem
cell
transplant
gallego
zapata
ramirez
c
portilla
quintero
de
charri
odontologia
gener
especializada
centro
medico
imbanaco
cali
colombia
bone
marrow
transplant
unit
centro
medico
imbanaco
cali
colombia
bone
marrow
transplant
unit
universidad
del
vall
cali
colombia
direct
medic
research
centro
medico
imbanaco
universidad
del
vall
cali
colombia
object
mucos
frequent
advers
event
condit
regimen
hsct
children
pain
complic
predispos
local
system
infect
due
disrupt
mucos
barrier
bmt
unit
establish
specif
protocol
prevent
complic
aim
compar
frequenc
local
infect
among
group
good
poor
adher
method
mucos
prevent
protocol
follow
panorex
radiographi
ondontogram
identifi
deterior
amalgam
bacteri
plaqu
index
soft
tissu
statu
use
antibacteri
disinfect
clorhexidin
famili
educ
frequent
use
sugar
free
gum
bmt
unit
dentist
daili
activ
surveil
applic
adher
protocol
also
classif
mucos
sever
estim
local
infect
adher
group
use
multivari
logist
regress
adjust
age
type
condit
regimen
graft
sourc
result
includ
protocol
patient
mean
age
year
old
male
show
optim
adher
protocol
overal
frequenc
mucos
local
infect
patient
mucos
gii
iii
adjust
local
infect
adher
group
ci
conclus
found
achiev
optim
oral
hygien
hsct
strongli
reduc
risk
local
mucos
infect
relev
decreas
risk
system
infect
also
improv
qualiti
life
phase
transplant
moreov
could
effect
decreas
occurr
acut
gvhd
issu
merit
studi
palli
care
pediatr
oncolog
matern
perspect
da
geronutti
rc
popim
vlp
tonet
palli
care
hospit
de
infanto
juvenil
president
luiz
lula
da
silva
barreto
brazil
nurs
universidad
estadu
paulista
botucatu
brazil
object
overal
goal
research
understand
concept
experi
palli
care
mother
whose
children
hospit
nation
cancer
hospit
locat
state
paulo
method
qualit
studi
descript
natur
data
analysi
method
content
analysi
bardin
use
themat
approach
result
matern
testimoni
collect
organ
five
theme
concept
palli
care
matern
care
announc
imposs
heal
profession
care
announc
imposs
heal
matern
feel
stage
palli
care
matern
perspect
children
feel
palli
care
matern
concept
palli
care
prove
vagu
distort
even
nonexist
show
need
institut
invest
chang
situat
experi
report
women
permeat
feel
differ
type
intens
especi
helpless
nonconform
religi
convict
prove
import
resourc
accept
overcom
problem
percept
matern
professionalcar
palli
phase
point
import
comprehens
care
children
famili
team
qualif
care
inclus
guidanc
activ
particip
famili
decis
taken
get
best
qualiti
life
children
phase
conclus
end
studi
addit
propos
could
confirm
necess
establish
line
comprehens
care
children
cancer
municip
well
import
continu
care
servic
famili
lost
children
peripher
neuropathi
cancer
comparison
diagnost
group
l
gilchrist
l
tanner
hematolog
oncolog
children
hospit
clinic
minnesota
minneapoli
usa
rehabilit
servic
children
hospit
clinic
minnesota
minneapoli
usa
object
peripher
neuropathi
cipn
common
cancer
treatment
children
last
neg
consequ
cipn
commonli
recogn
patient
acut
lymphoblast
leukemia
well
document
popul
purpos
studi
identifi
sever
clinic
characterist
cipn
occur
childrenadolesc
treat
across
varieti
cancer
method
pediatr
modifi
total
neuropathi
score
well
standard
measur
balanc
manual
dexter
administ
subject
n
patient
treat
n
test
near
end
delay
intensif
approxim
month
treatment
wherea
subject
treat
lymphoma
n
solid
tumor
n
test
approxim
month
treatment
treatment
inform
extract
medic
record
total
item
score
well
balanc
manual
dexter
score
compar
diagnost
group
use
anova
result
although
subject
treat
receiv
longer
durat
treatment
expos
higher
cumul
dose
vincristin
lymphoma
solid
tumor
lower
overal
score
patient
lymphoma
p
solid
tumor
p
subject
lymphoma
increas
sensori
symptom
vibratori
impair
deep
tendon
reflex
decrement
subject
wors
strength
deficit
group
mean
balanc
manual
dexter
score
significantli
differ
one
anoth
norm
valu
except
manual
dexter
subject
normal
rang
conclus
patient
lymphoma
solid
tumor
experi
cipn
may
signific
patient
increas
attent
cipn
need
occur
group
palli
care
issu
pediatr
oncolog
report
moroccan
pediatr
oncolog
unit
l
hessissen
ziani
elkababri
kili
elkhorassani
khattab
moham
v
univers
souissi
pediatr
center
rabat
morocco
univers
hospit
rabat
pediatr
center
rabat
morocco
object
care
children
end
life
may
particularli
complex
palli
care
expect
standard
end
life
better
understand
need
moroccan
children
famili
parent
termin
ill
children
ask
answer
questionnair
method
studi
conduct
pediatr
hematolog
oncolog
institut
rabat
interview
parent
children
palli
care
physic
symptom
need
whether
talk
death
child
questionnair
administ
arab
psychologist
medic
record
review
addit
inform
result
among
parent
particip
studi
refus
announc
palli
phase
children
frequent
parent
reaction
death
anticip
resign
parent
avoid
discuss
child
immin
death
talk
indirectli
discuss
death
other
concern
prefer
place
end
life
chose
patient
hous
hospit
main
symptom
report
pain
fatigu
final
rel
interview
express
physic
need
better
symptom
manag
contact
caregiv
express
need
social
support
transport
fee
support
medic
fee
parent
report
need
psycholog
support
conclus
pediatr
oncolog
palli
care
difficult
phase
parent
children
also
caregiv
especi
low
incom
countri
palli
care
poorli
structur
one
import
step
improv
manag
understand
need
person
involv
nutrit
statu
children
malign
islam
doherti
f
afroz
pediatr
hematolog
oncolog
bsmmu
dhaka
bangladesh
pediatr
hematolog
oncolog
bsmmu
dhaka
bangladesh
object
nutrit
assess
essenti
compon
initi
assess
children
cancer
malnutrit
associ
increas
risk
morbid
moral
studi
evalu
nutrit
statu
children
cancer
initi
diagnosi
tertiari
health
care
center
bangladesh
method
cross
section
observ
studi
done
paediatr
haematolog
oncolog
depart
bangabandhu
sheikh
mujib
medic
univers
bsmmu
may
octob
nutrit
statu
one
hundr
children
year
age
newli
diagnos
malign
evalu
weight
heightlength
mid
upper
arm
circumfer
muac
record
time
diagnosi
begin
treatment
use
standard
techniqu
weight
heightlength
heightlength
age
weight
age
deriv
use
nation
center
health
statit
nch
growth
curv
bodi
mass
index
bmi
calcul
use
standard
formula
result
total
one
hundr
patient
includ
mean
age
year
rang
month
year
percent
patient
male
percent
femal
hematolog
malign
account
diagnos
solid
tumor
compris
diagnos
overal
proport
nutrit
wast
stunt
respect
proport
malnutrit
bodi
mass
index
mid
upper
arm
circumfer
respect
conclus
studi
proport
malnutrit
among
children
cancer
high
percent
bangladeshi
children
wast
time
present
percent
underweight
children
solid
tumor
frequent
sever
wast
vs
sever
underweight
vs
children
hematolog
malign
result
suggest
intervent
improv
nutrit
statu
children
cancer
need
major
children
present
cancer
bangladesh
impact
cancer
financi
support
group
childhood
cancer
treatment
abandon
privat
pediatr
oncolog
centr
develop
countri
j
jame
martin
srinivasan
p
ramachandran
ramakrishnan
pediatr
hematolog
oncolog
kanchi
kamakoti
child
trust
hospit
chennai
india
pediatr
surgeri
kanchi
kamakoti
child
trust
hospit
chennai
india
child
trust
medic
research
foundat
kanchi
kamakoti
child
trust
hospit
chennai
india
object
global
estim
children
develop
cancer
year
live
develop
countri
india
approxim
children
diagnos
cancer
everi
year
treatment
abandon
signific
barrier
cancer
care
develop
world
though
reason
abandon
complex
multifactori
econom
issu
appear
main
factor
abandon
analys
impact
financi
support
two
cancer
support
group
treatment
abandon
pediatr
oncolog
aim
analyz
impact
two
cancer
support
group
treatment
abandon
childhood
cancer
method
method
materi
retrospect
review
children
cancer
fund
non
fund
treat
kanchi
kamakoti
child
trust
hospit
result
total
patient
fund
ray
light
foundat
pediatr
lymphoma
project
total
current
surviv
includ
complet
treatment
current
undergo
treatment
compar
group
abandon
treatment
initi
therapi
seen
financi
support
group
wherea
abandon
treatment
initi
seen
one
child
non
fund
group
conclus
besid
intens
treatment
good
support
care
financi
support
also
import
impact
complianc
abandon
socioeconom
strata
societi
financi
support
privat
cancer
support
group
also
impact
beyond
patient
famili
reduc
burden
govern
institut
fund
privat
sector
improv
deliveri
pediatr
oncolog
care
develop
countri
could
improv
financi
support
privat
sector
vitamin
defici
children
cancer
v
paramasivam
r
mohan
jx
jame
martin
pediatr
sri
ramachandra
univers
chennai
india
object
introduct
studi
measur
vitamin
level
pediatr
patient
malign
undertook
studi
assess
vitamin
statu
pediatr
cancer
patient
develop
countri
pediatr
oncolog
centr
aim
studi
aim
compar
vitamin
level
popul
group
childhood
cancer
patient
control
group
tertiari
care
pediatr
oncolog
unit
develop
countri
method
prospect
case
control
studi
conduct
sri
ramachandra
medic
colleg
pediatr
oncolog
tertiari
care
centr
total
children
includ
studi
age
group
one
month
year
age
diagnos
cancer
treatment
atleast
six
month
control
age
sex
match
without
cancer
durat
sampl
march
juli
oh
vitamin
level
assess
chemilumines
comparison
two
group
done
use
test
anova
mann
whitney
test
appropri
statist
analysi
done
use
result
mean
vitamin
level
among
case
found
ngdl
mean
vitamin
level
among
control
found
ngdl
children
cancer
found
insuffici
level
vitamin
oppos
control
factor
compar
includ
age
sex
type
malign
nutrit
statu
mild
variabl
seen
factor
deem
statist
signific
conclus
children
cancer
lower
vitamin
level
children
control
popul
sinc
cancer
survivor
higher
risk
low
bone
miner
densiti
intervent
improv
statu
vulner
popul
need
infect
associ
morbid
autolog
hematopoiet
stem
cell
transplant
children
adolesc
optim
prophylaxi
strategi
r
johnston
l
funston
paediatr
haematolog
oncolog
royal
belfast
hospit
sick
children
belfast
unit
kingdom
object
invas
infect
major
caus
morbid
mortal
follow
hematopoiet
stem
cell
transplant
hsct
standardis
strategi
prevent
infect
establish
allogen
hsct
howev
evid
recommend
prophylact
antimicrobi
drug
autolog
hsct
limit
addit
drug
potenti
signific
side
effect
aim
review
practic
experi
region
children
cancer
centr
ten
year
period
undertak
review
literatur
produc
guidanc
standardis
approach
infect
prophylaxi
manag
patient
group
method
retrospect
analys
data
relat
children
adolesc
undergo
autolog
hsct
institut
januari
decemb
addit
inform
includ
sourc
stem
cell
diagnosi
age
transplant
diagnosi
sourc
stem
cell
infect
prophylaxi
complic
outcom
result
children
underw
autolog
hsct
total
hsct
procedur
neuroblastoma
common
diagnosi
patient
underw
autolog
bone
marrow
transplant
peripher
blood
stem
cell
transplant
fungal
viral
combin
antimicrobi
prophylaxi
use
patient
bacteri
infect
occur
patient
includ
bacteraemia
patient
lower
respiratori
tract
infect
viral
infect
affect
patient
includ
episod
vzv
reactiv
hsv
reactiv
fungal
infect
uncommon
case
pulmonari
aspergillosi
strongli
suspect
clinic
imag
unproven
bal
relaps
diseas
account
death
follow
hsct
conclus
date
standard
practic
infect
prophylaxi
although
review
practic
reveal
high
incid
invas
infect
product
evid
base
guidelin
lead
patient
focuss
infect
prophylaxi
minimis
morbid
associ
infect
manag
abandon
treatment
bane
care
giver
peadiatr
oncolog
unit
univers
port
harcourt
teach
hospit
river
state
nigeria
kalagbor
g
eke
depart
scienc
laboratori
technolog
school
appli
scienc
river
state
polytechn
bori
nigeria
depart
paediatr
univers
port
harcourt
teach
hospit
port
harcourt
nigeria
object
peadiatr
oncolog
unit
univers
port
harcourt
teach
hospit
year
experienc
high
incid
abandon
treatment
parentsguardian
children
admit
undergo
chemotherapi
attribut
number
reason
cost
implic
ignor
denial
syndrom
grant
patronag
tradit
healer
often
latter
reason
account
late
present
patient
hospit
treatment
centr
across
state
method
studi
carri
use
cohort
patient
ward
come
time
time
chemotherapi
span
period
one
year
result
patient
present
four
week
onset
symptom
ill
cours
therapi
default
sever
reason
mortal
record
statist
evalu
use
anova
also
carri
conclus
late
present
due
variou
reason
high
default
rate
contributori
factor
poor
come
treatment
patient
even
good
prognosi
day
combin
initi
empir
therapi
febril
neutropenia
children
kanvind
deshpand
pediatr
hematolog
oncolog
deenanath
mangeshkar
hospit
pune
india
pediatr
deenanath
mangeshkar
hospit
pune
india
object
present
experi
regard
use
daili
od
ceftriaxon
cft
plu
amikacin
amk
initi
therapi
febril
neutropenia
fn
method
retrospect
studi
studi
period
inclus
criteria
age
year
treatment
cancer
fever
anc
cmm
exclus
criteria
fn
time
diagnosi
malign
patient
undergo
bmt
empir
therapi
fn
iv
cft
amk
od
patient
respiratori
distress
hypotens
alter
sensorium
treat
ptz
amk
initi
therapi
antibiot
upgrad
respons
within
hour
earlier
clinic
deterior
vancomycin
ad
case
skinsoft
tissu
infect
sepsi
document
infect
cultur
amphoterecin
ad
persist
fever
day
age
aml
chemotherapi
poor
perform
statu
need
blood
product
insur
patient
conveni
indic
admiss
fn
defin
durat
neutropenia
malign
remiss
poor
perform
statu
result
episod
fn
document
episod
initi
treat
malign
focu
infect
episod
episod
consid
high
risk
per
definit
episod
treat
initi
opd
basi
requir
admiss
persist
fever
death
group
episod
patient
initi
admit
treatment
could
discharg
within
day
death
admiss
group
overal
episod
could
manag
whollyparti
opd
basi
episod
respond
requir
switch
antibiot
addit
episod
breakthrough
fever
occur
initi
respons
requir
chang
antibiot
conclus
use
combin
initi
empir
therapi
fn
may
permit
opd
manag
signific
number
patient
consider
reduc
burden
indoor
servic
paediatr
palli
care
systemat
review
recommend
treatment
symptom
rrg
knop
lcm
kremer
aae
verhagen
paediatr
oncolog
academ
medic
center
amsterdam
netherland
paediatr
beatrix
children
hospitalunivers
groningen
groningen
netherland
object
children
die
life
threaten
diseas
suffer
great
deal
end
life
symptom
control
children
die
cancer
often
unsatisfactori
stage
diseas
partli
mani
caregiv
simpli
familiar
paediatr
palli
care
symptom
control
reliev
suffer
cornerston
paediatr
palli
care
evid
base
recommend
paediatr
palli
care
avail
aim
studi
improv
palli
care
children
make
high
qualiti
care
recommend
recogn
reliev
symptom
paediatr
palli
care
method
extens
search
perform
guidelin
systemat
review
paediatr
palli
care
expert
panel
combin
evid
result
search
consensu
form
recommend
treatment
symptom
paediatr
palli
care
result
apprais
guidelin
identifi
potenti
elig
articl
four
met
inclus
criteria
none
gave
recommend
recogn
treat
symptom
paediatr
palli
care
two
textbook
adult
palli
care
websit
eventu
main
sourc
evid
recogn
treat
symptom
paediatr
palli
care
conclus
hardli
evid
avail
treatment
symptom
paediatr
palli
care
combin
evid
adult
palli
care
spars
evid
paediatr
palli
care
paediatr
expert
opinion
abl
defin
uniqu
set
high
qualiti
care
recommend
reliev
symptom
lessen
suffer
children
palli
care
result
studi
import
tool
educ
caregiv
reliev
symptom
children
life
threaten
condit
improv
qualiti
paediatr
palli
care
develop
educ
booklet
famili
children
leukemia
k
kobayashi
e
yamaguchi
hayakawa
n
maeda
sawada
h
hisakawa
u
koudera
yoshida
imai
rikiishi
h
hori
school
nurs
jichi
medic
univers
shimotsuk
japan
depart
medic
qualiti
safeti
scienc
osaka
citi
univers
graduat
school
medicin
osaka
japan
depart
pediatr
kobe
univers
graduat
school
medicin
kobe
japan
depart
pediatr
nation
hospit
organ
nagoya
medic
center
nagoya
japan
depart
pediatr
takashima
municip
hospit
takashima
japan
depart
pediatr
adolesc
kochi
medic
univers
nankoku
japan
depart
pediatr
nakano
children
hospit
osaka
japan
depart
pediatr
asahikawa
medic
univers
asahikawa
japan
depart
pediatr
kagawa
univers
takamatsu
japan
depart
pediatr
tohoku
univers
sendai
japan
depart
pediatr
mie
univers
sendai
japan
object
although
surviv
rate
childhood
leukemia
japan
exceed
diagnos
leukemia
ill
still
caus
great
anxieti
patient
famili
ie
parent
sibl
famili
face
unpredict
uncertainti
present
situat
futur
live
provid
educ
patient
famili
prospect
recoveri
qualiti
life
qol
manag
famili
life
would
help
famili
deal
hardship
easili
purpos
studi
therefor
develop
educ
booklet
promot
parent
involv
provid
instruct
parent
manag
child
famili
life
treatment
method
compil
inform
select
content
educ
tool
member
committe
qol
japan
associ
childhood
leukemia
studi
group
jacl
review
previou
studi
regard
famili
life
qol
famili
children
leukemia
addit
literatur
review
refer
result
previou
longitudin
studi
conduct
jacl
clarifi
famili
life
trajectori
qol
children
leukemia
famili
result
base
result
research
educ
booklet
contain
three
theme
qol
children
leukemia
famili
member
famili
life
challeng
treatment
phase
support
resourc
hint
overcom
famili
life
challeng
cardin
messag
booklet
provid
hope
prospect
patient
famili
encourag
famili
manag
conclus
accept
util
help
educ
booklet
examin
futur
research
earli
palli
care
consult
high
risk
pediatr
oncolog
patient
feasibl
studi
l
mahmood
dozier
j
dolan
casey
c
mullen
koron
pediatr
hematolog
oncolog
golisano
children
hospit
univers
rochest
strong
memori
hospit
rochest
usa
public
health
scienc
univers
rochest
rochest
usa
food
drug
administr
us
depart
health
human
servic
maryland
usa
pediatr
hematolog
oncolog
golisano
children
hospit
univers
rochest
rochest
usa
object
part
larger
studi
evalu
impact
earli
palli
care
children
high
risk
malign
assess
feasibl
obtain
palli
care
consult
within
one
month
diagnosi
assess
feasibl
obtain
earli
diagnosi
palli
care
consult
children
high
risk
malign
method
children
elig
earli
palli
care
consult
high
risk
malign
defin
relaps
diseas
need
stem
cell
transplant
sct
newli
diagnos
estim
overal
surviv
pediatr
hematologyoncolog
divis
identifi
elig
patient
weekli
confer
medic
chart
review
everi
two
week
assess
statu
consult
number
visit
initi
consult
result
sinc
implement
march
elig
patient
receiv
earli
palli
care
consult
children
famili
declin
consult
four
patient
particip
studi
two
children
outsid
hospit
refer
institut
autolog
sct
two
children
recurr
diseas
treat
primarili
outpati
one
patient
long
cours
discharg
prior
receiv
consult
median
time
diagnosi
consult
day
seventeen
patient
receiv
consult
within
day
diagnosi
eight
newli
diagnos
relapsedrecurr
diseas
fifteen
follow
palli
care
visit
initi
consult
one
follow
visit
median
number
follow
visit
group
visit
conclus
earli
palli
care
consult
program
children
high
risk
malign
feasibl
pediatr
hematologistoncologist
children
famili
atyp
pellagra
pediatr
oncolog
patient
mysteri
rash
k
kulkarni
baker
eisenstat
pediatr
hematolog
oncolog
iwk
health
centr
dalhousi
univers
halifax
canada
pediatr
hematolog
oncolog
palli
care
environment
health
stolleri
children
hospit
edmonton
canada
object
pellagra
sever
state
niacin
defici
pellagra
pediatr
cancer
patient
unknown
develop
world
describ
two
pediatr
oncolog
patient
develop
pellagra
method
case
record
pediatr
cancer
patient
manag
stolleri
children
hospit
review
result
case
year
old
male
diagnos
burkitt
lymphoma
treat
use
protocol
group
c
day
consolid
chemotherapi
develop
hyperpig
symmetr
rash
neck
dorsum
hand
wrist
patient
also
week
histori
diarrhea
supplement
niacin
mg
daili
given
day
multivitamin
mg
niacin
given
daili
rash
resolv
within
day
supplement
preced
rash
patient
niacin
intak
mg
daili
dietari
refer
intak
mg
daili
case
year
old
male
acut
myeloid
leukemia
treat
per
protocol
day
patient
develop
dark
brown
hyperpig
rash
dorsum
wrist
elbow
face
without
diarrhea
fatigu
week
prior
present
day
dermatolog
servic
suggest
pellagra
niacin
supplement
mg
daili
initi
day
multivitamin
mg
niacin
provid
daili
rash
resolv
within
day
supplement
enter
parenter
niacin
intak
prior
pellagra
diagnosi
mg
daili
dietari
refer
intak
mg
daili
conclus
pellagra
extrem
unusu
pediatr
oncolog
patient
case
illustr
potenti
develop
rel
niacin
defici
follow
chemotherapi
possibl
relat
cytarabin
clinic
evid
pellagra
exist
despit
assess
adequ
niacin
intak
suggest
higher
requir
certain
phase
treatment
survey
explor
behavior
psychosoci
determin
physic
activ
diet
treatment
pediatr
malign
n
arbit
c
buck
e
lada
pediatr
columbia
univers
medic
center
new
york
usa
object
unhealthi
lifestyl
behavior
promot
develop
morbid
among
children
adolesc
cancer
across
phase
treatment
lifestyl
intervent
may
reduc
risk
treatment
perform
survey
learn
current
practic
barrier
healthi
lifestyl
behavior
method
inform
fruit
veget
fv
dietari
fat
intak
physic
activ
pa
associ
psychosoci
variabl
measur
use
assess
counsel
exercis
survey
routin
clinic
visit
frequenc
demograph
survey
respons
analyz
spss
result
data
patient
mean
age
rang
hispan
asian
black
avail
patient
report
meet
pa
recommend
though
intend
meet
guidelin
within
month
eighti
seven
percent
report
eat
serv
fv
per
day
intend
increas
fv
consumpt
within
month
report
consist
avoid
high
fat
food
yet
dietari
analysi
reveal
fat
intak
excess
guidelin
subject
consist
friend
famili
support
eat
low
fat
food
support
pa
support
fv
consumpt
conclus
pediatr
oncolog
patient
follow
healthi
lifestyl
behavior
despit
major
intend
gap
intent
report
behavior
may
partli
explain
data
indic
lack
support
behavior
improv
support
access
healthi
lifestyl
resourc
may
facilit
adopt
healthi
behavior
improv
health
outcom
qualiti
life
patient
palli
radiotherapi
childhood
cancer
k
mak
sw
lee
ta
balboni
kj
marcu
depart
radiat
oncolog
harvard
radiat
oncolog
program
women
cancer
center
boston
usa
depart
radiat
oncolog
women
cancer
center
boston
usa
depart
radiat
oncolog
depart
psychosoci
oncolog
palli
care
women
cancer
center
cancer
institut
boston
usa
depart
radiat
oncolog
depart
pediatr
oncolog
women
cancer
center
dana
farberboston
children
cancer
blood
disord
center
boston
usa
object
despit
accept
widespread
applic
palli
rt
children
advanc
malign
report
publish
use
goal
studi
describ
clinic
characterist
treatment
respons
surviv
children
receiv
palli
rt
method
pediatr
patient
age
year
treat
palli
rt
advanc
incur
cancer
includ
diagnosi
indic
detail
palli
rt
treatment
respons
toxic
surviv
retrospect
review
result
patient
treat
palli
treatment
cours
fifteen
patient
palli
rt
cours
maximum
cours
median
age
time
palli
rt
year
rang
male
common
diagnos
figur
neuroblastoma
diffus
intrins
pontin
glioma
retreat
common
indic
rt
radiolog
progress
asymptomat
patient
pain
figur
common
treatment
site
brain
bone
six
treatment
cours
complet
median
rt
dose
gy
rang
median
durat
rt
day
rang
treatment
cours
deliv
fraction
size
cgi
treatment
cours
given
gener
anesthesia
median
month
toxic
treatment
month
rt
respect
asymptomat
patient
symptomat
patient
improv
stabl
symptom
rt
month
afterward
respect
figur
median
surviv
palli
rt
month
surviv
patient
four
hospic
care
last
conclus
palli
rt
children
incur
malign
associ
improv
stabl
symptom
major
case
profil
infect
recipi
hematopoiet
stem
cell
singl
centr
experi
india
p
malhotra
gupta
kalra
n
radhakrishnan
sachdeva
pediatr
hemato
oncolog
bmt
unit
sir
ganga
ram
hospit
delhi
india
object
infect
import
caus
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
patient
knowledg
infect
pattern
centr
would
facilit
earli
initi
treatment
review
done
analyz
pattern
infect
first
day
follow
hsct
method
retrospect
review
data
pediatr
patient
underw
hsct
januari
decemb
done
find
number
type
infect
upto
day
result
hsct
patient
least
one
episod
proven
sepsi
transplant
allogen
autolog
f
ratio
mean
age
rang
accord
hsct
sourc
peripher
blood
stem
cell
transplant
pbsct
blood
transplant
cbt
bone
marrow
bm
bmcbt
among
allogen
transplant
match
sibl
donor
msd
cbt
msdcbt
haplotranspl
donor
bm
pbsct
total
episod
infect
cultur
proven
bacteri
infect
kleibsella
staphylococcu
staphylococcu
acinetobact
enterococcu
cmv
fungal
infect
probabl
proven
infect
aspergillu
trichosporon
episod
infect
allogen
transplant
auto
transplant
total
episod
infect
pbsct
cbt
bm
bmcbt
group
total
transplant
relat
mortal
attribut
infect
conclus
infect
common
post
hsct
kleibsella
sp
cmv
aspergillu
sp
common
infect
respect
categori
effort
control
invas
fungal
infect
develop
countri
e
ebeid
mansour
pediatr
hematolog
oncolog
nation
cancer
institut
cairo
egypt
pediatr
hematolog
oncolog
nasser
institut
cairo
egypt
object
singl
institut
retrospect
studi
analyz
outcom
pediatr
cancer
patient
risk
develop
invas
fungal
infect
ifi
patient
ifi
treat
antifung
drug
accord
avail
financi
support
diagnosi
ifi
done
ct
chest
method
studi
includ
pediatr
cancer
patient
femal
male
risk
develop
ifi
hematolog
malign
solid
tumor
respect
till
patient
divid
group
group
patient
patient
receiv
prophylact
itraconazol
patient
receiv
prophylact
voriconazol
group
b
patient
develop
fever
neutropenia
treatment
group
c
patient
present
ifi
result
group
patient
receiv
prophylact
itraconazol
receiv
prophylact
voriconazol
receiv
itraconazol
control
develop
ifi
develop
ifi
receiv
amphotericinb
die
shift
caspofungin
shift
voriconazol
receiv
voriconazol
control
develop
ifi
group
b
control
antibiot
given
empir
amphotericinb
control
ifi
control
amphotericinb
progress
ifi
goup
c
receiv
voriconazol
control
progress
ifi
receiv
amphotericinb
complet
respons
shift
voriconazol
caspofungin
better
voriconazol
salvag
p
voriconazol
significantli
superior
itraconazol
prophylaxi
p
conclus
prophylact
itraconazol
empir
amphotericinb
seem
suitabl
develop
countri
caspofungin
prefer
second
line
transiton
activ
palli
care
children
cancer
experi
parent
staff
r
mcandrew
p
smith
nelson
kelli
whb
wallac
k
kelsey
c
applegath
oncolog
royal
hospit
sick
children
edinburgh
unit
kingdom
nurs
studi
univers
edinburgh
edinburgh
unit
kingdom
nurs
research
cardiff
univers
edinburgh
unit
kingdom
object
explor
person
profession
challeng
associ
period
transit
activ
palli
care
paediatr
oncolog
uncertain
littl
research
turn
point
treatment
describ
aspect
effect
less
effect
practic
manag
situat
highlight
method
qualit
interview
group
took
place
firstli
staff
member
work
within
oncologyhaematolog
ward
singl
primari
treatment
centr
ptc
interview
staff
focu
group
follow
discuss
common
theme
aris
within
interview
secondli
set
parent
lost
child
cancer
within
last
year
parent
children
treat
cancer
ptc
parent
offer
second
interview
explor
theme
aris
first
interview
use
techniqu
emot
touch
point
stori
result
establish
transit
theori
support
although
complex
interplay
transit
group
present
requir
transit
describ
clearli
group
awar
acknowledg
move
activ
palli
care
particularli
evid
parent
group
import
support
system
strong
connect
other
strong
focu
group
particularli
staff
use
emot
touchpoint
tool
aid
famili
find
right
word
conclus
process
transit
differ
famili
differ
circumst
undeni
lead
individu
experi
howev
aris
theme
met
requir
aim
allow
effect
descript
transit
interview
natur
allud
greater
transit
follow
death
child
move
bereav
import
continu
support
mechan
identifi
lead
recommend
local
practic
especi
relat
introduct
ward
environ
continu
care
palliat
beyond
bereav
care
ketamin
halv
opiat
requir
simultan
reduc
pain
score
zero
high
risk
neuroblastoma
patient
receiv
immunotherapi
mcintosh
c
reilli
canning
g
paton
rongh
j
sastri
murphi
paediatr
oncolog
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
pain
team
royal
hospit
sick
children
yorkhil
glasgow
unit
kingdom
object
assess
ketamin
efficaci
toler
patient
receiv
immunotherapi
neuroblastoma
method
retrospect
case
note
pain
databas
review
patient
protocol
result
nine
patient
male
median
age
iqr
receiv
total
cycl
immunotherapi
patient
receiv
antibodi
aldesleukin
complet
cycl
treatment
possibl
antibodi
cycl
deliv
total
patient
relaps
die
follow
cycl
patient
receiv
ketamin
second
line
analgesia
combin
group
patient
high
pain
score
despit
multipl
nurs
control
analgesia
bolus
clinician
overrid
pain
score
fell
soon
ketamin
infus
commenc
despit
greater
decreas
opiat
requir
ketamin
administ
prophylact
subsequ
cycl
signific
pain
experienc
thereaft
conclus
ketamin
safe
effect
adjunct
morphin
administ
high
risk
neuroblastoma
patient
receiv
immunotherapi
ketamin
facilit
decreas
morphin
dosag
toxic
follow
ketamin
commenc
median
morphin
dose
reduc
compar
peak
morphin
dose
prior
introduct
use
ketamin
improv
toler
immunotherapi
allow
maxim
deliveri
may
posit
impact
high
risk
neuroblastoma
surviv
benefit
commun
engag
public
health
palli
care
servic
children
cancer
low
resourc
set
w
mwashala
drm
murtadha
nursingpalli
care
st
lucia
nurs
home
arusha
tanzania
pediatr
mount
meru
hospit
arusha
tanzania
object
facilit
earli
referr
identifi
risk
sick
children
local
district
hospit
clinic
referr
ocean
road
cancer
hospit
tanzania
diagnosi
treatment
method
global
fund
support
st
lucia
nurs
home
identifi
children
famili
commun
health
fund
includ
payment
scheme
vulner
children
attend
hospit
servic
special
card
name
tika
treatment
per
card
local
govern
author
identifi
children
well
individu
need
train
assist
identif
engag
participatori
servic
govern
hospit
treatment
train
modul
offer
introduct
palli
care
use
tool
help
identifi
earli
sign
cancer
children
creat
awar
gener
public
import
urgent
referr
earli
attend
hospit
help
tool
adapt
muhimbili
cancer
institut
describ
earli
diagnosi
cancer
translat
local
vernacular
languag
children
enrol
district
hospit
variou
medic
condit
record
hospit
registri
result
mean
children
follow
male
femal
age
yr
case
children
need
palli
care
children
hydrocephalu
cerebr
palsi
mental
retard
hivaid
albino
children
cancer
refer
ocean
road
cancer
hospit
manag
cancer
male
diagnos
burkitt
lymphoma
male
acut
lymphoblast
leukemia
femal
burkitt
lymphoma
femal
brain
tumor
conclus
train
commun
member
enhanc
qualiti
care
earli
referr
creat
commun
awar
regard
cancer
care
erad
stigma
set
resourc
infrastructur
limit
review
treatment
outcom
kaposi
sarcoma
children
attend
hospic
africa
uganda
implic
provis
palli
care
nandaula
clinic
hospic
africa
uganda
kampala
uganda
object
associ
preval
antibodi
hivaid
find
respons
treatment
given
patient
method
chart
review
children
hivaid
ks
hospic
africa
uganda
carri
children
programm
least
month
prior
review
result
children
review
male
femal
age
children
rang
year
mean
age
year
review
histolog
common
present
lymphadenopath
ks
children
receiv
treatment
term
chemotherapi
arv
wherea
children
unabl
start
either
treatment
three
children
receiv
chemotherapi
earlier
shown
sign
clinic
improv
follow
treatment
default
present
rapidli
progress
symptomatolog
three
children
fare
poorli
retreat
cours
chemotherapi
one
fatal
conclus
children
commonli
get
lymphadenopath
ks
common
older
children
although
review
small
scale
seem
suggest
combin
therapi
chemotherapi
arv
benefici
side
treatment
default
lead
rapidli
progress
symptomatolog
poor
respons
retreat
regimen
possibl
high
fatal
rate
within
provis
palli
care
implic
manag
ks
also
palliat
symptom
associ
treatment
diseas
progress
bigger
studi
recommend
pediatr
popul
studi
depth
palli
care
servic
childhood
cancer
bangladesh
current
situat
challeng
asm
nurunnabi
research
public
bangladesh
medic
research
council
dhaka
bangladesh
object
palli
care
major
prioriti
childhood
cancer
care
strategi
provid
compassion
support
children
famili
aim
present
studi
observ
current
situat
palli
care
servic
childhood
cancer
bangladesh
challeng
method
survey
done
juli
decemb
special
pediatr
oncolog
unit
differ
public
privat
hospit
dhaka
citi
bangladesh
base
questionnair
total
respond
includ
physician
nurs
caregiv
hospit
manag
deal
childhood
cancer
parent
children
suffer
cancer
took
part
survey
queri
address
access
treatment
avail
drug
palli
care
pain
manag
cost
treatment
qualiti
care
perceiv
challeng
result
difficulti
access
treatment
payment
oncolog
therapi
palli
care
evid
report
avail
special
palli
care
servic
pain
manag
psycholog
plu
support
invers
relat
incom
level
overal
respond
indic
palli
care
import
patient
indic
compet
provid
care
howev
indic
enough
time
deliv
qualiti
palli
care
challeng
includ
less
avail
facil
high
cost
limit
ineffici
manpow
low
qualiti
care
less
commun
health
profession
parentsfamili
member
patient
conclus
bangladesh
pediatr
oncolog
usual
practic
oncolog
unit
pediatr
divis
differ
public
hospit
along
privat
hospit
howev
survey
confirm
mani
children
lack
access
qualiti
palli
care
effect
palli
care
requir
establish
facil
cancer
registri
avail
drug
therapi
pain
manag
manpow
develop
commun
patient
famili
bodi
mass
index
screen
bacteremia
among
pediatr
cancer
patient
febril
neutropenia
r
ojha
km
johnson
b
phillip
caniza
depart
epidemiolog
cancer
control
st
jude
children
research
hospit
memphi
usa
depart
infecti
diseas
hospit
infantil
de
mexico
federico
gomez
mexico
citi
mexico
depart
infecti
diseas
st
jude
children
research
hospit
memphi
usa
centr
review
dissemin
univers
york
york
unit
kingdom
object
current
avail
clinic
predict
model
suboptim
screen
bacteremia
among
pediatr
cancer
patient
febril
neutropenia
addit
better
marker
bacteremia
may
improv
screen
given
evid
support
associ
bodi
mass
index
bmi
infect
explor
whether
bmi
could
improv
screen
bacteremia
among
pediatr
cancer
patient
febril
neutropenia
mexico
method
prospect
collect
data
febril
neutropenia
episod
among
pediatr
cancer
patient
admit
hospit
infantil
de
mexico
federico
gomez
mexico
citi
novemb
septemb
n
episod
febril
neutropenia
gener
estim
equat
logist
regress
use
predict
bacteremia
one
model
marker
commonli
use
previou
studi
protein
crp
hypotens
second
model
crp
hypotens
bmi
subsequ
estim
area
receiv
oper
characterist
curv
auc
correspond
confid
limit
cl
model
use
decis
curv
analysi
assess
clinic
net
benefit
ad
bmi
result
bacteremia
microbiolog
confirm
febril
neutropenia
episod
addit
bmi
improv
clinic
discrimin
bacteremia
bmi
auc
cl
without
bmi
auc
cl
model
bmi
also
yield
greater
clinic
net
benefit
compar
model
without
bmi
risk
threshold
conclus
result
suggest
bmi
may
promis
complementari
marker
screen
bacteremia
among
pediatr
cancer
patient
febril
neutropenia
particularli
individu
predict
bacteremia
risk
otherwis
clinic
ambigu
rang
ad
valu
bmi
screen
bacteremia
explor
geograph
area
could
particularli
use
countri
given
feasibl
measur
bmi
develop
integr
pediatr
palli
care
program
role
parent
volunt
peripher
clinic
nicaragua
r
ortiz
moya
l
pared
orozco
f
baltodano
r
carranza
n
ribera
pediatr
depart
manuel
de
jesu
rivera
la
mascota
children
hospit
managua
nicaragua
mapanica
parent
associ
manuel
de
jesu
rivera
la
mascota
children
hospit
managua
nicaragua
pediatr
peripher
clinic
matagalpa
region
hospit
matagalpa
nicaragua
pediatr
peripher
clinic
victoria
mota
region
hospit
jinotega
nicaragua
pediatr
peripher
clinic
est
region
hospit
est
nicaragua
object
backgroundpurpos
manuel
de
jesu
rivera
la
mascota
children
hospit
pediatr
cancer
unit
nicaragua
sinc
earli
pediatr
oncolog
staff
implement
palli
care
nation
ministri
health
introduc
palli
care
health
strategi
recommend
world
health
organ
although
nation
palli
care
protocol
exist
medic
staff
remain
unawar
presenc
low
incom
countri
patient
arriv
advanc
diseas
reason
program
develop
aim
provid
integr
palli
care
sinc
diagnosi
allevi
suffer
improv
qualiti
life
children
hospit
set
home
method
survey
assess
symptom
control
physician
report
famili
palli
care
set
perform
progress
diseas
oncolog
patient
newli
diagnos
find
survey
use
establish
work
plan
multidisciplinari
palli
care
team
result
patient
disturb
symptom
moder
control
half
famili
interview
refer
satisfi
commun
bad
news
prepar
termin
phase
multidisciplinari
meet
includ
parent
associ
volunt
member
staff
conduct
train
commun
skill
review
famili
need
assess
home
visit
member
mapanica
medic
nurs
staff
psychologist
social
worker
five
peripher
clinic
train
palli
care
three
five
clinic
provid
palli
care
follow
children
near
home
conclus
integr
effort
medic
personnel
parent
volunt
contribut
provid
good
palli
care
practic
countri
limit
resourc
assess
need
children
famili
contribut
improv
qualiti
care
feasibl
exercis
program
daili
clinic
practic
paediatr
oncolog
increas
motiv
benefit
platschek
l
kehe
f
berthold
ft
baumann
hk
institut
movement
neurosci
german
sport
univers
cologn
germani
children
hospit
univers
hospit
cologn
germani
institut
cardiolog
sport
medicin
german
sport
univers
cologn
germani
object
benefit
physic
activ
cancer
therapi
adult
well
document
addit
increas
physic
perform
posit
effect
qualiti
life
reduct
fatigu
syndrom
howev
paediatr
oncolog
approach
suffici
explor
well
control
exercis
programm
still
miss
purpos
physic
activ
paediatr
oncolog
investig
integr
exercis
program
paediatr
oncolog
furthermor
research
effect
intervent
motiv
benefit
result
could
underlin
need
exercis
therapi
use
support
care
paediatr
oncolog
method
ten
subject
malign
neoplasm
year
includ
intervent
includ
weekli
computer
exercis
program
three
month
intens
durat
depend
individu
day
form
contain
differ
sport
game
brief
emot
questionnair
answer
sport
unit
everi
month
integr
intervent
determin
dropout
analysi
number
intervent
result
subject
perform
averag
approxim
sport
unit
minut
dropout
sport
unit
mean
heart
rate
approxim
beat
per
minut
comparison
show
signific
increas
overal
motiv
state
includ
social
accept
readi
strain
willing
seek
contact
p
conclus
show
physic
activ
well
integr
paediatr
oncolog
clinic
practic
furthermor
exercis
intervent
produc
verifi
motiv
benefit
result
indic
import
physic
activ
qualiti
surviv
paediatr
oncolog
exercis
could
restor
piec
normal
children
live
help
handl
psycholog
side
effect
chemotherapi
studi
explor
approach
support
natur
need
movement
need
effect
malnutrit
treatment
relat
morbid
trm
surviv
children
cancer
nicaragua
pribnow
r
ortiz
f
baez
l
mendieta
depart
pediatr
stanford
univers
palo
alto
usa
depart
hematologyoncolog
children
hospit
manuel
de
jesu
rivera
la
mascota
managua
nicaragua
hematologyoncologysctcanc
biolog
stanford
univers
palo
alto
usa
depart
nutrit
children
hospit
manuel
de
jesu
rivera
la
mascota
managua
nicaragua
object
children
cancer
live
countri
rate
malnutrit
often
high
studi
aim
identifi
relationship
malnutrit
treatment
relat
morbid
trm
abandon
therapi
relaps
death
children
cancer
nicaragua
better
inform
target
nutrit
intervent
method
retrospect
studi
patient
age
year
newli
diagnos
aml
wilm
tumor
hodgkin
diseas
burkitt
lymphoma
januari
decemb
treat
children
hospit
manuel
de
jesu
rivera
managua
nicaragua
children
includ
nutrit
evalu
record
diagnosi
statist
analysi
examin
relationship
nutrit
statu
cancer
type
risk
categori
trm
surviv
ef
use
data
pond
databas
result
patient
includ
studi
malnourish
diagnosi
malnutrit
highest
among
wilm
tumor
burkitt
lymphoma
aml
lowest
hodgkin
diseas
malnourish
patient
inferior
ef
vs
year
signific
across
distribut
p
malnutrit
associ
abandon
year
p
patient
includ
trm
analysi
almost
experienc
morbid
first
day
treatment
experienc
sever
grade
morbid
malnutrit
significantli
associ
sever
infect
p
specif
morbid
type
malnourish
patient
sever
morbid
higher
proport
day
p
like
experi
sever
morbid
day
p
ci
conclus
pediatr
oncolog
patient
nicaragua
malnutrit
diagnosi
experi
increas
trm
particularli
sever
infect
inferior
ef
standard
nutrit
evalu
newli
diagnos
patient
target
provis
nutrit
support
essenti
decreas
trm
improv
outcom
identif
issu
involv
road
diagnosi
childhood
cancer
develop
countri
j
pulivadula
venkatasai
jx
scott
rajendran
r
manipriya
ms
latha
dept
pediatr
divis
sri
ramachandra
medic
colleg
research
institut
chennai
india
object
cure
rate
children
childhood
malign
countri
hic
howev
cure
rate
much
lower
mani
low
incom
countri
lic
global
estim
children
develop
cancer
year
live
develop
countri
unfortun
late
present
delay
diagnosi
childhood
cancer
remain
problem
develop
countri
principl
object
studi
assess
referr
pattern
identif
issu
relat
road
diagnosi
childhood
cancer
india
method
famili
children
undergo
treatment
particip
studi
parentsguardian
interview
prepar
questionnair
session
studi
period
aug
result
patient
hematolog
malign
male
femal
mean
age
year
diagnost
delay
patient
attribut
healthcar
system
delay
median
delay
day
mean
day
rang
parent
delay
significantli
higher
patient
rural
area
whose
parent
lower
level
educ
highest
day
diagnosi
physician
delay
rel
shorter
patient
visit
pediatrician
patient
whose
first
health
contact
gener
physician
specialti
number
differ
contact
hospit
admiss
health
system
signific
factor
caus
delay
diagnosi
median
number
healthcar
visit
parent
averag
number
day
admiss
day
evalu
specialist
geograph
distanc
access
tertiari
healthcar
also
posit
associ
diagnost
delay
conclus
prompt
earli
diagnosi
cancer
consid
corner
stone
healthi
prognosi
patient
outcom
surgic
insert
total
implant
venou
access
devic
institut
experi
pakistan
aq
qazi
zq
feroza
latif
surgic
oncolog
shaukat
khanum
memori
cancer
hospit
research
centr
lahor
pakistan
depart
paediatr
urolog
children
hospit
lahor
pakistan
object
determin
outcom
surgic
insert
total
implant
venou
access
devic
tivad
children
cancer
hospit
develop
world
method
retrospect
studi
patient
tivad
children
requir
chemotherapi
cancer
procedur
perform
special
cancer
hospit
pakistan
period
studi
june
june
data
retriev
hospit
inform
system
use
identifi
paramet
analys
use
spss
result
total
patient
underw
tivad
insert
studi
period
indic
insert
devic
chemotherapi
cancer
patient
male
one
hundr
seventeen
patient
lost
follow
tivad
place
line
either
remov
complet
treatment
due
infect
blockag
line
total
devic
remov
prior
complet
therapi
tivad
remov
due
infect
proven
microbiolog
cultur
line
tip
mean
life
devic
patient
day
studi
could
find
correl
neutropenia
line
infect
p
studi
factor
respons
earli
remov
line
larg
number
patient
lost
follow
role
nurs
care
long
distanc
hospit
advanc
stage
cancer
devic
care
also
highlight
conclus
benefit
central
venou
devic
chemotherapi
deni
howev
challeng
care
devic
chariti
cancer
hospit
develop
countri
set
studi
proven
tivad
safe
insert
manag
chemotherapi
children
low
resourc
set
extra
vigil
care
devic
place
vancomycin
resist
enterococci
colon
infect
children
cancer
farid
ragab
girgi
w
sarhan
pediatr
univers
cairo
egypt
clinic
patholog
univers
cairo
egypt
object
enterococci
vre
previous
report
respons
seriou
infect
studi
aim
identifi
risk
factor
resist
profil
associ
vre
intestin
colon
infect
cohort
children
cancer
method
seventi
five
children
includ
studi
divid
group
group
includ
cancer
outpati
symptom
sign
suggest
infect
neutrophil
count
group
includ
cancer
inpati
admit
febril
neutropenia
group
includ
healthi
age
sex
match
children
control
stool
analysi
rectal
swab
blood
cultur
perform
inpati
admiss
day
later
outpati
control
studi
rectal
swab
stool
analysi
analysi
sampl
includ
cultur
isol
identif
detect
suscept
isol
antibiot
result
median
durat
admiss
day
blood
cultur
show
vre
isol
vre
detect
one
inpati
admiss
compar
patient
one
week
p
infect
inpati
signific
lower
neutrophil
count
compar
one
p
meanwhil
signific
differ
age
sex
durat
neutropenia
durat
admiss
infect
inpati
p
use
vancomycin
metronidazol
imipinem
antibiot
significantli
higher
infect
vre
compar
one
p
twenti
eight
percent
inpati
posit
stool
cultur
one
week
enterococci
found
inpati
day
post
admiss
compar
one
week
post
admiss
conclus
conclud
children
cancer
high
risk
vre
colon
infect
sever
neutropenia
excess
use
vancomycin
import
risk
factor
invas
posit
pressur
ventil
children
febril
neutropenia
five
year
experi
paediatr
oncolog
intens
care
unit
k
riad
abdel
hadi
ghazal
mokhtar
pediatr
oncolog
south
egypt
cancer
institut
assiut
egypt
pediatr
oncolog
natin
cancer
institut
cairo
egypt
pediatr
hematolgi
faculti
medecin
assiut
egypt
pediatr
icu
faculti
medecin
assiut
egypt
object
evalu
feasibl
outcom
posit
pressur
ventil
ippv
children
febril
neutropenia
due
haematolog
malign
method
design
observ
retrospect
cohort
studi
set
pediatr
intens
care
unit
univers
hospit
patient
children
hematolog
cancer
febril
neutropenia
treat
ippv
regardless
indic
five
consecut
year
result
total
patient
includ
patient
success
treat
ippv
success
rate
ippv
significantli
lower
patient
acut
respiratori
distress
syndrom
p
patient
conclus
studi
demonstr
feasibl
efficaci
ippv
daili
practic
pediatr
oncolog
intens
care
uni
ventilatori
support
could
propos
treatment
children
acut
respiratori
distress
role
procalcitonin
diagnosi
sever
sepsi
clinic
outcom
critic
ill
febril
neutropen
children
cancer
k
riad
amr
abdel
hadi
ghazal
mokhtar
eman
zaki
pediatr
oncolog
south
egypt
cancer
institut
assiut
egypt
anathesea
icu
south
egypt
cancer
institut
assiut
egypt
pediatr
oncolog
nation
cancer
institut
cairo
egypt
pediatr
oncolog
faculti
medecin
assiut
egypt
pediatr
faculti
medecin
assiut
egypt
clinic
patholog
south
egypt
cancer
inestitut
assiut
egypt
object
evalu
signific
earli
diagnost
serum
procalcitonin
pct
febril
neutropen
children
valu
icu
admiss
outcom
method
studi
conduct
episod
febril
neutropen
children
hematolog
malign
present
south
egypt
cancer
institut
seci
diagnosedwith
fever
neutropenia
prior
treatment
antimicrobi
therapi
present
episod
patient
divid
two
equal
group
group
group
b
group
classifi
high
risk
group
hr
low
risk
group
lr
patient
group
complet
blood
count
serum
procalcitonin
pct
first
day
admiss
blood
cultur
cultur
sputum
urin
wound
liver
function
kidney
function
random
blood
sugar
serum
electrolyt
chest
radiograph
done
result
number
unimprov
patient
studi
gram
isol
patient
gram
isol
die
aliv
growth
unimprov
patient
patient
sepsi
level
pct
patient
system
infect
patient
local
infect
level
pct
differ
statist
signific
p
high
risk
patient
treat
insid
icu
patient
improv
treat
outsid
icu
patient
improv
differ
statist
signific
studied
group
case
put
mechan
ventil
patient
profound
neutropenia
patient
sepsi
level
serum
pct
level
patient
improv
conclus
sepsi
level
serum
pct
use
marker
suggest
sever
sepsi
estim
serum
pct
support
decis
start
antibiot
therapi
icu
admiss
infect
pattern
neutropen
children
phase
hematolog
malign
treatment
k
riad
abdel
hadi
h
ghazal
mokhtar
eman
zaki
pediatr
oncolog
south
egypt
cancer
institut
assiut
egypt
pediatr
oncolog
nation
cancer
inestitut
cairo
egypt
pediatr
assiut
univers
chidren
hospit
assiut
egypt
pediatr
icu
assiut
univers
chidren
hospit
assiut
egypt
clinic
patholog
south
egypt
cancer
inestitut
assiut
egypt
object
neutropenia
follow
chemotherapi
regimen
hematolog
malign
children
major
concern
sinc
make
patient
vulner
infect
studi
tri
identifi
pattern
infect
antibiot
resist
method
retrospect
studi
took
place
includ
patient
hematolog
malignaci
febril
least
hour
order
assess
type
infect
studi
took
place
place
egypt
result
posit
cultur
seen
bacteria
domin
e
coli
coloni
also
antibiogram
reveal
sensit
almost
amino
glycosid
contrast
literatur
conclus
patient
common
caus
infect
therefor
administ
amino
glycosid
would
safest
antibiot
therapi
prescrib
cultur
result
avail
impact
estim
serum
pct
level
earli
diagnost
marker
bacteremia
febril
neutropen
children
k
riad
abdel
hadi
h
ghazal
pediatr
oncolog
south
egypt
cancer
institut
assiut
egypt
object
mani
studi
succeed
identifi
subset
children
febril
neutropenia
fn
lower
higher
risk
infecti
complic
eventu
death
small
discuss
impact
estim
diagnost
marker
bacteremia
procalcitonin
pct
method
januari
juli
episod
fn
children
includ
prospect
studi
south
egypt
cancer
institut
assiut
univers
assiut
egypt
evalu
outcom
febril
neutropenia
children
hematolog
malign
determin
impact
estim
diagnost
marker
bacteremia
procalcitonin
pct
result
present
studi
profound
neutropenia
anc
less
significantli
observ
high
risk
febril
neutropen
patient
observ
also
patient
high
pct
level
sepsi
level
ie
ngml
system
infect
level
ngml
patient
posit
blood
cultur
comparison
pateint
mild
moder
neutropenia
anc
profound
neutropenia
also
signfcantli
observ
associ
monocytopenia
comparison
mild
moder
neutropenia
patient
profound
neutropenia
also
signfcantli
observ
laibl
develop
shock
higher
anc
bacteriolog
document
infect
detect
neutropen
episod
gram
posit
infect
detect
patient
gram
neg
detect
patient
growth
grame
neg
infect
signifcantli
observ
high
risk
febril
neutropenia
epesod
associ
poor
prognosi
conclus
conclud
sepsi
level
serum
pct
use
marker
strongli
suggest
sever
sepsi
bacteriolog
document
infect
serum
level
pct
may
help
stratif
patient
febril
neutropenia
high
risk
low
risk
group
venou
catheter
mirror
russian
pediatr
oncolog
rykov
e
gyokova
v
polyakov
gener
oncolog
institut
pediatr
oncolog
hematolog
n
n
blokhin
moscow
russia
object
treatment
oncolog
diseas
imposs
without
venou
access
kind
properti
possess
safe
easi
use
implant
treatment
cours
minim
risk
associ
implant
use
method
monitor
treatment
children
age
month
year
oncolog
diseas
patient
underw
subclavian
vein
catheter
patient
venou
port
implant
result
complic
technic
difficulti
cathet
insert
observ
case
venou
port
implant
case
complic
subclavian
cathet
venou
port
use
observ
case
respect
subclavian
cathet
compromis
cancer
treatment
patient
implant
venou
port
patient
patient
subclavian
cathet
underw
central
venou
catheter
time
mean
time
treatment
cathet
dwell
time
exceed
recommend
limit
patient
except
case
cathet
remov
patient
multipl
occas
patient
discharg
subclavian
cathet
place
conclus
venou
port
obvious
match
criteria
mention
introduct
subclavian
cathet
use
result
cancer
treatment
protocol
deviat
almost
case
thu
lead
poorer
prognosi
significantli
increas
number
invas
procedur
instanc
gener
anesthesia
need
applic
epidur
implant
access
system
pain
manag
incur
patient
rykov
v
polyakov
gener
oncolog
institut
pediatr
oncolog
hematolog
n
n
blokhin
moscow
russia
object
domiciliari
chronic
pain
syndrom
manag
incur
patient
dissemin
cancer
paramount
import
improv
qualiti
life
method
period
incur
patient
variou
type
cancer
age
year
mean
age
year
underw
epidur
access
system
implant
epidur
space
catheter
interspac
perform
follow
ensur
cathet
proper
placement
cm
skin
incis
blunt
dissect
subcutan
tissu
made
cathet
exit
site
clip
cathet
fixat
insert
creat
subcutan
space
sewn
adjac
tissu
port
implant
soft
tissu
right
rib
cathet
thread
subcutan
tunnel
port
incis
clip
port
close
layer
huber
needl
use
access
port
choic
type
dosag
analges
base
pain
syndrom
sever
well
cancer
local
stage
result
patient
note
improv
qualiti
life
improv
emot
state
almost
complet
pain
relief
patient
current
aliv
die
due
cancer
progress
epidur
implant
access
system
use
month
infect
occlus
system
observ
one
patient
experienc
blood
pressur
drop
due
opioid
analges
overdos
conclus
epidur
access
system
facilit
pain
syndrom
manag
improv
qualiti
life
reduc
opioid
dose
besid
rout
opioid
administr
commonli
associ
advers
effect
howev
introduct
epidur
access
system
russian
medic
set
stall
due
absenc
qualifi
medic
staff
hospic
well
outpati
depart
provid
care
incur
patient
recombin
human
solubl
thrombomodulin
safe
effici
use
dissemin
intravascular
coagul
dic
childhood
acut
promyelocyt
leukemia
apl
saito
yuza
ishimaru
yokokawa
kaneko
haematologyoncolog
tokyo
metropolitan
children
medic
hospit
tokyo
japan
object
patient
apl
usual
complic
dic
onset
occasion
lead
hemorrhag
efficaci
heparin
anticoagul
antifibrinolyt
therapi
remain
question
manag
dic
complic
apl
new
anticoagul
recombin
human
solubl
thrombomodulin
rtm
approv
treatment
dic
japan
retrospect
evalu
safeti
efficaci
rtm
treatment
dic
childhood
apl
method
review
three
patient
dic
associ
underlin
untreat
apl
treat
rtm
octob
februari
rtm
use
recommend
dosag
adult
ukgday
toxic
profil
grade
base
ctcae
diagnosi
dic
base
criteria
releas
japanes
ministri
health
labor
welfar
concurr
treatment
fresh
frozen
plasma
platelet
transfus
administ
anticoagul
therapi
perform
endpoint
efficaci
complet
resolut
bleed
disord
petechia
purpura
gingiv
hemorrhag
intramuscular
bleed
result
three
patient
apl
present
bleed
disord
onset
apl
median
age
diagnosi
year
rang
durat
rtm
treatment
day
rang
dic
statu
resolv
median
day
rang
bleed
disord
recov
median
day
rang
initi
rtm
patient
experienc
sever
hemorrhag
complic
well
grade
toxic
relat
rtm
neither
clinic
need
conclus
administr
rtm
treatment
dic
relat
childhood
apl
appear
safe
probabl
effect
control
hemorrhag
complic
dic
larg
prospect
trial
necessari
confirm
efficaci
safeti
rtm
treatment
dic
childhood
apl
prophylact
use
octreotid
acut
pancreat
sakaguchi
higa
suzuki
j
fujimura
shimizu
depart
pediatr
juntendo
univers
faculti
medicin
tokyo
japan
depart
pediatr
hematolog
oncolog
okinawa
prefectur
nanbu
medic
center
children
medic
center
okinawa
japan
object
acut
pancreat
develop
patient
acut
lymphoblast
leukemia
treat
asparaginas
asparaginas
often
avoid
risk
pancreat
recurr
octreotid
synthet
somatostatin
analogu
suggest
use
treatment
acut
pancreat
although
abil
prevent
pancreat
fulli
evalu
purpos
studi
evalu
prophylact
use
octreotid
acut
pancreat
method
perform
retrospect
chart
review
two
institut
evalu
pediatr
patient
experienc
pancreat
underw
prophylact
octreotid
treatment
asparaginas
also
perform
literatur
review
use
pubm
follow
search
term
octreotid
pancreat
asparaginas
result
identifi
seven
patient
receiv
prophylact
octreotid
two
institut
patient
four
experienc
recurr
pancreat
asparaginas
three
complet
treatment
without
recurr
literatur
review
yield
three
addit
case
recurr
among
six
patient
without
recurr
sever
first
episod
pancreat
grade
four
patient
grade
two
patient
among
four
patient
recurr
pancreat
sever
grade
three
patient
grade
one
patient
advers
event
associ
octreotid
report
patient
conclus
result
suggest
prophylact
use
octreotid
prevent
pancreat
therefor
asparaginas
octreotid
may
warrant
patient
mild
moder
pancreat
patient
sever
pancreat
howev
asparaginas
requir
caution
catatonia
cours
hsct
patient
aml
samardakiewicz
k
drabko
makarewicz
j
kowalczyk
pediatr
hematolog
oncolog
transplantolog
medic
univers
lublin
poland
chair
depart
psychiatri
spsk
lublin
poland
object
cataton
disord
form
inert
negativ
mutism
hyperact
echolalia
echopraxia
occur
rare
treatment
seriou
somat
diseas
sometim
catatonia
may
develop
result
psychic
trauma
aim
studi
present
catatonia
case
studi
femal
aml
treat
hsct
method
analysi
medic
histori
avail
lab
test
well
interdisciplinari
consult
basi
cataton
disord
diagnos
among
patient
hospit
due
sever
post
transplant
complic
result
patient
aml
deriv
md
treat
accord
aml
bfm
interimphas
protocol
requir
two
mud
pbsct
treatment
complic
occur
kidney
multiorgan
failur
requir
hemodialysi
day
ist
mud
pbsct
paroxysm
disord
observ
form
head
arm
shake
anxieti
without
lose
conscienc
without
sleepi
seizur
well
episod
sight
percept
disord
day
iind
mud
pbsct
progress
loss
verbal
contact
period
agit
activ
resist
attempt
move
feed
catalepsi
due
patient
multipl
time
consult
eeg
mri
ct
examin
organ
basi
disord
exclud
patient
state
imposs
explain
also
balanc
metabol
state
secondari
psychiatr
opinion
patient
classifi
pharmacolog
treatment
electroshock
therapi
question
due
deterior
somat
state
patient
progress
symptom
muscl
flaccid
psychiatr
treatment
cancel
week
start
conclus
cataton
disord
treatment
aggrav
somat
diseas
rare
diagnos
due
diagnost
difficulti
especi
among
patient
variou
complic
risk
diagnos
disord
diagnosi
catatonia
among
adolesc
cancer
treatment
requir
multidimension
diagnost
prior
difficult
therapeut
decis
undertak
proper
catatonia
treatment
threat
patient
life
frequenc
occur
mental
disord
among
adolesc
treat
cancer
samardakiewicz
makarewicz
k
faber
j
kowalczyk
pediatr
hematolog
oncolog
transplantolog
medic
univers
lublin
poland
chair
depart
psychiatri
spsk
lublin
poland
depart
psycholog
univers
maria
sklodowska
curi
lublin
poland
object
pediatr
cancer
intens
emot
physic
experi
patient
famili
comprehens
psychiatr
assess
children
complic
symptom
medic
comorbid
overlap
mental
health
condit
aim
studi
analysi
frequenc
symptom
mental
disord
among
adolesc
treat
cancer
method
jan
feb
consecut
adolesc
diagnos
cancer
hospit
singl
pediatr
oncolog
centr
lublin
poland
follow
patient
exclud
studi
patient
hospit
due
neutropenia
stem
cell
separ
mental
retard
patient
enter
studi
femal
averag
age
diagnosi
list
psychiatr
symptom
lp
use
assess
mental
function
result
patient
show
symptom
mental
disord
consult
psychiatrist
among
children
psychiatr
treatment
use
averag
time
occur
symptom
moment
diagnosi
month
among
femal
follow
symptom
frequent
talk
death
frequent
cri
low
refus
eat
decreas
concentr
mutism
p
moreov
among
patient
treatment
complic
aggrav
psychiatr
symptom
observ
talk
death
irrit
affect
instabl
sad
low
mood
anxieti
social
withdraw
lack
interest
environ
anhedonia
p
talk
death
anhedonia
frequent
observ
patient
oeteosarcoma
p
alarm
symptom
observ
patient
leukemia
among
conscienc
orient
disord
occur
observ
patient
lymphoma
solid
tumor
conclus
one
fourth
adolesc
cancer
reveal
differ
psychiatr
symptom
patient
consult
psychiatrist
treat
antidepress
lp
questionnair
use
clinic
tool
need
research
method
better
psychometr
featur
preval
symptomat
asymptomat
thrombosi
pediatr
oncolog
patient
tunnel
central
venou
cathet
r
schoot
van
de
weter
stijnen
w
tiss
h
heij
j
lieverst
l
spanjaard
hn
caron
ch
van
ommen
paediatr
oncolog
emma
children
hospitalacadem
medic
center
amsterdam
netherland
medic
statist
bioinformat
univers
leiden
leiden
netherland
paediatr
haematologyoncolog
univers
groningen
groningen
netherland
paediatr
surgeri
academ
medic
centr
vu
amsterdam
amsterdam
netherland
data
manag
dutch
childhood
oncolog
group
hagu
netherland
microbiolog
academ
medic
centr
amsterdam
netherland
paediatr
oncolog
emma
children
hospitalacadem
medic
centr
amsterdam
netherland
paediatr
haematolog
emma
children
hospitalacadem
medic
centr
amsterdam
netherland
paediatr
support
care
dutch
childhood
oncolog
group
hagu
netherland
object
pediatr
oncolog
patient
increas
risk
develop
venou
event
vte
time
higher
gener
pediatr
popul
incid
vte
pediatr
cancer
patient
cvc
vari
wide
among
studi
object
studi
determin
preval
symptomat
venou
event
vte
pediatr
oncolog
patient
tunnel
central
venou
cathet
cvc
method
systemat
screen
symptomat
vte
patient
includ
aristocath
studi
random
control
trial
investig
prophylact
effect
ethanol
lock
bloodstream
infect
cabsi
patient
monitor
clinic
symptomat
vte
ultrasound
us
end
studi
six
month
unless
patient
develop
one
follow
event
symptomat
vte
cabsi
cvc
remov
death
result
includ
patient
hematolog
malign
n
solid
tumor
n
symptomat
vte
patient
evalu
asymptomat
vte
twenti
patient
develop
vte
patient
develop
symptomat
vte
n
patient
evalu
us
asymptomat
vte
one
patient
diagnos
asymptomat
non
vte
signific
differ
symptomat
asymptomat
vte
ethanol
heparin
treatment
group
p
p
respect
conclus
first
systemat
assess
symptomat
vte
larg
cohort
pediatr
oncolog
patient
preval
symptomat
vte
asymptomat
vte
rate
lower
preval
report
literatur
may
part
explain
inclus
patient
solid
tumor
also
reduct
cabsi
ethanol
lock
may
influenc
develop
asymptomat
vte
clinic
evalu
oral
mucos
children
lymphoma
solid
tumor
b
sevinir
demirkaya
pediatr
oncolog
uludag
univers
medic
faculti
bursa
turkey
object
aim
studi
compar
demograph
clinic
characterist
children
without
oral
mucos
receiv
chemotherapi
cancer
method
studi
conduct
prospect
total
children
receiv
chemotherapi
lymphoma
solid
tumor
may
may
age
sex
diagnosi
chemotherapi
regimen
presenc
daili
oral
care
time
begin
chemotherapi
oral
mucos
durat
oral
mucos
record
sever
oral
mucos
assess
oral
toxic
scale
result
mean
age
patient
month
median
yr
patient
lymphoma
cn
tumor
bone
tumor
solid
tumor
case
develop
oral
mucos
sever
compar
accord
tumor
subgroup
signific
differ
patient
without
oral
mucos
mucos
observ
patient
lymphoma
patient
bone
sarcoma
mucos
ratio
hodgkin
lymphoma
case
patient
without
oral
mucos
appli
daili
oral
care
rate
patient
mucos
mean
time
onset
chemotherapi
develop
oral
mucos
found
day
mean
durat
oral
mucos
found
day
respect
recurr
oral
mucos
observ
patient
conclus
patient
lymphoma
bone
tumor
major
risk
group
develop
oral
mucos
daili
oral
care
anoth
factor
lower
mucos
ratio
studi
experi
opinion
break
bad
news
survey
childhood
cancer
survivor
parent
e
song
park
c
hong
h
joo
j
lee
h
kang
k
park
h
shin
depart
pediatr
cancer
research
institut
seoul
nation
univers
colleg
medicin
seoul
korea
object
purpos
studi
childhood
cancer
survivor
parent
diagnos
cancer
relat
awar
know
cancer
diagnosi
prefer
cancer
diagnosi
disclosur
intend
identifi
method
survey
conduct
patient
famili
member
diagnos
childhood
cancer
patholog
diagnosi
cancer
institut
juli
januari
patient
multipl
origin
carcinogenesi
tumor
histori
psychiatr
ill
exclud
patient
experienc
one
treatment
chemotherapi
radiat
therapi
surgeri
result
survey
dyad
pediatr
cancer
survivor
age
year
parent
answer
multipl
choic
question
respect
two
hundr
five
parent
knew
child
diagnosi
cancer
survivor
survivor
knew
diagnosi
one
hundr
parent
want
physician
explain
treatment
plan
prognosi
also
inform
survivor
contrast
parent
want
hear
diagnosi
first
explain
children
fifti
parent
want
physician
explain
directli
children
parent
nt
want
inform
diagnosi
children
among
survivor
survivor
inform
cancer
diagnosi
parent
inform
physician
respect
conclus
health
care
provid
effect
convey
inform
tailor
emot
need
patient
famili
experienc
never
experi
diagnos
cancer
role
abl
motiv
activ
particip
treatment
import
supervis
exercis
train
program
encourag
children
adolesc
cancer
practic
sport
f
spreafico
murelli
ferrari
terenziani
p
fanelli
b
giacon
l
veneroni
l
gandola
f
gariboldi
massimino
pediatr
oncolog
unit
hematolog
pediatr
depart
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
studio
fisioterapico
murelli
vergnaghi
srl
studio
fisioterapico
murelli
vergnaghi
srl
milano
itali
pediatr
depart
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
pediatr
radiotherapi
unit
depart
diagnost
imag
radiat
oncolog
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
palli
care
pain
servic
riabilit
unit
fondazion
ircc
istituto
nazional
dei
tumori
milano
itali
object
evid
posit
effect
physic
activ
children
adolesc
cancer
grow
past
dogma
cancer
diagnosi
preclud
particip
exercis
train
prevail
primari
object
hospit
outdoor
exercis
intervent
explor
effect
strategi
promot
physic
activ
cancer
patient
soon
treatment
method
characterist
exercis
train
program
develop
institut
gym
instal
floor
treadmil
exercis
bike
train
equip
supervis
treat
clinic
care
team
three
sport
profession
provid
individu
train
program
phase
cardiovascular
train
tone
exercis
exercis
muscl
stretch
connect
institut
physiotherapi
servic
joint
structur
outdoor
adventur
activ
sail
result
pilot
period
patient
particip
give
high
demand
move
twice
weekli
attend
delic
relat
individu
whish
capabl
possibl
alter
cancer
sometim
call
parallel
psychosoci
intervent
adapt
sport
meet
need
patient
disabl
report
benefit
activ
sport
engag
includ
recov
live
work
bodi
new
opportun
relat
comfort
without
frustrat
peer
limit
stay
difficulti
measur
physic
mental
condit
studi
conclus
hospit
exercis
train
demonstr
feasibl
treatment
improv
access
play
exercis
space
patient
despit
physic
activ
link
physic
psychosoci
integr
base
harmon
recommend
guid
particip
sport
activ
patient
treatment
might
help
treat
oncologist
knowledg
individu
medic
histori
provid
exercis
guidanc
move
safe
nearli
everi
patient
aknowledg
associazion
bianca
garavaglia
analysi
risk
factor
bacteraemia
among
children
cancer
earli
diagnost
j
suvada
plesko
sykora
e
kaiserova
sejnova
l
perdochova
children
hematolog
oncolog
st
elizabeth
univers
public
health
social
scienc
bratislava
slovakia
children
hematolog
oncolog
children
teach
hospit
bratislava
slovakia
hpl
dept
microbiolog
bratislava
slovakia
object
common
complic
cancer
therapi
occur
bacteri
infect
key
factor
risk
predict
bacteri
infect
consist
andreli
identifi
patient
risk
sever
risk
predict
model
propos
appli
pediatr
patient
method
studi
retrospect
analyt
studi
enrol
accord
criteria
patient
cancer
receiv
treatment
januari
februari
clinic
children
hematolog
oncolog
bratislava
slovakia
evalu
patient
hematolog
malign
well
studi
group
patient
posit
hemocultur
result
patient
staphylococci
con
respons
posit
hemocultur
clinic
present
median
patient
year
bacteraemia
patient
develop
infect
hai
develop
infect
hr
admiss
hospit
enrol
group
infect
cai
crp
procalcitonin
statisticali
signific
predictor
bacteri
inflam
marker
differenci
diagnosi
central
venos
cathet
group
hai
confirm
multidrug
resist
strain
hemocultur
patient
receiv
prior
admiss
antimicrobi
therapi
frequent
isol
staphylococci
corynebacterium
spp
ps
aeruginosa
enterobact
spp
klebsiella
spp
e
coli
enterococci
studi
patient
laboratori
confirm
bloodstream
infect
die
conclus
studi
observ
frequent
use
antimicrobi
drug
prior
blood
cultur
may
crucial
impact
detect
antibiot
test
suscept
commonli
use
antibiot
lack
mortal
definit
studi
children
adolesc
young
adult
lymphoma
solid
tumor
brain
tumor
systemat
review
th
tran
lee
alexand
p
gibson
u
bartel
johnson
c
portwin
silva
j
pole
l
sung
haematologyoncolog
hospit
sick
children
toronto
canada
child
health
evalu
scienc
hospit
sick
children
toronto
canada
pediatr
london
health
scienc
center
london
canada
haematologyoncolog
children
hospit
eastern
ontario
ottawa
canada
haematologyoncolog
mcmaster
children
hospit
hamilton
canada
haematologyoncolog
cancer
center
southeastern
ontario
kingston
canada
haematologyoncolog
pediatr
oncolog
group
ontario
toronto
canada
object
lack
standard
definit
mortal
trm
repres
import
endpoint
cancer
object
determin
frequenc
trm
defin
describ
util
trm
definit
among
studi
lymphoma
solid
tumor
brain
tumor
method
conduct
systemat
review
studi
enrol
children
adolesc
young
adult
lymphoma
solid
tumor
brain
tumor
intervent
random
studi
design
trm
primari
secondari
outcom
search
ovid
medlin
embas
medicin
review
june
two
review
evalu
studi
elig
abstract
data
result
total
titl
abstract
review
full
articl
retriev
detail
evalu
random
therapeut
studi
studi
trm
primari
secondari
outcom
trm
studi
satisfi
elig
criteria
includ
systemat
review
none
studi
provid
definit
trm
therapeut
trm
studi
report
trm
rate
among
therapeut
studi
trm
rate
rang
mean
patient
popul
consist
neuroblastoma
n
rhabdomyosarcoma
n
medulloblastoma
n
soft
tissu
sarcoma
n
hodgkin
lymphoma
n
lymphoma
n
hodgkin
lymphoma
patient
lowest
trm
rate
highest
trm
rate
report
among
neuroblastoma
patient
trm
studi
report
trm
rate
much
higher
rang
mean
conclus
unabl
identifi
trm
definit
use
studi
children
adolesc
young
adult
lymphoma
solid
tumor
brain
tumor
given
proport
patient
popul
may
receiv
intens
treatment
urgent
need
definit
trm
use
across
clinic
trial
prospect
pilot
studi
describ
expens
incur
famili
children
newli
diagnos
cancer
guatemala
bustamant
riva
de
pernillo
martiniuk
tsimicali
oncolog
unidad
nacion
de
oncologia
pediatrica
guatemala
guatemala
hemoncsctbio
cancer
divis
depart
pediatr
stanford
univers
stanford
usa
faculti
medicin
sydney
univers
sydney
australia
ingram
school
nurs
mcgill
univers
montreal
canada
object
resourc
poor
countri
parent
may
abandon
child
cancer
treatment
ensur
financi
sustain
famili
howev
precis
magnitud
ie
direct
cost
remain
unknown
guatemala
studi
object
identifi
cost
incur
famili
children
diagnos
cancer
period
prior
diagnosi
b
period
follow
diagnosi
method
ethic
approv
prospect
cost
ill
design
repeat
assess
time
frame
pilot
famili
household
perspect
parent
met
time
member
research
team
record
cost
resourc
util
valid
cost
diari
descript
statist
use
express
cost
guatemalan
quetzal
gtq
cost
analyz
accord
uniformli
determin
set
cost
categori
total
cost
comput
sum
cost
categori
result
eleven
famili
mean
monthli
incom
sd
report
util
cost
categori
cost
itemsresourc
ten
famili
elig
hospit
subsidi
follow
child
cancer
diagnosi
collect
famili
incur
total
sum
direct
cost
nearli
cost
attribut
food
travel
commun
famili
receiv
donat
cancer
commun
support
network
donat
payment
child
treatment
eg
use
health
servic
prior
diagnosi
medic
complementari
medicin
nearli
donat
monetari
given
famili
support
network
conclus
relianc
famili
scarc
resourc
philanthropi
subsidiesdon
essenti
diagnosi
treatment
children
cancer
guatemala
subsequ
grant
submiss
ensu
larger
studi
correl
famili
cost
abandon
therapi
outcom
develop
clinic
practic
guidelin
regard
support
care
childhood
cancer
netherland
priorit
topic
use
delphi
questionnair
e
loeffen
rl
mulder
vd
weter
lcm
kremer
wje
tiss
depart
pediatr
oncologyhematolog
beatrix
children
hospit
univers
medic
center
groningen
univers
groningen
groningen
netherland
depart
pediatr
oncolog
emma
children
hospit
academ
medic
center
amsterdam
netherland
object
current
nationwid
dutch
guidelin
support
care
children
cancer
year
old
evid
base
grow
support
need
clinic
practic
guidelin
cpg
bridg
gap
research
clinic
practic
howev
develop
cpg
time
consum
therefor
import
prioritis
subject
clinic
import
greatest
thu
object
prioritis
childhood
cancer
support
care
topic
develop
cpg
method
core
research
group
form
list
relev
topic
regard
support
care
childhood
cancer
topic
incorpor
modifi
delphi
questionnair
determin
order
develop
cpg
topic
support
care
childhood
cancer
see
figur
delphi
method
process
achiev
consensu
among
group
expert
pediatr
oncologist
pediatr
oncolog
nurs
pediatrician
involv
care
childhood
cancer
patient
base
anonym
iter
control
feedback
statist
group
respons
figur
outlin
delphi
method
use
questionnair
result
round
panellist
respond
five
topic
highest
score
round
infect
sepsi
febril
neutropenia
pain
nauseavomit
conclus
success
use
delphi
questionnair
priorit
childhood
cancer
support
care
topic
develop
clinic
practic
guidelin
first
step
toward
uniform
evid
base
dutch
guidelin
support
care
childhood
cancer
parent
talk
termin
ill
child
cancer
death
van
der
geest
van
den
l
van
vliet
pluijm
streng
e
michiel
r
pieter
darlington
pediatr
oncologyhematolog
erasmu
univers
medic
center
sophia
children
hospit
rotterdam
netherland
depart
palli
care
polici
rehabilit
cice
saunder
institut
king
colleg
london
unit
kingdom
school
health
scienc
univers
southampton
southampton
unit
kingdom
object
limit
data
avail
parent
reason
talk
termin
ill
child
death
studi
explor
parent
reason
convers
termin
ill
child
cancer
method
parent
ask
whether
talk
termin
ill
child
cancer
death
felt
decis
parent
talk
subsequ
ask
indic
reason
talk
parent
talk
ask
indic
convers
took
place
descript
qualit
analys
perform
identifi
emerg
theme
result
parent
talk
child
death
follow
theme
identifi
talk
death
reason
eg
unabl
cope
feel
confid
fear
consequ
prevent
pain
moment
reason
eg
child
want
talk
never
start
convers
avoid
convers
parent
percept
child
eg
alreadi
awar
young
parent
talk
death
use
stori
indic
simpli
tell
child
would
cure
allthough
major
parent
felt
good
decis
ten
parent
predominantli
base
subsequ
neg
emot
respons
child
conclus
major
parent
talk
termin
ill
child
death
parent
confid
uncertainti
consequ
play
import
part
reason
talk
child
addit
children
may
avoid
want
talk
alreadi
awar
impend
death
find
highlight
complex
engag
convers
role
clinician
support
parent
find
convers
difficult
euthanasia
minor
problem
patient
pediatrician
commun
van
gool
j
de
lepeleir
microbiolog
immunolog
ku
leuven
leuven
belgium
gener
medicin
ku
leuven
leuven
belgium
object
discuss
euthanasia
minor
flare
belgium
call
pediatrician
euthanasia
children
develop
legal
framework
practic
euthanasia
minor
pose
question
extent
neighbor
countri
need
perceiv
pediatr
oncologist
method
three
question
four
answer
sent
colleagu
email
list
ask
situat
adolesc
ask
express
person
opinion
afterward
result
colleagu
countri
answer
legal
framework
euthanasia
minor
exist
netherland
legal
framework
australia
austria
czech
republ
denmark
franc
hungari
ireland
israel
itali
norway
portug
slovenia
spain
sweden
uk
euthanasia
regul
state
us
germani
one
pediatrician
believ
discuss
start
develop
legal
framework
german
colleagu
repli
legal
framework
initi
develop
one
austria
czech
republ
denmark
hungari
ireland
israel
itali
norway
portug
slovenia
sweden
pediatrician
estim
question
develop
legal
framework
gener
popul
profession
categori
minor
gener
popul
pediatrician
estim
ask
legal
framework
australia
franc
germani
spain
uk
us
conclus
answer
came
canada
forti
two
pediatrician
took
chanc
write
person
comment
conclus
countri
legal
framework
euthanasia
minor
need
felt
gener
popul
pediatr
commun
nevertheless
debat
siop
might
need
sum
object
argument
help
discuss
issu
year
increas
resist
superbug
pediatr
oncolog
unit
tertiari
cancer
centr
correl
antibiot
util
commun
colon
vora
g
surwad
n
shah
tandon
prasad
g
chinnaswami
b
arora
banavali
pediatr
medic
oncolog
tata
memori
centr
mumbai
india
object
multi
drug
resist
organ
mdro
colon
infect
seriou
concern
due
associ
high
morbid
mortal
studi
undertaken
determin
tempor
trend
preval
mdro
pediatr
oncolog
unit
tertiari
cancer
centr
last
decad
correl
antibiot
util
commun
colon
method
analyz
preval
extend
spectrum
posit
esbl
carbapenem
resist
cre
vancomycin
resist
enterococci
vre
blood
cultur
audit
microbiolog
record
altern
year
result
blood
cultur
sent
posit
incid
esbl
vre
respect
cre
blood
cultur
sent
posit
preval
esbl
cre
respect
cultur
posit
cre
esbl
respect
blood
cultur
posit
esbl
cre
pan
sensit
bacteria
total
blood
cultur
sent
total
show
posit
esbl
cre
pan
sensit
organ
correl
antibiot
util
reveal
increas
use
carbapenem
well
colistin
patient
admiss
pediatr
oncolog
unit
assess
stool
cultur
rectal
swab
show
bacteri
growth
esbl
mdro
vre
rectal
swab
newli
regist
outpati
show
mdro
esbl
posit
conclus
studi
show
increas
trend
multidrug
resist
tertiari
cancer
care
centr
develop
countri
colon
mdro
commun
danger
trend
would
requir
stringent
polici
decis
curb
epidem
retrospect
clinic
analysi
neutropen
enterocol
childhood
acut
leukemia
h
xiong
j
fan
j
li
h
li
w
cai
hematolog
oncolog
wuhan
children
hospit
wuhan
china
object
summar
clinic
characterist
neutropen
enterocol
ne
secondari
childhood
acut
leukemia
al
method
pediatr
al
patient
diagnos
ne
januari
decemb
retrospect
analyz
clinic
featur
manag
experi
outcom
result
among
patient
diagnos
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
averag
age
diagnos
year
old
patient
present
enterocolit
symptom
fever
abdomin
distens
rigid
neutropenia
abdomin
imag
reveal
differ
sever
intestin
caviti
expans
bowel
wall
thicken
treatment
procedur
includ
fast
total
peripher
nutrit
maintain
till
recoveri
neutrophil
count
intestin
peristalsi
function
given
power
antibiot
anti
fungal
necessari
transfus
blood
compon
ivig
concentr
red
cell
apheresi
platelet
apheresi
granulocyt
averag
recoveri
time
day
patient
suffer
ne
immedi
neutrophil
count
recoveri
liquid
diet
restor
abdomin
distens
pain
digest
tract
hemorrhag
among
patient
receiv
surgic
oper
intestin
necrosi
enterococcu
faecium
infect
confirm
cultur
patient
blood
fecal
sampl
ne
symptom
repeat
patient
identifi
chemotherapi
patient
die
pulmonari
fungal
infect
sepsi
septic
shock
anoth
one
patient
reduc
formal
chemotherapi
dosag
total
seven
patient
surviv
conclus
ne
rare
complic
chemotherapi
childhood
al
patient
clinic
symptom
abdomin
imag
would
help
earli
diagnosi
immedi
power
support
treatment
necessari
ne
diagnos
subsequ
chemotherapi
could
interf
neg
ne
might
recurr
need
taken
high
premium
clinic
aggress
end
life
care
neuroblastoma
patient
yanai
k
miyata
ochi
saito
kozaki
ishida
hasegawa
k
kawasaki
kosaka
hematolog
oncolog
kobe
children
hospit
kobe
japan
object
pattern
end
life
care
poorli
understood
pediatr
cancer
popul
studi
aim
elucid
aggress
end
life
care
children
neuroblastoma
common
solid
tumor
japan
method
patient
diagnos
neuroblastoma
institut
die
septemb
decemb
enrol
medic
record
retrospect
review
chemotherapi
treatment
mechan
ventil
cpr
last
month
life
period
last
chemotherapi
death
place
death
investig
indic
aggress
end
life
care
result
fifteen
patient
male
femal
identifi
median
age
death
year
rang
year
thirteen
patient
die
neuroblastoma
die
toxic
chemotherapi
perform
patient
last
month
life
patient
continu
receiv
chemotherapi
last
week
life
hospit
sole
place
death
three
patient
receiv
treatment
due
toxic
die
icu
fourteen
patient
receiv
cardiac
cardiopulmonari
resuscit
median
period
last
chemotherapi
death
day
rang
conclus
proport
termin
ill
cancer
patient
receiv
chemotherapi
higher
previou
report
meanwhil
cardiac
cardiopulmonari
resuscit
perform
major
larg
research
requir
determin
aggress
end
life
care
pediatr
cancer
patient
japan
prospect
random
studi
fix
vs
flexibl
schedul
post
chemotherapi
administr
granulocyt
factor
preliminari
data
yankelevich
henri
k
bhambhani
jw
taub
hematologyoncolog
children
hospit
michigan
detroit
usa
object
commonli
use
chemotherapi
shorten
neutropen
period
administr
contribut
cost
treatment
may
caus
side
effect
base
studi
kinet
post
chemotherapi
bone
marrow
recoveri
hypothes
dose
given
first
day
chemotherapi
significantli
contribut
final
neutrophil
recoveri
due
absenc
myeloid
progenitor
bone
marrow
method
evalu
clinic
set
initi
prospect
random
clinic
studi
two
differ
prophylact
schedul
children
solid
tumor
fix
schedul
start
hour
complet
chemotherapi
flexibl
schedul
start
absolut
neutrophil
count
anc
fall
use
crossov
studi
design
patient
receiv
cycl
chemotherapi
follow
fix
flexibl
schedul
chosen
random
order
result
date
patient
enrol
sinc
octob
studi
continu
enrol
patient
signific
differ
time
neutrophil
recoveri
number
day
start
chemotherapi
anc
post
nadir
two
schedul
day
fix
vs
day
use
flexibl
schedul
patient
receiv
less
inject
vs
daili
inject
cycl
follow
flexibl
schedul
would
translat
averag
direct
save
reduc
inject
per
chemotherapi
cycl
conclus
preliminari
data
show
flexibl
schedul
post
chemotherapi
administr
result
signific
reduct
treatment
cost
without
compromis
effect
neutrophil
recoveri
myelotox
chemotherapi
children
solid
tumor
need
pediatr
palli
care
implement
mexico
case
report
g
lv
j
multicent
pediatr
resid
program
escuela
de
medicina
ciencia
de
la
salud
tecnologico
de
monterrey
monterrey
mexico
pediatr
oncolog
hospit
san
tec
de
monterrey
monterrey
mexico
object
analyz
miss
opportun
case
report
pediatr
palli
care
ppc
could
integr
order
creat
framework
mexican
pediatr
oncologist
recogn
need
implement
palli
care
patient
method
case
medulloblastoma
cerebellum
occur
patient
present
first
diagnos
treat
year
age
partial
surgic
resect
tumor
ventriculoperiton
shunt
placement
next
month
conclud
cycl
chemotherapi
develop
worsen
brain
edema
last
hospit
admit
progress
intracrani
hypertens
patient
ask
continu
chemotherapi
beg
team
give
receiv
chemotherapi
last
day
life
almost
none
palli
care
famili
result
within
patient
evolut
diagnosi
death
opportun
identifi
ppc
could
initi
conclus
pediatr
cancer
case
occur
develop
countri
low
resourc
set
mortal
approxim
even
world
poorest
countri
mexico
develop
countri
estim
childhood
cancer
incid
per
year
mortal
rate
approxim
per
year
mean
everi
hour
mexican
child
die
cancer
ppc
reduc
morbid
improv
qualiti
life
stage
diseas
clearli
patient
could
benefit
ppc
howev
situat
improv
get
mexican
pediatr
oncologist
recogn
need
integr
ppc
medic
practic
cknowledg
sebastian
llamazar
invalu
help
surgeri
ipso
ganglioneuroma
becom
symptomat
tumor
p
abad
calvo
melo
vall
rm
isnard
blanchar
f
ja
blanco
castellvi
gil
curbelo
rodriguez
de
diego
suarez
paediatr
surgeri
hospit
universitari
german
tria
pujol
badalona
spain
pediatr
oncolog
hospit
de
sabadel
corporacio
parc
tauli
sabadel
spain
pediatr
surgeri
hospit
universitari
german
tria
pujol
badalona
spain
pediatr
oncolog
hospit
universitari
german
tria
pujol
badalona
spain
object
ganglioneuroma
commonli
defin
benign
silent
tumor
frequent
adult
children
often
misdiagnos
surgeri
radiolog
appear
could
howev
surgic
approach
still
mean
treatment
becom
symptomat
realli
silent
tumor
becom
symptomat
method
review
patholog
report
neuroblast
tumor
two
pediatr
depart
focu
ganglioneuroma
diagnosi
complet
surgeri
last
year
also
review
literatur
adult
compar
children
result
describ
case
ganglioneuroma
institut
neck
thorax
abdomin
retroperiton
adren
liver
hilum
case
hormon
silent
ultrasound
taken
persist
abdomin
pain
neck
mass
iceberg
bilater
thorac
tumor
one
locat
liver
hilum
spontan
eye
movement
although
oper
optokinet
nistagmu
child
misdiagnosi
surgeri
ganglioneuroblastoma
suprarren
adenoma
cyst
duplic
complic
open
surgeri
case
conclus
case
report
symptomat
ganglioneuroma
children
compar
adult
pain
main
indic
surgeri
earli
difficult
obtain
diagnosi
previous
surgeri
imag
characterist
similar
tumor
mayb
becam
activ
surgeri
benign
tumor
symptom
appear
adult
long
follow
common
registr
also
benign
lesion
might
consid
combin
approach
manag
refractori
chylou
ascit
pediatr
oncolog
patient
alkudayri
z
habib
koussay
depart
surgeri
king
faisal
hospit
research
center
riyadh
saudi
arabia
introduct
postop
chylou
leak
rare
result
lymphat
channel
disrupt
obstruct
follow
surgic
resect
retroperiton
tumor
repres
difficult
manag
problem
due
seriou
mechan
nutrit
immunolog
consequ
constant
loss
protein
lymphocyt
manag
chylou
leak
either
conserv
intervent
surgic
andor
radiolog
method
report
two
pediatr
patient
refractori
chylou
ascit
follow
retroperiton
tumor
resect
neuroblastoma
nephroblastoma
manag
success
use
combin
approach
intra
oper
laparoscopi
intervent
dictat
failur
conserv
treatment
total
parent
nutrit
octerotid
low
fat
diet
andor
time
schedul
chemotherapi
cycl
combin
approach
util
identifi
treat
sourc
lymphat
leak
simultan
modal
intervent
includ
diagnost
laparoscopi
intraop
ultrasound
local
inguin
lymph
node
follow
lymph
angiogram
fluoroscop
guidanc
identifi
site
lymphat
leak
handl
sutur
ligat
oment
patch
hemostat
agent
patient
continu
chemotherapi
regimen
within
one
week
intervent
result
recurr
observ
six
month
follow
conclus
usual
conserv
manag
lymphat
leak
long
time
discourag
option
oncolog
patient
may
delay
complet
chemotherapeut
regimen
might
theoret
increas
risk
recurr
avail
advanc
resourc
earli
intervent
lymphat
leak
recommend
patient
congenit
juvenil
granulosa
cell
tumor
testi
case
report
review
literatur
aranha
jr
f
varga
l
noronha
e
gugelmin
l
matoso
r
galli
k
barszcz
r
possagno
e
mol
l
garbuio
surgeri
hospit
pequeno
curitiba
brazil
patholog
hospit
pequeno
curitiba
brazil
pediatr
hospit
municip
de
curitiba
brazil
medicin
universidad
estadu
de
ponta
grossa
ponta
grossa
brazil
object
even
though
repres
common
stromal
cord
tumor
infant
testi
juvenil
granulosa
cell
tumor
jgct
rare
diagnos
benign
tumor
account
prebubert
testicular
tumor
method
retrospect
review
data
one
patient
diagnos
first
day
life
result
case
report
healthi
neonat
diagnos
painless
left
escrot
mass
evalu
identifi
two
time
volum
contralater
testi
present
firm
consist
hard
consist
prenat
testicular
torsion
doppler
ultrasound
detect
multicyst
left
testicular
mass
normal
blood
flow
fail
detect
testi
human
chorion
gonadotropin
serum
afp
normal
inguin
approach
perform
expos
testi
spermat
cord
cord
clamp
section
lesion
sent
frozen
biopsi
exclud
yolk
sac
tumor
howev
imposs
detect
normal
testi
tissu
indic
orchiectomi
high
ligat
spermat
cord
histolog
evalu
demonstr
gray
testicular
parenchima
multicyst
aspect
fullfil
yellow
fluid
postop
evolut
uneventful
six
month
surgeri
patient
assymptomat
follow
pediatr
oncolog
conclus
usual
clinic
present
jgct
painless
scrotal
mass
detect
clinic
routin
examin
perceiv
parent
prenat
diagnosi
describ
radiolog
imag
demonstr
multicyst
circunscrib
tumor
tumor
marker
level
normal
standart
treatment
inguin
orchiectomi
tumor
present
benign
tumor
testicular
spare
surgeri
perform
case
normal
parenchima
identifi
adjuv
therapi
indic
ureterosigmoidostomi
case
bladder
rhabdomyosarcoma
total
cystectomi
bhatnagar
pediatr
surgeri
bj
wadia
hospit
children
mumbai
india
object
urinari
divers
mitrafanoff
format
util
option
bladder
rhabdomyosarcoma
child
undergon
total
cystectomi
present
child
underw
ureterosigmoidostomi
contin
urinari
divers
year
follow
total
cystectomi
subtot
urethrectomi
method
retrospect
case
studi
wherein
detail
patient
retriev
record
result
day
old
male
neonat
present
poor
stream
urin
palpabl
bladder
suspect
posterior
urethr
valv
underw
cystoscopi
fulgur
valv
month
later
child
brought
sever
urosepsi
fungat
mass
hypocondrium
found
origin
urinari
bladder
total
cystectomi
bilater
end
ureterostomi
perform
chemotherapi
given
confirm
diagnosi
rhabdomyosarcoma
tumor
recur
bladder
neckprostat
urethra
later
distal
urethra
subtot
urethrectomi
done
year
later
evid
recurr
child
underw
ureterosigmoidostomi
contin
urinari
divers
child
abl
pass
urin
everi
hour
per
rectal
also
contin
stool
evid
renal
upper
tract
damag
found
conclus
myriad
complic
bladder
creation
ileal
sigmoid
loop
catheter
via
mitraffanoff
ureterosigmoidostomi
seem
better
option
wherein
child
voluntarili
void
urin
per
rectal
remain
dri
without
need
repeatedli
catheter
event
late
recurr
tumor
would
much
easili
carri
till
control
tumor
done
import
surgic
treatment
prognost
factor
neuroblastoma
stage
accord
case
budi
depart
paediatr
semmelwei
univers
budapest
hungari
object
stage
neuroblastoma
said
favour
outcom
patient
metastat
neuroblastoma
often
demonstr
spontan
matur
regress
hardli
requir
treatment
true
realli
stage
neuroblastoma
benign
deadli
diseas
treat
benign
entiti
need
surgic
treatment
administ
chemotherapi
prognost
factor
method
case
report
day
old
matur
newborn
admit
clinic
bilater
advanc
tumor
adren
region
multiplex
liver
metastas
extrem
hepatomegali
substanti
distend
abdomen
dyspnoea
investig
biopsi
laesion
prove
neuroblastoma
stage
accord
case
review
literatur
result
month
age
neuroblastoma
stage
bad
prognosi
mani
case
end
death
death
caus
rapidli
worsen
abdomin
statu
infant
must
administ
chemotherapi
oper
urgent
first
sign
abdomin
compart
syndrom
conclus
stage
neuroblastoma
estim
surviv
rate
report
tumor
usual
associ
favour
biolog
featur
infant
month
age
bad
prognosi
mani
case
end
death
seem
month
age
intens
earlier
treatment
better
result
studi
may
identifi
marker
accur
predict
clinic
outcom
variou
subtyp
neuroblastoma
stage
moreov
surgeon
import
role
prevent
abdomin
compart
syndrom
rais
surviv
rate
conserv
surgeri
combin
high
dose
rate
brachytherapi
patient
rhabdomyosarcoma
technic
issu
challeng
initi
experi
j
fuch
f
paulsen
f
heinzelmann
sw
warmann
g
seitz
depart
pediatr
surgeri
pediatr
urolog
univers
children
hospit
germani
depart
radiat
oncolog
univers
hospit
germani
object
although
treatment
patient
suffer
bprm
improv
past
regard
outcom
bladder
preserv
rate
larg
multi
center
trial
still
low
past
conserv
surgeri
combin
low
dose
rate
brachytherapi
advoc
novel
treatment
option
nevertheless
low
dose
rate
brachytherapi
avail
mani
center
therefor
aim
studi
establish
new
treatment
modal
combin
high
dose
rate
brachytherapi
conserv
surgeri
method
principl
studi
perform
organ
preserv
microscop
complet
incomplet
tumor
resect
intraop
placement
brachytherapi
tubu
around
urethra
patient
tumor
extens
bladder
neck
treat
surgeri
high
dose
rate
brachytherapi
gy
fraction
carri
day
fraction
brachytherapi
tube
remov
total
number
patient
treat
result
patient
bladder
preserv
feasibl
conserv
surgeri
brachytherapi
well
toler
without
signific
side
effect
patient
first
complet
remiss
one
patient
develop
neurogen
bladder
requir
creation
mitrofanoff
stoma
conclus
combin
conserv
surgeri
high
dose
rate
brachytherapi
treatment
option
select
patient
bprm
paper
highlight
essenti
technic
challeng
clearli
show
limiti
treatment
approach
manag
wilm
tumour
inferior
vena
cava
extens
experi
yt
lee
jacobsen
ch
chui
nk
laksmi
paediatr
surgeri
kk
women
children
hospit
singapor
singapor
surgeri
centr
children
pte
ltd
mount
elizabeth
medic
centr
singapor
singapor
object
current
treatment
strategi
wilm
tumour
inferior
vena
cava
ivc
extens
includ
chemotherapi
follow
radic
nephrectomi
tumour
thrombectomi
literatur
report
regress
tumour
thrombu
chemotherapi
facilit
surgeri
howev
also
report
regard
dens
adher
tumour
thrombu
vessel
wall
result
chemotherapi
studi
aim
examin
manag
wilm
tumour
ivc
extens
institut
method
patient
diagnos
wilm
tumour
ivc
extens
includ
data
collect
patient
note
regard
present
oper
detail
outcom
result
case
wilm
tumour
treat
institut
studi
period
two
patient
tumour
extens
infrahepat
vena
cava
one
patient
thrombu
extend
iliac
vein
right
atrium
extend
left
renal
right
hepat
vein
lead
syndrom
patient
receiv
chemotherapi
base
regim
durat
week
follow
radic
nephrectomi
tumour
thrombectomi
chemotherapi
reduc
thrombu
extent
case
infrahepat
vena
cava
extens
complet
thrombectomi
achiev
howev
patient
extens
tumor
thrombu
clear
atrium
chemotherapi
thrombu
intrahepat
infraren
ivc
dens
adher
vessel
wall
could
complet
excis
tumour
favour
histolog
excis
thrombu
show
viabl
tumour
two
patient
receiv
radiotherapi
children
aliv
tumor
free
conclus
manag
wilm
tumour
ivc
extens
technic
challeng
chemotherapi
may
caus
dens
adher
thrombu
vessel
wall
may
effect
thrombu
excis
report
viabl
tumour
cell
care
studi
need
make
recommend
stage
treatment
wilm
tumour
extens
ivc
thrombu
unusu
primari
paediatr
testicular
tumour
f
li
jhi
chua
paediatr
sugeri
kk
women
children
hospit
singapor
singapor
object
describ
uniqu
clinic
present
diagnost
difficulti
uncommon
histolog
case
primari
paediatr
testicular
tumour
tt
method
retrospect
clinic
chart
review
male
rare
primari
tt
result
old
male
present
painless
left
scrotal
swell
year
bilater
inguin
orchidopexi
bilater
undescend
testicl
ultrasound
demonstr
enlarg
heterogen
left
testi
measur
cm
increas
vascular
serum
alphafetoprotein
normal
left
testicular
biopsi
perform
via
inguin
approach
frozen
section
inconclus
diagnosi
embryon
rhabdomyosarcom
made
paraffin
section
radic
inguin
orchidectomi
perform
tumour
margin
clear
except
focal
microscop
involv
spermat
cord
margin
receiv
adjuv
chemotherapi
per
arm
protocol
remain
anoth
child
old
present
durat
painless
right
scrotal
swell
ultrasound
scan
reveal
heterogen
enlarg
right
testi
measur
cm
increas
vascular
rais
possibl
germ
cell
tumour
gct
tumour
marker
normal
right
testi
measur
normal
testicular
tissu
evid
radic
orchidectomi
perform
histopatholog
diagnos
primari
paediatr
follicular
lymphoma
testi
grade
iiia
receiv
chemotherapi
lymphoma
remain
conclus
tradit
elev
serum
alphafetoprotein
play
signific
role
counsel
primari
paediatr
tt
experi
patient
illustr
limit
tumour
marker
frozen
section
direct
need
radic
orchidectomi
gct
commonest
primari
tt
children
rare
malign
consid
tumour
marker
normal
surgeri
primari
tt
may
possibl
patient
care
select
imag
thoroughli
evalu
multimod
therapi
wilmstumor
inferior
vena
cava
atrial
tumor
thrombu
li
xu
yong
huang
q
shu
j
wang
lai
j
yu
divis
pediatr
surgic
oncolog
depart
pediatr
surgeri
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
divis
urolog
depart
pediatr
surgeri
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
depart
radiolog
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
divis
cardial
surgeri
depart
pediatr
surgeri
children
hospit
zhejiang
univers
school
medicin
hangzhou
china
object
introduc
one
case
wilm
tumor
inferior
vena
cava
right
atrial
tumor
thrombu
success
treat
multimod
therapi
method
month
old
femal
admit
histori
abdomin
distens
hematuria
day
abdomin
ultrasound
ct
mri
show
right
renal
mass
measur
cm
tumor
thrombu
extend
inferior
vena
cava
right
atrium
echocardiogram
confirm
mass
cm
right
atrium
histolog
diagnosi
wilm
tumor
confirm
biopsi
neoadjuv
therapi
transcathet
arteri
chemoembol
tace
system
chemotherapi
taken
patient
subject
transcathet
arteri
chemoembol
selding
method
chemoembol
emuls
inject
involv
renal
arteri
chemoembol
emuls
consist
cisplatin
pirarubicin
vindesin
iodiz
oil
ml
two
session
intraven
chemotherapi
administ
week
tace
altern
use
ifosfamid
etoposid
vindesin
carboplatin
pirarubicin
vindesin
one
treatment
interv
week
tumor
decreas
size
cm
ct
imag
tumor
thrombu
within
ivc
ra
also
shrunk
disappear
result
patient
oper
twelv
week
neoadjuv
therapi
complet
resect
tumor
kidney
first
right
atrium
open
tumor
thrombu
complet
remov
cardiopulmonari
bypass
deep
hypothermia
circulatori
arrest
recoveri
unev
patholog
examin
resect
tumor
show
necrosi
child
given
radiotherapi
right
flank
follow
postop
chemotherapi
patient
free
recurr
month
conclus
multimod
therapi
effect
treatment
wilm
tumor
inferior
vena
cava
right
atrial
tumor
thrombu
surgic
intervent
residu
lung
nodul
chemotherapi
pediatr
malign
oue
uehara
k
nakahata
zenitani
k
nara
owari
ueno
n
usui
pediatr
surgeri
osaka
univers
graduat
school
medicin
osaka
japan
object
retrospect
review
surgic
manag
residu
lung
nodul
chemotherapi
pediatr
malign
method
eleven
pediatr
oncolog
patient
undergon
resect
pulmonari
nodul
includ
studi
includ
five
hepatoblastoma
three
wilm
tumor
two
osteosarcoma
one
neuroblastoma
lung
nodul
identifi
preoper
ct
imag
routin
surveil
resect
either
thoracotomi
thoracoscop
surgeri
patient
demograph
initi
diagnosi
locat
lung
nodul
procedur
perform
patholog
lesion
record
result
six
patient
lung
nodul
diagnosi
remain
five
develop
lung
nodul
treatment
biopsi
multipl
nodul
perform
case
bythoracoscop
surgeri
eight
case
complet
resect
lung
nodul
perform
bilater
case
side
resect
separ
oper
five
case
resect
thoracotomi
remain
three
resect
thoracoscop
surgeri
three
case
small
nodul
less
ct
guid
mark
success
perform
surgeri
patholog
examin
reveal
nodul
viabl
metastasi
five
case
complet
necrot
metastasi
case
benign
lesion
two
case
two
patient
die
recurr
howev
remain
nine
aliv
without
diseas
year
conclus
complet
resect
lung
nodul
contribut
achiev
complet
remiss
patholog
find
nodul
use
decid
manag
patient
ultim
improv
overal
surviv
ct
guid
mark
use
resect
small
nodul
less
mm
surgic
resect
buccal
mucosa
vaginoplasti
local
control
vagin
botryoid
rhabdomyosarcoma
rlp
romao
j
pierc
afzal
davi
cv
fernandez
bernstein
aj
lorenzo
surgeri
iwk
health
centr
dalhousi
univers
halifax
canada
oncolog
iwk
health
centr
dalhousi
univers
halifax
canada
surgeri
hospit
sick
children
univers
toronto
toronto
canada
object
standard
treatment
vagin
botryoid
rhabdomyosarcoma
rm
children
encompass
system
chemotherapi
radiat
therapi
rt
local
control
good
result
rt
young
pelvi
lead
signific
complic
herein
report
surgic
altern
local
control
goal
spare
rt
pelvi
method
case
report
inform
consent
new
surgic
techniqu
use
local
control
treatment
vagin
botryoid
rm
old
femal
result
child
treat
children
oncolog
group
protocol
vac
chemotherapi
group
iii
stage
ii
vagin
botryoid
rm
week
vaginoscopi
depict
good
respons
small
residu
lesion
contain
rhabdomyoblast
identifi
anterior
posterior
vagin
wall
week
instead
standard
rt
per
protocol
perform
subtot
vaginectomi
use
anterior
sagitt
approach
buccal
mucosa
vaginoplasti
bilater
graft
harvest
patient
cheek
figur
fr
chest
tube
left
situ
vagin
mold
cervix
intern
reproduct
organ
left
intact
graft
anastomos
fornic
mucosa
patient
discharg
postop
day
pod
vagin
stent
remov
fifteen
day
surgeri
patient
present
superfici
dehisc
perin
bodi
examin
anesthesia
reveal
graft
patent
vagina
evid
perin
infect
wound
heal
secondari
intent
without
complic
patholog
reveal
focal
residu
rhabdomyoblast
neg
margin
figur
conclus
subtot
vaginectomi
buccal
mucosa
vaginoplasti
use
anterior
sagitt
approach
offer
altern
local
control
children
botryoid
rm
may
spare
patient
receiv
rt
pelvi
assess
function
neovagina
oncolog
outcom
mandatori
surgic
problem
children
tract
rhabdomyosarcoma
z
sabirzyanova
pavlov
pediatr
urolog
russian
scientif
center
roentgenradiolog
moscow
russia
urolog
russian
scientif
center
roentgenradiolog
moscow
russia
object
prognosi
children
rabdomiosarcoma
rm
improv
last
year
surviv
rate
get
modern
algorithm
base
chemotherapi
radiotherapi
surgeri
come
second
plan
local
therapi
lot
surgic
problem
base
specif
urogenit
local
tumor
method
children
male
femal
age
month
year
tumor
local
paratesticular
bladder
withwithout
prostat
uteru
orand
vulva
follow
till
year
treatment
result
patient
surgic
reason
primari
treatment
abdomin
pain
acut
retent
urin
disuria
palpabl
visual
tumor
mass
primari
laparotomi
laparoscopi
done
children
abdomin
pain
common
surgeon
biopsi
nt
perform
case
primari
resect
tumor
done
complic
primari
surgeri
urin
infiltr
patient
larg
vascular
disrupt
primari
urin
divers
done
patient
bladder
catheter
nephrostomi
patient
undergon
xr
therapi
secondari
radic
resect
done
children
radiotherapi
total
cystectomi
andor
total
prostatectomi
vaginaectomi
later
reconstruct
urinari
tract
obstruct
side
effect
long
term
follow
radiotherapi
shown
patient
urethr
reimplant
done
vesicostomi
intern
urethr
stent
place
conclus
surgic
intervent
first
step
treatment
patient
rsm
genitourinari
tract
must
safeti
limit
biopsi
urinari
divers
delay
reconstruct
surgeri
necessari
patient
method
local
treatment
recurr
monophas
wilm
tumor
pelvic
kidney
therapeut
challeng
sarin
sinha
pediatr
surgeri
maulana
azad
medic
colleg
ln
hospit
delhi
india
object
report
unusu
case
repeat
recurr
patient
stage
monophas
epitheli
variant
wilm
tumor
wt
pelvic
kidney
requir
aggress
therapi
decad
method
retrospect
case
studi
result
male
present
lower
abdomin
lump
investig
show
wt
left
ectop
kidney
left
nephroureterectomi
done
hpe
confirm
wt
predomin
tubul
format
minim
atypia
mitosi
stage
repeat
cect
month
later
show
thrombu
inferior
vena
cava
ivc
right
common
iliac
vein
iliac
lymphadenopathi
follow
earli
abandon
therapi
patient
receiv
cycl
chemotherapi
vac
regimen
return
local
relaps
retroperiton
lymph
node
year
cycl
ice
chemotherapi
rplnd
done
hpe
show
tumor
fourteen
month
later
develop
second
recurr
mesocol
lymph
node
complet
excis
follow
cycl
ie
chemotherapi
gy
whole
abdomin
irradi
histopatholog
epitheli
variant
wt
four
month
later
present
recurr
larg
pelvic
mass
cm
trucut
biopsi
show
epitheli
predomin
wt
receiv
cycl
paclitaxel
base
salvag
chemotherapi
follow
excis
tumor
boost
radiotherapi
gy
pelvi
plan
excis
persist
calcifi
thrombu
subhepat
ivc
could
harbor
nidu
tumor
cell
suffer
acut
renal
failur
radiat
nephriti
month
later
repeat
dialysi
next
month
succumb
chronic
renal
failur
conclus
inert
tumor
cell
calcifi
ivc
thrombu
possibl
caus
repeat
recurr
local
monophas
wt
import
initi
complet
therapi
need
long
term
overemphas
synchron
ipsilater
wilm
tumor
neuroblastoma
infant
sarin
sinha
pediatr
surgeri
maulana
azad
medic
colleg
ln
hospit
delhi
india
object
report
synchron
ipsilater
adren
neuroblastoma
wilm
tumor
method
retrospect
case
studi
result
femal
admit
complaint
abdomin
distens
sinc
month
cough
fever
sinc
week
weight
loss
examin
reveal
larg
right
retroperiton
mass
clinic
diagnosi
right
wilm
tumor
wt
ultrasonographi
reveal
heterogen
echogen
well
defin
cm
mass
right
supraren
region
anoth
cm
mass
multipl
intern
anecho
area
along
anterolater
aspect
kidney
ct
scan
reveal
x
x
cm
well
defin
heterogen
mass
abut
right
kidney
loss
fat
plane
superiorli
lesion
round
compon
seen
abut
undersurfac
liver
inferiorli
extend
till
pelvic
brim
medial
cross
midlin
caus
effac
displac
inferior
vena
cava
howev
encas
major
vessel
note
wt
confirm
trucut
biopsi
metastat
workup
neg
administ
chemotherapi
vincristin
adriamycin
week
surgeri
x
x
cm
right
renal
mass
note
separ
mass
x
x
cm
area
right
supraren
gland
clear
plane
separ
two
mass
local
lymph
node
enlarg
complet
excis
mass
lymph
node
sampl
done
histopatholog
reveal
stage
wt
stage
neuroblastoma
nb
bone
survey
bone
scan
bone
marrow
aspir
mibg
scan
neg
child
start
opec
regimen
nb
posit
amplif
conclus
embryon
tumor
patient
may
mere
coincid
howev
accumul
data
similar
case
may
help
clarifi
associ
tumor
chemotherapi
induc
chang
wilm
tumor
experi
sarin
sinha
n
khurana
pediatr
surgeri
maulana
azad
medic
colleg
ln
hospit
delhi
india
patholog
maulana
azad
medic
colleg
ln
hospit
delhi
india
object
preoper
chemotherapi
propag
siop
renal
tumour
trial
reduc
tumor
ruptur
increas
favour
stage
distribut
wilm
tumor
wt
known
chemotherapi
induc
chang
cic
alter
tumor
histolog
featur
distribut
subtyp
make
stage
difficult
studi
cic
patient
method
histopatholog
slide
children
wt
treat
institut
per
siop
wt
protocol
review
light
current
knowledg
experienc
senior
pathologist
sinc
mandatori
needl
biopsi
done
patient
ukccg
protocol
tumor
morpholog
compar
chemotherapi
result
biopsi
could
subtyp
mix
n
epitheli
n
mean
tumor
volum
decreas
chemotherapi
mean
respons
patient
good
respons
reduct
common
histolog
subtyp
chemotherapi
mix
akin
tradit
terminolog
triphas
wt
n
follow
stromal
n
epitheli
n
regress
n
cystic
partial
differenti
nephroblastoma
cpdn
n
except
intermedi
risk
cpdn
low
risk
show
cic
remain
case
cic
demonstr
involv
mean
tumor
area
nephrectomi
specimen
correl
histolog
epitheli
subtyp
howev
nephrectomi
specimen
subtyp
concurr
mix
type
subtyp
subsequ
stromal
n
regress
n
cpdn
n
fibrou
pseudocapsul
seen
epitheli
subtyp
rhabdomyoblast
differenti
seen
stromal
subtyp
also
focal
anaplasia
conclus
possibl
subtyp
wt
trucut
biopsi
preoper
major
specimen
incid
regress
subtyp
much
lower
seri
compar
siop
studi
result
vs
vascular
tumor
approach
outcom
north
indian
children
yadav
acharya
khan
prasad
sami
l
ahmad
r
gupta
bagga
pediatr
surgeri
vardhman
mahavir
medic
colleg
safdarjung
hospit
delhi
india
radiolog
vardhman
mahavir
medic
colleg
safdarjung
hospit
delhi
india
object
evalu
present
treatment
outcom
vascular
tumor
malform
north
indian
children
method
retrospect
analysi
consecut
case
vascular
tumor
malform
present
vmmc
safdarjang
hospit
new
delhi
carri
age
present
type
vascular
tumor
malform
intern
societi
studi
vascuar
anomali
issva
classif
associ
abnorm
treatment
option
outcom
review
protocol
base
radiolog
examin
colour
doppler
ct
angiographi
treatment
option
conserv
oral
propranolol
steroid
intralesion
therapi
bleomycin
sodium
tetradecyl
sulphat
laser
therapi
compress
therapi
surgic
excis
result
two
hundr
six
patient
femal
identifi
vascular
tumor
pt
infantil
hemangioma
mean
age
present
week
head
neck
good
respons
propranolol
requir
excis
hepat
hemangoima
pt
larg
respond
well
prednisolon
congenit
hemangioma
pt
trunk
extrem
requir
excis
good
cosmesi
pyogen
granuloma
pt
excis
vascular
malform
venou
malform
pt
trunk
extrem
face
age
rang
year
major
role
colour
doppler
ct
angio
flow
pattern
vascular
anatomi
respond
well
inj
sclerotherapi
rare
excis
capillari
malform
lymphat
malform
pt
cystic
hygroma
cervic
respond
well
bleomycin
excis
pt
macrocyst
lymphangioma
respond
well
bleomycin
complex
vascular
malform
syndrmor
lower
extrem
perineum
boni
overgrowth
satisfactori
respons
compress
bandag
local
sclerotherapi
conclus
multidisciplinari
approach
treatment
appropri
clinic
radiolog
assess
provid
satisfactori
outcom
accept
morbid
vascular
tumor
malform
case
aabideen
k
aarsen
fk
aba
umar
abad
calvo
p
abat
abbasova
e
abbo
abbott
l
abboud
abd
al
karim
abd
elmoneim
abd
elmoneim
e
abdallah
abdel
hadi
abdel
hadi
abdelkhalek
e
abdelrahman
e
abdelrahman
hani
abdelzah
e
abdualieva
g
abdul
rahman
ej
abdullah
k
abdullah
abdullahi
abdulsalam
u
abela
c
abelson
j
abhyankar
h
abinum
abish
abla
abrahamsson
j
abramovitz
l
abramson
dh
abrar
aburatani
h
acar
acarli
k
acebo
j
acha
acharya
adachi
adachi
adam
j
e
adam
adamski
j
adamson
l
adan
r
adank
mc
adefehinti
adeodu
oo
adetokunboh
adewuyi
oa
adrianowska
n
adsuar
r
adu
ca
aejaz
shiekh
aert
af
sandeberg
affinita
mc
afonso
afroz
f
afzal
agaoglu
l
agarw
b
agarw
agarwala
agarwala
v
aggarw
r
aggarw
agha
aghajani
aghazadeh
h
agnihotri
agraw
agraw
aguiar
aguilar
aguirr
neto
jc
agyeman
p
ahenkorah
j
ahern
ch
ahmad
ahmad
l
ahm
moham
refaat
ahm
b
ahm
f
ahm
g
ahm
ahm
ahm
ahm
sk
ahm
ahn
hs
r
ahuja
ahuka
ona
l
ahumada
aida
n
aina
aisner
aissi
aiuti
akalan
n
akani
na
akar
hh
akar
n
akbarzad
akbiyik
akcay
akcay
h
akel
akici
f
akiko
ishibashi
akin
akinci
b
akiyama
aksoy
b
aksoylar
akta
akyurek
n
akyuz
c
al
nofal
al
saud
b
h
z
hala
h
alabba
f
alabi
alaggio
r
alakaya
alam
alam
mm
alapetit
c
albanez
souza
f
albanti
albertini
f
alboheisi
albrecht
albritton
kh
albudak
ozcan
e
alcasaba
alcasaba
ap
aldap
k
aldef
alderet
alderf
aldrink
j
alebouyeh
aleinikova
alemani
r
alexand
alfaro
e
alharbi
q
alhawsawi
z
ali
ali
ali
l
ali
ali
n
ali
alkan
alkema
alkhayat
n
alkofid
alkudayri
allen
c
allen
j
alman
b
almazan
b
f
almeida
gc
almeida
mta
almeida
psp
almeida
rs
almulla
n
alnass
alonso
alpash
alper
h
alshahrani
alshail
e
alshkteria
alsmadi
altawil
altshul
c
altun
altun
z
alumeti
alvarez
e
amano
r
amayiri
n
ambro
p
amendi
u
amichetti
amitabh
ammann
ra
ammar
h
amorim
j
amorim
r
ampofo
k
amport
n
amr
amr
p
amylon
x
anacak
anagnostopoul
p
anak
ananta
rao
k
ananth
p
ana
anastasi
anatriello
e
anderson
j
anderson
anderson
p
anderson
pm
andrad
af
andrad
pv
andr
n
n
andreev
e
angelov
l
angiolillo
anichini
g
ani
h
ansari
anstiss
anthoni
antonelli
antonini
srr
antonopoulo
c
antun
l
anwar
apollonio
appel
b
applegath
c
ara
z
arac
l
arad
n
arakawa
h
aranha
jr
aranjo
aravind
kl
araz
n
arbit
n
arbuckl
arca
arceci
r
are
c
ari
im
ariffin
h
ariffin
hani
ariga
arikan
c
aristizab
arjmandi
rafsanjani
k
armstrong
c
armstrong
g
armstrong
gt
arnaud
l
arndt
c
arnold
k
arola
arola
mo
arora
b
arora
p
arora
r
arreguin
f
arshanskaya
eg
arthi
arudchelvam
j
arvidson
j
arvind
asaftei
asami
k
asao
h
asarcikli
f
ascaiturrieta
z
aschero
asghar
n
asghar
nyla
asgharzadeh
ashley
ashraf
ashraf
aslar
asmar
c
asseri
astigarraga
atay
atay
atenafu
e
athal
athal
u
athanasiadi
athanasiadi
athanasiad
athanassiad
athanassopoulo
e
atkinson
atkinson
j
atsuta
attarbaschi
attebi
yao
jj
attia
iman
attia
j
auad
f
audri
g
august
aurora
b
auvrignon
aveh
f
aven
j
avrahami
g
awaad
awad
awadi
awadi
sh
ay
ayadi
ayan
aya
aydin
b
aydinok
aydogan
g
ayello
j
ayoujil
aysoy
e
aytac
ayuzawa
k
azambuja
amp
azambuja
ap
azarnoush
azinov
azizi
azizi
aa
azmi
sa
j
azura
b
babu
badarau
bader
p
badger
badhiwala
j
badoi
badowska
w
badur
badw
r
baez
f
bagai
p
bagatel
r
bagga
baggott
c
bahala
bahar
bahrami
bai
baik
c
bailey
bailli
c
bajciova
v
bajpai
j
bajpai
baka
baker
c
bakhshi
bakhti
bakx
r
c
bal
c
j
balagadd
j
balamuth
n
balashov
balat
balbaid
ali
balboni
ta
balcerska
ball
lm
ballo
l
balm
ajm
balouet
balsamo
l
baltodano
f
balwierz
w
bamburi
p
banavali
banavali
sd
bank
bansal
z
baraja
edid
barakat
l
baranska
barchana
barchina
e
barista
barker
barnett
g
barnhart
baroni
l
baroni
rh
barr
r
barra
barrera
barroca
h
barro
j
barro
barsaoui
barszcz
k
bartelheim
k
bartelink
ih
bartel
u
barth
bartholdson
c
bartholoma
bartlett
barton
c
bartosova
baruchel
basegio
r
basha
r
basharova
ev
basso
g
bastandji
basto
lnv
bate
j
batista
glf
batra
bauer
j
baujard
c
baumann
ft
baumann
bawa
bay
kapu
bayhan
bayliss
j
bayraktaroglu
bazzeh
f
bean
beaton
j
beaudri
p
beaun
l
beck
popov
beck
becker
ap
bedetti
b
beek
l
begum
f
begum
begun
behjati
beierl
e
beierl
ea
bejjani
r
bekic
z
belasco
j
belasco
jb
bielez
c
c
belgaumi
belgumi
bell
g
bellersen
l
bellia
f
belmont
j
belpaem
n
ben
ahm
ben
arush
ben
barak
ben
fatma
l
benaicha
n
benchekroun
benedicenti
f
benesch
benjamin
rs
benmiloud
bennett
c
benson
b
berberoglu
bergamaschi
l
berger
c
bergeron
c
berka
n
berkun
l
berlanga
p
berman
j
mm
jd
bernard
f
bernardi
b
v
bernstein
berri
jg
berthold
f
bertin
bertozzi
ai
bertrand
kc
bertrand
besani
c
beul
e
beynon
p
bhagat
bhalla
r
bhambhani
k
bhansali
sg
bhanupriya
bhatia
bhatnagar
bhatnagar
v
bhatt
md
bhatt
p
bhattacharya
bhattacharyya
bhimani
bhuiya
biagi
e
biassoni
v
bidadi
b
bidinotto
lt
bielack
bien
e
bier
n
bilgic
b
bilgin
b
bilgrami
billup
c
bilska
k
binaghi
binota
j
biondi
birindwa
bishop
h
bishop
mw
bisogno
g
bisoi
ak
bissig
k
bisson
g
biswa
b
bittencourt
h
blackmon
je
blais
blanco
ja
blank
b
blanquer
blanquer
blay
jy
bleeker
g
blidaru
blijdorp
k
blom
j
blomgren
k
blufpand
h
blufpand
hn
boccieri
e
bodem
c
boechat
j
boelen
jj
bogner
v
bohosiewicz
j
jpm
bokun
j
boldrini
e
boldrini
r
boll
boll
bolster
aa
boman
kk
bomanji
j
bomfim
e
bomfim
eo
bompa
e
bona
k
bonaldo
mdf
bonatelli
bonilla
bora
h
borg
ks
borgstein
es
borkhardt
bornfeld
n
borodina
borowitz
borowitz
mj
g
bortolini
bosomprah
e
botafogo
v
bouaouina
n
boubak
bouchabki
g
bouchair
n
bouffet
e
bouffet
eric
bouguila
h
boulet
e
bourdeaut
f
bourgey
bourn
bourquin
jp
boutroux
h
bouzid
k
bowman
p
bowman
wp
bown
n
boydel
k
boyunaga
bozinov
bozkurt
c
braam
k
braam
ki
bradfield
bradley
c
bradley
cl
bradley
j
bradley
n
bradnam
ms
bradshaw
n
bradi
sl
braeutigam
c
branchereau
brand
c
brand
brandalis
sr
brandao
lr
branowicki
p
brassesco
ms
bravo
le
brecht
brecht
ib
breen
r
brennan
r
bressac
b
brester
brindl
brinksma
brister
l
britton
v
brochado
mm
brock
p
brodi
se
bronisc
bronowicki
k
brook
l
bror
b
brouchet
brougham
mfh
brown
p
brown
brown
brozyna
l
brugier
l
brugnon
f
bruin
mca
brumatti
brumley
l
brummel
b
bryan
g
bubanska
e
buchner
buchpigel
c
buchsbaum
j
buck
c
buck
buckl
gc
budi
buettner
sc
buffa
p
buffard
k
buffart
lm
buffet
e
bui
b
bui
n
buke
e
bukhari
n
bukreeva
e
bulut
burdach
burdal
burgerhof
jgm
burk
mj
burn
l
burn
w
bush
j
bustamant
busto
j
busweil
l
buttarelli
f
buyukcelik
buyukun
c
buzzaccarini
ms
c
cabaret
cabrera
p
caccavillano
w
cacchion
cacciavillano
w
cadario
cadogan
l
caetano
cd
cafferata
c
cagnano
e
cai
h
cai
w
cairo
cakir
b
cakir
fb
calaminu
g
calkoen
fgj
camacho
estrada
l
cameron
campbel
pc
campillo
p
campion
l
candela
j
candir
mo
candir
caniza
canning
canonico
cant
cao
capelli
p
cappellano
capra
caprini
f
caraglia
carai
caran
emm
caranto
k
carbon
carcano
fm
r
cardena
r
cardena
w
cardin
cardoso
caf
cargil
j
carleton
bc
carli
carlotti
jr
ca
carlsen
n
caron
h
caron
hn
caron
carranza
r
carrasquel
valecillo
v
carreno
carret
carret
carri
c
carrol
aj
carrol
carter
carti
caruso
caruso
carvalho
carvalho
r
casal
f
casanova
casa
c
casa
casa
fleca
case
j
casey
casey
rl
casey
caspi
v
cassadi
ka
cassoux
n
hernandez
g
castel
v
castelan
martinez
castelijn
ja
castellani
mr
castellano
castellvi
gil
castex
mp
castor
castro
p
catania
cataudella
catchpool
caufield
w
n
cavalcant
c
cavalcant
ce
cavalcant
ceb
cayrol
j
cazzaniga
g
ceccanti
cecchetto
g
cecen
e
cefalo
g
cefalo
mg
cela
de
e
cela
e
celik
celikarslan
celik
celkan
cellier
c
cellini
cepelova
cetin
cetingul
n
chabchoub
chaber
r
chabert
c
chagaluka
g
chagtai
chakraborti
chakraborti
r
chalandon
challinor
j
chalmer
e
chambon
f
chamorro
vina
c
champagn
champion
v
chan
chan
ak
chan
cy
chan
h
chan
hsl
chan
j
chan
chan
chan
tsi
chandra
chandra
chandra
p
chandrakanth
mv
chang
chang
al
chang
j
chang
k
channa
chantada
g
chao
charafeddin
k
charlton
charpi
c
chastagn
p
chastain
k
chaterje
chattopadhyay
pp
chaudhari
chawla
b
chawr
chelmecka
l
chemaitilli
w
chen
c
chen
fj
chen
j
chen
jf
chen
l
chen
lian
chen
xy
chen
cherkaoui
cheshir
j
cheung
v
chevanc
chevret
l
chhabra
chi
chi
sn
chiang
chiang
cw
chiang
k
chiarav
chiba
k
chiba
chien
child
chin
rfh
chin
rt
chinna
swami
g
chinnabhandar
v
chinnaswami
g
chinnaswami
g
chintagumpala
chiozza
j
chisholm
j
chisholm
jc
chiu
b
chiu
yl
chiucchiuini
cho
b
cho
chochol
choi
e
choneska
jovanova
b
choo
choo
j
chopra
chopra
yr
chorda
c
chorg
chou
chou
j
choudhari
chougul
chow
c
chowdhri
chowdhuri
chowdhuri
chraibi
f
chraiet
n
chrupek
chu
chua
hy
chua
jhi
chuang
df
chuangsuwanich
chui
ch
chung
ng
chung
ok
chusovitin
chybicka
ciblak
cikwanin
b
cimen
myb
cinal
g
cino
cioni
cipolotti
r
citak
c
clapp
clara
c
clark
peralta
p
clark
r
clark
clarkston
c
claud
l
clerico
clinton
f
cloo
j
cockcroft
r
cocquyt
v
coelho
cohen
n
cohn
rj
colafati
sg
cola
c
cole
ka
coleman
n
colita
collier
l
collini
p
collin
c
comoli
p
comsa
c
confer
conley
connelli
connolli
b
constantini
constantino
mga
cont
cooper
ljn
corbett
r
cordeiro
mg
cork
n
corn
cornet
cornu
coronado
corradini
n
f
cortez
p
costa
cr
costello
c
couillault
g
coulomb
cowi
f
cox
p
coyl
b
coyt
cozza
r
cozzi
cozzi
f
crabtre
v
crack
l
craft
aw
crasto
creutzig
u
crichton
n
crippa
f
cristofani
lm
cristofani
lmc
croal
l
crocoli
crompton
b
crook
b
cruzeiro
gav
cuccovia
b
cuglievan
b
cui
l
cui
lei
cui
x
cui
cullen
cullen
ml
n
cuppl
p
curado
mp
curbelo
rodriguez
czauderna
p
czech
dambra
damico
dangelo
p
dangelo
v
donofrio
v
dsouza
da
dababo
dada
r
dai
dai
daines
l
dalhat
hg
dalligna
p
dall
jh
dalvi
mitra
dalvi
n
danielson
j
daniluk
k
danta
pereira
ca
dantonello
dantonello
tm
danysh
h
darci
l
darendelil
e
darlington
daryani
vm
da
da
r
dasgupta
r
david
david
davidoff
davidoff
davidovici
b
davidson
davidson
r
davi
davi
psw
davila
fajardo
r
davi
j
daw
n
daw
nc
dawidowska
dawman
l
day
day
de
angulo
g
de
antonelli
p
de
bont
es
de
bont
esjm
de
camargo
b
de
courci
mj
de
davila
mtg
de
diego
suarez
de
gouveia
p
de
graaf
p
de
grazia
de
ha
de
haa
v
de
iori
de
iori
de
jong
fh
de
jong
de
jong
r
de
kraker
j
de
krijger
r
de
krijger
rr
de
la
rey
de
lambert
g
de
leonardi
f
de
lepeleir
j
de
luca
l
de
matto
guaraldi
de
moerloos
b
de
paep
de
pasqual
md
de
paula
queiroz
rg
de
pernillo
de
pinieux
g
de
rooij
j
de
rooij
jde
de
ruiter
de
ryck
de
salvo
gl
de
smedt
f
de
vito
r
de
vleeschouw
de
vri
ach
deang
dearn
p
debatin
km
debski
r
decarli
e
decoen
e
deebajah
r
deepak
j
defachel
dehner
lp
dekermach
dekker
del
bufalo
f
del
toro
n
delahay
j
delani
jp
delattr
delbey
c
delisl
mb
dellacasa
c
dellaretti
filho
delpon
g
deman
k
b
dementieva
n
f
demir
b
demir
e
demir
k
demir
demirag
b
demir
demirkaya
demk
den
boer
e
den
boer
ml
den
ho
den
ho
mah
denburg
depani
dervisoglu
derwich
k
desai
desai
desand
e
deshmukh
deshpand
desjardin
l
dessypri
n
detoni
dettmer
e
deurlo
e
devecioglu
devida
devin
devriendt
dhall
g
dhamankar
v
dhamija
dhanmankar
v
dharma
c
p
dhawan
dhull
v
di
battista
di
carlo
di
cataldo
di
gennaro
di
giusepp
g
di
martino
di
meco
f
di
pinto
di
trapani
f
diagn
fb
l
diaz
dicataldo
dick
b
dieckmann
k
dieng
ac
diez
b
diezi
digra
dillen
l
diller
l
diller
lr
dilley
k
dimara
h
dimont
b
dinand
v
dincaslan
h
dinda
ak
dindar
ding
lx
diniz
g
diniz
gtn
diomedi
camassei
f
diouf
mn
dirk
p
dirk
pb
dirksen
u
dix
dixon
k
dixon
b
djuric
dogan
doganay
l
doherti
dokmanov
l
dolai
dolan
j
dolbi
dolendo
mc
dolzan
v
dome
j
dome
js
domingo
e
donadi
ea
donadi
eav
donadieu
j
donahu
dj
donen
r
dong
k
dong
r
dongr
donnelli
p
donohou
p
em
p
doski
j
dosti
j
downi
p
doz
f
dozier
drabko
k
dragomir
dreschler
wa
drew
drissi
r
drogosiewicz
dror
druy
du
plessi
nm
duan
c
dubashi
b
duboi
sg
dubuc
duc
jk
duckworth
j
dudkiewicz
e
e
dufour
c
dufour
f
dunaway
duncan
r
dunham
c
dunkel
ij
dunn
dunt
dupont
jck
dupraz
c
dupui
f
dupui
l
dupui
dupuy
duqu
durosinmi
dursun
durugappa
dutra
dutra
ap
duval
dvir
r
dwight
c
dwinata
dwivedi
sn
dworzak
dy
dyer
dylewska
k
k
dziuk
e
eandi
eaton
russel
c
eaton
b
ebb
ebeid
e
echavez
j
echebarria
j
edgington
edroff
j
edward
edward
h
efron
b
eftink
egan
k
ega
egel
rm
eggert
eguiguren
leon
jm
eguiguren
jm
eguiguren
ehrlich
p
ehrlich
pf
ehsani
eibaik
l
eid
eikmeier
k
eilertsen
b
eino
eisenstat
eke
g
eke
gk
el
desouki
el
desouki
e
el
kababri
el
khattabi
el
kinaai
n
el
midaoui
f
el
shafi
el
solh
h
el
traboulsi
el
trabulsi
el
wakil
r
n
u
h
elamin
elbeltagi
eldebawi
e
elger
b
elhadad
alaa
elhaddad
alaa
elhasid
r
elhemali
elhoudzi
j
elizald
elkababri
elkhateeb
n
elkhatib
nada
elkhorassani
elkinaai
n
elleithi
h
eller
elliot
ellison
elmor
elnadi
e
elnashar
elshafiey
elsherif
n
elwakeel
emam
emil
jf
emst
l
emtsova
v
emura
endr
engel
ee
english
english
mw
enright
k
entz
werl
n
n
eran
erbay
erbey
f
ercetin
p
erden
e
erdogan
ergin
f
erminio
g
erol
ertem
au
escamilla
g
escot
l
esiashvili
n
eslin
espinosa
j
espinoza
manjarr
essiaf
ml
estefan
eterov
ak
evan
b
c
ezer
u
ezzat
ezzian
k
f
faber
k
fadel
e
fadel
fadhil
g
fadip
fadoo
z
fagioli
f
fainboim
l
faizan
fajardo
p
falconi
faldum
fan
j
fan
r
fan
x
fanelli
p
farah
r
faranoush
farhat
r
faria
cc
faria
pa
farid
faridi
r
faridi
rm
farinha
nj
farmer
jp
farrag
farranoush
faur
conter
c
c
fauri
favr
fawzi
fawzi
mf
fayter
fechina
l
fedatto
pf
federico
federico
federico
sm
fedoriw
g
feijen
eam
feinmess
felic
felini
feltbow
r
feltbow
rg
feracini
lf
ferdousi
ferguson
p
ferman
ferman
se
fernand
sm
fernandez
c
fernandez
cv
fernandez
l
feroza
zq
ferrar
f
ferrara
e
ferrari
ferrari
c
ferreira
f
ferrer
f
ferri
feusner
j
fiandrino
f
figaji
j
figueroa
j
filipek
filippi
rz
filomia
l
finlay
jl
finlayson
fiori
cmcm
firat
firoozi
fischer
fisher
fisher
mj
fishman
l
fitoz
flanagan
flank
j
fleer
j
fleischer
j
fleme
flood
flore
p
flore
v
ce
fonseca
fonseca
tc
fontana
fontebasso
foreman
n
foresti
e
fornerod
forni
foster
j
fouda
fouladi
fouquet
v
fowler
j
fox
e
fraioli
f
fraitag
franci
jh
franco
l
francois
j
frandsen
frappaz
fraser
j
frasunkiewicz
k
frazier
l
frebourg
frederick
n
frediani
freeman
b
freeman
cr
frees
dk
freneaux
p
fresneau
b
freyer
freyer
dr
friedman
gk
friedmann
friedrich
p
friedrichsdorf
frikha
frisch
haug
h
mc
fruit
l
frybova
b
fryer
c
fu
r
fuchimoto
fuchita
fuch
j
fuent
alabi
fuent
l
fujimoto
j
fujimoto
fujimura
j
fujisaki
h
fujita
n
fujiwara
k
fukuda
k
fukuda
fukushima
h
fukushima
n
fukushima
fukuya
fumiko
fumino
funk
aj
funston
l
furlong
w
furman
wl
furtwangl
r
r
fusco
c
fuster
soler
jl
futerman
b
fynn
e
g
gabri
gachi
f
gadd
gagin
r
gaillard
mc
gain
je
gajdosova
e
gajjar
galant
galardi
p
galera
gallego
zapata
gallego
galley
mt
galli
r
galli
b
galli
bl
gallo
galluzzo
l
gandhi
b
gandola
l
ganesh
gantan
gao
c
gao
chao
garab
mm
garami
garaventa
garbuio
l
garcia
de
andoin
n
garcia
lombardi
garcia
prada
p
j
p
p
garcia
e
gardner
garganes
mc
gargoura
gariboldi
f
ml
garrido
colino
c
garrido
c
garwar
garzia
l
gasperini
gasperini
dg
gassa
j
gatz
gauthier
f
gayden
gaze
gaze
mn
gazikalov
ge
gebhardt
mc
geismar
geller
j
geller
ji
geludkova
gemayel
g
gendoo
genel
f
genelhu
genitori
l
genma
genneri
gentet
j
gentet
jc
geoerger
b
geoffray
georg
c
gerg
n
gerhard
gerhard
ds
german
geron
l
geronimo
meza
j
geronimo
j
geronutti
geronutti
da
gerstl
jt
gerstl
gesku
rb
gessler
geuen
ghandour
k
ghantou
n
gharbi
ghazal
h
ghazal
ghazali
ea
ghazali
gheriani
n
ghod
gholami
r
ghosh
ghzalli
mh
giacon
b
giangaspero
f
gibson
b
gibson
be
gibson
f
gibson
gibson
p
gid
c
j
gilbert
gilberto
j
gilchrist
l
gill
f
gillespi
gy
ginevri
f
g
ginsberg
j
giordano
attianes
gmp
gireud
girgi
gisselsson
glamochanin
gleissman
h
glick
r
glogova
e
glomstein
glosli
h
gnanachandran
j
gobin
yp
goddard
k
godzinski
j
goga
gokc
samar
z
gokc
golbourn
b
gold
r
golden
goldfarb
goldin
goldman
goma
g
gomer
gome
rg
gome
rpq
gomez
gompaki
n
gonen
gongbao
l
ruiz
de
leon
e
gonzalez
sansegundo
c
gonzalez
gonzalez
c
gonzalez
ml
goosken
goosken
slm
gopal
gopalakrishnan
gorbatyh
gorczynska
e
gordon
gordu
z
gore
l
goretzki
sc
gorgun
goricar
k
gorter
j
goshorn
dr
gosiengfiao
goswami
goto
h
goto
gotou
h
gottardo
n
gotti
g
gouthro
j
govend
gow
k
gowrishankar
bc
gozman
gozmen
graf
n
graham
r
grainger
j
grajkowska
w
granado
granata
c
granhagen
jungner
j
grant
r
grant
rm
granzen
b
grasemann
c
gratia
e
grazzini
green
green
green
hl
green
greenberg
greenberg
ml
green
h
greenwood
gregori
j
gremeau
grigorovski
n
grill
j
grimard
l
grootenhui
grootenhui
grosshan
gruber
e
gruhn
b
grundi
p
grundi
pe
grupp
sa
gryfe
r
grynszpancholc
e
guajardo
c
guatta
r
f
l
guettier
c
gugelmin
e
guger
guhanika
c
guibelald
guidri
auvil
j
jm
guilbaud
n
guillaudbatail
guillerman
p
guitter
gujral
guler
e
guleryuz
h
n
gulia
gulia
gull
bhat
gumruk
f
gundaz
k
gundi
p
guney
gunn
gupta
gupta
ak
gupta
gupta
dk
gupta
l
gupta
n
gupta
p
gupta
r
gupta
gupta
gupta
v
gurakan
f
gurgey
gururangan
guseva
gustafsson
g
guthmann
guvenc
u
guy
k
guzman
guzzo
gyokova
e
gyurina
k
h
ha
sy
haa
mc
haberl
c
habib
f
habib
z
habrand
jl
haddad
hadley
l
haeberl
b
haeri
mazanderani
af
haer
hafez
h
hafiz
h
hahashi
hain
k
haioun
c
haj
mansour
halalsheh
h
hale
kc
haley
k
hallahan
hallman
j
hallmen
e
halnayak
halparin
j
hama
hamalainen
hamanou
hambir
hambleton
hamdi
n
hami
h
hamid
hamidieh
hamilton
hamilton
hammarlund
k
hammond
p
hamoda
hamouda
ah
hamsar
h
hanaratri
hancerli
torun
hancock
k
handgreting
r
hanif
k
hanmod
hanoo
hansen
j
hansson
h
haouilou
j
haq
haqu
haqu
r
haqu
hara
j
hara
harada
k
hard
v
hargrav
dr
harish
r
harrap
r
harrison
l
hart
n
hartley
b
hartley
l
hartsel
w
hartung
hasan
h
hasan
mk
hasegawa
hasenclev
hashii
hashimoto
n
hashw
n
haskin
c
hasl
h
hassal
te
hassan
r
hassanain
oh
hassanein
hasselblatt
hassounah
hata
j
hattingen
e
hatzipant
e
hauffa
bp
hauffa
pk
haupt
r
hauschner
h
hauser
p
havaldar
r
havinga
j
hawaldar
r
hawkin
c
hawwari
hayakawa
hayasaka
k
hayashi
hayashi
hayden
mr
hay
jordan
hazan
f
hazar
v
hazarika
n
hda
n
l
heap
heath
ja
heawood
hebiguchi
hedayati
asl
aa
hedman
b
heerema
na
heij
h
heijkoop
hein
heinzelmann
f
helfr
hellebostad
helouri
hempel
g
hendershot
e
hendershot
k
hendrick
hendson
g
hennig
henriqu
r
henri
henter
ji
henwood
e
herd
f
c
hermiston
hermiston
ml
hernand
r
hernandez
alomso
hernandez
alonso
hernandez
arrazola
hernandez
ruperez
b
b
hernandez
hernandez
hernandez
f
hernandez
p
hero
b
herrainz
cristob
r
herraiz
r
r
herrero
b
hertzel
g
herzog
ce
hess
k
hesselgrav
j
hessel
pb
hessissen
l
heyman
hick
j
higa
higashimoto
higgin
higham
c
higuchi
hiiyama
eiso
hijja
hilden
j
hilkay
karapinar
c
ce
hill
ad
hill
da
hill
r
hind
p
hine
hinkl
n
hinojosa
j
hirabayashi
hirado
j
hiramatsu
h
hirayama
r
hiros
hirst
hisakawa
h
hiscox
hishiki
hitzler
j
hiyama
e
hizhnikov
hjalgrim
l
hjorth
l
hla
hmood
ho
c
ho
cm
ho
kc
ho
r
hobbi
w
hochlef
hockenberri
hock
mc
hodak
e
hodgson
hofer
g
hoffer
f
hoffmann
c
hogarti
hogarti
md
hojo
h
holland
holli
r
holm
k
honeycutt
j
hong
c
hong
cr
hooft
l
hoogerbrugg
p
hoogerbrugg
pm
hook
mc
hooker
l
hopyan
horakova
j
horan
g
hori
h
horib
k
hori
h
horikawa
r
l
horsman
j
horton
hosgor
hoshi
r
hoshino
k
hoshino
n
hosoi
h
hosoya
hossain
ms
hotchkin
houdzi
j
houghton
houlahan
ke
houw
howard
f
howard
howard
sc
howel
l
hu
l
huang
huang
cc
huang
huang
huang
yong
hudson
hudson
mm
huerta
j
huerta
j
p
huff
v
huh
w
huh
ww
hui
j
hui
k
huisman
j
hukin
j
hullmann
se
humbert
n
hunger
hunger
sp
husain
husain
n
hutchinson
rj
iaconelli
r
iannotta
ibrahim
ibrahim
icher
c
ida
k
ideno
k
iehara
iguchi
ijiri
r
ijovskyi
ikeda
ikeda
h
ikegami
ilari
ilhan
ilic
v
im
h
imai
c
imai
imran
inada
h
inagaki
j
inc
indelicato
indelicato
dj
indolfi
c
indolfi
p
ingen
inomistova
inou
f
insel
k
inserra
inserra
ae
interiano
r
ionkina
n
iqbal
n
n
iriso
r
irtan
irwin
gj
isa
n
ishida
ishida
ishikawa
f
ishikawa
h
ishimaru
ishizuka
isidor
b
isik
islam
islam
k
islam
ismael
isnard
blanchar
rm
isob
israel
israel
itek
f
ito
itriago
e
ivanova
n
ivanovski
ivanovski
p
iwabuchi
h
iwai
j
iwanaka
iwasakai
f
iwasaki
f
iwata
w
iyer
p
iyer
vk
izumi
c
izumino
h
e
j
jabado
n
jabr
jacob
jacobsen
jahnukainen
k
jahnukainen
jain
jain
jain
k
jain
p
jalali
r
jalilitahmasebi
z
jalmsel
l
jamal
cy
jame
martin
j
jame
martin
jx
jame
pw
jana
jang
ps
janic
janku
f
janni
l
janzen
l
jaradat
jardini
vmg
ls
jaspan
jastaniah
w
javakhadz
jawaid
w
jayabos
jayalakshmi
jayaram
h
jazdon
jebet
jeibmann
jelveh
jenei
jenholt
nolbri
jenney
jensen
c
jeong
dc
jereb
b
c
jezierska
jha
ji
l
jia
jiang
h
jiang
j
jiang
mw
jiang
jibb
l
jibb
la
jillela
b
jillella
b
jimenez
jin
l
jin
ling
jin
jin
rm
jindal
b
jmean
h
jogal
johann
p
johnsen
j
johnson
johnson
johnson
km
johnston
johnston
k
johnston
p
johnston
r
joksic
jone
b
jone
c
jone
dtw
jone
h
jone
j
jone
r
og
joo
h
jorgensen
f
jose
ns
joshi
joshi
v
jouglar
e
jovanov
jovanovska
jovic
ju
hy
jubierr
l
judkin
juergen
h
juffri
julien
r
junqueira
v
juraeva
jurair
h
jurcoan
jurgen
h
h
jyoti
b
k
kabbara
n
kabickova
e
kabra
kabra
sk
kachanov
n
ns
kadioglu
b
kagawa
n
kager
l
kai
q
kaiserova
e
kakkar
c
kakkar
n
kakkar
kakuda
h
kalagbor
kalapurak
j
kalfa
n
kallala
n
kalra
kalwak
k
kalyani
n
kamal
kamal
n
kamel
kamer
kamibeppu
k
kamienska
e
kaminska
kaminskaya
kamiyango
w
kamiza
kamkar
kampimba
b
kamp
wa
kan
r
kanamori
kancharla
r
kandel
j
kaneko
kang
h
kang
hj
kanmaz
kannan
kanno
kanold
j
kansoy
kantar
kanvind
kanwar
v
kapelushnik
j
kapkova
kaplan
j
kaplan
joel
kapoor
r
kappler
r
kapucu
lo
kapusta
l
karaca
karadeniz
c
karaer
dk
karahroudi
karaka
z
karakukcu
karaku
oz
karaman
karaman
karaman
karapinar
karapinar
th
karim
karkouri
karlag
karli
oguz
k
k
karner
karpinska
kashyap
kasi
viswanathan
kasi
v
kasper
h
kasper
g
kasper
gj
kasper
gjl
kasper
gsl
kast
sc
katayama
katewa
kato
kato
k
kato
katoh
h
kaufman
ra
kaur
h
kawaguchi
h
kawaguchi
kawakami
c
kawano
kawasaki
k
kawashima
h
kawatsu
kaya
kayilioglu
h
kazak
ae
kazanowska
b
kazantcev
kazantcev
kazantsev
kazemb
p
kearn
p
keat
kebudi
kebudi
kebudi
r
kecman
z
keen
kehe
l
kelli
kelli
k
kelli
kara
kelli
vm
kelsey
kelsey
k
kembhavi
kemp
tj
kenney
lb
kent
p
kerimov
p
kero
kersseboom
r
keskindemirci
g
kettlun
c
key
khafaga
khaleifeh
k
khalif
h
khan
ghazi
e
khan
f
khan
fm
khan
h
khan
j
khan
khan
ms
khan
p
khan
r
khan
khan
khandelw
v
khanfir
khanna
g
khanna
n
khanna
v
kharoubi
khatoon
khattab
khattab
khedr
g
khedr
r
khoo
ym
khoubila
n
khranovska
n
da
da
khurana
n
khurma
khvedelidz
kieler
h
kienesberg
kigasawa
h
kijima
kikuchi
kikuchi
kilborn
kili
kilic
kim
h
kim
hk
kim
kim
kim
sg
kim
sk
kimani
k
kimura
k
king
kinoshita
kinsey
kiper
misirlioglu
p
kir
kirchhoff
kiren
v
kirimlioglu
h
kirov
kislyakov
kiss
c
kitagawa
n
kitamura
kitonyi
g
kitumaini
j
kiwan
p
kiyaga
c
kiyotani
c
kizmazoglu
klaassen
r
klassen
kleinenberg
kleinerman
e
kleinman
c
klekawka
kliebsch
u
klingebiel
klymnyuk
g
knight
k
knop
rrg
knutsson
kobayashi
k
kobayashi
r
koc
koc
b
kocak
u
kocer
ne
kochbati
l
kocheva
kodama
k
kodet
r
kodetova
koehler
g
kogaki
kogner
p
koh
k
koh
pl
kohorst
koivisto
kolatan
e
kolenova
koliouska
koliouska
de
kollar
koltan
komatsu
komolaf
ao
kompani
f
kondo
kondo
h
kong
qy
konovalova
kontio
kontogeorgi
e
kool
koppling
j
kord
ur
korgenski
k
koron
korpela
r
kor
wa
korshunov
kortmann
rd
korzeniewska
j
kosaka
koscielniak
e
koshechkina
n
koshinaga
koskenvuo
kosmalska
kostel
bal
koudera
u
kourti
koussay
koutecki
j
kouya
f
kouzi
r
kovac
g
kovarik
c
kowalczyk
j
kozaki
kozlowska
krafcik
fr
krailo
md
krajinov
krasin
krasin
mj
krasko
e
kravljanac
r
krawczyk
krcmeri
v
kreicberg
u
kreissman
sg
kreitler
kremer
l
kremer
lc
kremer
lcm
kremer
v
krifa
h
krishnan
pk
krishnan
kristensen
krivoy
e
krstovski
n
kruczynski
kruger
krull
k
krumbholz
krysiak
r
kubota
k
kuchakzadeh
l
kuczynski
kudo
k
kuehn
kuhlthau
k
kuiper
r
kuiran
kulej
kulekci
gd
kulikova
ss
kulkarni
k
kulkarni
kulkova
n
kulozik
kumab
kumar
kumar
k
kumar
r
kumar
kumar
sb
kumirova
e
kurap
j
kurekci
e
kurihara
kurimoto
kurkur
p
kurkur
pa
kuroda
kurugoglu
kurylak
kurzrock
r
kusano
kushel
kushel
yu
kuskonmaz
b
kustanovich
kutluk
kuwahara
kuzmanov
kyaw
kyncl
l
la
spina
laack
nn
laban
labarqu
v
lada
e
ladenstein
r
ladogana
ladra
l
laffont
lagaerspada
lage
c
lagomarsino
e
lago
j
lahay
lahoti
b
p
pm
lai
laila
r
laksmi
nk
lalioti
n
lam
c
lam
cg
lambert
b
lambourn
j
lambrou
lamchahab
lamchaheb
lamont
j
lamprecht
lanctot
jq
land
landier
w
lang
l
langat
langat
sc
langer
langham
mr
lankest
lanner
b
lansiaux
laohapansang
laplanch
lappan
j
larouch
v
larroquet
larsen
u
lartigau
e
laskar
lassaletta
latha
ms
latif
latorr
e
lau
l
laur
hj
laurent
v
laurey
g
lauri
f
lausen
b
laven
jse
laverdier
c
c
lavorator
sr
lazic
j
le
chinh
dai
le
deley
le
deley
mc
le
gouill
leal
lf
jq
r
leblanc
leblond
p
lechtap
b
leclair
md
leclair
lederman
lederman
lee
hs
lee
j
lee
jw
lee
jy
lee
lee
mlm
lee
qw
lee
lee
sw
lee
v
lee
yt
lee
gm
leeuw
ja
leeuwen
f
lehmann
l
lehrnbech
lehtinen
leibundgut
k
leiss
u
lejar
lejeun
lemay
lemesheva
lemier
j
lenko
hl
leon
hernandez
leon
lepretr
leroux
lervat
c
leszczynska
e
lethabi
c
leung
w
leuschner
leverg
g
levin
levitt
g
levi
c
levi
lewi
f
lewi
lewi
v
li
bs
li
c
li
ch
li
li
f
li
fx
li
h
li
hong
li
j
li
jun
li
k
li
kai
li
l
li
li
mh
li
r
li
w
li
wj
li
x
li
li
z
li
zg
li
zy
liang
hh
liben
libe
j
lieverst
j
k
likar
lim
k
lim
lima
f
lima
lmmr
lima
r
lima
rag
lin
j
lin
w
linar
lindequist
lindh
j
lindh
v
lindsay
p
ling
z
lingappa
l
ling
link
z
linn
liomba
g
liphshiz
liptak
c
lira
rcp
liu
g
liu
j
liu
l
liu
liu
q
liu
z
liuhto
n
ljungblad
l
ljungman
g
lo
nigro
l
lo
lo
k
lober
j
locatelli
f
lock
r
lockart
b
lockwood
l
lode
hn
loeffen
e
jj
loh
ah
loh
ahp
loh
ml
dja
loibner
h
loisel
c
loisel
cg
lolli
lombardi
london
w
london
wb
lone
longo
cj
look
loonen
j
lope
junior
lc
l
lope
jm
lope
l
lope
lf
lope
luiz
lopez
guerra
jl
lopez
marti
j
lopez
yurda
r
j
b
e
lorenzana
lorenzo
lorenzo
aj
losti
p
lotin
lou
loughnan
p
louni
c
mlpc
louterneau
l
lovvorn
h
sa
lu
f
lu
h
lu
lu
x
lu
lu
z
lubieniecki
f
luca
luca
j
lucchetta
n
lucena
e
luck
aj
ludwig
ja
luepker
r
luhiriri
n
lukashenko
lukina
ai
luksch
r
lum
luna
cf
lunin
vv
luo
cy
lupo
p
lupo
pj
lustig
ra
lutz
p
k
lymberi
labib
r
mhamdi
l
x
xl
mabbott
mac
donald
macdonald
macdonald
macdonald
macgregor
f
machado
e
machin
l
macintyr
g
mack
mack
sc
mack
sm
l
lm
madanat
f
madani
madden
j
madeni
madero
l
madney
madsen
madziara
w
maeda
maeda
n
mage
k
magnani
cf
mahajan
mahamad
zaki
h
mahdi
mahfouz
r
oukhatar
c
mahiou
mahmood
l
mahmood
mahmoud
mai
trong
khoa
mai
h
maibach
r
l
majewski
j
mak
k
makadia
makarawo
makarewicz
makhoul
khouri
makimbetov
e
makohusova
makroo
rn
malcic
malekera
l
malheiro
malhotra
p
malila
n
malinowska
mali
j
malkan
malkin
malogolowkin
mh
maloney
maluf
jr
pt
malvar
j
malyapa
r
mamoud
garba
manab
bm
mandevil
h
mandevil
hc
mandrel
b
mangat
nk
manikyam
manipriya
r
manley
p
manley
pe
manor
manraj
h
mansour
mansuy
l
manu
v
manullang
manzitti
c
mao
marabel
p
marco
antonio
da
marcoux
marcu
k
marcu
kj
p
p
margol
mari
j
marjerrison
mark
r
markel
markert
jm
marliot
g
marqu
eav
marr
bp
marri
p
l
marron
j
marron
l
martelli
h
martimianaki
g
martimianaki
martin
j
martin
l
martin
martin
v
martinelli
jr
ce
mv
r
mj
martinez
martinez
martiniuk
martino
martinova
k
martin
c
martin
g
martin
ge
ij
martucci
c
maru
marwaha
rk
marwick
th
masafumi
masaki
h
mascarenha
l
maschan
maschietto
masetti
r
masih
mason
c
massag
n
massimino
mastellaro
mj
mastronuzzi
mata
c
mata
c
matano
matend
mateu
c
mathur
r
matloob
r
j
matoso
l
matsufuji
h
matsui
matsumoto
jm
matsumoto
k
matsuoka
k
matsushita
mattar
matthay
k
matthay
kk
mattosinho
cc
maturi
p
matut
r
matysiak
maud
sl
mauersberg
f
maupain
c
h
amc
may
l
mayank
mayaphi
mayorga
jl
maza
medina
maza
mazewski
c
mazzocchi
l
mcandrew
r
mcbride
mcbride
mccaffrey
g
mccall
j
mccarten
k
mccarthi
mccarthi
mccarvil
e
mccarvil
mb
mcclain
k
mccowag
gb
mccusker
c
mcgowan
mcguir
n
mchugh
k
mcintosh
mcintosh
n
mckenzi
jm
mclean
j
mcloon
jk
mcnalli
r
mcneil
r
mcpherson
j
mcpherson
v
mda
meazza
c
mechinaud
f
meciakova
medhi
medina
medina
meerzaman
megaro
g
mehanna
mehrotra
r
mehrotra
mehrvar
mehrvar
n
mehta
p
mehta
ps
mehta
mehyar
meignan
mei
e
meisami
ap
mejia
sanchez
g
melam
melchor
melen
gj
melendr
e
melendr
em
meli
melikyan
melo
vall
melo
miaa
melvin
p
mendelsohn
r
mendenhal
n
mendieta
l
oa
menez
w
menon
b
menon
p
meral
r
mercado
gv
merchant
merchant
te
mercier
merck
c
merck
h
merino
l
merk
jhm
merlin
e
nm
messacar
k
metrangolo
metzler
meyer
p
meyer
r
meza
r
mezher
ih
mezlini
mezziani
mia
miao
h
miao
hui
miao
liu
michalski
michel
g
michiel
e
michon
j
micic
mick
eo
middaugh
j
migita
migliorati
r
migliozzi
c
mikchailova
e
mikroutsiko
l
mile
r
milito
c
miller
gm
mill
milosev
g
minami
minard
colin
v
v
minguela
pura
mininni
mf
mintor
r
minturn
j
minturn
je
mir
mir
miraglia
v
miron
miron
mishra
misra
misra
r
mitchel
mitchel
hr
mitchel
l
mitra
mitrofanova
mitsui
mittal
n
mixa
v
miyachi
miyagawa
n
miyagi
h
miyamoto
miyamura
miyano
miyashita
e
miyata
k
mizumoto
mlotha
r
mlynarski
w
mnayarji
mngomezulu
moalem
mochizuki
k
modena
pg
modi
r
moham
moham
r
mohan
r
mohanti
bk
mohd
ibrahim
h
mohsin
moiseenko
r
moiyadi
mokhl
mokhtar
g
mokhtar
mokhtari
mokotedi
mt
mol
e
molinari
pcc
molist
c
moll
ac
molla
lr
molyneux
e
molyneux
em
monib
h
montanari
l
mont
jl
montgomeri
montini
e
montpetit
moodley
k
moonsami
n
moor
moor
moor
moormann
moormann
morach
p
moraleda
jm
mordechai
mordechai
oz
moreira
c
moreno
da
moreno
l
morgan
e
morgant
morgenstern
da
mori
bo
mori
morici
morikawa
morita
n
moritak
h
morken
mornar
dan
morosi
c
moroz
v
morreau
p
morri
c
morri
morrissey
l
morrissi
morrissi
mors
morsellino
v
moscheo
c
moschovi
moskowitz
c
mosleh
mosseri
v
mostert
moteab
motoki
n
motta
mottl
h
moul
n
moulik
n
moura
junior
moussa
e
moussa
emad
mowbray
c
moya
mozzilli
mpunga
mrazova
v
msefer
alaoui
f
mtete
mudaliar
mudegoudra
muftahova
g
mufti
mugamba
j
muggeri
muirhead
cr
muka
mukasa
mukhwana
r
mulder
rl
muleri
mullaney
mullasseri
mullen
c
mullen
e
mullen
ea
mullen
em
mullighan
cg
mulrooney
mulrooney
da
mumcuoglu
mund
j
munier
f
munshi
muracciol
x
murawski
murayama
murelli
muroi
murphi
murphi
c
murphi
murphi
e
murra
murra
ms
murray
j
murray
murtadha
drm
muscal
j
mushinskaya
mushtaq
n
musimbi
j
musiol
k
muskat
b
mussano
k
mutafoglu
k
mutai
muwakkit
mwashala
w
n
nabarret
jm
nadel
hr
nademi
z
nader
r
nag
tc
naga
g
nagai
j
nagao
nagas
h
nagayoshi
nageswara
rao
aa
nagrulkar
nahar
k
na
nair
v
najjar
n
nakagawa
n
nakagawara
nakahata
k
nakamura
nakamura
nakanishi
k
nakano
nakazawa
nakimbugw
namagala
e
nan
l
nana
nandaula
nanji
naqvi
nara
k
naranjo
narasimhan
kl
narayanan
v
narciso
naredi
b
narendra
babu
narijo
naru
j
narula
g
nascimento
jb
nascimento
l
nascimento
lc
nasedkina
nasef
n
nasr
nathan
p
nathan
pc
navaja
navarro
nave
r
navid
f
nawaiseh
nayiag
naz
f
ndiay
ndiay
sm
nechesnyuk
neck
c
neder
l
neel
neel
md
neethl
b
negger
nejadnik
b
nelson
neme
k
nerli
r
ness
k
ness
kk
neto
neuwelt
e
l
neve
nsh
nevil
nevil
c
nevil
k
neyman
g
nfundiko
k
ng
ngo
c
nguyen
c
nguyen
ha
ngwa
e
ngwang
j
nichol
nichola
nicholson
jc
nickol
c
nicola
nicola
p
niedobitek
g
niedzwiecki
nielsen
mm
nielson
niemey
c
niemey
cm
niemierko
niggli
f
nightingal
nihayah
nilsson
k
nishi
nishikawa
r
nishimura
r
nitani
c
nitin
g
nixon
c
njambi
l
njom
v
njuguna
f
noellk
p
nonomura
k
noonan
n
noriega
garcia
norman
g
normand
f
noronha
l
northcott
pa
northman
l
norton
noubari
z
nouhou
h
noun
p
nouri
n
nourkami
n
n
novichkova
g
nozaki
nuchtern
j
nune
nune
mdr
nurunnabi
asm
nurzynska
j
j
nyamori
jm
nyberg
nyenz
e
nyholm
nyo
obrien
oconnel
oneil
oneil
af
j
osullivan
oaits
w
oba
j
oberlin
oberthu
obulkasim
ochi
v
odor
k
oeffing
k
ofir
r
oflaz
sozmen
b
ogawa
e
ogawa
j
ogawa
ogawa
oguz
oguz
b
ohizumi
h
ohki
k
ohno
ohshima
j
ohshima
k
ohsumi
ohta
h
ohta
ohtak
h
oja
ojala
th
ojha
r
oka
okab
k
okada
k
okamoto
okamura
j
okcu
okcu
mf
okimoto
okita
h
okumura
okur
olagunju
olagunju
olaiz
campo
r
oldridg
olgun
n
olgun
olhova
l
oliveira
e
oliveira
rs
oliveira
v
olkhova
l
olshanskaya
omar
fe
omar
w
omenah
omollo
p
onakpoya
uu
onen
ono
onoda
oom
ahag
oosterlaan
j
opara
r
opoku
oravkinova
orbach
orest
orfao
orlov
orm
l
orozco
orren
orsey
ortac
r
ortiz
mj
ortiz
r
oscanoa
gutierrez
oscanoa
oshiro
oskarsson
ospina
osugi
otieno
ja
otsubo
ouchi
k
oudoux
oue
overmy
l
owari
owen
e
j
oyelohunnu
oymak
oyomb
j
ozaeta
ozawa
ozcimen
aa
ozdemir
ozek
g
ozer
e
ozerov
ozerova
v
ozono
k
ozsurekci
ozturk
g
p
pacheco
p
paciarotti
packer
r
pacquement
h
padayachi
l
padaychi
l
padovani
l
paez
pagnier
pai
g
pai
paiano
paillard
c
paintsil
v
paintsil
v
paiva
bs
pal
n
palacio
acosta
j
palacio
j
pall
j
paltin
pampallona
pampin
pamukoglu
pan
c
panagouli
panda
nk
panda
panda
sp
pandey
rm
pane
ee
panferova
j
panick
j
panthe
papadaki
v
papakonstantin
e
papathoma
e
papkevich
pappo
paradkar
paramasivam
v
parashar
parasuraman
pardal
f
pared
l
pared
parent
v
parikh
n
parimkayala
r
paripov
l
park
jr
park
k
park
kd
park
park
j
parkkola
k
pasa
pascalini
c
pascual
jf
pasqualini
c
pastinen
pasvogel
patel
c
patel
j
patel
k
patel
r
pathi
patil
patiroglu
paton
g
patriarchi
f
patt
c
patton
g
paul
r
paula
paulsen
f
paulu
w
paulussen
pavlotski
f
pavlov
pavlyk
pawlak
peacock
j
pearc
pearlman
e
pearson
pearson
ad
pecoraro
g
pecori
e
pedrosa
f
peinado
j
pekpak
e
pelleti
w
k
h
penel
n
pentz
r
percin
ep
perci
v
perdochova
l
peregud
j
pereira
ms
perek
peretta
p
perez
de
antueno
f
perez
ea
pergert
p
perini
perkin
perlep
c
perlman
e
perlman
ej
perruccio
k
pesmatzogl
k
peszynska
k
peter
n
peter
amj
peter
c
peter
gj
peter
k
petersen
g
petit
p
petrasch
k
petrichenko
petrid
e
peyrl
pezuk
ja
pfister
pfister
sc
pfister
sm
pham
cam
p
phillip
b
phillip
f
phillip
p
phillip
pc
phuakpet
k
picard
picton
pidini
pierani
p
pierc
j
pierc
l
pierson
cr
pieter
br
pieter
r
pieter
rob
pietsch
piguet
c
j
pilarczyk
j
pill
l
pillay
k
pillon
pillon
pimentel
j
pinarli
f
pinarli
fg
pinheiro
c
pinnagoda
k
pinto
f
pio
l
pire
pizer
b
pizzi
n
pizzoferro
plana
jc
plancher
c
plantaz
plaschk
platschek
plavskyi
p
plesko
plon
plonowski
plouvier
e
pluijm
pluijm
smf
pobudejska
podda
poetschger
u
pogorzala
polastri
polczynska
k
pole
j
pole
jd
poling
pollett
polyakov
v
polychronopoul
pomicino
l
popim
rc
popov
popov
v
popova
n
popova
popova
portela
l
portilla
c
portilla
ca
porto
l
portwin
c
po
l
possagno
r
postovski
pota
e
potratz
j
pouli
jl
pourier
powi
poyraz
prabha
pradhan
k
pradhan
n
pradhan
nd
pradhananga
k
jm
prasad
prasad
l
prasad
prasad
maya
prateek
b
pratt
l
j
preeti
pribnow
price
v
k
pritchard
e
pritchard
prityko
privalova
l
priya
r
priyanka
prokurat
proust
pruitt
r
przybyszewski
b
puchmajerova
pudrlja
slovic
puget
puglisi
f
pui
ch
pulivadula
venkatasai
j
pulsif
puma
n
punanov
yu
punatar
punjwani
r
punnett
purden
puri
puri
ajay
puri
k
pushker
n
pycha
k
k
pyle
q
qaddoumi
qayyum
qazi
aq
qian
x
qian
z
qin
h
qin
mq
qin
x
qingzhao
shi
qiu
quachouh
quaghebeur
quaglietta
l
quah
tc
rgp
quereshi
quessar
quinn
avila
quinonez
quintero
de
charri
quintero
qureshi
quyou
r
raafat
rabagliati
r
rabeh
w
rabin
k
rabinovicz
r
rabi
kl
rachid
raciborska
rademak
radhakrishnan
n
radhakrishnan
nita
radic
radu
c
radulov
radwan
r
rae
c
raek
l
rae
raetz
e
raetz
ea
rafaat
rafailovici
l
ragab
ragg
raghunath
bv
rahabarimanesh
aa
rahiminejad
ms
rahman
smr
raiz
rajagop
r
rajat
rajendran
rajeswari
rajput
k
raju
rajwanshi
rakotonjanahari
j
raletshegwana
ramachandran
p
ramadwar
ramaglia
ramakrishnan
l
ramakrishnan
ramalho
lnz
ramanujachar
r
ramanujan
v
ramaswami
v
ramdwar
ramesh
ramesh
xa
ramirez
g
ramirez
ramirez
oo
ramnarain
ramo
rezend
f
ramo
aml
ramo
pmm
ramphal
r
ramyar
ramzaan
ramzan
ranasingh
n
rand
kl
randal
l
randisi
f
ranft
ranganathan
p
rangarajan
v
rangaswami
rangaswami
aa
rangel
mru
rani
rankin
f
rao
bn
rao
kln
rao
n
rapala
rapoport
rash
w
rashid
lone
rashid
rasmussen
p
rassekh
r
rassekh
sr
rastogi
rathnam
k
ratho
rk
rathor
aw
ravindra
ravindranath
rawashdeh
k
e
rayar
raz
h
real
g
reaman
g
recino
v
reckliti
c
reckliti
cj
reddi
c
f
reed
n
reed
r
refaat
rego
em
reguerr
reich
reichek
j
reilli
reilli
c
reinaud
c
reinhardt
rei
mbf
rei
r
rei
rm
rekhi
b
reme
remk
renbarg
j
renbarg
jl
renner
l
renner
la
rent
e
rent
p
revuelta
iniesta
r
rey
g
reychler
h
rey
reynder
dt
reynold
ra
rezgui
rheingold
riad
k
riaz
ribeiro
k
ribeiro
r
ribera
n
riccheri
c
riccipetitoni
g
richardson
richter
ridd
rifi
h
f
riger
rigillo
g
rihani
r
riki
n
rikiishi
rinaldi
e
ritter
ritu
c
riva
ruiz
r
riva
r
rizvi
sah
rizzari
c
robaey
p
robb
sl
robert
c
robert
robert
r
robertson
robertson
k
robinson
gw
robinson
l
robison
l
robison
robison
n
robledo
p
robl
r
rodenbach
c
rodger
c
rodic
p
c
rodriguez
rodriguez
v
roe
l
roebuck
rogena
e
roger
rohani
l
rohr
r
rohrer
r
rohrer
roja
rokeach
roland
p
roma
j
romanzo
romao
rlp
rombi
b
romero
c
roncker
cm
rong
tang
rongh
rono
h
roodbol
pf
roquet
f
rosa
rosa
jc
roschin
v
rose
rose
ps
z
rosenberg
n
ross
cj
ross
rossa
rossel
n
rossi
j
c
rossini
r
rota
r
rotatori
j
roth
l
rotondo
r
rousseau
j
roy
moulik
n
rozek
ls
ruano
rubanskaya
rubanski
c
rubi
h
rubio
c
ruccion
k
ruggiero
ruhe
k
j
ruiz
c
ruiz
ruland
v
rumiantsev
ag
russel
h
russel
nh
russo
g
russo
rutka
jt
rutkowski
rutynowska
ryan
rybak
rybakova
rychlowska
rychlowska
rygl
rykov
ryzhova
souza
saab
r
sadek
saad
f
um
saavedra
lozano
j
j
saba
dasilva
n
sabati
f
saberi
nejad
j
sabirzyanova
z
sachdeva
sachs
k
saddi
c
sadowska
j
saeed
h
saeed
p
sagar
saggar
k
sagna
mt
sah
k
saha
saha
v
sahaf
ia
sahin
g
saini
hk
saito
saito
saito
n
saito
sakaguchi
k
sakaguchi
sakamoto
h
sakji
sakoda
sakurada
ry
sakurai
h
salaverria
c
salcioglu
z
saleem
saleh
salem
salisburi
l
sall
g
salman
salman
n
salom
salzer
w
samarasingh
samardakiewicz
sami
samie
samperi
p
sampor
c
sampson
c
samson
samujh
r
sanadhya
b
de
toledo
j
sanchez
la
rosa
c
la
rosa
c
salina
fa
sanchez
g
g
sander
sanderman
r
sandler
e
sandor
gs
j
sandstedt
b
sanglard
wo
sanjeev
sankpal
u
sankpal
ut
sanpakit
k
santana
g
santana
vm
santiago
garcia
b
santiago
b
santo
cg
santo
mm
santo
r
sapra
sarabia
saraceno
saran
f
sarashina
saravanja
v
sardi
sarhan
sarhan
w
sarialioglu
f
sariban
e
sarimiy
f
sarin
sarkar
b
sarkar
sarkola
sarmiento
sarnacki
sarnthein
j
sarri
sassi
e
sastri
j
sathiaseelan
v
sato
h
sato
sato
k
sato
sato
n
sato
sato
satoaki
n
satya
prakash
satyendra
k
sauerwein
w
saulat
saunder
sautu
u
saveliev
l
sawada
sawada
sawamura
sawicki
gs
sawyer
saxena
ak
say
saye
h
sayin
sbeiti
n
scanlan
c
scardella
e
scarzello
g
schaefer
c
scharf
j
schechter
schecter
scheijen
b
scheinemann
k
schenk
jp
scheper
scherbenko
scheurer
scheurer
schiavello
e
schiavetti
schleiermach
g
schleithoff
c
schmid
schmid
schmidt
r
schmiegelow
k
schmitt
e
schmugg
schneider
c
schneider
schneider
dt
schneider
p
schneider
r
schoot
r
schoot
ra
schott
c
meeteren
meeteren
ayn
schrapp
schreier
g
schueller
u
schult
f
mm
schutz
g
schwartz
c
schwartz
l
schwartzentrub
j
schwarzmayr
scimon
g
scorson
k
scott
jx
scride
ca
seba
sebil
g
sebir
n
secola
r
sedek
l
sedki
sedlacek
p
segg
p
segura
mf
segura
v
sehop
seiding
ml
seiersen
k
seifu
seijffert
seitz
g
sejnova
seki
sekimizu
seligsohn
u
selkirk
e
selva
semczuk
k
semenova
n
semetsa
p
semochkin
semper
sen
h
sen
seo
j
seppa
sergentani
sergi
c
sergi
cm
serinan
e
serra
serrano
sv
serva
seth
r
seth
sevinir
b
shaaban
k
shabbir
ali
shah
n
shah
shaheen
n
shahgholi
e
shahzad
shaida
e
shaida
shaikh
shaikh
f
shaikh
g
shaikh
shalkow
j
shama
w
shamanskaya
shamma
shammasov
r
z
shankar
shao
j
shapiro
l
sharma
sharma
dn
sharma
ks
sharma
sharma
mc
sharma
p
sharma
r
sharma
sharma
sc
sharma
v
sharoev
sharon
n
shaverskyi
shayda
e
shchepotin
shcherbenko
sheereen
sheikh
sheikh
shelat
aa
shelli
shen
g
shen
np
shen
p
shen
sh
sheng
q
shengelaia
shep
sheren
j
sherief
l
sherratt
sheth
shetti
n
shevcov
shi
shi
shiba
n
shichino
h
shih
shih
c
shih
djh
shimada
shimamura
shimbo
h
shimizu
shin
h
shin
hy
shinkai
shiraishi
shirinian
shishkina
l
shook
dr
shorikov
e
shrivastava
r
shternin
shu
q
shu
xh
shulkin
b
shusterman
shyiramber
c
sialer
l
sibui
siddaiahgari
siddiqu
r
siddiqui
k
siddiqui
siden
h
sidhom
sidi
v
siebert
n
siklar
z
sill
silva
costa
b
silva
acl
silva
cla
silva
e
silva
eca
silva
jm
silva
silva
mm
silva
rzm
silveira
jr
jc
silveira
vs
silverman
lb
silvestr
de
faria
pa
simard
simard
mr
simic
simko
simon
simoneaux
v
simpson
p
p
singh
singh
b
singh
l
singh
singh
mk
singh
p
singh
tb
singh
u
singhai
singhal
n
sinha
r
sinha
sinnett
sint
nicolaa
sm
siracusa
f
sirin
koc
b
sirisaengtaksin
n
sitaresmi
mn
skachkova
skalkid
skamen
skeen
j
skender
skile
j
skile
jl
skinner
r
skinner
skion
aristocath
skoric
skowron
p
skuman
slater
slathia
ss
slatter
slavc
slone
slone
js
slot
ajm
smedbi
k
smeel
le
smelhau
v
smet
k
smet
smet
amjb
smet
ema
smit
smith
smith
b
smith
ca
smith
e
smith
j
smith
smith
smith
p
smith
snajdauf
j
soar
g
g
sobol
g
sobral
da
costa
e
sobrero
sobrino
sobti
p
sodhi
ks
soejima
soh
sy
sokol
sola
je
soler
c
soliman
e
soliman
r
soliman
solodovnikov
somasundaram
j
somer
somer
g
sondel
pm
sondhi
v
song
e
song
x
sonneveld
e
sonsala
sool
f
soriano
sorrentino
soulaymani
sousa
filho
jl
souzaki
r
soylemezoglu
f
spagnoli
spanjaard
l
spenc
spencer
p
spiegler
b
spinelli
sposto
r
spreafico
f
spunt
squir
r
sredni
st
sreeniva
v
sridhar
e
sridharan
sriniva
srinivasan
srinivasan
r
sriplung
h
srirambhatla
j
srivastava
srivastava
srivastava
k
srivastava
p
ssenyonga
p
stamatopoulo
k
stanley
c
stanulla
stark
stari
j
staval
jn
stefan
stefanowicz
j
steffen
stegenga
k
steif
b
stein
steinbach
steineck
g
stellet
al
stenman
j
stephansson
stephen
steven
stewart
cf
stewart
e
stijnen
stiller
ca
stinson
j
stinson
jn
stish
b
stoker
j
stoke
dc
stolpa
w
stoneham
stone
stone
dk
storek
j
strachota
k
stracke
sd
strahlendorf
c
strahm
b
stratton
mr
streneva
streng
strobel
k
strom
tm
strother
hk
strullu
styczynski
j
stypinska
suarez
n
suarez
nlg
suazo
vk
subbiah
v
subova
z
subramamanium
pg
subramanyam
pg
sudour
h
sugito
k
sugiyama
k
sugiyama
suh
j
sulka
w
sulker
e
sultan
sultan
suman
mb
sumerau
sun
j
sun
xf
sun
xx
sun
sunami
sundar
g
sundler
johansson
sung
l
superti
supiot
supriyadi
e
suresh
p
surwad
g
susam
sen
h
sutcu
sutherland
j
sutphin
r
suvada
j
suyama
suzuki
suzuki
suzuki
svensson
pj
svensson
svergun
n
svojgr
k
swaim
swami
e
swenson
r
swieszkowska
e
swigonski
n
swysten
z
sy
asb
sy
sykora
symecko
h
h
symond
synakiewicz
szalda
szalewska
b
szczepankiewicz
szczepanski
sznajder
b
tabak
n
tabbori
u
tabon
tabon
md
tabor
l
tabori
u
tacyildiz
n
taga
taguchi
taha
g
taha
h
taha
hala
tailor
k
taj
tajiri
takachi
takahashi
h
takahashi
j
takahashi
takahashi
n
takahashi
takahashi
takano
k
takano
koji
takatori
takei
takeuchi
e
takezo
takimoto
takita
j
takizawa
takken
talleur
talol
talwar
r
tamaichi
h
tamaro
p
tamburini
tamim
h
tamir
tan
tan
e
tan
p
tan
z
tanaanunmongkol
p
tanaka
h
tanaka
tanaka
tandon
n
tandon
taneyamai
tang
tang
h
tang
jy
tang
yj
tanner
l
tantawi
tanyildiz
g
tanyildiz
hg
tao
tapark
tapela
n
tapp
taqu
tarangini
tarasevich
r
tarasinska
tarbel
n
taringini
tarpey
ps
tarrillo
f
tashiro
j
tashvighi
tasian
sk
tasic
g
tatli
gune
b
taub
j
taub
jw
tavil
b
tawa
tawfiq
tawfiqu
tayeb
c
taylor
g
taylor
taylor
md
taylor
taylor
olga
taylor
r
taylor
te
kronni
g
te
winkel
ml
teachey
dt
techavichit
p
teh
kh
teira
p
teixeira
rap
teixeira
sa
tejocot
tekautz
tekgunduz
sa
tekkesin
f
tele
ta
teleshova
tello
templeton
j
tendler
tennant
teramukai
terasaki
terashita
terenziani
tereschenko
g
terwisscha
van
scheltinga
c
tessonni
l
tettamanti
teuffel
tewari
r
thacker
n
thackray
j
thakar
thakkar
thakur
thariat
j
thejpal
r
theunissen
ear
thiago
thoma
j
thoma
k
thoma
thoma
x
thompson
j
thompson
p
thomsen
c
thornton
l
thorp
n
thulkar
tillmann
tilman
h
timmermann
b
tiseliu
e
tiss
w
tiss
wj
tiss
wje
tiwari
r
tochner
z
todesco
tognon
c
tohm
b
toia
j
tokuc
g
toller
ea
tolstykh
tn
tomaselli
tomioka
tomita
tomizawa
tomlin
j
tomoka
tone
lg
tonet
vlp
toprak
torbidoni
torchia
j
toret
e
torfa
e
l
totadri
tozzi
ae
trabzi
trajkova
antevska
z
tran
dinh
ha
tran
h
tran
q
tran
tran
th
trauneck
h
trehan
trejo
j
trelinska
j
j
tripathi
g
trippel
f
trippett
trka
j
truong
b
tsaur
g
tsavachidi
tseitlin
g
tsilimido
g
tsimicali
tsuboi
k
tsuboi
koji
tsuchiya
k
tsurusawa
tucci
jr
tufegdz
tugcu
tuncer
tunnacliff
jm
tuponogov
turanlahti
turazzi
n
twardoch
tweddl
da
twose
tyagi
tychon
e
tylor
md
tytgat
g
tytgat
ga
u
uckan
udgir
uehara
uekusa
ueno
uitdehaag
mrn
ulloa
mt
ullrich
n
uludag
um
umeda
k
umezawa
k
umuhizi
unal
cabi
e
unal
e
unal
unuvar
unver
h
upadhyaya
sk
uppugunduri
cr
upreti
r
urabayen
r
urasinski
urbanik
urbieta
lv
uriz
j
uryu
h
uslan
ussowicz
usui
h
usui
n
usychkina
uysal
b
uysalol
e
v
vachon
mf
vadikolia
f
valent
p
j
valera
et
valero
j
vali
r
valiev
vallanc
p
valteau
couanet
van
casteren
nj
van
dalen
e
van
dalen
ec
van
de
brekel
van
de
veld
v
van
de
ven
c
van
de
ven
pm
van
de
weter
van
de
weter
md
van
den
akker
elt
van
den
berg
h
van
den
van
den
mm
van
den
heuvel
van
den
c
van
der
burgt
rhm
van
der
geest
van
der
leli
aj
van
der
meer
l
van
der
pal
hj
van
der
werff
ten
bosch
j
van
em
van
dorp
w
van
broeder
e
van
b
van
eyssen
van
gennip
van
gool
van
heerden
j
van
laar
van
ommen
ch
van
rensburg
ej
van
ryn
c
van
tinteren
h
van
tol
mjd
van
vliet
l
van
vuurden
van
zyl
vandenabeel
k
vandeven
c
vandierendonck
vanni
vapor
l
z
varan
varfolomeeva
varga
neri
j
varga
varga
f
varlet
p
varma
n
varma
r
varrasso
g
vasconcelo
ejr
vashu
r
vashura
vasquez
ponc
l
vasquez
f
vasquez
l
vasquez
r
vassal
g
vasudevan
vatanen
vathana
n
vazquez
j
vedi
veen
veerman
ajp
l
vega
l
l
velasco
l
velasco
p
velloso
e
veneroni
l
venkatramani
r
venman
lmaj
vennarini
g
vercruyss
vergin
c
verhaak
cm
verhaegh
verhagen
aae
verit
c
verma
n
vermeulen
j
veron
verrico
versacci
p
verschuur
vervaek
vervat
c
verzhbitskaya
viana
ss
viani
k
vianna
carvalho
r
c
v
vidal
vignesh
sr
vik
vilain
c
villa
kf
villa
villanueva
e
villiera
j
vinant
l
vinay
j
vinc
csc
vindrola
c
vinesh
sr
vipin
k
viqaruddin
viscardi
e
visscher
h
visscher
vittaz
vivanco
jl
vivek
vivekanandan
vlodavski
e
vogel
e
vogel
p
voinea
vokuhl
c
vol
h
volc
sm
volp
j
von
schweinitz
von
stackelberg
vora
vraetz
vrani
vreeman
rc
vrooman
lm
vujan
g
vujan
gm
vulet
l
vv
c
vyatkin
w
waander
aj
wachowiak
k
wachowiak
j
wachtel
ae
wada
k
wagner
wahid
fn
wainwright
rd
wakefield
ce
wakefield
walker
da
wall
wallac
hj
wallac
whb
walterhous
wan
ariffin
wan
wang
b
wang
g
wang
h
wang
hm
wang
j
wang
jf
wang
jm
wang
wang
q
wang
r
wang
wang
wang
x
wang
xs
wang
xw
wang
wang
z
wangmo
wani
k
wanv
ba
warad
dm
warmann
warmann
sw
warri
l
warwick
wasik
wasserman
jd
watanab
k
watanab
watanab
wataya
watt
wawi
wazneh
l
weaver
weber
dc
wegert
j
wegner
wehbi
e
weichert
n
weigel
b
weinblatt
weismil
weiss
wa
weitao
weitzman
wekesa
jw
well
e
well
em
wen
wendtland
edslev
p
werneck
f
wernikowski
j
r
west
c
west
n
westermann
f
wexler
l
weyl
weyman
e
wheeler
wheeler
g
wheeler
k
whelan
j
white
white
white
white
whitfield
k
whitlock
j
whitton
g
widger
ka
wide
e
wieb
k
wieczorek
wieczorek
wijnen
wild
j
wilejto
wilhelm
aj
willasch
william
c
william
william
william
r
william
williamson
j
p
wilson
cl
wilson
dc
wilson
mw
winship
winter
c
wise
withycomb
j
witt
h
witt
wlodarski
wolden
wolf
j
wolff
jea
womer
r
wong
wood
wood
b
wood
c
wood
j
woodfield
woodgat
r
woodman
j
wool
sv
wo
h
woszczyk
wozniak
w
wright
wrobel
g
wrzesien
v
wu
wu
h
wu
j
wu
wu
ml
wu
wu
q
wu
w
wu
x
wu
xy
wu
wu
ym
wurz
wysocki
x
xess
ima
xiao
x
ximao
c
xiong
h
xiong
q
xu
xu
w
xue
hl
yabe
h
yadav
yadav
j
yadav
yadav
sp
yagmurlu
aydi
yahr
yaich
yalcin
b
yamada
h
yamaguchi
e
yamamoto
f
yamamoto
yaman
agaoglu
f
yaman
yamanaka
j
yamaoka
yamasaki
k
yamashita
k
yamin
b
yan
jie
yanagisawa
yanai
yang
f
yang
g
yang
j
yang
l
yang
q
yang
yaniv
yankelevich
yano
yao
w
yap
yaqub
g
yarher
ie
yasmin
f
yassilibek
yassin
yassin
n
yavuz
g
yazici
n
ye
qd
yeap
yenen
vz
yenigurbuz
f
yeoh
ae
yesil
yetgin
yhap
yi
j
yildiz
f
yilmaz
b
yilmaz
yilmaz
sn
yin
c
yin
mz
ying
ying
j
yock
yogalingam
p
yogiraj
c
yokokawa
yokosuka
yoneda
yone
yontanov
yoshida
h
yoshida
k
yoshida
yoshimi
yoshimin
yoshinaga
yoshiwara
h
yoshizawa
j
yoshizawa
yotsumoto
k
youn
yousef
yousef
r
yousef
yousif
f
youssef
youssef
ayda
youssef
b
youssef
youssef
yu
yu
g
yu
j
yu
lj
yu
yuan
x
yuan
xy
yudina
n
yuksek
n
yune
ja
yuniati
l
yuza
z
zabriski
r
zadra
n
zadravec
zaletel
l
zage
p
zaghlol
zaghloul
zaghloul
ms
zaghouani
h
zagozewski
j
zaher
az
zaichikov
zaidman
zain
g
zairi
f
zakaria
zaki
eman
zaki
zaki
iman
zaletel
zameer
f
g
zanazzo
g
zane
k
zanett
zapata
zapotocki
zarnegar
zavala
zecca
zehani
n
zeinab
zekri
w
zeller
b
zelunka
e
zeng
hui
zeng
q
zenitani
zhai
h
zhai
x
zhang
zhang
zhang
dw
zhang
j
zhang
k
zhang
l
zhang
n
zhang
q
zhang
rd
zhang
w
zhang
x
zhang
zhao
j
zhao
q
zhao
w
zheng
hy
zhou
cj
zhou
e
zhou
zhou
x
zhou
xuan
zhu
zhu
x
zia
n
ziani
zielinska
e
zihar
z
zill
c
zimmermann
ziniel
ziro
j
zolali
zollo
zorlu
f
zubarovskaya
n
zubieta
zubizarreta
p
zubowska
zuk
zulfikar
b
g
zupanec
zuur
cl
zuzulova
zvulumov
zwaan
cm
zwaan
pa
zwinderman
ah
zyabchenko
v
